PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	DIETZEN, DJ; HASTINGS, WR; LUBLIN, DM				DIETZEN, DJ; HASTINGS, WR; LUBLIN, DM			CAVEOLIN IS PALMITOYLATED ON MULTIPLE CYSTEINE RESIDUES - PALMITOYLATION IS NOT NECESSARY FOR LOCALIZATION OF CAVEOLIN TO CAVEOLAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; ROUS-SARCOMA VIRUS; DECAY-ACCELERATING FACTOR; TRANS-GOLGI-NETWORK; ANCHORED PROTEINS; EPITHELIAL-CELLS; PLASMA-MEMBRANE; ALPHA-SUBUNITS; COMPONENT; RECEPTOR	Caveolae are subdomains of the plasma membrane which concentrate cholesterol, glycosphingolipids, and glycosylphosphatidylinositol-linked proteins. It has recently been demonstrated that specific members of the Src family of protein tyrosine kinases require palmitoylation of NH2-terminal cysteine residues to localize in caveolae. Here we report that caveolin, an integral membrane protein which forms part of the coat of caveolae, also incorporates palmitate through linkage to cysteine residues. Caveolin contains only three cysteine residues which are all located on the COOH-terminal side of the hydrophobic transmembrane region. Immunofluorescent staining of cells transfected with caveolin indicated that, like the NH2 terminus, this COOH-terminal region is located on the cytoplasmic side of the plasma membrane. Studies of cysteine substitution mutants showed that all three cysteines are capable of incorporating palmitate and that the juxtamembrane Cys(133) residue is the predominant site of palmitoylation. Simultaneous mutation of all three cysteine residues in caveolin resulted in the loss of ability to incorporate palmitate; however, this did not affect localization of the protein. Thus, palmitoylation of cysteine residues in nonmembrane spanning Src family protein tyrosine kinases has different consequences than in the transmembrane protein caveolin.	WASHINGTON UNIV, SCH MED, DEPT PATHOL, DIV LAB MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT INTERNAL MED, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM041297, R01GM041297] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 07038] Funding Source: Medline; NIGMS NIH HHS [GM 41297] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAND L, 1994, J BIOL CHEM, V269, P16701; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CAMP LA, 1994, J BIOL CHEM, V269, P23212; CINEK T, 1992, J IMMUNOL, V149, P2262; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DEGTYAREV MY, 1993, BIOCHEMISTRY-US, V32, P8057, DOI 10.1021/bi00083a001; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; PALADE GE, 1953, J APPL PHYS, V24, P1424; PALADE GE, 1958, ANAT REC, V130, P467; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; QUESNEL S, 1994, BIOCHEMISTRY-US, V33, P13340, DOI 10.1021/bi00249a021; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SEYA T, 1987, J IMMUNOL, V139, P1260; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SHENOYSCARIA AM, 1992, J IMMUNOL, V149, P3535; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445; ZURZOLO C, 1993, J CELL BIOL, V121, P1031, DOI 10.1083/jcb.121.5.1031; ZURZOLO C, 1994, EMBO J, V13, P42, DOI 10.1002/j.1460-2075.1994.tb06233.x	41	282	287	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6838	6842		10.1074/jbc.270.12.6838	http://dx.doi.org/10.1074/jbc.270.12.6838			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896831	hybrid			2022-12-25	WOS:A1995QQ85500062
J	ZERANGUE, N; ARRIZA, JL; AMARA, SG; KAVANAUGH, MP				ZERANGUE, N; ARRIZA, JL; AMARA, SG; KAVANAUGH, MP			DIFFERENTIAL MODULATION OF HUMAN GLUTAMATE TRANSPORTER SUBTYPES BY ARACHIDONIC-ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GAMMA-AMINOBUTYRIC ACID; SYNAPTIC TRANSMISSION; STRIATAL NEURONS; PRIMARY CULTURES; NMDA RECEPTORS; FATTY-ACIDS; RAT-BRAIN; SYNAPTOSOMES; EXPRESSION; ASTROCYTES	Arachidonic acid has been proposed to be a messenger molecule released following synaptic activation of glutamate receptors and during ischemia. Here we demonstrate that micromolar levels of arachidonic acid inhibit glutamate uptake mediated by EAAT1, a human excitatory amino acid transporter widely expressed in brain and cerebellum, by reducing the maximal transport rate approximately 30%. In contrast, arachidonic acid increased transport mediated by EAAT2, a subtype abundantly expressed in forebrain and midbrain, by causing the apparent affinity for glutamate to increase more than 2-fold. The results demonstrate that the response of different glutamate transporter subtypes to arachidonic acid could influence synaptic transmission and modulate excitotoxicity via positive or negative feedback according to the transporter(s) present in a particular region.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,HOWARD HUGHES MED INST,PORTLAND,OR 97201	Oregon Health & Science University; Howard Hughes Medical Institute; Oregon Health & Science University				Amara, Susan/0000-0001-8914-1106	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048709] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48709] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARRIZA JL, 1994, J NEUROSCI, V14, P5559; BARBOUR B, 1989, NATURE, V342, P918, DOI 10.1038/342918a0; BARBOUR B, 1994, NEURON, V12, P1331, DOI 10.1016/0896-6273(94)90448-0; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; CHAN PH, 1983, J NEUROCHEM, V40, P309, DOI 10.1111/j.1471-4159.1983.tb11284.x; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; DUMUIS A, 1990, NATURE, V347, P182, DOI 10.1038/347182a0; HAUN SE, 1994, SOC NEUR ABSTR, V20, P225; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; LAZAREWICZ JW, 1988, NEUROPHARMACOLOGY, V27, P765, DOI 10.1016/0028-3908(88)90088-3; MENNERICK S, 1994, NATURE, V368, P59, DOI 10.1038/368059a0; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; REHNCRONA S, 1982, J NEUROCHEM, V38, P84, DOI 10.1111/j.1471-4159.1982.tb10857.x; RHOADS DE, 1982, J NEUROCHEM, V38, P1255, DOI 10.1111/j.1471-4159.1982.tb07898.x; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; SAH P, 1989, SCIENCE, V246, P815, DOI 10.1126/science.2573153; STELLA N, 1994, J NEUROSCI, V14, P568; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; VOLTERRA A, 1992, J NEUROCHEM, V59, P600, DOI 10.1111/j.1471-4159.1992.tb09411.x; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; YU ACH, 1986, J NEUROCHEM, V47, P1181	24	148	151	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6433	6435		10.1074/jbc.270.12.6433	http://dx.doi.org/10.1074/jbc.270.12.6433			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896776	hybrid, Green Published			2022-12-25	WOS:A1995QQ85500004
J	ZHANG, J; ZHANG, J; BENOVIC, JL; SUGAI, M; WETZKER, R; GOUT, I; RITTENHOUSE, SE				ZHANG, J; ZHANG, J; BENOVIC, JL; SUGAI, M; WETZKER, R; GOUT, I; RITTENHOUSE, SE			SEQUESTRATION OF A G-PROTEIN BETA-GAMMA SUBUNIT OR ADP-RIBOSYLATION OF RHO CAN INHIBIT THROMBIN-INDUCED ACTIVATION OF PLATELET PHOSPHOINOSITIDE 3-KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENERGIC-RECEPTOR KINASE; GTP-BINDING PROTEIN; ADENYLATE-CYCLASE; PURIFICATION	Stimulation of platelets by thrombin leads to an increased association of activated phosphoinositide 3-kinase (PI 3-K) with a membrane cytoskeletal fraction (CSK). Activation of PI 3-K is dependent upon GTP-binding protein(s), since PI 3-K in permeabilized platelets is stimulated by GTP gamma S (guanosine 5'-3-O-(thio)triphosphate), and stimulation of platelet cytosolic PI 3-K by GTP gamma S requires a functional small G protein, Rho. Recent reports indicate that cytosolic PI 3-Ks can also be activated by the beta gamma subunits of heterotrimeric G-proteins (G beta gamma). We now report that the activated PI 3-K that is associated with CSK can be inhibited by a recombinant protein containing the G beta gamma-binding pleckstrin homology domain of beta-adrenergic receptor kinase 1 (beta ARK-PH). Inhibition is blocked by G beta gamma. PI 3-K in nonactivated platelet CSK is activated by GTP gamma S but unaffected by beta ARK-PH or G beta gamma, Western blots indicate that activated platelet CSK contains a novel 110-kDa PI 3-K(gamma) that has been shown to be stimulated by G beta gamma and to lack binding sites for the 85-kDa subunit of conventional PI 3-K. PI 3-K in immunoprecipitates obtained via p85 subunit-directed antibodies can be activated by GTP gamma S but not by G beta gamma. PI 3-K that is stimulatable by G beta gamma remains soluble, as does PI 3-K(gamma), and is unaffected by Rho, In contrast, ADP-ribosylation of Rho present in p85 immunoprecipitates is inhibitory, Further, activation of PI 3-K in permeabilized platelets exposed to thrombin or GTP gamma S is inhibited by beta ARK-PH and/or Rho-specific ADP-ribosylating enzymes. We conclude that Rho and G beta gamma each, respectively, contributes to the activation of different PI 3-Ks (p85-containing heterodimer and PI3-K (gamma)) in thrombin-stimulated platelets.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, JEFFERSON CANC INST, DEPT PHARMACOL, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, CARDEZA FDN HEMATOL RES, PHILADELPHIA, PA 19107 USA; HIROSHIMA UNIV, SCH DENT, DEPT MICROBIOL, MINAMI KU, HIROSHIMA 734, JAPAN; UNIV JENA, MAX PLANCK RES GRP GROWTH FACTROR SIGNAL TRANSDUC, D-07747 JENA, GERMANY; UCL, LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND	Jefferson University; Jefferson University; Hiroshima University; Friedrich Schiller University of Jena; Max Planck Society; Ludwig Institute for Cancer Research; University of London; University College London			Wetzker, Reinhard/AAD-8713-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038622] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 38622] Funding Source: Medline; CGH CDC HHS [GH 44944] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); CGH CDC HHS		AKTORIES K, 1984, EUR J BIOCHEM, V145, P333, DOI 10.1111/j.1432-1033.1984.tb08558.x; BANGA HS, 1988, BIOCHEM J, V252, P297, DOI 10.1042/bj2520297; BRASS LF, 1986, J BIOL CHEM, V261, P6838; CARTER AN, 1994, BIOCHEM J, V301, P415, DOI 10.1042/bj3010415; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HUANG R, 1991, J BIOL CHEM, V266, P1652; KIKUCHI A, 1992, J BIOL CHEM, V267, P14611; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; MORII N, 1992, J BIOL CHEM, V267, P20921; OKADA T, 1994, J BIOL CHEM, V269, P3563; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PLOW EF, 1992, SEMIN THROMB HEMOST, V18, P324, DOI 10.1055/s-2007-1002571; RITTENHOUSE SE, 1995, IN PRESS METHODS E B; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; SUGAI M, 1990, BIOCHEM BIOPH RES CO, V173, P92, DOI 10.1016/S0006-291X(05)81026-5; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; ZHANG J, 1992, J BIOL CHEM, V267, P4686; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	23	100	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6589	6594		10.1074/jbc.270.12.6589	http://dx.doi.org/10.1074/jbc.270.12.6589			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896797	hybrid			2022-12-25	WOS:A1995QQ85500027
J	ZHANG, SY; JAGENDORF, AT				ZHANG, SY; JAGENDORF, AT			SOME UNIQUE CHARACTERISTICS OF THYLAKOID UNISITE ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPLAST COUPLING FACTOR; HEART MITOCHONDRIAL ATPASE; ESCHERICHIA-COLI F1-ATPASE; BINDING CHANGE MECHANISM; CATALYTIC SITE; FACTOR-I; F1 ATPASE; MG-2+-ATPASE ACTIVITY; ANION ACTIVATION; H+-ATPASE	Under unisite conditions (ratio of ATP to chloroplast coupling factor (CF0CF1), approximately 1:2.8), spinach thylakoid ATPase depends on prior reductive activation of CF1, just as multisite ATPase does, and is sensitive to removal of CF1, by EDTA, Faster rates in room light than in semidarkness and up to 80% inhibition by uncouplers only in room light indicate a strong effect of protonmotive force, which can be provided by room light. In addition, unisite ATPase is inhibited by azide as long as some ADP is bound to the CF1. Several differences were found between unisite and multisite ATPase, 1) The unisite activities of both membrane-bound and free enzyme were stimulated up to 3-fold by 4 mM free MgCl2 (a strong inhibitor of multisite ATPase). 2) Thylakoid unisite ATPase was inhibited by sulfite (50% inhibition at 5 mM), a powerful activator of multisite ATPase. This inhibition is attributed to a nonspecific ionic strength effect. 3) Unisite ATPase was inhibited by trypsin treatment, which increases multisite ATPase severalfold. 4) The pH profile of thylakoid unisite ATPase is somewhat different from that of mul tisite. 5) Alkylation of Cys-89 of the gamma subunit by N-ethylmaleimide did not affect the unisite activity, but inhibited multisite activity more than 90%.	CORNELL UNIV,PLANT BIOL SECT,ITHACA,NY 14853	Cornell University								ALSHAWI MK, 1988, J BIOL CHEM, V263, P19640; ALSHAWI MK, 1992, BIOCHEMISTRY-US, V31, P878, DOI 10.1021/bi00118a033; ANDRALOJC PJ, 1990, BIOCHIM BIOPHYS ACTA, V1016, P55, DOI 10.1016/0005-2728(90)90006-P; COHEN WS, 1989, PLANT PHYSIOL, V91, P1107, DOI 10.1104/pp.91.3.1107; CROSS RL, 1982, J BIOL CHEM, V257, P2101; CUNNINGHAM D, 1988, J BIOL CHEM, V263, P18850; DU ZY, 1990, BIOCHEMISTRY-US, V29, P402, DOI 10.1021/bi00454a014; FROMME P, 1990, BIOCHIM BIOPHYS ACTA, V1020, P187, DOI 10.1016/0005-2728(90)90050-E; FROMME P, 1990, BIOCHIM BIOPHYS ACTA, V1016, P29, DOI 10.1016/0005-2728(90)90003-M; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; GUERRERO KJ, 1990, J BIOL CHEM, V265, P16280; HARRIS DA, 1985, BIOCHEMISTRY-US, V24, P3876, DOI 10.1021/bi00336a010; HARRIS DA, 1989, BIOCHIM BIOPHYS ACTA, V974, P156, DOI 10.1016/S0005-2728(89)80368-8; HOCHMAN Y, 1976, FEBS LETT, V61, P255, DOI 10.1016/0014-5793(76)81051-4; IZAWA S, 1966, PLANT PHYSIOL, V41, P544, DOI 10.1104/pp.41.3.544; IZAWA S, 1966, PLANT PHYSIOL, V41, P533, DOI 10.1104/pp.41.3.533; JAGENDORF AT, 1982, METHODS CHLOROPLAST, P881; KASHO VN, 1984, J BIOENERG BIOMEMBR, V16, P407, DOI 10.1007/BF00743235; KHYM JX, 1975, CLIN CHEM, V21, P1245; KRAMER DM, 1990, PHOTOSYNTH RES, V26, P213, DOI 10.1007/BF00033134; LABAHN A, 1993, BIOCHIM BIOPHYS ACTA, V1141, P288, DOI 10.1016/0005-2728(93)90055-K; LARSON EM, 1989, BIOCHIM BIOPHYS ACTA, V973, P67, DOI 10.1016/S0005-2728(89)80404-9; LARSON EM, 1989, BIOCHIM BIOPHYS ACTA, V973, P78, DOI 10.1016/S0005-2728(89)80405-0; MATSUNOYAGI A, 1993, J BIOL CHEM, V268, P1539; MILGROM YM, 1987, FEBS LETT, V222, P32, DOI 10.1016/0014-5793(87)80186-2; MINKOV IB, 1989, BIOCHIM BIOPHYS ACTA, V973, P7, DOI 10.1016/S0005-2728(89)80394-9; MORONEY JV, 1982, J BIOL CHEM, V257, P5915; MORONEY JV, 1982, J BIOL CHEM, V257, P5910; MUNEYUKI E, 1991, BIOCHIM BIOPHYS ACTA, V1058, P304, DOI 10.1016/S0005-2728(05)80251-8; MURATALIEV MB, 1991, BIOCHEMISTRY-US, V30, P8305, DOI 10.1021/bi00098a004; MURATALIEV MB, 1992, EUR J BIOCHEM, V209, P681, DOI 10.1111/j.1432-1033.1992.tb17336.x; NALIN CM, 1983, J BIOL CHEM, V258, P3376; NOUMI T, 1987, FEBS LETT, V213, P381, DOI 10.1016/0014-5793(87)81526-0; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PENEFSKY HS, 1984, H PLUS ATPASE ATP SY, P195; POSORSKE L, 1976, ARCH BIOCHEM BIOPHYS, V177, P276, DOI 10.1016/0003-9861(76)90437-9; QUICK WP, 1986, BIOCHIM BIOPHYS ACTA, V851, P166, DOI 10.1016/0005-2728(86)90122-2; ROVERI OA, 1985, FEBS LETT, V192, P123, DOI 10.1016/0014-5793(85)80056-9; SOTEROPOULOS P, 1994, J BIOL CHEM, V269, P19810; VAMBUSTA.VK, 1965, J BIOL CHEM, V240, P2660; WEI JM, 1988, BIOCHIM BIOPHYS ACTA, V934, P72, DOI 10.1016/0005-2728(88)90121-1; WINTERMANS JF, 1965, BIOCHIM BIOPHYS ACTA, V109, P448, DOI 10.1016/0926-6585(65)90170-6; WONG SY, 1984, BIOCHEMISTRY-US, V23, P5004, DOI 10.1021/bi00316a027; ZHANG SY, 1993, PLANT PHYSIOL, V101, P127, DOI 10.1104/pp.101.1.127	44	9	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6607	6614		10.1074/jbc.270.12.6607	http://dx.doi.org/10.1074/jbc.270.12.6607			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896800	hybrid			2022-12-25	WOS:A1995QQ85500030
J	COPPENS, I; LEVADE, T; COURTOY, PJ				COPPENS, I; LEVADE, T; COURTOY, PJ			HOST PLASMA LOW-DENSITY-LIPOPROTEIN PARTICLES AS AN ESSENTIAL SOURCE OF LIPIDS FOR THE BLOOD-STREAM FORMS OF TRYPANOSOMA-BRUCEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM FORMS; TRYPANOCIDAL DRUG; CHOLESTEROL; ACID; GLYCOPROTEIN; METABOLISM; HYDROLASES; RECEPTOR; DISEASE	In contrast to mammalian cells, bloodstream forms of Trypanosoma brucei show no activity for fatty acid and sterol synthesis and critically depend on plasma low density lipoprotein (LDL) particles for their rapid growth, We report here that these parasites acquire such lipids by receptor-mediated endocytosis of LDL, subsequent lysosomal degradation of apoprotein B-LDL, and utilization of these lipids, Uptake of LDL-associated [H-3]sphingomyelin and of LDL-associated [H-3]cholesteryl oleate paralleled each other, and that of I-125-apoprotein B-LDL showed saturation and could be inhibited by unlabeled LDL or by anti-LDL receptor antibodies. Metabolism of lipids carried by LDL was abolished by chloroquine and by the thiol protease inhibitor, leupeptin, Sphingomyelin was cleaved by an acid sphingomyelinase to yield ceramide, which was itself split up into sphingosine and fatty acids. The latter were further incorporated into phosphatidylcholine, triacylglycerols, or cholesteryl esters, Similarly, cholesteryl oleate was hydrolyzed by an acid lipase to yield free cholesterol, which was reesterified with fatty acids, presumably in the cytosol. Like free cholesterol, LDL provided substrate for cholesterol esterification. In the culture-adapted procyclic form of T. brucei, which is capable of sterol synthesis, exogenous LDL-cholesterol rather than endogenously synthesized sterol was utilized for sterol esterification. Interference with exogenous supply of lipids via receptor-mediated endocytosis of LDL should be explored to fight against trypanosomiasis.	INT INST CELLULAR & MOLEC PATHOL,B-1200 BRUSSELS,BELGIUM; UNIV CATHOLIQUE LOUVAIN,SCH MED,CELL BIOL UNIT,B-1200 BRUSSELS,BELGIUM; CHU RANGUEIL,INSERM,CJF 9206,BIOCHIM LAB,F-31054 TOULOUSE,FRANCE	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)			Levade, Thierry/O-8948-2014					BASTIN P, 1994, MOL BIOCHEM PARASIT, V63, P193, DOI 10.1016/0166-6851(94)90055-8; BLACK S, 1989, MOL BIOCHEM PARASIT, V37, P201; BRUN R, 1979, ACTA TROP, V36, P286; CARROLL M, 1986, COMP BIOCHEM PHYS B, V83, P647, DOI 10.1016/0305-0491(86)90312-3; COPPENS I, 1991, BIOCHEM BIOPH RES CO, V178, P185, DOI 10.1016/0006-291X(91)91797-G; COPPENS I, 1988, P NATL ACAD SCI USA, V85, P6753, DOI 10.1073/pnas.85.18.6753; COPPENS I, 1995, MOL BIOCHEM PARASIT, V69, P29, DOI 10.1016/0166-6851(94)00192-P; COPPENS I, 1987, J PROTOZOOL, V34, P465, DOI 10.1111/j.1550-7408.1987.tb03216.x; COPPENS I, 1993, MOL BIOCHEM PARASIT, V58, P223, DOI 10.1016/0166-6851(93)90044-X; DIXON H, 1972, COMP BIOCHEM PHYSIOL, V41, P1, DOI 10.1016/0305-0491(72)90002-8; DIXON H, 1971, COMP BIOCH PHYSL, V398, P247; DOERING TL, 1993, J BIOL CHEM, V268, P9215; FOLCH J, 1957, J BIOL CHEM, V226, P497; GILLETT MPT, 1992, BIOCHIM BIOPHYS ACTA, V1123, P239, DOI 10.1016/0005-2760(92)90002-D; GILLETT MPT, 1987, BIOCHEM SOC T, V15, P258, DOI 10.1042/bst0150258; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1974, P NATL ACAD SCI USA, V71, P4288, DOI 10.1073/pnas.71.11.4288; GRABER D, 1994, J NEUROCHEM, V63, P1060; GRELLIER P, 1991, J CELL BIOL, V112, P267, DOI 10.1083/jcb.112.2.267; HAGER KM, 1994, J CELL BIOL, V126, P155, DOI 10.1083/jcb.126.1.155; HAMBREY PN, 1981, MOL BIOCHEM PARASIT, V2, P177, DOI 10.1016/0166-6851(81)90098-0; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; JACKSON RL, 1976, PHYSIOL REV, V56, P259, DOI 10.1152/physrev.1976.56.2.259; LANHAM SM, 1968, NATURE, V218, P1273, DOI 10.1038/2181273a0; LEVADE T, 1983, J NEUROCHEM, V40, P1762, DOI 10.1111/j.1471-4159.1983.tb08153.x; LEVADE T, 1993, FEBS LETT, V329, P306, DOI 10.1016/0014-5793(93)80243-N; LONSDALEECCLES JD, 1987, EUR J BIOCHEM, V169, P467, DOI 10.1111/j.1432-1033.1987.tb13634.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MELLORS A, 1989, PARASITOL TODAY, V8, P239; NEGRE A, 1984, BIOCHIM BIOPHYS ACTA, V794, P89, DOI 10.1016/0005-2760(84)90301-1; Opperdoes F.R., 1987, NATO ASI Series Series H Cell Biology, V11, P51; OPPERDOES FR, 1976, EXP PARASITOL, V40, P198, DOI 10.1016/0014-4894(76)90082-5; OPPERDOES FR, 1981, MOL BIOCHEM PARASIT, V4, P311, DOI 10.1016/0166-6851(81)90063-3; OPPERDOES FR, 1982, MOL BIOCHEM PARASIT, V5, P309, DOI 10.1016/0166-6851(82)90038-X; POUMAY Y, 1984, J LIPID RES, V26, P1476; VANDEWEERD V, 1989, MOL BIOCHEM PARASIT, V37, P201, DOI 10.1016/0166-6851(89)90152-7; VANSTERKENBURG ELM, 1993, ACTA TROP, V54, P237, DOI 10.1016/0001-706X(93)90096-T	38	67	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					5736	5741		10.1074/jbc.270.11.5736	http://dx.doi.org/10.1074/jbc.270.11.5736			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890701	hybrid			2022-12-25	WOS:A1995QM94500011
J	NAKAMURA, F; KATO, M; KAMEYAMA, K; NUKADA, T; HAGA, T; KATO, N; TAKENAWA, T; KIKKAWA, U				NAKAMURA, F; KATO, M; KAMEYAMA, K; NUKADA, T; HAGA, T; KATO, N; TAKENAWA, T; KIKKAWA, U			CHARACTERIZATION OF G(Q) FAMILY G-PROTEINS G(L1)ALPHA(G(14)ALPHA), G(L2)ALPHA(G(11)ALPHA), AND G(Q)ALPHA EXPRESSED IN THE BACULOVIRUS-INSECT CELL SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; INHIBITS PHOSPHOINOSITIDE HYDROLYSIS; PHOSPHOLIPASE-C ISOZYMES; ALPHA-SUBUNITS; KINASE-C; REGULATORY PROTEINS; ADENYLATE-CYCLASE; BINDING-PROTEIN; XENOPUS-OOCYTES; SF9 CELLS	The a subunits of G(q) family G proteins, G(L1)alpha(G(14)alpha), G(L2)alpha(G(11)alpha), and G(q) alpha were expressed with G protein beta(1) and gamma(2) subunits in insect cells using a baculovirus system, The trimeric forms of G proteins, G(L1) (G(L1)alpha beta gamma), G(L2) (C(L2)alpha beta gamma), and G(q) (G(q) alpha beta gamma), were solubilized by 1% sodium cholate and purified by sequential chromatography on three kinds of columns, G(L1), G(L2), and G(q) activated phospholipase C-beta purified from bovine brain in the presence of aluminum fluoride to the same extent, Muscarinic acetylcholine receptor m1 subtype stimulated the guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S) binding to G(L1), G(L2) and G(q) in the presence of similar concentrations of carbamylcholine. When m1 receptor, G protein, and phospholipase C-beta were reconstituted in lipid vesicles, each subtype of G(q) family G proteins mediated the activation of phospholipase C-beta by carbamylcholine in the presence of either 1 mu M GTP gamma S or 1 mM GTP. Phospholipase C-beta stimulated the GTPase activity of G(L1), G(L2), and G(q) in the presence of mi receptor and carbamylcholine but did not stimulate the GTPase activity of G(o). Protein kinase C phosphorylated m1 receptor and phospholipase C-beta, but the phosphorylation did not significantly affect the ability of the m1 receptor to stimulate phospholipase C-beta in the reconstitution system of purified proteins.	UNIV TOKYO, FAC MED, INST BRAIN RES, DEPT BIOCHEM, BUNKYO KU, TOKYO 113, JAPAN; UNIV TOKYO, INST MED SCI, DEPT MOLEC ONCOL, MINATO KU, TOKYO 108, JAPAN; KOBE UNIV, BIOSIGNAL RES CTR, NADA KU, KOBE 657, JAPAN	University of Tokyo; University of Tokyo; Kobe University			Hayashi, Mariko/HHY-7722-2022; Hayashi, Mariko K/L-1187-2013	Hayashi, Mariko/0000-0001-8296-4599; Hayashi, Mariko K/0000-0001-8296-4599				AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; ASHKENAZI A, 1989, TRENDS PHARMACOL SCI, P16; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BONNER TI, 1989, TRENDS NEUROSCI, V12, P148, DOI 10.1016/0166-2236(89)90054-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT DR, 1985, J BIOL CHEM, V260, P266; ELFAKAHANY EE, 1988, FASEB J, V2, P2575, DOI 10.1096/fasebj.2.10.2838363; FELDER CC, 1989, J BIOL CHEM, V264, P20356; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GRABER SG, 1992, J BIOL CHEM, V267, P1271; HAGA K, 1990, J NEUROCHEM, V54, P1639, DOI 10.1111/j.1471-4159.1990.tb01216.x; HAGA K, 1989, MOL PHARMACOL, V35, P286; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; Kitano T, 1986, Methods Enzymol, V124, P349; KOZASA T, 1993, P NATL ACAD SCI USA, V90, P9176, DOI 10.1073/pnas.90.19.9176; LEE CH, 1992, J BIOL CHEM, V267, P16044; LIPINSKY D, 1992, FEBS LETT, V307, P237, DOI 10.1016/0014-5793(92)80775-C; MA HW, 1993, J BIOL CHEM, V268, P19915; NAKAMURA F, 1991, J BIOL CHEM, V266, P12676; NAKAMURA K, 1994, J PHYSIOL-LONDON, V474, P35, DOI 10.1113/jphysiol.1994.sp020000; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; ORELLANA SA, 1985, J BIOL CHEM, V260, P5236; PARKER EM, 1991, J BIOL CHEM, V266, P519; RHEE SG, 1991, METHOD ENZYMOL, V197, P502; RYU SH, 1990, J BIOL CHEM, V265, P17941; RYU SH, 1987, J BIOL CHEM, V262, P12511; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHIOZAKI K, 1992, BIOCHEMISTRY-US, V31, P10634, DOI 10.1021/bi00158a028; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; SUGIMOTO K, 1985, FEBS LETT, V191, P235, DOI 10.1016/0014-5793(85)80015-6; Summers MD, 1987, TEXAS AGR EXPT STATI; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TOTA MR, 1987, BIOCHEMISTRY-US, V26, P8175, DOI 10.1021/bi00399a023; VANHEESWIJK MPE, 1984, J MEMBRANE BIOL, V79, P19, DOI 10.1007/BF01868523; VICENTINI LM, 1985, BIOCHEM BIOPH RES CO, V127, P310, DOI 10.1016/S0006-291X(85)80160-1; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049	43	69	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					6246	6253		10.1074/jbc.270.11.6246	http://dx.doi.org/10.1074/jbc.270.11.6246			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890762	hybrid			2022-12-25	WOS:A1995QM94500080
J	SCHWIENTEK, T; LORENZ, C; ERNST, JF				SCHWIENTEK, T; LORENZ, C; ERNST, JF			GOLGI LOCALIZATION IN YEAST IS MEDIATED BY THE MEMBRANE ANCHOR REGION OF RAT-LIVER SIALYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; SIGNAL ANCHOR; PLASMA-MEMBRANE; PROTEIN; RETENTION; APPARATUS; INVERTASE; GLYCOSYLATION	To investigate the function of the membrane anchor region of a mammalian glycosyltransferase in yeast we constructed a fusion gene that encodes the 34 amino terminal residues of rat liver beta-galactoside alpha-2,6-sialyltransferase (EC 2.4.99.1) (ST) fused to the mature form of yeast invertase. Transformants of Saccharomyces cerevisiae expressing the fusion gene produced an intracellular heterogeneously N-glycosylated fusion protein of intermediate molecular weight between the core and fully extended N-glycosylated form of invertase, suggesting a post endoplasmic reticulum (ER) localization. In two types of cell fractionation using sucrose density gradients the ST-invertase fusion protein cofractionated with Golgi marker proteins, whereas a minor fraction (about 30%) comigrated with a vacuolar marker; ST-invertase was not detected in other cell fractions including the ER and the plasma membrane. Consistent with Golgi localization, about 70% of the total amount of the ST-invertase fusion was immunoprecipitated with an antibody directed against alpha-1,6 mannose linkages. The results demonstrate that the membrane anchor region of a mammalian type II glycosyltransferase is able to target a protein to the secretory pathway and to a Golgi compartment of the yeast S. cerevisiae, indicating conservation of targeting mechanisms between higher and lower eukaryotes. Since typical yeast Golgi localization signals are missing in the ST-membrane anchor region the results also suggest that yeast as mammalian cells utilize diverse mechanisms to direct proteins to the Golgi.	UNIV DUSSELDORF, INST MIKROBIOL, D-40225 DUSSELDORF, GERMANY	Heinrich Heine University Dusseldorf								ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; BIELEFELD M, 1992, CURR GENET, V21, P265, DOI 10.1007/BF00351680; BOWSER R, 1991, J CELL BIOL, V112, P1117, DOI 10.1083/jcb.112.6.1117; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BURKE J, 1994, J BIOL CHEM, V269, P12049; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHAPMAN RE, 1994, EMBO J, V13, P4896, DOI 10.1002/j.1460-2075.1994.tb06817.x; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; COOPER A, 1992, J CELL BIOL, V119, P1459, DOI 10.1083/jcb.119.6.1459; DAHDAL RY, 1993, J BIOL CHEM, V268, P26310; ERNST JF, 1986, DNA-J MOLEC CELL BIO, V5, P483, DOI 10.1089/dna.1.1986.5.483; ERNST JF, 1992, EUR J BIOCHEM, V203, P663, DOI 10.1111/j.1432-1033.1992.tb16596.x; ESMON PC, 1987, J BIOL CHEM, V262, P4387; FRANZUSOFF A, 1991, METHOD ENZYMOL, V194, P662; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; GELLERFORS P, 1989, J BIOL CHEM, V264, P11444; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; HARDWICK KG, 1990, EMBO J, V9, P623, DOI 10.1002/j.1460-2075.1990.tb08154.x; HAUSLER A, 1992, GLYCOBIOLOGY, V2, P77, DOI 10.1093/glycob/2.1.77; HITZEMAN RA, 1983, SCIENCE, V219, P620, DOI 10.1126/science.6186023; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; KAISER CA, 1987, SCIENCE, V235, P312, DOI 10.1126/science.3541205; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KREZDORN CH, 1994, EUR J BIOCHEM, V220, P809, DOI 10.1111/j.1432-1033.1994.tb18683.x; MASIBAY AS, 1993, J BIOL CHEM, V268, P9908; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MORMENEO S, 1989, FEMS MICROBIOL LETT, V57, P271, DOI 10.1016/0378-1097(89)90312-1; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; NOTHWEHR SF, 1993, J CELL BIOL, V121, P1197, DOI 10.1083/jcb.121.6.1197; ORLEAN P, 1991, METHOD ENZYMOL, V194, P682; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROBERTS CJ, 1992, J CELL BIOL, V119, P69, DOI 10.1083/jcb.119.1.69; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; Sherman F., 1986, METHODS YEAST GENETI; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIDA TA, 1990, J CELL BIOL, V111, P2871, DOI 10.1083/jcb.111.6.2871; WALWORTH NC, 1989, METHOD CELL BIOL, V31, P335; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEISZ OA, 1993, J CELL BIOL, V122, P1185, DOI 10.1083/jcb.122.6.1185; WILCOX CA, 1992, MOL BIOL CELL, V3, P1353, DOI 10.1091/mbc.3.12.1353	47	24	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5483	5489		10.1074/jbc.270.10.5483	http://dx.doi.org/10.1074/jbc.270.10.5483			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890665	hybrid			2022-12-25	WOS:A1995QL58000081
J	SUMNER, JP; DOW, JAT; EARLEY, FGP; KLEIN, U; JAGER, D; WIECZOREK, H				SUMNER, JP; DOW, JAT; EARLEY, FGP; KLEIN, U; JAGER, D; WIECZOREK, H			REGULATION OF PLASMA-MEMBRANE V-ATPASE ACTIVITY BY DISSOCIATION OF PERIPHERAL SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOBACCO HORNWORM MIDGUT; MANDUCA-SEXTA MIDGUT; VACUOLAR-TYPE ATPASE; PROTON PUMP; H+-ATPASES; TRANSPORTING EPITHELIA; MAMMALIAN KIDNEY; ULTRASTRUCTURE; PURIFICATION; EVOLUTION	The plasma membrane V-ATPase of Manduca sexta larval midgut is an electrogenic proton pump located in goblet cell apical membranes (GCAM); it energizes, by the voltage component of its proton motive force, an electrophoretic K+/nH(+) antiport and thus K+ secretion (Wieczorek, H., Putzenlechner, M., Zeiske, W., and Klein, U. (1991) J. Biol Chem. 266, 15340-15347). Midgut transepithelial voltage, indicating net active K+ transport, was found to be more than 100 mV during intermoult stages but was abolished during moulting. Simultaneously, ATP hydrolysis and ATP-dependent proton transport in GCAM vesicles were found to be reduced to 10-15% of the intermoult level. Immunocytochemistry of midgut cryosections as well as SDS-polyacrylamide gel electrophoresis and immunoblots of GCAM demonstrated that loss of ATPase activity paralleled the disappearance of specific subunits. The subunits missing were those considered to compose the peripheral V-1 sector, whereas the membrane integral V-0 subunits remained in the GCAM of moulting larvae. The results provide, for the first time, evidence that a V-ATPase activity can be controlled in vivo by the loss of the peripheral V-1 domain.	UNIV MUNICH,INST ZOOL,D-80021 MUNICH,GERMANY; ZENECA,AGROCHEM JEALLOLS HILL RES STN,BRACKNELL RG12 6EY,BERKS,ENGLAND; UNIV GLASGOW,DEPT CELL BIOL,GLASGOW G12 8QQ,LANARK,SCOTLAND	University of Munich; University of Glasgow			Dow, Julian/M-2371-2019	Dow, Julian/0000-0002-9595-5146	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022444] Funding Source: NIH RePORTER; NIAID NIH HHS [AI22444] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANRAKU Y, 1992, J EXP BIOL, V172, P67; BALDWIN KM, 1991, TISSUE CELL, V23, P411, DOI 10.1016/0040-8166(91)90058-2; BELL RA, 1974, ANN ENTOMOL SOC AM, V69, P365; BROWN D, 1991, KIDNEY INT S, V40, P79; CIOFFI M, 1984, AM ZOOL, V24, P139; CIOFFI M, 1983, TISSUE CELL, V15, P781, DOI 10.1016/0040-8166(83)90050-2; DOW JAT, 1992, GENE, V122, P355, DOI 10.1016/0378-1119(92)90226-F; DOW JAT, 1992, J EXP BIOL, V172, P355; DOW JAT, 1984, AM J PHYSIOL, V246, pR633, DOI 10.1152/ajpregu.1984.246.4.R633; DOW JAT, 1990, J EXP BIOL, V150, P247; DOW JAT, 1985, J EXP BIOL, V116, P685; GLUCK SL, 1992, J EXP BIOL, V172, P219; GRAF R, 1994, J BIOL CHEM, V269, P3767; GRAF R, 1992, FEBS LETT, V300, P119, DOI 10.1016/0014-5793(92)80177-I; GRAF R, 1994, BBA-BIOMEMBRANES, V1190, P193, DOI 10.1016/0005-2736(94)90053-1; GRAHAM LA, 1994, J BIOL CHEM, V269, P25974; HARVEY WR, 1992, J EXP BIOL, V172, P1; HARVEY WR, 1964, P NATL ACAD SCI USA, V51, P757; HARVEY WR, 1992, J EXP BIOL, V172; KLEIN U, 1991, J EXP BIOL, V161, P61; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MYERS M, 1993, J CELL PHYSIOL, V156, P35, DOI 10.1002/jcp.1041560106; NELSON H, 1994, J BIOL CHEM, V269, P24150; NELSON N, 1992, J EXP BIOL, V172, P19; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; NOVAK FJS, 1992, BIOCHIM BIOPHYS ACTA, V1132, P67, DOI 10.1016/0167-4781(92)90053-3; PUOPOLO K, 1990, J BIOL CHEM, V265, P14836; SCHWEIKL H, 1989, J BIOL CHEM, V264, P11136; TRUMAN JW, 1992, PROG BRAIN RES, V92, P361, DOI 10.1016/S0079-6123(08)61189-9; WIECZOREK H, 1991, J BIOL CHEM, V266, P15340; WIECZOREK H, 1992, J EXP BIOL, V172, P335; WIECZOREK H, 1989, J BIOL CHEM, V264, P11143; WIECZOREK H, 1990, METHOD ENZYMOL, V192, P608; YAMAMOTO RT, 1969, J ECON ENTOMOL, V62, P1427, DOI 10.1093/jee/62.6.1427; ZHANG JM, 1992, J BIOL CHEM, V267, P9773; ZHANG K, 1992, J BIOL CHEM, V267, P14539; ZHANG K, 1992, J BIOL CHEM, V267, P9701; ZHENG XY, 1992, J EXP BIOL, V165, P273	39	280	284	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5649	5653		10.1074/jbc.270.10.5649	http://dx.doi.org/10.1074/jbc.270.10.5649			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890686	hybrid			2022-12-25	WOS:A1995QL58000105
J	BORG, JP; DELAPEYRIERE, O; NOGUCHI, T; ROTTAPEL, R; DUBREUIL, P; BIRNBAUM, D				BORG, JP; DELAPEYRIERE, O; NOGUCHI, T; ROTTAPEL, R; DUBREUIL, P; BIRNBAUM, D			BIOCHEMICAL-CHARACTERIZATION OF 2 ISOFORMS OF FLT4, A VEGF RECEPTOR-RELATED TYROSINE KINASE	ONCOGENE			English	Article						ANGIOGENESIS; ENDOTHELIUM; CYTOPLASMIC SUBSTRATES; FLT1; FLK1; KDR; FLT4; IN SITU HYBRIDIZATION; ONCOGENE; VEGF; TYROSINE KINASE; RECEPTORS	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; SIGNAL TRANSDUCTION; MOUSE DEVELOPMENT; FMS PROTEIN; CELL-LINES; EXPRESSION; FAMILY; INVIVO; CDNA	The FLT4 gene encodes a tyrosine kinase receptor related to the two identified receptors for vascular endothelial growth factor (VEGF), FLT1 and FLK1/KDR. Two isoforms of FLT4, differing by their C-terminal ends, have been identified. The long form has 65 additional amino acid residues. We have shown that FLT4 is a highly glycosylated, relatively stable, cell surface associated kinase of approximately 180 kDa. In order to study the signal transduction molecules associated with the FLT4 pathway, and in the absence of a known ligand, we constructed two chimeric molecules (FF4S and FF4L) made of the extracellular region of the CSF1 receptor (Fms gene product) and of the transmembrane and intracellular regions of either form of FLT4. These two chimeric forms were expressed in Rat 2 transfectants. We assayed the ligand-induced capacity of the FF4 short and long forms to sustain growth of Rat 2 cells in semisolid medium. In a soft agar assay, only the long form was able to induce the growth of Rat 2 cells upon ligand treatment. The two forms of FLT4 therefore have different functional capacities. We looked for association and/or phosphorylation of phospholipase C gamma (PLC gamma) and phosphatidylinositol-3'-phosphate (PI3K), after stimulation of the FF4 molecules by CSF1. Finally, we have studied the expression of the Flt4 gene in mouse embryos and in the adult by in situ hybridization. Flt4 transcripts were found at day 12.5 post-coitum and thereafter, including the adult mouse, predominantly in the pericardium, pleural membranes and in the lung.	INSERM,U119,ONCOL LAB,F-13009 MARSEILLE,FRANCE; WELLESLEY COLL HOSP,RES INST,TORONTO,ON,CANADA; INSERM,U119,HEMATOL FONCT & MOLEC LAB,F-13009 MARSEILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Institut National de la Sante et de la Recherche Medicale (Inserm)			dubreuil, patrice/F-5346-2011; Dubreuil, Patrice/V-4816-2019; Borg, Jean-Paul/AAX-8096-2020	dubreuil, patrice/0000-0003-1155-1150; Dubreuil, Patrice/0000-0003-1155-1150; Borg, Jean-Paul/0000-0001-8418-3382; Rottapel, Robert/0000-0002-6024-5558; Birnbaum, Daniel/0000-0001-7920-9883				BROWN LF, 1993, AM J PATHOL, V143, P1255; BROWN LF, 1993, CANCER RES, V53, P4727; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CAO Y, 1990, Technique (Philadelphia), V2, P109; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DELAPEYRIERE O, 1993, DEVELOPMENT, V118, P601; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; EICHMANN A, 1993, MECH DEVELOP, V42, P33, DOI 10.1016/0925-4773(93)90096-G; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FINNERTY H, 1993, ONCOGENE, V8, P2293; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GALLAND F, 1993, ONCOGENE, V8, P1233; GALLAND F, 1992, GENOMICS, V13, P475, DOI 10.1016/0888-7543(92)90277-Y; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; IHLE J, 1994, ITBC, V19, P222; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KLAGSBRUN M, 1993, CURR BIOL, V3, P699, DOI 10.1016/0960-9822(93)90073-W; KORHONEN J, 1994, ONCOGENE, V9, P395; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; MAROC N, 1993, ONCOGENE, V8, P909; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1993, NATURE, V367, P576; OELRICHS RB, 1993, ONCOGENE, V8, P11; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PAJUSOLA K, 1993, ONCOGENE, V8, P2931; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PEBUSQUE MJ, 1993, GENE CHROMOSOME CANC, V8, P119, DOI 10.1002/gcc.2870080209; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; ROSNET O, 1993, CRIT REV ONCOGENESIS, V4, P595; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; ROTTAPEL R, 1994, ONCOGENE, V9, P1755; SARZANI R, 1992, BIOCHEM BIOPH RES CO, V186, P706, DOI 10.1016/0006-291X(92)90804-T; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960; SHIBUYA M, 1990, ONCOGENE, V5, P519; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STANTON B, 1989, THESIS U MARYLAND BA; TAYLOR GR, 1989, EMBO J, V8, P2029, DOI 10.1002/j.1460-2075.1989.tb03611.x; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; WILKS AF, 1993, ADV CANCER RES, V60, P43; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489	62	39	53	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					973	984						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898938				2022-12-25	WOS:A1995QL03800019
J	ISHIOKA, C; BALLESTER, R; ENGELSTEIN, M; VIDAL, M; KASSEL, J; THE, I; BERNARDS, A; GUSELLA, JF; FRIEND, SH				ISHIOKA, C; BALLESTER, R; ENGELSTEIN, M; VIDAL, M; KASSEL, J; THE, I; BERNARDS, A; GUSELLA, JF; FRIEND, SH			A FUNCTIONAL ASSAY FOR HETEROZYGOUS MUTATIONS IN THE GTPASE-ACTIVATING PROTEIN RELATED DOMAIN OF THE NEUROFIBROMATOSIS TYPE-1 GENE	ONCOGENE			English	Article						NF1; FUNCTIONAL ASSAY IN YEAST FASAY	GAP-RELATED DOMAIN; SACCHAROMYCES-CEREVISIAE; RAS GTPASE; VONRECKLINGHAUSEN NEUROFIBROMATOSIS; GEL-ELECTROPHORESIS; ADENYLATE-CYCLASE; MAMMALIAN GAP; CDC25 GENE; YEAST; PRODUCT	The GTPase-activating protein related domain of the human neurofibromatosis type 1 protein (NF1GRD) can down-regulate RAS in Saccharomyces cerevisiae, Using a technique termed the FASAY method, for Functional Analysis of Separated Alleles in Yeast, we designed a rapid method for detection of heterozygous NF1GRD loss-of-function mutations, In our method, PCR amplified NF1GRD cDNA is directly cloned into a centromeric vector by homologous recombination in a cdc25 temperature-sensitive mutant strain expressing human Ha-ras. This strain is dependent on the Ha-uas for growth, allowing a simple growth assay for NF1GRD loss-of-function mutations, In a test of our method, two alternatively spliced NF1GRD cDNAs (type I and II) inhibited yeast growth whereas four mutants with amino acid substitutions at highly conserved residues did not, This simple method thus permits the rapid screening for heterozygous germline or somatic NF1GRD mutations, In an initial application of this method, no mutations disrupting NF1GRD function were detected in lymphoblasts from 11 previously untested neurofibromatosis type 1 patients.	MASSACHUSETTS GEN HOSP, MOLEC NEUROGENET UNIT, BOSTON, MA 02129 USA; TOHOKU UNIV, INST DEV AGING & CANC, SENDAI, MIYAGI 980, JAPAN; UNIV CALIF SANTA BARBARA, DEPT BIOL SCI, SANTA BARBARA, CA 93106 USA; HARVARD UNIV, CHILDRENS HOSP,SCH MED,DANA FARBER INST, DEP PEDIAT,DIV HEMATOL ONCOL, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital; Tohoku University; University of California System; University of California Santa Barbara; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School	ISHIOKA, C (corresponding author), MASSACHUSETTS GEN HOSP, CTR CANC, BOSTON, MA 02129 USA.		The, Inge/B-8884-2011		PHS HHS [WS 22224] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSEN LB, 1993, MOL CELL BIOL, V13, P487, DOI 10.1128/MCB.13.1.487; [Anonymous], 1988, ARCH NEUROL-CHICAGO, V45, P575, DOI 10.1097/00005537-199606000-00007; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BERNARDS A, 1992, DNA CELL BIOL, V11, P727, DOI 10.1089/dna.1992.11.727; BORRESEN AL, 1991, P NATL ACAD SCI USA, V88, P8405, DOI 10.1073/pnas.88.19.8405; BOUTELET F, 1985, EMBO J, V4, P2635, DOI 10.1002/j.1460-2075.1985.tb03981.x; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CAMONIS JH, 1986, EMBO J, V5, P375, DOI 10.1002/j.1460-2075.1986.tb04222.x; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; ENG C, 1993, FASEB J, V7, P910, DOI 10.1096/fasebj.7.10.8102106; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GROMPE M, 1993, NAT GENET, V5, P111, DOI 10.1038/ng1093-111; Guthrie C., 1991, GUIDE YEAST GENETICS, V194; GUTMANN DH, 1993, ONCOGENE, V8, P761; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KNUNDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; LUNBERG KS, 1991, GENE, V108, P1; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; NAGAMINE CM, 1989, AM J HUM GENET, V45, P337; NAKAFUKU M, 1993, P NATL ACAD SCI USA, V90, P6706, DOI 10.1073/pnas.90.14.6706; NISHI T, 1991, ONCOGENE, V6, P1555; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; RICCARDI VM, 1981, NEW ENGL J MED, V305, P1617, DOI 10.1056/NEJM198112313052704; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; SHEFFIELD VC, 1991, AM J HUM GENET, V49, P699; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; UPADHYAYA M, 1990, J MED GENET, V27, P738, DOI 10.1136/jmg.27.12.738; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; WANG Y, 1991, CELL REGUL, V2, P453, DOI 10.1091/mbc.2.6.453; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	48	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	1995	10	5					841	847						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898926				2022-12-25	WOS:A1995QL03800005
J	LEPLEY, RA; FITZPATRICK, FA				LEPLEY, RA; FITZPATRICK, FA			5-LIPOXYGENASE CONTAINS A FUNCTIONAL SRC HOMOLOGY-3 BINDING MOTIF THAT INTERACTS WITH THE SRC HOMOLOGY-3 DOMAIN OF GRB2 AND CYTOSKELETAL PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOTRIENE BIOSYNTHESIS INHIBITOR; RECEPTOR TYROSINE KINASES; SH3 DOMAINS; ACTIVE 5-LIPOXYGENASE; MEMBRANE ASSOCIATION; MOLECULAR-CLONING; TRANSLOCATION; LEUKOCYTES; CELLS; ACTIVATION	A short, proline-rich region spanning residues 566-577 in human 5-lipoxygenase is a binding site for the Src homology 3 (SH3) domain of growth factor receptor-bound protein 2 (Grb2), an ''adaptor'' protein for tyrosine kinase-mediated cell signaling. Purified 5-lipoxygenase bound to glutathione S-transferase fusion products of Grb2 and a truncated version of Grb2 containing its SH3 domain. A peptide corresponding to the proline-rich, SH3-binding motif inhibited formation of the 5-lipoxygenase.Grb2 complex in vitro. The peptide also inhibited the redistribution of 5-lipoxygenase from the cytosol to the membrane in intact or permeabilized neutrophils activated by calcium ionophore A23187. 5-Lipoxygenase did not bind to the SH3 domains of other signaling proteins, such as GTPase-activating protein and phosphilipase C gamma however, it bound to certain cytoskeletal proteins including alpha-actinin and actin. 5-Lipoxygenase contains a consensus guanine nucleotide-binding site at residues 296-299, and guanine nucleotides inhibit 5-lipoxygenase activity in vitro. Our results suggest that 5-lipoxygenase may have a previously unrecognized role in tyrosine kinase signaling, distinct from its catalysis of lipid mediator formation. Our results also clarify the molecular basis for compartmentalization and translocation of 5-lipoxygenase in myeloid cells, implying that it binds to proteins other than its activating protein.			LEPLEY, RA (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL C236,4200 E 9TH AVE,DENVER,CO 80262, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026730] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 26730] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BELL RL, 1992, INT J IMMUNOPHARMACO, V14, P505, DOI 10.1016/0192-0561(92)90182-K; BROCK TG, 1994, 9TH INT C PROST REL, P19; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHARLESON S, 1992, MOL PHARMACOL, V41, P873; COFFEY M, 1992, J BIOL CHEM, V267, P570; DENIS D, 1991, J BIOL CHEM, V266, P5072; DIXON RAF, 1988, P NATL ACAD SCI USA, V85, P416, DOI 10.1073/pnas.85.2.416; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FUNK CD, 1990, P NATL ACAD SCI USA, V87, P5638, DOI 10.1073/pnas.87.15.5638; GILLARD J, 1989, CAN J PHYSIOL PHARM, V67, P456, DOI 10.1139/y89-073; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; KARGMAN S, 1992, J CELL BIOL, V119, P1701, DOI 10.1083/jcb.119.6.1701; KARGMAN S, 1991, J BIOL CHEM, V266, P23745; KARGMAN S, 1989, J BIOL CHEM, V264, P13313; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEBART MC, 1994, J BIOL CHEM, V269, P4279; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUMOTO T, 1988, P NATL ACAD SCI USA, V85, P26, DOI 10.1073/pnas.85.1.26; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; OCHI K, 1983, J BIOL CHEM, V258, P5754; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEPPELENBOSCH MP, 1993, CELL, V74, P566; REIF K, 1994, J BIOL CHEM, V269, P14081; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; ROUZER CA, 1990, J BIOL CHEM, V265, P1436; SAMUELSSON B, 1989, J BIOL CHEM, V264, P19469; SCHLESSINGER J, 1992, COLD SPRING HARB SYM, V57, P67, DOI 10.1101/SQB.1992.057.01.009; SIERKE SL, 1993, BIOCHEMISTRY-US, V32, P10102, DOI 10.1021/bi00089a028; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WISEMAN JS, 1989, BIOCHEMISTRY-US, V28, P2106, DOI 10.1021/bi00431a021; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	38	108	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24163	24168						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929073				2022-12-25	WOS:A1994PQ34600051
J	YAMASHIRO, DJ; ADACHI, M; KONITZER, P; SURREY, S; ADACHI, K				YAMASHIRO, DJ; ADACHI, M; KONITZER, P; SURREY, S; ADACHI, K			POLYMERIZATION AND INSTABILITY OF A RECOMBINANT HEMOGLOBIN CONTAINING VALINE BETA-7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID; HB-S; SOLUBILITY; STABILITY; HYDROPHOBICITY; YEAST; KINETICS; GELATION; DISEASE	A recombinant hemoglobin containing Val(beta 7) (Hb beta E7V) was engineered and expressed in yeast to evaluate amino acid specificity of the Glu(beta 6) --> Val mutation (Hb beta E6V) in promoting polymer formation of deoxyhemoglobin. The purified CO Hb beta E7V migrated as a single band on electrophoresis with a slightly decreased positive charge compared with CO Hb S. The oxygen affinity of Hb beta E7V was slightly higher than Hb S, while the absorption spectrum of the mutant was similar to Hb S. Critical concentrations for polymerization in 1.8 M phosphate of the deoxy forms of Hb beta E7V and Hb A were 15- and 25-fold, respectively, higher than Hb S. Oversaturated deoxy Hb beta E7V polymerized without a delay time prior to polymerization like deoxy Hb beta E6F and Hb beta E6W. These results demonstrate that Val(beta 6) in Hb S is critical for rapid polymerization of deoxyhemoglobin. The oxy form of Hb beta E7V was approximately 2-3-fold more unstable to heat and mechanical agitation than oxy Hb S, suggesting that instability and polymerization of hemoglobin are distinct properties,	UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,DIV HEMATOL,PHILADELPHIA,PA 19104	University of Pennsylvania; Childrens Hospital of Philadelphia			Adachi, Megumi/M-7746-2017	Adachi, Megumi/0000-0003-3404-6640	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL038632, R01HL032908] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-32908, P60 HL-38632] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI K, 1993, HEMOGLOBIN, V17, P329, DOI 10.3109/03630269308997486; ADACHI K, 1984, BIOCHIM BIOPHYS ACTA, V790, P132, DOI 10.1016/0167-4838(84)90216-4; ADACHI K, 1993, J BIOL CHEM, V268, P21650; ADACHI K, 1979, J BIOL CHEM, V254, P2273; ADACHI K, 1991, HEMOGLOBIN, V15, P417, DOI 10.3109/03630269108998861; ADACHI K, 1987, J BIOL CHEM, V262, P12920; ADACHI K, 1993, FEBS LETT, V315, P47, DOI 10.1016/0014-5793(93)81130-R; ADACHI K, 1992, PROTEIN ENG, V5, P807, DOI 10.1093/protein/5.8.807; Antonini E., 1971, FRONT BIOL, V21, P19; ASAKURA T, 1974, P NATL ACAD SCI USA, V71, P1594, DOI 10.1073/pnas.71.5.1594; BAUDINCHICH V, 1990, P NATL ACAD SCI USA, V87, P1845, DOI 10.1073/pnas.87.5.1845; BIHOREAU MT, 1992, PROTEIN SCI, V1, P145; BLACKWELL RQ, 1970, BIOCHIM BIOPHYS ACTA, V214, P396; BUNN HF, 1966, HEMOGLOBIN MOL GENET; CUO D, 1986, J CHROMATOGR, V359, P499; DELLANO JJM, 1993, P NATL ACAD SCI USA, V90, P918, DOI 10.1073/pnas.90.3.918; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; HEBBEL RP, 1991, BLOOD, V77, P214; HOFRICHTER J, 1974, P NATL ACAD SCI USA, V71, P4864, DOI 10.1073/pnas.71.12.4864; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; NOZAKI Y, 1971, J BIOL CHEM, V246, P2211; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; RHODA MD, 1986, HEMOGLOBIN, V10, P21, DOI 10.3109/03630268609072468; ROSEMAN MA, 1988, J MOL BIOL, V200, P513, DOI 10.1016/0022-2836(88)90540-2; ROTH EF, 1977, J LAB CLIN MED, V90, P837; WAGENBACH M, 1991, BIO-TECHNOL, V9, P57, DOI 10.1038/nbt0191-57	26	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23996	23999						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929049				2022-12-25	WOS:A1994PQ34600025
J	KUZNETSOV, G; CHEN, LB; NIGAM, SK				KUZNETSOV, G; CHEN, LB; NIGAM, SK			SEVERAL ENDOPLASMIC-RETICULUM STRESS PROTEINS, INCLUDING ERP72, INTERACT WITH THYROGLOBULIN DURING ITS MATURATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE ISOMERASE; BINDING-PROTEINS; CELLS; RAT; BIP; CALCIUM; AGGREGATION; EXPRESSION; GLUCOSE; OCCURS	We have previously demonstrated that several endoplasmic reticulum (ER) proteins, including BiP, ERp72, grp94, and protein disulfide isomerase, bind to a denatured thyroglobulin (Tg) affinity column and can be specifically eluted by ATP (Nigam, S. K., Goldberg, A. L., Ho, S., Rohde, M. F., Bush, K. T., and Sherman, M. Y. (1994) J. Biol. Chem. 269, 1744-1749). Using chemical cross linking, we now demonstrate that BiP, ERp72, and grp94 associate with Tg in two types of cultured thyroid cells, FRTL-5 and PCCl3. Whereas BiP could be coimmunoprecipitated with anti-Tg antibodies in the absence of crosslinking, only trace amounts of ERp72 and grp94 were coimmunoprecipitated. Likewise, in both cell types, anti BiP antibodies were able to coimmunoprecipitate Tg in the absence of cross-linking, though ERp72 and grp94 were only minimally present. Coprecipitation of BiP and Tg was abolished when ATP and Mg2+ were added to cell lysates. In contrast, after cross-linking, there was a large increase in the amount of ERp72 and grp94 that coimmunoprecipitated with anti-Tg antibodies, although there was only a slight increase in BiP. Similarly, in cross-linked lysates, grp94 and ERp72 were also coimmunoprecipitated with anti-BiP antibodies. An apparently novel 200-kDa protein was also consistently immunoprecipitated by anti-BiP antibodies in both cell types. In addition, anti-ERp72 antibodies coimmunoprecipitated Tg, BiP, and grp94 only after cross-linking. Analysis of uncross-linked and cross-linked samples by sucrose density gradient centrifugation confirmed that Tg, BiP, grp94, and ERp72 are present together in high molecular weight complexes only after treatment of cells with cross linking reagent. These results suggest that ERp72, as well as BiP and grp94, function as molecular chaperones in the maturation of Tg, potentially as part of a macromolecular complex.	HARVARD UNIV, BRIGHAM & WOMENS HOSP, DEPT MED, DIV RENAL, BOSTON, MA 02115 USA; DANA FARBER CANC INST, DIV CELLULAR & MOLEC BIOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute					NIGMS NIH HHS [GM38318-07] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038318] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BERLINGIERI MT, 1993, ONCOGENE, V8, P249; CHANG SC, 1989, MOL CELL BIOL, V9, P2153, DOI 10.1128/MCB.9.5.2153; DORNER AJ, 1990, J BIOL CHEM, V265, P22029; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GROLLMAN EF, 1993, J BIOL CHEM, V268, P3604; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; KIM PS, 1991, J BIOL CHEM, V266, P12412; KIM PS, 1993, AM J PHYSIOL, V265, pC704, DOI 10.1152/ajpcell.1993.265.3.C704; KIM PS, 1993, J BIOL CHEM, V268, P4873; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MELNICK J, 1992, J BIOL CHEM, V267, P21303; NG DTW, 1992, MOL BIOL CELL, V3, P143, DOI 10.1091/mbc.3.2.143; NIGAM SK, 1990, J CELL BIOL, V111, P197, DOI 10.1083/jcb.111.1.197; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; NIGAM SK, 1989, J BIOL CHEM, V264, P16927; PELHAM HRB, 1989, EMBO J, V8, P3171, DOI 10.1002/j.1460-2075.1989.tb08475.x; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; URADE R, 1993, J BIOL CHEM, V268, P22004; VAN PN, 1989, J BIOL CHEM, V264, P17494; VAN PN, 1993, EUR J BIOCHEM, V213, P789, DOI 10.1111/j.1432-1033.1993.tb17821.x; WAGAR G, 1974, ACTA ENDOCRINOL-COP, V77, P64, DOI 10.1530/acta.0.0770064	28	95	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					22990	22995						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	7916014				2022-12-25	WOS:A1994PQ16400016
J	CALDENHOVEN, E; COFFER, P; YUAN, JP; VANDESTOLPE, A; HORN, F; KRUIJER, W; VANDERSAAG, PT				CALDENHOVEN, E; COFFER, P; YUAN, JP; VANDESTOLPE, A; HORN, F; KRUIJER, W; VANDERSAAG, PT			STIMULATION OF THE HUMAN INTERCELLULAR-ADHESION MOLECULE-1 PROMOTER BY INTERLEUKIN-6 AND INTERFERON-GAMMA INVOLVES BINDING OF DISTINCT FACTORS TO A PALINDROMIC RESPONSE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ALPHA-2-MACROGLOBULIN GENE; SIGNAL-TRANSDUCTION PATHWAY; LEUKEMIA INHIBITORY FACTOR; HUMAN ENDOTHELIAL-CELLS; REGULATORY FACTOR-I; TYROSINE PHOSPHORYLATION; TRANSCRIPTIONAL ACTIVATOR; NUCLEAR FACTOR; IFN-GAMMA; MYELOID DIFFERENTIATION	Intercellular adhesion molecule-1 (ICAM-1) is a transmembrane glycoprotein that promotes adhesion in immunological and inflammatory reactions. ICAM-1 is expressed on cells of many lineages and is induced by interleukin-6 (IL-6) and interferon-gamma (IFN-gamma). Functional analysis of ICAM-1 promoter-luciferase constructs in HepG2 cells enabled us to identify a region between -110 and -37 mediating IL-6 and IFN-gamma responsiveness and containing a palindromic IL-6/IFN-gamma response element (pIRE). Site-directed mutagenesis of key nucleotides in the ICAM-1 pIRE abolished the effect of both IL-6 and IFN-gamma stimulation, while this pIRE element was sufficient to confer IL-6 and IFN-gamma responsiveness to a heterologous promoter. We further show by gel retardation analysis that distinct nuclear factors induced by both IL-6 or IFN-gamma specifically bind to this pIRE. Furthermore, treatment with IL-6 results in the formation of multiple complexes while IFN-gamma induces a single binding complex, both in HepG2 and monocytic U937 cells. Differentiation of U937 cells by exposure to 12-O-tetradecanoyl phorbol-13-acetate abolishes response to IL-6 but not IFN-gamma. Supershift data utilizing the ICAM-1 pIRE revealed that IFN-gamma and IL-6 both induce a factor antigenically related to IFN-gamma activation factor. me further provide data suggesting that IL-6 additionally activates an ICAM-1 pIRE binding factor related to the previously described acute-phase response factor in disparate cell types. We therefore conclude that the activation of these related nuclear factors by IL-6 and IFN-gamma is important in the regulation of ICAM-1 gene expression.	NETHERLANDS INST DEV BIOL,HUBRECHT LAB,3584 CT UTRECHT,NETHERLANDS; INST BIOCHEM,D-52057 AACHEN,GERMANY; UNIV UTRECHT HOSP,DEPT PULM DIS,UTRECHT,NETHERLANDS	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; Utrecht University Medical Center			Coffer, Paul/AAF-7970-2020; Coffer, Paul J/A-5769-2009					ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; ADAMS DO, 1989, IMMUNOL TODAY, V10, P33, DOI 10.1016/0167-5699(89)90298-3; AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AMALDI I, 1989, J IMMUNOL, V142, P999; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BLANAR MA, 1989, EMBO J, V8, P1139, DOI 10.1002/j.1460-2075.1989.tb03484.x; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BRECHNER T, 1991, MOL BIOL MED, V8, P267; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DEGITZ K, 1991, J BIOL CHEM, V266, P14024; Demaeyer E., 1988, INTERFERONS OTHER RE; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DUITS AJ, 1992, J LEUKOCYTE BIOL, V51, P237, DOI 10.1002/jlb.51.3.237; DUSTIN ML, 1986, J IMMUNOL, V137, P245; EILERS A, 1993, MOL CELL BIOL, V13, P3245, DOI 10.1128/MCB.13.6.3245; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GRAHAM FL, 1973, MOL CELL BIOL, V2, P607; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; ITO T, 1989, NUCLEIC ACIDS RES, V17, P9425, DOI 10.1093/nar/17.22.9425; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KISHIMOTO T, 1988, ANNU REV IMMUNOL, V6, P485, DOI 10.1146/annurev.iy.06.040188.002413; KRESS C, 1990, DEVELOPMENT, V109, P775; KVALE D, 1993, J HEPATOL, V17, P347, DOI 10.1016/S0168-8278(05)80216-8; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LOOK DC, 1992, AM J PHYSIOL, V263, pL79, DOI 10.1152/ajplung.1992.263.1.L79; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; MIYAURA C, 1988, FEBS LETT, V234, P17, DOI 10.1016/0014-5793(88)81293-6; MOST J, 1992, J IMMUNOL, V148, P1635; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; MYERS CL, 1992, AM J PHYSIOL, V263, pC767, DOI 10.1152/ajpcell.1992.263.4.C767; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; ROTHLEIN R, 1988, J IMMUNOL, V141, P1665; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SHEN S, 1993, MECH DEVELOP, V40, P177, DOI 10.1016/0925-4773(93)90075-9; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STADE BG, 1990, IMMUNOBIOLOGY, V182, P79, DOI 10.1016/S0171-2985(11)80585-1; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; VANDESTOLPE A, 1993, AM J RESP CELL MOL, V8, P340, DOI 10.1165/ajrcmb/8.3.340; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WERTHEIMER SJ, 1992, J BIOL CHEM, V267, P12030; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546	70	121	122	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21146	21154						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	7914891				2022-12-25	WOS:A1994PC40300052
J	BIBI, E; BEJA, O				BIBI, E; BEJA, O			MEMBRANE TOPOLOGY OF MULTIDRUG-RESISTANCE PROTEIN EXPRESSED IN ESCHERICHIA-COLI - N-TERMINAL DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P-GLYCOPROTEIN; ALKALINE-PHOSPHATASE; GENE FUSIONS; BACTERIAL TRANSPORT; STRUCTURAL MODEL; EXPORT SIGNALS; MOUSE MDR1; SEQUENCE; CDNA; ORIENTATION	Expression of eukaryotic polytopic membrane proteins in Escherichia coli could provide an invaluable system for structure-function studies. Recently, the functional expression of a mouse multidrug resistance protein (Mdr1) in E. coli was described (Bibi, E., Gros, P., and Kaback, H. R. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 9209-9213). In the present study, the phoA gene fusion approach has been utilized to determine the membrane topology of the N-terminal domain of Mdr. The results support the idea that the N-terminal half of Mdr contains six transmembrane helices (TMs). However, our observations suggest that the previously proposed TM4 (amino acid residues Thr(214)-Ala(232)) is located at the periplasmic face of the membrane. Alternatively, we propose that another stretch of amino acid residues (Leu(243) (out) to Ile(260) (in)) traverses the membrane. This assignment is indicated also by the following observations: 1) deletion of a segment containing the originally predicted TM4 (Delta T214-K241) does not reverse the orientation of the Mdr-alkaline phosphatase hybrid that is located in the following cytoplasmic loop; 2) a ''sandwich'' chimera, in which alkaline phosphatase is inserted in-frame between amino acid residues Leu(226) and Ser(227), exhibits high alkaline phosphatase activity. The existence of an externally exposed hydrophobic domain in Mdr may have special structural and functional implications, and these may also be relevant to other members of the ABC superfamily.			BIBI, E (corresponding author), WEIZMANN INST SCI, DEPT BIOCHEM, IL-76100 REHOVOT, ISRAEL.			Bibi, Eitan/0000-0003-3700-2707				ALLARD JD, 1992, J BIOL CHEM, V267, P17809; BIBI E, 1991, P NATL ACAD SCI USA, V88, P7271, DOI 10.1073/pnas.88.16.7271; BIBI E, 1993, P NATL ACAD SCI USA, V90, P9209, DOI 10.1073/pnas.90.19.9209; BOSCOBOINIK D, 1990, BIOCHIM BIOPHYS ACTA, V1027, P225, DOI 10.1016/0005-2736(90)90311-B; BOYD D, 1993, J BACTERIOL, V175, P553, DOI 10.1128/JB.175.2.553-556.1993; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; CALAMIA J, 1992, J MOL BIOL, V224, P539, DOI 10.1016/0022-2836(92)90542-R; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; EHRMANN M, 1990, P NATL ACAD SCI USA, V87, P7574, DOI 10.1073/pnas.87.19.7574; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GEORGES E, 1993, J BIOL CHEM, V268, P1792; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; Gros P, 1993, Int Rev Cytol, V137C, P169; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANAVALAN P, 1993, J PROTEIN CHEM, V12, P279, DOI 10.1007/BF01028190; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MANOIL C, 1991, METHOD CELL BIOL, V34, P61; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; SAFA AR, 1986, J BIOL CHEM, V261, P6137; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SCHINKEL AH, 1993, J BIOL CHEM, V268, P7474; SCHURR E, 1989, CANCER RES, V49, P2729; SKACH WR, 1993, J BIOL CHEM, V268, P23552; SKACH WR, 1993, J BIOL CHEM, V268, P6903; TRAXLER B, 1993, J MEMBRANE BIOL, V132, P1; YOSHIMURA A, 1989, J BIOL CHEM, V264, P16282; YUN CH, 1991, J BIOL CHEM, V266, P10967; ZHANG JT, 1991, J BIOL CHEM, V266, P18224; ZHANG JT, 1993, J BIOL CHEM, V268, P15101	36	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19910	19915						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	7914193				2022-12-25	WOS:A1994PA12600040
J	FISHER, MT				FISHER, MT			THE EFFECT OF GROES ON THE GROEL-DEPENDENT ASSEMBLY OF DODECAMERIC GLUTAMINE-SYNTHETASE IN THE PRESENCE OF ATP AND ADP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; TIME-RESOLVED FLUORESCENCE; ESCHERICHIA-COLI; MOLECULAR CHAPERONE; PROTEIN; STATE; INTERMEDIATE; COMPLEXES; PLANT; MODEL	The yields of active dodecameric glutamine synthetase (GS) are significantly increased when in vitro folding is initiated in the presence of the Escherichia coli groE chaperonins and ATP (37 degrees C). To observe the effects of chaperonins and ATP on GS assembly, the GS assembly intermediates were separated by nondenaturing gel electrophoresis, visualized by Western analysis, and studied as a function of time. The form of GS that was initially released from groEL is monomeric, After the monomers formed dimers, active GS oligomers were assembled by the association of assembly competent dimers with higher order even-numbered oligomers until the dodecamer was formed, When ATP was added to the groEL GS complex (no groES), a groEL GS complex remained visible for up to 30 min after the renaturation was initiated. This slow disappearance of the groEL.GS complex is consistent with observed lags in both the GS activity regain profile and the assembly-dependent increase in GS tryptophan fluorescence. When groES was present, the addition of ATP resulted in the disappearance of observable complex at early sample times (<2 min). Concomitantly, the rates of the regain of GS activity and the GS-dependent increase in tryptophan fluorescence intensity showed substantial accelerations. These results indicate that groES facilitates GS assembly from groEL by inducing the rapid release of GS from groEL, which in turn increases the concentration of assembly competent GS monomers. In addition, groES can initiate renaturation of GS from the groEL.GS arrested complex in the presence of ADP. When chaperonin-dependent GS renaturation was initiated with ATP or ADP (greater than or equal to 2 mM), the rates were identical. Since ATP hydrolysis is not absolutely required, the combined binding energies of groES and ATP (or ADP) appear to be sufficient to weaken the binding affinity of groEL for GS subunits and facilitate the release and refolding of assembly competent GS monomers from groEL.			FISHER, MT (corresponding author), UNIV KANSAS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, KANSAS CITY, KS 66160 USA.				NCRR NIH HHS [S07RR05373] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005373] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AGARD DA, 1993, SCIENCE, V260, P1903, DOI 10.1126/science.8100365; ATKINS WM, 1991, BIOCHEMISTRY-US, V30, P3406, DOI 10.1021/bi00228a008; ATKINS WM, 1992, PROTEIN SCI, V1, P342; BACKMAN K, 1981, P NATL ACAD SCI-BIOL, V78, P3743, DOI 10.1073/pnas.78.6.3743; BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CARRILLO N, 1992, J BIOL CHEM, V267, P15537; DEMCHENKO AP, 1986, ULTRAVIOLET SPECTROS, P122; FISHER MT, 1992, J BIOL CHEM, V267, P1872; FISHER MT, 1993, J BIOL CHEM, V268, P13777; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; FONG GH, 1992, BIOCHEMISTRY-US, V31, P5661, DOI 10.1021/bi00139a033; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GRAY TE, 1993, J MOL BIOL, V232, P1197, DOI 10.1006/jmbi.1993.1471; HAMMARBACK JA, 1990, J BIOL CHEM, V265, P12763; HASCHEMEYER RH, 1982, J BIOL CHEM, V257, P7252; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HOHMAN RJ, 1978, BIOCHEM BIOPH RES CO, V82, P865, DOI 10.1016/0006-291X(78)90863-X; HOLMGREN A, 1992, EMBO J, V11, P1617, DOI 10.1002/j.1460-2075.1992.tb05207.x; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Hurn B A, 1980, Methods Enzymol, V70, P104; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KING J, 1973, J MOL BIOL, V80, P697, DOI 10.1016/0022-2836(73)90205-2; KUBO T, 1993, J BIOL CHEM, V268, P19346; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P23; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LUBBEN TH, 1989, PLANT CELL, V1, P1223, DOI 10.1105/tpc.1.12.1223; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MATTINGLY JR, 1993, J BIOL CHEM, V268, P26320; MATTINGLY JR, 1993, PROT SCI S1, V2, P139; MAURIZI MR, 1982, J BIOL CHEM, V257, P7246; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MILLER AD, 1993, BIOCHEM J, V291, P139, DOI 10.1042/bj2910139; MIZOBATA T, 1992, J BIOL CHEM, V267, P17773; RAGONE R, 1984, BIOCHEMISTRY-US, V26, P2130; ROY H, 1992, PROTEIN SCI, V1, P925, DOI 10.1002/pro.5560010711; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SATHER S, 1991, COLD SPRING HARB SYM, V19, P84; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; Shapiro B., 1970, METHOD ENZYMOL, V17A, P910, DOI 10.1016/0076-6879(71)17305-3; STADTMAN ER, 1979, ANAL BIOCHEM, V95, P275, DOI 10.1016/0003-2697(79)90217-3; TIMMONS RB, 1974, BIOCHEMISTRY-US, V13, P4479, DOI 10.1021/bi00719a002; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; TSALKOVA T, 1993, BIOCHEMISTRY-US, V32, P3377, DOI 10.1021/bi00064a022; VANDERVIES SM, 1992, BIOCHEMISTRY-US, V31, P3635, DOI 10.1021/bi00129a012; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WANG Z, 1992, PROTEIN SCI, V1, P522; WYNN RM, 1992, J BIOL CHEM, V267, P12400; YAMASHITA MM, 1989, J BIOL CHEM, V264, P17681; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	56	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13629	13636						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	7909810				2022-12-25	WOS:A1994NK18400083
J	MELLOR, H; FLOWERS, KM; KIMBALL, SR; JEFFERSON, LS				MELLOR, H; FLOWERS, KM; KIMBALL, SR; JEFFERSON, LS			CLONING AND CHARACTERIZATION OF CDNA-ENCODING RAT HEMIN-SENSITIVE INITIATION FACTOR-2-ALPHA (EIF-2-ALPHA) KINASE - EVIDENCE FOR MULTITISSUE EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GCN2 PROTEIN-KINASE; MOLECULAR-CLONING; P68 KINASE; FACTOR-II; INTERFERON; DOMAINS; RETICULOCYTES; ANTIBODIES; MECHANISM; HOMOLOGY	Reticulocytes contain an eukaryotic initiation factor-2 alpha (eIF-2 alpha) kinase that is negatively regulated by hemin. This protein kinase, which has been termed heme-regulated inhibitor and heme-controlled repressor (HCR), has a strong inhibitory effect on the initiation of protein synthesis and plays:an important role in translational control in these cells. Previous evidence has suggested that HCR may be an erythroid-specific enzyme. As reported herein, we have cloned and characterized the cDNA encoding an eIF-2 alpha kinase from rat brain. The predicted amino acid sequence of the kinase from rat brain shows 82% homology to rabbit reticulocyte HCR with the greatest variation concentrated in a central region of approximately 135 amino acids located between protein kinase subdomains IV and VI. We have expressed the rat brain cDNA in Escherichia coli and have demonstrated that the recombinant enzyme is a hemin-sensitive eIF-2 alpha kinase. We have also shown that mRNA recognized by the rat brain cDNA is expressed in a wide range of non-erythroid rat tissues at a lower but significant level compared with reticulocytes. These findings raise the possibility of additional, uncharacterized roles for HCR in non erythroid cells.	PENN STATE UNIV,COLL MED,DEPT CELLULAR & MOLEC PHYSIOL,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health				Mellor, Harry/0000-0003-3894-0623	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015658, R01DK013499, T32DK007684, R37DK013499] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK15658, DK13499, DK07684] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CHEN JJ, 1993, TRANSLATIONAL REGULA, V2, P349; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; CLEMENS MJ, 1974, P NATL ACAD SCI USA, V71, P2946, DOI 10.1073/pnas.71.8.2946; DUNCANR, 1984, J BIOL CHEM, V259, P11882; FENG GS, 1992, P NATL ACAD SCI USA, V89, P5447, DOI 10.1073/pnas.89.12.5447; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERSHEY JWB, 1993, CELL BIOL BIOTECHNOL, P93; ICELY PL, 1991, J BIOL CHEM, V266, P16073; MATTS RL, 1992, J BIOL CHEM, V267, P18160; MATTS RL, 1989, J BIOL CHEM, V264, P15542; MATTS RL, 1993, BIOCHEMISTRY-US, V32, P7323, DOI 10.1021/bi00080a001; MELLOR H, 1993, EUR J BIOCHEM, V211, P529, DOI 10.1111/j.1432-1033.1993.tb17579.x; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; PAL JK, 1991, BIOCHEMISTRY-US, V30, P2555, DOI 10.1021/bi00223a037; PORZIG H, 1991, J CELL PHYSIOL, V147, P439, DOI 10.1002/jcp.1041470309; PRICE NT, 1989, BIOCHIM BIOPHYS ACTA, V1008, P177, DOI 10.1016/0167-4781(80)90005-6; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; ROUSSOU I, 1988, MOL CELL BIOL, V8, P2132, DOI 10.1128/MCB.8.5.2132; SATOH H, 1987, BIOCHEM BIOPH RES CO, V146, P618, DOI 10.1016/0006-291X(87)90573-0; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; THOMIS DC, 1992, VIROLOGY, V188, P33, DOI 10.1016/0042-6822(92)90732-5; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579	24	61	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10201	10204						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7908290				2022-12-25	WOS:A1994NF01700005
J	KOLLMAR, R; SUKOW, KA; SPONAGLE, SK; FARNHAM, PJ				KOLLMAR, R; SUKOW, KA; SPONAGLE, SK; FARNHAM, PJ			START SITE SELECTION AT THE TATA-LESS CARBAMOYL-PHOSPHATE SYNTHASE (GLUTAMINE-HYDROLYZING) ASPARTATE CARBAMOYLTRANSFERASE DIHYDROOROTASE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR; PROXIMAL PROMOTER; SP1 ACTIVATION; CAD GENE; SEQUENCES; IDENTIFICATION; ORGANIZATION; INITIATION; COMPLEXES	Transcription of the carbamoyl-phosphate synthase (glutamine-hydrolyzing)/aspartate carbamoyltransferase/dihydroorotase (CAD) gene from the Syrian hamster, Mesocricetus auratus, starts at a single major site. We characterized the cis-acting elements that position RNA polymerase II at the correct start site in the CAD promoter. Sequence alignment showed that the CAD promoter lacks a TATA box, but contains a consensus initiator. Mutational analysis of the CAD promoter demonstrated that the sequences between -81 and +26 were sufficient for accurate and efficient transcription in vitro and in vivo; binding sites for the transcription factor Spl around -70 and -49 were necessary for transcriptional activity. The binding site at -49 directed initiation about 50 base pairs downstream. A ubiquitous activator protein, Honk, bound to the CAD promoter between -30 and -12, but did not participate in start site selection. The sequences around +1, which contain the consensus initiator, contributed to promoter activity; however, the presence of a consensus initiator in this region was neither necessary nor sufficient for transcription. We concluded from these results that the Spl binding site at -49 substituted for the missing TATA box and played a major role in start site selection at the CAD promoter.	UNIV WISCONSIN,MCARDLE LAB CANC RES,1400 UNIV AVE,MADISON,WI 53706; UNIV WISCONSIN,PROGRAM CELL & MOLEC BIOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison				Farnham, Peggy/0000-0003-4469-7914	NATIONAL CANCER INSTITUTE [P30CA007175, P01CA023076] Funding Source: NIH RePORTER; NCI NIH HHS [CA07175, CA23076] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEIN K, 1991, J BIOL CHEM, V266, P3791; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Evans D.R., 1986, MULTIDOMAIN PROTEINS, P283; FARNHAM PJ, 1990, CELL GROWTH DIFFER, V1, P179; FARNHAM PJ, 1991, GENE EXPRESSION, V1, P137; FREUND JN, 1986, J MOL BIOL, V189, P25, DOI 10.1016/0022-2836(86)90378-5; GHOSH D, 1992, NUCLEIC ACIDS RES, V20, P2091, DOI 10.1093/nar/20.suppl.2091; GILMAN M, 1987, CURRENT PROTOCOLS MO; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; KOLLMAR R, 1993, P SOC EXP BIOL MED, V203, P127; KOLLMAR R, 1992, J BIOL CHEM, V267, P385; KOLLMAR RJE, 1993, THESIS U WISCONSIN M; LEE KAW, 1992, J CELL SCI, V103, P9; LESCURE A, 1992, NUCLEIC ACIDS RES, V20, P1573, DOI 10.1093/nar/20.7.1573; MARK WH, 1981, THESIS U WISCONSIN M; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; RAYCHAUDHURI P, 1987, EMBO J, V6, P4073, DOI 10.1002/j.1460-2075.1987.tb02753.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHATT MD, 1990, EMBO J, V9, P481, DOI 10.1002/j.1460-2075.1990.tb08134.x; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SMALE ST, 1985, MOL CELL BIOL, V5, P352, DOI 10.1128/MCB.5.2.352; SOUCIET JL, 1989, GENE, V79, P59, DOI 10.1016/0378-1119(89)90092-9; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WIELAND S, 1990, NUCLEIC ACIDS RES, V18, P5113, DOI 10.1093/nar/18.17.5113	27	77	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2252	2257						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	7905000				2022-12-25	WOS:A1994MR98800104
J	MONFARDINI, C; KIEBEREMMONS, T; VONFELDT, JM; OMALLEY, B; ROSENBAUM, H; GODILLOT, AP; KAUSHANSKY, K; BROWN, CB; VOET, D; MCCALLUS, DE; WEINER, DB; WILLIAMS, WV				MONFARDINI, C; KIEBEREMMONS, T; VONFELDT, JM; OMALLEY, B; ROSENBAUM, H; GODILLOT, AP; KAUSHANSKY, K; BROWN, CB; VOET, D; MCCALLUS, DE; WEINER, DB; WILLIAMS, WV			RECOMBINANT ANTIBODIES IN BIOACTIVE PEPTIDE DESIGN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; HUMAN-IMMUNODEFICIENCY-VIRUS; CELL-SURFACE RECEPTOR; GM-CSF RECEPTOR; MONOCLONAL-ANTIBODIES; COMBINATORIAL LIBRARY; AFFINITY BINDING; GRANULOCYTE; IDENTIFICATION; REGIONS	Granulocyte-macrophage colony-stimulating factor (GM-CSF) is important in many immune and inflammatory processes. GM-CSF binds to specific cellular receptors which belong to a recently described supergene family, These receptors are potential targets for pharmacologic design, and such design depends on a molecular understanding of ligand-receptor interactions, One approach to dissecting out critical intermolecular interactions is to develop analogs of specific interaction sites of potential importance, Monoclonal antibodies have been employed for these purposes in prior studies, Here we present application of recombinant antibody technology to the development of analogs of a site on GM-CSF bound by a neutralizing anti-GM-CSF monoclonal antibody, Polyclonal antisera with high titer neutralizing activity against human GM-CSF were developed in BALB/c mice, purified immunoglobulins were prepared and used to immunize syngeneic mice, Anti-anti-GM-CSF was developed which demonstrated biological antagonist activity against GM-CSF-dependent cellular proliferation, RNA was extracted from spleen cells of mice with biologically active anti-anti-GM-CSF, cDNA synthesized, and polymerase chain reaction performed with primers specific for murine kappa light chain V regions, Polymerase chain reaction products were cloned into the pDAB(L) vector and an expression library developed, This was screened with anti GM-CSF neutralizing mAb 126.213, and several binding clones isolated, One clone (23.2) which inhibited 126.213 binding to GM CSF was sequenced revealing a murine kappa light chain of subgroup III, Comparison of the 23.2 sequence with the human GM-CSF sequence revealed only weak sequence similarity of specific complementarity determining regions (CDRs) with human GM-CSF, Structural analysis revealed potential mimicry of specific amino acids in the CDR I, CDR II and FR3 regions of 23.2 with residues on the B and C helices of GM-CSF. A synthetic peptide analog of the CDR I was bound by 126.213, specifically antagonized GM-CSF binding to cells and blocked GM-CSF bioactivity, These studies indicate the feasibility of using recombinant antibody libraries as sources of interaction site analogs.	UNIV PENN,SCH MED,INST BIOTECHNOL & ADV MOLEC MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; UNIV PENN,DEPT CHEM,PHILADELPHIA,PA 19104; UNIV PENN,CHILDRENS HOSP PHILADELPHIA,PHILADELPHIA,PA 19104; UNIV WASHINGTON,DIV HEMATOL,SEATTLE,WA 98195; UNIV CALGARY,HLTH SCI CTR,CALGARY,AB T2N 4N1,CANADA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Washington; University of Washington Seattle; University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba	MONFARDINI, C (corresponding author), UNIV PENN,SCH MED,DEPT MED,DIV RHEUMATOL,PHILADELPHIA,PA 19104, USA.		Weiner, David B/H-8579-2014		NCI NIH HHS [R01 CA 31615] Funding Source: Medline; NIGMS NIH HHS [GM-46400] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046400] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN SW, 1991, J BIOL CHEM, V266, P5333; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BALAJI VN, 1992, BIOL ACTIVE PEPTIDES, V1, P35; BARBAS CF, 1992, P NATL ACAD SCI USA, V89, P4457, DOI 10.1073/pnas.89.10.4457; BARBAS CF, 1992, P NATL ACAD SCI USA, V89, P10164, DOI 10.1073/pnas.89.21.10164; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BOROFSKY MA, 1992, IMMUNOL RES, V11, P154, DOI 10.1007/BF02918620; BROWN CB, 1990, J IMMUNOL, V144, P2184; BRUCK C, 1986, P NATL ACAD SCI USA, V83, P6578, DOI 10.1073/pnas.83.17.6578; BURTON DR, 1991, P NATL ACAD SCI USA, V88, P10134, DOI 10.1073/pnas.88.22.10134; CANNISTRA SA, 1990, P NATL ACAD SCI USA, V87, P93, DOI 10.1073/pnas.87.1.93; CARDWELL MC, 1988, J CELL BIOL, V107, P1551, DOI 10.1083/jcb.107.4.1551; CHIBA S, 1990, LEUKEMIA, V4, P29; CLARKLEWIS I, 1988, J IMMUNOL, V141, P881; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; DIPERSIO J, 1988, J BIOL CHEM, V263, P1834; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOUGH NM, 1987, EUR J BIOCHEM, V169, P353, DOI 10.1111/j.1432-1033.1987.tb13619.x; GRAF J, 1987, BIOCHEMISTRY-US, V26, P6896, DOI 10.1021/bi00396a004; GREENFIELD RS, 1993, J IMMUNOL, V150, P5241; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; Kabat EA, 1991, SEQUENCES PROTEINS I; KANAKURA Y, 1991, BLOOD, V77, P1033; KARP SL, 1983, J IMMUNOL, V150, P867; KAUSHANSKY K, 1989, P NATL ACAD SCI USA, V86, P1213, DOI 10.1073/pnas.86.4.1213; KIEBEREMMONS T, 1994, LUPUS, V3, P379, DOI 10.1177/096120339400300504; KIEBEREMMONS T, 1992, BIOL ACTIVE PEPTIDES, V1, P3; KLEINMAN HK, 1989, ARCH BIOCHEM BIOPHYS, V272, P39, DOI 10.1016/0003-9861(89)90192-6; LEVI M, 1993, P NATL ACAD SCI USA, V90, P4374, DOI 10.1073/pnas.90.10.4374; LOHMAN KL, 1993, MOL IMMUNOL, V30, P1295, DOI 10.1016/0161-5890(93)90046-E; LOPEZ AF, 1992, EMBO J, V11, P909, DOI 10.1002/j.1460-2075.1992.tb05129.x; MCCALLUS DE, 1992, VIRAL IMMUNOL, V5, P163, DOI 10.1089/vim.1992.5.163; MIELE L, 1988, NATURE, V335, P726, DOI 10.1038/335726a0; Nice E, 1990, GROWTH FACTORS, V3, P159, DOI 10.3109/08977199009108278; ONETTOPOTHIER N, 1990, BLOOD, V75, P59; PARK LS, 1986, J BIOL CHEM, V261, P4177; PRIDE MW, 1992, P NATL ACAD SCI USA, V89, P1190; ROMANO C, 1989, J NEUROCHEM, V53, P362, DOI 10.1111/j.1471-4159.1989.tb07343.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHIFFER M, 1973, BIOCHEMISTRY-US, V12, P4620, DOI 10.1021/bi00747a013; SEELIG G, 1990, J CELL BIOCHEM, V14, P246; SHANAFELT AB, 1992, J BIOL CHEM, V267, P25466; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; SHANAFELT AB, 1989, P NATL ACAD SCI USA, V86, P4872, DOI 10.1073/pnas.86.13.4872; TAUB R, 1989, J BIOL CHEM, V264, P259; TAUB R, 1992, J BIOL CHEM, V267, P5977; UGEN KE, 1993, VACCINES93 : MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P215; UGEN KE, 1992, J CLIN INVEST, V89, P1923, DOI 10.1172/JCI115798; VONFELDT JM, 1992, BIOL ACTIVE PEPTIDES, V1, P55; WANG H, 1932, BIOTECHNIQUES, V13, P527; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0; WEIGERT M, 1978, NATURE, V276, P785, DOI 10.1038/276785a0; WEINER D, 1989, NATURE, V389, P230; WEINER DB, 1989, ONCOGENE, V4, P1175; WILLIAMS WV, 1988, P NATL ACAD SCI USA, V85, P6488, DOI 10.1073/pnas.85.17.6488; WILLIAMS WV, 1991, J BIOL CHEM, V266, P9241; WILLIAMS WV, 1991, J BIOL CHEM, V266, P5182; WILLIAMS WV, 1994, ARTHRITIS RHEUM, V37, P1468, DOI 10.1002/art.1780371010; WILLIAMS WV, 1989, P NATL ACAD SCI USA, V86, P5537, DOI 10.1073/pnas.86.14.5537; WILLIAMS WV, 1993, TRANSGENE, V1, P113; YOKOTA T, 1993, LEUKEMIA, V7, pS102	65	19	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6628	6638		10.1074/jbc.270.12.6628	http://dx.doi.org/10.1074/jbc.270.12.6628			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896802	hybrid			2022-12-25	WOS:A1995QQ85500033
J	ARORA, PD; MA, J; MIN, WX; CRUZ, T; MCCULLOCH, CAG				ARORA, PD; MA, J; MIN, WX; CRUZ, T; MCCULLOCH, CAG			INTERLEUKIN-1-INDUCED CALCIUM FLUX IN HUMAN FIBROBLASTS IS MEDIATED THROUGH FOCAL ADHESIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GINGIVAL CREVICULAR FLUID; IL-1 RECEPTOR; SIGNAL TRANSDUCTION; HIGH-AFFINITY; EXTRACELLULAR-MATRIX; TYROSINE PHOSPHORYLATION; ARTICULAR CHONDROCYTES; RAPID PHOSPHORYLATION; INTRACELLULAR CALCIUM	Interleukin-1 (IL-1) is an important mediator of inflammation and also modulates fibroblast metabolism. To assess mechanisms of IL-1-induced signal transduction and calcium flux, early passage human fibroblasts were loaded with fura2/AM. Cells grown on coverslips exhibited dose-dependent [Ca2+](i) responses that were maximal at 10(-8) M IL-1 beta with time to maximum flux of 50 s. Cells incubated with anti-Type 1-IL-1 receptor antibody exhibited a 45 nM increase in [Ca2+](i) above baseline but demonstrated no calcium response after IL-1 beta treatment. Incubation with EGTA (5 mM) or thapsigargin (1 mu M) caused 75% and 37% reductions, respectively, in the IL-1-induced [Ca2+](i) increase, suggesting that extracellular Ca2+ predominates in IL-1-stimulated calcium flux. Cells in suspension did not exhibit [Ca2+](i) responses to IL-1 beta. The relationship between [Ca2+](i) signaling and focal adhesions was examined by plating cells on fibronectin or poly-L-lysine, conditions that either permitted or blocked the formation of focal adhesions. Cells on fibronectin exhibited co-distribution of immunostaining for talin, vinculin, IL-1 receptor, and focal adhesion kinase (pp125(fak)) in focal adhesions and demonstrated [Ca2+](i) responses with 10(-8) M IL-1 beta. Cells on poly-L-lysine or cells in suspension did not exhibit co-distribution of pp125(fak), IL-1 receptor, and focal adhesion proteins and did not exhibit calcium flux. The dependence of IL-1-stimulated [Ca2+](i) responses on tyrosine kinases was examined first by treating cells with genistein, a selective inhibitor of tyrosine kinases. Genistein (100 mu M) completely blocked [Ca2+](i) responses to 10(-8) M IL-1, whereas its inactive analogue genistin was not inhibitory. Second, fibroblast lysates were immunoprecipitated with an antiphosphotyrosine antibody and the lysates were Western-blotted with an anti-pp125(fak) antibody. Cells grown on fibronectin and stimulated with IL-1 exhibited tyrosine phosphorylation of pp125(fak) whereas untreated cells or cells grown on poly-L-lysine and treated with IL-1 showed no reaction. Fibroblasts electroinjected with anti-pp125(fak) monoclonal antibody showed no [Ca2+](i) response, whereas cells treated with an irrelevant antibody exhibited a normal [Ca2+](i) response. Collectively, these data indicate that fibroblasts require substrate attachment and clustering of IL-1 receptors to focal adhesions for IL-1-induced [Ca2+](i) responses. Calcium fluxes are mediated through tyrosine kinases whose substrates include pp125(fak). These studies therefore demonstrate that activation of intracellular signaling pathways by IL-1 is dependent on IL-1 receptor-cytoskeletal protein interactions.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1X5,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	ARORA, PD (corresponding author), UNIV TORONTO,FAC DENT,MRC,PERIODONTAL PHYSIOL GRP,124 EDWARD ST,TORONTO,ON M5S 1A8,CANADA.							ABRAHAM RT, 1987, J BIOL CHEM, V262, P2719; ARORA PD, 1994, J CELL PHYSIOL, V161, P187, DOI 10.1002/jcp.1041610202; ARORA PD, 1994, J CELL PHYSIOL, V159, P161, DOI 10.1002/jcp.1041590120; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BIRD TA, 1986, NATURE, V324, P263, DOI 10.1038/324263a0; BOCQUET J, 1986, BIOCHEM BIOPH RES CO, V134, P539, DOI 10.1016/S0006-291X(86)80454-5; BOUCHELOUCHE PN, 1988, LEUKEMIA, V2, P691; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CANALIS E, 1986, ENDOCRINOLOGY, V118, P74, DOI 10.1210/endo-118-1-74; CARROLL GJ, 1986, BRIT J RHEUMATOL, V25, P359; CHIN J, 1987, J EXP MED, V165, P70, DOI 10.1084/jem.165.1.70; DEYERLE KL, 1992, J IMMUNOL, V149, P1657; DINARELLO CA, 1991, BLOOD, V77, P1627; DOWER SK, 1985, J EXP MED, V162, P501, DOI 10.1084/jem.162.2.501; DOWER SK, 1990, J INVEST DERMATOL, V94, pS68, DOI 10.1111/1523-1747.ep12875154; DURUM SK, 1990, IMMUNOPHYSIOLOGY ROL, P210; GALLIS B, 1989, J IMMUNOL, V143, P3235; GEARING AJH, 1985, IMMUNOL LETT, V10, P297, DOI 10.1016/0165-2478(85)90105-1; GEORGILIS K, 1987, J IMMUNOL, V138, P3403; GLOGAUER M, 1992, EXP CELL RES, V200, P227, DOI 10.1016/0014-4827(92)90168-8; GOWEN M, 1983, NATURE, V306, P378, DOI 10.1038/306378a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HULKOWER KI, 1991, AGENTS ACTIONS, V34, P278, DOI 10.1007/BF01993302; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JACONI MEE, 1990, J CELL BIOL, V112, P1249; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; JOHNSON GD, 1981, J IMMUNOL METHODS, V43, P349, DOI 10.1016/0022-1759(81)90183-6; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KABASHIMA H, 1991, INFECT IMMUN, V59, P4271, DOI 10.1128/IAI.59.11.4271-4274.1991; KAUR P, 1988, FEBS LETT, V241, P6, DOI 10.1016/0014-5793(88)81019-6; KINANE DF, 1992, ARCH ORAL BIOL, V37, P153, DOI 10.1016/0003-9969(92)90011-V; KORNBERG L, 1991, P NATL ACAD SCI USA, V89, P5192; LICHTMAN AH, 1983, BLOOD, V61, P413; LOWENTHAL JW, 1986, J EXP MED, V164, P1060, DOI 10.1084/jem.164.4.1060; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MATSUSHIMA K, 1986, J IMMUNOL, V136, P4496; MATSUSHIMA K, 1988, BIOCHEMISTRY-US, V27, P3765, DOI 10.1021/bi00410a037; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MIZEL SB, 1990, IMMUNOL TODAY, V11, P390, DOI 10.1016/0167-5699(90)90154-2; OGISO B, 1992, CELL SIGNAL, V4, P627, DOI 10.1016/0898-6568(92)90044-9; ONEILL LAJ, 1990, J BIOL CHEM, V265, P3146; ONEILL LAJ, 1992, J IMMUNOL, V148, P474; PACIFICI R, 1988, J BONE MINER RES, V3, P107; PENDER N, 1991, J CELL SCI, V100, P187; POSTLETHWAITE AE, 1983, J EXP MED, V157, P801, DOI 10.1084/jem.157.2.801; QWARNSTROM EE, 1988, J BIOL CHEM, V263, P8261; QWARNSTROM EE, 1991, P NATL ACAD SCI USA, V88, P1232, DOI 10.1073/pnas.88.4.1232; QWARNSTROM EE, 1989, J CELL PHYSIOL, V139, P501, DOI 10.1002/jcp.1041390308; RASMUSSEN H, 1986, NEW ENGL J MED, V314, P1164; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; SCHMIDT JA, 1982, J IMMUNOL, V128, P2177; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; SHIRAKAWA F, 1988, P NATL ACAD SCI USA, V85, P8201, DOI 10.1073/pnas.85.21.8201; SIEGELBAUM SA, 1994, CURR BIOL, V4, P242, DOI 10.1016/S0960-9822(00)00054-3; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; STANTON TH, 1986, J BIOL CHEM, V261, P5699; WIJETUNGE S, 1992, BIOCHEM BIOPH RES CO, V189, P1620, DOI 10.1016/0006-291X(92)90262-J	63	78	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					6042	6049		10.1074/jbc.270.11.6042	http://dx.doi.org/10.1074/jbc.270.11.6042			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890736	hybrid			2022-12-25	WOS:A1995QM94500052
J	ERNST, A; HELMHOLD, M; BRUNNER, C; PETHOSCHRAMM, A; ARMSTRONG, VW; MULLER, HJ				ERNST, A; HELMHOLD, M; BRUNNER, C; PETHOSCHRAMM, A; ARMSTRONG, VW; MULLER, HJ			IDENTIFICATION OF 2 FUNCTIONALLY DISTINCT LYSINE-BINDING SITES IN KRINGLE-37 AND IN KRINGLES 32-36 OF HUMAN APOLIPOPROTEIN(A)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PLASMINOGEN KRINGLE-4; RHESUS-MONKEY; MYOCARDIAL-INFARCTION; LIPOPROTEIN(A) BINDS; ARTERIAL-WALL; FIBRIN; LP(A); ATHEROSCLEROSIS; PLASMA; HETEROGENEITY	The well documented association between high plasma levels of lipoprotein(a) (Lp(a)) and cardiovascular disease might be mediated by the lysine binding of apolipoprotein(a) (apo(a)), the plasminogen-like, multikringle glycoprotein in Lp(a), We employed a mutational analysis to localize the lysine-binding domains within human apo(a), Recombinant apo(a) (r-apo(a)) with 17 plasminogen kringle IV-like domains, one plasminogen kringle V-like domain, and a protease domain or mutants thereof were expressed in the human hepatocarcinoma cell line HepG2. The lysine binding of plasma Lp(a) and r-apo(a) in the culture supernatants of transfected HepG2 cells was analyzed by lysine-Sepharose affinity chromatography. Wild type recombinant Lp(a) (r-Lp(a)) revealed lysine binding in the range observed for human plasma Lp(a). A single accessible lysine binding site in Lp(a) is indicated by a complete loss of lysine binding observed for r-Lp(a) species that contain either a truncated r-apo(a) lacking kringle IV-37, kringle V, and the protease or a point-mutated r-apo(a) with a Trp 4174 --> Arg substitution in the putative lysine-binding pocket of kringle IV-37, Evidence is also presented for additional lysine-binding sites within kringles 32-36 of apo(a) that are masked in Lp(a) as indicated by an increased lysine binding for the point mutant (Cys-4057 --> Ser), which is unable to assemble into particles, An important role of these lysine-binding site(s) for Lp(a) assembly is suggested by a decreased assembly efficiency for deletion mutants lacking either kringle 32 or kringles 32-35.	BOEHRINGER MANNHEIM GMBH, DEPT BIOL MOLEC, TF MM, D-68305 MANNHEIM, GERMANY; UNIV GOTTINGEN, DEPT CLIN CHEM, D-37075 GOTTINGEN, GERMANY; UNIV INNSBRUCK, INST MED BIOL & HUMAN GENET, A-6020 INNSBRUCK, AUSTRIA	University of Gottingen; University of Innsbruck								ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; ARMSTRONG VW, 1990, J LIPID RES, V31, P429; ARMSTRONG VW, 1986, ATHEROSCLEROSIS, V62, P249, DOI 10.1016/0021-9150(86)90099-7; BEISIEGEL U, 1990, EUR HEART J, V11, P174, DOI 10.1093/eurheartj/11.suppl_E.174; BROWN MS, 1987, NATURE, V330, P113, DOI 10.1038/330113a0; BRUNNER C, 1993, P NATL ACAD SCI USA, V90, P11643, DOI 10.1073/pnas.90.24.11643; CASTELLINO FJ, 1990, LIPOPROTEIN A, P87; CHIESA G, 1992, J BIOL CHEM, V267, P24369; CHRISTENSEN U, 1992, BIOCHEM J, V285, P419, DOI 10.1042/bj2850419; CREMER P, 1994, EUR J CLIN INVEST, V24, P444, DOI 10.1111/j.1365-2362.1994.tb02373.x; DEVOS AM, 1992, BIOCHEMISTRY-US, V31, P270, DOI 10.1021/bi00116a037; EATON DL, 1987, P NATL ACAD SCI USA, V84, P3224, DOI 10.1073/pnas.84.10.3224; EZRATTY A, 1993, BIOCHEMISTRY-US, V32, P4628, DOI 10.1021/bi00068a021; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FLEURY V, 1991, BIOCHEMISTRY-US, V30, P7630, DOI 10.1021/bi00244a035; GONZALEZGRONOW M, 1989, BIOCHEMISTRY-US, V28, P2374, DOI 10.1021/bi00432a005; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; GUEVARA J, 1992, PROTEINS, V12, P188, DOI 10.1002/prot.340120212; GUEVARA J, 1993, ARTERIOSCLER THROMB, V13, P758, DOI 10.1161/01.ATV.13.5.758; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HAJJAR KA, 1991, J BIOL CHEM, V266, P21962; HARPEL PC, 1989, P NATL ACAD SCI USA, V86, P3847, DOI 10.1073/pnas.86.10.3847; HERVIO L, 1993, BLOOD, V82, P392; KOSCHINSKY ML, 1993, J BIOL CHEM, V268, P19819; KRAFT HG, 1988, ARTERIOSCLEROSIS, V8, P212, DOI 10.1161/01.ATV.8.3.212; KRATZIN H, 1987, BIOL CHEM H-S, V368, P1533, DOI 10.1515/bchm3.1987.368.2.1533; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUSUMI Y, 1993, ATHEROSCLEROSIS, V99, P165, DOI 10.1016/0021-9150(93)90019-Q; LACKNER C, 1993, HUM MOL GENET, V2, P933, DOI 10.1093/hmg/2.7.933; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; LEERINK CB, 1991, FIBRINOLYSIS, V5, P233, DOI 10.1016/0268-9499(91)90005-O; LEERINK CB, 1992, THROMB HAEMOSTASIS, V68, P185; LERCH PG, 1980, EUR J BIOCHEM, V107, P7, DOI 10.1111/j.1432-1033.1980.tb04617.x; LI ZG, 1992, PROTEIN EXPRES PURIF, V3, P212, DOI 10.1016/1046-5928(92)90017-Q; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; LOGRASSO PV, 1994, J BIOL CHEM, V269, P21820; LUCAS MA, 1983, J BIOL CHEM, V258, P4249; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; MULICHAK AM, 1991, BIOCHEMISTRY-US, V30, P10576, DOI 10.1021/bi00107a029; NACHMAN RL, 1991, ARTERIOSCLER THROMB, V11, P32, DOI 10.1161/01.ATV.11.1.32; PEPIN JM, 1991, J LIPID RES, V32, P317; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; REJANTE M, 1991, FIBRINOLYSIS, V5, P87, DOI 10.1016/0268-9499(91)90048-9; REJANTE MR, 1991, BIOCHEMISTRY-US, V30, P11081, DOI 10.1021/bi00110a010; RHOADS GG, 1986, JAMA-J AM MED ASSOC, V256, P2540, DOI 10.1001/jama.256.18.2540; RIDKER PM, 1993, JAMA-J AM MED ASSOC, V270, P2195, DOI 10.1001/jama.270.18.2195; ROSENGREN A, 1990, BRIT MED J, V301, P1248, DOI 10.1136/bmj.301.6763.1248; ROUY D, 1991, ARTERIOSCLER THROMB, V11, P629, DOI 10.1161/01.ATV.11.3.629; ROUY D, 1992, BIOCHEMISTRY-US, V31, P6333, DOI 10.1021/bi00142a024; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANGRAR W, 1994, PROTEIN ENG, V7, P723, DOI 10.1093/protein/7.5.723; SCANU AM, 1990, J LAB CLIN MED, V116, P142; SCANU AM, 1993, J CLIN INVEST, V91, P283, DOI 10.1172/JCI116182; SCHAEFER EJ, 1994, JAMA-J AM MED ASSOC, V271, P999, DOI 10.1001/jama.271.13.999; THEWES T, 1990, J BIOL CHEM, V265, P3906; THORSEN S, 1975, BIOCHIM BIOPHYS ACTA, V393, P55, DOI 10.1016/0005-2795(75)90216-0; TOMLINSON JE, 1989, J BIOL CHEM, V264, P5957; TRIEU VN, 1991, J BIOL CHEM, V266, P5480; TULINSKY A, 1988, J MOL BIOL, V202, P885, DOI 10.1016/0022-2836(88)90565-7; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; UTERMANN G, 1987, J CLIN INVEST, V80, P458, DOI 10.1172/JCI113093; VANDERHOEK YY, 1993, HUM MOL GENET, V2, P361, DOI 10.1093/hmg/2.4.361; WILLIAMS JK, 1993, ARTERIOSCLER THROMB, V13, P548, DOI 10.1161/01.ATV.13.4.548; WU TP, 1991, BIOCHEMISTRY-US, V30, P10589, DOI 10.1021/bi00107a030	66	108	110	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					6227	6234		10.1074/jbc.270.11.6227	http://dx.doi.org/10.1074/jbc.270.11.6227			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890760	hybrid			2022-12-25	WOS:A1995QM94500077
J	LANFRANCONE, L; PELICCI, G; BRIZZI, MF; AROUICA, MG; CASCIARI, C; GIULI, S; PEGORARO, L; PAWSON, T; PELICCI, PG				LANFRANCONE, L; PELICCI, G; BRIZZI, MF; AROUICA, MG; CASCIARI, C; GIULI, S; PEGORARO, L; PAWSON, T; PELICCI, PG			OVEREXPRESSION OF SHC PROTEINS POTENTIATES THE PROLIFERATIVE RESPONSE TO THE GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AND RECRUITMENT OF GRB2/SOS AND GRB2/P140 COMPLEXES TO THE BETA-RECEPTOR SUBUNIT	ONCOGENE			English	Article						GM-CSF; SIGNAL; SHE; GRB2	GUANINE-NUCLEOTIDE EXCHANGE; GM-CSF RECEPTOR; EPIDERMAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; ADAPTER PROTEIN; MOLECULAR-CLONING; CELL-LINE; KINASE; RAS	The high affinity receptor for GM-CSF consists of a unique a subunit and a beta subunit that is shared with receptors for IL-3 and IL-5. Activation of GM-CSF receptor (GMR) triggers two distinct cytoplasmic signalling pathways, JAK2, and Pas, and is sufficient to maintain proliferation of growth factor-dependent cell lines, She proteins are phosphorylated upon activation of GMR and may be involved in the transmission of GM-CSF signals to Pas. To define the role of She proteins in cells stimulated with GM-CSF, we investigated both the network of interactions that involve She after GM-CSF stimulation and the effects of overexpressing She proteins on the proliferative response to GM-CSF. Two cytoplasmic complexes, Grb2/Sos and Grb2/p140 bind through the Grb2 SH2 domain to phosphorylated She, and are thereby recruited to the beta subunit, Both complexes are stable, even in the absence of ligand, and depend on the direct association of p140 and Sos respectively with the SH3 domains of Grb2, p140 is an uncharacterized protein constitutively phosphorylated on tyrosine and, in its Grb2-bonnd form, expressed only in hematopoietic cells, the oligomeric complex formed by phosphorylated beta subunit-phosphorylated Shc-Grb2-SoS-p140 is also induced by IL-3 and L-5 stimulation of growth-factor dependent cell lines, Overexpression of wild-type She proteins in growth factor-dependent cells increases both MAP kinase activation and proliferation in response to GM-CSF, These effects require the association of She with Grb2, Taken together these results indicate that phosphorylation of She proteins is a crucial step in the transmission of GM-CSP proliferative stimuli, since it creates a high affinity binding site for the Grb2/SoS complex, whose function is to activate Ras and, for the Grb2/p140 complex, whose function remains unknown.	DIPARTIMENTO SCI BIOMED & ONCOL UMANA,SEZ CLIN,I-10126 TURIN,ITALY; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,TORONTO,ON M5G 1X5,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	LANFRANCONE, L (corresponding author), UNIV PERUGIA,IST MED INTERNA & SCI ONCOL,I-06122 PERUGIA,ITALY.		Pelicci, Giuliana/AAA-8921-2022; Brizzi, Maria Felice/J-7882-2016; Pelicci, Pier Giuseppe/AAL-6572-2020; Lanfrancone, Luisa/AAC-8671-2019; Pawson, Tony J/E-4578-2013	Pelicci, Giuliana/0000-0003-0986-8255; Lanfrancone, Luisa/0000-0002-4523-3815; CASCIARI, CRISTINA/0000-0002-9170-370X				ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BATZER LN, 1993, NATURE, V363, P85; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DAMEN JE, 1993, BLOOD, V82, P2296; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; HARLOW E, 1988, ANTIBODIES LABORATOR; HARPUR AG, 1992, ONCOGENE, V7, P1347; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; KASTELEIN RA, 1993, ONCOGENE, V8, P231; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KITAMURA T, 1991, INT IMMUNOL, V3, P571, DOI 10.1093/intimm/3.6.571; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LIOUBIN NM, 1994, MOL CELL BIOL, V14, P5682; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; METCALF D, 1993, BLOOD, V82, P3515; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MIYAJIMA A, 1993, BLOOD, V82, P1960; OKUDA K, 1992, BLOOD, V79, P2880; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SALCINI AE, 1994, IN PRESS ONCOGENE; Sambrook J, 1989, MOL CLONING LABORATO; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SAXTON TM, 1994, J IMMUNOL, V153, P623; SEGATTO O, 1993, ONCOGENE, V8, P2105; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SONYANG Z, 1994, MOL CELL BIOL, V14, P2777; SORENSEN PHB, 1989, BLOOD, V73, P406; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; WELHAM MJ, 1992, J IMMUNOL, V149, P1683	44	105	107	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					907	917						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898932				2022-12-25	WOS:A1995QL03800012
J	BOCHKAREVA, ES; GIRSHOVICH, AS				BOCHKAREVA, ES; GIRSHOVICH, AS			ATP INDUCES NONIDENTITY OF 2 RINGS IN CHAPERONIN GROEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; HYDROLYSIS; COOPERATIVITY; PURIFICATION; MUTATION	For its function, the Escherichia coli chaperonin GroEL requires the presence of ATP and co-chaperonin GroES. We have observed that ADP displays a two-step inhibition of GroEL-dependent ATP hydrolysis, wherein one-half of the GroEL ATPase sites is strongly inhibited by ADP while the other half is affected very mildly. It is suggested that interaction with ATP induces structural and functional differences between two initially identical rings in GroEL (inter-ring negative cooperativity) and that the subsequent binding of GroES occurs to the ring that is occupied first by ATP in a positively cooperative manner.	WEIZMANN INST SCI,DEPT BIOL STRUCT,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								BANEYX F, 1992, J BIOL CHEM, V267, P11637; BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BOCHKAREVA ES, 1994, J BIOL CHEM, V269, P44; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GIRSHOVICH AS, 1981, J MOL BIOL, V151, P229, DOI 10.1016/0022-2836(81)90513-1; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HOROVITZ A, 1993, J MOL BIOL, V231, P58, DOI 10.1006/jmbi.1993.1256; ISHII N, 1992, FEBS LETT, V299, P169, DOI 10.1016/0014-5793(92)80240-H; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LEVITZKI A, 1969, FED EUR BIOCHEM SOC, V19, P263; LONG CW, 1970, J BIOL CHEM, V245, P80; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SVENSSON LA, 1994, J MOL BIOL, V235, P47; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003	27	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23869	23871						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929031				2022-12-25	WOS:A1994PQ34600005
J	HOFMANN, F; ANAGLI, J; CARAFOLI, E; VORHERR, T				HOFMANN, F; ANAGLI, J; CARAFOLI, E; VORHERR, T			PHOSPHORYLATION OF THE CALMODULIN-BINDING DOMAIN OF THE PLASMA-MEMBRANE CA2+ PUMP BY PROTEIN-KINASE-C REDUCES ITS INTERACTION WITH CALMODULIN AND WITH ITS PUMP RECEPTOR-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+ PUMP; SARCOPLASMIC-RETICULUM; CALCIUM-PUMP; CA-2+-PUMPING ATPASE; MUSCLE-CELLS; PHOSPHOLAMBAN; IDENTIFICATION; SARCOLEMMA; ACTIVATION; SUBSTRATE	Two versions of the calmodulin binding domain of the plasma membrane Ca(2+)ATPase, a 24-amino acid peptide, C24W (Q-I-L-W-F-R-G-L-N-R-I-Q-T-Q-I-R-V-V-N-A-F-R-S-S-NH2), and the corresponding phosphothreonine containing peptide, C24W-P (Q-I-L-W-F-R-G-L-N-R-I-Q-T(phospho)-Q-I-R-V-V-N-A-F-R-S-S-NH2), were synthesized. They were used to investigate the effect of threonine phosphorylation by protein kinase C on the binding of calmodulin by the calmodulin binding domain and on the inhibitory role of the domain on the activity of the Ca2+ pump. The phosphopeptide C24W-P was obtained after global phosphorylation of the free Thr side chain on the protected resin bound peptide. The phosphorylated calmodulin binding domain failed to bind calmodulin; this was shown by gel shift experiments, by fluorescence energy transfer studies and by competition experiments against calmodulin stimulation of the pump. The inhibition of the Ca2+ pump activity by the calmodulin binding domain in the absence of calmodulin was also affected by the phosphorylation of the threonine; the inhibition of the fully active calpain-truncated pump by the phosphothreonine containing peptide was lower than that by the unphosphorylated synthetic domain.	ETH ZURICH,INST BIOCHEM,CH-8092 ZURICH,SWITZERLAND; HOFFMANN LA ROCHE AG,CH-4002 BASEL,SWITZERLAND	ETH Zurich; Roche Holding			Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094				ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; APEL ED, 1990, BIOCHEMISTRY-US, V29, P2330, DOI 10.1021/bi00461a017; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CARONI P, 1981, J BIOL CHEM, V256, P9371; CHAPMAN ER, 1992, BIOCHEMISTRY-US, V31, P12819, DOI 10.1021/bi00166a016; CHIESI M, 1991, BIOCHEMISTRY-US, V30, P7978, DOI 10.1021/bi00246a015; DIXON DA, 1989, J BIOL CHEM, V264, P13612; ERIKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FALCHETTO R, 1992, PROTEIN SCI, V1, P1613, DOI 10.1002/pro.5560011209; FALCHETTO R, 1991, J BIOL CHEM, V266, P2930; FURUKAWA KI, 1989, J BIOL CHEM, V264, P4844; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HASHIMOTO Y, 1989, J BIOL CHEM, V264, P16524; HOUSE C, 1987, J BIOL CHEM, V262, P772; JAMES P, 1989, J BIOL CHEM, V264, P8289; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; JAMES PH, 1989, BIOCHEMISTRY-US, V28, P4253, DOI 10.1021/bi00436a020; KATAOKA M, 1991, BIOCHEMISTRY-US, V30, P6247, DOI 10.1021/bi00239a024; KITAS EA, 1991, HELV CHIM ACTA, V74, P1314, DOI 10.1002/hlca.19910740621; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KUO TH, 1991, J BIOL CHEM, V266, P2520; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEPEUCH CJ, 1979, BIOCHEMISTRY-US, V18, P5150, DOI 10.1021/bi00590a019; MOVSESIAN MA, 1984, J BIOL CHEM, V259, P8029; NEYES L, 1985, J BIOL CHEM, V260, P10283; NIGGLI V, 1979, J BIOL CHEM, V254, P9955; NISHIKAWA M, 1985, J BIOL CHEM, V260, P8978; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P213, DOI 10.1016/0010-4655(82)90173-4; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; SMALLWOOD JI, 1988, J BIOL CHEM, V263, P2195; VORHERR T, 1992, BIOCHEMISTRY-US, V31, P371, DOI 10.1021/bi00117a009; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; WANG KKW, 1991, J BIOL CHEM, V266, P9078; WANG KKW, 1991, ARCH BIOCHEM BIOPHYS, V289, P103, DOI 10.1016/0003-9861(91)90448-R	35	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24298	24303						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929086				2022-12-25	WOS:A1994PQ34600069
J	WILSON, MT; ANTONINI, G; MALATESTA, F; SARTI, P; BRUNORI, M				WILSON, MT; ANTONINI, G; MALATESTA, F; SARTI, P; BRUNORI, M			PROBING THE OXYGEN-BINDING SITE OF CYTOCHROME-C-OXIDASE BY CYANIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGULAR VALUE DECOMPOSITION; ELECTRON-TRANSFER; PROTON TRANSLOCATION; REDUCTION; COPPER; ACTIVATION; ENZYME; FORM; PH	Cyanide binding to cytochrome c oxidase has been investigated by sequential mixing and rapid scan stopped flow spectroscopy. Double mixing experiments confirm earlier reports that cyanide binds rapidly to partially reduced enzyme species formed in turnover. The absorbance/time/wavelength matrices, captured during the onset of cyanide inhibition of cytochrome c oxidase by rapid scan stopped flow, were analyzed by singular value decomposition and the spectral contributions of the chromophores separated. Examination of the time courses and amplitudes of the spectral signals provide evidence that entry of a single (1-1.3) electron into the enzyme is sufficient to trigger rapid cyanide binding. This electron resides predominantly on the cytochrome a/Cu-A, pair in the inhibited enzyme. In addition, although cytochrome a(3) remains oxidized, it does not appear to be the site for the initial inhibitory binding of cyanide. Our data suggest that CU(B)2+ is the initial binding site.	UNIV ROMA LA SAPIENZA, DEPT BIOCHEM SCI, I-00185 ROME, ITALY; UNIV ROMA LA SAPIENZA, CNR, CTR MOLEC BIOL, I-00185 ROME, ITALY; UNIV ROMA TOR VERGATA, DEPT BIOCHEM SCI, ROME, ITALY; UNIV ROMA TOR VERGATA, CNR, CTR MOLEC BIOL, ROME, ITALY	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); University of Rome Tor Vergata	WILSON, MT (corresponding author), UNIV ESSEX, DEPT CHEM & BIOL CHEM, WIVENHOE PK, COLCHESTER CO4 3SQ, ESSEX, ENGLAND.		Malatesta, Francesco/AAT-4757-2020; Sarti, Paolo/D-2946-2009	Brunori, Maurizio/0000-0002-7795-1635; Sarti, Paolo/0000-0002-8219-4827; Antonini, Giovanni/0000-0002-2115-8961				ANTALIS TM, 1982, J BIOL CHEM, V257, P6194; ANTONINI E, 1971, EUR J BIOCHEM, V23, P396, DOI 10.1111/j.1432-1033.1971.tb01633.x; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BAKER GM, 1987, J BIOL CHEM, V262, P595; BELLELLI A, 1990, J BIOL CHEM, V265, P18898; BERKA V, 1993, FEBS LETT, V315, P237, DOI 10.1016/0014-5793(93)81171-U; BRUNORI M, 1979, J BIOL CHEM, V254, P769; BRZEZINSKI P, 1987, BIOCHIM BIOPHYS ACTA, V894, P29, DOI 10.1016/0005-2728(87)90209-X; GOLUB GH, 1970, NUMER MATH, V14, P403, DOI 10.1007/BF02163027; GRAY HB, 1989, BIOCHEMISTRY-US, V28, P7499, DOI 10.1021/bi00445a001; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; HOSLER JP, 1993, J BIOENERG BIOMEMBR, V25, P121, DOI 10.1007/BF00762854; JENSEN P, 1984, BIOCHEM J, V224, P829, DOI 10.1042/bj2240829; JONES MG, 1984, BIOCHEM J, V220, P57, DOI 10.1042/bj2200057; LINDSAY JG, 1975, ARCH BIOCHEM BIOPHYS, V169, P492, DOI 10.1016/0003-9861(75)90192-7; MALATESTA F, 1990, P NATL ACAD SCI USA, V74, P2222; MITCHELL P, 1988, ANN NY ACAD SCI, V550, P185, DOI 10.1111/j.1749-6632.1988.tb35335.x; MITCHELL R, 1992, BIOCHIM BIOPHYS ACTA, V1100, P40, DOI 10.1016/0005-2728(92)90124-K; MOODY AJ, 1991, BIOCHIM BIOPHYS ACTA, V1059, P189, DOI 10.1016/S0005-2728(05)80204-X; PALMER G, 1993, J BIOENERG BIOMEMBR, V25, P145, DOI 10.1007/BF00762856; ROUSSEAU DL, 1993, J BIOENERG BIOMEMBR, V25, P165, DOI 10.1007/BF00762858; SCHOLES CP, 1986, FEBS LETT, V198, P125, DOI 10.1016/0014-5793(86)81197-8; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P164, DOI 10.1021/bi00052a022; VANBUUREN KJ, 1972, BIOCHIM BIOPHYS ACTA, V256, P258, DOI 10.1016/0005-2728(72)90057-6; WILSON MT, 1975, BIOCHEM J, V147, P145, DOI 10.1042/bj1470145; WOODRUFF WH, 1993, J BIOENERG BIOMEMBR, V25, P177, DOI 10.1007/BF00762859; WRIGGLESWORTH JM, 1988, BIOCHIM BIOPHYS ACTA, V936, P452, DOI 10.1016/0005-2728(88)90023-0; YONETANI T, 1960, J BIOL CHEM, V235, P845; YOSHIKAWA S, 1990, J BIOL CHEM, V265, P7945	29	33	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24114	24119						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929065				2022-12-25	WOS:A1994PQ34600043
J	GROSS, M; OLIN, A; HESSEFORT, S; BENDER, S				GROSS, M; OLIN, A; HESSEFORT, S; BENDER, S			CONTROL OF PROTEIN-SYNTHESIS BY HEMIN - PURIFICATION OF A RABBIT RETICULOCYTE HSP-70 AND CHARACTERIZATION OF ITS REGULATION OF THE ACTIVATION OF THE HEMIN-CONTROLLED EIF-2(ALPHA) KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROLLED TRANSLATIONAL REPRESSOR; DOUBLE-STRANDED-RNA; HEAT-SHOCK PROTEINS; GLOBIN-SYNTHESIS; EIF-2-ALPHA KINASE; INITIATION-COMPLEXES; HEMOGLOBIN SYNTHESIS; 67-KDA POLYPEPTIDE; SUPERNATANT FACTOR; CHAIN INITIATION	We have purified a soluble rabbit reticulocyte protein, previously termed the supernatant factor, that reverses the inhibition of protein synthesis in hemin-deficient lysate by promoting the inactivation of the hemin-controlled eIF-2 alpha kinase (HCR) mediating the effect of hemin deficiency. We have identified the supernatant factor as a member of the heat shock protein 70 family, denoted hsp 70(R), based upon its size (72 kDa), specific: reaction to a monoclonal antibody against eukaryotic hsp 70, strong binding affinity for ATP, and endogenous ATPase activity. me have investigated the role of hsp 70(R) and hemin in the regulation of the activation of HCR from its latent precursor (ProHCR) and the translational control of protein synthesis in rabbit reticulocyte lysate. We find that autophosphorylation of ProHCR is reduced by about 75% by adding saturating hsp 70(R) and almost completely reduced by adding either saturating hemin or limiting hemin plus Limiting hsp 70(R). In contrast, autophosphorylation of HCR, which is similar in magnitude to that of ProHCR, is unaffected by adding either saturating hsp 70(R), saturating hemin, or limiting amounts of both. The activation of HCR (measured by inhibition of protein synthesis) hom isolated ProHCR is completely prevented by hsp 70(R) in the presence, but not absence, of dithiothreitol. This suppression appears to be due to the association of hsp 70(R) with ProHCR, since hsp 70(R) action is prevented by ATP/mg(2+) and because activation of HCR from less purified ProHCR, that has associated hsp 70(R), is suppressed by dithiothreitol alone. This association is confirmed by sucrose gradient centrifugation, which shows co-sedimentation of some hsp 70(R) with ProHCR following preincubation together that is prevented by ATP/ Mg2+ and does not occur after conversion of ProHCR to HCR. Limiting hsp 70(R) reduces the concentration of hemin required to prevent activation of HCR from isolated ProHCR from 0.75 to 0.15 mu M and the optimal hemin concentration needed to maintain protein synthesis in reticulocyte lysate from 25 to 10 mu M. Limiting hsp 70(R) also allows the delayed addition of hemin to suppress activation of HCR hom ProHCR and to reverse inhibition of protein synthesis in hemin deficient lysate. The association of hsp 70(R) with ProHCR also underlies the observation that much more protein is synthesized in reticulocyte lysate in the absence of hemin at 25 degrees C than at temperatures of 30 degrees C or greater. These observed effects may be specific to hsp 70(R), since they are not observed with rabbit reticulocyte eIF-2 or eIF-2B, and since the comparable hsp 70 from bovine brain is incapable of maintaining or restoring protein synthesis in hemin-deficient lysate.			GROSS, M (corresponding author), UNIV CHICAGO,DEPT PATHOL,5841 S MARYLAND AVE,CHICAGO,IL 60637, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030121] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-30121] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMSON SD, 1972, J MOL BIOL, V63, P247, DOI 10.1016/0022-2836(72)90373-7; ADAMSON SD, 1969, J MOL BIOL, V42, P247, DOI 10.1016/0022-2836(69)90041-2; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHEN JJ, 1989, J BIOL CHEM, V264, P9559; CLEMENS MJ, 1974, P NATL ACAD SCI USA, V71, P2946, DOI 10.1073/pnas.71.8.2946; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; GRAYZEL AI, 1966, P NATL ACAD SCI USA, V55, P650, DOI 10.1073/pnas.55.3.650; GROSS M, 1972, BIOCHIM BIOPHYS ACTA, V287, P340, DOI 10.1016/0005-2787(72)90383-8; GROSS M, 1987, J BIOL CHEM, V262, P6899; GROSS M, 1991, BIOCHEM BIOPH RES CO, V181, P1500, DOI 10.1016/0006-291X(91)92109-W; GROSS M, 1978, BIOCHIM BIOPHYS ACTA, V520, P650, DOI 10.1016/0005-2787(78)90150-8; GROSS M, 1972, P NATL ACAD SCI USA, V69, P1565, DOI 10.1073/pnas.69.6.1565; GROSS M, 1992, J BIOL CHEM, V267, P2073; GROSS M, 1980, J BIOL CHEM, V255, P6270; GROSS M, 1973, BIOCHIM BIOPHYS ACTA, V299, P472, DOI 10.1016/0005-2787(73)90272-4; GROSS M, 1974, BIOCHIM BIOPHYS ACTA, V366, P319, DOI 10.1016/0005-2787(74)90292-5; GROSS M, 1974, BIOCHIM BIOPHYS ACTA, V340, P484, DOI 10.1016/0005-2787(74)90069-0; GROSS M, 1983, BIOCHIM BIOPHYS ACTA, V740, P255, DOI 10.1016/0167-4781(83)90134-3; GROSS M, 1979, J BIOL CHEM, V254, P2370; GROSS M, 1981, BIOCHIM BIOPHYS ACTA, V654, P219, DOI 10.1016/0005-2787(81)90175-1; GROSS M, 1976, BIOCHIM BIOPHYS ACTA, V447, P445, DOI 10.1016/0005-2787(76)90082-4; GROSS M, 1977, BIOCHEM BIOPH RES CO, V74, P559, DOI 10.1016/0006-291X(77)90340-0; HUNT T, 1972, J MOL BIOL, V66, P471, DOI 10.1016/0022-2836(72)90427-5; HUNT T, 1979, WIN MIAM S GEN PROT, V16, P321; HUNTER AR, 1975, EUR J BIOCHEM, V58, P421, DOI 10.1111/j.1432-1033.1975.tb02389.x; JACKSON RJ, 1983, EUR J BIOCHEM, V131, P313, DOI 10.1111/j.1432-1033.1983.tb07264.x; KRAMER G, 1976, P NATL ACAD SCI USA, V73, P3078, DOI 10.1073/pnas.73.9.3078; KURTZ S, 1986, SCIENCE, V231, P1154, DOI 10.1126/science.3511530; LEGON S, 1973, NATURE-NEW BIOL, V241, P150, DOI 10.1038/newbio241150a0; LEVIN D, 1978, P NATL ACAD SCI USA, V75, P1121, DOI 10.1073/pnas.75.3.1121; LEVIN DH, 1976, P NATL ACAD SCI USA, V73, P3112, DOI 10.1073/pnas.73.9.3112; LODISH HF, 1993, J BIOL CHEM, V268, P20598; MATTS RL, 1992, J BIOL CHEM, V267, P18160; MATTS RL, 1989, J BIOL CHEM, V264, P15542; MATTS RL, 1993, BIOCHEMISTRY-US, V32, P7323, DOI 10.1021/bi00080a001; MATTS RL, 1992, J BIOL CHEM, V267, P18168; MAXWELL CR, 1971, J MOL BIOL, V58, P317, DOI 10.1016/0022-2836(71)90249-X; MENDEZ R, 1992, J BIOL CHEM, V267, P11500; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PETRYSHYN R, 1982, P NATL ACAD SCI-BIOL, V79, P6512, DOI 10.1073/pnas.79.21.6512; PETRYSHYN R, 1979, P NATL ACAD SCI USA, V76, P1575, DOI 10.1073/pnas.76.4.1575; RAY MK, 1992, P NATL ACAD SCI USA, V89, P539, DOI 10.1073/pnas.89.2.539; RAY MK, 1993, BIOCHEMISTRY-US, V32, P5151, DOI 10.1021/bi00070a026; ROSE DW, 1987, BIOCHEMISTRY-US, V26, P6583, DOI 10.1021/bi00395a003; SCHMID SL, 1985, J BIOL CHEM, V260, P57; VELAZQUEZ JM, 1983, J CELL BIOL, V96, P286, DOI 10.1083/jcb.96.1.286; WAXMAN HS, 1965, BIOCHEM BIOPH RES CO, V19, P538, DOI 10.1016/0006-291X(65)90159-2; WAXMAN HS, 1966, BIOCHIM BIOPHYS ACTA, V129, P369, DOI 10.1016/0005-2787(66)90379-0; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WU CH, 1988, PLANT PHYSIOL, V88, P731, DOI 10.1104/pp.88.3.731; YANG JM, 1992, J BIOL CHEM, V267, P20519	51	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22738	22748						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	7915718				2022-12-25	WOS:A1994PQ16300045
J	MURTHY, SNP; WILSON, J; ZHANG, Y; LORAND, L				MURTHY, SNP; WILSON, J; ZHANG, Y; LORAND, L			RESIDUE GLN-30 OF HUMAN ERYTHROCYTE ANION TRANSPORTER IS A PRIME SITE FOR REACTION WITH INTRINSIC TRANSGLUTAMINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKED ENVELOPE; ANKYRIN-BINDING SITE; INTERCALATED CELLS; MEMBRANE-PROTEINS; COLLECTING DUCT; ENZYMATIC BASIS; BAND-3 PROTEIN; CDNA SEQUENCE; HUMAN-KIDNEY; EXCHANGER	Elevating the intracellular concentration of Ca2+ ions in human erythrocytes leads to the formation of membrane-associated polymers, composed of skeletal and cytoplasmic proteins. The anion transporter band 3 serves as a membrane anchor for this N-epsilon-(gamma-glutamyl)lysine cross-linked polymer. The reaction is catalyzed by an intrinsic transglutaminase, and it can be observed in broken cells merely by the addition of Ca2+. Certain primary amines, such as dansylcadaverine, inhibit the process by virtue of competition against the epsilon-lysyl or donor functionalities of the protein substrates. Dansylcadaverine itself becomes incorporated into the enzyme-specific gamma-glutaminyl or acceptor residues, blocking these from participating in the formation of protein-to-protein cross-links. This labeling procedure, coupled with an anti-dansyl antibody affinity procedure to isolate dansyl-labeled compounds, was employed to identify Gln-30 as the preferred transglutaminase-reactive acceptor site in the band 3 protein.	NORTHWESTERN UNIV,SCH MED,DEPT MOLEC & CELL BIOL,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,FEINBERG CARDIOVASC RES INST,CHICAGO,IL 60611	Northwestern University; Northwestern University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045168] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45168] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BJERRUM OJ, 1981, J SUPRAMOL STR CELL, V16, P289, DOI 10.1002/jsscb.1981.380160309; BJERRUMOJ, 1974, BIOCHIM BIOPHYS ACTA, V342, P69; CURTIS CG, 1974, BIOCHEMISTRY-US, V13, P3257, DOI 10.1021/bi00713a012; DAVIS L, 1989, J BIOL CHEM, V264, P9665; DRENCKHAHN D, 1987, EUR J CELL BIOL, V45, P107; DRENCKHAHN D, 1985, SCIENCE, V230, P1287, DOI 10.1126/science.2933809; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FESUS L, 1989, FEBS LETT, V245, P150, DOI 10.1016/0014-5793(89)80210-8; HAZENMARTIN DJ, 1986, J HISTOCHEM CYTOCHEM, V34, P823, DOI 10.1177/34.6.3517151; JACOBSON GR, 1973, J BIOL CHEM, V248, P6583; KAUL R K, 1983, Journal of Biological Chemistry, V258, P7981; KAY MMB, 1983, P NATL ACAD SCI-BIOL, V80, P6882, DOI 10.1073/pnas.80.22.6882; KELLOKUMPU S, 1988, SCIENCE, V242, P1308, DOI 10.1126/science.2461589; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT S, 1990, P NATL ACAD SCI USA, V87, P1730, DOI 10.1073/pnas.87.5.1730; LORAND L, 1986, BIOCHEM BIOPH RES CO, V134, P685, DOI 10.1016/S0006-291X(86)80474-0; LORAND L, 1979, SEMIN HEMATOL, V16, P65; LORAND L, 1978, J SUPRAMOL STR CELL, V9, P427, DOI 10.1002/jss.400090313; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; LORAND L, 1976, P NATL ACAD SCI USA, V73, P4479, DOI 10.1073/pnas.73.12.4479; MARCHESI V. T., 1968, SCIENCE, V159, P203, DOI 10.1126/science.159.3811.203; MURTHY SNP, 1981, J BIOL CHEM, V256, P1203; MURTHY SNP, 1984, H-S Z PHYSIOL CHEM, V365, P9, DOI 10.1515/bchm2.1984.365.1.9; MURTHY SNP, 1988, FASEB J, V2, pA1300; RICE RH, 1978, J CELL BIOL, V76, P705, DOI 10.1083/jcb.76.3.705; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; SCHUSTER VL, 1986, AM J PHYSIOL, V251, pC347, DOI 10.1152/ajpcell.1986.251.3.C347; SIEFRING GE, 1978, BIOCHEMISTRY-US, V17, P2598, DOI 10.1021/bi00606a022; SMITH BD, 1981, J MEMBRANE BIOL, V61, P75, DOI 10.1007/BF02007633; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; STECK TL, 1978, BIOCHEMISTRY-US, V17, P1216, DOI 10.1021/bi00600a013; TANNER MJA, 1988, BIOCHEM J, V256, P703, DOI 10.1042/bj2560703; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI IH, 1982, J BIOL CHEM, V257, P1438; WAGNER S, 1987, AM J PHYSIOL, V253, pF213, DOI 10.1152/ajprenal.1987.253.2.F213; WALDER JA, 1984, J BIOL CHEM, V259, P238; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893	37	29	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22907	22911						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	7915720				2022-12-25	WOS:A1994PQ16300068
J	JOYCEBRADY, M; TAKAHASHI, Y; OAKES, SM; RISHI, AK; LEVINE, RA; KINLOUGH, CL; HUGHEY, RP				JOYCEBRADY, M; TAKAHASHI, Y; OAKES, SM; RISHI, AK; LEVINE, RA; KINLOUGH, CL; HUGHEY, RP			SYNTHESIS AND RELEASE OF AMPHIPATHIC GAMMA-GLUTAMYL-TRANSFERASE BY THE PULMONARY ALVEOLAR TYPE-2 CELL - ITS REDISTRIBUTION THROUGHOUT THE GAS-EXCHANGE PORTION OF THE LUNG INDICATES A NEW ROLE FOR SURFACTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE COPY GENE; RAT-KIDNEY; GLUTATHIONE METABOLISM; NUCLEOTIDE-SEQUENCE; MEMBRANE-PROTEINS; MOLECULAR-CLONING; TRANSPEPTIDASE; IDENTIFICATION; EXPRESSION; SECRETION	gamma-Glutamyl transferase (gamma-GT) catalyzes a transpeptidation reaction which is involved in the metabolism of glutathione. Glutathione is abundant within the epithelial lining fluid of the lung. However, little is known about gamma-GT expression in the epithelial cells of the lung alveolus. Herein we show that the pulmonary alveolar epithelial type 2 cell expresses the gene for gamma-GT We were unable to detect expression in the pulmonary alveolar epithelial type 1 cell or in the pulmonary alveolar macrophage. gamma-GT expression in the pulmonary alveolar epithelial type 2 cell is via mRNA III, a transcript that was initially cloned from the liver. This cell synthesizes gamma-GT protein and releases enzyme activity into a surfactant-associated pool within the lung alveolus. The specific activity of this surfactant-associated enzyme is almost 10-fold higher than that of whole lung. This activity results from amphipathic gamma-GT since it partitions with lung surfactant phospholipid and with the detergent phase of Triton X-114. Activity can be dissociated from each by papain proteolysis. These results demonstrate that gamma-GT is expressed in the differentiated pulmonary alveolar epithelial type 2 cell and that amphipathic gamma-GT protein is released by this cell along with lung surfactant. These results suggest that surfactant may serve an expanded role in lung cell biology as the vehicle for the redistribution of amphipathic signal anchored proteins throughout the gas exchange surface of the lung.	UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	JOYCEBRADY, M (corresponding author), BOSTON UNIV,CTR PULM,SCH MED,K603,80 E CONCORD ST,BOSTON,MA 02118, USA.			Joyce-Brady, Martin/0000-0002-1898-6002	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047049, R01HL043395] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026012] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL47049, R01 HL43395] Funding Source: Medline; NIDDK NIH HHS [R01 DK26012] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BATTISTINI B, 1990, LIFE SCI, V47, P2435, DOI 10.1016/0024-3205(90)90488-D; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRODY JS, 1986, LAB INVEST, V59, P522; CANTIN AM, 1987, J APPL PHYSIOL, V63, P152, DOI 10.1152/jappl.1987.63.1.152; CASTLE JD, 1985, J MEMBRANE BIOL, V87, P13; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOBERT MN, 1990, J BIOL CHEM, V265, P2352; COLOMA J, 1986, NUCLEIC ACIDS RES, V14, P1393, DOI 10.1093/nar/14.3.1393; CRAPO JD, 1980, AM REV RESPIR DIS, V122, P123; CRYSTAL RG, 1991, LUNG SCI F, P247; CURTHOYS NP, 1979, ENZYME, V24, P383, DOI 10.1159/000458694; DARBOUY M, 1991, AM J PHYSIOL, V261, pC1130, DOI 10.1152/ajpcell.1991.261.6.C1130; DINSDALE D, 1992, HISTOCHEM J, V24, P144, DOI 10.1007/BF01047464; DOBBS LG, 1979, J CLIN INVEST, V63, P378, DOI 10.1172/JCI109313; EDWARDS AM, 1985, CARCINOGENESIS, V6, P733, DOI 10.1093/carcin/6.5.733; EVERS C, 1978, MEMBRANE BIOCHEM, V1, P203, DOI 10.3109/09687687809063848; FOLCH J, 1957, J BIOL CHEM, V226, P497; FORKERT PG, 1989, HISTOCHEM J, V21, P634, DOI 10.1007/BF01002482; FORMAN HJ, 1990, AM J PHYSIOL, V259, pL102, DOI 10.1152/ajplung.1990.259.2.L102; FUNKHOUSER JD, 1991, AM J PHYSIOL, V260, pL381, DOI 10.1152/ajplung.1991.260.6.L381; GLENNER GG, 1962, J HISTOCHEM CYTOCHEM, V10, P481, DOI 10.1177/10.4.481; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; GRIFFITHS SA, 1989, CANCER LETT, V46, P69, DOI 10.1016/0304-3835(89)90217-6; HABIB GM, 1992, MOL CARCINOGEN, V5, P75; HENDRICH S, 1987, CANCER METAST REV, V6, P155, DOI 10.1007/BF00052847; HIRATA E, 1984, J BIOCHEM-TOKYO, V96, P289, DOI 10.1093/oxfordjournals.jbchem.a134837; HOOFTMAN RN, 1988, J APPL TOXICOL, V8, P59, DOI 10.1002/jat.2550080110; HUGHEY RP, 1976, J BIOL CHEM, V251, P7863; HUGHEY RP, 1986, BIOCHIM BIOPHYS ACTA, V874, P150, DOI 10.1016/0167-4838(86)90112-3; INGBAR D H, 1989, American Review of Respiratory Disease, V139, pA256; JONES DT, 1987, J BIOL CHEM, V262, P14241; JOYCEBRADY M, 1991, J BIOL CHEM, V266, P6859; JOYCEBRADY MF, 1990, DEV BIOL, V137, P331, DOI 10.1016/0012-1606(90)90258-K; KOZAK EM, 1982, J BIOL CHEM, V257, P6322; KURAUCHI O, 1991, BIOCHEMISTRY-US, V30, P1618, DOI 10.1021/bi00220a025; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHUNA O, 1992, BIOCHEMISTRY-US, V31, P9190, DOI 10.1021/bi00153a011; LAPERCHE Y, 1986, P NATL ACAD SCI USA, V83, P937, DOI 10.1073/pnas.83.4.937; LEVINE RA, 1990, CELL REGUL, V1, P215, DOI 10.1091/mbc.1.2.215; MARSHALL BC, 1988, BIOCHIM BIOPHYS ACTA, V966, P403, DOI 10.1016/0304-4165(88)90091-8; MARTENSSON J, 1989, P NATL ACAD SCI USA, V86, P5296, DOI 10.1073/pnas.86.14.5296; MATSUDA Y, 1983, ADV ENZYME REGUL, V21, P103, DOI 10.1016/0065-2571(83)90010-9; MEISTER A, 1985, METHOD ENZYMOL, V113, P571; MEISTER A, 1973, SCIENCE, V180, P33, DOI 10.1126/science.180.4081.33; NIELSON DW, 1981, P NATL ACAD SCI-BIOL, V78, P7119, DOI 10.1073/pnas.78.11.7119; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; PAWLAK A, 1988, J BIOL CHEM, V263, P9913; RAJAGOPALAN S, 1990, J BIOL CHEM, V265, P11721; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUTENBURG AM, 1969, J HISTOCHEM CYTOCHEM, V17, P517, DOI 10.1177/17.8.517; SEMENZA G, 1986, ANNU REV CELL BIOL, V2, P255, DOI 10.1146/annurev.cellbio.2.1.255; SERABJITSINGH CJ, 1988, MOL PHARMACOL, V33, P279; SMITH GD, 1979, ANAL BIOCHEM, V100, P136, DOI 10.1016/0003-2697(79)90122-2; TATE SS, 1987, J BIOL CHEM, V262, P11403; TATE SS, 1981, MOL CELL BIOCHEM, V39, P357, DOI 10.1007/BF00232585; TATE SS, 1978, P NATL ACAD SCI USA, V75, P4806, DOI 10.1073/pnas.75.10.4806; TATE SS, 1985, METHOD ENZYMOL, V113, P400; TSUJI A, 1980, CLIN CHIM ACTA, V104, P361; TSUJI A, 1980, BIOMED RES-TOKYO, V1, P410, DOI 10.2220/biomedres.1.410; VANGOLDE LMG, 1988, PHYSIOL REV, V68, P374, DOI 10.1152/physrev.1988.68.2.374; VINA J, 1991, GLUTATHIONE METABOLI, P79; WEAVER TE, 1991, BIOCHEM J, V273, P249, DOI 10.1042/bj2730249; WILLIAMS MC, 1981, J HISTOCHEM CYTOCHEM, V29, P291, DOI 10.1177/29.2.7019304; WRIGHT JR, 1987, AM REV RESPIR DIS, V135, P426; YAMAMOTO K, 1988, CARCINOGENESIS, V9, P399, DOI 10.1093/carcin/9.3.399; YAMASHITA K, 1983, J BIOL CHEM, V258, P1098	66	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14219	14226						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	7910609				2022-12-25	WOS:A1994NL60600075
J	VENIER, P; MAGGS, AC; CARLIER, MF; PANTALONI, D				VENIER, P; MAGGS, AC; CARLIER, MF; PANTALONI, D			ANALYSIS OF MICROTUBULE RIGIDITY USING HYDRODYNAMIC FLOW AND THERMAL FLUCTUATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIC INSTABILITY; INDIVIDUAL MICROTUBULES; SURFACE LATTICE; TUBULIN; MICROSCOPY; POLYMERIZATION; RESOLUTION; HYDROLYSIS; PHOSPHATE; ANALOGS	We report the use of two independent new methods to measure the flexural rigidity of microtubules. Microtubules were grown off axonemal pieces adhering to a glass coverslip. In the first method, a hydrodynamic flow was applied to microtubules and the flexural rigidity was derived from the analysis of the bending shape of the microtubules at equilibrium in the flow. In the second method, the flexural rigidity was derived from the thermal fluctuations of the free end of axoneme-bound microtubules. With both methods, the flexural rigidity of standard GDP microtubules was estimated to be 0.85 +/- 0.2 x 10(-23) newtons x m(2) which corresponded to a persistence length of 2 +/- 0.2 mm. Binding of ligands known to affect the biochemical properties of microtubules affected their rigidity. The structural analogs of inorganic phosphate A1F(4)(-) and [BeF3-, H2O], which bind to the site of the gamma-phosphate of GTP on GDP microtubule and reconstitute the GDP-P-i microtubule intermediate state of GTP hydrolysis, cause an similar to 3-fold increase in microtubule flexural rigidity and persistence length. Taxol and taxotere, antitumoral microtubule stabilizing drugs, in contrast cause a decrease in flexural rigidity and appear to affect the three-dimensional superstructure of microtubules, which can no longer be considered as semi-flexible rods. The relationship between the mechanical properties of microtubules and their biological function is discussed.	ECOLE SUPER PHYS & CHIM IND VILLE PARIS, PHYSICOCHIM THEOR GRP, F-75231 PARIS 05, FRANCE	UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)	VENIER, P (corresponding author), CNRS, ENZYMOL LAB, F-91198 GIF SUR YVETTE, FRANCE.							AMOS LA, 1974, J CELL SCI, V14, P523; AMOS LA, 1991, J CELL SCI, P95; ANDREU JM, 1992, J MOL BIOL, V226, P169, DOI 10.1016/0022-2836(92)90132-4; BEESE L, 1987, J MOL BIOL, V194, P257, DOI 10.1016/0022-2836(87)90373-1; BISSERY MC, 1991, CANCER RES, V51, P4845; CARLIER MF, 1989, INT REV CYTOL, V115, P139; CARLIER MF, 1987, P NATL ACAD SCI USA, V84, P5257, DOI 10.1073/pnas.84.15.5257; CARLIER MF, 1989, BIOCHEMISTRY-US, V28, P1783, DOI 10.1021/bi00430a054; CARLIER MF, 1988, BIOCHEMISTRY-US, V27, P3555, DOI 10.1021/bi00410a005; CHRETIEN D, 1991, BIOL CELL, V71, P161, DOI 10.1016/0248-4900(91)90062-R; CROSS AR, 1991, CELL MOTIL CYTOSKEL, V20, P272, DOI 10.1002/cm.970200403; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P2747, DOI 10.1021/bi00062a003; DOI M, 1989, THEORY POLYM DYNAMIC, P318; DYE RB, 1993, J BIOL CHEM, V268, P6847; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; HORIO T, 1986, NATURE, V321, P605, DOI 10.1038/321605a0; INOUE S, 1986, VIDEO MICROSCOPY, P118; Landau L. D., 1986, THEORY ELASTICITY; MAGGS AC, 1990, EUROPHYS LETT, V12, P19, DOI 10.1209/0295-5075/12/1/004; MARKO JF, 1994, MACROMOLECULES, V27, P981, DOI 10.1021/ma00082a015; MIZUSHIMASUGANO J, 1983, BIOCHIM BIOPHYS ACTA, V755, P257, DOI 10.1016/0304-4165(83)90212-X; MURPHY DB, 1977, J MOL BIOL, V117, P33, DOI 10.1016/0022-2836(77)90021-3; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHREVEL J, 1975, J CELL BIOL, V66, P492, DOI 10.1083/jcb.66.3.492; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SIMON JR, 1992, CELL MOTIL CYTOSKEL, V21, P1, DOI 10.1002/cm.970210102; WADE RH, 1990, J MOL BIOL, V212, P775, DOI 10.1016/0022-2836(90)90236-F; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858	29	216	219	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13353	13360						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	7909808				2022-12-25	WOS:A1994NK18400047
J	WADA, I; OU, WJ; LIU, MC; SCHEELE, G				WADA, I; OU, WJ; LIU, MC; SCHEELE, G			CHAPERONE FUNCTION OF CALNEXIN FOR THE FOLDING INTERMEDIATE OF GP80, THE MAJOR SECRETORY PROTEIN IN MDCK CELLS - REGULATION BY REDOX STATE AND ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN BINDING-PROTEIN; POLYACRYLAMIDE-GEL ELECTROPHORESIS; ENDOPLASMIC-RETICULUM MEMBRANE; MOLECULAR CHAPERONE; DISULFIDE BONDS; BIP; SUBUNITS; GLYCOPROTEIN; GLUTATHIONE; RECEPTOR	The endoplasmic reticulum (ER) not only links the translational machinery to the endomembrane system in eukaryotic cells but also provides a protective environment for the folding of exoplasmic proteins translocated across the ER membrane. Here we describe that the lumenal surface of the ER membranes transiently tethers the folding intermediate of secretory proteins via a 90-kDa ER membrane protein, calnexin. We demonstrate that p70, the precursor to gp80, the major secretory protein in Madin-Darby canine kidney (MDCK) cells, was bound transiently to calnexin in the immediate post synthetic period (0-10 min) and showed a t(1/2) for dissociation from calnexin of 2.5 min. The bound p70 was found to be incompletely folded as assessed by susceptibility to proteinase K digestion. Perturbation of the redox state by 5 mM dithiothreitol or 1 mM diamide markedly inhibited the dissociation of p70 from calnexin (t(1/2) > 30 min). Cellular depletion of ATP led to premature dissociation of p70 from calnexin and the formation of p70 aggregates that did not bind calnexin. These findings demonstrate that nascent unfolded p70 is tethered to calnexin during normal protein maturation, including the formation and editing of disulfide bonds and that ATP is required for the productive interaction of gp80 and calnexin.	BETH ISRAEL HOSP, DIV GASTROENTEROL, CHARLES A DANA RES INST, CELL & MOLEC BIOL LAB, BOSTON, MA 02155 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02155 USA; MCGILL UNIV, DEPT ANAT & CELL BIOL, MONTREAL H3A 2B2, PQ, CANADA; UNIV OKLAHOMA, DEPT CHEM & BIOCHEM, NORMAN, OK 73019 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; McGill University; University of Oklahoma System; University of Oklahoma - Norman				Wada, Ikuo/0000-0001-5668-6994				AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; BLOUNT P, 1991, J CELL BIOL, V113, P1125, DOI 10.1083/jcb.113.5.1125; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; CALA SE, 1993, J BIOL CHEM, V268, P2969; DAVID V, 1993, J BIOL CHEM, V268, P9585; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DEVIRGILIO C, 1993, YEAST, V9, P185, DOI 10.1002/yea.320090209; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; DUNBAR BS, 1990, METHOD ENZYMOL, V182, P441; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FORSAYETH JR, 1992, J CELL BIOL, V117, P841, DOI 10.1083/jcb.117.4.841; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILCHRIST JSC, 1993, J BIOL CHEM, V268, P4291; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HORWICH AL, 1990, TRENDS BIOTECHNOL, V8, P126, DOI 10.1016/0167-7799(90)90153-O; HUANG LQ, 1993, J BIOL CHEM, V268, P6560; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; KONDORKOCH C, 1985, CELL, V43, P297, DOI 10.1016/0092-8674(85)90035-2; LIU JW, 1991, BIOCHEM INT, V25, P109; LODISH HF, 1991, J BIOL CHEM, V266, P14835; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MARGOLESE L, 1993, J BIOL CHEM, V268, P17959; MERILE JP, 1983, CELL, V34, P747; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NOIVA R, 1992, J BIOL CHEM, V267, P3553; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHEELE G, 1981, ANAL BIOCHEM, V112, P304, DOI 10.1016/0003-2697(81)90298-0; SCHEELE G, 1982, J BIOL CHEM, V257, P2277; SCHEELE G, 1983, J BIOL CHEM, V258, P2005; SELA M, 1957, SCIENCE, V125, P691, DOI 10.1126/science.125.3250.691; SILVA AD, 1993, J CELL BIOL, V260, P647; TATU U, 1993, EMBO J, V12, P2151, DOI 10.1002/j.1460-2075.1993.tb05863.x; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; VILLA A, 1992, NEUROSCIENCE, V49, P467, DOI 10.1016/0306-4522(92)90111-E; WADA I, 1991, J BIOL CHEM, V266, P19599	45	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7464	7472						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7907329				2022-12-25	WOS:A1994NA03200069
J	MENDOZA, JA; DEMELER, B; HOROWITZ, PM				MENDOZA, JA; DEMELER, B; HOROWITZ, PM			ALTERATION OF THE QUATERNARY STRUCTURE OF CPN60 MODULATES CHAPERONIN-ASSISTED FOLDING - IMPLICATIONS FOR THE MECHANISM OF CHAPERONIN ACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; MITOCHONDRIAL RHODANESE; ESCHERICHIA-COLI; PROTEIN; GROEL; PURIFICATION; PATHWAY; ATP	Chaperonin-mediated, in vitro folding of rhodanese by the intact protein cpn60 has previously been shown to require cpn10 and ATP hydrolysis (Martin, J., Langer, T., Boteva, R., Schramel, A, Horwich, A. L., and Hartl, F.-U. (1991) Nature 352, 36-42; Mendoza, J. A., Rogers, E., Lorimer, G. H., and Horowitz, P. M. (1991) J. Biol. Chem. 266, 13044-13049). The present work demonstrates that the rhodanese-cpn60 complex can be dissociated by urea to allow folding to proceed, thus removing the obligatory requirement for cpn10 and ATP. Analytical ultracentrifugation and circular dichroism show that tetradecameric cpn60 can be disassembled into monomers that retain substantial secondary structure. Unfolded rhodanese induces the reassembly of tetradecameric cpn60 from monomers, and binding of rhodanese stabilizes cpn60 quaternary structure. Intermediate cpn60 species, possibly heptamers, are detected at intermediate urea concentrations after addition of unfolded rhodanese. The use of urea has demonstrated a functionally related loosening of subunit interactions in cpn60 that is not detectable under usual solution conditions. Our data suggest a highly dynamic role for the quaternary structure of cpn60 in chaperonin-mediated protein folding.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78240	University of Texas System; University of Texas Health San Antonio				Demeler, Borries/0000-0002-2414-9518	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HOROWITZ PM, 1993, J BIOL CHEM, V268, P2500; HOROWITZ PM, 1978, ANAL BIOCHEM, V86, P751, DOI 10.1016/0003-2697(78)90803-5; JARABAK R, 1993, J BIOCHEM TOXICOL, V8, P41, DOI 10.1002/jbt.2570080107; LANDRY SJ, 1994, IN PRESS NATURE; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13587; MENDOZA JA, 1992, J BIOL CHEM, V267, P24648; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; TANDON S, 1986, J BIOL CHEM, V261, P5615; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; VITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665; VITANEN PV, 1992, J BIOL CHEM, V267, P695; ZAHN R, 1992, BIOCHEMISTRY-US, V31, P3249, DOI 10.1021/bi00127a029	32	61	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2447	2451						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	7905478				2022-12-25	WOS:A1994MV43200019
J	ALTUVIA, S; STEIN, WD; GOLDENBERG, S; KANE, SE; PASTAN, I; GOTTESMAN, MM				ALTUVIA, S; STEIN, WD; GOLDENBERG, S; KANE, SE; PASTAN, I; GOTTESMAN, MM			TARGETED DISRUPTION OF THE MOUSE MDR1B GENE REVEALS THAT STEROID-HORMONES ENHANCE MDR GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE GENE; DEPENDENT PROTEIN-KINASE; P-GLYCOPROTEIN; SECRETORY EPITHELIUM; TISSUES; UTERUS; MUTATIONS; FAMILY; CELLS	To evaluate the role of P-glycoprotein in steroid secretion in adrenal cells, we have used gene targeting to introduce a null mutation into one allele of the mdr1b gene in mouse Y1 adrenal cells. Characterization of both the wild-type and the mutant cell lines revealed the following. 1) The expression of mdr1b is enhanced by steroid hormones, in a feedback regulatory mechanism. Inhibition of steroid biosynthesis by 2-aminoglutethimide blocks the adrenocorticotropin (ACTH)-induced increase in mdr1b mRNA levels. 2) ACTH-stimulated steroid secretion is markedly decreased in the mutant cell line. This decreased steroid secretion in the mutant cells occurs despite an increase in the levels of mdr1b mRNA and P-glycoprotein. Kinetic analyses of vinblastine and daunomycin accumulation in both the wild-type and the mutant cell lines during ACTH-stimulated steroidogenesis show that in the mutant cells both drugs accumulated to higher levels than in Y1 cells, suggesting that the remaining mdr1b allele in the mutant cells is relatively inactive as an exporter of steroids, or that the targeted disruption of the mdr1b allele is associated with other changes in the mutant cells which block ACTH-stimulated steroid secretion.	NCI,CELL BIOL LAB,9000 ROCKVILLE PIKE,37-4E16,BETHESDA,MD 20892; CITY HOPE NATL MED CTR,DEPT CELLULAR & MOLEC BIOL,DUARTE,CA 91010; NCI,MOLEC BIOL LAB,BETHESDA,MD 20892; HEBREW UNIV JERUSALEM,SILBERMAN INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); City of Hope; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Hebrew University of Jerusalem			pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270				ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; ARCECI RJ, 1990, MOL REPROD DEV, V25, P101, DOI 10.1002/mrd.1080250202; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAUHAN SS, 1992, GENE, V120, P281, DOI 10.1016/0378-1119(92)90106-Y; CHIN KV, 1992, J CELL PHYSIOL, V152, P87, DOI 10.1002/jcp.1041520112; COHEN D, 1991, J BIOL CHEM, V266, P2239; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; KOREN R, 1979, EUR J BIOCHEM, V95, P333, DOI 10.1111/j.1432-1033.1979.tb12970.x; Kowal J, 1970, Recent Prog Horm Res, V26, P623; KOWAL J, 1968, ARCH BIOCHEM BIOPHYS, V128, P406, DOI 10.1016/0003-9861(68)90047-7; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; ORMEJOHNSON NR, 1990, BIOCHIM BIOPHYS ACTA, V1020, P213, DOI 10.1016/0005-2728(90)90151-S; PIEKARZ RL, 1993, J BIOL CHEM, V268, P7613; RAE PA, 1979, P NATL ACAD SCI USA, V76, P1896, DOI 10.1073/pnas.76.4.1896; TANAKA S, 1990, BIOCHEM BIOPH RES CO, V166, P180, DOI 10.1016/0006-291X(90)91928-L; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; UEDA K, 1992, J BIOL CHEM, V267, P2428; VANKALKEN CK, 1993, BRIT J CANCER, V67, P284, DOI 10.1038/bjc.1993.54; WOLF CR, 1992, INT J CANCER, V52, P3141; YANG CPH, 1989, J BIOL CHEM, V264, P782	28	59	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27127	27132						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	7903303				2022-12-25	WOS:A1993MM26200044
J	CARR, SF; PAPP, E; WU, JC; NATSUMEDA, Y				CARR, SF; PAPP, E; WU, JC; NATSUMEDA, Y			CHARACTERIZATION OF HUMAN TYPE-I AND TYPE-II IMP DEHYDROGENASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSINE 5'-MONOPHOSPHATE DEHYDROGENASE; HUMAN NORMAL LYMPHOCYTES; MYCOPHENOLIC-ACID; ESCHERICHIA-COLI; GENE-EXPRESSION; HEPATOMA 3924A; CELL LINES; INHIBITION; PURIFICATION; TIAZOFURIN	Human IMP dehydrogenase, a target for anticancer and immunosuppressive chemotherapy, exists as two isoforms, types I and II. Nonfusion sequences of each isoform were overexpressed in an IMP dehydrogenase-deficient strain of Escherichia coli and purified to homogeneity. Both recombinant isoforms were tetramers, which was in agreement with the subunit structure of the native mammalian enzyme. The results of initial velocity and product inhibition studies were consistent with an Ordered Bi Bi kinetic mechanism for both isoforms. Substrate affinities were similar for types I and II with K(m) values of 18 and 9.3 muM, respectively, for IMP, and 46 and 32 muM, respectively, for NAD. k(cat) values were 1.5 and 1.3 s-1 at 37-degrees-C for types I and II, respectively. Xanthosine 5'-monophosphate and NADH inhibited the two isoforms with identical inhibition patterns and inhibition constants. Mycophenolic acid, however, inhibited the type II enzyme with a 4.8-fold lower K(i) than the type I. Selective inhibitors of the inducible type II isoform may mitigate toxicity caused by inhibition of the constitutively expressed type I isoform.	SCHERING PLOUGH KK, 2-3-7 HIRANOMACHI, CHUO KU, OSAKA 541, JAPAN; SYNTEX DISCOVERY RES, INST BIOCHEM & CELL BIOL, PALO ALTO, CA 94303 USA	Merck & Company; Schering Plough Corporation; Syntex Corporation					NATIONAL CANCER INSTITUTE [R55CA060344] Funding Source: NIH RePORTER; NCI NIH HHS [1R55 CA60344-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; ANDERSON JH, 1967, FED PROC, V26, P730; BROX LW, 1968, BIOCHEMISTRY-US, V7, P2589, DOI 10.1021/bi00847a021; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; COLLART FR, 1992, CANCER RES, V52, P5826; COLLART FR, 1988, J BIOL CHEM, V263, P15769; DEIERHOI MH, 1993, TRANSPLANT P, V25, P693; EPINETTE WW, 1987, J AM ACAD DERMATOL, V17, P962, DOI 10.1016/S0190-9622(87)70285-0; GILBERT HJ, 1979, BIOCHEM J, V183, P481, DOI 10.1042/bj1830481; GLESNE DA, 1991, MOL CELL BIOL, V11, P5417, DOI 10.1128/MCB.11.11.5417; Gosio B., 1896, RIV DIGIENE SANITA P, V7, P825; HEDSTROM L, 1990, BIOCHEMISTRY-US, V29, P849, DOI 10.1021/bi00456a001; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; HODGES SD, 1989, J BIOL CHEM, V264, P18137; HOLMES EW, 1974, BIOCHIM BIOPHYS ACTA, V364, P209, DOI 10.1016/0005-2744(74)90006-0; HUPE DJ, 1986, J BIOL CHEM, V261, P8363; IKEGAMI T, 1987, LIFE SCI, V40, P2277, DOI 10.1016/0024-3205(87)90064-6; JACKSON RC, 1975, NATURE, V256, P331, DOI 10.1038/256331a0; KHARBANDA SM, 1990, BLOOD, V75, P583; KONNO Y, 1991, J BIOL CHEM, V266, P506; LIU MS, 1984, J BIOL CHEM, V259, P5078; METZ SA, 1992, J BIOL CHEM, V267, P12517; MORRIS RE, 1990, TRANSPLANT P, V22, P1659; MORRIS RE, 1991, TRANSPLANT P, V23, P19; NAGAI M, 1991, CANCER RES, V51, P3886; NAGAI M, 1992, CANCER RES, V52, P258; NATSUMEDA Y, 1990, J BIOL CHEM, V265, P5292; NATSUMEDA Y, 1988, CANCER RES, V48, P507; NIJKAMP HJJ, 1967, BIOCHIM BIOPHYS ACTA, V145, P31, DOI 10.1016/0005-2787(67)90651-X; PLATZ KP, 1991, TRANSPLANTATION, V51, P27, DOI 10.1097/00007890-199101000-00003; Sambrook J, 1989, MOL CLONING LABORATO; Segel I.H., 1975, ENZYME KINETICS; SIDI Y, 1988, BRIT J CANCER, V58, P61, DOI 10.1038/bjc.1988.162; SOLLINGER HW, 1993, TRANSPL P, V25, P698; STREETER DG, 1973, P NATL ACAD SCI USA, V70, P1174, DOI 10.1073/pnas.70.4.1174; TRICOT GJ, 1989, CANCER RES, V49, P3696; VERHAM R, 1987, MOL BIOCHEM PARASIT, V24, P1, DOI 10.1016/0166-6851(87)90110-1; YAMADA Y, 1988, BIOCHEMISTRY-US, V27, P2193, DOI 10.1021/bi00406a057	39	342	361	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27286	27290						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	7903306				2022-12-25	WOS:A1993MM26200065
J	AROCA, P; URABE, K; KOBAYASHI, T; TSUKAMOTO, K; HEARING, VJ				AROCA, P; URABE, K; KOBAYASHI, T; TSUKAMOTO, K; HEARING, VJ			MELANIN BIOSYNTHESIS PATTERNS FOLLOWING HORMONAL-STIMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HUMAN MELANOCYTES; HAIR FOLLICULAR MELANOCYTES; TYROSINASE MESSAGE LEVEL; MAMMALIAN TYROSINASE; DOPACHROME OXIDOREDUCTASE; CONTROL POINT; METAL-IONS; CELL-LINE; MELANOGENESIS; MOUSE	The effect of melanocyte-stimulating hormone (MSH) on the differentiation of mammalian melanocytes has been widely studied since the early 1950s. There have been many reports about the stimulatory effect of MSH on melanin production and specifically on the activity of tyrosinase, the critical enzyme in the melanogenic pathway. However, few and variable results have been obtained concerning the effect of this hormone on the regulation of DOPAchrome tautomerase (TRP2), another melanogenic enzyme which functions later in the melanogenic pathway, or on other melanogenic activities, such as TRP1. In this study, we show that the MSH-induced stimulation of tyrosinase is accompanied by no significant change in the synthesis or catalytic activities of other melanogenic enzymes such as TRP1 or TRP2. This in turn elicits a dramatic increase in melanin production accompanied by a significant decrease in the incorporation of carboxylated precursors into that melanin biopolymer, although the biological implication of that is still unclear.	NCI, CELL BIOL LAB, BLDG 37, RM 1B22, BETHESDA, MD 20892 USA; YAMANASHI MED UNIV, DEPT DERMATOL, YAMANASHI 40938, JAPAN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Yamanashi				Kobayashi, Takeshi/0000-0002-4372-5285; Aroca, Pilar/0000-0002-7557-6931				ABDELMALEK ZA, 1987, CANCER RES, V47, P3141; ABDELMALEK ZA, 1988, J CELL PHYSIOL, V136, P273, DOI 10.1002/jcp.1041360209; AROCA P, 1990, BIOCHIM BIOPHYS ACTA, V1035, P266, DOI 10.1016/0304-4165(90)90088-E; BARBER JI, 1985, J HERED, V76, P59, DOI 10.1093/oxfordjournals.jhered.a110019; BARBER JI, 1984, J INVEST DERMATOL, V83, P145, DOI 10.1111/1523-1747.ep12263381; BURCHILL SA, 1986, J ENDOCRINOL, V109, P15, DOI 10.1677/joe.0.1090015; BURCHILL SA, 1986, J ENDOCRINOL, V111, P225, DOI 10.1677/joe.0.1110225; CHAKRABORTY AK, 1991, J CELL PHYSIOL, V147, P1, DOI 10.1002/jcp.1041470102; CHAKRABORTY AK, 1992, PIGM CELL RES, V5, P84; DEXTER TJ, 1987, EXP CELL RES, V168, P255, DOI 10.1016/0014-4827(87)90433-2; ELLER M, 1990, J INVEST DERMATOL, V94, P521; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; FISHER PB, 1981, BIOCHEM BIOPH RES CO, V100, P823, DOI 10.1016/S0006-291X(81)80248-3; FRIEDMANN PS, 1987, J CELL PHYSIOL, V133, P88, DOI 10.1002/jcp.1041330111; FRIEDMANN PS, 1990, J CELL PHYSIOL, V142, P334, DOI 10.1002/jcp.1041420216; FULLER BB, 1987, J BIOL CHEM, V262, P4024; FULLER BB, 1979, LIFE SCI, V24, P2405, DOI 10.1016/0024-3205(79)90448-X; GORDON PR, 1989, J INVEST DERMATOL, V93, P700, DOI 10.1111/1523-1747.ep12319900; HALABAN R, 1990, P NATL ACAD SCI USA, V87, P4809, DOI 10.1073/pnas.87.12.4809; HALABAN R, 1984, ARCH BIOCHEM BIOPHYS, V230, P383, DOI 10.1016/0003-9861(84)90121-8; HALABAN R, 1983, J CELL BIOL, V97, P480, DOI 10.1083/jcb.97.2.480; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; HEARING VJ, 1987, METHOD ENZYMOL, V142, P154; HEARING VJ, 1987, INT J BIOCHEM, V19, P1141, DOI 10.1016/0020-711X(87)90095-4; HEARING VJ, 1976, BIOCHEM J, V157, P549, DOI 10.1042/bj1570549; HOSOI J, 1985, CANCER RES, V45, P1474; IMOKAWA G, 1982, CANCER RES, V42, P1994; IMOKAWA G, 1986, J INVEST DERMATOL, V87, P319, DOI 10.1111/1523-1747.ep12524388; JIMENEZ M, 1988, P NATL ACAD SCI USA, V85, P3830, DOI 10.1073/pnas.85.11.3830; JIMENEZ M, 1989, J BIOL CHEM, V264, P3397; JIMENEZ M, 1991, J BIOL CHEM, V266, P1147; KAMEYAMA K, 1993, J INVEST DERMATOL, V100, P126, DOI 10.1111/1523-1747.ep12462778; KAMEYAMA K, 1989, DIFFERENTIATION, V42, P28, DOI 10.1111/j.1432-0436.1989.tb00604.x; KAMEYAMA K, 1989, J CLIN INVEST, V83, P213, DOI 10.1172/JCI113861; KAMEYAMA K, 1988, J CELL PHYSIOL, V137, P35, DOI 10.1002/jcp.1041370105; KORNER A, 1977, NATURE, V267, P444, DOI 10.1038/267444a0; KORNER A, 1982, SCIENCE, V217, P1163, DOI 10.1126/science.6810464; KORNER AM, 1980, J INVEST DERMATOL, V75, P192, DOI 10.1111/1523-1747.ep12522650; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONARD LJ, 1988, BIOCHEMISTRY-US, V27, P6156, DOI 10.1021/bi00416a049; LERNER AB, 1950, PHYSIOL REV, V30, P91, DOI 10.1152/physrev.1950.30.1.91; MALEK ZAA, 1986, J NATL CANCER I, V76, P857; MARTINEZLIARTE JH, 1992, J INVEST DERMATOL, V99, P435, DOI 10.1111/1523-1747.ep12616139; MIRANDA M, 1985, BIOCHIM BIOPHYS ACTA, V841, P159, DOI 10.1016/0304-4165(85)90017-0; NAEYAERT JM, 1991, BRIT J DERMATOL, V125, P297, DOI 10.1111/j.1365-2133.1991.tb14161.x; ORLOW SJ, 1992, PIGM CELL RES, V5, P113, DOI 10.1111/j.1600-0749.1992.tb00007.x; ORLOW SJ, 1990, J CELL PHYSIOL, V142, P129, DOI 10.1002/jcp.1041420116; PALUMBO A, 1987, BIOCHIM BIOPHYS ACTA, V925, P203, DOI 10.1016/0304-4165(87)90110-3; PAVLOVITCH JH, 1982, MOL CELL ENDOCRINOL, V25, P295, DOI 10.1016/0303-7207(82)90085-5; PAWELEK J, 1980, NATURE, V286, P617, DOI 10.1038/286617a0; PAWELEK JM, 1976, J INVEST DERMATOL, V66, P201, DOI 10.1111/1523-1747.ep12482134; PAWELEK JM, 1991, PIGM CELL RES, V4, P53, DOI 10.1111/j.1600-0749.1991.tb00315.x; PAWELEK JM, 1985, YALE J BIOL MED, V58, P571; PAWELEK JM, 1992, PIGM CELL RES, V5, P91; PRESTON SF, 1987, P NATL ACAD SCI USA, V84, P5247, DOI 10.1073/pnas.84.15.5247; SWOPE VB, 1991, J INVEST DERMATOL, V96, P180, DOI 10.1111/1523-1747.ep12460991; SWOPE VB, 1989, J IMMUNOL, V142, P1943; TOMITA Y, 1988, J INVEST DERMATOL, V90, P882, DOI 10.1111/1523-1747.ep12462151; TOMITA Y, 1986, TOHOKU J EXP MED, V149, P451, DOI 10.1620/tjem.149.451; TRIPATHI RK, 1992, J BIOL CHEM, V267, P23707; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; TSUKAMOTO K, 1992, BIOCHEM J, V286, P491, DOI 10.1042/bj2860491; URABE K, 1993, PIGM CELL RES, V6, P186, DOI 10.1111/j.1600-0749.1993.tb00601.x; VALVERDE P, 1992, FEBS LETT, V304, P114, DOI 10.1016/0014-5793(92)80600-L; WONG G, 1975, NATURE, V255, P644, DOI 10.1038/255644a0; WONG G, 1973, NATURE-NEW BIOL, V241, P213, DOI 10.1038/newbio241213a0; [No title captured]	67	94	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25650	25655						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7902353				2022-12-25	WOS:A1993MK10000055
J	JAMIL, H; DICKSON, JK; CHU, CH; LAGO, MW; RINEHART, JK; BILLER, SA; GREGG, RE; WETTERAU, JR				JAMIL, H; DICKSON, JK; CHU, CH; LAGO, MW; RINEHART, JK; BILLER, SA; GREGG, RE; WETTERAU, JR			MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN - SPECIFICITY OF LIPID-BINDING AND TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; ESTER TRANSFER PROTEIN; DISULFIDE ISOMERASE; SECRETION; LIPASE; HEPATOCYTES; MECHANISM; COMPLEX; ABETALIPOPROTEINEMIA; PHOSPHATIDYLCHOLINE	Microsomal triglyceride transfer protein (MTP) is a lipid transfer protein that is required for the assembly and secretion of very low density lipoproteins by the liver and chylomicrons by the intestine. To further elucidate the nature of the lipid molecule binding and transport site on MTP, we have studied the relative rates at which MTP transports different lipid species. Assay conditions were chosen in which there were minimal changes in the physical properties of the substrate membranes so that transfer rates would reflect MTP-lipid interactions at a membrane surface. Lipid transport rates decreased in order of triglyceride > cholesteryl ester > diglyceride > cholesterol > phosphatidylcholine. Changes in the hydrophobic nature of a lipid molecule by the addition of a fatty acid, modulated the ability of MTP to transport it. Addition of one acyl chain from diglyceride to triglyceride, lysophosphatidylcholine to phosphatidylcholine, or cholesterol to cholesteryl ester increased the rate of MTP-mediated transport 10-fold. In contrast, the lipid transport rate was insensitive to the changes in the structure or charge of the polar head group on phospholipid substrates. Zwitterionic, net negative, or net positive charged phospholipid molecules were all transported at a comparable rate. The ability of MTP to transport lipids is strongly correlated to the binding of these lipids to MTP. Thus, MTP has a specific preference for binding and transporting nonpolar lipid compared with phospholipids, and within a class of lipid molecules, a decrease in polarity increases its tendency to be transported.			JAMIL, H (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT METAB DIS,POB 4000,PRINCETON,NJ 08543, USA.							ARVIDSON GA, 1968, EUR J BIOCHEM, V4, P478, DOI 10.1111/j.1432-1033.1968.tb00237.x; ATZEL A, 1993, BIOCHEMISTRY-US, V32, P10444, DOI 10.1021/bi00090a021; ATZEL A, 1993, FASEB J, V7, pA1268; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOLLEN IC, 1980, BIOCHEM J, V189, P475, DOI 10.1042/bj1890475; BOREN J, 1991, PROG LIPID RES, V30, P205, DOI 10.1016/0163-7827(91)90017-Y; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; Davis R A, 1993, Subcell Biochem, V21, P169; DECKELBAUM RJ, 1992, BIOCHEMISTRY-US, V31, P8544, DOI 10.1021/bi00151a023; DEREWENDA ZS, 1993, TRENDS BIOCHEM SCI, V18, P20, DOI 10.1016/0968-0004(93)90082-X; GIBBONS GF, 1990, BIOCHEM J, V268, P1; Gregg Richard E., 1994, Current Opinion in Lipidology, V5, P81, DOI 10.1097/00041433-199404000-00003; HIDE WA, 1992, J LIPID RES, V33, P167; HIGGINS JA, 1984, J LIPID RES, V25, P1295; HUANG C, 1978, P NATL ACAD SCI USA, V75, P388; HUTSON JL, 1982, BIOCHIM BIOPHYS ACTA, V687, P247, DOI 10.1016/0005-2736(82)90553-3; JANERO DR, 1983, J BIOL CHEM, V258, P4496; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHIRAI K, 1983, J LIPID RES, V24, P721; SHOULDERS CC, 1994, STRUCTURAL BIOL, V1, P285; SHOULDERS CC, 1993, HUM MOL GENET, V12, P2109; SWENSON TL, 1988, J BIOL CHEM, V263, P5150; VANCE JE, 1985, CAN J BIOCHEM CELL B, V63, P870, DOI 10.1139/o85-108; VANCE JE, 1990, ANNU REV NUTR, V10, P337, DOI 10.1146/annurev.nu.10.070190.002005; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; WETTERAU JR, 1985, CHEM PHYS LIPIDS, V38, P205, DOI 10.1016/0009-3084(85)90068-4; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P4406, DOI 10.1021/bi00232a006; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73; WOOD R, 1969, ARCH BIOCHEM BIOPHYS, V131, P478, DOI 10.1016/0003-9861(69)90420-2; YAO ZM, 1994, BBA-LIPID LIPID MET, V1212, P152, DOI 10.1016/0005-2760(94)90249-6; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1; [No title captured]	39	145	151	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6549	6554		10.1074/jbc.270.12.6549	http://dx.doi.org/10.1074/jbc.270.12.6549			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896791	Green Submitted, hybrid			2022-12-25	WOS:A1995QQ85500021
J	KILBOURNE, EJ; WIDOM, R; HARNISH, DC; MALIK, S; KARATHANASIS, SK				KILBOURNE, EJ; WIDOM, R; HARNISH, DC; MALIK, S; KARATHANASIS, SK			INVOLVEMENT OF EARLY GROWTH-RESPONSE FACTOR EGR-1 IN APOLIPOPROTEIN AI GENE-TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I GENE; RETINOIC ACID; RECEPTOR SUPERFAMILY; CONTROL EXPRESSION; CELL-GROWTH; 3T3 CELLS; C-FOS; BINDING; DNA; RAT	Liver-specific expression of the apolipoprotein AI (apoAI) gene is mediated by transcription factors bound to three sites (A, B, and C) in the apoAI enhancer. Sites A and C bind various members of the nuclear receptor superfamily, including the orphan nuclear receptor apolipoprotein regulatory protein-1 (ARP-1); site B binds the liver enriched factor hepatic nuclear factor-3. The immediate early growth response factor (Egr-1), which is transiently expressed in various pathophysiologic states of the liver, activates the apoAI enhancer and overcomes ARP-1-mediated repression of the enhancer in hepatoblastoma HepG2 cells. Deletion mapping analysis revealed two Egr-1 binding sites, E1 and E2, flanking site A. Egr-1 bound efficiently to both E1 and E2. Sp1 in HepG2 nuclear extracts bound to E2 but not E1. In HepG2 cells, E1 functioned as an Egr-1 response element, whereas E2 had high basal activity and was not further induced by Egr-1. Mutations that prevent Egr-1 binding to the apoAI enhancer abolished its responsiveness to Egr-1, while they had only minor effects on its constitutive activity. These mutations also diminished the ability of Egr-1 to overcome ARP-1-mediated repression. Elimination of transcription factor binding to sites A, B, or C reduced enhancer activity without affecting Egr-1 dependent activation. We argue that Egr-1 is recruited to the apoAI enhancer complex under unusual circumstances, such as those prevailing during liver regeneration, to maintain apoAI transcription levels by overriding prior transcriptional controls.	AMER CYANAMID CO, LEDERLE LABS, DEPT CARDIOVASC MOLEC BIOL, PEARL RIVER, NY 10965 USA; CHILDRENS HOSP, DEPT CARDIOL, MOLEC & CELLULAR CARDIOL LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School								ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; APOSTOLOPOULOS JJ, 1988, BIOCHEM BIOPH RES CO, V154, P997, DOI 10.1016/0006-291X(88)90238-0; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CAO XM, 1993, J BIOL CHEM, V268, P16949; CHAN J, 1993, NUCLEIC ACIDS RES, V21, P1205, DOI 10.1093/nar/21.5.1205; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; EDWARDS SA, 1991, DEV BIOL, V148, P165, DOI 10.1016/0012-1606(91)90327-Y; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P8242, DOI 10.1073/pnas.82.23.8242; ETTINGER WH, 1994, ARTERIOSCLER THROMB, V14, P8, DOI 10.1161/01.ATV.14.1.8; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fausto N, 1990, CURR OPIN CELL BIOL, V2, P1036, DOI 10.1016/0955-0674(90)90153-6; FLODBY P, 1993, EXP CELL RES, V208, P248, DOI 10.1006/excr.1993.1244; GE RW, 1994, J BIOL CHEM, V269, P13185; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HADDAD IA, 1986, J BIOL CHEM, V261, P3268; HARNISH DC, 1994, J BIOL CHEM, V269, P28220; HENDERSON SA, 1994, J BIOL CHEM, V269, P25239; KARATHANASIS SK, 1992, MONOGR HUM GENET, V14, P140; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LIM RW, 1987, ONCOGENE, V1, P263; MADDEN SL, 1993, ANN NY ACAD SCI, V684, P75, DOI 10.1111/j.1749-6632.1993.tb32272.x; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MERRYMAN PF, 1993, ARTHRITIS RHEUM, V36, P1414, DOI 10.1002/art.1780361014; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MIRKOVITCH J, 1991, GENE DEV, V1, P256; MISCHOULON D, 1992, MOL CELL BIOL, V12, P2553, DOI 10.1128/MCB.12.6.2553; NATHANS D, 1988, COLD SPRING HARB SYM, V53, P893, DOI 10.1101/SQB.1988.053.01.102; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; PANDURO A, 1990, BIOCHEMISTRY-US, V29, P8430, DOI 10.1021/bi00488a033; PAPAZAFIRI P, 1991, J BIOL CHEM, V266, P5790; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; Sambrook J, 1989, MOL CLONING LABORATO; SASTRY KN, 1988, MOL CELL BIOL, V8, P605, DOI 10.1128/MCB.8.2.605; SEYFERT VL, 1989, MOL CELL BIOL, V9, P2083, DOI 10.1128/MCB.9.5.2083; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SORCITHOMAS M, 1989, J LIPID RES, V30, P1397; STAELS B, 1992, ARTERIOSCLER THROMB, V12, P286, DOI 10.1161/01.ATV.12.3.286; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUVA LJ, 1991, MOL CELL BIOL, V11, P2503, DOI 10.1128/MCB.11.5.2503; TAM SP, 1986, P NATL ACAD SCI USA, V83, P3111, DOI 10.1073/pnas.83.10.3111; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TRIPODI M, 1991, EMBO J, V10, P3177, DOI 10.1002/j.1460-2075.1991.tb04879.x; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WIDOM RL, 1991, MOL CELL BIOL, V11, P677, DOI 10.1128/MCB.11.2.677; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; XANTHOPOULOS KG, 1993, EUR J BIOCHEM, V216, P353, DOI 10.1111/j.1432-1033.1993.tb18152.x; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	54	51	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					7004	7010		10.1074/jbc.270.12.7004	http://dx.doi.org/10.1074/jbc.270.12.7004			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896852	hybrid			2022-12-25	WOS:A1995QQ85500083
J	MENDEZ, AJ				MENDEZ, AJ			MONENSIN AND BREFELDIN-A INHIBIT HIGH-DENSITY LIPOPROTEIN-MEDIATED CHOLESTEROL EFFLUX FROM CHOLESTEROL-ENRICHED CELLS - IMPLICATIONS FOR INTRACELLULAR CHOLESTEROL TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE SPHINGOMYELIN; PROTEIN-KINASE-C; CULTURED FIBROBLASTS; GOLGI-APPARATUS; ENDOPLASMIC-RETICULUM; ADIPOSE-CELLS; SMOOTH-MUSCLE; APOLIPOPROTEINS; MACROPHAGES; ESTERIFICATION	Mechanisms and pathways of excess cholesterol removal from intracellular sites of accumulation to extracellular cholesterol accepters remain poorly defined. To gain further insights, compounds known to affect cellular protein transport pathways were tested for their effects on high density lipoprotein (HDL) mediated cholesterol efflux from cultured cells enriched with cholesterol. Monensin, nigericin, and brefeldin A inhibited the ability of HDL to decrease cellular cholesterol esterification, stimulate sterol biosynthesis, and promote the efflux of labeled cholesterol and cholesterol mass from fibroblasts and smooth muscle cells. HDL-mediated decrease in cell cholesterol esterification was inhibited up to 80% by these compounds compared with control incubations over an HDL concentration of 5-100 mu g/ml and up to 18 h of incubation, Up-regulation of sterol biosynthesis after depletion of cell cholesterol by HDL increased over 10- fold; however, inclusion of monensin or brefeldin A during the incubation completely prevented the increase of sterol biosynthesis by HDL. Efflux of [H-3]cholesterol to HDL from prelabeled cells was inhibited up to 40% by these compounds, and this effect persisted when cholesterol esterification was blocked. Similarly, monensin and brefeldin A inhibited up to 50% of HDL-mediated cholesterol mass efflux relative to controls, Treatment of cells with cholesterol oxidase demonstrated an increase of intracellular cholesterol after exposure to monensin or nigericin and to a lesser extent with brefeldin A. These data show that monensin, nigericin, and brefeldin A sequester cholesterol from sites normally available for efflux by HDL. Since these compounds act by disruption of Golgi complex structure and function, a rob for this intracellular organelle in transport of cholesterol between intracellular sites and the plasma membrane for eventual removal by extracellular accepters such as HDL is suggested.			MENDEZ, AJ (corresponding author), MASSACHUSETTS GEN HOSP, CARDIAC UNIT, JACKSON 1422, 32 FRUIT ST, BOSTON, MA 02114 USA.							AZHAR S, 1994, J LIPID RES, V35, P1161; BARKIA A, 1991, ATHEROSCLEROSIS, V87, P135, DOI 10.1016/0021-9150(91)90016-V; BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; BERNARD DW, 1991, J BIOL CHEM, V266, P710; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CABAUD PG, 1958, AM J CLIN PATHOL, V30, P234, DOI 10.1093/ajcp/30.3.234; DELAMATRE J, 1986, BIOCHIM BIOPHYS ACTA, V875, P419, DOI 10.1016/0005-2760(86)90061-5; ECHEVARRIA F, 1990, J BIOL CHEM, V265, P8484; FIELDING CJ, 1982, MED CLIN N AM, V66, P363, DOI 10.1016/S0025-7125(16)31425-0; FOLCH J, 1957, J BIOL CHEM, V226, P497; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; HASUMI K, 1993, BIOCHIM BIOPHYS ACTA, V1167, P155, DOI 10.1016/0005-2760(93)90156-4; HOKLAND BM, 1993, J BIOL CHEM, V268, P25343; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; KALLEN KJ, 1993, BIOCHEM J, V289, P307, DOI 10.1042/bj2890307; KALLEN KJ, 1993, BIOCHIM BIOPHYS ACTA, V1166, P305, DOI 10.1016/0005-2760(93)90111-L; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LANGE Y, 1983, J BIOL CHEM, V258, P5130; LANGE Y, 1993, J BIOL CHEM, V268, P13838; LEE M, 1992, ARTERIOSCLER THROMB, V12, P1329, DOI 10.1161/01.ATV.12.11.1329; LIPSKY NG, 1985, J CELL BIOL, V100, P27, DOI 10.1083/jcb.100.1.27; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLBERG FH, 1992, J BIOL CHEM, V267, P4541; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MENDEZ AJ, 1994, J CLIN INVEST, V94, P1698, DOI 10.1172/JCI117515; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; MORRE DJ, 1983, EUR J CELL BIOL, V30, P25; Oram J F, 1986, Methods Enzymol, V129, P645; ORAM JF, 1983, ARTERIOSCLEROSIS, V3, P420, DOI 10.1161/01.ATV.3.5.420; ORAM JF, 1991, ARTERIOSCLER THROMB, V11, P403, DOI 10.1161/01.ATV.11.2.403; ORCI L, 1981, P NATL ACAD SCI-BIOL, V78, P293, DOI 10.1073/pnas.78.1.293; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; SHIAO YJ, 1993, J BIOL CHEM, V268, P26085; SLOTTE JP, 1990, BIOCHIM BIOPHYS ACTA, V1025, P152; SLOTTE JP, 1987, J BIOL CHEM, V262, P12904; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; STEIN O, 1992, BIOCHIM BIOPHYS ACTA, V1125, P28, DOI 10.1016/0005-2760(92)90151-K; TABAS I, 1988, J BIOL CHEM, V263, P1266; THERET N, 1990, BIOCHEM BIOPH RES CO, V173, P1361, DOI 10.1016/S0006-291X(05)80938-6; URBANI L, 1990, J BIOL CHEM, V265, P1919; VAN MEER G, 1993, J CELL SCI, V104, P833; WATTENBERG BW, 1983, J BIOL CHEM, V258, P2284; WIESGRABER KH, 1980, J LIPID RES, V21, P623; YEAGLE PL, 1986, J BIOL CHEM, V261, P8175	49	69	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					5891	5900		10.1074/jbc.270.11.5891	http://dx.doi.org/10.1074/jbc.270.11.5891			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890720	hybrid			2022-12-25	WOS:A1995QM94500032
J	LOETSCHER, P; SEITZ, M; CLARKLEWIS, I; BAGGIOLINI, M; MOSER, B				LOETSCHER, P; SEITZ, M; CLARKLEWIS, I; BAGGIOLINI, M; MOSER, B			MONOCYTE CHEMOTACTIC PROTEINS MCP-1, MCP-2, AND MCP-3 ARE MAJOR ATTRACTANTS FOR HUMAN CD4(+) AND CD8(+) T-LYMPHOCYTES	FASEB JOURNAL			English	Article						CHEMOKINES; MONOCYTE CHEMOTACTIC PROTEINS; CHEMOTAXIS; CA2+ MOBILIZATION	NEUTROPHIL-ACTIVATING PEPTIDE-2; CELL ADHESION; GRO-ALPHA; MIGRATION; INTERLEUKIN-8; RECEPTORS; CYTOKINE; RANTES; MIP-1-BETA; CHEMOATTRACTANT	The responses of lymphocytes to six CC chemokines-MCP-1, MCP-2, MCP-3, MIP-1 alpha, MIP-1 beta, and RANTES-were studied using cloned human CD4(+) and CD8(+) T cells. All CC chemokines tested induced migration of both types of lymphocytes, whereas two CXC chemokines used as controls, IL-8 and IP-10, were inactive. The monocyte chemotactic proteins (MCP-1, MCP-2, and MCP-3) showed a typically bimodal concentration dependence, and were considerably more effective than MIP-1 alpha, MIP-1 beta, or RANTES. All CC chemokines also induced a rapid and transient rise in cytosolic free Ca2+ in either type of T cell. The rise was prevented by Bordetella pertussis toxin treatment, indicating that G-protein-coupled receptors are involved in signaling. It was most pronounced with MCP-1 and MCP-3, which is in agreement with the efficacy of these chemokines as chemoattractants. The responses to MCP-2, MIP-1 alpha, MIP-1 beta, and RANTES were weaker, and no changes were obtained on stimulation with IL-8 or IP-10. Freshly isolated human blood lymphocytes were also tested, but neither migration nor Ca2+ changes were observed. Low numbers of high-affinity receptors for MCP-1 were found on CD4(+) and CD8(+) cells (< 900 per cell, K-d <1 nM), and desensitization experiments showed that MCP-1, MCP-2, and MCP-3 share receptors. Owing to their superior effectiveness on CD4(+) and CD8(+) T cells, the monocyte chemotactic proteins could play a major role in the recruitment of activated T lymphocytes.	UNIV HOSP BERN,DIV RHEUMATOL,CH-3010 BERN,SWITZERLAND; UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT BIOCHEM,VANCOUVER V6T 1Z3,BC,CANADA	University of Bern; University Hospital of Bern; University of British Columbia; University of British Columbia	LOETSCHER, P (corresponding author), UNIV BERN,THEODOR KOCHER INST,PO BOX,FREIESTR 1,CH-3000 BERN 9,SWITZERLAND.			Moser, Bernhard/0000-0002-4354-4572				BACON KB, 1990, BIOCHEM BIOPH RES CO, V169, P1099, DOI 10.1016/0006-291X(90)92008-N; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BISCHOFF SC, 1993, EUR J IMMUNOL, V23, P761, DOI 10.1002/eji.1830230329; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; COLOTTA F, 1984, J IMMUNOL, V132, P936; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; GEISER T, 1993, J BIOL CHEM, V268, P15419; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LUSTER AD, 1993, J EXP MED, V178, P1057, DOI 10.1084/jem.178.3.1057; MEURER R, 1993, J EXP MED, V178, P1913, DOI 10.1084/jem.178.6.1913; MOSER B, 1991, J BIOL CHEM, V266, P10666; NAPOLITANO M, 1990, J EXP MED, V172, P285, DOI 10.1084/jem.172.1.285; PILARO AM, 1990, J IMMUNOL METHODS, V135, P213, DOI 10.1016/0022-1759(90)90275-Z; ROLLINS BJ, 1991, BLOOD, V78, P1112; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; SCHALL TJ, 1993, J EXP MED, V177, P1821, DOI 10.1084/jem.177.6.1821; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHNITZEL W, 1991, BIOCHEM BIOPH RES CO, V180, P301, DOI 10.1016/S0006-291X(05)81292-6; SCHUMACHER C, 1992, P NATL ACAD SCI USA, V89, P10542, DOI 10.1073/pnas.89.21.10542; SOZZANI S, 1991, J IMMUNOL, V147, P2215; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; TAUB DD, 1993, J EXP MED, V177, P1809, DOI 10.1084/jem.177.6.1809; VANDAMME J, 1992, J EXP MED, V176, P59, DOI 10.1084/jem.176.1.59; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0; WALZ A, 1991, J EXP MED, V174, P1355, DOI 10.1084/jem.174.6.1355; ZACHARIAE COC, 1990, J EXP MED, V171, P2177, DOI 10.1084/jem.171.6.2177	29	298	310	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1994	8	13					1055	1060		10.1096/fasebj.8.13.7926371	http://dx.doi.org/10.1096/fasebj.8.13.7926371			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PN069	7926371				2022-12-25	WOS:A1994PN06900010
J	RASCLE, A; GHYSDAEL, J; SAMARUT, J				RASCLE, A; GHYSDAEL, J; SAMARUT, J			C-ERBA, BUT NOT V-ERBA, COMPETES WITH A PUTATIVE ERYTHROID REPRESSOR FOR BINDING TO THE CARBONIC-ANHYDRASE-II PROMOTER	ONCOGENE			English	Article							THYROID-HORMONE RECEPTOR; RETINOID-X-RECEPTOR; BETA-GLOBIN GENE; ACID RECEPTORS; RESPONSE ELEMENT; NUCLEAR RECEPTORS; VITAMIN-D; TRANSCRIPTION; PROTEIN; CELLS	The carbonic anhydrase II (CAII) gene is the only known gene identified as direct target for v-ErbA-mediated repression in avian erythroleukemic cells transformed by Avian Erythroblastosis Virus (AEV). This gene is transcriptionally activated by thyroid hormone (T3) in normal erythrocytic cells. In this work we have analysed the molecular basis of the transcriptional control of the CAII gene by c-ErbA and v-ErbA. We show that several domains in the promoter control hormonal regulation of transcription. One domain proximal to the TATA box mediates T3 response but contains no identified binding site for c-ErbA. An other domain termed PAL2 is approximately 600 bp upstream the transcription initiation site and contains a c-ErbA binding site. We show that when it is associated to a heterologous promoter this site mediates transcriptional repression in erythrocytic cells but not in HeLa cells. Moreover, this site binds a nuclear erythrocyte-specific factor that we called NFX, which is different from c-ErbA. Heterodimers between c-ErbA and the 9-cis retinoic acid receptor (RXR) compete with NFX for binding to PAL2. In contrast, v-ErbA alone or in association with RXR is a very poor competitor and is unable to chase NFX out of the PAL2 site. We propose that NFX is a transcription repressor whose activity is inhibited by c-ErbA but not v-ErbA. This mechanism might contribute to the overall regulation of the carbonic anhydrase II promoter. These data illustrate another possible mechanism through which v-ErbA might antagonize the function of c-ErbA in controlling gene expression.	ECOLE NORMALE SUPER LYON,INRA,BIOL MOLEC & CELLULAIRE LAB,CNRS,UMR49,F-69364 LYON 07,FRANCE; CTR UNIV ORSAY,INST CURIE,BIOL SECT,F-91405 ORSAY,FRANCE	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); INRAE; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay			Samarut, Jacques/AAD-2587-2019; GHYSDAEL, Jacques/F-3377-2013; Rascle, Anne/AAC-1904-2019	Rascle, Anne/0000-0001-7464-8545				ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; BIGLER J, 1988, MOL CELL BIOL, V8, P4155, DOI 10.1128/MCB.8.10.4155; CHEN HW, 1993, MOL CELL BIOL, V13, P5970, DOI 10.1128/MCB.13.10.5970; CHOI OR, 1986, NATURE, V323, P731, DOI 10.1038/323731a0; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; CRENON I, 1993, ONCOGENE, V8, P867; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; EMERSON BM, 1987, P NATL ACAD SCI USA, V84, P4786, DOI 10.1073/pnas.84.14.4786; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; GANDRILLON O, 1994, ONCOGENE, V9, P749; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HALLENBECK PL, 1993, J BIOL CHEM, V268, P3825; HARDING PP, 1992, J BIOL CHEM, V267, P14145; HENTZEN D, 1987, MOL CELL BIOL, V7, P2416, DOI 10.1128/MCB.7.7.2416; HERMANN T, 1993, ONCOGENE, V8, P55; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LEHMANN JM, 1993, MOL CELL BIOL, V13, P7698, DOI 10.1128/MCB.13.12.7698; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LIEBER MR, 1987, J CELL BIOL, V105, P1055, DOI 10.1083/jcb.105.3.1055; LU XP, 1993, MOL CELL BIOL, V13, P6509, DOI 10.1128/MCB.13.10.6509; LUCAS PC, 1991, MOL CELL BIOL, V11, P5164, DOI 10.1128/MCB.11.10.5164; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; PAIN B, 1990, New Biologist, V2, P284; PARK HY, 1993, MOL ENDOCRINOL, V7, P319, DOI 10.1210/me.7.3.319; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; SANDE S, 1993, J VIROL, V67, P1067, DOI 10.1128/JVI.67.2.1067-1074.1993; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SCHROEDER C, 1992, ONCOGENE, V7, P217; SEGARS JH, 1993, MOL CELL BIOL, V13, P2258, DOI 10.1128/MCB.13.4.2258; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; VENNSTROM B, 1980, J VIROL, V36, P575; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WILLIAMS GR, 1992, MOL ENDOCRINOL, V6, P1527, DOI 10.1210/me.6.10.1527; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	54	21	21	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2853	2867						15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	7916146				2022-12-25	WOS:A1994PG82200011
J	ZHANG, L; SACHS, CW; FINE, RL; CASEY, PJ				ZHANG, L; SACHS, CW; FINE, RL; CASEY, PJ			INTERACTION OF PRENYLCYSTEINE METHYL-ESTERS WITH THE MULTIDRUG-RESISTANCE TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INSECT CELLS; EXPRESSION; IDENTIFICATION; QUANTITATION; GLYCOPROTEIN; BINDING	The multidrug resistance transporter is an integral membrane protein, termed P-glycoprotein, which can function as an ATP dependent drug efflux pump to reduce intracellular drug accumulation in treated cells. The physiologic function of this protein in normal cells, however, is not completely understood. We report here that prenylcysteine methyl esters, which represent the C-terminal structures of prenylated proteins, both stimulate the transporter's intrinsic ATPase activity and compete for drug binding. The structural elements of prenylcysteine methyl esters involved in their interaction with P-glycoprotein include the isoprenoid moiety, the carboxyl methyl group, and the free amino group. These findings indicate that these molecules are potential physiologic ligands of the transporter. Furthermore, as the structures of the active prenylcysteines are distinct from the known substrates of P-glycoprotein, this information may facilitate design of novel inhibitors of the transporter.	DUKE UNIV,VET ADM MED CTR,MED CTR,DEPT MOLEC CANC BIOL,DURHAM,NC 27710; DUKE UNIV,VET ADM MED CTR,MED CTR,DEPT MED,DIV HEMATOL ONCOL,DURHAM,NC 27710; DUKE UNIV,VET ADM MED CTR,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710; DUKE UNIV,VET ADM MED CTR,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)				Casey, Patrick/0000-0002-7366-9309				AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; BECK WT, 1992, BIOCHEM PHARMACOL, V43, P89, DOI 10.1016/0006-2952(92)90665-6; BLOBE GC, 1993, J BIOL CHEM, V268, P658; BODANSKY M, 1984, PRACTICE PEPTIDE SYN, P16; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MJ, 1991, J AM CHEM SOC, V113, P2176; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CORNWELL MM, 1986, J BIOL CHEM, V261, P7921; DAVISSON VJ, 1985, METHOD ENZYMOL, V110, P130; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; EPSTEIN WW, 1991, P NATL ACAD SCI USA, V88, P9668, DOI 10.1073/pnas.88.21.9668; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Michaelis S, 1993, Semin Cell Biol, V4, P17, DOI 10.1006/scel.1993.1003; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P124; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; SAFA AR, 1987, J BIOL CHEM, V262, P7884; SAPPERSTEIN S, 1994, MOL CELL BIOL, V14, P1438, DOI 10.1128/MCB.14.2.1438; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; WANG WWH, 1993, P NATL ACAD SCI USA, V90, P868	25	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					15973	15976						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	7911465				2022-12-25	WOS:A1994NQ72900005
J	KIM, TD; BURSTYN, JN				KIM, TD; BURSTYN, JN			IDENTIFICATION AND PARTIAL-PURIFICATION OF AN ENDOGENOUS INHIBITOR OF SOLUBLE GUANYLYL CYCLASE FROM BOVINE LUNG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; DEPENDENT PROTEIN-KINASE; NITRIC-OXIDE; CYCLIC-GMP; RELAXING FACTOR; PROTOPORPHYRIN-IX; HEME-DEFICIENT; NITROSYL-HEME; ACTIVATION; ENZYME	An endogenous inhibitor of soluble guanylyl cyclase from bovine lung has been partially purified by use of anion exchange, hydrophobic interaction, and gel filtration chromatography. This inhibitor is a protein with a molecular weight of about 149,000 which was estimated from its elution behavior, versus that of a series of standards, on a Sephacryl S-300-HR column. Its activity was measured by comparison of the level of cGMP production from soluble guanylyl cyclase in the presence and absence of the inhibitor protein. Soluble guanylyl cyclase is inhibited by this protein when either Mg2+ or Mn2+ is used as a cofactor. The insensitivity of its inhibitory activity to both isobutylmethylxanthine and the presence of cGMP demonstrates that this new protein is not a phosphodiesterase. This new protein inhibits both activated and unactivated soluble guanylyl cyclase. Because the inhibition was found to be noncompetitive with respect to the substrate, GTP, it appears that this inhibitor may be an allosteric regulator of soluble guanylyl cyclase.	UNIV WISCONSIN,DEPT CHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison				Burstyn, Judith/0000-0003-3245-5563				Bliss CI, 1935, ANN APPL BIOL, V22, P134, DOI 10.1111/j.1744-7348.1935.tb07713.x; BRANDWEIN HJ, 1981, J BIOL CHEM, V256, P2958; BUSYGINA OG, 1991, BIOCHEMISTRY-US, V55, P1354; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; CRAVEN PA, 1978, J BIOL CHEM, V253, P8433; FARRUKH IS, 1992, AM REV RESPIR DIS, V145, P1389, DOI 10.1164/ajrccm/145.6.1389; FELBEL J, 1988, J BIOL CHEM, V263, P16764; FURUKAWA KI, 1988, J BIOL CHEM, V263, P8058; GARBERS DL, 1979, J BIOL CHEM, V254, P240; GARBERS DL, 1991, PHARMACOL THERAPEUT, V50, P337, DOI 10.1016/0163-7258(91)90049-R; GERZER R, 1981, EUR J BIOCHEM, V116, P479, DOI 10.1111/j.1432-1033.1981.tb05361.x; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0; IGNARRO LJ, 1985, ANNU REV PHARMACOL, V25, P171, DOI 10.1146/annurev.pharmtox.25.1.171; IGNARRO LJ, 1984, J BIOL CHEM, V259, P6201; IGNARRO LJ, 1990, HYPERTENSION, V16, P477, DOI 10.1161/01.HYP.16.5.477; IGNARRO LJ, 1982, P NATL ACAD SCI-BIOL, V79, P2870, DOI 10.1073/pnas.79.9.2870; IGNARRO LJ, 1982, BIOCHIM BIOPHYS ACTA, V718, P49, DOI 10.1016/0304-4165(82)90008-3; IGNARRO LJ, 1986, J BIOL CHEM, V261, P4997; IGNARRO LJ, 1989, CIRC RES, V65, P1, DOI 10.1161/01.RES.65.1.1; IGNARRO LJ, 1987, BIOCHIM BIOPHYS ACTA, V982, P160; KAVIPURAPU PR, 1982, EXP EYE RES, V34, P181, DOI 10.1016/0014-4835(82)90052-5; LAVAN BE, 1989, BIOCHEM PHARMACOL, V38, P4123, DOI 10.1016/0006-2952(89)90694-1; MARLETTA M A, 1990, Biofactors, V2, P219; MONCADA S, 1986, P NATL ACAD SCI USA, V83, P9164, DOI 10.1073/pnas.83.23.9164; MONCADA S, 1988, BIOCHEM PHARMACOL, V37, P2495, DOI 10.1016/0006-2952(88)90236-5; Murad F, 1978, Adv Cyclic Nucleotide Res, V9, P145; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; POPESCU LM, 1985, EUR J PHARMACOL, V107, P393, DOI 10.1016/0014-2999(85)90269-9; RAIFER J, 1992, NEW ENGL J MED, V326, P90; SARCEVIC B, 1989, J BIOL CHEM, V264, P20648; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; TAKAI Y, 1981, BIOCHEM BIOPH RES CO, V101, P61, DOI 10.1016/S0006-291X(81)80010-1; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; WOLIN MS, 1982, J BIOL CHEM, V257, P13312; YOSHIDA Y, 1991, J BIOL CHEM, V266, P19819	36	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15540	15545						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	7910826				2022-12-25	WOS:A1994NP51300025
J	SU, MJ; BIKLE, DD; MANCIANTI, ML; PILLAI, S				SU, MJ; BIKLE, DD; MANCIANTI, ML; PILLAI, S			1,25-DIHYDROXYVITAMIN D-3 POTENTIATES THE KERATINOCYTE RESPONSE TO CALCIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE EPIDERMAL-CELLS; CULTURED HUMAN KERATINOCYTES; MESSENGER-RNA STABILITY; HL-60 LEUKEMIA-CELLS; TERMINAL DIFFERENTIATION; EXTRACELLULAR CALCIUM; RETINOIC ACID; 1-ALPHA,25-DIHYDROXYVITAMIN-D3; GROWTH; GENE	Extracellular calcium (Ca-0) stimulates the differentiation of keratinocytes; 1,25 dihydroxyvitamin D-3 (1,25(OH)(2)D-3) does likewise. Since 1,25(OH)(2)D-3 regulates calcium flux in other cells, we hypothesized that 1,25(OH)(2)D-3 acted through and promoted the effects of calcium on keratinocyte differentiation. To test this hypothesis, we evaluated the effects of calcium and 1,25(OH)(2)D-3 alone and in combination on the mRNA and protein levels of involucrin and transglutaminase in neonatal human keratinocytes. Ca-0 alone increased these mRNA levels in a dose-dependent fashion (0.03 to 1.2 mM) over a 24-h period. This increase in mRNA levels was associated with a stimulation by calcium of involucrin and transglutaminase gene transcription. However, by 72 h, the mRNA levels of involucrin and transglutaminase decreased. At 0.03 mM Ca-0, 1,25(OH)(2)D-3 showed a dose-dependent stimulation of involucrin and transglutaminase mRNA for up to 48 h and potentiated the initial (4-h) stimulation by Ca-0 of involucrin and transglutaminase mRNA As for calcium alone, this increase in mRNA was associated with an increase in transcription of the involucrin and transglutaminase genes. However, by 24 h of exposure to both calcium and 1,25(OH)(2)D-3, a dose-dependent fall in mRNA levels was seen. The mRNA levels of involucrin and transglutaminase were stable for 24 h when neonatal human keratinocytes were grown in serum-free keratinocyte growth medium containing 0.03 or 1.2 mM Ca-0 alone. However, the mRNAs of both genes underwent rapid degradation when neonatal human keratinocytes were treated with 1,25(OH)(2)D-3, especially in high Ca-0. 1,25(OH)(2)D-3 and Ca-0 increased the protein levels of involucrin and transglutaminase activity in a synergistic fashion throughout the 48-h time course. These data support the hypothesis that 1,25(OH)(2)D-3 promotes calcium-induced differentiation at the level of both gene expression and mRNA stability.	UNIV CALIF SAN FRANCISCO,DEPT DERMATOL,SAN FRANCISCO,CA 94121; VET ADM MED CTR,SAN FRANCISCO,CA 94121	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	SU, MJ (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94121, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038386, P01AR039448] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 39448, AR 38386] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABE E, 1981, P NATL ACAD SCI-BIOL, V78, P4990, DOI 10.1073/pnas.78.8.4990; BIKLE DD, 1991, J INVEST DERMATOL, V97, P435, DOI 10.1111/1523-1747.ep12481267; BIKLE DD, 1986, BIOCHEMISTRY-US, V25, P1545, DOI 10.1021/bi00355a013; BIKLE DD, 1986, J CLIN INVEST, V78, P557, DOI 10.1172/JCI112609; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLSTON K, 1981, ENDOCRINOLOGY, V108, P1083, DOI 10.1210/endo-108-3-1083; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; FURUICHI Y, 1977, NATURE, V266, P235, DOI 10.1038/266235a0; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HENNINGS H, 1983, J CELL PHYSIOL, V116, P265, DOI 10.1002/jcp.1041160303; HOHL D, 1991, J INVEST DERMATOL, V96, P414, DOI 10.1111/1523-1747.ep12469779; HOSOMI J, 1983, ENDOCRINOLOGY, V113, P1950, DOI 10.1210/endo-113-6-1950; JAKEN S, 1988, CARCINOGENESIS, V9, P1033, DOI 10.1093/carcin/9.6.1033; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KWAN SW, 1972, P NATL ACAD SCI USA, V69, P3247, DOI 10.1073/pnas.69.11.3247; MAJESKA RJ, 1982, J BIOL CHEM, V257, P3362; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MCLANE JA, 1990, IN VITRO CELL DEV B, V26, P379; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MURAO S, 1983, CANCER RES, V43, P4989; NIELSEN DA, 1990, MOL ENDOCRINOL, V4, P953, DOI 10.1210/mend-4-7-953; PILLAI S, 1988, Skin Pharmacology, V1, P149; PILLAI S, 1988, J CELL PHYSIOL, V134, P229, DOI 10.1002/jcp.1041340208; PILLAI S, 1988, J BIOL CHEM, V263, P5390; PILLAI S, 1991, J CELL PHYSIOL, V146, P94, DOI 10.1002/jcp.1041460113; PILLAI S, 1990, J CELL PHYSIOL, V143, P294, DOI 10.1002/jcp.1041430213; PRESTON GM, 1990, MOL CELL BIOL, V10, P442, DOI 10.1128/MCB.10.2.442; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; SCHMIDT R, 1985, FEBS LETT, V186, P201, DOI 10.1016/0014-5793(85)80708-0; SIMPSON RU, 1987, J BIOL CHEM, V262, P4104; SMITH EL, 1986, J INVEST DERMATOL, V86, P709, DOI 10.1111/1523-1747.ep12276343; TANG W, 1987, J CELL PHYSIOL, V132, P131, DOI 10.1002/jcp.1041320118; VANDENPLAS ML, 1990, BIOCHEM J, V267, P349, DOI 10.1042/bj2670349; WATT FM, 1984, J CELL BIOL, V99, P2211, DOI 10.1083/jcb.99.6.2211; YUSPA SH, 1982, J BIOL CHEM, V257, P9906; YUSPA SH, 1988, J CELL BIOL, V109, P1217; YUSPA SH, 1985, METHODS SKIN RES, P213; ZEEVI M, 1982, MOL CELL BIOL, V2, P517, DOI 10.1128/MCB.2.5.517	40	102	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14723	14729						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7910167				2022-12-25	WOS:A1994NM06500066
J	RAO, PV; HORWITZ, J; ZIGLER, JS				RAO, PV; HORWITZ, J; ZIGLER, JS			CHAPERONE-LIKE ACTIVITY OF ALPHA-CRYSTALLIN - THE EFFECT OF NADPH ON ITS INTERACTION WITH ZETA-CRYSTALLIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; GUINEA-PIG LENS; B-CRYSTALLIN; ESCHERICHIA-COLI; QUATERNARY STRUCTURE; MOLECULAR CHAPERONE; EYE LENS; GROEL; EXPRESSION; TISSUES	alpha-Crystallin, a major structural protein of the ocular lens of vertebrates, has been characterized recently as a molecular chaperone (Horwitz, J. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 10449-10453 and Jakob, U., Gaestel, M., Engel, K., and Buchner, J. (1993) J. Biol. Chem. 268, 1517-1520). While alpha-crystallins prevent the aggregation of various proteins denatured by heat or chaotropic agents, neither the mode of interaction between target proteins and alpha-crystallin nor the specific conformational requirements, if any, of the target protein are known. Here, we demonstrate that the ability of alpha-crystallin to prevent thermally induced aggregation of xi-crystallin/NADPH:quinone oxidoreductase, an abundant crystallin of guinea pigs and camelids, is strongly dependent on the presence of the obligate cofactor (NADPH) of the target enzyme. xi-crystallin in the absence of NADPH is readily aggregated at 41 degrees C, and alpha-crystallin added at a 1:1 (w/w) ratio offers very little protection. In contrast, in the presence of NADPH xi-crystallin remains stable to 45 degrees C and with the addition of alpha-crystallin (1:1 (w/w)) is protected from aggregation even at 55 degrees C. Cibacron blue 3GA a nonmetabolized pyridine nucleotide analog, which has very high binding affinity to xi-crystallin had similar effects. NADH and NAD(+), which are not bound by xi-crystallin, had no such effect. Complex formation between alpha-crystallin and non-native xi-crystallin was demonstrated in the presence of either cibacron blue 3GA or NADPB Circular dichroism spectroscopy of xi-crystallin in the presence and absence of NADPH or cibacron blue indicated that nucleotide binding was accompanied by a change in the protein's aromatic amino acid environment but that the secondary structure was unaffected. The data suggest that subtle change in the conformation of denaturing proteins can markedly affect the ability of alpha-crystallin to protect them from aggregation.	NEI,MECHANISMS OCULAR DIS LAB,BETHESDA,MD 20892; UNIV CALIF LOS ANGELES,SCH MED,JULES STEIN EYE INST,LOS ANGELES,CA 90024	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NEI NIH HHS [EY03897] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY003897, R37EY003897] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AOYAMA A, 1993, MOL CELL BIOL, V13, P1824, DOI 10.1128/MCB.13.3.1824; AUGUSTEYN RC, 1987, FEBS LETT, V222, P1, DOI 10.1016/0014-5793(87)80180-1; BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BENEDEK GB, 1971, APPL OPTICS, V10, P459, DOI 10.1364/AO.10.000459; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; Bloemendal H., 1981, MOL CELLULAR BIOL EY; BOYLE D, 1993, BIOCHEM BIOPH RES CO, V192, P1147, DOI 10.1006/bbrc.1993.1536; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHIESI M, 1990, MOL CELL BIOCHEM, V97, P129; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; DEJONG WW, 1986, J CELL BIOL, V102, P104, DOI 10.1083/jcb.102.1.104; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; EDWARDS RA, 1977, BIOCHEM BIOPH RES CO, V79, P470, DOI 10.1016/0006-291X(77)90181-4; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; HUANG QL, 1987, CURR EYE RES, V6, P725, DOI 10.3109/02713688709034836; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1992, AM J PATHOL, V140, P345; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; KATO K, 1992, J BIOL CHEM, V267, P7718; KLEMENZ R, 1991, MOL CELL BIOL, V11, P803, DOI 10.1128/MCB.11.2.803; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LOWE J, 1990, LANCET, V336, P515, DOI 10.1016/0140-6736(90)92075-S; MAITI M, 1988, FEBS LETT, V236, P109, DOI 10.1016/0014-5793(88)80295-3; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MENDOZA JA, 1992, J BIOL CHEM, V267, P24648; MENDOZA JA, 1992, J BIOL CHEM, V267, P17631; MERCK KB, 1993, J BIOL CHEM, V268, P1046; MIZOBATA T, 1992, J BIOL CHEM, V267, P17773; MURANO S, 1991, MOL CELL BIOL, V11, P3905, DOI 10.1128/MCB.11.8.3905; PARK K, 1993, PROTEIN SCI, V2, P325; RAO PV, 1992, J BIOL CHEM, V267, P96; RAO PV, 1993, BIOCHEM BIOPH RES CO, V190, P786, DOI 10.1006/bbrc.1993.1118; RAO PV, 1990, BIOCHEM BIOPH RES CO, V167, P1221, DOI 10.1016/0006-291X(90)90654-6; RIZZO V, 1987, PYRIDINE NUCLEOTID A, P129; ROQUEMORE EP, 1992, J BIOL CHEM, V267, P555; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; SHERMAN MY, 1992, NATURE, V357, P167, DOI 10.1038/357167a0; SIEZEN RJ, 1980, EUR J BIOCHEM, V111, P435, DOI 10.1111/j.1432-1033.1980.tb04958.x; SPECTOR A, 1985, P NATL ACAD SCI USA, V82, P4712, DOI 10.1073/pnas.82.14.4712; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; TAGUCHI H, 1993, J BIOL CHEM, V268, P5371; TARDIEU A, 1986, J MOL BIOL, V192, P711, DOI 10.1016/0022-2836(86)90023-9; THOMSON JA, 1983, EXP EYE RES, V37, P367, DOI 10.1016/0014-4835(83)90173-2; VANDENOETELAAR PJM, 1985, J BIOL CHEM, V260, P4030; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WALSH MT, 1991, J BIOL CHEM, V266, P20079; WISTOW G, 1990, J MOL EVOL, V30, P140, DOI 10.1007/BF02099940; WISTOW G, 1993, EXP EYE RES, V56, P729, DOI 10.1006/exer.1993.1090; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936; ZIGLER JS, 1991, FASEB J, V5, P223, DOI 10.1096/fasebj.5.2.2004667	66	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13266	13272						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	7909806				2022-12-25	WOS:A1994NK18400035
J	LEMAS, MV; HAMRICK, M; TAKEYASU, K; FAMBROUGH, DM				LEMAS, MV; HAMRICK, M; TAKEYASU, K; FAMBROUGH, DM			26 AMINO-ACIDS OF AN EXTRACELLULAR DOMAIN OF THE NA,K-ATPASE ALPHA-SUBUNIT ARE SUFFICIENT FOR ASSEMBLY WITH THE NA,K-ATPASE BETA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA+ + K+)-ATPASE; NA+-K+-ATPASE; INTRACELLULAR-TRANSPORT; SARCOPLASMIC-RETICULUM; SKELETAL-MUSCLE; COMPLEMENTARY-DNA; XENOPUS OOCYTES; SODIUM-PUMP; EXPRESSION; NA+,K+-ATPASE	Chimeric cDNAs encoding a sarcoplasmic/endoplasmic reticulum Ca-ATPase (SERCA1) and regions of the Na,K-ATPase alpha-subunit were constructed to seek the minimal region of the alpha-subunit sufficient for assembly with the Na,K-ATPase beta-subunit. cDNAs encoding a chimera and the chicken beta-subunit were coexpressed in mammalian cells and assembly was assayed by immune precipitation of the chimeric subunit with a monoclonal antibody to the chicken beta-subunit. A chimera containing 26 amino acyl residues of the Na,K-ATPase alpha 1-subunit (NDVEDSYGQQWTFEQRKIVEFTCHTA) (Asn(894) to Ala(919)) that replaced the corresponding avian SERCA1 Ca-ATPase amino acyl residues (Thr(871) to Thr(898)) was able to assemble with the chicken beta-subunit. This alpha-subunit region is predicted to be extracellular, located between membrane-spanning domains 7 and 8 (H7-H8). Chimeras that assembled with full-length beta-subunit also assembled with a beta-subunit chimera that retained only the ectodomain of the chicken beta 1-subunit. These results suggest that the Na,K ATPase alpha-subunit has the same topology in the membrane as the sarcoplasmic reticulum Ca-ATPase, probably with 10 membrane-spanning domains, and that the aminoacyl residues between membrane domains H7 and H8 are involved in assembly with the beta-subunit in the extracellular/lumenal space.	JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA; OHIO STATE UNIV, CTR BIOTECHNOL, COLUMBUS, OH 43210 USA	Johns Hopkins University; Ohio State University					NHLBI NIH HHS [HL-27867] Funding Source: Medline; NIGMS NIH HHS [GM-44373] Funding Source: Medline; NINDS NIH HHS [NS-23241] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027867] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044373, R21GM044373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023241] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; BAMBERG K, 1992, BIOCHIM BIOPHYS ACTA, V1131, P69, DOI 10.1016/0167-4781(92)90100-E; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CLARKE DM, 1990, J BIOL CHEM, V265, P17405; FAMBROUGH DM, 1983, J BIOL CHEM, V258, P3926; FAMBROUGH DM, 1988, TRENDS NEUROSCI, V11, P325, DOI 10.1016/0166-2236(88)90096-3; FLACHMANN R, 1992, J BIOL CHEM, V267, P10576; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; Hall Z W, 1992, Trends Cell Biol, V2, P66, DOI 10.1016/0962-8924(92)90058-U; HAMRICK M, 1993, J BIOL CHEM, V268, P24367; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; JAUNIN P, 1992, J BIOL CHEM, V267, P577; KAPRIELIAN Z, 1987, DEV BIOL, V124, P490, DOI 10.1016/0012-1606(87)90502-1; KARIN NJ, 1989, MOL CELL BIOL, V9, P1978, DOI 10.1128/MCB.9.5.1978; LEMAS MV, 1992, J BIOL CHEM, V267, P20987; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MATTHEWS I, 1990, J BIOL CHEM, V265, P18737; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; RENAUD KJ, 1991, J BIOL CHEM, V266, P20491; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SMITH DL, 1993, J BIOL CHEM, V268, P22469; STULTS NL, 1989, ANAL BIOCHEM, V180, P114, DOI 10.1016/0003-2697(89)90097-3; TAKEYASU K, 1990, AM J PHYSIOL, V259, pC619, DOI 10.1152/ajpcell.1990.259.4.C619; TAKEYASU K, 1989, CURR TOP MEMBR TRANS, V34, P143; TAKEYASU K, 1988, J BIOL CHEM, V263, P4347; TAMKUN MM, 1986, J BIOL CHEM, V261, P1009; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; YU XM, 1991, NATURE, V352, P64, DOI 10.1038/352064a0	33	103	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8255	8259						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7907590				2022-12-25	WOS:A1994NB40900065
J	LOO, TW; CLARKE, DM				LOO, TW; CLARKE, DM			FUNCTIONAL CONSEQUENCES OF GLYCINE MUTATIONS IN THE PREDICTED CYTOPLASMIC LOOPS OF P-GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG RESISTANT CELLS; CYSTIC-FIBROSIS; ENDOPLASMIC-RETICULUM; INTRACELLULAR-TRANSPORT; SARCOPLASMIC-RETICULUM; MOLECULAR-BASIS; BINDING-SITE; TUMOR-CELLS; PROTEINS; GENE	Site-directed mutagenesis was used to investigate whether glycine residues in the predicted cytoplasmic loops play essential roles in the structure and function of human P-glycoprotein. Mutant cDNAs in which codons for each of the 20 glycine residues were changed to valine, were expressed in mouse NIH 3T3 cells and analyzed with respect to their ability to confer resistance to various drugs. Mutation of Gly-251, -268, -269, or -781 yielded mutant proteins which were unable to confer drug resistance in transfected cells. Each of these mutant P-glycoproteins had an apparent mass of 150 kDa, compared with 170 kDa for wild-type P-glycoprotein and the apparent mass was altered by endoglycosidase H digestion. These observations suggest that these mutant proteins were improperly processed so that they were located in the endoplasmic reticulum and were not targeted correctly to the plasma membrane. The in vivo processing of mutants Gly-269 to Val and Gly-781 to Val was temperature sensitive. When cells expressing these mutants were grown at a lower temperature (26 degrees C), the mature 170 kDa form of P-glycoprotein was the major product. Substitution of glycine with alanine at positions 251, 268, 269, or 781 yielded mutants with structural and functional characteristics similar to wild-type enzyme. Mutation of Gly-141, 187, 288, 812, or 830 to Val, altered the drug resistance profile conferred by P-glycoproteins expressed in transfected cells. All five mutations increased relative resistance to colchicine or adriamycin, without altering relative resistance to vinblastine. These results demonstrate that glycines located in the cytoplasmic loops play important roles in structure and function of P-glycoprotein.	UNIV TORONTO,DEPT MED,MED RES COUNCIL,MEMBRANE BIOL GRP,TORONTO M5S 1A8,ON,CANADA; UNIV TORONTO,DEPT BIOCHEM,MED RES COUNCIL,MEMBRANE BIOL GRP,TORONTO M5S 1A8,ON,CANADA	University of Toronto; University of Toronto			Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188				ALLEY MC, 1988, CANCER RES, V48, P589; ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; BECK WT, 1992, BIOCHEM PHARMACOL, V43, P89, DOI 10.1016/0006-2952(92)90665-6; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; BUSCHE R, 1989, EUR J BIOCHEM, V183, P189, DOI 10.1111/j.1432-1033.1989.tb14912.x; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CORNWELL MM, 1986, P NATL ACAD SCI USA, V83, P3847, DOI 10.1073/pnas.83.11.3847; CURRIER SJ, 1992, J BIOL CHEM, V267, P25153; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GREENBERGER LM, 1987, J BIOL CHEM, V262, P13685; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HSU SIH, 1990, MOL CELL BIOL, V10, P3596, DOI 10.1128/MCB.10.7.3596; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P553; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JURUNKA PF, 1989, FASEB J, V3, P2583; KANE SE, 1990, J BIOENERG BIOMEMBR, V22, P593, DOI 10.1007/BF00762963; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LOO TW, 1993, J BIOL CHEM, V268, P3143; LOO TW, 1993, J BIOL CHEM, V268, P19965; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; PASTAN I, 1993, ANNU REV BIOCHEM, V62, P385; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; RICHERT ND, 1988, BIOCHEMISTRY-US, V27, P7606; SAFA AR, 1989, BIOCHEM BIOPH RES CO, V162, P1402, DOI 10.1016/0006-291X(89)90830-9; SAFA AR, 1990, P NATL ACAD SCI USA, V87, P7225, DOI 10.1073/pnas.87.18.7225; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKADI B, 1992, J BIOL CHEM, V267, P4854; TAMAI I, 1991, J BIOL CHEM, V266, P16796; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ZUBRZYCKAGAARN E, 1984, J BIOENERG BIOMEMBR, V16, P441, DOI 10.1007/BF00743238	42	120	123	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7243	7248						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7907326				2022-12-25	WOS:A1994NA03200034
J	MOHAMED, AH; HUANG, WY; HUANG, WZ; VENKATACHALAM, KV; WAKIL, SJ				MOHAMED, AH; HUANG, WY; HUANG, WZ; VENKATACHALAM, KV; WAKIL, SJ			ISOLATION AND CHARACTERIZATION OF A NOVEL ACETYL-COA CARBOXYLASE KINASE FROM RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; COENZYME-A CARBOXYLASE; FATTY-ACID SYNTHESIS; PHOSPHORYLATION SITES; PURIFICATION; POLYMERIZATION; PEPTIDE	Acetyl-CoA carboxylase is regulated allosterically by citrate and covalently by a phosphorylation/ dephosphorylation mechanism. We have isolated and purified from rat livers a novel kinase that phosphorylates and inactivates the carboxylase, This kinase is: bound to the carboxylase and can be eluted in salt-rich solution, The native kinase exists as high molecular weight aggregates of a subunit that has a molecular weight of 40,000. The phosphorylation sites of the carboxylase were determined after tryptic and cyanogen bromide digestions of P-32-labeled carboxylase and separation of the peptides by various chromatographic pro cedures. Amino acid analyses of the phosphopeptides showed that the Ser(77) and Ser(1200) residues were the sites of phosphorylation. Treating the phosphorylated carboxylase with the Mn2+-dependent acetyl-CoA carboxylase phosphatase 2 removed the phosphate and reactivated the carboxylase. These results suggest that both this kinase and the acetyl-CoA carboxylase phosphatase 2 act at the same site(s) in the acetyl-CoA carboxylase molecule. Citrate dramatically inhibits the kinase-mediated phosphorylation of the carboxylase, suggesting that the allosteric modification and activation by citrate render the phosphorylation sites inaccessible to the kinase and therefore maintain high carboxylase activity. This observation indicates that there is a close interplay between the citrate effect on and phosphorylation of the carboxylase in regulating its activity.	BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030	Baylor College of Medicine				Venkatachalam, K.V./0000-0001-6692-9099	NIGMS NIH HHS [GM-19091] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEATY NB, 1983, J BIOL CHEM, V258, P3043; BEATY NB, 1983, J BIOL CHEM, V258, P3051; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLING D, 1986, BIOCHEM SOC T, V14, P1076, DOI 10.1042/bst0141076; CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; DAVIES SP, 1990, EUR J BIOCHEM, V187, P183, DOI 10.1111/j.1432-1033.1990.tb15293.x; GROSS E, 1962, J BIOL CHEM, V237, P1856; HARDIE DG, 1989, PROG LIPID RES, V28, P117, DOI 10.1016/0163-7827(89)90010-6; HARDIE DG, 1992, BIOCHIM BIOPHYS ACTA, V1123, P231, DOI 10.1016/0005-2760(92)90001-C; HARDIE DG, 1989, TRENDS BIOCHEM SCI, V14, P20; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HUNKAPILLER MW, 1986, USERS MANUAL APPLIED; JAMIL H, 1987, J BIOL CHEM, V262, P638; KIM KH, 1989, FASEB J, V3, P2250, DOI 10.1096/fasebj.3.11.2570725; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENT B, 1982, J BIOL CHEM, V257, P1897; LOPEZCASILLAS F, 1988, P NATL ACAD SCI USA, V85, P5784, DOI 10.1073/pnas.85.16.5784; MABROUK GM, 1990, J BIOL CHEM, V265, P6330; MEREDITH MJ, 1978, J BIOL CHEM, V253, P3381; MUNDAY MR, 1988, EUR J BIOCHEM, V175, P331, DOI 10.1111/j.1432-1033.1988.tb14201.x; REIMANN EM, 1971, J BIOL CHEM, V246, P1986; SWITZER RC, 1979, ANAL BIOCHEM, V98, P231, DOI 10.1016/0003-2697(79)90732-2; THAMPY KG, 1985, J BIOL CHEM, V260, P6318; THAMPY KG, 1988, J BIOL CHEM, V263, P6447; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WANG YH, 1986, J BIOL CHEM, V261, P6909	29	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6859	6865						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7907095				2022-12-25	WOS:A1994MZ50300093
J	HAWLEY, RG; FONG, AZC; LU, M; HAWLEY, TS				HAWLEY, RG; FONG, AZC; LU, M; HAWLEY, TS			THE HOX11 HOMEOBOX-CONTAINING GENE OF HUMAN LEUKEMIA IMMORTALIZES MURINE HEMATOPOIETIC PRECURSORS	ONCOGENE			English	Article							T-CELL LEUKEMIA; STEM-CELLS; BONE-MARROW; MYELOID-LEUKEMIA; DIFFERENTIATION; EXPRESSION; GROWTH; LINES; MICE; INTERLEUKIN-6	The t(10;14) chromosomal translocation of T-cell acute lymphoblastic leukemia joins the T-cell receptor delta gene to a region upstream of a diverged homeobox-containing gene called HOX11. To better understand the pathogenetic role of HOX11 in leukemogenesis, post 5-fluorouracil-treated murine bone marrow cells were infected with a replication-defective retrovirus bearing the gene. Constitutive expression of HOX11 in hematopoietic precursors yielded cell lines at high frequency consisting of immature cells belonging to the myeloid lineage. HOX11-transformed cell lines displayed a strict dependence on IL-3 for their survival and proliferation in culture and were not leukemogenic. The results support the hypothesis that the transforming capacity of HOX11 derives from its ability to alter the expression of genes regulating hematopoietic differentiation and that secondary mutations promoting cell survival or stimulating proliferation are required for progression to malignancy. The findings further suggest that the oncogenic activity of HOX11 might not be restricted to T-cell leukemias in humans.	UNIV TORONTO, DEPT MED BIOPHYS, TORONTO M4N 3M5, ON, CANADA; UNIV OTTAWA, NE ONTARIO REG CANC CTR, SUDBURY P3E 5J1, ON, CANADA; UNIV OTTAWA, DEPT MED, SUDBURY P3E 5J1, ON, CANADA	University of Toronto; University of Ottawa; University of Ottawa	HAWLEY, RG (corresponding author), UNIV TORONTO, SUNNYBROOK MED CTR, DIV CANC RES, REICHMANN RES BLDG, 2075 BAYVIEW AVE, TORONTO M4N 3M5, ON, CANADA.			Hawley, Robert/0000-0003-3512-5818				BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; BLATT C, 1988, EMBO J, V7, P4283, DOI 10.1002/j.1460-2075.1988.tb03326.x; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; DIBIRDIK I, 1991, BLOOD, V78, P564, DOI 10.1182/blood.V78.3.564.bloodjournal783564; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; DUBE ID, 1991, BLOOD, V78, P2996; DUHRSEN U, 1990, BLOOD, V75, P190; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GOODWIN RG, 1991, CYTOKINE HDB, P191; GREEN SM, 1989, ONCOGENE, V4, P737; HARLOW E, 1988, ANTIBODIES LABORATOR; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HATANO M, 1992, BLOOD S, V80, pA355; HAWLEY RG, 1987, P NATL ACAD SCI USA, V84, P2406, DOI 10.1073/pnas.84.8.2406; HAWLEY RG, 1982, P NATL ACAD SCI-BIOL, V79, P7425, DOI 10.1073/pnas.79.23.7425; HAWLEY RG, 1993, CLIN EXP METASTAS, V11, P213, DOI 10.1007/BF00114979; HAWLEY RG, 1992, J EXP MED, V176, P1149, DOI 10.1084/jem.176.4.1149; HAWLEY RG, 1993, IN PRESS J EXP MED, V178; HAWLEY TS, 1991, LEUKEMIA RES, V15, P659, DOI 10.1016/0145-2126(91)90068-5; HAWLEY TS, 1991, CYTOKINE, V3, P60, DOI 10.1016/1043-4666(91)90011-2; JUTILA MA, 1988, EUR J IMMUNOL, V18, P1819, DOI 10.1002/eji.1830181125; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KELLER JR, 1989, J IMMUNOL, V143, P4025; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KONGSUWAN K, 1989, NUCLEIC ACIDS RES, V17, P1881, DOI 10.1093/nar/17.5.1881; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; LANG RA, 1990, IMMUNOL TODAY, V11, P244, DOI 10.1016/0167-5699(90)90098-T; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LAWRENCE HJ, 1992, BLOOD, V80, P2445; LEE JC, 1981, P NATL ACAD SCI-BIOL, V78, P7712, DOI 10.1073/pnas.78.12.7712; LEONARD EJ, 1990, BIOTECHNIQUES, V9, P684; LOZZIO BB, 1981, P SOC EXP BIOL MED, V166, P546; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MILLER BA, 1985, J IMMUNOL, V134, P3286; MING L, 1992, ONCOGENE, V7, P1325; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; NAKAHATA T, 1982, P NATL ACAD SCI-BIOL, V79, P3843, DOI 10.1073/pnas.79.12.3843; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PALACIOS R, 1987, J EXP MED, V166, P12, DOI 10.1084/jem.166.1.12; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; RODEWALD HR, 1992, CELL, V69, P139, DOI 10.1016/0092-8674(92)90125-V; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; SABOURIN LA, 1990, J CELL PHYSIOL, V145, P564, DOI 10.1002/jcp.1041450325; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; VANDERIJN M, 1989, P NATL ACAD SCI USA, V86, P4634; WALKER F, 1985, CELL, V43, P269, DOI 10.1016/0092-8674(85)90032-7; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; ZHANG N, 1993, IN PRESS ONCOGENE, V8	61	80	85	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					1	12						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	7905617				2022-12-25	WOS:A1994MW24700001
J	MURLEY, LL; MEJIA, NR; MACKENZIE, RE				MURLEY, LL; MEJIA, NR; MACKENZIE, RE			THE NUCLEOTIDE-SEQUENCE OF PORCINE FORMIMINOTRANSFERASE CYCLODEAMINASE - EXPRESSION AND PURIFICATION FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNAS; PROTEINS; QUANTITIES; BINDING; LIVER; SITE	We have isolated and characterized cDNA clones encoding the porcine liver octameric enzyme, 5-formiminotetrahydrofolate:L-glutamate N-formiminotransferase (EC 2.1.2.5)-formiminotetrahydrofolate cyclodeaminase (EC 4.3.1.4). The cDNA encodes a novel amino acid sequence of 541 residues which contains exact matches to two sequences derived by automated sequence analysis of CNBr cleavage fragments isolated from the porcine enzyme. The recombinant enzyme has been expressed as a soluble protein in Escherichia coli at levels 4-fold higher than those observed in liver, and is bifunctional, displaying both transferase and deaminase activities. With a calculated subunit molecular mass of 58,926 Da, it is similar in size to the enzyme isolated from porcine liver. Purification of the enzyme from E. coli involves chromatography on a novel polyglutamate column which might interact with the folylpolyglutamate binding site of the protein. The purified recombinant enzyme has a transferase specific activity of 39-41 units/mg/min.	MCGILL UNIV,DEPT BIOCHEM,3655 DRUMMOND ST,MONTREAL H3G 1Y6,QUEBEC,CANADA	McGill University								AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BEAUDET R, 1976, BIOCHIM BIOPHYS ACTA, V453, P151, DOI 10.1016/0005-2795(76)90259-2; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COOK RJ, 1991, J BIOL CHEM, V266, P4965; DRURY EJ, 1975, ARCH BIOCHEM BIOPHYS, V169, P662, DOI 10.1016/0003-9861(75)90210-6; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FINDLAY WA, 1989, BIOCHIM BIOPHYS ACTA, V999, P52, DOI 10.1016/0167-4838(89)90029-0; FINDLAY WA, 1987, BIOCHEMISTRY-US, V26, P1948, DOI 10.1021/bi00381a024; FINDLAY WA, 1988, BIOCHEMISTRY-US, V27, P3404, DOI 10.1021/bi00409a042; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JAFFE JJ, 1980, J PARASITOL, V66, P428, DOI 10.2307/3280743; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MacKenzie R E, 1980, Methods Enzymol, V66, P626; MACKENZIE RE, 1980, J BIOL CHEM, V255, P9474; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NOUR JM, 1992, J BIOL CHEM, V267, P16292; OLINS PO, 1989, J BIOL CHEM, V264, P16973; PAQUIN J, 1985, J BIOL CHEM, V260, P4925; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RABINOWITZ JC, 1956, J AM CHEM SOC, V78, P5702, DOI 10.1021/ja01602a073; RANKIN CA, 1993, PROTEIN SCI, V2, P197; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHANE B, 1984, FOLATES PTERINS, V1, P433; TABOR H, 1959, J BIOL CHEM, V234, P1830; TABOR H, 1956, J AM CHEM SOC, V78, P5705, DOI 10.1021/ja01602a075; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074	33	22	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22820	22824						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7901203				2022-12-25	WOS:A1993MD34800093
J	BRUNO, MD; BOHINSKI, RJ; HUELSMAN, KM; WHITSETT, JA; KORFHAGEN, TR				BRUNO, MD; BOHINSKI, RJ; HUELSMAN, KM; WHITSETT, JA; KORFHAGEN, TR			LUNG CELL-SPECIFIC EXPRESSION OF THE MURINE SURFACTANT PROTEIN-A (SP-A) GENE IS MEDIATED BY INTERACTIONS BETWEEN THE SP-A PROMOTER AND THYROID TRANSCRIPTION FACTOR-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SPECIFICITY; PULMONARY SURFACTANT; PHORBOL ESTER; RAT; IDENTIFICATION; LOCALIZATION; INVITRO; REGIONS; ALPHA	Cis-acting elements determining lung epithelial cell-selective transcription of the murine surfactant protein A (SP-A) gene were identified between nucleotide positions -255 and -57. This region of the murine SP-A gene contained nucleotide sequences consistent with thyroid transcription factor-1 (TTF-1) binding motifs. An SP-A-CAT plasmid containing the TTF-1 binding sites was transcriptionally active in mouse lung epithelial (MLE-15) cells but not in HeLa, 3T3, or H441 cells. However, transcription of the SP-A-CAT construct was activated after cotransfection of HeLa cells with a vector expressing recombinant TTF-1, pCMV-TTF-1. Recombinant TTF-1 homeodomain protein bound to four distinct binding sites located between nucleotides -231 to -168. Proteins in nuclear extracts of MLE-15 cells bound TTF-1 binding sites and were supershifted by TTF-1 antibody. Mutations of three of the TTF-1 binding sites in this region reduced expression of the SP-A-CAT construct in transfected MLE-IB cells and reduced transactivation in HeLa cells. TTF-1 interacts with complex protein/DNA binding sites located in the 5'-flanking region of the murine SP-A gene enhancing lung epithelial cell-specific expression in vitro.	CHILDRENS HOSP,MED CTR,DIV PULM BIOL,CINCINNATI,OH 45229	Cincinnati Children's Hospital Medical Center					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028623, P01HL051832] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28623, HL51832] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALCORN JL, 1993, MOL ENDOCRINOL, V7, P1072, DOI 10.1210/me.7.8.1072; BALLARD PL, 1989, ENDOCR REV, V10, P165, DOI 10.1210/edrv-10-2-165; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; CLEVIDENCE DE, 1994, DEV BIOL, V166, P195, DOI 10.1006/dbio.1994.1307; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; DAMANTE G, 1991, P NATL ACAD SCI USA, V88, P5388, DOI 10.1073/pnas.88.12.5388; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; GAO E, 1993, J BIOL CHEM, V268, P19697; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; KHOOR A, 1994, J HISTOCHEM CYTOCHEM, V42, P1187, DOI 10.1177/42.9.8064126; KHOOR A, 1993, J HISTOCHEM CYTOCHEM, V41, P1311, DOI 10.1177/41.9.8354874; KORFHAGEN TR, 1992, AM J PHYSIOL, V263, pL546, DOI 10.1152/ajplung.1992.263.5.L546; KOURETAS D, 1993, EXP LUNG RES, V19, P485, DOI 10.3109/01902149309064359; KUROKI Y, 1994, J BIOL CHEM, V269, P25943; LACAZEMASMONTEIL T, 1992, EUR J BIOCHEM, V206, P613, DOI 10.1111/j.1432-1033.1992.tb16966.x; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; PHELPS DS, 1991, EXP LUNG RES, V17, P985, DOI 10.3109/01902149109064330; PRYHUBER GS, 1990, J BIOL CHEM, V265, P20822; ROONEY SA, 1994, FASEB J, V8, P957, DOI 10.1096/fasebj.8.12.8088461; SAWAYA PL, 1993, MOL CELL BIOL, V13, P3860, DOI 10.1128/MCB.13.7.3860; SINGH G, 1988, J HISTOCHEM CYTOCHEM, V36, P73, DOI 10.1177/36.1.3275712; WEAVER TE, 1991, BIOCHEM J, V273, P249, DOI 10.1042/bj2730249; WHITSETT JA, 1992, AM J PHYSIOL, V262, pL688, DOI 10.1152/ajplung.1992.262.6.L688; WHITSETT JA, 1992, BIOCHIM BIOPHYS ACTA, V1123, P257, DOI 10.1016/0005-2760(92)90004-F; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; WISPE JR, 1990, J CLIN INVEST, V86, P1954, DOI 10.1172/JCI114929	27	234	240	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6531	6536		10.1074/jbc.270.12.6531	http://dx.doi.org/10.1074/jbc.270.12.6531			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896788				2022-12-25	WOS:A1995QQ85500018
J	GUO, DQ; JIA, Q; SONG, HY; WARREN, RS; DONNER, DB				GUO, DQ; JIA, Q; SONG, HY; WARREN, RS; DONNER, DB			VASCULAR ENDOTHELIAL-CELL GROWTH-FACTOR PROMOTES TYROSINE PHOSPHORYLATION OF MEDIATORS OF SIGNAL-TRANSDUCTION THAT CONTAIN SH2 DOMAINS - ASSOCIATION WITH ENDOTHELIAL-CELL PROLIFERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY FACTOR; DEVELOPMENTAL EXPRESSION; MOLECULAR-CLONING; PROTEIN; ANGIOGENESIS; RECEPTOR; KINASE; MITOGEN; BINDING; PDGF	Vascular endothelial cell growth factor (VEGF), an endothelial cell-specific mitogen that plays an important role in angiogenesis, promotes the tyrosine phosphorylation of at least 11 proteins in bovine aortic endothelial cells (BAEC). Proteins immunoprecipitated fr om lysates of control- and VEGF stimulated BAEC with antisera to phospholipase C-gamma (PLC-gamma) were fractionated by SDS-polyacrylamide gel electrophoresis and transferred to Immobilon-P. Evaluation of the Western blots with antisera to phosphotyrosine demonstrated that PLC-gamma and two proteins (100 and 85 kDa) that associate with PLC-gamma were phosphorylated in response to VEGF. By using antisera specific to other mediators of signal transduction that contain SH2 domains for immunoprecipitation, it was demonstrated that VEGF promotes phosphorylation of phosphatidylinositol 3-kinase, Ras GTPase activating protein (GAP), and the oncogenic adaptor protein NcK. Proteins of M(r) consistent with the VEGF receptors Flt-1 and Flk-1/KDR were also tyrosine phosphorylated in stimulated cells, Tyrosine-phosphorylated Nck, PLC-gamma, and two GAP-associated proteins, p190 and p62, were in GAP immunoprecipitates of VEGF-stimulated BAEC, and tyrosine-phosphorylated NcK was in phosphatidylinositol 3-kinase immunoprecipitates, These observations suggest that VEGF promotes formation of multimeric aggregates of VEGF receptors with proteins that contain SH2 domains and activate various signaling pathways. VEGF-promoted proliferation of endothelial cells and tyrosine phosphorylation of SH2 domain containing signaling molecules were inhibited by the tyrosine kinase inhibitor genistein.	INDIANA UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,WALTHER ONCOL CTR,INDIANAPOLIS,IN 46202; UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; University of California System; University of California San Francisco								BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BREIER G, 1992, DEVELOPMENT, V114, P521; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; CONNOLLY DT, 1991, J CELL BIOCHEM, V47, P219, DOI 10.1002/jcb.240470306; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; JAKEMAN LB, 1993, ENDOCRINOLOGY, V133, P848, DOI 10.1210/en.133.2.848; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LYNCH JJ, 1990, J CLIN INVEST, V85, P1991, DOI 10.1172/JCI114663; MATHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MONACCI WT, 1993, AM J PHYSIOL, V264, pC995, DOI 10.1152/ajpcell.1993.264.4.C995; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PAWSON T, 1988, ONCOGENE, V3, P491; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SCHWEIKI D, 1993, J CLIN INVEST, V91, P2235; SENGER DR, 1986, CANCER RES, V46, P5629; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L	40	393	401	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6729	6733		10.1074/jbc.270.12.6729	http://dx.doi.org/10.1074/jbc.270.12.6729			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896817	hybrid			2022-12-25	WOS:A1995QQ85500048
J	MATHIEU, M; KIEFER, P; MASON, I; DICKSON, C				MATHIEU, M; KIEFER, P; MASON, I; DICKSON, C			FIBROBLAST GROWTH-FACTOR (FGF)-3 FROM XENOPUS-LAEVIS (XFGF3) BINDS WITH HIGH-AFFINITY TO FGF RECEPTOR-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTO-ONCOGENE INT-2; LIGAND-BINDING; SIGNAL-TRANSDUCTION; SKELETAL-MUSCLE; FACTOR FAMILY; DEVELOPMENTAL EXPRESSION; MOUSE EMBRYO; CDNA CLONING; INNER-EAR; GENE	We demonstrate that purified fibroblast growth factor (FGF) 3 from Xenopus laevis (XFGF3) activates the mitogen-activated protein kinase pathway and induces DNA synthesis in quiescent cells. To characterize the high affinity cell surface receptors that mediate these responses, the ligand binding domains of different FGF receptors (FGFR) were expressed on COS-1 cells, and their affinity for XFGF3 was determined. Unlabeled XFGF3 efficiently competed with I-125-FGF1 for binding to the IIIb and IIIc isoforms of FGFR2, giving 50% displacement (ID50) at 0.3-0.8 nM. Higher XFGF3 concentrations were needed to displace I-125-FGF1 from FGFR3 and FGFR1 (ID50 similar to 4 and 21 nM, respectively), indicating that XFGF3 has a lower affinity for these receptors. No association of XFGF3 with FGFR4 was found using this assay. FGFR2 isoforms isolated from both mouse and Xenopus showed similar high affinity binding of XFGF3 as determined by direct binding assays (K-d values in the range of 0.2-0.6 nM). These results indicate that the binding specificity of XFGF3 is different from that of other FGFs, and identifies FGFR2 as its high affinity receptor.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; DIV ANAT & CELL BIOL,LONDON SE1 9RT,ENGLAND	Cancer Research UK			Mason, Ivor/B-1859-2008	Mason, Ivor/0000-0001-8390-3050				ADAMS PD, 1991, FEBS LETT, V290, P77, DOI 10.1016/0014-5793(91)81230-6; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; AVIEZER D, 1994, J BIOL CHEM, V269, P114; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHEON HG, 1994, P NATL ACAD SCI USA, V91, P989, DOI 10.1073/pnas.91.3.989; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DELAPEYRIERE O, 1993, DEVELOPMENT, V118, P601; DELL KR, 1992, J BIOL CHEM, V267, P21225; Dickson C, 1989, Prog Growth Factor Res, V1, P123, DOI 10.1016/0955-2235(89)90006-9; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DIXON M, 1989, MOL CELL BIOL, V9, P4896, DOI 10.1128/MCB.9.11.4896; DRUCKER BJ, 1993, MECH DEVELOP, V40, P155, DOI 10.1016/0925-4773(93)90073-7; EMORI Y, 1992, FEBS LETT, V314, P176, DOI 10.1016/0014-5793(92)80968-M; FRIESEL R, 1991, MOL CELL BIOL, V11, P2481, DOI 10.1128/MCB.11.5.2481; FRIESEL R, 1992, DEVELOPMENT, V116, P1051; GIMOND S, 1993, J BIOL CHEM, V268, P23906; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; GRAVES L, 1964, P NATL ACAD SCI USA, V91, P1662; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HAUB O, 1991, DEVELOPMENT, V112, P397; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; HEBERT JM, 1990, DEV BIOL, V138, P453; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KAN M, 1991, METHOD ENZYMOL C, V198, P158; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KIEFER P, 1993, EMBO J, V12, P4159, DOI 10.1002/j.1460-2075.1993.tb06100.x; KIEFER P, 1993, MOL CELL BIOL, V13, P5781, DOI 10.1128/MCB.13.9.5781; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MASON IJ, 1994, MECH DEVELOP, V45, P15, DOI 10.1016/0925-4773(94)90050-7; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1992, DEVELOPMENT, V114, P755; ORNITZ DM, 1992, JNCI-J NATL CANCER I, V84, P887, DOI 10.1093/jnci/84.11.887; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; POULIN ML, 1994, BBA-MOL CELL RES, V1220, P209, DOI 10.1016/0167-4889(94)90137-6; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; REPRESA J, 1991, NATURE, V353, P561, DOI 10.1038/353561a0; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SATO M, 1991, ONCOGENE, V6, P1279; SHI DL, 1994, DEV BIOL, V164, P173, DOI 10.1006/dbio.1994.1189; SHI DL, 1992, DEVELOPMENT, V116, P261; SHI E, 1993, MOL CELL BIOL, V13, P3907, DOI 10.1128/MCB.13.7.3907; STAMP G, 1992, CELL GROWTH DIFFER, V3, P929; STARK KL, 1991, DEVELOPMENT, V113, P641; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; TANNAHILL D, 1992, DEVELOPMENT, V115, P695; UEKI K, 1994, J BIOL CHEM, V269, P15756; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; WILKINSON DG, 1990, TRENDS NEUROSCI, V13, P335, DOI 10.1016/0166-2236(90)90145-Z; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; ZIMMER Y, 1993, J BIOL CHEM, V268, P7899	74	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6779	6787		10.1074/jbc.270.12.6779	http://dx.doi.org/10.1074/jbc.270.12.6779			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896824	hybrid			2022-12-25	WOS:A1995QQ85500055
J	LEE, HJ; CHANG, CS				LEE, HJ; CHANG, CS			IDENTIFICATION OF HUMAN TR2 ORPHAN RECEPTOR RESPONSE ELEMENT IN THE TRANSCRIPTIONAL INITIATION SITE OF THE SIMIAN-VIRUS-40 MAJOR LATE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; LONG TERMINAL REPEAT; DNA-BINDING DOMAIN; GENE; SUPERFAMILY; DETERMINANTS	A DNA response element (TR2RE-SV40) for the TR2 orphan receptor, a member of the steroid-thyroid hormone receptor superfamily, has been identified in the simian virus 40 (SV40) +55 region (nucleotide numbers 368-389, 5'-GTTAAGGTTCGTAGGTCATGGA-3'). Electrophoretic mobility shift assay, using in vitro translated TR2 orphan receptor with a molecular mass of 67 kilodaltons, showed a specific binding with high affinity (dissociation constant = 9 nM) for this DNA sequence. DNA-swap experiments using chloramphenicol acetyltransferase assay demonstrated that androgen can suppress the transcriptional activities of SV40 early promoter via the interaction between this TR2RE-SV40 and the chimeric receptor AR/TR2/AR with the DNA-binding domain of the TR2 orphan receptor flanked by the N-terminal anal androgen-binding domains of the androgen receptor. In addition, this TR2RE-SV40 can function as a repressor to suppress the transcriptional activities of both SV40 early and late promoters. Together, these data suggest the TR2RE-SV40 may represent the first identified natural DNA response element for the TR2 orphan receptor that may function as a repressor for the SV40 gene expression.	UNIV WISCONSIN,CTR COMPREHENS CANC,DEPT HUMAN ONCOL,MADISON,WI 53792; UNIV WISCONSIN,CTR COMPREHENS CANC,ENDOCRINOL REPROD PHYSIOL PROGRAM,MADISON,WI 53792	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NCI NIH HHS [CA 55639] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055639, R29CA055639] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; CHANG C, 1988, BIOCHEM BIOPH RES CO, V155, P971, DOI 10.1016/S0006-291X(88)80591-6; CHANG C, 1989, J STEROID BIOCHEM, V34, P391; CHANG C, 1989, BIOCHEM BIOPH RES CO, V165, P735, DOI 10.1016/S0006-291X(89)80028-2; Chang C, 1993, ENDOCR J, V1, P541; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COONEY AJ, 1991, J VIROL, V65, P2853, DOI 10.1128/JVI.65.6.2853-2860.1991; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GARCIA AD, 1993, J VIROL, V67, P3940, DOI 10.1128/JVI.67.7.3940-3950.1993; GIGUERE V, 1987, NATURE, V331, P91; Kokontis J, 1991, Receptor, V1, P261; KOKONTIS J, 1991, MOLECULAR AND CELLULAR BIOLOGY OF PROSTATE CANCER, P229; LEE HJ, 1993, BIOCHEM BIOPH RES CO, V194, P97, DOI 10.1006/bbrc.1993.1790; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Lydon John P., 1992, Gene Expression, V2, P273; MARTINEZ E, 1991, NUCLEAR HORMONE RECE, P125; MOWSZOWICZ I, 1993, MOL ENDOCRINOL, V7, P861, DOI 10.1210/me.7.7.861; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; OMALLEY BW, 1992, MOL ENDOCRINOL, V6, P1359, DOI 10.1210/me.6.9.1359; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; SAGAMI I, 1986, MOL CELL BIOL, V6, P4259, DOI 10.1128/MCB.6.12.4259; Sambrook J, 1989, MOL CLONING LABORATO; SCHRADER M, 1994, NATURE, V370, P382, DOI 10.1038/370382a0; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; TALBOT SJ, 1994, BIOCHEMISTRY-US, V33, P1399, DOI 10.1021/bi00172a016; Tooze J, 1981, MOL BIOL TUMOR VIRUS; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; WILEY SR, 1993, GENE DEV, V7, P2206, DOI 10.1101/gad.7.11.2206; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541	31	54	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5434	5440		10.1074/jbc.270.10.5434	http://dx.doi.org/10.1074/jbc.270.10.5434			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890658	hybrid			2022-12-25	WOS:A1995QL58000074
J	COFFER, P; LUTTICKEN, C; VANPUIJENBROEK, A; KLOPDEJONGE, M; HORN, F; KRUIJER, W				COFFER, P; LUTTICKEN, C; VANPUIJENBROEK, A; KLOPDEJONGE, M; HORN, F; KRUIJER, W			TRANSCRIPTIONAL REGULATION OF THE JUNB PROMOTER - ANALYSIS OF STAT-MEDIATED SIGNAL-TRANSDUCTION	ONCOGENE			English	Article						JUNB; STAT; IL-6; IFN-GAMMA; SIGNAL TRANSDUCTION	DNA-BINDING; C-JUN; GENE-EXPRESSION; PROTEIN-KINASE; LEUCINE ZIPPER; NUCLEAR FACTOR; INTERLEUKIN-6; ACTIVATION; PHOSPHORYLATION; ELEMENTS	The product of the junB gene is a member of the AP-1 family of transcription factors that activate transcription by binding to TPA-responsive elements (TREs) within the promoters of target genes, Components of AP-1 are immediate-early genes whose expression is upregulated by a plethora of extracellular stimuli and are important in mediating cellular proliferation and differentiation, Such stimuli include the pleiotropic cytokine interleukin-6 (IL-6) which plays a role in immune and inflammatory responses and ciliary neurotrophic factor (CNTF) which enhances survival and differentiation of neurons and glia. We have analysed expression from junB promoter-CAT reporter constructs in HepG2 cells and found that a region between -196 and -91 can mediate response to IL-6 and CNTF and was able to confer responsiveness to a heterologous promoter, We further show by gel retardation analysis that distinct nuclear factors induced by IL-6 specifically bind to this interleukin-6 response element (IRE). This region contains both a putative ETS- and a STAT-transcription factor binding site, We show by mutational analysis and supershift data that the IL-6 induced complex indeed contains the transcription factor APRF/Stat3 that is both necessary and sufficient for activation, Interestingly this site does not appear to bind Stat1 itself, as shown by supershift analysis and a lack of response to IFN-gamma both at the DNA-binding and transcriptional level, Furthermore, we demonstrate that the junB IRE-binding activity induced by IL-6 requires tyrosine kinase activity, whereas induced transactivation of IRE-constructs additionally occurs through an H7-sensitive pathway that is p21ras-independent, implicating serine/threonine kinases in the transactivation of IRE-binding factors.	RHEIN WESTFAL TH AACHEN,INST BIOCHEM,D-52057 AACHEN,GERMANY; UNIV GRONINGEN,DEPT GENET,9750 AA HAREN,NETHERLANDS	RWTH Aachen University; University of Groningen	COFFER, P (corresponding author), HUBRECHT LAB DEV BIOL,UPPSALALAAN 8,3584 CT UTRECHT,NETHERLANDS.		Coffer, Paul/AAF-7970-2020; Coffer, Paul J/A-5769-2009					AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; APEL I, 1992, MOL CELL BIOL, V12, P3357; BOHMANN D, 1988, SCIENCE, V238, P1386; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; CALDENHOVEN E, 1994, J BIOL CHEM, V269, P21146; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COFFER P, 1994, ONCOGENE, V9, P911; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DEGROOT RP, 1990, NUCLEIC ACIDS RES, V18, P3195, DOI 10.1093/nar/18.11.3195; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GRAHAM FL, 1973, MOL CELL BIOL, V2, P607; HARROCH S, 1994, EMBO J, V13, P1942, DOI 10.1002/j.1460-2075.1994.tb06463.x; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; KITABAYASHI I, 1993, J BIOL CHEM, V268, P14482; KORNHAUSER JM, 1992, SCIENCE, V255, P1581, DOI 10.1126/science.1549784; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KUNZ D, 1989, NUCLEIC ACIDS RES, V17, P1121, DOI 10.1093/nar/17.3.1121; LAMPH WW, 1988, NATURE, V334, P592; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MIYAJIMA A, 1992, TRENDS BIOCHEM SCI, V17, P378, DOI 10.1016/0968-0004(92)90004-S; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1991, ONCOGENE, V6, P533; SADOWSKI HB, 1993, SCIENCE, V261, P1738; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SHEN S, 1993, MECH DEVELOP, V40, P177, DOI 10.1016/0925-4773(93)90075-9; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; YIN TG, 1994, J BIOL CHEM, V269, P3731; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	60	109	115	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					985	994						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898939				2022-12-25	WOS:A1995QL03800020
J	DELLARAGIONE, F; RUSSO, GL; OLIVA, A; MASTROPIETRO, S; MANCINI, A; BORRELLI, A; CASERO, RA; IOLASCON, A; ZAPPIA, V				DELLARAGIONE, F; RUSSO, GL; OLIVA, A; MASTROPIETRO, S; MANCINI, A; BORRELLI, A; CASERO, RA; IOLASCON, A; ZAPPIA, V			5'-DEOXY-5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND P16(INK4) DEFICIENCY IN MULTIPLE TUMOR-CELL LINES	ONCOGENE			English	Article						5'-METHYLTHIOADENOSINE PHOSPHORYLASE; P16(INK4) GENE; TUMOR SUPPRESSOR GENE; HUMAN CANCERS; 9P21 CHROMOSOME	METHYLTHIOADENOSINE PHOSPHORYLASE; HUMAN GLIOMAS; CHROMOSOME-9; MALIGNANCY; DELETIONS; ABSENCE; ENZYME; GENE	5'-Deoxy-5'-methylthioadenosine phosphorylase (MTA-Pase) gene is localized at the 9p21 region linked to the recently identified putative tumor suppressor gene, p16(INK4), which appears implicated in the control of cell division cycle, The phosphorylase is a housekeeping enzyme involved in the purine and amino acid metabolism whose activity is evidentiable in all the normal tissues, Chromosomal deletions encompassing both MTAPase and p16(INK4) genes cause the total absence of the enzymatic activity only in malignant cells, thus resulting in defined metabolic differences between malignant and normal cells, MTAPase deficiency was investigated by direct radiochemical assay method and by immunochemical techniques in 35 different human malignant cell lines established from several tumor types, The enzyme-deficient cells derived from breast, lung, ovary and liver cancer, malignant melanomas, malignant gliomas and liposarcomas, Two of the MTAPase-deficient cell preparations (from a liver carcinoma and from a melanoma) are primary cultures thus directly representing the original cancer genotypes, Several of the MTAPase-negative cells were studied for p16(INK4) gene deletions and for p16(INK4) protein deficiency, In all the examined samples a full correlation exists between the lack of MTAPase and that of p16(INK4). A similar result was obtained analysing extracts of Vero cell line, which is a fibroblast MTAPase-negative cell line established from the kidney of a normal adult monkey, Conversely, Cos cells, which also are fibroblasts derived from monkey kidney, show both MTAPase and p16(INK4) protein, These results: (i) demonstrate that the phosphorylase deficiency is distributed among almost all the most important human cancers; (ii) confirm and extend the tumor types were p16(INK4) gene inactivation is observable and (iii) suggest that deletions at 9p21 (in humans) or at syntenic chromosomes (in other species) might represent a general mechanism of p16(INK4) gene loss of function and possibly, in turn, of cancer development and/or progression.	UNIV NAPLES 2,SCH MED,DEPT PEDIAT,NAPLES,ITALY; G PASCALE FDN,INST STUDY & TREATMENT TUMORS,NAPLES,ITALY; JOHNS HOPKINS UNIV,SCH MED,ONCOL CTR LABS,BALTIMORE,MD 21231	Universita della Campania Vanvitelli; IRCCS Fondazione Pascale; Johns Hopkins University	DELLARAGIONE, F (corresponding author), UNIV NAPLES 2,SCH MED,INST BIOCHEM MACROMOLEC,NAPLES,ITALY.		Iolascon, Achille/A-4461-2014; RUSSO, GIAN LUIGI/GQB-0962-2022	Casero, Robert/0000-0001-5653-3306; Borrelli, Antonella/0000-0002-4439-6882; RUSSO, GIAN LUIGI/0000-0001-9321-1613; Della Ragione, Fulvio/0000-0002-0592-4283				BACKLUND PS, 1982, J BIOL CHEM, V257, P4196; CAIRNS P, 1993, ONCOGENE, V8, P1083; CAIRNS P, 1994, SCIENCE, V265, P414; CARRERA CJ, 1984, P NATL ACAD SCI-BIOL, V81, P2665, DOI 10.1073/pnas.81.9.2665; COLEMAN A, 1993, AM J HUM GENET S, V53, pA287; DELLARAGIONE F, 1986, J BIOL CHEM, V261, P2324; DELLARAGIONE F, 1990, J BIOL CHEM, V265, P6241; DELLARAGIONE F, 1992, BIOCHEM J, V281, P533, DOI 10.1042/bj2810533; DELLARAGIONE F, 1993, ADV EXP MED BIOL, V348, P31; DELLARAGIONE F, 1989, PHYSL POLYAMINES, P231; DELLARAGIONE F, 1981, J CHROMATOGR, V226, P2243; HEGI M, 1994, 59 COLD SPR HARB LAB, P85; HOLLAND EA, 1994, ONCOGENE, V9, P1361; JONASSON J, 1977, J CELL SCI, V24, P217; KAMATANI N, 1981, P NATL ACAD SCI-BIOL, V78, P1219, DOI 10.1073/pnas.78.2.1219; KAMATANI N, 1981, BIOCHIM BIOPHYS ACTA, V675, P344, DOI 10.1016/0304-4165(81)90024-6; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; MARX J, 1994, SCIENCE, V264, P344, DOI 10.1126/science.8153613; NOBORI T, 1991, CANCER RES, V51, P3193; NOBORI T, 1992, CANCER RES, V53, P1098; NOBORI T, 1994, NATURE, V358, P753; OLOPADE OI, 1992, CANCER RES, V52, P2523; SAIKI RK, 1988, SCIENCE, V238, P487; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; TAGUCHI T, 1993, CANCER RES, V53, P4349; TRAWEEK ST, 1988, BLOOD, V71, P1568; WILLIAMSASHMAN HG, 1982, BIOCHEM PHARMACOL, V31, P277, DOI 10.1016/0006-2952(82)90171-X; WORSHAM MJ, 1993, GENE CHROMOSOME CANC, V6, P58, DOI 10.1002/gcc.2870060111	29	50	54	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					827	833						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898924				2022-12-25	WOS:A1995QL03800003
J	GETHER, U; NILSSON, L; LOWE, JA; SCHWARTZ, TW				GETHER, U; NILSSON, L; LOWE, JA; SCHWARTZ, TW			SPECIFIC RESIDUES AT THE TOP OF TRANSMEMBRANE SEGMENT-V AND SEGMENT-VI OF THE NEUROKININ-1 RECEPTOR INVOLVED IN BINDING OF THE NONPEPTIDE ANTAGONIST CP-96,345	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P NK1 RECEPTOR; SUBSTANCE-P; EXPRESSION; EPITOPES	Previously we have found that binding of the nonpeptide substance P antagonists, CP 96,345, to the neurokinin-1 (NK-1) receptor was critically dependent on two short segments adjacent to the top of transmembrane segments (TM) V and VI, called segments A (residues 183-195) and D (residues 271-276), respectively. In the present study we have systematically performed substitutions of nonconserved residues within these two segments with residues from the homologous NK-3 and/or NK-2 receptor. In segment A, deletion of residues Glu(193) and Lys(194), which are not present in the NK-3 receptor, or substituting them with leucines as in the NK-2 receptor, decreased the affinity of CP 96,345 10- and 22-fold, respectively. Surprisingly, switching the position of Glu(193) and Lys(194) did not affect the affinity of CP 96,345, suggesting that, rather than interacting directly with CP 96,345, an interaction of these residues with one another is important for CP 96,345 binding. In segment D substitution of Tyr(272) with threonine as in the NK-2 receptor and with alanine as in the NK-3 receptor decreased the affinity of CP 96,345 7- and 24-fold, respectively. Mutation of the preceding Pro(271) to, glycine alone did not affect CP 96,345 binding, but, combined with the mutation of Tyr(272) to threonine, the affinity decreased 28-fold. A series of CP 96,345 analogues with modifications of the major chemical moieties exhibited equally reduced affinity as that of CP 96,345 for the Tyr(272)- and Lys(193)-Glu(194)- substituted constructs, except CP 95,555, which lacks one of the phenyl rings in the benzhydryl group and which was almost unaffected by these mutations, In conclusion, our data indicate a direct interaction between CP 96,345 and Tyr(272), which are located at the top of TM VI likely in close spatial proximity to the previously identified interaction point, His(197), at the top of the adjacent TM V. Furthermore, the data demonstrated a critical involvement in CP 96,345 binding of Lys(193) and Glu(194) located one alpha-helical turn above His(197).	UNIV COPENHAGEN,RIGSHOSP 6321,DEPT CLIN BIOCHEM,MOLEC ENDOCRINOL LAB,DK-2100 COPENHAGEN,DENMARK; PFIZER INC,DIV CENT RES,DEPT EXPLORATORY MED CHEM,GROTON,CT 06340	Rigshospitalet; University of Copenhagen; Pfizer				Schwartz, Thue W./0000-0002-0261-6904; Gether, Ulrik/0000-0002-0020-3807; nilsson, lars/0000-0002-8362-1042				BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; DEBLASI A, 1989, TRENDS PHARMACOL SCI, V10, P227, DOI 10.1016/0165-6147(89)90266-6; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1993, NATURE, V362, P350; Freidinger R M, 1993, Prog Drug Res, V40, P33; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GETHER U, 1993, P NATL ACAD SCI USA, V90, P6194, DOI 10.1073/pnas.90.13.6194; GETHER U, 1992, FEBS LETT, V296, P241, DOI 10.1016/0014-5793(92)80295-R; GETHER U, 1994, MOL PHARMACOL, V45, P500; HOKFELT T, 1991, NEURON, V7, P867, DOI 10.1016/0896-6273(91)90333-U; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; LEFKOWITZ RJ, 1993, NATURE, V365, P603, DOI 10.1038/365603a0; LOWE JA, 1992, J MED CHEM, V35, P2591, DOI 10.1021/jm00092a009; LOWE JA, 1993, BIOORG MED CHEM LETT, V3, P921, DOI 10.1016/S0960-894X(00)80693-9; MAGGI CA, 1993, J AUTON PHARMACOL, V13, P23, DOI 10.1111/j.1474-8673.1993.tb00396.x; MCLEAN S, 1991, SCIENCE, V251, P437, DOI 10.1126/science.1703324; SACHAIS BS, 1993, J BIOL CHEM, V268, P2319; SNIDER RM, 1991, SCIENCE, V251, P435, DOI 10.1126/science.1703323; STAPPERT J, 1992, NUCLEIC ACIDS RES, V20, P624, DOI 10.1093/nar/20.3.624; TOTA MR, 1990, J BIOL CHEM, V265, P16891; WATLING KJ, 1992, TRENDS PHARMACOL SCI, V13, P266, DOI 10.1016/0165-6147(92)90082-H; WATLING KJ, 1993, TRENDS PHARMACOL SCI, V14, P14; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649; ZOFFMANN S, 1993, FEBS LETT, V336, P506, DOI 10.1016/0014-5793(93)80865-R	26	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23959	23964						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929043				2022-12-25	WOS:A1994PQ34600019
J	SPUHLER, P; ANANTHARAMAIAH, GM; SEGREST, JP; SEELIG, J				SPUHLER, P; ANANTHARAMAIAH, GM; SEGREST, JP; SEELIG, J			BINDING OF APOLIPOPROTEIN-A-I MODEL PEPTIDES TO LIPID BILAYERS - MEASUREMENT OF BINDING ISOTHERMS AND PEPTIDE-LIPID HEADGROUP INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; CYCLIC SOMATOSTATIN ANALOG; PHOSPHOLIPID HEAD GROUPS; AMPHIPATHIC HELIX; PHOSPHATIDYLCHOLINE BILAYERS; ELECTRIC CHARGE; CALCIUM-BINDING; MEMBRANES; DEUTERIUM; HYDROPHOBICITY	Amphiphatic cu-helices are the lipid-binding motif in many apolipoproteins. Two model peptides, namely Asp-Trp-Leu-Lys-Ala-Phe-Tyr-Asp-Lys-Val-Ala-Glu-Lys-Leu-Lys-Glu-Ala-Phe (18A) and Lys-Trp-Leu-Asp-Ala-Phe-Tyr-Lys-Asp-Val -Ala-Lys-Glu-Leu-Glu-Lys-Ala-Phe (18R), have been synthesized previously to mimic the structural and functional properties of apolipoprotein A-1. Here a quantitative thermodynamic analysis of the binding process of 18A and 18R to neutral and negatively charged lipid membranes is provided. Peptide 18A has a higher lipid affinity than 18R, and both peptides bind better to mixed 1-palmitoyl-2-oleoyl-3-sn-glycero phosphocholine/1-palmitoyl-2-oleoyl-3-sn-glycero-phosphoglycerol (POPC/POPG) bilayers than to pure POPC bilayers. At lipid-to-peptide ratios >100, the binding of 18A and 18R to phospholipid bilayers can be described by an apparent surface partition equilibrium with binding constants in the range of 40-900 M(-1). At high peptide concentrations, the membrane affinity of 18A and 18R increases dramatically NMR studies provide evidence that peptide-peptide interactions make additional contributions to the binding energy. A cooperative binding model is developed to describe the binding process over the whole concentration range. The cooperativity parameter a is identical for 18A and 18R yielding a peptide-peptide interaction energy of about -2.4 kcal/mol. The free energy of membrane insertion is about -6.5 kcal/mol for 18A and -5.5 kcal/mol for 18R. The binding reaction is driven by the hydrophobic surface energy which is partially balanced by the loss in translational and rotational degrees of freedom. A molecular analysis of the free energy of binding predicts a 40-60% insertion of the peptides into the hydrophobic membrane environment. Deuterium and phosphorus solid state NMR were used to monitor the influence of 18A and 18R on the long range and short range order of the phospholipids. The sprectra are characteristic of fluid-like lipid bilayers and provide no evidence for the formation of discoidal particles. However, both peptides change the conformation of the phosphocholine dipoles, moving the N+ end of the latter toward the water phase. The rotation of the P---N+ dipoles is due to the interaction of the phospholipids with the positive charges on 18A and 18R, with 18A being more effective than 18R. For 18R the NMR data predict a pK shift and a partial charge neutralization of the carboxylate groups located at the edge of the polar/nonpolar interface.	UNIV BASEL,BIOCTR,DEPT BIOPHYS,CH-4056 BASEL,SWITZERLAND; UNIV ALABAMA,MED CTR,DEPT MED,BIRMINGHAM,AL 35294; UNIV ALABAMA,MED CTR,DEPT BIOCHEM,BIRMINGHAM,AL 35294; UNIV ALABAMA,MED CTR,ARTERIOSCLEROSIS RES UNIT,BIRMINGHAM,AL 35294	University of Basel; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NHLBI NIH HHS [HL34343] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034343] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTENBACH C, 1984, BIOCHEMISTRY-US, V23, P3913, DOI 10.1021/bi00312a019; ANANTHARAMAIAH GM, 1985, J BIOL CHEM, V260, P248; ANANTHARAMAIAH GM, 1993, AMPHIPATHIC HELIX, P109; BAUERLE HD, 1991, BIOCHEMISTRY-US, V30, P7203, DOI 10.1021/bi00243a023; BAUERLE HD, 1991, THESIS U BASEL; BECHINGER B, 1991, BIOCHEMISTRY-US, V30, P3923, DOI 10.1021/bi00230a017; BESCHIASCHVILI G, 1992, BIOCHEMISTRY-US, V31, P10044, DOI 10.1021/bi00156a026; BESCHIASCHVILI G, 1991, BIOCHIM BIOPHYS ACTA, V1061, P78, DOI 10.1016/0005-2736(91)90270-I; BESCHIASCHVILI G, 1990, BIOCHEMISTRY-US, V29, P10995, DOI 10.1021/bi00501a018; BOULANGER Y, 1981, BIOCHEMISTRY-US, V20, P6824, DOI 10.1021/bi00527a013; CANTOR CR, 1980, BIOPHYSICAL CHEM, V1, P283; DAVIS JH, 1976, CHEM PHYS LETT, V42, P390, DOI 10.1016/0009-2614(76)80392-2; EPAND RM, 1987, J BIOL CHEM, V262, P9389; EPAND RM, 1989, J BIOL CHEM, V264, P4628; FERNANDEZ MS, 1977, J PHYS CHEM-US, V81, P1755, DOI 10.1021/j100533a009; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HABIGER RGK, 1992, BIOCHIM BIOPHYS ACTA, V1103, P69, DOI 10.1016/0005-2736(92)90058-T; JAHNIG F, 1983, P NATL ACAD SCI-BIOL, V80, P3691, DOI 10.1073/pnas.80.12.3691; JANIN J, 1978, BIOCHEMISTRY-US, V17, P2943, DOI 10.1021/bi00608a001; KUCHINKA E, 1989, BIOCHEMISTRY-US, V28, P4216, DOI 10.1021/bi00436a014; MACDONALD PM, 1987, BIOCHEMISTRY-US, V26, P6292, DOI 10.1021/bi00393a050; MACDONALD PM, 1987, BIOCHEMISTRY-US, V26, P1231, DOI 10.1021/bi00379a005; MACDONALD PM, 1988, BIOCHEMISTRY-US, V27, P6769, DOI 10.1021/bi00418a019; MISHRA VK, 1994, J BIOL CHEM, V269, P7185; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; ROBINSON BH, 1975, CHEM BIOL APPLICATIO, P481; ROUX M, 1989, BIOCHEMISTRY-US, V28, P2313, DOI 10.1021/bi00431a050; SCHERER PG, 1989, BIOCHEMISTRY-US, V28, P7720, DOI 10.1021/bi00445a030; SEELIG A, 1988, BIOCHIM BIOPHYS ACTA, V939, P267, DOI 10.1016/0005-2736(88)90070-3; SEELIG J, 1993, BIOCHEMISTRY-US, V32, P9714, DOI 10.1021/bi00088a025; SEELIG J, 1987, BIOCHEMISTRY-US, V26, P7535, DOI 10.1021/bi00398a001; SEELIG J, 1978, BIOCHIM BIOPHYS ACTA, V515, P105, DOI 10.1016/0304-4157(78)90001-1; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; SEGREST JP, 1991, MOL CONFORMATION BIO, P597; TAMM LK, 1983, BIOCHEMISTRY-US, V22, P1474, DOI 10.1021/bi00275a023; TERZI E, 1994, BIOCHEMISTRY-US, V33, P7434, DOI 10.1021/bi00189a051; YEAGLE PL, 1993, BIOCHEMISTRY-US, V32, P12197, DOI 10.1021/bi00096a032	38	49	51	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23904	23910						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929037				2022-12-25	WOS:A1994PQ34600012
J	YUKIHIRO, S; POSNER, GH; GUGGINO, SE				YUKIHIRO, S; POSNER, GH; GUGGINO, SE			VITAMIN-D-3 ANALOGS STIMULATE CALCIUM CURRENTS IN RAT OSTEOSARCOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; OSTEO-SARCOMA; CHANNEL; OSTEOBLASTS; TRANSCALTACHIA; METABOLITES; CALCITRIOL; D3	1 alpha,25-Dihydroxyvitamin D-3 (1,25-D-3) rapidly (within seconds) shifts the threshold for activation of inward calcium currents to more negative and physiological potentials. To determine whether the opening of calcium channels in bone cells is mediated by the cytosolic 1,25-dihydroxyvitamin D-3 receptor (VDR), several natural metabolites 1,25-D-3, 25-hydroxyvitamin D-3, and 24R,25-dihydroxyvitamin D-3 and synthetic analogs 25-hydroxy-16,23E-diene D-3 (HO), 25-hydroxy-23-yne D-3 (Y), and 1 alpha,25-dihydroxy-16-ene-23-yne-26,27-F6 D-3 (EO) were tested on dihydropyridine-sensitive inward barium currents. In order to probe the structural specificity at the 1 position of the steroid for stimulation of barium currents, we used several synthetic 1-(1'-hydroxyethyl) (NP, ON, NN, OP) and 1-(2'-hydroxyethyl)-25-hydroxyvitamin D-3 analogs (14w-1 alpha and 14w-1 beta). Using the perforated patch-clamp technique, we found that the naturally occurring vitamin D-3 analogs gave nearly the same rank order potency for stimulation of barium currents as their affinity for VDR with 1,25-D-3 being the most potent analog. Using the synthetic analogs which have minimal affinity for VDR, we found that the compounds without 1-OH group but with additional double bonds in positions 16 and 23 or with a triple bond in position 23 retained high affinity for calcium channel activation. Furthermore, 1-hydroxyethyl-25-hydroxyvitamin D-3 R isomers at the 1' position had greater affinity than the S isomers at this position, and a beta oriented 2'-hydroxyethyl group gave the homolog greater affinity than did the alpha-oriented 2'-hydroxyethyl group. The fact that these synthetic analogs cause rapid effects on calcium channels and show pharmacological specificity different from the binding to the cytosolic vitamin D-3 receptor suggests that calcium influx is mediated by a distinct signal transduction pathway. The high and physiological affinity of 1,25-D-3 (50 pM) suggests that it is a biological regulator of calcium channels.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT CHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH ARTS & SCI,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043423] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030052] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-43423] Funding Source: Medline; NIGMS NIH HHS [GM-30052] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIKLE DD, 1978, J BIOL CHEM, V253, P8382; CAFFREY JM, 1989, J BIOL CHEM, V264, P20265; CHESNOYMARCHAIS D, 1988, J PHYSIOL-LONDON, V398, P291, DOI 10.1113/jphysiol.1988.sp017043; DUNCAN RL, 1992, FEBS LETT, V307, P219, DOI 10.1016/0014-5793(92)80771-8; FARACHCARSON MC, 1991, ENDOCRINOLOGY, V129, P1876, DOI 10.1210/endo-129-4-1876; FERRARA J, 1994, J BIOL CHEM, V269, P2971; GUGGINO SE, 1989, P NATL ACAD SCI USA, V86, P2957, DOI 10.1073/pnas.86.8.2957; HENRY PD, 1980, AM J CARDIOL, V46, P1047, DOI 10.1016/0002-9149(80)90366-5; KIM YS, 1994, 9TH WORKSH VIT D ORL; KRAFTE DS, 1988, J GEN PHYSIOL, V91, P641, DOI 10.1085/jgp.91.5.641; LIEBERHERR M, 1987, J BIOL CHEM, V262, P13168; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo-107-5-1494; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MINGHETTI PP, 1988, FASEB J, V2, P3043, DOI 10.1096/fasebj.2.15.2847948; NORMAN AW, 1992, BIOCHEM BIOPH RES CO, V189, P1450, DOI 10.1016/0006-291X(92)90237-F; POSNER GH, 1993, BIOORG MED CHEM LETT, V3, P1829, DOI 10.1016/S0960-894X(00)80114-6; POSNER GH, 1993, J ORG CHEM, V58, P7209, DOI 10.1021/jo00077a052; PROCSAL DA, 1975, J BIOL CHEM, V250, P8382; RODAN GA, 1981, CALCIFIED TISSUE INT, V33, P349, DOI 10.1007/BF02409454; SCHAUF CL, 1975, J PHYSIOL-LONDON, V248, P613, DOI 10.1113/jphysiol.1975.sp010991; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; ZHOU LX, 1992, J BONE MINER RES, V7, P457	23	59	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23889	23893						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929036				2022-12-25	WOS:A1994PQ34600010
J	BAUBICHONCORTAY, H; BAGGETTO, LG; DAYAN, G; DIPIETRO, A				BAUBICHONCORTAY, H; BAGGETTO, LG; DAYAN, G; DIPIETRO, A			OVEREXPRESSION AND PURIFICATION OF THE CARBOXYL-TERMINAL NUCLEOTIDE-BINDING DOMAIN FROM MOUSE P-GLYCOPROTEIN - STRATEGIC LOCATION OF A TRYPTOPHAN RESIDUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; GLUTATHIONE-S-TRANSFERASE; CONFER MULTIDRUG RESISTANCE; ATP-DEPENDENT TRANSPORT; CYSTIC-FIBROSIS; ESCHERICHIA-COLI; ADENYLATE KINASE; CATALYTIC SITE; SCHIZOSACCHAROMYCES-POMBE; ADENOSINE-TRIPHOSPHATASE	The cDNA encoding the C-terminal nucleotide binding domain (NBD2) from mouse P-glycoprotein involved in multidrug resistance was obtained from adrenal cell mRNA and amplified by reverse transcriptase polymerase chain reaction. NBD2 was highly overexpressed in Escherichia coli in fusion with glutathione S-transferase and could be purified after efficient thrombin cleavage. Both fused and purified NBD2 bound TNP (2',3'-O-(2,4,6-trinitrophenyl))-derivatives of nucleotides with high affinity. TNP-ATP or TNP-ADP binding at micromolar concentrations produced a characteristic blueshifted enhancement of extrinsic fluorescence and was specifically prevented or chased by ATP or ADP at millimolar concentrations. A similar affinity binding was monitored by quenching of intrinsic fluorescence. The spectrum of fusion protein, containing 5 tryptophan residues, was maximally quenched at 328 nm upon interaction with TNP-nucleotides. TNP-GTP exhibited a lower affinity than TNP-ATP but produced a higher maximal quenching (44% instead of 28%). The intrinsic fluorescence of purified NBD2, containing a single tryptophan residue, exhibited a narrow spectrum with a maximum at 328 nm characteristic of a hydrophobic tryptophan environment. A high quenching was observed upon nucleotide interaction with similar affinity The results put forward a functional role for the tryptophan-containing sequence of P-glycoprotein NBD2 that was not detected up to now.	UNIV LYON 1, INST BIOL & CHIM PROT,BIOCHIM STRUCT & FONCT LAB, CNRS,UPR 412, F-69367 LYON 07, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1				, Loris G/0000-0002-2412-8661				ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ARISPE N, 1992, P NATL ACAD SCI USA, V89, P1539, DOI 10.1073/pnas.89.5.1539; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BALZI E, 1994, J BIOL CHEM, V269, P2206; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPIEAUX E, 1993, J BIOL CHEM, V268, P21895; CHANG JY, 1985, EUR J BIOCHEM, V151, P217, DOI 10.1111/j.1432-1033.1985.tb09091.x; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DIEDERICHS K, 1991, J MOL BIOL, V217, P541, DOI 10.1016/0022-2836(91)90756-V; DIVITA G, 1993, J BIOL CHEM, V268, P13178; DIVITA G, 1992, BIOCHEMISTRY-US, V31, P5791, DOI 10.1021/bi00140a015; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P14; DREUSICKE D, 1988, J MOL BIOL, V199, P359, DOI 10.1016/0022-2836(88)90319-1; DUPONT Y, 1983, FEBS LETT, V156, P93, DOI 10.1016/0014-5793(83)80255-5; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FALSON P, 1993, BIOCHEMISTRY-US, V32, P10387, DOI 10.1021/bi00090a014; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUILLOT D, 1993, J BIOL CHEM, V268, P20911; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; HIRATSUKA T, 1976, BIOCHIM BIOPHYS ACTA, V453, P293, DOI 10.1016/0005-2795(76)90277-4; HIRATSUKA T, 1982, BIOCHIM BIOPHYS ACTA, V719, P509, DOI 10.1016/0304-4165(82)90240-9; HIRATSUKA T, 1985, J BIOL CHEM, V260, P4784; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HOYER PB, 1986, ARCH BIOCHEM BIOPHYS, V245, P369, DOI 10.1016/0003-9861(86)90228-6; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JAULT JM, 1993, J BIOL CHEM, V268, P20762; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; KIM HJ, 1990, BIOCHEMISTRY-US, V29, P1107, DOI 10.1021/bi00457a002; KO YH, 1993, J BIOL CHEM, V268, P24330; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J. R., 1983, PRINCIPLES FLUORESCE, P3; LELONG IH, 1992, FEBS LETT, V304, P256, DOI 10.1016/0014-5793(92)80632-Q; LOO TW, 1994, J BIOL CHEM, V269, P7750; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; MOCZYDLOWSKI EG, 1981, J BIOL CHEM, V256, P2346; MORBACH S, 1993, J BIOL CHEM, V268, P18617; OKAJIMA T, 1993, FEBS LETT, V334, P86, DOI 10.1016/0014-5793(93)81687-U; PORUCHYNSKY MS, 1994, BIOCHEMISTRY-US, V33, P4163, DOI 10.1021/bi00180a009; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; RONINSON IB, 1992, BIOCHEM PHARMACOL, V43, P95, DOI 10.1016/0006-2952(92)90666-7; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SCHULZ GE, 1974, NATURE, V250, P120, DOI 10.1038/250120a0; SHIMABUKU AM, 1992, J BIOL CHEM, V267, P4308; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; TEEM JL, 1993, CELL, V73, P335, DOI 10.1016/0092-8674(93)90233-G; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; TRAVIS SM, 1993, J BIOL CHEM, V268, P15336; UEDA K, 1992, J BIOL CHEM, V267, P24248; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALTER C, 1992, J BIOL CHEM, V267, P8863; YAN HG, 1990, BIOCHEMISTRY-US, V29, P10956, DOI 10.1021/bi00501a013; YANG CPH, 1989, J BIOL CHEM, V264, P782	70	72	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					22983	22989						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	7916013				2022-12-25	WOS:A1994PQ16400015
J	SOMMERLADE, HJ; SELMER, T; INGENDOH, A; GIESELMANN, V; VONFIGURA, K; NEIFER, K; SCHMIDT, B				SOMMERLADE, HJ; SELMER, T; INGENDOH, A; GIESELMANN, V; VONFIGURA, K; NEIFER, K; SCHMIDT, B			GLYCOSYLATION AND PHOSPHORYLATION OF ARYLSULFATASE-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; LYSOSOMAL-ENZYME; LINKED OLIGOSACCHARIDES; PROTEIN; FIBROBLASTS; EXPRESSION; RECEPTOR; SIGNAL	The glycosylation and phosphorylation of the lysosomal enzyme arylsulfatase A was analyzed by a combination of metabolic labeling, tryptic fragmentation, mass spectrometry, and radiosequencing. The results demonstrate that all three potential N-glycosylation sites at Asn residues 158, 184, and 350 are utilized in arylsufatase A and carry high mannose or hybride type oligosaccharides. Phosphorylation of mannose residues is restricted to oligosaccharides at the first and third N-glycosylation site (Asn-158 and Asn-350). Both are phosphorylated with comparable efficiency. An earlier study had shown that a mutant arylsulfatase A containing only the second N-glycosylation site at Asn-184 folds correctly and is phosphorylated (Gieselmann, V., Schmidt, B., and von Figura, K. (1992) J. Biol. Chem. 267, 13262-13266). The lack of phosphorylation at Asn-184 in wild type arylsulfatase A therefore indicates that in vivo the presence of oligosaccharides can interfere with phosphorylation of other sites or that phosphorylation occurs in an ordered manner whereby phosphorylation of one site can affect the phosphorylation of another site.	UNIV GOTTINGEN,ZENTRUM BIOCHEM & MOLEK ZELLBIOL,BIOCHEM ABT 2,D-37073 GOTTINGEN,GERMANY; UNIV MUNSTER,INST MED PHYS & BIOPHYS,D-48149 MUNSTER,GERMANY	University of Gottingen; University of Munster								BACH G, 1983, BIOCHEM BIOPH RES CO, V112, P198, DOI 10.1016/0006-291X(83)91816-8; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; CANTOR AB, 1992, J BIOL CHEM, V267, P23349; CANTOR AB, 1992, J BIOL CHEM, V267, P23357; CHAO HHJ, 1990, EMBO J, V9, P3507, DOI 10.1002/j.1460-2075.1990.tb07559.x; FLUHARTY AL, 1983, BIOCHEM BIOPH RES CO, V112, P191, DOI 10.1016/0006-291X(83)91815-6; GIESELMANN V, 1989, P NATL ACAD SCI USA, V86, P9436, DOI 10.1073/pnas.86.23.9436; GIESELMANN V, 1992, J BIOL CHEM, V267, P13262; HERMANS MMP, 1993, BIOCHEM J, V289, P681, DOI 10.1042/bj2890681; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; INGENDOH A, 1994, INT J MASS SPECTROM, V131, P345, DOI 10.1016/0168-1176(93)03873-K; KOBATA A, 1979, ANAL BIOCHEM, V100, P1, DOI 10.1016/0003-2697(79)90102-7; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; MORREAU H, 1992, J BIOL CHEM, V267, P17949; RODRIGUEZ H, 1981, ANAL BIOCHEM, V140, P538; SHIPLEY JM, 1993, J BIOL CHEM, V268, P12193; SOMMERLADE HJ, 1994, BIOCHEM J, V297, P123, DOI 10.1042/bj2970123; SONDERFELDFRESKO S, 1989, J BIOL CHEM, V264, P7692; STEIN C, 1989, J BIOL CHEM, V264, P1252; STEIN M, 1987, EMBO J, V6, P2677, DOI 10.1002/j.1460-2075.1987.tb02559.x; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WAHEED A, 1982, H-S Z PHYSIOL CHEM, V363, P425, DOI 10.1515/bchm2.1982.363.1.425; WAHEED A, 1983, AM J HUM GENET, V35, P228; WEITZ G, 1992, J BIOL CHEM, V267, P10039	25	38	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					20977	20981						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	7914890				2022-12-25	WOS:A1994PC40300027
J	YOUNG, J; BUTTENSHAW, R; BUTTERWORTH, L; WARD, M; SEARLE, J; LEGGETT, B; CHENEVIXTRENCH, G				YOUNG, J; BUTTENSHAW, R; BUTTERWORTH, L; WARD, M; SEARLE, J; LEGGETT, B; CHENEVIXTRENCH, G			ASSOCIATION OF THE SS GENOTYPE OF THE L-MYC GENE AND LOSS OF 18Q SEQUENCES WITH A WORSE CLINICAL PROGNOSIS IN COLORECTAL CANCERS	ONCOGENE			English	Article							FRAGMENT-LENGTH-POLYMORPHISM; HUMAN-BREAST-CANCER; LUNG-CANCER; METASTASIS; HETEROZYGOSITY; CARCINOMAS; FREQUENCY; TUMORS; COLON; LOCUS	L-myc is a nuclear oncogene which is sometimes activated late in tumourigenesis. Digestion of DNA with EcoRI reveals a simple restriction fragment length polymorphism (RFLP) located in the second intron of L-myc, with allele sizes 10 kb (L-allele) and 6.6 kb (S-allele). Some studies have suggested that the presence of the S-allele in the constitutional DNA of a patient with cancer is associated with a higher risk of metastasis in lung, breast and renal cell carcinomas. The aims of this study were to determine if the S-allele was significantly associated with metastasis and also with inactivation of tumour suppressor genes in colorectal cancer. One hundred and twenty-four Caucasian colorectal cancer patients were studied for L-myc genotype, and a subgroup of these (108) had their tumours examined for allele loss at multiple loci on nine chromosomal arms (1p, 1q, 5q, 8p, 14q, 17p, 17q, 18q, 22q) and for mutations in the 12th codon of K-ras. The percentage of individuals with the SS genotype was 19% (4/21) Dukes Stage A, 19% (10/54) Dukes B, 25% (8/32) Dukes C and 40% (8/20) Dukes D. The trend observed here is significant (P<0.05, Wilcoxon Rank Sum Test). Also, the SS genotype was significantly more common in individuals whose tumours showed allelic loss on 18q (P<0.01, Fishers Exact Test). This work suggests that the S-allele of L-myc, or a gene in linkage disequilibrium with it, may modify the development of colorectal cancer.	UNIV QUEENSLAND,SCH MED,DEPT PATHOL,BRISBANE,QLD 4029,AUSTRALIA; ROYAL BRISBANE HOSP,DEPT PATHOL,BRISBANE,QLD 4029,AUSTRALIA; QUEENSLAND INST MED RES,BRISBANE,QLD 4029,AUSTRALIA	University of Queensland; Royal Brisbane & Women's Hospital; QIMR Berghofer Medical Research Institute	YOUNG, J (corresponding author), GLAXO GASTROENTEROL LAB,CLIN RES CTR,BANCROFT CTR,300 HERSTON RD,BRISBANE,QLD 4029,AUSTRALIA.		Young, Joanne P/H-7774-2014; Young, Joanne P/B-9981-2011; Leggett, Barbara A/D-3579-2011	Leggett, Barbara/0000-0003-2062-7380; Chenevix-Trench, Georgia/0000-0002-1878-2587				BELL SM, 1991, BRIT J CANCER, V64, P174, DOI 10.1038/bjc.1991.264; BIECHE I, 1990, HUM GENET, V85, P101; CHAMPEME MH, 1992, INT J CANCER, V50, P6, DOI 10.1002/ijc.2910500103; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; CHENEVIXTRENCH G, 1989, BRIT J CANCER, V60, P872, DOI 10.1038/bjc.1989.382; DEPHINO RA, 1987, GENE DEV, V1, P1311; IKEDA I, 1988, JPN J CANCER RES, V79, P674, DOI 10.1111/j.1349-7006.1988.tb02220.x; ISHIZAKI K, 1990, J NATL CANCER I, V82, P238, DOI 10.1093/jnci/82.3.238; KAKEHI Y, 1989, INT J CANCER, V43, P391, DOI 10.1002/ijc.2910430307; KATO M, 1990, INT J CANCER, V45, P47, DOI 10.1002/ijc.2910450110; KAWASHIMA K, 1988, P NATL ACAD SCI USA, V85, P2353, DOI 10.1073/pnas.85.7.2353; KAWASHIMA K, 1992, INT J CANCER, V50, P557, DOI 10.1002/ijc.2910500411; KAWASHIMA K, 1987, P JPN ACAD B-PHYS, V63, P300, DOI 10.2183/pjab.63.300; KAYE F, 1988, MOL CELL BIOL, V8, P186, DOI 10.1128/MCB.8.1.186; LAURENTPUIG P, 1992, GASTROENTEROLOGY, V102, P1136; LEISTER I, 1990, CANCER RES, V50, P7232; LEPPERT M, 1990, NEW ENGL J MED, V322, P904, DOI 10.1056/NEJM199003293221306; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NEWLAND RC, 1987, CANCER, V60, P852, DOI 10.1002/1097-0142(19870815)60:4<852::AID-CNCR2820600422>3.0.CO;2-5; OOKAWA K, 1993, INT J CANCER, V53, P382, DOI 10.1002/ijc.2910530307; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; SARANATH D, 1990, BRIT J CANCER, V61, P530, DOI 10.1038/bjc.1990.119; TAMAI S, 1990, INT J CANCER, V46, P411, DOI 10.1002/ijc.2910460314; TAYLOR JA, 1993, INT J CANCER, V54, P927, DOI 10.1002/ijc.2910540610; TEFRE T, 1990, BRIT J CANCER, V61, P809, DOI 10.1038/bjc.1990.182; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WEINBERG RA, 1989, CANCER RES, V49, P3713; YOUNG J, 1992, CANCER RES, V52, P285	29	34	35	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1053	1056						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	7907781				2022-12-25	WOS:A1994NC04800007
J	GUTHEIL, JC; HART, SR; BELANI, CP; MELERA, PW; HUSSAIN, A				GUTHEIL, JC; HART, SR; BELANI, CP; MELERA, PW; HUSSAIN, A			ALTERATIONS IN CA2+ TRANSPORT ATPASE AND P-GLYCOPROTEIN EXPRESSION CAN MEDIATE RESISTANCE TO THAPSIGARGIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHINESE-HAMSTER CELLS; MULTIDRUG-RESISTANCE; CELLULAR RESISTANCE; ENDOTHELIAL-CELLS; CROSS-RESISTANCE; DRUG-RESISTANCE; ACTINOMYCIN-D; IN-VITRO; GROWTH; BRAIN	Resistance to the intracellular Ca2+ pump inhibitor thapsigargin (TG) is associated with overexpression of both Ca2+ transport ATPase and the multidrug resistance (mdr) transporter P-glycoprotein (pgp). This is supported by increased resistance to TG following transfection of a functional pgp1 cDNA, and reversal of TG resistance with known inhibitors of pgp function. However, pgp is unlikely to represent the only mechanism of resistance to TG. Cell lines selected for high levels of resistance to TG (250-fold) show only a 3.7-fold increase in pgp expression and a 2-fold increase in cross-resistance to other drugs of the mdr class. Overexpression of endogenous Ca2+ transport ATPase may represent a second mechanism of resistance to TG. Increased Ca2+ ATPase expression (3-fold) is seen in cells made resistant to TG, and TG resistance increases with the transfection of a specific Ca2+ ATPase cDNA into DC-3F cells. If these transfectants are then made resistant to TG, both the endogenous Ca2+ ATPase and the exogenously transfected Ca2+ ATPase become overexpressed. These studies suggest that while TG may be a substrate for pgp, acquired resistance to TG can involve alterations in both pgp and Ca(2+)ATPase expression. Additional, as yet unidentified, mechanisms of resistance may be involved in resistance to TG.	UNIV MARYLAND,CTR CANC,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT MED,DIV MED ONCOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,GRAD PROGRAM MOLEC & CELL BIOL,BALTIMORE,MD 21201; VET ADM MED CTR,BALTIMORE,MD	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA)				Belani, Chandra/0000-0001-5049-5329				BATES SE, 1991, J CLIN ENDOCR METAB, V73, P18, DOI 10.1210/jcem-73-1-18; BECK WT, 1992, BIOCHEM PHARMACOL, V43, P89, DOI 10.1016/0006-2952(92)90665-6; BIEDLER JL, 1975, J NATL CANCER I, V55, P671, DOI 10.1093/jnci/55.3.671; BIEDLER JL, 1970, CANCER RES, V30, P1174; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; DEVINE SE, 1994, J BIOL CHEM, V269, P6133; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; GESSNER T, 1990, CANCER RES, V50, P3921; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; Gill Donald L., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P265; GOLDIE JH, 1984, CANCER RES, V44, P3643; GOSLAND M P, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P426; GOTTESMAN MM, 1993, CANCER RES, V53, P747; GREENWOOD J, 1992, J NEUROIMMUNOL, V39, P123, DOI 10.1016/0165-5728(92)90181-J; GROS P, 1992, BIOCHEMISTRY-US, V31, P1992, DOI 10.1021/bi00122a014; HOLLAND JF, 1993, CANCER MED, P618; HUSSAIN A, 1992, ARCH BIOCHEM BIOPHYS, V296, P539, DOI 10.1016/0003-9861(92)90608-Y; HWANG JL, 1987, J CELL PHYSIOL, V133, P127, DOI 10.1002/jcp.1041330116; JORGENSEN AO, 1988, CELL MOTIL CYTOSKEL, V9, P164, DOI 10.1002/cm.970090208; KARIN NJ, 1989, MOL CELL BIOL, V9, P1978, DOI 10.1128/MCB.9.5.1978; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU DHM, 1991, CANCER RES, V51, P5181; LEWIS AD, 1988, P NATL ACAD SCI USA, V85, P8511, DOI 10.1073/pnas.85.22.8511; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OZOLS RF, 1989, DRUG RESISTANCE CANC, P27; PETERSON RH, 1974, J CELL BIOL, V63, P773, DOI 10.1083/jcb.63.3.773; RIEHM H, 1971, CANCER RES, V31, P409; Scanlon K J, 1989, Cancer Commun, V1, P269; SCHONTHAL A, 1991, P NATL ACAD SCI USA, V88, P7096, DOI 10.1073/pnas.88.16.7096; SCOTTO KW, 1986, SCIENCE, V232, P751, DOI 10.1126/science.2421411; TAKISHIMA K, 1988, BIOCHEM BIOPH RES CO, V157, P740, DOI 10.1016/S0006-291X(88)80312-7; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TSUJI A, 1992, LIFE SCI, V51, P1427, DOI 10.1016/0024-3205(92)90537-Y; VANKALKEN CK, 1993, BRIT J CANCER, V67, P284, DOI 10.1038/bjc.1993.54	35	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					7976	7981						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7907587				2022-12-25	WOS:A1994NB40900025
J	DEVINE, SE; MELERA, PW				DEVINE, SE; MELERA, PW			DIVERSITY OF MULTIDRUG-RESISTANCE IN MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHINESE-HAMSTER CELLS; MDR GENE FAMILY; P-GLYCOPROTEIN GENES; HIGH-LEVEL; CELLULAR RESISTANCE; CROSS-RESISTANCE; DRUG-RESISTANCE; FULL-LENGTH; IN-VITRO; 5 GENES	Mammalian cells displaying the multidrug resistance (mdr) phenotype are refractory to the toxic effects of a group of unrelated natural product drugs, many of which are used for cancer chemotherapy. The pattern of cross-resistance can be extremely variable among independently selected cell lines, even though such cells are often exposed to only a single drug. The overexpression of P-glycoprotein (pgp), a 150-180-kDa drug efflux pump, has been shown to confer mdr to otherwise drug-sensitive cells; however, the variable nature of cross-resistance indicates that normal pgps alone are unlikely to account for all of the observed cross-resistance phenotypes. In this report, we examined possible factors contributing to cross-resistance diversity in mammalian cells. We show that drug-resistant Chinese hamster lung cells selected during relatively short periods of drug exposure in vitro (less than 6-8 weeks) routinely overexpressed endogenous pgps and predominantly showed a cross-resistance pattern that was similar to that conferred by the introduction and overexpression of the hamster wild-type pgp1 cDNA alone. Longer drug exposure periods at higher drug concentrations, however, led to the selection of cell lines with altered cross-resistance properties. Like the short term clones, these cell lines all overexpressed endogenous pgp. In one case, the altered phenotype was shown to be caused by the acquisition of point mutations within codons 338 and 339 of the pgp1 gene, leading to two adjacent amino acid substitutions within the encoded pgp. Although the basis for the remaining altered phenotypes remains unknown, these results indicate that additional genetic alterations beyond those responsible for the initial acquisition of mdr emerge in the face of increased selective pressure, thus further modifying or complementing the cross-resistance phenotype initially conferred by wildtype pgp.	UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,MOLEC & CELL BIOL GRAD PROGRAM,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,CTR CANC,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore					NATIONAL CANCER INSTITUTE [R01CA044678] Funding Source: NIH RePORTER; NCI NIH HHS [CA44678] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BASS F, 1990, CANCER RES, V50, P5392; BECK WT, 1991, MOL CELLULAR BIOL MU, P3; BIEDLER JL, 1970, CANCER RES, V30, P1174; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; CROOP JM, 1987, CANCER RES, V47, P5982; DEBRUIJN MHL, 1986, MOL CELL BIOL, V6, P4717, DOI 10.1128/MCB.6.12.4717; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DEVINE SE, 1991, J BIOL CHEM, V266, P4545; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; DHIR R, 1992, BIOCHEMISTRY-US, V31, P6103, DOI 10.1021/bi00141a021; Endicott J A, 1991, DNA Seq, V2, P89, DOI 10.3109/10425179109039677; ENDICOTT JA, 1987, MOL CELL BIOL, V7, P4075, DOI 10.1128/MCB.7.11.4075; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRESHNEY RI, 1983, CULTURE ANIMAL CELLS, P129; GREENBERGER LM, 1987, J BIOL CHEM, V262, P13685; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; GROS P, 1986, P NATL ACAD SCI USA, V83, P337, DOI 10.1073/pnas.83.2.337; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HOWELL N, 1984, CANCER RES, V44, P4023; HSU SIH, 1989, J BIOL CHEM, V264, P12053; HUSSAIN A, 1992, GENE, V112, P179, DOI 10.1016/0378-1119(92)90374-X; KARTNER N, 1989, SCI AM, V260, P44, DOI 10.1038/scientificamerican0389-44; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; MEYERS MB, 1985, J CELL BIOL, V100, P588, DOI 10.1083/jcb.100.2.588; Mickley L., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P233; NG WF, 1989, MOL CELL BIOL, V9, P1224, DOI 10.1128/MCB.9.3.1224; PETERSON RHF, 1983, CANCER RES, V43, P222; RIEHM H, 1971, CANCER RES, V31, P409; RIORDAN JR, 1985, NATURE, V316, P817, DOI 10.1038/316817a0; RONINSON IB, 1984, NATURE, V309, P626, DOI 10.1038/309626a0; ROY SN, 1985, CANCER RES, V45, P3856; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; SCOTTO KW, 1986, SCIENCE, V232, P751, DOI 10.1126/science.2421411; SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471; SHEN DW, 1986, J BIOL CHEM, V261, P7762; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUGIMOTO Y, 1991, MOL CELLULAR BIOL MU, P57; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; VANDERBLIEK AM, 1986, MOL CELL BIOL, V6, P1671, DOI 10.1128/MCB.6.5.1671	46	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6133	6139						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7907088				2022-12-25	WOS:A1994MY84000098
J	SASAKI, Y; HAKAMADA, K; SUAMA, Y; NAGANO, Y; FURUSAWA, I; MATSUNO, R				SASAKI, Y; HAKAMADA, K; SUAMA, Y; NAGANO, Y; FURUSAWA, I; MATSUNO, R			CHLOROPLAST-ENCODED PROTEIN AS A SUBUNIT OF ACETYL-COA CARBOXYLASE IN PEA PLANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; ZINC FINGER PROTEIN; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; GENE ORGANIZATION; GENOME; PURIFICATION; RECOMBINATION; POLYPEPTIDE; EXPRESSION	The gene product of an open reading frame of the chloroplast genome, accD, that has sequence similarity with a subunit of acetyl-CoA carboxylase from Escherichia coli was detected immunochemically in pea chloroplasts. The apparent molecular mass of the accD protein was 87 kDa on SDS-polyacrylamide gel electrophoresis. The protein was acidic and had less mobility than the calculated value, 67,116. Acetyl-CoA carboxylase activity solubilized from pea chloroplasts was inhibited by antibodies against recombinant accD protein. The antibodies precipitated a polypeptide of 35 kDa containing biotin and a polypeptide of 91 kDa together with the 87-kDa-accD protein. The accD protein formed a complex with the molecular mass of about 700 kDa, probably with the 35- and 91-kDa proteins. These results indicate that the chloroplast-encoded polypeptide, accD protein, is a component of a functional acetyl-CoA carboxylase in chloroplasts and this enzyme is a multi-subunit complex, like that from E. coli. The synthesis of accD protein was not induced by light.	KYOTO UNIV,FAC AGR,PLANT PATHOL LAB,KYOTO 606,JAPAN	Kyoto University	SASAKI, Y (corresponding author), KYOTO UNIV,FAC AGR,DEPT FOOD SCI & TECHNOL,KYOTO 606,JAPAN.			Nagano, Yukio/0000-0001-5030-676X				EGINBUHLER B, 1983, EUR J BIOCHEM, V133, P335, DOI 10.1111/j.1432-1033.1983.tb07467.x; EGLI MA, 1993, PLANT PHYSIOL, V101, P499, DOI 10.1104/pp.101.2.499; HARLOW E, 1988, ANTIBODIES LABORATOR, P488; HARLOW E, 1988, ANTIBODIES LAB MANUA, P92; HARWOOD JL, 1988, ANNU REV PLANT PHYS, V39, P101, DOI 10.1146/annurev.arplant.39.1.101; HIRATSUKA J, 1989, MOL GEN GENET, V217, P185, DOI 10.1007/BF02464880; KANNANGA.CG, 1972, ARCH BIOCHEM BIOPHYS, V152, P83, DOI 10.1016/0003-9861(72)90196-8; KASTEN B, 1992, CURR GENET, V22, P327, DOI 10.1007/BF00317930; KLEINSCHMIDT J, 1986, EMBO J, V5, P3547, DOI 10.1002/j.1460-2075.1986.tb04681.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI SJ, 1992, J BIOL CHEM, V267, P16841; LI SJ, 1992, PLANT MOL BIOL, V20, P759, DOI 10.1007/BF00027147; LIVNE A, 1990, PLANT CELL PHYSIOL, V31, P851; NAGAI K, 1985, P NATL ACAD SCI USA, V82, P7252, DOI 10.1073/pnas.82.21.7252; NAGANO Y, 1991, MOL GEN GENET, V228, P62, DOI 10.1007/BF00282448; NAGANO Y, 1991, CURR GENET, V20, P431, DOI 10.1007/BF00317074; NAKAMURA Y, 1979, PLANT SCI LETT, V14, P291, DOI 10.1016/S0304-4211(79)90173-1; NIELSEN NC, 1981, METHOD ENZYMOL, V71, P44; NIKOLAU BJ, 1981, ARCH BIOCHEM BIOPHYS, V211, P605, DOI 10.1016/0003-9861(81)90495-1; NIKOLAU BJ, 1984, ARCH BIOCHEM BIOPHYS, V228, P86, DOI 10.1016/0003-9861(84)90049-3; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OGIHARA Y, 1988, P NATL ACAD SCI USA, V85, P8573, DOI 10.1073/pnas.85.22.8573; OGURA Y, 1991, AGR BIOL CHEM TOKYO, V55, P2259, DOI 10.1080/00021369.1991.10870948; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; OROZCO EM, 1986, METHOD ENZYMOL, V118, P232; PALMER JD, 1981, GENE, V15, P21, DOI 10.1016/0378-1119(81)90100-1; ROSCOE TJ, 1982, METHODS CHLOROPLAST, P1015; SASAKI Y, 1989, NUCLEIC ACIDS RES, V17, P6217, DOI 10.1093/nar/17.15.6217; SASAKI Y, 1985, EUR J BIOCHEM, V152, P179, DOI 10.1111/j.1432-1033.1985.tb09179.x; SASAKI Y, 1993, FEBS LETT, V316, P93, DOI 10.1016/0014-5793(93)81743-J; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; SLABAS AR, 1985, PLANT SCI, V39, P177, DOI 10.1016/0168-9452(85)90171-2; SMITH AG, 1991, CURR GENET, V19, P403, DOI 10.1007/BF00309603; TAKAI T, 1988, J BIOL CHEM, V263, P2651; TAMURA T, 1983, CELL, V34, P587, DOI 10.1016/0092-8674(83)90391-4; WOLFE KH, 1992, P NATL ACAD SCI USA, V89, P10648, DOI 10.1073/pnas.89.22.10648; WOOD HG, 1977, ANNU REV BIOCHEM, V46, P385, DOI 10.1146/annurev.bi.46.070177.002125; YOSHINAGA K, 1992, PLANT MOL BIOL, V18, P79, DOI 10.1007/BF00018458	38	115	129	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25118	25123						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	7901221				2022-12-25	WOS:A1993MG67300086
J	CATASUS, L; VENDRELL, J; AVILES, FX; CARREIRA, S; PUIGSERVER, A; BILLETER, M				CATASUS, L; VENDRELL, J; AVILES, FX; CARREIRA, S; PUIGSERVER, A; BILLETER, M			THE SEQUENCE AND CONFORMATION OF HUMAN PANCREATIC PROCARBOXYPEPTIDASE A2 - CDNA CLONING, SEQUENCE-ANALYSIS, AND 3-DIMENSIONAL MODEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYPEPTIDASE GENE FAMILY; RAT CARBOXYPEPTIDASE; PROTEIN; IDENTIFICATION	A full-length cDNA clone coding for human pancreatic preprocarboxypeptidase A2 has been isolated from a lambda gt11 human pancreatic library, Expression clones were identified by specific interaction with antisera raised against the native protein. The open reading frame of the polynucleotide sequence is 1254 base pairs in length and encodes a protein of 417 amino acids, This cDNA includes a short leader signal peptide of 16 amino acids and a 94-amino acid-long activation segment, The amino acid sequence shows 89% identity to that of rat procarboxypeptidase A2, the only A2 form sequenced so far, and 64% identity to that of human procarboxypeptidase A1. The newly determined sequence was modeled to the three-dimensional crystal structures of both bovine carboxypeptidase A and porcine procarboxypeptidase A1 by a novel distance geometry approach, Biases in the modeling were avoided by relying exclusively on automatic procedures and by using random structures as starting points, Information taken from the known homologous structures refers only to the backbone since no explicit data describing the conformation of side chains were transferred, Ten structures of human carboxypeptidase A2 were determined on the basis of each of the two known crystal structures, The root-mean-square distance for the backbone atoms between the 10 structures and their mean for 237 selected residues is 0.7 Angstrom when starting from the bovine protein and 0.8 Angstrom for 251 selected residues when starting from the porcine protein. The 94 residue-long activation segment was also determined in the modeling based on the porcine zymogen; its structure is well defined but not its orientation with respect to the enzyme moiety. The model obtained for human procarboxypeptidase A2 is discussed with respect to the specificity and activation of the enzyme.	UNIV AUTONOMA BARCELONA, DEPT BIOQUIM & BIOL MOLEC, UNITAT CIENCIAS, E-08193 BARCELONA, SPAIN; UNIV AIX MARSEILLE 3, FAC SCI ST JEROME,BIOCHIM & BIOL NUTR LAB,CNRS, URA 1820, F-13397 MARSEILLE 20, FRANCE; ETH HONGGERBERG, INST MOLEK BIOL & BIOPHYS, CH-8093 ZURICH, SWITZERLAND	Autonomous University of Barcelona; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Swiss Federal Institutes of Technology Domain; ETH Zurich			Avilés, Francesc Xavier/A-2664-2015; Carreira, Suzanne/C-8445-2012; Billeter, Martin/A-8293-2010; Catasus, Lluis/K-4620-2013; Vendrell, Josep/A-6731-2010; Aviles, Francesc Xavier/F-3482-2019; Catasus, Luis/G-6811-2011	Avilés, Francesc Xavier/0000-0002-1399-6789; Catasus, Lluis/0000-0001-6075-6238; Vendrell, Josep/0000-0002-9378-4742; Aviles, Francesc Xavier/0000-0002-1399-6789; Carreira, Suzanne/0000-0002-5077-5379				AVILES FX, 1993, EUR J BIOCHEM, V211, P381, DOI 10.1111/j.1432-1033.1993.tb17561.x; BENSON JA, 1987, BIOTECHNIQUES, V2, P126; CATASUS L, 1992, BIOCHEM J, V287, P299, DOI 10.1042/bj2870299; CLAUSER E, 1988, J BIOL CHEM, V263, P17837; COLL M, 1991, EMBO J, V10, P1; GARDELL SJ, 1988, J BIOL CHEM, V263, P17828; GUASCH A, 1992, J MOL BIOL, V224, P149; GUNTERT P, 1991, Journal of Biomolecular NMR, V1, P447, DOI 10.1007/BF02192866; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HOBOHM U, 1992, PROTEIN SCI, V1, P409; KOBAYASHI R, 1978, J BIOL CHEM, V253, P5526; LEHUEROU I, 1991, BIOCHEM BIOPH RES CO, V175, P110, DOI 10.1016/S0006-291X(05)81207-0; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MIERENDORF RC, 1987, METHOD ENZYMOL, V152, P458; OPPEZZO O, 1994, EUR J BIOCHEM, V222, P55, DOI 10.1111/j.1432-1033.1994.tb18841.x; PASCUAL R, 1989, EUR J BIOCHEM, V179, P609, DOI 10.1111/j.1432-1033.1989.tb14590.x; Quiocho F A, 1971, Adv Protein Chem, V25, P1, DOI 10.1016/S0065-3233(08)60278-8; REES DC, 1983, J MOL BIOL, V168, P367, DOI 10.1016/S0022-2836(83)80024-2; REYNOLDS DS, 1989, P NATL ACAD SCI USA, V86, P9480, DOI 10.1073/pnas.86.23.9480; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VENDRELL J, 1986, BIOCHEM BIOPH RES CO, V141, P517, DOI 10.1016/S0006-291X(86)80203-0; YAMAMOTO KK, 1992, J BIOL CHEM, V267, P2575; ZHANG FM, 1991, J BIOL CHEM, V266, P24606	24	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6651	6657		10.1074/jbc.270.12.6651	http://dx.doi.org/10.1074/jbc.270.12.6651			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896805	hybrid			2022-12-25	WOS:A1995QQ85500036
J	JESSBERGER, R; RIWAR, B; ROLINK, A; RODEWALD, HR				JESSBERGER, R; RIWAR, B; ROLINK, A; RODEWALD, HR			STIMULATION OF DEFECTIVE-DNA TRANSFER ACTIVITY IN RECOMBINATION DEFICIENT SCID CELL-EXTRACTS BY A 72-KDA PROTEIN FROM WILD-TYPE THYMOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND-BREAK REPAIR; LYMPHOID V(D)J RECOMBINATION; MOUSE L-CELLS; GENE REARRANGEMENT; MOLECULAR-CLONING; ANTIGEN RECEPTOR; SIGNAL SEQUENCE; CODING SEGMENTS; KINASE; MECHANISM	The SCID (Severe Combined Immune Deficiency) mutation causes two DNA recombination deficiencies: an aberrant joining of V(D)J immunoglobulin gene elements and a failure to perform efficient repair of DNA double-strand breaks. A recently established cell-free assay for DNA transfer (DTA) was applied to study nuclear extracts from normal and SCID-derived cells. The recombination deficiency was reflected in the cell-free system: SCID lymphocyte and fibroblast extracts showed reduced levels of DTA activity on a variety of DNA substrates. Analysis of nuclear extracts prepared from wild-type thymocytes and B cells representing different stages in lymphocyte ontogeny revealed the highest activities at the most immature stages. With progression of development, DTA activity decreased. Corresponding to their early developmental arrest, V(D)J rearrangement-incompetent RAG-2(-/-) lymphocyte extracts show high DTA activity. In contrast, extracts from SCID early lymphocytes express very low DNA transfer activity. Induction of V(D)J rearrangement in vivo in a normal preB cell line lead to a co-induction of the cell-free recombination activity. This indicates a development stage specificity of cell-free DNA recombination, which temporally parallels V(D)J recombination. A protein could be purified to near-homogeneity from wild-type thymocytes which stimulates the recombination activity specifically in SCID thymocyte and proB cell extracts. This protein, SRSP (SCID Recombination Stimulatory Protein), migrates as a single band of approximately 72 kDa in SDS-polyacrylamide gel electrophoresis.			JESSBERGER, R (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4005 BASEL,SWITZERLAND.							AGUILERA RJ, 1987, CELL, V51, P909, DOI 10.1016/0092-8674(87)90578-2; ANDREWS R, 1993, BIOCHEM BIOPH RES CO, V193, P139, DOI 10.1006/bbrc.1993.1601; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GELLERT M, 1992, ANNU REV GENET, V22, P425; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GOTTLIEB TM, 1994, TRENDS BIOCHEM SCI, V19, P500, DOI 10.1016/0968-0004(94)90138-4; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HABER J E, 1992, Current Opinion in Cell Biology, V4, P401, DOI 10.1016/0955-0674(92)90005-W; HARRINGTON J, 1992, MOL CELL BIOL, V12, P4758, DOI 10.1128/MCB.12.10.4758; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HSIEH CL, 1991, MOL CELL BIOL, V11, P3972, DOI 10.1128/MCB.11.8.3972; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; JESSBERGER R, 1991, MOL CELL BIOL, V11, P445, DOI 10.1128/MCB.11.1.445; JESSBERGER R, 1994, IMMUNOLOGIST, V2, P201; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; LANDAU NR, 1987, MOL CELL BIOL, V7, P3237, DOI 10.1128/MCB.7.9.3237; LEESMILLER SP, 1989, J BIOL CHEM, V264, P17275; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LI M, 1989, GENE DEV, V3, P1801, DOI 10.1101/gad.3.11.1801; LIEBER MR, 1991, FASEB J, V5, P2934, DOI 10.1096/fasebj.5.14.1752360; LIEBER MR, 1988, P NATL ACAD SCI USA, V85, P8588, DOI 10.1073/pnas.85.22.8588; LIEBER MR, 1987, GENE DEV, V1, P751, DOI 10.1101/gad.1.8.751; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; LIEBER MR, 1992, CELL, V70, P873, DOI 10.1016/0092-8674(92)90237-7; LIN FLM, 1990, MOL CELL BIOL, V10, P103, DOI 10.1128/MCB.10.1.103; LIN FLM, 1990, MOL CELL BIOL, V10, P113, DOI 10.1128/MCB.10.1.113; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; MATSUNAMI N, 1989, NATURE, V342, P934, DOI 10.1038/342934a0; MCCORMACK WT, 1989, CELL, V56, P785, DOI 10.1016/0092-8674(89)90683-1; MESELSON MS, 1975, P NATL ACAD SCI USA, V72, P358, DOI 10.1073/pnas.72.1.358; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; REEVES WH, 1989, J BIOL CHEM, V264, P5047; ROLINK A, 1993, CURR OPIN IMMUNOL, V5, P207, DOI 10.1016/0952-7915(93)90006-E; ROLINK A, 1993, J EXP MED, V178, P1263, DOI 10.1084/jem.178.4.1263; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SCHATZ DG, 1992, ANNU REV IMMUNOL, V10, P359, DOI 10.1146/annurev.iy.10.040192.002043; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; STAUNTON JE, 1994, MOL CELL BIOL, V14, P3876, DOI 10.1128/MCB.14.6.3876; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Taccioli G E, 1992, Curr Top Microbiol Immunol, V182, P107; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; Warburg O., 1942, BIOCHEM Z, V310, P384; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WU JM, 1993, BIOCHEM BIOPH RES CO, V193, P13, DOI 10.1006/bbrc.1993.1583; WU LC, 1993, NUCLEIC ACIDS RES, V21, P5067, DOI 10.1093/nar/21.22.5067	62	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6788	6797		10.1074/jbc.270.12.6788	http://dx.doi.org/10.1074/jbc.270.12.6788			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896825	hybrid			2022-12-25	WOS:A1995QQ85500056
J	MA, GT; HONG, YS; IVES, DH				MA, GT; HONG, YS; IVES, DH			CLONING AND EXPRESSION OF THE HETERODIMERIC DEOXYGUANOSINE KINASE DEOXYADENOSINE KINASE OF LACTOBACILLUS-ACIDOPHILUS R-26	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DEOXYCYTIDINE KINASE; NUCLEOSIDE-BINDING-SITE; ADENYLATE KINASE; DEOXYTHYMIDINE KINASE; GENERAL PROPERTIES; BACILLUS-SUBTILIS; DNA; PURIFICATION; MECHANISM; TRANSCRIPTION	Two uniquely paired deoxynucleoside kinases, deoxycytidine kinase/deoxyadenosine kinase (dCK/dAK) and deoxyguanosine kinase/deoxyadenosine kinase (dGK/dAK) are required, together with thymidine kinase (TK), for deoxynucleotide synthesis in Lactobacillus acidophilus R-26. Using polymerase chain reaction-generated probes based on N-terminal amino acid sequences, me have cloned tandem genes for 25- and 26-kDa polypeptides, whose derived amino acid sequences and size correspond to wild-type Lactobacillus enzyme subunits. Expression in Escherichia coli uses a single endogenous promoter and yields active dGK/dAK (similar to 3% of extracted protein) closely resembling wild-type dGK/dAK in specificity, kinetics, heterotropic activation, and end product inhibition. Alignment of cloned genes reveals 65% identity in their DNA sequences and 61% identity in derived amino acid sequences. Comparison with herpes-viral TKs reveals three conserved regions: glycine- and arginine-rich ATP-binding motifs and a D/E-R-S/H motif at the putative TK deoxynucleoside site. Greater homology, however, is seen upon multiple alignment of dGK with mammalian deoxycytidine kinases, yielding the consensus sequence -D/E-R-S-I/V-Y-x-D-, dGK also shares a sequence (-Y-D-P-T-I/L-E-D-S/Y-Y-) required for GTP hydrolysis by p21(ras).	OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210	University System of Ohio; Ohio State University					NATIONAL CANCER INSTITUTE [R01CA047828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049635] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47828] Funding Source: Medline; NIGMS NIH HHS [GM49635] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1994, J MOL BIOL, V215, P403; BALASUBRAMANIAM NK, 1990, J GEN VIROL, V71, P2979, DOI 10.1099/0022-1317-71-12-2979; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHAKRAVARTY R, 1984, BIOCHEMISTRY-US, V23, P6235, DOI 10.1021/bi00320a053; CHENG YC, 1974, BIOCHEMISTRY-US, V13, P1179, DOI 10.1021/bi00703a019; CHOTTINER EG, 1991, P NATL ACAD SCI USA, V88, P1531, DOI 10.1073/pnas.88.4.1531; DATTA NS, 1989, BIOCHEMISTRY-US, V28, P114, DOI 10.1021/bi00427a017; Deibel M R Jr, 1978, Methods Enzymol, V51, P346, DOI 10.1016/S0076-6879(78)51046-X; DEIBEL MR, 1977, J BIOL CHEM, V252, P8240; DEIBEL MR, 1977, J BIOL CHEM, V252, P8235; DREUSICKE D, 1988, J MOL BIOL, V199, P359, DOI 10.1016/0022-2836(88)90319-1; DUBE DK, 1991, BIOCHEMISTRY-US, V30, P11760, DOI 10.1021/bi00115a004; DURHAM JP, 1970, J BIOL CHEM, V245, P2276; DURHAM JP, 1971, BIOCHIM BIOPHYS ACTA, V228, P9, DOI 10.1016/0005-2787(71)90542-9; FIRSHEIN W, 1970, BIOCHIM BIOPHYS ACTA, V204, P60, DOI 10.1016/0005-2787(70)90490-9; GENTRY GA, 1992, PHARMACOL THERAPEUT, V54, P319, DOI 10.1016/0163-7258(92)90006-L; GRAVES MC, 1986, J BIOL CHEM, V261, P1409; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HOFFJORGENSEN E, 1952, BIOCHEM J, V50, P400, DOI 10.1042/bj0500400; HONG YS, 1995, J BIOL CHEM, V270, P6602, DOI 10.1074/jbc.270.12.6595; IKEDA S, 1994, BIOCHEMISTRY-US, V33, P5328, DOI 10.1021/bi00183a041; IKEDA S, 1988, BIOCHEMISTRY-US, V27, P8648, DOI 10.1021/bi00423a021; IKEDA S, 1994, BIOCHEMISTRY-US, V33, P13373, DOI 10.1021/bi00249a025; JOVIN TM, 1973, BIOCHEMISTRY-US, V12, P891; KARLSSON A, 1994, J BIOL CHEM, V269, P24374; KIM MY, 1989, BIOCHEMISTRY-US, V28, P9043, DOI 10.1021/bi00449a012; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MCELWAIN MC, 1988, INT J SYST BACTERIOL, V38, P417, DOI 10.1099/00207713-38-4-417; MIHOVILOVIC M, 1989, BIOTECHNIQUES, V7, P14; MOLLGAARD H, 1980, J BIOL CHEM, V255, P8216; MOOS M, 1988, J BIOL CHEM, V263, P6005; MUNIR KM, 1992, J BIOL CHEM, V267, P6584; OKAZAKI R, 1964, J BIOL CHEM, V239, P275; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; POUWELS PH, 1994, NUCLEIC ACIDS RES, V22, P929, DOI 10.1093/nar/22.6.929; RIMA BK, 1977, J BACTERIOL, V129, P574, DOI 10.1128/JB.129.2.574-579.1977; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ GE, 1986, EUR J BIOCHEM, V161, P127, DOI 10.1111/j.1432-1033.1986.tb10132.x; WACHSMAN JT, 1973, APPL MICROBIOL, V25, P506, DOI 10.1128/AEM.25.3.506-508.1973; YAN HG, 1990, BIOCHEMISTRY-US, V29, P6385, DOI 10.1021/bi00479a007; [No title captured]	43	16	20	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6595	6601		10.1074/jbc.270.12.6595	http://dx.doi.org/10.1074/jbc.270.12.6595			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896798	hybrid			2022-12-25	WOS:A1995QQ85500028
J	RONG, LA; FEI, YJ; PRASAD, PD; RAMAMOORTHY, S; HAN, H; YANGFENG, TL; HEDIGER, MA; GANAPATHY, V; LEIBACH, FH				RONG, LA; FEI, YJ; PRASAD, PD; RAMAMOORTHY, S; HAN, H; YANGFENG, TL; HEDIGER, MA; GANAPATHY, V; LEIBACH, FH			HUMAN INTESTINAL H+/PEPTIDE COTRANSPORTER - CLONING, FUNCTIONAL EXPRESSION, AND CHROMOSOMAL LOCALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORDER MEMBRANE-VESICLES; PEPTIDE-TRANSPORT; BACILLUS-SUBTILIS; OLIGOPEPTIDES; SPORULATION; BACTERIA; NITRATE; SYSTEM; LOCUS; GENE	In mammalian small intestine, a H+-coupled peptide transporter is responsible for the absorption of small peptides arising from digestion of dietary proteins. Recently a cDNA clone encoding a H+/peptide cotransporter has been isolated from a rabbit intestinal cDNA library (Fei, Y, J., Kanai, Y., Nussberger, S., Ganapathy, V., Leibach, F. H., Romero, M. F., Singh, S. K., Boron, W. F., and Hediger, M. A. (1994) Nature 368, 563-566). Screening of a human intestinal cDNA library with a probe derived from the rabbit H+/peptide cotransporter cDNA resulted in the identification of a cDNA which when expressed in HeLa cells or in Xenopus laevis oocytes induced H+-dependent peptide transport activity. The predicted protein consists of 708 amino acids with 12 membrane-spanning domains and two putative sites for protein kinase C-dependent phosphorylation. The cDNA-induced transport process accepts dipeptides, tripeptides, and amino beta-lactam antibiotics but not free amino acids as substrates. The human H+/peptide cotransporter exhibits a high degree of homology (81% identity and 92% similarity) to the rabbit H+/peptide cotransporter. But surprisingly these transporters show only a weak homology to the H+-coupled peptide transport proteins present in bacteria and yeast. Chromosomal assignment studies with somatic cell hybrid analysis and in situ hybridization have located the gene encoding the cloned human H+/peptide cotransporter to chromosome 13 q33-->q34.	MED COLL GEORGIA,DEPT BIOCHEM & MOLEC BIOL,AUGUSTA,GA 30912; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	University System of Georgia; Augusta University; Yale University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School				Hediger, Matthias/0000-0003-1946-027X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028389] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 28389] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLOING G, 1990, MOL MICROBIOL, V4, P633, DOI 10.1111/j.1365-2958.1990.tb00632.x; AMIDON GL, 1994, ANNU REV PHARMACOL, V34, P321; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BRANDSCH M, 1994, BIOCHEM J, V299, P253, DOI 10.1042/bj2990253; DANTZIG AH, 1994, SCIENCE, V264, P430, DOI 10.1126/science.8153632; DANTZIG AH, 1988, BIOCHEM BIOPH RES CO, V155, P1082, DOI 10.1016/S0006-291X(88)80607-7; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; GANAPATHY ME, 1985, AM J OBSTET GYNECOL, V153, P83, DOI 10.1016/0002-9378(85)90600-3; GANAPATHY V, 1985, AM J PHYSIOL, V249, pG153, DOI 10.1152/ajpgi.1985.249.2.G153; GANAPATHY V, 1982, LIFE SCI, V30, P2137, DOI 10.1016/0024-3205(82)90287-9; GANAPATHY V, 1991, Current Opinion in Cell Biology, V3, P695, DOI 10.1016/0955-0674(91)90043-X; GANAPATHY V, 1987, ADV BIOSCI, V65, P91; GANAPATHY V, 1987, AM J PHYSIOL, V251, pF945; GANAPATHY V, 1987, CONTRIB INFUSION THE, V17, P54; GANAPATHY V, 1974, PHYSL GASTROINTESTIN, P1773; HAGTING A, 1994, J BIOL CHEM, V269, P11391; HARPER ME, 1981, CHROMOSOMA, V83, P431, DOI 10.1007/BF00327364; HEDIGER MA, 1989, P NATL ACAD SCI USA, V86, P5748, DOI 10.1073/pnas.86.15.5748; HIGGINS CF, 1986, METHOD ENZYMOL, V125, P365; KABACK HR, 1992, INT REV CYTOL, V137A, P97; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUNJI ERS, 1993, J BACTERIOL, V175, P2052, DOI 10.1128/JB.175.7.2052-2059.1993; LOMBARDO YB, 1988, J BIOL CHEM, V263, P12920; MCCLURE PR, 1990, PLANT PHYSIOL, V93, P281, DOI 10.1104/pp.93.1.281; MIYAMOTO Y, 1991, J BIOL CHEM, V266, P4742; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; PEREGO M, 1991, MOL MICROBIOL, V5, P173, DOI 10.1111/j.1365-2958.1991.tb01838.x; PERRY JR, 1994, MOL CELL BIOL, V14, P104, DOI 10.1128/MCB.14.1.104; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; RAMAMOORTHY S, 1994, BIOCHEM J, V300, P893, DOI 10.1042/bj3000893; RUDNER DZ, 1991, J BACTERIOL, V173, P1388, DOI 10.1128/jb.173.4.1388-1398.1991; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKUWA N, 1985, BIOCHIM BIOPHYS ACTA, V814, P186, DOI 10.1016/0005-2736(85)90435-3; TIRUPPATHI C, 1990, J BIOL CHEM, V265, P14870; TIRUPPATHI C, 1990, BIOCHEM J, V268, P27, DOI 10.1042/bj2680027; TSAY YF, 1993, CELL, V72, P705, DOI 10.1016/0092-8674(93)90399-B; TSUJI A, 1987, ADV BIOSCI, V65, P125; YANGFENG TL, 1985, AM J HUM GENET, V37, P1117	38	451	478	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6456	6463		10.1074/jbc.270.12.6456	http://dx.doi.org/10.1074/jbc.270.12.6456			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896779	hybrid			2022-12-25	WOS:A1995QQ85500008
J	SAMSON, SLA; GEDAMU, L				SAMSON, SLA; GEDAMU, L			METAL-RESPONSIVE ELEMENTS OF THE RAINBOW-TROUT METALLOTHIONEIN-B GENE-FUNCTION FOR BASAL AND METAL-INDUCED ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL EXPRESSION; NUCLEAR FACTOR; I PROMOTER; DEPENDENT BINDING; MAMMALIAN-CELLS; MESSENGER-RNA; IIA GENE; TRANSCRIPTION; ACTIVATION; INDUCTION	In this study, the contributions of the two metal-responsive elements (MREs) of the rainbow trout (Salmo gairdnerii) metallothionein (tMT)-B gene promoter (-137 to +5) were analyzed. The effect of MRE mutations on the basal and zinc-induced activities of tMT-B promoter-reporter gene fusions were determined by transfection of a rainbow trout hepatoma (RTH-149) cell line. Together, MREa and MREb cooperate to elicit a significant response to zinc but exhibit differential basal and metal-induced activity. The MREa sequence (-62 to -51) is important for basal promoter activity and can function independently, whereas the more distal MREb (-89 to -100) mainly contributes to metal induction through cooperative interactions with MREa. The degree of basal character of the MREs is partially determined by nucleotide differences at the flexible position N of the MRE consensus TGC(G/A)CNC. In mouse L and HepG2 cells, MREa activity is conserved, but the contributions of the MREb region differ, including reduced cooperativity with MREa. There are also differences in the apparent molecular masses of the rainbow trout and mammalian nuclear factors that bind to the tMT-B promoter and MREa sequence.	UNIV CALGARY,DEPT BIOL SCI,CALGARY,AB T2N 1N4,CANADA	University of Calgary								ANDERSEN RD, 1990, NUCLEIC ACIDS RES, V18, P6049, DOI 10.1093/nar/18.20.6049; ANDERSEN RD, 1987, MOL CELL BIOL, V7, P3574, DOI 10.1128/MCB.7.10.3574; ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BRUGNERA E, 1994, NUCLEIC ACIDS RES, V22, P3167, DOI 10.1093/nar/22.15.3167; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CULOTTA VC, 1989, MOL CELL BIOL, V9, P1376, DOI 10.1128/MCB.9.3.1376; CZUPRYN M, 1992, P NATL ACAD SCI USA, V89, P10395, DOI 10.1073/pnas.89.21.10395; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FOSTER R, 1991, J BIOL CHEM, V266, P9866; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FRYER JL, 1980, ANN NY ACAD SCI, V126, P566; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1989, CELL, V47, P767; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; IMBERT J, 1990, ADV INORG BIOCHEM, V8, P140; IMBERT J, 1989, MOL CELL BIOL, V9, P5313; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; JAHROUDI N, 1990, J BIOL CHEM, V265, P6506; KAGI JHR, 1988, BIOCHEMISTRY-US, V27, P8509, DOI 10.1021/bi00423a001; KARIN M, 1987, MOL CELL BIOL, V7, P606, DOI 10.1128/MCB.7.2.606; KARIN M, 1985, MOL CELL BIOL, V5, P2866, DOI 10.1128/MCB.5.10.2866; KARIN M, 1981, EUR J BIOCHEM, V118, P527, DOI 10.1111/j.1432-1033.1981.tb05551.x; KNOWLES BB, 1984, ADV HEPATITIS RES; KOIZUMI S, 1992, J BIOL CHEM, V267, P18659; KOIZUMI S, 1992, EUR J BIOCHEM, V210, P555, DOI 10.1111/j.1432-1033.1992.tb17454.x; LABBE S, 1991, NUCLEIC ACIDS RES, V19, P4225, DOI 10.1093/nar/19.15.4225; Maniatis T., 1982, MOL CLONING; MEULLER PR, 1988, GENE DEV, V2, P412; OLSSON PE, 1990, BIOCHIM BIOPHYS ACTA, V1049, P78, DOI 10.1016/0167-4781(90)90086-H; PRICEHAUGHEY J, 1987, BIOCHIM BIOPHYS ACTA, V908, P158, DOI 10.1016/0167-4781(87)90055-8; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; SADHU C, 1988, J BIOL CHEM, V263, P2679; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHROEDER JJ, 1990, P NATL ACAD SCI USA, V87, P3137, DOI 10.1073/pnas.87.8.3137; Searle P F, 1987, Experientia Suppl, V52, P407; SEARLE PF, 1990, NUCLEIC ACIDS RES, V19, P4683; SHWORAK NW, 1993, J BIOL CHEM, V268, P24460; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; ZAFARULLAH M, 1988, MOL CELL BIOL, V8, P4469, DOI 10.1128/MCB.8.10.4469; ZAFARULLAH M, 1989, GENE, V83, P85, DOI 10.1016/0378-1119(89)90406-X; [No title captured]	42	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6864	6871		10.1074/jbc.270.12.6864	http://dx.doi.org/10.1074/jbc.270.12.6864			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896834	hybrid			2022-12-25	WOS:A1995QQ85500065
J	WANG, J; ROSS, EM				WANG, J; ROSS, EM			THE CARBOXYL-TERMINAL ANCHORAGE DOMAIN OF THE TURKEY BETA(1)-ADRENERGIC RECEPTOR IS ENCODED BY AN ALTERNATIVELY SPLICED EXON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; AGONIST-INDUCED DESENSITIZATION; 2 ISOFORMS; BETA-2-ADRENERGIC RECEPTORS; DOWN-REGULATION; BINDING; CELLS; GENE; RNA; ERYTHROCYTE	The originally described cDNA of the turkey beta(1)-adrenergic receptor encodes a receptor with a carboxyl-terminal, 59-amino acid extension that was not found in several mammalian beta(1)- adrenergic receptors. This extension blocks agonist-promoted endocytosis and downregulation of the receptor. This carboxyl-terminal domain is encoded by an exon distinct from that which encodes the body of the receptor, and the originally described cDNA results from removal of an 849-nucleotide intron. Unspliced mRNA encodes a shorter open reading frame whose translated carboxyl terminus is identical with that of the mammalian beta(1)-adrenergic receptors. There is no evidence for other introns in the coding region. Splicing of the intron to produce the nonendocytosing receptor is highest in fetal blood cells, is appreciable in adult brain and heart, and is detectable in other tissues. Thus, different tissues use alternative splicing to express beta-adrenergic receptors that either do or do not endocytose and down-regulate in response to agonist.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIGMS NIH HHS [R37GM30355] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030355] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHEN XH, 1994, J BIOL CHEM, V269, P24810; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALTOSO R, 1989, EMBO J, V8, P4025, DOI 10.1002/j.1460-2075.1989.tb08585.x; DELAPENA P, 1992, J BIOL CHEM, V267, P25703; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FISHMAN PH, 1991, J NEUROCHEM, V56, P596, DOI 10.1111/j.1471-4159.1991.tb08191.x; FREDERICH RC, 1983, J CYCLIC NUCL PROT, V9, P103; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; GIROS B, 1989, NATURE, V342, P823; GRANNEMAN JG, 1992, ENDOCRINOLOGY, V130, P109, DOI 10.1210/en.130.1.109; GRANNEMAN JG, 1992, MOL PHARMACOL, V42, P964; HANSKI E, 1978, LIFE SCI, V22, P53, DOI 10.1016/0024-3205(78)90411-3; HARDEN TK, 1979, J CYCLIC NUCL PROT, V5, P99; HARDEN TK, 1980, SCIENCE, V210, P441, DOI 10.1126/science.6254143; HERTEL C, 1983, J CYCLIC NUCL PROT, V9, P119; HERTEL C, 1990, J BIOL CHEM, V265, P17988; HOUGH C, 1990, BIOCHEM BIOPH RES CO, V170, P46, DOI 10.1016/0006-291X(90)91238-N; KOBILKA BK, 1987, J BIOL CHEM, V262, P7321; Lucas AM, 1961, AGR MONOGRAPH, V25; LUXEMBOURG A, 1991, FEBS LETT, V283, P155, DOI 10.1016/0014-5793(91)80575-N; MINNEMAN KP, 1980, MOL PHARMACOL, V17, P1; MONSMA FJ, 1989, NATURE, V342, P926, DOI 10.1038/342926a0; MUNTZ KH, 1994, CIRC RES, V74, P369, DOI 10.1161/01.RES.74.3.369; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; NANOFF C, 1989, J CARDIOVASC PHARM, V13, P198, DOI 10.1097/00005344-198902000-00004; NEGISHI M, 1993, J BIOL CHEM, V268, P9517; NEVE KA, 1986, MOL PHARMACOL, V30, P104; NEVE KA, 1985, J PHARMACOL EXP THER, V235, P657; OMALLEY KL, 1990, BIOCHEMISTRY-US, V29, P1367, DOI 10.1021/bi00458a003; PARKER EM, 1995, J BIOL CHEM, V270, P6482, DOI 10.1074/jbc.270.12.6482; PARKER EM, 1991, J BIOL CHEM, V266, P9987; PERKINS JP, 1990, BETA ADRENERGIC RECE, P73; PIN JP, 1992, P NATL ACAD SCI USA, V89, P10331, DOI 10.1073/pnas.89.21.10331; Sambrook J., 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEARLES RP, 1994, DNA SEQUENCE, V4, P231, DOI 10.3109/10425179409020846; SHIMOMURA H, 1990, NUCLEIC ACIDS RES, V18, P4591, DOI 10.1093/nar/18.15.4591; SIMPSON IA, 1980, FEBS LETT, V115, P113, DOI 10.1016/0014-5793(80)80738-1; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; SPRONSEN AV, 1993, EUR J BIOCHEM, V23, P1117; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; VALET P, 1988, J PHARMACOL EXP THER, V249, P271; WALDO GL, 1983, J BIOL CHEM, V258, P3900; YARDEN Y, 1986, P NATL ACAD SCI USA, V83, P6795, DOI 10.1073/pnas.83.18.6795; YU SS, 1993, J BIOL CHEM, V268, P337	48	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6488	6495		10.1074/jbc.270.12.6488	http://dx.doi.org/10.1074/jbc.270.12.6488			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896783	hybrid			2022-12-25	WOS:A1995QQ85500013
J	KIELBASSA, K; MULLER, HJ; MEYER, HE; MARKS, F; GSCHWENDT, M				KIELBASSA, K; MULLER, HJ; MEYER, HE; MARKS, F; GSCHWENDT, M			PROTEIN-KINASE C-DELTA-SPECIFIC PHOSPHORYLATION OF THE ELONGATION-FACTOR EEF-1-ALPHA AND AN EEF-1-ALPHA PEPTIDE AT THREONINE 431	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER RECEPTOR; TRANSFER RNA-SYNTHETASE; 3 DISTINCT TYPES; SUBSTRATE-SPECIFICITY; ADDITIONAL MEMBERS; RAT FIBROBLASTS; BINDING PROTEIN; FACTOR-I; EXPRESSION; ZETA	Two cytosolic proteins of murine epidermis or porcine spleen with molecular masses of 37 kDa (p37) and 50 kDa (p50) are differentially phosphorylated in vitro by the purified protein kinase C (PKC) isoenzymes alpha, beta, gamma (cPKC) and PKC delta. p37, identified as annexin I, is preferentially phosphorylated by cPKC, whereas p50, identified as elongation factor eEF-1 alpha, is phosphorylated with much greater efficacy by PKC delta than by cPKC. Using the recombinant PKC isoenzymes alpha, beta, gamma, delta, epsilon, eta, and zeta, we could show that purified eEF-1 alpha is indeed a specific substrate of PKC delta. It is not significantly phosphorylated by PKC epsilon, -eta and -zeta and only slightly by PKC alpha, -beta, and -gamma. PKC delta phosphorylates eEF-1 alpha at Thr-431 (based on the murine amino acid sequence). The peptide RFAVRDMRQTVAVGVIKAVDKK with a sequence corresponding to that of 422-443 from murine eEF-1 alpha and containing Thr-431 is an absolutely specific substrate for the delta-type of PKC. The single basic amino acid close to Thr-431 (Arg-429) is essential for recognition of the peptide as a substrate by PKC delta and for the selectivity of this recognition. Substitution of Arg-429 by alanine abolishes the ability of PKC delta to phosphorylate the peptide, and insertion of additional basic amino acids in the vicinity of Thr-431 causes a complete loss of selectivity.	GERMAN CANC RES CTR, D-69120 HEIDELBERG, GERMANY; RUHR UNIV BOCHUM, D-44780 BOCHUM, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Ruhr University Bochum								AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BASU A, 1993, PHARMACOL THERAPEUT, V59, P257, DOI 10.1016/0163-7258(93)90070-T; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; CACACE AM, 1993, ONCOGENE, V8, P2095; CAVALLIUS J, 1986, EXP GERONTOL, V21, P149, DOI 10.1016/0531-5565(86)90068-9; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DEKKER LV, 1992, FEBS LETT, V312, P195, DOI 10.1016/0014-5793(92)80934-9; DERVENTZI A, 1993, MECH AGEING DEV, V69, P193, DOI 10.1016/0047-6374(93)90023-K; EDMONDS BT, 1993, J CELL BIOCHEM, V52, P134, DOI 10.1002/jcb.240520204; GONEN H, 1994, P NATL ACAD SCI USA, V91, P7648, DOI 10.1073/pnas.91.16.7648; GOODE N, 1992, J BIOL CHEM, V267, P16878; GOODNIGHT J, 1992, GENE, V122, P305, DOI 10.1016/0378-1119(92)90219-F; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; GSCHWENDT M, 1992, FEBS LETT, V307, P151, DOI 10.1016/0014-5793(92)80756-7; GSCHWENDT M, 1989, J CELL BIOCHEM, V40, P295, DOI 10.1002/jcb.240400306; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; IDO M, 1987, FEBS LETT, V219, P215, DOI 10.1016/0014-5793(87)81219-X; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KOCHS G, 1993, EUR J BIOCHEM, V216, P597, DOI 10.1111/j.1432-1033.1993.tb18179.x; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; LEIBERSPERGER H, 1990, J BIOL CHEM, V265, P16108; LEIBERSPERGER H, 1991, J BIOL CHEM, V266, P14778; LIYANAGE M, 1992, BIOCHEM J, V283, P781, DOI 10.1042/bj2830781; MARAIS RM, 1989, EUR J BIOCHEM, V182, P129, DOI 10.1111/j.1432-1033.1989.tb14809.x; MARAIS RM, 1990, FEBS LETT, V277, P151, DOI 10.1016/0014-5793(90)80831-3; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; MEYER HE, 1993, FASEB J, V7, P776, DOI 10.1096/fasebj.7.9.7687226; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; OHTA K, 1990, J BIOL CHEM, V265, P3240; OLIVIER AR, 1991, EUR J BIOCHEM, V200, P805, DOI 10.1111/j.1432-1033.1991.tb16248.x; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1987, FEBS LETT, V226, P125, DOI 10.1016/0014-5793(87)80564-1; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; OSADA S, 1990, J BIOL CHEM, V265, P22434; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; RIIS B, 1990, TRENDS BIOCHEM SCI, V15, P420, DOI 10.1016/0968-0004(90)90279-K; SAIDO TC, 1992, BIOCHEMISTRY-US, V31, P482, DOI 10.1021/bi00117a026; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; SHEU FS, 1990, BIOCHEM BIOPH RES CO, V171, P1236, DOI 10.1016/0006-291X(90)90818-8; SHIINA N, 1994, SCIENCE, V266, P282, DOI 10.1126/science.7939665; SOZERI O, 1992, ONCOGENE, V7, P2259; Stabel S., 1993, INTRACELLULAR MESSEN, P167; TURNER RS, 1985, J BIOL CHEM, V260, P1503; VENEMA RC, 1991, J BIOL CHEM, V266, P12574; VENEMA RC, 1991, J BIOL CHEM, V266, P11993; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0; ZANG R, 1994, BIOCHEM J, V304, P641, DOI 10.1042/bj3040641	64	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					6156	6162		10.1074/jbc.270.11.6156	http://dx.doi.org/10.1074/jbc.270.11.6156			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890750	hybrid			2022-12-25	WOS:A1995QM94500066
J	MYERS, SJ; WONG, LM; CHARO, IF				MYERS, SJ; WONG, LM; CHARO, IF			SIGNAL-TRANSDUCTION AND LIGAND SPECIFICITY OF THE HUMAN MONOCYTE CHEMOATTRACTANT PROTEIN-1 RECEPTOR IN TRANSFECTED EMBRYONIC KIDNEY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; ACTIVATING FACTOR MCAF; FUNCTIONAL EXPRESSION; CHEMOTACTIC PROTEIN-1; MOLECULAR-CLONING; CYTOKINE FAMILY; ALPHA-SUBUNITS; IDENTIFICATION; RANTES; INTERLEUKIN-8	We have examined the ligand specificity and signal transduction pathways of a recently cloned receptor for monocyte chemoattractant protein-1 (MCP-1). In human 293 cells stably transfected with the MCP-1 receptor, MCP-1 bound specifically with high affinity (K-d = 260 pM) and induced a rapid mobilization of calcium from intracellular stores, The closely related chemokines MIP-1 alpha, MIP-1 beta, RANTES, interleukin 8 (IL-8), and Gro-alpha were inactive at concentrations as high as 300 nM. Activation of the MCP-1 receptor potently inhibited adenylyl cyclase with an IC50 = 90 pM. Activation of the MIP-1 alpha/RANTES receptor also mediated inhibition of adenylyl cyclase activity but with a different pharmacological profile: MIP-1 alpha (110 pM, IC50), RANTES (140 pM), MIP-1 beta (10 nM), and MCP-1 (820 nM). Mobilization of intracellular calcium and inhibition of adenylyl cyclase were blocked by pertussis toxin, suggesting that the MCP-1 receptor coupled to G alpha i. These results demonstrate that the MCP-1 receptor binds and signals in response to picomolar concentrations of MCP-1 in a highly specific manner. Signaling was manifested as mobilization of intracellular calcium and inhibition of adenylyl cyclase and was mediated by a pertussis toxin-sensitive G-protein(s).	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DAIICHI RES CTR,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052773] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52773] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; ERNST CA, 1994, J IMMUNOL, V152, P3541; FURUTANI Y, 1989, BIOCHEM BIOPH RES CO, V159, P249, DOI 10.1016/0006-291X(89)92430-3; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GRONENBORN AM, 1991, PROTEIN ENG, V4, P263, DOI 10.1093/protein/4.3.263; HUNG DT, 1992, J BIOL CHEM, V267, P20831; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; JIANG YL, 1992, J IMMUNOL, V148, P2423; KIMURA T, 1992, NATURE, V356, P526, DOI 10.1038/356526a0; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OPDENAKKER G, 1993, BIOCHEM BIOPH RES CO, V191, P535, DOI 10.1006/bbrc.1993.1251; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PUTNEY JW, 1994, TRENDS ENDOCRIN MET, V5, P256, DOI 10.1016/1043-2760(94)P3085-L; ROLLINS BJ, 1991, CANCER CELL-MON REV, V3, P517; ROLLINS BJ, 1990, AM J PATHOL, V136, P1229; SAGE SO, 1987, J BIOL CHEM, V262, P16364; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; SOZZANI S, 1993, J IMMUNOL, V150, P1544; SOZZANI S, 1991, J IMMUNOL, V147, P2215; SPANGRUDE GJ, 1985, J IMMUNOL, V135, P4135; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Thomas A.P., 1991, CELLULAR CALCIUM PRA, P1; VADDI K, 1994, J LEUKOCYTE BIOL, V55, P756, DOI 10.1002/jlb.55.6.756; VANDAMME J, 1992, J EXP MED, V176, P59, DOI 10.1084/jem.176.1.59; VANRIPER G, 1993, J EXP MED, V177, P851, DOI 10.1084/jem.177.3.851; WANG JM, 1993, J EXP MED, V177, P699, DOI 10.1084/jem.177.3.699; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252; YOSHIMURA T, 1990, J IMMUNOL, V145, P292; ZACHARIAE COC, 1990, J EXP MED, V171, P2177, DOI 10.1084/jem.171.6.2177; ZHANG YJ, 1994, J BIOL CHEM, V269, P15918	43	155	163	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					5786	5792		10.1074/jbc.270.11.5786	http://dx.doi.org/10.1074/jbc.270.11.5786			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890708	hybrid			2022-12-25	WOS:A1995QM94500018
J	PSHENICHKIN, SP; WISE, BC				PSHENICHKIN, SP; WISE, BC			OKADAIC ACID INCREASES NERVE GROWTH-FACTOR SECRETION, MESSENGER-RNA STABILITY, AND GENE-TRANSCRIPTION IN PRIMARY CULTURES OF CORTICAL ASTROCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR MESSENGER-RNA; BETA-ADRENERGIC-RECEPTOR; C-FOS; HIPPOCAMPAL CULTURES; ASTROGLIAL CULTURES; EXPRESSION; INTERLEUKIN-1; CELLS; ACTIVATION; IDENTIFICATION	Neonatal rat cortical astrocytes ire primary culture synthesize and secrete nerve growth factor (NGF) in response to cytokines, growth factors, and activators of protein kinases. To further implicate a protein phosphorylation mechanism in the regulation of NGF expression, astrocytes were treated with okadaic acid and calyculin A, inhibitors of phosphoprotein phosphatases 1 and 2A. Okadaic acid dramatically increased both NGF mRNA content (50-fold) and NGF secretion (100-fold) in astrocytes, while calyculin A, which has a spectrum of phosphatase inhibitory activity different from okadaic acid, failed to augment NGF expression. The increased mRNA accumulation was due mainly to an increase (4-fold) in the half-life of the NGF mRNA following 9 or 24 h of treatment. Nuclear run on assays indicated that okadaic acid also activated NGF gene transcription, which was preceded by an induction of c-fos and c-jun gene transcription. The induction of NGF expression by okadaic acid appeared independent from protein kinase C activity because down-regulating protein kinase C activity failed to decrease the okadaic acid stimulation. In contrast, interleukin-1 beta acted synergistically with okadaic acid to stimulate NGF secretion. The results indicate that okadaic acid profoundly stimulates NGF expression in astrocytes mainly by enhancing NGF mRNA stability and suggest important roles for phosphoprotein phosphatases in regulating NGF production.	GEORGETOWN UNIV, MED CTR, DEPT PHARMACOL, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, MED CTR, FIDIA GEORGETOWN INST NEUROSCI, WASHINGTON, DC 20007 USA	Georgetown University; Georgetown University					NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045181] Funding Source: NIH RePORTER; NIMH NIH HHS [MH45181] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		CARMANKRZAN M, 1993, J NEUROSCI RES, V34, P225, DOI 10.1002/jnr.490340210; CARMANKRZAN M, 1991, J NEUROCHEM, V56, P636, DOI 10.1111/j.1471-4159.1991.tb08197.x; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; D'MELLO SR, 1991, MOL BRAIN RES, V11, P255, DOI 10.1016/0169-328X(91)90034-U; D'MELLO SR, 1990, J NEUROCHEM, V55, P718, DOI 10.1111/j.1471-4159.1990.tb04192.x; D'MELLO SR, 1991, J NEUROCHEM, V57, P1570, DOI 10.1111/j.1471-4159.1991.tb06353.x; DALTOSO R, 1988, J PHARMACOL EXP THER, V246, P1190; FRIEDMAN WJ, 1990, J NEUROSCI RES, V27, P374, DOI 10.1002/jnr.490270316; FRIEDMAN WJ, 1992, J NEUROSCI RES, V33, P37, DOI 10.1002/jnr.490330106; FURUKAWA S, 1987, BIOCHEM BIOPH RES CO, V142, P395, DOI 10.1016/0006-291X(87)90287-7; GUY GR, 1992, J BIOL CHEM, V267, P1846; HENGERER B, 1990, P NATL ACAD SCI USA, V87, P3899, DOI 10.1073/pnas.87.10.3899; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LINDHOLM D, 1988, J BIOL CHEM, V263, P16348; Lindholm D, 1990, Neuroreport, V1, P9; LINDHOLM D, 1992, EUR J NEUROSCI, V4, P404, DOI 10.1111/j.1460-9568.1992.tb00889.x; LU B, 1991, J NEUROSCI, V11, P318; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MOCCHETTI I, 1989, P NATL ACAD SCI USA, V86, P3891, DOI 10.1073/pnas.86.10.3891; NEVEU I, 1992, BRAIN RES, V570, P316, DOI 10.1016/0006-8993(92)90596-2; PSHENICHKIN SP, 1994, J NEUROCHEM, V63, P419; SCHIAVI SC, 1992, BIOCHIM BIOPHYS ACTA, V1114, P95, DOI 10.1016/0304-419X(92)90009-N; SCHONTHAL A, 1991, ONCOGENE, V6, P423; SCHWARTZ JP, 1977, BRAIN RES, V137, P369, DOI 10.1016/0006-8993(77)90349-3; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SPRANGER M, 1990, EUR J NEUROSCI, V2, P69, DOI 10.1111/j.1460-9568.1990.tb00382.x; SPRINGER JE, 1993, EXP NEUROL, V124, P2, DOI 10.1006/exnr.1993.1166; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; TIMMUSK T, 1993, NEURON, V10, P475, DOI 10.1016/0896-6273(93)90335-O; VIGE X, 1991, MOL PHARMACOL, V40, P186; YOSHIDA K, 1991, BRAIN RES, V538, P118, DOI 10.1016/0006-8993(91)90385-9; ZAFRA F, 1992, J NEUROSCI, V12, P4793	33	43	44	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					5994	5999		10.1074/jbc.270.11.5994	http://dx.doi.org/10.1074/jbc.270.11.5994			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890729	hybrid			2022-12-25	WOS:A1995QM94500044
J	TOULME, F; LECAM, E; TEYSSIER, C; DELAIN, E; SAUTIERE, P; MAURIZOT, JC; CULARD, F				TOULME, F; LECAM, E; TEYSSIER, C; DELAIN, E; SAUTIERE, P; MAURIZOT, JC; CULARD, F			CONFORMATIONAL-CHANGES OF DNA MINICIRCLES UPON THE BINDING OF THE ARCHAEBACTERIAL HISTONE-LIKE PROTEIN MC1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-MICROSCOPY; LAC REPRESSOR; METHANOSARCINA-BARKERI; HU; NUCLEOSOME; DEPENDENCE; INVITRO; RINGS	Binding of the archaebacterial histone-like protein MC1 to DNA minicircles has been examined by gel retardation and electron microscopy, MC1 preferentially binds to a 207-base pair relaxed DNA minicircle as compared with the linear fragment. Random binding is observed at very low ionic strength, and a slight increase in salt concentration highly favors the formation of a complex that corresponds to the binding of two MC1 molecules per DNA ring. Measurements of dissociation rates show that this complex is remarkably stable, and electron microscopy reveals that it is characterized by two diametrically opposed kinks. These results are discussed in regard to the mechanisms by which MC1 affects DNA structure.	CTR BIOPHYS MOLEC, F-45071 ORLEANS 2, FRANCE; INST GUSTAVE ROUSSY, MICROSCOPIE CELLULAIRE & MOLEC LAB, CNRS, URA 147, F-94805 VILLEJUIF, FRANCE; INST PASTEUR, F-59019 LILLE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille				Le cam, Eric/0000-0002-6832-6117				BAUER WR, 1993, P NATL ACAD SCI USA, V90, P833, DOI 10.1073/pnas.90.3.833; BONNEFOY E, 1994, J MOL BIOL, V242, P116, DOI 10.1006/jmbi.1994.1563; BROYLES SS, 1986, J MOL BIOL, V187, P47, DOI 10.1016/0022-2836(86)90405-5; CAIRNEY KL, 1982, BIOPOLYMERS, V21, P923, DOI 10.1002/bip.360210506; CHARTIER F, 1988, BIOCHIM BIOPHYS ACTA, V951, P149, DOI 10.1016/0167-4781(88)90035-8; CHARTIER F, 1989, J BIOL CHEM, V264, P17006; CHARTIER F, 1985, FEBS LETT, V183, P119, DOI 10.1016/0014-5793(85)80967-4; CREVEL G, 1989, CR ACAD SCI III-VIE, V309, P1; CULARD F, 1993, FEBS LETT, V315, P335, DOI 10.1016/0014-5793(93)81189-7; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; DUBOCHET J, 1971, J ULTRA MOL STRUCT R, V35, P147, DOI 10.1016/S0022-5320(71)80148-X; EISMANN ER, 1990, J MOL BIOL, V213, P763, DOI 10.1016/S0022-2836(05)80262-1; FULLER F, 1982, GENE, V19, P43, DOI 10.1016/0378-1119(82)90187-1; GUALERZI CO, 1986, BACTERIAL CHROMATIN, P101; HODGESGARCIA Y, 1989, J BIOL CHEM, V264, P14621; IMBERT M, 1988, CAN J MICROBIOL, V34, P931, DOI 10.1139/m88-165; JOANICOT M, 1987, BIOPOLYMERS, V26, P315, DOI 10.1002/bip.360260211; KAM Z, 1981, BIOPOLYMERS, V20, P2671, DOI 10.1002/bip.1981.360201213; KATOUZIANSAFADI M, 1991, NUCLEIC ACIDS RES, V19, P4937, DOI 10.1093/nar/19.18.4937; KRZYCKI JA, 1990, 6TH P INT S GEN IND, P603; LAINE B, 1990, FEMS SYMP, V54, P291; LAINE B, 1991, NUCLEIC ACIDS RES, V19, P3041, DOI 10.1093/nar/19.11.3041; LAINE B, 1991, CHROMATINE, P37; LECAM E, 1991, J ELECTRON MICR TECH, V18, P375; LOBELL RB, 1990, SCIENCE, V250, P528, DOI 10.1126/science.2237403; MUZARD G, 1990, EMBO J, V9, P1289, DOI 10.1002/j.1460-2075.1990.tb08238.x; PETTIJOHN DE, 1990, NUCLEIC ACIDS MOL BI, V4, P152; PONTIGGIA A, 1993, MOL MICROBIOL, V7, P343, DOI 10.1111/j.1365-2958.1993.tb01126.x; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; SASMOR HM, 1990, BIOCHEMISTRY-US, V29, P9023, DOI 10.1021/bi00490a020; SCHMID MB, 1990, CELL, V63, P451, DOI 10.1016/0092-8674(90)90438-K; SROS M, 1994, NUCLEIC ACIDS RES, V22, P1044; TEYSSIER C, 1994, BIOCHEM J, V303, P567, DOI 10.1042/bj3030567; THEVENY B, 1988, STRUCTURE EXPRESSION, V3, P35; ZIVANOVIC Y, 1988, J MOL BIOL, V200, P267, DOI 10.1016/0022-2836(88)90239-2	35	23	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					6286	6291		10.1074/jbc.270.11.6286	http://dx.doi.org/10.1074/jbc.270.11.6286			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890766	hybrid			2022-12-25	WOS:A1995QM94500086
J	SCHMIDT, HHJ; REMALEY, AT; STONIK, JA; RONAN, R; WELLMANN, A; THOMAS, F; ZECH, LA; BREWER, HB; HOEG, JM				SCHMIDT, HHJ; REMALEY, AT; STONIK, JA; RONAN, R; WELLMANN, A; THOMAS, F; ZECH, LA; BREWER, HB; HOEG, JM			CARBOXYL-TERMINAL DOMAIN TRUNCATION ALTERS APOLIPOPROTEIN-A-I IN-VIVO CATABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEINS; LECITHIN-CHOLESTEROL ACYLTRANSFERASE; CORONARY HEART-DISEASE; INVIVO METABOLISM; EXCHANGEABLE APOLIPOPROTEINS; AMPHIPATHIC HELIX; APOA-I; PLASMA; DEGRADATION; CONVERSION	Apolipoprotein A-I (apoA-I), the major protein of high density lipoproteins, facilitates reverse cholesterol transport from peripheral tissue to liver. To determine the structural motifs important for modulating the in vivo catabolism of human apoA-I (h-apoA-I), we generated carboxyl-terminal truncation mutants at residues 201 (apoA-I-201), 217 (apoA-I-217), and 226 (apoA-I-226) by site directed mutagenesis. ApoA-I was expressed in Escherichia coli as a fusion protein with the maltose binding protein, which was removed by factor Xa cleavage. The in vivo kinetic analysis of the radioiodinated apoA-I in normolipemic rabbits revealed a markedly increased rate of catabolism for the truncated forms of apoA-I. The fractional catabolic rates (FCR) of 9.10 +/- 1.28/day (+/-S.D.) for apoA-I-201, 6.34 +/- 0.81/day for apoA-I-217, and 4.42 +/- 0.51/day for apoA-I-226 were much faster than the FCR of recombinant intact apoA-I (r-apoA-I, 0.93 +/- 0.07/day) and h-apoA-I (0.91 +/- 0.34/day), All the truncated forms of apoA-I were associated with very high density lipoproteins, whereas the intact recombinant apoA-I (r-apoA-I) and h-apoA-I associated with HDL(2) and HDL(3), Gel filtration chromatography revealed that in contrast to r-apoA-I, the mutant apoA-I-201 associated with a phospholipid-rich rabbit apoA-I containing particle. Analysis by agarose gel electrophoresis demonstrated that the same mutant migrated in the pre-beta position, but not within the alpha position as did r-apoA-I. These results indicate that the carboxyl-terminal region (residue 227-243) of apoA-I is critical in modulating the association of apoA-I with lipoproteins and in vivo metabolism of apoA-I.	NHLBI, CELL BIOL SECT, MOLEC DIS BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								ALLAN CM, 1992, J BIOL CHEM, V267, P13257; ASSMANN G, 1974, P NATL ACAD SCI USA, V71, P989, DOI 10.1073/pnas.71.3.989; BARRANS A, 1994, J BIOL CHEM, V269, P11572; BAUSSERMAN LL, 1984, BIOCHEMISTRY-US, V23, P2241, DOI 10.1021/bi00305a023; BEG ZH, 1989, J BIOL CHEM, V264, P6913; BERMAN M, 1978, DHEW NIH78 PUBL, P180; BOGUSKI MS, 1986, J LIPID RES, V27, P1011; BOJANOVSKI D, 1987, J CLIN INVEST, V80, P1742, DOI 10.1172/JCI113266; BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1043, P245, DOI 10.1016/0005-2760(90)90023-Q; BREWER HB, 1978, BIOCHEM BIOPH RES CO, V80, P623, DOI 10.1016/0006-291X(78)91614-5; BRINTON EA, 1991, J CLIN INVEST, V87, P536, DOI 10.1172/JCI115028; BYRNE RE, 1983, BIOCHEMISTRY-US, V22, P2894, DOI 10.1021/bi00281a018; CALABRESI L, 1993, BIOCHEMISTRY-US, V32, P6477, DOI 10.1021/bi00076a023; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; CHAPMAN MJ, 1986, METHOD ENZYMOL, V128, P70; CHEUNG P, 1983, NUCLEIC ACIDS RES, V11, P3703, DOI 10.1093/nar/11.11.3703; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CLAY MA, 1992, BIOCHIM BIOPHYS ACTA, V1124, P52, DOI 10.1016/0005-2760(92)90125-F; DALTON MB, 1993, J BIOL CHEM, V268, P19274; DEEB SS, 1991, J BIOL CHEM, V266, P13654; EDELSTEIN C, 1983, J BIOL CHEM, V258, P1430; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; FORMISANO S, 1978, J BIOL CHEM, V253, P354; FUNKE H, 1991, J CLIN INVEST, V87, P371, DOI 10.1172/JCI114997; GARBER DW, 1992, ARTERIOSCLER THROMB, V12, P886, DOI 10.1161/01.ATV.12.8.886; GLASS C, 1985, J BIOL CHEM, V260, P744; GLASS CK, 1983, J BIOL CHEM, V258, P7161; GLOMSET JA, 1968, J LIPID RES, V9, P155; GORDON JI, 1983, J BIOL CHEM, V258, P4037; GREGG RE, 1985, CIRCULATION, V72, P364; HARA H, 1991, J BIOL CHEM, V266, P3080; HOROWITZ BS, 1993, J CLIN INVEST, V91, P1743, DOI 10.1172/JCI116384; IKEWAKI K, 1993, J LIPID RES, V34, P2207; JENG I, 1980, BIOCHEM BIOPH RES CO, V92, P876, DOI 10.1016/0006-291X(80)90784-6; JIA S, 1990, METABOLISM, V39, P155; KHOUW AS, 1993, J LIPID RES, V34, P1483; KUNITAKE ST, 1990, ARTERIOSCLEROSIS, V10, P25, DOI 10.1161/01.ATV.10.1.25; LE NA, 1988, METABOLISM, V37, P614, DOI 10.1016/0026-0495(88)90077-7; LI WH, 1988, J LIPID RES, V29, P245; LIJNEN HR, 1981, THROMB RES, V24, P151, DOI 10.1016/0049-3848(81)90040-2; LINS L, 1993, BIOCHIM BIOPHYS ACTA, V1151, P137, DOI 10.1016/0005-2736(93)90096-I; LIU JN, 1993, BLOOD, V81, P980; MALLORY JB, 1987, J BIOL CHEM, V262, P4241; MARCEL YL, 1991, J BIOL CHEM, V266, P3644; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MILLER NE, 1977, LANCET, V1, P965, DOI 10.1016/S0140-6736(77)92274-7; MINNICH A, 1992, J BIOL CHEM, V267, P16553; MISHRA VK, 1994, J BIOL CHEM, V269, P7185; MORRIS BJ, 1992, J HYPERTENS, V10, P209, DOI 10.1097/00004872-199203000-00002; MORRISON J, 1991, J BIOL CHEM, V266, P18780; MORRISON JR, 1992, J BIOL CHEM, V267, P13205; NOLTE RT, 1992, BIOPHYS J, V63, P1221, DOI 10.1016/S0006-3495(92)81698-3; ORAM JF, 1990, ATHEROSCLER REV, V20, P103; OSBORNE JC, 1984, J BIOL CHEM, V259, P347; PAN TC, 1987, EUR J BIOCHEM, V170, P99, DOI 10.1111/j.1432-1033.1987.tb13672.x; PONTING CP, 1992, BLOOD COAGUL FIBRIN, V3, P605, DOI 10.1097/00001721-199210000-00012; RADER DJ, 1992, J LIPID RES, V33, P755; REMALEY AT, 1993, J BIOL CHEM, V268, P6785; RIEGER KJ, 1993, BIOCHEM J, V296, P373, DOI 10.1042/bj2960373; ROMA P, 1993, J CLIN INVEST, V91, P1445, DOI 10.1172/JCI116349; SAKU K, 1993, BIOCHIM BIOPHYS ACTA, V1167, P257, DOI 10.1016/0005-2760(93)90227-Z; SAKU K, 1984, METABOLISM, V33, P432, DOI 10.1016/0026-0495(84)90143-4; SCANU AM, 1987, ATHEROSCLER REV, V16, P9; SCHAEFER EJ, 1982, ARTERIOSCLEROSIS, V2, P16, DOI 10.1161/01.ATV.2.1.16; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEGREST JP, 1992, J LIPID RES, V33, P141; SHORE VG, 1978, BIOCHIM BIOPHYS ACTA, V529, P319, DOI 10.1016/0005-2760(78)90075-9; Skidgel R A, 1992, Agents Actions Suppl, V38 ( Pt 1), P359; SLOTTE JP, 1987, J BIOL CHEM, V262, P12904; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; SWANEY JB, 1993, J LIPID RES, V24, P245; VADIVELOO PK, 1993, BIOCHEMISTRY-US, V32, P9480, DOI 10.1021/bi00087a028; WARD PE, 1991, BIOCHEM PHARMACOL, V42, P721, DOI 10.1016/0006-2952(91)90028-4; WESTERLUND JA, 1993, J BIOL CHEM, V268, P15745; ZANNIS VI, 1983, P NATL ACAD SCI-BIOL, V80, P2574, DOI 10.1073/pnas.80.9.2574	75	65	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5469	5475		10.1074/jbc.270.10.5469	http://dx.doi.org/10.1074/jbc.270.10.5469			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890663	hybrid			2022-12-25	WOS:A1995QL58000079
J	PAPPAS, TC; GAMETCHU, B; WATSON, CS				PAPPAS, TC; GAMETCHU, B; WATSON, CS			MEMBRANE ESTROGEN-RECEPTORS IDENTIFIED BY MULTIPLE ANTIBODY LABELING AND IMPEDED-LIGAND BINDING	FASEB JOURNAL			English	Article						GH(3)/B6; CONFOCAL MICROSCOPY; MONOCLONAL ANTIBODY; E(2)	S-49 LYMPHOMA-CELLS; PLASMA-MEMBRANE; GLUCOCORTICOID RECEPTOR; MONOCLONAL-ANTIBODIES; NUCLEAR-LOCALIZATION; STEROID-BINDING; PROTEIN-KINASE; RAT-BRAIN; OOCYTES; MYRISTYLATION	GH(3)/B6 rat pituitary tumor cells exhibit rapid prolactin release (within 5 min) when treated with nanomolar amounts of estrogen. However, the putative protein mediator of this nongenomic action has not been described, Using antibodies directed against a peptide representing the hinge region of the intracellular estrogen receptor (iER), we have demonstrated that these cells contain a membrane ER (mER). We now report that confocal scanning laser microscopy of cells labeled live with the anti-peptide antibody further supports a membrane localization of ER. The monoclonal antibodies H226 and H222 and a polyclonal antibody, ER21, each recognizing a unique epitope on iER (NH2 terminal to the DNA-binding region, within the steroid binding region, and the NH2-terminal end, respectively), also immunohistochemically label membrane proteins of immune-selected GH(3)/B6 cells. These cells also specifically bind a fluorescent estrogen-BSA conjugate. Coincubation of cells with anti-ER antibody and the fluorescent estrogen-BSA conjugate reveals that these labels colocalize on cells. These results suggest that mER may be structurally similar to iER.	UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77555; MED COLL WISCONSIN,DEPT PEDIAT,MILWAUKEE,WI 53226	University of Texas System; University of Texas Medical Branch Galveston; Medical College of Wisconsin								BERTHOIS Y, 1986, J STEROID BIOCHEM, V25, P963, DOI 10.1016/0022-4731(86)90330-4; BLAUSTEIN JD, 1992, ENDOCRINOLOGY, V131, P1336, DOI 10.1210/en.131.3.1336; BLAUSTEIN JD, 1993, ENDOCRINOLOGY, V132, P1218, DOI 10.1210/en.132.3.1218; BLONDEAU JP, 1984, BIOCHEM J, V219, P785, DOI 10.1042/bj2190785; BRESSION D, 1986, ENDOCRINOLOGY, V119, P1048, DOI 10.1210/endo-119-3-1048; BRINK M, 1992, ENDOCRINOLOGY, V130, P3575, DOI 10.1210/en.130.6.3575; CHEN SSL, 1991, INTERVIROLOGY, V32, P193, DOI 10.1159/000150199; DUFY B, 1979, SCIENCE, V204, P509, DOI 10.1126/science.107590; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FALETTO DL, 1992, ONCOGENE, V7, P1149; GAMETCHU B, 1991, STEROIDS, V56, P411, DOI 10.1016/0039-128X(91)90029-U; GAMETCHU B, 1991, STEROIDS, V56, P402, DOI 10.1016/0039-128X(91)90028-T; GAMETCHU B, 1993, FASEB J, V7, P1283, DOI 10.1096/fasebj.7.13.8405814; GAMETCHU B, 1987, SCIENCE, V236, P456, DOI 10.1126/science.3563523; GREENE GL, 1980, P NATL ACAD SCI-BIOL, V77, P5115, DOI 10.1073/pnas.77.9.5115; GREENE GL, 1984, J STEROID BIOCHEM, V20, P51, DOI 10.1016/0022-4731(84)90188-2; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HAYASHI I, 1976, NATURE, V259, P132, DOI 10.1038/259132a0; HENDERSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P339, DOI 10.1073/pnas.80.2.339; HOFFMAN M, 1991, SCIENCE, V254, P650, DOI 10.1126/science.1948044; KING WJ, 1984, NATURE, V307, P745, DOI 10.1038/307745a0; LIEBERHERR M, 1993, J BONE MINER RES, V8, P1365; MAJEWSKA MD, 1992, PROG NEUROBIOL, V38, P379, DOI 10.1016/0301-0082(92)90025-A; MARCHILDON GA, 1984, P NATL ACAD SCI-BIOL, V81, P7679, DOI 10.1073/pnas.81.24.7679; MEIZEL S, 1990, Journal of Cell Biology, V111, p89A; NENCI I, 1980, PERSPECTIVES STEROID, P61; PAPPAS TC, 1994, ENDOCRINE, V2, P813; PATINO R, 1990, GEN COMP ENDOCR, V78, P204, DOI 10.1016/0016-6480(90)90007-9; PIETRAS RJ, 1979, J CELL PHYSIOL, V98, P145, DOI 10.1002/jcp.1040980116; SADLER SE, 1985, J STEROID BIOCHEM, V22, P419, DOI 10.1016/0022-4731(85)90448-0; SADLER SE, 1982, P NATL ACAD SCI USA, V77, P1534; Scheffe H, 1959, ANAL VARIANCE; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; SMITH LD, 1971, DEV BIOL, V25, P232, DOI 10.1016/0012-1606(71)90029-7; SMITH SS, 1989, BRAIN RES, V476, P307, DOI 10.1016/0006-8993(89)91251-1; SZEGO CM, 1985, NATURE, V317, P88, DOI 10.1038/317088a0; TOWLE AC, 1983, J STEROID BIOCHEM, V18, P135, DOI 10.1016/0022-4731(83)90079-1; WATSON CS, 1995, IN PRESS ENV HLTH PE; WELSHONS WV, 1984, NATURE, V307, P747, DOI 10.1038/307747a0; WELSHONS WV, 1985, ENDOCRINOLOGY, V117, P2140, DOI 10.1210/endo-117-5-2140	41	442	457	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1995	9	5					404	410		10.1096/fasebj.9.5.7896011	http://dx.doi.org/10.1096/fasebj.9.5.7896011			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QP451	7896011				2022-12-25	WOS:A1995QP45100014
J	VOELKEL, NF; LOBEL, K; WESTCOTT, JY; BURKE, TJ				VOELKEL, NF; LOBEL, K; WESTCOTT, JY; BURKE, TJ			NITRIC OXIDE-RELATED VASOCONSTRICTION IN LUNGS PERFUSED WITH RED-CELL LYSATE	FASEB JOURNAL			English	Article						PULMONARY VASOCONSTRICTION; HEMOSYLATE; MITOCHONDRIAL ELECTRON TRANSPORT; KCL	VASCULAR SMOOTH-MUSCLE; PULMONARY-HYPERTENSION; RELAXING FACTOR; INHIBITION; RELAXATION; MACROPHAGE; MECHANISM; ARTERY	The present study in isolated rat lungs demonstrates that nitric oxide gas (. NO, 70 nM) added to the perfusate containing a small amount of hemolysate [175 mu l of lysed red blood cells (RBC) per 50 ml of Earle's balanced salt solution (EBSS)] triggered profound and sustained vasoconstriction, Vasoconstriction was not observed when . NO was added to lungs perfused with washed intact rat or human RBC or with oxyhemoglobin (Hgb 20 mu M). The presence of hemolysate in the perfusate also caused vasoconstriction in response to n-acetylcysteine (50 mu M), glutathione (10(-4) M), or ascorbic acid (10(-4) M) and potentiated greatly the vasoconstrictor response to 5 mM KCl. Not only . NO, but also nitroprusside (SNP) or L-arginine and paradoxically three . NO synthesis inhibitors, including N-monomethyl L-arginine, L-NAME, and nitroblue tetrazolium, which have different mechanisms of action, each caused in the presence of hemolysate large vasoconstrictive responses. Hemolysate itself enhanced O-2 consumption by slices of lung; no effects of this dose of . NO on lung slice respiration were seen in the absence of hemolysate. Both Hgb and hemolysate lowered perfusate cGMP levels to the same degree suggesting that the vasoconstrictive response was not due to unique effects of hemolysate on guanylyl cyclase, Addition of superoxide dismutase (SOD) and catalase (CAT) to the hemolysate containing perfusate, or addition of a cyclooxygenase or 5-lipoxygenase inhibitor, virtually abolished the . NO induced vasoconstriction. The latter data are consistent with the concept that exposure of the vasculature to hemolysate may result in the formation of peroxynitrite. However, SOD and CAT did not abolish the pulmonary vasoconstriction induced by L-arginine or by NAG. Our data indicate that hemolysate has profound effects on lung vessel tone regulation and on lung tissue mitochondrial function, yet the precise molecular mechanisms responsible for the action of hemolysate are likely to be very complex.	UNIV COLORADO,HLTH SCI CTR,DEPT MED,DIV RENAL DIS & HYPERTENS,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	VOELKEL, NF (corresponding author), UNIV COLORADO,HLTH SCI CTR,CTR PULM HYPERTENS,DENVER,CO 80262, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043180] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL43180] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARCHER SL, 1992, BIOCHEM BIOPH RES CO, V188, P590, DOI 10.1016/0006-291X(92)91097-A; BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; CHANG SW, 1989, J APPL PHYSIOL, V66, P2407, DOI 10.1152/jappl.1989.66.5.2407; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DRAPIER JC, 1988, J IMMUNOL, V140, P2829; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; GENG Y, 1992, CIRC RES, V71, P1268, DOI 10.1161/01.RES.71.5.1268; HAYNES F, 1994, SICKLE CELL DISEASE, P623; HAYNES J, 1993, AM J PHYSIOL, V264, pH484, DOI 10.1152/ajpheart.1993.264.2.H484; HENRY Y, 1993, FASEB J, V7, P1124, DOI 10.1096/fasebj.7.12.8397130; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; KINSELLA JP, 1992, LANCET, V340, P819, DOI 10.1016/0140-6736(92)92687-B; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; KUROSE I, 1993, HEPATOLOGY, V18, P380, DOI 10.1002/hep.1840180223; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LOSCALZO J, 1985, J CLIN INVEST, V76, P703, DOI 10.1172/JCI112024; MARTIN W, 1985, J PHARMACOL EXP THER, V232, P708; MEHRKE G, 1990, J PHYSIOL-LONDON, V430, P251, DOI 10.1113/jphysiol.1990.sp018290; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MONTGOMERY MR, 1982, TOXICOL APPL PHARM, V65, P63, DOI 10.1016/0041-008X(82)90362-3; MORO MA, 1994, P NATL ACAD SCI USA, V91, P6702, DOI 10.1073/pnas.91.14.6702; NEEDLEMAN P, 1973, J PHARMACOL EXP THER, V187, P324; OKABE K, 1987, PFLUG ARCH EUR J PHY, V409, P561, DOI 10.1007/BF00584654; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PARENT RA, 1992, COMP BIOL NORMAL LUN, V1, P587; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; POST JM, 1992, AM J PHYSIOL, V262, pC882, DOI 10.1152/ajpcell.1992.262.4.C882; RIMAR S, 1993, CIRCULATION, V88, P2884, DOI 10.1161/01.CIR.88.6.2884; ROUNDS S, 1981, CIRC RES, V48, P393, DOI 10.1161/01.RES.48.3.393; SCHMIDT HHHW, 1992, LANCET, V339, P986, DOI 10.1016/0140-6736(92)91556-N; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; SCHWEIZER M, 1994, BIOCHEM BIOPH RES CO, V204, P169, DOI 10.1006/bbrc.1994.2441; SNYDER SH, 1993, NATURE, V364, P577, DOI 10.1038/364577a0; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; VOELKEL NF, 1994, FASEB J, V8, P4613; WRIGHT CE, 1992, CARDIOVASC RES, V26, P48, DOI 10.1093/cvr/26.1.48; YU L, 1994, P NATL ACAD SCI USA, V65, P1691; YUAN XJ, 1993, AM J PHYSIOL, V264, pL116, DOI 10.1152/ajplung.1993.264.2.L116	41	28	28	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1995	9	5					379	386		10.1096/fasebj.9.5.7896007	http://dx.doi.org/10.1096/fasebj.9.5.7896007			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QP451	7896007				2022-12-25	WOS:A1995QP45100010
J	LEE, WY; LOCKNISKAR, MF; FISCHER, SM				LEE, WY; LOCKNISKAR, MF; FISCHER, SM			INTERLEUKIN-1-ALPHA MEDIATES PHORBOL ESTER-INDUCED INFLAMMATION AND EPIDERMAL HYPERPLASIA	FASEB JOURNAL			English	Article						TPA; MURINE SKIN; CYTOKINE; VASCULAR PERMEABILITY; KERATINOCYTE	MESSENGER-RNA EXPRESSION; HUMAN KERATINOCYTES; ORNITHINE DECARBOXYLASE; VASCULAR-PERMEABILITY; CYTOKINE MODULATION; ADHESION MOLECULES; DERMAL FIBROBLASTS; ACTIVATING FACTOR; TUMOR PROMOTION; SKIN DISEASES	The topical application of the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) to murine skin produces acute inflammatory and hyperplastic responses that have been associated with the promotion stage of skin carcinogenesis. It has been shown in a previous study that TPA induces the expression of the highly inflammatory cytokine, interleukin (IL) -1 alpha, in the epidermis of SENCAR mice. The goal of this study induced responses in skin. Topical application of TPA (1 mu g) enhanced the production of immunoreactive IL-1 alpha protein, primarily associated with the suprabasal keratinocytes. IL-1 alpha intradermally injected in the dorsal surface significantly increased (P < 0.001) vascular permeability at low concentrations (1-1000 mu U) and increased (P < 0.001) inflammatory cell infiltration and epidermal hyperplasia at higher concentrations (10(3) U). TPA produced fourfold increases in vascular permeability as measured by Evans blue dye leakage; this effect was prevented by intradermal injection of anti-IL-1 alpha antibody (25-75 mu g). Furthermore, injected anti-IL-1 alpha antibody significantly reduced (P < 0.001) TPA-induced inflammatory cell infiltration and epidermal hyperplasia. This study suggests that IL-1 alpha directly or indirectly mediates the inflammatory and hyperplastic responses elicited by topical treatment with TPA.	UNIV TEXAS, MD ANDERSON CANC CTR, DIV SCI PK RES, SMITHVILLE, TX 78957 USA; UNIV TEXAS, COLL PHARM, DIV PHARMACOL TOXICOL, AUSTIN, TX 78712 USA; UNIV TEXAS, DIV NUTR SCI, AUSTIN, TX 78712 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin					NCI NIH HHS [CA 42211, CA 34443] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034443, R01CA042211] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDAZ CM, 1985, CANCER RES, V45, P2753; ANSEL J, 1990, J INVEST DERMATOL, V94, pS101, DOI 10.1111/1523-1747.ep12876053; ANSEL JC, 1988, J IMMUNOL, V140, P2274; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BLANTON RA, 1989, P NATL ACAD SCI USA, V86, P1273, DOI 10.1073/pnas.86.4.1273; CAMP R, 1990, J INVEST DERMATOL, V94, P735, DOI 10.1111/1523-1747.ep12874591; DEYOUNG LM, 1987, AGENTS ACTIONS, V21, P325; DIDIERJEAN L, 1989, J INVEST DERMATOL, V92, P809, DOI 10.1111/1523-1747.ep12696825; DINARELLO CA, 1991, BLOOD, V77, P1627; DUSTIN ML, 1986, J IMMUNOL, V137, P245; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FISCHER SM, 1989, CANCER RES, V49, P6693; FISCHER SM, 1990, CARCINOGENESIS, V11, P991, DOI 10.1093/carcin/11.6.991; FURSTENBERGER G, 1989, INT J CANCER, V43, P915; GRANSTEIN RD, 1986, J CLIN INVEST, V77, P1020, DOI 10.1172/JCI112354; GROVES RW, 1992, J INVEST DERMATOL, V98, P384, DOI 10.1111/1523-1747.ep12499816; HECKMANN M, 1993, J INVEST DERMATOL, V100, P780, DOI 10.1111/1523-1747.ep12476479; KUPPER TS, 1989, ARCH DERMATOL, V125, P1406, DOI 10.1001/archderm.125.10.1406; KUPPER TS, 1989, ANN NY ACAD SCI, V557, P454; KUPPER TS, 1986, J EXP MED, V164, P2095, DOI 10.1084/jem.164.6.2095; KUPPER TS, 1988, J CLIN INVEST, V82, P1787, DOI 10.1172/JCI113792; LARSEN CG, 1989, IMMUNOLOGY, V68, P31; LEE WY, 1993, MOL CARCINOGEN, V7, P26, DOI 10.1002/mc.2940070106; LOMEDICO PT, 1984, NATURE, V312, P458, DOI 10.1038/312458a0; MARTIN S, 1988, IMMUNOLOGY, V64, P301; MCGUIRE J, 1988, ANN NY ACAD SCI, V548, P283, DOI 10.1111/j.1749-6632.1988.tb18816.x; MORHENN VB, 1988, IMMUNOL TODAY, V9, P104, DOI 10.1016/0167-5699(88)91278-9; NAKADATE T, 1982, CANCER RES, V42, P2841; NORRIS DA, 1990, J INVEST DERMATOL, V95, pS111, DOI 10.1111/1523-1747.ep12874977; OBERYSZYN TM, 1993, MOL CARCINOGEN, V7, P238, DOI 10.1002/mc.2940070406; RISTOW HJ, 1987, P NATL ACAD SCI USA, V84, P1940, DOI 10.1073/pnas.84.7.1940; SCHMIDT JA, 1982, J IMMUNOL, V128, P2177; SCHMITT A, 1986, LYMPHOKINE RES, V5, P105; Slaga T. J., 1984, MECH TUMOR PROMOTION, P1; SLAGA TJ, 1984, MECHANISMS TUMOR PRO, P189; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896	36	55	56	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1994	8	13					1081	1087		10.1096/fasebj.8.13.7926375	http://dx.doi.org/10.1096/fasebj.8.13.7926375			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PN069	7926375				2022-12-25	WOS:A1994PN06900014
J	DALY, SE; LANE, LK; BLOSTEIN, R				DALY, SE; LANE, LK; BLOSTEIN, R			FUNCTIONAL CONSEQUENCES OF AMINO-TERMINAL DIVERSITY OF THE CATALYTIC SUBUNIT OF THE NA,K-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+/K+-ATPASE; ALPHA-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; SODIUM; POTASSIUM; K+; ACTIVATION; EXPRESSION; TRANSPORT; VESICLES	One region of marked sequence diversity among the highly homologous a isoforms of the Na,K-ATPase is the lysine rich NH2 terminus. Expression of a mutant cDNA encoding an alpha 1 protein, minus the 32 NH2-terminal residues, results in a modified enzyme (alpha 1M32), which be haves similarly to alpha 1 in overall Na/K exchange activity (V-max) and apparent affinities for intracellular Na+ and extracellular K+. However, with membranes isolated from HeLa cells expressing the rat alpha 1M32 mutant, as well as membranes from cells expressing the rat alpha 1 and the ouabain-resistant mutated forms of rat alpha 2 (alpha 2*) and alpha 3 (alpha 3*) developed by Jewell and Lingrel (Jewell, E. A., and Lingrel, J. B (1991) J. Biol. Chem. 266, 16925-16930), distinct Na,K-ATPase kinetics are observed. Thus, at 1 mu M ATP, the effects of K+ on the Na-ATPase activity of alpha 2* and (alpha 1M32 are similar; both are activated, whereas alpha 1 and (alpha 3 are inhibited by the addition of K+ at low (0.1 mM) concentration. These effects are attributed to different rates of a step involved in K+ deocclusion (E(2)(K) <----> E(1)K <---->, E(1) + K+) and are consistent with our earlier evidence (Wierzbicki, W., and Blostein, R. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 70-74) for a role of the NH2 terminus in the K+ deocclusion pathway of the Na,K-ATPase reaction. These differences are not directly related to differences in apparent affinities for ATP, since alpha 3* has alpha 1-like high affinity K+ inhibition but resembles (alpha 2* and (alpha 1M32 with respect to a lower K'(ATP).Na-ATPase activities of alpha 2*, alpha 3*, and alpha 1M32, but not alpha 1, are activated by Li+ but not Rb+, consistent with a relatively faster rate of Li+ deoclusion (Post, R. L., Hegyvary, C., and Kume, S. (1972) J. Biol. Chem. 247, 6530-6540), as well as higher affinity of alpha 3 for extracellular K+(Li+) activation of dephosphorylation (E(2)P + K+ <----> E(2)(K) + P-i). Inhibition of Na ATPase by higher concentrations (greater than or equal to mM) of K+ is observed with all isoforms and is attributed to K+ acting at inhibitory cytoplasmic sites. Taken together, these results suggest that the weakening of intramolecular associations between the lysine-rich NH2 terminus and other parts of the protein, either by removal of the terminus as in alpha 1M32 or by alteration in secondary structure as expected of the Gly-14-Gly-16 triplet in rat (alpha 2*, alters the rate of the K+ deocclusion pathway of the Na,K-ATPase reaction mechanism.	MCGILL UNIV, DEPT MED, MONTREAL H3G 1A4, PQ, CANADA; UNIV CINCINNATI, COLL MED, DEPT PHARMACOL & CELL BIOPHYS, CINCINNATI, OH 45267 USA	McGill University; University of Cincinnati								BEAUGE L, 1978, BIOCHIM BIOPHYS ACTA, V527, P472, DOI 10.1016/0005-2744(78)90361-3; BEAUGE LA, 1976, BIOCHIM BIOPHYS ACTA, V433, P547, DOI 10.1016/0005-2736(76)90280-7; BLOSTEIN R, 1977, J BIOL CHEM, V252, P3035; BLOSTEIN R, 1988, METHOD ENZYMOL, V156, P171; BLOSTEIN R, 1979, NA K ATPASE STRUCTUR, P233; BURGENERKAIRUZ P, 1991, FEBS LETT, V290, P83, DOI 10.1016/0014-5793(91)81231-V; CORNELIUS F, 1991, BIOCHIM BIOPHYS ACTA, V1067, P227, DOI 10.1016/0005-2736(91)90048-D; DUNHAM PB, 1977, P NATL ACAD SCI USA, V74, P3099, DOI 10.1073/pnas.74.7.3099; HORISBERGER JD, 1991, ANNU REV PHYSIOL, V53, P565, DOI 10.1146/annurev.physiol.53.1.565; HORISBERGER JD, 1993, 7 INT C SOD PUMP, V374, P593; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; JORGENSEN PL, 1975, BIOCHIM BIOPHYS ACTA, V401, P399, DOI 10.1016/0005-2736(75)90239-4; JORGENSEN PL, 1988, NA PLUS K PLUS PUM A, P85; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANE LK, 1993, J BIOL CHEM, V268, P17930; Markwell M A, 1981, Methods Enzymol, V72, P296; MUNZER JS, 1994, J BIOL CHEM, V269, P16668; OHTA T, 1991, BIOCHIM BIOPHYS ACTA, V1059, P157, DOI 10.1016/S0005-2728(05)80200-2; POST RL, 1972, J BIOL CHEM, V247, P6530; SHAINSKAYA A, 1994, J BIOL CHEM, V269, P10780; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; VASILETS LA, 1991, J BIOL CHEM, V266, P16285; VASILETS LA, 1993, EUR BIOPHYS J BIOPHY, V21, P433, DOI 10.1007/BF00185871; WIERZBICKI W, 1993, P NATL ACAD SCI USA, V90, P70, DOI 10.1073/pnas.90.1.70	27	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23944	23948						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929042				2022-12-25	WOS:A1994PQ34600017
J	DEWEERS, M; BROUNS, GS; HINSHELWOOD, S; KINNON, C; SCHUURMAN, RKB; HENDRIKS, RW; BORST, J				DEWEERS, M; BROUNS, GS; HINSHELWOOD, S; KINNON, C; SCHUURMAN, RKB; HENDRIKS, RW; BORST, J			B-CELL ANTIGEN RECEPTOR STIMULATION ACTIVATES THE HUMAN BRUTONS TYROSINE KINASE, WHICH IS DEFICIENT IN X-LINKED AGAMMAGLOBULINEMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LYMPHOCYTES-B; AGAMMAGLOBULINEMIA; PROTEIN; GENE; PHOSPHORYLATION; EXPRESSION; MOUSE	X-linked agammaglobulinemia (XLA) is an inherited human immunodeficiency disease, characterized by an arrest in B-cell development, which results in a dramatic decrease in immunoglobulin production. The gene product defective in XLA has been identified as a cytoplasmic protein tyrosine kinase, named Bruton's tyrosine kinase (Btk). The dramatic XLA phenotype indicates a critical role for Btk in the regulation of B-cell development. However, neither external stimuli leading to Btk activation nor any of its in vivo substrates have thus far been identified, and the mechanism of disease induction remains unexplained, We report here that stimulation of the B-cell antigen receptor (membrane immunoglobulin) on mature B-cells induces tyrosine phosphorylation of Btk in vivo, accompanied by an increase in its kinase activity in vitro. These results place Btk in the B-cell receptor signal transduction pathway, which is known to be essential in driving B-cell differentiation.	UNIV LEIDEN HOSP,DEPT IMMUNOHAEMATOL,2300 RC LEIDEN,NETHERLANDS; NETHERLANDS CANC INST,DIV CELLULAR BIOCHEM,1006 CX AMSTERDAM,NETHERLANDS; INST CHILD HLTH,MOLEC IMMUNOL UNIT,LONDON WC1N 1EH,ENGLAND; ERASMUS UNIV ROTTERDAM,DEPT CELL BIOL & GENET,3000 DR ROTTERDAM,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Netherlands Cancer Institute; University of London; University College London; Erasmus University Rotterdam			Kinnon, Christine/A-1585-2010	Borst, Jannie/0000-0002-8043-5009				BORST J, 1993, IMMUNOL REV, V132, P49, DOI 10.1111/j.1600-065X.1993.tb00837.x; BRADLEY LAD, 1994, HUM MOL GENET, V3, P79, DOI 10.1093/hmg/3.1.79; BROUNS GS, 1993, EUR J IMMUNOL, V23, P1088, DOI 10.1002/eji.1830230517; BRUTON OC, 1952, PEDIATRICS, V9, P722; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; CAMPANA D, 1990, J IMMUNOL, V145, P1675; CONLEY ME, 1986, NEW ENGL J MED, V315, P564, DOI 10.1056/NEJM198608283150907; CONLEY ME, 1985, J IMMUNOL, V134, P3070; DESIDERIO S, 1993, NATURE, V361, P201; DEWEERS M, 1994, HUM MOL GENET, V3, P161, DOI 10.1093/hmg/3.1.161; DEWEERS M, 1993, EUR J IMMUNOL, V23, P3109, DOI 10.1002/eji.1830231210; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; KATZ FE, 1994, LEUKEMIA, V8, P574; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; PEARL ER, 1978, J IMMUNOL, V120, P1169; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; RAWLINGS DJ, 1994, IMMUNOL REV, V138, P105, DOI 10.1111/j.1600-065X.1994.tb00849.x; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; ROSEN FS, 1984, NEW ENGL J MED, V311, P235, DOI 10.1056/NEJM198407263110406; SCHER I, 1982, ADV IMMUNOL, V33, P1, DOI 10.1016/S0065-2776(08)60834-2; SCHULTE RJ, 1992, SCIENCE, V258, P1001, DOI 10.1126/science.1279802; SMIT L, 1994, J BIOL CHEM, V269, P20209; SMITH CIE, 1994, IMMUNOL REV, V138, P159, DOI 10.1111/j.1600-065X.1994.tb00851.x; SMITH CIE, 1994, J IMMUNOL, V152, P567; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TIMMERS E, 1991, CLIN IMMUNOL IMMUNOP, V61, pS83, DOI 10.1016/S0090-1229(05)80042-X; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0	33	162	162	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23857	23860						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929028				2022-12-25	WOS:A1994PQ34600002
J	KIM, JI; TAKAHASHI, M; OGURA, A; KOHNO, T; KUDO, Y; SATO, K				KIM, JI; TAKAHASHI, M; OGURA, A; KOHNO, T; KUDO, Y; SATO, K			HYDROXYL GROUP OF TYR(13) IS ESSENTIAL FOR THE ACTIVITY OF OMEGA-CONOTOXIN GVIA, A PEPTIDE TOXIN FOR N-TYPE CALCIUM-CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MUSCLE SODIUM-CHANNELS; 3-DIMENSIONAL STRUCTURE; FUNCTIONAL EXPRESSION; GEOGRAPHUTOXIN-II; CA2+ CHANNELS; SAXITOXIN; BLOCKER; TETRODOTOXIN; SITE; INHIBITOR	A series of analogs of omega-conotoxin GVIA, a peptide neurotoxin having 27 amino acid residues with three disulfide bridges, were synthesized by replacing each amino acid residue except for Cys and Hyp with Ala. CD spectra were virtually identical between native and all of the analogs, indicating the overall conformations were not changed by the substitutions. The inhibitory effects of these analogs on I-125-omega-conotoxin GVIA binding to chick brain synaptic plasma membranes showed that replacement of Tyr(13) with Ala drastically lowered the affinity of the toxin to the N-type Ca2+ channel. Substitution of Tyr(13) with Phe also showed reduction of the affinity, indicating that the hydroxyl group of Tyr(13) is critical for binding. Since Lys(2) is also important for binding (Sato, K. Park, N.-G., Kohno, T. Maeda, T., Kim, J.-I., Kato, R., and Takahashi, M. (1993) Biochem. Biophys. Res. Commun. 194, 1292-1296), we propose a two-point binding model in which Tyr(13) and Lys(2) interact with specific amino acid residues of the Ca2+ channel through hydrogen bonding and ionic interaction, respectively.	MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN					Kudo, Yoshihisa/0000-0002-5978-8264				CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; DAVIS JH, 1993, BIOCHEMISTRY-US, V32, P7396, DOI 10.1021/bi00080a009; GRAY WR, 1988, ANNU REV BIOCHEM, V57, P665, DOI 10.1146/annurev.bi.57.070188.003313; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HESS P, 1990, ANNU REV NEUROSCI, V13, P337, DOI 10.1146/annurev.ne.13.030190.002005; HILLYARD DR, 1992, NEURON, V9, P69, DOI 10.1016/0896-6273(92)90221-X; KAO CY, 1982, J PHYSIOL-LONDON, V323, P619, DOI 10.1113/jphysiol.1982.sp014095; KIRSCH GE, 1992, NEURON, V8, P499, DOI 10.1016/0896-6273(92)90278-L; KURODA Y, 1992, NEUROSCI LETT, V135, P255, DOI 10.1016/0304-3940(92)90449-H; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; MILLER RJ, 1992, J BIOL CHEM, V267, P1403; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NODA M, 1989, FEBS LETT, V259, P213, DOI 10.1016/0014-5793(89)81531-5; OGURA A, 1990, NEUROSCI RES, V9, P103, DOI 10.1016/0168-0102(90)90026-B; OGURA A, 1987, NEUROSCI LETT, V78, P69, DOI 10.1016/0304-3940(87)90563-5; OHIZUMI Y, 1986, J BIOL CHEM, V261, P6149; OHIZUMI Y, 1986, J PHARMACOL EXP THER, V239, P243; OLIVERA BM, 1987, BIOCHEMISTRY-US, V26, P2086, DOI 10.1021/bi00382a004; PALLAGHY PK, 1993, J MOL BIOL, V234, P405, DOI 10.1006/jmbi.1993.1595; SATO K, 1991, J BIOL CHEM, V266, P16989; SATO K, 1993, BIOCHEM BIOPH RES CO, V194, P12932; SEVILLA P, 1993, BIOCHEM BIOPH RES CO, V192, P1238, DOI 10.1006/bbrc.1993.1549; TERLAU H, 1991, FEBS LETT, V293, P93, DOI 10.1016/0014-5793(91)81159-6; WAKAMATSU K, 1992, BIOCHEMISTRY-US, V31, P12577, DOI 10.1021/bi00165a006; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; YOOL AJ, 1991, NATUR, V349, P702	28	93	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23876	23878						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929033				2022-12-25	WOS:A1994PQ34600007
J	ZENG, XR; HAO, HL; JIANG, YQ; LEE, MYWT				ZENG, XR; HAO, HL; JIANG, YQ; LEE, MYWT			REGULATION OF HUMAN DNA-POLYMERASE-DELTA DURING THE CELL-CYCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR ANTIGEN; GENE-EXPRESSION; SACCHAROMYCES-CEREVISIAE; REPLICATION FACTOR; CATALYTIC SUBUNIT; THYMIDINE KINASE; SIMIAN VIRUS-40; EXCISION REPAIR; S-PHASE; ALPHA	The expression of polymerase delta (pol delta) during the cell cycle was studied in Molt 4 cells separated by counterflow centrifugal elutriation. Northern blotting showed that pol delta mRNA levels increased by 3-fold at the G(1)/S border. Levels of pol delta protein determined by Western blotting also peaked at the G(1)/S border with qualitatively similar changes as the mRNA levels, Thus, pol delta gene expression appears to be regulated during the cell cycle at the transcriptional level. The mRNA half-life for pol delta was determined to be about 8 h and the protein half-life about 10 h. Parallel examination of the expression of proliferating cell nuclear antigen showed that the mRNA levels also increased about 2-fold at the G(1)/S border, while the protein levels of proliferating cell nuclear antigen increased steadily through the whole cell cycle period, and remained high at G(2)/M. Analysis of pol or expression showed qualitatively similar behavior as pol delta, but the magnitude of the changes were higher. Pulse labeling of cells metabolically arrested in G(1), S, or G(2)/M with P-32(i) showed that pol delta is a phosphoprotein and that it is most actively phosphorylated during the S phase.	UNIV MIAMI, SCH MED, DEPT MED R57, MIAMI, FL 33101 USA	University of Miami					NIAID NIH HHS [AI 29158] Funding Source: Medline; NIGMS NIH HHS [GM 31973] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029158] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031973] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS BJ, 1993, SCIENCE, V261, P1543, DOI 10.1126/science.8372349; BASNAKIAN A, 1989, NUCLEIC ACIDS RES, V17, P4757, DOI 10.1093/nar/17.12.4757; BROTT DA, 1993, J CELL BIOCHEM, V52, P362, DOI 10.1002/jcb.240520312; BURGERS PMJ, 1990, EUR J BIOCHEM, V191, P617, DOI 10.1111/j.1432-1033.1990.tb19165.x; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPPOCK DL, 1987, MOL CELL BIOL, V7, P2925, DOI 10.1128/MCB.7.8.2925; CRIPPSWOLFMAN J, 1989, J BIOL CHEM, V264, P19478; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; GORDON CB, 1991, P NATL ACAD SCI USA, V88, P6058, DOI 10.1073/pnas.88.14.6058; HAO HL, 1992, CHROMOSOMA, V102, pS121, DOI 10.1007/BF02451795; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; INSDORF NF, 1989, J BIOL CHEM, V264, P21491; JOHNSTON LH, 1992, NUCLEIC ACIDS RES, V20, P2403, DOI 10.1093/nar/20.10.2403; KELLY TJ, 1988, J BIOL CHEM, V263, P17889; KOCH C, 1993, SCIENCE, V261, P1551, DOI 10.1126/science.8372350; KONIECKI J, 1991, CANCER RES, V51, P1465; KRISHAN A, 1981, CANCER RES, V41, P2745; LEE MYWT, 1991, J BIOL CHEM, V266, P2423; LIU YC, 1989, BIOCHEMISTRY-US, V28, P2967, DOI 10.1021/bi00433a034; MARRACCINO RL, 1987, BIOCHEMISTRY-US, V26, P7864, DOI 10.1021/bi00398a049; MCINTOSH EM, 1991, MOL CELL BIOL, V11, P329, DOI 10.1128/MCB.11.1.329; MERRILL GF, 1992, BIOESSAYS, V14, P823, DOI 10.1002/bies.950141206; MINOWADA J, 1972, J NATL CANCER I, V49, P891; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; NASHEUER HP, 1991, J BIOL CHEM, V266, P7893; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NETHANEL T, 1992, J VIROL, V66, P6634, DOI 10.1128/JVI.66.11.6634-6640.1992; NETHANEL T, 1990, J VIROL, V64, P5912, DOI 10.1128/JVI.64.12.5912-5918.1990; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; PARK H, 1993, MOL BIOL CELL, V4, P145, DOI 10.1091/mbc.4.2.145; PODUST VN, 1993, NUCLEIC ACIDS RES, V21, P841, DOI 10.1093/nar/21.4.841; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; VRIZ S, 1992, MOL CELL BIOL, V12, P3548, DOI 10.1128/MCB.12.8.3548; WAHL AF, 1988, MOL CELL BIOL, V8, P5016, DOI 10.1128/MCB.8.11.5016; Wilson SH, 1990, EUKARYOTIC NUCLEUS, V1, P199; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YANG CL, 1992, NUCLEIC ACIDS RES, V20, P735, DOI 10.1093/nar/20.4.735; YANG CL, 1991, BIOCHEMISTRY-US, V30, P7534, DOI 10.1021/bi00244a024; ZENG XR, 1994, J BIOL CHEM, V269, P13748; ZHANG SJ, 1987, ARCH BIOCHEM BIOPHYS, V252, P24, DOI 10.1016/0003-9861(87)90004-X	48	55	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24027	24033						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929054				2022-12-25	WOS:A1994PQ34600030
J	CAPLOW, M; SHANKS, J; RUHLEN, R				CAPLOW, M; SHANKS, J; RUHLEN, R			HOW TAXOL MODULATES MICROTUBULE DISASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note								Measurement of the affinity of microtubules for the anti-cancer drug taxol is problematic, because microtubules are not stable at the very low concentrations required to detect taxol dissociation. We have circumvented this problem by using the GTP analogue GMPCPP (guanylyl alpha,beta-methylenediphosphonate), which renders microtubules sufficiently stable to allow binding studies with nonsaturating concentrations of taxol. A K-d value equal to about 10 nM was estimated from the effect of taxol concentration on the dilution-induced disassembly rate and on the binding of [H-3]taxol. With GTP-microtubules the K-d value for taxol binding by tubulin-GDP subunits in the core of the microtubule appears to be comparable with that of GMPCPP-microtubules. However, the stabilizing effect of the drug bound to tubulin subunits that arrive at ends of disassembling microtubules is attenuated by a two-step reaction sequence in which taxol dissociates (k = 30 s(-1)), followed by rapid (k = 1000 s(-1)) loss of the taxol-free tubulin subunit. This sequential reaction can be disrupted by high (micromolar) concentrations of taxol, which react rapidly with tubulin subunits at the ends of microtubules (k = 2 x 10(9) M(-1) s(-1)). The inhibitory effect of taxol on microtubule disassembly at concentrations a thousand-fold greater than the K-d value suggests the desirability of using high taxol concentrations in chemotherapy with this compound.	UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill					NIGMS NIH HHS [GM46773] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046773] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Butler J A, 1940, J Gen Physiol, V24, P189, DOI 10.1085/jgp.24.2.189; CAPLOW M, 1982, EUR J BIOCHEM, V127, P319, DOI 10.1111/j.1432-1033.1982.tb06873.x; CAPLOW M, 1989, BIOCHEMISTRY-US, V28, P8136, DOI 10.1021/bi00446a026; HYMAN AA, 1992, MOL BIOL CELL, V3, P1155, DOI 10.1091/mbc.3.10.1155; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; PARNESS J, 1981, J CELL BIOL, V91, P479, DOI 10.1083/jcb.91.2.479; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0	7	60	63	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23399	23402						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	7916343				2022-12-25	WOS:A1994PQ34500005
J	PUIG, A; LYLES, MM; NOIVA, R; GILBERT, HF				PUIG, A; LYLES, MM; NOIVA, R; GILBERT, HF			THE ROLE OF THE THIOL/DISULFIDE CENTERS AND PEPTIDE BINDING-SITE IN THE CHAPERONE AND ANTI-CHAPERONE ACTIVITIES OF PROTEIN DISULFIDE-ISOMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; AGGREGATION; CATALYSIS; LYSOZYME; RESIDENT; SEQUENCE; LUMEN; BONDS	The complexity of protein folding is often aggravated by the low solubility of the denatured state. The inefficiency of the oxidative refolding of reduced, denatured lysozyme results from a kinetic partitioning of the unfolded protein between pathways leading to aggregation and pathways leading to the native structure. Protein disulfide isomerase (PDI), a resident foldase of the endoplasmic reticulum, catalyzes the in vitro oxidative refolding of reduced, disulfide containing proteins, including denatured lysozyme. Depending on the concentrations of foldase and denatured substrate and the order in which they are added to initiate folding, PDI can exhibit either a chaperone activity or an anti-chaperone activity (Puig, A., and Gilbert, H. F. (1994) J. Biol. Chem 269, 7764-7771). PDI's chaperone activity leads to quantitative recovery of native lysozyme. Its anti-chaperone activity diverts substrate away from productive folding and facilitates disulfide cross-linking of lysozyme into large, inactive aggregates that specifically incorporate PDI. A mutant PDI (NmCm-PDI), in which both the N- and C-terminal active site cysteines have been changed to serines, loses all chaperone activity and behaves as an anti chaperone at all substrate and PDI concentrations tested. The dithiol/disulfide sites of PDI are essential for the chaperone activity observed at high PDI concentrations, but they are not required for the anti-chaperone activity found at low PDI concentrations. Inactivation of PDI's peptide/protein binding site by a specific photoaffinity label (Noiva, R., Freedman, R. B., and Lennarz, W. J. (1993) J. Biol. Chem. 268, 19210-19217) inhibits the disulfide isomerase and chaperone activity, but the protein still retains its anti-chaperone activity. In a glutathione redox buffer, lysozyme PDI aggregates are disulfide crosslinked; however, disulfide cross-linking is not required for aggregate formation or for the incorporation of PDI into the aggregates. Although both the peptide binding site and the catalytic active sites of PDI are required for chaperone and disulfide isomerase activity, neither of these sites are involved in PDI's anti-chaperone activity. PDI's anti-chaperone activity could serve as a quality control device by providing an efficient mechanism to retain misfolded proteins in the endoplasmic reticulum (Marquardt, T., and Helenius, A. (1992) J. Cell. Biol. 117, 505-513).	BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; UNIV S DAKOTA,SCH MED,DEPT BIOCHEM & MOLEC BIOL,VERMILLION,SD 57069	Baylor College of Medicine; University of South Dakota					NIGMS NIH HHS [GM40379] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040379] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; DESILVA A, 1993, J CELL BIOL, V120, P647, DOI 10.1083/jcb.120.3.647; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gilbert H F, 1991, Protein Expr Purif, V2, P194, DOI 10.1016/1046-5928(91)90071-P; GILBERT HF, 1989, BIOCHEMISTRY-US, V28, P7298, DOI 10.1021/bi00444a023; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; GUNTHER R, 1993, J BIOL CHEM, V268, P7728; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; LODISH HF, 1993, J BIOL CHEM, V268, P20598; LU X, 1992, BIOCHEMISTRY-US, V3, P4205; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; NOIVA R, 1993, J BIOL CHEM, V268, P19210; NOIVA R, 1992, J BIOL CHEM, V267, P3553; NOIVA R, 1991, J BIOL CHEM, V266, P19645; PUIG A, 1994, J BIOL CHEM, V269, P7764; SAXENA VP, 1970, BIOCHEMISTRY-US, V9, P5015; SCHERENS B, 1991, YEAST, V7, P185, DOI 10.1002/yea.320070212; VAN PN, 1993, EUR J BIOCHEM, V213, P789, DOI 10.1111/j.1432-1033.1993.tb17821.x; VUORI K, 1992, J BIOL CHEM, V267, P7211; WETLAUFER DB, 1974, LYSOZYME, P269; ZAPUN A, 1992, PROTEINS, V14, P10, DOI 10.1002/prot.340140104	28	87	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19128	19135						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	7913469				2022-12-25	WOS:A1994NX32700065
J	ROSPERT, S; MULLER, S; SCHATZ, G; GLICK, BS				ROSPERT, S; MULLER, S; SCHATZ, G; GLICK, BS			FUSION PROTEINS CONTAINING THE CYTOCHROME B(2) PRESEQUENCE ARE SORTED TO THE MITOCHONDRIAL INTERMEMBRANE SPACE INDEPENDENTLY OF HSP60	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED YEAST MITOCHONDRIA; HEAT-SHOCK PROTEIN-70; PRECURSOR PROTEIN; OUTER-MEMBRANE; NUCLEOSIDE TRIPHOSPHATES; INNER MEMBRANE; IMPORT; MATRIX; TRANSLOCATION; BINDING	hsp60 is a chaperonin located in the mitochondrial matrix. It has been suggested that hsp60 participates in two processes: protein folding in the matrix, and the sorting of imported proteins to the intermembrane space. We analyzed hsp60 function by allowing isolated mitochondria to import two model precursor proteins and then measuring the binding of these proteins to the chaperonin. Of the methods that we tested for monitoring the association of imported proteins with hsp60, only co-immunoprecipitation with specific anti-hsp60 antibodies proved to be reliable. A chimeric matrix-targeted precursor, consisting of a mitochondrial presequence fused to a chloroplast-encoded protein, bound stably to hsp60 after import. In contrast, there was no detectable binding to hsp60 with a fusion protein that was targeted to the intermembrane space by the bipartite cytochrome b(2) presequence. Analysis of a translocation intermediate demonstrated that the cytochrome b(2) presequence arrests import through the inner membrane, with the result that the attached passenger protein is never exposed to hsp60.	UNIV BASEL, BIOCTR, CH-4056 BASEL, SWITZERLAND	University of Basel				Rospert, Sabine/0000-0002-3089-9614; Muller, Sabina/0000-0002-4580-2758	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037803] Funding Source: NIH RePORTER; NIGMS NIH HHS [2 R01 GM37803] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEASLEY EM, 1993, EMBO J, V12, P2303, DOI 10.1002/j.1460-2075.1993.tb05884.x; CHAPMAN SK, 1991, ADV INORG CHEM, V36, P257, DOI 10.1016/S0898-8838(08)60041-0; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; DAUM G, 1982, J BIOL CHEM, V257, P3075; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; ENDO T, 1989, J BIOL CHEM, V264, P2951; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; GASSER SM, 1982, P NATL ACAD SCI-BIOL, V79, P267, DOI 10.1073/pnas.79.2.267; GATENBY AA, 1990, ANNU REV CELL BIOL, V6, P125; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GLICK BS, 1993, PROTEIN SCI, V2, P1901, DOI 10.1002/pro.5560021112; GLICK BS, 1991, METHOD CELL BIOL, V34, P389; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; GUIARD B, 1976, BIOCHIMIE, V58, P305, DOI 10.1016/S0300-9084(76)80437-3; GUIARD B, 1985, EMBO J, V4, P3265, DOI 10.1002/j.1460-2075.1985.tb04076.x; HALLBERG EM, 1993, MOL CELL BIOL, V13, P3050, DOI 10.1128/MCB.13.5.3050; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HARTMAN DJ, 1992, P NATL ACAD SCI USA, V89, P3394, DOI 10.1073/pnas.89.8.3394; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORWICH AL, 1993, MOL CHAPERONES, P55; HURT EC, 1986, TRENDS BIOCHEM SCI, V11, P204, DOI 10.1016/0968-0004(86)90007-1; HURT EC, 1986, J BIOL CHEM, V261, P1440; HWANG ST, 1991, J BIOL CHEM, V266, P21083; HWANG ST, 1989, P NATL ACAD SCI USA, V86, P8432, DOI 10.1073/pnas.86.21.8432; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KOLL H, 1992, CELL, V68, P1163, DOI 10.1016/0092-8674(92)90086-R; Lorimer G. H., 1993, P41; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MARTIN J, 1993, STRUCTURE, V1, P161, DOI 10.1016/0969-2126(93)90017-B; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PRASAD TK, 1990, MOL CELL BIOL, V10, P3979, DOI 10.1128/MCB.10.8.3979; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; ROSPERT S, 1993, P NATL ACAD SCI USA, V90, P10967, DOI 10.1073/pnas.90.23.10967; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHWARZ E, 1993, EMBO J, V12, P2295, DOI 10.1002/j.1460-2075.1993.tb05883.x; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; STUEBER D, 1984, EMBO J, V3, P3143, DOI 10.1002/j.1460-2075.1984.tb02271.x; VANLOON APGM, 1987, EMBO J, V6, P2441, DOI 10.1002/j.1460-2075.1987.tb02523.x; VOOS W, 1993, J CELL BIOL, V123, P119, DOI 10.1083/jcb.123.1.119; WACHTER C, 1992, EMBO J, V11, P4787, DOI 10.1002/j.1460-2075.1992.tb05584.x	47	26	26	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17279	17288						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	7911803				2022-12-25	WOS:A1994NT84600047
J	VAANDRAGER, AB; VANDERWIEL, E; HOM, ML; LUTHJENS, LH; DEJONGE, HR				VAANDRAGER, AB; VANDERWIEL, E; HOM, ML; LUTHJENS, LH; DEJONGE, HR			HEAT-STABLE ENTEROTOXIN RECEPTOR GUANYLYL CYCLASE-C IS AN OLIGOMER CONSISTING OF FUNCTIONALLY DISTINCT SUBUNITS, WHICH ARE NONCOVALENTLY LINKED IN THE INTESTINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATRIURETIC-PEPTIDE RECEPTOR; ESCHERICHIA-COLI; RADIATION-INACTIVATION; ELECTROLYTE TRANSPORT; DIARRHEAL DISEASE; CELL-LINE; EXPRESSION; IDENTIFICATION; ACTIVATION; MODULATION	Guanylyl cyclase (GC) C is a heat-stable enterotoxin (STa) receptor with a monomeric M(r) of approximately 140,000. We calculated from its hydrodynamic parameters that an active GC-C complex has a M(r) of 393,000, suggesting that GC-C is a trimer under native conditions. Both trimeric and dimeric GC-C complexes were detected by I-125-STa binding and SDS-polyacrylamide gel electrophoresis under non-reducing conditions. The GC activity and STa binding from intestinal brush border membranes comigrated in gel filtration and velocity sedimentation with recombinant GC-C. However, I-125-STa cross-linking demonstrated that STa receptors with molecular masses of 52 and 74 kDa are non-covalently attached to GC in the intestine. Radiation inactivation revealed different functional sizes for basal GC activity, STa-stimulated GC activity, and STa binding (59, 210-240, and 32-52 kDa, respectively). At low radiation doses, basal GC activity was stimulated, suggesting that GC-C is inhibited by a relatively large, probably internal structure. These results suggest that STa may activate GC-C by promoting monomer-monomer interaction (internal ''dimerization'') within a homotrimeric GC-C complex, and that GC-C is proteolytically modified in the brush border membrane but retains its function.	DELFT UNIV TECHNOL,INTERFAC REACTOR INST,DEPT RADIAT CHEM,2629 JB DELFT,NETHERLANDS	Delft University of Technology	VAANDRAGER, AB (corresponding author), ERASMUS UNIV ROTTERDAM,FAC MED,DEPT BIOCHEM,POB 1738,3000 DR ROTTERDAM,NETHERLANDS.			Vaandrager, Arie/0000-0001-9394-9239				BRAUN HJ, 1984, BIOCHIM BIOPHYS ACTA, V774, P81, DOI 10.1016/0005-2736(84)90277-3; CHINKERS M, 1992, J BIOL CHEM, V267, P18589; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; COHEN MB, 1993, J CELL PHYSIOL, V156, P138, DOI 10.1002/jcp.1041560119; CRANE MR, 1992, MOL PHARMACOL, V41, P1073; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; DEJONGE HR, 1990, TXB SECRETORY DIARRH, P190; DESAUVAGE FJ, 1991, J BIOL CHEM, V266, P17912; DESAUVAGE FJ, 1992, J BIOL CHEM, V267, P6479; FIELD M, 1989, NEW ENGL J MED, V321, P879; FIELD M, 1989, NEW ENGL J MED, V321, P800; GIANNELLA RA, 1981, ANNU REV MED, V32, P341, DOI 10.1146/annurev.me.32.020181.002013; HARMON JT, 1985, METHOD ENZYMOL, V117, P65; HARMON JT, 1980, J BIOL CHEM, V255, P3412; HIRAYAMA T, 1992, INFECT IMMUN, V60, P4213, DOI 10.1128/IAI.60.10.4213-4220.1992; ISHIDO M, 1989, J BIOL CHEM, V264, P641; IWATA T, 1991, J BIOCHEM-TOKYO, V110, P35, DOI 10.1093/oxfordjournals.jbchem.a123539; JEWETT JRS, 1993, EMBO J, V12, P769, DOI 10.1002/j.1460-2075.1993.tb05711.x; KUNO T, 1986, J BIOL CHEM, V261, P1470; LEE JS, 1993, J BIOL CHEM, V268, P4092; LOWE DG, 1992, BIOCHEMISTRY-US, V31, P10421, DOI 10.1021/bi00158a001; MCINTYRE JO, 1985, ANAL BIOCHEM, V147, P468, DOI 10.1016/0003-2697(85)90300-8; MCKERNAN RM, 1990, BIOCHEM J, V269, P623, DOI 10.1042/bj2690623; SCHULZ S, 1992, J BIOL CHEM, V267, P16019; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SINGH S, 1991, BIOCHEM BIOPH RES CO, V179, P1455, DOI 10.1016/0006-291X(91)91736-V; THORPE DS, 1991, BIOCHEM BIOPH RES CO, V180, P538, DOI 10.1016/S0006-291X(05)81098-8; TREMBLAY J, 1991, J BIOL CHEM, V266, P8171; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAANDRAGER AB, 1993, J BIOL CHEM, V268, P2174; VAANDRAGER AB, 1993, J BIOL CHEM, V268, P19598; VAANDRAGER AB, 1992, GASTROENTEROLOGY, V102, P1161; VANHOEK AN, 1992, BIOCHEM BIOPH RES CO, V184, P331; VANNDRAGER AB, 1994, ADV PHARMACOL, V26, P253; WILSON SP, 1988, SEC MESS PHOSPHOPROT, V12, P1; WONG SKF, 1992, J CLIN INVEST, V90, P299, DOI 10.1172/JCI115862	37	59	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16409	16415						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	7911466				2022-12-25	WOS:A1994NQ72900069
J	MATIN, A; HUNG, MC				MATIN, A; HUNG, MC			THE RETINOBLASTOMA GENE-PRODUCT, RB, REPRESSES NEU EXPRESSION THROUGH 2 REGIONS WITHIN THE NEU REGULATORY SEQUENCE	ONCOGENE			English	Article							TRANSCRIPTION FACTOR E2F; LARGE T-ANTIGEN; CELL-CYCLE; SUSCEPTIBILITY GENE; OVARIAN-CANCER; DNA-BINDING; ENCODED PROTEIN; MAMMALIAN-CELLS; POINT MUTATION; C-ERBB-2 GENE	The neu oncogene is frequently overexpressed in breast, ovarian and lung cancers, and its overexpression correlates with poor disease prognosis. The exact mechanism of deregulation of neu expression is not well understood. Our previous studies indicate that the tumor suppressor retinoblastoma gene product, Rb, represses transcription of neu through the GTG enhancer (-243 to -234 relative to initiation of translation site of rat neu). We carried out further deletion analysis of the regulatory sequences of neu and found that Rb also represses neu close to transcription initiation sites (-172 to -79). Bal 31 deletions downstream of nucleotide -172 show that the sequence TCGAGGAA (-172 to -165) is important for efficient transcription from the neu promoter and also for repression by Rb. Rb mutants with mutations in the large T/E1a binding domain repress transcription from transcription initiation sites but not the GTG enhancer, suggesting that Rb modulates different regions of the regulatory sequence of neu by different pathways. The net effect of the Rb mutants is to repress not only transcription but also the transforming activity of activated neu in focus-forming assays. Thus, one mechanism whereby Rb may act as a tumor suppressor is to repress transcription of the strongly transforming nea oncogene.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NCI NIH HHS [NCI CA58880, NCI CA16672, NCI CA60856] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060856, P30CA016672, R01CA058880] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERCHUCK A, 1990, CANCER RES, V50, P4087; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAHMUS ME, 1992, TRANSCRIPTIONAL REGU, P109; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEMILIA J, 1989, ONCOGENE, V4, P1233; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; HUDSON LG, 1990, J BIOL CHEM, V265, P4389; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KERN JA, 1990, CANCER RES, V50, P5184; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MILLER SJ, 1994, IN PRESS INT J ONCOL; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; PARK JB, 1989, CANCER RES, V49, P6005; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RUSSELL KS, 1992, CANCER RES, V52, P6624; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; SHEW JY, 1990, CELL GROWTH DIFFER, V1, P17; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SHI DR, 1992, MOL CARCINOGEN, V5, P213, DOI 10.1002/mc.2940050308; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; VIJVER M, 1987, MOL CELL BIOL, V7, P2019; WANG NP, 1993, ONCOGENE, V8, P279; WATANABE H, 1988, MOL CELL BIOL, V8, P1290, DOI 10.1128/MCB.8.3.1290; WEINER DB, 1990, CANCER RES, V50, P421; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WHITE MRA, 1992, ONCOGENE, V7, P677; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOKOTA J, 1988, ONCOGENE, V2, P283; YU DH, 1992, J BIOL CHEM, V267, P10203; YU DH, 1991, ONCOGENE, V6, P1991; ZHANG X, 1989, ONCOGENE, V4, P985; ZHAO XY, 1992, MOL CELL BIOL, V12, P2739, DOI 10.1128/MCB.12.6.2739	68	17	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1333	1339						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	7908732				2022-12-25	WOS:A1994NH40100004
J	TAE, HJ; LUO, XC; KIM, KH				TAE, HJ; LUO, XC; KIM, KH			ROLES OF CCAAT/ENHANCER-BINDING PROTEIN AND ITS BINDING-SITE ON REPRESSION AND DEREPRESSION OF ACETYL-COA CARBOXYLASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; TUMOR-NECROSIS-FACTOR; HANDED Z-DNA; MESSENGER-RNA; 5' END; 3T3-L1 PREADIPOCYTES; FATTY-ACIDS; EXPRESSION; DIFFERENTIATION; CELLS	The gene for acetyl-CoA carboxylase, the rate-limiting enzyme in the biosynthesis of long-chain fatty acids, contains two distinct promoter regions, denoted PI and PII, which control the generation of different forms of mRNA. Multiple forms of acetyl-CoA carboxylase (ACC) mRNA with 5'-end heterogeneity are generated as a result of differential splicing of two primary transcripts formed under the control of these two promoters. PI is responsible for the generation of class I mRNAs of ACC, which are induced in a tissue-specific manner under lipogenic conditions. PII generates class II mRNAs of ACC, which are expressed constitutively. Possible mechanisms for the regulation of PI under normal physiological conditions and agents that activate the promoter have been investigated. PI contains a TATA and a CCAAT box. In addition to these sequences, this promoter contains a 28-CA repeat sequence 220 bases upstream from the transcription initiation site; the presence of this sequence leads to about 70% repression of the basal promoter activity. Repression by the 28-CA repeat sequence requires the GCAAT sequence in the CCAAT box. The negative effect of the 28-CA repeat sequence is relieved by a CCAAT/enhancer-binding protein (C/EBP), which binds to the GCAAT sequence. Insertion of the 28-CA repeat sequence into the thymidine kinase promoter results in repression that can also be relieved by the C/EBP gene product. However, the same sequence exerts no effect on ACC promoter II, which has no CCAAT box. During the differentiation of 30A5 preadipocytes into adipocytes, the expression of class I ACC mRNA and C/EBP mRNA is coordinately increased. Therefore, the presence of the CA repeat in the promoter may be responsible for the inactivity of PI, and C/EBP may be one of the factors that is responsible for the activation of PI under lipogenic conditions. Interaction of the CA repeat and the CCAAT box in the repression and derepression of the ACC gene provides a novel function for the CCAAT box and C/EBP in gene regulation.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NATIONAL CANCER INSTITUTE [R01CA046882] Funding Source: NIH RePORTER; NCI NIH HHS [CA 46882] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; BAI DH, 1986, J BIOL CHEM, V261, P2395; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROSS DS, 1985, J MOL BIOL, V183, P251, DOI 10.1016/0022-2836(85)90218-9; HAMADA H, 1982, NATURE, V298, P396, DOI 10.1038/298396a0; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KIM KH, 1989, FASEB J, V3, P2250, DOI 10.1096/fasebj.3.11.2570725; KONIECZNY SF, 1989, ONCOGENE, V4, P473; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LOPEZCASILLAS F, 1988, P NATL ACAD SCI USA, V85, P5784, DOI 10.1073/pnas.85.16.5784; LOPEZCASILLAS F, 1989, J BIOL CHEM, V264, P7176; LOPEZCASILLAS F, 1991, EUR J BIOCHEM, V201, P119, DOI 10.1111/j.1432-1033.1991.tb16264.x; LOPEZCASILLAS F, 1989, GENE, V83, P311, DOI 10.1016/0378-1119(89)90117-0; LOPEZCASILLAS F, 1991, ENDOCRINOLOGY, V129, P1049, DOI 10.1210/endo-129-2-1049; LUO X, 1990, THESIS PURDUE U; LUO XC, 1990, NUCLEIC ACIDS RES, V18, P3249, DOI 10.1093/nar/18.11.3249; LUO XC, 1989, P NATL ACAD SCI USA, V86, P4042, DOI 10.1073/pnas.86.11.4042; Maniatis T., 1982, MOL CLONING; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; NAYLOR LH, 1990, NUCLEIC ACIDS RES, V18, P1595, DOI 10.1093/nar/18.6.1595; NORDHEIM A, 1982, P NATL ACAD SCI-BIOL, V79, P7729, DOI 10.1073/pnas.79.24.7729; NORDHEIM A, 1983, P NATL ACAD SCI-BIOL, V80, P1821, DOI 10.1073/pnas.80.7.1821; Numa S, 1974, Curr Top Cell Regul, V8, P197; ORDWAY RW, 1991, TRENDS NEUROSCI, V14, P96, DOI 10.1016/0166-2236(91)90069-7; PAPE ME, 1988, ARCH BIOCHEM BIOPHYS, V267, P104, DOI 10.1016/0003-9861(88)90013-6; PAPE ME, 1988, MOL ENDOCRINOL, V2, P395, DOI 10.1210/mend-2-5-395; PAPE ME, 1989, MOL CELL BIOL, V9, P974, DOI 10.1128/MCB.9.3.974; PAPE ME, 1989, THESIS PURDUE U; PARK K, 1993, J BIOL CHEM, V268, P17811; PARK KR, 1991, J BIOL CHEM, V266, P12249; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIH C, 1990, J VIROL, V64, P1517; SIVARAM P, 1990, J BIOL CHEM, V265, P5774; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEPHENS JM, 1992, J BIOL CHEM, V267, P13580; TAVININI MA, 1994, J BIOL CHEM, V259, P11798; WILLIAMS PM, 1992, MOL ENDOCRINOL, V6, P1135, DOI 10.1210/me.6.7.1135	51	85	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10475	10484						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7908293				2022-12-25	WOS:A1994NF01700045
J	SCHREIER, H; MORAN, P; CARAS, IW				SCHREIER, H; MORAN, P; CARAS, IW			TARGETING OF LIPOSOMES TO CELLS EXPRESSING CD4 USING GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED GP120 - INFLUENCE OF LIPOSOME COMPOSITION ON INTRACELLULAR TRAFFICKING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DECAY-ACCELERATING FACTOR; MEMBRANE ANCHOR; COMPLEMENT ACTIVATION; T4 MOLECULE; ATTACHMENT; VESICLES; PROTEINS; BINDING; INVITRO	To test the concept that glycosylphosphatidylinositol (GPI)-anchored proteins might be useful as targeting molecules for liposomes, we engineered a GPI-anchored form of gp120 from human immunodeficiency virus type 1 (termed gp120DAF) using the GPI signal of decay-accelerating factor (DAF). We show that (i) purified gp120DAF spontaneously inserts into liposome membranes via the GPI anchor; (ii) liposomes bearing gp120DAF bind specifically to cells expressing CD4, the cellular receptor for gp120; and (iii) the receptor-bound liposomes are internalized and recycle in Chinese ham ster ovary cells. To test whether the lipid composition of the liposome affects any of these processes, we compared small unilamellar liposomes containing only phosphatidylcholine and cholesterol in a 7:1 molar ratio with artificial viral envelopes that mimic the lipid com position of human immunodeficiency virus type 1. We show that when tagged with gp120DAF, both liposome preparations bind specifically to cells expressing CD4, and both are endocytosed. However, artificial viral en velope liposomes are transported to late endosomes or lysosomes in the cell interior, whereas phosphatidylcholine:cholesterol liposomes are confined to a population of vesicles that remain close to the plasma membrane. Since the binding and internalization of both liposome preparations are mediated by the same receptor, we conclude that the lipid composition of the liposome pro foundry influences the subsequent intracellular trafficking of the liposome-receptor complex.	GENENTECH INC,DEPT NEUROBIOL,S SAN FRANCISCO,CA 94080; VANDERBILT UNIV,SCH MED,CTR LUNG RES,NASHVILLE,TN 37232	Roche Holding; Genentech; Vanderbilt University				Caras, Ingrid/0000-0002-8902-808X				ALOIA RC, 1988, P NATL ACAD SCI USA, V85, P900, DOI 10.1073/pnas.85.3.900; BERMAN PW, 1989, J VIROL, V63, P3489, DOI 10.1128/JVI.63.8.3489-3498.1989; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CARAS IW, 1987, SCIENCE, V238, P1280, DOI 10.1126/science.2446389; CHANDER R, 1992, LIFE SCI, V50, P481, DOI 10.1016/0024-3205(92)90387-5; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; HELENIUS A, 1982, CIBA F SYMP, V92, P59; HUANG C, 1978, P NATL ACAD SCI USA, V75, P308, DOI 10.1073/pnas.75.1.308; KELLER GA, 1992, EMBO J, V11, P863, DOI 10.1002/j.1460-2075.1992.tb05124.x; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; LOW MG, 1989, FASEB J, V3, P1600, DOI 10.1096/fasebj.3.5.2522071; MARSH M, 1984, BIOCHEM J, V218, P1; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MEDOF ME, 1984, J EXP MED, V160, P1558, DOI 10.1084/jem.160.5.1558; MORAN P, 1992, J CELL BIOL, V119, P763, DOI 10.1083/jcb.119.4.763; MORAN P, 1991, J BIOL CHEM, V266, P1250; MORAN P, 1992, J IMMUNOL, V149, P1736; RALSTON E, 1981, BIOCHIM BIOPHYS ACTA, V649, P133, DOI 10.1016/0005-2736(81)90019-5; RUBAS W, 1990, J MICROENCAPSUL, V7, P385, DOI 10.3109/02652049009021848; SATO T, 1992, PROG LIPID RES, V31, P345, DOI 10.1016/0163-7827(92)90001-Y; SCHREIER H, 1992, INT J PHARMACEUT, V87, P183, DOI 10.1016/0378-5173(92)90242-T; SCHWENDENER RA, 1990, BIOCHIM BIOPHYS ACTA, V1026, P69, DOI 10.1016/0005-2736(90)90334-K; SECHOY O, 1989, EXP CELL RES, V185, P122, DOI 10.1016/0014-4827(89)90042-6; STECENKO AA, 1992, PHARM PHARM LETT, V1, P127; STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; Van Meer Gerrit, 1992, Trends in Cell Biology, V2, P332; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55; WEISSING V, 1993, LIPOSOME TECHNOLOGY, V3, P231; WEISSMANN G, 1975, P NATL ACAD SCI USA, V72, P88, DOI 10.1073/pnas.72.1.88; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WRIGHT S, 1989, Advanced Drug Delivery Reviews, V3, P343, DOI 10.1016/0169-409X(89)90027-6	33	29	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9090	9098						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7907597				2022-12-25	WOS:A1994NB41100072
J	BOROVSKY, D; POWELL, CA; NAYAR, JK; BLALOCK, JE; HAYES, TK				BOROVSKY, D; POWELL, CA; NAYAR, JK; BLALOCK, JE; HAYES, TK			CHARACTERIZATION AND LOCALIZATION OF MOSQUITO-GUT RECEPTORS FOR TRYPSIN MODULATING OOSTATIC FACTOR USING A COMPLEMENTARY PEPTIDE AND IMMUNOCYTOCHEMISTRY	FASEB JOURNAL			English	Note						IMMUNOCYTOCHEMISTRY; RECEPTOR; BINDING; ELISA; PEPTIDE HORMONE	JUVENILE-HORMONE; MIDGUT	The gut receptor of trypsin-modulating oostatic factor (TMOF), a decapeptide hormone that regulates trypsin biosynthesis in the mosquito gut, has been characterized. The binding of TMOF to mosquito gut membranes reached maximum at pH 7.4 and 24 degrees C. No binding was observed at pH 2.5 and the binding to the membranes declined rapidly at pH 8.0. At equilibrium, maximum binding to the receptor was observed at 60 min and 24 degrees C. A synthetic complementary decapeptide NH2-Ile-Leu-Gly-Arg-Gly-Gly-Gly-Gly-Gly-Gly-COOH (FOMT) for TMOF successfully competed with the gut receptor, and specifically bound TMOF (K-d = 4: mu M and K-assoc = 2.5 x 10(5) M(-1)). TMOF binding to gut membranes was characterized with FOMT and a specific ELISA to the hormone at 24 and 72 h after blood feeding. Two classes of binding sites were found on the gut membrane; high affinity (K-d1 = 4.6 +/- 0.7 x 10(-7) M; K-assoc = 2.2 x 10(6) M(-1) B-max = 0.1 pmol/gut) and low affinity (K-d2 = 4.43 +/- 1 x 10(-6) M; K-assoc = 2.3 x 10(5) M(-1); B-max = 0.2 pmol/gut). The total binding sites for high and low affinity classes of TMOF per put were estimated as 6.3 x 10(10) and 1.1 x 10(11) sites, respectively. Specific binding sites on the put increased after the blood meal and were visualized by immunocytochemical staining. These results suggest that TMOF regulates trypsin biosynthesis by binding to specific receptor sites that are located on the mosquito gut, and that this receptor can be studied using a complementary peptide approach.	UNIV FLORIDA,INST FOOD & AGR SCI,CTR AGR RES & EDUC,FT PIERCE,FL 34954; UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294; TEXAS A&M UNIV,DEPT ENTOMOL,COLL STN,TX 77843	State University System of Florida; University of Florida; University of Alabama System; University of Alabama Birmingham; Texas A&M University System; Texas A&M University College Station	BOROVSKY, D (corresponding author), UNIV FLORIDA,INST FOOD & AGR SCI,FLORIDA MED ENTOMOL LAB,VERO BEACH,FL 32962, USA.			Blalock, J. Edwin/0000-0001-5303-8123	NIDDK NIH HHS [DK 38024] Funding Source: Medline; NINDS NIH HHS [NS 29719] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS029719] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLALOCK JE, 1984, BIOCHEM BIOPH RES CO, V121, P203, DOI 10.1016/0006-291X(84)90707-1; BOROVSKY D, 1993, INSECT BIOCHEM MOLEC, V23, P703, DOI 10.1016/0965-1748(93)90044-S; BOROVSKY D, 1990, FASEB J, V4, P3015, DOI 10.1096/fasebj.4.12.2394318; BOROVSKY D, 1985, ARCH INSECT BIOCHEM, V2, P333, DOI 10.1002/arch.940020402; BOROVSKY D, 1992, ARCH INSECT BIOCHEM, V21, P13, DOI 10.1002/arch.940210103; BOROVSKY D, 1985, ARCH INSECT BIOCHEM, V2, P75, DOI 10.1002/arch.940020108; BOROVSKY D, 1988, ARCH INSECT BIOCHEM, V8, P249, DOI 10.1002/arch.940080406; BOROVSKY D, 1993, IN PRESS ARCH INSECT; Borovsky Dov, 1993, P36; BOST KL, 1985, P NATL ACAD SCI USA, V82, P1372, DOI 10.1073/pnas.82.5.1372; BRIEGEL H, 1975, J INSECT PHYSIOL, V21, P1597, DOI 10.1016/0022-1910(75)90197-3; Clements AN., 1992, BIOL MOSQUITOES DEV; CURTO EV, 1993, BIOCHEM BIOPH RES CO, V193, P688, DOI 10.1006/bbrc.1993.1679; ENGELMANN F, 1987, INSECT BIOCHEM, V17, P1045, DOI 10.1016/0020-1790(87)90118-1; GOODING RH, 1966, COMP BIOCHEM PHYSIOL, V17, P115, DOI 10.1016/0010-406X(66)90013-2; HANDLER AM, 1989, MOL CELL ENDOCRINOL, V63, P103, DOI 10.1016/0303-7207(89)90086-5; JARPE MA, 1993, IN PRESS PEPTIDES DE; RING CS, 1993, P NATL ACAD SCI USA, V90, P3583, DOI 10.1073/pnas.90.8.3583; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; STERNBERGER LA, 1986, IMMUNOCYTOCHEMISTRY; VANDESANDE P, 1983, IMMUNOCYTOCHEMISTRY, P257	21	49	59	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR 1	1994	8	3					350	355		10.1096/fasebj.8.3.7908271	http://dx.doi.org/10.1096/fasebj.8.3.7908271			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NB623	7908271				2022-12-25	WOS:A1994NB62300010
J	VENTURA, C; GUARNIERI, C; VAONA, I; CAMPANA, G; PINTUS, G; SPAMPINATO, S				VENTURA, C; GUARNIERI, C; VAONA, I; CAMPANA, G; PINTUS, G; SPAMPINATO, S			DYNORPHIN GENE-EXPRESSION AND RELEASE IN THE MYOCARDIAL-CELL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT CARDIAC MYOCYTES; CHROMAFFIN CELLS; SPINAL-CORD; DEPOLARIZATION; CHANNELS; RABBIT; ALPHA; HEART; BRAIN; CA2+	The expression of the prodynorphin gene was investigated in adult cultured rat ventricular cardiac myocytes by using a sensitive solution hybridization RNase protection assay for the quantitative analysis of prodynorphin mRNA. Myocyte culture in high KCL resulted, after 4 h, in a marked increase in cellular prodynorphin mRNA, while a KCl treatment for 6, 12, or 24 h progressively down-regulated the levels of prodynorphin mRNA below the control value. Immunoreactive dynorphin B, a biologically active end product of the precursor, was found to be present in the culture medium in significantly higher amounts than in the cardiac myocytes. The levels of this biologically active K opioid receptor agonist significantly increased after 4 h of KCl treatment and were markedly reduced following a 24-h exposure of the cardiac myocytes to KCl. These KCl-induced effects were all abolished by cell incubation in the presence of the calcium channel blocker verapamil. In single cardiac myocytes, acute stimulation of K opioid receptors with dynorphin B or with the selective agonist U-50,488H increased the level of cytosolic calcium. This effect was abolished by the specific K opioid receptor antagonist (Mr-1452) and was not affected by the removal of calcium from the bathing medium. These results suggest that an opioid gene may influence the myocardial function in an autocrine or paracrine fashion.	UNIV BOLOGNA, DEPT BIOCHEM, I-40126 BOLOGNA, ITALY; UNIV BOLOGNA, DEPT PHARMACOL, I-40126 BOLOGNA, ITALY	University of Bologna; University of Bologna	VENTURA, C (corresponding author), UNIV SASSARI, INST BIOL CHEM A BONSIGNORE, VIALE SAN PIETRO 43-B, I-07100 SASSARI, ITALY.		Campana, Gabriele/A-8285-2010; Pintus, Gianfranco/C-2975-2009	Campana, Gabriele/0000-0001-8978-0530; Pintus, Gianfranco/0000-0002-3031-7733; Spampinato, Santi/0000-0001-5656-564X				BLUM M, 1989, METHOD ENZYMOL, V168, P618; CANOSSA M, 1993, BIOCHIM BIOPHYS ACTA, V1172, P247, DOI 10.1016/0167-4781(93)90210-5; CAPOGROSSI MC, 1986, J GEN PHYSIOL, V88, P589, DOI 10.1085/jgp.88.5.589; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONE RI, 1983, J NEUROSCI, V3, P2146; EIDEN LE, 1984, NATURE, V312, P661, DOI 10.1038/312661a0; FOSTER KA, 1990, AM J PHYSIOL, V259, pH432, DOI 10.1152/ajpheart.1990.259.2.H432; GAUTRET B, 1985, EUR J PHARMACOL, V111, P263, DOI 10.1016/0014-2999(85)90766-6; GOLDSTEIN A, 1983, PEPTIDES ANAL SYNTHE, V7, P95; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOLADAY JW, 1983, ANNU REV PHARMACOL, V23, P541, DOI 10.1146/annurev.pa.23.040183.002545; HUGHES J, 1981, TRENDS PHARMACOL SCI, V2, P21, DOI 10.1016/0165-6147(81)90249-2; JAMIESON JD, 1964, J CELL BIOL, V23, P151, DOI 10.1083/jcb.23.1.151; KLEY N, 1987, J BIOL CHEM, V262, P4083; KLEY N, 1988, EMBO J, V5, P970; KRAUSE JE, 1989, METHOD ENZYMOL, V168, P634; LAHTI RA, 1982, LIFE SCI, V31, P2257, DOI 10.1016/0024-3205(82)90132-1; LANG RE, 1983, LIFE SCI, V32, P399, DOI 10.1016/0024-3205(83)90086-3; LUETJE CW, 1988, J NEUROCHEM, V50, P1775, DOI 10.1111/j.1471-4159.1988.tb02478.x; PANERAI AE, 1984, BRAIN RES, V304, P153, DOI 10.1016/0006-8993(84)90872-2; PIPER HM, 1982, J MOL CELL CARDIOL, V14, P397, DOI 10.1016/0022-2828(82)90171-7; POENIE M, 1986, SCIENCE, V233, P886, DOI 10.1126/science.3755550; PRUSS RM, 1988, J BIOL CHEM, V263, P13173; SPAMPINATO S, 1992, BRAIN RES, V580, P225, DOI 10.1016/0006-8993(92)90948-9; SPAMPINATO S, 1991, LIFE SCI, V48, P551, DOI 10.1016/0024-3205(91)90470-V; SPURGEON HA, 1990, AM J PHYSIOL, V258, pH574, DOI 10.1152/ajpheart.1990.258.2.H574; VENTURA C, 1991, BIOCHEM BIOPH RES CO, V179, P972, DOI 10.1016/0006-291X(91)91913-W; VENTURA C, 1991, AM J PHYSIOL, V261, pH1671, DOI 10.1152/ajpheart.1991.261.5.H1671; VENTURA C, 1992, CIRC RES, V70, P66, DOI 10.1161/01.RES.70.1.66; VENTURA C, 1989, BIOCHIM BIOPHYS ACTA, V987, P69, DOI 10.1016/0005-2736(89)90456-2; WONGDUSTING HK, 1985, EUR J PHARMACOL, V111, P65, DOI 10.1016/0014-2999(85)90114-1; XIE GX, 1987, J NEUROSCI, V7, P2049	32	57	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5384	5386						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7906274				2022-12-25	WOS:A1994MX57100102
J	GONZALEZGRONOW, M; GAWDI, G; PIZZO, SV				GONZALEZGRONOW, M; GAWDI, G; PIZZO, SV			CHARACTERIZATION OF THE PLASMINOGEN RECEPTORS OF NORMAL AND RHEUMATOID-ARTHRITIS HUMAN SYNOVIAL FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL PEPTIDASE-IV; MEMBRANE GLYCOPROTEIN-IIB; HUMAN-ENDOTHELIAL CELLS; AFFINITY CHROMATOGRAPHY; PLATELET-AGGREGATION; POLYACRYLAMIDE GELS; MONOCLONAL-ANTIBODY; HEYMANN NEPHRITIS; HUMAN-PLASMA; PROTEIN	Plasminogen (Pg) activation on the surface of rheumatoid arthritis (RA) synovial fibroblasts by the urinary-type Pg activator induced a significant increase in cytosolic free Ca2+ concentration. This response was not observed in normal synovial fibroblasts, suggesting different Pg binding and activation mechanisms in these cell types. Pg receptors from both cell types were isolated by affinity chromatography using Pg covalently bound to Sepharose 4B. RA synovial fibroblasts express a Pg receptor complex composed of a glycoprotein IIb/ IIIa-related protein in association with a 130-kDa protein that is antigenically related to the alpha 2-macroglobulin receptor-associated protein and dipeptidyl peptidase IV. This receptor complex appears to bind to both Pg and fibronectin. The Pg ''receptor'' in normal synovial fibroblasts is composed of a 97-kDa protein also antigenically related to the alpha 2-macroglobulin receptor-associated protein. Both cell types express the urinary-type Pg activator receptor on their surfaces. Our results suggest that RA synovial fibroblasts express novel proteins involved in Pg binding, activation, and signal transduction, which are absent in normal synovial fibroblasts.			GONZALEZGRONOW, M (corresponding author), DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710, USA.				NHLBI NIH HHS [HL-43339, HL-31932] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031932, R01HL043339] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELMAN B, 1988, BLOOD, V72, P1530; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; CASTOR CW, 1971, J LAB CLIN MED, V77, P65; CHARO IF, 1986, P NATL ACAD SCI USA, V83, P8351, DOI 10.1073/pnas.83.21.8351; CHEN YQ, 1992, J BIOL CHEM, V267, P17314; CHUCHOLOWSKI N, 1992, FIBRINOLYSIS, V6, P95; CUATRECASAS P, 1970, J BIOL CHEM, V245, P3059; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; GANZ PR, 1991, BIOCHEM CELL BIOL, V69, P442, DOI 10.1139/o91-067; GONZALEZGRONOW M, 1989, BIOCHEMISTRY-US, V28, P2374, DOI 10.1021/bi00432a005; GONZALEZGRONOW M, 1984, BIOCHEMISTRY-US, V23, P190, DOI 10.1021/bi00297a003; GONZALEZGRONOW M, 1993, J BIOL CHEM, V268, P20791; GRABER N, 1990, J IMMUNOL, V145, P819; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUCCIONE MA, 1985, THROMB HAEMOSTASIS, V53, P8; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; Harlow E, 1988, ANTIBODIES LABORATOR, P359; IBRAHIM GK, 1993, J UROLOGY, V149, P170, DOI 10.1016/S0022-5347(17)36032-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFYATIS R, 1989, J CLIN INVEST, V83, P1267, DOI 10.1172/JCI114011; LO SK, 1989, J CLIN INVEST, V84, P793, DOI 10.1172/JCI114238; MAKKER SP, 1984, LAB INVEST, V50, P287; MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MCGREGOR BC, 1989, AM J CLIN PATHOL, V92, P495, DOI 10.1093/ajcp/92.4.495; MILES L A, 1988, Fibrinolysis, V2, P61, DOI 10.1016/0268-9499(88)90369-4; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; PENNY WF, 1992, BLOOD, V79, P91; PHILLIPS DR, 1988, BLOOD, V71, P831; PIAZZA GA, 1989, BIOCHEM J, V262, P327, DOI 10.1042/bj2620327; PLOUG M, 1991, SEMIN THROMB HEMOST, V17, P183, DOI 10.1055/s-2007-1002608; PLOW EF, 1986, P NATL ACAD SCI USA, V83, P6002, DOI 10.1073/pnas.83.16.6002; RUAN CG, 1987, BLOOD, V69, P570; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SCHAFER AI, 1986, J CLIN INVEST, V78, P73, DOI 10.1172/JCI112576; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; TANAKA T, 1992, J IMMUNOL, V149, P481; THIAGARAJAN P, 1985, J CLIN INVEST, V75, P896, DOI 10.1172/JCI111789; TORIMOTO Y, 1991, J IMMUNOL, V147, P2514; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRANQUI L, 1979, BIOL CELLULAIRE, V34, P39; VUENTO M, 1979, BIOCHEM J, V183, P331, DOI 10.1042/bj1830331; WALBORG EF, 1985, EXP CELL RES, V158, P509, DOI 10.1016/0014-4827(85)90474-4; WILDER RL, 1991, J CELL BIOCHEM, V45, P162, DOI 10.1002/jcb.240450207; WINTERS KJ, 1990, BLOOD, V76, P1546; YOCUM DE, 1988, AM J PATHOL, V132, P32; ZIFF M, 1989, RHEUMATOL INT, V9, P97	50	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4360	4366						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7905877				2022-12-25	WOS:A1994MW98900073
J	HUANG, AP; WRIGHT, JA				HUANG, AP; WRIGHT, JA			FIBROBLAST GROWTH-FACTOR MEDIATED ALTERATIONS IN DRUG-RESISTANCE, AND EVIDENCE OF GENE AMPLIFICATION	ONCOGENE			English	Article							DIHYDROFOLATE-REDUCTASE GENE; RIBONUCLEOTIDE REDUCTASE; CELL-LINES; DNA AMPLIFICATION; TUMOR PROGRESSION; AUTOCRINE GROWTH; FACTOR RECEPTOR; 3T3 CELLS; CAD GENE; TRANSFORMATION	We have investigated the drug resistance and gene amplification potential of NIH3T3 cells transfected with sequences coding for K-FGF, a known oncogene product, or bFGF, a non-oncogene member of the fibroblast growth factor family. Resistance to methotrexate, N-(phosphonacetyl)-L-aspartate and hydroxyurea was observed with K-fgf transfectants, due to amplification of dihydrofolate reductase, CAD or ribonucleotide reductase R2 genes, respectively. In keeping with the increase in gene amplification frequency, cells transfected with the K-fgf gene also exhibited a marked increase in CAD gene amplification rate, as determined by fluctuation analysis in the presence of N-(phosphonacetyl)-L-asparate. Cells transfected with bFGF encoding cDNA also exhibited a significant elevation in N-(phosphonacetyl)-L-aspartate resistance, and CAD gene amplification. Treatment with suramin, which interferes with the interaction of fibroblast growth factors with their cell surface receptors, did not decrease the drug resistance properties of K-fgf transfected cells. These observations with suramin and the findings with bFGF, which lacks a conventional signal sequence for secretion, suggests that the growth factor-mediated effects on drug resistance and gene amplification occur through an intracellular as opposed to autocrine mode of action. The finding that aberrant growth factor expression regulates gene amplification opens up new possibilities for investigating intracellular mechanisms relevant to this process and also describes new functions for the altered expression of K-FGF and bFGF, which are relevant to mechanisms of malignant progression.	UNIV MANITOBA, MANITOBA INST CELL BIOL, 100 OLIVIA ST, WINNIPEG R3E 0V9, MB, CANADA	University of Manitoba								AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BERRIDGE MJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P33, DOI 10.1016/0304-419X(87)90017-5; BLAM SB, 1988, ONCOGENE, V3, P129; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; Brigstock DR, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104815; CAPIZZI RL, 1973, MUTAT RES, V17, P147, DOI 10.1016/0027-5107(73)90265-0; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; CHANG ACY, 1978, NATURE, V275, P617, DOI 10.1038/275617a0; CILLO C, 1987, CANCER RES, V47, P2604; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; CUADRADO A, 1990, MOL CELL BIOL, V10, P6069, DOI 10.1128/MCB.10.11.6069; DAMEN JE, 1991, BIOCHIM BIOPHYS ACTA, V1097, P103, DOI 10.1016/0925-4439(91)90092-N; DELLIBOVI P, 1988, MOL CELL BIOL, V8, P2933, DOI 10.1128/MCB.8.7.2933; DREWS RE, 1992, MOL CELL BIOL, V12, P198, DOI 10.1128/MCB.12.1.198; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; EDWARDS DR, 1985, MOL CELL BIOL, V5, P3280, DOI 10.1128/MCB.5.11.3280; EGAN SE, 1991, ENVIRON HEALTH PERSP, V93, P91, DOI 10.2307/3431175; EGAN SE, 1990, ANTICANCER RES, V10, P1341; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; Florkiewicz RZ, 1991, GROWTH FACTORS, V4, P265, DOI 10.3109/08977199109043912; GIULOTTO E, 1987, CELL, V48, P837, DOI 10.1016/0092-8674(87)90080-8; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARDS RG, 1981, J CELL PHYSIOL, V106, P309, DOI 10.1002/jcp.1041060218; HILL RP, 1990, CANCER METAST REV, V9, P137, DOI 10.1007/BF00046340; HUANG SS, 1988, J BIOL CHEM, V263, P12608; Issandou M, 1991, GROWTH FACTORS, V5, DOI 10.3109/08977199109000289; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; LAROCCA RV, 1990, CANCER CELL-MON REV, V2, P106; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Luria SE, 1943, GENETICS, V28, P491; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MCINTYRE P, 1988, ANAL BIOCHEM, V174, P209, DOI 10.1016/0003-2697(88)90537-4; MOSCATELLI D, 1989, J CELL BIOL, V109, P2519, DOI 10.1083/jcb.109.5.2519; NOWELL PC, 1986, CANCER RES, V46, P2203; OTTO E, 1989, J BIOL CHEM, V264, P3390; PERRY ME, 1992, P NATL ACAD SCI USA, V89, P8112, DOI 10.1073/pnas.89.17.8112; RICE GC, 1986, P NATL ACAD SCI USA, V83, P5978, DOI 10.1073/pnas.83.16.5978; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; RODECK U, 1991, CANCER CELL-MON REV, V3, P308; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; SAMUEL SK, 1992, EMBO J, V11, P1599, DOI 10.1002/j.1460-2075.1992.tb05205.x; SASADA R, 1988, MOL CELL BIOL, V8, P588, DOI 10.1128/MCB.8.2.588; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SCHWAB M, 1990, Critical Reviews in Oncogenesis, V2, P35; SCHWARZ LC, 1988, CANCER RES, V48, P6999; Schwarz LC, 1990, GROWTH FACTORS, V3, P115, DOI 10.3109/08977199009108274; SHIGESADA K, 1985, MOL CELL BIOL, V5, P1735, DOI 10.1128/MCB.5.7.1735; STARK GR, 1990, GENE REARRANGEMENT F, P99; TALARICO D, 1991, MOL CELL BIOL, V11, P1138, DOI 10.1128/MCB.11.2.1138; TAYLOR WR, 1993, EXP CELL RES, V204, P295, DOI 10.1006/excr.1993.1036; THELANDER L, 1986, MOL CELL BIOL, V6, P3433, DOI 10.1128/MCB.6.10.3433; TLSTY TD, 1990, P NATL ACAD SCI USA, V87, P3132, DOI 10.1073/pnas.87.8.3132; TLSTY TD, 1989, P NATL ACAD SCI USA, V86, P9441, DOI 10.1073/pnas.86.23.9441; TLSTY TD, 1984, MOL CELL BIOL, V4, P1050, DOI 10.1128/MCB.4.6.1050; TLSTY TD, 1992, SCIENCE, V255, P1425, DOI 10.1126/science.1542791; WELLSTEIN A, 1990, CELL GROWTH DIFFER, V1, P63; WRIGHT JA, 1990, BIOCHEM CELL BIOL, V68, P1364, DOI 10.1139/o90-199; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791; WRIGHT JA, 1993, CRIT REV ONCOGENESIS, V4, P473; WRIGHT JA, 1987, SOMAT CELL MOLEC GEN, V13, P155, DOI 10.1007/BF01534695; WRIGHT JA, 1990, ANTICANCER RES, V10, P1247; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	67	28	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1994	9	2					491	499						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	7904743				2022-12-25	WOS:A1994MW24800016
J	HUSSAIN, SP; AGUILAR, F; CERUTTI, P				HUSSAIN, SP; AGUILAR, F; CERUTTI, P			MUTAGENESIS OF CODON-248 OF THE HUMAN P53 TUMOR-SUPPRESSOR GENE BY N-ETHYL-N-NITROSOUREA	ONCOGENE			English	Article							POLYMERASE CHAIN-REACTION; GENOTYPIC ANALYSIS; DNA-POLYMERASE; NITRIC-OXIDE; MUTATIONS; SEQUENCES; REPAIR; DAMAGE; INVIVO; SITES	Base pair mutations in the p53 tumor suppressor gene are among the most frequently observed genetic changes in human malignancies. Several mutational hotspots have been identified and tumor- and tissue-specific differences have been observed. We studied the mutability of hotspot codon 248, CGG, in human fibroblasts in response to the alkylating agent N-ethyl-N-nitrosourea (ENU) by MspI RFLP/PCR analysis. Alkylating agents are implicated as etiological agents in carcinogenesis in the gut and other tissues in the human. ENU induced preferentially G to A transitions in the non-transcribed strand. The predominant mutation involving the G-residue of the CpG dinudeotide was observed with an absolute frequency of 4 x 10(-7). The corresponding C to T transition in the first position of codon 248 was observed at several fold lower frequency suggesting more efficient excision repair of the transcribed strand. The G to A transition in the third position of codon 248 occurred at low frequency. Our results are compatible with a role for aliphatic alkylating agents in human tumors with codon 248 mutations since almost all mutations reported in this codon are transitions in the CpG-dinucleotide.	SWISS INST EXPTL CANC RES, DEPT CARCINOGENESIS, CH-1066 LAUSANNE, SWITZERLAND	Swiss Institute Experimental Cancer Research				Hussain, S. Perwez/0000-0002-2294-522X				AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586; AGUILAR F, 1993, IN PRESS METHODS T B, V1; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTSCH H, 1990, MUTAT RES, V238, P255, DOI 10.1016/0165-1110(90)90017-6; BRONSTEIN SM, 1991, CANCER RES, V51, P5188; CHIOCCA SM, 1992, P NATL ACAD SCI USA, V89, P5331, DOI 10.1073/pnas.89.12.5331; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; ECKERT KA, 1990, NUCLEIC ACIDS RES, V18, P3739, DOI 10.1093/nar/18.13.3739; FELLEYBOSCO E, 1991, NUCLEIC ACIDS RES, V19, P2913, DOI 10.1093/nar/19.11.2913; HANAWALT PC, 1989, GENOME, V31, P605, DOI 10.1139/g89-113; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN MC, 1991, CANCER RES, V51, P4102; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; LUNDBERG KS, 1991, GENE, V108, P1, DOI 10.1016/0378-1119(91)90480-Y; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; RECIO L, 1990, MUTAGENESIS, V5, P505, DOI 10.1093/mutage/5.5.505; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; SANDY MS, 1992, P NATL ACAD SCI USA, V89, P890, DOI 10.1073/pnas.89.3.890; Singer B., 1983, MOL BIOL MUTAGENS CA; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; ZIJLSTRA J, 1990, PROG CLIN BIOL RES, V347, P187	24	40	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					13	18						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	7905619				2022-12-25	WOS:A1994MW24700002
J	ZHANG, N; GONG, ZZ; MINDEN, M; LU, M				ZHANG, N; GONG, ZZ; MINDEN, M; LU, M			THE HOX-11 (TCL-3) HOMEOBOX PROTOONCOGENE ENCODES A NUCLEAR-PROTEIN THAT UNDERGOES CELL CYCLE-DEPENDENT REGULATION	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; ACUTE LYMPHOBLASTIC-LEUKEMIA; E2F TRANSCRIPTION FACTOR; SACCHAROMYCES-CEREVISIAE; G1-SPECIFIC CYCLINS; BINDING PROTEIN; EXPRESSION; PHOSPHORYLATION; PROLIFERATION; YEAST	Molecular analysis of the t(10;14) chromosomal translocation found in pediatric patients with T-cell acute lymphoblastic leukemia has led to the identification of the HOX-11 (TCL-3) protooncogene. The HOX-11 cDNA contains an open reading frame encoding a homeoprotein with features of DNA-binding. The majority of the t(10;14) chromosomal translocation breakpoints have been mapped to the 5' end of the HOX-11 gene, supporting the notion that deregulation of the HOX-11 gene by the t(10;14) chromosomal translocation contributed importantly to leukemia formation. To further define the role of the HOX-11 homeoprotein, we have prepared rabbit antiserum against a trpE-HOX-11 fusion protein. The purified anti-HOX-11 IgG immunoprecipitated a protein with apparent relative molecular mass of 40 kD. Biochemical fractionation demonstrated that the protein is localized in the nucleus. Furthermore, the HOX-11 RNA and protein appeared to be modulated during the cell cycle, with the highest level of expression at G(1)/S phase boundary. Taken together, these data suggest that the HOX-11 gene product may function as a transcription factor for G(1) progression in the cell cycle.	UNIV OTTAWA, NE ONTARIO REG CANC CTR, SUDBURY P3E 5J1, ON, CANADA; UNIV OTTAWA, DEPT MED, SUDBURY P3E 5J1, ON, CANADA; UNIV TORONTO, ONTARIO CANC INST, TORONTO M4X 1K9, ON, CANADA; UNIV TORONTO, DEPT MED BIOPHYS, TORONTO M4X 1K9, ON, CANADA	University of Ottawa; University of Ottawa; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto								AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; ANDREWS BJ, 1990, J BIOL CHEM, V265, P14057; ANDREWS BJ, 1992, NATURE, V355, P393, DOI 10.1038/355393a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CASTRILLO JL, 1991, SCIENCE, V253, P197, DOI 10.1126/science.1677216; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; DUBE ID, 1991, BLOOD, V78, P2996; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; GEHRING WJ, 1992, TRENDS BIOCHEM SCI, V17, P277, DOI 10.1016/0968-0004(92)90434-B; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HATANO M, 1992, BLOOD S, V80, pA355; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAGAN J, 1989, P NATL ACAD SCI USA, V86, P4161, DOI 10.1073/pnas.86.11.4161; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KONGSUWAN K, 1988, EMBO J, V7, P2131, DOI 10.1002/j.1460-2075.1988.tb03052.x; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LU M, 1992, NUCLEIC ACIDS RES, V20, P263, DOI 10.1093/nar/20.2.263; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; LU M, 1990, GENE CHROMOSOME CANC, V2, P217, DOI 10.1002/gcc.2870020309; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MING L, 1992, ONCOGENE, V7, P1325; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NASMYTH KA, 1990, CELL, V63, P1117, DOI 10.1016/0092-8674(90)90404-3; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHEN WF, 1989, P NATL ACAD SCI USA, V86, P8536, DOI 10.1073/pnas.86.21.8536; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; ZUTTER M, 1990, P NATL ACAD SCI USA, V87, P3161, DOI 10.1073/pnas.87.8.3161	41	16	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3265	3270						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	7902555				2022-12-25	WOS:A1993MG78200009
J	ANTOINE, R; TALLETT, A; VANHEYNINGEN, S; LOCHT, C				ANTOINE, R; TALLETT, A; VANHEYNINGEN, S; LOCHT, C			EVIDENCE FOR A CATALYTIC ROLE OF GLUTAMIC ACID-129 IN THE NAD-GLYCOHYDROLASE ACTIVITY OF THE PERTUSSIS TOXIN-S1 SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA EXOTOXIN; ISLET-ACTIVATING PROTEIN; ADP-RIBOSYLTRANSFERASE ACTIVITY; DIPHTHERIA-TOXIN; ESCHERICHIA-COLI; S-1 SUBUNIT; BORDETELLA-PERTUSSIS; ENZYMATIC-ACTIVITIES; ADENYLATE-CYCLASE; CRYSTAL-STRUCTURE	The Sl subunit of pertussis toxin is an ADP-ribosyltransferase capable of transferring the ADP-ribose moiety of NAD+ to nucleotide-binding signal-transducing proteins of the G(i)/G(o) family. In the absence of G proteins, the enzyme also catalyzes the hydrolysis of NAD+. Glu-129 was previously shown to be critical for both enzymatic activities. In this study, site-directed mutagenesis was used to make the conservative substitution of aspartate for Glu-129. The recombinant wild type and mutant proteins were purified to near homogeneity and used for enzymatic analyses. Kinetic experiments showed that the k(cat) of the mutant protein was about 200 times less than that of the wild type enzyme, whereas the K(m) for NAD+ of the two proteins were very similar, suggesting that Glu-129 is a catalytic residue for the NAD-glycohydrolase reaction of S1. This hypothesis was confirmed by a less than 2-fold change in K(d) as measured by fluorescence quenching studies, indicating that the binding of NAD+ is not affected in the mutant protein in any important way. In another experiment, the replacement of Glu-129 by cysteine resulted in a disulfide bridge between Cys-129 and Cys-41 in rS1d-E129C, suggesting that the folding of the polypeptide chain is such that the catalytic Glu-129 residue is close to the amino-terminal NAD-binding site of S1. These findings imply that Glu-129 plays a key role in catalysis of the NAD-glycohydrolase reaction, possibly by electrostatically stabilizing a cationic transition state intermediate, or by serving as a general base to deprotonate the ADP-ribosyl acceptor substrates.	INST PASTEUR, CJF9109,INSERM,MICROBIOL GENET & MOLEC, 1 RUE PROF CALMETTE, F-59019 LILLE, FRANCE; UNIV EDINBURGH, DEPT BIOCHEM, EDINBURGH EH8 9XD, SCOTLAND	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; University of Edinburgh			Locht, Camille/L-3516-2018; Antoine, Rudy/CAH-6653-2022; Antoine, Rudy/L-1630-2018	Antoine, Rudy/0000-0002-7369-0626; Antoine, Rudy/0000-0002-7369-0626				ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; ANTOINE R, 1990, INFECT IMMUN, V58, P1518, DOI 10.1128/IAI.58.6.1518-1526.1990; BARBIERI JT, 1988, INFECT IMMUN, V56, P1934, DOI 10.1128/IAI.56.8.1934-1941.1988; BARBIERI JT, 1989, INFECT IMMUN, V57, P3549, DOI 10.1128/IAI.57.11.3549-3554.1989; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1988, BIO-TECHNOL, V6, P699, DOI 10.1038/nbt0688-699; BURNETTE WN, 1988, SCIENCE, V242, P72, DOI 10.1126/science.2459776; CARROLL SF, 1984, P NATL ACAD SCI-BIOL, V81, P3307, DOI 10.1073/pnas.81.11.3307; CARROLL SF, 1987, J BIOL CHEM, V262, P8707; CARROLL SF, 1985, P NATL ACAD SCI USA, V82, P7237, DOI 10.1073/pnas.82.21.7237; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; CIEPLAK W, 1990, BIOCHEM J, V268, P547, DOI 10.1042/bj2680547; COCKLE SA, 1989, FEBS LETT, V249, P329, DOI 10.1016/0014-5793(89)80652-0; CORTINA G, 1989, J BIOL CHEM, V264, P17322; CORTINA G, 1991, J BIOL CHEM, V266, P23810; DOUGLAS CM, 1990, BIOCHEMISTRY-US, V29, P5043, DOI 10.1021/bi00473a007; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; Francotte M., 1989, VACCINES 89, P243; HONORE B, 1989, BIOCHEM J, V258, P199, DOI 10.1042/bj2580199; KANDEL J, 1974, J BIOL CHEM, V249, P2088; KASLOW HR, 1989, J BIOL CHEM, V264, P6386; KATADA T, 1982, J BIOL CHEM, V257, P7210; KRAUT J, 1988, SCIENCE, V242, P533, DOI 10.1126/science.3051385; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOBBAN MD, 1991, BIOCHIM BIOPHYS ACTA, V1078, P155, DOI 10.1016/0167-4838(91)99004-C; LOBET Y, 1993, J EXP MED, V177, P79, DOI 10.1084/jem.177.1.79; LOCHT C, 1990, VACCINES 90, P435; LOCHT C, 1989, P NATL ACAD SCI USA, V86, P3075, DOI 10.1073/pnas.86.9.3075; LOCHT C, 1990, J BIOL CHEM, V265, P4552; LOCHT C, 1986, NUCLEIC ACIDS RES, V14, P3251, DOI 10.1093/nar/14.8.3251; LOCHT C, 1987, INFECT IMMUN, V55, P2546, DOI 10.1128/IAI.55.11.2546-2553.1987; LOCHT C, 1986, SCIENCE, V232, P1258, DOI 10.1126/science.3704651; LOCHT C, 1990, Zentralblatt fuer Bakteriologie Supplement, V19, P89; LOOSMORE SM, 1990, INFECT IMMUN, V58, P3653, DOI 10.1128/IAI.58.11.3653-3662.1990; LUKAC M, 1988, J BIOL CHEM, V263, P6146; MENTCH F, 1987, BIOCHEMISTRY-US, V26, P921, DOI 10.1021/bi00377a037; MONZINGO AF, 1992, J MOL BIOL, V227, P1136, DOI 10.1016/0022-2836(92)90526-P; Moss J, 1990, ADP RIBOSYLATING TOX; MURAYAMA T, 1983, J BIOL CHEM, V258, P3319; NICOSIA A, 1986, P NATL ACAD SCI USA, V83, P4631, DOI 10.1073/pnas.83.13.4631; PIZZA M, 1989, SCIENCE, V246, P497, DOI 10.1126/science.2683073; PIZZA M, 1988, P NATL ACAD SCI USA, V85, P7521, DOI 10.1073/pnas.85.20.7521; Sambrook J, 1989, MOL CLONING LABORATO; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TAMURA M, 1983, J BIOL CHEM, V258, P6756; TARNUS C, 1988, BIOORG CHEM, V16, P38, DOI 10.1016/0045-2068(88)90036-3; TSAI SC, 1987, P NATL ACAD SCI USA, V84, P5139, DOI 10.1073/pnas.84.15.5139; VANHEYNINGEN S, 1992, POST TRANSLATIONAL M, P153; WATKINS PA, 1985, J BIOL CHEM, V260, P3478; WEISS AA, 1986, ANNU REV MICROBIOL, V40, P661, DOI 10.1146/annurev.micro.40.1.661; WILSON BA, 1990, BIOCHEMISTRY-US, V29, P8643, DOI 10.1021/bi00489a021; ZVELEBIL MJJM, 1988, PROTEIN ENG, V2, P127, DOI 10.1093/protein/2.2.127	54	30	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24149	24155						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	7901213				2022-12-25	WOS:A1993MF29400066
J	GARCIA, KC; DESAUVAGE, FJ; STRUBLE, M; HENZEL, W; REILLY, D; GOEDDEL, DV				GARCIA, KC; DESAUVAGE, FJ; STRUBLE, M; HENZEL, W; REILLY, D; GOEDDEL, DV			PROCESSING AND CHARACTERIZATION OF HUMAN PROGUANYLIN EXPRESSED IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-STABLE ENTEROTOXIN; INTESTINAL GUANYLATE-CYCLASE; ENDOGENOUS ACTIVATOR; HUMAN RECEPTOR; CYCLIC-GMP; PRECURSOR	Guanylin is a 15-amino acid peptide hormone that was originally isolated from the jejunum of the rat small intestine and shown to be an endogenous activator of the intestinal heat-stable enterotoxin receptor-guanylyl cyclase. Guanylin is synthesized as a 115-amino acid prohormone, proguanylin, which is processed at a site yet to be determined, into a C-terminal bioactive fragment(s). In order to examine the processing of proguanylin in vitro, we have generated large quantities of the properly folded prohormone by constructing an expression vector that directs its secretion into the periplasmic space of Escherichia coli. The bacterially expressed human proguanylin was then processed to smaller C-terminal fragments by protease digestion. Digestion with trypsin or lysine-C generated C-terminal peptides of different length, which have been purified and characterized. Guanylin-22 and guanylin-32 have binding affinities and biological activities similar to guanylin-15, while guanylin-63 and the entire proguanylin have only minimal bioactivity. Circular dichroism spectroscopy reveals that proguanylin is a stably folded protein containing mostly beta-sheet and beta-turn structure.	GENENTECH INC, DEPT MOLEC BIOL, 460 POINT SAN BRUNO BLVD, S SAN FRANCISCO, CA 94080 USA; GENENTECH INC, DEPT PROT ENGN, S SAN FRANCISCO, CA 94080 USA; GENENTECH INC, DEPT BIOORGAN CHEM, S SAN FRANCISCO, CA 94080 USA; GENENTECH INC, DEPT PROT CHEM, S SAN FRANCISCO, CA 94080 USA; GENENTECH INC, DEPT PROC DEV, S SAN FRANCISCO, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech			de Sauvage, Frederic/ABE-8400-2020	de Sauvage, Frederic/0000-0002-5275-2584; Henzel, William/0000-0003-2940-3797				BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; CARTER P, 1992, BIO-TECHNOL, V10, P163, DOI 10.1038/nbt0292-163; CHAN SK, 1981, J BIOL CHEM, V256, P7744; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; DESAUVAGE FJ, 1992, P NATL ACAD SCI USA, V89, P9089, DOI 10.1073/pnas.89.19.9089; DESAUVAGE FJ, 1991, J BIOL CHEM, V266, P17912; DESAUVAGE FJ, 1992, J BIOL CHEM, V267, P6479; FIELD M, 1978, P NATL ACAD SCI USA, V75, P2800, DOI 10.1073/pnas.75.6.2800; HUGHES JM, 1978, NATURE, V271, P755, DOI 10.1038/271755a0; SAXENA VP, 1971, P NATL ACAD SCI USA, V68, P969, DOI 10.1073/pnas.68.5.969; SCHULZ S, 1992, J BIOL CHEM, V267, P16019; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; STADER JA, 1990, METHOD ENZYMOL, V185, P166; WIEGAND RC, 1992, BIOCHEM BIOPH RES CO, V185, P812, DOI 10.1016/0006-291X(92)91699-Q; YOSHIMURA S, 1985, FEBS LETT, V181, P138, DOI 10.1016/0014-5793(85)81129-7	16	25	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22397	22401						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7901199				2022-12-25	WOS:A1993MD34800034
J	BAO, J; CHEUNG, WY; WU, JY				BAO, J; CHEUNG, WY; WU, JY			BRAIN L-GLUTAMATE DECARBOXYLASE - INHIBITION BY PHOSPHORYLATION AND ACTIVATION BY DEPHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; RAT-BRAIN; TRYPTOPHAN-HYDROXYLASE; TYROSINE-HYDROXYLASE; ACID DECARBOXYLASE; OKADAIC ACID; PHOSPHATASES; CALMODULIN; EXPRESSION	Previously we showed that the activity of the gamma-aminobutyric acid-synthesizing enzyme L-glutamate decarboxylase (GAD) in crude brain extract is inhibited by ATP and protein phosphatase inhibitors. We suggested that GAD activity is regulated by protein phosphorylation. In this paper we further present evidence to support our hypothesis that protein kinase A and calcineurin may be involved in regulation of GAD activity through phosphorylation and dephosphorylation of GAD, respectively. In addition, the effect of neuronal stimulation on GAD activity in cultured neurons is also included. A model to link neuronal excitation and activation of GAD by Ca2+ dependent phosphatase is proposed.	UNIV KANSAS, DEPT PHYSIOL & CELL BIOL, LAWRENCE, KS 66045 USA; ACAD SINICA, INST BIOMED SCI, TAIPEI 11529, TAIWAN	University of Kansas; Academia Sinica - Taiwan			WU, JANG-YEN/I-6424-2013		NINDS NIH HHS [NS 20978, NS 20922] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020978, R01NS020922] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMES MM, 1978, J BIOL CHEM, V253, P27; ARIAS C, 1992, J NEUROCHEM, V58, P369, DOI 10.1111/j.1471-4159.1992.tb09320.x; Bao Jun, 1994, Journal of Biomedical Science, V1, P237, DOI 10.1007/BF02253308; BENSON DL, 1991, J NEUROSCI, V11, P1540; BLUMP, 1991, MOVEMENT DISORD, V6, P12; BROWNING MD, 1985, J NEUROCHEM, V45, P11, DOI 10.1111/j.1471-4159.1985.tb05468.x; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; EHRET M, 1989, J NEUROCHEM, V52, P1886, DOI 10.1111/j.1471-4159.1989.tb07272.x; GOTO S, 1986, BRAIN RES, V397, P161, DOI 10.1016/0006-8993(86)91381-8; HARDIE DG, 1991, METHOD ENZYMOL, V201, P469; HARRIS KA, 1993, ANN NEUROL, V33, P77, DOI 10.1002/ana.410330113; HAYCOCK JW, 1987, BRAIN RES BULL, V19, P619, DOI 10.1016/0361-9230(87)90046-3; HORNYKIEWICZ O, 1976, GABA NERVOUS SYSTEM, P479; HUBBARD MJ, 1991, MOL NEUROBIOL, P135; JONES EG, 1994, J NEUROSCI, V14, P611; KRAVITZ EA, 1967, NEUROSCIENCES, P433; KUHN DM, 1980, P NATL ACAD SCI-BIOL, V77, P4688, DOI 10.1073/pnas.77.8.4688; LEE YH, 1994, J NEUROCHEM, V62, P2325; McGeer P.L., 1976, GABA NERVOUS SYSTEM, P487; MILLER LP, 1977, NATURE, V266, P847, DOI 10.1038/266847a0; MILLER LP, 1979, J NEUROCHEM, V33, P533, DOI 10.1111/j.1471-4159.1979.tb05185.x; OGITA K, 1991, METHOD ENZYMOL, V200, P228; Roberts E, 1975, NERVOUS SYSTEM, V1, P541; ROBERTS EUGENE, 1968, BRAIN RES, V8, P1, DOI 10.1016/0006-8993(68)90170-4; SCHMIDT BM, 1993, J NEUROCHEM, V61, P1774, DOI 10.1111/j.1471-4159.1993.tb09815.x; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SHERMAN AD, 1991, NEUROSCI LETT, V121, P77, DOI 10.1016/0304-3940(91)90653-B; TOWER DB, 1976, GABA NERVOUS SYSTEM, P461; WU JY, 1990, NEUROCHEM INT, V17, P449, DOI 10.1016/0197-0186(90)90027-Q; WU JY, 1976, GABA NERVOUS SYSTEM, P7	30	64	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6464	6467		10.1074/jbc.270.12.6464	http://dx.doi.org/10.1074/jbc.270.12.6464			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896780	hybrid			2022-12-25	WOS:A1995QQ85500009
J	CRAWFORD, MJ; SHERMAN, DR; GOLDBERG, DE				CRAWFORD, MJ; SHERMAN, DR; GOLDBERG, DE			REGULATION OF SACCHAROMYCES-CEREVISIAE FLAVOHEMOGLOBIN GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-BINDING FLAVOHEMOPROTEIN; ESCHERICHIA-COLI; ALCALIGENES-EUTROPHUS; BACTERIAL HEMOGLOBIN; NUCLEOTIDE-SEQUENCE; YEAST HEMOGLOBIN; STATIONARY-PHASE; LACZ FUSIONS; CLONED GENES; VITREOSCILLA	The Saccharomyces cerevisiae hemoglobin is a flavoprotein of unknown function. It shares extensive sequence homology with the globin of Candida as well as those of several bacterial species. We have studied its gene regulation in order to better understand its purpose in the cell. Transcriptional analyses indicate that, in sharp contrast to the bacterial globins of Vitreoscilla and Alcaligenes eutrophus, the S. cerevisiae globin message is induced during logarithmic growth and under oxygen-replete conditions. Transcription of the S. cerevisiae hemoglobin gene is positively regulated by the transcription factors heme-activated protein (HAP) 1 and HAP2/3/4, which respond to intracellular heme levels. Anaerobically, there is a low level, HAP-independent induction of hemoglobin mRNA. Unlike other systems influenced by the HAP2/3/4 transcription factor complex, no activation of hemoglobin expression by growth in non-fermentable carbon sources is observed. Flavohemoglobin gene disruption does not alter cell viability or growth in a variety of oxygen conditions and carbon sources. Physical and genetic mapping of the S. cerevisiae flavohemoglobin gene places it on chromosome seven near the formyltetrahydrofolate synthase (ADE3) locus. These data indicate that, despite the high degree of homology, the S. cerevisiae globin may have a function distinct from those proposed for bacterial globins.	WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MED,ST LOUIS,MO 63110; JEWISH HOSP ST LOUIS,ST LOUIS,MO 63110	Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Barnes-Jewish Hospital					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007172] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BISSINGER PH, 1989, MOL CELL BIOL, V9, P1309, DOI 10.1128/MCB.9.3.1309; BOERMAN SJ, 1982, J GEN APPL MICROBIOL, V28, P35, DOI 10.2323/jgam.28.35; Cooper T., 1982, MOL BIOL YEAST SACCH, P39, DOI DOI 10.1101/087969180.11B.39; COSTANZO MC, 1989, GENETICS, V122, P297; COWMAN AF, 1991, J CELL BIOL, V113, P1033, DOI 10.1083/jcb.113.5.1033; CRAMM R, 1994, J BIOL CHEM, V269, P7349; CUMSKY MG, 1987, MOL CELL BIOL, V7, P3511, DOI 10.1128/MCB.7.10.3511; DEWINDE JH, 1993, PROG NUCLEIC ACID RE, V46, P51, DOI 10.1016/S0079-6603(08)61018-1; DIKSHIT KL, 1990, NUCLEIC ACIDS RES, V18, P4149, DOI 10.1093/nar/18.14.4149; DIKSHIT RP, 1992, ARCH BIOCHEM BIOPHYS, V293, P241, DOI 10.1016/0003-9861(92)90391-9; ELDER RT, 1983, P NATL ACAD SCI-BIOL, V80, P2432, DOI 10.1073/pnas.80.9.2432; FORSBURG SL, 1989, ANNU REV CELL BIOL, V5, P153, DOI 10.1146/annurev.cb.05.110189.001101; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; GALIAZZO F, 1993, FEBS LETT, V315, P197, DOI 10.1016/0014-5793(93)81162-S; GALLWITZ D, 1980, P NATL ACAD SCI-BIOL, V77, P2546, DOI 10.1073/pnas.77.5.2546; GILLESGONZALES MA, 1991, NATURE, V360, P170; GOLDRING ES, 1970, J MOL BIOL, V52, P323, DOI 10.1016/0022-2836(70)90033-1; GONZALESPREVATT V, 1980, J BIOL CHEM, V255, P1478; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Guthrie C, 1991, GUIDE YEAST GENETICS; HARLOW E, 1988, ANTIBODIES LAB MANUA, pCH12; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; IWAASA H, 1992, J MOL BIOL, V227, P948, DOI 10.1016/0022-2836(92)90236-D; JOSHI M, 1994, BIOCHEM BIOPH RES CO, V202, P535, DOI 10.1006/bbrc.1994.1961; KHOSLA C, 1989, J BACTERIOL, V171, P5995, DOI 10.1128/jb.171.11.5995-6004.1989; KHOSLA C, 1988, NATURE, V331, P633, DOI 10.1038/331633a0; Konat Gregory W., 1994, P37; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT JR, 1994, P NATL ACAD SCI USA, V91, P7345, DOI 10.1073/pnas.91.15.7345; LOWRY CV, 1988, MOL CELL BIOL, V8, P4651, DOI 10.1128/MCB.8.11.4651; MATOON JR, 1979, BIOL CLIN ASPECTS OX, P421; METHA KD, 1990, J BIOL CHEM, V265, P8802; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; OLESEN J, 1987, CELL, V51, P953, DOI 10.1016/0092-8674(87)90582-4; ORII Y, 1986, J BIOL CHEM, V261, P3544; OSHINO R, 1973, EUR J BIOCHEM, V39, P581, DOI 10.1111/j.1432-1033.1973.tb03157.x; PILLAR TM, 1991, CURR GENET, V20, P185, DOI 10.1007/BF00326230; POOLE RK, 1994, P ROY SOC B-BIOL SCI, V255, P251, DOI 10.1098/rspb.1994.0036; PROBST I, 1979, BIOCHIM BIOPHYS ACTA, V576, P471, DOI 10.1016/0005-2795(79)90422-7; RIGGS AF, 1991, AM ZOOL, V31, P535; RILES L, 1993, GENETICS, V134, P81; Sambrook J, 1989, MOL CLONING LABORATO; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; Sherman F., 1983, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VASUDEVAN SG, 1991, MOL GEN GENET, V226, P49, DOI 10.1007/BF00273586; VINOGRADOV SN, 1993, COMP BIOCHEM PHYS B, V106, P1, DOI 10.1016/0305-0491(93)90002-M; WEIHS V, 1989, ARCH MICROBIOL, V151, P546, DOI 10.1007/BF00454873; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; WINKLER H, 1988, EMBO J, V7, P1799, DOI 10.1002/j.1460-2075.1988.tb03011.x; WITTENBERG JB, 1990, ANNU REV BIOPHYS BIO, V19, P217; YON J, 1989, NUCLEIC ACIDS RES, V17, P4895, DOI 10.1093/nar/17.12.4895; ZHU H, 1992, P NATL ACAD SCI USA, V89, P5015, DOI 10.1073/pnas.89.11.5015; ZITOMER RS, 1992, MICROBIOL REV, V56, P1	55	43	45	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6991	6996		10.1074/jbc.270.12.6991	http://dx.doi.org/10.1074/jbc.270.12.6991			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896850	hybrid			2022-12-25	WOS:A1995QQ85500081
J	PULIDO, R; KRUEGER, NX; SERRAPAGES, C; SAITO, H; STREULI, M				PULIDO, R; KRUEGER, NX; SERRAPAGES, C; SAITO, H; STREULI, M			MOLECULAR CHARACTERIZATION OF THE HUMAN TRANSMEMBRANE PROTEIN-TYROSINE-PHOSPHATASE-DELTA - EVIDENCE FOR TISSUE-SPECIFIC EXPRESSION OF ALTERNATIVE HUMAN TRANSMEMBRANE PROTEIN-TYROSINE-PHOSPHATASE-DELTA ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE COMMON ANTIGEN; CELL-ADHESION MOLECULES; IMMUNOGLOBULIN SUPERFAMILY; NERVOUS-SYSTEM; EXTRACELLULAR REGION; SURFACE RECOGNITION; POINT MUTATION; CLEAVAGE SITE; VASE EXON; NG-CAM	Protein-tyrosine phosphatases (PTPases) play an essential role in the regulation of cell activation, proliferation, and differentiation. A major subfamily of these enzymes is the transmembrane-type PTPases that contain extracellular regions comprised of Ig-like and fibronectin type III (FN-III)-like domains, Characterization of the human transmembrane PTPase delta (HPTP delta) revealed the existence of multiple HPTP delta isoforms that vary in their extracellular regions. The full-length HPTP delta isoform has an extracellular region containing three Ig-like and eight FN-III-like domains connected via a transmembrane peptide to an intracellular region with two PTPase domains, whereas another isoform lacks four of the eight FN-III like domains. Furthermore, other HPTP delta isoforms exist that lack 9 amino acids within the second Ig-like domain and 4 amino acids at the junction of the second and third Ig-like domains or 9 amino acids within the fifth FN-III-like domain, Reverse transcription polymerase chain reaction analysis demonstrated that HPTP delta isoforms lacking these short peptides are expressed in kidney, whereas isoforms containing these peptides are expressed in the brain, Analysis of HPTP delta biosynthesis demonstrated that HPTP delta is expressed as a complex of two noncovalently associated subunits derived from a proprotein and that the HPTP delta ectodomain is shed from the cell surface. Mutational analysis of the HPTP delta proprotein cleavage site revealed the existence of two or three functional and overlapping furin-like endoprotease cleavage sites.	HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	PULIDO, R (corresponding author), CHILDRENS HOSP, DANA FARBER CANC INST, DIV TUMOR IMMUNOL, BOSTON, MA 02115 USA.		Saito, Haruo/AAF-6113-2019	Saito, Haruo/0000-0001-7891-1689; Pulido, Rafael/0000-0001-9100-248X	NCI NIH HHS [CA55547] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055547] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BARNEA G, 1994, J BIOL CHEM, V269, P14349; BARNEA G, 1993, MOL CELL BIOL, V13, P1497, DOI 10.1128/MCB.13.3.1497; BECKMANN G, 1993, TRENDS BIOCHEM SCI, V18, P40, DOI 10.1016/0968-0004(93)90049-S; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BRAUTIGAN DL, 1992, BIOCHIM BIOPHYS ACTA, V1114, P63, DOI 10.1016/0304-419X(92)90007-L; BRUMMENDORF T, 1993, J NEUROCHEM, V61, P1207, DOI 10.1111/j.1471-4159.1993.tb13611.x; BURGOON MP, 1991, J CELL BIOL, V112, P1017, DOI 10.1083/jcb.112.5.1017; DAUM G, 1994, J BIOL CHEM, V269, P10524; DOHERTY P, 1992, NATURE, V356, P791, DOI 10.1038/356791a0; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GRUMET M, 1991, J CELL BIOL, V113, P1399, DOI 10.1083/jcb.113.6.1399; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; KAYYEM JF, 1992, J CELL BIOL, V118, P1259, DOI 10.1083/jcb.118.5.1259; KOBAYASHI M, 1988, BIOCHEM BIOPH RES CO, V153, P657, DOI 10.1016/S0006-291X(88)81145-8; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LEVY JB, 1993, J BIOL CHEM, V268, P10573; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MILLAN JL, 1986, J BIOL CHEM, V261, P3112; MIZUNO K, 1993, MOL CELL BIOL, V13, P5513, DOI 10.1128/MCB.13.9.5513; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; OGRADY P, 1994, J BIOL CHEM, V269, P25193; PAN MG, 1993, J BIOL CHEM, V268, P19284; PULIDO R, 1994, J EXP MED, V179, P1035, DOI 10.1084/jem.179.3.1035; Saito H, 1993, Semin Cell Biol, V4, P379, DOI 10.1006/scel.1993.1045; SAP J, 1994, MOL CELL BIOL, V14, P1; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SERRAPAGES C, 1994, J BIOL CHEM, V269, P23632; SMALL SJ, 1990, J CELL BIOL, V111, P2089, DOI 10.1083/jcb.111.5.2089; SONDEREGGER P, 1992, J CELL BIOL, V119, P1387, DOI 10.1083/jcb.119.6.1387; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1992, EMBO J, V11, P897, DOI 10.1002/j.1460-2075.1992.tb05128.x; STREULI M, 1989, EMBO J, V8, P787, DOI 10.1002/j.1460-2075.1989.tb03439.x; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; Tonks N K, 1993, Semin Cell Biol, V4, P373, DOI 10.1006/scel.1993.1044; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; VOLKMER H, 1992, J CELL BIOL, V118, P149, DOI 10.1083/jcb.118.1.149; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WALTON KM, 1993, NEURON, V11, P387, DOI 10.1016/0896-6273(93)90193-U; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS JF, 1990, J BIOL CHEM, V265, P8463; YAN H, 1993, J BIOL CHEM, V268, P24880; YOSHIMASA Y, 1988, SCIENCE, V240, P784, DOI 10.1126/science.3283938; YOSHIMASA Y, 1990, J BIOL CHEM, V265, P17230; YU Q, 1992, ONCOGENE, V7, P1051; ZHANG WR, 1994, BIOCHEM J, V302, P39, DOI 10.1042/bj3020039	54	68	70	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6722	6728		10.1074/jbc.270.12.6722	http://dx.doi.org/10.1074/jbc.270.12.6722			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896816	hybrid			2022-12-25	WOS:A1995QQ85500047
J	SLATER, SJ; KELLY, MB; TADDEO, FJ; LARKIN, JD; YEAGER, MD; MCLANE, JA; HO, C; STUBBS, CD				SLATER, SJ; KELLY, MB; TADDEO, FJ; LARKIN, JD; YEAGER, MD; MCLANE, JA; HO, C; STUBBS, CD			DIRECT ACTIVATION OF PROTEIN-KINASE-C BY 1-ALPHA,25-DIHYDROXYVITAMIN D-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED DIFFERENTIATION; CYTOSOLIC CALCIUM; GENE-EXPRESSION; PHORBOL ESTERS; CELLS; 1,25-DIHYDROXYVITAMIN-D3; DIACYLGLYCEROL; INVOLVEMENT; MEMBRANES; RECEPTOR	The key metabolite of vitamin D-3, 1 alpha,25-dihydroxyvitamin D-3 (1,25-D-3), induces rapid cellular responses that constitute a so-called ''non-genomic'' response. This effect is distinguished from its ''classic'' genomic role in calcium homeostasis involving the nuclear 1,25-D-3 receptor. Evidence is presented that protein kinase C (PKC) is directly activated by 1,25-D, at physiological concentrations (EC(50) = 16 +/- 1 nM). The effect was demonstrable with single PKC-alpha, -gamma, and -epsilon isoform preparations, assayed in a system containing only purified enzyme, substrate, co-factors, and lipid vesicles, from which it is inferred that a direct interaction with the enzyme is involved. The finding that calcium-dependent isoform PKC-epsilon was also activated by 1,25-D-3 shows that the calcium binding C2 domain is not required. The level of 1,25-D-3-induced activation, paired with either diacylglycerol or 4 beta-12-O-tetradecanoylphorbol-13-acetate, was greater than that achievable by any individual activator alone, each at a saturating concentration, a result that implies two distinct activator sites on the PKC molecule. Phosphatidylethanolamine present in the lipid vesicles potentiated 4 beta-12-O-tetradecanoyl-phorbol-13-acetate- and diacylglycerol-induced PKC activities, whereas 1,25-D-3-induced activity decreased, consistent with 1,25 D-3-activated PKC possessing a distinct conformation. The results suggest that PKC is a ''membrane-bound receptor'' for 1,25-D-3 and that it could be important in the control of non-genomic cellular responses to the hormone.	THOMAS JEFFERSON UNIV, DEPT PATHOL & CELL BIOL, PHILADELPHIA, PA 19107 USA; HOFFMANN LA ROCHE INC, NUTLEY, NJ 07110 USA	Jefferson University; Roche Holding				Larkin, Jonathan/0000-0002-1202-9287	NIAAA NIH HHS [AA08022, AA07215, AA07186] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R29AA008022, R01AA008022, P50AA007186] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BAZZI MD, 1992, BIOCHEMISTRY-US, V31, P1125, DOI 10.1021/bi00119a022; BAZZI MD, 1988, BIOCHEMISTRY-US, V27, P6776, DOI 10.1021/bi00418a020; BELL R, 1992, ADV EXP MED BIOL, V318, P275; BLUMBERG PM, 1988, CANCER RES, V48, P1; BOLAND RL, 1991, BIOCHEM BIOPH RES CO, V180, P833, DOI 10.1016/S0006-291X(05)81140-4; BONI LT, 1985, J BIOL CHEM, V260, P819; BOSCA L, 1993, BIOCHEM J, V290, P827, DOI 10.1042/bj2900827; BOURDEAU A, 1990, ENDOCRINOLOGY, V127, P2738, DOI 10.1210/endo-127-6-2738; BRUMFELD V, 1990, ARCH BIOCHEM BIOPHYS, V277, P318, DOI 10.1016/0003-9861(90)90586-N; BURGOSTRINIDAD M, 1990, ANAL BIOCHEM, V190, P102, DOI 10.1016/0003-2697(90)90141-U; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; CIVITELLI R, 1990, ENDOCRINOLOGY, V127, P2253, DOI 10.1210/endo-127-5-2253; Darwish Hisham, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P89; DEBOLAND AR, 1990, ENDOCRINOLOGY, V127, P39, DOI 10.1210/endo-127-1-39; DEBOLAND AR, 1994, J BIOL CHEM, V269, P8675; DELUCA HF, 1990, KIDNEY INT, V38, pS2; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GRUNER SM, 1985, P NATL ACAD SCI USA, V82, P3665, DOI 10.1073/pnas.82.11.3665; HANNUN YA, 1986, J BIOL CHEM, V261, P7184; HANNUN YA, 1990, J BIOL CHEM, V265, P2962; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HUI SW, 1989, P NATL ACAD SCI USA, V86, P5825, DOI 10.1073/pnas.86.15.5825; ISRAELACHVILI JN, 1980, Q REV BIOPHYS, V13, P121, DOI 10.1017/S0033583500001645; KAIBUCHI K, 1981, J BIOL CHEM, V256, P7146; KAZANIETZ MG, 1992, J BIOL CHEM, V267, P20878; KHARE S, 1993, ENDOCRINOLOGY, V133, P2213, DOI 10.1210/en.133.5.2213; KIRK GL, 1984, BIOCHEMISTRY-US, V23, P1093, DOI 10.1021/bi00301a009; KISHIMOTO A, 1980, J BIOL CHEM, V255, P2273; Kitano T, 1986, Methods Enzymol, V124, P349; KRAFT AS, 1986, P NATL ACAD SCI USA, V83, P1334, DOI 10.1073/pnas.83.5.1334; LIEBERHERR M, 1989, J BIOL CHEM, V264, P20403; LISSOOS TW, 1993, J BIOL CHEM, V268, P25132; LOWE K E, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P65; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MORELLI S, 1993, BIOCHEM J, V289, P675, DOI 10.1042/bj2890675; MOSIOR M, 1993, BIOCHEMISTRY-US, V32, P65, DOI 10.1021/bi00052a010; NELSESTUEN GL, 1993, J BIOENERG BIOMEMBR, V3, P277; NEMERE I, 1993, RECEPTOR, V3, P277; NEMERE I, 1994, J BIOL CHEM, V269, P23750; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NORMAN AW, 1993, J BIOL CHEM, V268, P13811; OBEID LM, 1990, J BIOL CHEM, V265, P2370; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; SAIDO TC, 1992, BIOCHEMISTRY-US, V31, P482, DOI 10.1021/bi00117a026; SEDDON JM, 1990, BIOCHIM BIOPHYS ACTA, V1031, P1, DOI 10.1016/0304-4157(90)90002-T; SIMBOLICAMPBELL M, 1992, CELL SIGNAL, V4, P99, DOI 10.1016/0898-6568(92)90011-V; SIMBOLICAMPBELL M, 1994, J BIOL CHEM, V269, P3257; SIMPSON RU, 1989, J BIOL CHEM, V264, P19710; SLATER SJ, 1994, J BIOL CHEM, V269, P17160; SLATER SJ, 1994, J BIOL CHEM, V269, P4866; SNOEK GT, 1988, BIOCHEM J, V255, P629; STABEL S, 1991, METHOD ENZYMOL, V200, P670; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; Studzinski George P., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P279; VANLEEUWEN JPTM, 1992, J BIOL CHEM, V267, P12562; WALI RK, 1990, J CLIN INVEST, V85, P1296, DOI 10.1172/JCI114567; WENDER PA, 1988, P NATL ACAD SCI USA, V85, P7197, DOI 10.1073/pnas.85.19.7197; WOLF M, 1985, J BIOL CHEM, V260, P5718	61	117	118	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6639	6643		10.1074/jbc.270.12.6639	http://dx.doi.org/10.1074/jbc.270.12.6639			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896803	hybrid			2022-12-25	WOS:A1995QQ85500034
J	TAYLOR, ICA; ROY, S; YASWEN, P; STAMPFER, MR; VARMUS, HE				TAYLOR, ICA; ROY, S; YASWEN, P; STAMPFER, MR; VARMUS, HE			MOUSE MAMMARY-TUMORS EXPRESS ELEVATED LEVELS OF RNA-ENCODING THE MURINE HOMOLOG OF SKY, A PUTATIVE RECEPTOR TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BREAST-CANCER; PP60C-SRC PROTEIN-KINASE; EPITHELIAL-CELL LINE; SIGNAL TRANSDUCTION; TRANSGENIC MICE; GROWTH-FACTOR; GENE; ONCOGENE; TRANSFORMATION; VIRUS	To gain insight into the signal transduction pathways utilized by the Wnt-1-responsive mammary epithelial cell line C57MG, we screened for non-src family member tyrosine kinases expressed in these cells using a polymerase chain reaction-based technique. We identified five cDNA clones encoding receptor tyrosine kinases for which the ligand is known (fibroblast growth factor receptor, platelet-derived growth factor receptor, epithelial growth factor receptor, insulin receptor, and insulin-like growth factor receptor), two putative receptor tyrosine kinases for which the ligand remains to be identified (the products of ryk and the mouse klg homolog), and a novel tyrosine kinase. We cloned cDNAs encoding both the murine and human homologs of this kinase, the sequences of which were subsequently published under the names sky (Ohashi, K., Mizuno, K., Kuma, K., Miyata, T., and Nakamura, T. (1994) Oncogene 9, 699-705) and rse (Mark, M. R., Scadden, D. T., Wang, Z., Gu, Q., Goddard, A., and Godowski, P. J. (1994) J. Biol. Chem. 269, 10720-10728). Mouse sky RNA levels are abundant in mammary tumors derived from transgenic mice that express wnt-1, fgf-3, or both oncogenes in their mammary glands. However, little or no expression of sky is detected in mammary glands from virgin animals or in preneoplastic mammary glands from wnt-1 transgenic mice. Moreover, we find that the human homolog of sky is expressed at elevated levels when normal human mammary epithelial cells are rendered tumorigenic by the introduction of two viral oncogenes. Transient transfection of the human SKY cDNA into the quail fibrosarcoma cell line QT6 reveals that SKY is an active tyrosine kinase that augments the level of cellular phosphotyrosine. Introduction of murine Sky into RatB1a fibroblasts by retrovirus-mediated gene transfer results in morphological transformation, growth in soft agar, and the formation of tumors in nude mice. These data raise the possibility that the Sky tyrosine kinase is involved in the development and/or progression of mammary tumors.	NCI,BETHESDA,MD 20892; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,BERKELEY,CA 94720	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California San Francisco; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley					NATIONAL CANCER INSTITUTE [R01CA024844, R55CA054247, R01CA054247, R37CA024844, R35CA039832] Funding Source: NIH RePORTER; NCI NIH HHS [CA-24844, CA-39832, CA-54247] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRES AC, 1994, ONCOGENE, V9, P1461; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; CANCE WG, 1993, INT J CANCER, V54, P571, DOI 10.1002/ijc.2910540409; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLARK R, 1988, CANCER RES, V48, P4689; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HENNIPMAN A, 1989, CANCER RES, V49, P516; HIRSCH R, 1988, VIROLOGY, V167, P136, DOI 10.1016/0042-6822(88)90062-1; HOVENS CM, 1992, P NATL ACAD SCI USA, V89, P11818, DOI 10.1073/pnas.89.24.11818; JACOBS C, 1983, CANCER RES, V43, P1696; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; LEHTOLA L, 1992, INT J CANCER, V50, P598, DOI 10.1002/ijc.2910500419; MARK MR, 1994, J BIOL CHEM, V269, P10720; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1994, ONCOGENE, V9, P699; ORNITZ DM, 1991, P NATL ACAD SCI USA, V88, P698, DOI 10.1073/pnas.88.3.698; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PAPA V, 1990, J CLIN INVEST, V86, P1503, DOI 10.1172/JCI114868; ROSEN N, 1986, J BIOL CHEM, V261, P3754; Sambrook J, 1989, MOL CLONING LABORATO; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; STAMPFER MR, 1992, TRANSFORMATION HUMAN, P118; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAIDYA AB, 1978, VIROLOGY, V90, P12, DOI 10.1016/0042-6822(78)90328-8	37	48	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6872	6880		10.1074/jbc.270.12.6872	http://dx.doi.org/10.1074/jbc.270.12.6872			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896835	hybrid			2022-12-25	WOS:A1995QQ85500066
J	DAI, TN; RUBIE, E; FRANKLIN, CC; KRAFT, A; GILLESPIE, DAF; AVRUCH, J; KYRIAKIS, JM; WOODGETT, JR				DAI, TN; RUBIE, E; FRANKLIN, CC; KRAFT, A; GILLESPIE, DAF; AVRUCH, J; KYRIAKIS, JM; WOODGETT, JR			STRESS-ACTIVATED PROTEIN-KINASES BIND DIRECTLY TO THE DELTA-DOMAIN OF C-JUN IN RESTING CELLS - IMPLICATIONS FOR REPRESSION OF C-JUN FUNCTION	ONCOGENE			English	Article						JUN; AP-1; KINASE; SAPK	GLYCOGEN-SYNTHASE KINASE-3; TUMOR-NECROSIS-FACTOR; DNA-BINDING; V-JUN; PHOSPHORYLATION; TRANSCRIPTION; AP-1; INVITRO; FOS	The transactivating function of the c-Jun proto-oncogene component of the AP-1 transcription factor is acutely regulated by a wide variety of cellular signals via modulation of phosphorylation of two serines (63 and 73). The viral oncoprotein, v-Jun, while containing homologous serines, is not phosphorylated in cells. A novel family of stress-activated protein kinases (SAPKs), also termed Jun N-terminal domain kinases (JNKs), are responsible for mediating S63/73 phosphorylation in response to a variety of cellular stimuli including tumor necrosis factor-alpha, heat stress and u.v. light. The p54 alpha(1), alpha(2), p54 beta and p46 beta SAPKs are shown to bind directly to c-Jun but not to v-Jun, with an absolute requirement for c-Jun amino acids 31-47, a region deleted in v-Jun. Inactive SAPKs tightly bind c-Jun in resting cells and may be a manifestation of the 'delta' inhibitor, a previously described repressor of c-Jun function.	ONTARIO CANC INST,DIV CELL & MOLEC BIOL,TORONTO,ON M4X 1K9,CANADA; UNIV ALABAMA,DIV HEMATOL ONCOL,BIRMINGHAM,AL 35294; BEATSON INST CANC RES,CANC RES CAMPAIGN,BEATSON LABS,GLASGOW G61 1BD,LANARK,SCOTLAND; MASSACHUSETTS GEN HOSP E,DIABET RES LABS,MED SERV,BOSTON,MA 02129	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Alabama System; University of Alabama Birmingham; Beatson Institute			Woodgett, Jim/F-1087-2010; Gillespie, David/R-4771-2019	Woodgett, Jim/0000-0003-3731-5797; Gillespie, David/0000-0002-6338-0544	NATIONAL CANCER INSTITUTE [R01CA042533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046577, R29GM046577] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42533] Funding Source: Medline; NIGMS NIH HHS [GM 46577] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; ADLER V, 1994, J BIOL CHEM, V269, P11186; ADLER V, 1992, J BIOL CHEM, V267, P17001; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BERNSTEIN LR, 1994, J BIOL CHEM, V269, P9401; BLACK EJ, 1994, ONCOGENE, V9, P2363; BLACK EJ, 1991, ONCOGENE, V6, P1949; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRACH MA, 1993, MOL CELL BIOL, V13, P4284, DOI 10.1128/MCB.13.7.4284; DEGROOT RP, 1993, ONCOGENE, V8, P841; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIXIT VM, 1989, J BIOL CHEM, V264, P16905; FRANKLIN CC, 1993, CELL GROWTH DIFFER, V4, P377; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOEFFLER WK, 1994, NUCLEIC ACIDS RES, V22, P1305, DOI 10.1093/nar/22.7.1305; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; PAPAVASSILIOU AG, 1992, ANAL BIOCHEM, V203, P302, DOI 10.1016/0003-2697(92)90317-Z; POMBO CM, 1994, J BIOL CHEM, V269, P26546; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; YAN MH, 1994, NATURE, V372, P798	35	108	109	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					849	855						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898927				2022-12-25	WOS:A1995QL03800006
J	DIB, A; ADELAIDE, J; CHAFFANET, M; IMBERT, A; LEPASLIER, D; JACQUEMIER, J; GAUDRAY, P; THEILLET, C; BIRNBAUM, D; PEBUSQUE, MJ				DIB, A; ADELAIDE, J; CHAFFANET, M; IMBERT, A; LEPASLIER, D; JACQUEMIER, J; GAUDRAY, P; THEILLET, C; BIRNBAUM, D; PEBUSQUE, MJ			CHARACTERIZATION OF THE REGION OF THE SHORT ARM OF CHROMOSOME-8 AMPLIFIED IN BREAST-CARCINOMA	ONCOGENE			English	Article						AMPLIFICATION; BREAST CANCER; CHROMOSOME 8; MAPPING; ONCOGENE; YEAST ARTIFICIAL CHROMOSOMES	POLYMERASE CHAIN-REACTION; HUMAN GENOME; LINKAGE MAP; DNA AMPLIFICATION; HUMAN-TUMORS; PLAT GENES; CANCER; RECEPTOR; LIBRARY; CLONING	Chromosomal region 8p11.2-p12 is consistently amplified in human breast cancer, We have constructed a 2.8 Mb YAC contig of this region, centered on the human Fibroblast Growth Factor Receptor 1 (FGRF1) locus and encompassing the Adrenergic beta 3 Receptor (ADRB3) focus. A smaller centromeric YAC contig spanning 1.4 Mb was also assembled, and included the Ankyrin 1 (ANK1) and Tissue-type Plasminogen Activator (FLAT) genes, Results from mapping of the contigs showed physical linkage of the ADRB3 and FGFR1 genes, which were colocalized within the same YAC clone and separated by about 900 kb, FGFR1 being in centromeric position, It also showed physical linkage of ANK1 and FLAT genes, which appear to be separated by a maximum of 700 kb. In parallel, several loci were mapped according to their amplification status in a large panel of breast tumor samples. The overall amplification pattern suggested a continuous amplicon with a core around FGFR1. Data from both the detailed physical map and the amplification status allowed to establish the following gene order, from telomere to centromere: ADRB3-D8S105-FGFR1-ANK1-PLAT-POLB. The precise localization and YAC cloning of the core of the amplicon will allow to isolate a putative oncogene involved in mammary carcinogenesis.	INSERM,U119,MOLEC ONCOL LAB,F-13009 MARSEILLE,FRANCE; INST J PAOLI I CALMETTES,BIOL TUMEURS LAB,F-13009 MARSEILLE,FRANCE; CTR ETUD POLYMORPHISME HUMAIN,F-75010 PARIS,FRANCE; INST J PAOLI I CALMETTES,DEPT ANATOMOPATHOL,F-13009 MARSEILLE,FRANCE; IGMM,CNRS,URA 9942,MONTPELLIER,FRANCE; LGMCH,CNRS,URA 1462,NICE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC); Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)			Theillet, Charles/O-7634-2018; CHAFFANET, Max/AAU-5743-2020; ADELAIDE, José JA/O-4390-2017	ADELAIDE, José JA/0000-0003-4364-9857; Birnbaum, Daniel/0000-0001-7920-9883; Theillet, Charles/0000-0001-5555-2759; CHAFFANET, Max/0000-0002-2344-1488; Le Paslier, Denis/0000-0003-4335-9956				ADELAIDE J, 1994, GENE CHROMOSOME CANC, V11, P66, DOI 10.1002/gcc.2870110111; ADNANE J, 1991, ONCOGENE, V6, P659; ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ANAND R, 1990, NUCLEIC ACIDS RES, V18, P1951, DOI 10.1093/nar/18.8.1951; BELLANNECHANTEL.C, 1992, CELL, V70, P1059; BRADFORD CR, 1991, GENE CHROMOSOME CANC, V3, P272, DOI 10.1002/gcc.2870030406; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; BROWNSTEIN BH, 1989, SCIENCE, V244, P1348, DOI 10.1126/science.2544027; BUETOW KH, 1994, NAT GENET, V6, P391, DOI 10.1038/ng0494-391; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; EMI M, 1993, GENOMICS, V15, P530, DOI 10.1006/geno.1993.1105; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; H/CEPH Collaborative Mapping Group, 1992, SCIENCE, V258, P67; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HYNES NE, 1993, SEMIN CANCER BIOL, V4, P19; IMBERT A, 1994, CYTOGENET CELL GENET, V67, P175, DOI 10.1159/000133817; JACQUEMIER J, 1994, INT J CANCER, V59, P373, DOI 10.1002/ijc.2910590314; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KARLSEDER J, 1994, GENE CHROMOSOME CANC, V9, P42, DOI 10.1002/gcc.2870090108; KERANGUEVEN F, 1995, IN PRESS ONCOGENE; LAFAGE M, 1992, GENE CHROMOSOME CANC, V5, P40, DOI 10.1002/gcc.2870050107; LAMBERT S, 1990, P NATL ACAD SCI US, V87; LI X, 1994, GENOMICS, V19, P470, DOI 10.1006/geno.1994.1096; MARICS I, 1989, ONCOGENE, V4, P335; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MUENKE M, 1994, NAT GENET, V8, P269, DOI 10.1038/ng1194-269; NY T, 1984, P NATL ACAD SCI-BIOL, V81, P5355, DOI 10.1073/pnas.81.17.5355; OCHMAN H, 1988, GENETICS, V120, P621; OSHIMA J, 1994, GENOMICS, V23, P100, DOI 10.1006/geno.1994.1464; PEBUSQUE MJ, 1993, GENE CHROMOSOME CANC, V8, P119, DOI 10.1002/gcc.2870080209; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; SAINTRUF C, 1991, CANCER GENET CYTOGEN, V52, P27, DOI 10.1016/0165-4608(91)90050-5; SENGUPTA DN, 1986, BIOCHEM BIOPH RES CO, V136, P341, DOI 10.1016/0006-291X(86)90916-2; SZEPETOWSKI P, 1993, GENOMICS, V16, P745, DOI 10.1006/geno.1993.1257; SZEPETOWSKI P, 1992, ONCOGENE, V7, P2513; THEILLET C, 1989, ONCOGENE, V4, P915; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; TOMFOHRDE J, 1992, GENOMICS, V14, P144, DOI 10.1016/S0888-7543(05)80297-6; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; TUTIC M, 1990, EUR J BIOCHEM, V188, P523, DOI 10.1111/j.1432-1033.1990.tb15431.x; WAGNER MJ, 1991, GENOMICS, V10, P114, DOI 10.1016/0888-7543(91)90491-V; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WIEGANT J, 1991, GENOMICS, V10, P345, DOI 10.1016/0888-7543(91)90318-9; Wood S, 1993, Cytogenet Cell Genet, V64, P134; 1991, CYTOGENET CELL GENET, V58, P1	53	43	45	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					995	1001						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898940				2022-12-25	WOS:A1995QL03800021
J	HAUSKEN, ZE; COGHLAN, VM; HASTINGS, CAS; REIMANN, EM; SCOTT, JD				HAUSKEN, ZE; COGHLAN, VM; HASTINGS, CAS; REIMANN, EM; SCOTT, JD			TYPE-II REGULATORY SUBUNIT (RII) OF THE CAMP-DEPENDENT PROTEIN-KINASE INTERACTION WITH A-KINASE ANCHOR PROTEINS REQUIRES ISOLEUCINE-3 AND ISOLEUCINE-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN-2; HIGH-AFFINITY BINDING; AMINO-ACID-SEQUENCE; BOVINE BRAIN; CLONING; DOMAIN; BETA; IDENTIFICATION; LOCALIZATION; EXPRESSION	Compartmentalization of the type II cAMP-dependent protein kinase is maintained by association of the regulatory subunit (RII) with A-Kinase Anchor Proteins (AKAPs). In previous studies (Scott, J. D., Stofko, R.E., McDonald, J. R., Comer, J. D., Vitalis, E. A., and Mangili J. (1990) J. Biol. Chem. 265, 21561-21566) we have shown that dimerization of RII alpha was required for interaction with the cytoskeletal component microtubule-associated protein 2. In this report we show that the localization and dimerization domains of RII alpha are contained within the first thirty residues of each RII protomer, RII des-5 (an amino terminal deletion mutant lacking residues 1-5) was unable to bind AKAPs but retained the ability to dimerize. RII alpha I3,I5A (a mutant where isoleucines 3 and 5 were replaced with alanine) was unable to bind a variety of AKAPs. Mutation of both isoleucines decreased AKAP binding without affecting dimerization, cAMP binding, or the overall secondary structure of the protein. Measurement of RII alpha I3A,I5A interaction with the human thyroid AKAP, Ht 31, by two independent methods suggests that mutation of isoleucines 3 and 5 decreases affinity by at least 6-fold. Therefore, we propose that two isoleucine side chains on each RII protomer are principle sites of contact with the conserved amphipathic helix binding domain on AKAPs.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; MED COLL OHIO,TOLEDO,OH 43699	Oregon Health & Science University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044238] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 44238] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEEBE SJ, 1986, ENZYMES, V17, P43; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; BREGMAN DB, 1991, J BIOL CHEM, V266, P7202; BUBIS J, 1987, J BIOL CHEM, V262, P14961; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARR DW, 1991, J BIOL CHEM, V266, P14188; CARR DW, 1993, J BIOL CHEM, V268, P20729; COGHLAN VM, 1994, J BIOL CHEM, V269, P7658; CORBIN JD, 1978, J BIOL CHEM, V253, P3997; CORBIN JD, 1975, J BIOL CHEM, V250, P218; FIRST EA, 1984, J BIOL CHEM, V259, P4011; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; KERYER G, 1993, P NATL ACAD SCI USA, V90, P5418, DOI 10.1073/pnas.90.12.5418; LEISER M, 1986, J BIOL CHEM, V261, P1904; LOHMANN SM, 1984, P NATL ACAD SCI-BIOL, V81, P6723, DOI 10.1073/pnas.81.21.6723; LUO ZJ, 1990, J BIOL CHEM, V265, P21804; OBAR RA, 1989, NEURON, V3, P639, DOI 10.1016/0896-6273(89)90274-2; REIMANN EM, 1986, BIOCHEMISTRY-US, V25, P119, DOI 10.1021/bi00349a018; RINGHEIM GE, 1990, J BIOL CHEM, V265, P4800; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; RUBIN CS, 1972, J BIOL CHEM, V247, P6135; RUBIN CS, 1979, J BIOL CHEM, V254, P3797; RUBINO HM, 1989, NEURON, V3, P631, DOI 10.1016/0896-6273(89)90273-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR D, 1984, J BIOL CHEM, V259, P9840; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P4379, DOI 10.1073/pnas.82.13.4379; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; SCOTT JD, 1987, P NATL ACAD SCI USA, V84, P5192, DOI 10.1073/pnas.84.15.5192; SCOTT JD, 1994, MOL ENDOCRINOL, V13, P5; SUTHERLAND EW, 1972, SCIENCE, V177, P401, DOI 10.1126/science.177.4047.401; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4200, DOI 10.1021/bi00313a029; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; THEURKAUF WE, 1982, J BIOL CHEM, V257, P3284; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	40	101	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24245	24251						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929081				2022-12-25	WOS:A1994PQ34600062
J	MCCORMICK, SPA; LINTON, MF; HOBBS, HH; TAYLOR, S; CURTISS, LK; YOUNG, SG				MCCORMICK, SPA; LINTON, MF; HOBBS, HH; TAYLOR, S; CURTISS, LK; YOUNG, SG			EXPRESSION OF HUMAN APOLIPOPROTEIN B90 IN TRANSGENIC MICE - DEMONSTRATION THAT APOLIPOPROTEIN B90 LACES THE STRUCTURAL REQUIREMENTS TO FORM LIPOPROTEIN(A)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; FAMILIAL HYPOBETALIPOPROTEINEMIA; MYOCARDIAL-INFARCTION; HEART-DISEASE; B GENE; BINDING; PLASMA; ANTIBODIES; CYSTEINE; RISK	Lipoprotein(a) (Lp(a)) is a lipoprotein formed by the disulfide linkage of apolipoprotein(a) (apo(a)) to the apoB100 of a low density lipoprotein particle. Earlier site-directed mutagenesis studies of apo(a) demonstrated that apo(a) cysteine 4057 is required for the disulfide linkage; however, the cysteine residue within apoB100 that is involved in the disulfide bond has not been identified. We previously demonstrated that the apoB100 produced by human apoB transgenic mice binds to apo(a) and forms Lp(a) (Linton, M. F., Farese, R. V., Jr., Chiesa, G., Grass, D. S., Chin, P., Hammer, R. E., Hobbs, H. H., and Young, S. G. (1993) J. Clin. Invest. 92, 3029-3037). To further explore the structural features of human apoB that are required for the formation of Lp(a), we used a transposon-interrupted human apoB gene clone to develop transgenic mice that express high levels of a truncated form of human apoB, apoB90, which contains the amino-terminal 4084 amino acids of apoB. In vitro incubation of apo(a) with the plasma of human apoB90 transgenic mice did not yield Lp(a), as judged by Western blots of SDS-polyacrylamide gels or by a monoclonal antibody-based radioimmunoassay. In contrast, incubation of apo(a) with the plasma of a mouse that expressed an equivalent amount of the full-length apoB100 did yield Lp(a). In addition to these in vitro incubation studies, no Lp(a) could be detected in the plasma of a ''double transgenic'' mouse expressing both human apoB90 and apo(a). These data indicate that the carboxyl-terminal 10% of apoB100 contains amino acid sequences that are essential for the formation of Lp(a).	UNIV CALIF SAN FRANCISCO, DEPT MED, GLADSTONE INST CARDIOVASC DIS, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, INST CARDIOVASC RES, SAN FRANCISCO, CA 94141 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; UNIV TEXAS, SW MED CTR, DALLAS, TX 75235 USA; Scripps Res Inst, DEPT VASC BIOL IMM17, LA JOLLA, CA 92037 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; Scripps Research Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Scripps Research Institute				Young, Stephen/0000-0001-7270-3176	NHLBI NIH HHS [HL41633, HL-02925] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633, K08HL002925] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG VW, 1985, J LIPID RES, V26, P1314; BRUNNER C, 1993, P NATL ACAD SCI USA, V90, P11643, DOI 10.1073/pnas.90.24.11643; CHIESA G, 1992, J BIOL CHEM, V267, P24369; COLEMAN RD, 1990, BIOCHIM BIOPHYS ACTA, V1037, P129, DOI 10.1016/0167-4838(90)90111-R; CURTISS LK, 1982, J BIOL CHEM, V257, P5213; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; FERRIN LJ, 1991, SCIENCE, V254, P1494, DOI 10.1126/science.1962209; GUEVARA J, 1993, BIOPHYS J, V64, P686, DOI 10.1016/S0006-3495(93)81428-0; GUEVARA J, 1993, CIRCULATION, V88, P271; GUREWICH V, 1994, JAMA-J AM MED ASSOC, V271, P1025, DOI 10.1001/jama.271.13.1025; HARPEL PC, 1989, P NATL ACAD SCI USA, V86, P3847, DOI 10.1073/pnas.86.10.3847; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOGAN B, 1986, MANIPULATING MOUSE E; HORIE Y, 1992, J BIOL CHEM, V267, P1962; JAUHIAINEN M, 1991, ATHEROSCLEROSIS, V89, P59, DOI 10.1016/0021-9150(91)90007-P; KOSCHINSKY ML, 1993, J BIOL CHEM, V268, P19819; KOSTNER GM, 1981, ATHEROSCLEROSIS, V38, P51, DOI 10.1016/0021-9150(81)90103-9; KRUL ES, 1988, J LIPID RES, V29, P937; LAWN RM, 1992, SCI AM, V266, P54, DOI 10.1038/scientificamerican0692-54; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; LINTON MF, 1993, J LIPID RES, V34, P521; LINTON MF, 1992, P NATL ACAD SCI USA, V89, P11431, DOI 10.1073/pnas.89.23.11431; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MCLEOD RS, 1994, J BIOL CHEM, V269, P2852; PEASE RJ, 1990, J BIOL CHEM, V265, P553; RIDKER PM, 1993, JAMA-J AM MED ASSOC, V270, P2195, DOI 10.1001/jama.270.18.2195; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J, 1989, MOL CLONING LABORATO; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SCHEDL A, 1993, NATURE, V362, P258, DOI 10.1038/362258a0; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; STERNBERG N, 1994, MAMM GENOME, V5, P397, DOI 10.1007/BF00356999; STERNBERG NL, 1992, TRENDS GENET, V8, P11, DOI 10.1016/0168-9525(92)90018-Y; TRIEU VN, 1990, BIOCHEMISTRY-US, V29, P5919, DOI 10.1021/bi00477a006; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; UTERMANN G, 1987, J CLIN INVEST, V80, P458, DOI 10.1172/JCI113093; WELTY FK, 1991, J CLIN INVEST, V87, P1748, DOI 10.1172/JCI115193; YANG CY, 1990, P NATL ACAD SCI USA, V87, P5523, DOI 10.1073/pnas.87.14.5523; YAO ZM, 1991, J BIOL CHEM, V266, P3300; YOUNG SG, 1986, ARTERIOSCLEROSIS, V6, P178, DOI 10.1161/01.ATV.6.2.178; YOUNG SG, 1987, J CLIN INVEST, V79, P1831, DOI 10.1172/JCI113025; YOUNG SG, 1994, HUM MOL GENET, V3, P741; YOUNG SG, 1988, SCIENCE, V241, P591, DOI 10.1126/science.3399894; YOUNG SG, 1986, J BIOL CHEM, V261, P2995	44	45	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24284	24289						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929084				2022-12-25	WOS:A1994PQ34600067
J	XU, HX; SHIELDS, D				XU, HX; SHIELDS, D			PROSOMATOSTATIN PROCESSING IN PERMEABILIZED CELLS - ENDOPROTEOLYTIC CLEAVAGE IS MEDIATED BY A VACUOLAR ATPASE THAT GENERATES AN ACIDIC PH IN THE TRANS-GOLGI NETWORK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROINJECTED XENOPUS OOCYTES; PROHORMONE CONVERTASES PC1; SITE-DIRECTED MUTAGENESIS; ISLET SECRETORY GRANULES; HAMSTER OVARY CELLS; PROPROTEIN CONVERTASE; SUBTILISIN FAMILY; VESICLE MEMBRANE; H+-ATPASE; PROINSULIN	To investigate the relationship between prohormone processing and sorting of mature polypeptides into nascent secretory vesicles, we recently developed a permeabilized cell system that supports both these reactions (Xu, H., and Shields, D. (1993) J. Cell Biol. 122, 1169-1184). Rat anterior pituitary GH(3) cells expressing high levels of prosomatostatin (proSRIF) were incubated at 20 degrees C; this temperature prevented exit from the trans-Golgi network and inhibited proSRIF processing. Following the 20 degrees C block, the cells mere mechanically permeabilized and incubated at 37 degrees C, and proSRIF processing was determined. Cleavage of proSRIF to the mature hormone required ATP hydrolysis and was inhibited by chloroquine, a weak base, or carbonyl cyanide m-chlorophenylhydrazone, a protonophore. This suggested that a proton gradient and/or an acidic pH facilitated by a vacuolar H+-ATPase was required for prohormone processing. We have now utilized the permeabilized cell system in conjunction with the antibiotic bafilomycin A(1), a specific inhibitor of vacuolar H+-ATPases, to elucidate the role of acidic pH in prohormone processing. Here we report that (i) proSRIF processing was inhibited in vivo and in vitro by low concentrations of bafilomycin A(1), confirming the involvement of a vacuolar type ATPase in prohormone processing; (ii) the ATP requirement for processing could be circumvented in vitro by incubating permeabilized cells at acidic pH in the presence of protonophores, indicating that an acidic pH rather than a H+ gradient is necessary for processing; and (iii) a pH of between 6 and 6.2 in the trans-Golgi network was optimal for proSRIF cleavage. We also demonstrate that prohormone convertase 2 exhibited temperature-dependent activity in which proSRIF processing was inhibited at 20 degrees C in vitro. This result explains our previous observation that prohormone processing is inhibited when intact cells are incubated at 20 degrees C.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT DEV & MOLEC BIOL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT ANAT & STRUCT BIOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine			Xu, Huaxi/AAV-7177-2021		NCI NIH HHS [P30CA13330] Funding Source: Medline; NIDDK NIH HHS [DK21860] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK021860, R01DK021860] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALARCON C, 1993, J BIOL CHEM, V268, P4276; ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; BAILYES EM, 1992, BIOCHEM J, V285, P391, DOI 10.1042/bj2850391; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BRESLIN MB, 1993, J BIOL CHEM, V268, P27084; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DIPAOLA M, 1984, J BIOL CHEM, V259, P9163; FLETCHER DJ, 1981, J CELL BIOL, V90, P312, DOI 10.1083/jcb.90.2.312; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FRICKER LD, 1990, J BIOL CHEM, V265, P2476; GERDES HH, 1989, J BIOL CHEM, V264, P12009; GLICKMAN J, 1983, J CELL BIOL, V97, P1303, DOI 10.1083/jcb.97.4.1303; GUEST PC, 1992, J BIOL CHEM, V267, P22401; HAASS C, 1993, J BIOL CHEM, V268, P3021; HUTTON JC, 1982, BIOCHEM J, V204, P171, DOI 10.1042/bj2040171; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; JUNG LJ, 1991, SCIENCE, V251, P1330, DOI 10.1126/science.2003219; KELLY R B, 1991, Current Opinion in Cell Biology, V3, P654, DOI 10.1016/0955-0674(91)90037-Y; KIELIAN M, 1994, IN PRESS ADV VIRUS R; LINDBERG I, 1992, BIOCHEM BIOPH RES CO, V183, P1, DOI 10.1016/0006-291X(92)91599-L; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; MAINS RE, 1988, J BIOL CHEM, V263, P7887; MARQUEZSTERLING N, 1991, EUR J CELL BIOL, V56, P19; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MOORE HP, 1983, NATURE, V302, P434, DOI 10.1038/302434a0; NAKAGAWA T, 1993, FEBS LETT, V327, P165, DOI 10.1016/0014-5793(93)80163-O; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; PARISH DC, 1986, J BIOL CHEM, V261, P4392; RHODES CJ, 1987, J BIOL CHEM, V262, P10712; SCHMID S, 1989, J CELL BIOL, V108, P1291, DOI 10.1083/jcb.108.4.1291; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHEN FS, 1993, J BIOL CHEM, V268, P24910; SHENNAN KIJ, 1991, J BIOL CHEM, V266, P24011; SHENNAN KIJ, 1991, FEBS LETT, V284, P277, DOI 10.1016/0014-5793(91)80703-6; SOSSIN WS, 1990, J CELL BIOL, V110, P1, DOI 10.1083/jcb.110.1.1; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STOLLER TJ, 1989, J BIOL CHEM, V264, P6922; STOLLER TJ, 1988, J CELL BIOL, V107, P2087, DOI 10.1083/jcb.107.6.2087; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; TORII S, 1993, FEBS LETT, V316, P12, DOI 10.1016/0014-5793(93)81726-G; UMATA T, 1990, J BIOL CHEM, V265, P21940; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; XU H, 1994, IN PRESS BIOCHIMIE P; XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169; YI Z, 1993, J BIOL CHEM, V268, P5615; YOO SH, 1993, BIOCHEMISTRY-US, V32, P8213, DOI 10.1021/bi00083a023; YOO SH, 1993, BIOCHIM BIOPHYS ACTA, V1179, P239, DOI 10.1016/0167-4889(93)90078-4; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; YOUNG GPH, 1988, P NATL ACAD SCI USA, V85, P9590, DOI 10.1073/pnas.85.24.9590; ZHOU A, 1993, J BIOL CHEM, V268, P1763	62	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22875	22881						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	7915719				2022-12-25	WOS:A1994PQ16300063
J	CHEN, YY; GILL, GN				CHEN, YY; GILL, GN			POSITIVE AND NEGATIVE REGULATORY ELEMENTS IN THE HUMAN ERBB-2 GENE PROMOTER	ONCOGENE			English	Article							FACTOR RECEPTOR PROMOTER; HUMAN-BREAST-CANCER; RNA POLYMERASE-II; NEU ONCOGENE; C-ERBB-2 PROTOONCOGENE; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; THYROID-HORMONE; PROTO-ONCOGENE; DNA	Analysis of the proximal promoter of the human erbB-2 gene identified a 100 bp region that enhanced activity of the proximal TATA box 200-fold. DNase I footprinting mapped three Sp1 binding sites within this 100 bp region but only one of these sites was of high affinity and strongly correlated to Sp1-dependent activity in who. This Sp1 site overlapped the distal of two similar palindromic sequences. The proximal palindrome did not bind Sp1 but overlaps the CAAT box. When placed in the context of a heterologous promoter, the palindrome functioned as a positive response element. However, removal of the 5' half of the proximal palindrome increased promoter activity indicating that it functions as an inhibitory element within the erbB-2 context. Using electrophoretic mobility shift assays, a nuclear protein was detected that bound to either the 5' or 3' half of the palindrome but not to both. Analysis of the function of mutant sequences revealed maximal activity when both halves of the palindrome were intact with decreased but significant activity persisting when the 3' half of the palindrome was disrupted. Disruption of the 5' half of the palindrome impaired activity to a greater extent. These studies indicate erbB-2 promoter activity is positively regulated by Sp1 and negatively regulated in a position-dependent context by a protein that binds to a palindromic sequence.	UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NIDDK NIH HHS [DK 13149] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013149, R37DK013149] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERTL AP, 1993, GENE, V136, P361, DOI 10.1016/0378-1119(93)90496-P; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; HUDSON LG, 1990, J BIOL CHEM, V265, P4389; ISHII S, 1987, P NATL ACAD SCI USA, V84, P4374, DOI 10.1073/pnas.84.13.4374; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEMOINE NR, 1990, ONCOGENE, V5, P237; LO K, 1991, MOL CELL BIOL, V11, P5229, DOI 10.1128/MCB.11.10.5229; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; PRADHY LC, 1982, CELL, V28, P865; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYA H, 1990, MOL CARCINOGEN, V3, P198, DOI 10.1002/mc.2940030406; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; TAL M, 1987, MOL CELL BIOL, V7, P2587; WHITE MRA, 1992, ONCOGENE, V7, P677; XU J, 1993, J BIOL CHEM, V268, P16065; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499	32	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2269	2276						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	7913545				2022-12-25	WOS:A1994NX62900019
J	SARKADI, B; MULLER, M; HOMOLYA, L; HOLLO, Z; SEPRODI, J; GERMANN, UA; GOTTESMAN, MM; PRICE, EM; BOUCHER, RC				SARKADI, B; MULLER, M; HOMOLYA, L; HOLLO, Z; SEPRODI, J; GERMANN, UA; GOTTESMAN, MM; PRICE, EM; BOUCHER, RC			INTERACTION OF BIOACTIVE HYDROPHOBIC PEPTIDES WITH THE HUMAN MULTIDRUG TRANSPORTER	FASEB JOURNAL			English	Article						MDR1; P-GLYCOPROTEIN; PEPTIDES; MULTIDRUG TRANSPORTER; ATPASE ACTIVITY; FLUORESCENT DYE EXTRUSION	P-GLYCOPROTEIN; RESISTANCE PUMP; INSECT CELLS; GENE; VINCRISTINE; EXPRESSION; INVITRO	In this report we demonstrate that various biologically active hydrophobic peptide derivatives, e.g., proteinase inhibitors, chemoattractants, ionophores, enkephalins, and immunosuppressants, stimulate a membrane ATPase activity associated with the human multidrug transporter (MDR1). The stimulation of the MDR1-ATPase by these agents does not correlate with their known biochemical or pharmacological activities but rather with their hydrophobicity. The peptides that show high-affinity interaction with the MDR1-ATPase also interfere strongly with fluorescent dye extrusion catalyzed by the multidrug transporter in intact cells and some have been shown to reverse drug resistance in cultured cells. These data suggest that several hydrophobic peptides behave as substrates of the multidrug transporter and may be used to modulate the chemotherapy resistance of tumor cells.	SEMMELWEIS UNIV MED, INST BIOCHEM 1, BUDAPEST, HUNGARY; NCI, BETHESDA, MD 20892 USA; UNIV N CAROLINA, CHAPEL HILL, NC 27599 USA	Semmelweis University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of North Carolina; University of North Carolina Chapel Hill	SARKADI, B (corresponding author), NATL INST HAEMATOL BLOOD TRANSFUS & IMMUNOL, DAROCZI 24, H-1113 BUDAPEST, HUNGARY.		Sarkadi, Balazs/I-5024-2013; Homolya, Laszlo/N-1154-2016	Homolya, Laszlo/0000-0003-1639-8140				AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; CALLAGHAN R, 1993, J BIOL CHEM, V268, P16059; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; DAOUD SS, 1989, CANCER RES, V49, P2661; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOLLO Z, 1993, IN PRESS BIOCH BIOPH; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MINTENIG GM, 1993, RECEPTOR CHANNEL, V1, P305; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; SAEKI T, 1993, J BIOL CHEM, V268, P6077; SARKADI B, 1992, J BIOL CHEM, V267, P2087; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SHARMA RC, 1992, J BIOL CHEM, V267, P5731; SLATER LM, 1986, J CLIN INVEST, V77, P1405, DOI 10.1172/JCI112450; SLOVAK ML, 1988, CANCER RES, V48, P2793; TARNAI I, 1990, J BIOL CHEM, V265, P16509; TSURUO T, 1983, CANCER RES, V43, P2905; TWENTYMAN PR, 1992, BIOCHEM PHARMACOL, V43, P109, DOI 10.1016/0006-2952(92)90668-9; VANDERBLIEK AM, 1989, ADV CANCER RES, V52, P165	25	89	93	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1994	8	10					766	770		10.1096/fasebj.8.10.7914178	http://dx.doi.org/10.1096/fasebj.8.10.7914178			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NY350	7914178				2022-12-25	WOS:A1994NY35000015
J	ZENG, XR; JIANG, YQ; ZHANG, SJ; HAO, HL; LEE, MYWT				ZENG, XR; JIANG, YQ; ZHANG, SJ; HAO, HL; LEE, MYWT			DNA-POLYMERASE-DELTA IS INVOLVED IN THE CELLULAR-RESPONSE TO UV DAMAGE IN HUMAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BUTYLPHENYL-DEOXYGUANOSINE TRIPHOSPHATE; PERMEABLE HUMAN-FIBROBLASTS; REPAIR SYNTHESIS; NUCLEAR ANTIGEN; EXCISION REPAIR; REPLICATION; PROTEIN; ALPHA; BETA; INHIBITION	We have used antibodies specific for either polymerase delta (pol delta) or its accessory protein, proliferating cell nuclear antigen (PCNA), to demonstrate that they can markedly inhibit the capacity of HeLa nuclear extracts to effect repair of UV-damaged plasmid DNA. This pro vides the first unambiguous evidence for the involvement of pol delta in DNA repair synthesis. The mRNA levels of both pol delta and PCNA were significantly stimulated subsequent to UV irradiation of cultured cells, providing the first evidence that the cellular response to UV damage may involve regulation of pol delta and PCNA at the gene level. Thus, DNA polymerase delta and its accessory proteins, in addition to their function in replicative DNA synthesis, also function in DNA repair synthesis.	UNIV MIAMI,SCH MED,DEPT MED R57,MIAMI,FL 33101	University of Miami					NIAID NIH HHS [AI 29158] Funding Source: Medline; NIGMS NIH HHS [GM 31973] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029158] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031973] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; BURGERS PMJ, 1990, EUR J BIOCHEM, V191, P617, DOI 10.1111/j.1432-1033.1990.tb19165.x; BYRNES JJ, 1976, BIOCHEMISTRY-US, V15, P2817, DOI 10.1021/bi00658a018; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; DRESLER SL, 1988, BIOCHEM PHARMACOL, V37, P1033, DOI 10.1016/0006-2952(88)90506-0; DRESLER SL, 1988, BIOCHEMISTRY-US, V27, P7247, DOI 10.1021/bi00419a011; DRESLER SL, 1986, NUCLEIC ACIDS RES, V14, P7093, DOI 10.1093/nar/14.17.7093; FORNACE AJ, 1989, MOL CELL BIOL, V9, P851, DOI 10.1128/MCB.9.2.851; HAMMOND RA, 1990, BIOCHEMISTRY-US, V29, P286, DOI 10.1021/bi00453a039; HAO HL, 1992, CHROMOSOMA, V102, pS121, DOI 10.1007/BF02451795; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; KEDAR PS, 1991, P NATL ACAD SCI USA, V88, P3729, DOI 10.1073/pnas.88.9.3729; KEENEY S, 1990, MUTAT RES, V236, P239, DOI 10.1016/0921-8777(90)90008-S; KELLY TJ, 1988, J BIOL CHEM, V263, P17889; LEE MYWT, 1989, ARCH BIOCHEM BIOPHYS, V272, P1, DOI 10.1016/0003-9861(89)90187-2; LEE MYWT, 1991, J BIOL CHEM, V266, P2423; LEE MYWT, 1987, BIOCHEMISTRY-US, V26, P1076, DOI 10.1021/bi00378a014; LEE MYWT, 1985, NUCLEIC ACIDS RES, V13, P8623, DOI 10.1093/nar/13.23.8623; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; MIURA M, 1992, EXP CELL RES, V201, P541, DOI 10.1016/0014-4827(92)90308-U; NAZIMIEC M, 1992, J BIOL CHEM, V267, P24716; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; NISHIDA C, 1988, J BIOL CHEM, V263, P501; OHNISHI T, 1990, NUCLEIC ACIDS RES, V18, P5673, DOI 10.1093/nar/18.19.5673; POPANDA O, 1992, BIOCHIM BIOPHYS ACTA, V1129, P155, DOI 10.1016/0167-4781(92)90480-N; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PROSPERI E, 1993, EXP CELL RES, V205, P320, DOI 10.1006/excr.1993.1092; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SWEASY JB, 1993, P NATL ACAD SCI USA, V90, P4626, DOI 10.1073/pnas.90.10.4626; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TYRRELL RM, 1987, CANCER RES, V47, P3725; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; WOOD RD, 1989, BIOCHEMISTRY-US, V28, P8287, DOI 10.1021/bi00447a005; YANG CL, 1992, NUCLEIC ACIDS RES, V20, P735, DOI 10.1093/nar/20.4.735; YANG CL, 1991, BIOCHEMISTRY-US, V30, P7534, DOI 10.1021/bi00244a024	41	105	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13748	13751						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	7910606				2022-12-25	WOS:A1994NL60600007
J	WANG, KY; SPECTOR, A				WANG, KY; SPECTOR, A			THE CHAPERONE ACTIVITY OF BOVINE ALPHA-CRYSTALLIN - INTERACTION WITH OTHER LENS CRYSTALLINS IN NATIVE AND DENATURED STATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CRYSTALLIN; A-CRYSTALLIN; HEAT-SHOCK; QUATERNARY STRUCTURE; CATARACT FORMATION; PROTEIN; TISSUES; GENE; PHOSPHORYLATION; DIFFERENTIATION	It has previously been reported that alpha crystallin (alpha) a major lens protein composed of alpha(A) and alpha(B) subunits, can act as a chaperone interacting with other proteins to prevent heat-induced insolubilization. It is now shown that with gamma (gamma), beta(L) (beta(L)), and beta(H) (beta(H)), other major crystallin groups, this interaction occurs exclusively with soluble denatured protein. Based on studies primarily conducted with the gamma and the beta(L) crystallins, there is at least one binding site per alpha monomer (alpha(m)). This conclusion is derived from the following evidence. The binding of soluble denatured protein to alpha increases in a linear stoichiometric manner until a 1:1 ratio of alpha(m) to gamma or to the presumed (beta(L))(m) is achieved. This is based upon determination of the apparent molecular weight of the a denatured protein aggregate with a calibrated TSK-G4000 SW column and on the determination of the relative masses from the areas of the aggregate peak and those of the reactants. SDS-polyacrylamide gel electrophoresis confirms that the aggregates contain the presumed components following reaction with either gamma, beta(L), or beta(H). Studies in which gamma or beta(L) crystallins have been independently heat denatured indicate that species representing 50% of the gamma population and 30% of beta(L) population have not heat denatured under the conditions employed. When the abundance of the denatured soluble protein exceeds that of the alpha subunits present in the macromolecular complex, further interaction occurs leading to a loss of solubility of the complex. A small increase in the size of the complex remaining in solution is also observed. The results contribute to understanding earlier observations that soluble native low molecular weight alpha species cannot be found in the inner regions of old human lenses but have shifted to large aggregates containing other crystallin components. The work tentatively suggests that the interaction rates of alpha with denatured soluble crystallins are gamma > beta(L) > beta(H).	COLUMBIA UNIV,COLL PHYS & SURG,DEPT OPHTHALMOL,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10032	Columbia University								AGARD DA, 1993, SCIENCE, V260, P1903, DOI 10.1126/science.8100365; AUGUSTEYN RC, 1987, FEBS LETT, V222, P1, DOI 10.1016/0014-5793(87)80180-1; AUGUSTEYN RC, 1971, BIOCHEM J, V124, P345, DOI 10.1042/bj1240345; BERBERS GAM, 1984, EUR J BIOCHEM, V139, P467, DOI 10.1111/j.1432-1033.1984.tb08029.x; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; Bloemendal H, 1981, MOL CELLULAR BIOL EY, P1; BOYLE D, 1993, BIOCHEM BIOPH RES CO, V192, P1147, DOI 10.1006/bbrc.1993.1536; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BRAKENHOFF RH, 1990, HUM GENET, V85, P237, DOI 10.1007/BF00193203; CARVER JA, 1993, BIOCHIM BIOPHYS ACTA, V1164, P22, DOI 10.1016/0167-4838(93)90107-3; CHIESA R, 1987, BIOCHEM BIOPH RES CO, V144, P1340, DOI 10.1016/0006-291X(87)91457-4; CHIESA R, 1987, CURR EYE RES, V6, P539, DOI 10.3109/02713688709025211; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; de Jong W W, 1974, Eur J Biochem, V48, P271; De Jong W.W., 1981, MOL CELLULAR BIOL EY, P221, DOI DOI 10.1146/ANNUREV.ECOLSYS.33.020602.095451; DELCOUR J, 1974, BIOCHEM BIOPH RES CO, V57, P134, DOI 10.1016/S0006-291X(74)80367-0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; GARNER WH, 1978, P NATL ACAD SCI USA, V75, P3618, DOI 10.1073/pnas.75.8.3618; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAWKINS JW, 1987, HUM GENET, V76, P375, DOI 10.1007/BF00272448; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HORWITZ J, 1992, CURR EYE RES, V11, P817, DOI 10.3109/02713689209000754; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; HORWITZ J, 1993, INVEST OPHTH VIS SCI, V34, P10; INAGUMA Y, 1992, BIOCHEM BIOPH RES CO, V182, P844, DOI 10.1016/0006-291X(92)91809-5; IWAKI T, 1992, AM J PATHOL, V140, P345; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JAENICKE R, 1993, CHEMTRACTS BIOCH MOL, V4, P1; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KATO K, 1993, BIOCHIM BIOPHYS ACTA, V1175, P257, DOI 10.1016/0167-4889(93)90214-A; KLEMENZ R, 1991, MOL CELL BIOL, V11, P803, DOI 10.1128/MCB.11.2.803; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE J, 1990, LANCET, V336, P515, DOI 10.1016/0140-6736(90)92075-S; MAITI M, 1988, FEBS LETT, V236, P109, DOI 10.1016/0014-5793(88)80295-3; MASTERS PM, 1977, NATURE, V268, P71, DOI 10.1038/268071a0; MERCK KB, 1993, J BIOL CHEM, V268, P1046; NGO JT, 1989, GENOMICS, V5, P665, DOI 10.1016/0888-7543(89)90106-7; PERRY RE, 1986, J CHROMATOGR, V351, P103, DOI 10.1016/S0021-9673(01)83476-2; RAO PV, 1993, BIOCHEM BIOPH RES CO, V190, P786, DOI 10.1006/bbrc.1993.1118; RENKAWEK K, 1992, ACTA NEUROPATHOL, V83, P324, DOI 10.1007/BF00296796; ROQUEMORE EP, 1992, J BIOL CHEM, V267, P555; ROY D, 1976, P NATL ACAD SCI USA, V73, P3484, DOI 10.1073/pnas.73.10.3484; ROY D, 1976, BIOCHEMISTRY-US, V15, P1180, DOI 10.1021/bi00650a034; SIEZEN RJ, 1980, EUR J BIOCHEM, V111, P435, DOI 10.1111/j.1432-1033.1980.tb04958.x; SPECTOR A, 1971, BIOCHEM J, V124, P337, DOI 10.1042/bj1240337; SPECTOR A, 1985, P NATL ACAD SCI USA, V82, P4712, DOI 10.1073/pnas.82.14.4712; SPECTOR A, 1976, INVEST OPHTH VISUAL, V15, P288; SPECTOR A, 1968, INVEST OPHTH VISUAL, V7, P179; SPECTOR A, 1967, J BIOL CHEM, V242, P3594; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; TARDIEU A, 1986, J MOL BIOL, V192, P711, DOI 10.1016/0022-2836(86)90023-9; VANDENHEUVEL R, 1985, J MOL BIOL, V185, P273, DOI 10.1016/0022-2836(85)90403-6; VANKLEEF FS, 1974, EUR J BIOCHEM, V48, P563; VERMORKEN AJM, 1978, J CELL BIOL, V76, P175, DOI 10.1083/jcb.76.1.175; VOORTER CEM, 1992, FEBS LETT, V309, P111, DOI 10.1016/0014-5793(92)81075-W; VOORTER CEM, 1987, FEBS LETT, V221, P249, DOI 10.1016/0014-5793(87)80935-3; WANG K, 1993, INVEST OPHTH VIS SCI, V34, P1340; WISTOW G, 1993, EXP EYE RES, V56, P729, DOI 10.1006/exer.1993.1090	59	185	187	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13601	13608						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	7909809				2022-12-25	WOS:A1994NK18400079
J	MATSUOKA, S; YAMAGUCHI, M; MATSUKAGE, A				MATSUOKA, S; YAMAGUCHI, M; MATSUKAGE, A			D-TYPE CYCLIN-BINDING REGIONS OF PROLIFERATING CELL NUCLEAR ANTIGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-AUXILIARY PROTEIN; EUKARYOTIC DNA-POLYMERASES; ESCHERICHIA-COLI; REPLICATION INVITRO; ACCESSORY PROTEINS; MOLECULAR-CLONING; PCNA; GENE; EXPRESSION; YEAST	Proliferating cell nuclear antigen (PCNA) is an auxiliary protein for DNA polymerase delta and is required for both DNA replication and DNA repair. PCNA forms complexes with D-type cyclins, candidate G1 cyclins in mammalian cells. To better understand the functions of the complexes, we examined interactions between PCNA and D-type cyclins, using in vitro-translated mouse PCNA and mouse cyclin D1 or D3 fused to glutathione S-transferase (GST). Analysis of a set of deletion mutants of PCNA revealed that either the N-terminal (residues 2-64) or the C-terminal (residues 197-228) region is necessary for association with D-type cyclins. The cyclin binding of the chimeric protein of the N-terminal (residues 1-68) or the C-terminal (residues 195-261) region of PCNA and rat DNA polymerase beta which does not bind to the cyclins by itself supports this notion. The purified recombinant mouse PCNA expressed in Escherichia coli bound to the D-type cyclin-GST fusion proteins, thereby suggesting that PCNA binds directly to D-type cyclins, without the requirement of other cellular factors. This is apparently the first report on the structure-function relationship of PCNA which may link DNA replication and DNA repair with cell cycle control.	AICHI CANC CTR, RES INST, CELL BIOL LAB, CHIKUSA KU, NAGOYA, AICHI 464, JAPAN; TOHOKU UNIV, INST CHEM REACT SCI, AOBA KU, SENDAI, MIYAGI 980, JAPAN	Aichi Cancer Center; Tohoku University								AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BAUER GA, 1990, NUCLEIC ACIDS RES, V18, P261, DOI 10.1093/nar/18.2.261; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; DATE T, 1991, BIOCHEMISTRY-US, V30, P5286, DOI 10.1021/bi00235a023; DATE T, 1990, GENE, V90, P141, DOI 10.1016/0378-1119(90)90450-6; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; HANNA Z, 1993, ONCOGENE, V8, P1661; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; LEIBOVICI M, 1990, DEV BIOL, V141, P183, DOI 10.1016/0012-1606(90)90113-W; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LIU YC, 1989, BIOCHEMISTRY-US, V28, P2967, DOI 10.1021/bi00433a034; MATSUMOTO K, 1987, EMBO J, V6, P637, DOI 10.1002/j.1460-2075.1987.tb04802.x; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NG L, 1993, J BIOL CHEM, V268, P13571; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUZUKA I, 1991, EUR J BIOCHEM, V195, P571, DOI 10.1111/j.1432-1033.1991.tb15739.x; SUZUKA I, 1989, P NATL ACAD SCI USA, V86, P3189, DOI 10.1073/pnas.86.9.3189; TAN CK, 1986, J BIOL CHEM, V261, P2310; TRAVALI S, 1989, J BIOL CHEM, V264, P7466; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; WASEEM NH, 1992, EMBO J, V11, P5111, DOI 10.1002/j.1460-2075.1992.tb05618.x; WASEEM NH, 1990, J CELL SCI, V96, P121; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YAMAGUCHI M, 1990, MOL CELL BIOL, V10, P872, DOI 10.1128/MCB.10.3.872; YAMAGUCHI M, 1991, NUCLEIC ACIDS RES, V19, P2403, DOI 10.1093/nar/19.9.2403; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; [No title captured]	40	89	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11030	11036						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7908906				2022-12-25	WOS:A1994NF96600013
J	GUY, HI; EVANS, DR				GUY, HI; EVANS, DR			CLONING, EXPRESSION, AND FUNCTIONAL INTERACTIONS OF THE AMIDOTRANSFERASE DOMAIN OF MAMMALIAN CAD CARBAMYL-PHOSPHATE SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIFUNCTIONAL PROTEIN CAD; INITIATES PYRIMIDINE BIOSYNTHESIS; EHRLICH ASCITES-CARCINOMA; GLUTAMINE BINDING-SITE; ESCHERICHIA-COLI; ASPARTATE-TRANSCARBAMYLASE; REVERSIBLE DISSOCIATION; SERRATIA-MARCESCENS; CYSTEINE RESIDUE; HAMSTER CELLS	The trpG-type amidotransferases, a homologous but structurally diverse family of molecules, catalyze glutamine hydrolysis to supply ammonia for many biosynthetic reactions. The amidotransferase or glutaminase (GLNase) domain of mammalian carbamyl phosphate synthetase (CPSase), part of a 243-kDa polypeptide that initiates de novo pyrimidine biosynthesis, has been cloned and expressed in Escherichia coli. Complementation studies showed that a functional protein was produced in vivo which could provide ammonia for carbamyl phosphate synthesis by the host CPSase synthetase subunit. The recombinant 38-kDa protein was identified by immunoblotting, but when purified to homogeneity, had marginal glutaminase activity. Titration of the E. coli CPSase synthetase subunit with the mammalian GLNase domain resulted in the formation of a fully active 1:1 stoichiometric stable complex which catalyzed the glutamine-dependent overall reaction. The hybrid, isolated by gel filtration, had kinetic parameters (K-m(GLN) = 102 mu M, K-m(ATP) = 1.8 mM, k(cat) = 5.7 s-(1)) similar to those of the native E. coli CPSase. Thus, the amidotransferase activity of mammalian CPSase is carried by an autonomous domain which folds independently. However, optimal catalytic activity requires association of the glutaminase and synthetase domains. The conservation of this linkage in the mammalian E. coli hybrid suggests that the subunit interfaces must be nearly identical in the eukaryotic and prokaryotic proteins.			GUY, HI (corresponding author), WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM, DETROIT, MI 48201 USA.							ANDERSON PM, 1973, BIOCHEM BIOPH RES CO, V55, P246, DOI 10.1016/S0006-291X(73)80086-5; ANDERSON PM, 1975, BIOCHEMISTRY-US, V14, P3688, DOI 10.1021/bi00687a027; ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3157, DOI 10.1021/bi00874a012; ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3164, DOI 10.1021/bi00874a013; BEIN K, 1991, J BIOL CHEM, V266, P3791; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPARIAN MG, 1991, J BIOL CHEM, V266, P3387; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; GOTO Y, 1976, J BIOL CHEM, V251, P941; GRAYSON DR, 1985, J BIOL CHEM, V260, P5840; GUILLOU F, 1989, P NATL ACAD SCI USA, V86, P8304, DOI 10.1073/pnas.86.21.8304; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; Hartman SC, 1973, ENZYMES GLUTAMINE ME, P319; HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7; HOOGENRAAD NJ, 1971, BIOCHEM BIOPH RES CO, V44, P981, DOI 10.1016/0006-291X(71)90808-4; KAWAMURA M, 1978, J BIOL CHEM, V253, P4659; KELLY RE, 1986, THESIS WAYNE STATE U; KHEDOURI E, 1966, BIOCHEMISTRY-US, V5, P3552, DOI 10.1021/bi00875a024; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE L, 1985, P NATL ACAD SCI USA, V82, P6802, DOI 10.1073/pnas.82.20.6802; MALLY MI, 1980, J BIOL CHEM, V255, P1372; Maniatis T., 1982, MOL CLONING; MEISTER A, 1989, ADV ENZYMOL RAMB, V62, P315; MIRAN SG, 1991, BIOCHEMISTRY-US, V30, P7901, DOI 10.1021/bi00246a005; MORI M, 1975, BIOCHEMISTRY-US, V14, P2622, DOI 10.1021/bi00683a010; NICHOLS BP, 1980, J MOL BIOL, V142, P503, DOI 10.1016/0022-2836(80)90260-0; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; PALUH JL, 1985, J BIOL CHEM, V260, P1889; PAUKERT JL, 1982, ARCH BIOCHEM BIOPHYS, V218, P443, DOI 10.1016/0003-9861(82)90366-6; PERBAL B, 1988, PRACTICAL GUIDE MOL, P305; PINKUS LM, 1972, J BIOL CHEM, V247, P6119; RAUSHEL FM, 1978, BIOCHEMISTRY-US, V17, P5587, DOI 10.1021/bi00619a001; RUBINO SD, 1987, J BIOL CHEM, V262, P4382; RUBINO SD, 1986, J BIOL CHEM, V261, P1320; SHOAF WT, 1973, BIOCHEMISTRY-US, V12, P4039, DOI 10.1021/bi00745a004; SHOAF WT, 1971, BIOCHEM BIOPH RES CO, V45, P796; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; SIMMER JP, 1990, P NATL ACAD SCI USA, V87, P174, DOI 10.1073/pnas.87.1.174; SIMMER JP, 1989, P NATL ACAD SCI USA, V86, P4382, DOI 10.1073/pnas.86.12.4382; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROTTA PP, 1971, P NATL ACAD SCI USA, V68, P2599, DOI 10.1073/pnas.68.10.2599; TROTTA PP, 1974, J BIOL CHEM, V249, P492; TSO JY, 1980, J BIOL CHEM, V255, P1451; WELLNER VP, 1975, J BIOL CHEM, V250, P3261; WENG M, 1987, J BACTERIOL, V169, P3023, DOI 10.1128/jb.169.7.3023-3028.1987; ZALKIN H, 1980, MULTIFUNCTIONAL PROT, P123	46	16	16	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7702	7708						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7907330				2022-12-25	WOS:A1994NA03200104
J	PUIG, A; GILBERT, HF				PUIG, A; GILBERT, HF			PROTEIN DISULFIDE-ISOMERASE EXHIBITS CHAPERONE AND ANTI-CHAPERONE ACTIVITY IN THE OXIDATIVE REFOLDING OF LYSOZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; AGGREGATION; CATALYSIS; BONDS; REDUCTION; RESIDENT; SEQUENCE; BINDING; LUMEN	Reduced, denatured lysozyme tends to aggregate at neutral pH, and competition between productive folding and aggregation substantially reduces the efficiency of refolding (Goldberg, M. E., Rudolph; R., and Jaenicke, R. (1991) Biochemistry 30, 2790-2797). Protein disulfide isomerase (PDI), a catalyst of oxidative protein folding, has a variety of effects on the yield of native lysozyme during the oxidative refolding of the reduced, denatured protein. Depending on the concentration of lysozyme, the concentration of PDI, and the order in which lysozyme and PDI are added to initiate folding, PDI can produce a substantial increase or a substantial decrease in the recovery of native lysozyme, when compared with the uncatalyzed reaction. In the presence of a glutathione redox buffer, denatured lysozyme (1-10 mu M) partitions almost equally between productive folding leading to native lysozyme (50-63%) and non-productive fates including the formation of disulfide cross-linked aggregates. At the higher lysozyme concentrations examined (5-10 mu M), substoichiometric concentrations of PDI (0.5-1 mu M) exhibit ''anti-chaperone'' activity; PDI actively diverts most of the denatured lysozyme away from productive folding so that only 17 +/- 9% of the lysozyme is recovered as native enzyme, PDI's anti-chaperone activity results in extensive intermolecular disulfide crosslinking of lysozyme into large, inactive aggregates. On the other hand, if PDI is initially present at a large molar excess (5-10-fold) when denatured lysozyme is diluted to initiate folding, PDI demonstrates a chaperone-like activity that prevents aggregate formation and promotes correct folding. When PDI's chaperone activity is dominant, virtually all of the denatured lysozyme is correctly folded. The schizophrenic chaperone/anti-chaperone nature of PDI activity accounts for a number of observations on in vivo protein folding, including the necessity for maintaining a high concentration of PDI in the endoplasmic reticulum and the formation of disulfide cross-linked aggregates in the endoplasmic reticulum during the expression of disulfide containing proteins (deSilva, A., Braakman, I., and Helenius, A. (1993) J. Cell. Biol. 120, 647-655).	BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030	Baylor College of Medicine					NIGMS NIH HHS [GM40379] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040379] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; DESILVA A, 1993, J CELL BIOL, V120, P647, DOI 10.1083/jcb.120.3.647; DORNER AJ, 1988, MOL CELL BIOL, V8, P4063, DOI 10.1128/MCB.8.10.4063; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gilbert H F, 1991, Protein Expr Purif, V2, P194, DOI 10.1016/1046-5928(91)90071-P; GILBERT HF, 1989, BIOCHEMISTRY-US, V28, P7298, DOI 10.1021/bi00444a023; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; GUNTHER R, 1993, J BIOL CHEM, V268, P7728; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; HUTH JR, 1993, J BIOL CHEM, V268; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; KNOWLES JR, 1977, ACCOUNTS CHEM RES, V10, P105, DOI 10.1021/ar50112a001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; LODISH HF, 1993, J BIOL CHEM, V268; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; NOIVA R, 1992, J BIOL CHEM, V267, P3553; NOIVA R, 1991, J BIOL CHEM, V266, P19645; PACE M, 1979, INT J PEPT PROT RES, V14, P409; PUIG A, 1992, ASBMB KEYSTONE S MOL, P59; SAXENA VP, 1970, BIOCHEMISTRY-US, V9, P5015; SCHERENS B, 1991, YEAST, V7, P185, DOI 10.1002/yea.320070212; VAN PN, 1993, EUR J BIOCHEM, V213, P789, DOI 10.1111/j.1432-1033.1993.tb17821.x; VUORI K, 1992, J BIOL CHEM, V267, P7211; WETLAUFER DB, 1974, LYSOZYME, P269; ZAPUN A, 1992, PROTEINS, V14, P10, DOI 10.1002/prot.340140104	34	249	266	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7764	7771						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7907332				2022-12-25	WOS:A1994NA03200112
J	HANSEN, JE; GAFNI, A				HANSEN, JE; GAFNI, A			FLUORESCENCE DETECTION OF CONFORMATIONAL-CHANGES IN GROEL INDUCED BY THERMAL SWITCHING AND NUCLEOTIDE-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ESCHERICHIA-COLI; MOLECULAR CHAPERONE; ATP HYDROLYSIS; PROTEIN; COOPERATIVITY; CARBOXYLASE; PRECURSOR; INVITRO	GroEL assists other proteins to fold in vivo, usually requiring Mg2+ and ATP to function. Electron micrographs reveal that ATP binding induces a conformational change in this protein. Previously we have suggested that a thermally induced conformational change in GroEL results in the switching between enhanced and arrested reactivation of bacterial glucose-6-phosphate dehydrogenase. This thermal switching occurs over a narrow temperature range (25-30 degrees C). Recently it has also been reported that the binding affinity of the P22 tail spike polypeptide to GroEL changes abruptly over this same temperature range. To determine whether these conformational changes occur in GroEL in solution in absence of folding intermediates, the protein was stoichiometrically labelled with AEDANS (N-(acetylaminoacyl)-5-naphthalene-1-sulfonic acid), a fluorescent label whose emission is environment sensitive. By measuring changes in the fluorescence Stokes shift we have detected two thermally induced conformational changes between 25 and 30 degrees C. The first change occurs between 25 and 26 degrees C, resulting in less than a 1-nm shift in the fluorescence. The second conformational change occurs between 27 and 30 degrees C, re suiting in a 3-nm fluorescence shift. The conformational change induced by ATP binding also results in a 3-nm shift in fluorescence. Our data provide a correlation between functional change and structural change in GroEL.	UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, INST GERONTOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NIA NIH HHS [AG09761, T32AG00114] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009761, T32AG000114] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HANSEN JE, 1993, J BIOL CHEM, V268, P21632; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HUDSON EN, 1973, BIOCHEMISTRY-US, V12, P4154, DOI 10.1021/bi00745a019; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; MACGREGOR RB, 1986, NATURE, V319, P70, DOI 10.1038/319070a0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; SAIBIL H, 1993, CURR OPIN STRUC BIOL, V3, P207, DOI 10.1016/S0959-440X(05)80154-X; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VANDERVIES SM, 1993, ACS SYM SER, V526, P72; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021	24	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6286	6289						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7907093				2022-12-25	WOS:A1994MZ50300008
J	CHABRE, O; CONKLIN, BR; BRANDON, S; BOURNE, HR; LIMBIRD, LE				CHABRE, O; CONKLIN, BR; BRANDON, S; BOURNE, HR; LIMBIRD, LE			COUPLING OF THE ALPHA(2A)-ADRENERGIC RECEPTOR TO MULTIPLE G-PROTEINS - A SIMPLE APPROACH FOR ESTIMATING RECEPTOR-G-PROTEIN COUPLING EFFICIENCY IN A TRANSIENT EXPRESSION SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; BETA-ADRENERGIC RECEPTORS; CYCLIC-AMP ACCUMULATION; ADENYLATE-CYCLASE; ALPHA-2-ADRENERGIC RECEPTORS; CALCIUM CURRENTS; ALPHA-SUBUNITS; LIGAND-BINDING; ACTIVATION; CELLS	It is now widely appreciated that G-protein-coupled cell-surface receptors can modulate distinct signal transduction pathways via coupling to different GTP-binding proteins. In the present study, we have used a transient co expression approach to study the coupling of a single alpha(2)-adrenergic receptor (alpha(2A)AR) population to three different G protein subtypes (G(i), C-q, and G(s)) acting on two different cellular effecters in HER 293 cells. In all cases, the affinity of the receptor for the alpha(2A)-adrenergic agonist, UK14304, is unchanged (K-D congruent to 670 nM). However there is a dramatic difference in the EC(50) of UK14304 in eliciting inhibition of endogenous adenylyl cyclase via endogenous G(i) (0.09 nM) versus activation of phospholipase C via co-transfected G(q) (50 nm) or stimulation of endogenous adenylyl cyclase via co-transfected G(s) (70 nm) in HEK 293 cells. These findings are consistent with the interpretations that the alpha(2A)AR preferentially interacts with G(i) rather than G(s) or G(q). When the alpha(2A)AR was mutated at Asp(79), a residue highly conserved among G-protein-coupled receptors, the mutant D79N alpha(2A)AR lost the ability to couple to G,and G, and, although it was able to couple to inhibition of cyclase via pertussis toxin-sensitive pathways (Gi), it did so with a lower potency than observed for the wild-type alpha(2A)AR (EC(50) = 7.2 nM). The most straightforward interpretation of these data is that the D79N mutation in the alpha(2A)AR reduces the efficiency of coupling of the alpha(2A)AR to all G-proteins, thus eliminating signal transduction through those path ways less efficiently coupled to the alpha(2A)AR Since the transient expression assays described permit manipulation of the structure of both the receptor or the G-protein, the present strategies could be exploited to delineate the complementary domains specifying the affinity and/or efficacy of receptor coupling to distinct GTP-binding proteins.	VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37215; UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143	Vanderbilt University; University of California System; University of California San Francisco			Conklin, Bruce/E-4738-2019	CHABRE, Olivier/0000-0001-8756-7218; Conklin, Bruce/0000-0003-1463-6061	NCI NIH HHS [CA54427] Funding Source: Medline; NHLBI NIH HHS [K11HL02555] Funding Source: Medline; NIGMS NIH HHS [GM27800] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054427] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL002555] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027800, R37GM027800] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ASANO T, 1984, J BIOL CHEM, V259, P9351; ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BLACK JW, 1983, PROC R SOC SER B-BIO, V220, P141, DOI 10.1098/rspb.1983.0093; CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551; CHUNG FZ, 1988, J BIOL CHEM, V263, P4052; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; EASON MG, 1992, J BIOL CHEM, V267, P15795; FLORIO VA, 1985, J BIOL CHEM, V260, P3477; FRASER CM, 1989, MOL PHARMACOL, V36, P840; FRASER CM, 1989, J BIOL CHEM, V264, P11754; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; GUYER CA, 1990, J BIOL CHEM, V265, P17307; HERZOG H, 1992, P NATL ACAD SCI USA, V89, P5794, DOI 10.1073/pnas.89.13.5794; HORSTMAN DA, 1990, J BIOL CHEM, V265, P21590; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; LIMBIRD LE, 1988, FASEB J, V2, P2686, DOI 10.1096/fasebj.2.11.2840317; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; NUNNARI JM, 1987, J BIOL CHEM, V262, P12387; SMITH SK, 1981, P NATL ACAD SCI-BIOL, V78, P4026, DOI 10.1073/pnas.78.7.4026; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; SULLIVAN KA, 1986, P NATL ACAD SCI USA, V83, P6687, DOI 10.1073/pnas.83.18.6687; SURPRENANT A, 1992, SCIENCE, V257, P977, DOI 10.1126/science.1354394; VANSANDE J, 1990, MOL CELL ENDOCRINOL, V74, pR1, DOI 10.1016/0303-7207(90)90209-Q; WANG CD, 1991, MOL PHARMACOL, V40, P168; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0	31	144	145	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5730	5734						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7907086				2022-12-25	WOS:A1994MY84000041
J	FRODIN, M; PERALDI, P; VANOBBERGHEN, E				FRODIN, M; PERALDI, P; VANOBBERGHEN, E			CYCLIC-AMP ACTIVATES THE MITOGEN-ACTIVATED PROTEIN-KINASE CASCADE IN PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; ADENOSINE 3'-5'-CYCLIC MONOPHOSPHATE; MAP KINASE; ADENYLATE-CYCLASE; TYROSINE-HYDROXYLASE; NEURITE OUTGROWTH; PHEOCHROMOCYTOMA CELLS; RECEPTOR ACTIVATION; STIMULATED PROTEIN; PHOSPHORYLATION	Mitogen-activated protein (MAP) kinases are activated in response to a large variety of extracellular signals, including growth factors, hormones, and neurotransmitters, which activate distinct intracellular signaling pathways. Their activation by the cAMP-dependent pathway, however, has not been reported. In rat pheochromocytoma PC12 cells, we demonstrate here a stimulation of the MAP kinase isozyme extracellular signal-regulated kinase 1 (ERK1) following elevation of intracellular cAMP after exposure of the cells to isobutyl-methylxanthine, cholera toxin, forskolin, or cAMP-analogues. cAMP acted synergistically with phorbol ester, an activator of protein kinase C, in the stimulation of ERK1. In accordance with this observation, the peptide neurotransmitter pituitary adenylate cyclase-activating polypeptide 38 (PACAP38), which stimulates cAMP production as well as phosphatidylinositol breakdown in PC12 cells, was an efficient activator of ERK1. In combination with various growth factors, cAMP acted in a more than additive manner on ERK1 activity. Elevation of intracellular cAMP increased in vivo P-32-labeling of ERK1, suggesting that cAMP stimulated ERK1 by activating MAP kinase kinase, an immediate upstream activator of ERK1 in the MAP kinase cascade. Supporting this view, forskolin and a cAMP analogue were found to increase the activity of MAP kinase kinase in PC12 cells, alone as well as in combination with phorbol ester. PACAP38 also stimulated in vivo P-32-labeling of ERK1 and MAP kinase kinase activity. Finally, cAMP or PACAP38 increased by 3-fold nerve growth factor-stimulated neurite formation in PC12 cells, which may be correlated with the potentiating effect of these agents on nerve growth factor-stimulated ERK1 activity.	FAC MED NICE, INSERM, U145, F-06107 NICE 2, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur			Peraldi, Pascal/O-4592-2016	Peraldi, Pascal/0000-0003-0205-9252; Frodin, Morten/0000-0003-3691-9820				AHN NG, 1991, J BIOL CHEM, V266, P4220; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BEEBE SJ, 1986, ENZYMES, V17, P43; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRUGGEMANN A, 1993, NATURE, V365, P445, DOI 10.1038/365445a0; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUNNING PW, 1981, J CELL BIOL, V89, P240, DOI 10.1083/jcb.89.2.240; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HAYCOCK JW, 1990, J BIOL CHEM, V265, P11682; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; HAYCOCK JW, 1992, J NEUROCHEM, V58, P57, DOI 10.1111/j.1471-4159.1992.tb09276.x; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; ISOBE K, 1993, ENDOCRINOLOGY, V132, P1757, DOI 10.1210/en.132.4.1757; KAUFMAN S, 1985, FOLATE PTERINS, V2; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MONTAGUE W, 1971, BIOCHEM J, V122, P115, DOI 10.1042/bj1220115; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OHMICHI M, 1992, J BIOL CHEM, V267, P14604; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PIPER RC, 1993, J BIOL CHEM, V268, P16557; PISEGNA JR, 1993, P NATL ACAD SCI USA, V90, P6345, DOI 10.1073/pnas.90.13.6345; Posternak T, 1974, Methods Enzymol, V38, P399; PRASAD KN, 1971, NATURE-NEW BIOL, V233, P141, DOI 10.1038/newbio233141a0; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RICHTERLANDSBERG C, 1986, J CELL BIOL, V102, P821, DOI 10.1083/jcb.102.3.821; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; SALOMON Y, 1991, METHODS ENZYMOL, V22; SCHUBERT D, 1978, NATURE, V273, P718, DOI 10.1038/273718a0; SCIMECA JC, 1992, J BIOL CHEM, V267, P17369; SCIMECA JC, 1991, BIOCHEMISTRY-US, V30, P9313, DOI 10.1021/bi00102a025; SEAMON K, 1981, J BIOL CHEM, V256, P9799; SEGER R, 1992, J BIOL CHEM, V267, P14373; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WATANABE T, 1992, BIOCHEM BIOPH RES CO, V182, P403, DOI 10.1016/S0006-291X(05)80159-7; WATANABE T, 1990, BIOCHEM BIOPH RES CO, V173, P252, DOI 10.1016/S0006-291X(05)81049-6; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU YY, 1993, J CELL BIOL, V121, P409, DOI 10.1083/jcb.121.2.409; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.ne.12.030189.002215	67	325	330	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6207	6214						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7907091				2022-12-25	WOS:A1994MY84000108
J	TAKEBAYASHI, K; SASAI, Y; SAKAI, Y; WATANABE, T; NAKANISHI, S; KAGEYAMA, R				TAKEBAYASHI, K; SASAI, Y; SAKAI, Y; WATANABE, T; NAKANISHI, S; KAGEYAMA, R			STRUCTURE, CHROMOSOMAL LOCUS, AND PROMOTER ANALYSIS OF THE GENE ENCODING THE MOUSE HELIX-LOOP-HELIX FACTOR HES-1 - NEGATIVE AUTOREGULATION THROUGH THE MULTIPLE N-BOX ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-MELANOGASTER; NERVOUS-SYSTEM; BINDING-SITE; TRANSCRIPTION; PROTEIN; SEGMENTATION; SELECTION; REPRESSOR; ENHANCER; HAIRY	HES-1 is a mammalian helix-loop-helix factor structurally related to the Drosophila hairy and Enhancer of split proteins. It binds more preferentially to the N box (CACNAG) than to the E box (CANNTG) and acts as a negative regulator. In this study, we have isolated and characterized the mouse HES-1 gene. This gene consists of four exons, and the positions of introns are well conserved when compared with those of the Drosophila hairy gene, except for the third intron. Southern blot and interspecies backcross analyses suggest that the mouse HES-1 gene is a single-copy gene and is located around position 26 on chromosome 16. The transcription initiation site, determined by the S1 nuclease and primer extension experiments, is located 31 nucleotides downstream of a TATA box. In the 5'-regulatory region, there are four N box sequences, and the DNase I footprinting and gel mobility shift analyses show that HES-1 binds to these sequences. Transient transfection assays using C3H10T1/2 cells suggest that there are several positive regulatory regions in the HES-1 gene. However, cotransfection of the Hes-1 expression vector leads to similar to-40-fold repression in promoter activity. Furthermore, when the N box sequences are disrupted, this negative regulation is severely impaired. These results raise the possibility that HES-1 gene expression may be negatively autoregulated through the N box sequences.	KYOTO UNIV,FAC MED,INST IMMUNOL,SAKYO KU,KYOTO 606,JAPAN; AICHI PREFECTURAL COLONY,INST DEV RES,DEPT BIOCHEM,KASUGAI,AICHI 48003,JAPAN	Kyoto University								AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; CAMPOSORTEGA JA, 1990, EUR J BIOCHEM, V190, P1, DOI 10.1111/j.1432-1033.1990.tb15538.x; EPSTEIN R, 1986, IMMUNOGENETICS, V23, P78, DOI 10.1007/BF00377965; FEDER JN, 1993, MOL CELL BIOL, V13, P105, DOI 10.1128/MCB.13.1.105; Green MC., 1989, GENETIC VARIANTS STR, P12; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; INGHAM PW, 1985, NATURE, V318, P439, DOI 10.1038/318439a0; ISHIBASHI M, 1993, EUR J BIOCHEM, V215, P645, DOI 10.1111/j.1432-1033.1993.tb18075.x; JAN YN, 1990, TRENDS NEUROSCI, V13, P493, DOI 10.1016/0166-2236(90)90083-M; JOHNSON FB, 1992, GENE DEV, V6, P2177, DOI 10.1101/gad.6.11.2177; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAGEYAMA R, 1987, J BIOL CHEM, V262, P2345; KLAMBT C, 1989, EMBO J, V8, P203, DOI 10.1002/j.1460-2075.1989.tb03365.x; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; TAKAHASHI K, 1992, EUR J BIOCHEM, V204, P1025, DOI 10.1111/j.1432-1033.1992.tb16724.x; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; WATANABE T, 1989, BIOCHEM GENET, V27, P689, DOI 10.1007/BF02396061	24	265	267	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5150	5156						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7906273				2022-12-25	WOS:A1994MX57100072
J	CHELEY, S; PANCHAL, RG; CARR, DW; SCOTT, JD; BAYLEY, H				CHELEY, S; PANCHAL, RG; CARR, DW; SCOTT, JD; BAYLEY, H			TYPE-II REGULATORY SUBUNITS OF CAMP-DEPENDENT PROTEIN-KINASE AND THEIR BINDING-PROTEINS IN THE NERVOUS-SYSTEM OF APLYSIA-CALIFORNICA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLEURAL SENSORY NEURONS; LONG-TERM SENSITIZATION; BOVINE CARDIAC-MUSCLE; HIGH-AFFINITY BINDING; 2 CATALYTIC SUBUNITS; BEHAVIORAL SENSITIZATION; TRANSMITTER RELEASE; SYNAPTIC FACILITATION; CYCLIC-AMP; MODULATION	Two type II regulatory (R) subunits of cAMP-dependent protein kinase (PKA) of 50 and 47 kDa have been identified in Aplysia neurons by several criteria which include phosphorylation by the catalytic subunit of PKA and nanomolar affinity for a peptide fragment of the human thyroid protein Ht 31, properties that in mammals distinguish type II from type I R subunits. The neuronal type II R subunits are differentially localized within cells. For example, the 50-kDa polypeptide is enriched in taxol-stabilized microtubules. In addition, at least seven high molecular mass neuronal RII-binding proteins ranging in mass from 110 to 420 kDa have been demonstrated by a blot overlay technique, which uses P-32-labeled bovine RIIalpha as a probe. The RII-binding proteins also exhibit discrete patterns of subcellular localization. For example, the 420 kDa species is enriched in taxol-stabilized microtubules and therefore may serve to anchor the 50-kDa RH subunit. The localization of PKA through the association of RII subunits with the binding proteins may anchor the multifunctional kinase close to key substrates and thereby contribute to the spatial organization required to mediate the orderly phosphorylation events that underly neuronal modulation.	WORCESTER FDN EXPTL BIOL INC,222 MAPLE AVE,SHREWSBURY,MA 01545; VOLLUM INST ADV BIOMED RES,PORTLAND,OR 97201	Worcester Foundation for Biomedical Research			Panchal, Rekha/None	Panchal, Rekha/0000-0001-8621-9078; Bayley, Hagan/0000-0003-2499-6116	NIGMS NIH HHS [GM 48231] Funding Source: Medline; NINDS NIH HHS [NS26760] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM048231, R01GM048231] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026760] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMBRON RT, 1992, J NEUROSCI, V12, P2813; ASZODI A, 1991, P NATL ACAD SCI USA, V88, P5832, DOI 10.1073/pnas.88.13.5832; BACSKAI BJ, 1993, SCIENCE, V260, P222, DOI 10.1126/science.7682336; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BAXTER DA, 1990, J NEUROPHYSIOL, V64, P978, DOI 10.1152/jn.1990.64.3.978; BAXTER DA, 1989, J NEUROPHYSIOL, V62, P665, DOI 10.1152/jn.1989.62.3.665; BERGOLD PJ, 1992, NEURON, V8, P387, DOI 10.1016/0896-6273(92)90304-V; BERNIER L, 1982, J NEUROSCI, V2, P1682; BEUSHAUSEN S, 1992, P NATL ACAD SCI USA, V89, P1641, DOI 10.1073/pnas.89.5.1641; BEUSHAUSEN S, 1988, NEURON, V1, P853, DOI 10.1016/0896-6273(88)90133-X; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; BRUNELLI M, 1976, SCIENCE, V194, P1178, DOI 10.1126/science.186870; BUXBAUM JD, 1989, J BIOL CHEM, V264, P9344; CARR DW, 1992, J BIOL CHEM, V267, P13376; CASTELLUCCI VF, 1982, J NEUROSCI, V2, P1673; CASTELLUCCI VF, 1980, P NATL ACAD SCI-BIOL, V77, P7492, DOI 10.1073/pnas.77.12.7492; CHELEY S, 1991, BIOTECHNIQUES, V10, P730; CHELEY S, 1991, BIOCHEMISTRY-US, V30, P10246, DOI 10.1021/bi00106a024; CHELEY S, 1992, J CELL SCI, V102, P739; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; CLARK GA, 1984, P NATL ACAD SCI-BIOL, V81, P2577, DOI 10.1073/pnas.81.8.2577; CLARK GA, 1993, IN PRESS P NATL ACAD; CORBIN JD, 1981, J BIOL CHEM, V256, P1671; DALE N, 1988, SCIENCE, V239, P282, DOI 10.1126/science.2892269; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; EMPTAGE NJ, 1993, SCIENCE, V262, P253, DOI 10.1126/science.8211146; EPPLER CM, 1986, J CELL BIOL, V102, P320, DOI 10.1083/jcb.102.1.320; GOLDSMITH BA, 1992, P NATL ACAD SCI USA, V89, P11481, DOI 10.1073/pnas.89.23.11481; GREENBERG SM, 1987, NATURE, V329, P62, DOI 10.1038/329062a0; HAWKINS RD, 1989, J NEUROSCI, V9, P4214; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HOCHNER B, 1992, P NATL ACAD SCI USA, V89, P11476, DOI 10.1073/pnas.89.23.11476; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; Kaczmarek LK, 1987, NEUROMODULATION BIOC; KALDERON D, 1988, GENE DEV, V2, P1539, DOI 10.1101/gad.2.12a.1539; KANDEL ER, 1982, SCIENCE, V218, P433, DOI 10.1126/science.6289442; KENNEDY MB, 1989, CELL, V59, P777, DOI 10.1016/0092-8674(89)90601-6; KLEIN M, 1978, P NATL ACAD SCI USA, V75, P3512, DOI 10.1073/pnas.75.7.3512; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHMANN SM, 1984, P NATL ACAD SCI-BIOL, V81, P6723, DOI 10.1073/pnas.81.21.6723; LU XY, 1990, J BIOL CHEM, V265, P3293; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MERCER AR, 1991, SCIENCE, V254, P1811, DOI 10.1126/science.1662413; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; OBAR RA, 1989, NEURON, V3, P639, DOI 10.1016/0896-6273(89)90274-2; Panchal R. G., 1992, Society for Neuroscience Abstracts, V18, P942; Probst W. C., 1992, Society for Neuroscience Abstracts, V18, P1104; RANGELALDAO R, 1979, J BIOL CHEM, V254, P2499; RANGELALDAO R, 1976, J BIOL CHEM, V251, P3375; RANNELS SR, 1983, METHOD ENZYMOL, V99, P55; RUBINO HM, 1989, NEURON, V3, P631, DOI 10.1016/0896-6273(89)90273-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHOLZ KP, 1987, SCIENCE, V235, P685, DOI 10.1126/science.2433766; SCHWARTZ JH, 1987, ANNU REV NEUROSCI, V10, P459; SCHWARTZ JH, 1987, METHOD ENZYMOL, V139, P227; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SOLOMON F, 1979, CELL, V18, P431, DOI 10.1016/0092-8674(79)90062-X; SWEATT JD, 1989, NATURE, V339, P51, DOI 10.1038/339051a0; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; ZHANG ZS, 1991, J COMP NEUROL, V311, P259, DOI 10.1002/cne.903110207	61	12	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2911	2920						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	7905481				2022-12-25	WOS:A1994MV43200081
J	CASADO, M; BENDAHAN, A; ZAFRA, F; DANBOLT, NC; ARAGON, C; GIMENEZ, C; KANNER, BI				CASADO, M; BENDAHAN, A; ZAFRA, F; DANBOLT, NC; ARAGON, C; GIMENEZ, C; KANNER, BI			PHOSPHORYLATION AND MODULATION OF BRAIN GLUTAMATE TRANSPORTERS BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED GLIAL-CELLS; RAT-BRAIN; NEUROTRANSMITTER TRANSPORTERS; RECONSTITUTED PREPARATIONS; GABA TRANSPORTER; ACID TRANSPORTER; EXPRESSION; SODIUM; CLONING; INHIBITION	High affinity sodium- and potassium-coupled L-glutamate transport into presynaptic nerve terminals and fine glial processes removes the neurotransmitter from the synaptic cleft, thereby terminating glutamergic transmission. This report describes that the purified L-glutamate transporter from pig brain is phosphorylated by protein kinase C, predominantly at serine residues. Upon exposure of C6 cells, a cell line of glial origin, to 12-O-tetradecanoylphorbol-13-acetate, about a 2-fold stimulation of L-glutamate transport is observed within 30 min. Concomitantly, the level of phosphorylation increases with similar kinetics. The phorbol ester also stimulates L-glutamate transport in HeLa cells infected with a recombinant vaccinia virus expressing T7 RNA polymerase and transfected with pT7-GLT-1. The latter is a recently cloned rat brain glutamate transporter of glial origin. Mutation of serine 113 to asparagine does not affect the levels of expressed transport but abolishes its stimulation by the phorbol ester. To our knowledge, this is the first direct demonstration of the regulation of a neurotransmitter transporter by phosphorylation.	HEBREW UNIV JERUSALEM, HADASSAH MED SCH, DEPT BIOCHEM, POB 1172, IL-91010 JERUSALEM, ISRAEL; UNIV AUTONOMA MADRID, FAC CIENCIAS, CTR BIOL MOLEC, MADRID 34, SPAIN; UNIV OSLO, INST ANAT, OSLO 3, NORWAY	Hebrew University of Jerusalem; Autonomous University of Madrid; University of Oslo			Danbolt, Niels Christian/A-1907-2014; Gimenez, Cecilio/K-8027-2014; Aragon, Carmen/K-9783-2014; Zafra, Francisco/A-6121-2008	Danbolt, Niels Christian/0000-0003-4227-4520; Gimenez, Cecilio/0000-0001-6726-8405; Aragon, Carmen/0000-0001-8287-9386; Zafra, Francisco/0000-0003-3801-3109; Casado, Mariano/0000-0001-8049-8096				BARBOUR B, 1989, NATURE, V342, P918, DOI 10.1038/342918a0; BENDA P, 1968, SCIENCE, V161, P370, DOI 10.1126/science.161.3839.370; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CASADO M, 1991, J NEUROCHEM, V57, P1185, DOI 10.1111/j.1471-4159.1991.tb08278.x; CHO Y, 1990, J NEUROCHEM, V55, P2091, DOI 10.1111/j.1471-4159.1990.tb05800.x; DANBOLT NC, 1992, NEUROSCIENCE, V51, P295, DOI 10.1016/0306-4522(92)90316-T; DANBOLT NC, 1990, BIOCHEMISTRY-US, V29, P6734, DOI 10.1021/bi00480a025; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; GUNDERSEN V, 1993, IN PRESS NEUROSCIENC; HARLOW E, 1988, ANTIBODIES, P506; HENN FA, 1974, NATURE, V249, P663, DOI 10.1038/249663a0; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1993, FEBS LETT, V325, P95, DOI 10.1016/0014-5793(93)81421-U; KANNER BI, 1982, BIOCHEMISTRY-US, V21, P6327, DOI 10.1021/bi00267a044; KERKERIAN L, 1987, J NEUROCHEM, V48, P1301, DOI 10.1111/j.1471-4159.1987.tb05661.x; KEYNAN S, 1988, BIOCHEMISTRY-US, V27, P12, DOI 10.1021/bi00401a003; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KIKKAWA U, 1983, METHOD ENZYMOL, V99, P288; KUHAR MJ, 1973, LIFE SCI, V13, P1623, DOI 10.1016/0024-3205(73)90110-0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NIEOULLON A, 1983, NEUROSCI LETT, V43, P191, DOI 10.1016/0304-3940(83)90186-6; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PINES G, 1990, BIOCHEMISTRY-US, V29, P11209, DOI 10.1021/bi00503a008; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; RADIAN R, 1990, J NEUROSCI, V10, P1319; RHOADS DE, 1983, BIOCHEMISTRY-US, V22, P1965, DOI 10.1021/bi00277a035; SCHLOSS P, 1992, FEBS LETT, V307, P76, DOI 10.1016/0014-5793(92)80905-V; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; UHL GR, 1992, TRENDS NEUROSCI, V15, P265, DOI 10.1016/0166-2236(92)90068-J; VOLPE JJ, 1975, J NEUROCHEM, V25, P333, DOI 10.1111/j.1471-4159.1975.tb06976.x; ZAFRA F, 1990, BIOCHEM J, V271, P237, DOI 10.1042/bj2710237; [No title captured]	35	271	274	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27313	27317						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	7903307				2022-12-25	WOS:A1993MM26200069
J	GREEN, SA; COLE, G; JACINTO, M; INNIS, M; LIGGETT, SB				GREEN, SA; COLE, G; JACINTO, M; INNIS, M; LIGGETT, SB			A POLYMORPHISM OF THE HUMAN BETA(2)-ADRENERGIC RECEPTOR WITHIN THE 4TH TRANSMEMBRANE DOMAIN ALTERS LIGAND-BINDING AND FUNCTIONAL-PROPERTIES OF THE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; HUMAN BETA-2-ADRENERGIC RECEPTOR; PHOSPHORYLATION SITES; CYTOPLASMIC DOMAINS; DISTINCT PATHWAYS; GS; DESENSITIZATION; SPECIFICITY; ACTIVATION	We have recently identified several naturally occurring variants of the human beta2-adrenergic receptor (beta2AR). One of these polymorphisms, which is relatively uncommon, is a mutation occurring in the fourth transmembrane spanning domain, with Ile substituted for Thr at amino acid 164 within the proposed ligand binding pocket. This mutation is adjacent to Ser165 which has been predicted to interact with the beta-carbon hydroxyl group of adrenergic ligands. To determine the functional significance of this variant, we constructed by site-directed techniques a mutated beta2AR (Ile164) with this substitution and expressed it in CHW-1102 cells. In the presence of guanine nucleotide, Ile164 displayed a lower binding affinity for epinephrine as compared with the wild-type beta2AR (K(i) = 1450 +/- 79 versus 368 +/- 39 nM; p < 0.001). A similarly decreased affinity was found with the catecholamines isoproterenol and norepinephrine, but not with dobutamine or dopamine which lack hydroxyl groups on their beta-carbons. In addition, antagonists without aromatic ring polar substituents displayed a decreased affinity for the mutated receptor. In agonist competition experiments conducted in the absence of guanine nucleotide, Ile164 failed to exhibit detectable high affinity binding, suggesting an impairment in the formation of the agonist-receptor-Gs complex. Consistent with this finding, functional coupling to Gs as determined in adenylyl cyclase assays was significantly (approximately 50%) depressed with Ile164 under both basal and agonist-stimulated conditions. Beta2AR sequestration, which is also triggered by agonist binding, was also found to be approximately 65% reduced in the Ile164 polymorphism. This study represents the first characterization of a naturally occurring mutation of a human adrenergic receptor. Our findings generally support the hypothesized role of this region of the receptor for ligand binding and receptor activation, as well as for establishing critical interactions for overall receptor conformation.	UNIV CINCINNATI,COLL MED,DEPT MED PULM,231 BETHESDA AVE,ML 0564,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET & PHARMACOL,CINCINNATI,OH 45267; CETUS CHIRON CORP,EMERYVILLE,CA 94608	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati			liggett, stephen b/E-7453-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045967] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL45967] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOUVIER M, 1989, J BIOL CHEM, V264, P16786; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; CHEUNG AH, 1990, MOL PHARMACOL, V37, P775; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DELEAN A, 1981, MOL PHARMACOL, V21, P5; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; DIXON RAF, 1988, COLD SPRING HARB SYM, V53, P487, DOI 10.1101/SQB.1988.053.01.056; FRIELLE T, 1988, P NATL ACAD SCI USA, V85, P9494, DOI 10.1073/pnas.85.24.9494; GREEN SA, 1992, MOL PHARMACOL, V41, P889; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LIGGETT SB, 1989, MOL PHARMACOL, V36, P641; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; LIGGETT SB, 1988, AM J PHYSIOL, V254, pE795, DOI 10.1152/ajpendo.1988.254.6.E795; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; LIGGETT SB, 1993, CATECHOLAMINES, P279; MALONEYHUSS K, 1992, J MOL BIOL, V225, P859, DOI 10.1016/0022-2836(92)90406-A; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; PERKINS JP, 1991, MECHANISMS LIGAND IN, P125; REISHAUS E, 1993, AM J RESPIR CELL MOL, V8, P334; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; STRADER CD, 1987, J BIOL CHEM, V262, P16439; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, J BIOL CHEM, V264, P13572; STRADER CD, 1989, J BIOL CHEM, V264, P16470; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002	30	380	400	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23116	23121						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7901205				2022-12-25	WOS:A1993MF51500027
J	GARDE, J; KINGHORN, JR; TOMSETT, AB				GARDE, J; KINGHORN, JR; TOMSETT, AB			SITE-DIRECTED MUTAGENESIS OF NITRATE REDUCTASE FROM ASPERGILLUS-NIDULANS - IDENTIFICATION OF SOME ESSENTIAL AND SOME NONESSENTIAL AMINO-ACIDS AMONG CONSERVED RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-CYTOCHROME-B5 REDUCTASE; ASSIMILATORY NADH; HEME DOMAIN; NIAD; EXPRESSION; CHLORELLA; CYSTEINE; MUTANTS; CORN; DNA	Nitrate reductase is a multiredox enzyme possessing three functional domains associated with the prosthetic groups FAD, heme iron, and molybdopterin, In Aspergillus nidulans, it is encoded by the niaD gene, A homologous transformation system has been used whereby a major deletion at the niiAniaD locus of the host was repaired by gene replacement, Employing site directed mutagenesis and this transformation system, nine niaD mutants were generated carrying specific amino acid substitutions, Mutants in which alanine replaced cysteine 150, which is thought to bind the molybdenum atom of the molybdenum-pterin, and in which alanine replaced histidine 547, which putatively binds heme iron, had no detectable nitrate reductase (NAR) activity, This clearly establishes an essential catalytic role for these residues, Of the remaining mutants, all altered in the NADPH/FAD domain, two were temperature-sensitive for NAR activity, two had reduced NAR activity levels, and three had normal levels, Since some of these mutants change residues conserved between homologous nitrate reductases from a wide range of species, it is clear that such amino acid identities do not necessarily signify essential roles for the activity of the enzyme, These findings are considered in the light of predicted structural/functional roles for the altered amino acids.	UNIV LIVERPOOL, DEPT GENET & MICROBIOL, DONNAN LABS, LIVERPOOL L69 3BX, MERSEYSIDE, ENGLAND; UNIV ST ANDREWS, DEPT BIOCHEM & MICROBIOL, ST ANDREWS KY16 9AL, FIFE, SCOTLAND	University of Liverpool; University of St Andrews								BAIJAL M, 1987, PHYTOCHEMISTRY, V27, P1969; BARBER MJ, 1990, J BIOL CHEM, V265, P20912; BARBER MJ, 1986, J BIOL CHEM, V261, P4562; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL WH, 1986, PLANT PHYSIOL, V82, P729, DOI 10.1104/pp.82.3.729; CAMPBELL WH, 1986, BIOCH BASIS PLANT BR, V11, P1; CANNONS AC, 1993, J BIOL CHEM, V268, P3268; COOLEY RN, 1985, BIOCHIM BIOPHYS ACTA, V831, P89, DOI 10.1016/0167-4838(85)90153-0; COVE DJ, 1979, BIOL REV, V54, P291, DOI 10.1111/j.1469-185X.1979.tb01014.x; COVE DJ, 1966, BIOCHIM BIOPHYS ACTA, V113, P51, DOI 10.1016/S0926-6593(66)80120-0; CRAWFORD NM, 1993, ANNU REV GENET, V27, P115, DOI 10.1146/annurev.ge.27.120193.000555; DUNNCOLEMAN NS, 1977, MOL GEN GENET, V152, P285, DOI 10.1007/BF00693082; DWIVEDI UN, 1994, J BIOL CHEM, V269, P13785; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRIEMANN A, 1991, MOL GEN GENET, V227, P97, DOI 10.1007/BF00260713; GARRETT RH, 1976, MOL GEN GENET, V149, P179, DOI 10.1007/BF00332887; GARRETT RH, 1969, J BIOL CHEM, V244, P2870; GEORGE GN, 1989, BIOCHEMISTRY-US, V28, P5075, DOI 10.1021/bi00438a026; HACKETT CS, 1986, J BIOL CHEM, V261, P9854; HAWKER KL, 1992, MOL GEN GENET, V231, P485, DOI 10.1007/BF00292720; HYDE GE, 1990, BIOCHEM BIOPH RES CO, V168, P1285, DOI 10.1016/0006-291X(90)91168-R; HYDE GE, 1989, PLANT MOL BIOL, V13, P233, DOI 10.1007/BF00016141; JOHNSTONE IL, 1990, GENE, V90, P181, DOI 10.1016/0378-1119(90)90178-T; Kinghorn J. R., 1989, Molecular and genetic aspects of nitrate assimilation., P385; KUBO Y, 1988, J BIOL CHEM, V263, P19684; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LU GG, 1994, STRUCTURE, V2, P809, DOI 10.1016/S0969-2126(94)00082-4; MACDONALD DW, 1974, MOL GEN GENET, V128, P187, DOI 10.1007/BF00267108; MATTHEWS FS, 1972, NATURE-NEW BIOL, V233, P15; MEYER C, 1991, J BIOL CHEM, V266, P20561; MINAGAWA N, 1982, J BIOCHEM, V91, P761, DOI 10.1093/oxfordjournals.jbchem.a133763; OKAMOTO PM, 1993, MOL GEN GENET, V240, P221, DOI 10.1007/BF00277060; PATEMAN JA, 1967, BIOCHEM J, V104, P103, DOI 10.1042/bj1040103; ROUZE P, 1992, SOC EXP BIOL SEMIN S, V49, P45, DOI 10.1017/CBO9780511600395.004; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOLOMONSON LP, 1986, J BIOL CHEM, V261, P1290; SOLOMONSON LP, 1987, J BIOL CHEM, V262, P8934; STRITTMATTER P, 1961, J BIOL CHEM, V236, P2329; TILBURN J, 1983, GENE, V26, P205, DOI 10.1016/0378-1119(83)90191-9; TOMSETT AB, 1979, GENET RES, V34, P19, DOI 10.1017/S001667230001925X; TOMSETT AB, 1989, NITROGEN PHOSPHORUS, P33; VONBODMAN SB, 1986, P NATL ACAD SCI USA, V83, P9443; WAHL RC, 1984, ARCH BIOCHEM BIOPHYS, V230, P264, DOI 10.1016/0003-9861(84)90107-3; Wray J.L., 1989, MOL GENETIC ASPECTS	46	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6644	6650		10.1074/jbc.270.12.6644	http://dx.doi.org/10.1074/jbc.270.12.6644			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896804	hybrid			2022-12-25	WOS:A1995QQ85500035
J	GARDELLA, TJ; LUCK, MD; WILSON, AK; KEUTMANN, HT; NUSSBAUM, SR; POTTS, JT; KRONENBERG, HM				GARDELLA, TJ; LUCK, MD; WILSON, AK; KEUTMANN, HT; NUSSBAUM, SR; POTTS, JT; KRONENBERG, HM			PARATHYROID-HORMONE (PTH)-PTH-RELATED PEPTIDE HYBRID PEPTIDES REVEAL FUNCTIONAL INTERACTIONS BETWEEN THE 1-14 AND 15-34 DOMAINS OF THE LIGAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BINDING DOMAINS; NMR SOLUTION STRUCTURE; HUMORAL HYPERCALCEMIA; MALIGNANCY; FRAGMENT; PROTEIN; KIDNEY; SPECTROSCOPY; MEMBRANES; SEQUENCES	Parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) bind to a common PTH/ PTHrP receptor. To explore structure-function relations in these ligands, we synthesized and functionally evaluated PTH-PTHrP hybrid peptides in which the homologous 1-14 portions were exchanged. Hybrid-2, PTH(1-14)-PTHrP-(15-34)NH2, bound to LLC-PK1 cells expressing the cloned rat PTH/PTHrP receptor with high affinity (IC50 congruent to 7 nM). In contrast, hybrid-1, PTHrP(1-14)-PTH-(15-34)NH2, bound with much weaker affinity (IC50 congruent to 8,700 nM). Thus, the 1-14 region of PTHrP is incompatible with the 15-34 region of PTH. The carboxyl-terminal incompatibility site was identified as residues 19-21 (Glu-Arg-Val in PTH and Arg-Arg-Arg in PTHrP); extending the amino-terminal PTHrP sequence to residue 21 but not to 18 cured the hybrid's binding defect. The amino-terminal incompatibility site was identified as position 5 (Ile in PTH and His in PTHrP), because Ile(5)-hybrid-1 bound with high affinity (IC50 congruent to 20 nM). The importance of these identified residues in the native ligands was established by evaluating the effects of substitutions at these sites in a series of PTH and PTHrP analog peptides. Overall, the results are consistent with the hypothesis that, in both PTH and PTHrP, the 1-14 and 15-34 domains interact when binding to the receptor and that residues 5, 19, and 21 contribute either directly or indirectly to this interaction.	HARVARD UNIV,SCH MED,BOSTON,MA 02114	Harvard University; Harvard Medical School	GARDELLA, TJ (corresponding author), MASSACHUSETTS GEN HOSP,ENDOCRINE UNIT,BOSTON,MA 02114, USA.							ABOUSAMRA AB, 1989, ENDOCRINOLOGY, V125, P2215, DOI 10.1210/endo-125-4-2215; BARANY G, 1979, PEPTIDES ANAL SYNTHE, P1; BARDEN JA, 1989, EUR J BIOCHEM, V184, P379, DOI 10.1111/j.1432-1033.1989.tb15030.x; BARDEN JA, 1993, EUR J BIOCHEM, V215, P315, DOI 10.1111/j.1432-1033.1993.tb18037.x; BARDEN JA, 1993, BIOCHEMISTRY-US, V32, P7126, DOI 10.1021/bi00079a008; BRINGHURST FR, 1993, ENDOCRINOLOGY, V132, P2090, DOI 10.1210/en.132.5.2090; CAULFIELD MP, 1990, ENDOCRINOLOGY, V127, P83, DOI 10.1210/endo-127-1-83; COHEN FE, 1991, J BIOL CHEM, V266, P1997; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FRELINGER AL, 1986, ARCH BIOCHEM BIOPHYS, V244, P641, DOI 10.1016/0003-9861(86)90632-6; GOLTZMANN D, 1975, J BIOL CHEM, V250, P3199; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KEMP BE, 1987, SCIENCE, V238, P1558; KLAUS W, 1991, BIOCHEMISTRY-US, V30, P6936, DOI 10.1021/bi00242a018; MCFARLANE DR, 1993, BIOCHIM BIOPHYS ACTA, V1162, P187, DOI 10.1016/0167-4838(93)90146-I; MCKEE RL, 1988, ENDOCRINOLOGY, V122, P3008, DOI 10.1210/endo-122-6-3008; NUSSBAUM SR, 1980, J BIOL CHEM, V255, P183; NUTT RF, 1990, ENDOCRINOLOGY, V127, P491, DOI 10.1210/endo-127-1-491; ORLOFF JJ, 1992, ENDOCRINOLOGY, V131, P1603, DOI 10.1210/en.131.4.1603; POTTS JT, 1971, P NATL ACAD SCI USA, V68, P63, DOI 10.1073/pnas.68.1.63; RAY FR, 1993, EUR J BIOCHEM, V211, P205, DOI 10.1111/j.1432-1033.1993.tb19887.x; ROSENBLATT M, 1980, ENDOCRINOLOGY, V107, P545, DOI 10.1210/endo-107-2-545; ROSENBLATT M, 1982, ENDOCRINOLOGY CALCIU, P103; SEGRE GV, 1979, J BIOL CHEM, V254, P6980; SMITH LM, 1987, ARCH BIOCHEM BIOPHYS, V253, P81, DOI 10.1016/0003-9861(87)90639-4; STRICKLAND LA, 1993, BIOCHEMISTRY-US, V32, P6050, DOI 10.1021/bi00074a016; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; ZULL JE, 1980, P NATL ACAD SCI-BIOL, V77, P3791, DOI 10.1073/pnas.77.7.3791	29	54	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6584	6588		10.1074/jbc.270.12.6584	http://dx.doi.org/10.1074/jbc.270.12.6584			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896796	hybrid			2022-12-25	WOS:A1995QQ85500026
J	GERENDASY, DD; HERRON, SR; JENNINGS, PA; SUTCLIFFE, JG				GERENDASY, DD; HERRON, SR; JENNINGS, PA; SUTCLIFFE, JG			CALMODULIN STABILIZES AN AMPHIPHILIC ALPHA-HELIX WITHIN RC3/NEUROGRANIN AND GAP-43/NEUROMODULIN ONLY WHEN CA2+ IS ABSENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C SUBSTRATE; PERTUSSIS ADENYLATE-CYCLASE; LONG-TERM POTENTIATION; LIGHT CHAIN KINASE; BINDING DOMAIN; B-50 GAP-43; PHOSPHORYLATION SITE; SECONDARY STRUCTURE; GLOBULAR-PROTEINS; GANGLION-CELLS	Two neuronal protein kinase C substrates, RC3/neurogranin and GAP-43/neuromodulin, preferentially bind to calmodulin (CaM) when Ca2+ is absent. We examine RC3 . CaM and GAP-43 . CaM interactions by circular dichroism spectroscopy using purified, recombinant RC3 and GAP-43, sequence variants of RC3 displaying qualitative and quantitative differences in CaM binding affinities, and overlapping peptides that cumulatively span the entire amino acid sequence of RC3. We conclude that CaM stabilizes a basic, amphiphilic cu-helix within RC3 and GAP-43 under physiological salt concentrations only when Ca2+ is absent. This provides structural confirmation for two binding modes and suggests that CaM regulates the biological activities of RC3 and GAP-43 through an allosteric, Ca2+-sensitive mechanism that can be uncoupled by protein kinase C-mediated phosphorylation. More generally, our observations imply an alternative allosteric regulatory role for the Ca2+-free form of CaM.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA	Scripps Research Institute; University of California System; University of California San Diego					NINDS NIH HHS [NS22111, NS22347] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS022347, R01NS022111] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; ANDERSON SR, 1986, CALCIUM CELL FUNCTIO, V6, P2; ANDREASEN TJ, 1983, BIOCHEMISTRY-US, V22, P4615, DOI 10.1021/bi00289a001; APEL ED, 1990, BIOCHEMISTRY-US, V29, P2330, DOI 10.1021/bi00461a017; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BENOWITZ LI, 1991, ANN NY ACAD SCI, V627, P58; BLUMENTHAL DK, 1988, MOL ASPECTS CELLULAR, V5, P341; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BUELT MK, 1994, J BIOL CHEM, V269, P29367; CARAFOLI E, 1992, ANN NY ACAD SCI, V671, P58, DOI 10.1111/j.1749-6632.1992.tb43784.x; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; CHEN SJ, 1993, BIOCHEMISTRY-US, V32, P1032, DOI 10.1021/bi00055a006; CHEN SJ, 1993, 23RD P ANN M SOC NEU; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; COGGINS PJ, 1989, BIOCHEM SOC T, V17, P785, DOI 10.1042/bst0170785; COGGINS PJ, 1991, J NEUROCHEM, V56, P1095, DOI 10.1111/j.1471-4159.1991.tb11398.x; COGGINS PJ, 1991, NEUROSCI RES COMMUN, V8, P49; COHEN P, 1988, CALMODULIN, V5; COHEN RW, 1993, BRAIN RES, V627, P147, DOI 10.1016/0006-8993(93)90758-F; COX JA, 1985, J BIOL CHEM, V260, P2527; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; DEGRAAN PNE, 1991, PROG BRAIN RES, V89, P187; DEGRADO WF, 1985, J CELL BIOCHEM, V29, P83, DOI 10.1002/jcb.240290204; DEKKER LV, 1991, J NEUROCHEM, V56, P1146, DOI 10.1111/j.1471-4159.1991.tb11404.x; DOSTER SK, 1991, NEURON, V6, P635, DOI 10.1016/0896-6273(91)90066-9; FITZGERALD M, 1991, NEUROSCIENCE, V41, P187, DOI 10.1016/0306-4522(91)90209-7; FORSEN S, 1986, CALCIUM CELL FUNCT, V6, P114; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GASCUEL O, 1988, COMPUT APPL BIOSCI, V4, P357; GERENDASY DD, 1994, J BIOL CHEM, V269, P22420; GERENDASY DD, 1995, IN PRESS J MOL NEURO; GIANOTTI C, 1992, NEURON, V8, P843, DOI 10.1016/0896-6273(92)90198-M; GISPEN WH, 1986, BIOCHEM SOC T, V14, P163, DOI 10.1042/bst0140163; GISPEN WH, 1991, MOL NEUROBIOL, V5, P61, DOI 10.1007/BF02935540; HENNESSEY JP, 1987, BIOPOLYMERS, V26, P561, DOI 10.1002/bip.360260409; HOUBRE D, 1991, J BIOL CHEM, V266, P7121; HUANG KP, 1993, ARCH BIOCHEM BIOPHYS, V305, P570, DOI 10.1006/abbi.1993.1463; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; IKURA M, 1992, CELL CALCIUM, V13, P391, DOI 10.1016/0143-4160(92)90052-T; KINCAID RL, 1986, CALCIUM CELL FUNCTIO, V6, P44; KLANN E, 1992, J NEUROCHEM, V58, P1576, DOI 10.1111/j.1471-4159.1992.tb11382.x; KLEE CB, 1991, NEUROCHEM RES, V16, P1059, DOI 10.1007/BF00965851; KLEVIT RE, 1985, BIOCHEMISTRY-US, V24, P8152, DOI 10.1021/bi00348a047; KRETSINGER RH, 1992, CELL CALCIUM, V13, P363, DOI 10.1016/0143-4160(92)90050-3; LADANT D, 1988, J BIOL CHEM, V263, P2612; LAPORTE DC, 1980, BIOCHEMISTRY-US, V19, P3814, DOI 10.1021/bi00557a025; LIN LH, 1992, MOL BRAIN RES, V14, P147, DOI 10.1016/0169-328X(92)90024-6; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; LOVINGER DM, 1985, BRAIN RES, V343, P137, DOI 10.1016/0006-8993(85)91167-9; MACLACHLAN LK, 1990, J BIOL CHEM, V265, P9764; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; MASURE HR, 1986, BIOCHEMISTRY-US, V25, P7553, DOI 10.1021/bi00371a044; MCDOWELL L, 1985, BIOCHEMISTRY-US, V24, P2979, DOI 10.1021/bi00333a026; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEANS AR, 1988, RECENT PROG HORM RES, V44, P223; MEANS AR, 1987, CELLULAR REGULATORS; MEIRI KF, 1991, J CELL BIOL, V112, P991, DOI 10.1083/jcb.112.5.991; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; MUNIER H, 1993, J BIOL CHEM, V268, P1695; NEEL VA, 1994, DEVELOPMENT, V120, P2235; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PADMANABHAN S, 1990, NATURE, V344, P268, DOI 10.1038/344268a0; PRECHEUR B, 1992, BIOCHEMISTRY-US, V31, P229, DOI 10.1021/bi00116a032; PRECHEUR B, 1991, EUR J BIOCHEM, V196, P67; REPRESA A, 1990, J NEUROSCI, V10, P3782, DOI 10.1523/JNEUROSCI.10-12-03782.1990; RYU SH, 1987, FASEB J, V1, P388, DOI 10.1096/fasebj.1.5.2824270; SEEHOLZER SH, 1986, P NATL ACAD SCI USA, V83, P3634, DOI 10.1073/pnas.83.11.3634; SHARMA RK, 1986, J BIOL CHEM, V261, P14160; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; SOMMERVAILLE T, 1991, NEUROSCIENCE, V45, P213, DOI 10.1016/0306-4522(91)90117-7; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; STRITTMATTER SM, 1992, J NEUROBIOL, V23, P507, DOI 10.1002/neu.480230506; STRITTMATTER SM, 1993, P NATL ACAD SCI USA, V90, P5327, DOI 10.1073/pnas.90.11.5327; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TALLANT EA, 1986, CALCIUM CELL FUNCTIO, V6, P72; TANAKA T, 1980, J BIOL CHEM, V255, P1078; VANHOOFF COM, 1988, J NEUROSCI, V8, P1789; VORHERR T, 1992, BIOCHEMISTRY-US, V31, P371, DOI 10.1021/bi00117a009; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; WATSON JB, 1992, P NATL ACAD SCI USA, V89, P8581, DOI 10.1073/pnas.89.18.8581; WATSON JB, 1990, J NEUROSCI RES, V26, P397, DOI 10.1002/jnr.490260402; WEINSTEIN H, 1994, ANNU REV PHYSIOL, V56, P213, DOI 10.1146/annurev.ph.56.030194.001241; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; ZHANG MJ, 1994, BIOCHEMISTRY-US, V33, P1163, DOI 10.1021/bi00171a016; ZHANG MJ, 1994, J BIOL CHEM, V269, P981; ZHANG MJ, 1993, PROTEIN SCI, V2, P1931, DOI 10.1002/pro.5560021114; ZWIERS H, 1991, PROG BRAIN RES, V89, P3	89	77	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6741	6750		10.1074/jbc.270.12.6741	http://dx.doi.org/10.1074/jbc.270.12.6741			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896819	hybrid			2022-12-25	WOS:A1995QQ85500050
J	IMAI, K; YOKOHAMA, Y; NAKANISHI, I; OHUCHI, E; FUJII, Y; NAKAI, N; OKADA, Y				IMAI, K; YOKOHAMA, Y; NAKANISHI, I; OHUCHI, E; FUJII, Y; NAKAI, N; OKADA, Y			MATRIX METALLOPROTEINASE-7 (MATRILYSIN) FROM HUMAN RECTAL-CARCINOMA CELLS - ACTIVATION OF THE PRECURSOR, INTERACTION WITH OTHER MATRIX METALLOPROTEINASES AND ENZYMATIC-PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHEUMATOID SYNOVIAL FIBROBLASTS; MONOCLONAL-ANTIBODIES; ENZYMATIC-PROPERTIES; COLLAGENASE FAMILY; HUMAN-NEUTROPHILS; TERMINAL DOMAIN; IV COLLAGENASE; STROMELYSIN; PURIFICATION; PROCOLLAGENASE	Matrix metalloproteinase 7 (MMP-7) has been purified as an inactive zymogen of M(r), 28,000 (proMMP-7) from the culture medium of CaR-1 human rectal carcinoma cells. The NH2-terminal sequence of proMMP-7 is Lys-Pro-Lys-Pro-Gln-Glu, which is identical to that of matrilysin. The zymogen is activated by 4-aminophenylmercuric acetate (APMA), yielding an intermediate form of M(r) 21,000 and an active species of M(r) 19,000 which shows the new NH2-terminal sequence of Tyr(78)-Ser-Leu-Phe-Pro-Asn-Ser. Although trypsin fully activates the zymogen, the activation rate by plasmin or leukocyte elastase is confined to similar to 50%. ProMMP-7 can be activated by MMP-3 (stromelysin 1) to its full activity in a single-step mechanism and generates the same NH2 terminus obtained by APMA activation, whereas MMP-1 (tissue collagenase), MMP-2 (gelatinase A), and MMP-9 (gelatinase B) do not have such an effect, On the other hand, proMMP-1 is activated by MMP-7 to an activity similar to that obtained by APMA and the activation by MMP-7 is enhanced up to similar to 6.5 fold in the presence of APMA, This enhanced activity is donated by specific cleavage at the Gln(80)-Phe(81) bond of proMMP-1. MMP-7 can also activate proMMP-9 up to similar to 50% of the full activity with a new NH2 terminus of Leu(16)-Arg-Thr-(Asn)-Leu. Incubation of proMMP-2 or proMMP-3 with MMP-7 results in no activation of these proMMPs. MMP-7 degrades type IV collagen, laminin-1, fibronectin, proteoglycan, type I gelatin, and insoluble elastin, These results suggest that in vivo MMP-7 may play a role in degradation of extracellular matrix macromolecules in concert with MMP-1, -3, and -9 under pathological conditions.	KANAZAWA UNIV, CANC RES INST, DEPT MOLEC IMMUNOL & PATHOL, KANAZAWA, ISHIKAWA 920, JAPAN; KANAZAWA UNIV, SCH MED, DEPT ORTHOPED SURG, KANAZAWA, ISHIKAWA 920, JAPAN; KANAZAWA UNIV, SCH MED, DEPT PATHOL, KANAZAWA, ISHIKAWA 920, JAPAN; FUJI CHEM IND CO LTD, TAKAOKA, TOYAMA 933, JAPAN; FUKUI MED SCH, DEPT CHEM, FUKUI 91011, JAPAN	Kanazawa University; Kanazawa University; Kanazawa University; University of Fukui			Imai, Kazushi/E-7206-2012; Okada, Yasunori/B-5550-2014	Okada, Yasunori/0000-0001-9208-4755; Fujii, Yutaka/0000-0001-6357-3795				ALLAN JA, 1991, J CELL SCI, V99, P789; BANDA MJ, 1987, METHOD ENZYMOL, V144, P288; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; BUSIEK DF, 1992, J BIOL CHEM, V267, P9087; CAWSTON TE, 1979, ANAL BIOCHEM, V99, P340, DOI 10.1016/S0003-2697(79)80017-2; CRABBE T, 1992, BIOCHEMISTRY-US, V31, P8500, DOI 10.1021/bi00151a017; DAVIS GE, 1990, CANCER RES, V50, P1113; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; FUJIMOTO N, 1993, CLIN CHIM ACTA, V220, P31, DOI 10.1016/0009-8981(93)90004-N; GIRARD MT, 1993, J CELL SCI, V104, P1001; ITO A, 1988, ARCH BIOCHEM BIOPHYS, V267, P211, DOI 10.1016/0003-9861(88)90025-2; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KNAUPER V, 1993, BIOCHEM J, V295, P581; KODAMA S, 1990, J IMMUNOL METHODS, V127, P103, DOI 10.1016/0022-1759(90)90345-V; MARTI HP, 1992, BIOCHEM J, V285, P899, DOI 10.1042/bj2850899; MARTI HP, 1994, AM J PATHOL, V144, P82; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCDONNELL S, 1991, MOL CARCINOGEN, V4, P527, DOI 10.1002/mc.2940040617; MINAMOTO T, 1988, HUM PATHOL, V19, P815, DOI 10.1016/S0046-8177(88)80265-X; MIYAZAKI K, 1990, CANCER RES, V50, P7758; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MULLER D, 1991, INT J CANCER, V48, P550, DOI 10.1002/ijc.2910480412; MURPHY G, 1993, J BIOL CHEM, V268, P15435; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; NAGASE H, 1980, ANAL BIOCHEM, V107, P385, DOI 10.1016/0003-2697(80)90400-5; NAKANO A, 1993, BIOCHEM BIOPH RES CO, V192, P999, DOI 10.1006/bbrc.1993.1515; OBATA K, 1992, CLIN CHIM ACTA, V211, P59, DOI 10.1016/0009-8981(92)90105-Y; OCONNELL JP, 1994, J BIOL CHEM, V269, P14967; ODERMATT E, 1983, BIOCHEM J, V211, P295, DOI 10.1042/bj2110295; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OKADA Y, 1988, BIOCHEM J, V254, P731, DOI 10.1042/bj2540731; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OKADA Y, 1989, ANN RHEUM DIS, V48, P645, DOI 10.1136/ard.48.8.645; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OKADA Y, 1986, J BIOL CHEM, V261, P14245; OKADA Y, 1995, IN PRESS LAB INVEST; PAJOUH MS, 1991, J CANCER RES CLIN, V117, P144, DOI 10.1007/BF01613138; PEPPIN GJ, 1986, P NATL ACAD SCI USA, V83, P4322, DOI 10.1073/pnas.83.12.4322; QUANTIN B, 1989, BIOCHEMISTRY-US, V28, P5327, DOI 10.1021/bi00439a004; REINEMER P, 1994, FEBS LETT, V338, P227, DOI 10.1016/0014-5793(94)80370-6; RODGERS WH, 1994, J CLIN INVEST, V94, P946, DOI 10.1172/JCI117461; Ruoslahti E, 1978, Ann N Y Acad Sci, V312, P178, DOI 10.1111/j.1749-6632.1978.tb16802.x; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; SIRES UI, 1993, J BIOL CHEM, V268, P2069; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P1353; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; WEISS SJ, 1985, SCIENCE, V227, P747, DOI 10.1126/science.2982211; WINDSOR LJ, 1993, J BIOL CHEM, V268, P17341; WOESSNER JF, 1988, J BIOL CHEM, V263, P16918; WOLF C, 1993, P NATL ACAD SCI USA, V90, P1843, DOI 10.1073/pnas.90.5.1843; YURCHENCO PD, 1984, BIOCHEMISTRY-US, V23, P1839, DOI 10.1021/bi00303a040; ZHANG J, 1993, CLIN CHIM ACTA, V219, P1, DOI 10.1016/0009-8981(93)90192-7	57	259	265	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6691	6697		10.1074/jbc.270.12.6691	http://dx.doi.org/10.1074/jbc.270.12.6691			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896811	hybrid			2022-12-25	WOS:A1995QQ85500042
J	JIN, JP				JIN, JP			CLONED RAT CARDIAC TITIN CLASS-I AND CLASS-II MOTIFS - EXPRESSION, PURIFICATION, CHARACTERIZATION, AND INTERACTION WITH F-ACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEBULIN FRAGMENTS; LIGHT CHAIN KINASE; SKELETAL-MUSCLE; TROPONIN-T; MONOCLONAL-ANTIBODIES; STRIATED-MUSCLE; Z-LINE; MOLECULAR CHARACTERIZATION; IMMUNOELECTRON MICROSCOPY; SARCOMERE MATRIX	Titin (connectin) is a giant protein that forms a single-molecule elastic filament extending from the M-line to the Z-line in the striated muscle sarcomere. The sequence of titin consists mainly of repeats of two types of similar to 100-amino acid motifs (class I and class II that show homology to the fibronectin type III and immunoglobulin-C2 domains, respectively). To investigate the functions of the two classes of titin moths as the basic units of this large sarcomere organizer molecule, titin cDNA segments encoding single class I or class II or linked class I-II motifs were cloned by polymerase chain reaction from a rat cardiac cDNA library into the T7 RNA polymerase-based pAED4 vector to express non-fusion titin fragments in Escherichia coli. High level expression of the three titin fragments was achieved, and effective rapid purification procedures were developed. The purified titin fragments were verified by their amino acid composition, apparent molecular mass, and charge. Antibodies raised against the genetically expressed titin motifs specifically recognized intact rat cardiac and skeletal muscle titins in Western blotting and immunofluorescence microscopy, confirming the authenticity of the cloned fragments. High beta-sheet contents of these titin motifs indicate a folding state very similar to that of intact native titin. Solid-phase protein-binding assays demonstrated that a single class I motif was able to bind both myosin and F-actin. In comparison, a single class II motif had weaker binding to only F-actin but the fragment containing linked class I and class II motifs showed significantly stronger interactions with both myosin and F-actin. The binding of titin motifs to myosin supports the proposed association of A-band titin with the thick filament, and the novel titin-F-actin interaction was confirmed by F actin cosedimentation assays, suggesting that titin may also be involved in the structure and/or function of the thin filament.			JIN, JP (corresponding author), UNIV CALGARY,FAC MED,DEPT MED BIOCHEM,3330 HOSP DR NW,CALGARY,AB T2N 4N1,CANADA.			Jin, JP/0000-0001-9932-1063				Ausubel F.M., 1987, CURRENT PROTOCOL MOL; AYMESOUTHGATE A, 1991, P NATL ACAD SCI USA, V88, P7973, DOI 10.1073/pnas.88.18.7973; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; DICKINSON CD, 1994, J MOL BIOL, V236, P1079, DOI 10.1016/0022-2836(94)90013-2; EATON BL, 1975, BIOCHEMISTRY-US, V14, P2718, DOI 10.1021/bi00683a025; EINHEBER S, 1990, P NATL ACAD SCI USA, V87, P2157, DOI 10.1073/pnas.87.6.2157; FRITZ JD, 1993, J MUSCLE RES CELL M, V14, P347, DOI 10.1007/BF00123100; FULTON AB, 1991, BIOESSAYS, V13, P157, DOI 10.1002/bies.950130403; FURST DO, 1989, J CELL SCI, V94, P119; FURST DO, 1988, J CELL BIOL, V106, P1563, DOI 10.1083/jcb.106.5.1563; GAUTEL M, 1993, NEUROLOGY, V43, P1581, DOI 10.1212/WNL.43.8.1581; HEELEY DH, 1989, J BIOL CHEM, V264, P2424; HILL C, 1986, J CELL BIOL, V102, P1099, DOI 10.1083/jcb.102.3.1099; HITCHCOCK SE, 1973, J MOL BIOL, V80, P825, DOI 10.1016/0022-2836(73)90212-X; HOLDEN HM, 1992, J MOL BIOL, V227, P840, DOI 10.1016/0022-2836(92)90226-A; HOROWITS R, 1992, BIOPHYS J, V61, P392, DOI 10.1016/S0006-3495(92)81845-3; JIN JP, 1994, FEBS LETT, V341, P135, DOI 10.1016/0014-5793(94)80256-4; JIN JP, 1988, J BIOL CHEM, V263, P7309; JIN JP, 1992, J MOL BIOL, V227, P1269, DOI 10.1016/0022-2836(92)90540-Z; JIN JP, 1991, J BIOL CHEM, V266, P21215; JIN JP, 1991, FEBS LETT, V281, P93, DOI 10.1016/0014-5793(91)80366-B; JIN JP, 1989, J BIOL CHEM, V264, P14471; JIN JP, 1990, HYBRIDOMA, V9, P597, DOI 10.1089/hyb.1990.9.597; KIMURA S, 1983, BIOMED RES-TOKYO, V4, P607; KIMURA S, 1984, J BIOCHEM, V96, P499, DOI 10.1093/oxfordjournals.jbchem.a134862; LABEIT S, 1992, EMBO J, V11, P1711, DOI 10.1002/j.1460-2075.1992.tb05222.x; LABEIT S, 1990, NATURE, V345, P273, DOI 10.1038/345273a0; LAKI K, 1962, ARCH BIOCHEM BIOPHYS, V98, P323, DOI 10.1016/0003-9861(62)90190-X; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MARUYAMA K, 1985, J CELL BIOL, V101, P2167, DOI 10.1083/jcb.101.6.2167; MARUYAMA K, 1993, BIOCHEM BIOPH RES CO, V194, P1288, DOI 10.1006/bbrc.1993.1963; MARUYAMA K, 1986, INT REV CYTOL, V104, P81, DOI 10.1016/S0074-7696(08)61924-5; MULLERSEITZ M, 1993, GENOMICS, V18, P559, DOI 10.1016/S0888-7543(05)80356-8; NAVE R, 1990, J CELL SCI, V95, P535; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; PAN KM, 1994, BIOCHEMISTRY-US, V33, P8255, DOI 10.1021/bi00193a012; PEARLSTONE JR, 1977, CAN J BIOCHEM CELL B, V55, P1032, DOI 10.1139/o77-154; PEARLSTONE JR, 1976, P NATL ACAD SCI USA, V73, P1902, DOI 10.1073/pnas.73.6.1902; PRICE MG, 1993, J BIOL CHEM, V268, P21800; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SOTERIOU A, 1993, P ROY SOC B-BIOL SCI, V254, P83, DOI 10.1098/rspb.1993.0130; SOTERIOU A, 1993, J CELL SCI, V104, P119; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAN KO, 1993, J BIOL CHEM, V268, P22900; TRINICK J, 1992, FEBS LETT, V307, P44, DOI 10.1016/0014-5793(92)80899-R; Trinick J, 1991, CURR OPIN CELL BIOL, V3, P112, DOI 10.1016/0955-0674(91)90173-V; TROMBITAS K, 1993, J MUSCLE RES CELL M, V14, P416, DOI 10.1007/BF00121293; WANG K, 1993, BIOPHYS J, V64, P1161, DOI 10.1016/S0006-3495(93)81482-6; WANG K, 1991, P NATL ACAD SCI USA, V88, P7101, DOI 10.1073/pnas.88.16.7101; Wang K, 1985, Cell Muscle Motil, V6, P315; WANG K, 1988, J CELL BIOL, V107, P2199, DOI 10.1083/jcb.107.6.2199; WANG K, 1986, METHOD ENZYMOL, V85, P264	55	78	79	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6908	6916						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896840				2022-12-25	WOS:A1995QQ85500071
J	MORALES, MJ; CASTELLINO, RC; CREWS, AL; RASMUSSON, RL; STRAUSS, HC				MORALES, MJ; CASTELLINO, RC; CREWS, AL; RASMUSSON, RL; STRAUSS, HC			A NOVEL BETA-SUBUNIT INCREASES RATE OF INACTIVATION OF SPECIFIC VOLTAGE-GATED POTASSIUM CHANNEL ALPHA-SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCES; HETEROMULTIMERIC K+ CHANNELS; POLYMERASE CHAIN-REACTION; MESSENGER-RNA; SECONDARY-STRUCTURE; XENOPUS OOCYTES; IK(A) CHANNELS; PROTEINS; BRAIN; DNA	Voltage-gated potassium channel beta subunits are cytoplasmic proteins that co-purify with the pore-forming a subunits. One of these subunits, Kv beta 1 from rat brain, was previously demonstrated to increase the rate of inactivation of Kv1.1 and Kv1.4 when co-expressed in Xenopus oocytes, We have cloned and characterized a novel voltage-gated K+ channel beta subunit. The cDNA, designated Kv beta S, has a 408-amino acid open reading frame. It possesses a unique 79-amino acid N-terminal leader, but is identical with rat Kv beta 1 over the 329 C-terminal amino acids. The Kv beta 3 transcript was found in many tissues, but was most abundant in aorta and left ventricle of the heart. Go-expression of Kv beta 3 with K+ channel alpha subunits shows that this beta subunit can increase the rate of inactivation from 4- to 7-fold in a Kv1.4 or Shaker B channel, Kv beta 3 had no effect on Kv1.1, unlike KvP1 which can increase rate of inactivation of this alpha subunit more than 100-fold, Other kinetic parameters were unaffected. This study shows that voltage-gated K+ channel beta subunits are present outside the central nervous system, and that at least one member of this family selectively modulates inactivation of K+ channel alpha subunits.	DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, SCH ENGN, DEPT BIOMED ENGN, DURHAM, NC 27708 USA	Duke University; Duke University; Duke University; Duke University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL019216, R01HL019216, R01HL052874] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52874, HL19216] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BAIROCH A, 1993, NUCLEIC ACIDS RES, V21, P3097, DOI 10.1093/nar/21.13.3097; BROWN AM, 1993, ANNU REV BIOPH BIOM, V22, P173, DOI 10.1146/annurev.bb.22.060193.001133; CELI FS, 1993, NUCLEIC ACIDS RES, V21, P1047, DOI 10.1093/nar/21.4.1047; CHABALA LD, 1993, J GEN PHYSIOL, V102, P713, DOI 10.1085/jgp.102.4.713; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COMER MB, 1994, AM J PHYSIOL-HEART C, V267, pH1383, DOI 10.1152/ajpheart.1994.267.4.H1383; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; Hille B., 1992, IONIC CHANNELS EXCIT; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; JAN LY, 1992, ANNU REV PHYSIOL, V54, P535, DOI 10.1146/annurev.physiol.54.1.535; KASS RS, 1993, TRENDS CARDIOVAS MED, V3, P149, DOI 10.1016/1050-1738(93)90016-Y; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MAROM S, 1993, RECEPTOR CHANNEL, V1, P81; MURRELLLAGNADO RD, 1993, J GEN PHYSIOL, V102, P949, DOI 10.1085/jgp.102.6.949; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PENNEFATHER P, 1990, CARDIAC ELECTROPHYSI, P17; PETERSON MG, 1993, METHOD ENZYMOL, V218, P493; PO S, 1993, CIRC RES, V72, P1326, DOI 10.1161/01.RES.72.6.1326; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; RUDY B, 1988, NEURON, V1, P649, DOI 10.1016/0896-6273(88)90164-X; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; RUPPERSBERG JP, 1991, NATURE, V353, P657, DOI 10.1038/353657a0; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; Sambrook J, 1989, MOL CLONING LABORATO; SCOTT VES, 1990, J BIOL CHEM, V265, P20094; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; SNYDERS DJ, 1993, J GEN PHYSIOL, V101, P513, DOI 10.1085/jgp.101.4.513; TAGLIALATELA M, 1992, BIOPHYS J, V61, P78, DOI 10.1016/S0006-3495(92)81817-9; TEMPEL BL, 1988, NATURE, V332, P837, DOI 10.1038/332837a0; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0	45	143	145	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					6272	6277		10.1074/jbc.270.11.6272	http://dx.doi.org/10.1074/jbc.270.11.6272			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890764	hybrid			2022-12-25	WOS:A1995QM94500084
J	SMALLEY, DL; SHANKLIN, DR; HALL, MF; STEVENS, MV; HANISSIAN, A				SMALLEY, DL; SHANKLIN, DR; HALL, MF; STEVENS, MV; HANISSIAN, A			IMMUNOLOGICAL STIMULATION OF T-LYMPHOCYTES BY SILICA AFTER USE OF SILICONE MAMMARY IMPLANTS	FASEB JOURNAL			English	Article						LYMPHOCYTE STIMULATION; SILICON DIOXIDE; SILICONE BREAST IMPLANTS; SILICONES	BREAST IMPLANTS; TISSUE; DISEASE	Difficulties in showing the biologic activity of silicones in vitro have contributed to the controversy over effects of silicone mammary implants in vivo. We adapted a standard lymphocyte stimulation test to detect evidence of cellular immunity in patients with silicone gel implants. Initially, lymphocytes were harvested from 70 implant patients, 76 normal controls without implants or symptoms, and 18 patients with classic rheumatic disorders and without a history of silicone implants. The harvested lymphocytes were stimulated with PWM, PHA, Con A, and pharmaceutical grade colloidal silicon dioxide (silica). Implant patients showed increased SI compared to controls and those with rheumatic disorders. The mean SI of implant patients was 195.0 +/- 19.3, 18-fold that of normal controls (< 0.0001). Patients with rheumatic disease showed the same SI as controls (P = 0.3577). A follow-up study included 220 normal controls without implants, 942 silicone gel implant patients with demonstrable rheumatic symptoms, and 34 implant patients without symptoms at the time of the study. The average SI for the 220 normal controls was 10.0 +/- 0.41. Among the symptomatic implant women, 860 (91.3%) had SI significantly above those of the normal controls. Of these, 171 (18.2%) had SI between 25 and 50, 316 (33.5%) had SI between 50 and 100, and 373 (39.6%) had SI over 100. The data presented confirms that silicone implant patients respond immunologically to the silicon dioxide contained in mammary prostheses.	BAPTIST MEM HLTH CARE SYST, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, DEPT PATHOL, MEMPHIS, TN 38163 USA; UNIV TENNESSEE, DEPT OBSTET & GYNECOL, MEMPHIS, TN 38163 USA; BAPTIST MEM HOSP, DEPT MED, MEMPHIS, TN 38120 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Baptist Memorial Hospital Memphis; University of Tennessee System; University of Tennessee Health Science Center								BAKER JL, 1982, PLAST RECONSTR SURG, V69, P56, DOI 10.1097/00006534-198269010-00008; BRIDGES AJ, 1993, ANN INTERN MED, V118, P929, DOI 10.7326/0003-4819-118-12-199306150-00003; CHILSON OP, 1989, EUR J IMMUNOL, V19, P389, DOI 10.1002/eji.1830190225; GARRIDO L, 1993, MAGNET RESON MED, V29, P839, DOI 10.1002/mrm.1910290620; GEHA RS, 1974, EUR J IMMUNOL, V4, P193, DOI 10.1002/eji.1830040308; GOLDBLUM RM, 1992, LANCET, V340, P510, DOI 10.1016/0140-6736(92)91710-P; OJOMAIZE EA, 1994, CLIN DIAGN LAB IMMUN, V1, P689, DOI 10.1128/CDLI.1.6.689-695.1994; PICHA GJ, 1991, PLAST RECONSTR SURG, V87, P490, DOI 10.1097/00006534-199103000-00017; RUDOLPH R, 1978, PLAST RECONSTR SURG, V62, P185, DOI 10.1097/00006534-197808000-00006; SCHMITERLOW CG, 1975, ACTA PHARMACOL TOX, V36, P131; SHANKLIN DR, 1991, SILICONE MED DEVICES, P103; SHANKLIN DR, 1993, SOUTH MED J, V86, pS104; SHONS AR, 1992, ANN PLAS SURG, V28, P491, DOI 10.1097/00000637-199205000-00017; SILVER RM, 1993, ARCH DERMATOL, V129, P63, DOI 10.1001/archderm.129.1.63; SMALLEY DL, 1995, IN PRESS J OCCUPAT M; SPIERA H, 1993, J RHEUMATOL, V20, P958; THOMSEN JL, 1990, PLAST RECONSTR SURG, V85, P38, DOI 10.1097/00006534-199001000-00007; VARGA J, 1989, ANN INTERN MED, V111, P377, DOI 10.7326/0003-4819-111-5-377; WOLF LE, 1993, FASEB J, V7, P1265, DOI 10.1096/fasebj.7.13.8405812; 1993, SIL BREAST IMPL TEAM	20	40	43	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1995	9	5					424	427		10.1096/fasebj.9.5.7896014	http://dx.doi.org/10.1096/fasebj.9.5.7896014			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QP451	7896014				2022-12-25	WOS:A1995QP45100017
J	KONDO, M; SUZUKI, H; UEDA, R; TAKAGI, K; TAKAHASHI, T; TAKAHASHI, T				KONDO, M; SUZUKI, H; UEDA, R; TAKAGI, K; TAKAHASHI, T; TAKAHASHI, T			PARENTAL ORIGIN OF 11P15 DELETIONS IN HUMAN LUNG-CANCER	ONCOGENE			English	Note							SHORT ARM; WILMS-TUMOR; CHROMOSOME-11; GENES; CARCINOGENESIS; ABNORMALITIES; RELAXATION; CARCINOMAS; ALLELE	Frequent occurrence of 11p deletions has been reported for diverse types of human cancers including lung cancers and Wilms' tumors. In contrast to the well documented identification of preferential retention of the paternal allele in Wihms' tumors, no data have hitherto been available for cancers of adults. Taking advantage of the paternal allele-specific expression of IGF2 in the normal lung, we examined 79 lung cancer cases to investigate allelic loss at 11p15 and the parental origin of the retained alleles. While 11 of 36 (31%) informative lung cancer cases exhibited 11p15 deletions, only seven of these (64%) retained the paternal allele in tumors (P = 0.274), showing a contrast to the strong paternal bias in childhood tumors. Our strategy eliminates the need for parental DNAs for the determination and should be applicable to other adulthood tumors carrying 11P deletions such as breast and bladder cancers.	AICHI CANC CTR, RES INST, CHEMOTHERAPY LAB, CHIKUSA KU, NAGOYA 464, AICHI, JAPAN; AICHI CANC CTR, RES INST, IMMUNOL LAB, CHIKUSA KU, NAGOYA 464, AICHI, JAPAN; NAGOYA UNIV, SCH MED, DEPT INTERNAL MED 2, SHOWA KU, NAGOYA, AICHI 466, JAPAN	Aichi Cancer Center; Aichi Cancer Center; Nagoya University			Takahashi, Takashi/I-7262-2014; Kondo, Masashi/I-7378-2014	Takahashi, Takashi/0000-0003-0615-7001; 				FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; LEE JH, 1989, CANCER RES, V49, P1220; LUDWIG CU, 1991, INT J CANCER, V49, P661, DOI 10.1002/ijc.2910490506; MINNA JD, 1991, BRIS MYER C, V12, P63; Minna JD, 1989, CANCER PRINCIPLES PR, P591; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; REIK W, 1989, NATURE, V338, P112, DOI 10.1038/338112a0; SAPIENZA C, 1991, BIOCHIM BIOPHYS ACTA, V1072, P51, DOI 10.1016/0304-419X(91)90006-7; SHIRAISHI M, 1987, JPN J CANCER RES, V78, P1302; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THEILLET C, 1986, CANCER RES, V46, P4776; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WILKINS RJ, 1988, LANCET, V1, P329	19	12	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3063	3065						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	7916149				2022-12-25	WOS:A1994PG82200038
J	FRONTICELLI, C; PECHIK, I; BRINIGAR, WS; KOWALCZYK, J; GILLILAND, GL				FRONTICELLI, C; PECHIK, I; BRINIGAR, WS; KOWALCZYK, J; GILLILAND, GL			CHLORIDE-ION INDEPENDENCE OF THE BOHR EFFECT IN A MUTANT HUMAN HEMOGLOBIN BETA(V1M+H2DELETED)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; HUMAN DEOXYHEMOGLOBIN; ESCHERICHIA-COLI; BINDING-SITE; RESOLUTION	A mutant human hemoglobin, beta(V1M+H2 Delta), has been constructed. Analysis of the oxygen binding curves obtained at pH 8.3, where the Bohr effect is inoperative, indicates that this mutation results in an additional stabilization of the T-state conformation by 0.9 kcal/mol. The crystal structure of deoxy-beta(V1M+H2 Delta) has been determined to 2.2-Angstrom resolution and compared with the deoxy structure of human hemoglobin at the same resolution. In human hemoglobin, a sulfate anion is anchored to the beta-chains by a complex network of H-bonds and electrostatic interactions with the amino terminus and Lys(beta 82). In the mutant hemoglobin, the shortening of the amino-terminal region of the A helix by 1 residue results in the formation of an intrachain electrostatic interaction between the amino-terminal amino and Asp(beta 79). This eliminates the sulfate binding site, and the sulfate is replaced by two water molecules. At variance with human hemoglobin, the alkaline Bohr effect for beta(V1M+H2 Delta) is not sensitive to the presence of Cl-. This indicates that the sulfate binding site in human hemoglobin also serves as a Cl- binding site, and that the amino terminal Val(beta 1) is essential for oxygen-linked Cl- binding to hemoglobin as well as the Cl--dependent Bohr effect. Analysis of the oxygen binding curves indicates that the oxygen-linked Cl- ions are released upon binding of the first oxygen molecule.	UNIV MARYLAND,MARYLAND BIOTECHNOL INST,CTR ADV RES BIOTECHNOL,ROCKVILLE,MD 20850; TEMPLE UNIV,DEPT CHEM,PHILADELPHIA,PA 19122; NATL INST STAND & TECHNOL,ROCKVILLE,MD 20850	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; National Institute of Standards & Technology (NIST) - USA	FRONTICELLI, C (corresponding author), UNIV MARYLAND,SCH MED,DEPT BIOCHEM,108 N GREENE ST,BALTIMORE,MD 21201, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL013164, P01HL048517] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL48517, HLBI-13164] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adair GS, 1925, J BIOL CHEM, V63, P529; [Anonymous], 1968, J CRYST GROWTH, DOI [rg/10.1016/00220248(68)900717, DOI 10.1016/0022-0248(68)90071-7]; ARNONE A, 1972, NATURE, V237, P146, DOI 10.1038/237146a0; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1992, X PLOR VERSION 3 1; BUCCI E, 1988, BIOPHYS CHEM, V32, P187, DOI 10.1016/0301-4622(88)87006-6; DOLMAN D, 1978, ANAL BIOCHEM, V87, P127, DOI 10.1016/0003-2697(78)90576-6; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; FRONTICELLI C, 1991, J PROTEIN CHEM, V10, P495, DOI 10.1007/BF01025477; FRONTICELLI C, 1982, TECHNIQUES PROTEIN C, V3, P399; GILL SJ, 1987, BIOCHEMISTRY-US, V26, P3995, DOI 10.1021/bi00387a038; HO C, 1987, BIOCHEMISTRY-US, V26, P6299, DOI 10.1021/bi00394a001; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KAVANAUGH JS, 1992, BIOCHEMISTRY-US, V31, P4111, DOI 10.1021/bi00131a030; KAVANAUGH JS, 1992, BIOCHEMISTRY-US, V31, P8640, DOI 10.1021/bi00151a034; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; ODONNELL S, 1979, J BIOL CHEM, V254, P2204; PERUTZ MF, 1980, J MOL BIOL, V136, P183, DOI 10.1016/0022-2836(80)90312-5; PERUTZ MF, 1993, J MOL BIOL, V233, P536, DOI 10.1006/jmbi.1993.1530; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4; Wyman J, 1990, BINDING LINKAGE FUNC	25	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23965	23969						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929044				2022-12-25	WOS:A1994PQ34600020
J	STALLINGSMANN, ML; BURKE, MG; TROUT, WE; ROBERTS, RM				STALLINGSMANN, ML; BURKE, MG; TROUT, WE; ROBERTS, RM			PURIFICATION, CHARACTERIZATION, AND CDNA CLONING OF A KUNITZ-TYPE PROTEINASE-INHIBITOR SECRETED BY THE PORCINE UTERUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; PLASMINOGEN-ACTIVATOR PRODUCTION; RETINOL-BINDING PROTEIN; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; PIG TROPHOBLAST; MESSENGER-RNA; EXPRESSION; PREGNANCY; IMPLANTATION	The porcine uterus synthesizes a proteinase inhibitor (M(r) 14,000) under the influence of progesterone that is relatively specific for plasmin and trypsin, but that also has weak affinity for chymotrypsin. Several isoforms of this uterine plasmin/trypsin inhibitor were purified by a procedure whose final two steps involved affinity chromatography on immobilized chymotrypsin and cation exchange chromatography. Amino-terminal sequencing showed that at least three of the isoforms were closely related. An oligonucleotide probe based on the protein sequence was used to identify a cDNA that contained an open reading frame coding for a mature protein (M(r) 10,295) of 98 amino acids. The inhibitor had a well defined, but unique, Kunitz domain of 64 residues at its amino terminus that shared 67% sequence identity to bovine pancreatic trypsin inhibitor. Its P-1 residue was arginine rather than lysine. Northern analysis showed the presence of a single mRNA species (700 bases) that in adult female pigs appeared to be confined to the uterus. During pregnancy, UPTI mRNA expression was high until Day 30 and decreased significantly thereafter. By contrast, uteroferrin mRNA reached maximal concentrations in late pregnancy. These data are consistent with an earlier hypothesis that the inhibitor serves to neutralize the activities of one or more serine proteinases generated by the proliferating trophoblast during the formation of the noninvasive placenta of the pig.	UNIV MISSOURI,AMIM SCI RES CTR 158,DEPT ANIM SCI,COLUMBIA,MO 65211; UNIV MISSOURI,DEPT BIOCHEM,COLUMBIA,MO 65211	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia				Stallings-Mann, Melody/0000-0003-3227-6063	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021980] Funding Source: NIH RePORTER; NICHD NIH HHS [HD21980] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		APLIN JD, 1991, J CELL SCI, V99, P681; AXEN R, 1967, NATURE, V214, P1302, DOI 10.1038/2141302a0; BAZER FW, 1983, J ANIM SCI, V57, P425; BISCHOF P, 1992, PLACENTA, V13, P17, DOI 10.1016/0143-4004(92)90003-C; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CREIGHTON TE, 1987, COLD SPRING HARB SYM, V52, P511, DOI 10.1101/SQB.1987.052.01.058; DANIEL JC, 1978, METHODS MAMMALIAN RE, P503; DAVIS LG, 1986, BASIC METHODS MOL BI, P75; DROBNICKOSOROK M, 1990, BIOL CHEM H-S, V371, P57, DOI 10.1515/bchm3.1990.371.1.57; FAZLEABAS AT, 1982, J BIOL CHEM, V257, P6886; FAZLEABAS AT, 1983, BIOL REPROD, V29, P225, DOI 10.1095/biolreprod29.1.225; FAZLEABAS AT, 1984, ENDOCRINOLOGY, V116, P240; FRANK M, 1977, PROSTAGLANDINS, V14, P1183, DOI 10.1016/0090-6980(77)90295-7; FRIESS AE, 1980, ANAT EMBRYOL, V158, P179, DOI 10.1007/BF00315905; FRITZ H, 1983, ARZNEIMITTELFORSCH, V33-1, P479; HAFEZ ESE, 1987, REPRODUCTION FARM AN, P229; HARNEY JP, 1994, BIOL REPROD, V50, P1126, DOI 10.1095/biolreprod50.5.1126; HYNES TR, 1990, BIOCHEMISTRY-US, V29, P10018, DOI 10.1021/bi00495a002; KINGSTON IB, 1986, BIOCHEM J, V233, P443, DOI 10.1042/bj2330443; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; MALATHY PV, 1990, MOL ENDOCRINOL, V4, P428, DOI 10.1210/mend-4-3-428; MARTIN O, 1982, AM J OBSTET GYNECOL, V142, P402, DOI 10.1016/S0002-9378(16)32380-8; MATTA MS, 1977, J BIOL CHEM, V252, P8423; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MULLINS DE, 1980, CELL, V20, P865, DOI 10.1016/0092-8674(80)90333-5; MURRAY FA, 1972, BIOL REPROD, V7, P314, DOI 10.1093/biolreprod/7.3.314; QUEENAN JT, 1987, J BIOL CHEM, V262, P10903; RUHLMANN A, 1973, J MOL BIOL, V77, P417, DOI 10.1016/0022-2836(73)90448-8; SALIER JP, 1990, TRENDS BIOCHEM SCI, V15, P435, DOI 10.1016/0968-0004(90)90282-G; Sambrook J, 1989, MOL CLONING LABORATO; SAMUEL CA, 1972, J ANAT, V113, P139; SAMUEL CA, 1971, J REPROD FERTIL, V27, P494; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; SIMMEN RCM, 1988, MOL ENDOCRINOL, V2, P253, DOI 10.1210/mend-2-3-253; STRICKLAND S, 1992, CELL, V71, P355, DOI 10.1016/0092-8674(92)90503-5; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; TROUT WE, 1992, ENDOCRINOLOGY, V130, P2557, DOI 10.1210/en.130.5.2557; TROUT WE, 1991, MOL ENDOCRINOL, V5, P1533, DOI 10.1210/mend-5-10-1533; VINCENT JP, 1972, BIOCHEMISTRY-US, V11, P2967, DOI 10.1021/bi00766a007; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WADA KN, 1990, NUCLEIC ACIDS RES, V18, P2367, DOI 10.1093/nar/18.suppl.2367; WEISSMAN JS, 1992, CELL, V71, P841, DOI 10.1016/0092-8674(92)90559-U; WLODAWER A, 1984, J MOL BIOL, V180, P301, DOI 10.1016/S0022-2836(84)80006-6; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	47	18	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24090	24094						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929061				2022-12-25	WOS:A1994PQ34600039
J	KANDROR, O; BUSCONI, L; SHERMAN, M; GOLDBERG, AL				KANDROR, O; BUSCONI, L; SHERMAN, M; GOLDBERG, AL			RAPID DEGRADATION OF AN ABNORMAL PROTEIN IN ESCHERICHIA-COLI INVOLVES THE CHAPERONES GROEL AND GROES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASE; HEAT-SHOCK; CLP PROTEASE; GENE-PRODUCT; ACTIVATED ATPASE; HSP70 HOMOLOG; ION GENE; DNAK; PROTEOLYSIS; COMPONENT	In Escherichia coli, the molecular chaperones (DnaK, DnaJ, and GrpE) are essential for the rapid degradation of certain proteins. To see if chaperones are involved more generally in proteolysis, we studied the degradation of a short-lived fusion protein, CRAG, which associates with DnaK and GroEL in vivo. Its rapid degradation requires ATP and ClpP, the proteolytic subunit of protease Ti (Clp). However, this process is not reduced in strains lacking the complementary ATPase subunit, ClpA, or its homologs, ClpB and CLpX. At 37 degrees C, but not at 42 degrees C, protease La also contributes partially to CRAG degradation. Nevertheless, CRAG is not degraded in cell-free extracts or upon incubation with ClpP or protease La. We tested whether the chaperones associated with CRAG might be involved in its degradation. CRAG breakdown was accelerated 2-3 fold in strains with high levels of heat-shock proteins (hsps), i.e. in those that overproduce the hsp transcription factor (sigma(32)) or carry a dnaK deletion. A similar stimulation of proteolysis was observed in cells overproducing GroEL or both GroEL and GroES; in these cells, more CRAG was associated with GroEL than in the wild type. In a temperature-sensitive groEL44 mutant at the nonpermissive temperature, CRAG breakdown was accelerated, and more CRAG was found complexed with GroEL. However, in a temperature-sensitive groES mutant, CRAG was completely stable at the nonpermissive temperature and accumulated bound to GroEL. These findings indicate that the association of CRAG with GroEL is a rate-limiting step in CRAG degradation, which also requires a subsequent action of GroES. We propose that if the hsp60/ hsp10 chaperonins fail to catalyze the proper folding of a protein, they can facilitate its rapid degradation.			KANDROR, O (corresponding author), HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA.							BANEYX F, 1992, J BIOL CHEM, V267, P11637; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; CHUNG CH, 1981, P NATL ACAD SCI-BIOL, V78, P4931, DOI 10.1073/pnas.78.8.4931; CRAIG E, 1990, TRENDS BIOCHEM SCI, V16, P135; DAMERAU K, 1993, J BACTERIOL, V175, P53, DOI 10.1128/JB.175.1.53-63.1993; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GEUSKENS V, 1992, EMBO J, V11, P5121, DOI 10.1002/j.1460-2075.1992.tb05619.x; GOFF SA, 1984, P NATL ACAD SCI-BIOL, V81, P6647, DOI 10.1073/pnas.81.21.6647; GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3; GOFF SA, 1987, J BIOL CHEM, V262, P4508; Goff SA, 1988, UBIQUITIN, P207; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GOTTESMAN S, 1989, ANNU REV GENET, V23, P163, DOI 10.1146/annurev.ge.23.120189.001115; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; GROSSMAN AD, 1984, CELL, V38, P383, DOI 10.1016/0092-8674(84)90493-8; Hartl F U, 1991, Semin Immunol, V3, P5; HELLEBUST H, 1990, J BACTERIOL, V172, P5030, DOI 10.1128/jb.172.9.5030-5034.1990; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; HWANG BJ, 1987, P NATL ACAD SCI USA, V84, P5550, DOI 10.1073/pnas.84.16.5550; KATAYAMAFUJIMURA Y, 1987, J BIOL CHEM, V262, P4477; KELLER JA, 1988, MOL MICROBIOL, V2, P31, DOI 10.1111/j.1365-2958.1988.tb00004.x; KROH HE, 1990, J BACTERIOL, V172, P6026, DOI 10.1128/jb.172.10.6026-6034.1990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MAURIZI MR, 1985, J BACTERIOL, V164, P1124, DOI 10.1128/JB.164.3.1124-1135.1985; Miller J.H., 1972, EXPT MOL GENETICS; OLDEN K, 1978, BIOCHIM BIOPHYS ACTA, V542, P385, DOI 10.1016/0304-4165(78)90370-7; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PFANNER N, 1990, ANTON LEEUW INT J G, V58, P191, DOI 10.1007/BF00548932; SHERMAN M, 1991, J BACTERIOL, V173, P4249; SHERMAN MY, 1992, NATURE, V357, P167, DOI 10.1038/357167a0; SHERMAN MY, 1992, EMBO J, V11, P71; SHERMAN MY, 1993, P NATL ACAD SCI USA, V90, P8648, DOI 10.1073/pnas.90.18.8648; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SQUIRES C, 1991, J BACTERIOL, V173, P4259; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; Welch WJ, 1991, CURR OPIN CELL BIOL, V3, P1033, DOI 10.1016/0955-0674(91)90125-I; WICKNER W, 1989, TRENDS BIOCHEM SCI, V14, P280, DOI 10.1016/0968-0004(89)90064-9; WOO KM, 1989, J BIOL CHEM, V264, P2088; WOO KM, 1992, J BIOL CHEM, V267, P20429	43	118	119	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23575	23582						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	7916344				2022-12-25	WOS:A1994PQ34500031
J	DESSAUER, CW; BARTLETT, SG				DESSAUER, CW; BARTLETT, SG			IDENTIFICATION OF A CHAPERONIN BINDING-SITE IN A CHLOROPLAST PRECURSOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SMALL SUBUNIT; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; MOLECULAR CHAPERONE; BETA-LACTAMASE; GROEL PROTEIN; HSP60; GENES; HELIX; PURIFICATION	Although chaperonin-assisted protein folding has been studied in vitro by a number of investigators, the feature(s) of the unfolded polypeptide that are recognized and bound by chaperonins is not known. We have addressed this question using the precursor of the small subunit of ribulose-1,5-bisphosphate carboxylase (pS) as a substrate for GroEL. The protein was expressed in Escherichia coli as a C-terminal fusion to protein A. Protein A-pS and any associated cellular proteins were then purified by affinity chromatography. GroEL could be eluted from the fusion protein by incubation with ATP and either GroES or casein, consistent with results of in vitro folding assays. At least half of the transit sequence of pS is required to maintain this high stoichiometry of chaperonin binding. Using deletion mutagenesis from the C terminus of pS, we defined the smallest truncation of pS, PAxpS90T, that binds GroEL with high avidity (dissociation constant = 53 nM). A series of site-specific mutations targeting the C-terminal 15-20 amino acids of PAxpS90T was constructed and analyzed for the ability to bind GroEL. Our results show that complex formation between GroEL and pS is not dependent upon any single feature such as overall hydrophobicity, a net positive charge, or secondary structure but may be dependent upon a combination of these features.	LOUISIANA STATE UNIV, DEPT BIOCHEM, BATON ROUGE, LA 70803 USA; UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	Louisiana State University System; Louisiana State University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Dessauer, Carmen/N-6933-2018	Dessauer, Carmen/0000-0003-1210-4280				BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROGLIE R, 1983, BIO-TECHNOL, V1, P55, DOI 10.1038/nbt0383-55; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHAKRABARTTY A, 1991, NATURE, V351, P586, DOI 10.1038/351586a0; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; ELLIS RJ, 1988, PHOTOSYNTH RES, V16, P101, DOI 10.1007/BF00039488; FAWCETT TW, 1990, BIOTECHNIQUES, V9, P46; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOVEZENSKY D, 1991, J BACTERIOL, V173, P6339, DOI 10.1128/jb.173.20.6339-6346.1991; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KNIGHT S, 1989, SCIENCE, V244, P702, DOI 10.1126/science.244.4905.702; KOLL H, 1992, CELL, V68, P1163, DOI 10.1016/0092-8674(92)90086-R; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1989, J BIOL CHEM, V264, P9090; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LEVITT M, 1978, BIOCHEMISTRY-US, V17, P4277, DOI 10.1021/bi00613a026; LIU G, 1988, J BIOL CHEM, V263, P14790; LUBBEN TH, 1989, PLANT CELL, V1, P1223, DOI 10.1105/tpc.1.12.1223; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; MADUENO F, 1993, PLANT CELL, V5, P1865, DOI 10.1105/tpc.5.12.1865; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MCMULLIN TW, 1988, MOL CELL BIOL, V8, P371, DOI 10.1128/MCB.8.1.371; MCPHERSON GA, 1983, COMPUT PROG BIOMED, V17, P107, DOI 10.1016/0010-468X(83)90031-4; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PINGCHIANG LC, 1990, SCIENCE, V250, P669; PUSHKIN AV, 1982, BIOCHIM BIOPHYS ACTA, V704, P379, DOI 10.1016/0167-4838(82)90169-8; PUTKEY JA, 1983, J BIOL CHEM, V258, P1864; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; RANDALL LL, 1992, SCIENCE, V257, P241, DOI 10.1126/science.1631545; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; ROSENBERG HF, 1993, J BIOL CHEM, V268, P4499; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; STREHLOW KG, 1991, BIOCHEMISTRY-US, V30, P5810, DOI 10.1021/bi00237a026; TANDON S, 1986, J BIOL CHEM, V261, P5615; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; ZAHN R, 1992, BIOCHEMISTRY-US, V31, P3249, DOI 10.1021/bi00127a029	50	23	24	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19766	19776						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	7914191				2022-12-25	WOS:A1994PA12600021
J	PIETRAS, RJ; FENDLY, BM; CHAZIN, VR; PEGRAM, MD; HOWELL, SB; SLAMON, DJ				PIETRAS, RJ; FENDLY, BM; CHAZIN, VR; PEGRAM, MD; HOWELL, SB; SLAMON, DJ			ANTIBODY TO HER-2/NEU RECEPTOR BLOCKS DNA-REPAIR AFTER CISPLATIN IN HUMAN BREAST AND OVARIAN-CANCER CELLS	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; MONOCLONAL-ANTIBODIES; NEU ONCOGENE; TUMOR-CELLS; CARCINOMA-CELLS; PROTO-ONCOGENE; EXPRESSION; GENE; OVEREXPRESSION; C-ERBB-2	Approximately 30% of human breast and ovarian cancers have amplification and/or overexpression of HER-2/neu gene which encodes a cell surface growth-factor receptor. Overexpression of this receptor, P185(HER-2/neu), is associated with poor outcome and may predict clinical response to chemotherapy. Antibodies to HER-2/neu receptor have a cytostatic effect in suppressing growth of cells with overexpression of p185(HER-2/neu). To elicit a cytocidal effect, therapy with antireceptor antibody was used in combination with the DNA-damaging drug, cisplatin, and this combined treatment produced a synergistic decrease in cell growth. In addition, antibody mediated an increased sensitivity to cisplatin in drug-resistant ovarian carcinoma cells containing multiple copies of HER-2/neu gene. To evaluate the mechanism for this synergy, unscheduled DNA synthesis was measured in cancer cells using incorporation of [H-3]thymidine and autoradiography, and formation and repair of cisplatin-induced DNA adducts was also measured. Treatment with cisplatin led to a marked, dose-dependent increase in unscheduled DNA synthesis which was significantly reduced by combined treatment with antireceptor antibody in HER-2/neu-overexpressing cells. Therapy with antibody to HER-2/neu receptor also led to a 35-40% reduction in repair of cisplatin-DNA adducts after cisplatin exposure and, as a result, promoted drug-induced killing in target cells. This phenomenon which we term receptor-enhanced chemosensitivity may provide a rationale for more selective targeting and exploitation of overexpressed growth factor receptors in canter cells, thus leading to new strategies for clinical intervention.	GENENTECH INC,S SAN FRANCISCO,CA 94080; UNIV CALIF SAN DIEGO,CTR CANC,SAN DIEGO,CA 92093	Roche Holding; Genentech; University of California System; University of California San Diego	PIETRAS, RJ (corresponding author), UNIV CALIF LOS ANGELES,DIV HEMATOL ONCOL,LOS ANGELES,CA 90024, USA.			Pietras, Richard/0000-0002-2846-3192	NCI NIH HHS [CA01714-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K12CA001714] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ABOUDPIRAK E, 1988, J NATL CANCER I, V80, P1605, DOI 10.1093/jnci/80.20.1605; ALLRED DC, 1992, J CLIN ONCOL, V10, P599, DOI 10.1200/JCO.1992.10.4.599; ANDREWS PA, 1988, CANCER RES, V48, P68; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERCHUCK A, 1991, AM J OBSTET GYNECOL, V164, P15, DOI 10.1016/0002-9378(91)90615-X; BERENBAUM MC, 1989, PHARMACOL REV, V41, P93; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; Bohr VA, 1988, DNA REPAIR LABORATOR, V3, P347; BUTTERWORTH BE, 1987, MUTAT RES, V189, P113, DOI 10.1016/0165-1218(87)90017-6; CAMPBELL RC, 1967, STATISTICS BIOL; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CHAZIN VR, 1992, ONCOGENE, V7, P1859; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; CHRISTEN R D, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P430; CHRISTEN RD, 1990, J CLIN INVEST, V86, P1632, DOI 10.1172/JCI114885; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DESANTES K, 1992, CANCER RES, V52, P1916; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DISAIA PJ, 1972, AM J OBSTET GYNECOL, V114, P979, DOI 10.1016/0002-9378(72)90109-3; DOMINICI C, 1989, J CLIN ONCOL, V7, P100, DOI 10.1200/JCO.1989.7.1.100; DOOLITTLE RF, 1986, NATURE, V323, P451, DOI 10.1038/323451a0; DREBIN JA, 1988, ONCOGENE, V2, P387; FENDLY BM, 1990, CANCER RES, V50, P1550; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; HAIMOVITZFRIEDMAN A, 1991, CANCER RES, V51, P2552; HANCOCK MC, 1991, CANCER RES, V51, P4575; HARRIS JR, 1992, NEW ENGL J MED, V327, P473, DOI 10.1056/NEJM199208133270706; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; ISONISHI S, 1991, CANCER RES, V51, P5903; JENSEN L, 1988, MOL CELL BIOL, V8, P3964, DOI 10.1128/MCB.8.9.3964; JONES JC, 1991, J BIOL CHEM, V266, P7101; KASPRZYK PG, 1992, CANCER RES, V52, P2771; KINZEL V, 1990, CANCER RES, V50, P7932; KLIJN JGM, 1992, P AN M AM SOC CLIN, V11, P53; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; KWOK TT, 1989, J NATL CANCER I, V81, P1020, DOI 10.1093/jnci/81.13.1020; LEMOINE NR, 1990, ONCOGENE, V5, P237; Lofts F J, 1992, Cancer Treat Res, V61, P161; MARTIN M, 1992, J CLIN ONCOL, V10, P433, DOI 10.1200/JCO.1992.10.3.433; MASUDA H, 1988, CANCER RES, V48, P5713; MASUI H, 1984, CANCER RES, V44, P1002; MCCLAY EF, 1990, GYNECOL ONCOL, V36, P1, DOI 10.1016/0090-8258(90)90099-7; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MONTINE TJ, 1988, CANCER RES, V48, P6017; MROCZKOWSKI B, 1984, NATURE, V309, P270, DOI 10.1038/309270a0; PARK JB, 1989, CANCER RES, V49, P6605; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PERA MF, 1981, CHEM-BIOL INTERACT, V37, P245, DOI 10.1016/0009-2797(81)90181-2; PEREZ RP, 1991, SEMIN ONCOL, V18, P186; PIERCE JH, 1991, ONCOGENE, V6, P1189; PIETRAS R J, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P547; PIETRAS RJ, 1991, J CELL BIOL, V115, P416; PRESS MF, 1993, CANCER RES, V53, P4960; SARUP JC, 1991, GROWTH REGULAT, V1, P72; SCANLON KJ, 1989, ANTICANCER RES, V9, P1301; SCANLON KJ, 1988, P NATL ACAD SCI USA, V85, P650, DOI 10.1073/pnas.85.3.650; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936; SHEPARD HM, 1991, J CLIN IMMUNOL, V11, P117, DOI 10.1007/BF00918679; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SKLAR MD, 1988, CANCER RES, V48, P793; SLAMON DJ, 1989, CANCER CEL, V7, P371; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TROSKO JE, 1974, EXP CELL RES, V88, P47, DOI 10.1016/0014-4827(74)90616-8; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; WHITAKER SJ, 1992, EUR J CANCER, V28A, P273, DOI 10.1016/0959-8049(92)90432-2; WILLIAMS GM, 1977, CANCER RES, V37, P1845; WRIGHT C, 1989, CANCER RES, V49, P2087; YAMAMOTO T, 1986, CANCER RES, V46, P414; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHEN WP, 1992, MOL CELL BIOL, V12, P3689, DOI 10.1128/MCB.12.9.3689	76	407	462	1	21	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1829	1838						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	7911565				2022-12-25	WOS:A1994NR68500004
J	CZYZYKRZESKA, MF; DOMINSKI, Z; KOLE, R; MILLHORN, DE				CZYZYKRZESKA, MF; DOMINSKI, Z; KOLE, R; MILLHORN, DE			HYPOXIA STIMULATES BINDING OF A CYTOPLASMIC PROTEIN TO A PYRIMIDINE-RICH SEQUENCE IN THE 3'-UNTRANSLATED REGION OF RAT TYROSINE-HYDROXYLASE MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPYRIMIDINE TRACT; UNTRANSLATED REGION; SPLICE SITES; GENE; IDENTIFICATION; TRANSLATION; STABILITY; ELEMENTS	Reduced oxygen tension (hypoxia) induces a 3-fold increase in stability of mRNA for tyrosine hydroxylase (TH), the rate-limiting enzyme in catecholamine synthesis, in the pheochromocytoma (PC12) clonal cell line. To investigate the possibility that RNA-protein interactions are involved in mediating this increase in stability, RNA gel shift assays were performed using different fragments of labeled TH mRNA and the S-100 fraction of PC12 cytoplasmic protein extracts. We identified a sequence within the 3'-untranslated region of TH mRNA that binds cytoplasmic protein. RNase T1 mapping revealed that the protein was bound to a 28 nucleotide long sequence that is located between bases 1551-1579 of TH mRNA. Moreover, protein binding to this fragment was prevented with an antisense oligonucleotide directed against bases 1551-1579 and subsequent RNase H digestion. This fragment of the 3'-untranslated region of TH mRNA is rich in pyrimidine nucleotides, and the binding of cytoplasmic protein to this fragment was reduced by competition with other polypyrimidine sequences including poly(C) but not poly(U) polymers. The binding of the protein to TH mRNA was increased when cytoplasmic proteins were extracted from PC12 cells exposed to hypoxia (5% O2) for 24 h. Electrophoresis of the UV cross-linked RNA-protein complex on SDS-polyacrylamide gel electrophoresis revealed a complex of 74 kDa. The potential role of this protein-TH mRNA interaction in regulation of TH mRNA stability during hypoxia is discussed.	UNIV N CAROLINA,MOLEC & DEV NEUROSCI LAB,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PEDIAT,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	CZYZYKRZESKA, MF (corresponding author), UNIV N CAROLINA,DEPT PHYSIOL,474 MED RES BLDG,CHAPEL HILL,NC 27599, USA.				NHLBI NIH HHS [HL 33831, HL 51078, HL 34919] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL051078, R37HL033831, R01HL033831, R01HL034919] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABMAYR SM, 1992, CURRENT PROTOCOLS MO, V2; ATWATER JA, 1990, ANNU REV GENET, V24, P519; BROWN ER, 1987, BIOCHEMISTRY-US, V26, P5208, DOI 10.1021/bi00390a046; CARTER BZ, 1991, LAB INVEST, V65, P610; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; CZYZYKKRZESKA MF, 1992, J NEUROCHEM, V58, P1538, DOI 10.1111/j.1471-4159.1992.tb11376.x; DOMINSKI Z, 1991, MOL CELL BIOL, V11, P6075, DOI 10.1128/MCB.11.12.6075; DREYFUSS G, 1988, J CELL BIOL, V106, P1419, DOI 10.1083/jcb.106.5.1419; FEINSILVER SH, 1987, BIOCHIM BIOPHYS ACTA, V928, P56, DOI 10.1016/0167-4889(87)90085-1; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GHETTI A, 1992, NUCLEIC ACIDS RES, V20, P3671, DOI 10.1093/nar/20.14.3671; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GONZALEZ C, 1979, J NEUROCHEM, V33, P713, DOI 10.1111/j.1471-4159.1979.tb05216.x; GRIMA B, 1985, P NATL ACAD SCI USA, V74, P4835; HANBAUER I, 1977, NEUROPHARMACOLOGY, V16, P277, DOI 10.1016/0028-3908(77)90107-1; KASPAR RL, 1992, J BIOL CHEM, V267, P508; KAUFMAN S, 1966, PHARMACOL REV, V18, P61; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEVY S, 1991, P NATL ACAD SCI USA, V88, P3319, DOI 10.1073/pnas.88.8.3319; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; MORRIS DR, 1993, BIOCHEMISTRY-US, V32, P2931, DOI 10.1021/bi00063a001; OMALLEY KL, 1987, BIOCHEMISTRY-US, V26, P6910, DOI 10.1021/bi00396a007; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; RONDON IJ, 1991, J BIOL CHEM, V266, P16594; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; UNDENFRIEND S, 1966, PHARMACOL REV, V18, P43; YOUNG S, 1991, NUCLEIC ACIDS RES, V19, P2463, DOI 10.1093/nar/19.9.2463	30	94	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9940	9945						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	7908289				2022-12-25	WOS:A1994NE05300083
J	ADAMS, AD; CHOATE, DM; THOMPSON, MA				ADAMS, AD; CHOATE, DM; THOMPSON, MA			NF1-L IS THE DNA-BINDING COMPONENT OF THE PROTEIN COMPLEX AT THE PERIPHERIN NEGATIVE REGULATORY ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; INTERMEDIATE FILAMENT PROTEIN; NEURAL-SPECIFIC GENE; C-FOS; TRANSCRIPTION FACTOR; PC12 CELLS; RETINOBLASTOMA PROTEIN; EXPRESSION; PURIFICATION; PROMOTER	The peripherin gene, which encodes a neuronal-specific intermediate filament protein, is transcriptionally induced with a late time course when nerve growth factor stimulates PC12 cells to differentiate into neurons. We have defined a negative regulatory element (NRE) that has a functional role in repressing peripherin expression in undifferentiated and nonneuronal cells. Nerve growth factor-induced derepression of peripherin gene expression is associated with alterations in proteins binding to a GC-rich DNA sequence in the NRE as detected by the DNA electrophoretic mobility shift assay (EMSA). We have utilized DNA affinity chromatography to purify from rat liver a 33-kDa DNA-binding protein that specifically recognizes the NRE. Microsequencing reveals identity with NF1-L, a member of the CTF/NF-1 transcription factor family. This protein forms a single complex when incubated with the NRE probe using EMSA analysis. The more slowly migrating complexes characteristic of crude undifferentiated PC12 cell extract are reconstituted by mixing the purified protein with the flow-through from the DNA affinity column, thereby demonstrating that protein-protein interactions are involved in complex formation. Supershift experiments incubating anti-CTF-1 antibody with undifferentiated PC12 cell extract prior to EMSA analysis confirm that NF1-L, or a closely related family member, is the DNA-binding protein component of the multiprotein complex at the NRE.	VANDERBILT UNIV, MED CTR N C2210, SCH MED, DEPT CELL BIOL, NASHVILLE, TN 37232 USA	Vanderbilt University					NINDS NIH HHS [NS-30943] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030943] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON DJ, 1986, CELL, V47, P1079, DOI 10.1016/0092-8674(86)90823-8; ANDERSON DJ, 1993, ANNU REV NEUROSCI, V16, P129, DOI 10.1146/annurev.ne.16.030193.001021; BALDWIN AS, 1987, CURRENT PROTOCOLS MO; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BOONSTRA J, 1983, J CELL BIOL, V97, P92, DOI 10.1083/jcb.97.1.92; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BRODY BA, 1989, J NEUROSCI, V9, P2391; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CHODOSH LA, 1991, CURRENT PROTOCOLS MO; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOUPE AJ, 1985, J NEUROSCI, V5, P2119; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GORHAM JD, 1990, DEV BRAIN RES, V57, P235, DOI 10.1016/0165-3806(90)90049-5; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; KADONAGA JT, 1991, METHOD ENZYMOL, V208, P10; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KRUSE U, 1994, FEBS LETT, V348, P46, DOI 10.1016/0014-5793(94)00585-0; LANDIS SC, 1981, TRENDS NEUROSCI, V4, P172, DOI 10.1016/0166-2236(81)90056-4; LEONARD DGB, 1988, J CELL BIOL, V106, P181, DOI 10.1083/jcb.106.1.181; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; MANDEL G, 1993, ANNU REV NEUROSCI, V16, P323, DOI 10.1146/annurev.ne.16.030193.001543; MARKOVITZ A, 1972, BIOCHIM BIOPHYS ACTA, V281, P522, DOI 10.1016/0005-2787(72)90153-0; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; PARYSEK LM, 1988, J NEUROSCI, V8, P555; PORTIER MM, 1984, DEV NEUROSCI-BASEL, V6, P215, DOI 10.1159/000112348; RUPP RAW, 1987, NUCLEIC ACIDS RES, V15, P9707, DOI 10.1093/nar/15.23.9707; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHOONJANS K, 1993, FEBS LETT, V329, P89, DOI 10.1016/0014-5793(93)80200-E; SHELTON DL, 1984, P NATL ACAD SCI-BIOL, V81, P7951, DOI 10.1073/pnas.81.24.7951; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SPANDAU DF, 1992, J GEN VIROL, V73, P131, DOI 10.1099/0022-1317-73-1-131; STEIN R, 1988, DEV BIOL, V127, P316, DOI 10.1016/0012-1606(88)90318-1; THOMPSON MA, 1989, NEURON, V2, P1043, DOI 10.1016/0896-6273(89)90228-6; THOMPSON MA, 1992, MOL CELL BIOL, V12, P2501, DOI 10.1128/MCB.12.6.2501; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WUENSCHELL CW, 1990, NEURON, V4, P595, DOI 10.1016/0896-6273(90)90117-X; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093	55	62	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6975	6983		10.1074/jbc.270.12.6975	http://dx.doi.org/10.1074/jbc.270.12.6975			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896848	hybrid			2022-12-25	WOS:A1995QQ85500079
J	FUKUDA, K; KATO, S; MORI, K				FUKUDA, K; KATO, S; MORI, K			LOCATION OF REGIONS OF THE OPIOID RECEPTOR INVOLVED IN SELECTIVE AGONIST BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHARMACOLOGICAL CHARACTERIZATION; MOLECULAR-CLONING; FUNCTIONAL EXPRESSION; EXTRACELLULAR DOMAIN; OPIATE RECEPTOR; HIGH-AFFINITY; CDNA CLONING; SUBSTANCE-P; DELTA; ANTAGONIST	To elucidate which portions of the opioid receptor molecules are involved in the ligand selectivity, we have expressed chimeric receptors between the rat delta- and mu-opioid receptors from cDNAs and analyzed their ligand binding properties, We demonstrate that the major binding determinant for the delta-selective enkephalin related peptide, [D-Pen(2),D-Pen(5)]enkephalin, resides within the region comprising the transmembrane segments V-VII and the intervening loop regions, On the other hand, the region spanning from the intracellular loop I to the amino terminal half of the transmembrane segment III is shown to be involved in determining high-affinity binding of the mu-selective enkephalin-related peptides, [D-Ala(2),MePhe(4),Gly-ol(5)]enkephalin and [D-Ala(2), MePhe(4),Met-ol(5)]enkephalin, whereas the major determinant nant for binding of the mu-selective alkaloids, morphine and codeine, is demonstrated to exist in the region spanning the transmembrane segments V-VII, These results indicate that distinct regions of the opioid receptor determine the selectivity for the delta- and the mu-selective enkephalin-related peptides and that the binding determinant for the mu-selective alkaloids is distinct from that for the mu-selective enkephalin-related peptides.			FUKUDA, K (corresponding author), KYOTO UNIV HOSP,DEPT ANESTHESIA,SAKYO KU,54 KAWAHARA CHO,KYOTO 60601,JAPAN.							BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; BZDEGA T, 1993, P NATL ACAD SCI USA, V90, P9305, DOI 10.1073/pnas.90.20.9305; CHEN Y, 1993, MOL PHARMACOL, V44, P8; CHEN Y, 1993, BIOCHEM J, V295, P625, DOI 10.1042/bj2950625; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FONG TM, 1992, J BIOL CHEM, V267, P25664; FUKUDA K, 1993, FEBS LETT, V327, P311, DOI 10.1016/0014-5793(93)81011-N; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KONG HY, 1993, J BIOL CHEM, V268, P23055; KRYSTEK SR, 1994, J BIOL CHEM, V269, P12383; LI SX, 1993, BIOCHEM J, V295, P629, DOI 10.1042/bj2950629; MENG F, 1993, P NATL ACAD SCI USA, V90, P9954, DOI 10.1073/pnas.90.21.9954; MINAMI M, 1993, FEBS LETT, V329, P291, DOI 10.1016/0014-5793(93)80240-U; MISHINA M, 1984, NATURE, V307, P604, DOI 10.1038/307604a0; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; NISHI M, 1993, FEBS LETT, V330, P77, DOI 10.1016/0014-5793(93)80923-I; PORTOGHESE PS, 1989, TRENDS PHARMACOL SCI, V10, P230, DOI 10.1016/0165-6147(89)90267-8; ROEMER D, 1977, NATURE, V268, P547, DOI 10.1038/268547a0; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; Schiller P. W., 1984, PEPTIDES ANAL SYNTHE, V6, P219; SIMON EJ, 1986, ANN NY ACAD SCI, V463, P31, DOI 10.1111/j.1749-6632.1986.tb21501.x; SIMONDS WF, 1988, ENDOCR REV, V9, P200, DOI 10.1210/edrv-9-2-200; THOMPSON RC, 1993, NEURON, V11, P903, DOI 10.1016/0896-6273(93)90120-G; WANG JB, 1993, P NATL ACAD SCI USA, V90, P10230, DOI 10.1073/pnas.90.21.10230; XIE YB, 1990, J BIOL CHEM, V265, P21411; YASUDA K, 1993, P NATL ACAD SCI USA, V90, P6736, DOI 10.1073/pnas.90.14.6736; YOKOTA Y, 1992, EMBO J, V11, P3585, DOI 10.1002/j.1460-2075.1992.tb05442.x	31	83	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6702	6709		10.1074/jbc.270.12.6702	http://dx.doi.org/10.1074/jbc.270.12.6702			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896813	hybrid			2022-12-25	WOS:A1995QQ85500044
J	RAO, US				RAO, US			MUTATION OF GLYCINE-185 TO VALINE ALTERS THE ATPASE FUNCTION OF THE HUMAN P-GLYCOPROTEIN EXPRESSED IN SF9 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; MULTIDRUG-RESISTANCE; PHOTOACTIVE ANALOGS; BINDING; GENE; COLCHICINE; AZIDOPINE; PROTEINS; PATTERN	A single amino acid substitution, Gly(185) --> Val, in the human P-glycoprotein (Pgp) was previously shown to cause an altered pattern of drug resistance in cell lines transfected with the MDR1 cDNA carrying this mutation, To further define the function of amino acid 185 in the Pgp, the wild-type and the mutant Val(185) Pgps were expressed in Sf9 insect cells, and their biochemical properties were compared, Verapamil- and colchicine-stimulated ATPase activities were markedly increased with concomitant increase in affinity for these compounds with Gly(185) --> Val substitution in the Pgp, However, the vinblastine-stimulated ATPase activities of the wild type and Val(185) Pgps were nearly identical. Because transport substrate-induced ATP hydrolysis is generally thought to reflect transport function, these data suggest that colchicine and verapamil are transported at an increased rate with Gly(185) --> Val substitution in the Pgp. These results also indicate that amino acid 185 is involved in verapamil and colchicine, but not in vinblastine, binding/transport. Kinetic analyses indi cate that cyclosporin A, an inhibitor of Pgp, binds to the verapamil and vinblastine binding/transport site(s) in the Pgp, Taken together, the results presented herein reveal that the verapamil and vinblastine binding/transport site(s) are in close proximity and that the cyclosporin A binding site spans the common region of these two drug binding/transport site(s) in the Pgp molecule.			RAO, US (corresponding author), UNIV N CAROLINA,DEPT PHARMACOL,CB 7020,BURNETT WOMACK BLDG,CHAPEL HILL,NC 27599, USA.				NATIONAL CANCER INSTITUTE [R01CA058491] Funding Source: NIH RePORTER; NCI NIH HHS [CA58491] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; ANDERSEN JP, 1985, P NATL ACAD SCI USA, V82, P4573, DOI 10.1073/pnas.82.14.4573; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; BUSCHE R, 1989, EUR J BIOCHEM, V183, P189, DOI 10.1111/j.1432-1033.1989.tb14912.x; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CORNWELL MM, 1986, P NATL ACAD SCI USA, V83, P3847, DOI 10.1073/pnas.83.11.3847; CRAIG WS, 1982, BIOCHEMISTRY-US, V21, P5707, DOI 10.1021/bi00265a049; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOMOLYA L, 1993, J BIOL CHEM, V268, P21498; KAJIJI S, 1994, BIOCHEMISTRY-US, V33, P5041, DOI 10.1021/bi00183a006; KIOKA N, 1989, BIOCHEM BIOPH RES CO, V162, P224, DOI 10.1016/0006-291X(89)91985-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOO TW, 1993, J BIOL CHEM, V268, P3143; LOWRY OH, 1961, J BIOL CHEM, V193, P265; MAHANTY SK, 1994, J BIOL CHEM, V269, P17705; MARTIN DW, 1984, P NATL ACAD SCI-BIOL, V81, P6623, DOI 10.1073/pnas.81.21.6623; PASTAN I, 1991, ANNU REV MED, V42, P277, DOI 10.1146/annurev.me.42.020191.001425; RAO US, 1994, MOL PHARMACOL, V45, P773; RAO US, 1994, BIOCHEM PHARMACOL, V48, P287, DOI 10.1016/0006-2952(94)90099-X; RONINSON IBE, 1991, MOL CELLULAR BIOL MU; SAFA AR, 1989, BIOCHEM BIOPH RES CO, V162, P1402, DOI 10.1016/0006-291X(89)90830-9; SAFA AR, 1988, P NATL ACAD SCI USA, V85, P7187, DOI 10.1073/pnas.85.19.7187; SAFA AR, 1990, P NATL ACAD SCI USA, V87, P7225, DOI 10.1073/pnas.87.18.7225; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKADI B, 1992, J BIOL CHEM, V267, P4864; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SUMMERS MD, 1988, B TEXAS AGR EXPT STA, V1555	34	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6686	6690						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896810				2022-12-25	WOS:A1995QQ85500041
J	REMPEL, RE; SLEIGHT, SB; MALLER, JL				REMPEL, RE; SLEIGHT, SB; MALLER, JL			MATERNAL XENOPUS CDK2-CYCLIN-E COMPLEXES FUNCTION DURING MEIOTIC AND EARLY EMBRYONIC-CELL CYCLES THAT LACK A G(1) PHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-TYPE CYCLINS; MATURATION-PROMOTING FACTOR; PROTEIN-KINASE COMPLEX; DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; S-PHASE; A-TYPE; RETINOBLASTOMA PROTEIN; MAMMALIAN FIBROBLASTS; CDC2-RELATED KINASE	Earlier work demonstrated that cyclins A1, B1, and B2 are not associated with Cdk2 from unfertilized Xenopus eggs. As a potential Cdk2 partner during meiosis, a cyclin E homolog was cloned from a Xenopus oocyte cDNA library and found to be 60% identical at the amino acid level to human cyclin E. Cyclin E1 protein was detected in resting oocytes, and the level increased severalfold in meiosis II, concomitant with the appearance of forms with decreased electrophoretic mobility. During oocyte maturation, the patterns of cyclin E1-associated kinase activity and Cdk2 activity were identical, with activity low until after germinal vesicle breakdown, peaking during meiosis II. Cyclin E1 complexes immunoprecipitated from unfertilized Xenopus eggs contained Cdk2 but not Cdc2. In cycling egg extracts Cdk2-cyclin E1-associated kinase activity oscillated, but the level of cyclin E1 protein and its association with Cdk2 did not vary appreciably; complex activity appeared to be regulated neither by the synthesis and destruction of the cyclin subunit nor by association/disassociation of the two subunits. During the early cleavage divisions in embryos, cyclin E1 and Cdk2 remained associated. The data indicate that the Cdk2-cyclin E complex functions during meiotic and embryonic cell cycles in addition to performing its established role during G(1) in somatic cells.	UNIV COLORADO, SCH MED, HOWARD HUGHES MED INST, DENVER, CO 80262 USA; UNIV COLORADO, SCH MED, DEPT PHARMACOL, DENVER, CO 80262 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NIGMS NIH HHS [GM26743] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026743] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; BENBOW RM, 1975, P NATL ACAD SCI USA, V72, P2437, DOI 10.1073/pnas.72.6.2437; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; CLARKE PR, 1992, EMBO J, V11, P1751, DOI 10.1002/j.1460-2075.1992.tb05227.x; CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DEVAULT A, 1992, J CELL BIOL, V118, P1109, DOI 10.1083/jcb.118.5.1109; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; FREDERICK DL, 1994, J EXP ZOOL, V270, P410, DOI 10.1002/jez.1402700411; GABRIELLI BG, 1993, SCIENCE, V259, P1766, DOI 10.1126/science.8456304; GABRIELLI BG, 1992, J BIOL CHEM, V267, P1969; GABRIELLI BG, 1992, J BIOL CHEM, V267, P18040; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GRANDIN N, 1993, MOL CELL BIOL, V13, P2113, DOI 10.1128/MCB.13.4.2113; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GURDON JB, 1967, P NATL ACAD SCI USA, V58, P545, DOI 10.1073/pnas.58.2.545; HEMMATIBRIVANLOU A, 1991, DEVELOPMENT, V111, P715; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Honigberg SM, 1993, CURR OPIN CELL BIOL, V5, P219, DOI 10.1016/0955-0674(93)90106-Z; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; KIMELMAN D, 1987, CELL, V48, P399, DOI 10.1016/0092-8674(87)90191-7; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KOBAYASHI H, 1991, COLD SH Q B, V56, P437; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; KOBAYASHI H, 1991, J CELL BIOL, V114, P755, DOI 10.1083/jcb.114.4.755; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEHNER CF, 1991, COLD SH Q B, V56, P465; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Maller JL, 1991, CURR OPIN CELL BIOL, V3, P269; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MILARSKI KL, 1991, COLD SH Q B, V56, P377; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; NEVINS JR, 1992, SCIENCE, V258, P424; NEWPORT J, 1989, J CELL SCI, P149; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; Nieuwkoop P. D., 1975, NORMAL TABLE XENOPUS; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PEEPER DS, 1993, EMBO J, V12, P1947, DOI 10.1002/j.1460-2075.1993.tb05844.x; PHILPOTT A, 1994, MOL CELL BIOL, V14, P5000, DOI 10.1128/MCB.14.7.5000; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RICHARDSON HE, 1993, DEVELOPMENT, V119, P673; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SCLAFANI RA, 1988, MOL CELL BIOL, V8, P293, DOI 10.1128/MCB.8.1.293; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; STEELE RE, 1989, J BIOL CHEM, V264, P10649; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WITTENBERG C, 1989, MOL CELL BIOL, V9, P4064, DOI 10.1128/MCB.9.9.4064; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0	89	136	139	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6843	6855		10.1074/jbc.270.12.6843	http://dx.doi.org/10.1074/jbc.270.12.6843			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896832				2022-12-25	WOS:A1995QQ85500063
J	ZIMMERMANN, AG; SPYCHALA, J; MITCHELL, BS				ZIMMERMANN, AG; SPYCHALA, J; MITCHELL, BS			CHARACTERIZATION OF THE HUMAN INOSINE-5'-MONOPHOSPHATE DEHYDROGENASE TYPE-II GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; INOSINE 5'-PHOSPHATE DEHYDROGENASE; RNA POLYMERASE-II; IMP DEHYDROGENASE; TRANSCRIPTION FACTOR; LEUKEMIA-CELLS; DEOXYCYTIDINE KINASE; MYCOPHENOLIC-ACID; CHROMOSOMAL LOCALIZATION; DEPENDENT REGULATION	Inosine-5'-monophosphate dehydrogenase (IMPDH) activity and mRNA levels are induced up to 15-fold upon mitogenic or antigenic stimulation of human peripheral blood T lymphocytes. This increase in IMPDH activity is required for cellular proliferation and has been associated with malignant transformation. We have cloned the human IMPDH type II gene and show that it contains 14 exons and is approximately 5.8 kilobases in length. Exons vary in size from 49 to 207 base pairs and introns from 73 to 1065 base pairs. The transcription start site was mapped to a position 50 nucleotides upstream of the translation initiation site. The 5'-flanking region consisting of 463 base pairs upstream of the translation initiation site confers induced transcription and differential regulation upon a chloramphenicol acetyltransferase reporter gene when transfected into Jurkat T cells and human peripheral blood T lymphocytes, respectively. DNase I footprinting analysis using Jurkat T cell nuclear extract identified four protected regions in the promoter which coincide with consensus transcription factor binding sites for the nuclear factors AP2, ATF, CREB, Egr-1, Nm23, and Sp1. These findings suggest that several of these nuclear factors may play a critical role in the regulation of IMPDH type II gene expression during T lymphocyte activation.	UNIV N CAROLINA, SCH MED, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT MED, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NATIONAL CANCER INSTITUTE [R01CA034085, R01CA064192] Funding Source: NIH RePORTER; NCI NIH HHS [CA34085, CA64192] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; ARNER ESJ, 1988, EXP CELL RES, V178, P335, DOI 10.1016/0014-4827(88)90403-X; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; CARR SF, 1993, J BIOL CHEM, V268, P27286; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; COLLART FR, 1992, CANCER RES, V52, P5826; COLLART FR, 1988, J BIOL CHEM, V263, P15769; DAYTON JS, 1994, J IMMUNOL, V152, P984; DAYTON JS, 1992, MOL PHARMACOL, V41, P671; DAYTON JS, 1994, RECENT DEV TRANSPLAN, P129; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELDER PK, 1988, MOL CELL BIOL, V8, P480, DOI 10.1128/MCB.8.1.480; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GLESNE D, 1993, GENOMICS, V16, P274, DOI 10.1006/geno.1993.1177; GLESNE DA, 1991, MOL CELL BIOL, V11, P5417, DOI 10.1128/MCB.11.11.5417; GREENE JM, 1987, MOL CELL BIOL, V7, P3646, DOI 10.1128/MCB.7.10.3646; GU JJ, 1994, GENOMICS, V24, P179, DOI 10.1006/geno.1994.1597; HAGER PW, 1995, IN PRESS BIOCH PHARM; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JACKSON RC, 1975, NATURE, V256, P331, DOI 10.1038/256331a0; JAMESON JL, 1988, J BIOL CHEM, V263, P9879; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KEIM D, 1992, J CLIN INVEST, V89, P919, DOI 10.1172/JCI115672; KIGUCHI K, 1990, EXP CELL RES, V187, P47, DOI 10.1016/0014-4827(90)90114-P; KIGUCHI K, 1990, CELL GROWTH DIFFER, V1, P259; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MITCHELL BS, 1993, ADV ENZYME REGUL, V33, P61; NAGAI M, 1991, CANCER RES, V51, P3886; NAGAI M, 1992, CANCER RES, V52, P258; NATSUMEDA Y, 1990, J BIOL CHEM, V265, P5292; NATSUMEDA Y, 1988, CANCER RES, V48, P507; NELSON PH, 1990, J MED CHEM, V33, P833, DOI 10.1021/jm00164a057; OKABEKADO J, 1992, BIOCHEM BIOPH RES CO, V182, P987, DOI 10.1016/0006-291X(92)91829-F; OLAH E, 1988, P NATL ACAD SCI USA, V85, P6533, DOI 10.1073/pnas.85.17.6533; PARK JH, 1993, J BIOL CHEM, V268, P6299; PEREZCASTILLO A, 1993, J BIOL CHEM, V268, P19445; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; POSTEL EH, 1994, J BIOL CHEM, V269, P8627; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSONECORSI P, 1988, P NATL ACAD SCI USA, V85, P7192, DOI 10.1073/pnas.85.19.7192; SOKOLOSKI JA, 1986, CANCER RES, V46, P2314; SONG JJ, 1993, P NATL ACAD SCI USA, V90, P431, DOI 10.1073/pnas.90.2.431; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SZEKERES T, 1992, LIFE SCI, V51, P1309, DOI 10.1016/0024-3205(92)90021-G; TRICOT GJ, 1989, CANCER RES, V49, P3696; YOUNG CJ, 1994, RECENT DEV TRANSPLAN, P93	55	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6808	6814		10.1074/jbc.270.12.6808	http://dx.doi.org/10.1074/jbc.270.12.6808			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896827	hybrid, Green Published			2022-12-25	WOS:A1995QQ85500058
J	HANADA, K; NISHIJIMA, M; AKAMATSU, Y; PAGANO, RE				HANADA, K; NISHIJIMA, M; AKAMATSU, Y; PAGANO, RE			BOTH SPHINGOLIPIDS AND CHOLESTEROL PARTICIPATE IN THE DETERGENT INSOLUBILITY OF ALKALINE-PHOSPHATASE, A GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED PROTEIN, IN MAMMALIAN MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; GLYCOSYL-PHOSPHATIDYLINOSITOL; INTRACELLULAR-TRANSPORT; CULTURED-CELLS; SURFACE; GLYCOPROTEINS; BIOSYNTHESIS; ASSOCIATION; METABOLISM; REDUCTASE	SPB-1, a Chinese hamster ovary cell variant defective in serine palmitoyltransferase activity for sphingolipid synthesis, provides a useful system for studying the effects of sphingolipids and/or cholesterol deprivation on cellular functions and membrane properties. To investigate whether there was an interaction among sphingolipids, cholesterol, and glycosylphosphatidylinositol (GPI)-anchored proteins in biological membranes, we introduced human placental alkaline phosphatase (FLAP) in SPB-1 and in wild type cells by stable transfection and examined the effects of sphingolipid and/or cholesterol deprivation on the solubility of FLAP in Triton X-100. Although the FLAP solubility of the membranes isolated from the control cells in Triton X-100 was only 10%, deprivation of sphingolipid and cholesterol further enhanced the solubility, which reached 50% when both sphingolipids and cholesterol were deprived. The enhanced solubility was suppressed to the control level by metabolic complementation with exogenous sphingosine and cholesterol. The sphingolipid and cholesterol content of the isolated membranes changed independently, eliminating the possibility that sphingolipid deprivation induced a reduction in cellular cholesterol and enhanced FLAP solubility and vice versa. It was also unlikely that the enhanced solubility was due to structural changes in FLAP molecules since, regardless of sphingolipid and cholesterol deprivations, almost all FLAP had the GPI-anchor moiety and there were no differences in the apparent molecular weight of the protein in supernatant and precipitate fractions of the detergent-treated membranes. In addition, the expression level of caveolin in the isolated membranes was not significantly affected by sphingolipids and/or cholesterol depletion. These results indicated that both sphingolipids and cholesterol were involved in the FLAP insolubility and suggested that these lipids coordinately played a role in formation of Triton X-100-resistant complexes.	CARNEGIE INST WASHINGTON,DEPT EMBRYOL,BALTIMORE,MD 21210	Carnegie Institution for Science	HANADA, K (corresponding author), NATL INST HLTH,DEPT BIOCHEM & CELL BIOL,SHINJUKU KU,1-23-1 TOYAMA,TOKYO 162,JAPAN.			Hanada, Kentaro/0000-0003-1383-2781				BERGER J, 1989, P NATL ACAD SCI USA, V86, P1457, DOI 10.1073/pnas.86.5.1457; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRILES EB, 1977, J BIOL CHEM, V252, P1107; BROWN AG, 1976, J CHEM SOC PERK T 1, P1165, DOI 10.1039/p19760001165; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CERNEUS DP, 1993, J BIOL CHEM, V268, P3150; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CINEK T, 1992, J IMMUNOL, V149, P2262; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DRABEROVA L, 1993, P NATL ACAD SCI USA, V90, P3611, DOI 10.1073/pnas.90.8.3611; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; ENDO A, 1976, FEBS LETT, V72, P323, DOI 10.1016/0014-5793(76)80996-9; GAMBLE W, 1978, J LIPID RES, V19, P1068; GARCIA M, 1993, J CELL SCI, V104, P1281; GLASER M, 1993, CURR OPIN STRUC BIOL, V3, P475, DOI 10.1016/0959-440X(93)90070-2; HANADA K, 1993, J BIOL CHEM, V268, P13820; HANADA K, 1992, J BIOL CHEM, V267, P23527; HANADA K, 1990, J BIOL CHEM, V265, P22137; HOESSLI D, 1985, EXP CELL RES, V156, P239, DOI 10.1016/0014-4827(85)90278-2; HOOPER NM, 1988, BIOCHEM J, V250, P865, DOI 10.1042/bj2500865; Ikezawa H, 1981, METHODS ENZYMOLOGY C, P731, DOI [10.1016/0076-6879(81)71086-3, DOI 10.1016/0076-6879(81)71086-3]; ITO M, 1993, EUR J BIOCHEM, V218, P637, DOI 10.1111/j.1432-1033.1993.tb18417.x; KANEKO I, 1978, EUR J BIOCHEM, V87, P313; KARLSSON KA, 1970, CHEM PHYS LIPIDS, V5, P6, DOI 10.1016/0009-3084(70)90008-3; KIM HS, 1983, J MEMBRANE BIOL, V75, P115, DOI 10.1007/BF01995631; KOVAL M, 1991, BIOCHIM BIOPHYS ACTA, V1082, P113, DOI 10.1016/0005-2760(91)90184-J; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LOW MG, 1989, FASEB J, V3, P1600, DOI 10.1096/fasebj.3.5.2522071; MCCOMB RB, 1972, CLIN CHEM, V18, P97; NAKAMURA K, 1984, ANAL BIOCHEM, V142, P406, DOI 10.1016/0003-2697(84)90484-6; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SLOTTE JP, 1994, CURR TOP MEMBR, V40, P483, DOI 10.1016/S0070-2161(08)60993-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; VAZ WLC, 1993, CURR OPIN STRUC BIOL, V3, P482, DOI 10.1016/0959-440X(93)90071-R; WARNOCK DE, 1993, J BIOL CHEM, V268, P10145; White D.A., 1973, FORM FUNCTION PHOSPH; YOGEESWARAN G, 1974, BIOCHEM BIOPH RES CO, V56, P1010, DOI 10.1016/S0006-291X(74)80289-5; ZURZOLO C, 1994, EMBO J, V13, P42, DOI 10.1002/j.1460-2075.1994.tb06233.x	42	188	189	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					6254	6260		10.1074/jbc.270.11.6254	http://dx.doi.org/10.1074/jbc.270.11.6254			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890763	hybrid			2022-12-25	WOS:A1995QM94500081
J	GAO, B; SPECTOR, MS; KUNOS, G				GAO, B; SPECTOR, MS; KUNOS, G			THE RAT ALPHA(1B) ADRENERGIC-RECEPTOR GENE MIDDLE PROMOTER CONTAINS MULTIPLE BINDING-SITES FOR SEQUENCE-SPECIFIC PROTEINS INCLUDING A NOVEL UBIQUITOUS TRANSCRIPTION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR PROTEINS; MESSENGER-RNAS; KINASE-C; TISSUE; LIVER; CELLS; EXPRESSION; ALBUMIN; ELEMENT; PURIFICATION	Transcription of the rat alpha(1B) adrenergic receptor (alpha(1B)AR) gene in the liver is controlled by three promoters that generate three mRNAs. The middle promoter (P2), located between -432 and -813 base pairs upstream from the translation start codon and lacking a TATA box, is responsible for generating the major, 2.7-kilobase mRNA species expressed in many tissues (Gao, B., and Kunos, G. (1994) J. Biol. Chem. 269, 15762-15767). DNase I footprinting using rat liver nuclear extracts identified three protected regions in P2: footprint I (-432 to -452), footprint II(-490 to -540), and footprint III (-609 to -690). Putative response elements in footprints I and III were not analyzed except the AP2 binding site in footprint III, which could be protected by purified AP2 protein. Footprint II contains four sites corresponding to half of the NF-I consensus sequence, but DNA mobility shift assays indicate that this footprint binds two proteins distinct from NF-I: a ubiquitous CP1-related factor and another novel factor, termed alpha-Adrenergic Receptor Transcription Factor (alpha ARTF), which binds to two separate sites in this region. The alpha ARTF is widely distributed, with the highest amounts found in brain, followed by liver, kidney, lung, and spleen, but no detectable activity in heart. Deletions of alpha ARTF binding sites nearly abolished P2 promoter activity, which suggests that the alpha ARTF is essential for the transcription of the alpha(1B)AR gene in most tissues.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, SCH MED, DEPT PHARMACOL, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, SCH MED, DEPT TOXICOL, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, SCH MED, DEPT MED, RICHMOND, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University					NHLBI NIH HHS [HL49938] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049938] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; DUSSERRE Y, 1992, MOL CELL BIOL, V12, P5228, DOI 10.1128/MCB.12.11.5228; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FORD APDW, 1994, TRENDS PHARMACOL SCI, V15, P167, DOI 10.1016/0165-6147(94)90136-8; FRENCH BA, 1991, MOL CELL BIOL, V11, P2439, DOI 10.1128/MCB.11.5.2439; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GAO B, 1993, GENE, V131, P243, DOI 10.1016/0378-1119(93)90300-R; GAO B, 1994, J BIOL CHEM, V269, P15762; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GOTTSCHALK LR, 1990, MOL CELL BIOL, V10, P5486, DOI 10.1128/MCB.10.10.5486; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; HARRISON JK, 1991, TRENDS PHARMACOL SCI, V12, P62, DOI 10.1016/0165-6147(91)90499-I; HU ZW, 1993, J BIOL CHEM, V268, P3610; IANNELLO RC, 1993, J BIOL CHEM, V268, P22581; IANNELLO RC, 1991, J BIOL CHEM, V266, P3309; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; LAZARWESLEY E, 1991, ENDOCRINOLOGY, V129, P1116, DOI 10.1210/endo-129-2-1116; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LOMASNEY JW, 1991, J BIOL CHEM, V266, P6365; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; Maxam A M, 1980, Methods Enzymol, V65, P499; MCGEHEE RE, 1990, MOL CELL ENDOCRINOL, V74, P1, DOI 10.1016/0303-7207(90)90200-R; MCGEHEE RE, 1991, J RECEPTOR RES, V11, P773, DOI 10.3109/10799899109064679; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAWLINS DR, 1984, CELL, V37, P309, DOI 10.1016/0092-8674(84)90327-1; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROY RJ, 1991, BIOTECHNIQUES, V11, P770; Sambrook J, 1989, MOL CLONING LABORATO; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; YANAGIDA A, 1990, MOL CELL BIOL, V10, P1470, DOI 10.1128/MCB.10.4.1470	39	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5614	5619		10.1074/jbc.270.10.5614	http://dx.doi.org/10.1074/jbc.270.10.5614			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890681	hybrid			2022-12-25	WOS:A1995QL58000099
J	BUTZ, K; SHAHABEDDIN, L; GEISEN, C; SPITKOVSKY, D; ULLMANN, A; HOPPESEYLER, F				BUTZ, K; SHAHABEDDIN, L; GEISEN, C; SPITKOVSKY, D; ULLMANN, A; HOPPESEYLER, F			FUNCTIONAL P53 PROTEIN IN HUMAN PAPILLOMAVIRUS-POSITIVE CANCER-CELLS	ONCOGENE			English	Article						TUMOR VIRUS; TUMOR SUPPRESSOR GENES; P21; P53; HPV	WILD-TYPE P53; DNA-DAMAGE; ONCOGENE EXPRESSION; IONIZING-RADIATION; CELLULAR-RESPONSE; MUTANT P53; TRANSCRIPTION; BINDING; E6; SEQUENCES	There is accumulating evidence that the p53 protein contributes to tumor suppression by stimulating the transcription of specific cellular genes, such as the cell cycle control gene WAF1/ClP1. p53-mediated transcriptional activation is inhibited in cotransfection assays by overexpressed E6 protein from cancer-associated human papillomavirus (HPV) types, pointing at a possible molecular mechanism by which these viruses contribute to malignant cell, transformation. Here we analysed the transcriptional transactivation function of endogenous p53 protein in a series of cervical cancer cell lines, which express the E6 gene from integrated viral sequences. Transient and stable transfection analyses employing p53-responsive reporter constructs indicated that HPV-positive cervical cancer cells contained transactivating p53 protein, Treatment of HPV-positive cells with genotoxic agents, such as mitomycin C, cisplatin, or u.v. irradiation, resulted in an increase of nuclear p53 protein levels and enhanced binding of p53 to a p53-recognition site. These effects were accompanied by an increase of WAF1/ClP1 mRNA levels. In several HPV-positive cell lines, these molecular events were linked to a cell cycle arrest in G(1). In contrast, cancer cells containing mutant p53 genes did not contain transactivating endogenous p53 protein and lacked the p53-mediated response to DNA damaging agents. These results indicate that the tumorigenic phenotype of HPV-positive cancer cell lines does not necessarily correlate with a lack of basal or DNA damage induced p53 activities and that therefore the presence of high risk HPV sequences is not functionally equivalent to the loss of p53 function through somatic mutations of the p53 gene.	DEUTSCH KREBSFORSCHUNGSZENTRUM, PROJEKTGRP ANGEW TUMORVIROL, D-69120 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)				Hoppe-Seyler, Felix/0000-0002-1864-300X				ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BOHM S, 1993, INT J CANCER, V55, P791, DOI 10.1002/ijc.2910550517; BUTZ K, 1993, J VIROL, V67, P6476, DOI 10.1128/JVI.67.11.6476-6486.1993; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROOK T, 1992, LANCET, V339, P1070, DOI 10.1016/0140-6736(92)90662-M; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1994, ONCOGENE, V9, P1225; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUJITA M, 1992, CANCER RES, V52, P5323; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GU ZM, 1994, ONCOGENE, V9, P629; HARPER JW, 1993, CELL, V75, P805; HAUSEN HZ, 1989, CANCER RES, V49, P4677; HICKMAN ES, 1994, ONCOGENE, V9, P2177; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HOPPESEYLER F, 1991, J VIROL, V65, P5613, DOI 10.1128/JVI.65.10.5613-5618.1991; HOPPESEYLER F, 1991, NUCLEIC ACIDS RES, V19, P5080, DOI 10.1093/nar/19.18.5080; HOPPESEYLER F, 1992, NUCLEIC ACIDS RES, V20, P6701, DOI 10.1093/nar/20.24.6701; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MITSUDOMI T, 1992, ONCOGENE, V7, P171; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; PARK DJ, 1994, ONCOGENE, V9, P205; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; PIM D, 1994, ONCOGENE, V9, P1869; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REUTER S, 1991, J VIROL, V65, P5564, DOI 10.1128/JVI.65.10.5564-5568.1991; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VONKNEBELDOEBERITZ M, 1994, J VIROL, V68, P2811, DOI 10.1128/JVI.68.5.2811-2821.1994; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YEE C, 1985, AM J PATHOL, V119, P361; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	65	164	166	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	1995	10	5					927	936						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898934				2022-12-25	WOS:A1995QL03800014
J	KERANGUEVEN, F; ESSIOUX, L; DIB, A; NOGUCHI, T; ALLIONE, F; GENEIX, J; LONGY, M; LIDEREAU, R; EISINGER, F; PEBUSQUE, MJ; JACQUEMIER, J; BONAITIPELLIE, C; SOBOL, H; BIRNBAUM, D				KERANGUEVEN, F; ESSIOUX, L; DIB, A; NOGUCHI, T; ALLIONE, F; GENEIX, J; LONGY, M; LIDEREAU, R; EISINGER, F; PEBUSQUE, MJ; JACQUEMIER, J; BONAITIPELLIE, C; SOBOL, H; BIRNBAUM, D			LOSS OF HETEROZYGOSITY AND LINKAGE ANALYSIS IN BREAST-CARCINOMA - INDICATION FOR A PUTATIVE 3RD SUSCEPTIBILITY GENE ON THE SHORT ARM OF CHROMOSOME-8	ONCOGENE			English	Note						BREAST CANCER; CHROMOSOME 8; DELETIONS; TUMOR SUPPRESSOR GENES; MICROSATELLITES; LINKAGE ANALYSIS	TUMOR-SUPPRESSOR GENES; FAMILIAL BREAST; OVARIAN-CANCER; COLORECTAL-CANCER; ALLELIC LOSS; DELETION; POLYMORPHISMS; ALLELOTYPE	We have analysed losses of heterozygosity (LOH) at eight markers from the p12-p22 region of human chromosome 8 in a panel of 113 breast tumors. LOH were detected in almost half of the tumors. The most frequently deleted region included microsatellite (CA)n repeats markers D8S258, D8S133 and D8S259, located at 8p12-p22, while markers NEFL and LPL appeared less frequently altered. In parallel, linkage analysis was performed using the same informative markers, to test for the involvement of chromosome 8p loci in familial breast cancer. Positive cumulative multipoint lod score of 2.51 at Theta=0.0 was obtained with markers NEFL and D8S259. These results suggest that region 8p12-p22 carries at least one tumor suppressor gene involved in sporadic and perhaps also in familial breast cancer.	INST J PAOLI I CALMETTES,BIOL TUMEURS LAB,F-13009 MARSEILLE,FRANCE; INSERM,U155,PARIS,FRANCE; INSERM,U119,MARSEILLE,FRANCE; INST J PAOLI I CALMETTES,DEPT NUCL MED,F-13009 MARSEILLE,FRANCE; FDN BERGONIE,F-33076 BORDEAUX,FRANCE; CTR RENE HUGUENIN,ST CLOUD,FRANCE; INST J PAOLI I CALMETTES,DEPT ANATOMOPATHOL,F-13009 MARSEILLE,FRANCE	UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Bergonie; Rene Huguenin Hospital; UNICANCER; Institut Paoli-Calmette (IPC)				Eisinger, Francois/0000-0002-8794-0681				BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BIECHE I, 1992, B CANCER, V79, P1115; BOVA GS, 1993, CANCER RES, V53, P3869; BOWCOCK AM, 1993, BREAST CANCER RES TR, V28, P121, DOI 10.1007/BF00666425; BUETOW KH, 1994, NAT GENET, V6, P391, DOI 10.1038/ng0494-391; CALLAHAN R, 1992, CANCER, V69, P1582, DOI 10.1002/1097-0142(19920315)69:6+<1582::AID-CNCR2820691313>3.0.CO;2-Y; CLAUS EB, 1991, AM J HUM GENET, V48, P232; CLIBY W, 1993, CANCER RES, V53, P2393; CROPP CS, 1994, CANCER RES, V54, P2548; CUNNINGHAM C, 1993, ONCOGENE, V8, P1391; DEVILEE P, 1991, ONCOGENE, V6, P1705; EASTON DF, 1993, AM J HUM GENET, V52, P678; EMI M, 1992, CANCER RES, V52, P5368; EMI M, 1993, GENE CHROMOSOME CANC, V7, P152, DOI 10.1002/gcc.2870070307; FUJIWARA Y, 1994, GENE CHROMOSOME CANC, V10, P7, DOI 10.1002/gcc.2870100103; FUJIWARA Y, 1993, CANCER RES, V53, P1172; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; ICHIKAWA T, 1994, CANCER RES, V54, P2299; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KELEMEN PR, 1994, GENE CHROMOSOME CANC, V11, P195, DOI 10.1002/gcc.2870110308; KERANGUEVEN F, 1994, ONCOL REP, V1, P393; KIRCHWEGER R, 1994, INT J CANCER, V56, P193, DOI 10.1002/ijc.2910560208; KNOWLES MA, 1993, ONCOGENE, V8, P1357; KUNIMI K, 1991, GENOMICS, V11, P530, DOI 10.1016/0888-7543(91)90059-N; LALLE P, 1994, ONCOGENE, V9, P437; LATHROP GM, 1984, P NATL ACAD SCI USA, V81, P3343; LATIL A, 1994, GENE CHROMOSOME CANC, V11, P119, DOI 10.1002/gcc.2870110208; LINDBLOM A, 1993, CANCER RES, V53, P4356; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MAZOYER S, 1993, AM J HUM GENET, V52, P754; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAROD SA, 1991, LANCET, V338, P82; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OHATA H, 1993, GENE CHROMOSOME CANC, V7, P85, DOI 10.1002/gcc.2870070204; OSHIMA J, 1994, GENOMICS, V23, P100, DOI 10.1006/geno.1994.1464; OTT J, 1989, P NATL ACAD SCI USA, V86, P4175, DOI 10.1073/pnas.86.11.4175; Rogaev E., 1992, Human Molecular Genetics, V1, P781, DOI 10.1093/hmg/1.9.781; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; SOBOL H, 1994, LANCET, V344, P1151, DOI 10.1016/S0140-6736(94)90655-6; SOBOL H, 1992, HUM GENET, V89, P381; STEICHENGERSDOR.E, 1994, AM J HUM GENET, V55, P870; THEILLET C, 1989, ONCOGENE, V4, P915; TOMFOHRDE J, 1992, GENOMICS, V14, P144, DOI 10.1016/S0888-7543(05)80297-6; VANDERBOSCH K, 1992, GENE CHROMOSOME CANC, V5, P91, DOI 10.1002/gcc.2870050114; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WASYLYSHYN ML, 1991, SURGERY, V110, P265; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEEKS DE, 1990, AM J HUM GENET S, V47, pA204; WEINBERG R, 1993, NEURON, V11, P191, DOI 10.1016/0896-6273(93)90177-S; Wood S, 1993, Cytogenet Cell Genet, V64, P134; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; YAREMKO L, 1994, GENE CHROMOSOME CANC, V10, P1	54	126	128	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					1023	1026						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898921				2022-12-25	WOS:A1995QL03800026
J	CHARNG, YY; IGLESIAS, AA; PREISS, J				CHARNG, YY; IGLESIAS, AA; PREISS, J			STRUCTURE-FUNCTION-RELATIONSHIPS OF CYANOBACTERIAL ADP-GLUCOSE PYROPHOSPHORYLASE - SITE-DIRECTED MUTAGENESIS AND CHEMICAL MODIFICATION OF THE ACTIVATOR-BINDING SITES OF ADP-GLUCOSE PYROPHOSPHORYLASE FROM ANABAENA PCC-7120	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI-B; BACTERIAL GLYCOGEN; REGULATORY PROPERTIES; NUCLEOTIDE-SEQUENCE; GLGC GENE; MUTANT; BIOSYNTHESIS; EXPRESSION; CLONING; ACID	Chemical modification studies of spinach leaf ADP-glucose pyrophosphorylase with pyridoxal-P have shown that a highly conserved lysyl residue near the C terminus might be involved in the binding of 3-P-glycerate, the allosteric activator. Site directed mutagenesis of the corresponding residue (Lys(419)) of the Anabaena enzyme was performed to determine the role of this conserved residue. Replacing Lys(419) with either arginine, alanine, glutamine, or glutamic acid produced mutant enzymes with apparent affinities for 3-P-glycerate, 25-150-fold lower than that of the wild-type enzyme. The mutant enzymes, however, were still activated to a great extent at higher concentrations of activator suggesting that an additional site or residue was involved in the binding of the activator. These mutations caused lesser or no effect on the kinetic constants for the substrates and inhibitor, P-i, as well as on the catalytic efficiency and thermal stability. The results suggest that both the charge and size of lysine residue 419 are required for the proper binding of 3-P-glycerate. Chemical modification of the Anabaena wild-type enzyme with pyridoxal-P indicated that Lys(419) was the only lysyl residue modified. We further performed the same experiment on the K419R mutant enzyme and found another lysyl residue, Lys(382), was modified. Reductive phosphopyridoxylation of the wild-type and K419R enzymes caused dramatic alteration in allosteric properties. The activator, 3-P-glycerate, and inhibitor, P-i, protected the enzyme from reductive phosphopyridoxylation, The modified enzymes were more active in the absence of 3-P-glycerate and less sensitive to P-i inhibition.	MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA	Michigan State University			Charng, Yee-yung/F-3296-2015	Charng, Yee-yung/0000-0002-9107-3955; Iglesias, Alberto/0000-0001-9729-7338	NIAID NIH HHS [AI 022385] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHRENS H, 1969, ANAL BIOCHEM, V30, P413, DOI 10.1016/0003-2697(69)90135-3; BALL S, 1991, PLANTA, V185, P17, DOI 10.1007/BF00194509; CANELLAS PF, 1980, ARCH BIOCHEM BIOPHYS, V199, P259, DOI 10.1016/0003-9861(80)90279-9; CARLSON CA, 1976, J BIOL CHEM, V251, P7886; CHARNG YY, 1992, PLANT MOL BIOL, V20, P37, DOI 10.1007/BF00029147; FIRST EA, 1993, BIOCHEMISTRY-US, V32, P13651, DOI 10.1021/bi00212a033; GHOSH P, 1992, ARCH BIOCHEM BIOPHYS, V296, P122, DOI 10.1016/0003-9861(92)90553-9; GOVONS S, 1973, J BIOL CHEM, V248, P1731; IGLESIAS AA, 1993, AN ASOC QUIM ARGENT, V81, P213; IGLESIAS AA, 1991, PLANT PHYSIOL, V97, P1187, DOI 10.1104/pp.97.3.1187; KUMAR A, 1989, J BIOL CHEM, V264, P10464; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVI C, 1976, PLANT PHYSIOL, V58, P753, DOI 10.1104/pp.58.6.753; MEYER CR, 1992, J BACTERIOL, V174, P4509, DOI 10.1128/JB.174.13.4509-4512.1992; MORELL M, 1988, J BIOL CHEM, V263, P633; NAKAMURA Y, 1985, PLANT PHYSIOL, V78, P601, DOI 10.1104/pp.78.3.601; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PREISS J, 1966, BIOCHEMISTRY-US, V5, P1833, DOI 10.1021/bi00870a008; PREISS J, 1994, PROG NUCLEIC ACID RE, V47, P299, DOI 10.1016/S0079-6603(08)60255-X; PREISS J, 1989, ADV MICROB PHYSIOL, V30, P183; PREISS J, 1992, PHOTOSYNTH RES, V3, P697; Preiss J, 1991, OXFORD SURVEYS PLANT, V7, P59; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANWAL GG, 1967, ARCH BIOCHEM BIOPHYS, V119, P454, DOI 10.1016/0003-9861(67)90477-8; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITHWHITE BJ, 1992, J MOL EVOL, V34, P449, DOI 10.1007/BF00162999; STEBBINS JW, 1992, BIOCHEMISTRY-US, V31, P2328, DOI 10.1021/bi00123a017; STOCK A, 1966, BIOCHEM Z, V344, P353; [No title captured]	30	32	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24107	24113						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929064				2022-12-25	WOS:A1994PQ34600042
J	HACKER, KJ; ALBERTS, BM				HACKER, KJ; ALBERTS, BM			THE SLOW DISSOCIATION OF THE T4 DNA-POLYMERASE HOLOENZYME WHEN STALLED BY NUCLEOTIDE OMISSION - AN INDICATION OF A HIGHLY PROCESSIVE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCESSORY PROTEIN COMPLEX; PRIMER-TEMPLATE JUNCTION; CELL NUCLEAR ANTIGEN; III HOLOENZYME; ESCHERICHIA-COLI; REPLICATION COMPLEX; ATP HYDROLYSIS; BACTERIOPHAGE-T4 PROTEINS; INVITRO REPLICATION; T4-DNA POLYMERASE	We have developed an experimental assay to monitor the rate of dissociation of the T4 DNA polymerase holoenzyme (polymerase plus gene 44/62 and 45 proteins) once it has been stalled by nucleotide omission. Using this assay, we determined that the dissociation of the DNA polymerase holoenzyme follows a first order decay with a half-life of 2.5 min. The long half-life resembles that expected for the holoenzyme processively synthesizing DNA on the leading strand of the replication fork. The holoenzyme dissociation rate is independent of polymerase accessory protein concentration and of ATP hydrolysis. The dissociation rate is increased if the gene 32 protein is omitted or if the primer-template region is shortened from 46 to 28 base pairs. But the rate of holoenzyme dissociation is most strikingly increased when the circular DNA template is converted to a linear form. By analogy with other well studied systems, these results support a model in which ATP hydrolysis by the 44/62 proteins serves to load a ring-like 45 protein onto the DNA. Once loaded, the 45 protein, possibly along with the 44/62 complex, acts as a sliding clamp that tethers the DNA polymerase to the template.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NATIONAL CANCER INSTITUTE [T32CA009270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024020, R01GM024020] Funding Source: NIH RePORTER; NCI NIH HHS [5 T32 CA09270] Funding Source: Medline; NIGMS NIH HHS [GM24020] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1982, COLD SPRING HARB SYM, V47, P655, DOI 10.1101/SQB.1983.047.01.077; ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; BEDINGER P, 1983, J BIOL CHEM, V258, P9649; BITTNER M, 1979, J BIOL CHEM, V254, P9565; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1468; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; CHA TA, 1988, EUKARYOTIC DNA REPLI, P1; EPSTEIN RH, 1963, COLD SPRING HARB SYM, V28, P375, DOI 10.1101/SQB.1963.028.01.053; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; GOGOL EP, 1992, J MOL BIOL, V224, P395, DOI 10.1016/0022-2836(92)91003-8; HACKER KJ, 1994, THESIS U CALIF, V269, P24221; HERPICH B, 1992, HRC-J HIGH RES CHROM, V15, P41; HIBNER U, 1980, NATURE, V285, P300, DOI 10.1038/285300a0; HUANG CC, 1981, J BIOL CHEM, V256, P4087; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; JARVIS TC, 1991, J BIOL CHEM, V266, P1830; JARVIS TC, 1989, J BIOL CHEM, V264, P12717; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; KABOORD BF, 1993, P NATL ACAD SCI USA, V90, P10881, DOI 10.1073/pnas.90.22.10881; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KORNBERG A, 1909, DNA REPLICATION; LABAER J, 1989, COMMENTS, V15, P19; LADUCA RJ, 1986, J BIOL CHEM, V261, P7550; LIU CC, 1980, P NATL ACAD SCI-BIOL, V77, P5698, DOI 10.1073/pnas.77.10.5698; MACE DC, 1984, J MOL BIOL, V177, P313, DOI 10.1016/0022-2836(84)90459-5; MCCARTHY D, 1976, J MOL BIOL, V106, P963, DOI 10.1016/0022-2836(76)90346-6; MORRIS CF, 1979, J BIOL CHEM, V254, P6787; MUNN MM, 1991, J BIOL CHEM, V266, P20034; MUNN MM, 1991, J BIOL CHEM, V266, P20024; NEWPORT JW, 1981, J MOL BIOL, V145, P105, DOI 10.1016/0022-2836(81)90336-3; NEWPORT JW, 1980, THESIS U OREGON EUGE; NEWPORT JW, 1980, MECHANISTIC STUDIES, V19, P485; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; NOSSAL NG, 1980, J BIOL CHEM, V255, P2176; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ODONNELL M, 1992, MOL BIOL CELL, V3, P953, DOI 10.1091/mbc.3.9.953; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; ONRUST R, 1991, J BIOL CHEM, V266, P21681; PIPERNO JR, 1978, J BIOL CHEM, V253, P5174; REDDY MK, 1993, P NATL ACAD SCI USA, V90, P3211, DOI 10.1073/pnas.90.8.3211; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4732; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; RUSH J, 1989, J BIOL CHEM, V264, P10943; Sambrook J, 1989, MOL CLONING LABORATO; SELICK HE, 1987, DNA REPLICATION RECO, P183; SINHA NK, 1980, J BIOL CHEM, V255, P4290; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P447; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; VENKATESAN M, 1982, J BIOL CHEM, V257, P1243; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	57	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24209	24220						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929077				2022-12-25	WOS:A1994PQ34600058
J	RAJAGOPALAN, LE; MALTER, JS				RAJAGOPALAN, LE; MALTER, JS			MODULATION OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR MESSENGER-RNA STABILITY IN-VITRO BY THE ADENOSINE-URIDINE BINDING-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; 3' UNTRANSLATED REGION; CELL-FREE SYSTEM; 3'-UNTRANSLATED REGION; RICH SEQUENCES; PROTEIN; DEGRADATION; IDENTIFICATION; LYMPHOKINE; INVITRO	In vitro decay of granulocyte-macrophage colony-stimulating factor (GM-CSF) mRNA was examined on polysomes prepared from normal human peripheral blood mononuclear cells stimulated with phorbol ester (TPA) and phytohemagglutinin for 14 h. GM-CSF mRNA decayed with a half-life of 90 min while 18 S rRNA was stable. RNA gel mobility assay performed on crude cytosolic lysate (S20) with radiolabeled AUUUA containing RNA identified a 42-kDa RNA-protein complex on SDS-polyacrylamide gel electrophoresis. The binding specificity was identical to that of the previously described adenosine-uridine binding factor (AUBF) (Malter, J. S. (1989) Science 246, 664-666). Further fractionation of the S20 cytosol through a sucrose gradient showed >90% of AUBF activity associated with polysomes and <10% with the S130 fraction. Solution phase RNAs containing AUUUA reiterations specifically competed for polysome-bound AUBF and accelerated the decay of GM-CSF mRNA (t(1/2) = 17 min). We linked biotinylated AUUUA RNA to streptavidin magnetic beads and removed >95% of polysome-associated AUBF. A decay system thus depleted of AUBF activity also showed accelerated decay of GM-CSF mRNA (t(1/2) = 20 min). These data show that AUBF is preferentially located on polysomes and that its removal destabilizes GM-CSF mRNA. Therefore, AUBF likely prevents GM-CSF mRNA decay by binding to the AUUUA instability determinants in the 3'-untranslated region.	UNIV WISCONSIN,DEPT PATHOL & LAB MED,MADISON,WI 53792; UNIV WISCONSIN,CTR COMPREHENS CANC,MADISON,WI 53792	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NIDDK NIH HHS [DK45213] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045213] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; ALTUS MS, 1991, J BIOL CHEM, V266, P21190; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BICKEL M, 1990, J IMMUNOL, V145, P840; BICKEL M, 1987, P NATL ACAD SCI USA, V84, P3274, DOI 10.1073/pnas.84.10.3274; BICKEL M, 1987, J IMMUNOL, V139, P2984; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; GILLIS P, 1991, J BIOL CHEM, V266, P3172; HARROLD S, 1991, ANAL BIOCHEM, V198, P19, DOI 10.1016/0003-2697(91)90500-S; HEPLER JE, 1990, ENDOCRINOLOGY, V127, P1550, DOI 10.1210/endo-127-3-1550; IWAI Y, 1991, J BIOL CHEM, V266, P17959; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MUNKER R, 1986, NATURE, V323, P79, DOI 10.1038/323079a0; PEI R, 1988, MOL CELL BIOL, V8, P2860, DOI 10.1128/MCB.8.7.2860; ROSS HJ, 1991, BLOOD, V77, P1787; ROSS J, 1986, J MOL BIOL, V188, P579, DOI 10.1016/S0022-2836(86)80008-0; ROSS J, 1987, J BIOL CHEM, V262, P9374; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SCHRECK R, 1990, MOL CELL BIOL, V10, P1281, DOI 10.1128/MCB.10.3.1281; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STEPHENS JM, 1992, J BIOL CHEM, V267, P8336; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	32	67	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23882	23888						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929035				2022-12-25	WOS:A1994PQ34600009
J	BARBIERI, MA; LI, GP; COLOMBO, MI; STAHL, PD				BARBIERI, MA; LI, GP; COLOMBO, MI; STAHL, PD			RAB5, AN EARLY ACTING ENDOSOMAL GTPASE, SUPPORTS IN-VITRO ENDOSOME FUSION WITHOUT GTP HYDROLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RECEPTOR-MEDIATED ENDOCYTOSIS; CELL-FREE SYSTEM; BINDING-PROTEINS; GOLGI MEMBRANES; VESICLE FUSION; TRANSPORT; PATHWAY; RECONSTITUTION; REQUIRES	Endocytosis is regulated by several GTPases including Rab5 and one or more heterotrimeric G proteins. We show here that RabS, in the GTP gamma S (guanosine 5'-O-(thiotriphosphate))-bound form, fully supports in vitro endosome fusion, indicating that GTP hydrolysis is not required, whereas Rab5:S34N and Rab5:N133I, mutants unable to bind GTP, are potent inhibitors of endosome fusion. Double mutants (Rab5:S34N/Delta C4 and Rab5: N133I/Delta C4) lacking the C-terminal prenylation site were inactive, indicating that prenylation is required. Endosomes became resistant to the inhibitory effects of Rab5:S34N by preincubating the vesicles with cytosol prior to the addition of the inhibitor. The acquisition of resistance to Rab5:S34N was more rapid than to N-ethylmaleimide, indicating that Rab5 mutants are early acting. G(beta gamma) subunits of heterotrimeric G proteins block endosome fusion. However the effect of G(beta gamma) Was abrogated by Rab5.GTP gamma S, indicating that a heterotrimeric G protein may operate upstream of Rab5.	ST LOUIS UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Saint Louis University			Stahl, Philip/D-6315-2012; Li, Guangpu/GRS-5397-2022					BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAELL WA, 1987, P NATL ACAD SCI USA, V84, P1137, DOI 10.1073/pnas.84.5.1137; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; COLOMBO MI, 1994, MOL MEMBR BIOL, V11, P93, DOI 10.3109/09687689409162226; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; GRUENBERG JE, 1986, EMBO J, V5, P3091, DOI 10.1002/j.1460-2075.1986.tb04615.x; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; LENHARD J, IN PRESS ARCH BIOCH; LENHARD J, 1992, J BIOL CHEM, V267; LI GP, 1994, J BIOL CHEM, V269, P14631; LI GP, 1993, J BIOL CHEM, V268, P24475; MAYORGA LS, 1989, METHOD CELL BIOL, V31, P179; MAYORGA LS, 1993, P NATL ACAD SCI USA, V90, P10255, DOI 10.1073/pnas.90.21.10255; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MAYORGA LS, 1989, CELL REGUL, V1, P113, DOI 10.1091/mbc.1.1.113; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; SANFORD JC, 1993, J BIOL CHEM, V268, P23773; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; WOODMAN PG, 1988, EUR J BIOCHEM, V173, P101, DOI 10.1111/j.1432-1033.1988.tb13972.x	33	89	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18720	18722						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	7913465				2022-12-25	WOS:A1994NX32700005
J	MENDEZ, R; DEHARO, C				MENDEZ, R; DEHARO, C			CASEIN KINASE-II IS IMPLICATED IN THE REGULATION OF HEME-CONTROLLED TRANSLATIONAL INHIBITOR OF RETICULOCYTE LYSATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; INITIATION-FACTOR EIF-2; EIF-2-ALPHA KINASE; ALPHA-SUBUNIT; CALCIUM-IONS; BINDING-SITE; RNA; PHOSPHORYLATION; ACTIVATION; CLONING	The hemin-controlled inhibitor, or HCI, is a cyclic nucleotide-independent protein kinase which specifically phosphorylates the cu subunit of eukaryotic initiation factor 2 (eIF-2) leading to potential Limitations in functional eIF-2 and decreases in protein synthesis initiation. We have recently demonstrated that hemin regulates eIF-2 alpha kinase activity by promoting formation of the inactive heterodimer between HCI and the 90-kDa heat shock protein (hsp90). The formation of the inactive form of HCI by hemin is prevented by treatment with sulfhydryl reagents such as N-ethylmaleimide or when hsp90 is previously phosphorylated (Mendez, R., Moreno, A., and de Haro, C. (1992) J. Biol. Chem. 267, 11500-11501). In this report, using isoelectric focusing and Western blot analyses with antibodies against a synthetic HCI peptide, we have demonstrated that HCT was also phosphorylated when a heme-reversible HCI preparation was preincubated with ATP. Furthermore, our results indicate that casein kinase II (CH II) is the enzyme involved in the regulation of HCI. Thus, the synthetic peptide RRREEETEEE, which is a specific substrate for CK II, acts as a competitive inhibitor of HCI and hsp90 phosphorylation and, at the same time, inhibits the activation of HCI, whereas a synthetic peptide which corresponds to residues 45-59 of the a subunit of eIF-2, including the Ser(51) phosphorylated by HCI, only inhibits competitively the phosphorylation of eIF-2 alpha. In addition, treatments which modify hsp90 disabling the formation of the inactive dimer with HCI make unnecessary the presence of CK II for activation of HCI. The data strongly suggest that hemin promotes formation of an inactive HCI-hsp90 dimer preventing phosphorylation by CK II. Interestingly, the addition of the CK II peptide substrate also prevents the activation of HCI in a heme-deficient reticulocyte lysate. We hypothesize, therefore, that under physiological conditions, CK II activity appears to be necessary for activation of HCI.	UNIV AUTONOMA MADRID,CONSEJO SUPER INVEST CIENT,CTR BIOL MOLEC SEVERO OCHOA,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)				Mendez, Raul/0000-0002-1952-6905				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P315, DOI 10.1073/pnas.88.2.315; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; COLTHURST DR, 1987, EUR J BIOCHEM, V166, P357, DOI 10.1111/j.1432-1033.1987.tb13523.x; CORREAS I, 1986, J BIOL CHEM, V261, P3362; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; DEHARO C, 1983, P NATL ACAD SCI-BIOL, V80, P6843; DEHERREROS AG, 1985, P NATL ACAD SCI USA, V82, P3119, DOI 10.1073/pnas.82.10.3119; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; ERNST H, 1987, J BIOL CHEM, V262, P1206; GAITERO F, 1989, FEBS LETT, V257, P297, DOI 10.1016/0014-5793(89)81556-X; Harlow E., 1988, ANTIBODIES LABORATOR, P1; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HUNT T, 1972, J MOL BIOL, V66, P471, DOI 10.1016/0022-2836(72)90427-5; HUNT T, 1979, WIN MIAM S GEN PROT, V16, P321; Jackson RJ, 1991, TRANSLATION EUKARYOT, P193; KOSOWER NS, 1972, BIOCHIM BIOPHYS ACTA, V272, P623, DOI 10.1016/0005-2787(72)90518-7; KUDLICKI W, 1985, P NATL ACAD SCI USA, V82, P5332, DOI 10.1073/pnas.82.16.5332; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEESMILLER SP, 1989, J BIOL CHEM, V264, P2431; LEESMILLER SP, 1989, J BIOL CHEM, V264; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LONDON IM, 1987, ENZYMES, V18, P359; MATTS RL, 1992, J BIOL CHEM, V267, P18160; MATTS RL, 1992, J BIOL CHEM, V267, P18168; MATTS RL, 1992, J BIOL CHEM, V267; MENDEZ R, 1992, J BIOL CHEM, V267; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MIYATA Y, 1991, J BIOL CHEM, V266, P8779; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; PAL JK, 1991, BIOCHEMISTRY-US, V30, P2555, DOI 10.1021/bi00223a037; PALOMO C, 1985, ARCH BIOCHEM BIOPHYS, V239, P497, DOI 10.1016/0003-9861(85)90718-0; PATHAK VK, 1988, MOL CELL BIOL, V8, P993, DOI 10.1128/MCB.8.2.993; PELAEZ F, 1989, FEBS LETT, V250, P523, DOI 10.1016/0014-5793(89)80789-6; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; RAMIREZ M, 1991, MOL CELL BIOL, V11, P3027, DOI 10.1128/MCB.11.6.3027; SOMMERCORN J, 1987, J BIOL CHEM, V262, P3839; SZYSZKA R, 1989, BIOCHEMISTRY-US, V28, P1435, DOI 10.1021/bi00430a001; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YANG JM, 1992, J BIOL CHEM, V267, P20519	42	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6170	6176						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7907089				2022-12-25	WOS:A1994MY84000103
J	HARADA, R; DUFORT, D; DENISLAROSE, C; NEPVEU, A				HARADA, R; DUFORT, D; DENISLAROSE, C; NEPVEU, A			CONSERVED CUT REPEATS IN THE HUMAN CUT HOMEODOMAIN PROTEIN FUNCTION AS DNA-BINDING DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL TYPE SPECIFICATION; SENSORY ORGAN IDENTITY; POU-DOMAIN; PAIRED BOX; DROSOPHILA; EXPRESSION; TRANSCRIPTION; MUTATION; LOCUS; GENE	Homeodomain-containing proteins are believed to function as sequence-specific DNA binding proteins, regulating gene expression. Specificity of sequence recognition is conferred by the homeodomain acting either alone or in conjunction with other conserved.DNA binding domains as is the case for Pou domain and Paired domain proteins. The recent isolation of cDNAs encoding mammalian homologues of the Drosophila Cut homeodomain protein has revealed that the 72-amino acid Cut Repeats are conserved in evolution. We have investigated the biochemical activity of human Cut Repeats by expressing fusion proteins containing glutathione S-transferase linked to various combinations of Cut Repeats and Cut homeodomain. We show by gel retardation and DNase footprinting assays that Cut Repeats can function as DNA binding domains, either independently or in cooperation with the homeodomain. The binding affinity (K(D)) to a specific recognition site was estimated to be 8 x 10(-9) m for Cut Repeat 3 and 4 x 10(-10) m for Cut Repeat 1. When both Cut Repeat 3 and the Cut homeodomain were present in the fusion protein, the binding affinity was increased to 4 x 10(-11) m. These results define a novel class of proteins that contain in addition to the homeodomain a second conserved protein domain, the Cut Repeats, that also function as a DNA binding domain.	MCGILL UNIV,ROYAL VICTORIA HOSP,DEPT MED,MOLEC ONCOL GRP,687 PINE AVE W,MONTREAL H3A 1A1,QUEBEC,CANADA; MCGILL UNIV,ROYAL VICTORIA HOSP,DEPT MED,MOLEC ONCOL GRP,MONTREAL H3A 1A1,QUEBEC,CANADA	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital			/AAB-8315-2020	Dufort, Daniel/0000-0002-6477-596X				ANDRES V, 1992, DEVELOPMENT, V116, P324; AURORA R, 1992, MOL CELL BIOL, V12, P455, DOI 10.1128/MCB.12.2.455; BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BLOCHLINGER K, 1993, DEVELOPMENT, V117, P441; BLOCHLINGER K, 1990, GENE DEV, V4, P1322, DOI 10.1101/gad.4.8.1322; BLOCHLINGER K, 1991, GENE DEV, V5, P1124, DOI 10.1101/gad.5.7.1124; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CAREY J, 1988, P NATL ACAD SCI USA, V85, P975, DOI 10.1073/pnas.85.4.975; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CLEAT PH, 1989, FEBS LETT, V258, P51, DOI 10.1016/0014-5793(89)81613-8; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; FRIED MG, 1984, J MOL BIOL, V172, P241, DOI 10.1016/S0022-2836(84)80025-X; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; JACK J, 1991, DEVELOPMENT, V113, P735; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LIU S, 1992, DEV BIOL, V150, P133, DOI 10.1016/0012-1606(92)90013-7; LIU S, 1991, GENETICS, V127, P151; MCGUINNIS, 1992, CELL, V68, P283; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; TREISMAN J, 1992, BIOESSAYS, V14, P145, DOI 10.1002/bies.950140302; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; TREISMAN J, 1989, CELL, V59, P553; VERRIJZER CP, 1992, EMBO J, V11, P4993, DOI 10.1002/j.1460-2075.1992.tb05606.x	38	76	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2062	2067						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	7904999				2022-12-25	WOS:A1994MR98800078
J	ELBLING, L; BERGER, W; REHBERGER, A; WALDHOR, T; MICKSCHE, M				ELBLING, L; BERGER, W; REHBERGER, A; WALDHOR, T; MICKSCHE, M			P-GLYCOPROTEIN REGULATES CHEMOSENSITIVITY IN EARLY DEVELOPMENTAL STAGES OF THE MOUSE	FASEB JOURNAL			English	Note						OOCYTES; EARLY CLEAVAGE EMBRYOS; MDR-GENE PRODUCTS; DRUG RESISTANCE; IN-VITRO IN-VIVO	RESISTANT CELL-LINES; MULTIDRUG-RESISTANCE; MONOCLONAL-ANTIBODIES; KB-CELL; EXPRESSION; METALLOTHIONEIN; POLARIZATION; BLASTOMERES; COMPACTION; PATTERNS	The multidrug resistance (MDR) P-glycoprotein (P-gp) is an active transporter associated with chemoresistance of tumor cells. A fundamental aspect not yet entirely clarified is the physiological role of MDR-P-gp in normal mammalian tissues. In this paper we report that multidrug (chemo)resistance is already present in mouse oocytes and early cleavage embryos. Expression of MDR-specific P-gp is detectable by antibody (C219) staining from the primary oocyte onward to the eight-cell embryo. MDR-mRNA is demonstrated in mature oocytes using an Mdr1-specific cDNA probe. Functional activity of P-gp is shown by the efficacy of MDR reversers (verapamil or quinidine) in enhancement of: 1) drug accumulation (daunomycin) in all stages investigated, 2) drug cytotoxicity (daunomycin or mitomycin C-induced developmental impairment) in two-cell embryos cultured for 24 h, and 3) drug cytokinesis-blocking activity (cytochalasin D; our recent findings demonstrate cytochalasins to be substrates for P-gp and to indicate the presence of MDR by their microfilament-disrupting action on cycling cells) in four- and eight-cell embryos cultured for 24 h. Furthermore, functional involvement of P-gp in vivo is demonstrated. Concurrent administration of verapamil increases doxorubicin-induced developmental impairment in the zygote stage during the first cleavage cycle in pregnant females. Results provide evidence that MDR-P-gp has an efficient protective function in early reproduction.			ELBLING, L (corresponding author), UNIV VIENNA,INST TUMOR BIOL CANC RES,A-1090 VIENNA,AUSTRIA.			Berger, Walter/0000-0003-0014-1658				AKIYAMA SI, 1985, SOMAT CELL MOLEC GEN, V11, P117, DOI 10.1007/BF01534700; ANDREWS GK, 1991, DEV BIOL, V145, P13, DOI 10.1016/0012-1606(91)90209-L; AUSTIN CR, 1973, NATURE, V244, P333, DOI 10.1038/244333a0; BECK WT, 1987, BIOCHEM PHARMACOL, V36, P2879, DOI 10.1016/0006-2952(87)90198-5; BERGER W, 1992, ANN HEMATOL S, V65, P27; CARDONCARDO C, 1990, J BIOL CHEM, V38, P1277; CARTER SB, 1967, NATURE, V213, P261, DOI 10.1038/213261a0; CHAUDHARY PM, 1991, CELL, V66, P85, DOI 10.1016/0092-8674(91)90141-K; CHAUDHARY PM, 1992, BLOOD, V80, P2735; CHIN JE, 1989, MOL CELL BIOL, V9, P3808, DOI 10.1128/MCB.9.9.3808; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; CURCI A, 1991, DEV BIOL, V144, P362, DOI 10.1016/0012-1606(91)90428-6; EDMONDS DK, 1982, FERTIL STERIL, V38, P447; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FLEMING TP, 1988, ANNU REV CELL BIOL, V4, P459, DOI 10.1146/annurev.cellbio.4.1.459; FORD JM, 1990, PHARMACOL REV, V42, P155; FULTON BP, 1978, NATURE, V273, P149, DOI 10.1038/273149a0; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GOTTESMAN MM, 1993, CANCER RES, V53, P747; Holden HE, 1982, J APPL TOXICOL, V2, P196, DOI 10.1002/jat.2550020405; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JOHNSON MH, 1986, J EMBRYOL EXP MORPH, V93, P239; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; KAGI JHR, 1988, BIOCHEMISTRY-US, V27, P8509, DOI 10.1021/bi00423a001; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; KESSEL D, 1991, CANCER RES, V51, P4665; KIM S, 1972, CANCER RES, V34, P323; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; MYERS CE, 1977, SCIENCE, V197, P165, DOI 10.1126/science.877547; NIELSEN D, 1992, BIOCHIM BIOPHYS ACTA, V1139, P169, DOI 10.1016/0925-4439(92)90131-6; PIKO L, 1982, DEV BIOL, V89, P362, DOI 10.1016/0012-1606(82)90325-6; PRATT HPM, 1981, CELL, V26, P279, DOI 10.1016/0092-8674(81)90310-X; SCHULTZ RM, 1979, DEV BIOL, V73, P120, DOI 10.1016/0012-1606(79)90142-8; SMITH CD, 1993, CANCER RES, V53, P1343; TELFORD NA, 1990, MOL REPROD DEV, V26, P90, DOI 10.1002/mrd.1080260113; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; TSURUO T, 1981, CANCER RES, V41, P1967; VANKALKEN CK, 1992, AM J PATHOL, V141, P1063; VOLM M, 1988, ANTICANCER RES, V8, P1169; Whittingham D G, 1971, J Reprod Fertil Suppl, V14, P7; YOSHIMURA A, 1989, BIOCHIM BIOPHYS ACTA, V992, P307, DOI 10.1016/0304-4165(89)90089-5; ZIOMEK CA, 1980, CELL, V21, P935, DOI 10.1016/0092-8674(80)90457-2; 1991, STATISTICAL SOFTWARE; 1984, TECHNICAL B PROMEGA, V1	44	28	28	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1993	7	15					1499	1506		10.1096/fasebj.7.15.7903262	http://dx.doi.org/10.1096/fasebj.7.15.7903262			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ML740	7903262				2022-12-25	WOS:A1993ML74000013
J	BRUSCHI, SA; WEST, KA; CRABB, JW; GUPTA, RS; STEVENS, JL				BRUSCHI, SA; WEST, KA; CRABB, JW; GUPTA, RS; STEVENS, JL			MITOCHONDRIAL HSP60 (P1 PROTEIN) AND A HSP70-LIKE PROTEIN (MORTALIN) ARE MAJOR TARGETS FOR MODIFICATION DURING S-(1,1,2,2-TETRAFLUOROETHYL)-L-CYSTEINE-INDUCED NEPHROTOXICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; GLUTAMINE TRANSAMINASE-K; RAT-KIDNEY; YEAST MITOCHONDRIA; ESCHERICHIA-COLI; ADDUCT FORMATION; CHAPERONIN; TOXICITY; BINDING; HALOTHANE	The potent and site-selective nephrotoxicity of S-(1,1,2,2-tetrafluoroethyl)-L-cysteine (TFEC) in vivo has been associated with difluorothioamidyl-L-lysine formation on critical mitochondrial target proteins. Dose-response studies in the Fischer 344 rat indicate that five proteins with apparent molecular masses of 99, 84, 66, 52, and 48 kDa are predominantly adducted in vivo after nephrotoxic doses of TFEC (>10 mg/kg, intraperitoneally). Microsequence analysis of the major difluorothioamidyl-L-lysine proteins indicated that P66 is identical, over 14 NH2-terminal residues, to mitochondrial P1 protein (HSP60, a chaperonin) and that P84 is identical, over 14 residues, to a recently isolated novel member of the HSP70 family known as mortalin. These studies indicate that mitochondrial heat shock proteins are major targets for modification by reactive metabolites of TFEC. The implications of these data in relation to the nephrotoxicity of cysteine conjugates are discussed.	W ALTON JONES CELL SCI CTR,LAKE PLACID,NY 12946; MCMASTER UNIV,DEPT BIOCHEM,HAMILTON L8N 3Z5,ONTARIO,CANADA	McMaster University					NIDDK NIH HHS [DK38925] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038925] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; ANDERSON NL, 1992, FUND APPL TOXICOL, V18, P570, DOI 10.1016/0272-0590(92)90116-Y; BOOGAARD PJ, 1989, BIOCHEM PHARMACOL, V38, P3731, DOI 10.1016/0006-2952(89)90579-0; BUTLER LE, 1992, CHEM RES TOXICOL, V5, P406, DOI 10.1021/tx00027a014; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; COOPER AJL, 1985, METHOD ENZYMOL, V113, P344; CRABB JW, 1986, BIOCHEMISTRY-US, V25, P4988, DOI 10.1021/bi00366a003; DARNERUD PO, 1988, TOXICOL APPL PHARM, V95, P423, DOI 10.1016/0041-008X(88)90360-2; DAVILA JC, 1992, TOXICOLOGIST, V12, P255; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAY RE, 1990, FEBS LETT, V267, P265; GUPTA RS, 1987, EUR J CELL BIOL, V45, P170; HARGUS SJ, 1991, BIOCHEM PHARMACOL, V42, pR17, DOI 10.1016/0006-2952(91)90580-X; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; HARRIS JW, 1992, CHEM RES TOXICOL, V5, P34, DOI 10.1021/tx00025a007; HAYDEN PJ, 1990, MOL PHARMACOL, V37, P468; HAYDEN PJ, 1991, J BIOL CHEM, V266, P18415; HAYDEN PJ, 1991, BIOCHEMISTRY-US, V30, P5935, DOI 10.1021/bi00238a018; HOROVITZ A, 1993, J BIOL CHEM, V268, P9957; JINDAL S, 1989, MOL CELL BIOL, V9, P2279, DOI 10.1128/MCB.9.5.2279; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NELSON SD, 1990, ANNU REV PHARMACOL, V30, P169; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PASSARELLA S, 1990, BIOCHIM BIOPHYS ACTA, V1022, P273, DOI 10.1016/0005-2736(90)90274-R; PICKETTS DJ, 1989, J BIOL CHEM, V264, P12001; SATOH H, 1985, J PHARMACOL EXP THER, V233, P857; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; SHERMAN MY, 1992, EMBO J, V11, P71; SINGH B, 1992, DNA CELL BIOL, V11, P489, DOI 10.1089/dna.1992.11.489; SPEICHER DW, 1989, TECHNIQUES PROTEIN C, V1, P24; STEVENS JL, 1986, J BIOL CHEM, V261, P5529; STEVENS JL, 1988, J BIOL CHEM, V263, P3395; THOMPSON D, 1992, BIOTECHNIQUES, V12, P656; VENNER TJ, 1990, NUCLEIC ACIDS RES, V18, P5309, DOI 10.1093/nar/18.17.5309; WADA I, 1991, J BIOL CHEM, V266, P19599; WADHWA R, 1993, J BIOL CHEM, V268, P6615; WAKSMAN A, 1977, BIOCHEMISTRY-US, V16, P4703, DOI 10.1021/bi00640a026	40	56	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23157	23161						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7901206				2022-12-25	WOS:A1993MF51500033
J	TANNER, JW; CHEN, W; YOUNG, RL; LONGMORE, GD; SHAW, AS				TANNER, JW; CHEN, W; YOUNG, RL; LONGMORE, GD; SHAW, AS			THE CONSERVED BOX-1 MOTIF OF CYTOKINE RECEPTORS IS REQUIRED FOR ASSOCIATION WITH JAK KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; GAMMA SIGNAL-TRANSDUCTION; POLYMERASE CHAIN-REACTION; GROWTH-FACTOR RECEPTOR; AMINO-TERMINAL DOMAIN; ERYTHROPOIETIN RECEPTOR; INTERFERON-ALPHA/BETA; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; GLYCOPROTEIN	The JAK2 tyrosine kinase is known to associate with the receptors for growth hormone (GH) and erythropoietin (EPO) and with the interleukin-6 receptor signal transducing protein, gp130. Here we demonstrate that chimeric cytokine receptors which contain the cytoplasmic domain of the receptors for GH and EPO or for gp130 can form complexes with JAK2 when transiently co expressed in HeLa cells. Mutational analyses of chimeras for the the GH and EPO receptors and gp130 demonstrated that box 1, a motif critical for cytokine receptor signal transduction, was required for the association of JAK2. Although JAK2 was capable of associating with all three of the chimeras, JAK1 co-precipitated only with the gp130 chimera. Association of JAK1 and JAK2 with cytokine receptor proteins, therefore, requires the highly conserved box 1 domain, but other sequences within the receptor proteins may influence the specificity of JAK binding. Mutational analysis of JAK2 revealed that multiple or complex protein sequences within JAK2 are required for association with cytokine receptors.	WASHINGTON UNIV, SCH MED, CTR IMMUNOL, DEPT PATHOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)								AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; CLEVENGER CV, 1994, MOL ENDOCRINOL, V8, P674, DOI 10.1210/me.8.6.674; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GOUJON L, 1994, P NATL ACAD SCI USA, V91, P957, DOI 10.1073/pnas.91.3.957; HARPUR AG, 1992, ONCOGENE, V7, P1347; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Higuchi R., 1989, PCR TECHNOLOGY PRINC; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; LEFRANCOIS L, 1982, VIROLOGY, V121, P168, DOI 10.1016/0042-6822(82)90126-X; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NICHOLSON SE, 1994, P NATL ACAD SCI USA, V91, P2985, DOI 10.1073/pnas.91.8.2985; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; RUI H, 1994, J BIOL CHEM, V269, P5364; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1991, METHOD ENZYMOL, V200, P533; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZIEGLER SF, 1993, MOL CELL BIOL, V13, P2384, DOI 10.1128/MCB.13.4.2384	53	218	223	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6523	6530		10.1074/jbc.270.12.6523	http://dx.doi.org/10.1074/jbc.270.12.6523			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896787	hybrid			2022-12-25	WOS:A1995QQ85500017
J	GUAGLIARDI, A; DEPASCALE, D; CANNIO, R; NOBILE, V; BARTOLUCCI, S; ROSSI, M				GUAGLIARDI, A; DEPASCALE, D; CANNIO, R; NOBILE, V; BARTOLUCCI, S; ROSSI, M			THE PURIFICATION, CLONING, AND HIGH-LEVEL EXPRESSION OF A GLUTAREDOXIN-LIKE PROTEIN FROM THE HYPERTHERMOPHILIC ARCHAEON PYROCOCCUS-FURIOSUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; THIOREDOXIN-F; ESCHERICHIA-COLI; THIOLTRANSFERASE; ARCHAEBACTERIUM; ORGANISMS; BACTERIA; LIVER	A protein has been purified to homogeneity from crude extracts of the hyperthermophilic archaeon Pyrococcus furiosus based on its ability to catalyze the reduction of insulin disulfides in the presence of dithiothreitol; the protein has a molecular mass of 24.8 kDa and a pi of 4.9, and it is highly heat-stable. The first 29 amino acid residues at the N terminus of the P. furiosus protein were determined by Edman degradation, and its gene was cloned in Escherichia coli, The amino acid sequence derived from the DNA sequence contains the CPYC sequence, which is typical of the active site of glutaredoxin (also called thioltransferase), The C-terminal portion of the P. furiosus protein, containing the conserved sequence, shows sequence similarity with glutaredoxins from different sources. The P. furiosus protein can reduce disulfide bonds in L-cystine in the presence of GSH (the thioltransferase activity) with an optimum pH of 8.0, The expression of the P. furiosus protein, with full activity, in E. coli at a very high level (21% of total soluble protein) is described; the recombinant protein was purified to homogeneity by merely two successive heat treatments and gel filtration chromatography. The features of the P. furiosus protein here described are discussed in light of the current knowledge about the ubiquitous family of protein disulfide oxidoreductases.	CNR,IST BIOCHIM PROT & ENZIMOL,I-80125 NAPLES,ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR)	GUAGLIARDI, A (corresponding author), UNIV NAPLES,DIPARTIMENTO CHIM ORGAN & BIOL,VIA MEZZOCANNONE 16,I-80134 NAPLES,ITALY.			Bartolucci, Simonetta/0000-0002-1968-2959				ADAMS MWW, 1993, ANNU REV MICROBIOL, V47, P627, DOI 10.1146/annurev.micro.47.1.627; ADAMS MWW, 1994, IN PRESS FEMS MICROB; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; AXELSSON K, 1978, BIOCHEMISTRY-US, V17, P2978, DOI 10.1021/bi00608a006; BARDWELL JCA, 1993, CELL, V74, P769, DOI 10.1016/0092-8674(93)90455-Y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANNIO R, 1994, EUR J BIOCHEM, V222, P345, DOI 10.1111/j.1432-1033.1994.tb18873.x; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; Freedman Robert B., 1992, P455; GAN ZR, 1990, BIOCHEM BIOPH RES CO, V168, P944, DOI 10.1016/0006-291X(90)91120-H; GAN ZR, 1987, J BIOL CHEM, V262, P6699; GUAGLIARDI A, 1994, INT J BIOCHEM, V26, P375, DOI 10.1016/0020-711X(94)90057-4; HAIN J, 1992, NUCLEIC ACIDS RES, V20, P5423, DOI 10.1093/nar/20.20.5423; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOOG JO, 1983, EUR J BIOCHEM, V136, P223, DOI 10.1111/j.1432-1033.1983.tb07730.x; HOPPER S, 1989, J BIOL CHEM, V264, P20438; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGLOTZ P, 1986, Z NATURFORSCH C, V41, P275; LANGLOTZ P, 1987, Z NATURFORSCH C, V42, P1364; LOFERER H, 1994, TRENDS BIOCHEM SCI, V19, P169, DOI 10.1016/0968-0004(94)90279-8; MCFARLAN SC, 1992, J BIOL CHEM, V267, P10561; MINAKUCHI K, 1994, FEBS LETT, V337, P157, DOI 10.1016/0014-5793(94)80264-5; PAPAYANNOPOULOS IA, 1989, BIOCHEM BIOPH RES CO, V159, P1448, DOI 10.1016/0006-291X(89)92272-9; REITER WD, 1988, NUCLEIC ACIDS RES, V16, P1, DOI 10.1093/nar/16.1.1; RIGHETTI PE, 1976, LAB TECHNIQUES BIOCH, V5, P562; SAIKI RK, 1990, PCR PROTOCOLS GUIDE; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLICHT F, 1985, NATURWISSENSCHAFTEN, V72, P328, DOI 10.1007/BF00454779; SJOBERG BM, 1972, J BIOL CHEM, V247, P8063; WHITTAKER MM, 1984, J BIOL CHEM, V259, P4088; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576	34	49	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					5748	5755		10.1074/jbc.270.11.5748	http://dx.doi.org/10.1074/jbc.270.11.5748			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890703				2022-12-25	WOS:A1995QM94500013
J	YAMASHIRO, S; HARAGUCHI, M; FURUKAWA, K; TAKAMIYA, K; YAMAMOTO, A; NAGATA, Y; LLOYD, KO; SHIKU, H; FURUKAWA, K				YAMASHIRO, S; HARAGUCHI, M; FURUKAWA, K; TAKAMIYA, K; YAMAMOTO, A; NAGATA, Y; LLOYD, KO; SHIKU, H; FURUKAWA, K			SUBSTRATE-SPECIFICITY OF BETA-1,4-N-ACETYLGALACTOSAMINYLTRANSFERASE IN-VITRO AND IN CDNA-TRANSFECTED CELLS - G(M2)/G(D2) SYNTHASE EFFICIENTLY GENERATES ASIALO-G(M2) IN CERTAIN CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; BREFELDIN-A; RAT-LIVER; GANGLIOSIDE; GLYCOSYLATION; EXPRESSION; MELANOMA; CANCER; GM2; GLYCOSYLTRANSFERASES	The substrate specificity of beta 1,4-N-acetylgalactosaminyltransferase has been analyzed using a fusion enzyme which consisted of the catalytic domain of the enzyme and the IgG binding domain of protein A, and also by extracts from cDNA transfectants, Both enzyme sources were capable of producing not only G(M2) and G(D2), but also asialo-G(M2), GalNAc-sialylparagloboside, and Gal-NAc-G(D1a) from appropriate accepters, although the efficiencies were at most 1-3% of those of G(M2)/G(D2). The biological significance of these low specificities was studied with transient and stable transfectant cells. From the results of transient expression of the cDNA, asialo-G(M2) expression appeared to inversely correlate with G(M3) synthase levels in those lines. Consequently, G(M2) seemed to be preferentially synthesized when both G(M3) and lactosylceramide are available, and asialo-G(M2) is synthesized in the absence of G(M3) synthesis. However, the results of double immunostaining of CHO transfectants with anti-G(M2) and anti-asialo-G(M2) antibodies indicated that another factor may be involved in asialo-G(M2) synthesis. From the in vitro assay using mixed acceptors, it was concluded that the presence of certain levels of G(M2) might enhance the asialo-G(M2) synthesis. These results suggest that even accepters showing low efficiencies in vitro might be used in certain cells depending on the availability of precursors, expression levels of other gangliosides, as well as the kinetic properties of tile enzyme, and the compartmentation of the glycosylation machineries in the cells.	NAGASAKI UNIV,SCH MED,DEPT ONCOL,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH DENT,DEPT PROSTHODONT,NAGASAKI 852,JAPAN; MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021	Nagasaki University; Nagasaki University; Memorial Sloan Kettering Cancer Center				Takamiya, Kogo/0000-0001-7240-6307	NATIONAL CANCER INSTITUTE [R01CA060680] Funding Source: NIH RePORTER; NCI NIH HHS [CA 60680] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beyer T A, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P23; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; DOHI T, 1990, J BIOL CHEM, V265, P7880; FURUKAWA K, 1985, BIOCHEMISTRY-US, V24, P7820, DOI 10.1021/bi00347a047; FURUKAWA K, 1988, J BIOL CHEM, V263, P14939; HASHIMOTO Y, 1993, J BIOL CHEM, V268, P25857; HIRABAYASHI Y, 1985, J BIOL CHEM, V260, P3328; KALISIAK A, 1991, GLYCOCONJUGATE J, V8, P55, DOI 10.1007/BF00731643; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; NATOLI EJ, 1986, CANCER RES, V46, P4116; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; POHLENTZ G, 1988, P NATL ACAD SCI USA, V85, P7044, DOI 10.1073/pnas.85.19.7044; RUAN S, 1992, CANCER RES, V52, P5725; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SMITH PL, 1994, J BIOL CHEM, V269, P15162; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; THAMPOE IJ, 1989, CANCER RES, V49, P6258; TRINCHERA M, 1989, J BIOL CHEM, V264, P15766; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; WARREN L, 1959, J BIOL CHEM, V234, P1971; YAMASHIRO S, 1993, CANCER RES, V53, P5395; YOUNG WW, 1990, P NATL ACAD SCI USA, V87, P6838, DOI 10.1073/pnas.87.17.6838; YOUNG WW, 1979, J EXP MED, V150, P1008, DOI 10.1084/jem.150.4.1008	23	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					6149	6155		10.1074/jbc.270.11.6149	http://dx.doi.org/10.1074/jbc.270.11.6149			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890749	hybrid			2022-12-25	WOS:A1995QM94500065
J	COSO, OA; CHIARIELLO, R; KALINEC, G; KYRIAKIS, JM; WOODGETT, J; GUTKIND, JS				COSO, OA; CHIARIELLO, R; KALINEC, G; KYRIAKIS, JM; WOODGETT, J; GUTKIND, JS			TRANSFORMING G-PROTEIN-COUPLED RECEPTORS POTENTLY ACTIVATE JNK (SAPK) - EVIDENCE FOR A DIVERGENCE FROM THE TYROSINE KINASE SIGNALING PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENES; JUN; PHOSPHORYLATION; TRANSDUCTION; RAS	The expression of human muscarinic acetylcholine receptors (mAChRs) in NIH 3T3 cells has been used as a model for studying proliferative signaling through G protein-coupled receptors. In this biological system, the mi class of mAChRs can effectively transduce mitogenic signals (Stephens, E. V., Kalinec, G., Brann, M. R., and Gutkind, J. S. (1993) Oncogene 8, 19-26) and induce malignant transformation if persistently activated (Gutkind, J. S., Novotny, E. A., Brann, M. R., and Robbins, K. C. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 4703-4708). Moreover, available evidence suggests that the mi-signaling pathway converges at the level of p21(ras) with that emerging from tyrosine kinase receptors (Crespo, P., Xu, N., Simonds, W. F., and Gutkind, J. S. (1994) Nature 369, 418-420). To explore nuclear events involved in growth regulation by G protein-coupled receptors in this setting, we compared the effect of platelet-derived growth factor (PDGF) and the cholinerse agonist, carbachol, on the expression of mRNA for members of the jun and fos family of nuclear proto-oncogenes. We found that activation of m1 receptors by carbachol induces the expression of a distinct set of nuclear transcription factors. In particular, carbachol caused a much greater induction of c-jun mRNA and AP-1 activity. These responses did not correlate with protein kinase C stimulation nor with the activation of mitogen-activated protein (MAP) kinases. Recently, it has been shown that a novel family of kinases structurally related to MAP kinases, stress-activated protein kinases, or Jun kinases (JNKs), phospho rylate in vivo the amino-terminal transactivating domain of the c-Jun protein, thereby increasing its transcriptional activity. In view of our results, this observation prompted us to ask whether m1 and PDGF can differentially activate JNKs. Here, we show that m1 mAChRs can induce a remarkable increase in JNK activity, which was temporally distinct from that of MAP kinase and was entirely protein kinase C independent. In contrast, PDGF failed to activate JNK in these cells, although it stimulated MAP kinase to an extent even greater than that for carbachol. These findings demonstrate that G protein-coupled receptors can signal through pathways leading to the activation of JNK, thus diverging at this level with those signaling routes utilized by tyrosine kinase receptors.	NIDR,CELLULAR DEV & ONCOL LAB,MOLEC SIGNALING UNIT,BETHESDA,MD 20892; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DIABET UNIT,BOSTON,MA 02129; PRINCESS MARGARET HOSP,ONTARIO CANC INST,TORONTO,ON M4X 1K9,CANADA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre			Gutkind, J. Silvio/J-1201-2016; Woodgett, Jim/F-1087-2010; Gutkind, J. Silvio/A-1053-2009; Chiariello, Mario/O-3642-2014	Gutkind, J. Silvio/0000-0002-5150-4482; Woodgett, Jim/0000-0003-3731-5797; Chiariello, Mario/0000-0001-8434-5177				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRAVO R, 1990, CELL GROWTH DIFFER, V1, P305; CRESPO P, 1994, J BIOL CHEM, V269, P21103; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HER JH, 1991, NUCLEIC ACIDS RES, V19, P3743, DOI 10.1093/nar/19.13.3743; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIPSKIND R, 1992, NATURE, V354, P19; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PELECH SL, 1993, CURR BIOL, V3, P513, DOI 10.1016/0960-9822(93)90043-N; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; STEPHENS EV, 1993, ONCOGENE, V8, P19; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396	28	215	216	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5620	5624		10.1074/jbc.270.10.5620	http://dx.doi.org/10.1074/jbc.270.10.5620			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890682	hybrid			2022-12-25	WOS:A1995QL58000100
J	DEVRIESSMITS, AMM; PRONK, GJ; MEDEMA, JP; BURGERING, BMT; BOS, JL				DEVRIESSMITS, AMM; PRONK, GJ; MEDEMA, JP; BURGERING, BMT; BOS, JL			SHC ASSOCIATES WITH AN UNPHOSPHORYLATED FORM OF THE P21RAS GUANINE-NUCLEOTIDE EXCHANGE FACTOR MSOS	ONCOGENE			English	Article						EGF RECEPTOR; INSULIN RECEPTOR; SIGNAL TRANSDUCTION	EPIDERMAL GROWTH-FACTOR; INSULIN-RECEPTOR SUBSTRATE-1; SIGNAL-REGULATED KINASE-2; TYROSINE KINASES; MITOGENIC SIGNAL; RAS; PROTEIN; GRB2; ACTIVATION; PHOSPHORYLATION	Association of the p21ras guanine nucleotide exchange factor mSOS with tyrosine-phosphorylated She has been implicated in the activation of p21ras, In addition, after growth factor stimulation mSOS becomes phosphorylated as indicated by the appearance of a form of mSOS with reduced electrophoretic mobility. This phosphorylation is delayed with respect to Shc-Grb2-mSOS complex formation and activation of p21ras. To investigate the role of mSOS phosphorylation in further detail we have investigated the effect of phosphorylation on mSOS complex formation and p21ras activation, We found that She is associated with the unphosphorylated, faster migrating form of mSOS. Furthermore, although there is a correlation between the amount of complexes formed and the activation of p21ras, there is no such a correlation between mSOS phosphorylation and p21ras activation. In addition, inhibition of mSOS phosphorylation did not affect complex formation of mSOS with tyrosine phosphorylated She. Also, induction of mSOS phosphorylation prior to complex formation did not affect EGF-induced association of mSOS with She significantly, and She still associated predominantly with the faster migrating form of mSOS. From these results we conclude that the unphosphorylated form of mSOS is associated with She and that perhaps a phosphorylation-dephosphorylation step is part of the mSOS activation-inactivation cycle.	UNIV UTRECHT,PHYSIOL CHEM LAB,3508 TA UTRECHT,NETHERLANDS	Utrecht University				Medema, Jan Paul/0000-0003-3045-2924				BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V192, P1303, DOI 10.1006/bbrc.1993.1558; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MEYER MG, 1994, MOL CELL BIOL, V14, P3577; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, ONCOGENE, V8, P2773; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; TOBE K, 1993, J BIOL CHEM, V268, P11167; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F	30	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					919	925						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898933				2022-12-25	WOS:A1995QL03800013
J	MORRIS, C; BENJES, S; HAATAJA, L; LEDBETTER, DH; HEISTERKAMP, N; GROFFEN, J				MORRIS, C; BENJES, S; HAATAJA, L; LEDBETTER, DH; HEISTERKAMP, N; GROFFEN, J			SPATIAL-ORGANIZATION OF ABR AND CRK GENES ON HUMAN-CHROMOSOME BAND 17P13.3	ONCOGENE			English	Note						ABR GENE; CRK GENE; CHROMOSOME; 17P13.3; D17S34	GUANINE-NUCLEOTIDE EXCHANGE; INTERPHASE CELL-NUCLEI; MILLER-DIEKER SYNDROME; HYPERVARIABLE RFLP; DNA-SEQUENCES; ONCOGENE; PROTEIN; P53; LOCALIZATION; HOMOLOGY	Deletion of part or all of chromosome 17p is among the most frequent chromosome abnormalities in human cancer. We show that the CRK and ABR genes are close to a marker on chromosome 17p13.3, D17S34, which is frequently deleted in different tumours, and demonstrate that CRK is centromeric to ABR. CRK and ABR may be involved in cancer themselves, or otherwise may function as points of reference for further experiments to clone genes from chromosome 17p which may play a role in cancer.	CHILDRENS HOSP LOS ANGELES,DEPT PATHOL,MOLEC DIAGNOSIS SECT,LOS ANGELES,CA 90027; CHRISTCHURCH HOSP,CYTOGENET & MOLEC ONCOL UNIT,CHRISTCHURCH,NEW ZEALAND; NIH,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892	Children's Hospital Los Angeles; Christchurch Hospital New Zealand; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)			Morris, Christine/G-1690-2011; Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273	NATIONAL CANCER INSTITUTE [R55CA047456, R01CA047456] Funding Source: NIH RePORTER; NCI NIH HHS [CA47456] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1992, ONCOGENE, V7, P611; BIEGEL JA, 1992, CANCER RES, V52, P3391; CHAN AML, 1994, ONCOGENE, V9, P1057; DISILVESTRE D, 1990, NUCLEIC ACIDS RES, V18, P5925, DOI 10.1093/nar/18.19.5925; DISILVESTRE D, 1990, NUCLEIC ACIDS RES, V18, P5924, DOI 10.1093/nar/18.19.5924; FIORETOS T, 1993, ONCOGENE, V8, P2853; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HEISTERKAMP N, 1989, NUCLEIC ACIDS RES, V17, P8821, DOI 10.1093/nar/17.21.8821; HEISTERKAMP N, 1993, J BIOL CHEM, V268, P16903; HEISTERKAMP N, 1993, CAUSES CONSEQUENCES, P359; ISOMURA M, 1994, GENE CHROMOSOME CANC, V9, P173, DOI 10.1002/gcc.2870090305; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KWIATKOWSKI DJ, 1990, AM J HUM GENET, V46, P559; LAWRENCE JB, 1990, SCIENCE, V249, P928, DOI 10.1126/science.2203143; LEDBETTER SA, 1990, GENOMICS, V7, P264, DOI 10.1016/0888-7543(90)90549-A; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MORRIS C, 1993, HUM GENET, V91, P31, DOI 10.1007/BF00230218; NISHIDA N, 1993, CANCER RES, V53, P368; PRESTI JC, 1991, CANCER RES, V51, P5405; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; RON D, 1991, NEW BIOL, V3, P372; SAXENA A, 1992, CANCER RES, V52, P6716; TAN EC, 1993, J BIOL CHEM, V268, P27291; TENHOEVE J, 1993, ONCOGENE, V8, P2469; TRASK B, 1989, GENOMICS, V5, P710, DOI 10.1016/0888-7543(89)90112-2; TRASK BJ, 1991, AM J HUM GENET, V48, P1; TSAO SW, 1991, ANTICANCER RES, V11, P1975; UMBRICHT CB, 1994, GENOMICS, V20, P249, DOI 10.1006/geno.1994.1161; VANTUINEN P, 1988, AM J HUM GENET, V43, P587; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0	36	17	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					1009	1011						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898918				2022-12-25	WOS:A1995QL03800023
J	IVANOVA, VS; HATCH, CL; BONNER, WM				IVANOVA, VS; HATCH, CL; BONNER, WM			CHARACTERIZATION OF THE HUMAN HISTONE H2A.X GENE - COMPARISON OF ITS PROMOTER WITH OTHER H2A GENE PROMOTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; CELL-CYCLE; DNA-REPLICATION; S-PHASE; EXPRESSION; SEQUENCE; PROTEIN; PHOSPHORYLATION; TRANSCRIPTION; BINDING	The human gene for the replication-unlinked histone protein H2A.X is a naturally occurring chimera that contains a replication-unlinked promoter yet produces a stemloop mRNA characteristic of replication-linked histone genes. Consistent with the latter attribute, the H2A.X gene was found to lack introns. The promoter of the H2A.X gene was localized to a 120-base pair region upstream of the transcription start site, a region which included a TATA and two CCAAT sequence elements. The proximal of the two CCAAT elements was shown to be an important determinant of H2A.X gene promoter activity. In a comparative study with the CCAAT elements from the replication-linked H2A.1a gene and the replication-unlinked H2A.Z gene, the proximal CCAAT element of the H2A.X gene was found to bind nuclear factors also bound by CCAAT elements in the latter but not in the former, The specificity of the replication-unlinked H2A.X and H2A.Z gene promoters for CCAAT-binding transcription factors appeared to also reside in short homologous sequences about 10 base pairs away on either side of the CCAAT sequence.	NCI,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,MOLEC PHARMACOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BONNER WM, 1993, MOL CELL BIOL, V13, P984, DOI 10.1128/MCB.13.2.984; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHALLONER PB, 1989, MOL CELL BIOL, V9, P902, DOI 10.1128/MCB.9.3.902; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DALTON S, 1988, EMBO J, V7, P49, DOI 10.1002/j.1460-2075.1988.tb02782.x; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; FELGNER PL, 1989, FOCUS, V11, P21; GREEN GR, 1989, DEV BIOL, V134, P413, DOI 10.1016/0012-1606(89)90113-9; GREEN GR, 1991, EXP CELL RES, V195, P8, DOI 10.1016/0014-4827(91)90493-E; HARRIS ME, 1991, MOL CELL BIOL, V11, P2416, DOI 10.1128/MCB.11.5.2416; HATCH CL, 1990, J BIOL CHEM, V265, P15211; HATCH CL, 1988, NUCLEIC ACIDS RES, V16, P1113, DOI 10.1093/nar/16.3.1113; HEINTZ N, 1981, CELL, V24, P661, DOI 10.1016/0092-8674(81)90092-1; HEINTZ N, 1991, BIOCHIM BIOPHYS ACTA, V1088, P327, DOI 10.1016/0167-4781(91)90122-3; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; IVANOVA VS, 1994, IN PRESS HUMAN GENET; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KLEINSCHMIDT JA, 1991, EMBO J, V10, P3043, DOI 10.1002/j.1460-2075.1991.tb07855.x; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; MANNIRONI C, 1989, NUCLEIC ACIDS RES, V17, P9113, DOI 10.1093/nar/17.22.9113; MANNIRONI C, 1994, DNA CELL BIOL, V13, P161, DOI 10.1089/dna.1994.13.161; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OSLEY MA, 1991, ANNU REV BIOCHEM, V60, P827, DOI 10.1146/annurev.biochem.60.1.827; PANDEY NB, 1990, NUCLEIC ACIDS RES, V18, P3161, DOI 10.1093/nar/18.11.3161; SITTMAN DB, 1983, P NATL ACAD SCI-BIOL, V80, P1849, DOI 10.1073/pnas.80.7.1849; TRIPPUTI P, 1986, P NATL ACAD SCI USA, V83, P3185, DOI 10.1073/pnas.83.10.3185; VANWIJNEN AJ, 1992, MOL CELL BIOL, V12, P3273, DOI 10.1128/MCB.12.7.3273; WELLS D, 1985, P NATL ACAD SCI USA, V82, P2834, DOI 10.1073/pnas.82.9.2834; WU RS, 1982, CELL, V31, P367, DOI 10.1016/0092-8674(82)90130-1; WU RS, 1981, CELL, V27, P321, DOI 10.1016/0092-8674(81)90415-3; YOO HW, 1993, GENOMICS, V15, P21, DOI 10.1006/geno.1993.1005; ZHONG R, 1983, NUCLEIC ACIDS RES, V11, P7409, DOI 10.1093/nar/11.21.7409; 1991, PROGRAM MANUAL GCG P	34	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24189	24194						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929075				2022-12-25	WOS:A1994PQ34600055
J	TURI, TG; WEBSTER, P; ROSE, JK				TURI, TG; WEBSTER, P; ROSE, JK			BREFELDIN-A SENSITIVITY AND RESISTANCE IN SCHIZOSACCHAROMYCES-POMBE - ISOLATION OF MULTIPLE GENES CONFERRING RESISTANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SECRETORY PATHWAY; SACCHAROMYCES-CEREVISIAE GENE; PLEIOTROPIC DRUG-RESISTANCE; FISSION YEAST; G-PROTEIN; INTRACELLULAR-TRANSPORT; ENDOPLASMIC-RETICULUM; GUANINE-NUCLEOTIDE; GOLGI MEMBRANES; RAT HEPATOCYTES	The fungal metabolite brefeldin A (BFA) causes the inhibition of protein Secretion and the disruption of the structure and function of the Golgi complex in mammalian cells. Here we show that BFA has identical effects in the fission yeast Schizosaccharomyces pombe which normally contains a Golgi complex of stacked cisternae similar to the Golgi complexes in animal cells. After treatment with BFA, secretion was inhibited, Golgi complexes disappeared, and there was an accumulation of endoplasmic reticulum. These results indicate that the effects of BFA in fungi are very similar to those in mammalian cells and provide direct evidence for an effect of BFA on Golgi morphology in fungi. Five spontaneous BFA-resistant mutants were isolated. Genetic analysis showed that the mutations conferring BFA resistance were dominant and in two separate linkage groups. One of the BFA-resistant mutations was found to be allelic: to crm1, a gene affecting chromatin structure. Ah BFA-resistant mutants overexpressed a 20-kDa protein, and the corresponding gene obr1 was isolated and sequenced. However, obr1 overexpression was not sufficient to confer BFA resistance. Plasmids capable of conferring BFA resistance to wild type cells were isolated from libraries constructed from the two BFA-resistant mutants. These plasmids contain six different genes capable of conferring resistance when present in high copy. One of these genes encoded the transcription factor pap1, a homolog of the mammalian AP1 protein. The overexpression of pap1 probably confers BFA resistance indirectly by inducing expression of one or more other proteins. The isolation of several genes conferring BFA resistance suggests several mechanisms are involved.	YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA	Yale University; Yale University					NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015502] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA46128-03] Funding Source: Medline; NIGMS NIH HHS [GM15502-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; BALLOU L, 1991, P NATL ACAD SCI USA, V88, P3209, DOI 10.1073/pnas.88.8.3209; BOLARD J, 1986, BIOCHIM BIOPHYS ACTA, V864, P257, DOI 10.1016/0304-4157(86)90002-X; BRIZUELA L, 1991, MOL CELL BIOL, V11, P4616, DOI 10.1128/MCB.11.9.4616; BRUNING A, 1992, J BIOL CHEM, V267, P7726; CHAPPELL TG, 1989, J CELL BIOL, V109, P2693, DOI 10.1083/jcb.109.6.2693; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; FALCO SC, 1985, GENETICS, V109, P21; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GRAHAM TR, 1993, EMBO J, V12, P869, DOI 10.1002/j.1460-2075.1993.tb05727.x; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HERTLE K, 1991, CURR GENET, V19, P429, DOI 10.1007/BF00312733; HUSSAIN M, 1991, GENE, V101, P149, DOI 10.1016/0378-1119(91)90238-7; KNEUSEL RE, 1994, J BIOL CHEM, V269, P3449; KNEUSEL RE, 1990, FEBS LETT, V275, P107, DOI 10.1016/0014-5793(90)81450-3; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPPERT G, 1990, GENETICS, V125, P13; Leupold U., 1970, METHODS CELL PHYSL, V4, P169; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOSSON R, 1983, CELL, V32, P371, DOI 10.1016/0092-8674(83)90456-7; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Mitchison JM, 1970, METHOD CELL PHYSIOL, V4, P131; NEWMAN AP, 1987, J CELL BIOL, V105, P1587, DOI 10.1083/jcb.105.4.1587; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; OKAZAKI K, 1990, NUCLEIC ACIDS RES, V18, P6485, DOI 10.1093/nar/18.22.6485; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; RANK GH, 1973, MOL GEN GENET, V126, P93, DOI 10.1007/BF00330986; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAUNDERS GW, 1982, CAN J GENET CYTOL, V24, P493, DOI 10.1139/g82-053; SCHNELL N, 1991, EUR J BIOCHEM, V200, P487, DOI 10.1111/j.1432-1033.1991.tb16209.x; Sherman F., 1981, METHODS YEAST GENETI; SUBIK J, 1986, CURR GENET, V10, P665, DOI 10.1007/BF00410914; TAKATSUKI A, 1985, AGR BIOL CHEM TOKYO, V49, P899, DOI 10.1080/00021369.1985.10866826; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; TODA T, 1992, MOL CELL BIOL, V12, P5474, DOI 10.1128/MCB.12.12.5474; ULASZEWSKI S, 1986, CURR GENET, V10, P359, DOI 10.1007/BF00418407; VOGEL JP, 1993, J BIOL CHEM, V268, P3040; WU AL, 1993, J BIOL CHEM, V268, P18850; [No title captured]	50	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24229	24236						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929079				2022-12-25	WOS:A1994PQ34600060
J	KREYSING, J; POLTEN, A; LUKATELA, G; MATZNER, U; VONFIGURA, K; GIESELMANN, V				KREYSING, J; POLTEN, A; LUKATELA, G; MATZNER, U; VONFIGURA, K; GIESELMANN, V			TRANSLATIONAL CONTROL OF ARYLSULFATASE-A EXPRESSION IN MOUSE TESTIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; SPERMATOGENIC CELLS; GENE-EXPRESSION; SEQUENCES	Arylsulfatase A is a lysosomal enzyme that is involved in the degradation of sulfated glycolipids. High levels of arylsulfatase A mRNA are found in germ cells of mouse testis. In late pachytene and secondary spermatocytes the level of arylsulfatase A mRNA is increased 20-fold when compared with other tissues. These high levels of arylsulfatase A mRNA are maintained in round spermatids and decrease in late elongating spermatids. The increase of arylsulfatase A mRNA levels is not accompanied by a similar increase in enzyme activity or polypeptides. Subcellular fractionation revealed that the majority of arylsulfatase A mRNA is not associated with polysomes but is found in fractions of lower buoyancy. The failure to become translated is ascribed to the association of arylsulfatase A mRNA with nonpolysomal ribonucleoproteins. This translational repression may be due to proteins that bind to arylsulfatase A mRNA and prevent its translation. Within the 639-nucleotide B'-untranslated region and the 700-nucleotide 3'-untranslated region of the arylsulfatase A mRNA, we identified two regions that specifically bind proteins present in extracts prepared from testicular cells, These RNA binding proteins were absent from extracts prepared from liver or brain.	UNIV GOTTINGEN, D-37073 GOTTINGEN, GERMANY	University of Gottingen								Bellve A.R., 1979, Oxford Reviews of Reproductive Biology, V1, P159; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BELLVE AR, 1977, J HISTOCHEM CYTOCHEM, V25, P480, DOI 10.1177/25.7.893996; BRAUN RE, 1989, GENE DEV, V3, P793, DOI 10.1101/gad.3.6.793; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; ERICKSON RP, 1990, TRENDS GENET, V6, P264, DOI 10.1016/0168-9525(90)90209-O; FAROOQUI AA, 1979, BIOCHEM J, V181, P331, DOI 10.1042/bj1810331; FLUHARTY AL, 1974, BIOCHEM BIOPH RES CO, V61, P348, DOI 10.1016/0006-291X(74)90573-7; GOLD B, 1983, DEV BIOL, V98, P392, DOI 10.1016/0012-1606(83)90368-8; GRABSKE RJ, 1975, J CELL PHYSIOL, V86, P177, DOI 10.1002/jcp.1040860119; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; KLEENE KC, 1984, DEV BIOL, V105, P71, DOI 10.1016/0012-1606(84)90262-8; KLEENE KC, 1983, DEV BIOL, V98, P455, DOI 10.1016/0012-1606(83)90375-5; KOLODNY EH, 1989, METABOLIC BASIS INHE, V2, P1721; KREYSING J, 1994, GENOMICS, V19, P249, DOI 10.1006/geno.1994.1055; KREYSING J, 1990, EUR J BIOCHEM, V191, P627, DOI 10.1111/j.1432-1033.1990.tb19167.x; KWON YK, 1991, P NATL ACAD SCI USA, V88, P3584, DOI 10.1073/pnas.88.9.3584; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MATZNER U, 1992, DEVELOPMENT, V114, P965; STEIN C, 1989, J BIOL CHEM, V264, P1252; WILLISON K, 1987, TRENDS GENET, V3, P351, DOI 10.1016/0168-9525(87)90296-4; YANG CH, 1974, P SOC EXP BIOL MED, V145, P721; ZAKERI ZF, 1988, DEV BIOL, V125, P417, DOI 10.1016/0012-1606(88)90222-9	24	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23255	23261						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	7916017				2022-12-25	WOS:A1994PQ16400054
J	WOLBRING, G; HOLLENBERG, MD; SCHNETKAMP, PPM				WOLBRING, G; HOLLENBERG, MD; SCHNETKAMP, PPM			INHIBITION OF GTP-UTILIZING ENZYMES BY TYRPHOSTINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TYROSINE KINASE INHIBITORS; EPIDERMAL GROWTH-FACTOR; ROD OUTER SEGMENTS; CELL-PROLIFERATION; PROTEIN-KINASE; GENE-PRODUCT; ACTIVATION; EXPRESSION	Tyrphostins are a group of organic compounds which are widely used as a tool to specifically inhibit protein tyrosine kinases (Yaish, P., Gazit, A, Gilon, C., and Levitzki A. (1988) Science 242, 933-935; Gazit, A., Yaish, P., Gilon, C., and Levitzki A. (1989) J. Med. Chem. 32, 2344-2352; Lyall, R. M., Zilberstein, A., Gazit, A., Gilon, C., Levitzki, A., and Schlessinger J. (1989) J. Biol. Chem. 264, 14503-14509; Osherov, N., Gazit, A., Gilon, C., and Levitzki, A. (1993) J. Biol. Chem. 268, 11134-11142). We report here that members of the tyrphostin family inhibit the GTPase activity of transducin and the enzymatic activities of other GTP-utilizing proteins in retinal rod outer segments, such as guanylyl cyclase or fructose-6-phosphate kinase. In contrast, ATP-utilizing enzymes such as hexokinase or rhodopsin kinase were not effected.	UNIV CALGARY,DEPT MED,CALGARY T2N 4N1,AB,CANADA; UNIV CALGARY,DEPT PHARMACOL & THERAPEUT,CALGARY T2N 4N1,AB,CANADA	University of Calgary; University of Calgary	WOLBRING, G (corresponding author), UNIV CALGARY,FAC MED,DEPT MED BIOCHEM,3330 HOSP DR NW,CALGARY T2N 4N1,AB,CANADA.		Hollenberg, Morley/AFV-6966-2022	Wolbring, Gregor/0000-0003-1363-0346				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; FUJIHARA M, 1993, J BIOL CHEM, V268, P14898; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GAZIT A, 1991, J MED CHEM, V34, P1396; GLEMBOTSKI CC, 1993, J BIOL CHEM, V268, P20646; HOFMANN KP, 1983, BIOCHIM BIOPHYS ACTA, V725, P60, DOI 10.1016/0005-2728(83)90224-4; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; LEE KM, 1993, J BIOL CHEM, V268, P9945; LEVITZKI A, 1991, J BIOL CHEM, V266, P2965; LEVITZKI A, 1992, FASEB J, V6, P3276; LYALL RM, 1989, J BIOL CHEM, V264, P14503; OBRIEN WE, 1976, ANAL BIOCHEM, V76, P423, DOI 10.1016/0003-2697(76)90337-7; OSHEROV N, 1993, J BIOL CHEM, V268, P11134; RENDU F, 1992, BIOCHEM PHARMACOL, V44, P8881; ROIFMAN CM, 1991, J IMMUNOL, V146, P2965; SCHNETKAMP PPM, 1986, J PHYSIOL-LONDON, V373, P25, DOI 10.1113/jphysiol.1986.sp016033; SCHNETKAMP PPM, 1979, BIOCHIM BIOPHYS ACTA, V552, P379, DOI 10.1016/0005-2736(79)90182-2; SCHNETKAMP PPM, 1981, BIOCHIM BIOPHYS ACTA, V672, P307, DOI 10.1016/0304-4165(81)90298-1; SECKL M, 1993, J BIOL CHEM, V268, P9548; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702; YAMANAKA G, 1985, BIOCHEMISTRY-US, V24, P8094, DOI 10.1021/bi00348a039; YAMAZAKI T, 1993, J BIOL CHEM, V268, P12069	24	40	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22470	22472						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	7915715				2022-12-25	WOS:A1994PQ16300004
J	HANSSON, E				HANSSON, E			METABOTROPIC GLUTAMATE-RECEPTOR ACTIVATION INDUCES ASTROGLIAL SWELLING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-VOLUME REGULATION; AMINO-ACID RECEPTORS; CYCLIC-AMP FORMATION; CULTURED ASTROCYTES; GLIAL-CELLS; CALCIUM CURRENTS; POTASSIUM; CHANNELS; RELEASE; NEURONS	The activation of metabotropic glutamate receptors (mGluRs) by 1-aminocyclopentane-1,3-dicarboxylic acid (1S,3R-ACPD) or ibotenate induced a rapid cell volume increase in primary cultures of type 1 astroglial cells from the cerebral cortex of a newborn rat. These relative volume changes and parallel Ca2+ transients in single cells were examined by microspectrofluorimetry after loading the cells with fura-2/AM and varying the excitation wavelengths between the isosbestic point of the probe and its ion- sensitive wavelength. L(+)-2-Amino-4-phosphonobutyric acid (L-AP4) evoked an astroglial swelling but few or no cytosolic Ca2+ transients. No rapid swelling was observed after stimulation of ionotropic Glu receptors. The Glu-induced volume increase was unaffected by gluconate or amiloride, partially blocked by Glu-carrier blockers, and totally blocked by ketamine. The Glu- or L-AP4-induced volume increases were blocked by BaCl2 or furosemide. Tetraethylammoniumchloride-1-hydrate blocked the Glu- and 1S,3R-ACPD-induced astroglial swelling but the voltage-dependent L-, N-, or T-type Ca2+ channels were not primarily involved in the Glu-, 1S,3R-ACPD-, or L-AP4-induced swelling. mGluRs induce inositol 1,4,5-trisphosphate synthesis, intracellular Ca2+ increase, and the opening of a delayed outward K+ rectifier, and along another route they activate a G(i) protein and open an inward K+ rectifier. One Na+-K+-2Cl(-) cotransporter and a Na+-K+-ATPase is activated and so also is an electrogenic Na+-dependent Glu carrier. Thus, Glu-induced astroglial swelling is not only the result of the above mechanisms, but requires another, until now unidentified mechanism, probably some ketamine-sensitive K+ outflux or Na+ influx.	LINKOPING UNIV,FAC HLTH SCI,DEPT CELL BIOL,S-58185 LINKOPING,SWEDEN	Linkoping University	HANSSON, E (corresponding author), GOTHENBURG UNIV,INST NEUROBIOL,MEDICINAREGATAN 5,S-41390 GOTHENBURG,SWEDEN.							BABA A, 1993, NEUROSCI LETT, V149, P182, DOI 10.1016/0304-3940(93)90766-E; BARBOUR B, 1988, NATURE, V335, P433, DOI 10.1038/335433a0; BEVAN S, 1985, PROC R SOC SER B-BIO, V225, P299, DOI 10.1098/rspb.1985.0063; BIRNBAUMER L, 1991, BIOL REPROD, V44, P207, DOI 10.1095/biolreprod44.2.207; BLATZ AL, 1987, TRENDS NEUROSCI, V10, P463, DOI 10.1016/0166-2236(87)90101-9; BOSS V, 1992, J NEUROCHEM, V59, P2340; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; Boyle PJ, 1941, J PHYSIOL-LONDON, V100, P1; CHAN PH, 1989, BRAIN RES, V487, P380, DOI 10.1016/0006-8993(89)90845-7; CONN PJ, 1991, DRUG DEVELOP RES, V24, P207, DOI 10.1002/ddr.430240303; DAVIS CW, 1985, FED PROC, V44, P2520; ERECINSKA M, 1989, J NEUROCHEM, V52, P135, DOI 10.1111/j.1471-4159.1989.tb10907.x; ERECINSKA M, 1988, BRIT J PHARMACOL, V94, P871, DOI 10.1111/j.1476-5381.1988.tb11599.x; ERIKSSON PS, 1992, NEUROSCI LETT, V143, P195, DOI 10.1016/0304-3940(92)90264-8; FAGNI L, 1991, EUR J NEUROSCI, V3, P778, DOI 10.1111/j.1460-9568.1991.tb01674.x; GECK P, 1985, ANN NY ACAD SCI, V456, P166, DOI 10.1111/j.1749-6632.1985.tb14862.x; GECK P, 1986, J MEMBRANE BIOL, V91, P97, DOI 10.1007/BF01925787; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANSSON E, 1984, BRAIN RES, V300, P9, DOI 10.1016/0006-8993(84)91335-0; HANSSON E, 1994, IN PRESS NEUROSCIENC; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KIMELBERG HK, 1990, BRAIN RES, V529, P255, DOI 10.1016/0006-8993(90)90835-Y; KIMELBERG HK, 1988, GLIA, V1, P219, DOI 10.1002/glia.440010307; KOYAMA Y, 1991, NEUROSCI LETT, V122, P210, DOI 10.1016/0304-3940(91)90860-V; KOYAMA Y, 1991, NEUROSCI LETT, V124, P235, DOI 10.1016/0304-3940(91)90102-Y; LESTER RAJ, 1990, NEURON, V4, P741, DOI 10.1016/0896-6273(90)90200-Y; MANZONI O, 1992, EUR J PHARM-MOLEC PH, V225, P357, DOI 10.1016/0922-4106(92)90112-9; MAYER ML, 1990, TRENDS PHARMACOL SCI, V11, P254, DOI 10.1016/0165-6147(90)90254-6; MCBEAN GJ, 1985, J NEUROCHEM, V44, P247, DOI 10.1111/j.1471-4159.1985.tb07137.x; MCCARTHY KD, 1988, GLIAL CELL RECEPTORS, P1; MCCARTY NA, 1992, PHYSIOL REV, V72, P1037, DOI 10.1152/physrev.1992.72.4.1037; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; NILSSON M, 1993, NEUROSCIENCE, V54, P605, DOI 10.1016/0306-4522(93)90232-5; PEARCE B, 1993, ASTROCYTES PHARM FUN, P47; POENIE M, 1987, EMBO J, V6, P2223, DOI 10.1002/j.1460-2075.1987.tb02494.x; RAFF MC, 1984, TRENDS NEUROSCI, V7, P469; ROE MW, 1990, CELL CALCIUM, V11, P63, DOI 10.1016/0143-4160(90)90060-8; SARANTIS M, 1990, BRAIN RES, V516, P322, DOI 10.1016/0006-8993(90)90935-5; SCHNEIDER GH, 1992, J PHYSL PHARM, V70, pS334; SCHOEPP D, 1990, TRENDS PHARMACOL SCI, V11, P508, DOI 10.1016/0165-6147(90)90052-A; SCHOEPP DD, 1992, J NEUROCHEM, V58, P1184, DOI 10.1111/j.1471-4159.1992.tb09381.x; SCHOEPP DD, 1993, TRENDS PHARMACOL SCI, V14, P13, DOI 10.1016/0165-6147(93)90107-U; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SURPRENANT A, 1988, PROC R SOC SER B-BIO, V234, P85, DOI 10.1098/rspb.1988.0039; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; TAUC M, 1990, BIOCHIM BIOPHYS ACTA, V1052, P278, DOI 10.1016/0167-4889(90)90222-Y; THOMSEN C, 1992, EUR J PHARM-MOLEC PH, V227, P361, DOI 10.1016/0922-4106(92)90018-Q; TROMBLEY PQ, 1992, J NEUROSCI, V12, P2043; TSE FW, 1992, J NEUROSCI, V12, P1781; WALZ W, 1989, PROG NEUROBIOL, V33, P309, DOI 10.1016/0301-0082(89)90005-1; WILLIAMS JT, 1988, J NEUROSCI, V8, P4299; WINDER DG, 1992, J NEUROCHEM, V59, P375, DOI 10.1111/j.1471-4159.1992.tb08914.x; WONG BS, 1993, LIFE SCI, V53, P359	54	56	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					21955	21961						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	7915278				2022-12-25	WOS:A1994PE09800009
J	TAGUCHI, H; MAKINO, Y; YOSHIDA, M				TAGUCHI, H; MAKINO, Y; YOSHIDA, M			MONOMERIC CHAPERONIN-60 AND ITS 50-KDA FRAGMENT POSSESS THE ABILITY TO INTERACT WITH NONNATIVE PROTEINS, TO SUPPRESS AGGREGATION, AND TO PROMOTE PROTEIN-FOLDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GROE; RHODANESE; PURIFICATION; INVITRO	Chaperonin-60 is usually isolated as a tetradecameric form arranged as two stacked seven-member rings, and this structure has been considered to be required for promoting protein folding. However, monomeric chaperonin-60 (cpn60(m)), isolated from holo-chaperonin of Thermus thermophilus, and its proteolytic 50-kDa fragment, which lacks amino-terminal 78 amino acid residues, can interact with non-native rhodanese and lactate dehydrogenase, suppress formation of aggregates, and promote productive folding under the appropriate conditions. However, different from tetradecameric chaperonin-60, folding promoted by cpn60(m) and the 50-kDa fragment produces lower yields of active enzymes and does not require ATP or chaperonin-10. These effects are not due to transient reassembly of cpn60(m) into a tetradecamer during the reaction, since immobilized cpn60(m), and the 50-kDa fragment, both of which can not reassemble into a tetradecamer, can still promote protein folding. An excess amount of the 50-kDa fragment shows an inhibitory effect on MgATP-triggered holechaperonin-dependent folding, indicating the 50-kDa fragment and holo-chaperonin can interact with the same species of non-native proteins. Thus, cpn60(m), has an intrinsic activity as a molecular chaperone and amino-terminal region of cpn60 is dispensable for this activity.	TOKYO INST TECHNOL,RESOURCES UTILIZAT RES LAB,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN	Tokyo Institute of Technology			taguchi, hideki/AAM-2663-2021; Taguchi, Hideki/B-6946-2009	taguchi, hideki/0000-0002-6612-9339; Taguchi, Hideki/0000-0002-6612-9339				ALCONADA A, 1993, TRENDS BIOCHEM SCI, V18, P81, DOI 10.1016/0968-0004(93)90158-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDA PK, 1985, J BACTERIOL, V161, P446, DOI 10.1128/JB.161.1.446-449.1985; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HOROVITZ A, 1993, J BIOL CHEM, V268, P9957; HOROVITZ A, 1993, J MOL BIOL, V231, P58, DOI 10.1006/jmbi.1993.1256; ISHII N, 1992, FEBS LETT, V299, P169, DOI 10.1016/0014-5793(92)80240-H; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KIEFHABER T, 1991, BIO-TECHNOL, V9, P825, DOI 10.1038/nbt0991-825; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; LISSIN NM, 1993, FEBS LETT, V324, P41, DOI 10.1016/0014-5793(93)81528-8; LORIMER GH, 1992, CURR OPIN STRUC BIOL, V2, P26; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13587; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; PRICE NC, 1993, BIOCHIM BIOPHYS ACTA, V1161, P52, DOI 10.1016/0167-4838(93)90195-W; PUSHKIN AV, 1982, BIOCHIM BIOPHYS ACTA, V704, P379, DOI 10.1016/0167-4838(82)90169-8; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; TAGUCHI H, 1991, J BIOL CHEM, V266, P22411; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; YOSHIDA M, 1993, PHILOS T ROY SOC B, V339, P305, DOI 10.1098/rstb.1993.0029; YUTANI K, 1967, J BIOCHEM-TOKYO, V62, P576, DOI 10.1093/oxfordjournals.jbchem.a128707; ZEILSTRARYALLS J, 1991, ANNU REV MICROBIOL, V45, P301, DOI 10.1146/annurev.mi.45.100191.001505; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	38	47	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8529	8534						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7907593				2022-12-25	WOS:A1994NB40900105
J	AOYAGI, N; MATSUOKA, S; FURUNOBU, A; MATSUKAGE, A; SAKAGUCHI, K				AOYAGI, N; MATSUOKA, S; FURUNOBU, A; MATSUKAGE, A; SAKAGUCHI, K			DROSOPHILA DNA-POLYMERASE-DELTA - PURIFICATION AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; MOLECULAR-CLONING; RIBONUCLEASE-H; CALF THYMUS; SACCHAROMYCES-CEREVISIAE; MELANOGASTER EMBRYOS; REPLICATION INVITRO; AUXILIARY PROTEIN; PRIMASE COMPLEX; SV40 ORIGIN	A DNA polymerase with properties similar to mammalian polymerase delta has been isolated to near homogeneity from early embryos of Drosophila melanogaster. A combination of exclusion chromatography and sodium dodecyl sulfate-polyacrylamide gel electrophoresis indicates that this enzyme has a total molecular mass of 185 kDa and is composed of 138- and 47-kDa polypeptides. Its isoelectric point is 6.8. This polymerase activity is strongly inhibited by N-ethylmaleimide, aphidicolin, and high KCl concentration but is relatively insensitive to 2',3' dideoxythymidine 5'-triphosphate. There was no reaction in an immunological test using monoclonal antibody against Drosophila DNA polymerase alpha. In a final purification step, this polymerase activity was accompanied by 3' --> 5' exonuclease activity as expected proofreading activity. This polymerase activity is remarkably stimulated by mouse proliferating cell nuclear antigen, which is structurally and immunologically very similar to a Drosophila counterpart. These properties clearly indicate this enzyme belongs to the category of DNA polymerase delta.	SCI UNIV TOKYO,FAC SCI & TECHNOL,DEPT APPL BIOL SCI,NODA,CHIBA 278,JAPAN; AICHI CANC CTR,RES INST,CELL BIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Tokyo University of Science; Aichi Cancer Center								ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BANKS GR, 1979, J BIOL CHEM, V254, P9886; BAUER GA, 1990, NUCLEIC ACIDS RES, V18, P261, DOI 10.1093/nar/18.2.261; BIALEK G, 1993, J BIOL CHEM, V268, P6024; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKE RG, 1991, J BIOL CHEM, V266, P3005; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; BURGERS PMJ, 1988, NUCLEIC ACIDS RES, V16, P6297, DOI 10.1093/nar/16.14.6297; BURGERS PMJ, 1990, EUR J BIOCHEM, V191, P617, DOI 10.1111/j.1432-1033.1990.tb19165.x; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; COTTERILL SM, 1987, P NATL ACAD SCI USA, V84, P5635, DOI 10.1073/pnas.84.16.5635; DIFRANCESCO RA, 1985, J BIOL CHEM, V260, P4764; GAUDETTE MF, 1986, P NATL ACAD SCI USA, V83, P5953, DOI 10.1073/pnas.83.16.5953; GOULIAN M, 1990, J BIOL CHEM, V265, P16402; HAGEMEIER A, 1989, EUR J BIOCHEM, V185, P621, DOI 10.1111/j.1432-1033.1989.tb15158.x; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KAGUNI LS, 1983, P NATL ACAD SCI-BIOL, V80, P2221, DOI 10.1073/pnas.80.8.2221; KARWAN R, 1983, BIOCHEMISTRY-US, V22, P5500, DOI 10.1021/bi00293a008; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KURODA K, 1990, J BIOCHEM-TOKYO, V108, P926, DOI 10.1093/oxfordjournals.jbchem.a123316; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; LEE SK, 1993, FEBS LETT, V316, P261, DOI 10.1016/0014-5793(93)81304-I; LEHMAN IR, 1989, J BIOL CHEM, V264, P4265; LINN S, 1991, CELL, V66, P185, DOI 10.1016/0092-8674(91)90608-2; LU CD, 1992, BIOCHEMISTRY-US, V31, P12403, DOI 10.1021/bi00164a015; MATSUMOTO K, 1987, EMBO J, V6, P637, DOI 10.1002/j.1460-2075.1987.tb04802.x; MICCHELI G, 1982, EXP CELL RES, V137, P127; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; NG L, 1990, J BIOL CHEM, V265, P11948; NIRANJANAKUMARI S, 1992, J BIOL CHEM, V263, P17531; PECK VM, 1992, NUCLEIC ACIDS RES, V20, P5779, DOI 10.1093/nar/20.21.5779; SAKAGUCHI K, 1992, MUTAT RES, V274, P11, DOI 10.1016/0921-8777(92)90039-6; SAKAGUCHI K, 1985, J BIOL CHEM, V260, P406; SPRADLING A, 1987, ANNU REV GENET, V21, P373, DOI 10.1146/annurev.ge.21.120187.002105; SPRADLING AC, 1981, ANNU REV GENET, V15, P219, DOI 10.1146/annurev.ge.15.120181.001251; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; SUZUKA I, 1989, P NATL ACAD SCI USA, V86, P3189, DOI 10.1073/pnas.86.9.3189; THOMMES P, 1990, EUR J BIOCHEM, V194, P699, DOI 10.1111/j.1432-1033.1990.tb19460.x; TRAVALI S, 1989, J BIOL CHEM, V264, P7466; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; WEISER T, 1991, J BIOL CHEM, V266, P10420; WERNETTE CM, 1986, J BIOL CHEM, V261, P4764; YAMAGUCHI M, 1990, MOL CELL BIOL, V10, P872, DOI 10.1128/MCB.10.3.872; YAMAGUCHI M, 1991, NUCLEIC ACIDS RES, V19, P2403, DOI 10.1093/nar/19.9.2403	50	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6045	6050						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7907087				2022-12-25	WOS:A1994MY84000086
J	SANFRIDSON, A; CULLEN, BR; DOYLE, C				SANFRIDSON, A; CULLEN, BR; DOYLE, C			THE SIMIAN IMMUNODEFICIENCY VIRUS NEF PROTEIN PROMOTES DEGRADATION OF CD4 IN HUMAN T-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HIV-1 NEF; SERINE PHOSPHORYLATION; ENDOPLASMIC-RETICULUM; MUTATIONAL ANALYSIS; HUMAN-LYMPHOCYTES; GENE-PRODUCT; TYPE-1; INTERNALIZATION; REPLICATION; ENDOCYTOSIS	Expression of the Nef protein encoded by human and simian immunodeficiency viruses results in the specific down-regulation of CD4 from dhe cell surface in both lymphoid and non lymphoid cells. In this report, we examine the biosynthesis and cell surface expression of CD4 in the human T cell line, CEM-SS, that has been stably transduced with the SIV nef gene. Quantification of CD4 in Nef-expressing cells reveals that the steady state level of CD4 is significantly reduced as compared to control transductants. The presence of Nef in these cells promotes the degradation of newly synthesized CD4 protein. The biosynthesis and oligosaccharide processing of CD4 in Nef-expressing T cells appears to be normal through the endoplasmic reticulum and Golgi compartments, suggesting that the degradation of CD4 is a late event in the biosynthetic pathway. Treatment with the lysosomotropic agents chloroquine and primaquine prevents the degradation of CD4 in Nef-expressing CEM-SS cells, indicating that the degradation of CD4 likely occurs in an acidic compartment. Thus the reduced cell surface expression observed in Nef expressing CEM-SS cells is the likely consequence of a Nef-induced sorting of CD4 into a cellular compartment where CD4 is then degraded.	DUKE UNIV,MED CTR,DEPT IMMUNOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT GENET,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710	Duke University; Duke University; Duke University; Howard Hughes Medical Institute					NATIONAL CANCER INSTITUTE [T32CA009058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046391] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA09058] Funding Source: Medline; NIGMS NIH HHS [GM46391] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON S, 1993, J VIROL, V67, P4923, DOI 10.1128/JVI.67.8.4923-4931.1993; BENSON RE, 1993, J EXP MED, V177, P1561, DOI 10.1084/jem.177.6.1561; CHEN MY, 1993, J VIROL, V67, P3877, DOI 10.1128/JVI.67.7.3877-3884.1993; CRISE B, 1990, J VIROL, V64, P5585, DOI 10.1128/JVI.64.11.5585-5593.1990; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; DERONDE A, 1992, VIROLOGY, V188, P391, DOI 10.1016/0042-6822(92)90772-H; DOYLE C, 1989, IMMUNOL REV, V109, P17, DOI 10.1111/j.1600-065X.1989.tb00018.x; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; GARCIA JV, 1993, J VIROL, V67, P1511, DOI 10.1128/JVI.67.3.1511-1516.1993; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; HAMMES SR, 1989, P NATL ACAD SCI USA, V86, P9549, DOI 10.1073/pnas.86.23.9549; HIEBSCH RR, 1991, J BIOL CHEM, V266, P20323; INOUE M, 1993, INT IMMUNOL, V5, P1067, DOI 10.1093/intimm/5.9.1067; JABBAR MA, 1990, J VIROL, V64, P6297, DOI 10.1128/JVI.64.12.6297-6304.1990; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KONIG R, 1988, J BIOL CHEM, V263, P9502; LURIA S, 1991, P NATL ACAD SCI USA, V88, P5236; MARIANI R, 1993, P NATL ACAD SCI USA, V90, P5549, DOI 10.1073/pnas.90.12.5549; NEBREDA AR, 1991, VIROLOGY, V183, P151, DOI 10.1016/0042-6822(91)90128-X; NIEDERMAN TMJ, 1993, VIROLOGY, V194, P338, DOI 10.1006/viro.1993.1264; OHKUMA S, 1981, J CELL BIOL, V90, P656, DOI 10.1083/jcb.90.3.656; POULIN L, 1992, AIDS, V6, P787, DOI 10.1097/00002030-199208000-00003; REIF JS, 1991, EXP CELL RES, V192, P581, DOI 10.1016/0014-4827(91)90079-A; REPKE H, 1992, J IMMUNOL, V149, P2585; RUEGG CL, 1992, J BIOL CHEM, V267, P18837; SAGGIORO D, 1993, J BIOL CHEM, V268, P1368; SATTENTAU QJ, 1988, CELL, V52, P631, DOI 10.1016/0092-8674(88)90397-2; SCHWARTZ O, 1993, J VIROL, V67, P3274, DOI 10.1128/JVI.67.6.3274-3280.1993; SHIN J, 1990, EMBO J, V9, P425, DOI 10.1002/j.1460-2075.1990.tb08127.x; SHIN J, 1991, P NATL ACAD SCI USA, V88, P1918, DOI 10.1073/pnas.88.5.1918; Veillette A, 1991, Semin Immunol, V3, P143; WERNER T, 1991, AIDS, V5, P1301, DOI 10.1097/00002030-199111000-00003; WILLEY RL, 1992, J VIROL, V66, P7193, DOI 10.1128/JVI.66.12.7193-7200.1992; WOLBER V, 1992, EUR J BIOCHEM, V205, P1115, DOI 10.1111/j.1432-1033.1992.tb16880.x; YAMASHIRO DJ, 1983, J CELL BIOL, V97, P929, DOI 10.1083/jcb.97.3.929; YU G, 1992, VIROLOGY, V187, P46, DOI 10.1016/0042-6822(92)90293-X; ZAZOPOULOS E, 1993, VIROLOGY, V194, P20, DOI 10.1006/viro.1993.1230; ZAZOPOULOS E, 1992, P NATL ACAD SCI USA, V89, P6634, DOI 10.1073/pnas.89.14.6634	38	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3917	3920						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7905875				2022-12-25	WOS:A1994MW98900004
J	CZYZYKKRZESKA, MF; FURNARI, BA; LAWSON, EE; MILLHORN, DE				CZYZYKKRZESKA, MF; FURNARI, BA; LAWSON, EE; MILLHORN, DE			HYPOXIA INCREASES RATE OF TRANSCRIPTION AND STABILITY OF TYROSINE-HYDROXYLASE MESSENGER-RNA IN PHEOCHROMOCYTOMA (PC12) CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAROTID-BODY INVITRO; GENE-EXPRESSION; CYCLIC-AMP; CATECHOLAMINE SYNTHESIS; ERYTHROPOIETIN; OXYGEN; STIMULATION; RELEASE	Reduced arterial oxygen tension (i.e. hypoxia) is a powerful physiological stimulus that induces synthesis and release of dopamine from O2-sensitive (type I) cells in the mammalian carotid bodies. We reported recently that hypoxia stimulates gene expression for tyrosine hydroxylase (TH), the rate-limiting enzyme in catecholamine synthesis in type I cells of the carotid body. Efforts to identify the mechanisms regulating TH gene expression in O2-sensitive cells during hypoxia have been hampered by the lack of an appropriate model cell culture system. Here we report that TH gene expression in the rat pheochromocytoma cell line (PC12) is regulated during hypoxia in a manner similar to that measured in carotid body type I cells. PC12 cells might therefore be useful as an experimental model for identifying the molecular mechanisms that regulate TH gene expression during hypoxia. Nuclear runoff assays revealed that transcription of the wild type TH gene was enhanced during exposures to hypoxia lasting 12 h. Chloramphenicol acetyltransferase assays with constructs that contained different fragments of TH promoter revealed that the regulatory sequences that mediate the hypoxia-induced increase in transcription are located between bases -272 and +27 of the TH gene. Findings from experiments in which transcription was inhibited either with actinomycin D or 5,6-dichloro-1-D-ribofuranosylbenzimidazole, as well as pulse-chase experiments using 4-thiouridine showed that the half-life of TH mRNA was substantially increased during hypoxia. Thus, in the present paper we show that TH gene expression in PC12 cells during hypoxia is regulated by increases in both the rate of TH gene transcription and TH mRNA stability.	UNIV N CAROLINA, DEPT PEDIAT, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	CZYZYKKRZESKA, MF (corresponding author), UNIV N CAROLINA, DEPT PHYSIOL, MOLEC & DEV NEUROSCI LAB, MED SCI RES BLDG 68, CHAPEL HILL, NC 27599 USA.				NHLBI NIH HHS [HL 33831, HL 34919] Funding Source: Medline; NICHD NIH HHS [HD 28948] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028948] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL033831, R01HL034919, R01HL033831] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CARVISO GL, 1992, SOC NEUR ABSTR, V18; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CZYZYKKRZESKA MF, 1992, J NEUROCHEM, V58, P1538, DOI 10.1111/j.1471-4159.1992.tb11376.x; FEINSILVER SH, 1987, BIOCHIM BIOPHYS ACTA, V928, P56, DOI 10.1016/0167-4889(87)90085-1; FOSSOM LH, 1992, MOL PHARMACOL, V42, P898; FUNG BP, 1992, J NEUROCHEM, V58, P2044, DOI 10.1111/j.1471-4159.1992.tb10945.x; GEBALLE AP, 1988, J VIROL, V62, P3334, DOI 10.1128/JVI.62.9.3334-3340.1988; GOLDBERG MA, 1989, CONTRIB NEPHROL, V76, P39; GOLDBERG MA, 1991, BLOOD, V77, P271; GONZALEZ C, 1992, TRENDS NEUROSCI, V15, P146, DOI 10.1016/0166-2236(92)90357-E; GONZALEZ C, 1981, AM J PHYSIOL, V240, pR38, DOI 10.1152/ajpregu.1981.240.1.R38; GONZALEZ C, 1979, J NEUROCHEM, V33, P713, DOI 10.1111/j.1471-4159.1979.tb05216.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GRIMA B, 1985, P NATL ACAD SCI USA, V82, P617, DOI 10.1073/pnas.82.2.617; HANBAUER I, 1977, NEUROPHARMACOLOGY, V16, P277, DOI 10.1016/0028-3908(77)90107-1; HEYMANS C, 1958, REFLEXOGENIC AREAS C, P1; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; KILBOURNE EJ, 1992, J BIOL CHEM, V267, P7563; KOBAYASHI K, 1988, J BIOCHEM, V103, P907, DOI 10.1093/oxfordjournals.jbchem.a122386; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; MARZLUFF WF, 1985, TRANSCRIPTION TRANSL, P89; McDonald DM., 1981, REGULATION BREATHI 1, P105; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MULLER SR, 1990, DNA CELL BIOL, V9, P221, DOI 10.1089/dna.1990.9.221; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; PEREZGARCIA MT, 1990, J NEUROCHEM, V55, P1287, DOI 10.1111/j.1471-4159.1990.tb03137.x; PERRY RP, 1970, J CELL PHYSIOL, V76, P127, DOI 10.1002/jcp.1040760202; SUMMERHILL EM, 1987, MOL BRAIN RES, V2, P99, DOI 10.1016/0169-328X(87)90002-7; TAMM I, 1978, ADV VIRUS RES, V22, P188; TAN CC, 1992, KIDNEY INT, V41, P1581, DOI 10.1038/ki.1992.228; VYAS S, 1990, EMBO J, V9, P3707, DOI 10.1002/j.1460-2075.1990.tb07583.x; WANG WJ, 1989, NEUROSCI LETT, V105, P164, DOI 10.1016/0304-3940(89)90030-X; WANG WJ, 1991, BRAIN RES, V540, P96, DOI 10.1016/0006-8993(91)90495-H; WOODFORD TA, 1988, ANAL BIOCHEM, V171, P166, DOI 10.1016/0003-2697(88)90138-8; Zhu W. H., 1992, Society for Neuroscience Abstracts, V18, P1500	41	237	246	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					760	764						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	7903970				2022-12-25	WOS:A1994MR21900119
J	RICHARME, G; KOHIYAMA, M				RICHARME, G; KOHIYAMA, M			SPECIFICITY OF THE ESCHERICHIA-COLI CHAPERONE DNAK (70-KDA HEAT-SHOCK PROTEIN) FOR HYDROPHOBIC AMINO-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE-CHAIN; PEPTIDE-BINDING; PREDICTION; CATALYSTS; SURFACE; GROEL	Molecular chaperones form a class of proteins that bind selectively to nascent, unfolded, misfolded, or aggregated polypeptides. This property is the basis of their implication in many cellular processes such as protein folding, protein targeting to membranes, or protein renaturation after stress. It has been suggested that the recognition of non-native proteins by chaperones is mediated by their binding to exposed hydrophobic areas, to the polypeptide backbone, or to specific secondary structures. We show in the present study that DnaK, the 70-kDa chaperone of Escherichia coli specifically recognizes hydrophobic amino acids. The peptide-dependent ATPase activity of DnaK is specifically stimulated by Ile, Phe, Leu, and Val in a manner which is consistent with an interaction of these amino acids with the polypeptide binding site of DnaK. Two classes of amino acid binding site can be distinguished, one being specific for the aliphatic amino acids and the other for the aromatic amino acids. Since the hydrophobic amino acids are buried inside the hydrophobic core of native proteins and are exposed in non-native forms, their interaction with DnaK could be the basis of the specific interaction of the chaperone with non-native proteins in protein folding, protein targeting to membranes, or protein renaturation.			RICHARME, G (corresponding author), UNIV PARIS 07,INST JACQUES MONOD,GENET & BIOCHIM LAB,2 PL JUSSIEU,F-75221 PARIS 05,FRANCE.							BARTON GJ, 1990, J MOL BIOL, V212, P389, DOI 10.1016/0022-2836(90)90133-7; BORK P, 1992, TRENDS BIOCHEM SCI, V17, P129, DOI 10.1016/0968-0004(92)90319-5; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; CREIGHTON TE, 1980, NATURE, V284, P487, DOI 10.1038/284487a0; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDICK R, 1987, ESCHERICHIA COLI SAL, P1276; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; MORIMOTO R I, 1990, P1; NOZAKI Y, 1971, J BIOL CHEM, V246, P2211; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PTITSYN OB, 1992, CONFORMATIONS FORCES, P155; RACKOVSKY S, 1977, P NATL ACAD SCI USA, V74, P5248, DOI 10.1073/pnas.74.12.5248; RICHARME G, 1993, FEBS LETT, V322, P277, DOI 10.1016/0014-5793(93)81585-N; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHULZ GE, 1988, ANNU REV BIOPHYS BIO, V17, P1; SHRAKE A, 1973, J MOL BIOL, V79, P351, DOI 10.1016/0022-2836(73)90011-9; VONHEIJNE G, 1981, EUR J BIOCHEM, V116, P419; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; ZYLICZ M, 1984, J BIOL CHEM, V259, P8820; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437	32	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24074	24077						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	7901212				2022-12-25	WOS:A1993MF29400056
J	SKACH, WR; LINGAPPA, VR				SKACH, WR; LINGAPPA, VR			AMINO-TERMINAL ASSEMBLY OF HUMAN P-GLYCOPROTEIN AT THE ENDOPLASMIC-RETICULUM IS DIRECTED BY COOPERATIVE ACTIONS OF 2 INTERNAL SEQUENCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHESIZING SECRETORY PROTEIN; ONE SIGNAL SEQUENCE; MULTIDRUG-RESISTANCE; MICROSOMAL-MEMBRANES; STOP TRANSFER; TRANSMEMBRANE PROTEIN; BACTERIAL TRANSPORT; TOPOGENIC SEQUENCE; APOLIPOPROTEIN-B; CYSTIC-FIBROSIS	Transmembrane topology of polytopic integral membrane proteins is established during protein synthesis at the endoplasmic reticulum membrane. For some polytopic proteins, sequential and independent signal, stop transfer, and/or signal anchor sequences contained in the nascent chain direct this process. Here we define the topology of human P-glycoprotein (MDR1) through the first two transmembrane regions (TM1 and TM2, respectively) of the amino-terminal half of the protein. We show that unlike TM7 and TM8, which comprise homologous regions in the carboxyl half of the protein (Skach, W., Calayag, M. C., and Lingappa, V. (1993) J. Biol. Chem. 268, 6903-6908), TM1 and TM2 achieve the orientation predicted by conventional structural models. However, TM1 and TM2 appear to utilize a mechanism of biogenesis different in a key respect from that observed in multispanning proteins studied previously. TM1 and TM2, with their flanking regions, independently direct the topology observed for each of these sequences in the native protein. Each can interact with signal recognition particle to direct targetting to the endoplasmic reticulum, nascent chain translocation, and correct transmembrane orientation. Unlike the transmembrane regions of previously studied multispanning membrane proteins, neither TM1 nor TM2 alone is sufficient to integrate the chain into the membrane. However, when TM1 and TM2 are both present, as occurs in native MDR1, integration is achieved. These results suggest that cooperative interactions between TM1 and TM2 are necessary for chain integration and thus add a new complexity to the current view of polytopic integral membrane protein biogenesis.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CANC RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	SKACH, WR (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143, USA.			Lingappa, Vishwanath R./0000-0003-0962-6571	NATIONAL CANCER INSTITUTE [K11CA001614] Funding Source: NIH RePORTER; NCI NIH HHS [CA01614] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUDIGIER Y, 1987, P NATL ACAD SCI USA, V84, P5783, DOI 10.1073/pnas.84.16.5783; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BRUGGEMANN EP, 1991, BIOTECHNIQUES, V10, P202; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; CHAVEZ RA, 1991, J BIOL CHEM, V266, P15532; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FOOTE SJ, 1990, NATURE, V345, P255, DOI 10.1038/345255a0; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GETHING MJ, 1982, NATURE, V300, P598, DOI 10.1038/300598a0; GOERLICH D, 1992, Nature (London), V357, P47; GOERLICH D, 1990, J CELL BIOL, V111, P1183; GOTTESMAN MM, 1991, BIOCH MOL ASPECTS SE, P339; GUAN JL, 1984, CELL, V37, P779, DOI 10.1016/0092-8674(84)90413-6; HIGH S, 1991, J CELL BIOL, V113, P25, DOI 10.1083/jcb.113.1.25; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KATZ FN, 1977, P NATL ACAD SCI USA, V74, P3278, DOI 10.1073/pnas.74.8.3278; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; LINGAPPA VR, 1991, CELL, V65, P527, DOI 10.1016/0092-8674(91)90081-9; LINGAPPA VR, 1984, P NATL ACAD SCI-BIOL, V81, P456, DOI 10.1073/pnas.81.2.456; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; LIPP J, 1986, J CELL BIOL, V102, P2169, DOI 10.1083/jcb.102.6.2169; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MUECKLER M, 1986, CELL, V44, P629, DOI 10.1016/0092-8674(86)90272-2; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; NELSON DR, 1988, J BIOL CHEM, V263, P6038; PERARA E, 1986, SCIENCE, V232, P348, DOI 10.1126/science.3961485; PERARA E, 1988, PROTEIN TRANSFER ORG, P3; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROTHMAN RE, 1988, J BIOL CHEM, V263, P10470; SILVE S, 1991, MOL CELL BIOL, V11, P1114, DOI 10.1128/MCB.11.2.1114; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SKACH W, 1992, MECHANISMS INTRACELL, P19; SKACH WR, 1993, J BIOL CHEM, V268, P6903; SPIESS M, 1986, CELL, V44, P177, DOI 10.1016/0092-8674(86)90496-4; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1981, J CELL BIOL, V91, P551, DOI 10.1083/jcb.91.2.551; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; YOSHIMURA A, 1989, J BIOL CHEM, V264, P16282; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0; YOST CS, 1983, CELL, V34, P759; ZHANG JT, 1991, J BIOL CHEM, V266, P18224	60	81	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23552	23561						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7901209				2022-12-25	WOS:A1993MF51500091
J	BAGLIA, FA; JAMESON, BA; WALSH, PN				BAGLIA, FA; JAMESON, BA; WALSH, PN			IDENTIFICATION AND CHARACTERIZATION OF A BINDING-SITE FOR PLATELETS IN THE APPLE-3 DOMAIN OF COAGULATION-FACTOR-XI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; WASHED HUMAN-PLATELETS; CONTACT ACTIVATION; PLASMA; SEQUENCE	Activated platelets expose a specific, reversible high affinity (K-dapp similar or equal to 10 nM) binding site (n similar or equal to 1500 sites/platelet platelet) for factor XI that requires the presence of high molecular weight kininogen (HK) and ZnCl2 (Greengard, J. S., Heeb, M. J., Ersdal, E., Walsh, P. N., and Griffin, J. H. (1986) Biochemistry 25, 3884-3890), Synthetic, conformationally constrained peptides from four tandem repeat (Apple) domains were tested for their capacity to inhibit I-125-factor XI binding to platelets, A peptide from the Apple 3 (A3) domain (Asn(235)-Arg(266)) inhibits factor XI binding to platelets in the presence of HK (42 nM), CaCl2, (2 mM), and ZnCl2 (25 mu M), with a K-i similar or equal to 10 nM which is identical to the K-d for factor XI binding to platelets, A peptide from the A1 domain (Phe(56)-Ser(86)) partially inhibits factor XI binding to platelets (Ki = 6 mu M) by inhibiting factor M binding to HK, whereas peptides from the A2 and A4 domains have no effect, Using computer modeling for rational design, conformationally constrained peptides were synthesized (Pro(229) Gln(233), Thr(241)-Leu(246), and Ser(248)-Ser(261)) each of which acted alone and synergistically when added together to inhibit factor XI: binding to platelets, Finally, the I-125-labeled A3 domain peptide (Asn(235)-Arg(266)) was found to bind to thrombin activated platelets in a specific, reversible, and saturable manner, Thus, the sequence of amino acids Asn(235)-Arg(266) Of the A3 domain of factor XI comprises a contact surface for interaction with a platelet receptor.	TEMPLE UNIV,SCH MED,SOL SHERRY THROMBOSIS RES CTR,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT MED,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; THOMAS JEFFERSON UNIV,PHILADELPHIA,PA 19107	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University					NHLBI NIH HHS [HL46213, HL25661, HL45486] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025661, P50HL045486, R01HL046213] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGLIA FA, 1991, J BIOL CHEM, V266, P24190; BAGLIA FA, 1992, J BIOL CHEM, V267, P4247; BAGLIA FA, 1990, J BIOL CHEM, V265, P4149; BAGLIA FA, 1993, J BIOL CHEM, V268, P3838; Davie E W, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P277; FAIR BD, 1977, P SOC EXP BIOL MED, V155, P199; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; GREENGARD JS, 1984, BIOCHEMISTRY-US, V23, P6863, DOI 10.1021/bi00321a090; GREENGARD JS, 1986, BIOCHEMISTRY-US, V25, P3884, DOI 10.1021/bi00361a022; GRIFFIN JH, 1979, SEMIN THROMB HEMOST, V5, P254; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HUI KY, 1992, BIOCHEM BIOPH RES CO, V184, P790, DOI 10.1016/0006-291X(92)90659-9; KAMP FH, 1991, ANAL CHEM, V63, pA1193; KENT SBH, 1985, SYNTHETIC PEPTIDES B, P29; KERBIRIOU DM, 1979, J BIOL CHEM, V254, P2020; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2056, DOI 10.1021/bi00222a008; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PROCTOR RR, 1961, AM J CLIN PATHOL, V36, P212; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SINHA D, 1985, J BIOL CHEM, V260, P714; THOMPSON RE, 1977, J CLIN INVEST, V60, P1376, DOI 10.1172/JCI108898; WALSH PN, 1993, METHOD ENZYMOL, V222, P65; WALSH PN, 1981, BLOOD, V57, P106	23	60	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6734	6740		10.1074/jbc.270.12.6734	http://dx.doi.org/10.1074/jbc.270.12.6734			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896818	hybrid			2022-12-25	WOS:A1995QQ85500049
J	STAUFFER, KA				STAUFFER, KA			THE GAP JUNCTION PROTEINS BETA(1)-CONNEXIN (CONNEXIN-32) AND BETA(2)-CONNEXIN (CONNEXIN-26) CAN FORM HETEROMERIC HEMICHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER	Two different types of gap junction proteins, beta(1)- and beta(2)-connexin, were expressed in insect cells, either singly or together, using infection with recombinant baculovirus. Membrane fractions enriched in gap junction proteins were isolated, and connexons (hemichannels) were solubilized with detergent. These solubilized connexons were then run out on a gel filtration column which was capable of partially separating the two homomeric connexons. It was found that connexons from cells co-infected with both types of baculovirus ran together on this column, whereas connexons from cells infected separately and mixed before solubilization did not, suggesting that in the co-infected cells the two types of connexin are assembled into heteromeric hemichannels.	MRC,MOLEC BIOL LAB,CAMBRIDGE,ENGLAND	MRC Laboratory Molecular Biology								Beyer E C, 1993, Int Rev Cytol, V137C, P1; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; BUEHLER LK, 1995, IN PRESS BIOPHYS J; HERTZBERG EL, 1979, J BIOL CHEM, V254, P2138; HERTZBERG EL, 1984, J BIOL CHEM, V259, P9936; KISTLER J, 1994, J CELL BIOL, V126, P1047, DOI 10.1083/jcb.126.4.1047; KORDEL M, 1993, BIOPHYS J, V64, pA192; Kumar N M, 1992, Semin Cell Biol, V3, P3; Kumar Nalin M., 1991, Advances in Structural Biology, V1, P209; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; RUBIN JB, 1992, BIOPHYS J, V62, P183, DOI 10.1016/S0006-3495(92)81804-0; STAUFFER KA, 1991, J CELL BIOL, V115, P141, DOI 10.1083/jcb.115.1.141; SUMMERS MD, 1987, TEX AGR EXP ST B, V1555; TANFORD C, 1974, BIOCHEMISTRY-US, V11, P2369; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAUB O, 1989, J CELL BIOL, V108, P1039, DOI 10.1083/jcb.108.3.1039	16	167	170	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6768	6772						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896822				2022-12-25	WOS:A1995QQ85500053
J	THOMAS, D; HANLEY, MR				THOMAS, D; HANLEY, MR			EVALUATION OF CALCIUM INFLUX FACTORS FROM STIMULATED JURKAT T-LYMPHOCYTES BY MICROINJECTION INTO XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INTRACELLULAR CA2+ STORES; ENTRY; THAPSIGARGIN; DEPLETION; INHIBITION; MESSENGER; CELLS	Acid extracts of thapsigargin-activated Jurkat cells have been shown to have intracellular activity in inducing a dose-dependent rapid chloride current upon microinjection in Xenopus laevis oocytes. The extracts act by elevation of calcium through calcium entry. The factor(s) responsible for this activity have been termed calcium influx factor (CIF) and have been found to be small, relatively polar molecules (<1000 daltons) whose activity is abolished by alkaline phosphatase treatment and potentiated by co-injection of okadaic acid (a protein phosphatase inhibitor). CIF is produced in a time-dependent manner following thapsigargin treatment of Jurkat cells, being first elevated above basal levels by 2 min. Intracellular CIF activity is completely absent from NG115-401L neuronal cells, which lack capacitative entry. On this basis, it appears that Jurkat cells, activated by stimuli that deplete internal calcium stores, produce one or more CIF activities acting intracellularly, and Xenopus oocytes may be a powerful tool to purify and characterize CIFs.	UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616	University of California System; University of California Davis								ALVAREZ J, 1992, FASEB J, V6, P786, DOI 10.1096/fasebj.6.2.1537469; BAHNSON TD, 1993, J BIOL CHEM, V268, P10808; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRD GS, 1993, J BIOL CHEM, V268, P21486; BREITTMAYER JP, 1994, J BIOL CHEM, V269, P5054; FERGUSON JE, 1992, ARCH BIOCHEM BIOPHYS, V297, P388, DOI 10.1016/0003-9861(92)90689-T; GRYNKIEWICZ G, 1985, J BIOL CHEM, V60, P3440; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LEE KM, 1993, J BIOL CHEM, V268, P9945; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PREMACK BA, 1994, J IMMUNOL, V152, P5226; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SASAKAWA N, 1994, FEBS LETT, V347, P181, DOI 10.1016/0014-5793(94)00532-X; THOMAS D, 1994, METHOD CELL BIOL, V40, P65; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	19	75	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6429	6432		10.1074/jbc.270.12.6429	http://dx.doi.org/10.1074/jbc.270.12.6429			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896775	hybrid			2022-12-25	WOS:A1995QQ85500003
J	IIRI, T; HOMMA, Y; OHOKA, Y; ROBISHAW, JD; KATADA, T; BOURNE, HR				IIRI, T; HOMMA, Y; OHOKA, Y; ROBISHAW, JD; KATADA, T; BOURNE, HR			POTENTIATION OF G(I)-MEDIATED PHOSPHOLIPASE-C ACTIVATION BY RETINOIC ACID IN HL-60 CELLS - POSSIBLE ROLE OF G(GAMMA-2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; CHEMOTACTIC PEPTIDE RECEPTORS; NUCLEOTIDE-BINDING PROTEIN; PERTUSSIS TOXIN; ALPHA-SUBUNIT; SIGNAL TRANSDUCTION; RAT-BRAIN; EXPRESSION; DIFFERENTIATION; FORMS	Differentiated HL-60 cells acquire responsiveness to fMet-Leu-Phe (fMLP), which activates phospholipase C and O-2(-) generation in a pertussis toxin-sensitive manner. Addition of retinoic acid (RA) for the last 24 h during dimethyl sulfoxide (Me(2)SO)-induced differentiation enhanced fMLP dependent signals and interaction between fMLP receptor and G(i). RA modifies both the function and subunit composition of G(i2), the predominant G(i) of HL-60 membranes, as shown by comparing purified G(i2) from membranes of Me(2)SO-treated cells (D-G(i2)) to G(i) from membranes of cells treated with both Me(2)SO and RA (DR-G(i2)). As compared to D-G(i2), DR-G(i2) induced more fMLP binding when added to membranes of pertussis toxin treated HL-60 cells and, in the presence of GTP gamma S, stimulated beta gamma-sensitive phospholipase C in extracts of HL-60 cells to a much greater extent and at lower concentrations. Immunoblots revealed that RA induced expression of the gamma(2) subunit, which was otherwise undetectable in G(i2) purified from HL-60 cells or in HL-60 membranes. Possibly by inducing expression of gamma(2), RA alters two functions of the G(i) beta gamma subunit, modulation of fMLP receptor-G(i2) coupling and activation of the effector, phospholipase C.	UNIV CALIF SAN FRANCISCO, MED CTR, DEPT PHARMACOL, CELL BIOL PROGRAM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, CELL BIOL PROGRAM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA; TOKYO METROPOLITAN GERIATR HOSP & INST GERENTOL, DEPT BIOSIGNAL RES, TOKYO 173, JAPAN; GEISINGER MED CLIN, WEIS CTR RES, DANVILLE, PA 17822 USA; UNIV TOKYO, FAC PHARMACEUT SCI, DEPT PHYS CHEM, BUNKYO KU, TOKYO 113, JAPAN	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Geisinger Medical Center; University of Tokyo					NCI NIH HHS [CA54427] Funding Source: Medline; NIGMS NIH HHS [GM 39867, GM27800] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039867, R01GM039867, R37GM027800, R01GM027800] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; ASANO T, 1993, J BIOL CHEM, V268, P20512; BLANK JL, 1993, J BIOL CHEM, V268, P25184; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOYER JL, 1994, J BIOL CHEM, V269, P2814; BRABET P, 1990, J NEUROCHEM, V54, P1310, DOI 10.1111/j.1471-4159.1990.tb01964.x; BRANDT SJ, 1985, P NATL ACAD SCI USA, V82, P3277, DOI 10.1073/pnas.82.10.3277; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CHAN SDH, 1990, J BIOL CHEM, V265, P20081; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; COLLINS SJ, 1987, BLOOD, V70, P1233; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FAURE M, 1994, J BIOL CHEM, V269, P7821; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; GIERSCHIK P, 1989, EUR J BIOCHEM, V183, P97, DOI 10.1111/j.1432-1033.1989.tb14901.x; HANSEN CA, 1994, J CELL BIOL, V126, P811, DOI 10.1083/jcb.126.3.811; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HOMMA Y, 1988, J BIOL CHEM, V263, P6592; IIRI T, 1991, EUR J BIOCHEM, V202, P635, DOI 10.1111/j.1432-1033.1991.tb16417.x; IIRI T, 1992, J BIOL CHEM, V267, P1020; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; KATADA T, 1986, J BIOL CHEM, V261, P8182; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KIKUCHI A, 1986, J BIOL CHEM, V261, P1558; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; LEE RH, 1992, J BIOL CHEM, V267, P24776; LEE SB, 1993, J BIOL CHEM, V268, P25952; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; MANGELSDORF DJ, 1984, J CELL BIOL, V98, P391, DOI 10.1083/jcb.98.2.391; MURPHY PM, 1987, FEBS LETT, V221, P81, DOI 10.1016/0014-5793(87)80356-3; OINUMA M, 1987, J BIOL CHEM, V262, P8347; PARK DG, 1993, J BIOL CHEM, V268, P4573; PENG YW, 1992, P NATL ACAD SCI USA, V89, P10882, DOI 10.1073/pnas.89.22.10882; PEREZ HD, 1992, J BIOL CHEM, V267, P358; RAO KMK, 1988, CANCER RES, V48, P6721; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; ROBISHAW JD, 1994, METHOD ENZYMOL, V237, P498; ROBISHAW JD, 1993, ANAL BIOCHEM, V208, P283, DOI 10.1006/abio.1993.1047; SEISHIMA M, 1988, BIOCHEM BIOPH RES CO, V156, P1077, DOI 10.1016/S0006-291X(88)80742-3; SIMCHOWITZ L, 1979, J LAB CLIN MED, V93, P583; SKUBITZ KM, 1982, BLOOD, V59, P586; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TOHKIN M, 1991, EUR J BIOCHEM, V195, P527, DOI 10.1111/j.1432-1033.1991.tb15733.x; UEDA N, 1994, J BIOL CHEM, V269, P4388; UHING RJ, 1987, J BIOL CHEM, V262, P15575; VONWEIZSACKER E, 1992, BIOCHEM BIOPH RES CO, V183, P350, DOI 10.1016/0006-291X(92)91650-F; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0	61	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					5901	5908		10.1074/jbc.270.11.5901	http://dx.doi.org/10.1074/jbc.270.11.5901			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890721	hybrid			2022-12-25	WOS:A1995QM94500033
J	INAGAKI, N; TSUURA, Y; NAMBA, N; MASUDA, K; GONOI, T; HORIE, M; SEINO, Y; MIZUTA, M; SEINO, S				INAGAKI, N; TSUURA, Y; NAMBA, N; MASUDA, K; GONOI, T; HORIE, M; SEINO, Y; MIZUTA, M; SEINO, S			CLONING AND FUNCTIONAL-CHARACTERIZATION OF A NOVEL ATP-SENSITIVE POTASSIUM CHANNEL UBIQUITOUSLY EXPRESSED IN RAT-TISSUES, INCLUDING PANCREATIC-ISLETS, PITUITARY, SKELETAL-MUSCLE, AND HEART	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							K+ CHANNELS; B-CELLS; BETA-CELLS	ATP-sensitive K+ (K-ATP) channels play a crucial role in coupling metabolic energy to the membrane potential of cells. We have isolated a cDNA encoding a novel member (uK(ATP)-1) of the inward rectifier K+ channel family from a rat pancreatic islet cDNA library, Rat uK(ATP)-1 is a 424-amino acid residue protein (M(r) = 47,960), Electrophysiological studies of uK(ATP)-1 expressed in Xenopus laevis oocytes show that uK(ATP)-1 is a weak rectifier and is blocked with Ba2+ ions, Single-channel patch clamp study of clonal human kidney epithelial cells (HEK293) transfected with uK(ATP)-1 cDNA reveals that uK(ATP)-1 closes in response to 1 mM ATP and has a single channel conductance of 70 +/- 2 picosiemens (n = 6), indicating that uK(ATP)-1 is an ATP-sensitive inward rectifier K+ channel. In addition, uK(ATP)-1 is activated by the K-ATP channel opener, diazoxide. RNA blot analysis shows that uK(ATP)-1 mRNA is expressed ubiquitously in rat tissues, including pancreatic islets, pituitary, skeletal muscle, and heart, suggesting that uK(ATP)-1 may play a physiological role as a link between the metabolic state and membrane K+ permeability of cells in almost every normal tissue. Since uK(ATP)-1 shares only 43-46% amino acid identity with members of previously reported inward rectifier K+ channel subfamilies, including ROMK1, IRK1, GIRK1, and cK(ATP)-1, uK(ATP)-1 is not an isoform of these subfamilies and, therefore, represents a new subfamily of the inward rectifier K+ channel family having two transmembrane segments.	CHIBA UNIV,SCH MED,CTR BIOMED SCI,DIV MOLEC MED,CHUO KU,CHIBA 260,JAPAN; KYOTO UNIV,SCH MED,DEPT INTERNAL MED 3,SAKYO KU,KYOTO 606,JAPAN; KYOTO UNIV,SCH MED,DEPT METAB & CLIN NUTR,SAKYO KU,KYOTO 606,JAPAN; CHIBA UNIV,PATHOGEN FUNGI & MICROBIAL TOXICOSES RES CTR,CHUO KU,CHIBA 260,JAPAN	Chiba University; Kyoto University; Kyoto University; Chiba University			gonoi, tohru/AAC-5181-2021; , gonoi/GRS-0648-2022; Horie, Minoru/ABG-7128-2020	gonoi, tohru/0000-0003-3655-7911; , gonoi/0000-0003-3655-7911; Inagaki, Nobuya/0000-0001-8261-2593				ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; ASHFORD MLJ, 1988, PFLUG ARCH EUR J PHY, V412, P297, DOI 10.1007/BF00582512; ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; BERNARDI H, 1993, P NATL ACAD SCI USA, V90, P1340, DOI 10.1073/pnas.90.4.1340; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; COOK NS, 1988, TRENDS PHARMACOL SCI, V9, P21, DOI 10.1016/0165-6147(88)90238-6; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; FAN Z, 1990, J PHYSIOL-LONDON, V430, P273, DOI 10.1113/jphysiol.1990.sp018291; FUKUMOTO H, 1988, P NATL ACAD SCI USA, V85, P5343; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; INGAKI N, 1994, P NATL ACAD SCI USA, V91, P2679; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; KAKEI M, 1986, FEBS LETT, V208, P63, DOI 10.1016/0014-5793(86)81533-2; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MAKHINA EN, 1994, J BIOL CHEM, V269, P20468; MISLER S, 1986, P NATL ACAD SCI USA, V83, P7119, DOI 10.1073/pnas.83.18.7119; MORISHIGE KI, 1994, FEBS LETT, V346, P251, DOI 10.1016/0014-5793(94)00483-8; NICHOLS CG, 1993, TRENDS PHARMACOL SCI, V14, P320; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; PERIER F, 1994, P NATL ACAD SCI USA, V91, P6240, DOI 10.1073/pnas.91.13.6240; SPRUCE AE, 1985, NATURE, V316, P736, DOI 10.1038/316736a0; STANDEN NB, 1989, SCIENCE, V245, P177, DOI 10.1126/science.2501869; TAKAHASHI N, 1994, J BIOL CHEM, V269, P23274; TAN W, 1994, FEBS LETT, V348, P239; TSUURA Y, 1992, DIABETES, V41, P861, DOI 10.2337/diabetes.41.7.861; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251	31	345	359	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					5691	5694		10.1074/jbc.270.11.5691	http://dx.doi.org/10.1074/jbc.270.11.5691			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890693	hybrid			2022-12-25	WOS:A1995QM94500002
J	KIM, YM; BERGONIA, HA; MULLER, C; PITT, BR; WATKINS, WD; LANCASTER, JR				KIM, YM; BERGONIA, HA; MULLER, C; PITT, BR; WATKINS, WD; LANCASTER, JR			LOSS AND DEGRADATION OF ENZYME-BOUND HEME INDUCED BY CELLULAR NITRIC-OXIDE SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RAT HEPATOCYTES; CYTOCHROME-P-450 HEME; SERUM-ALBUMIN; OXYGENASE; IRON; INDUCTION; LIVER; OXIDATION; PROTEIN; CELLS	We report here that, like nonheme iron, protein-bound intracellular heme iron is also a target for destruction by endogenously produced nitric oxide ((NO)-N-.). In isolated rat hepatocytes (NO)-N-. synthesis results in substantial (approximately 60%) and comparable loss of catalase and cytochrome P450 as well as total microsomal heme, and decreased heme synthetic (delta-aminolevulinate synthetase and ferrochelatase) and increased degradative (heme oxygenase) enzymatic activities, The effect is reversible, and intact cytochrome P450 apoproteins are still present, as judged by heme reconstitution of isolated microsomes. The effects on delta-aminolevulinate synthetase and heme oxygenase are likely to be secondary to heme liberation, while the effects on ferrochelatase appear to be a direct effect of (NO)-N-., perhaps destruction of its nonheme iron-sulfur center.	UNIV PITTSBURGH, SCH MED, DEPT SURG, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, SCH MED, DEPT PHARMACOL, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, SCH MED, DEPT ANESTHESIOL & CRIT CARE MED, PITTSBURGH, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NHLBI NIH HHS [HL32154] Funding Source: Medline; NIDDK NIH HHS [DK46935] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032154] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046935] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; BILLIAR TR, 1989, SURGERY, V106, P364; BISSELL DM, 1976, ARCH BIOCHEM BIOPHYS, V176, P91, DOI 10.1016/0003-9861(76)90144-2; BISSELL DM, 1976, ARCH BIOCHEM BIOPHYS, V176, P103, DOI 10.1016/0003-9861(76)90145-4; BONKOVSKY HL, 1990, EUR J BIOCHEM, V189, P155, DOI 10.1111/j.1432-1033.1990.tb15472.x; BONKOVSKY HL, 1984, BIOCHEM J, V222, P453, DOI 10.1042/bj2220453; Bonkovsky HL, 1982, HEPATOLOGY TXB LIVER, P351; BONNETT R, 1978, J CHEM SOC PERK T 1, P974, DOI 10.1039/p19780000974; BORNHEIM LM, 1986, ARCH BIOCHEM BIOPHYS, V246, P63, DOI 10.1016/0003-9861(86)90449-2; CABLE EE, 1991, BIOCHIM BIOPHYS ACTA, V1080, P245, DOI 10.1016/0167-4838(91)90009-O; DAILEY HA, 1994, BIOCHEMISTRY-US, V33, P403, DOI 10.1021/bi00168a003; Estabrook R W, 1978, Methods Enzymol, V52, P212; FIELD L, 1978, J CHEM SOC CHEM COMM, P249, DOI 10.1039/c39780000249; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; FUCHS D, 1991, EUR J HAEMATOL, V46, P65; FUKUDA Y, 1993, BIOCHEM BIOPH RES CO, V193, P297, DOI 10.1006/bbrc.1993.1623; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; Grisham MB, 1992, REACTIVE METABOLITES; GUENGERICH FP, 1992, FASEB J, V6, P667, DOI 10.1096/fasebj.6.2.1537453; HELQVIST S, 1991, DIABETOLOGIA, V34, P150, DOI 10.1007/BF00418268; HENRY Y, 1993, FASEB J, V7, P1124, DOI 10.1096/fasebj.7.12.8397130; HIBBS JB, 1990, INT CONGR SER, V897, P189; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; KHATSENKO OG, 1993, P NATL ACAD SCI USA, V90, P11147, DOI 10.1073/pnas.90.23.11147; KIM YM, 1993, FEBS LETT, V332, P255, DOI 10.1016/0014-5793(93)80644-A; KRAEMER MJ, 1982, PEDIATRICS, V69, P476; LEIBOLD EA, 1992, ANNU REV NUTR, V12, P345, DOI 10.1146/annurev.nu.12.070192.002021; MARDEN MC, 1989, BIOCHEMISTRY-US, V28, P4422, DOI 10.1021/bi00436a045; McDonald W., 1985, CRC HDB METHODS OXYG, P291; MITANI K, 1992, BLOOD, V79, P1255; MIWA M, 1987, CARCINOGENESIS, V8, P955, DOI 10.1093/carcin/8.7.955; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NUSSLER AK, 1993, BIOCHEM BIOPH RES CO, V194, P826, DOI 10.1006/bbrc.1993.1896; OKEEFFE DH, 1978, J BIOL CHEM, V253, P3509; PIKULEVA IA, 1992, J BIOL CHEM, V267, P1438; RADI R, 1991, J BIOL CHEM, V266, P4244; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; SAVILLE B, 1958, ANALYST, V83, P670, DOI 10.1039/an9588300670; STADLER J, 1994, P NATL ACAD SCI USA, V91, P3559, DOI 10.1073/pnas.91.9.3559; STADLER J, 1993, ARCH BIOCHEM BIOPHYS, V302, P4, DOI 10.1006/abbi.1993.1173; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; TAKETANI S, 1981, J BIOL CHEM, V256, P2748; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; WINK DA, 1993, ARCH BIOCHEM BIOPHYS, V300, P115, DOI 10.1006/abbi.1993.1016; YOSHIDA T, 1988, EUR J BIOCHEM, V171, P457, DOI 10.1111/j.1432-1033.1988.tb13811.x; YU CA, 1974, J BIOL CHEM, V249, P107	47	229	239	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					5710	5713		10.1074/jbc.270.11.5710	http://dx.doi.org/10.1074/jbc.270.11.5710			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890697	hybrid			2022-12-25	WOS:A1995QM94500007
J	MERCHANT, JL; SHIOTANI, A; MORTENSEN, ER; SHUMAKER, DK; ABRACZINSKAS, DR				MERCHANT, JL; SHIOTANI, A; MORTENSEN, ER; SHUMAKER, DK; ABRACZINSKAS, DR			EPIDERMAL GROWTH-FACTOR STIMULATION OF THE HUMAN GASTRIN PROMOTER REQUIRES SP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SP1; ZINC-FINGER PROTEIN; C-FOS GENE; DNA-BINDING; EXPRESSION; CELLS; SITE; ACTIVATION; RECEPTORS; SEQUENCES	Growth factors coordinately regulate a variety of different genes to stimulate cellular proliferation. In the stomach, gastrin, epidermal growth factor (EGF), and transforming growth factor-a all mediate gastric mucosal homeostasis by promoting cell renewal, We have previously shown that EGF and phorbol esters stimulate the human gastrin promoter through a novel GC-rich DNA element 5'-(-68)GGGGCGGGGTGGGGGG-53 called gERE (gastrin EGF response element). In this report, we show that three factors bind to this element, the transcription factor Sp1 and two fast migrating complexes designated gastrin EGF response proteins (gERP 1 and 2). To understand how these factors bind and confer EGF responsiveness, mutations of gERE were tested in vitro for protein binding and in vivo for promoter activation. Both gel shift assays and UV cross-linking studies revealed that the factors bind to overlapping domains, Sp1 to the 5' half-site and gERP 1 and 2 to the 3' half-site. Placing either the 5' or 3' mutations upstream of a minimal gastrin promoter abolished EGF induction. Therefore both the 5' and 3' domains were required to confer EGF induction. Collectively, these results demonstrate that complex interactions between Spl and other factors binding to overlapping gERE half-sites confer EGF responsiveness to the gastrin promoter.	UNIV MICHIGAN,DEPT PHYSIOL,ANN ARBOR,MI 48109; HOWARD HUGHES MED INST,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; Howard Hughes Medical Institute	MERCHANT, JL (corresponding author), UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109, USA.		Merchant, Juanita/AAF-8277-2019	Merchant, Juanita/0000-0002-6559-8184	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034533, R01DK045729, R37DK045729] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-45729, DK-34533] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKERMAN SL, 1993, P NATL ACAD SCI USA, V88, P7523; BORELLINI F, 1991, J BIOL CHEM, V266, P15850; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; BURGESS AW, 1989, BRIT MED BULL, V45, P401, DOI 10.1093/oxfordjournals.bmb.a072331; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHEN XR, 1992, ONCOGENE, V7, P1805; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, P743; ELSHOLTZ HP, 1986, SCIENCE, V234, P1552, DOI 10.1126/science.3491428; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GODLEY JM, 1989, P NATL ACAD SCI USA, V86, P3036, DOI 10.1073/pnas.86.9.3036; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HUANG HC, 1990, GENE DEV, V4, P287, DOI 10.1101/gad.4.2.287; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KITADAI Y, 1992, BIOCHEM BIOPH RES CO, V189, P1342, DOI 10.1016/0006-291X(92)90221-6; KUTOH E, 1993, BIOCHEM BIOPH RES CO, V194, P1475, DOI 10.1006/bbrc.1993.1991; LEHMANN JM, 1992, MOL CELL BIOL, V12, P2976, DOI 10.1128/MCB.12.7.2976; LEMAIGRE FP, 1990, MOL CELL BIOL, V10, P1811, DOI 10.1128/MCB.10.4.1811; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; LEWIS EJ, 1987, MOL CELL BIOL, V7, P3332, DOI 10.1128/MCB.7.9.3332; MERCHANT JL, 1991, MOL CELL BIOL, V11, P2686, DOI 10.1128/MCB.11.5.2686; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; NEHLS MC, 1992, DNA CELL BIOL, V11, P443, DOI 10.1089/dna.1992.11.443; NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x; PYRC JJ, 1992, BIOCHEMISTRY-US, V31, P4102, DOI 10.1021/bi00131a029; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SCHMIDT MC, 1989, MOL CELL BIOL, V9, P3299, DOI 10.1128/MCB.9.8.3299; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHIN TH, 1992, MOL CELL BIOL, V12, P3998, DOI 10.1128/MCB.12.9.3998; THIESEN HJ, 1991, BIOCHEM BIOPH RES CO, V176, P551, DOI 10.1016/S0006-291X(05)80219-0; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; WALSH JH, 1975, NEW ENGL J MED, V292, P1324, DOI 10.1056/NEJM197506192922505; WESTIN G, 1988, NUCLEIC ACIDS RES, V16, P5771, DOI 10.1093/nar/16.13.5771	40	79	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					6314	6319		10.1074/jbc.270.11.6314	http://dx.doi.org/10.1074/jbc.270.11.6314			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890769	hybrid			2022-12-25	WOS:A1995QM94500090
J	HAYES, G; BUSCH, A; LOTSCHER, M; WALDEGGER, S; LANG, F; VERREY, F; BIBER, J; MURER, H				HAYES, G; BUSCH, A; LOTSCHER, M; WALDEGGER, S; LANG, F; VERREY, F; BIBER, J; MURER, H			ROLE OF N-LINKED GLYCOSYLATION IN RAT RENAL NA/P-I-COTRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY PROXIMAL TUBULES; CELLULAR MECHANISMS; INORGANIC-PHOSPHATE; EXPRESSION; TRANSPORT; OLIGOSACCHARIDES; REABSORPTION; LOCALIZATION; MEMBRANE; CLONING	Our laboratory recently identified a sodium-dependent transport system for phosphate from rat kidney cortex (NaPi-2; Magagnin, S., Werner, A., Markovich, D., Sorribas, V., Stange, G., Biber, J., and Murer, H. (1993) Proc. Natl. Acad Sci. U.S.A. 90, 5979-5983). In the present study we have investigated whether or not this cotransporter is glycosylated and the role of N-glycosylation in determining its function. Glycosidase digestion of the NaPi-2 protein from rat brush border membranes, in vitro translation studies, or oocyte expression of the NaPi-2 cRNA indicate that the mature protein is glycosylated. Glycosidase treatment reduces the size of the protein from similar to 70-110 kDa to similar to 60-65 kDa. We therefore used site-directed mutagenesis to identify which of the putative consensus sites for N-linked glycosylation are utilized in the mature NaPi-2 protein. Altering the nucleotide sequences encoding both of the Asn-298 and Asn-328 residues to Gln produced mutants that are completely devoid of glycosylation, whereas mutants in which each of these sites were mutated separately are glycosylated when expressed in oocytes. These results suggest that both of these sites are modified by N-linked glycosylation in the mature protein. Surface expression of glycosylated and unglycosylated NaPi-2-related proteins was documented by biotinylation experiments. In contrast to the wild-type (fully glycosylated) transporter, immunocytochemistry provides evidence for a partial intracellular localization of mutant unglycosylated cotransporters. Na/P-i cotransport was studied in oocytes expressing wild-type or mutagenized NaPi-2 proteins using tracer or electrophysiological techniques. Although the transport rates are lower (by a factor of 2-3) after expression of the unglycosylated NaPi-2 protein, the P-i transport characteristics (pH dependence, apparent affinity for P-i or Na+) are similar in oocytes expressing either wild-type or glycosylation-deficient proteins.	UNIV ZURICH,INST PHYSIOL,CH-8057 ZURICH,SWITZERLAND; UNIV TUBINGEN,INST PHYSIOL,D-72076 TUBINGEN,GERMANY	University of Zurich; Eberhard Karls University of Tubingen				Verrey, Francois/0000-0003-3250-9824				BERON J, 1994, AM J PHYSIOL, V266, pC1278, DOI 10.1152/ajpcell.1994.266.5.C1278; BIBER J, 1993, PFLUG ARCH EUR J PHY, V424, P210, DOI 10.1007/BF00384344; BIBER J, 1994, CELL PHYSIOL BIOCHEM, V4, P185, DOI 10.1159/000154725; BIBER J, 1981, BIOCHIM BIOPHYS ACTA, V647, P169, DOI 10.1016/0005-2736(81)90243-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSCH AE, 1994, IN PRESS P NATL ACAD; CUSTER M, 1994, AM J PHYSIOL, V266, pF767, DOI 10.1152/ajprenal.1994.266.5.F767; CUSTER M, 1993, PFLUG ARCH EUR J PHY, V424, P203, DOI 10.1007/BF00384343; FUCENTESE M, 1994, EXPERIENTIA, V50, pS15; MAGAGNIN S, 1993, P NATL ACAD SCI USA, V90, P5979, DOI 10.1073/pnas.90.13.5979; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MARKOVICH D, 1993, J BIOL CHEM, V268, P1362; MURER H, 1991, AM J PHYSIOL, V260, pC885, DOI 10.1152/ajpcell.1991.260.5.C885; MURER H, 1992, J AM SOC NEPHROL, V2, P1649; RESHKIN SJ, 1990, PFLUG ARCH EUR J PHY, V416, P554, DOI 10.1007/BF00382689; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SORRIBAS V, 1994, J BIOL CHEM, V269, P6615; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WERNER A, 1990, J BIOL CHEM, V265, P12331; WERNER A, 1991, P NATL ACAD SCI USA, V88, P9608, DOI 10.1073/pnas.88.21.9608; YUSUFI ANK, 1988, J BIOL CHEM, V263, P13683	23	103	104	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24143	24149						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929070				2022-12-25	WOS:A1994PQ34600048
J	IRBY, RB; ADAIR, WL				IRBY, RB; ADAIR, WL			INTERMEDIATES IN THE FOLIC-ACID BIOSYNTHETIC-PATHWAY ARE INCORPORATED INTO MOLYBDOPTERIN THE YEAST, PICHIA-CANADENSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM COFACTOR; NITRATE REDUCTASE; ESCHERICHIA-COLI; CONVERTING FACTOR; ENZYMATIC FORMATION; PTERINS; TETRAHYDROBIOPTERIN; PRECURSOR; ENZYMES; LIVER	Biosynthesis of molybdopterin was followed in the yeast, Pichia canadensis, using labeled precursors. High performance liquid chromatography analysis of extracts from cells labeled with [U-C-14]guanosine showed that the label was incorporated into the molybdopterin oxidation product, dephospho Form A. Dephospho Form A isolated from cells labeled with [(UC)-C-14,5'-H-3]guanosine was devoid of tritium, indicating partial loss of the ribose moiety of guanosine during the synthesis of molybdopterin. In vivo labeling of P. canadensis using [7-C-14]neopterin and [6,7,1-C-14]hydroxymethylpterin led to label from both compounds appearing in dephospho Form A as well as in folic acid in wild type cells. When these labeled precursors were incubated with P. canadensis mutants blocked in molybdopterin synthesis, only folic acid was labeled. These results suggest a shared pathway in the biosyntheses of molybdopterin and folic acid. [6-C-14]Glucose labeling experiments led to exclusive incorporation into the 4'-position of dephospho Form A but not in folic acid, It is proposed that molybdopterin synthesis branches from the folic acid biosynthetic pathway at dihydrohydroxymethylpterin and that a 5-carbon phosphorylated compound such as glyceraldehyde 3-phosphate may condense with dihydrohydroxymethylpterin to form the 4-carbon side chain precursor to molybdopterin.	UNIV S FLORIDA, COLL MED, DEPT BIOCHEM & MOLEC BIOL, TAMPA, FL 33612 USA	State University System of Florida; University of South Florida					NIGMS NIH HHS [GM41003] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041003] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMY NK, 1979, J BACTERIOL, V140, P114, DOI 10.1128/JB.140.1.114-124.1979; BURG AW, 1968, J BIOL CHEM, V243, P2349; DHONDT JL, 1990, J INHERIT METAB DIS, V13, P879, DOI 10.1007/BF01800213; DHONDT JL, 1985, J INHERIT METAB DIS, V8, P47, DOI 10.1007/BF01801660; EISENREICH W, 1991, J BIOL CHEM, V266, P9622; ETO I, 1992, J AUTISM DEV DISORD, V22, P295, DOI 10.1007/BF01058157; FRIEDKIN M, 1962, FED PROC, V21, P176; GOLDBERG M, 1991, J VET MED A, V38, P49, DOI 10.1111/j.1439-0442.1991.tb00983.x; HAGEMAN RV, 1986, METHOD ENZYMOL, V122, P399; HARADA T, 1993, SCIENCE, V260, P1507, DOI 10.1126/science.8502995; HYLAND K, 1993, PEDIATR RES, V34, P10, DOI 10.1203/00006450-199307000-00003; IRBY R, 1994, ANAL BIOCHEM, V218, P413, DOI 10.1006/abio.1994.1200; JOHNSON JL, 1980, J BIOL CHEM, V255, P1783; JOHNSON JL, 1977, J BIOL CHEM, V252, P4994; JOHNSON JL, 1989, J BIOL CHEM, V264, P13440; JOHNSON JL, 1969, METABOLIC BASIS INHE, P1463; JOHNSON ME, 1987, J BACTERIOL, V169, P117, DOI 10.1128/jb.169.1.117-125.1987; JONES THD, 1967, J BIOL CHEM, V242, P3989; KERLER F, 1989, BIOCHIM BIOPHYS ACTA, V990, P15, DOI 10.1016/S0304-4165(89)80005-4; KLEIN R, 1993, CHROMATOGRAPHIA, V36, P71, DOI 10.1007/BF02263840; MAILANDER B, 1976, J BIOL CHEM, V251, P3623; MANJULA S, 1993, ACTA ONCOL, V32, P29, DOI 10.3109/02841869309083881; MATHIS JB, 1970, J BIOL CHEM, V245, P3015; MURAKAMI K, 1975, BIOCHIM BIOPHYS ACTA, V384, P390, DOI 10.1016/0005-2744(75)90040-6; NASON A, 1971, P NATL ACAD SCI USA, V68, P3242, DOI 10.1073/pnas.68.12.3242; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; NIELSEN P, 1986, J BIOL CHEM, V261, P3661; PATEMAN JA, 1964, NATURE, V201, P58, DOI 10.1038/201058a0; PIENKOS PT, 1977, P NATL ACAD SCI USA, V74, P5468, DOI 10.1073/pnas.74.12.5468; PITTERLE DM, 1993, J BIOL CHEM, V268, P13499; PITTERLE DM, 1989, J BACTERIOL, V171, P3373, DOI 10.1128/jb.171.6.3373-3378.1989; PITTERLE DM, 1993, J BIOL CHEM, V268, P13506; Plagemann P.G.W., 1980, CURR TOP MEMBR TRANS, P225; RAJAGOPALAN KV, 1988, ANNU REV NUTR, V8, P401, DOI 10.1146/annurev.nu.08.070188.002153; RAJAGOPALAN KV, 1991, ADV ENZYMOL RAMB, V64, P215; REMBOLD H, 1963, CHEM BER, V96, P1395; Rembold H., 1963, CHEM BER-RECL, V96, P1406; SEBESTA I, 1991, ADV EXP MED BIOL, V309, P261; SEO N, 1991, BIOCHIM BIOPHYS ACTA, V1074, P439, DOI 10.1016/0304-4165(91)90097-Z; SOLOMONS.LP, 1972, PLANT PHYSIOL, V50, P421, DOI 10.1104/pp.50.4.421; SOLOMONSON LP, 1986, J BIOL CHEM, V261, P1290; VAN QL, 1988, BIOCHEM BIOPH RES CO, V151, P512, DOI 10.1016/0006-291X(88)90623-7; WOLF WA, 1969, BIOCHIM BIOPHYS ACTA, V192, P468, DOI 10.1016/0304-4165(69)90396-1; WOOTTON JC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P157, DOI 10.1016/S0005-2728(05)80100-8; WUEBBENS MM, 1993, J BIOL CHEM, V268, P13493; ZAGALAK B, 1988, BIOL CHEM H-S, V369, P535	46	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23981	23987						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929047				2022-12-25	WOS:A1994PQ34600023
J	VALE, RD; COPPIN, CM; MALIK, F; KULL, FJ; MILLIGAN, RA				VALE, RD; COPPIN, CM; MALIK, F; KULL, FJ; MILLIGAN, RA			TUBULIN GTP HYDROLYSIS INFLUENCES THE STRUCTURE, MECHANICAL-PROPERTIES, AND KINESIN DRIVEN TRANSPORT OF MICROTUBULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIC INSTABILITY; INDIVIDUAL MICROTUBULES; CRYOELECTRON MICROSCOPY; SURFACE LATTICE; MOVEMENT; POLYMERIZATION; MOLECULES; INVITRO; CELLS	Tubulin is a GTPase that hydrolyzes its bound nucleotide triphosphate after it becomes incorporated into a microtubule. The only known consequence of nucleotide hydrolysis is that it increases the dissociation rate of tubulin from the end of the microtubule by 2 orders of magnitude. In this study, we investigated whether microtubules composed of tubulin-GMPCPP (guanylyl alpha,beta-methylenediphosphate) (a very slowly hydrolyzed GTP analog) or tubulin-GDP exhibit additional structural or functional differences. We show that tubulin-GMPCPP microtubules are significantly stiffer than tubulin-GDP microtubules and have a 21% shallower protofilament twist angle. We also find that kinesin, a microtubule-based motor protein, transports tubulin-GMPCPP microtubules at similar to 30% faster rates than tubulin-GDP microtubules. These findings suggest that growing microtubule ends, which are thought to be composed of tubulin-GTP, may have different structural and mechanical properties from the remainder of the microtubule polymer.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA; MARINE BIOL LAB, WOODS HOLE, MA 02543 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	University of California System; University of California San Francisco; Marine Biological Laboratory - Woods Hole; Scripps Research Institute	VALE, RD (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039155] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39155] Funding Source: Medline; PHS HHS [38499] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADRIAN M, 1984, NATURE, V308, P32, DOI 10.1038/308032a0; ALLEN RD, 1985, J CELL BIOL, V100, P1736, DOI 10.1083/jcb.100.5.1736; AMOS LA, 1991, J CELL SCI, P95; ANDREWS SB, 1993, P NATL ACAD SCI USA, V90, P6503, DOI 10.1073/pnas.90.14.6503; CASSIMERIS L, 1988, J CELL BIOL, V107, P2223, DOI 10.1083/jcb.107.6.2223; CATTERALL WA, 1971, J BIOL CHEM, V246, P4987; CHRETIEN D, 1991, BIOL CELL, V71, P161, DOI 10.1016/0248-4900(91)90062-R; Cleveland Don W., 1993, P101; DYE RB, 1993, J BIOL CHEM, V268, P6847; ERICKSON HP, 1992, ANNU REV BIOPH BIOM, V21, P145, DOI 10.1146/annurev.bb.21.060192.001045; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; HORIO T, 1986, NATURE, V321, P605, DOI 10.1038/321605a0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUNT AJ, 1993, P NATL ACAD SCI USA, V90, P11653, DOI 10.1073/pnas.90.24.11653; HYMAN AA, 1992, MOL BIOL CELL, V3, P1155, DOI 10.1091/mbc.3.10.1155; HYMAN AA, 1991, J CELL SCI, P125; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P306; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; MILLIGAN RA, 1984, ULTRAMICROSCOPY, V13, P1, DOI 10.1016/0304-3991(84)90051-2; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; Oosawa F., 1975, THERMODYNAMICS POLYM; SAMMAK PJ, 1988, CELL MOTIL CYTOSKEL, V10, P237, DOI 10.1002/cm.970100128; SANDOVAL IV, 1978, P NATL ACAD SCI USA, V75, P3178, DOI 10.1073/pnas.75.7.3178; SANDOVAL IV, 1977, P NATL ACAD SCI USA, V74, P4881, DOI 10.1073/pnas.74.11.4881; SCHNAPP BJ, 1989, P NATL ACAD SCI USA, V86, P1548, DOI 10.1073/pnas.86.5.1548; SCHULZE E, 1988, NATURE, V334, P356, DOI 10.1038/334356a0; Skoufias DA, 1993, CURR OPIN CELL BIOL, V5, P95, DOI 10.1016/S0955-0674(05)80014-6; STEWART RJ, 1990, BIOCHEMISTRY-US, V29, P6489, DOI 10.1021/bi00479a022; STOOPS JK, 1991, J STRUCT BIOL, V106, P172, DOI 10.1016/1047-8477(91)90086-C; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1992, TRENDS BIOCHEM SCI, V17, P300, DOI 10.1016/0968-0004(92)90440-K; VALE RD, 1989, J CELL BIOL, V108, P2327, DOI 10.1083/jcb.108.6.2327; WADE RH, 1990, J MOL BIOL, V212, P775, DOI 10.1016/0022-2836(90)90236-F; WALKER RA, 1991, J CELL BIOL, V114, P73, DOI 10.1083/jcb.114.1.73; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453	38	90	90	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23769	23775						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	7916345				2022-12-25	WOS:A1994PQ34500059
J	DEFEA, KA; NAKAHARA, DH; CALAYAG, MC; YOST, CS; MIRELS, LF; PRUSINER, SB; LINGAPPA, VR				DEFEA, KA; NAKAHARA, DH; CALAYAG, MC; YOST, CS; MIRELS, LF; PRUSINER, SB; LINGAPPA, VR			DETERMINANTS OF CARBOXYL-TERMINAL DOMAIN TRANSLOCATION DURING PRION PROTEIN BIOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE SIGNAL SEQUENCE; STOP-TRANSFER; TRANSMEMBRANE ORIENTATION; ENDOPLASMIC-RETICULUM; TOPOGENIC SEQUENCE; MEMBRANE-PROTEIN; APOLIPOPROTEIN-B; ER MEMBRANE; SCRAPIE; TRANSLATION	The prion protein (PrP) displays some unusual features in its biogenesis. In cell-free systems it can be synthesized as either an integral transmembrane protein spanning the membrane twice, with both amino and carboxyl domains in the lumen of the endoplasmic reticulum, or as a fully translocated polypeptide, A charged, extracytoplasmic region, termed the Stop Transfer Effector (STE) sequence, has been shown to direct the nascent translocating chain to stop at the adjoining hydrophobic domain to generate the first membrane-spanning region (TM1). However, the determinants of the second translocation event in the biogenesis of the transmembrane form have not been identified previously. Moreover, the relationship of transmembrane and fully translocated forms of PrP has not been well understood. Here, we report progress in resolving both of these issues. Using protein chimeras in cell-free translation systems and Xenopus oocytes, we identify the sequence which directs nascent PrP to span the membrane a second time, with its carboxyl-terminal domain in the endoplasmic reticulum lumen. Surprisingly, PrP carboxyl-terminal domain translocation does not appear to be directed by an internal signal or signal-anchor sequence located downstream of TM1, as would have been expected from studies of other multispanning membrane proteins. Rather, carboxyl-terminal domain translocation appears to be another consequence of the action of STE-TM1, that is, the same sequence responsible for generating the first membrane-spanning region. Studies of an STE-TM1-containing protein chimera in Xenopus oocytes demonstrate that most of these chains upon completion of their translation, initially span the membrane twice, with a topology similar to that of transmembrane PrP, but are carbonate-extractable. These chains have the transmembrane orientation only transiently and chase into a fully translocated form. These results support a model in which a metastable ''transmembrane'' intermediate, residing within the aqueous environment of the translocation channel, can be converted into either the integrated transmembrane or the fully translocated form of PrP, perhaps directed by trans-acting factor (s). Such a model may explain why stable the transmembrane isoform of PrP has not been observed in normal cells and how nascent PrP might be directed to alternate pathways of folding.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANESTHESIA,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Lingappa, Vishwanath R./0000-0003-0962-6571				BARRY RA, 1988, J IMMUNOL, V140, P1188; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; BAZAN JF, 1987, PROTEIN ENG, V1, P125, DOI 10.1093/protein/1.2.125; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BONIFACINO JS, 1990, NATURE, V344, P247, DOI 10.1038/344247a0; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; BUELERH, 1992, NATURE, V356, P111; CARAS IW, 1991, J CELL BIOL, V113, P77, DOI 10.1083/jcb.113.1.77; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; EBLE BE, 1987, MOL CELL BIOL, V7, P3591, DOI 10.1128/MCB.7.10.3591; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; HAY B, 1987, BIOCHEMISTRY-US, V26, P8110, DOI 10.1021/bi00399a014; HAY B, 1987, MOL CELL BIOL, V7, P914, DOI 10.1128/MCB.7.2.914; KATZ FN, 1979, J CELL BIOL, V80, P416, DOI 10.1083/jcb.80.2.416; KEHRY M, 1980, CELL, V21, P393, DOI 10.1016/0092-8674(80)90476-6; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LINGAPPA VR, 1991, CELL, V65, P527, DOI 10.1016/0092-8674(91)90081-9; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; MEYERS RK, 1986, P NATL ACAD SCI USA, V85, P2310; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PERARA E, 1985, J CELL BIOL, V101, P2292, DOI 10.1083/jcb.101.6.2292; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; ROTHMAN RE, 1988, J BIOL CHEM, V263, P10470; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; SIMON K, 1987, J CELL BIOL, V104, P1165, DOI 10.1083/jcb.104.5.1165; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SPIESS M, 1989, J BIOL CHEM, V264, P19117; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; STAHL N, 1990, BIOCHEMISTRY-US, V29, P5405, DOI 10.1021/bi00474a028; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0; YOST CS, 1983, CELL, V34, P759	41	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16810	16820						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	7911469				2022-12-25	WOS:A1994NR29600048
J	COLOTTA, F; RE, F; MUZIO, M; POLENTARUTTI, N; MINTY, A; CAPUT, D; FERRARA, P; MANTOVANI, A				COLOTTA, F; RE, F; MUZIO, M; POLENTARUTTI, N; MINTY, A; CAPUT, D; FERRARA, P; MANTOVANI, A			INTERLEUKIN-13 INDUCES EXPRESSION AND RELEASE OF INTERLEUKIN-1 DECOY RECEPTOR IN HUMAN POLYMORPHONUCLEAR CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							IL-1 RECEPTOR; SUPERFAMILY; LYMPHOKINE; RNA	The aim of this study was to examine whether interleukin-13 (IL-13), a cytokine with anti-inflammatory activities, affected expression of interleukin-1 (IL-1) receptors (R) in human polymorphonuclear cells (PMN). Treatment with IL-13 augmented both type I and type II (decoy) R transcripts, with the latter being by far the most represented. The transcriptional inhibitor actinomycin D blocked the induction of IL-1 R mRNAs by IL-13. Nuclear run-off experiments demonstrated an augmented transcriptional rate of IL-1 decoy R in IL-13-treated B lymphoblastoid cells. The protein synthesis inhibitor cycloheximide blocked type I R expression but superinduced decoy R expression. IL-13 augmented the binding of radiolabeled IL-1 beta on the PMN surface with an increased number of IL-1 receptors and no change in K-d values. IL-13 induced the surface expression of IL-1 decoy R and the release by PMN of an IL-1-binding protein identified as a soluble version of the IL-1 decoy R. These results show that PMN is an important target for IL-13 and that induction of expression and release of the IL-1 decoy R, in concert with inhibition of cytokine synthesis, may represent an important mechanism by which IL-13 blocks IL-1, a central mediator of inflammatory reactions.	SANOFI ELF BIORECH,F-31676 LABEGE,FRANCE	Sanofi-Aventis	COLOTTA, F (corresponding author), IST RIC FARMACOL MARIO NEGRI,CTR DANIELA & CATULLO BORGOMAINERIO,VIA ERITREA 62,I-20157 MILAN,ITALY.		Muzio, Marta/J-9360-2018; Mantovani, Alberto/HCI-7449-2022	Muzio, Marta/0000-0002-7761-759X; Mantovani, Alberto/0000-0001-5578-236X; Colotta, Francesco/0000-0001-8601-2309				BROWN KD, 1989, J IMMUNOL, V142, P679; CHERWINSKI HM, 1987, J EXP MED, V166, P1229, DOI 10.1084/jem.166.5.1229; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; DINARELLO CA, 1991, BLOOD, V77, P1627; HERBERT JM, 1993, FEBS LETT, V328, P268, DOI 10.1016/0014-5793(93)80941-M; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; MCKENZIE ANJ, 1993, J IMMUNOL, V150, P5436; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MOSSMAN TR, 1991, IMMUNOL REV, V123, P209; MUZIO M, 1994, BLOOD, V83, P1738, DOI 10.1182/blood.V83.7.1738.bloodjournal8371738; PAUL WE, 1991, BLOOD, V77, P1859; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; RE F, 1994, J EXP MED, V179, P739, DOI 10.1084/jem.179.2.739; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SPRIGGS MK, 1990, J BIOL CHEM, V265, P22499; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	19	89	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12403	12406						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	7909801				2022-12-25	WOS:A1994NH71600006
J	SAIJO, T; WELCH, WJ; TANAKA, K				SAIJO, T; WELCH, WJ; TANAKA, K			INTRAMITOCHONDRIAL FOLDING AND ASSEMBLY OF MEDIUM-CHAIN ACYL-COA DEHYDROGENASE (MCAD) - DEMONSTRATION OF IMPAIRED TRANSFER OF K304E-VARIANT MCAD FROM ITS COMPLEX WITH HSP60 TO THE NATIVE TETRAMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A DEHYDROGENASE; MOLECULAR CHARACTERIZATION; NUCLEOTIDE-SEQUENCE; LIVER MITOCHONDRIA; YEAST MITOCHONDRIA; PRECURSOR PROTEINS; ESCHERICHIA-COLI; DEFICIENCY; MATRIX; GROEL	We incubated in vitro translated precursor of medium-chain acyl-CoA dehydrogenase (MCAD) with isolated rat liver mitochondria and fractionated the solubilized mitochondria on gel filtration. After a 5-min import into mitochondria, MCAD was recovered exclusively as a high molecular weight (hM(r)) complex (700,000), while after a 10 min import, it was recovered mainly in the hM(r) complex and mature tetramer, with a small amount in monomer. Either a further 15-min chase or exposure to ATP caused a marked decrease of MCAD in the hM(r) complex and an increase in the mature tetramer in comparable amounts, suggesting that the hM(r) complex was the precursor of tetramer. No monomer was detected in either case. Using specific antibodies, we have shown that the hM(r) complex represented a complex of MCAD and heat shock protein 60 (hsp60), and, that upon import into mitochondria, unfolded MCAD first formed a transient complex with mitochondrial heat-shock protein 70 (hsp70(mit)) and then transferred to hsp60 to complete its folding into an assembly-competent conformation. We also examined the assembly of K304E MCAD, which is a prevalent variant enzyme among patients with MCAD deficiency. The assembly of the K304E into its tetrameric form was severely impaired. The binding of K304E with hsp70(mit) and its transfer from hsp70(mit) to hsp60 were normal. However, the hsp60 complex of K304E was much more stable than the wild-type counterpart upon a 15-min chase or exposure to ATP, suggesting that the folding in, or the transfer of K304E subunit to tetramer from, the complex with hsp60 was impaired.	YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	Yale University; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIDDK NIH HHS [DK38154] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038154] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; COATES PM, 1992, PEDIATR RES, V31, P34, DOI 10.1203/00006450-199201000-00006; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; GREGERSEN N, 1991, HUM GENET, V86, P545; HARTMAN DJ, 1993, P NATL ACAD SCI USA, V90, P2276, DOI 10.1073/pnas.90.6.2276; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; IKEDA Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P662, DOI 10.1016/0003-9861(87)90072-5; IKEDA Y, 1985, J BIOL CHEM, V260, P1311; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KELLY DP, 1990, P NATL ACAD SCI USA, V87, P9236, DOI 10.1073/pnas.87.23.9236; KELLY DP, 1987, P NATL ACAD SCI USA, V84, P4068, DOI 10.1073/pnas.84.12.4068; KIM JJP, 1993, P NATL ACAD SCI USA, V90, P7523, DOI 10.1073/pnas.90.16.7523; KIM JJP, 1988, P NATL ACAD SCI USA, V85, P6677, DOI 10.1073/pnas.85.18.6677; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LOEWENSTEIN J, 1970, Biochimica et Biophysica Acta, V223, P432, DOI 10.1016/0005-2728(70)90201-X; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MATSUBARA Y, 1987, J BIOL CHEM, V262, P10104; MILLER AD, 1993, BIOCHEM J, V291, P139, DOI 10.1042/bj2910139; MIZZEN LA, 1991, CELL REGUL, V2, P165, DOI 10.1091/mbc.2.2.165; MIZZEN LA, 1989, J BIOL CHEM, V264; NAGAO M, 1992, J BIOL CHEM, V267, P17925; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; OSTERMANN J, 1990, FEBS LETT, V277, P281, DOI 10.1016/0014-5793(90)80865-G; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; Tanaka K., 1992, Human Mutation, V1, P271, DOI 10.1002/humu.1380010402; Towbin H, 1979, P NATL ACAD SCI USA, V76, P4530; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; WYNN RM, 1992, J BIOL CHEM, V267, P12400; YOKOTA I, 1992, J BIOL CHEM, V267, P26004; YOKOTA I, 1990, J CLIN INVEST, V86, P1000, DOI 10.1172/JCI114761; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	35	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4401	4408						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7905878				2022-12-25	WOS:A1994MW98900079
J	OSHIMA, H; SIMONS, SS				OSHIMA, H; SIMONS, SS			SEQUENCE-SELECTIVE INTERACTIONS OF TRANSCRIPTION FACTOR ELEMENTS WITH TANDEM GLUCOCORTICOID-RESPONSIVE ELEMENTS AT PHYSIOLOGICAL STEROID CONCENTRATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE AMINOTRANSFERASE GENE; TISSUE-CULTURE CELLS; DEXAMETHASONE 21-MESYLATE; HORMONE RECEPTORS; SYNERGISTIC ACTIVATION; AGONIST ACTIVITY; MMTV PROMOTER; INDUCTION; MODULATION; MECHANISM	Synergism in transcription is said to occur when the combined response from two DNA elements for the binding of trans-acting factors is greater than the sum of the responses from each element in isolation. The synergism of steroid receptors with themselves or with other trans-acting factors at saturating concentrations of steroid has proved to be an important component of steroid-regulated gene transcription. We have recently described a glucocorticoid modulatory element (GME) of the rat tyrosine aminotransferase gene that, in conjunction with a trans-acting factor, modulates the transcriptional activity of receptor-glucocorticoid and -antiglucocorticoid complexes with homologous and heterologous genes and promoters (Oshima, H., and Simons, S. S., Jr. (1992) Mol. Endocrinol. 6, 416-428). We now report that, under certain circumstances, the GME displays synergistic activity with a glucocorticoid-responsive element (GRE). However, several properties of GME action are different from those previously observed for synergism. The effects of the GME were marked at subsaturating or physiological concentrations of glucocorticoids but insignificant at saturating concentrations, which are the established conditions for synergism. The GME was found to increase the agonist activity of partial antiglucocorticoids, while synergism involving antisteroids has yet to be reported. Furthermore, the GRE was active in conjunction with two tandem repeats of a GRE, which was a combination that did not support conventional synergism. Most importantly, the effects of the GME were greater than with any other trans-acting factor binding element tested, indicative of a sequence-selective activity. The efficacy of the GME was also insensitive to the spacing between elements. Thus, the GME provides a mechanism for selective transcriptional modulation by physiological concentrations of steroid, and by antisteroids, of a common class of genes that are under the control of two or more GREs.	NIDDKD,STEROID HORMONES SECT,MOLEC & CELLULAR BIOL LAB,BLDG 8,RM B2A07,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ANKENBAUER W, 1988, P NATL ACAD SCI USA, V85, P7526, DOI 10.1073/pnas.85.20.7526; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BASTIAN LS, 1991, MOL ENDOCRINOL, V5, P619, DOI 10.1210/mend-5-5-619; BEATO M, 1989, J STEROID BIOCHEM, V32, P737, DOI 10.1016/0022-4731(89)90521-9; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRADSHAW MS, 1991, J BIOL CHEM, V266, P16684; BRASIER AR, 1990, MOL ENDOCRINOL, V4, P1921, DOI 10.1210/mend-4-12-1921; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; HASHIMOTO S, 1984, P NATL ACAD SCI-BIOL, V81, P6637, DOI 10.1073/pnas.81.21.6637; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KLOCK G, 1987, NATURE, V329, P734, DOI 10.1038/329734a0; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; Maniatis T., 1982, MOL CLONING; MERCIER L, 1983, ENDOCRINOLOGY, V112, P601, DOI 10.1210/endo-112-2-601; MERCIER L, 1986, J STEROID BIOCHEM, V25, P11, DOI 10.1016/0022-4731(86)90275-X; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MULLER M, 1991, MOL ENDOCRINOL, V5, P1498, DOI 10.1210/mend-5-10-1498; OSHIMA H, 1992, MOL ENDOCRINOL, V6, P416, DOI 10.1210/me.6.3.416; OSHIMA H, 1992, ENDOCRINOLOGY, V130, P2106, DOI 10.1210/en.130.4.2106; PONS M, 1981, J ORG CHEM, V46, P3262, DOI 10.1021/jo00329a024; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; ROUSSEAU GG, 1979, GLUCOCORTICOID HORMO, P49; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATT MD, 1990, EMBO J, V9, P481, DOI 10.1002/j.1460-2075.1990.tb08134.x; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SIMONS SS, 1980, J ORG CHEM, V45, P3084, DOI 10.1021/jo01303a030; SIMONS SS, 1992, MOL ENDOCRINOL, V6, P995, DOI 10.1210/me.6.7.995; SIMONS SS, 1988, J STEROID BIOCHEM, V31, P1, DOI 10.1016/0022-4731(88)90198-7; SIMONS SS, 1989, CANCER RES, V49, pS2244; SIMONS SS, 1981, P NATL ACAD SCI-BIOL, V78, P3541, DOI 10.1073/pnas.78.6.3541; SIMONS SS, 1987, STEROID STEROL HORMO, P251; SISTARE FD, 1987, MOL ENDOCRINOL, V1, P648, DOI 10.1210/mend-1-9-648; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; SZAPARY D, 1992, ENDOCRINOLOGY, V130, P3492, DOI 10.1210/en.130.6.3492; THOMPSON EB, 1989, GENE REGULATION STER, P63; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; VANDERBILT JN, 1987, MOL ENDOCRINOL, V1, P68, DOI 10.1210/mend-1-1-68; WIELAND S, 1991, EMBO J, V10, P2513, DOI 10.1002/j.1460-2075.1991.tb07791.x; WRIGHT APH, 1991, P NATL ACAD SCI USA, V88, P8283, DOI 10.1073/pnas.88.19.8283	43	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26858	26865						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	7903299				2022-12-25	WOS:A1993MM26200008
J	IKEBE, M; MITRA, S; HARTSHORNE, DJ				IKEBE, M; MITRA, S; HARTSHORNE, DJ			CLEAVAGE AT SITE-A, GLU-642 TO SER-643, OF THE GIZZARD MYOSIN HEAVY-CHAIN DECREASES AFFINITY FOR ACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; LIGHT-CHAIN; CHICKEN GIZZARD; CONFORMATION; PHOSPHORYLATION; PROTEOLYSIS; PROTEINS; SUBFRAGMENT-1; MEROMYOSIN; ACTOMYOSIN	The actin-activated ATPase activities of subfragment 1 (S1) produced from gizzard myosin by papain or Staphylococcus aureus protease are different. The activity of the latter is lower, in spite of the presence of intact 20,000-dalton light chains. To study this difference, the S. aureus protease S1 was subjected to further proteolysis by papain. This second stage of proteolysis markedly increased actin-activated ATPase, due to a decrease in K(actin) with no change in V(m) and increased the affinity of S1 for actin in the presence of ATP. Treatment with papain caused degradation of the 20-kDa light chain, a decrease in the 26-kDa C-terminal domain of S1 and the 68-kDa fragment containing the N-terminal and central domains, and in the appearance and progressive increase of a 94-kDa fragment. The increase in actin-activated ATPase activity was due to the production of the 94-kDa fragment but not due to light chain degradation. Analyses of N-terminal sequences following papain digestion showed that the 94-kDa fragment was formed from a combination of the 68- and 26-kDa fragments. The bond formed probably involved the N-terminal residue of the 26-kDa fragment (Ser-643) and a side chain carboxyl (Glu-642) or amine (Glu-636). From the sequence data site A was identified as Glu-642-Ser-643. These results confirm the importance of site A in actin-binding of gizzard myosin. It is suggested that the sequence Ser-643 and Val-659, as well as the 3 lysine residues, are important for actin binding.	UNIV ARIZONA,DEPT ANIM SCI,TUCSON,AZ 85721	University of Arizona	IKEBE, M (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106, USA.				NHLBI NIH HHS [HL 37117] Funding Source: Medline; NIAMS NIH HHS [AR38888, AR 41653] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL037117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653, R01AR038888] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CRAIG R, 1983, NATURE, V302, P436, DOI 10.1038/302436a0; DRISKA S, 1975, ARCH BIOCHEM BIOPHYS, V167, P203, DOI 10.1016/0003-9861(75)90457-9; FRASER AB, 1975, BIOCHEMISTRY-US, V14, P2207, DOI 10.1021/bi00681a025; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V1, P423; Higashihara M, 1989, J BIOL CHEM, V264, P5218; IKEBE M, 1988, J BIOL CHEM, V263, P10698; IKEBE M, 1983, BIOCHEMISTRY-US, V22, P4580, DOI 10.1021/bi00288a036; IKEBE M, 1984, J BIOL CHEM, V259, P1639; IKEBE M, 1985, J BIOL CHEM, V260, P3146; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; IKEBE M, 1986, BIOCHEMISTRY-US, V25, P6177, DOI 10.1021/bi00368a052; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORAND L, 1962, BIOCHEM BIOPH RES CO, V7, P457, DOI 10.1016/0006-291X(62)90335-2; MARIANNEPEPIN T, 1985, BIOCHEMISTRY-US, V24, P3024, DOI 10.1021/bi00333a033; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORITA JI, 1991, BIOCHEMISTRY-US, V30, P9539, DOI 10.1021/bi00103a022; MORNET D, 1989, J MUSCLE RES CELL M, V10, P10, DOI 10.1007/BF01739853; ONISHI H, 1984, J BIOCHEM, V95, P899, DOI 10.1093/oxfordjournals.jbchem.a134685; ONISHI H, 1982, J BIOCHEM-TOKYO, V92, P871, DOI 10.1093/oxfordjournals.jbchem.a134001; SMITH EL, 1960, ENZYMES, V4, P156; STEIN LA, 1979, BIOCHEMISTRY-US, V18, P3895, DOI 10.1021/bi00585a009; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; WALSH MP, 1983, METHOD ENZYMOL, V99, P279; YANAGISAWA M, 1987, J MOL BIOL, V198, P143, DOI 10.1016/0022-2836(87)90302-0	24	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25948	25951						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7902357				2022-12-25	WOS:A1993MK10000094
J	GABELLINI, N; IWATA, T; CARAFOLI, E				GABELLINI, N; IWATA, T; CARAFOLI, E			ALTERNATIVE SPLICING SITE MODIFIES THE CARBOXYL-TERMINAL TRANS-MEMBRANE DOMAINS OF THE NA+/CA2+ EXCHANGER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGER; SARCOLEMMAL NA+-CA2+ EXCHANGER; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; HELA-CELLS; STIMULATION; VESICLES; ISOFORMS; PROTEIN; MGATP	The 6-kilobase (kb) cDNA of pTB11 clone and its 5' fragment of 3.7 kb encoding the canine heart Na+/Ca2+ exchanger (Nicoll, D. A., Longoni, S., and Philipson, K. D. (1990) Science 250, 562-565) were transiently expressed in 293 cells to investigate the role of the 3'-''untranslated'' region. Both fragments yielded high levels of expressed protein that were well incorporated in the membranes. Cells expressing the 6-kb cDNA produced rearranged transcripts of smaller than expected size. A 120-kDa polypeptide was produced in cells expressing the modified exchanger, and Ca2+ uptake was higher in this type of transfected cells. A constant stretch of nucleotides located at the 3' end of the 6 kb cDNA was found to be connected, by alternative RNA splicing, to four different upstream sequence positions. The deduced hydrophobic sequence of the spliced-in exon could replace the IX or the XI trans-membrane domain of the exchanger protein in two spliced isoforms. The new exon sequence was not completely included in the pTB11 insert, i.e. these two products were artificially truncated. The RNA processing of these two alternative 5'-splicing sites also occurred in tissues, as shown by RNase protection analysis. In a third type of isoform the splicing took place downstream of the originally proposed stop codon, whereas in a fourth type a stop codon was introduced after the V hydrophobic segment in the large intracellular loop.	ETH ZURICH,BIOCHEM LAB,CH-8028 ZURICH,SWITZERLAND	ETH Zurich	GABELLINI, N (corresponding author), UNIV PADUA,DIPARTIMENTO CHIM BIOL,VIA TRIESTE 75,I-35121 PADUA,ITALY.		Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094				ACETO JF, 1992, ARCH BIOCHEM BIOPHYS, V298, P553, DOI 10.1016/0003-9861(92)90449-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARONI P, 1980, P NATL ACAD SCI-BIOL, V77, P6354, DOI 10.1073/pnas.77.11.6354; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS A, 1992, J PHYSIOL-LONDON, V454, P27, DOI 10.1113/jphysiol.1992.sp019253; FURMAN I, 1993, FEBS LETT, V319, P105, DOI 10.1016/0014-5793(93)80046-W; GABELLINI N, 1993, NEUROREPORT, V4, P531, DOI 10.1097/00001756-199305000-00017; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HILGEMANN DW, 1992, J PHYSIOL-LONDON, V454, P59, DOI 10.1113/jphysiol.1992.sp019254; HOLTZ J, 1993, BASIC RES CARDIOL, V88, P183; HRYSHKO LV, 1993, BIOCHIM BIOPHYS ACTA, V1151, P35, DOI 10.1016/0005-2736(93)90068-B; HUARTE J, 1992, CELL, V69, P1021, DOI 10.1016/0092-8674(92)90620-R; KOFUJI P, 1993, AM J PHYSIOL, V265, pF598, DOI 10.1152/ajprenal.1993.265.4.F598; KOFUJI P, 1994, J BIOL CHEM, V269, P5145; KOFUJI P, 1992, AM J PHYSIOL, V263, pC1241, DOI 10.1152/ajpcell.1992.263.6.C1241; KOMURO I, 1992, P NATL ACAD SCI USA, V89, P4769, DOI 10.1073/pnas.89.10.4769; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; LEE SL, 1994, J BIOL CHEM, V269, P14849; LI ZP, 1992, J BIOL CHEM, V267, P7828; LI ZP, 1994, J BIOL CHEM, V269, P17434; LOW W, 1993, FEBS LETT, V316, P63, DOI 10.1016/0014-5793(93)81737-K; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; NICOLL DA, 1991, ANN NY ACAD SCI, V639, P181, DOI 10.1111/j.1749-6632.1991.tb17305.x; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; PHILIPSON KD, 1988, BIOCHIM BIOPHYS ACTA, V945, P298, DOI 10.1016/0005-2736(88)90492-0; PIJUAN V, 1993, AM J PHYSIOL, V264, pC1066, DOI 10.1152/ajpcell.1993.264.4.C1066; REEVES JP, 1992, ARCH BIOCHEM BIOPHYS, V292, P329, DOI 10.1016/0003-9861(92)90001-D; REEVES JP, 1979, P NATL ACAD SCI USA, V76, P590, DOI 10.1073/pnas.76.2.590; TREISMAN R, 1983, NATURE, V302, P590	30	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6917	6924		10.1074/jbc.270.12.6917	http://dx.doi.org/10.1074/jbc.270.12.6917			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896841	hybrid			2022-12-25	WOS:A1995QQ85500072
J	MIYOSHI, E; NISHIKAWA, A; IHARA, Y; SAITO, H; UOZUMI, N; HAYASHI, N; FUSAMOTO, H; KAMADA, T; TANIGUCHI, N				MIYOSHI, E; NISHIKAWA, A; IHARA, Y; SAITO, H; UOZUMI, N; HAYASHI, N; FUSAMOTO, H; KAMADA, T; TANIGUCHI, N			TRANSFORMING GROWTH-FACTOR-BETA UP-REGULATES EXPRESSION OF THE N-ACETYLGLYCOSAMINYLTRANSFERASE-V GENE IN MOUSE MELANOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; MESSENGER-RNA STABILITY; HAMSTER-KIDNEY CELLS; HUMAN LYMPHOCYTES-T; ACETYLGLUCOSAMINYLTRANSFERASE-V; PHASEOLUS-VULGARIS; FACTOR-BETA-1; TISSUES; GLYCOPROTEINS; TRANSCRIPTION	beta-1,6-N acetylglucosaminyltransferase V (GnT-V) (EC 2.4.1.155) that catalyzes beta-1,6 branching in asparaginelinked oligosaccharides is activated on viral or oncogenic transformation and is associated with tumor metastasis. To study the molecular mechanisms involved in regulation of expression of the GnT-V gene, we cloned cDNA and genomic DNA for the enzyme (Saito, H., Nishikawa, A., Gu, J., Ihara, Y., Soejima, Y., Sekiya, C., Niikawa, N., and Taniguchi, N. (1994) Biochem. Biophys. Res. Commun. 198, 318-327). We found that transforming growth factor beta (TGF beta) specifically induced GnT-V expression in mouse melanoma cells. The activity of GnT-V was increased 24 h after the addition of TGF beta and remained at high levels up to 72 h. Northern blot analysis showed that the mRNA levels of GnT-V were consistent with the increased activity. To further investigate the nature of the induction, mRNA stability and transcriptional activity were assayed. The enhancement of the GnT-V mRNA expression resulted from prolonged mRNA stability, not from increased transcription. Consequently, elevated mRNA levels were observed even 72 h after the addition of TGF beta. Lectin blot analysis involving leukoagglutinin showed newly synthesized beta-1,6 branching structures in the sugar chains of a protein of approximately 130 kDa at 48 h after TGF beta treatment. These results suggested that TGF beta caused changes in the sugar chains of proteins in melanoma cells by upregulating GnT-V expression.	OSAKA UNIV,SCH MED,DEPT BIOCHEM,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT MED 1,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University			Nishikawa, Atsushi/E-6766-2013; Taniguchi, Naoyuki/I-4182-2014	Nishikawa, Atsushi/0000-0003-4325-1160; Taniguchi, Naoyuki/0000-0001-5889-5968				ANZANO MA, 1985, MOL CELL BIOL, V5, P242, DOI 10.1128/MCB.5.1.242; ARANGO J, 1988, J CELL BIOCHEM, V37, P225, DOI 10.1002/jcb.240370209; AYANLARBATUMAN O, 1991, J CLIN INVEST, V88, P1574, DOI 10.1172/JCI115469; BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUMMINGS RD, 1982, J BIOL CHEM, V257, P13421; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1230; DENNIS JW, 1989, CANCER RES, V49, P945; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; DERYNCK R, 1987, CANCER RES, V47, P707; DODGE GR, 1990, J BIOL CHEM, V265, P18023; FILDER IJ, 1987, ADV CANCER RES, V28, P149; GALERA P, 1992, J CELL PHYSIOL, V153, P596, DOI 10.1002/jcp.1041530322; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GU JG, 1993, J BIOCHEM, V113, P614, DOI 10.1093/oxfordjournals.jbchem.a124091; HAHN TJ, 1992, J BIOL CHEM, V267, P23982; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; HEFFERNAN M, 1993, J BIOL CHEM, V268, P1242; Herlyn M, 1990, Adv Cancer Res, V54, P213, DOI 10.1016/S0065-230X(08)60812-X; KAHARI VM, 1992, LAB INVEST, V66, P580; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MIYOSHI E, 1993, CANCER RES, V53, P3899; MOORADIAN DL, 1992, J NATL CANCER I, V84, P523, DOI 10.1093/jnci/84.7.523; NEVINS JR, 1987, METHOD ENZYMOL, V152, P238; NEWMAN MJ, 1990, P NATL ACAD SCI USA, V87, P5543, DOI 10.1073/pnas.87.14.5543; NIITSU Y, 1988, BLOOD, V71, P263; NISHIKAWA A, 1990, BIOCHIM BIOPHYS ACTA, V1035, P313, DOI 10.1016/0304-4165(90)90094-D; NISHIURA T, 1990, CANCER RES, V50, P5345; OLSEN AS, 1989, MATRIX, V9, P73, DOI 10.1016/S0934-8832(89)80024-1; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; PIERCE M, 1986, J BIOL CHEM, V261, P772; PITTELKOW MR, 1989, J CELL PHYSIOL, V140, P565, DOI 10.1002/jcp.1041400323; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; RODECK U, 1991, CANCER METAST REV, V10, P89, DOI 10.1007/BF00049407; SAITO H, 1994, BIOCHEM BIOPH RES CO, V198, P318, DOI 10.1006/bbrc.1994.1045; Sambrook J, 1989, MOL CLONING LABORATO; Schwarz LC, 1990, GROWTH FACTORS, V3, P115, DOI 10.3109/08977199009108274; SHOREIBAH M, 1993, J BIOL CHEM, V268, P15381; SHOREIBAH MG, 1992, J BIOL CHEM, V267, P2920; STEINER MS, 1992, MOL ENDOCRINOL, V6, P15, DOI 10.1210/me.6.1.15; TORREAMIONE G, 1990, P NATL ACAD SCI USA, V87, P1486, DOI 10.1073/pnas.87.4.1486; YAMASHITA K, 1985, J BIOL CHEM, V260, P3963	44	49	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					6216	6220		10.1074/jbc.270.11.6216	http://dx.doi.org/10.1074/jbc.270.11.6216			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890758	hybrid			2022-12-25	WOS:A1995QM94500075
J	WARNER, GJ; STOUDT, G; BAMBERGER, M; JOHNSON, WJ; ROTHBLAT, GH				WARNER, GJ; STOUDT, G; BAMBERGER, M; JOHNSON, WJ; ROTHBLAT, GH			CELL TOXICITY INDUCED BY INHIBITION OF ACYL-COENZYME A-CHOLESTEROL ACYLTRANSFERASE AND ACCUMULATION OF UNESTERIFIED CHOLESTEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; MACROPHAGE FOAM CELLS; ATHEROSCLEROTIC LESIONS; CULTURED-CELLS; ESTER CYCLE; COA; METABOLISM; ESTERIFICATION; CYTOTOXICITY; FIBROBLASTS	Considerable evidence supports the involvement of acyl-CoA:cholesterol acyltransferase (ACAT) in the maintenance of intracellular cholesterol homeostasis, A number of recently developed ACAT inhibitors may have potential use as pharmacological agents to reduce the development of atherosclerosis, Recently, however, reports arose describing cytotoxic effects following administration of a specific ACAT inhibitor to experimental animals, In order to address the specific intracellular mechanisms involved with the cytotoxic effect, we examined the consequences of ACAT inhibition in cholesterol-enriched mouse peritoneal macrophages, Mouse peritoneal macrophages were cholesterol-enriched by incubation with acetylated low density lipoprotein and free cholesterol:phospholipid dispersions prior to the addition of an ACAT inhibitor, either Sandoz 58-035 or Pfizer CP-113,818, The adenine pool of the macrophages was radiolabeled prior to addition of the ACAT inhibitors, in order to monitor the release of radiolabeled adenine, a technique shown to be a sensitive method to monitor drug-induced toxicity, The ACAT inhibitors were added for up to 48 h and at concentrations up to 2 mu g/ml, These conditions resulted in an approximately a-fold increase in adenine release, The increase in cell toxicity paralleled an increase in the cellular free cholesterol content, Reducing the cellular free cholesterol content, by the addition of extracellular accepters, decreased the cytotoxic effects of the ACAT inhibitors, Addition of an intracellular cholesterol transport inhibitor, either progesterone or U18666A, together with CP-113,818 blocked the toxic effect of CP-113,818, These results suggest that ACAT inhibition of cholesterol-enriched macrophages increases cell toxicity due to the buildup of cellular free cholesterol, Removal of free cholesterol by the addition of extracellular cholesterol accepters or by blocking intracellular sterol transport relieves the ACAT inhibitor-induced toxicity.	MED COLL PENN,DEPT BIOCHEM,PHILADELPHIA,PA 19129; PFIZER INC,CENT RES,GROTON,CT 06340	Drexel University; Pfizer					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007443, P01HL022633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL22633, HL07443] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELMAN SJ, 1984, J BIOL CHEM, V259, P3844; ARBOGAST LY, 1976, P NATL ACAD SCI USA, V73, P3680, DOI 10.1073/pnas.73.10.3680; BAMBERGER M, 1985, BIOCHEMISTRY-US, V24, P3693, DOI 10.1021/bi00335a044; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BERNARD DW, 1990, ARTERIOSCLEROSIS, V10, P135, DOI 10.1161/01.ATV.10.1.135; BOCAN TMA, 1993, ATHEROSCLEROSIS, V99, P175, DOI 10.1016/0021-9150(93)90020-U; BROWN BG, 1993, CIRCULATION, V87, P1781, DOI 10.1161/01.CIR.87.6.1781; BROWN MS, 1980, J BIOL CHEM, V255, P9344; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BROWN MS, 1979, J CELL BIOL, V82, P597, DOI 10.1083/jcb.82.3.597; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; CARR TP, 1995, J LIPID RES, V36, P25; CIANFLONE KM, 1990, J LIPID RES, V31, P2045; CONSTANTINIDES P, 1966, J ATHEROSCLER RES, V61, P1; DOMINICK MA, 1993, TOXICOL PATHOL, V21, P54, DOI 10.1177/019262339302100107; DOMINICK MA, 1993, FUND APPL TOXICOL, V20, P217, DOI 10.1006/faat.1993.1029; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HARMALA AS, 1994, BBA-LIPID LIPID MET, V1211, P317, DOI 10.1016/0005-2760(94)90156-2; Hatch F T, 1968, Adv Lipid Res, V6, P1; ISHIKAWA TT, 1974, J LIPID RES, V15, P286; LANGE Y, 1994, J BIOL CHEM, V269, P3411; LENDON CL, 1991, ATHEROSCLEROSIS, V87, P87, DOI 10.1016/0021-9150(91)90235-U; LISCUM L, 1989, J BIOL CHEM, V264, P11796; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLBERG FH, 1992, J BIOL CHEM, V267, P4541; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCCLOSKEY HM, 1987, BIOCHIM BIOPHYS ACTA, V921, P320, DOI 10.1016/0005-2760(87)90033-6; MCGOOKEY DJ, 1983, J CELL BIOL, V97, P1156, DOI 10.1083/jcb.97.4.1156; MIDDLETON B, 1987, BIOCHEM BIOPH RES CO, V145, P350, DOI 10.1016/0006-291X(87)91328-3; REID VC, 1992, ATHEROSCLEROSIS, V92, P251, DOI 10.1016/0021-9150(92)90285-O; ROSS AC, 1984, J BIOL CHEM, V259, P815; ROTHBLAT GH, 1982, J BIOL CHEM, V257, P4775; SHIRATORI Y, 1994, J BIOL CHEM, V269, P11337; SHIRHATTI V, 1985, ANAL BIOCHEM, V147, P410, DOI 10.1016/0003-2697(85)90290-8; SLISKOVIC DR, 1991, TRENDS PHARMACOL SCI, V12, P194, DOI 10.1016/0165-6147(91)90546-5; SMALL DM, 1988, ARTERIOSCLEROSIS, V8, P103, DOI 10.1161/01.ATV.8.2.103; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; SUCKLING KE, 1985, J LIPID RES, V26, P647; TANAKA H, 1994, ATHEROSCLEROSIS, V107, P187, DOI 10.1016/0021-9150(94)90020-5; VERNETTI LA, 1993, TOXICOL APPL PHARM, V118, P30, DOI 10.1006/taap.1993.1005; YANCEY PG, 1991, ARTERIOSCLER THER, V12, P1291	41	226	229	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					5772	5778		10.1074/jbc.270.11.5772	http://dx.doi.org/10.1074/jbc.270.11.5772			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890706	hybrid			2022-12-25	WOS:A1995QM94500016
J	WEI, CL; MACMILLAN, SE; HERSHEY, JWB				WEI, CL; MACMILLAN, SE; HERSHEY, JWB			PROTEIN-SYNTHESIS INITIATION-FACTOR EIF-1A IS A MODERATELY ABUNDANT RNA-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNAS; TRANSLATIONAL CONTROL; RABBIT RETICULOCYTES; EXPRESSION; CELLS; PHOSPHORYLATION; MECHANISM; SEQUENCES; CLONING; SUBUNIT	Eukaryotic initiation factor (eIF) 1A (formerly called eIF-4C) is a small protein that promotes dissociation of 80 S ribosomes into subunits, stabilizes methionyl-tRNA binding to 40 S ribosomal subunits, and is required for the binding of mRNA to ribosomes. The sequence of eIF-1A derived from its cloned cDNA possesses a high frequency of basic residues and acidic residues at its N and C termini, respectively. Northwestern blotting with a fragment of mRNA indicates that eIF-1A binds RNA. Overexpression of the human eIF-1A cDNA in Escherichia coli and subsequent purification enabled us to prepare large quantities of active factor. The level of eIF-1A in HeLa cells determined by Western immunoblotting is 0.01% of total protein, which corresponds to 0.2 molecules of eIF-1A/ribosome. The moderate abundance means that eIF-1A is equal to or in excess of native 40 S subunits and suggests that the factor may not be limiting for protein synthesis, a conclusion reinforced by the failure of overproduced eIF-1A to stimulate translation rates in transiently transfected COS-1 cells. S1 nuclease protection and primer extension analyses show that eIF-1A mRNA possesses an unusually long 5'-untranslated leader that is very G/C-rich (72%), Unexpectedly, the mRNA is efficiently translated in HeLa cells as judged by polysome profile analyses.	UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616	University of California System; University of California Davis					NIGMS NIH HHS [GM22135] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022135] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNE R, 1978, J BIOL CHEM, V253, P3078; BRAWERMAN G, 1981, CRC CR REV BIOCH MOL, V10, P1, DOI 10.3109/10409238109114634; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEVER TE, 1994, J BIOL CHEM, V269, P3212; DUNCAN R, 1983, J BIOL CHEM, V258, P7228; DUNCAN R, 1987, J BIOL CHEM, V262, P380; ERNST H, 1987, J BIOL CHEM, V262, P1206; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; KAUFMAN RJ, 1987, MOL CELL BIOL, V7, P1568, DOI 10.1128/MCB.7.4.1568; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Maniatis T., 1982, MOL CLONING; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MILBURN SC, 1990, EMBO J, V9, P2783, DOI 10.1002/j.1460-2075.1990.tb07466.x; SMITMCBRIDE Z, 1989, J BIOL CHEM, V264, P18527; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; THOMAS A, 1979, EUR J BIOCHEM, V98, P329, DOI 10.1111/j.1432-1033.1979.tb13192.x; THOMAS A, 1980, EUR J BIOCHEM, V107, P39, DOI 10.1111/j.1432-1033.1980.tb04621.x; THOMAS AAM, 1981, FEBS LETT, V128, P177, DOI 10.1016/0014-5793(81)80076-2; TIMMER RT, 1993, J BIOL CHEM, V268, P24863; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	25	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					5764	5771		10.1074/jbc.270.11.5764	http://dx.doi.org/10.1074/jbc.270.11.5764			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890705				2022-12-25	WOS:A1995QM94500015
J	ZHAO, JM; LAST, RL				ZHAO, JM; LAST, RL			IMMUNOLOGICAL CHARACTERIZATION AND CHLOROPLAST LOCALIZATION OF THE TRYPTOPHAN BIOSYNTHETIC-ENZYMES OF THE FLOWERING PLANT ARABIDOPSIS-THALIANA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHASE-BETA-SUBUNIT; AROMATIC AMINO-ACIDS; SPINACH-CHLOROPLASTS; ESCHERICHIA-COLI; ANTHRANILATE SYNTHASE; MUTANTS; GENE; PURIFICATION; TRANSFERASE; RESISTANT	In order to study the tryptophan biosynthetic enzymes of the plant Arabidopsis thaliana, polyclonal antibodies were raised against five of the tryptophan biosynthetic pathway proteins: anthranilate synthase a subunit, phosphoribosylanthranilate transferase, phosphoribosylanthranilate isomerase, and the tryptophan synthase alpha and beta subunits. Immunoblot analysis of Arabidopsis leaf protein extracts revealed that the antibodies identify the corresponding proteins that are enriched in Arabidopsis chloroplast fractions. Precursors of phosphoribosylanthranilate isomerase and tryptophan synthase alpha subunit were synthesized by in vitro translation. The precursors were efficiently imported and processed by isolated spinach chloroplasts, and the cleavage sites within the precursors were determined. These results provide the first direct evidence that the tryptophan biosynthetic enzymes from Arabidopsis are synthesized as higher molecular weight precursors and then imported into chloroplasts and processed into their mature forms.	CORNELL UNIV,GENET & DEV SECT,ITHACA,NY 14853	Cornell University	ZHAO, JM (corresponding author), CORNELL UNIV,BOYCE THOMPSON INST PLANT RES,TOWER RD,ITHACA,NY 14853, USA.		Last, Robert L/D-9197-2011	Last, Robert/0000-0001-6974-9587	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043134, R01GM043134] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43134] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F. M., 1993, CURRENT PROTOCOLS MO, V1; BERLYN MB, 1989, P NATL ACAD SCI USA, V86, P4604, DOI 10.1073/pnas.86.12.4604; BERNASCONI P, 1994, PLANT PHYSIOL, V106, P353, DOI 10.1104/pp.106.1.353; BICKEL H, 1978, PHYTOCHEMISTRY, V17, P119, DOI 10.1016/S0031-9422(00)89691-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DELLACIOPPA G, 1986, P NATL ACAD SCI USA, V83, P6873, DOI 10.1073/pnas.83.18.6873; HAUGHN GW, 1986, MOL GEN GENET, V204, P430, DOI 10.1007/BF00331020; HERRMANN KM, 1991, NATO ADV SCI I A-LIF, V212, P729; HINNEBUSCH AG, 1992, MOL CELLULAR BIOL YE, V2, P321; KREPS JA, 1992, PLANT PHYSIOL, V99, P269, DOI 10.1104/pp.99.1.269; LAST RL, 1991, PLANT CELL, V3, P345, DOI 10.1105/tpc.3.4.345; LAST RL, 1988, SCIENCE, V240, P305, DOI 10.1126/science.240.4850.305; LI J, 1995, IN PRESS PLANT PHYSL; MISHKIND ML, 1987, METHOD ENZYMOL, V148, P274; NIYOGI KK, 1993, PLANT CELL, V5, P1011, DOI 10.1105/tpc.5.9.1011; NIYOGI KK, 1992, PLANT CELL, V4, P721, DOI 10.1105/tpc.4.6.721; POULSEN C, 1993, EUR J BIOCHEM, V212, P431, DOI 10.1111/j.1432-1033.1993.tb17679.x; ROSE AB, 1992, PLANT PHYSIOL, V100, P582, DOI 10.1104/pp.100.2.582; ROSE AB, 1994, ARABIDOPSIS, P835; SCHULZESIEBERT D, 1984, PLANT PHYSIOL, V76, P465, DOI 10.1104/pp.76.2.465; SCHULZESIEBERT D, 1989, PLANT SCI, V59, P167, DOI 10.1016/0168-9452(89)90134-9; SINGH B, 1992, PLANT PHYSIOL, V99, P812, DOI 10.1104/pp.99.3.812; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WEAVER LM, 1993, BIOORG MED CHEM LETT, V3, P1421, DOI 10.1016/S0960-894X(01)80423-6; YANOFSKY C, 1987, ESCHERICHIA COLI SAL, V2, P1453	25	58	78	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					6081	6087		10.1074/jbc.270.11.6081	http://dx.doi.org/10.1074/jbc.270.11.6081			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890741	hybrid			2022-12-25	WOS:A1995QM94500057
J	MANNO, S; TAKAKUWA, Y; NAGAO, K; MOHANDAS, N				MANNO, S; TAKAKUWA, Y; NAGAO, K; MOHANDAS, N			MODULATION OF ERYTHROCYTE-MEMBRANE MECHANICAL FUNCTION BY BETA-SPECTRIN PHOSPHORYLATION AND DEPHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; INDUCED SHAPE CHANGES; RED-CELL; CASEIN KINASE; CYTOSKELETAL PROTEINS; SKELETAL PROTEINS; SELF-ASSOCIATION; PLASMA-MEMBRANE; OKADAIC ACID; 4.1 BINDING	The mechanical properties of human erythrocyte membrane are largely regulated by submembranous protein skeleton whose principal components are alpha- and beta-spectrin, actin, protein 4.1, adducin, and dematin, All of these proteins, except for actin, are phosphorylated by various kinases present in the erythrocyte. In vitro studies with purified skeletal proteins and various kinases has shown that while phosphorylation of these proteins can modify some of the binary and ternary protein interactions, it has no effect on certain other interactions between these proteins. Most importantly, at present there is no direct evidence that phosphorylation of skeletal protein(s) alters the function of the intact membrane. To explore this critical issue, we have developed experimental strategies to determine the functional consequences of phosphorylation of beta-spectrin on mechanical properties of intact erythrocyte membrane. We have been able to document that membrane mechanical stability is exquisitely regulated by phosphorylation of beta-spectrin by membrane-bound casein kinase I. Increased phosphorylation of beta-spectrin decreases membrane mechanical stability while decreased phosphorylation increases membrane mechanical stability. Our data for the first time demonstrate that phosphorylation of a skeletal protein in situ can modulate physiological function of native erythrocyte membrane.	UNIV CALIF BERKELEY, DIV LIFE SCI, LAWRENCE BERKELEY LAB, BERKELEY, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	MANNO, S (corresponding author), TOKYO WOMENS MED COLL, DEPT BIOCHEM, SHINJUKU KU, 8-1 KAWADA CHO, TOKYO 162, JAPAN.				NIDDK NIH HHS [DK26263] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK026263, R01DK026263] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON JM, 1980, J BIOL CHEM, V255, P1259; ANDERSON JM, 1979, J BIOL CHEM, V254, P939; AVRUCH J, 1974, BIOCHEMISTRY-US, V13, P5507, DOI 10.1021/bi00724a009; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BESSIS N, 1977, BLOOD CELLS BERL, V3, P209; BIRCHMEIER W, 1977, J CELL BIOL, V73, P647, DOI 10.1083/jcb.73.3.647; BOIVIN P, 1980, BIOCHEM BIOPH RES CO, V93, P24, DOI 10.1016/S0006-291X(80)80240-3; BOIVIN P, 1981, BIOCHIM BIOPHYS ACTA, V647, P1, DOI 10.1016/0005-2736(81)90289-3; BRENNER SL, 1979, J BIOL CHEM, V254, P8620; CHAO TS, 1991, BIOCHEMISTRY-US, V30, P10529, DOI 10.1021/bi00107a023; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; CLARI G, 1981, BIOCHIM BIOPHYS ACTA, V640, P240, DOI 10.1016/0005-2736(81)90549-6; COHEN CM, 1992, SEMIN HEMATOL, V29, P244; COHEN CM, 1986, J BIOL CHEM, V261, P7701; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DANILOV YN, 1990, J BIOL CHEM, V265, P2556; DEKOWSKI SA, 1983, J BIOL CHEM, V258, P2750; DUNBAR JC, 1978, BIOCHIM BIOPHYS ACTA, V510, P283, DOI 10.1016/0005-2736(78)90028-7; EDER PS, 1986, BIOCHEMISTRY-US, V25, P1764, DOI 10.1021/bi00355a047; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FRIEDMAN DL, 1985, BIOCHIM BIOPHYS ACTA, V847, P165, DOI 10.1016/0167-4889(85)90017-5; GILLIGAN DM, 1993, SEMIN HEMATOL, V30, P74; HARRIS HW, 1980, J BIOL CHEM, V255, P1521; HARRIS HW, 1980, J BIOL CHEM, V255, P1512; HOSEY MM, 1977, BIOCHIM BIOPHYS ACTA, V482, P348; HOSEY MM, 1977, J BIOL CHEM, V252, P102; HOSEY MM, 1976, BIOCHEMISTRY-US, V15, P1561, DOI 10.1021/bi00652a029; HUSAINCHISHTI A, 1988, NATURE, V334, P718, DOI 10.1038/334718a0; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KUMAR R, 1975, BIOCHIM BIOPHYS ACTA, V410, P87, DOI 10.1016/0005-2744(75)90209-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LING E, 1988, J BIOL CHEM, V263, P2209; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU PW, 1985, J BIOL CHEM, V260, P4958; LUTZ HU, 1984, FEBS LETT, V169, P323, DOI 10.1016/0014-5793(84)80343-9; MOHANDAS N, 1993, SEMIN HEMATOL, V30, P171; MOHANDAS N, 1982, BLOOD, V59, P768; PALFREY HC, 1985, J BIOL CHEM, V260, P6021; PLUT DA, 1978, EUR J BIOCHEM, V82, P333, DOI 10.1111/j.1432-1033.1978.tb12027.x; SHAHBAKHTI F, 1986, BIOCHEMISTRY-US, V25, P5969, DOI 10.1021/bi00368a020; SHEETZ MP, 1977, J CELL BIOL, V73, P638, DOI 10.1083/jcb.73.3.638; SIMONS TJB, 1979, NATURE, V281, P337, DOI 10.1038/281337a0; SOONG CJ, 1987, ARCH BIOCHEM BIOPHYS, V254, P509, DOI 10.1016/0003-9861(87)90131-7; TAO M, 1980, J BIOL CHEM, V255, P2563; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; UNGEWICKELL E, 1979, NATURE, V280, P811, DOI 10.1038/280811a0; UNGEWICKELL E, 1978, EUR J BIOCHEM, V88, P379, DOI 10.1111/j.1432-1033.1978.tb12459.x; USUI H, 1983, J BIOL CHEM, V258, P455; USUI H, 1988, J BIOL CHEM, V263, P3752; WAXMAN L, 1979, ARCH BIOCHEM BIOPHYS, V195, P300, DOI 10.1016/0003-9861(79)90356-4; WEI TQ, 1993, ARCH BIOCHEM BIOPHYS, V307, P206, DOI 10.1006/abbi.1993.1580; YAN TFJ, 1982, J BIOL CHEM, V257, P7037	52	123	126	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5659	5665		10.1074/jbc.270.10.5659	http://dx.doi.org/10.1074/jbc.270.10.5659			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890688	hybrid			2022-12-25	WOS:A1995QL58000107
J	MARCHAND, P; TANG, J; JOHNSON, GD; BOND, JS				MARCHAND, P; TANG, J; JOHNSON, GD; BOND, JS			COOH-TERMINAL PROTEOLYTIC PROCESSING OF SECRETED AND MEMBRANE FORMS OF THE ALPHA-SUBUNIT OF THE METALLOPROTEASE MEPRIN-A - REQUIREMENT OF THE I-DOMAIN FOR PROCESSING IN THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DEGRADATION; COS-1 CELLS; EXPRESSION; HYDROLASE; CLONING; RAT; PURIFICATION; RECEPTORS; PROTEASES; KIDNEY	Cell surface isoforms of meprin A (EC 3.4.24.18) from mice and rats contain beta subunits that are type I integral membrane proteins and alpha subunits that are disulfide linked to or noncovalently associated with membrane-anchored meprin subunits. Both alpha and beta subunits are synthesized with COOH-terminal domains predicted to be cytoplasmic, transmembrane, and epidermal growth factor-like; these domains are retained in beta subunits but are removed from alpha during maturation. The present studies establish that an inserted 56-amino acid domain (the ''I'' domain), present in alpha but not in beta, is necessary and sufficient for COOH-terminal proteolytic processing of the alpha subunit. This was demonstrated by expression of mutant meprin subunits (deletion mutants, chimeric alpha beta subunits, and beta mutants containing the I domain) in COS-1 cells. Mutations of two common processing sites present in the I domain (a dibasic site and a furin site) did not prevent COOH-terminal proteolytic processing, indicating that the proteases responsible for cleavage are distinct from those having these specificities, Deletion of the I domain from the alpha subunit resulted in accumulation of unprocessed subunits in a preGolgi compartment. Furthermore, COOH-terminal proteolytic processing of wild-type alpha subunits occurred before acquisition of endoglycosidase H resistance. Pulse chase experiments and expression of an alpha subunit transcript containing a c-myc epitope tag, confirmed that proteolytic lytic processing at the COOH terminus occurs in the endoplasmic reticulum. This work identifies the region of the alpha subunit that is essential for COOH-terminal processing and demonstrates that the differential processing of the evolutionarily-related subunits of meprin A that results in a structurally unique tetrameric protease begins in the endoplasmic reticulum.	PENN STATE UNIV, COLL MED, DEPT BIOCHEM & MOLEC BIOL, HERSHEY, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK019691, R37DK019691, R01DK019691] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 19691] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKUSJARVI G, 1987, MOL CELL BIOL, V7, P549, DOI 10.1128/MCB.7.1.549; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BECKMANN G, 1993, TRENDS BIOCHEM SCI, V18, P40, DOI 10.1016/0968-0004(93)90049-S; BOND JS, 1994, IN PRESS ZINC METALL; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BREWER JW, 1994, J BIOL CHEM, V269, P17338; CORBEIL D, 1993, FEBS LETT, V335, P361, DOI 10.1016/0014-5793(93)80420-Y; COSSON P, 1992, SCIENCE, V258, P659, DOI 10.1126/science.1329208; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; DUMERMUTH E, 1993, FEBS LETT, V335, P367, DOI 10.1016/0014-5793(93)80421-P; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GARDNER AM, 1993, J BIOL CHEM, V268, P25940; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; GORBEA CM, 1993, J BIOL CHEM, V268, P21035; GORBEA CM, 1991, ARCH BIOCHEM BIOPHYS, V290, P549, DOI 10.1016/0003-9861(91)90580-C; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBURG G, 1994, J BIOL CHEM, V269, P25354; GRUNBERG J, 1993, FEBS LETT, V335, P376, DOI 10.1016/0014-5793(93)80422-Q; HAMMOND SA, 1993, NATURE, V364, P158, DOI 10.1038/364158a0; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JIANG WP, 1992, J BIOL CHEM, V267, P9185; JOHNSON GD, 1994, J BIOL CHEM, V269, P7682; JOHNSON GD, 1992, J BIOL CHEM, V267, P13505; KENNY AJ, 1987, BIOCHEM J, V245, P515, DOI 10.1042/bj2450515; KITAMOTO Y, 1994, P NATL ACAD SCI USA, V91, P7588, DOI 10.1073/pnas.91.16.7588; KOUNNAS MZ, 1991, J BIOL CHEM, V266, P17350; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LAKE RA, 1991, GENE TRANSFER EXPRES, P23; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; MARCHAND P, 1994, J BIOL CHEM, V269, P15388; MCCRACKEN AA, 1993, MOL BIOL CELL, V4, P729, DOI 10.1091/mbc.4.7.729; MILHIET PE, 1994, BIOCHEM J, V300, P37, DOI 10.1042/bj3000037; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; STERCHI EE, 1988, ARCH BIOCHEM BIOPHYS, V265, P105, DOI 10.1016/0003-9861(88)90376-1; URADE R, 1992, FEBS LETT, V312, P83, DOI 10.1016/0014-5793(92)81415-I; URADE R, 1993, J BIOL CHEM, V268, P22004; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; WIKSTROM L, 1993, J BIOL CHEM, V268, P14412; WILEMAN T, 1991, CELL REGUL, V2, P753, DOI 10.1091/mbc.2.9.753; YANG B, 1993, J BIOL CHEM, V268, P7435	46	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5449	5456		10.1074/jbc.270.10.5449	http://dx.doi.org/10.1074/jbc.270.10.5449			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890660	hybrid			2022-12-25	WOS:A1995QL58000076
J	MILNE, DM; CAMPBELL, LE; CAMPBELL, DG; MEEK, DW				MILNE, DM; CAMPBELL, LE; CAMPBELL, DG; MEEK, DW			P53 IS PHOSPHORYLATED IN-VITRO AND IN-VIVO BY AN ULTRAVIOLET RADIATION-INDUCED PROTEIN-KINASE CHARACTERISTIC OF THE C-JUN KINASE, JNK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; ACTIVATION DOMAIN; BINDING PROTEIN; 3T3 CELLS; MOUSE P53; T-ANTIGEN; TRANSCRIPTION; MUTATION; SITE; IDENTIFICATION	The p53 tumor suppressor protein is thought to play a major role in the defense of the cell against agents that damage DNA. In this report, we describe the identification and characterization of a protein kinase that phosphorylates mouse p53 at a single site, serine 34, a major site of phosphorylation in the cell. The protein kinase is activated strikingly following treatment of cells with ultraviolet radiation, has a native molecular weight of approximately 45,000, and can be resolved from mitogen-activated protein (MAP) kinase by chromatography on Superose 6 and DEAE cellulose. The p53 kinase activity co-purifies with UV-activated c-Jun kinase activity on heparin Sepharose and on a c-Jun (but not a v-Jun-) affinity column. Treatment of the partially purified kinase with CL100, a protein phosphatase that specifically dephosphorylates MAP kinase homologues, inhibits its activity. Taken together, the data suggest that this p53 kinase is likely to be activated by phosphorylation and may be a member of the stress-activated protein kinase subfamily of MAP kinases. UV irradiation of SV3T3 cells leads to increased phosphorylation of p53 at serine 34, indicating that phosphorylation of p53 by this kinase is likely to be physiological. Phosphorylation of p53 by this protein kinase may be a key event in a signal transduction mechanism that coordinately controls key nuclear proteins in response to oxidative stress or DNA damaging agents.	UNIV DUNDEE,NINEWELLS HOSP & MED SCH,BIOMED RES CTR,DUNDEE DD1 9SY,SCOTLAND; UNIV DUNDEE,DEPT BIOCHEM,MRC,PROT PHOSPHORYLAT UNIT,DUNDEE DD1 4HN,SCOTLAND	University of Dundee; University of Dundee			Campbell, David G/K-1874-2015	Campbell, David G/0000-0003-2278-2149				ADDISON C, 1990, ONCOGENE, V5, P423; ADLER V, 1992, J BIOL CHEM, V267, P17001; ALESSI DR, 1993, ONCOGENE, V8, P2015; ANDERSON CW, 1994, IN PRESS SEMIN CELL; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BLACK EJ, 1991, ONCOGENE, V6, P1949; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DOVER R, 1994, J CELL SCI, V107, P1181; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FISCELLA M, 1993, ONCOGENE, V8, P1519; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HARPER JW, 1993, CELL, V75, P805; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MEEK DW, 1990, J VIROL, V64, P1734, DOI 10.1128/JVI.64.4.1734-1744.1990; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; RAGIMOV N, 1993, ONCOGENE, V8, P1183; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; TACK LC, 1992, J VIROL, V66, P1312, DOI 10.1128/JVI.66.3.1312-1320.1992; VAIDYA AB, 1978, VIROLOGY, V90, P12, DOI 10.1016/0042-6822(78)90328-8; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	60	251	258	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5511	5518		10.1074/jbc.270.10.5511	http://dx.doi.org/10.1074/jbc.270.10.5511			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890669	hybrid			2022-12-25	WOS:A1995QL58000085
J	YANAGISAWA, T; LEE, JT; WU, HC; KAWAKAMI, M				YANAGISAWA, T; LEE, JT; WU, HC; KAWAKAMI, M			RELATIONSHIP OF PROTEIN-STRUCTURE OF ISOLEUCYL-TRANSFER-RNA SYNTHETASE WITH PSEUDOMONIC ACID RESISTANCE OF ESCHERICHIA-COLI - PROPOSED MODE OF ACTION OF PSEUDOMONIC ACID AS AN INHIBITOR OF ISOLEUCYL-TRANSFER-RNA SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; TYROSYL-TRANSFER RNA; SITE-DIRECTED MUTAGENESIS; NUCLEOTIDE-SEQUENCE; 3-DIMENSIONAL STRUCTURE; DNA-SEQUENCE; BINDING-SITE; GENE; FLUORESCENS; CLONING	To elucidate the mode of action of pseudomonic acid, we have compared the deduced amino acid sequences of isoleucyl-tRNA synthetases (IleRS) from wild-type Escherichia coli strain MC4100, a pseudomonic acid-resistant mutant (strain PS102) of MC4100, and a pseudomonic acid-producing strain, Pseudomonas fluorescens. Compared with the wild-type enzyme, the deduced amino acid sequence of E. coli mutant ileS gene in strain PS102 shows a single amino acid substitution of leucine for phenylalanine at residue 594 of the IleRS. This mutational alteration in IleRS of an E. coli pseudomonic acid-resistant mutant resides in a region of the enzyme in close proximity to one of the consensus sequences of class I aminoacyl-tRNA synthetases, the KMSKS sequence between residues 602 and 606 of the E. coli IleRS, DNA sequence of the cloned ileS gene predicts that the P. fluorescens IleRS consists of 943 amino acids with 54% identity with the E. coli IleRS. The P. fluorescens ileS gene and the wild type and PS102 alleles of E. coli ileS were cloned into an expression vector, pEXPCR, and the sensitivities of E. coli DH5 alpha cells harboring each of these plasmids were compared. The cells harboring the P. fluorescens ileS were found to be most resistant to pseudomonic acid, while the transformants expressing the PS102 IleRS were more resistant than those containing the wild-type E. coli IleRS. IleRS purified from the wild-type E. coli was specifically cleaved by trypsin between Lys(605) and Ser(606) in the region of K(602)MSKS(606). The protection of the IleRS from the trypsin digestion was found with pseudomonic acid or ATP, but not with isoleucine or tRNA(1)(Ile). Based on these results, we propose that pseudomonic acid binds to IleRS in the vicinity of the KMSKS sequence that is an ATP-binding subsite, and that pseudomonic acid is a bifunctional inhibitor with characteristics of both isoleucine and ATP, for example, an analog of isoleucyladenylate.	NAGOYA UNIV,SCH SCI,DEPT MOLEC BIOL,CHIKUSA KU,NAGOYA,AICHI 46401,JAPAN; UNIFORMED SERV UNIV HLTH SCI,DEPT MICROBIOL & IMMUNOL,BETHESDA,MD 20814	Nagoya University; Uniformed Services University of the Health Sciences - USA					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028811] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28811] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER RG, 1978, J CHEM SOC P1, V1, P561; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; BRYAN LE, 1988, J ANTIMICROB CHEMOTH, V22, P1; BURBAUM JJ, 1990, PROTEINS, V7, P99, DOI 10.1002/prot.340070202; CASSIO D, 1967, BIOCHEMISTRY-US, V6, P827, DOI 10.1021/bi00855a024; CHAIN EB, 1974, J CHEM SOC CHEM COMM, P847, DOI 10.1039/c39740000847; CHAIN SEB, 1977, J CHEM SOC P1, V1, P294; CLACKSON T, 1991, PCR PRACTICAL APPROA, P187; CLARKE ND, 1988, SCIENCE, V240, P521, DOI 10.1126/science.3282306; CSANK C, 1992, J BIOL CHEM, V267, P4592; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; ENGLISCH U, 1987, BIOL CHEM H-S, V368, P971, DOI 10.1515/bchm3.1987.368.2.971; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; ERIANI G, 1991, NUCLEIC ACIDS RES, V19, P265, DOI 10.1093/nar/19.2.265; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1581, DOI 10.1021/bi00405a028; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P8031, DOI 10.1021/bi00399a001; FULLER AT, 1971, NATURE, V234, P416, DOI 10.1038/234416a0; HOU YM, 1991, P NATL ACAD SCI USA, V88, P976, DOI 10.1073/pnas.88.3.976; HOUNTONDJI C, 1985, BIOCHEMISTRY-US, V24, P1175, DOI 10.1021/bi00326a018; HOUNTONDJI C, 1986, BIOCHEMISTRY-US, V25, P16, DOI 10.1021/bi00349a003; HUGHES J, 1980, BIOCHEM J, V191, P209, DOI 10.1042/bj1910209; HUGHES J, 1978, BIOCHEM J, V176, P305, DOI 10.1042/bj1760305; HUGHES J, 1980, FEBS LETT, V122, P322, DOI 10.1016/0014-5793(80)80465-0; ISAKI L, 1990, J BACTERIOL, V172, P469, DOI 10.1128/JB.172.1.469-472.1990; ISAKI L, 1990, J BACTERIOL, V172, P6512, DOI 10.1128/jb.172.11.6512-6517.1990; ISAKSSON LA, 1977, MOL GEN GENET, V156, P233, DOI 10.1007/BF00267177; JENAL U, 1991, J BIOL CHEM, V266, P10570; KAWAKAMI M, 1985, FEBS LETT, V185, P162, DOI 10.1016/0014-5793(85)80762-6; KLEIN LL, 1989, J MED CHEM, V32, P151, DOI 10.1021/jm00121a028; LEGENDRE N, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P49; MECHULAM Y, 1991, J MOL BIOL, V217, P465, DOI 10.1016/0022-2836(91)90750-Z; MILLER JH, 1972, EXPT MOL GENETICS, P93; MILLER KW, 1987, J BIOL CHEM, V262, P7391; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; PARENTI MA, 1987, CLIN PHARMACY, V6, P761; PERONA JJ, 1991, P NATL ACAD SCI USA, V88, P2903, DOI 10.1073/pnas.88.7.2903; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT E, 1994, SCIENCE, V264, P265, DOI 10.1126/science.8146659; SNIDER BB, 1983, J ORG CHEM, V48, P3003, DOI 10.1021/jo00166a013; SNIDER BB, 1982, J AM CHEM SOC, V104, P1113, DOI 10.1021/ja00368a042; WEBSTER T, 1984, SCIENCE, V226, P1315, DOI 10.1126/science.6390679; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YUE VT, 1977, BIOCHEMISTRY-US, V16, P4678, DOI 10.1021/bi00640a023	44	69	76	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24304	24309						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929087				2022-12-25	WOS:A1994PQ34600070
J	SENOGLES, SE				SENOGLES, SE			THE D2 DOPAMINE-RECEPTOR ISOFORMS SIGNAL THROUGH DISTINCT G(I-ALPHA)ADENYLYL CYCLASE - A STUDY WITH SITE-DIRECTED MUTANT G(I-ALPHA) PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTERIOR-PITUITARY-CELLS; CYCLIC-AMP ACCUMULATION; ADENYLATE-CYCLASE; SOMATOSTATIN RECEPTORS; MESSENGER-RNA; RAT-BRAIN; INHIBITION; BINDING; IDENTIFICATION; GI2	Site-directed mutations of the cDNA for G(i1 alpha), G(i2 alpha), G(i3 alpha) were constructed which changed the cysteine residue at the C terminus to a glycine residue (G(i alpha)PT). This mutation of the G(i alpha) would not permit the subsequent covalent modification by pertussis toxin, which requires the cysteine moiety. The cDNA for each of the mutant G(i alpha) subunits was transfected into GH4C1 cells with either of the alternative splice forms of the D2 dopamine receptor and clonal lines were generated. After treatment with pertussis toxin to remove the contribution from endogenous G(i) proteins, the receptor-mediated inhibition of adenylyl cyclase was examined. The D2 dopamine receptor, short form (D2s) signaled through the G(i2 alpha)PT mutant in these cells with an affinity for agonist which was comparable to that observed in cells transfected with the cDNA for D2s alone or the signaling observed in the absence of pertussis toxin. The long form of the D2 dopamine receptor (D21) signaled through the G(i3 alpha)PT mutant to inhibit forskolin-stimulated adenylyl cyclase, with an affinity for agonist comparable to that observed in cells transfected with the cDNA for D21 alone. The receptor for somatostatin (somatotropin release inhibiting factor) was used as an endogenous control receptor in these cell lines. The somatotropin release inhibiting factor was able to signal through both G(i1 alpha)PT and G(i3 alpha)PT to inhibit forskolin-stimulated adenylyl cyclase. These results indicated that receptors use distinct G(i) proteins to signal to a common effector.			SENOGLES, SE (corresponding author), UNIV TENNESSEE, DEPT BIOCHEM, 858 MADISON AVE G01, MEMPHIS, TN 38163 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [S15NS028111] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 28111] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN JQ, 1993, J BIOL CHEM, V268, P12253; COTE TE, 1982, MOL PHARMACOL, V22, P290; CRONIN MJ, 1980, ENDOCRINOLOGY, V106, P718, DOI 10.1210/endo-106-3-718; DALTOSO R, 1989, EMBO J, V8, P4025, DOI 10.1002/j.1460-2075.1989.tb08585.x; EINHORN LC, 1991, J NEUROSCI, V11, P3727; GIANNATTASIO G, 1981, LIFE SCI, V28, P1605, DOI 10.1016/0024-3205(81)90315-5; GOLDSMITH P, 1988, J BIOL CHEM, V263, P6476; GOLDSMITH P, 1988, BIOCHEMISTRY-US, V27, P7085, DOI 10.1021/bi00418a062; KANTERMAN RY, 1991, MOL PHARMACOL, V39, P364; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLEDO PM, 1992, NEURON, V8, P455, DOI 10.1016/0896-6273(92)90273-G; MALARKEY WB, 1977, NATURE, V266, P640, DOI 10.1038/266640a0; MANSOUR A, 1990, J NEUROSCI, V10, P2587; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MCDONALD WM, 1984, MOL CELL ENDOCRINOL, V36, P201, DOI 10.1016/0303-7207(84)90037-6; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; MONTMAYEUR JP, 1991, P NATL ACAD SCI USA, V88, P3135, DOI 10.1073/pnas.88.8.3135; OMALLEY KL, 1990, BIOCHEMISTRY-US, V29, P1367, DOI 10.1021/bi00458a003; RAYNOR K, 1993, J PHARMACOL EXP THER, V264, P110; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; SIBLEY DR, 1992, TRENDS PHARMACOL SCI, V13, P61, DOI 10.1016/0165-6147(92)90025-2; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; TALLENT M, 1992, MOL PHARMACOL, V41, P452; TAM SW, 1981, ENDOCRINOLOGY, V109, P403; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TASHJIAN AH, 1968, ENDOCRINOLOGY, V82, P342, DOI 10.1210/endo-82-2-342; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; WEINER DM, 1989, FEBS LETT, V253, P207, DOI 10.1016/0014-5793(89)80960-3; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0	32	168	168	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23120	23127						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	7916015				2022-12-25	WOS:A1994PQ16400036
J	DICKSON, PW; JENNINGS, IG; COTTON, RGH				DICKSON, PW; JENNINGS, IG; COTTON, RGH			DELINEATION OF THE CATALYTIC CORE OF PHENYLALANINE-HYDROXYLASE AND IDENTIFICATION OF GLUTAMATE-286 AS A CRITICAL RESIDUE FOR PTERIN FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID HYDROXYLASES; SITE-DIRECTED MUTAGENESIS; RAT-LIVER; ESCHERICHIA-COLI; BINDING-SITES; TYROSINE-HYDROXYLASE; PURIFICATION; ACTIVATION; EXPRESSION; PHENYLKETONURIA	Rat phenylalanine hydroxylase was expressed in Escherichia coli. High level expression was achieved when the transformed E. coli were incubated at 27 degrees C for 24 h. A series of truncated fragments were expressed. The smallest fragment that gave an active soluble protein was from Leu(142) to Phe(410). This fragment corresponds closely to the region where there is highest homology between the three aromatic amino acid hydroxylases. The circular dichroism spectra of the phenylalanine hydroxylase catalytic core suggested that it contains around 50% alpha-helix. The core fragment is monomeric in dilute solutions but self-associates at higher concentrations. The E. coli expression system was used to generate a number of mutations in phenylalanine hydroxylase from position 264 to 290. This region had been previously shown to be important for pterin binding. Characterization of the mutant phenylalanine hydroxylase molecules identified Glu(286) as an amino acid critical for pterin function in phenylalanine hydroxylase.	ROYAL CHILDRENS HOSP, MURDOCH INST, OLIVE MILLER PROT LAB, PARKVILLE, VIC 3052, AUSTRALIA	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne	DICKSON, PW (corresponding author), UNIV MELBOURNE, RUSSELL GRIMWADE SCH BIOCHEM, RUSSELL GRIMWADE LAB PROT ENGN, GRATTAN ST, PARKVILLE, VIC 3052, AUSTRALIA.			Jennings, Ian/0000-0002-4781-9465				ABITA JP, 1984, J BIOL CHEM, V259, P4560; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOO KH, 1979, BIOCHEM GENET, V17, P921, DOI 10.1007/BF00504313; COTTON RGH, 1988, BIOCHEM J, V255, P193, DOI 10.1042/bj2550193; COTTON RGH, 1978, EUR J BIOCHEM, V85, P357, DOI 10.1111/j.1432-1033.1978.tb12247.x; DAHL HHM, 1986, J BIOL CHEM, V261, P4148; DIX TA, 1985, BIOCHEMISTRY-US, V24, P5839, DOI 10.1021/bi00342a022; FISHER DB, 1973, J BIOL CHEM, V248, P4345; FITZPATRICK PF, 1990, J BIOL CHEM, V265, P2042; GIBBS BS, 1993, J BIOL CHEM, V268, P8046; GOTTSCHALL DW, 1982, J BIOL CHEM, V257, P845; GRENETT HE, 1987, P NATL ACAD SCI USA, V84, P5530, DOI 10.1073/pnas.84.16.5530; Guttler Flemming, 1993, Developmental Brain Dysfunction, V6, P92; HOWELLS DW, 1994, IN PRESS J INHERITED; IWAKI M, 1986, J BIOL CHEM, V261, P2051; JENNINGS I, 1990, J BIOL CHEM, V265, P1885; JENNINGS IG, 1991, P NATL ACAD SCI USA, V88, P5734, DOI 10.1073/pnas.88.13.5734; KAUFMAN S, 1987, METHOD ENZYMOL, V142, P3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEDLEY FD, 1987, J BIOL CHEM, V262, P2228; NIELSEN KH, 1969, EUR J BIOCHEM, V7, P360, DOI 10.1111/j.1432-1033.1969.tb19617.x; OKANO Y, 1991, NEW ENGL J MED, V324, P1232, DOI 10.1056/NEJM199105023241802; ONISHI A, 1991, J BIOL CHEM, V266, P18454; RAMUS SJ, 1993, J MED GENET, V30, P401, DOI 10.1136/jmg.30.5.401; SHIMAN R, 1979, J BIOL CHEM, V254, P1300; SHIMAN R, 1980, J BIOL CHEM, V255, P4793; SHIMAN R, 1985, FOLATES PTERINS, V2, P179; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TOURIAN A, 1971, BIOCHIM BIOPHYS ACTA, V242, P345, DOI 10.1016/0005-2744(71)90226-9	30	61	63	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20369	20375						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	7914195				2022-12-25	WOS:A1994PB31700027
J	KOHNO, K; TANIMURA, H; SATO, S; NAKAYAMA, Y; MAKINO, Y; WADA, M; FOJO, AT; KUWANO, M				KOHNO, K; TANIMURA, H; SATO, S; NAKAYAMA, Y; MAKINO, Y; WADA, M; FOJO, AT; KUWANO, M			CELLULAR CONTROL OF HUMAN MULTIDRUG-RESISTANCE-1 (MDR-1) GENE-EXPRESSION IN ABSENCE AND PRESENCE OF GENE AMPLIFICATION IN HUMAN CANCER-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-RESISTANCE; CARCINOMA-CELLS; HEAT-SHOCK; DNA; PROMOTER; LINES; ACTIVATION; MODULATION; SEQUENCE; AGENTS	The Kst-6 cell line is a human KB carcinoma cell line that has a stably integrated chloramphenicol acetyltransferase (CAT) reporter gene under the control of the human mdr-1 promoter. Using Kst-6 cells as the parental cell line, five vincristine resistant sublines, designated Kst-V5, -V25, V50, -V75, and -V100, were isolated by exposure to increasing concentrations of drug. These sublines showed increased resistance to vincristine when compared with parental Kst-6 cells. Two sublines, V25-1 and V25-2, were further isolated from Kst-V25 after culture in the presence of vincristine, and V100-1 and V100-2 were also isolated from Kst-V100. Southern analysis demonstrated mdr-1 gene amplification in Kst-V50, Kst-V75, Kst-V100, V100-1, and V100-2 cells, respectively, but not in Kst-V5, Kst-V25, V25-1, and V25-2 cells. In contrast, increased mdr-1 expression was documented by Northern analysis in Kst-V25, V25-1, and V25-2 cells and five cell lines with mdr-1 amplification. Southern blot analysis utilizing a CAT probe demonstrated a stable copy number in all vincristine-resistant sublines. However, Northern analysis documented increased CAT expression in Kst-V5, Kst-V25, V25-1, and V25-2 cells but reduced mRNA levels in the cell line with amplification of the endogenous mdr-1 gene. Expression of the CAT gene was increased along with the endogenous mdr-1 gene in the early steps of the selection but decreased with the onset of gene amplification. There appeared almost similar mRNA levels of two trans-acting factor genes, SP-1 and MDR-NF1/YB-1, which are supposed to be involved in mdr-1 gene promoter activation, among all cell lines used in this study. These findings suggest that transcription of both the CAT gene fused to the mdr-1 promoter and the endogenous mdr-1 gene is enhanced through activation by trans-acting factors in the early steps of drug selection. However, the quantity of trans-activating factor is limiting, and with the onset of gene amplification, less is available for activation of the CAT gene, resulting in decreased expression.	NCI, MED BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	KOHNO, K (corresponding author), KYUSHU UNIV, SCH MED, DEPT BIOCHEM, FUKUOKA 812, JAPAN.							ASAKUNO K, 1994, BIOCHEM BIOPH RES CO, V199, P1428, DOI 10.1006/bbrc.1994.1390; BATES SE, 1989, MOL CELL BIOL, V9, P4337, DOI 10.1128/MCB.9.10.4337; BRADLEY G, 1988, BIOCHIM BIOPHYS ACTA, V948, P87, DOI 10.1016/0304-419X(88)90006-6; CHIN KV, 1990, J BIOL CHEM, V265, P221; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FAIRCHILD CR, 1987, P NATL ACAD SCI USA, V84, P7701, DOI 10.1073/pnas.84.21.7701; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; HAMADA H, 1986, P NATL ACAD SCI USA, V83, P7785, DOI 10.1073/pnas.83.20.7785; HAMANAKA R, 1992, J BIOL CHEM, V267, P13160; KOHNO K, 1988, JPN J CANCER RES, V79, P1238, DOI 10.1111/j.1349-7006.1988.tb01550.x; KOHNO K, 1990, J BIOL CHEM, V265, P19690; KOHNO K, 1989, BIOCHEM BIOPH RES CO, V165, P1415, DOI 10.1016/0006-291X(89)92761-7; KOHNO K, 1992, INT J ONCOL, V1, P73; KOHNO K, 1993, INT CONGR SER, V1026, P21; KOHNO K, 1992, MOL BIOL DNA TOPOISO, P247; Maniatis T., 1982, MOL CLONING; MARINO PA, 1990, CELL GROWTH DIFFER, V1, P57; MICKLEY LA, 1989, J BIOL CHEM, V264, P18031; MIYAZAKI M, 1992, BIOCHEM BIOPH RES CO, V187, P677, DOI 10.1016/0006-291X(92)91248-O; MIYAZAKI M, 1990, BIOCHEM BIOPH RES CO, V166, P1358, DOI 10.1016/0006-291X(90)91016-L; NAKAGAWARA A, 1990, CANCER RES, V50, P3043; PASTAN I, 1987, NEW ENGL J MED, V316, P1388; RIORDAN JR, 1985, NATURE, V316, P817, DOI 10.1038/316817a0; RONINSON IB, 1984, NATURE, V309, P626, DOI 10.1038/309626a0; RONINSON IB, 1986, P NATL ACAD SCI USA, V83, P4538, DOI 10.1073/pnas.83.12.4538; SCHIMKE RT, 1978, SCIENCE, V202, P1051, DOI 10.1126/science.715457; SCOTTO KW, 1986, SCIENCE, V232, P751, DOI 10.1126/science.2421411; SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471; SUGIMOTO Y, 1987, MOL CELL BIOL, V7, P4549, DOI 10.1128/MCB.7.12.4549; TANIMURA H, 1992, BIOCHEM BIOPH RES CO, V183, P917, DOI 10.1016/0006-291X(92)90571-2; THORGEIRSSON SS, 1987, SCIENCE, V236, P1120, DOI 10.1126/science.3576227; UCHIUMI T, 1993, CELL GROWTH DIFFER, V4, P147; UCHIUMI T, 1993, INT CONGR SER, V1026, P71; UEDA K, 1987, J BIOL CHEM, V262, P17432; VANDERBLIEK AM, 1989, ADV CANCER RES, V52, P165	37	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20503	20508						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	7914196				2022-12-25	WOS:A1994PB31700047
J	LI, Y; JENKINS, CW; NICHOLS, MA; XIONG, Y				LI, Y; JENKINS, CW; NICHOLS, MA; XIONG, Y			CELL-CYCLE EXPRESSION AND P53 REGULATION OF THE CYCLIN-DEPENDENT KINASE INHIBITOR P21	ONCOGENE			English	Article							DIRECTED PROTEIN-KINASE; WILD-TYPE P53; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; GENE AMPLIFICATION; MESSENGER-RNA; CANCER; MUTATIONS; TRANSFORMATION	In normal human fibroblast cells, the primary cell cycle regulators, the cyclin-dependent kinases (CDKs), exist predominantly in multiple quarternary complexes, each consisting of a CDK, a cyclin, proliferating cell nuclear antigen (PCNA) and p21. p21 encodes a universal inhibitor of cyclin-dependent kinases, Here we show that the level of p21 mRNA and the interaction of p21 protein with cyclin-CDK enzymes are regulated during the cell cycle. When normal human fibroblast IMR90 cells were released from serum starvation, p21 mRNA reached its highest level immediately following serum stimulation, began to decrease at the G1/S boundary, fell to its lowest level during S phase, and accumulated again as cells exited from S phase. p21 protein associates with each cyclin-CDK complex in a cell cycle dependent manner. Cyclin A-CDK2-p21-PCNA and Cyclin B1-CDC2-p21-PCNA complexes are assembled in early S and G2 phase, respectively, indicating that p21 and/or PCNA regulates the enzymatic activity of each kinase at the time of their functioning. Cyclin D1-CDK4-p21-PCNA complexes, on the other hand, persist throughout the cell cycle, suggesting that cyclin D1-CDK4 quarternary complexes may play a role in monitoring an event(s) that may occur at any time, rather than at a specific stage of the cell cycle. The level of p21 mRNA in early passage Li-Fraumeni cells that are heterozygous for p53 mutation remained similar to that in normal fibroblasts, but was undetectable in immortalized Li-Fraumeni cells homozygous for mutant p53. This finding provides a plausible molecular explanation for the loss of genetic stability associated with cells homozygous, but not heterozygous, for p53 mutation.	UNIV N CAROLINA, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, PROGRAM MOLEC BIOL & BIOTECHNOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, CURRICULUM GENET & MOLEC BIOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill								BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BISCHOFF FZ, 1991, ONCOGENE, V6, P183; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHANG F, 1992, MOL BIOL CELL, V3, P445, DOI 10.1091/mbc.3.4.445; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HAYLES J, 1986, EMBO J, V5, P3373, DOI 10.1002/j.1460-2075.1986.tb04653.x; HINDLEY J, 1987, MOL CELL BIOL, V7, P504, DOI 10.1128/MCB.7.1.504; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; KUSUBATA M, 1992, J BIOL CHEM, V267, P20937; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1992, J BIOL CHEM, V267, P13383; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, J NATL CANCER I, V43, P1365; LITTLE JB, 1987, CELL, V70, P923; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; NASMYTH K, 1993, NATURE, V366, P634, DOI 10.1038/366634a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PEPPERKOK R, 1988, P NATL ACAD SCI USA, V85, P6748, DOI 10.1073/pnas.85.18.6748; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANG Y, 1993, GENE DEV, V7, P822, DOI 10.1101/gad.7.5.822; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	54	376	390	7	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1994	9	8					2261	2268						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	7913544				2022-12-25	WOS:A1994NX62900018
J	REITER, Y; BRINKMANN, U; JUNG, SH; LEE, BK; KASPRZYK, PG; KING, CR; PASTAN, I				REITER, Y; BRINKMANN, U; JUNG, SH; LEE, BK; KASPRZYK, PG; KING, CR; PASTAN, I			IMPROVED BINDING AND ANTITUMOR-ACTIVITY OF A RECOMBINANT ANTI-ERBB2 IMMUNOTOXIN BY DISULFIDE STABILIZATION OF THE FV FRAGMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN FV; PSEUDOMONAS EXOTOXIN; PROTEINS; TOXINS; FORMS	e23(dsFv)-PE38KDEL is a recombinant immunotoxin composed of the Pv region of anti-erbB2 monoclonal antibody e23 connected to a truncated form of Pseudomonas exotoxin (PE38KDEL), in which the inherently unstable Fv heterodimer (composed of V-H and V-L) is stabilized by a disulfide bond engineered between structurally conserved framework positions of V-H and V-L. We have now found that e23(dsFv)-PE38KDEL is considerably more cytotoxic to antigen-positive cell lines than the corresponding single-chain immunotoxin. The basis for the enhanced cytotoxic activity is that the e23 dsFv-immunotoxin binds to erbB2 with greater affinity than the single-chain counterpart. The dsFv-immunotoxin had 4-fold increased binding compared to the scFv and almost identical to the binding affinity of e23 Fab. e23(dsFv)-PE38KDEL was also considerably more stable at 37 degrees C than the single-chain immunotoxin. The therapeutic potential of the disulfide-stabilized immunotoxin was compared with its single-chain counterpart using two animal models of immunodeficient mice bearing subcutaneous tumor xenografts of human gastric tumor N87 cells or human A431 epidermoid carcinoma cells. The antitumor effect of e23(dsFv)-PE38KDEL was significantly better than that of the single-chain immunotoxin. e23(dsFv)-PE38KDEL caused complete regression of tumors at doses which caused no toxic effects in mice, whereas the single-chain immunotoxin did not cause complete regressions at the same doses.	NCI,DIV CANC BIOL DIAG & CTR,MOLEC BIOL LAB,BETHESDA,MD 20892; ONCOLOGIX INC,GAITHERSBURG,MD 20878	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Brinkmann, Ulrich/AAF-8216-2019; Lee, Byungkook/E-4564-2011; pastan, ira/P-9319-2019	Brinkmann, Ulrich/0000-0002-5558-0212; Lee, Byungkook/0000-0002-3339-4582; pastan, ira/0000-0002-9223-0270				BATRA JK, 1992, P NATL ACAD SCI USA, V89, P5867, DOI 10.1073/pnas.89.13.5867; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; BRINKMANN U, 1993, P NATL ACAD SCI USA, V90, P7538, DOI 10.1073/pnas.90.16.7538; BRINKMANN U, 1991, P NATL ACAD SCI USA, V88, P8616, DOI 10.1073/pnas.88.19.8616; BUCHNER J, 1992, ANAL BIOCHEM, V205, P263, DOI 10.1016/0003-2697(92)90433-8; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; JUNG SH, 1994, PROTEINS, V19, P35, DOI 10.1002/prot.340190106; MILENIC DE, 1991, CANCER RES, V51, P6363; PAI LH, 1991, P NATL ACAD SCI USA, V88, P3358, DOI 10.1073/pnas.88.8.3358; PASTAN I, 1991, SCIENCE, V254, P1173, DOI 10.1126/science.1683495; REITER Y, 1994, PROTEIN ENG, V7, P697, DOI 10.1093/protein/7.5.697; REITER Y, 1994, CANCER RES, V54, P2714; REITER Y, 1994, BIOCHEMISTRY-US, V33, P5454; REITER Y, 1994, IN PRESS INT J CANCE; SEETHARAM S, 1991, J BIOL CHEM, V266, P17376; YOKOTA T, 1992, CANCER RES, V52, P3402	18	92	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18327	18331						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	7913461				2022-12-25	WOS:A1994NW79800017
J	ZHANG, SH; LAWTON, MA; HUNTER, T; LAMB, CJ				ZHANG, SH; LAWTON, MA; HUNTER, T; LAMB, CJ			ATPK1, A NOVEL RIBOSOMAL-PROTEIN KINASE GENE FROM ARABIDOPSIS .1. ISOLATION, CHARACTERIZATION, AND EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; FAMILY; THALIANA; SEQUENCE; PLANTS; RNA; PHOSPHORYLATION; TRANSCRIPTION; TRANSDUCTION; POLYMERASE	Two protein kinase genes (atpk1 and atpk2) were isolated from Arabidopsis thaliana genomic DNA with a probe generated by polymerase chain reaction (PCR) using oligonucleotide primers encoding conserved eukaryotic protein kinase sequences. atpk1 and atpk2 are organized in a head-to-tail tandem array on chromosome 3 and have about 80% nucleotide sequence identity. atpk1 encodes a hydrophilic polypeptide of 465 amino acids, M(r)=52,554. The centrally located catalytic domain contains all the conserved residues characteristic of eukaryotic protein kinases, with greatest similarity to the catalytic domains of 70-kDa ribosomal S6 protein kinase, protein kinase C, and protein kinase A. The C-terminal 75 residues also show homology to protein kinase C and S6 protein kinase. In contrast, the N-terminal 130 residues have no homology to any known protein, and thus may represent a new class of protein kinase regulatory domain. Other motifs found in the Atpk1 protein include two putative autophosphorylation sites, a pseudosubstrate site, two acidic domains, a lysine-rich domain, and two putative PEST sequences, which may contribute to the regulation of protein kinase activity. RNA-blot hybridization showed that atpk1 encoded a 1.8-kb mRNA Analysis of atpk1 promoter/beta-glucuronidase reporter gene fusions in transgenic plants showed that atpk1 was expressed in all tissues and at all developmental stages, with the strongest expression observed in metabolically active tissues, suggesting that atpk1 is involved in the control of plant growth and development. The first intron of atpk1 functions as an enhancer in atpk1 expression.	SALK INST BIOL STUDIES, PLANT BIOL LAB, LA JOLLA, CA 92037 USA; SALK INST BIOL STUDIES, MOLEC BIOL & VIROL LAB, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, GRAD PROGRAM CHEM, LA JOLLA, CA 92093 USA	Salk Institute; Salk Institute; University of California System; University of California San Diego								BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BUDDE RJA, 1990, PLANT BIOL, V9, P351; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GORING DR, 1993, PLANT CELL, V5, P531, DOI 10.1105/tpc.5.5.531; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAUGE BM, 1993, PLANT J, V3, P745, DOI 10.1111/j.1365-313X.1993.00745.x; HUANG SH, 1990, NUCLEIC ACIDS RES, V18, P1922, DOI 10.1093/nar/18.7.1922; JEFFERSON RA, 1987, EMBO J, V6, P3901; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNELLY PJ, 1991, J BIOL CHEM, V266, P1555; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMB CJ, 1989, CELL, V56, P215, DOI 10.1016/0092-8674(89)90894-5; LAWTON MA, 1989, P NATL ACAD SCI USA, V86, P3140, DOI 10.1073/pnas.86.9.3140; MA H, 1993, TRENDS GENET, V9, P228, DOI 10.1016/0168-9525(93)90075-S; MALDONADO F, 1988, NUCLEIC ACIDS RES, V16, P8189, DOI 10.1093/nar/16.16.8189; Maniatis T., 1982, MOL CLONING; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHL S, 1990, PLANT CELL, V2, P837, DOI 10.1105/tpc.2.9.837; ONO Y, 1988, NUCLEIC ACIDS RES, V16, P5199, DOI 10.1093/nar/16.11.5199; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; RANJEVA R, 1987, ANNU REV PLANT PHYS, V38, P73, DOI 10.1146/annurev.pp.38.060187.000445; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHAEFFER E, 1989, CELL, V57, P403, DOI 10.1016/0092-8674(89)90915-X; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; STEIN JC, 1991, P NATL ACAD SCI USA, V88, P8816, DOI 10.1073/pnas.88.19.8816; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; VASIL V, 1989, PLANT PHYSIOL, V91, P1575, DOI 10.1104/pp.91.4.1575; VOYTAS DF, 1990, GENETICS, V126, P713; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0; ZHANG SH, 1994, J BIOL CHEM, V269, P17593; ZHANG SH, 1993, THESIS U CALIFORNIA	40	55	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17586	17592						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	7912697				2022-12-25	WOS:A1994NU12800040
J	GOVEZENSKY, D; BOCHKAREVA, ES; ZAMIR, A; GIRSHOVICH, AS				GOVEZENSKY, D; BOCHKAREVA, ES; ZAMIR, A; GIRSHOVICH, AS			CHAPERONINS AS POTENTIAL GENE REGULATORY FACTORS - IN-VITRO INTERACTION AND SOLUBILIZATION OF NIFA, THE NIF TRANSCRIPTIONAL ACTIVATOR, WITH GROEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLEBSIELLA-PNEUMONIAE; BACTERIAL PROTEINS; ESCHERICHIA-COLI; INVITRO; PURIFICATION; PROMOTERS	A previous study (Govezensky, D., Greener, T., and Zamir, A. (1991) J. Bacteriol, 20, 6339-6346) indicated that the chaperonin GroEL was required for maximal expression from nif promoters in Klebsiella pneumoniae and nif-transformed Escherichia coli. That this requirement stemmed from the ability of GroEL to properly fold NifA, the nif transcriptional activator, was first supported by co-immunoprecipitation of NifA in K. pneumoniae extracts with anti-GroEL antibodies. In the present in vitro study, NifA, partially purified from E. coli overexpressing the protein, was diluted from a 6 M urea solution into a refolding buffer in the presence or absence of GroEL. Dilution in the absence of GroEL caused the complete precipitation of NifA. When present in the dilution buffer, GroEL bound NifA and maintained it in a soluble state. GroEL was also found to bind NifA newly synthesized in an in vitro translation system. For both NifA preparations, cochaperonin GroES and ATP promoted release of NifA from GroEL. These results provide evidence for the association of NifA with GroEL and for the role of both GroEL and GroES in the solubilization and thereby folding of the nif transcriptional activator.	WEIZMANN INST SCI,DEPT BIOCHEM,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT BIOL STRUCT,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science								AUSTIN S, 1990, EUR J BIOCHEM, V187, P353, DOI 10.1111/j.1432-1033.1990.tb15312.x; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BUCK M, 1986, NATURE, V294, P776; CANNON W, 1991, J MOL BIOL, V220, P915, DOI 10.1016/0022-2836(91)90363-B; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FISCHER HM, 1993, EMBO J, V12, P2901, DOI 10.1002/j.1460-2075.1993.tb05952.x; GOVEZENSKY D, 1991, J BACTERIOL, V173, P6339, DOI 10.1128/jb.173.20.6339-6346.1991; GREENER T, 1993, EMBO J, V12, P889, DOI 10.1002/j.1460-2075.1993.tb05729.x; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HOROVITZ A, 1993, J MOL BIOL, V231, P58, DOI 10.1006/jmbi.1993.1256; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; LEE HS, 1993, P NATL ACAD SCI USA, V90, P2266, DOI 10.1073/pnas.90.6.2266; LONG SR, 1991, ADV MOL GENETICS PLA, V1, P127; MERRICK MJ, 1993, NEW HORIZONS NITROGE, P43; MORETT E, 1989, J MOL BIOL, V210, P65, DOI 10.1016/0022-2836(89)90291-X; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7421, DOI 10.1073/pnas.81.23.7421; ROBERTS GP, 1980, J BACTERIOL, V144, P210, DOI 10.1128/JB.144.1.210-216.1980; SANTERO E, 1989, P NATL ACAD SCI USA, V86, P7346, DOI 10.1073/pnas.86.19.7346	24	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14003	14006						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	7910608				2022-12-25	WOS:A1994NL60600044
J	QIAN, XL; DOUGALL, WC; HELLMAN, ME; GREENE, MI				QIAN, XL; DOUGALL, WC; HELLMAN, ME; GREENE, MI			KINASE-DEFICIENT NEU PROTEINS SUPPRESS EPIDERMAL GROWTH-FACTOR RECEPTOR FUNCTION AND ABOLISH CELL-TRANSFORMATION	ONCOGENE			English	Article							ATP-BINDING-SITE; NIH 3T3 CELLS; INSULIN-RECEPTOR; POINT MUTATION; HUMAN-BREAST; INTERMOLECULAR AUTOPHOSPHORYLATION; ONCOGENE; HETERODIMERIZATION; PHOSPHORYLATION; EXPRESSION	p185(c-neu) and epidermal growth factor receptor (EGFR) associate into an active heterodimer, and overexpression of these two receptors leads to a transformed phenotype. However, the association of EGFR and kinase-deficient Neu proteins (point mutant N757 or cytoplasmic domain deletion mutant N691stop) results in a defective or inactive heterodimeric complex. In this report we explore the biological consequences of heterodimerization between EGFR and wild-type (WT) or kinase-deficient mutant Neu proteins in living cells. We show that co-expression of EGFR and kinase-deficient Neu proteins abolished the synergistic transformation and tumorigenicity. Moreover, the normal responses of EGFR to ligand were significantly suppressed, e.g., loss of EGF-dependent transformation, reduced rate of receptor endocytosis and turnover, diminished DNA synthesis, and decreased EGF binding affinity. These results provide the first evidence that kinase-deficient Neu proteins suppress normal EGFR function and display a dominant negative mutant phenotype. Together with the stimulatory effects observed in cells forming active heterodimers, these studies provide a role for heterodimerization of EGFR and Neu/c-erbB2 in interreceptor activation and synergistic signaling which may be responsible for the transition from normal receptor function into oncogenesis.			QIAN, XL (corresponding author), UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104, USA.			Dougall, William/0000-0001-9487-251X				AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; BENLEVY R, 1992, J BIOL CHEM, V267, P17304; BONISCHNETZLER M, 1988, J BIOL CHEM, V263, P6822; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; CHAZIN VR, 1992, ONCOGENE, V7, P1859; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CONNELLY PA, 1990, P NATL ACAD SCI USA, V87, P6054, DOI 10.1073/pnas.87.16.6054; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; DECKER SJ, 1989, J BIOL CHEM, V264, P9204; DEFIZE LHK, 1989, J CELL BIOL, V109, P2495, DOI 10.1083/jcb.109.5.2495; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; DOUGALL WC, 1993, J CELL BIOCHEM, V53, P61, DOI 10.1002/jcb.240530108; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; HONEGGER AM, 1990, J CELL BIOL, V110, P1541, DOI 10.1083/jcb.110.5.1541; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KERN JA, 1990, CANCER RES, V50, P5184; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KORNILOVA ES, 1992, ONCOGENE, V7, P511; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MOOLENAAR BF, 1990, J CELL BIOL, V110, P491; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; QIAN X, 1994, IN PRESS P NATL ACAD; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SCOTT GK, 1993, MOL CELL BIOL, V13, P2247, DOI 10.1128/MCB.13.4.2247; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WILLIAMS TM, 1991, PATHOBIOLOGY, V59, P46, DOI 10.1159/000163614; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	41	76	81	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1507	1514						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	7908733				2022-12-25	WOS:A1994NH40100026
J	ZHANG, Y; OLDENBURG, M; FILLINGAME, RH				ZHANG, Y; OLDENBURG, M; FILLINGAME, RH			SUPPRESSOR MUTATIONS IN F1 SUBUNIT-EPSILON RECOUPLE ATP-DRIVEN H+ TRANSLOCATION IN UNCOUPLED Q42E SUBUNIT C-MUTANT OF ESCHERICHIA-COLI F1F0 ATP SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							OXIDATIVE-PHOSPHORYLATION; CRYOELECTRON MICROSCOPY; NUCLEOTIDE-SEQUENCE; CATALYTIC SITE; GAMMA-SUBUNIT; ALPHA-SUBUNIT; IDENTIFICATION; F1-ATPASE; RESIDUES; COMPLEX	The Q42E mutation in the polar loop of subunit c of the Escherichia coli F1F0 ATP synthase leads to an uncoupling of H+ translocation through F-0 and ATP synthesis/hydrolysis in F-1. We have isolated four second-site suppressor mutants in which the coupling defect is corrected. Substitutions for Glu(31) in F-1 subunit epsilon were found in each suppressor mutant, where the substitutitions were E31G, E31V, and E31K (the last being found twice). The different substitutions vary in effectiveness in restoring wild type growth properties in the order epsilon E31G > epsilon E31V > epsilon E31K. Biochemical properties of epsilon E31G/cQ42E and epsilon E31K/cQ42E membranes were compared. In epsilon E31G/cQ42E mutant membranes, ATP-driven H+ translocation by F1F0 and the binding and coupling of F-1 to F-0 showed a striking pH dependence. Near normal function was observed at pH 7.0, but function was lost at pH 7.8. The function of epsilon E31K/cQ42E membranes was much less affected by changes in pH. Relative to epsilon E31G/cQ42E membranes, the ATP-driven H+ transport function of epsilon E31K/cQ42E membranes was approximately the same at pH 7.5, greater at pH 7.8, and less at pH 7.0. The differences between mutants could be explained if cGlu(42) ionized at pH 7.8 with loss of function in epsilon E31G/cQ42E membrane and a similar ionization were compensated for by the positively charged Lys in the epsilon E31K/cQ42E membrane.	UNIV WISCONSIN,SCH MED,DEPT BIOMOLEC CHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison			Zhang, Ying E/G-3657-2015	Zhang, Ying E/0000-0003-2753-7601	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023105, R01GM023105] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23105] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; CAPALDI RA, 1992, J BIOENERG BIOMEMBR, V24, P435, DOI 10.1007/BF00762359; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DUNN SD, 1982, J BIOL CHEM, V257, P7354; FELTON J, 1980, J BACTERIOL, V142, P221, DOI 10.1128/JB.142.1.221-228.1980; FILLINGAME RH, 1975, J BACTERIOL, V124, P870, DOI 10.1128/JB.124.2.870-883.1975; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; FRAGA D, 1994, J BIOL CHEM, V269, P7532; FRAGA D, 1994, J BIOL CHEM, V269, P2562; GIBSON F, 1977, BIOCHEM J, V162, P665, DOI 10.1042/bj1620665; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; KANAZAWA H, 1981, BIOCHEM BIOPH RES CO, V103, P604, DOI 10.1016/0006-291X(81)90494-0; KUKI M, 1988, J BIOL CHEM, V263, P17437; LAROE DJ, 1992, J BACTERIOL, V174, P633, DOI 10.1128/jb.174.2.633-637.1992; LUCKEN U, 1990, BIOCHEMISTRY-US, V29, P5339; MAGGIO MB, 1987, J BIOL CHEM, V262, P8981; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P11097; Miller J.H., 1972, EXPT MOL GENETICS; MILLER MJ, 1989, J BIOL CHEM, V264, P305; MITRA B, 1990, BIOCHEMISTRY-US, V29, P9879, DOI 10.1021/bi00494a018; MOSHER ME, 1985, J BIOL CHEM, V260, P4807; PADAN E, 1981, BIOCHIM BIOPHYS ACTA, V650, P151, DOI 10.1016/0304-4157(81)90004-6; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SKAKOON EN, 1993, ARCH BIOCHEM BIOPHYS, V302, P272, DOI 10.1006/abbi.1993.1210; SKAKOON EN, 1993, ARCH BIOCHEM BIOPHYS, V302, P279, DOI 10.1006/abbi.1993.1211; STANLOTTER H, 1986, FEBS LETT, V197, P121, DOI 10.1016/0014-5793(86)80310-6; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; ZHANG Y, 1994, J BIOL CHEM, V269, P5473	31	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10221	10224						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7908291				2022-12-25	WOS:A1994NF01700010
J	MOHNEY, RP; KNEZ, JJ; RAVI, L; SEVLEVER, D; ROSENBERRY, TL; HIROSE, S; MEDOF, ME				MOHNEY, RP; KNEZ, JJ; RAVI, L; SEVLEVER, D; ROSENBERRY, TL; HIROSE, S; MEDOF, ME			GLYCOINOSITOL PHOSPHOLIPID ANCHOR-DEFECTIVE K562 MUTANTS WITH BIOCHEMICAL LESIONS DISTINCT FROM THOSE IN THY-1(-) MURINE LYMPHOMA MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; DECAY-ACCELERATING FACTOR; STRUCTURAL CHARACTERIZATION; MEMBRANE ANCHOR; GLYCOPHOSPHATIDYLINOSITOL ANCHORS; TRYPANOSOMA-BRUCEI; MASS-SPECTROMETRY; MAMMALIAN-CELLS; BIOSYNTHESIS	Deficient expression of glycoinositol phospholipid (GPI)-anchored surface proteins has been linked to six different genetic defects in Thy-1(-) murine lymphoma mutants. In this study, human K562 cell mutants defective in GPI anchoring were derived by anti-decay-accelerating factor (CD55) based negative fluorescent cell sorting of N-methyl-N'-nitro-N-nitrosoguanidine pretreated cells. Homologous cell fusions of six clones that complemented a previously described K562 mutant corresponding to one of the Thy-1(-) mutant classes (Hirose, S., Mohney, R. P., Mutka, S. C., Ravi, L., Singleton, D, R., Perry, G., Tartakoff, A., and Medof, M. E, (1992) J. Biol. Chem. 267, 5272-5278) showed that they segregated into two complementation groups. In heterologous cell fusions, representative clones of each group complemented Thy-1 expression by all of the previously described GPI anchor pathway defective Thy-1(-) murine lymphoma classes (A, B, C, E, F, and H) but not class(es) D (and I) defective in the Thy-1 structural gene. Analyses of putative GPI anchor precursors synthesized by the two lines revealed that one mutant exhibited a complete block in deacetylation of N-acetyl-D-glucosamine-inositol phospholipid to glucosamine (GlcN)-inositol phospholipid, whereas the other mutant assembled GlcN-inositol phospholipid and subsequent mannose (Man)-containing intermediates but showed markedly increased amounts of the terminal ethanolamine (EthN)-phosphate (P)-substituted putative anchor precursors, EthN-P-6ManMan(EthN-P-->)ManGlcN- and EthN-P-6Man(EthN-P-6) Man(EthN-P-->)ManGlcN-acylinositol phospholipid (H7 and H8). We designate these new complementation classes J, harboring a defect in N-acetyl-D-glucosamine-inositol phospholipid deacetylation, and K, deficient in a step preliminary to or associated with protein transfer of assembled anchor precursors, The availability of these new mutant classes should aid in characterization of the GPI anchor pathway enzymes providing for these reactions.	CASE WESTERN RESERVE UNIV,INST PATHOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT PHARMACOL,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University					NIAID NIH HHS [AI23598] Funding Source: Medline; NIDDK NIH HHS [P01DK38181] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038181] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARMSTRONG C, 1992, J BIOL CHEM, V267, P25347; BAILEY CA, 1989, P NATL ACAD SCI USA, V86, P22, DOI 10.1073/pnas.86.1.22; BALDWIN MA, 1990, ANAL BIOCHEM, V191, P174, DOI 10.1016/0003-2697(90)90405-X; CAMP LA, 1993, J BIOL CHEM, V268, P6721; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DAVIES A, 1989, J EXP MED, V170, P637, DOI 10.1084/jem.170.3.637; DEEG MA, 1992, J BIOL CHEM, V267, P18573; DEGASPERI R, 1990, SCIENCE, V250, P988, DOI 10.1126/science.1978413; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; HIROSE S, 1992, J BIOL CHEM, V267, P5272; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HIROSE S, 1992, P NATL ACAD SCI USA, V89, P6025, DOI 10.1073/pnas.89.13.6025; HIROSE S, 1991, FASEB J, V5, P2459; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; HYMAN R, 1978, COLD SPRING HARBOR C, V5, P741; KAMITANI T, 1992, J BIOL CHEM, V267, P16968; KINOSHITA T, 1985, J EXP MED, V162, P75, DOI 10.1084/jem.162.1.75; LEMANSKY P, 1991, MOL CELL BIOL, V11, P3879, DOI 10.1128/MCB.11.8.3879; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MEDOF ME, 1987, P NATL ACAD SCI USA, V84, P2007, DOI 10.1073/pnas.84.7.2007; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; Okada N, 1989, Int Immunol, V1, P205, DOI 10.1093/intimm/1.2.205; PUOTI A, 1991, J BIOL CHEM, V266, P21051; PUOTI A, 1992, J BIOL CHEM, V267, P22673; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; SCHUBERT J, 1993, J BIOL CHEM, V268, P6281; SEGA GA, 1984, MUTAT RES, V134, P113, DOI 10.1016/0165-1110(84)90007-1; SINGH N, 1991, MOL CELL BIOL, V11, P2362, DOI 10.1128/MCB.11.5.2362; SLONINA AE, 1993, J BIOL CHEM, V268, P6729; STAFFORD HA, 1988, P NATL ACAD SCI USA, V85, P880, DOI 10.1073/pnas.85.3.880; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; TAKAHASHI M, 1993, J EXP MED, V177, P517, DOI 10.1084/jem.177.2.517; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; UEDA E, 1993, J BIOL CHEM, V268, P9998; URAKAZE M, 1992, J BIOL CHEM, V267, P6459; VARKI A, 1980, J BIOL CHEM, V255, P847	41	56	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6536	6542						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7907094				2022-12-25	WOS:A1994MZ50300044
J	RAWLINGS, SR; DEMAUREX, N; SCHLEGEL, W				RAWLINGS, SR; DEMAUREX, N; SCHLEGEL, W			PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE INCREASES [CA2+](I) IN RAT GONADOTROPHS THROUGH AN INOSITOL TRISPHOSPHATE-DEPENDENT MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-PROTEIN; HORMONE-RELEASING HORMONE; HYPOTHALAMIC PEPTIDE; CYCLIC-AMP; SARCOPLASMIC-RETICULUM; CALCIUM MOBILIZATION; CYTOSOLIC CALCIUM; CELLS; OSCILLATIONS; PACAP	Pituitary adenylate cyclase-activating polypeptide (PACAP) increases cAMP production and stimulates hormone release from a variety of anterior pituitary cells. However, in anterior pituitary gonadotrophs PACAP stimulates oscillations in cytosolic free Ca2+ concentration ([Ca2+](i)) that appear to be independent of cAMP. To study the mechanisms involved in this response, we used the patch-clamp technique to microperfuse various agents into single rat gonadotrophs while monitoring [Ca2+](i) with microfluorometry. Extracellular application of PACAP to single gonadotrophs stimulated high amplitude (>1 mu M) oscillations in [Ca2+](i), which were blocked by intracellular application of GDP beta S (guanosine 5'-O-2-thiodiphosphate), indicating the involvement of a G-protein. To identify the intracellular messenger(s) involved, we microperfused gonadotrophs with cAMP, inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3), or heparin, an antagonist of the Ins(1,4,5)P-3 receptor. A high concentration of cAMP (100 mu m) had no significant effect on basal [Ca2+](i) and did not alter the PACAP-stimulated Ca2+ response. Heparin, but not its inactive isoform, completely blocked the PACAP-stimulated increase in [Ca2+](i), while Ins(1,4,5)P-3 stimulated oscillations in [Ca2+](i) very similar to those observed in response to PACAP. These results strongly suggest that PACAP mobilizes Ca2+ through an Ins(1,4,5)P-3-dependent mechanism. The fact that PACAP stimulates two signaling pathways in pituitary cells could substantially enhance the signaling potential of this hypothalamic peptide.	UNIV HOSP GENEVA,DIV INFECT DIS,GENEVA,SWITZERLAND	University of Geneva	RAWLINGS, SR (corresponding author), UNIV GENEVA,FDN RECH MED,CH-1211 GENEVA 4,SWITZERLAND.			Demaurex, Nicolas/0000-0002-9933-6772				ALMERS W, 1985, FEBS LETT, V192, P13, DOI 10.1016/0014-5793(85)80033-8; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CANNY BJ, 1992, ENDOCRINOLOGY, V130, P211, DOI 10.1210/en.130.1.211; CAPIOD T, 1991, BIOCHEM J, V275, P277, DOI 10.1042/bj2750277; CHANG JP, 1988, J BIOL CHEM, V263, P18614; CONN PM, 1987, RECENT PROG HORM RES, V43, P29; CULLER MD, 1991, ENDOCRINOLOGY, V129, P2260, DOI 10.1210/endo-129-4-2260; DEMAUREX N, 1993, IN PRESS METHODS ENZ; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; GALIONE A, 1993, NATURE, V259, P325; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GOTH MI, 1992, ENDOCRINOLOGY, V130, P939, DOI 10.1210/en.130.2.939; GOTTSCHALL PE, 1990, ENDOCRINOLOGY, V127, P272, DOI 10.1210/endo-127-1-272; GRACIANAVARRO F, 1992, ENDOCRINOLOGY, V131, P1069, DOI 10.1210/en.131.3.1069; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUSOVSKY F, 1993, J BIOL CHEM, V268, P7768; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HART GR, 1992, J ENDOCRINOL, V134, P33, DOI 10.1677/joe.0.1340033; HASHIMOTO H, 1993, NEURON, V11, P333, DOI 10.1016/0896-6273(93)90188-W; HOUSLAY MD, 1991, EUR J BIOCHEM, V195, P9, DOI 10.1111/j.1432-1033.1991.tb15671.x; IIDA T, 1991, MOL ENDOCRINOL, V5, P949, DOI 10.1210/mend-5-7-949; ISOBE K, 1993, ENDOCRINOLOGY, V132, P1757, DOI 10.1210/en.132.4.1757; JARRY H, 1992, LIFE SCI, V51, P823, DOI 10.1016/0024-3205(92)90609-S; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KOCH B, 1992, REGUL PEPTIDES, V38, P45, DOI 10.1016/0167-0115(92)90071-2; KOVES K, 1990, ENDOCRINOLOGY, V127, P264; KUKULJAN M, 1992, FEBS LETT, V301, P19, DOI 10.1016/0014-5793(92)80201-Q; LEONG DA, 1991, CELL CALCIUM, V12, P255, DOI 10.1016/0143-4160(91)90025-A; LEONG DA, 1991, J BIOL CHEM, V266, P9016; Marty A., 1983, SINGLE CHANNEL RECOR, P107; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MIYATA A, 1990, BIOCHEM BIOPH RES CO, V170, P643, DOI 10.1016/0006-291X(90)92140-U; MORGAN RO, 1987, J BIOL CHEM, V262, P1166; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; NAOR Z, 1990, ENDOCR REV, V11, P326, DOI 10.1210/edrv-11-2-326; NAOR Z, 1986, J BIOL CHEM, V261, P2506; OSUGA Y, 1992, ENDOCRINOL JAPON, V39, P153; PALADE P, 1989, J BIOENERG BIOMEMBR, V21, P295, DOI 10.1007/BF00812074; PAPE PC, 1988, FEBS LETT, V235, P57, DOI 10.1016/0014-5793(88)81233-X; PAULSSEN RH, 1992, EUR J BIOCHEM, V204, P413, DOI 10.1111/j.1432-1033.1992.tb16651.x; PISEGNA JR, 1993, P NATL ACAD SCI USA, V90, P6345, DOI 10.1073/pnas.90.13.6345; RAWLINGS SR, 1993, ENDOCRINOLOGY, V132, P1447, DOI 10.1210/en.132.4.1447; RAWLINGS SR, 1991, J BIOL CHEM, V266, P22755; SCHAFER H, 1991, EUR J BIOCHEM, V202, P951, DOI 10.1111/j.1432-1033.1991.tb16455.x; SHANGOLD GA, 1988, P NATL ACAD SCI USA, V85, P6566, DOI 10.1073/pnas.85.17.6566; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STOJILKOVIC SS, 1990, SCIENCE, V248, P1663, DOI 10.1126/science.2163546; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TATSUNO I, 1991, ENDOCRINOLOGY, V129, P1797, DOI 10.1210/endo-129-4-1797; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TSE A, 1992, SCIENCE, V255, P462, DOI 10.1126/science.1734523; TSE A, 1993, SCIENCE, V260, P82, DOI 10.1126/science.8385366; VIGH S, 1992, REGUL PEPTIDES, V37, P315, DOI 10.1016/0167-0115(92)90630-D	55	73	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5680	5686						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7907085				2022-12-25	WOS:A1994MY84000033
J	PATEL, YC; PANETTA, R; ESCHER, E; GREENWOOD, M; SRIKANT, CB				PATEL, YC; PANETTA, R; ESCHER, E; GREENWOOD, M; SRIKANT, CB			EXPRESSION OF MULTIPLE SOMATOSTATIN RECEPTOR GENES IN ATT-20 CELLS - EVIDENCE FOR A NOVEL SOMATOSTATIN-28 SELECTIVE RECEPTOR SUBTYPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP-INDEPENDENT ACTIONS; PITUITARY-TUMOR CELLS; RAT-BRAIN; MOLECULAR CHARACTERIZATION; POTASSIUM CONDUCTANCE; GH CELLS; CLONING; BINDING; IDENTIFICATION; INHIBITION	The pattern of expression of somatostatin receptor (SSTR) genes and gene products in AtT-20 cells was characterized in an attempt to explain the SST-28 binding selectivity that typifies these cells. AtT-20 cells expressed multiple SSTR mRNAs. Paradoxically, this included mRNA for three of the four SST-14 selective receptors: SSTR2 (++++), SSTR1 (+), SSTR4 (+). The SST-28 selective SSTR5 was expressed as a 3.8-kilobase (kb) transcript of reLatively Low abundance (+) in contrast to normal mouse pituitary which dispLayed high Levels (+++) of a 2.4-kb SSTR5 MRNA. Immunoblot analysis of solubilized membranes with an antipeptide SSTR2 antibody revealed a single SSTR2 protein of 72 +/- 2 kDa. Preincubation of AtT-20 cell membranes with SSTR2 antibody reduced I-125-[Leu8,D-Trp22,Tyr25]SST-28 binding sites by 38%. Residual binding sites exhibited a 4.9-fold increase in affinity for SST-28, a 2.6-fold decrease in affinity for SST-14, and an SST-28:SST-14 potency ratio of 40:1 compared with a potency ratio of 3.5:1 in control membranes. These results demonstrate the expression of four SSTR genes in AtT-20 cells of which SSTR2 predominates. Blockade of SSTR2 with antibody exposes high affinity SST-28 selective sites with comparable binding characteristics to those reported for cloned SSTR5. These SST-28 binding sites may arise from a SSTR5 variant encoded by a high molecular weight 3.8-kb transcript or more likely from another as yet undiscovered member of the SST-28 selective SSTR subfamily.	ROYAL VICTORIA HOSP,DEPT NEUROL & NEUROSURG,MONTREAL H3A 1A1,QUEBEC,CANADA; MCGILL UNIV,FRASER LABS,MONTREAL H3A 2T5,QUEBEC,CANADA; MONTREAL NEUROL HOSP & INST,MONTREAL H3A 2B4,QUEBEC,CANADA; UNIV SHERBROOKE,DEPT PHARMACOL,SHERBROOKE J1H 5N4,QUEBEC,CANADA	McGill University; Royal Victoria Hospital; McGill University; McGill University; University of Sherbrooke	PATEL, YC (corresponding author), ROYAL VICTORIA HOSP,DEPT MED,RM M3-15,687 PINE AVE W,MONTREAL H3A 1A1,QUEBEC,CANADA.			Greenwood, Michael/0000-0003-0890-3434; Escher, Emanuel/0000-0001-6601-987X				AMHERDT M, 1987, J CLIN INVEST, V80, P1455, DOI 10.1172/JCI113225; BROWN PJ, 1990, J BIOL CHEM, V265, P17995; BRUNO JF, 1992, P NATL ACAD SCI USA, V89, P11151, DOI 10.1073/pnas.89.23.11151; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORNESS JD, 1993, FEBS LETT, V321, P279, DOI 10.1016/0014-5793(93)80124-D; DEMCHYSHYN LL, 1993, MOL PHARMACOL, V43, P894; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; KLUXEN FW, 1992, P NATL ACAD SCI USA, V89, P4618, DOI 10.1073/pnas.89.10.4618; KOCH BD, 1988, J BIOL CHEM, V263, P216; KOCH BD, 1988, J BIOL CHEM, V263, P226; LEWIS DL, 1986, P NATL ACAD SCI USA, V83, P9035, DOI 10.1073/pnas.83.23.9035; LI XJ, 1992, J BIOL CHEM, V267, P21307; MEYERHOF W, 1992, P NATL ACAD SCI USA, V89, P10267, DOI 10.1073/pnas.89.21.10267; MOREL G, 1985, ENDOCRINOLOGY, V116, P1615, DOI 10.1210/endo-116-4-1615; MURTHY KK, 1989, ENDOCRINOLOGY, V125, P948, DOI 10.1210/endo-125-2-948; OCARROLL AM, 1992, MOL PHARMACOL, V42, P939; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; PANETTA R, 1993, 75TH ANN M US END SO, P411; PATEL YC, 1993, BIOCHEM BIOPH RES CO, V192, P288, DOI 10.1006/bbrc.1993.1412; PATEL YC, 1990, METABOLISM, V39, P63, DOI 10.1016/0026-0495(90)90214-W; PATEL YC, 1988, J BIOL CHEM, V263, P7455; PATEL YC, 1992, RLE SOMATOSTATIN BAS, V5, P1; REICHLIN S, 1983, NEW ENGL J MED, V309, P1495, DOI 10.1056/NEJM198312153092406; REICHLIN S, 1983, NEW ENGL J MED, V309, P1556, DOI 10.1056/NEJM198312223092506; ROHRER L, 1993, P NATL ACAD SCI USA, V90, P4196, DOI 10.1073/pnas.90.9.4196; SCHONBRUNN A, 1983, ENDOCRINOLOGY, V113, P1559, DOI 10.1210/endo-113-5-1559; SCHONBRUNN A, 1993, 75TH AN M US END SOC, V3, P476; SRIKANT CB, 1992, ENDOCRINOLOGY, V130, P2937, DOI 10.1210/en.130.5.2937; SRIKANT CB, 1981, P NATL ACAD SCI-BIOL, V78, P3930, DOI 10.1073/pnas.78.6.3930; SRIKANT CB, 1981, NATURE, V294, P259, DOI 10.1038/294259a0; SRIKANT CB, 1985, ENDOCRINOLOGY, V117, P271, DOI 10.1210/endo-117-1-271; SRIKANT CB, 1987, SOMATOSTATIN BASIC C, P89; STRNAD J, 1993, BIOCHEM BIOPH RES CO, V191, P968, DOI 10.1006/bbrc.1993.1312; THEVENIAU M, 1992, P NATL ACAD SCI USA, V89, P4314, DOI 10.1073/pnas.89.10.4314; VANETTI M, 1992, FEBS LETT, V311, P290, DOI 10.1016/0014-5793(92)81122-3; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; YAMADA Y, 1993, GENOMICS, V15, P449, DOI 10.1006/geno.1993.1088; YAMADA Y, 1992, MOL ENDOCRINOL, V6, P2136, DOI 10.1210/me.6.12.2136; YASUDA K, 1992, J BIOL CHEM, V267, P20422	39	94	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1506	1509						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7904601				2022-12-25	WOS:A1994MR22000111
J	WANG, CC; TSOU, CL				WANG, CC; TSOU, CL			PROTEIN DISULFIDE-ISOMERASE IS BOTH AN ENZYME AND A CHAPERONE	FASEB JOURNAL			English	Article						PROTEIN DISULFIDE ISOMERASE; CHAPERONE; THIOREDOXIN; FOLDING	ENDOPLASMIC-RETICULUM; MULTIFUNCTIONAL PROTEIN; THIOREDOXIN; SUBSTRATE; RESIDENT; BINDING; LUMEN; CHAIN	Protein disulfide isomerase (PDI) catalyzes the formation of native disulfides of peptide chains from either the reduced form or randomly joined disulfides. So that thiols situated at distant parts of the polypeptide chain can be joined together to form the native disulfides, the polypeptide chain has to be folded, at least to some extent, into the native conformation. It is suggested that PDI promotes folding of the chains as well as formation of the disulfides and plays a role similar to the chaperones in the folding process. PDI is known to bc a multifunctional protein and capable of nonspecific peptide binding. These properties are closely connected to its possible function as a chaperone. Thioredoxin, which has an active site sequence similar to that of PDI but lacks the property of peptide binding, is much less efficient as a disulfide isomerase.			WANG, CC (corresponding author), CHINESE ACAD SCI,INST BIOPHYS,NATL LAB BIOMACROMOLEC,BEIJING,PEOPLES R CHINA.							AKIYAMA Y, 1992, J BIOL CHEM, V267, P22440; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BUCHNER J, 1992, BIO-TECHNOL, V10, P682, DOI 10.1038/nbt0692-682; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; ELLIS LBM, 1992, BIOCHEMISTRY-US, V31, P4882, DOI 10.1021/bi00135a020; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FLIEGEL L, 1990, J BIOL CHEM, V265, P1496; FREEDMAN RB, 1992, AAAS, V4, P448; FREEDMAN RB, 1991, CONFORMATIONS FORCES, V16, P204; FRESKGARD PO, 1992, SCIENCE, V258, P466, DOI 10.1126/science.1357751; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GIVOL D, 1964, J BIOL CHEM, V239, P3114; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HAWKINS HC, 1991, BIOCHEM J, V275, P349, DOI 10.1042/bj2750349; HEITMAN J, 1992, NEW BIOL, V4, P448; HU CH, 1991, FEBS LETT, V290, P87, DOI 10.1016/0014-5793(91)81232-W; JACOB U, 1993, J BIOL CHEM, V268, P1517; JAENICKE R, 1993, CURR OPIN STRUC BIOL, V3, P104, DOI 10.1016/0959-440X(93)90209-4; JOHN DCA, 1993, EMBO J, V12, P1587, DOI 10.1002/j.1460-2075.1993.tb05803.x; LAMANTIA M, 1991, P NATL ACAD SCI USA, V88, P4453, DOI 10.1073/pnas.88.10.4453; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; NOIVA R, 1992, J BIOL CHEM, V267, P3553; NOIVA R, 1991, J BIOL CHEM, V266, P19645; PIHLAJANIEMI T, 1991, ANN MED, V23, P393, DOI 10.3109/07853899109148079; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; TSOU CL, 1988, BIOCHEMISTRY-US, V27, P1809, DOI 10.1021/bi00406a001; VURORI K, 1992, P NATL ACAD SCI USA, V89, P7467; WELLS WW, 1990, J BIOL CHEM, V265, P15361; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; YU XC, 1992, BIOCHEM INT, V28, P461; ZAPUN A, 1992, PROTEINS, V14, P10, DOI 10.1002/prot.340140104	34	133	146	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1993	7	15					1515	1517		10.1096/fasebj.7.15.7903263	http://dx.doi.org/10.1096/fasebj.7.15.7903263			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ML740	7903263				2022-12-25	WOS:A1993ML74000015
J	HAMRICK, M; RENAUD, KJ; FAMBROUGH, DM				HAMRICK, M; RENAUD, KJ; FAMBROUGH, DM			ASSEMBLY OF THE EXTRACELLULAR DOMAIN OF THE NA,K-ATPASE BETA-SUBUNIT WITH THE ALPHA-SUBUNIT - ANALYSIS OF BETA-SUBUNIT CHIMERAS AND CARBOXYL-TERMINAL DELETIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA+ + K+)-ATPASE; XENOPUS-OOCYTES; INTRACELLULAR-TRANSPORT; DISULFIDE BONDS; SODIUM-PUMP; ENDOPLASMIC-RETICULUM; ADHESION MOLECULE; RNA-POLYMERASE; NA+/K+-ATPASE; EXPRESSION	The role of the extracellular domain of the Na,K-ATPase beta subunit in assembly with the alpha subunit was investigated. A chimeric protein consisting of the extracellular domain of the beta subunit fused with the transmembrane and cytoplasmic domains of dipeptidyl peptidase IV assembles with the alpha subunit. An inverse chimera consisting of the cytoplasmic and transmembrane domains of the beta subunit fused with the extracellular domain of dipeptidyl peptidase IV does not assemble with the alpha subunit. The assembly data from these chimeras demonstrate that the extracellular domain of the beta subunit is both necessary and sufficient for assembly with the alpha subunit. Deletions of up to 146 extracellular amino acids from the carboxyl terminus of the beta subunit appear to result in misfolding of the subunit, but do allow reduced assembly with the alpha subunit. Together, the assembly data from chimeras and carboxyl-terminal deletions have identified a 96-residue extracellular domain which contains sequences involved in subunit assembly. While the chimeric subunits properly localize to the plasma membrane, deletion of as few as 4 amino acids from the carboxyl terminus impairs the ability of the beta subunit to be transported to the plasma membrane.	JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA	Johns Hopkins University					NINDS NIH HHS [NS-23241] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023241] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARTLES JR, 1985, J BIOL CHEM, V260, P2792; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; EAKLE KA, 1992, P NATL ACAD SCI USA, V89, P2834, DOI 10.1073/pnas.89.7.2834; EAKLE KA, 1991, SODIUM PUMP RECENT D, P125; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FAMBROUGH DM, 1983, J BIOL CHEM, V258, P3926; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165; GOOD PJ, 1990, P NATL ACAD SCI USA, V87, P9088, DOI 10.1073/pnas.87.23.9088; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; Hall Z W, 1992, Trends Cell Biol, V2, P66, DOI 10.1016/0962-8924(92)90058-U; HORISBERGER JD, 1991, P NATL ACAD SCI USA, V88, P8397, DOI 10.1073/pnas.88.19.8397; HORISBERGER JD, 1991, J BIOL CHEM, V266, P19131; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JAUNIN P, 1992, J BIOL CHEM, V267, P577; KAWAKAMI K, 1988, J BIOCHEM-TOKYO, V103, P54, DOI 10.1093/oxfordjournals.jbchem.a122239; KAWAMURA M, 1984, BIOCHIM BIOPHYS ACTA, V774, P188, DOI 10.1016/0005-2736(84)90290-6; KIRLEY TL, 1989, J BIOL CHEM, V264, P7185; KIRLEY TL, 1990, J BIOL CHEM, V265, P4227; Kone BC., 1991, SODIUM PUMP RECENT D, P265; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEMAS MV, 1992, J BIOL CHEM, V267, P20987; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; MARXER A, 1989, J CELL BIOL, V109, P1057, DOI 10.1083/jcb.109.3.1057; MCDONOUGH AA, 1990, FASEB J, V4, P1598, DOI 10.1096/fasebj.4.6.2156741; MILLER RP, 1990, BIOCHEMISTRY-US, V29, P1524, DOI 10.1021/bi00458a025; NOGUCHI S, 1992, BIOCHEM BIOPH RES CO, V182, P659, DOI 10.1016/0006-291X(92)91783-M; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; OGATA S, 1989, J BIOL CHEM, V264, P3596; RENAUD KJ, 1991, J BIOL CHEM, V266, P20491; SCHMALZING G, 1991, BIOCHEM J, V279, P329, DOI 10.1042/bj2790329; SCHMALZING G, 1992, J BIOL CHEM, V267, P20212; STULTS NL, 1989, ANAL BIOCHEM, V180, P114, DOI 10.1016/0003-2697(89)90097-3; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; TAKEYASU K, 1988, J BIOL CHEM, V263, P4347; TAKEYASU K, 1987, J BIOL CHEM, V262, P10733; TAMKUN MM, 1986, J BIOL CHEM, V261, P1009	42	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24367	24373						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	7901216				2022-12-25	WOS:A1993MF29400097
J	HIREMAGALUR, B; NANKOVA, B; NITAHARA, J; ZEMAN, R; SABBAN, EL				HIREMAGALUR, B; NANKOVA, B; NITAHARA, J; ZEMAN, R; SABBAN, EL			NICOTINE INCREASES EXPRESSION OF TYROSINE-HYDROXYLASE GENE - INVOLVEMENT OF PROTEIN KINASE-A-MEDIATED PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE-BETA-HYDROXYLASE; NERVE GROWTH-FACTOR; ADRENAL CHROMAFFIN CELLS; PC12 PHEOCHROMOCYTOMA CELLS; CYCLIC-AMP; MESSENGER-RNAS; MEMBRANE DEPOLARIZATION; CHOLINERGIC AGONISTS; MEDULLARY CELLS; RAT-BRAIN	Nicotine, a major component of tobacco smoke, stimulates catecholamine secretion and activates catecholamine biosynthetic enzymes such as tyrosine hydroxylase (TH) and dopamine beta-hydroxylase (DBH) in adrenal medullary cells. We investigated the effect of long term treatment with nicotine on TH and DBH gene expression in rat PC12 pheochromocytoma cells. Nicotine treatment for 1-2 days increased both the TH and DBH mRNA levels. The effect of nicotine on TH mRNA seems to be transcriptionally mediated. Deletion analysis of the 5' promoter region of the TH gene showed that the region containing a cyclic AMP/calcium regulatory element is sufficient for the nicotinic induction of TH. Nicotine did not induce TH mRNA or chloramphenicol acetyltransferase reporter activity in mutant PC12 cells deficient in protein kinase A activity. However, the deficiency in protein kinase A activity did not affect the elevation in intracellular calcium concentration caused by nicotine, indicating normal receptor function. These results suggest that a cAMP-mediated pathway plays a crucial role in the long term nicotine-induced activation of the TH gene.	NEW YORK MED COLL,DEPT BIOCHEM & MOLEC BIOL,VALHALLA,NY 10595; NEW YORK MED COLL,DEPT CELL BIOL & ANAT,VALHALLA,NY 10595	New York Medical College; New York Medical College			Zeman, Richard/A-9295-2009	Nankova, Bistra/0000-0002-3997-4369	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028869] Funding Source: NIH RePORTER; NINDS NIH HHS [NS28869] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON K, 1992, BRIT J PHARMACOL, V106, P360, DOI 10.1111/j.1476-5381.1992.tb14341.x; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BADOYANNIS HC, 1991, MOL BRAIN RES, V11, P79, DOI 10.1016/0169-328X(91)90024-R; BAIZER L, 1985, J NEUROSCI, V5, P1176; BLACK IB, 1985, BRAIN RES, V339, P151, DOI 10.1016/0006-8993(85)90635-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALDWELL KK, 1992, CELL CALCIUM, V13, P107, DOI 10.1016/0143-4160(92)90004-C; CAMBI F, 1989, J NEUROCHEM, V53, P1656, DOI 10.1111/j.1471-4159.1989.tb08567.x; CHAN YL, 1984, J BIOL CHEM, V259, P224; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAVISO GL, 1992, J NEUROCHEM, V59, P2285; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DAS B, 1992, J NEUROCHEM, V59, P2263; EIDEN LE, 1984, NATURE, V312, P661, DOI 10.1038/312661a0; FADER D, 1990, MOL BRAIN RES, V8, P25, DOI 10.1016/0169-328X(90)90005-X; FOSSOM LH, 1991, J NEUROCHEM, V57, P2070, DOI 10.1111/j.1471-4159.1991.tb06424.x; FOSSOM LH, 1991, MOL PHARMACOL, V40, P193; FUNG BP, 1992, J NEUROCHEM, V58, P2044, DOI 10.1111/j.1471-4159.1992.tb10945.x; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GINTY DD, 1991, J BIOL CHEM, V266, P15325; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUIDOTTI A, 1974, J PHARMACOL EXP THER, V189, P665; GUIDOTTI A, 1975, P NATL ACAD SCI USA, V72, P1152, DOI 10.1073/pnas.72.3.1152; ICARDLIEPKALNS C, 1992, J NEUROSCI RES, V32, P290, DOI 10.1002/jnr.490320219; KILBOURNE EJ, 1992, J BIOL CHEM, V267, P7563; KILBOURNE EJ, 1990, MOL BRAIN RES, V8, P121, DOI 10.1016/0169-328X(90)90056-J; KVETNANSKY R, 1971, MOL PHARMACOL, V7, P81; KVETNANSKY R, 1973, FRONTIERS CATECHOLAM, P223; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; MACNICOL M, 1992, FEBS LETT, V304, P237, DOI 10.1016/0014-5793(92)80627-S; Martin W., 1987, TOBACCO SMOKING NICO, P1; MCMAHON A, 1992, J NEUROCHEM, V58, P2124, DOI 10.1111/j.1471-4159.1992.tb10954.x; MCMAHON A, 1992, J NEUROCHEM, V59, P2040; MCMAHON A, 1990, J NEUROSCI RES, V25, P395, DOI 10.1002/jnr.490250317; MESSING RO, 1989, J NEUROSCI, V9, P507; MINER LL, 1992, J NEUROSCI RES, V33, P10, DOI 10.1002/jnr.490330103; OLASMAA M, 1992, MOL PHARMACOL, V41, P456; RAYNAUD B, 1987, DEV BIOL, V119, P305, DOI 10.1016/0012-1606(87)90036-4; REIS DJ, 1975, J PHARMACOL EXP THER, V193, P775; SABBAN EL, 1983, J BIOL CHEM, V258, P7812; SANDS SB, 1991, BRAIN RES, V560, P38, DOI 10.1016/0006-8993(91)91211-I; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SLOTKIN TA, 1976, LIFE SCI, V16, P1613; SMITH KM, 1991, J NEUROCHEM, V57, P1750, DOI 10.1111/j.1471-4159.1991.tb06377.x; STACHOWIAK M K, 1990, Molecular and Cellular Neuroscience, V1, P202, DOI 10.1016/1044-7431(90)90003-M; STACHOWIAK MK, 1990, BRAIN RES, V510, P277, DOI 10.1016/0006-8993(90)91378-T; STACHOWIAK MK, 1986, J NEUROSCI RES, V16, P13, DOI 10.1002/jnr.490160104; TANK AW, 1986, MOL PHARMACOL, V30, P497; TERBUSH DR, 1986, J BIOL CHEM, V261, P7099; THOENEN H, 1969, J PHARMACOL EXP THER, V169, P249; TOUMINEN RK, 1992, J NEUROCHEM, V58, P1652; VANNGUYEN T, 1990, J NEUROSCI, V10, P2825; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WESSELSREIKER M, 1991, J BIOL CHEM, V266, P9347; YOON SO, 1992, NEURON, V9, P55, DOI 10.1016/0896-6273(92)90220-8	61	119	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23704	23711						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7901211				2022-12-25	WOS:A1993MF51500111
J	DASILVA, ACR; KENDRICKJONES, J; REINACH, FC				DASILVA, ACR; KENDRICKJONES, J; REINACH, FC			DETERMINANTS OF ION SPECIFICITY ON EF-HANDS SITES - CONVERSION OF THE CA2+/MG2+ SITE OF SMOOTH-MUSCLE MYOSIN REGULATORY LIGHT-CHAIN INTO A CA2+-SPECIFIC SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REFINED CRYSTAL-STRUCTURE; CALCIUM-BINDING PROTEINS; SCALLOP MYOSIN; TROPONIN-C; 3-DIMENSIONAL STRUCTURE; DIRECTED MUTAGENESIS; RESOLUTION; ONCOMODULIN; DISSOCIATION; PARVALBUMIN	Calcium binding proteins mediate a large number of cellular processes. These processes respond to micromolar fluctuations of cytosolic calcium in the presence of a large excess of magnesium. The metal binding sites present in these proteins are either calcium-specific (regulatory sites) or capable of binding both calcium and magnesium (structural sites). Using site-directed mutagenesis we were able to convert the single Ca2+/Mg2+ site present in chicken smooth muscle myosin regulatory light chain (RLC) into a Ca2+-specific site. The replacement of the aspartic acid present in the 12th position (-Z coordinating position) of the metal binding loop with a glutamic acid increases calcium affinity and abolishes magnesium binding, rendering the site calcium-specific. To explain this observation, we hypothesize that restrictions on the ability of side chains to change conformation, contributing one (for Mg2+ binding) or two (for Ca2+ binding) coordinations could alter the metal specificity in EF-hands. Other mutations which decrease or abolish calcium binding have also been characterized. When used to substitute the endogenous scallop myosin RLC, these mutants were capable of restoring the Ca2+ regulation to the actin-activated myosin ATPase demonstrating that in these hybrid myosins, the regulatory function of the Ca2+-specific site (present on the essential light chain) does not the occupancy of the Ca2+/Mg2+ site (present on the regulatory light chain).	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology	DASILVA, ACR (corresponding author), UNIV SAO PAULO,INST QUIM,DEPT BIOQUIM,CP 20780,BR-01498 SAO PAULO,SP,BRAZIL.							AHMED FR, 1993, J MOL BIOL, V230, P1216, DOI 10.1006/jmbi.1993.1237; AHMED FR, 1990, J MOL BIOL, V216, P127, DOI 10.1016/S0022-2836(05)80065-8; ANKRETT RJ, 1991, J MOL BIOL, V217, P323, DOI 10.1016/0022-2836(91)90546-I; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; CARTER P, 1985, NUCLEIC ACIDS RES, V13, P4431, DOI 10.1093/nar/13.12.4431; CHANTLER PD, 1980, J MOL BIOL, V138, P473, DOI 10.1016/S0022-2836(80)80013-1; DASILVA ACR, 1992, EUR J BIOCHEM, V204, P85; DASILVA ACR, 1991, TRENDS BIOCHEM SCI, V16, P53, DOI 10.1016/0968-0004(91)90024-P; DASILVA ACR, 1993, EUR J BIOCHEM, V213, P599; DECLERCQ JP, 1991, J MOL BIOL, V220, P1017, DOI 10.1016/0022-2836(91)90369-H; FALKE JJ, 1991, BIOCHEMISTRY-US, V30, P8690, DOI 10.1021/bi00099a029; GOODWIN EB, 1990, J MOL BIOL, V216, P85, DOI 10.1016/S0022-2836(05)80062-2; HAPAK RC, 1989, J BIOL CHEM, V264, P18751; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; KUMAR VD, 1990, BIOCHEMISTRY-US, V29, P1404, DOI 10.1021/bi00458a010; KWON H, 1990, P NATL ACAD SCI USA, V87, P4771, DOI 10.1073/pnas.87.12.4771; MARSDEN BJ, 1990, BIOCHEM CELL BIOL, V68, P587, DOI 10.1139/o90-084; MESSER N, 1991, J MOL BIOL, V218, P825, DOI 10.1016/0022-2836(91)90270-G; MESSER NG, 1988, FEBS LETT, V234, P49, DOI 10.1016/0014-5793(88)81300-0; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; REINACH FC, 1986, NATURE, V322, P80, DOI 10.1038/322080a0; RENNER M, 1993, P NATL ACAD SCI USA, V90, P6493, DOI 10.1073/pnas.90.14.6493; ROWE T, 1992, EMBO J, V11, P4715, DOI 10.1002/j.1460-2075.1992.tb05576.x; SELLERS JR, 1980, J MOL BIOL, V144, P223, DOI 10.1016/0022-2836(80)90088-1; SNYDER EE, 1990, BIOCHEMISTRY-US, V29, P3937, DOI 10.1021/bi00468a021; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; SZENTGYO.AG, 1973, J MOL BIOL, V74, P179, DOI 10.1016/0022-2836(73)90106-X; VIJAYKUMAR S, 1992, J MOL BIOL, V224, P413, DOI 10.1016/0022-2836(92)91004-9; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0	31	47	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6773	6778		10.1074/jbc.270.12.6773	http://dx.doi.org/10.1074/jbc.270.12.6773			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896823	hybrid			2022-12-25	WOS:A1995QQ85500054
J	INOUE, K; TAKEUCHI, Y; MIKI, D; ODO, S				INOUE, K; TAKEUCHI, Y; MIKI, D; ODO, S			MUSSEL ADHESIVE PLAQUE PROTEIN GENE IS A NOVEL MEMBER OF EPIDERMAL GROWTH FACTOR-LIKE GENE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF; SEQUENCE; ENCODES; DOMAINS; EXPRESSION; HOMOLOG; EMBRYO; NOTCH	A mussel (Mytilus galloprovincialis) cDNA encoding Mgfp2, a major component of the adhesive plaque that anchors mussels tightly to underwater surfaces was isolated, It encoded a protein mainly consisted of epidermal growth factor-like repeats, containing tyrosine residues that will be converted to 3,4-dihydroxyphenylalanine near C and N termini, Amino acid residues important for cell cell interaction in other epidermal growth factor-like proteins were, however, not con served in the structure of Mgfp2, RNA blot analysis on adult tissues showed foot-specific expression of this gene, while the analysis on developing larvae showed that the expression starts with formation of the foot, These results suggest that the function of Mgfp2 has been specialized to form the adhesive plaque.			INOUE, K (corresponding author), MARINE BIOTECHNOL INST,KAMAISHI LABS,3-75-1 HEITA,KAMAISHI,IWATE 026,JAPAN.							BISGROVE BW, 1993, DEV BIOL, V157, P526, DOI 10.1006/dbio.1993.1155; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; FULOP C, 1993, J BIOL CHEM, V268, P17377; HOJRUP P, 1985, FEBS LETT, V184, P333, DOI 10.1016/0014-5793(85)80633-5; HONG JC, 1987, J BIOL CHEM, V262, P8367; HUGHES PE, 1993, J BIOL CHEM, V268, P17727; HURSH DA, 1987, SCIENCE, V237, P1487, DOI 10.1126/science.3498216; INOUE K, 1994, BIOL BULL, V186, P349, DOI 10.2307/1542281; KUNST E, 1987, EMBO J, V6, P761; Laursen R.A., 1992, Results and Problems in Cell Differentiation, V19, P55; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; RZEPECKI LM, 1992, BIOL BULL, V183, P123, DOI 10.2307/1542413; SUZUKI H, 1991, FEBS LETT, V283, P281, DOI 10.1016/0014-5793(91)80608-6; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Waite J.H., 1992, Results and Problems in Cell Differentiation, V19, P27; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	21	106	123	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6698	6701		10.1074/jbc.270.12.6698	http://dx.doi.org/10.1074/jbc.270.12.6698			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896812	hybrid			2022-12-25	WOS:A1995QQ85500043
J	FUCHS, A; DAGHER, MC; VIGNAIS, PV				FUCHS, A; DAGHER, MC; VIGNAIS, PV			MAPPING THE DOMAINS OF INTERACTION OF P40(PHOX) WITH BOTH P47(PHOX) AND P67(PHOX) OF THE NEUTROPHIL OXIDASE COMPLEX USING THE 2-HYBRID SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CELL-FREE SYSTEM; RESPIRATORY BURST OXIDASE; PROTEIN; COMPONENTS; RAS	The superoxide generating NADPH oxidase complex in phagocytic cells is constituted of a heterodimeric flavocytochrome b and cytosolic factors, p67(phox), p47(phox) and p40(phox) as well as a small G protein Rac (for review, see Refs. 1-3). A truncated form of the p40(phox) cDNA was isolated by a two hybrid screen of a B lymphocyte library using a full length clone of p47(phox) as target, This truncated form of p40(phox) consisting of the Src Homology 3 (SH3) domain to the 3' stop codon was also shown to interact with p67(phox) in the same system. A Library of smaller fragments of the truncated p40 cDNA was constructed and screened against either p47(phox) or p67(phox). Results show that the SH3 domain of p40(phox) is sufficient for interaction with p47(phox), whereas the C terminus of p40(phox) but not its SH3 domain is involved in the interaction with p67(phox).			FUCHS, A (corresponding author), CEN GRENOBLE, CEA,DEPT BIOL MOLEC & STRUCT,BIOCHIM LAB,CNRS, URA 1130, 17 RUE MARTYRS, F-38054 GRENOBLE 09, FRANCE.			DAGHER, Marie-Claire/0000-0001-6878-3169; Fuchs, Alexandra/0000-0001-5536-8716				ABO A, 1992, J BIOL CHEM, V267, P16767; BABIOR B, 1982, ADV ENZYMOL RELAT AR, V65, P49; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DEMENDEZ I, 1994, J BIOL CHEM, V269, P16326; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINAN P, 1994, J BIOL CHEM, V269, P13752; FUCHS A, 1994, EUR J BIOCHEM, V226, P587, DOI 10.1111/j.1432-1033.1994.tb20084.x; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; IYER SS, 1994, J BIOL CHEM, V269, P22405; JOUAN A, 1993, BIOCHEM BIOPH RES CO, V197, P1296, DOI 10.1006/bbrc.1993.2618; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; MALY FE, 1988, J IMMUNOL, V140, P2334; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; PARK JW, 1992, J BIOL CHEM, V267, P17327; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SOMEYA A, 1993, FEBS LETT, V330, P215, DOI 10.1016/0014-5793(93)80276-Z; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; THRASHER AJ, 1994, BBA-MOL BASIS DIS, V1227, P1, DOI 10.1016/0925-4439(94)90100-7; TSUNAWAKI S, 1994, BIOCHEM BIOPH RES CO, V199, P1378, DOI 10.1006/bbrc.1994.1383; UHLINGER DJ, 1993, J BIOL CHEM, V268, P8624; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557	27	103	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					5695	5697		10.1074/jbc.270.11.5695	http://dx.doi.org/10.1074/jbc.270.11.5695			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890694	hybrid			2022-12-25	WOS:A1995QM94500003
J	MARECHAL, E; MIEGE, C; BLOCK, MA; DOUCE, R; JOYARD, J				MARECHAL, E; MIEGE, C; BLOCK, MA; DOUCE, R; JOYARD, J			THE CATALYTIC SITE OF MONOGALACTOSYLDIACYLGLYCEROL SYNTHASE FROM SPINACH CHLOROPLAST ENVELOPE MEMBRANES - BIOCHEMICAL ANALYSIS OF THE STRUCTURE AND OF THE METAL CONTENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; DIACYLGLYCEROL GALACTOSYLTRANSFERASE ACTIVITY; UDP-GALACTOSE; PARTIAL-PURIFICATION; N-ACETYLGLUCOSAMINE; BINDING-SITE; ZINC; MOTIFS; 1,10-PHENANTHROLINE; PHOSPHOTRIESTERASE	We have analyzed the structure of the active site of monogalactosyldiacylglycerol (MGDG) synthase from spinach chloroplast envelope. Since purification of this membrane-embedded enzyme yielded such low amounts of protein that analyses of the amino acid sequence were so far impossible, we used indirect strategies. Analyses of the inhibition of MGDG synthase by UDP and of its inactivation by citraconic anhydride first indicated that the enzyme contained two functionally independent and topologically distinct binding sites for each substrate, Whereas MGDG synthase binds both the nucleotidic part of UDP-Gal and the acyl chains of 1,2-diacylglycerol, UDP is a competitive inhibitor relatively to UDP-Gal, while it does not compete with 1,2-diacylglycerol for binding on the enzyme, The UDP-Gal-binding site contains lysine residues, as demonstrated for UDP-Gal-binding sites from all galactosyltransferases studied so far, Radiolabeling of MGDG synthase by sulfur labeling reagent, a S-35-labeled lysine-blocking reagent, confirmed that MGDG synthase was a polypeptide with a low molecular mass (around 20 kDa), The 1,2-diacylglycerol-binding site contains reduced cysteines and at least one metal, The divalent cation(s) associated to apo-MGDG synthase was not unambiguously identified, but the results suggest that it could be zinc, Therefore, MGDG synthase presents some structural features in common with diacylglycerol-manipulating enzymes, such as protein kinase C and 1,2-diacylglycerol kinase, which are characterized by the presence of a ubiquitous Cys(6)His(2) domain involved in zinc coordination in their 1,2-diacylglycerol-binding domains.	CEN GRENOBLE,CEA,DEPT BIOL MOLEC & STRUCT,PHYSIOL CELLULAIRE VEGETALE LAB,CNRS,UA 576,F-38054 GRENOBLE 9,FRANCE; UNIV GRENOBLE 1,F-38041 GRENOBLE,FRANCE	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)								[Anonymous], METHODS CHLOROPLAST; AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BARKER R, 1972, J BIOL CHEM, V247, P7135; BENSON AA, 1964, ANN REV PLANT PHYSIO, V15, P1, DOI 10.1146/annurev.pp.15.060164.000245; Beyer T A, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P23; BISHOP WR, 1986, J BIOL CHEM, V261, P6993; BLOCK MA, 1983, J BIOL CHEM, V258, P3281; Chua N. H, 1980, METHOD ENZYMOL, V69, P434; CLELAND WW, 1964, BIOCHEMISTRY-US, V3, P480, DOI 10.1021/bi00892a002; COVES J, 1986, FEBS LETT, V208, P401, DOI 10.1016/0014-5793(86)81057-2; COVES J, 1988, P NATL ACAD SCI USA, V85, P4966, DOI 10.1073/pnas.85.14.4966; COVES J, 1987, PLANT MEMBRANES STRU, P103; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; DOERING TL, 1989, J BIOL CHEM, V264, P11168; Douce, 1987, BIOCH PLANTS, P215, DOI 10.1016/B978-0-12-675409-4.50015-0; DOUCE R, 1974, SCIENCE, V183, P852, DOI 10.1126/science.183.4127.852; Douce R., 1980, The biochemistry of plants. A comprehensive treatise. Volume 4. Lipids: structure and function., P321; DRUM DE, 1969, BIOCHEMISTRY-US, V8, P3792, DOI 10.1021/bi00837a045; DRUM DE, 1969, BIOCHEMISTRY-US, V8, P3783, DOI 10.1021/bi00837a044; DRUM DE, 1970, BIOCHEMISTRY-US, V21, P4078; DUMAS DP, 1989, J BIOL CHEM, V264, P19659; FERRARI RA, 1961, ARCH BIOCHEM BIOPHYS, V93, P185, DOI 10.1016/0003-9861(61)90248-X; FREEMAN HC, 1973, INORGANIC BIOCH, P121; FUJIKAWA K, 1993, BIOCHEM J, V294, P443, DOI 10.1042/bj2940443; GSCHWENDT M, 1991, TRENDS BIOCHEM SCI, V16, P167, DOI 10.1016/0968-0004(91)90064-3; HANNUN YA, 1991, J BIOL CHEM, V260, P10039; HEEMSKERK JWM, 1986, THESIS U NIJMEGEN NE; HUBBARD SR, 1991, SCIENCE, V254, P1776; KANOH H, 1981, ARCH BIOCHEM BIOPHYS, V209, P266, DOI 10.1016/0003-9861(81)90280-0; KITCHEN BJ, 1974, BIOCHEM J, V143, P587, DOI 10.1042/bj1430587; LITTLE C, 1975, BIOCHIM BIOPHYS ACTA, V391, P326, DOI 10.1016/0005-2744(75)90256-9; LOOMIS CR, 1985, J BIOL CHEM, V260, P4091; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARECHAL E, 1994, J BIOL CHEM, V269, P5788; MARECHAL E, 1994, FEBS LETT, V352, P307, DOI 10.1016/0014-5793(94)00978-3; MARECHAL E, 1991, CR ACAD SCI III-VIE, V313, P521; MURATA N, 1983, PLANT CELL PHYSIOL, V24, P133, DOI 10.1093/oxfordjournals.pcp.a076508; MURATA N, 1987, BIOCH PLANTS, V9, P315; NEUFELD EF, 1964, BIOCHEM BIOPH RES CO, V14, P503, DOI 10.1016/0006-291X(64)90259-1; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; OMBURO GA, 1992, J BIOL CHEM, V267, P13278; POWELL JT, 1976, J BIOL CHEM, V251, P3645; POWERS JC, 1986, RES MONOGRAPHS CELL, V12, P219; QUEST AFG, 1994, J BIOL CHEM, V269, P2961; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; SALIER JP, 1980, ANAL BIOCHEM, V109, P273, DOI 10.1016/0003-2697(80)90649-1; SCHAAP D, 1990, FEBS LETT, V275, P151, DOI 10.1016/0014-5793(90)81461-V; SCHMIDTSCHULTZ T, 1994, J NEUROCHEM, V62, P1578; SCRUTTON MC, 1973, INORGANIC BIOCH, P381; SEGEL IH, 1975, ENZYME KINETICS, P957; STEINBUCH M, 1976, METHOD ENZYMOL, V19, P760; TEUCHER T, 1991, PLANTA, V184, P319, DOI 10.1007/BF00195332; VALLEE BL, 1993, ACCOUNTS CHEM RES, V26, P543, DOI 10.1021/ar00034a005; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; VANBESOUW A, 1979, FEBS LETT, V102, P33; WANG ZX, 1992, BIOCHEM J, V281, P285, DOI 10.1042/bj2810285; WISSING JB, 1992, PLANT PHYSIOL, V98, P1148, DOI 10.1104/pp.98.3.1148; WU HB, 1993, BIOCHEM J, V296, P435, DOI 10.1042/bj2960435; YADAV S, 1990, J BIOL CHEM, V265, P14163; YADAV SP, 1991, J BIOL CHEM, V266, P698	60	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					5714	5722		10.1074/jbc.270.11.5714	http://dx.doi.org/10.1074/jbc.270.11.5714			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890698	hybrid			2022-12-25	WOS:A1995QM94500008
J	CAO, W; DOUGLAS, MG				CAO, W; DOUGLAS, MG			BIOGENESIS OF ISP6, A SMALL CARBOXYL-TERMINAL ANCHORED PROTEIN OF THE RECEPTOR COMPLEX OF THE MITOCHONDRIAL OUTER-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; IMPORT MACHINERY; ADP/ATP CARRIER; YEAST; TRANSLOCATION; SEQUENCES; MOM19	To study the biogenesis of ISP6, an outer membrane component of the mitochondrial protein translocation complex, two fusion proteins have been made by fusing ISP6 to either the carboxyl- or amino-terminal end of the mouse dihydrofolate reductase (DHFR), In vitro import experiments showed that when DHFR was placed at the carboxyl-terminal end of ISP6, the resulting fusion protein 6-DHFR inserted into mitochondrial membrane less efficiently than the other form of the fusion proteins. In vivo this fusion protein lost its ability to suppress the temperature-sensitive phenotype of an isp42 mutant, while the other fusion protein DHFR-6, which was found targeted correctly to mitochondria, suppressed the mutant as well as the wild-type ISP6. Further analysis showed that the binding and insertion of DHFR-6 to mitochondrial outer membrane was not affected by deletion of either of the two mitochondrial protein receptors or by the predigestion of mitochondrial surface proteins prior to import. Additional data indicated that ISP42, which closely associates with ISP6 in the translocation complex, does not likely play the role of a targeting partner for ISP6. In summary, these data suggest that ISP6 may target to mitochondria by sequences at its carboxyl terminus and that the import process of ISP6 is most likely distinct from that of most other mitochondrial precursors, which are recognized by protein receptors on mitochondrial surface.	UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine				Cao, Wei/0000-0002-8952-9159				CYR DM, 1991, J BIOL CHEM, V266, P21700; DAUN G, 1982, J BIOL CHEM, V257, P13028; DOBBERSTEIN B, 1994, NATURE, V367, P599, DOI 10.1038/367599a0; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; HASE T, 1984, EMBO J, V3, P3157, DOI 10.1002/j.1460-2075.1984.tb02274.x; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; HURT EC, 1984, EMBO J, V3, P3149, DOI 10.1002/j.1460-2075.1984.tb02272.x; JANIAK F, 1994, J BIOL CHEM, V269, P9842; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; LITHGOW T, 1994, J BIOL CHEM, V269, P15325; MITOMA JY, 1992, EMBO J, V11, P4197, DOI 10.1002/j.1460-2075.1992.tb05513.x; MOCZKO M, 1994, J BIOL CHEM, V269, P9045; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; SCHATZ G, 1993, PROTEIN SCI, V2, P141; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHNEIDER H, 1991, SCIENCE, V254, P1659, DOI 10.1126/science.1661031; SEGUI RB, 1993, EMBO J, V12, P2211; SIKORSKI RS, 1989, GENETICS, V122, P19; SMAGULA C, 1988, J BIOL CHEM, V263, P6783; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; Stuart R A, 1993, Trends Cell Biol, V3, P135, DOI 10.1016/0962-8924(93)90176-2	27	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5674	5679		10.1074/jbc.270.10.5674	http://dx.doi.org/10.1074/jbc.270.10.5674			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890690	Green Published, hybrid			2022-12-25	WOS:A1995QL58000109
J	SHAO, HN; PANDEY, A; OSHEA, KS; SELDIN, M; DIXIT, VM				SHAO, HN; PANDEY, A; OSHEA, KS; SELDIN, M; DIXIT, VM			CHARACTERIZATION OF B61, THE LIGAND FOR THE ECK RECEPTOR PROTEIN-TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSERVED LINKAGE GROUP; GENE	B61 was originally described as a novel secreted tumor necrosis factor-alpha-inducible gene product in endothelial cells (Holzman, L. B., Marks, R. M., and Dixit, V. M. (1990) Mol. Cell. Biol. 10, 5830-5838). It was recently discovered that soluble recombinant B61 could serve as a ligand for the Eck receptor protein-tyrosine kinase, a member of the Eph/Eck subfamily of receptor protein tyrosine kinases (Bartley, T. D., Hunt, R. W., Welcher, A. A., Boyle, W. J,, Parker, V. P., Lindberg, R. A, Lu, H. S., Colombero, A. M., Elliott, R. L., Guthrie, R. A., Holst, P. L., Shrine, J. D., Toso, R. J., Zhang, M., Fernandez, E., Trail, G., Yarnum, B., Yarden, Y., Hunter, T., and Fox, G. M. (1994) Nature 368, 558-560). We now show that B61 can also exist as a cell surface glycosylphosphatidylinositol-linked protein that is capable of activating the Eck receptor protein-tyrosine kinase, the first such report of a receptor protein-tyrosine kinase ligand that is glycosylphosphatidylinositol-linked. In addition, the expression patterns of B61 and Eck during mouse ontogeny were determined by in situ hybridization. Both were found to be highly expressed in the developing lung and gut, while Eck was preferentially expressed in the thymus. Finally, the gene for B61 was localized to a specific position on mouse chromosome 3 by interspecific backcross analysis.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT ANAT & CELL BIOL,ANN ARBOR,MI 48109; DUKE UNIV,MED CTR,DEPT MED & MICROBIOL,DURHAM,NC 27710	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Duke University			dixit, vishva m/A-4496-2012; Pandey, Akhilesh/B-4127-2009	dixit, vishva m/0000-0001-6983-0326; Pandey, Akhilesh/0000-0001-9943-6127	NHLBI NIH HHS [HL45351] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045351] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BISHOP D T, 1985, Genetic Epidemiology, V2, P349, DOI 10.1002/gepi.1370020404; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; Green EL, 1981, GENETICS PROBABILITY, P77; HENNER DJ, 1988, NUCLEIC ACIDS RES, V16, P10383, DOI 10.1093/nar/16.21.10383; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6314; MOSELEY WS, 1989, GENOMICS, V5, P899, DOI 10.1016/0888-7543(89)90132-8; OAKEY RJ, 1992, IMMUNOGENETICS, V35, P279, DOI 10.1007/BF00166834; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; PANDEY A, 1994, J BIOL CHEM, V269, P30154; Sambrook J, 1989, MOL CLONING LABORATO; SAUNDERS AM, 1990, GENOMICS, V8, P524; SELDIN MF, 1988, J EXP MED, V167, P688, DOI 10.1084/jem.167.2.688; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WATSON MA, 1990, DEVELOPMENT, V110, P173; WOLF FW, 1994, J BIOL CHEM, V269, P3633	17	57	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5636	5641		10.1074/jbc.270.10.5636	http://dx.doi.org/10.1074/jbc.270.10.5636			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890684	hybrid			2022-12-25	WOS:A1995QL58000103
J	GAWLER, DJ; ZHANG, LJ; REEDIJK, M; TUNG, PS; MORAN, MF				GAWLER, DJ; ZHANG, LJ; REEDIJK, M; TUNG, PS; MORAN, MF			CALB - A 43 AMINO-ACID CALCIUM-DEPENDENT MEMBRANE PHOSPHOLIPID-BINDING DOMAIN IN P120 RAS GTPASE-ACTIVATING PROTEIN	ONCOGENE			English	Article						RAS; SRC; CALCIUM; CALB; C2; RAS-GAP	GUANINE-NUCLEOTIDE EXCHANGE; GROWTH-FACTOR RECEPTORS; SIGNAL TRANSDUCTION; TYROSINE KINASE; MYRISTYLATION SIGNAL; SYNAPTOTAGMIN P65; REGULATORY DOMAIN; PLASMA-MEMBRANE; GENE-PRODUCT; EGF RECEPTOR	CaLB was originally observed as a conserved sequence motif in various calcium-responsive signalling proteins and also in p120 Ras GTPase activating protein (p120(GAP)) (Clark et al. Cell 65: 1043-1051, 1991). Here we show the 43 residue CaLB motif in p120(GAP) is a functional protein domain that when expressed as a fusion protein in vitro confers Ca2+-dependent interactions with cellular membranes and phosphatidylserine and phosphatidylinositol vesicles. p120(GAP), but not a mutant lacking the CaLB domain, associates with the particulate fraction of cells in response to elevated intracellular Ca2+ suggesting that p120(GAP) may be regulated in part by calcium signals. Addition of the p120(GAP) CaLB domain was able to restore transforming activity and particulate localization to an otherwise transformation-defective and cytosolic mutant v-Src tyrosine kinase. The CaLB domain appears to be a prevalent protein module that may affect the molecular interactions and subcellular localization of signalling proteins.	UNIV TORONTO, BANTING & BEST DEPT MED RES, TORONTO, ON M5G 1L6, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO, ON M5G 1L6, CANADA	University of Toronto; University of Toronto			Moran, Michael/GYD-3631-2022					ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROOKSWILSON AR, 1989, MOL CELL BIOL, V9, P2214, DOI 10.1128/MCB.9.5.2214; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COURTNEIDGE SA, 1980, P NATL ACAD SCI-BIOL, V77, P3783, DOI 10.1073/pnas.77.7.3783; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; Downward J, 1992, CURR OPIN GENET DEV, V2, P13, DOI 10.1016/S0959-437X(05)80315-6; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; FEIG LA, 1994, NATURE, V370, P508, DOI 10.1038/370508a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; JOHNSTONE SA, 1993, BIOCHEM J, V294, P801, DOI 10.1042/bj2940801; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LUO JH, 1993, J BIOL CHEM, V268, P3715; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MOCHLYROSEN D, 1992, BIOCHEMISTRY-US, V31, P8120, DOI 10.1021/bi00150a003; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NORI M, 1990, MOL CELL BIOL, V10, P4155, DOI 10.1128/MCB.10.8.4155; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PERIN MS, 1991, J BIOL CHEM, V266, P615; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STONE JC, 1991, METHOD ENZYMOL, V200, P673; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TSAI MH, 1991, MOL CELL BIOL, V11, P2785, DOI 10.1128/MCB.11.5.2785; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	68	42	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	1995	10	5					817	825						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898923				2022-12-25	WOS:A1995QL03800002
J	HIYAMA, K; ISHIOKA, S; SHIROTANI, Y; INAI, K; HIYAMA, E; MURAKAMI, I; ISOBE, T; INAMIZU, T; YAMAKIDO, M				HIYAMA, K; ISHIOKA, S; SHIROTANI, Y; INAI, K; HIYAMA, E; MURAKAMI, I; ISOBE, T; INAMIZU, T; YAMAKIDO, M			ALTERATIONS IN TELOMERIC REPEAT LENGTH IN LUNG-CANCER ARE ASSOCIATED WITH LOSS OF HETEROZYGOSITY IN P53 AND RB	ONCOGENE			English	Article						LUNG CANCER; TELOMERE; P53; RB; IMMORTALITY; 1P32	CELLULAR SENESCENCE; RETINOBLASTOMA GENE; HUMAN FIBROBLASTS; L-MYC; MUTATIONS; POLYMORPHISM; TUMOR; DNA; IMMORTALIZATION; ADENOCARCINOMA	In the two-stage model of controlling cellular senescence in cultured human fibro blasts, retinoblastoma (Rb) and p53 proteins may be key factors regulating the mortality stage 1 mechanism. In addition, the critical loss of telomeric DNA due to the end-replication problem may result in the mortality stage 2 mechanism, Cells which acquire telomerase activity can overcome the M2 mechanism by stabilizing telomere length and thus become immortal (telomere hypothesis). At present it is known whether cellular immortality is a prerequisite for all human cancers, To investigate this question and the applicability of the two-stage model to human cancers, we analysed the relationship between alterations of telomere length and other genetic changes in lung cancer. Among 60 primary lung cancer tissues, telomere length alterations were observed in 16 tumors (26.7%) including 14 with short and two with elongated telomeres. Ten of them revealed allelic loss of both p53 and Rb genes, and remaining six showed no abnormalities in both genes. We propose that inactivation of both p53 and Rb genes may promote cell divisions causing telomere shortening in lung cancer as in the two-stage model, while there may be another pathway to overcome both M1 and M2 mechanisms, especially for adenocarcinoma.	HIROSHIMA UNIV,SCH MED,DEPT PATHOL 2,HIROSHIMA 734,JAPAN; HIROSHIMA UNIV,SCH MED,DEPT GEN MED,HIROSHIMA 734,JAPAN	Hiroshima University; Hiroshima University	HIYAMA, K (corresponding author), HIROSHIMA UNIV,SCH MED,DEPT INTERNAL MED 2,HIROSHIMA 734,JAPAN.		Hiyama, Eiso/A-2013-2019	Hiyama, Eiso/0000-0001-9179-5037				ALLSHIRE RC, 1989, NUCLEIC ACIDS RES, V17, P4611, DOI 10.1093/nar/17.12.4611; BERGH JCS, 1990, AM REV RESPIR DIS, V142, pS20, DOI 10.1164/ajrccm/142.6_Pt_2.S20; BLACKBURN EH, 1994, CELL, V77, P621, DOI 10.1016/0092-8674(94)90046-9; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BOND JA, 1994, ONCOGENE, V9, P1885; BRANDT B, 1992, AM J HUM GENET, V51, P1450; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CHUMAKOV PM, 1991, NUCLEIC ACIDS RES, V19, P4804; CORNELIS RS, 1994, CANCER RES, V54, P4200; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DAY JP, 1993, ENVIRON MOL MUTAGEN, V22, P245, DOI 10.1002/em.2850220411; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1992, EXP GERONTOL, V27, P375, DOI 10.1016/0531-5565(92)90068-B; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HASTIE ND, 1989, TRENDS GENET, V5, P326, DOI 10.1016/0168-9525(89)90137-6; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Hermanek P, 1987, TNM CLASSIFICATION M, P69; HIYAMA E, 1992, JPN J CANCER RES, V83, P159, DOI 10.1111/j.1349-7006.1992.tb00081.x; HIYAMA K, 1993, CHEST, V104, P1606, DOI 10.1378/chest.104.5.1606; HIYOSHI H, 1992, JPN J CANCER RES, V83, P101, DOI 10.1111/j.1349-7006.1992.tb02358.x; HORIO Y, 1993, CANCER RES, V53, P1; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; KAWASHIMA K, 1992, INT J CANCER, V50, P557, DOI 10.1002/ijc.2910500411; KAYE FJ, 1990, AM REV RESPIR DIS, V142, pS44, DOI 10.1164/ajrccm/142.6_Pt_2.S44; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; MAKELA TP, 1992, HUM MOL GENET, V1, P217, DOI 10.1093/hmg/1.3.217-a; MCGEE TL, 1990, NUCLEIC ACIDS RES, V18, P207, DOI 10.1093/nar/18.1.207-a; MELTZER PS, 1993, NAT GENET, V4, P252, DOI 10.1038/ng0793-252; MINNA JD, 1993, CHEST, V103, pS449, DOI 10.1378/chest.103.4_Supplement.449S; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MITSUDOMI T, 1991, CANCER RES, V51, P4999; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; NAKAYAMA H, 1992, NUCLEIC ACIDS RES, V20, P4939, DOI 10.1093/nar/20.18.4939; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PROSSER J, 1991, NUCLEIC ACIDS RES, V19, P4799, DOI 10.1093/nar/19.17.4799-a; SACHSE R, 1994, ONCOGENE, V9, P39; SHAY JW, 1993, ONCOGENE, V8, P1407; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1993, BREAST CANCER RES TR, V25, P83, DOI 10.1007/BF00662404; SHIROTANI Y, 1994, LUNG CANCER-J IASLC, V11, P29, DOI 10.1016/0169-5002(94)90280-1; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; STAMPS AC, 1992, EUR J CANCER, V28A, P1495, DOI 10.1016/0959-8049(92)90552-D; TAKAHASHI N, 1990, MUTAT RES, V234, P61, DOI 10.1016/0165-1161(90)90032-J; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TOGUCHIDA J, 1993, GENOMICS, V17, P535, DOI 10.1006/geno.1993.1368; TSUCHIYA E, 1992, CANCER RES, V52, P2478; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WILKIE AOM, 1990, NATURE, V346, P868, DOI 10.1038/346868a0; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	56	80	83	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					937	944						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898935				2022-12-25	WOS:A1995QL03800015
J	CHANDA, S; MEHENDALE, HM				CHANDA, S; MEHENDALE, HM			ROLE OF NUTRITIONAL FATTY-ACID AND L-CARNITINE IN THE FINAL OUTCOME OF THIOACETAMIDE HEPATOTOXICITY	FASEB JOURNAL			English	Article						TISSUE REPAIR; PALMITIC ACID; PROLIFERATING CELL NUCLEAR ANTIGEN; CYTOCHROME P-450	CARBON-TETRACHLORIDE; LIVER-REGENERATION; RAT; HEPATECTOMY; TISSUES; GLUCOSE; PLASMA	Male Sprague-Dawley rats (n = 10/group) were fully protected from a lethal dose (600 mg/kg, i.p.) of thioacetamide by adding 8% (w/w) palmitic acid to the diet and L-carnitine (2 mg/ml) to drinking water for the previous 7 days. Supplements of palmitic acid or L-carnitine alone did not confer protection. Liver injury induced by thioacetamide peaked between 36 and 48 h in both control and supplemented rats. Liver damage regressed thereafter in supplemented rats but progressed in control rats. Immunohistochemical and histopathological observations confirmed biochemical indicators of liver damage. Thus, hepatic tissue repair after thioacetamide-induced tissue injury seems to be stimulated by supplements of fatty acids together with L-carnitine, a mitochondrial transfer agent. The extent to which nutritional supplements may aid in inducing the recovery of liver from injury caused by other hepatotoxic agents remains to be explored.	NE LOUISIANA UNIV, COLL PHARM & HLTH SCI, DIV PHARMACOL & TOXICOL, MONROE, LA USA	University of Louisiana System; University of Louisiana Monroe								ANNINOJS, 1966, AM J CLIN PATHOL, V46, P397; BERGMEYER HU, 1978, CLIN CHEM, V24, P58; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CALABRESE EJ, 1993, TOXICOL APPL PHARM, V121, P1, DOI 10.1006/taap.1993.1121; CHANG LO, 1965, CANCER RES, V25, P1817; CHAUVEAU J, 1956, EXP CELL RES, V11, P317, DOI 10.1016/0014-4827(56)90107-0; DEMACKER PNM, 1982, CLIN CHEM, V28, P1765; DIAZGIL JJ, 1987, BRIT J CANCER, V55, P599, DOI 10.1038/bjc.1987.122; FITZHUGH OG, 1948, SCIENCE, V108, P626, DOI 10.1126/science.108.2814.626; GREENWELL A, 1991, CANCER LETT, V59, P251, DOI 10.1016/0304-3835(91)90149-C; HOLECEK M, 1991, J HEPATOL, V13, P14, DOI 10.1016/0168-8278(91)90857-8; HUNTER AL, 1977, J PHARMACOL EXP THER, V200, P439; IRIE R, 1983, J LAB CLIN MED, V101, P692; JUNGERMANN K, 1989, PHYSIOL REV, V69, P708, DOI 10.1152/physrev.1989.69.3.708; KODAVANTI PRS, 1989, ARCH TOXICOL, V63, P367, DOI 10.1007/BF00303125; KODAVANTI PRS, 1989, TOXICOL PATHOL, V17, P494, DOI 10.1177/019262338901700304; LAKE BG, 1987, BIOCH TOXICOLOGY PRA, P184; LEDUC EH, 1949, AM J ANAT, V84, P397, DOI 10.1002/aja.1000840304; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAKANO C, 1989, EARLY HUM DEV, V19, P21, DOI 10.1016/0378-3782(89)90101-1; NAKATA R, 1985, BIOCHEM PHARMACOL, V34, P586, DOI 10.1016/0006-2952(85)90195-9; NAKATANI T, 1981, J LAB CLIN MED, V97, P887; OMURA T, 1964, J BIOL CHEM, V239, P2370; REBOUCHE CJ, 1992, FASEB J, V6, P3379, DOI 10.1096/fasebj.6.15.1464372; SECCHI GC, 1971, ENZYME, V12, P63, DOI 10.1159/000459515; SHORT J, 1973, BIOCHEM BIOPH RES CO, V50, P430, DOI 10.1016/0006-291X(73)90858-9; SIMEK J, 1966, PHYSIOL BOHEMOSLOV, V15, P362	27	36	37	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1994	8	13					1061	1068		10.1096/fasebj.8.13.7926372	http://dx.doi.org/10.1096/fasebj.8.13.7926372			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PN069	7926372				2022-12-25	WOS:A1994PN06900011
J	ESCARGUEILBLANC, I; SALVAYRE, R; NEGRESALVAYRE, A				ESCARGUEILBLANC, I; SALVAYRE, R; NEGRESALVAYRE, A			NECROSIS AND APOPTOSIS INDUCED BY OXIDIZED LOW-DENSITY LIPOPROTEINS OCCUR THROUGH 2 CALCIUM-DEPENDENT PATHWAYS IN LYMPHOBLASTOID-CELLS	FASEB JOURNAL			English	Article						ENDONUCLEASE; PROTEASE; CYTOSOLIC CALCIUM; LDL OXIDATION; ENDOGENOUS PROTEOLYSIS; LDL ISOLATION; NDA FRAGMENTATION	KILLS IMMATURE THYMOCYTES; ENDONUCLEASE ACTIVATION; ENDOTHELIAL-CELLS; LIPID PEROXIDES; TREATED LIPOPROTEINS; DNA FRAGMENTATION; CULTURED-CELLS; MODEL SYSTEM; LDL; CYTOTOXICITY	Oxidized low density lipoproteins (LDL) elicit in cultured lymphoblastoid cell lines a delayed and sustained calcium rise followed by a progressive rise of DNA fragmentation, endogenous proteolysis, and morphological features of necrosis and apoptosis. All these events were blocked by chelating the calcium of the culture medium by EGTA, thus suggesting that the two types of cell death induced by oxidized LDL (necrosis and apoptosis) were subsequent to the rise in calcium. The protease inhibitors leupeptin and antipain were able to block (at least in part) the endogenous proteolysis and the necrotic process, but exhibited no effect on apoptosis and DNA fragmentation. At the opposite, aurintricarboxylic acid and spermine (inhibitors of DNA degradation by endonucleases) inhibit DNA fragmentation and morphological apoptosis, but not endogenous proteolysis and necrosis. These data suggest that cell death induced by oxidized LDL occurs through two calcium-dependent processes triggering 1) on one hand, proteolysis and subsequently necrosis characterized by the loss of cell membrane integrity; and 2) on the other hand, internucleosomal DNA cleavage and subsequently morphological apoptosis. The RNA or protein synthesis inhibitors, actinomycin D and cycloheximide, were completely ineffective in preventing endogenous proteolysis, DNA fragmentation, necrosis, and apoptosis induced by oxidized LDL. The subclassification of the type of apoptosis elicited by oxidized LDL is discussed.	UNIV TOULOUSE 3,FAC MED,DEPT BIOCHEM,METAB DIS SECT,TOULOUSE,FRANCE	Universite de Toulouse; Universite Toulouse III - Paul Sabatier				Negre-Salvayre, Anne/0000-0003-2136-5706				ARENDS MJ, 1990, AM J PATHOL, V136, P593; ARSLAN P, 1985, J BIOL CHEM, V260, P2719; BATISTATOU A, 1991, J CELL BIOL, V115, P461, DOI 10.1083/jcb.115.2.461; BOOBIS AR, 1989, TRENDS PHARMACOL SCI, V10, P275, DOI 10.1016/0165-6147(89)90027-8; BRUNE B, 1991, EXP CELL RES, V195, P323, DOI 10.1016/0014-4827(91)90380-D; CATHCART MK, 1989, J IMMUNOL, V142, P1963; ESCARGUEIL I, 1992, FEBS LETT, V305, P155, DOI 10.1016/0014-5793(92)80885-K; ESTERBAUER H, 1990, CHEM RES TOXICOL, V3, P77, DOI 10.1021/tx00014a001; FARBER JL, 1990, CHEM RES TOXICOL, V3, P503, DOI 10.1021/tx00018a003; FREI B, 1988, P NATL ACAD SCI USA, V85, P9748, DOI 10.1073/pnas.85.24.9748; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLSTEIN P, 1991, IMMUNOL REV, V121, P29, DOI 10.1111/j.1600-065X.1991.tb00822.x; GREGORY CD, 1991, NATURE, V349, P621; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAVEL RI, 1955, J CLIN INVEST, V39, P1345; HENRIKSEN T, 1979, SCAND J CLIN LAB INV, V39, P361, DOI 10.3109/00365517909106120; HESSLER JR, 1979, ATHEROSCLEROSIS, V32, P213, DOI 10.1016/0021-9150(79)90166-7; JURGENS G, 1987, CHEM PHYS LIPIDS, V45, P315, DOI 10.1016/0009-3084(87)90070-3; KAPUSCINSKI J, 1977, ANAL BIOCHEM, V83, P252, DOI 10.1016/0003-2697(77)90533-4; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; MELLGREN RL, 1986, ARCH BIOCHEM BIOPHYS, V246, P233, DOI 10.1016/0003-9861(86)90468-6; MELLONI E, 1992, BIOCHIMIE, V74, P217, DOI 10.1016/0300-9084(92)90120-4; MIRABELLI F, 1989, ARCH BIOCHEM BIOPHYS, V270, P478, DOI 10.1016/0003-9861(89)90529-8; MURACHI T, 1989, BIOCHEM INT, V18, P263; NEGRESALVAYRE A, 1992, BIOCHIM BIOPHYS ACTA, V1123, P207, DOI 10.1016/0005-2760(92)90113-A; NEGRESALVAYRE A, 1990, BIOCHIM BIOPHYS ACTA, V1045, P224, DOI 10.1016/0005-2760(90)90124-G; NEGRESALVAYRE A, 1992, PHOTOCHEM PHOTOBIOL, V55, P197, DOI 10.1111/j.1751-1097.1992.tb04228.x; NEGRESALVAYRE A, 1992, BRIT J PHARMACOL, V107, P738, DOI 10.1111/j.1476-5381.1992.tb14516.x; NEGRESALVAYRE A, 1992, FEBS LETT, V299, P60, DOI 10.1016/0014-5793(92)80101-L; NICOTERA P, 1986, FEBS LETT, V209, P139, DOI 10.1016/0014-5793(86)81099-7; NICOTERA P, 1992, ANNU REV PHARMACOL, V32, P449, DOI 10.1146/annurev.pa.32.040192.002313; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; PONTREMOLI S, 1986, BIOCHEM BIOPH RES CO, V138, P1370, DOI 10.1016/S0006-291X(86)80434-X; ROSL F, 1992, NUCLEIC ACIDS RES, V20, P5243, DOI 10.1093/nar/20.19.5243; SALVAYRE R, 1981, BIOCHIM BIOPHYS ACTA, V659, P445, DOI 10.1016/0005-2744(81)90070-X; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4; Thomas A.P., 1991, CELLULAR CALCIUM PRA, P1; Wyllie A.H., 1981, CELL DEATH BIOL PATH, P9; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAGI K, 1987, CHEM PHYS LIPIDS, V45, P337, DOI 10.1016/0009-3084(87)90071-5	43	123	123	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1994	8	13					1075	1080		10.1096/fasebj.8.13.7926374	http://dx.doi.org/10.1096/fasebj.8.13.7926374			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PN069	7926374				2022-12-25	WOS:A1994PN06900013
J	HACKER, KJ; ALBERTS, BM				HACKER, KJ; ALBERTS, BM			THE RAPID DISSOCIATION OF THE T4 DNA-POLYMERASE HOLOENZYME WHEN STOPPED BY A DNA HAIRPIN HELIX - A MODEL FOR POLYMERASE RELEASE FOLLOWING THE TERMINATION OF EACH OKAZAKI FRAGMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COORDINATED LEADING-STRAND; BACTERIOPHAGE T4-GENE 32-PROTEIN; REPLICATION FORK; ESCHERICHIA-COLI; III HOLOENZYME; ACCESSORY PROTEINS; INVITRO REPLICATION; MELTING PROTEINS; TEMPLATE; GENE-32	We have examined the molecular mechanism that enables the T4 bacteriophage DNA polymerase holoenzyme to synthesize DNA processively on the leading strand of the replication fork for many minutes, while allowing an identical holoenzyme on the lagging strand to recycle from one Okazaki fragment to the next in less than 4 s. We use a perfect hairpin helix of 15 base pairs to mimic the encounter of the polymerase with the end of a previously synthesized Okazaki fragment. Polymerase dissociation is monitored during the stall at the hairpin helix by the addition of excess T4 gene 32 protein (SSB protein), which rapidly melts the helix and allows a stalled polymerase molecule to continue DNA synthesis. In the accompanying paper, we show that polymerase holoenzyme dissociation is slow (half-life of 2.5 min) when this enzyme is stalled by nucleotide omission (Hacker, K. J., and Alberts, B. M. (1994) J. Biol. Chem. 269, 24209-24220). In contrast, the holoenzyme dissociates with a half-life of 1 s after hitting the hairpin helix, a rate sufficient to allow efficient polymerase recycling on the lagging strand in vivo. We conclude that, upon completing each Okazaki fragment, the holoenzyme senses an encounter with duplex DNA and then switches to a state that rapidly dissociates.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NCI NIH HHS [5 T32 CA09270] Funding Source: Medline; NIGMS NIH HHS [GM24020] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024020, R01GM024020] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1982, COLD SPRING HARB SYM, V47, P655, DOI 10.1101/SQB.1983.047.01.077; ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; BURKE RL, 1980, J BIOL CHEM, V255, P1484; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; CHA TA, 1989, J BIOL CHEM, V264, P12220; CHARETTE MF, 1986, NUCLEIC ACIDS RES, V14, P3343, DOI 10.1093/nar/14.8.3343; EGLI M, 1992, P NATL ACAD SCI USA, V89, P534, DOI 10.1073/pnas.89.2.534; FAIRFIELD FR, 1983, J BIOMOL STRUCT DYN, V1, P715, DOI 10.1080/07391102.1983.10507477; GOGOL EP, 1992, J MOL BIOL, V224, P395, DOI 10.1016/0022-2836(92)91003-8; GREVE J, 1978, BIOCHEMISTRY-US, V17, P893, DOI 10.1021/bi00598a023; HACKER KJ, 1994, J BIOL CHEM, V269, P24209; HACKER KJ, 1994, THESIS U CALIFORNIA; HERENDEEN DR, 1992, SCIENCE, V256, P1298, DOI 10.1126/science.1598572; HUANG CC, 1981, J BIOL CHEM, V256, P4087; JARVIS TC, 1991, J BIOL CHEM, V266, P1830; JENSEN DE, 1976, J BIOL CHEM, V251, P7215; KELLY RC, 1976, J BIOL CHEM, V251, P7240; LONBERG N, 1981, J MOL BIOL, V145, P123, DOI 10.1016/0022-2836(81)90337-5; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MUNN MM, 1991, J BIOL CHEM, V266, P20034; NEWPORT JW, 1980, THESIS U OREGON EUGE; NEWPORT JW, 1980, MECHANISTIC STUDIES, V19, P485; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL M, 1992, MOL BIOL CELL, V3, P953, DOI 10.1091/mbc.3.9.953; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; PORSCHKE D, 1974, BIOPHYS CHEM, V2, P97, DOI 10.1016/0301-4622(74)80029-3; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELICK HE, 1987, DNA REPLICATION RECO, P183; SINHA NK, 1980, J BIOL CHEM, V255, P4290; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4064; WU CA, 1992, J BIOL CHEM, V267, P4074; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	39	83	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24221	24228						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929078				2022-12-25	WOS:A1994PQ34600059
J	RICHARDSON, TH; JOHNSON, EF				RICHARDSON, TH; JOHNSON, EF			ALTERATIONS OF THE REGIOSPECIFICITY OF PROGESTERONE METABOLISM BY THE MUTAGENESIS OF 2 KEY AMINO-ACID-RESIDUES IN RABBIT CYTOCHROME-P450-2C3V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; SEQUENCES; FORM; 3B	Ser/Thr difference at position 364 underlies a phenotypic difference between naturally occurring variants of microsomal cytochrome P450 2C3 in their capacity to catalyze the 6 beta-hydroxylation of progesterone, as well as in their sensitivity to the inhibitor 16 alpha-methyl-progesterone. Position 364 of P450 2C3 maps to a substrate contacting domain suggested by models for mammalian P450 enzymes based on the structure of P450 101. In this study, Thr 364 of P450 2C3v, a progesterone 6 beta- and 16 alpha-hydroxylase, was replaced by Gly, Asp, Asn, Val, Leu, or Ile. The latter three amino acids did not alter the resospecificity of P450 2C3v, whereas the Gly,Asp, and Asn substitutions each produced enzymes with properties that correspond closely to the Ser mutant that catalyzes 16 alpha-hydroxylation but not 6 beta-hydroxylation, The former are distinguished from the latter amino acids by their greater hydrophobicity and size. In contrast, the 16 alpha-hydroxylase activity could be greatly diminished by the introduction of an alanine replacement for Val-113. This mutation conferred progesterone 21- and 17 alpha-hydroxylase activity to P450 2C3v at the expense of 16 alpha-hydroxylase activity, leaving the 6 beta-hydroxylase activity largely unaffected. Compound mutants displayed the additive effects of the two mutations. These results are consistent with two distinct orientations for the binding of progesterone to P450 2C3v, resulting in 6 beta- and 16 alpha-hydroxylation, respectively. The binding of progesterone in these two orientations can be modulated relatively independently by modifications of the two key amino acid residues at 113 and 364.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, DIV BIOCHEM NX4, LA JOLLA, CA 92037 USA	Scripps Research Institute					NIGMS NIH HHS [GM31001] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031001] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; DIETER HH, 1982, J BIOL CHEM, V257, P9315; GOTOH O, 1992, J BIOL CHEM, V267, P83; HALPERT JR, 1993, J BIOL CHEM, V268, P4453; HASEMANN CA, 1994, J MOL BIOL, V236, P1169, DOI 10.1016/0022-2836(94)90019-1; HSU MH, 1993, J BIOL CHEM, V268, P6939; JOHNSON EF, 1982, BIOCHEM BIOPH RES CO, V109, P786, DOI 10.1016/0006-291X(82)92008-3; KRONBACH T, 1991, BIOCHEMISTRY-US, V30, P6097, DOI 10.1021/bi00239a003; KRONBACH T, 1991, J BIOL CHEM, V266, P6215; KUPFER D, 1960, J CHROMATOGR, V4, P500, DOI 10.1016/S0021-9673(01)98442-0; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; MCMANUS ME, 1984, CARCINOGENESIS, V5, P1717, DOI 10.1093/carcin/5.12.1717; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; RICHARDSON TH, 1993, ARCH BIOCHEM BIOPHYS, V300, P510, DOI 10.1006/abbi.1993.1069; SAMBROOK J, 1908, MOL CLONING LABORATO, pA2; SCHWAB GE, 1985, BIOCHEMISTRY-US, V24, P7222, DOI 10.1021/bi00346a030; WAXMAN DJ, 1991, METHOD ENZYMOL, V206, P462	19	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23937	23943						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929041				2022-12-25	WOS:A1994PQ34600016
J	GUY, HI; EVANS, DR				GUY, HI; EVANS, DR			CLONING AND EXPRESSION OF THE MAMMALIAN MULTIFUNCTIONAL PROTEIN CAD IN ESCHERICHIA-COLI - CHARACTERIZATION OF THE RECOMBINANT PROTEIN AND A DELETION MUTANT LACKING THE MAJOR INTERDOMAIN LINKER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATES PYRIMIDINE BIOSYNTHESIS; CARBAMYL-PHOSPHATE SYNTHETASE; SYRIAN-HAMSTER CELLS; ASPARTATE-TRANSCARBAMYLASE; DIHYDROOROTASE DOMAIN; NUCLEOTIDE-SEQUENCE; SUBUNIT STRUCTURE; URA2 GENE; ORGANIZATION; PURIFICATION	The multifunctional protein CAD catalyzes the first three steps in de novo pyrimidine biosynthesis in mammalian cells. Glutamine-dependent carbamyl-phosphate synthetase (CPSase), aspartate transcarbamylase, and dihydroorotase activities are carried by a 243-kDa polypeptide chain that is organized into discrete functional domains connected by interdomain linkers. One of the connecting chain segments, the DA linker bridging the dihydroorotase and aspartate transcarbamylase domains, is unusually long (109 residues) and conserved in length in all eukaryotic species. A plasmid (pCK-CAD10) that encodes the entire 243-kDa polypeptide was constructed and expressed in Escherichia coli. The recombinant protein was purified to homogeneity by ion exchange and gel filtration chromatography. The purified protein had kinetic parameters that were close to those obtained for native CAD. Moreover, the CPSase activity was allosterically regulated. Gel filtration showed that the recombinant protein had the same molecular mass as native CAD. Thus, this complex mammalian protein is expressed and folds correctly in bacterial cells and, despite its extreme protease sensitivity, can be isolated intact. A deletion mutant that lacked the DA linker was then constructed. The kinetic parameters of the mutant protein were, for the most part, unaltered showing that the DA linker is not essential for the proper folding or optimal functioning of the individual domains, However, a significant decrease in the thermal stability of the CPSase domain suggested that the linker helps to stabilize the complex. Moreover, the channeling of carbamyl phosphate, determined by measuring the extent to which the exogenously added intermediate could dilute the endogenous carbamyl phosphate pool, was appreciably reduced when the DA linker was removed. Thus, although the domains function autonomously, some of the linkers are important for interdomain interactions in CAD.	WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM, DETROIT, MI 48201 USA	Wayne State University					NIGMS NIH HHS [GM47399] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047399] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEIN K, 1991, J BIOL CHEM, V266, P3791; BERGH ST, 1993, P NATL ACAD SCI USA, V90, P9818, DOI 10.1073/pnas.90.21.9818; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARREY EA, 1986, BIOCHEM J, V236, P327, DOI 10.1042/bj2360327; CARREY EA, 1985, EMBO J, V4, P3735, DOI 10.1002/j.1460-2075.1985.tb04142.x; CARREY EA, 1988, EUR J BIOCHEM, V171, P583, DOI 10.1111/j.1432-1033.1988.tb13828.x; CHEN JJ, 1979, J BIOL CHEM, V254, P2697; CHRISTOPHERSON RI, 1980, J BIOL CHEM, V255, P1381; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; DAVIDSON JN, 1990, DNA CELL BIOL, V9, P667, DOI 10.1089/dna.1990.9.667; DAVIDSON JN, 1993, BIOESSAYS, V15, P157, DOI 10.1002/bies.950150303; DAVIDSON JN, 1981, J BIOL CHEM, V256, P5220; Davis R.H., 1967, ORG BIOSYNTHESIS, P303, DOI [10.1016/b978-0-12-395658-3.50032-0, DOI 10.1016/B978-0-12-395658-3.50032-0]; EASTERBY JS, 1989, BIOCHEM J, V264, P605, DOI 10.1042/bj2640605; FAURE M, 1989, EUR J BIOCHEM, V179, P345, DOI 10.1111/j.1432-1033.1989.tb14560.x; FREUND JN, 1987, J MOL BIOL, V193, P1, DOI 10.1016/0022-2836(87)90621-8; GRAYSON DR, 1985, J BIOL CHEM, V260, P5840; GRAYSON DR, 1983, J BIOL CHEM, V258, P4123; GUY HI, 1994, J BIOL CHEM, V269, P7702; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7; KELLY RE, 1986, J BIOL CHEM, V261, P6073; KIM HS, 1992, J BIOL CHEM, V267, P7177; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LACROUTE F, 1968, J BACTERIOL, V95, P824, DOI 10.1128/JB.95.3.824-832.1968; LACROUTE F, 1964, CR HEBD ACAD SCI, V259, P1357; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE L, 1985, P NATL ACAD SCI USA, V82, P6802, DOI 10.1073/pnas.82.20.6802; LERNER CG, 1986, J BIOL CHEM, V261, P1156; LEVINE RL, 1971, BIOCHEMISTRY-US, V10, P3694; LUE P F, 1970, Biochimica et Biophysica Acta, V220, P365, DOI 10.1016/0005-2744(70)90268-8; MALEY JA, 1988, BIOCHEM BIOPH RES CO, V154, P1047, DOI 10.1016/0006-291X(88)90246-X; MALLY MI, 1980, J BIOL CHEM, V255, P1372; MALLY MI, 1981, P NATL ACAD SCI-BIOL, V78, P6647, DOI 10.1073/pnas.78.11.6647; Maniatis T., 1982, MOL CLONING; MORI M, 1975, BIOCHEMISTRY-US, V14, P2622, DOI 10.1021/bi00683a010; MUSMANNO LA, 1991, GENE, V99, P211, DOI 10.1016/0378-1119(91)90129-Y; MUSMANNO LA, 1992, SOMAT CELL MOLEC GEN, V18, P309, DOI 10.1007/BF01235754; NAGY M, 1989, J BIOL CHEM, V264, P8366; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; OTSUKI T, 1982, J BIOCHEM-TOKYO, V92, P1431, DOI 10.1093/oxfordjournals.jbchem.a134067; PADGETT RA, 1982, MOL CELL BIOL, V2, P293, DOI 10.1128/MCB.2.3.293; PRESCOTT LM, 1969, ANAL BIOCHEM, V32, P408, DOI 10.1016/S0003-2697(69)80008-4; RUMSBY PC, 1984, BIOCHEM J, V217, P435, DOI 10.1042/bj2170435; SCULLY JL, 1991, PROTEINS, V9, P191, DOI 10.1002/prot.340090305; SHIGESADA K, 1985, MOL CELL BIOL, V5, P1735, DOI 10.1128/MCB.5.7.1735; SHOAF WT, 1973, BIOCHEMISTRY-US, V12, P4039, DOI 10.1021/bi00745a004; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; SIMMER JP, 1990, P NATL ACAD SCI USA, V87, P174, DOI 10.1073/pnas.87.1.174; SIMMER JP, 1989, P NATL ACAD SCI USA, V86, P4382, DOI 10.1073/pnas.86.12.4382; SIMMER JP, 1990, THESIS WAYNE STATE U; SOUCIET JL, 1989, GENE, V79, P59, DOI 10.1016/0378-1119(89)90092-9; STARK GR, 1977, TRENDS BIOCHEM SCI, V2, P64, DOI 10.1016/0968-0004(77)90133-5; TATIBANA M, 1972, J BIOCHEM, V72, P549, DOI 10.1093/oxfordjournals.jbchem.a129934; TATIBANA M, 1967, BIOCHEM BIOPH RES CO, V26, P221, DOI 10.1016/0006-291X(67)90238-0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILLIAMS NK, 1993, PROTEIN ENG, V6, P333, DOI 10.1093/protein/6.3.333; WILLIAMS NK, 1990, GENE, V94, P283, DOI 10.1016/0378-1119(90)90399-C; ZIMMERMANN BH, 1993, BIOCHEMISTRY-US, V32, P1519, DOI 10.1021/bi00057a016; ZOLLER MJ, 1987, METHOD ENZYMOL, V154, P329	60	30	30	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23808	23816						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	7916346				2022-12-25	WOS:A1994PQ34500064
J	ALCONADA, A; FLORES, AI; BLANCO, L; CUEZVA, JM				ALCONADA, A; FLORES, AI; BLANCO, L; CUEZVA, JM			ANTIBODIES AGAINST F1-ATPASE ALPHA-SUBUNIT RECOGNIZE MITOCHONDRIAL CHAPERONES - EVIDENCE FOR AN EVOLUTIONARY RELATIONSHIP BETWEEN CHAPERONIN AND ATPASE PROTEIN FAMILIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROSPORA VACUOLAR ATPASE; AMINO-ACID-SEQUENCE; HEAT-SHOCK PROTEIN; ION MOTIVE ATPASES; BETA-SUBUNIT; ESCHERICHIA-COLI; RAT-LIVER; NUCLEAR GENE; SULFOLOBUS-ACIDOCALDARIUS; NUCLEOTIDE-SEQUENCE	Antibodies raised against two synthetic peptides from rat liver F-1-ATPase alpha-subunit sequence recognized two main heat-shock proteins from Drosophila (p71 and p56) and rat liver (p74 and p54) cells. One of the antisera showed a 20-fold higher reactivity toward Escherichia coli GroEL chaperonin than toward the cu-subunit purified from Drosophila. Indirect immunofluorescence microscopy and subcellular fractionation experiments located both mammalian heat-shock proteins in the mitochondria. The recent findings of functional homology between chaperonins and alpha-subunits, together with the unsuspected immunological reactivity of two mitochondrial molecular chaperones toward antisera derived from two different sequence motifs of the alpha-subunit, strongly argue in favor of the existence of an evolutionary relationship between chaperonins and alpha-subunits. The complete sequence alignment of F-type ATPase alpha-subunits and chaperonins revealed the existence of eleven most conserved regions (similar to 30% of each protein sequence) with an overall amino acid identity of 20 +/- 2% and similarity of 39 +/- 4%. A search of protein data bases with three different consensus sequences derived from this alignment identified a significant proportion of proteins belonging only to these two protein families. Since the alpha-subunit protein family is evolutionary related to the other catalytic (A and beta) and regulatory (B) subunits of V- and F-type ATPases, the homology reported herein allowed us to analyze, in the chaperonin sequences, the conservation of critical residues involved in nucleotide binding. These data support the hypothesis that chaperonins and the major subunits of V- and F-type ATPases are evolutionary related.	UNIV AUTONOMA MADRID, CSIC, CTR BIOL MOLEC SEVERO OCHOA, DEPT MOLEC BIOL, E-28049 MADRID, SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Flores, Ana I/L-2104-2015; Cuezva, Jose M/F-8381-2011; Blanco, Luis/I-1848-2015; Cuezva, Jose M/AAR-5392-2020	Flores, Ana I/0000-0002-5019-0434; Cuezva Marcos, Jose Manuel/0000-0003-1118-248X				ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; ACKERMAN SH, 1990, J BIOL CHEM, V265, P9952; ALCONADA A, 1993, TRENDS BIOCHEM SCI, V18, P81, DOI 10.1016/0968-0004(93)90158-J; AMZEL LM, 1983, ANNU REV BIOCHEM, V52, P801, DOI 10.1146/annurev.bi.52.070183.004101; ASCHENBRENNER M, 1993, FEBS LETT, V323, P27, DOI 10.1016/0014-5793(93)81441-2; AVITAL S, 1991, J BIOL CHEM, V266, P7067; AVNI A, 1991, J BIOL CHEM, V266, P7317; BARON M, 1991, TRENDS BIOCHEM SCI, V16, P13, DOI 10.1016/0968-0004(91)90009-K; BLUNDELL TL, 1987, NATURE, V326, P347, DOI 10.1038/326347a0; BOUTRY M, 1985, EMBO J, V4, P2159, DOI 10.1002/j.1460-2075.1985.tb03910.x; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; BRAUN CJ, 1985, PLANT PHYSIOL, V79, P571, DOI 10.1104/pp.79.2.571; CHANDA PK, 1985, J BACTERIOL, V161, P446, DOI 10.1128/JB.161.1.446-449.1985; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CUEZVA JM, 1990, FEBS LETT, V270, P71, DOI 10.1016/0014-5793(90)81237-I; CUEZVA JM, 1986, FEBS LETT, V194, P219, DOI 10.1016/0014-5793(86)80088-6; DENDA K, 1988, J BIOL CHEM, V263, P6012; DENDA K, 1988, J BIOL CHEM, V263, P17251; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; GARBOCZI DN, 1990, J BIOL CHEM, V265, P14632; GARBOCZI DN, 1988, BIOCHEMISTRY-US, V27, P553, DOI 10.1021/bi00402a008; GAY NJ, 1981, NUCLEIC ACIDS RES, V9, P2187, DOI 10.1093/nar/9.9.2187; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; GUPTA RS, 1989, BIOCHEM BIOPH RES CO, V163, P780, DOI 10.1016/0006-291X(89)92290-0; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HIRST JD, 1991, PROTEIN ENG, V4, P615; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; IZQUIERDO JM, 1990, J BIOL CHEM, V265, P9090; JINDAL S, 1989, MOL CELL BIOL, V9, P2279, DOI 10.1128/MCB.9.5.2279; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LEE JH, 1990, J BIOL CHEM, V265, P4664; LUIS AM, 1990, J BIOL CHEM, V265, P7713; MAGGIO MB, 1988, J BIOL CHEM, V263, P4619; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MARTIN J, 1993, NATURE, V366, P279, DOI 10.1038/366279a0; MORADIAMELI M, 1989, J BIOL CHEM, V264, P1361; MUELLER DM, 1988, J BIOL CHEM, V263, P5634; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; NELSON N, 1992, Current Opinion in Cell Biology, V4, P654, DOI 10.1016/0955-0674(92)90086-R; OHTA S, 1988, J BIOL CHEM, V263, P11257; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PENEFSKY HS, 1991, ADV ENZYMOL RELAT AR, V64, P173; PIERCE DJ, 1992, BIOCHIM BIOPHYS ACTA, V1132, P265, DOI 10.1016/0167-4781(92)90160-2; PRASAD TK, 1990, MOL CELL BIOL, V10, P3979, DOI 10.1128/MCB.10.8.3979; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; ROST B, 1993, TRENDS BIOCHEM SCI, V18, P120, DOI 10.1016/0968-0004(93)90017-H; SANTAREN JF, 1993, EXP CELL RES, V206, P220, DOI 10.1006/excr.1993.1141; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SMITH HO, 1990, P NATL ACAD SCI USA, V87, P826, DOI 10.1073/pnas.87.2.826; Sneath PHA., 1973, NUMERICAL TAXONOMY, P230, DOI DOI 10.1111/J.1523-1739.2007.00775.X; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; TAKEDA M, 1986, J BIOL CHEM, V261, P5126; THOLE JER, 1987, INFECT IMMUN, V55, P1466, DOI 10.1128/IAI.55.6.1466-1475.1987; TOZAWA K, 1993, J BIOL CHEM, V268, P19044; VALCARCE C, 1988, J BIOL CHEM, V263, P7767; VENNER TJ, 1990, DNA CELL BIOL, V9, P545, DOI 10.1089/dna.1990.9.545; VIALE AM, 1985, J BIOL CHEM, V260, P4958; VOGEL PD, 1991, J BIOL CHEM, V266, P6101; WALKER JE, 1984, BIOCHEM J, V224, P799, DOI 10.1042/bj2240799; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726; YUAN HB, 1992, J BIOL CHEM, V267, P14697; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	71	18	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13670	13679						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	7909811				2022-12-25	WOS:A1994NK18400089
J	YANO, S; FUKUNAGA, K; USHIO, Y; MIYAMOTO, E				YANO, S; FUKUNAGA, K; USHIO, Y; MIYAMOTO, E			ACTIVATION OF CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE-II AND PHOSPHORYLATION OF INTERMEDIATE FILAMENT PROTEINS BY STIMULATION OF GLUTAMATE RECEPTORS IN CULTURED RAT CORTICAL ASTROCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRILLARY ACIDIC PROTEIN; AMP-DEPENDENT PHOSPHORYLATION; EXCITATORY AMINO-ACIDS; CALCIUM WAVES; HEAD DOMAIN; CALMODULIN; BRAIN; CELLS; VIMENTIN; LOCALIZATION	We investigated the activation of Ca2+/calmodulin-dependent protein kinase II (CaM kinase II) via stimulation of glutamate receptors and subsequent phosphorylation of vimentin and glial fibrillary acidic protein (GFAP) in cultured rat cortical astrocytes. The indirect immunofluorescence analysis with the anti-CaM kinase II antibody revealed that the enzyme was detected diffusely in the cytoplasm and more intensely in the nucleus. Glutamate elevated the Ca2+-independent activity of CaM kinase II through autophosphorylation, and this response was blocked by both DL-2-amino-3- phosphonopropionate and 6-cyano-7-nitroquinoxaline-2,3-dione, but not by D-2-amino-5-phosphonovalerate. In the experiments using P-32-labeled astrocytes, the phosphorylation of vimentin and GFAP as well as autophosphorylation of CaM kinase II were found to be stimulated after the exposure to glutamate. It was concluded by two dimensional phosphopeptide analysis that the increased phosphorylation of vimentin and GFAP observed in intact cells were due to the activation of CaM kinase II by glutamate. These results suggest that glutamate can activate CaM kinase II through stimulation of both the metabotropic and non-N-methyl-D-aspartate receptors, and that the concomitant phosphorylation of vimentin and GFAP may in turn regulate the functions of intermediate filament proteins in intact astrocytes.	KUMAMOTO UNIV,SCH MED,DEPT PHARMACOL,KUMAMOTO 860,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT NEUROSURG,KUMAMOTO 860,JAPAN	Kumamoto University; Kumamoto University								ANDO S, 1991, BIOCHEM BIOPH RES CO, V175, P955, DOI 10.1016/0006-291X(91)91658-Y; ARVIN B, 1989, BRIT J PHARMACOL, V98, P225, DOI 10.1111/j.1476-5381.1989.tb16886.x; BABCOCKATKINSON E, 1989, GLIA, V2, P112, DOI 10.1002/glia.440020207; BARRES BA, 1991, J NEUROSCI, V11, P3685; BENDER AS, 1992, J NEUROCHEM, V58, P1874, DOI 10.1111/j.1471-4159.1992.tb10064.x; BERSHADSKY AD, 1990, P NATL ACAD SCI USA, V87, P1884, DOI 10.1073/pnas.87.5.1884; BRADFORD MM, 1976, ANAL CHEM, V226, P203; BRONSTEIN J, 1988, J NEUROCHEM, V50, P45, DOI 10.1111/j.1471-4159.1988.tb13227.x; BROWNING ET, 1984, J NEUROCHEM, V42, P718, DOI 10.1111/j.1471-4159.1984.tb02742.x; CHAN PH, 1989, BRAIN RES, V487, P380, DOI 10.1016/0006-8993(89)90845-7; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896-6273(92)90271-E; ERONDU NE, 1985, J NEUROSCI, V5, P3270; FUKUNAGA K, 1988, J NEUROCHEM, V51, P1070, DOI 10.1111/j.1471-4159.1988.tb03070.x; FUKUNAGA K, 1982, J NEUROCHEM, V39, P1607, DOI 10.1111/j.1471-4159.1982.tb07994.x; FUKUNAGA K, 1986, BIOMED RES-TOKYO, V7, P405; FUKUNAGA K, 1992, J BIOL CHEM, V267, P22527; FUKUNAGA K, 1990, Molecular and Cellular Neuroscience, V1, P133; FUKUNAGA K, 1989, J BIOL CHEM, V264, P21830; GEISLER N, 1989, EUR J BIOCHEM, V183, P441, DOI 10.1111/j.1432-1033.1989.tb14947.x; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HARRISON BC, 1991, J NEUROCHEM, V56, P1723, DOI 10.1111/j.1471-4159.1991.tb02073.x; HARRISON BC, 1992, J NEUROCHEM, V58, P320, DOI 10.1111/j.1471-4159.1992.tb09313.x; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; HOUSE C, 1987, J BIOL CHEM, V262, P772; INAGAKI M, 1990, J BIOL CHEM, V265, P4722; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; JENSEN AM, 1991, J NEUROSCI, V11, P1674; JENSEN AM, 1990, J NEUROSCI, V10, P1165; KOYAMA Y, 1991, NEUROSCI LETT, V124, P235, DOI 10.1016/0304-3940(91)90102-Y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZBRIONES LG, 1990, EXP EYE RES, V51, P277, DOI 10.1016/0014-4835(90)90024-O; MACNICOL M, 1992, J BIOL CHEM, V267, P12197; MCCARTHY KD, 1985, J NEUROCHEM, V44, P723, DOI 10.1111/j.1471-4159.1985.tb12875.x; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; OHTA Y, 1990, P NATL ACAD SCI USA, V87, P5341, DOI 10.1073/pnas.87.14.5341; OHTA Y, 1988, J BIOL CHEM, V263, P11549; OUIMET CC, 1984, P NATL ACAD SCI-BIOL, V81, P5604, DOI 10.1073/pnas.81.17.5604; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; REYNOLDS IJ, 1987, P NATL ACAD SCI USA, V84, P7744, DOI 10.1073/pnas.84.21.7744; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SCHOEPP DD, 1989, J NEUROCHEM, V53, P1865, DOI 10.1111/j.1471-4159.1989.tb09254.x; SCHOLZ WK, 1988, J NEUROSCI, V8, P1039; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; TANAKA E, 1984, BIOMED RES-TOKYO, V5, P239, DOI 10.2220/biomedres.5.239; TOKUI T, 1990, BIOCHEM BIOPH RES CO, V169, P896, DOI 10.1016/0006-291X(90)91977-Z; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; USOWICZ MM, 1989, NATURE, V339, P380, DOI 10.1038/339380a0; WOOTEN MW, 1987, EUR J BIOCHEM, V164, P461, DOI 10.1111/j.1432-1033.1987.tb11079.x; YAMAKAWA T, 1992, BRAIN RES, V597, P220, DOI 10.1016/0006-8993(92)91477-V; YAMAKAWA T, 1992, BIOMED RES-TOKYO, V13, P173, DOI 10.2220/biomedres.13.173; YAMAMOTO H, 1985, J NEUROCHEM, V44, P759, DOI 10.1111/j.1471-4159.1985.tb12880.x	54	72	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5428	5439						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7906275				2022-12-25	WOS:A1994MX57100108
J	ASTERMARK, J; SOTTILE, J; MOSHER, DF; STENFLO, J				ASTERMARK, J; SOTTILE, J; MOSHER, DF; STENFLO, J			BACULOVIRUS-MEDIATED EXPRESSION OF THE EPIDERMAL GROWTH FACTOR-LIKE MODULES OF HUMAN FACTOR-IX FUSED TO THE FACTOR-XIIIA TRANSAMIDATION SITE IN FIBRONECTIN - EVIDENCE FOR A DIRECT INTERACTION BETWEEN THE NH(2)-TERMINAL EPIDERMAL GROWTH FACTOR-LIKE MODULE OF FACTOR-IXA-BETA AND FACTOR-X	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; BOVINE FACTOR-X; ENDOTHELIAL-CELL BINDING; FACTOR-LIKE DOMAINS; COLD-INSOLUBLE GLOBULIN; K-DEPENDENT PROTEIN; HYDROXYASPARTIC ACID; BLOOD-COAGULATION; CALCIUM-BINDING; HUMAN-PLASMA	Factor IX is a vitamin K-dependent procoagulant zymogen of a serine protease. In the presence of Ca2+ the active form of factor IX (factor IXabeta) forms a complex with factor VIIIa on suitable phospholipid surfaces such as aggregated platelets. This macromolecular complex rapidly activates factor X. We have previously provided data that suggest an interaction between the NH2-terminal epidermal growth factor (EGF)-like module of factor IXabeta and the substrate factor X. In an alternative approach to study this protein-protein interaction, we have expressed three recombinant baculovirus constructs encoding the EGF-like modules of human factor IX and a truncated form of fibronectin in a system based on the infection of insect cells (Spodoptera frugiperda 21). This strategy allows a simple one-step purification of the recombinant proteins on a gelatin-Sepharose column, followed by removal of the gelatin-binding part derived from fibronectin by proteolytic cleavage. The fusion proteins were isolated at yields of 20-50 mug/ml culture medium. The recombinant EGF-like modules contained 0.2-0.4 mol of erythro-beta-hydroxyaspartic acid/mol of protein, i.e. similar to the amount found in factor IX from human plasma, and appeared to be glycosylated at Ser-53. The NH2-terminal EGF-like module, which contained a transamidation acceptor site derived from ribronectin, was cross-linked by factor Xllla in solution to intact and Gla-domainless factor X. There was no evidence of cross-linking to activated factor X or to factor X fragments containing only the gamma-carboxyglutamic acid module and the two EGF-like modules. The cross-linking results suggest a specific interaction between the NH2-terminal EGF-like module of factor IXabeta and the heavy chain of unactivated factor X. This interaction, albeit weak as judged by competition experiments, may be important for the targeting of factor X to the factor IXabeta-factor VIIIa complex on biological membranes and for the subsequent dissociation of factor Xa from the complex after activation.	LUND UNIV,MALMO GEN HOSP,DEPT CLIN CHEM,S-21401 MALMO,SWEDEN; UNIV WISCONSIN,DEPT MED,MADISON,WI 53706; UNIV WISCONSIN,DEPT BIOMOLEC CHEM,MADISON,WI 53706	Lund University; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021644] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 21644] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APPELLA E, 1987, J BIOL CHEM, V262, P4437; ASTERMARK J, 1994, J BIOL CHEM, V269, P3682; ASTERMARK J, 1991, J BIOL CHEM, V266, P2430; ASTERMARK J, 1992, J BIOL CHEM, V267, P3249; ASTERMARK J, 1991, J BIOL CHEM, V266, P2438; BARON M, 1991, TRENDS BIOCHEM SCI, V16, P13, DOI 10.1016/0968-0004(91)90009-K; CHEN AB, 1975, FED PROC, V34, P259; CLARKE BJ, 1992, FEBS LETT, V298, P206, DOI 10.1016/0014-5793(92)80058-O; DERIAN CK, 1989, J BIOL CHEM, V264, P6615; DICKSON JA, 1991, J VIROL, V65, P4006, DOI 10.1128/JVI.65.8.4006-4016.1991; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; DRAKENBERG T, 1983, P NATL ACAD SCI-BIOL, V80, P1802, DOI 10.1073/pnas.80.7.1802; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; FERNLUND P, 1983, J BIOL CHEM, V258, P2509; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P4508, DOI 10.1021/bi00719a006; FUJIKAWA K, 1972, BIOCHEMISTRY-US, V11, P2285; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; FURIE MB, 1980, J BIOL CHEM, V255, P3134; GORMAN JJ, 1980, J BIOL CHEM, V255, P419; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HARBON S, 1968, EUR J BIOCHEM, V4, P265, DOI 10.1111/j.1432-1033.1968.tb00203.x; HARLOS K, 1987, NATURE, V330, P82, DOI 10.1038/330082a0; HARWOOD R, 1980, ENZYMOLOGY POST TRAN, P3; HASHIMOTO N, 1985, J BIOCHEM, V97, P1347, DOI 10.1093/oxfordjournals.jbchem.a135187; HERTZBERG MS, 1992, J BIOL CHEM, V267, P14759; JACKSON CM, 1972, BIOCHEMISTRY-US, V11, P4873, DOI 10.1021/bi00776a001; Jesty J, 1976, Methods Enzymol, V45, P95; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4901, DOI 10.1021/bi00667a023; KNOPS J, 1991, J BIOL CHEM, V266, P7285; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; LIN SW, 1990, J BIOL CHEM, V265, P144; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MCCORD DM, 1990, J BIOL CHEM, V265, P10250; MCDONAGH RP, 1981, FEBS LETT, V127, P174, DOI 10.1016/0014-5793(81)80198-6; MCMULLEN BA, 1983, BIOCHEMISTRY-US, V22, P2875, DOI 10.1021/bi00281a016; MONKOVIC DD, 1992, BIOCHEM BIOPH RES CO, V189, P233, DOI 10.1016/0006-291X(92)91549-6; MORITA T, 1988, J BIOCHEM, V104, P368, DOI 10.1093/oxfordjournals.jbchem.a122475; MORITA T, 1986, J BIOL CHEM, V261, P4015; MORITA T, 1980, VITAMIN K METABOLISM, P124; MOSESSON MW, 1975, BIOCHIM BIOPHYS ACTA, V386, P509, DOI 10.1016/0005-2795(75)90294-9; MOSESSON MW, 1970, J BIOL CHEM, V245, P5728; MOSHER DF, 1980, J BIOL CHEM, V255, P1181; MOSHER DF, 1979, J CLIN INVEST, V64, P781, DOI 10.1172/JCI109524; NISHIMURA H, 1989, J BIOL CHEM, V264, P20320; NISHIMURA H, 1992, J BIOL CHEM, V267, P17520; OWEN W G, 1973, Thrombosis Research, V3, P705, DOI 10.1016/0049-3848(73)90017-0; OWEN WG, 1974, J BIOL CHEM, V249, P594; PATEL RS, 1987, EMBO J, V6, P2565, DOI 10.1002/j.1460-2075.1987.tb02545.x; PATTHY L, 1987, FEBS LETT, V214, P1, DOI 10.1016/0014-5793(87)80002-9; PERSSON E, 1989, J BIOL CHEM, V264, P16897; PERSSON E, 1991, J BIOL CHEM, V266, P2444; PERSSON E, 1991, J BIOL CHEM, V266, P2453; RYAN J, 1989, J BIOL CHEM, V264, P20283; SOTTILE J, 1993, BIOCHEMISTRY-US, V32, P1641, DOI 10.1021/bi00057a031; STENFLO J, 1991, BLOOD, V78, P1637; STENFLO J, 1989, P NATL ACAD SCI USA, V86, P444, DOI 10.1073/pnas.86.2.444; STENFLO J, 1976, J BIOL CHEM, V251, P355; SUGO T, 1984, J BIOL CHEM, V259, P5705; SUGO T, 1985, J BIOL CHEM, V260, P453; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; ZUSHI M, 1989, J BIOL CHEM, V264, P10351	62	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3690	3697						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7906269				2022-12-25	WOS:A1994MV63100082
J	RAO, S; KRAUSS, NE; HEERDING, JM; SWINDELL, CS; RINGEL, I; ORR, GA; HORWITZ, SB				RAO, S; KRAUSS, NE; HEERDING, JM; SWINDELL, CS; RINGEL, I; ORR, GA; HORWITZ, SB			3'-(P-AZIDOBENZAMIDO)TAXOL PHOTOLABELS THE N-TERMINAL 31 AMINO-ACIDS OF BETA-TUBULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MICROTUBULE ASSEMBLY INVITRO; GUANOSINE 5'-TRIPHOSPHATE; TAXOL; PROTEINS; SEQUENCE; POLYMERIZATION; CLEAVAGE; ABSENCE; PEPTIDE; FAMILY	Taxol possesses an unusual chemical structure, a unique mechanism of action, and demonstrated activity in human malignancies. It is the only antitumor agent that has a binding site on the microtubule polymer. The interaction of Taxol with the microtubule polymer results in the formation of stable bundles of cellular microtubules that are resistant to depolymerization. Although it has become evident that the microtubule, specifically beta-tubulin, is the target for Taxol, no information is available on the binding site for the drug. In this report, we demonstrate that 3'-(p-azidobenzamido)taxol, an analogue with similar biological activities as Taxol, covalently binds to the N-terminal domain of beta-tubulin after irradiation of the microtubule-drug complex. Taxol competes with [H-3]3'-(p-azidobenzamido)taxol binding, suggesting that the photoaffinity analog and Taxol are binding at the same or overlapping sites. Formic acid cleavage of [H-3]3'-(p-azidobenzamido)taxol-photolabeled beta-tubulin and subsequent protein sequence and mass analyses have identified the N-terminal 31 amino acids as the major site for [H-3]3'-(p-azidobenzamido)taxol photoincorporation.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,BRONX,NY 10461; BRYN MAWR COLL,DEPT CHEM,BRYN MAWR,PA 19010; HEBREW UNIV JERUSALEM,DEPT PHARMACOL,IL-91120 JERUSALEM,ISRAEL	Yeshiva University; Albert Einstein College of Medicine; Bryn Mawr College; Hebrew University of Jerusalem					NCI NIH HHS [CA39821, CA41349, CA55139] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041349, R35CA039821, R01CA055139] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARLIER MF, 1983, BIOCHEMISTRY-US, V22, P4814, DOI 10.1021/bi00289a031; DEWALD DB, 1986, ANAL BIOCHEM, V154, P502, DOI 10.1016/0003-2697(86)90022-9; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P2747, DOI 10.1021/bi00062a003; GASKIN F, 1974, J MOL BIOL, V89, P737, DOI 10.1016/0022-2836(74)90048-5; GURD FRN, 1967, METHOD ENZYMOL, V11, P532; HALL JL, 1983, MOL CELL BIOL, V3, P854, DOI 10.1128/MCB.3.5.854; HESSE J, 1987, J BIOL CHEM, V262, P15472; HOLMES FA, 1991, J NATL CANCER I, V83, P1797, DOI 10.1093/jnci/83.24.1797-a; KAPP OH, 1978, ANAL BIOCHEM, V91, P230, DOI 10.1016/0003-2697(78)90835-7; KIMMEL BE, 1985, GENE, V35, P237, DOI 10.1016/0378-1119(85)90002-2; KIRCHNER K, 1985, EMBO J, V4, P2397, DOI 10.1002/j.1460-2075.1985.tb03945.x; KUMAR N, 1981, J BIOL CHEM, V256, P435; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MGS, 1984, NUCLEIC ACIDS RES, V12, P5823, DOI 10.1093/nar/12.14.5823; LEWIS SA, 1985, J MOL BIOL, V182, P11, DOI 10.1016/0022-2836(85)90023-3; LINSE K, 1988, J BIOL CHEM, V263, P15205; LITTLE M, 1987, BIOCHIM BIOPHYS ACTA, V912, P28, DOI 10.1016/0167-4838(87)90243-3; MAK AS, 1978, ANAL BIOCHEM, V84, P432, DOI 10.1016/0003-2697(78)90061-1; MCGUIRE WP, 1989, ANN INTERN MED, V111, P273, DOI 10.7326/0003-4819-111-4-273; PARNESS J, 1982, BIOCHEM BIOPH RES CO, V105, P1082, DOI 10.1016/0006-291X(82)91080-4; PARNESS J, 1981, J CELL BIOL, V91, P479, DOI 10.1083/jcb.91.2.479; RAO S, 1992, J NATL CANCER I, V84, P785, DOI 10.1093/jnci/84.10.785; SCHIFF PB, 1981, BIOCHEMISTRY-US, V20, P3247, DOI 10.1021/bi00514a041; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SHIFF PB, 1980, P NATL ACAD SCI USA, V77, P1561; SHIVANNA BD, 1993, J BIOL CHEM, V268, P127; SONDEREGGER P, 1982, ANAL BIOCHEM, V122, P298, DOI 10.1016/0003-2697(82)90285-8; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045	29	262	279	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3132	3134						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7906266				2022-12-25	WOS:A1994MV63100003
J	RASOLA, A; GALIETTA, LJV; GRUENERT, DC; ROMEO, G				RASOLA, A; GALIETTA, LJV; GRUENERT, DC; ROMEO, G			VOLUME-SENSITIVE CHLORIDE CURRENTS IN 4 EPITHELIAL-CELL LINES ARE NOT DIRECTLY CORRELATED TO THE EXPRESSION OF THE MDR-1 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL TRANSPORT PROTEINS; RESISTANCE P-GLYCOPROTEIN; MULTIDRUG-RESISTANCE; CYSTIC-FIBROSIS; CHANNEL; CLONING; COMPLEMENTARY; SELECTIVITY; DOXORUBICIN; VERAPAMIL	It has been shown recently that heterologous expression of human MDR-1 gene, which is responsible for multidrug resistance during cancer therapy, causes appearance of volume-sensitive Cl- currents, thus suggesting that the product of the MDR-1 gene (the P-glycoprotein) has a Cl- channel activity (Valverde, M. A., Diaz, M., Sepulveda, M. A., Gill, D. R., Hyde, S. C., and Higgins, C, F. (1992) Nature 355, 830-833). In the present work, we have tested four epithelial cell lines both for the expression of MDR-1 gene and for the presence of volume-sensitive Cl- currents. LoVo/H and LoVo/Dx cells derive from a human colon adenocarcinoma, the latter cell line being resistant to high concentrations of the antitumoral drug doxorubicin. 9HTEo- cells were obtained by transformation of human tracheal epithelium. The 9HTEo-/Dx cell line was established from these cells by selection in doxorubicin. As expected, higher levels of P-glycoprotein expression were detected in LoVo/Dx and 9HTEo-/Dx by means of reverse transcriptase polymerase chain reaction technique, indirect immunofluorescence, and Western immunoblot assays. In contrast with these data, the size of swelling-induced Cl- current was the same in the sensitive cell line and in its drug-resistant counterpart. Actually, the Cl- conductance of 9HTEo- and 9HTEo-/Dx was 4-fold higher than that of either LoVo/H or LoVo/Dx cells. This indicates that the amplitude of this conductance is not directly related to the expression of the MDR-1 gene.	UNIV CALIF SAN FRANCISCO, CARDIOVASC & CANC RES INST, DEPT LAB MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	RASOLA, A (corresponding author), IST GIANNINA GASLINI, GENET MOLEC LAB, I-16148 GENOA, ITALY.		Galietta, Luis JV/HCG-8692-2022	Rasola, Andrea/0000-0003-4522-3008; Galietta, Luis/0000-0001-8686-3461				ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BIEDLER JL, 1992, CANCER-AM CANCER SOC, V70, P1799, DOI 10.1002/1097-0142(19920915)70:4+<1799::AID-CNCR2820701623>3.0.CO;2-B; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORRIAS MV, 1992, ANTICANCER RES, V12, P1431; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GALIETTA LJV, 1991, BIOCHEM BIOPH RES CO, V179, P1155, DOI 10.1016/0006-291X(91)91692-6; GALIETTA LJV, 1991, ADV EXP MED BIOL, V290, P307; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GOTTESMAN MM, 1988, TRENDS PHARMACOL SCI, V9, P54, DOI 10.1016/0165-6147(88)90117-4; GRANDI M, 1986, BRIT J CANCER, V54, P515, DOI 10.1038/bjc.1986.206; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; GRUENERT DC, 1988, P NATL ACAD SCI USA, V85, P5951, DOI 10.1073/pnas.85.16.5951; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HERZOG CE, 1992, J NATL CANCER I, V84, P711, DOI 10.1093/jnci/84.9.711; HORNES E, 1990, GENET ANAL-BIOMOL E, V7, P145, DOI 10.1016/0735-0651(90)90028-E; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; MCEWAN GTA, 1992, FEBS LETT, V304, P233, DOI 10.1016/0014-5793(92)80626-R; MELLADO W, 1987, BIOCHEMISTRY-US, V26, P6900, DOI 10.1021/bi00396a005; NG WF, 1989, MOL CELL BIOL, V9, P1224, DOI 10.1128/MCB.9.3.1224; NOONAN KE, 1990, P NATL ACAD SCI USA, V87, P7160, DOI 10.1073/pnas.87.18.7160; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; RASOLA A, 1992, BIOCHIM BIOPHYS ACTA, V1139, P319, DOI 10.1016/0925-4439(92)90108-Y; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIVOLTINI L, 1990, INT J CANCER, V46, P727, DOI 10.1002/ijc.2910460429; SCHINKEL AH, 1991, CANCER RES, V51, P2628; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111	33	93	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1432	1436						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7904600				2022-12-25	WOS:A1994MR22000102
J	YOSHIMURA, T; ASHIUCHI, M; ESAKI, N; KOBATAKE, C; CHOI, SY; SODA, K				YOSHIMURA, T; ASHIUCHI, M; ESAKI, N; KOBATAKE, C; CHOI, SY; SODA, K			EXPRESSION OF GLR (MURI, DGA) GENE ENCODING GLUTAMATE RACEMASE IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID AMINOTRANSFERASE; ACTIVE-SITE; SEQUENCE	The murI (dga) gene of Escherichia coli is required for the biosynthesis of D-glutamate, an essential component of bacterial peptidoglycan (Doublet, P., van Heijetnoort, J., and Mengin-Lecreulx, D. (1992) J. Bacteriol. 174, 5772-5779; Dougherty, T. J., Thanassi, J. A., and Pucci, M. J. (1993) J. Bacteriol. 175, 111-116), but its gene product has not been identified. We found that the amino acid sequence of protein deduced from the nucleotide sequence of the open reading frame of murI gene (ORF1) shows a significant homology with that of glutamate racemase of Pediococcus pentosaceus. The amino acid sequence of glutamate racemase of Lactobacillus fermenti recently reported also shows a homology with the deduced amino acid sequence of ORFI (Gallo, K. A., and Knowles, J. R. (1993) Biochemistry 32, 3981-3990). The murI (dga) gene was ligated into a plasmid, pKK223-3, with a designed ribosome binding site and expressed in E. coli JM109 cells. Glutamate racemase was produced by the transformant cells, whereas the enzyme was not found in the host cells. Accordingly, we newly termed the gene glr, which is more relevant than murI and dga. We partially purified the enzyme to characterize it. The enzyme consists of two identical subunits with a molecular weight of about 31,000 in contrast to the P. pentosaceus enzyme, a monomer protein.	KYOTO UNIV,INST CHEM RES,UJI,KYOTO 611,JAPAN	Kyoto University								BROSIUS J, 1981, J MOL BIOL, V148, P107, DOI 10.1016/0022-2836(81)90508-8; Choi S Y, 1991, Protein Expr Purif, V2, P90, DOI 10.1016/1046-5928(91)90016-C; CHOI SY, 1993, J BIOCH, V112, P139; DIVEN WF, 1969, BIOCHIM BIOPHYS ACTA, V191, P702, DOI 10.1016/0005-2744(69)90364-7; DOUBLET P, 1992, J BACTERIOL, V174, P5772, DOI 10.1128/jb.174.18.5772-5779.1992; DOUGHERTY TJ, 1993, J BACTERIOL, V175, P111, DOI 10.1128/JB.175.1.111-116.1993; GALLO KA, 1993, BIOCHEMISTRY-US, V32, P3991, DOI 10.1021/bi00066a020; GALLO KA, 1993, BIOCHEMISTRY-US, V32, P3981, DOI 10.1021/bi00066a019; GLASER L, 1960, J BIOL CHEM, V235, P2095; HELLER K, 1985, J BACTERIOL, V161, P904, DOI 10.1128/JB.161.3.904-908.1985; HUG DH, 1957, ARCH BIOCHEM BIOPHYS, V72, P369, DOI 10.1016/0003-9861(57)90213-8; KMEADOW P, 1958, BIOCHIM BIOPHYS ACTA, V524, P60; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KURAMITSU HK, 1962, BIOCHIM BIOPHYS ACTA, V62, P114, DOI 10.1016/0006-3002(62)90496-1; MARFEY P, 1984, CARLSBERG RES COMMUN, V49, P591, DOI 10.1007/BF02908688; MENGINLECREULX DC, 1989, J BACTERIOL, V176, P6126; NAGATA Y, 1992, J CHROMATOGR-BIOMED, V575, P147, DOI 10.1016/0378-4347(92)80516-S; NAKAJIMA N, 1986, AGR BIOL CHEM TOKYO, V50, P2823, DOI 10.1080/00021369.1986.10867827; NARROD SA, 1952, ARCH BIOCHEM BIOPHYS, V35, P462, DOI 10.1016/S0003-9861(52)80026-8; RUDNICK G, 1975, BIOCHEMISTRY-US, V14, P4515, DOI 10.1021/bi00691a028; TANIZAWA K, 1989, J BIOL CHEM, V264, P2445; TANIZAWA K, 1989, J BIOL CHEM, V264, P2450; TANNER ME, 1993, BIOCHEMISTRY-US, V32, P3998, DOI 10.1021/bi00066a021; THORNE CB, 1955, J BACTERIOL, V70, P420, DOI 10.1128/JB.70.4.420-426.1955; THORNE CURTIS B., 1955, JOUR BACT, V69, P357; TOYAMA H, 1991, J BIOL CHEM, V266, P13634	26	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24242	24246						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	7901215				2022-12-25	WOS:A1993MF29400078
J	BUURMAN, ET; KIM, KT; EPSTEIN, W				BUURMAN, ET; KIM, KT; EPSTEIN, W			GENETIC-EVIDENCE FOR 2 SEQUENTIALLY OCCUPIED K+ BINDING-SITES IN THE KDP TRANSPORT ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; MEMBRANE H+-ATPASE; DRIVEN POTASSIUM-TRANSPORT; ESCHERICHIA-COLI; SARCOPLASMIC-RETICULUM; FUNCTIONAL CONSEQUENCES; MOLECULAR-CLONING; TRANSMEMBRANE DOMAIN; ALKALINE-PHOSPHATASE; COMPLEMENTARY-DNA	Substrate binding sites in Kdp, a P-type ATPase of Escherichia coli, were identified by the isolation and characterization of mutants with reduced affinity for K+, its cation substrate, Most of the mutants have an altered KdpA subunit, a hydrophobic subunit not found in other P-type ATPases. Topological analysis of KdpA and the locations of the residues changed in the mutants suggest that KdpA has 10 membrane-spanning segments and forms two separate and distinct sites where K+ is bound. One site is formed by three periplasmic loops of the protein and is inferred to be the site of initial binding, The other site is cytoplasmic. We believe K+ moves from the periplasmic site through the membrane to the cytoplasmic site where it becomes ''occluded,'' i.e. inexchangeable with K+ outside the membrane, Membrane-spanning parts of KdpA probably form the path for transmembrane movement of K+, The kinetics of cation transport in the mutants indicate that each of the two binding sites contributes to the observed K-m for cations as well as to the marked discrimination between K+ and Rb+ characteristic of wild type Kdp, Energy coupling in Kdp, mediated by the KdpB subunit, is performed by a different subunit from the one that mediates transport.	UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA	University of Chicago					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022323] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22323] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDISON R, 1986, J BIOL CHEM, V261, P4896; ALLARD JD, 1992, J BIOL CHEM, V267, P17809; ALTENDORF K, 1992, ANN NY ACAD SCI, V671, P228, DOI 10.1111/j.1749-6632.1992.tb43799.x; BAKKER EP, 1992, ALKALI CATION TRANSP, P205; BOSSEMEYER D, 1989, J BACTERIOL, V171, P2219, DOI 10.1128/jb.171.4.2219-2221.1989; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; BROER S, 1993, J BACTERIOL, V175, P3480, DOI 10.1128/jb.175.11.3480-3485.1993; CALAMIA J, 1992, J MOL BIOL, V224, P539, DOI 10.1016/0022-2836(92)90542-R; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1993, J BIOL CHEM, V268, P18359; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DASSA E, 1993, MOL MICROBIOL, V7, P29, DOI 10.1111/j.1365-2958.1993.tb01094.x; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; EISENMAN G, 1987, ANNU REV BIOPHYS BIO, V16, P205; EPSTEIN W, 1978, J BIOL CHEM, V253, P6666; EPSTEIN W, 1990, PHIL T R SOC LOND B, V316, P479; FROSHAUER S, 1988, J MOL BIOL, V200, P501, DOI 10.1016/0022-2836(88)90539-6; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GHISLAIN M, 1987, J BIOL CHEM, V262, P17549; GLYNN IM, 1970, J PHYSIOL-LONDON, V207, P393, DOI 10.1113/jphysiol.1970.sp009068; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GROISMAN EA, 1986, J BACTERIOL, V168, P357, DOI 10.1128/jb.168.1.357-364.1986; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; HARDWICKE PMD, 1981, BIOCHEM BIOPH RES CO, V102, P250, DOI 10.1016/0006-291X(81)91514-X; HESSE JE, 1984, P NATL ACAD SCI-BIOL, V81, P4746, DOI 10.1073/pnas.81.15.4746; HOFFMAN CS, 1985, P NATL ACAD SCI USA, V82, P5107, DOI 10.1073/pnas.82.15.5107; INESI G, 1992, ADV ENZYMOL RAMB, V65, P185; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; JENCKS WP, 1989, J BIOL CHEM, V264, P18855; KAWAKAMI K, 1985, NATURE, V316, P733, DOI 10.1038/316733a0; KEPES A, 1962, BACTERIA, V4, P179; KOLLMANN R, 1993, BIOCHIM BIOPHYS ACTA, V1143, P62, DOI 10.1016/0005-2728(93)90216-3; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAIMINS LA, 1978, P NATL ACAD SCI USA, V75, P3216, DOI 10.1073/pnas.75.7.3216; LAIMINS LA, 1981, P NATL ACAD SCI-BIOL, V78, P464, DOI 10.1073/pnas.78.1.464; LEE KS, 1992, J BACTERIOL, V174, P2501, DOI 10.1128/jb.174.8.2501-2510.1992; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; MACLENNAN DH, 1992, ACTA PHYSIOL SCAND, V146, P141; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MANOIL C, 1988, TRENDS GENET, V4, P23; MERCER RW, 1993, J CELL BIOL, V121, P579, DOI 10.1083/jcb.121.3.579; MIERENDORF RC, 1987, METHOD ENZYMOL, V152, P458; MIERENDORF RC, 1987, METHOD ENZYMOL, V152, P556; Miller J.H., 1972, EXPT MOL GENETICS; MILLER JH, 1985, J MOL BIOL, V182, P45, DOI 10.1016/0022-2836(85)90026-9; NAVARRE C, 1994, J BIOL CHEM, V269, P21269; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; POLAREK JW, 1988, METHOD ENZYMOL, V157, P655; RABON EC, 1993, J BIOL CHEM, V268, P8012; RHOADS DB, 1976, J GEN PHYSIOL, V67, P325, DOI 10.1085/jgp.67.3.325; ROSEN BP, 1992, ANN NY ACAD SCI, V671, P257, DOI 10.1111/j.1749-6632.1992.tb43801.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARBOROUGH GA, 1990, J BIOL CHEM, V265, P16145; SERRANO R, 1986, NATURE, V319, P698; SHAINSKAYA A, 1994, J BIOL CHEM, V269, P10780; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SIEBERS A, 1988, EUR J BIOCHEM, V178, P131, DOI 10.1111/j.1432-1033.1988.tb14438.x; SIEBERS A, 1992, J BIOL CHEM, V267, P12717; SIEBERS A, 1988, THESIS U OSNABRUCK; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; STROUD RM, 1974, J MOL BIOL, V83, P185, DOI 10.1016/0022-2836(74)90387-8; TONEY MD, 1993, SCIENCE, V261, P756, DOI 10.1126/science.8342040; VILSEN B, 1991, J BIOL CHEM, V266, P18839; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	68	85	87	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6678	6685		10.1074/jbc.270.12.6678	http://dx.doi.org/10.1074/jbc.270.12.6678			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896809	hybrid			2022-12-25	WOS:A1995QQ85500040
J	HONG, YS; MA, GT; IVES, DH				HONG, YS; MA, GT; IVES, DH			DIRECTED MUTAGENESIS OF DEOXYGUANOSINE SITE AT ARGININE-79 UP-REGULATES TURNOVER ON DEOXYADENOSINE KINASE SUBUNIT OF HETERODIMERIC ENZYME FROM LACTOBACILLUS-ACIDOPHILUS R26	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS THYMIDINE KINASE; DEOXYCYTIDINE KINASE; ADENYLATE KINASE; BINDING-SITE; SECONDARY STRUCTURE; PROTEINS; PREDICTIONS; SELECTION	Examination of conserved motifs on the cloned subunits of the deoxyguanosine kinase/deoxyadenosine kinase (dGK/dAK) of Lactobacillus acidophilus R-26 has begun with the Asp-Arg-Ser (DRS) motif. Replacement of Asp-78 of both subunits with Glu, Ala, or Asn reduced dGK and dAK activities to less than 0.2%, whereas replacement of Arg-79 with Lys, either on both subunits in tandem (R79K), or on the dGK subunit only (R79K:dGK), yielded active but kinetically modified enzymes. These were partially purified, and their kinetic and regulatory properties were analyzed, For dAK activity, the V-max of the R79K:dGK enzyme was increased 28-fold, with no change in the limiting K-m, for dAdo, but with a slightly reduced K-m for MgATP, The V/K efficiency ratio of dAK was also increased 29-fold, but that of dGK was decreased to 5-10% due to a 10-fold increase in K-m, for dGuo and a reduced V-max. Therefore, the R79K substitution seems to have a greater effect on dGuo binding than on that of dAdo, but dGK modification appears to produce a stimulatory conformational effect on the opposite subunit, resembling the known unidirectional activation of dAK by either dGuo or dGTP.	OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,OHIO STATE BIOCHEM PROGRAM,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University					NATIONAL CANCER INSTITUTE [R01CA047828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049635] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47828] Funding Source: Medline; NIGMS NIH HHS [GM49635] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALASUBRAMANIAM NK, 1990, J GEN VIROL, V71, P2979, DOI 10.1099/0022-1317-71-12-2979; BLACK ME, 1993, BIOCHEMISTRY-US, V32, P11618, DOI 10.1021/bi00094a019; BOHMAN C, 1988, BIOCHEMISTRY-US, V27, P4258, DOI 10.1021/bi00412a009; CHAKRAVARTY R, 1984, BIOCHEMISTRY-US, V23, P6235, DOI 10.1021/bi00320a053; CHOTTINER EG, 1991, P NATL ACAD SCI USA, V88, P1531, DOI 10.1073/pnas.88.4.1531; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CRETTON EM, 1992, BIOCHEM PHARMACOL, V44, P973, DOI 10.1016/0006-2952(92)90130-B; DARBY G, 1986, J GEN VIROL, V67, P753, DOI 10.1099/0022-1317-67-4-753; DATTA NS, 1989, BIOCHEMISTRY-US, V28, P114, DOI 10.1021/bi00427a017; Deibel M R Jr, 1978, Methods Enzymol, V51, P346, DOI 10.1016/S0076-6879(78)51046-X; DEIBEL MR, 1977, J BIOL CHEM, V252, P8240; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GAO WY, 1990, J BIOL CHEM, V265, P20172; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GENTRY GA, 1992, PHARMACOL THERAPEUT, V54, P319, DOI 10.1016/0163-7258(92)90006-L; IKEDA S, 1986, J BIOL CHEM, V261, P5836; IKEDA S, 1994, BIOCHEMISTRY-US, V33, P5328, DOI 10.1021/bi00183a041; IKEDA S, 1988, BIOCHEMISTRY-US, V27, P8648, DOI 10.1021/bi00423a021; IKEDA S, 1994, BIOCHEMISTRY-US, V33, P13373, DOI 10.1021/bi00249a025; Ives D H, 1978, Methods Enzymol, V51, P337; IVES DH, 1984, ANAL BIOCHEM, V136, P416, DOI 10.1016/0003-2697(84)90237-9; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MA GT, 1994, J BIOL CHEM, V270, P6595; MUNIR KM, 1994, PROTEIN ENG, V7, P83, DOI 10.1093/protein/7.1.83; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Segel I. H., 1975, ENZYME KINETICS, P273; SUZUTANI T, 1993, J GEN VIROL, V74, P1011, DOI 10.1099/0022-1317-74-6-1011; TSAI MD, 1991, BIOCHEMISTRY-US, V30, P6806, DOI 10.1021/bi00242a002	29	6	8	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6602	6606		10.1074/jbc.270.12.6602	http://dx.doi.org/10.1074/jbc.270.12.6602			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896799				2022-12-25	WOS:A1995QQ85500029
J	HSU, YS; TANG, FM; LIU, WL; CHUANG, JY; LAI, MY; LIN, YS				HSU, YS; TANG, FM; LIU, WL; CHUANG, JY; LAI, MY; LIN, YS			TRANSCRIPTIONAL REGULATION BY P53 - FUNCTIONAL INTERACTIONS AMONG MULTIPLE REGULATORY DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; DNA-BINDING; GENE-EXPRESSION; MUTANT P53; SYNERGISTIC ACTIVATION; RESPONSIVE ELEMENT; PROTEIN; SEQUENCE; SUPPRESSOR; IDENTIFICATION	The tumor suppressor p53 protein possesses activities typical of eukaryotic transcriptional activators; p53 binds to specific DNA sequences and stimulates transcription of the target genes. By a series of deletion and domain-swapping studies, we report here that (i) p53 has two auxiliary domains, which have little effect on the DNA binding activity of its core domain but are capable of modulating its transactivation activity in a target site dependent manner; (ii) p53 contains two cell-specific transcriptional inhibitory domains, I1 and I2, which are active in Saos-2 and HeLa cells but not in HepG2 and Hep3B cells; and (iii) I1 inhibits the activity of several structurally different activating regions. These results demonstrate that the apparent transcrip tional activity of p53 is determined by collaborations among its regulatory domains, its target sites, and the cellular environment.	ACAD SINICA,INST BIOMED SCI,TAIPEI 11529,TAIWAN; NATL TAIWAN UNIV,COLL MED,GRAD INST CLIN MED,TAIPEI 11529,TAIWAN; NATL TAIWAN UNIV,COLL MED,DEPT PATHOL,TAIPEI 11529,TAIWAN	Academia Sinica - Taiwan; National Taiwan University; National Taiwan University								AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IWABUCHI K, 1993, ONCOGENE, V8, P1693; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KIM KS, 1990, P NATL ACAD SCI USA, V87, P4524, DOI 10.1073/pnas.87.12.4524; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1989, NATURE, V340, P656, DOI 10.1038/340656a0; LIN YS, 1989, P NATL ACAD SCI USA, V86, P109, DOI 10.1073/pnas.86.1.109; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MAKOS M, 1993, CANCER RES, V53, P2719; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; PTASHNE M, 1992, GENETIC SWITCH GENE; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; VERRIJZER CP, 1990, GENE DEV, V4, P1964, DOI 10.1101/gad.4.11.1964; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	56	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6966	6974		10.1074/jbc.270.12.6966	http://dx.doi.org/10.1074/jbc.270.12.6966			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896847	hybrid			2022-12-25	WOS:A1995QQ85500078
J	KOJRO, E; FAHRENHOLZ, F				KOJRO, E; FAHRENHOLZ, F			LIGAND-INDUCED CLEAVAGE OF THE V-2 VASOPRESSIN RECEPTOR BY A PLASMA-MEMBRANE METALLOPROTEINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; BINDING-SITE; IDENTIFICATION; EXPRESSION; PROTEIN; HORMONE; SUBUNIT; KIDNEY; RAT	The proteolytic cleavage of a G protein-coupled peptide hormone receptor, the renal V-2 vasopressin receptor, by a plasma membrane proteinase was investigated. In the absence of protease inhibitors during incubation of bovine kidney membranes with a photoreactive vasopressin agonist, V-2 receptor truncation leads to a labeled receptor fragment with M(r) 30,000. The V-2 receptor-degrading enzyme could be completely inhibited by zinc ions yielding the native V-2 receptor glycoprotein with M(r) 58,000. Studies with inhibitors of metalloendopeptidases involved in peptide hormone metabolism and with peptide substrates spanning the V-2 receptor cleavage site classify the receptor protease as metalloendoproteinase with specificity for longer substrates. Comparison of the NH2-terminal protein sequence of the truncated M(r) 30,000 V-2 receptor with the sequence deduced from the cDNA of the cloned bovine V-2 receptor shows that cleavage occurs between Gln(92) and Val(93) of the second transmembrane helix close to an extracellular agonist binding site. V-2 receptor proteolysis was dependent on the presence of a hormonal ligand. It occurred rapidly after hormone binding and led to a loss of ligand binding properties of the truncated V-2 receptor. The data suggest that the endogenous V-2 receptor-degrading metalloendoproteinase regulates V-2 receptor function. The novel pathway may contribute to the termination of signal transmission.	MAX PLANCK INST BIOPHYS,D-60596 FRANKFURT,GERMANY	Max Planck Society								BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; BOEGE F, 1987, BIOCHEMISTRY-US, V26, P2418, DOI 10.1021/bi00383a004; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; CHASE LR, 1968, SCIENCE, V159, P545, DOI 10.1126/science.159.3814.545; CRAUSE P, 1982, MOL CELL ENDOCRINOL, V28, P529, DOI 10.1016/0303-7207(82)90144-7; DAUCH P, 1991, EUR J BIOCHEM, V202, P269, DOI 10.1111/j.1432-1033.1991.tb16372.x; DUMERMUTH E, 1991, J BIOL CHEM, V266, P21381; FAHRENHOLZ F, 1985, EUR J BIOCHEM, V152, P589, DOI 10.1111/j.1432-1033.1985.tb09236.x; FAHRENHOLZ F, 1988, J RECEPTOR RES, V8, P283, DOI 10.3109/10799898809048993; FAHRENHOLZ F, 1986, ENDOCRINOLOGY, V118, P1026, DOI 10.1210/endo-118-3-1026; FAHRENHOLZ F, 1984, EUR J PHARMACOL, V100, P47, DOI 10.1016/0014-2999(84)90314-5; GORBEA CM, 1993, J BIOL CHEM, V268, P21035; GORBULEV V, 1993, EUR J BIOCHEM, V215, P1, DOI 10.1111/j.1432-1033.1993.tb18000.x; HECHTER O, 1978, J BIOL CHEM, V253, P3219; KIMURA T, 1992, NATURE, V356, P526, DOI 10.1038/356526a0; KOJRO E, 1993, BIOCHEMISTRY-US, V32, P13537, DOI 10.1021/bi00212a020; KOZUKA M, 1991, J BIOL CHEM, V26, P16892; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN KS, 1991, BIOCHEMISTRY-US, V30, P2613, DOI 10.1021/bi00224a007; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; MAIRE J, 1988, MOL PHARMACOL, V33, P432; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; ORLOFF J, 1967, AM J MED, V42, P757, DOI 10.1016/0002-9343(67)90093-9; ORLOWSKI M, 1988, BIOCHEMISTRY-US, V27, P597, DOI 10.1021/bi00402a015; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; PRICE JS, 1991, BRIT J PHARMACOL, V104, P321, DOI 10.1111/j.1476-5381.1991.tb12429.x; SAITO Y, 1991, J BIOL CHEM, V266, P23433; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; WESCH D, 1984, ANAL BIOCHEM, V138, P141; WILLIAMS CH, 1993, BIOCHEM J, V294, P681, DOI 10.1042/bj2940681	32	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6476	6481		10.1074/jbc.270.12.6476	http://dx.doi.org/10.1074/jbc.270.12.6476			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896781	hybrid			2022-12-25	WOS:A1995QQ85500011
J	RAO, P; MUFSON, RA				RAO, P; MUFSON, RA			A MEMBRANE PROXIMAL DOMAIN OF THE HUMAN INTERLEUKIN-3 RECEPTOR BETA(C) SUBUNIT THAT SIGNALS DNA-SYNTHESIS IN NIH 3T3 CELLS SPECIFICALLY BINDS A COMPLEX OF SRC AND JANUS FAMILY TYROSINE KINASES AND PHOSPHATIDYLINOSITOL 3-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; GTPASE-ACTIVATING PROTEIN; FACTOR-I RECEPTOR; CYTOPLASMIC DOMAINS; GM-CSF; TRANSDUCTION; PHOSPHORYLATION; ASSOCIATION; IDENTIFICATION; JAK2	The high affinity human interleukin 3 receptor is a heterodimeric protein consisting of alpha and beta(c) subunit. The beta(c) subunit is responsible for receptor signal transduction. We have shown that a membrane proximal domain of the cytoplasmic tail of the human beta(c) subunit (amino acids 451-517) is minimally required for human IL-3 to signal DNA synthesis in quiescent transfected NIH 3T3 cells. Glutathione S-transferase (GST) fusion proteins of this 451-517 region and another region 451-562 that includes an acidic domain previously shown in other receptors to bind Src family kinases were constructed. Purified Lyn and Lck kinase, but not Fes, could phosphorylate tyrosines in both domains. Adsorption with lysates from the human IL-3-dependent hematopoietic cell line (TF-1) or 3T3 cells and in vitro phosphorylation showed that both these domains were intensely phosphorylated. Phosphoamino acid analysis, however, revealed that the majority of phosphorylation was on serine and threonine rather than tyrosine. Adsorption of these domains with 3T3 or TF-1 cell lysates, followed by immunoblotting, showed that cytoplasmic tyrosine kinases Lyn, Fes, and JAK-2 could also stably associate with both domains; however, Src family kinases are more strongly recognized by both regions than JAK-2 kinase. In addition, phosphatidylinositol 3-kinase from cell lysates was also found stably associated with these domains, but GTPase activating protein, Vav, Sos1, or Grb2 were not.	AMER RED CROSS,JEROME H HOLLAND LAB BIOMED SCI,DEPT IMMUNOL,ROCKVILLE,MD 20855	American Red Cross					NCI NIH HHS [CA 53609] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053609] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAI KI, 1990, ANN REV BIOCH, V56, P783; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; CLEAVELAND JL, 1989, MOL CELL BIOL, V9, P5685; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; COUGHLIN SR, 1989, SCIENCE, V243, P1191; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; EDER M, 1993, EMBO J, V12, P1647, DOI 10.1002/j.1460-2075.1993.tb05810.x; GESNER T, 1989, BLOOD, V74, P2652; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HAYASHIDA K, 1989, P NATL ACAD SCI USA, V87, P9655; KANAKURA Y, 1990, BLOOD, V76, P706; KAPELLER R, 1991, MOL ENDOCRINOL, V5, P769, DOI 10.1210/mend-5-6-769; KRIEGLER M, 1990, GENE TRANSFER EXPRES, P85; LINNEKIN D, 1994, BLOOD, V84, P94, DOI 10.1182/blood.V84.1.94.bloodjournal84194; LOPEZ AF, 1991, J BIOL CHEM, V266, P24741; METCALF D, 1986, BLOOD, V67, P257; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; MURATA Y, 1990, BIOCHEM BIOPH RES CO, V173, P1102, DOI 10.1016/S0006-291X(05)80899-X; OCONNOR R, 1991, BLOOD, V80, P1017; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; QUELLE FW, 1994, MOL CELL BIOL, P4335; RAO P, 1995, J IMMUNOL, V154, P1664; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATOH T, 1992, J BIOL CHEM, V267, P2537; SATOH T, 1992, P NATL ACAD SCI USA, V87, P5993; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; TORIGOE T, 1992, BLOOD, V80, P617; TOYO A, 1987, EXP CELL RES, V171, P16; WATANABE S, 1993, MOL CELL BIOL, V13, P1440, DOI 10.1128/MCB.13.3.1440; WEISS M, 1993, BLOOD, V82, P3298; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	41	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6886	6893		10.1074/jbc.270.12.6886	http://dx.doi.org/10.1074/jbc.270.12.6886			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896837	hybrid			2022-12-25	WOS:A1995QQ85500068
J	YERUSHALMI, H; LEBENDIKER, M; SCHULDINER, S				YERUSHALMI, H; LEBENDIKER, M; SCHULDINER, S			EMRE, AN ESCHERICHIA-COLI 12-KDA MULTIDRUG TRANSPORTER, EXCHANGES TOXIC CATIONS AND H+ AND IS SOLUBLE IN ORGANIC-SOLVENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETHIDIUM EFFLUX GENE; NA+/H+ ANTIPORTER; BACILLUS-SUBTILIS; RESISTANCE GENE; CLONING; PROTEINS; SEQUENCE; SYSTEM; CDNA; PURIFICATION	The smallest membrane protein shown to catalyze ion-coupled transport is documented in this report. A gene coding for a small 110-amino acid membrane protein (emrE or mvrC) has been previously identified and cloned and shown to render Escherichia coli cells resistant to methyl viologen and to ethidium. In this report, it is shown that the resistance is due to extrusion of the toxic compounds in a process that requires a proton electrochemical gradient rather than ATP. For this purpose, cells in which the unc gene was inactivated were used so that the interconversion between the proton gradient and ATP is not possible, and the effect of agents, which specifically affect either of them, was tested on transport of ethidium in the intact cell. In addition, EmrE has been overexpressed and metabolically labeled with [S-35]methionine. Strikingly, the protein can be quantitatively extracted with a mixture of organic solvents such as chloroform:methanol and is practically pure after this extraction. Moreover, after addition of E. coli lipids to the chloroform:methanol extract, EmrE has been reconstituted in proteoliposomes loaded with ammonium chloride. Upon dilution of the proteoliposomes in ammonium-free medium, a pH gradient was formed that drove transport of ethidium and methyl viologen into the proteoliposome. Both substrates compete with each other and exchange with previously transported solute. EmrE is a multidrug transporter of a novel type, and, because of its size and its solubility properties, it provides a unique model to study structure-function aspects of transport reactions in ion-coupled processes.	HEBREW UNIV JERUSALEM,ALEXANDER SILBERMAN INST LIFE SCI,DIV MICROBIAL & MOLEC ECOL,IL-91904 JERUSALEM,ISRAEL	Hebrew University of Jerusalem			Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237				AHMED M, 1993, J BIOL CHEM, V268, P11086; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FILLINGAME RH, 1992, J BIOENERG BIOMEMBR, V24, P485, DOI 10.1007/BF00762366; GITLER C, 1977, BIOCHEM BIOPH RES CO, V74, P178; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRINIUS L, 1992, PLASMID, V27, P119, DOI 10.1016/0147-619X(92)90012-Y; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HARELBRONSTEIN M, 1995, J BIOL CHEM, V270, P3816, DOI 10.1074/jbc.270.8.3816; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; LAMBERT B, 1984, BIOCHEMISTRY-US, V23, P166, DOI 10.1021/bi00296a027; LEWIS K, 1994, TRENDS BIOCHEM SCI, V19, P119, DOI 10.1016/0968-0004(94)90204-6; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; MIDGLEY M, 1987, MICROBIOL SCI, V4, P125; MORIMYO M, 1992, NUCLEIC ACIDS RES, V20, P3159, DOI 10.1093/nar/20.12.3159; NEYFAKH AA, 1991, P NATL ACAD SCI USA, V88, P4781, DOI 10.1073/pnas.88.11.4781; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; PAULSEN IT, 1993, GENE, V124, P1, DOI 10.1016/0378-1119(93)90755-R; PEARCE HL, 1989, P NATL ACAD SCI USA, V86, P5128, DOI 10.1073/pnas.86.13.5128; PINNER E, 1992, J BIOL CHEM, V267, P11064; PUREWAL AS, 1990, FEMS MICROBIOL LETT, V68, P73; PUREWAL AS, 1991, FEMS MICROBIOL LETT, V82, P229, DOI 10.1111/j.1574-6968.1991.tb04870.x; ROSEN BP, 1986, METHOD ENZYMOL, V125, P328; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHULDINER S, 1994, J NEUROCHEM, V62, P2067; SCHULDINER S, 1995, IN PRESS PHYSL REV; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; TAGLICHT D, 1993, J BIOL CHEM, V268, P5382; VIITANEN P, 1986, METHOD ENZYMOL, V125, P429; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	36	242	255	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6856	6863		10.1074/jbc.270.12.6856	http://dx.doi.org/10.1074/jbc.270.12.6856			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896833	hybrid			2022-12-25	WOS:A1995QQ85500064
J	BELKIN, AM; BURRIDGE, K				BELKIN, AM; BURRIDGE, K			ASSOCIATION OF ACICULIN WITH DYSTROPHIN AND UTROPHIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; GLYCOPROTEIN COMPLEX; TISSUE DISTRIBUTION; SUBCELLULAR-DISTRIBUTION; ACETYLCHOLINE-RECEPTORS; ELECTRIC TISSUE; TERMINAL DOMAIN; SMOOTH-MUSCLE; GENE-PRODUCT; PROTEIN	Aciculin is a recently identified 60-kDa cytoskeletal protein, highly homologous to the glycolytic enzyme phosphoglucomutase type 1, (Belkin, A. M., Klimanskaya, I. V., Lukashev, M. E., Lilley, K., Critchley, D., and Koteliansky, V.E. (1994) J. Cell Sci. 107, 159-173). Aciculin expression in skeletal muscle is developmentally regulated, and this protein is particularly enriched at cell-matrix adherens junctions of muscle cells (Belkin, A. M., and Burridge, K. (1994) J. Cell Sci. 107, 1993-2003). The purpose of our study was to identify cytoskeletal protein(s) interacting with aciculin in various cell types. Using immunoprecipitation from cell lysates of metabolically labeled differentiating C2C12 muscle cells with anti-aciculin-specific antibodies, we detected a high molecular weight band (M(r) similar to 400,000), consistently coprecipitating with aciculin. We showed that this 400 kDa band comigrated with dystrophin and immunoblotted with anti-dystrophin antibodies. The association between aciculin and dystrophin in C2C12 cells was shown to resist Triton X-100 extraction and the majority of the complex could be extracted only in the presence of ionic detergents. In the reverse immunoprecipitation experiments, aciculin was detected in the precipitates with different anti-dystrophin antibodies. Immunodepletion experiments with lysates of metabolically labeled C2C12 myotubes showed that aciculin is a major dystrophin-associated protein in cultured skeletal muscle cells. Double immunostaining of differentiating and mature C2C12 myotubes with antibodies against aciculin and dystrophin revealed precise colocalization of these two cytoskeletal proteins throughout the process of myodifferentiation in culture. In skeletal muscle tissue, both proteins are concentrated at the sarcolemma and at myotendinous junctions. In contrast, utrophin, an autosomal homologue of dystrophin, was not codistributed with aciculin in muscle cell cultures and in skeletal muscle tissues. Analytical gel filtration experiments with purified aciculin and dystrophin showed interaction of these proteins in vitro, indicating that their association in skeletal muscle is due to direct binding. Whereas dystrophin was shown to be a major aciculin-associated protein in skeletal muscle, immunoblotting of anti-aciculin immunoprecipitates with antibodies against utrophin showed that aciculin is associated with utrophin in cultured A7r5 smooth muscle cells and REF52 fibroblasts. Immunodepletion experiments performed with lysates of metabolically labeled A7r5 cells demonstrated that aciculin is a major utrophin-binding protein in this cell type. Taken together, our data show that aciculin is a novel dystrophin- and utrophin-binding protein. Association of aciculin with dystrophin (utrophin) in various cell types might provide an additional cytoskeletal-matrix transmembrane link at sites where actin filaments terminate at the plasma membrane.			BELKIN, AM (corresponding author), UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CHAPEL HILL,NC 27599, USA.				NIGMS NIH HHS [GM 29860] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029860] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; ARAHATA K, 1988, NATURE, V333, P861, DOI 10.1038/333861a0; BAR S, 1990, BIOCHEM J, V272, P557, DOI 10.1042/bj2720557; BELKIN AM, 1994, J CELL SCI, V107, P159; BELKIN AM, 1994, J CELL SCI, V107, P1993; BENNETT V, 1989, BIOCHIM BIOPHYS ACTA, V988, P107, DOI 10.1016/0304-4157(89)90006-3; BIES RD, 1992, NUCLEIC ACIDS RES, V20, P1725, DOI 10.1093/nar/20.7.1725; Blake Derek J., 1992, Human Molecular Genetics, V1, P103, DOI 10.1093/hmg/1.2.103; BUTLER MH, 1992, J BIOL CHEM, V267, P6213; BYERS TJ, 1991, J CELL BIOL, V115, P411, DOI 10.1083/jcb.115.2.411; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; CARR C, 1989, J CELL BIOL, V109, P1753, DOI 10.1083/jcb.109.4.1753; CARTAUD A, 1993, J BIOL CHEM, V268, P13019; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; DAVISON MD, 1988, CELL, V52, P159, DOI 10.1016/0092-8674(88)90503-X; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FABBRIZIO E, 1993, BIOCHEMISTRY-US, V32, P10457, DOI 10.1021/bi00090a023; FEENER CA, 1989, NATURE, V338, P509, DOI 10.1038/338509a0; HEMMINGS L, 1992, J CELL BIOL, V116, P1369, DOI 10.1083/jcb.116.6.1369; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1987, SCIENCE, V238, P347, DOI 10.1126/science.3659917; HUGNOT JP, 1992, P NATL ACAD SCI USA, V89, P7506, DOI 10.1073/pnas.89.16.7506; KARPATI G, 1993, J NEUROPATH EXP NEUR, V52, P119, DOI 10.1097/00005072-199303000-00004; KELLY T, 1987, J BIOL CHEM, V262, P17189; KHURANA TS, 1992, J CELL BIOL, V119, P357, DOI 10.1083/jcb.119.2.357; KHURANA TS, 1990, J BIOL CHEM, V265, P16717; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KRAMARCY NR, 1994, J BIOL CHEM, V269, P2870; KRAMARCY NR, 1990, FEBS LETT, V272, P171; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKONISHOK M, 1992, DEV BIOL, V152, P209, DOI 10.1016/0012-1606(92)90129-5; LEDERFEIN D, 1992, P NATL ACAD SCI USA, V89, P5346, DOI 10.1073/pnas.89.12.5346; LEMAIRE C, 1988, EMBO J, V7, P4157, DOI 10.1002/j.1460-2075.1988.tb03311.x; LEV AA, 1987, J BIOL CHEM, V262, P15817; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; LOVE DR, 1991, P NATL ACAD SCI USA, V88, P3243, DOI 10.1073/pnas.88.8.3243; MASUDA T, 1992, J CELL BIOL, V119, P543, DOI 10.1083/jcb.119.3.543; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; MATSUMURA K, 1993, FEBS LETT; MATSUMURA K, 1992, NATURE, V320, P276; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; NOURSADEGHI M, 1993, FEBS LETT, V320, P155, DOI 10.1016/0014-5793(93)80082-6; NUDEL U, 1989, NATURE, V337, P76, DOI 10.1038/337076a0; NUDEL U, 1988, NATURE, V331, P635, DOI 10.1038/331635a0; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; PHILLIPS WD, 1993, J CELL BIOL, V123, P729, DOI 10.1083/jcb.123.3.729; PORTER GA, 1992, J CELL BIOL, V117, P997, DOI 10.1083/jcb.117.5.997; RAPAPORT D, 1992, DIFFERENTIATION, V49, P187, DOI 10.1111/j.1432-0436.1992.tb00666.x; SEALOCK R, 1991, J CELL BIOL, V113, P1133, DOI 10.1083/jcb.113.5.1133; STRAUB V, 1992, J CELL BIOL, V119, P1183, DOI 10.1083/jcb.119.5.1183; SUZUKI A, 1992, FEBS LETT, V308, P154, DOI 10.1016/0014-5793(92)81265-N; TANAKA H, 1991, HISTOCHEMISTRY, V96, P1, DOI 10.1007/BF00266753; THIMAN N, 1992, FEBS LETT, V308, P154; THIMAN N, 1991, J CELL BIOL, V115, P1695; TIDBALL JG, 1991, AM J PATHOL, V138, P17; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGNER KR, 1993, NEURON, V10, P511, DOI 10.1016/0896-6273(93)90338-R; WATKINS SC, 1988, NATURE, V333, P863, DOI 10.1038/333863a0; WAY M, 1992, FEBS LETT, V301, P243, DOI 10.1016/0014-5793(92)80249-G; YANG B, 1994, J BIOL CHEM, V269, P6040; YEADON JE, 1991, J CELL BIOL, V115, P1069, DOI 10.1083/jcb.115.4.1069; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276; ZYBRYCKAGAARN EE, 1988, NATURE, V333, P466	69	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					6328	6337		10.1074/jbc.270.11.6328	http://dx.doi.org/10.1074/jbc.270.11.6328			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890770	hybrid, Green Published			2022-12-25	WOS:A1995QM94500092
J	EGAN, MG; SIRLIN, S; RUMBERGER, BG; GARROW, TA; SHANE, B; SIROTNAK, FM				EGAN, MG; SIRLIN, S; RUMBERGER, BG; GARROW, TA; SHANE, B; SIROTNAK, FM			RAPID DECLINE IN FOLYLPOLYGLUTAMATE SYNTHETASE-ACTIVITY AND GENE-EXPRESSION DURING MATURATION OF HL-60 CELLS - NATURE OF THE EFFECT, IMPACT ON FOLATE COMPOUND POLYGLUTAMATE POOLS, AND EVIDENCE FOR PROGRAMMED DOWN-REGULATION DURING MATURATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTO-TOXICITY; TUMOR-CELLS; METHOTREXATE; TRANSPORT; LEUKEMIA; MOUSE; DIFFERENTIATION; PURIFICATION; RESISTANCE; ANALOGS	These studies in HL-60 cells examined the regulation of folylpolyglutamate synthetase (FPGS) activity at the level of gene expression during terminal maturation. Following addition of 210 mM Me(2)SO to cultures of HL-60 cells at a concentration that induces maturation of 85-90% of the cells, FPGS activity, but not folylpolyglutamate hydrolase (FPGH) activity, was reduced 2-7-fold within 1-5 days. The initial decline in FPGS activity preceded any effect of Me(2)SO on rate of growth and the increase in appearance of nitro blue tetrazolium-positive cells, a marker of cellular maturation, and the decrease after 5 days of exposure to Me(2)SO was solely accounted for by a 7-fold decrease in value for V-max. The same time and concentration dependence for Me(2)SO was shown for the decline in FPGS activity, increase in nitro blue tetrazolium-positive cells, and decline in the level of a 2.1-kilobase FPGS mRNA during exposure to this inducer. This decline in FPGS mRNA was reversible when Me(2)SO was removed from the culture medium but only until that time when an appreciable number of cells were committed to terminal maturation. Following growth of HL-60 cells with [H-3]MTX, used as a model folate compound, a large reduction in its intracellular polyglutamate pools was shown during maturation which quantitatively reflected the decline in FPGS activity as well as folate transport inward (Sirotnak, F. M., Jacobson, D. M., and Yang, C-H. (1986) J. Biol. Chem. 261, 11150-11156). Other data showed that folate status or obviation of the folate requirement during growth of these cells strongly influenced the rapidity of the onset of maturation following exposure to inducer. Overall, these results show that FPGS activity in HL 60 cells is a marker for proliferative capacity and that the underlying basis for the decline in FPGS activity during maturation is altered cognate gene expression which is manifested as early reversible and late irreversible phases. They also suggest that the coordinate reduction observed in folate transport, FPGS activity, dihydrofolate reductase, and probably other folate related enzymes by limiting macromolecular biosynthesis may be early programmed events in the maturation process that influence the switch from proliferation to senescence in these cells.	MEM SLOAN KETTERING CANC CTR, PROGRAM MOLEC BIOL & THERAPEUT, NEW YORK, NY 10021 USA; CORNELL UNIV, GRAD SCH MED SCI, NEW YORK, NY 10021 USA; UNIV CALIF BERKELEY, DEPT NUTR SCI, BERKELEY, CA 94720 USA	Memorial Sloan Kettering Cancer Center; Cornell University; University of California System; University of California Berkeley					NATIONAL CANCER INSTITUTE [P30CA008748, R01CA022764, R35CA056517] Funding Source: NIH RePORTER; NCI NIH HHS [CA22764, CA08748, CA56517] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BARREDO J, 1992, MOL PHARMACOL, V42, P687; BARRUECO JR, 1992, J BIOL CHEM, V267, P15356; BLOCH A, 1993, LEUKEMIA, V7, P1219; CHELLO PL, 1982, BIOCHEM PHARMACOL, V31, P1527, DOI 10.1016/0006-2952(82)90376-8; CORIN RE, 1984, J BIOL CHEM, V259, P206; Egan M. G., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P275; FABRE I, 1984, CANCER RES, V44, P3190; FANUCCHI MP, 1987, CANCER RES, V47, P2334; GALLAGHER R, 1979, BLOOD, V54, P713; GARROW TA, 1992, P NATL ACAD SCI USA, V89, P9151, DOI 10.1073/pnas.89.19.9151; GOLDMAN ID, 1986, INT ENCY PHARM THERA, P283; GRINDEY GB, 1984, FOLATE ANTAGONISTS T, V1, P290; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; KISLIUK RL, 1981, MOL CELL BIOCHEM, V39, P331, DOI 10.1007/BF00232583; KISLIUK RL, 1984, FOLATE ANTAGONISTS T, V1, P2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCBURNEY MW, 1974, CELL, V2, P173, DOI 10.1016/0092-8674(74)90091-9; MCCLOSKEY DE, 1991, J BIOL CHEM, V266, P6181; MCGUIRE JJ, 1981, MOL CELL BIOCHEM, V38, P19, DOI 10.1007/BF00235686; MCGUIRE JJ, 1984, FOLATES PTERINS, V1, P135; MORAN RG, 1985, MOL PHARMACOL, V27, P156; MORAN RG, 1984, BIOCHEMISTRY-US, V23, P4580, DOI 10.1021/bi00315a011; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; POSER RG, 1981, CANCER RES, V41, P4441; PRIEST DG, 1991, J NATL CANCER I, V83, P1806, DOI 10.1093/jnci/83.24.1806; RHEE MS, 1993, CANCER RES, V53, P2227; RUMBERGER BG, 1990, CANCER COMMUN, V2, P305; RUMBERGER BG, 1990, CANCER RES, V50, P4639; SAMUELS LL, 1986, CANCER RES, V46, P2230; SAMUELS LL, 1985, CANCER RES, V45, P1488; SHANE B, 1989, VITAM HORM, V45, P263; SIROTNAK FM, 1988, BIOCHEM PHARMACOL, V37, P4239, DOI 10.1016/0006-2952(88)90122-0; SIROTNAK FM, 1985, CANCER RES, V45, P3992; SIROTNAK FM, 1986, J BIOL CHEM, V261, P1150; SIROTNAK FM, 1984, FOLATE ANTAGONISTS T, V2, P43; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; YANG CH, 1992, J BIOL CHEM, V267, P6628	38	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5462	5468		10.1074/jbc.270.10.5462	http://dx.doi.org/10.1074/jbc.270.10.5462			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890662	hybrid			2022-12-25	WOS:A1995QL58000078
J	VARNUM, JM; THAKUR, ML; SCHALLY, AV; JANSEN, S; MAYO, KH				VARNUM, JM; THAKUR, ML; SCHALLY, AV; JANSEN, S; MAYO, KH			RHENIUM-LABELED SOMATOSTATIN ANALOG RC-160 - H-1-NMR AND COMPUTER MODELING CONFORMATIONAL-ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; SPECTROSCOPY; SECRETION; PROTEINS; HORMONE; H-1-NMR; TUMORS; CANCER	The solution conformations of RC-160, cyclic D-Phe(1)-Cys(2)-Tyr(3)-D-Trp(4)-Lys(5)-Val(6)-Cys(7)-Trp(8)-NH2, an analog of the tumor antiproliferatory neuropeptide somatostatin, and RC-160 labeled with rhenium (Re-RC-160), have been determined by using two-dimensional H-1 NMR spectroscopy (600 MHz) and restrained molecular dynamics simulations. Re-RC-160 yields the same average solution conformation as does the apo form with an antiparallel P-sheet fold and a type II' beta-turn centered at D-Trp(4)-Lys(5). These results indicate that the spatial topography of the side chains essential for somatostatin receptor binding is maintained in Re-RC-160.	UNIV MINNESOTA,CTR BIOMED ENGN,DEPT BIOCHEM,MINNEAPOLIS,MN 55455; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,STRUCT BIOL GRP,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,DEPT RADIAT ONCOL,PHILADELPHIA,PA 19107; TULANE UNIV,VET ADM MED CTR,SCH MED,INST ENDOCRINE POLYPEPTIDE & CANC,NEW ORLEANS,LA 70146; TEMPLE UNIV,DEPT CHEM,PHILADELPHIA,PA 19122	University of Minnesota System; University of Minnesota Twin Cities; Jefferson University; Jefferson University; Tulane University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University				Thakur, Mathew/0000-0003-2409-039X; Schally, Andrew/0000-0003-1273-6747				AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BRAZEAU P, 1973, SCIENCE, V179, P77, DOI 10.1126/science.179.4068.77; BYSTROV VF, 1973, TETRAHEDRON, V29, P873, DOI 10.1016/0040-4020(73)80031-6; CAI RZ, 1986, P NATL ACAD SCI USA, V83, P1896, DOI 10.1073/pnas.83.6.1896; COLES M, 1993, J MED CHEM, V36, P2658, DOI 10.1021/jm00070a009; CUNG MT, 1974, MACROMOLECULES, V7, P606, DOI 10.1021/ma60041a012; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; ELSEVIERS M, 1989, PEPTIDES CHEM STRUCT, P198; GIANNIS A, 1993, ANGEW CHEM INT EDIT, V32, P1244, DOI 10.1002/anie.199312441; HUANG ZW, 1992, J AM CHEM SOC, V114, P9390, DOI 10.1021/ja00050a019; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KVOLS LK, 1993, RADIOLOGY, V187, P129, DOI 10.1148/radiology.187.1.8383865; KVOLS LK, 1986, NEW ENGL J MED, V315, P702; LAMBERTS SWJ, 1990, BAILLIERE CLIN ENDOC, V4, P29, DOI 10.1016/S0950-351X(05)80314-3; LAMBERTS SWJ, 1988, ENDOCR REV, V9, P417, DOI 10.1210/edrv-9-4-417; LAMBERTS SWJ, 1987, EUR J CLIN INVEST, V17, P281, DOI 10.1111/j.1365-2362.1987.tb02188.x; NUTT RF, 1987, SOMATOSTATIN, P83; SCHALLY AV, 1988, CANCER RES, V48, P6977; SEYBOLD VS, 1982, PEPTIDES, V3, P49, DOI 10.1016/0196-9781(82)90141-3; SOUDAH HC, 1991, NEW ENGL J MED, V325, P1508; SRKALOVIC G, 1990, J CLIN ENDOCR METAB, V70, P661, DOI 10.1210/jcem-70-3-661; Stewart JM, 1984, SOLID PHASE PEPTIDE; THAKUR ML, 1992, J LABELLED COMPD, P365; VEBER DF, 1981, PEPTIDES SYNTHESIS S, P685; VEBER DF, 1992, PEPTIDES CHEM BIOL, P3; WIDER G, 1984, J MAGN RESON, V56, P207, DOI 10.1016/0022-2364(84)90099-4; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZAMORA PO, 1992, BIOCONJUGATE CHEM, V3, P493, DOI 10.1021/bc00018a005	29	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12583	12588						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	7909804				2022-12-25	WOS:A1994NH71600035
J	MORROW, CS; NAKAGAWA, M; GOLDSMITH, ME; MADDEN, MJ; COWAN, KH				MORROW, CS; NAKAGAWA, M; GOLDSMITH, ME; MADDEN, MJ; COWAN, KH			REVERSIBLE TRANSCRIPTIONAL ACTIVATION OF MDR1 BY SODIUM-BUTYRATE TREATMENT OF HUMAN COLON-CANCER CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE GENE; TUMOR VIRUS PROMOTER; S-TRANSFERASE-PI; HISTONE ACETYLATION; MAMMALIAN-CELLS; HEAT-SHOCK; DRUG-RESISTANCE; MESSENGER-RNA; RAT-LIVER; EXPRESSION	We investigated the mechanism of sodium butyrate (NaB)-mediated induction of mdr1 mRNA in parental (wild type) and multidrug-resistant (Ad1000) SW620 colon cancer cell lines. NaB treatment resulted in reversible, time-dependent increases in nuclear run-on transcription of endogenous mdr1 in these cell lines that paralleled the reversible increases of mdr1 mRNA in both timing and magnitude. In contrast, NaB treatment had no effect on mdr1 mRNA stability. Thus, the effects of NaB on mdr1 mRNA levels are fully attributable to altered mdr1 transcription. Furthermore, NaB induces the expression of transiently transfected chloramphenicol acetyltransferase reporter plasmids that are under the transcriptional control of the mdr1 promoter (mdrCAT vectors). Transfections using mdrCAT vectors modified by deletion and site-directed mutagenesis of the mdr1 promoter indicate that NaB-mediated induction of these vectors is at least partially dependent upon sequences present in the basal mdr1 promoter between -89 and +11 relative to the start site of transcription. The Y-box moth located between -82 and -73 contributes to NaB inducibility of mdrCAT vector expression in Ad1000 SW620 cells.	NCI,MED BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	MORROW, CS (corresponding author), WAKE FOREST UNIV,MED CTR,DEPT BIOCHEM,MED CTR BLVD,WINSTON SALEM,NC 27157, USA.				NCI NIH HHS [CA-12197] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA012197] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BATES SE, 1992, BIOCHEMISTRY-US, V31, P6366, DOI 10.1021/bi00143a002; BATES SE, 1989, MOL CELL BIOL, V9, P4337, DOI 10.1128/MCB.9.10.4337; BOHAN CA, 1989, VIROLOGY, V172, P573, DOI 10.1016/0042-6822(89)90200-6; BRESNICK EH, 1990, P NATL ACAD SCI USA, V87, P3977, DOI 10.1073/pnas.87.10.3977; BURT RK, 1988, CARCINOGENESIS, V9, P2329, DOI 10.1093/carcin/9.12.2329; BURT RK, 1988, J NATL CANCER I, V80, P1383, DOI 10.1093/jnci/80.17.1383; CHIN KV, 1990, J BIOL CHEM, V265, P221; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHIN KV, 1990, CELL GROWTH DIFFER, V1, P361; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; COOK JR, 1990, CELL BIOL INT REP, V14, P629; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; CORNWELL MM, 1993, J BIOL CHEM, V268, P19505; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FAIRCHILD CR, 1990, MOL PHARMACOL, V37, P801; FAIRCHILD CR, 1987, P NATL ACAD SCI USA, V84, P7701, DOI 10.1073/pnas.84.21.7701; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; FREGEAU CJ, 1992, NUCLEIC ACIDS RES, V20, P3113, DOI 10.1093/nar/20.12.3113; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1983, NUCLEIC ACIDS RES, V11, P7631, DOI 10.1093/nar/11.21.7631; GUILD BC, 1988, P NATL ACAD SCI USA, V85, P1595, DOI 10.1073/pnas.85.5.1595; HILL BT, 1990, J NATL CANCER I, V82, P607, DOI 10.1093/jnci/82.7.607; KIOKA N, 1992, FEBS LETT, V301, P37, DOI 10.1016/0014-5793(92)80205-U; KOHNO K, 1989, BIOCHEM BIOPH RES CO, V165, P1415, DOI 10.1016/0006-291X(89)92761-7; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; LAI GM, 1991, INT J CANCER, V49, P696, DOI 10.1002/ijc.2910490512; LIU JM, 1991, VIROLOGY, V182, P361, DOI 10.1016/0042-6822(91)90682-2; MADDEN MJ, 1993, J BIOL CHEM, V268, P8290; MICKLEY LA, 1989, J BIOL CHEM, V264, P18031; MIYAZAKI M, 1992, BIOCHEM BIOPH RES CO, V187, P677, DOI 10.1016/0006-291X(92)91248-O; MORROW CS, 1992, J BIOL CHEM, V267, P10544; NAKAGAWA M, 1992, CANCER RES, V52, P6175; OLIVA R, 1990, NUCLEIC ACIDS RES, V18, P2739, DOI 10.1093/nar/18.9.2739; PERRY CA, 1989, NUCLEIC ACIDS RES, V17, P4275, DOI 10.1093/nar/17.11.4275; REEVES R, 1985, NUCLEIC ACIDS RES, V13, P3599, DOI 10.1093/nar/13.10.3599; SAINI K, 1990, BIOCHEM J, V272, P541, DOI 10.1042/bj2720541; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; SHIBATA H, 1990, JPN J CANCER RES, V81, P1214, DOI 10.1111/j.1349-7006.1990.tb02681.x; SIMPSON RT, 1990, PROG NUCLEIC ACID RE, V64, P2907; TANG DC, 1990, J VIROL, V64, P2907, DOI 10.1128/JVI.64.6.2907-2911.1990; TANG SJ, 1990, BIOCHIM BIOPHYS ACTA, V1048, P59, DOI 10.1016/0167-4781(90)90022-T; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; THOMA F, 1992, BIOCHIM BIOPHYS ACTA, V1130, P1, DOI 10.1016/0167-4781(92)90455-9; THORGEIRSSON SS, 1987, SCIENCE, V236, P1120, DOI 10.1126/science.3576227; TURNER BM, 1991, J CELL SCI, V99, P13; VANGROENIGEN M, 1993, BIOCHIM BIOPHYS ACTA, V1172, P138, DOI 10.1016/0167-4781(93)90280-Q; WOLFFE AP, 1992, FASEB J, V6, P3354, DOI 10.1096/fasebj.6.15.1464369; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529	53	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10739	10746						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7908296				2022-12-25	WOS:A1994NF01700082
J	GANDRILLON, O; FERRAND, N; MICHAILLE, JJ; ROZE, L; ZILE, MH; SAMARUT, J				GANDRILLON, O; FERRAND, N; MICHAILLE, JJ; ROZE, L; ZILE, MH; SAMARUT, J			C-ERBA-ALPHA/T3R AND RARS CONTROL COMMITMENT OF HEMATOPOIETIC SELF-RENEWING PROGENITOR CELLS TO APOPTOSIS OR DIFFERENTIATION AND ARE ANTAGONIZED BY THE V-ERBA ONCOGENE	ONCOGENE			English	Article							AVIAN ERYTHROBLASTOSIS VIRUS; THYROID-HORMONE RECEPTOR; RETINOIC ACID RECEPTOR; C-ERBA; ERYTHROID-DIFFERENTIATION; TERMINAL DIFFERENTIATION; B-CELLS; DEATH; BCL-2; INVITRO	In AEV-transformed erythroleukemic cells the v-erbA gene product is likely to antagonize the function of triiodothyronine (T3) and retinoic acid (RA) receptors and thereby to block cell differentiation. We have thus investigated the effects of T3 and RA on normal early erythrocytic progenitor cells. Here we show: (1) that either RA or T3 play an essential role during the early commitment to erythrocytic differentiation, (2) that both T3 and RA induce death by apoptosis and a strong inhibition of self-renewal in progenitor cells grown in the absence of differentiation-inducing agents and (3) that the v-erbA oncogene renders erythrocytic progenitor cells insensitive to apoptosis and to self-renewal inhibition induced by RA or T3. The behaviour of a nontransforming mutant of v-evbA suggests that this v-erbA-induced protection is related to its transforming potential.	UNIV JOSEPH FOURIER,CERMO,BIOL DIFFERNTIAT EPITHELIALE LAB 621,F-38041 GRENOBLE,FRANCE; MICHIGAN STATE UNIV,DEPT FOOD SCI & HUMAN NUTR,E LANSING,MI 48824	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Michigan State University	GANDRILLON, O (corresponding author), ECOLE NORMALE SUPER LYON,INRA,BIOL MOLEC & CELLULAIRE LAB,CNRS,UMR 49,46 ALLEE ITALIE,F-69364 LYON 7,FRANCE.		Samarut, Jacques/AAD-2587-2019					BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BIGLER J, 1988, MOL CELL BIOL, V8, P4155, DOI 10.1128/MCB.8.10.4155; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CORREA PN, 1992, INT J CELL CLONING, V10, P286, DOI 10.1002/stem.5530100506; DAINIAK N, 1978, NATURE, V272, P260, DOI 10.1038/272260a0; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; EVANS CA, 1993, CANCER RES, V53, P1735; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FERRE F, 1989, NUCLEIC ACIDS RES, V17, P2141, DOI 10.1093/nar/17.5.2141; FUCHS E, 1981, CELL, V25, P617, DOI 10.1016/0092-8674(81)90169-0; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; Goodman DS, 1984, RETINOIDS, P41, DOI DOI 10.1016/B978-0-12-658102-7.50008-7; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENTZEN D, 1987, MOL CELL BIOL, V7, P2416, DOI 10.1128/MCB.7.7.2416; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KERR JFR, 1991, APOPTOSIS MOL BASIS, P5; KOURY MJ, 1992, EXP HEMATOL, V20, P391; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NOJI S, 1991, NATURE, V350, P83, DOI 10.1038/350083a0; PAIN B, 1990, New Biologist, V2, P284; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; POPOVIC WJ, 1977, J CLIN INVEST, V60, P907, DOI 10.1172/JCI108845; PRIVALSKY ML, 1988, MOL CELL BIOL, V8, P4510, DOI 10.1128/MCB.8.10.4510; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Robbins J., 1986, THYROID HORMONE META, P3; SAMARUT J, 1982, CELL, V28, P921, DOI 10.1016/0092-8674(82)90071-X; SANDE S, 1993, J VIROL, V67, P1067, DOI 10.1128/JVI.67.2.1067-1074.1993; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHROEDER C, 1992, ONCOGENE, V7, P203; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SCHROEDER C, 1992, ONCOGENE, V7, P217; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; STONE EM, 1985, P NATL ACAD SCI USA, V82, P1628, DOI 10.1073/pnas.82.6.1628; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VISANI G, 1992, BRIT J HAEMATOL, V81, P444, DOI 10.1111/j.1365-2141.1992.tb08254.x; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WELLINGER RJ, 1986, J VIROL, V60, P1; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; ZHOU HR, 1991, J IMMUNOL METHODS, V138, P211, DOI 10.1016/0022-1759(91)90169-G	48	64	65	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					749	758						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	7906409				2022-12-25	WOS:A1994MW55100009
J	SHAPIRO, AB; LING, V				SHAPIRO, AB; LING, V			ATPASE ACTIVITY OF PURIFIED AND RECONSTITUTED P-GLYCOPROTEIN FROM CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE VESICLES; MULTIDRUG-RESISTANCE; MONOCLONAL-ANTIBODIES; POLYACRYLAMIDE GELS; PURIFICATION; EXPRESSION; TRANSPORT; PROTEINS; COLCHICINE; HYDROLYSIS	P-glycoprotein was purified from multidrug-resistant Chinese hamster ovary CH(R)B30 cells by a combination of anion exchange and immunoaffinity chromatography. The P-glycoprotein was about 90% pure and had a V(max) for ATP hydrolysis in detergent solution of 321 nmol/min/mg with a K(m) of 0.94 mM. The ATPase activity was inhibited by low concentrations of vanadate and N-ethylmaleimide, but unaffected by azide or ouabain. When the purified P-glycoprotein was reconstituted into phospholipid bilayer membranes, the ATPase activity became highly stimulated by several chemosensitizers and drugs involved with multidrug resistance. Verapamil, a potent chemosensitizer, increased the V(max) for ATP hydrolysis by 22-fold and the K(m) for ATP by 5.4-fold. This effect of verapamil on P-glycoprotein has not previously been observed. These results demonstrate that purified P-glycoprotein has an intrinsic ATPase activity with unique properties. This activity appears sufficient to account for the ATP-dependent reduction in intracellular drug accumulation of P-glycoprotein-expressing multidrug-resistant cells.	ONTARIO CANC INST,DIV MOLEC & STRUCT BIOL,500 SHERBOURNE ST,TORONTO M4X 1K9,ONTARIO,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto					NCI NIH HHS [CA37130] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037130] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; CANOGAUCI DF, 1987, BIOCHEM PHARMACOL, V36, P2115, DOI 10.1016/0006-2952(87)90139-0; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; CHIN KV, 1993, ADV CANCER RES, V60, P157; DEUCHARS KL, 1992, THESIS U TORONTO; DOIGE CA, 1993, BIOCHIM BIOPHYS ACTA, V1146, P65, DOI 10.1016/0005-2736(93)90339-2; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P161, DOI 10.1016/0005-2736(92)90079-2; Endicott J A, 1991, DNA Seq, V2, P89, DOI 10.3109/10425179109039677; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GEORGES E, 1991, J CELL PHYSIOL, V148, P479, DOI 10.1002/jcp.1041480321; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GOTTESMAN MM, 1993, CANCER RES, V53, P747; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; HAMADA H, 1988, CANCER RES, V48, P4926; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RIORDAN JR, 1979, J BIOL CHEM, V254, P2701; ROEPE PD, 1992, BIOCHEMISTRY-US, V31, P12555, DOI 10.1021/bi00165a003; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SHIMABUKU AM, 1992, J BIOL CHEM, V267, P4308; SPOELSTRA EC, 1992, EUR J BIOCHEM, V207, P567, DOI 10.1111/j.1432-1033.1992.tb17083.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WEST IC, 1990, TRENDS BIOCHEM SCI, V15, P42, DOI 10.1016/0968-0004(90)90171-7; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	35	238	241	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3745	3754						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7906270				2022-12-25	WOS:A1994MV63100090
J	HIROSE, F; YAMAGUCHI, M; MATSUKAGE, A				HIROSE, F; YAMAGUCHI, M; MATSUKAGE, A			REPRESSION OF REGULATORY FACTOR FOR DROSOPHILA DNA REPLICATION-RELATED GENE PROMOTERS BY ZERKNULLT HOMEODOMAIN PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; POLYMERASE-ALPHA; BUDDING YEAST; TRANSCRIPTION; EXPRESSION; BINDING; EMBRYOS; CDC10+; SWI6	The expression of the chloramphenicol acetyltransferase gene under control of the 1152-base pair 5'-flanking region (-1107 to +45 nucleotide positions with respect to the major transcription initiation site) of the Drosophila DNA polymerase alpha gene was repressed by cotransfection into Drosophila Kc cells with a zerknullt (zen)-expressing plasmid as previously observed with the proliferating cell nuclear antigen (PCNA) gene promoter. The expression of the zen resulted in reduction of the abundance of mRNA for the transfected chloramphenicol acetyltransferase gene and also mRNAs for both DNA polymerase alpha and PCNA. Results obtained using various deletion derivatives of the promoter region and chemically synthesized oligonucleotides of the DNA replication-related element (DRE), a positive cis-acting element found in both DNA polymerase alpha and PCNA genes, revealed that the DRE sequences are responsible to repression by Zen protein. The nuclear extract of Kc cells transfected by the zen-expressing plasmid contained lesser amounts of the DRE-binding factor (DREF) than that of untransfected or mutant zen-transfected cells. These results suggest that the Zen protein represses expression of DNA replication-related genes by reducing DREF, although the detailed mechanism of the repression remains to be elucidated.	AICHI CANC CTR,RES INST,CELL BIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Aichi Cancer Center								ANDREWS BJ, 1992, NATURE, V355, P393, DOI 10.1038/355393a0; BOND BJ, 1986, MOL CELL BIOL, V6, P2080, DOI 10.1128/MCB.6.6.2080; BONDMATTHEWS B, 1988, GENE, V62, P289, DOI 10.1016/0378-1119(88)90566-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPOSORTEGA JA, 1985, EMBRYONIC DEV DROSOP, P210; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSS DP, 1978, J EMBRYOL EXP MORPH, V45, P161; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; DOYLE HJ, 1989, GENE DEV, V3, P1518, DOI 10.1101/gad.3.10.1518; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOE VE, 1989, DEVELOPMENT, V107, P1; GORDON CB, 1991, P NATL ACAD SCI USA, V88, P6058, DOI 10.1073/pnas.88.14.6058; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIROSE F, 1991, NUCLEIC ACIDS RES, V19, P4991, DOI 10.1093/nar/19.18.4991; HIROSE F, 1993, J BIOL CHEM, V268, P2092; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; Johnston Leland H., 1992, Trends in Cell Biology, V2, P353, DOI 10.1016/0962-8924(92)90041-K; LEWIS RA, 1980, GENETICS, V295, P383; LOWNDES NF, 1992, NATURE, V357, P505, DOI 10.1038/357505a0; LOWNDES NF, 1992, NATURE, V355, P449, DOI 10.1038/355449a0; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; Sambrook J, 1989, MOL CLONING LABORATO; TANAKA K, 1992, EMBO J, V11, P4923, DOI 10.1002/j.1460-2075.1992.tb05599.x; YAMAGUCHI M, 1990, MOL CELL BIOL, V10, P872, DOI 10.1128/MCB.10.3.872; YAMAGUCHI M, 1991, MOL CELL BIOL, V11, P4909, DOI 10.1128/MCB.11.10.4909; YAMAGUCHI M, 1988, NUCLEIC ACIDS RES, V16, P8773, DOI 10.1093/nar/16.18.8773	28	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2937	2942						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	7905482				2022-12-25	WOS:A1994MV43200084
J	NAUSEEF, WM; BRIGHAM, S; COGLEY, M				NAUSEEF, WM; BRIGHAM, S; COGLEY, M			HEREDITARY MYELOPEROXIDASE DEFICIENCY DUE TO A MISSENSE MUTATION OF ARGININE-569 TO TRYPTOPHAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA HL-60 CELLS; MYELOID LYSOSOMAL-ENZYME; PROMYELOCYTIC LEUKEMIA; INTRACELLULAR-TRANSPORT; MESSENGER-RNA; DIFFERENTIATION; GENE; EXPRESSION; BIOSYNTHESIS; LINE	Hereditary deficiency of myeloperoxidase (MPO) is a common disorder but its genetic basis is unknown. We have reported that neutrophils from individuals with MPO deficiency lack enzymatic and immunochemical evidence for mature MPO but have a 90-kDa precursor protein. We have thus hypothesized that hereditary MPO deficiency reflects a defect in processing of a mutated primary translation product. Genomic DNA's from normal subjects digested with BglII and probed with radiolabeled cDNA for MPO have a 2.6-kilobase (kb) band. Previously we described the presence of an aberrant 2.1-kb fragment in BglII digests from most individuals with either partial or complete MPO deficiency. We describe here the responsible mutation. The substitution of thymidine for cytosine in exon 10 at nucleotide 8,089 of the genomic sequence results in generation of a recognition site for BglII not present normally and converts the normal 2.6-kb BglII fragment to the 2.1-kb fragment associated with MPO deficiency. At the amino acid level this mutation would replace arginine at codon 569 with tryptophan. Six of seven patients with complete MPO deficiency had this mutation. One subject was homozygous for this mutation whereas five others were heterozygous at this locus. The seventh patient was the only completely deficient subject without this mutation. Thus, at least two mutations and three genotypes can produce the phenotype of MPO deficiency.	VET ADM MED CTR, DEPT MED, IOWA CITY, IA USA; UNIV IOWA, COLL MED, IOWA CITY, IA 52242 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Iowa	NAUSEEF, WM (corresponding author), UNIV IOWA, DEPT MED, 200 HAWKINS DR, IOWA CITY, IA 52242 USA.			Nauseef, William/0000-0003-4032-757X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI028412] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000513] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-28412] Funding Source: Medline; BLRD VA [I01 BX000513] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Veterans Affairs(US Department of Veterans Affairs); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); BLRD VA		AKIN DT, 1987, ARCH BIOCHEM BIOPHYS, V255, P428, DOI 10.1016/0003-9861(87)90411-5; AKIN DT, 1987, ARCH BIOCHEM BIOPHYS, V257, P451, DOI 10.1016/0003-9861(87)90590-X; AKIN DT, 1986, J BIOL CHEM, V261, P8370; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; HASHINAKA K, 1988, BIOCHEMISTRY-US, V27, P5906, DOI 10.1021/bi00416a013; HASILIK A, 1984, EMBO J, V3, P2671, DOI 10.1002/j.1460-2075.1984.tb02192.x; JOHNSON K, 1989, NUCLEIC ACIDS RES, V17, P7985, DOI 10.1093/nar/17.19.7985; Johnson K. R., 1991, PEROXIDASES CHEM BIO, P63; JOHNSON KR, 1987, NUCLEIC ACIDS RES, V15, P2013, DOI 10.1093/nar/15.5.2013; Klebanoff S. J, 1991, PEROXIDASES CHEM BIO, V1, P1; KOEFFLER HP, 1985, BLOOD, V65, P484; KUN SC, 1986, BLOOD, V68, P1411; LUBBERT M, 1991, BLOOD, V78, P345; LUBBERT M, 1991, BLOOD, V77, P909; MEIER RW, 1991, BIOCHEM BIOPH RES CO, V176, P1345, DOI 10.1016/0006-291X(91)90434-9; MORISHITA K, 1987, J BIOL CHEM, V262, P15208; NAUSEEF W M, 1990, Hematologic Pathology, V4, P165; NAUSEEF WM, 1988, EUR J HAEMATOL, V40, P97; NAUSEEF WM, 1986, BLOOD, V67, P865; NAUSEEF WM, 1983, J CLIN INVEST, V71, P1297, DOI 10.1172/JCI110880; NAUSEEF WM, 1986, BLOOD, V68, P442; NAUSEEF WM, 1989, BLOOD, V73, P290; NAUSEEF WM, 1987, BLOOD, V70, P1143; NAUSEEF WM, 1992, BLOOD, V80, P2622; OLSSON I, 1984, BIOCHEM J, V223, P911, DOI 10.1042/bj2230911; ROSMARIN AG, 1989, BLOOD, V73, P131; STROMBERG K, 1986, EUR J CELL BIOL, V39, P424; TOBLER A, 1989, BLOOD, V73, P1980; VANTUINEN P, 1987, ONCOGENE, V1, P319; WEIL SC, 1987, P NATL ACAD SCI USA, V84, P2057, DOI 10.1073/pnas.84.7.2057; YAMADA M, 1984, J BIOL CHEM, V259, P3021; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5	32	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1212	1216						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7904599				2022-12-25	WOS:A1994MR22000070
J	LOW, SY; RENNIE, MJ; TAYLOR, PM				LOW, SY; RENNIE, MJ; TAYLOR, PM			SODIUM-DEPENDENT GLUTAMATE TRANSPORT IN CULTURED RAT MYOTUBES INCREASES AFTER GLUTAMINE DEPRIVATION	FASEB JOURNAL			English	Note						AMINO ACID TRANSPORT; ADAPTIVE REGULATION; MUSCLE	AMINO-ACID-TRANSPORT; SKELETAL-MUSCLE CELLS; METABOLISM; LIVER	Glutamine produced and stored in skeletal muscle is an important source of nitrogen and energy for the whole body in health and disease and, unsurprisingly, glutamine turnover in muscle is subject to substantial metabolic control. L-Glutamate, a necessary substrate for glutamine synthetase, is transported into muscle cells by Na+-dependent and -independent transport systems. In primary cultures of rat skeletal muscle myotubes (a useful model system for studies of muscle metabolism and membrane transport), Na+-dependent glutamate transport (K(m) almost-equal-to 0.7 mM glutamate) shows adaptive up-regulation (65% increase in transport V(max) from 2.7 to 4.4 nmol . min-1 . mg protein-1) in cells within 24 h of glutamine depletion (t1/2 for increase of almost-equal-to 4 h), whereas Na+-independent glutamate uptake remains unaltered. Up-regulation of transport is suppressed by inhibitors of gene transcription (actinomycin-D) and translation (cycloheximide) and is reversed by glutamine supplementation. Increased glutamate transport capacity should provide extra substrate for glutamine synthesis in muscle cells. Thus, in concert with previously discovered increases in cell glutamine transport capacity and glutamine synthetase activity, it may represent part of a coordinated response to decreased glutamine availability (e.g., under circumstances of increased glutamine utilization by other tissues in vivo).			LOW, SY (corresponding author), UNIV DUNDEE,OLD MED SCH,DEPT ANAT & PHYSIOL,SMALLS WYND,DUNDEE DD1 4HN,SCOTLAND.		Taylor, Peter M/A-4667-2010					BANNAI S, 1980, J BIOL CHEM, V255, P2372; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; BURGER HJ, 1989, HEPATOLOGY, V9, P22, DOI 10.1002/hep.1840090105; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CLOSS EI, 1993, J BIOL CHEM, V268, P7538; DALLASTA V, 1983, J BIOL CHEM, V258, P6371; DURSCHLAG RP, 1985, AM J PHYSIOL, V248, pC442, DOI 10.1152/ajpcell.1985.248.5.C442; FENG B, 1990, J CELL PHYSIOL, V145, P376, DOI 10.1002/jcp.1041450224; HAUSSINGER D, 1990, BIOCHEM J, V267, P281; HORN LW, 1989, AM J PHYSIOL, V257, pC442, DOI 10.1152/ajpcell.1989.257.3.C442; HUNDAL HS, 1989, J PHYSIOL-LONDON, V408, P93, DOI 10.1113/jphysiol.1989.sp017449; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KLIP A, 1982, J CELL PHYSIOL, V113, P56, DOI 10.1002/jcp.1041130111; LOW SY, 1992, BIOCHEM J, V284, P333, DOI 10.1042/bj2840333; RENNIE MJ, 1989, METABOLISM, V38, P47, DOI 10.1016/0026-0495(89)90140-6; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TADROS LB, 1993, AM J PHYSIOL, V265, pE135, DOI 10.1152/ajpendo.1993.265.1.E135; TADROS LB, 1993, PROGR HEPATIC ENCEPH, V2; TADROS LB, 1993, IN PRESS AM J PHYSL; WATERLOW JC, 1978, PROTEIN TURNOVER MAM, P413	20	37	38	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1994	8	1					127	131		10.1096/fasebj.8.1.7905447	http://dx.doi.org/10.1096/fasebj.8.1.7905447			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MV282	7905447				2022-12-25	WOS:A1994MV28200019
J	WEISEL, JW; FRANCIS, CW; NAGASWAMI, C; MARDER, VJ				WEISEL, JW; FRANCIS, CW; NAGASWAMI, C; MARDER, VJ			DETERMINATION OF THE TOPOLOGY OF FACTOR-XIIIA-INDUCED FIBRIN GAMMA-CHAIN CROSS-LINKS BY ELECTRON-MICROSCOPY OF LIGATED FRAGMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSSLINKED FIBRIN; PLASMIC DEGRADATION; MODEL; MODULUS; CLOTS; COMPLEXES; POLYMERS; RHEOLOGY; DOMAINS; FIBERS	After fibrin polymerizes to form a clot, the transglutaminase Factor XIIIa cross-links the gamma and alpha chains to stabilize the clot. There has been conflicting evidence on whether the gamma chain isopeptide bonds occur between molecules that are interacting in a longitudinal (end-to-end) manner or transverse (half-staggered) manner between the two strands of the protofibril. Since the topology of the cross-links has important consequences for fibrin structure, as well as for its stability and susceptibility to and pattern of fibrinolysis, cross-linked fibrin fragments were examined by electron microscopy to distinguish between these two possibilities for the arrangement of the ligated molecules. Cross-linked fibrin clots were produced by prolonged incubation of fibrinogen with thrombin and Factor XIII, and then digested with plasmin. The resulting soluble cross-linked fibrin complexes were rotary-shadowed with tungsten and examined by electron microscopy, revealing protofibril-like structures consisting of clusters of globular domains with a repeat of 22.5 nm. Longer plasmin digestion times yielded increasingly shorter structures. Rotary-shadowed cross-linked fibrin fragments, produced by dilution of the complexes into 0.125% acetic acid at pH 3.5 to dissociate all non-covalently linked fragments, showed uniformly single-stranded structures with a characteristic spacing of nodules, consistent with longitudinal cross-linking. Long, thin strands were seen at short digestion times, while shorter strands appeared with longer digestion. The smallest structures observed included two nodules together, and two such nodules with another nodule at a short distance from one or both ends, compatible with fragments DD, DY, and YY. Longer strands had the appearance of fibrin molecules that were linked end-to-end, usually with a fragment D or Y at each end. In conclusion, these results are consistent with previously proposed structures of these derivatives and clearly demonstrate that the interactions between cross-linked gamma chains are longitudinal (end-to-end) and not transverse.	UNIV ROCHESTER, SCH MED & DENT, DEPT MED, HEMATOL UNIT, ROCHESTER, NY 14642 USA	University of Rochester	WEISEL, JW (corresponding author), UNIV PENN, SCH MED, DEPT CELL & DEV BIOL, PHILADELPHIA, PA 19104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030954, P01HL030616] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30616, HL30954] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALE MD, 1988, THROMB RES, V52, P565, DOI 10.1016/0049-3848(88)90129-6; BELITSER VA, 1968, BIOCHIM BIOPHYS ACTA, V154, P367, DOI 10.1016/0005-2795(68)90051-2; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; ERICKSON HP, 1983, ANN NY ACAD SCI, V408, P146, DOI 10.1111/j.1749-6632.1983.tb23242.x; FOWLER WE, 1981, P NATL ACAD SCI-BIOL, V78, P4872, DOI 10.1073/pnas.78.8.4872; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; FOWLER WE, 1981, SCIENCE, V211, P287, DOI 10.1126/science.6108612; FRANCIS CW, 1979, BLOOD, V54, P1282; FRANCIS CW, 1982, SEMIN THROMB HEMOST, V8, P25, DOI 10.1055/s-2007-1005040; FRANCIS CW, 1980, J CLIN INVEST, V66, P1033, DOI 10.1172/JCI109931; Henschen A., 1986, BLOOD COAGULATION, V171, P241; JANMEY PA, 1983, J RHEOL, V27, P135, DOI 10.1122/1.549722; LORAND L, 1983, ANN NY ACAD SCI, V408, P226, DOI 10.1111/j.1749-6632.1983.tb23247.x; Lorand L, 1980, Prog Hemost Thromb, V5, P245; MARDER VJ, 1969, J BIOL CHEM, V244, P2111; MARDER VJ, 1975, THROMB DIATH HAEMOST, V33, P199, DOI 10.1055/s-0038-1647872; MEDVED L, 1990, J MOL BIOL, V216, P503, DOI 10.1016/0022-2836(90)90376-W; MOSESSON MW, 1989, P NATL ACAD SCI USA, V86, P1113, DOI 10.1073/pnas.86.4.1113; NELB GW, 1981, BIOPHYS CHEM, V13, P15, DOI 10.1016/0301-4622(81)80020-8; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; RAO SPS, 1991, J MOL BIOL, V222, P89, DOI 10.1016/0022-2836(91)90739-S; SELMAYR E, 1985, THROMB RES, V39, P467, DOI 10.1016/0049-3848(85)90170-7; SELMAYR E, 1988, BIOPOLYMERS, V27, P1733, DOI 10.1002/bip.360271104; SELMAYR E, 1985, THROMB RES, V39, P459, DOI 10.1016/0049-3848(85)90169-0; VEKLICH YI, 1993, J BIOL CHEM, V268, P13577; WEBER K, 1969, J BIOL CHEM, V244, P4406; WEISEL JW, 1981, NATURE, V289, P263, DOI 10.1038/289263a0; WEISEL JW, 1985, SCIENCE, V230, P1388, DOI 10.1126/science.4071058	28	38	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26618	26624						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	7902838				2022-12-25	WOS:A1993MK42500088
J	ORR, GA; HAN, EKH; BROWNE, PC; NIEVES, E; OCONNOR, BM; YANG, CPH; HORWITZ, SB				ORR, GA; HAN, EKH; BROWNE, PC; NIEVES, E; OCONNOR, BM; YANG, CPH; HORWITZ, SB			IDENTIFICATION OF THE MAJOR PHOSPHORYLATION DOMAIN OF MURINE MDR1B P-GLYCOPROTEIN - ANALYSIS OF THE PROTEIN KINASE-A AND PROTEIN-KINASE-C PHOSPHORYLATION SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL TRANSPORT PROTEINS; MULTIDRUG-RESISTANCE GENE; DRUG ACCUMULATION; CYSTIC-FIBROSIS; J774.2 CELLS; KB CELLS; MEMBRANE GLYCOPROTEIN; CHLORIDE CHANNEL; HL60 CELLS; R-DOMAIN	P-glycoprotein is phosphorylated in cells, and it has been suggested that phosphorylation may regulate the drug transport activity of P-glycoprotein. Domain mapping, utilizing a combination of cyanogen bromide digestion and immunoblot analysis, was used to reveal the major phosphorylation sites in murine mdr1b P-glycoprotein. After labeling of J7.V1-1 cells with [P-32]P(i), or labeling membranes with [gamma-P-32]ATP and either protein kinase A or protein kinase C, it was found that the majority of the label was contained within a single cyanogen bromide fragment (amino acid 627-682) that encompassed the majority of the linker region. The in vitro protein kinase C phosphorylation sites within this fragment were analyzed by a combination of fast atom bombardment mass spectrometry (FABMS) and two-dimensional phosphopeptide mapping. FABMS analysis of a protein kinase C-phosphorylated synthetic peptide, corresponding to a segment of the linker region of P-glycoprotein, identified serine 669 as the single site of phosphorylation. Comparison of two-dimensional tryptic phosphopeptide maps prepared from synthetic peptide and P-glycoprotein, both of which were phosphorylated in vitro with protein kinase C, revealed that serine 669 was also the major phosphorylation site in the intact glycoprotein. The in vitro protein kinase A phosphorylation site was identified as serine 681 by site-directed mutagenesis. Inspection of the gene organization and the deduced amino acid sequence of mdr1b P-glycoprotein revealed that the linker region, although shorter than the R domain (55 versus 241 amino acids), fits the operational definition of the R domain of cystic fibrosis conductance regulator. Like the R domain, the linker region is encoded by a single exon, is highly charged with alternating acidic and basic side chains, and contains several protein kinase A/protein kinase C consensus phosphorylation sites. Since the R domain is believed to be involved in the regulation of cystic fibrosis conductance regulator function by phosphorylation, it is possible that the linker region plays a similar regulatory role in P-glycoprotein function.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT CELL BIOL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, MACROMOLEC ANAL LAB, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	ORR, GA (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOLEC PHARMACOL, BRONX, NY 10461 USA.				NATIONAL CANCER INSTITUTE [P30CA013330, R35CA039821, R01CA056677] Funding Source: NIH RePORTER; NCI NIH HHS [CA56677, 5P30 CA13330, CA39821] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CENTER MS, 1985, BIOCHEM PHARMACOL, V34, P1471, DOI 10.1016/0006-2952(85)90686-0; CHAMBERS TC, 1990, J BIOL CHEM, V265, P7679; CHAMBERS TC, 1993, J BIOL CHEM, V268, P4592; CHAMBERS TC, 1992, MOL PHARMACOL, V41, P1008; CHEN CJ, 1990, J BIOL CHEM, V265, P506; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CHIN JE, 1989, MOL CELL BIOL, V9, P3808, DOI 10.1128/MCB.9.9.3808; CORNWELL MM, 1986, J BIOL CHEM, V261, P7921; CORNWELL MM, 1987, FASEB J, V1, P51, DOI 10.1096/fasebj.1.1.2886389; ENDICOTT JA, 1987, MOL CELL BIOL, V7, P4075, DOI 10.1128/MCB.7.11.4075; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GREENBERGER LM, 1988, P NATL ACAD SCI USA, V85, P3762, DOI 10.1073/pnas.85.11.3762; GREENBERGER LM, 1990, J BIOL CHEM, V265, P4394; GREENBERGER LM, 1991, J BIOL CHEM, V266, P20744; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; HAMADA H, 1987, CANCER RES, V47, P2860; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOUMARD J, 1972, P NATL ACAD SCI USA, V69, P3506, DOI 10.1073/pnas.69.12.3506; HSU SIH, 1989, J BIOL CHEM, V264, P12053; KIRSCHNER LS, 1992, BIOCHEM PHARMACOL, V43, P77, DOI 10.1016/0006-2952(92)90664-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MA LD, 1991, J BIOL CHEM, V266, P5593; MELLADO W, 1987, BIOCHEMISTRY-US, V26, P6900, DOI 10.1021/bi00396a005; NG WF, 1989, MOL CELL BIOL, V9, P1224, DOI 10.1128/MCB.9.3.1224; PAPAYANNOPOULOU.IA, 1991, AM SOC MASS SPECTROM, V2, P176; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RAYMOND M, 1989, P NATL ACAD SCI USA, V86, P6488, DOI 10.1073/pnas.86.17.6488; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; ROY SN, 1985, CANCER RES, V45, P3856; SAEKI T, 1993, J BIOL CHEM, V268, P6077; SAFA AR, 1986, J BIOL CHEM, V261, P6137; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SATO W, 1990, BIOCHEM BIOPH RES CO, V173, P1252, DOI 10.1016/S0006-291X(05)80921-0; SHARMA RC, 1992, J BIOL CHEM, V267, P5731; STAATS J, 1990, J BIOL CHEM, V265, P4084; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; YANG CPH, 1988, BIOCHEM PHARMACOL, V37, P1417; YU G, 1991, CANCER COMMUN, V3, P181, DOI 10.3727/095535491820873263; ZEHEB R, 1987, BIOCHEM BIOPH RES CO, V143, P732, DOI 10.1016/0006-291X(87)91415-X	51	70	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25054	25062						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	7901220				2022-12-25	WOS:A1993MG67300079
J	TAXMAN, DJ; WOJCHOWSKI, DM				TAXMAN, DJ; WOJCHOWSKI, DM			ERYTHROPOIETIN-INDUCED TRANSCRIPTION AT THE MURINE BETA(MAJ)-GLOBIN PROMOTER - A CENTRAL ROLE FOR GATA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOBIN GENE-TRANSCRIPTION; MOUSE ERYTHROLEUKEMIA-CELLS; ERYTHROID PROGENITOR CELLS; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; DNA-SEQUENCES; DIFFERENTIATION; BINDING; EXPRESSION; RECEPTOR	Using J2E cells and the murine beta(maj)-globin promoter as a model, we have performed the first direct analyses of erythropoietin (EPO)-activated transcription from defined templates. The -348 to +26 beta(maj) promoter was shown to comprise a target for maximal activation. This included a positive role for a -346 to -107-base pair (bp) domain in J2E cells, but not in F-MEL cells, Mutagenesis of a -215 bp AGATAA element within this domain showed that this effect did not require GATA-1 binding, In contrast, a critical role for GATA-1 at a -60-bp (G)GATAG element was defined by mutagenesis (GGg-TAG and TGATAG), complementation with a synthetic TGATAA element, and the demonstrated specific binding of GATA-1. Proximal CCAAT (-75) and CACCC (-90) elements also were shown to contribute to transcriptional activation in J2E cells, yet exerted quantitatively distinct effects in the F-MEL system, Based on these results, minimal [TGATAA](4)-TATA and TGATAA-CACCC-TATA promoters were constructed and assayed in each system, Remarkably, the [TGATAA],-TATA promoter, but not the TGATAA-CACCC-TATA promoter, was induced efficiently by EPO in J2E cells, whereas the TGATAA-CACCC-TATA promoter was highly induced by Me,SO in F-MEL cells, These findings suggest that mechanisms of EPO-induced transcription in J2E cells involve GATA-1 and differ from chemically activated mechanisms studied previously in F-MEL cells, Globin induction in J2E cells was not associated with effects of EPO on levels or nuclear translocation of GATA-1, However, hemoglobinization was induced by okadaic acid, 8-Br-cAMP, and forskolin, a finding consistent with induction mechanisms that may involve modulated serine/threonine threonine phosphorylation.	PENN STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, UNIVERSITY PK, PA 16802 USA; PENN STATE UNIV, DEPT PATHOL & VET SCI, UNIVERSITY PK, PA 16802 USA; PENN STATE UNIV, CTR GENE REGULAT, UNIVERSITY PK, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park					NHLBI NIH HHS [HL44491, KO4HL203042] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044491] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BONDURANT MC, 1985, MOL CELL BIOL, V5, P675, DOI 10.1128/MCB.5.4.675; BRANCH DR, 1987, BLOOD, V69, P1782; BUSFIELD SJ, 1992, BLOOD, V80, P412; CHARNAY P, 1985, MOL CELL BIOL, V5, P1498, DOI 10.1128/MCB.5.6.1498; CHIBA T, 1991, NUCLEIC ACIDS RES, V19, P3843, DOI 10.1093/nar/19.14.3843; COWIE A, 1988, MOL CELL BIOL, V8, P3122, DOI 10.1128/MCB.8.8.3122; CROSSLEY M, 1994, J BIOL CHEM, V269, P16589; CROTTA S, 1990, NUCLEIC ACIDS RES, V18, P6863, DOI 10.1093/nar/18.23.6863; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DEBOER E, 1988, EMBO J, V7, P4203, DOI 10.1002/j.1460-2075.1988.tb03317.x; DEGEN JL, 1983, J BIOL CHEM, V258, P2153; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENVER T, 1988, P NATL ACAD SCI USA, V85, P9091, DOI 10.1073/pnas.85.23.9091; EVANS T, 1990, ANNU REV CELL BIOL, V6, P95, DOI 10.1146/annurev.cellbio.6.1.95; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FANTONI A, 1979, NUCLEIC ACIDS RES, V6, P3505, DOI 10.1093/nar/6.11.3505; FENG WC, 1994, J BIOL CHEM, V269, P1493; FRAMPTON J, 1990, MOL CELL BIOL, V10, P3838, DOI 10.1128/MCB.10.7.3838; FRASER JK, 1988, BLOOD, V71, P104; FUKUMOTO H, 1989, DEVELOPMENT, V105, P109; GONG QH, 1993, MOL CELL BIOL, V13, P911, DOI 10.1128/MCB.13.2.911; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HARDISON RC, 1983, J BIOL CHEM, V258, P8739; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; HE TC, 1993, BLOOD, V82, P3530; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; KAIHO SI, 1985, ANAL BIOCHEM, V149, P117, DOI 10.1016/0003-2697(85)90483-X; KITAMURA T, 1989, BLOOD, V73, P375; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KOMATSU N, 1993, BLOOD, V82, P456; KOURY MJ, 1988, J CELL PHYSIOL, V137, P65, DOI 10.1002/jcp.1041370108; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KOURY MJ, 1986, J CELL PHYSIOL, V126, P259, DOI 10.1002/jcp.1041260216; KURAMOCHI S, 1991, BIOCHEM BIOPH RES CO, V181, P1103, DOI 10.1016/0006-291X(91)92052-L; KURAMOCHI S, 1990, EUR J BIOCHEM, V193, P163, DOI 10.1111/j.1432-1033.1990.tb19318.x; LEONARD M, 1993, BLOOD, V82, P1071; MACLEOD K, 1991, MOL CELL BIOL, V11, P4324, DOI 10.1128/MCB.11.9.4324; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; ORKIN SH, 1992, BLOOD, V80, P575; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P73, DOI 10.1093/nar/17.1.73; QUELLE FW, 1991, J BIOL CHEM, V266, P609; RAY FA, 1992, BIOTECHNIQUES, V13, P342; REDDY PMS, 1993, MOL CELL BIOL, V13, P1093, DOI 10.1128/MCB.13.2.1093; ROCHAIX JD, 1978, GENE, V3, P9, DOI 10.1016/0378-1119(78)90003-3; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; STUVE LL, 1990, MOL CELL BIOL, V10, P972, DOI 10.1128/MCB.10.3.972; STUVE LL, 1993, MOL CELL BIOL, V13, P4311, DOI 10.1128/MCB.13.7.4311; TAXMAN DJ, 1993, ANAL BIOCHEM, V213, P97, DOI 10.1006/abio.1993.1391; TAXMAN DJ, 1994, PROTEIN EXPRES PURIF, V5, P587, DOI 10.1006/prep.1994.1081; TODOKORO K, 1987, P NATL ACAD SCI USA, V84, P4126, DOI 10.1073/pnas.84.12.4126; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410; WALTERS M, 1992, P NATL ACAD SCI USA, V89, P10444, DOI 10.1073/pnas.89.21.10444; WOJCHOWSKI DM, 1993, STEM CELLS, V11, P381, DOI 10.1002/stem.5530110505; YOST SE, 1991, JH S CONT M, P220; YOUSSOUFIAN H, 1993, BLOOD, V81, P2223; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411	59	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6619	6627		10.1074/jbc.270.12.6619	http://dx.doi.org/10.1074/jbc.270.12.6619			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896801	hybrid			2022-12-25	WOS:A1995QQ85500032
J	WU, YJ; FRAIZER, GC; SAUNDERS, GF				WU, YJ; FRAIZER, GC; SAUNDERS, GF			GATA-1 TRANSACTIVATES THE WT1 HEMATOPOIETIC SPECIFIC ENHANCER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILMS-TUMOR GENE; TRANSCRIPTION FACTOR GATA-1; NUCLEAR FACTOR; EXPRESSION; BINDING; DELETION; CELLS; DIFFERENTIATION; MUTATION; PROMOTER	The Wilms' tumor gene, WT1, is believed to play a role in hematopoiesis as it is expressed in the spleen and in immature leukemias in addition to the developing genitourinary system. WT1 is down-regulated in differentiated leukemia cells both in vivo and in vitro and is upregulated in fetal spleen and immature leukemia cells. The modulation of WT1 expression was examined in many cell types, and a hematopoietic-specific enhancer element has been identified. Here we describe the transcriptional response of this enhancer to hematopoietic-specific transcription factors. We found co-expression of WT1 and GATA-1 mRNA in K562 cells and in mouse spleen, suggesting potential interactions between these two transcription factors. We find that the activity of the 3' WT1 enhancer is positively correlated with the expression of GATA-1. Gel shift competition experiments and transactivation studies revealed that this functional activity is mediated via binding at a GATA-binding site in the WT1 enhancer. The transactivation of the WT1 enhancer by GATA-1 implies that GATA-1 plays a role in the regulation of WT1 during hematopoiesis.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA 34936, CA 16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, P01CA034936] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GESSLER M, 1992, GENOMICS, V12, P807, DOI 10.1016/0888-7543(92)90313-H; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HOFMANN W, 1993, ONCOGENE, V8, P3123; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; HUFF V, 1991, AM J HUM GENET, V48, P997; KIDD JM, 1984, WILMS TUMOR, P265; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; MANTOVANI R, 1988, NUCLEIC ACIDS RES, V16, P4299, DOI 10.1093/nar/16.10.4299; MIWA H, 1992, LEUKEMIA, V6, P405; MIYAGI T, 1993, LEUKEMIA, V7, P970; OKA T, 1991, ONCOGENE, V6, P2077; ORKIN SH, 1992, BLOOD, V80, P575; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PHELAN SA, 1994, CELL GROWTH DIFFER, V5, P677; PRITCHARDJONES K, 1994, HUM MOL GENET, V3, P1633, DOI 10.1093/hmg/3.9.1633; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; SEKIYA M, 1994, BLOOD, V83, P1876; SHIMAMOTO T, 1994, P AM ASSOC CANC RES, V35, P3554; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SPOSI NM, 1992, P NATL ACAD SCI USA, V89, P6353, DOI 10.1073/pnas.89.14.6353; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; TSAI SF, 1990, NATURE, V339, P446; YOUNG JL, 1975, J PEDIATR-US, V86, P254, DOI 10.1016/S0022-3476(75)80484-7	37	51	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					5944	5949		10.1074/jbc.270.11.5944	http://dx.doi.org/10.1074/jbc.270.11.5944			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890725	hybrid			2022-12-25	WOS:A1995QM94500038
J	PATCHEV, VK; HAYASHI, S; ORIKASA, C; ALMEIDA, OFX				PATCHEV, VK; HAYASHI, S; ORIKASA, C; ALMEIDA, OFX			IMPLICATIONS OF ESTROGEN-DEPENDENT BRAIN ORGANIZATION FOR GENDER DIFFERENCES IN HYPOTHALAMO-PITUITARY-ADRENAL REGULATION	FASEB JOURNAL			English	Article						CORTICOTROPIN-RELEASING HORMONE; VASOPRESSIN; GLUCOCORTICOID RECEPTOR; CORTICOSTERONE	CORTICOTROPIN-RELEASING HORMONE; RECEPTOR MESSENGER-RNA; RAT-BRAIN; SEXUAL DIMORPHISM; INSITU HYBRIDIZATION; STRESS-RESPONSE; GENE-EXPRESSION; FEMALE RATS; VASOPRESSIN GENE; OXYTOCIN	Estrogens, derived from the aromatization of testosterone in the brain, account for sex-specific organization of neural circuits controlling gonadotropin release and sexual behavior. This study examines the possible organizing role of perinatal gonadal steroids in the manifestation of known, albeit unexplained, male-female differences in basal and stress-related adrenocortical secretion. We document here the existence of gender-specific differences in the gene expression of hypothalamic corticotropin-releasing hormone (CRH), and hippocampal and hypothalamic glucocorticoid receptors (GR), diurnal corticosterone secretion, as well as in the responsiveness of CRH and GR mRNA levels to exogenous estradiol, In addition, we report that neonatal estrogenization of female rats profoundly affects several regulatory substrates of the hypothalamo-pituitary-adrenal (HPA) axis, namely, the gene expression of CRH, arginine-vasopressin (AVP) and GR in the brain, and the responsiveness of these parameters to estrogen, The neonatal treatment appeared to ''defeminize'' a number of neuroendocrine mechanisms related to HPA function; these changes were reminiscent of those observed in earlier studies on sexual differentiation of reproductive behavior and hormonal secretion, The results indicate a pivotal role for estrogens during early development for the determination of gender-specific differences in HPA function in the mature animal and demonstrate for the first time that the brain-organizing actions of gonadal steroids may extend to nonreproductive neuroendocrine axes.	TOKYO METROPOLITAN INST NEUROSCI, DEPT ANAT & EMBRYOL, FUCHU, TOKYO 183, JAPAN	Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science	PATCHEV, VK (corresponding author), MAX PLANCK INST PSYCHIAT, INST CLIN, DEPT NEUROENDOCRINOL, KRAEPELINSTR 2, D-80804 MUNICH, GERMANY.		Almeida, Osborne F.X. F/E-8402-2010	Almeida, Osborne F.X. F/0000-0001-7331-6928				ADAN RAH, 1992, PROG BRAIN RES, V92, P127, DOI 10.1016/S0079-6123(08)61169-3; AHIMA RS, 1992, ENDOCRINOLOGY, V131, P1409, DOI 10.1210/en.131.3.1409; ALMEIDA OFX, 1993, CIBA F SYMP, V172, P151; BARRACLOUGH C, 1961, ENDOCRINOLOGY, V68, P68, DOI 10.1210/endo-68-1-68; BINGAMAN EW, 1994, NEUROENDOCRINOLOGY, V59, P228, DOI 10.1159/000126663; BOHLER HCL, 1990, MOL BRAIN RES, V8, P259, DOI 10.1016/0169-328X(90)90025-9; BRADY LS, 1990, NEUROENDOCRINOLOGY, V52, P441, DOI 10.1159/000125626; BURGESS LH, 1992, ENDOCRINOLOGY, V131, P1261, DOI 10.1210/en.131.3.1261; CHROUSOS GP, 1992, JAMA-J AM MED ASSOC, V267, P1244, DOI 10.1001/jama.267.9.1244; CRITCHLOW V, 1963, AM J PHYSIOL, V205, P807, DOI 10.1152/ajplegacy.1963.205.5.807; CROWLEY RS, 1993, ENDOCRINOLOGY, V133, P2711, DOI 10.1210/en.133.6.2711; DEKLOET ER, 1991, FRONT NEUROENDOCRIN, V12, P95; DOrner G, 1976, HORMONES BRAIN DIFFE; GILLIES GE, 1982, NATURE, V299, P355, DOI 10.1038/299355a0; GORSKI RA, 1963, AM J PHYSIOL, V205, P842, DOI 10.1152/ajplegacy.1963.205.5.842; GOY RW, 1978, SEXUAL DIFFERENTIATI; GREER ER, 1986, LIFE SCI, V38, P2311, DOI 10.1016/0024-3205(86)90638-7; HAAS DA, 1988, BRAIN RES BULL, V20, P361, DOI 10.1016/0361-9230(88)90065-2; HAYASHI S, 1991, NEUROSCI RES, V12, P366, DOI 10.1016/0168-0102(91)90004-I; HERBERT J, 1993, PROG NEUROBIOL, V41, P723, DOI 10.1016/0301-0082(93)90033-O; HOLSBOER F, 1992, PROG BRAIN RES, V93, P385; IVELL R, 1984, P NATL ACAD SCI-BIOL, V81, P2006, DOI 10.1073/pnas.81.7.2006; JACOBSON L, 1991, ENDOCR REV, V12, P118, DOI 10.1210/edrv-12-2-118; JINGAMI H, 1985, FEBS LETT, V191, P63, DOI 10.1016/0014-5793(85)80994-7; KANT GJ, 1983, PSYCHONEUROENDOCRINO, V8, P421, DOI 10.1016/0306-4530(83)90021-5; KITAY JI, 1963, ENDOCRINOLOGY, V73, P253, DOI 10.1210/endo-73-2-253; LEHMAN MN, 1993, ENDOCRINOLOGY, V133, P876, DOI 10.1210/en.133.2.876; MACLUSKY NJ, 1981, SCIENCE, V211, P1294, DOI 10.1126/science.6163211; MCEWEN BS, 1991, J STEROID BIOCHEM, V39, P223, DOI 10.1016/0960-0760(91)90067-F; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MILLER MA, 1989, PEPTIDES, V10, P615, DOI 10.1016/0196-9781(89)90152-6; PEIFFER A, 1991, ENDOCRINOLOGY, V129, P2166; PLOTSKY PM, 1991, J NEUROENDOCRINOL, V3, P1, DOI 10.1111/j.1365-2826.1991.tb00231.x; RAINBOW TC, 1982, J NEUROSCI, V2, P1439; SAPOLSKY RM, 1986, BRAIN RES REV, V11, P65, DOI 10.1016/0165-0173(86)90010-X; SIMERLY RB, 1990, J COMP NEUROL, V294, P76, DOI 10.1002/cne.902940107; SZOT P, 1993, DEV BRAIN RES, V73, P177, DOI 10.1016/0165-3806(93)90136-X; TURNER BB, 1985, BRAIN RES, V343, P16, DOI 10.1016/0006-8993(85)91153-9; VAMVAKOPOULOS NC, 1993, J CLIN INVEST, V92, P1896, DOI 10.1172/JCI116782; VIAU V, 1991, ENDOCRINOLOGY, V129, P2503, DOI 10.1210/endo-129-5-2503; WHITFIELD HJ, 1990, CELL MOL NEUROBIOL, V10, P145, DOI 10.1007/BF00733641; YOKOSUKA M, 1992, NEUROSCI RES, V15, P90, DOI 10.1016/0168-0102(92)90021-4	42	163	165	1	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1995	9	5					419	423		10.1096/fasebj.9.5.7896013	http://dx.doi.org/10.1096/fasebj.9.5.7896013			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QP451	7896013				2022-12-25	WOS:A1995QP45100016
J	SCHWEERS, O; SCHONBRUNNHANEBECK, E; MARX, A; MANDELKOW, E				SCHWEERS, O; SCHONBRUNNHANEBECK, E; MARX, A; MANDELKOW, E			STRUCTURAL STUDIES OF TAU-PROTEIN AND ALZHEIMER PAIRED HELICAL FILAMENTS SHOW NO EVIDENCE FOR BETA-STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; MICROTUBULE-ASSOCIATED PROTEINS; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; INFRARED-SPECTROSCOPY; BINDING DOMAINS; AMYLOID PROTEIN; DISEASE; BRAIN; PHOSPHORYLATION	We have studied the conformation of tau protein and Alzheimer paired helical filaments (PHF) by several spectroscopic, scattering, and imaging methods revealing the overall shape and the conformation of the polypeptide backbone. Tau protein behaves in solution as if it were denatured; no evidence for compact folding was detected. The protein is highly extended, there is no defined radius of gyration, and the scattering is best described by that of a random (''Gaussian'') polymer. CD and Fourier transform infrared spectroscopy show only a minimal content of ordered secondary structure (alpha-helix or beta-sheet). Similarly, PHFs from Alzheimer brain tissue show no detectable secondary structure by x-ray diffraction or spectroscopy. It is thus unlikely that the aggregation of tau into Alzheimer PHFs is based on interactions between strands of beta-sheets (a model currently favored for other disease-related polymers such as beta-amyloid fibers of Alzheimer's disease).	DESY, MAX PLANCK UNIT STRUCT MOLEC BIOL, D-22603 HAMBURG, GERMANY	Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Max Planck Society				Schonbrunn, Ernst/0000-0002-3589-3510				BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; BLAKE CCF, 1978, J MOL BIOL, V121, P339, DOI 10.1016/0022-2836(78)90368-6; BOULIN CJ, 1988, NUCL INSTRUM METH A, V269, P312, DOI 10.1016/0168-9002(88)90895-9; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; CLORE GM, 1986, J MOL BIOL, V191, P553, DOI 10.1016/0022-2836(86)90147-6; CROWTHER RA, 1991, P NATL ACAD SCI USA, V88, P2288, DOI 10.1073/pnas.88.6.2288; CROWTHER RA, 1985, EMBO J, V4, P3661, DOI 10.1002/j.1460-2075.1985.tb04132.x; DAMASCHUN G, 1993, BIOCHEMISTRY-US, V32, P7739, DOI 10.1021/bi00081a019; DOWNING KH, 1992, J STRUCT BIOL, V109, P152, DOI 10.1016/1047-8477(92)90046-D; FELLOUS A, 1977, EUR J BIOCHEM, V78, P167, DOI 10.1111/j.1432-1033.1977.tb11726.x; FRASER PE, 1991, BIOPHYS J, V60, P1190, DOI 10.1016/S0006-3495(91)82154-3; GASCUEL O, 1988, COMPUT APPL BIOSCI, V4, P357; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; GEISLER N, 1993, J STRUCT BIOL, V110, P205, DOI 10.1006/jsbi.1993.1023; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; HILBICH C, 1992, J MOL BIOL, V228, P460, DOI 10.1016/0022-2836(92)90835-8; HIMMLER A, 1989, MOL CELL BIOL, V9, P1381, DOI 10.1128/MCB.9.4.1381; IHARA Y, 1983, NATURE, V304, P727, DOI 10.1038/304727a0; INOUYE H, 1993, BIOPHYS J, V64, P502, DOI 10.1016/S0006-3495(93)81393-6; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JARVIS JA, 1993, BIOCHEM BIOPH RES CO, V192, P991, DOI 10.1006/bbrc.1993.1514; JOHNSON WC, 1988, ANNU REV BIOPHYS BIO, V17, P145, DOI 10.1146/annurev.bb.17.060188.001045; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; Kirste R. G., 1982, SMALL ANGLE XRAY SCA, P387; KOCH MHJ, 1983, NUCL INSTRUM METHODS, V208, P461, DOI 10.1016/0167-5087(83)91169-9; KONDO J, 1988, NEURON, V1, P827, DOI 10.1016/0896-6273(88)90130-4; KOSIK KS, 1992, SCIENCE, V256, P780, DOI 10.1126/science.1589757; KOSIK KS, 1989, ANN NY ACAD SCI, V568, P125; KOSIK KS, 1986, P NATL ACAD SCI USA, V83, P4044, DOI 10.1073/pnas.83.11.4044; Kratky O., 1982, SMALL ANGLE XRAY SCA, P361; KSIEZAKREDING H, 1991, NEURON, V6, P717, DOI 10.1016/0896-6273(91)90169-Z; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; Lee V M, 1992, Curr Opin Neurobiol, V2, P653, DOI 10.1016/0959-4388(92)90034-I; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MANDELKOW E, 1977, P NATL ACAD SCI USA, V74, P3370, DOI 10.1073/pnas.74.8.3370; MANDELKOW E, 1986, METHOD ENZYMOL, V134, P633; NAVE R, 1989, J CELL BIOL, V109, P2177, DOI 10.1083/jcb.109.5.2177; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; Siakotos A N, 1974, Methods Enzymol, V31, P478; SPANN U, 1987, BIOCHEMISTRY-US, V26, P1123, DOI 10.1021/bi00378a021; SPILLANTINI MG, 1990, P NATL ACAD SCI USA, V87, P3947, DOI 10.1073/pnas.87.10.3947; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; SUSI H, 1986, METHOD ENZYMOL, V130, P290; TAUBOLD RD, 1975, LIPIDS, V10, P383, DOI 10.1007/BF02532441; TERRY CJ, 1993, EMBO J, V12, P735, DOI 10.1002/j.1460-2075.1993.tb05707.x; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; VOTER WA, 1982, J ULTRA MOL STRUCT R, V80, P374, DOI 10.1016/S0022-5320(82)80051-8; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4884, DOI 10.1073/pnas.85.13.4884; WOODY RW, 1983, BIOCHEMISTRY-US, V22, P2186, DOI 10.1021/bi00278a020; ZHANG SG, 1993, P NATL ACAD SCI USA, V90, P3334, DOI 10.1073/pnas.90.8.3334; ZINGSHEIM HP, 1979, EUR J CELL BIOL, V19, P175	58	460	475	2	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24290	24297						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929085				2022-12-25	WOS:A1994PQ34600068
J	YOSHIDA, T; WILLARDSON, BM; WILKINS, JF; JENSEN, GJ; THORNTON, BD; BITENSKY, MW				YOSHIDA, T; WILLARDSON, BM; WILKINS, JF; JENSEN, GJ; THORNTON, BD; BITENSKY, MW			THE PHOSPHORYLATION STATE OF PHOSDUCIN DETERMINES ITS ABILITY TO BLOCK TRANSDUCIN SUBUNIT INTERACTIONS AND INHIBIT TRANSDUCIN BINDING TO ACTIVATED RHODOPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; ROD OUTER SEGMENTS; G-PROTEIN; PHOTORECEPTOR CELLS; PHOSPHOLIPASE-C; CYCLIC-GMP; BOVINE; LIGHT; RETINA; KINASE	Heterotrimeric GTP-binding proteins (G-proteins) serve many different signal transduction pathways. Phosducin, a 28-kDa phosphoprotein, is expressed in a variety of mammalian cell types and blocks activation of several classes of G-proteins. Phosphorylation of phosducin by cyclic AMP-dependent protein kinase prevents phosducin-mediated inhibition of G-protein GTPase activity (Bauer, P. H., Muller, S., Puzicha, M., Pippig, S., Obermaier, B., Helmreich, E. J. M., and Lohse, M. J. (1992) Nature 358, 73-76). In retinal rods, phosducin inhibits transducin (G(t)) activation by binding its beta gamma subunits. While rod phosducin is phosphorylated in the dark and dephosphorylated after illumination (Lee, R.H., Brown, B. M., and Lolley, R. N. (1984) Biochemistry 23, 1972-1977), the significance of these reactions is still unclear. The data presented here permit a more precise characterization of phosducin function and the consequences of its phosphorylation. Dephosphophosducin blocked binding of the G(t) alpha(1) subunit to activated rhodopsin in the presence of stoichiometric amounts of G(t) beta gamma, whereas phosphophosducin did not. Surprisingly, the binding affinity of phosphophosducin for G(t) beta gamma was not significantly reduced compared with the binding affinity of dephosphophosducin. However, the association of phosducin with G(t) beta gamma in a size exclusion column matrix was dependent on the phosphorylation state of phosducin. Moreover, the ability of phosducin to compete with G(t) alpha for binding to G(t) beta gamma was also dependent on the phosphorylation state of phosducin. No interaction was found between phosducin and G(t) alpha. These data indicate that phosducin decreases rod responsiveness by binding to the beta gamma subunits of G(t) and preventing their interaction with G(t) alpha, thereby inhibiting G(t) alpha activation by the activated receptor. Moreover phosphorylation of phosducin blocks its ability to compete with G(t) alpha for binding to G(t) beta gamma.	LOS ALAMOS NATL LAB,DIV PHYS,BIOPHYS GRP,LOS ALAMOS,NM 87545	United States Department of Energy (DOE); Los Alamos National Laboratory			Wilkins, Jon/A-4984-2009	Wilkins, Jon/0000-0001-6405-6538; Willardson, Barry/0000-0002-8503-2268	NEI NIH HHS [EY 06816] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABE T, 1990, GENE, V91, P209, DOI 10.1016/0378-1119(90)90090-E; BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BLAZYNSKI C, 1986, J BIOL CHEM, V261, P14142; BLAZYNSKI C, 1984, EXP EYE RES, V38, P279, DOI 10.1016/0014-4835(84)90166-0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CASEY PJ, 1988, J BIOL CHEM, V263, P2577; COHEN AI, 1982, J NEUROCHEM, V38, P781, DOI 10.1111/j.1471-4159.1982.tb08699.x; COTE RH, 1984, J BIOL CHEM, V259, P9635; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KUO CH, 1986, MOL BRAIN RES, V1, P251, DOI 10.1016/0169-328X(86)90031-8; KUO CH, 1993, BIOCHEM BIOPH RES CO, V191, P1097, DOI 10.1006/bbrc.1993.1329; KUO CH, 1989, BIOCHEM BIOPH RES CO, V162, P1063, DOI 10.1016/0006-291X(89)90781-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RH, 1990, J BIOL CHEM, V265, P15867; LEE RH, 1991, INVEST OPHTH VIS SCI, V32, P1054; LEE RH, 1990, J BIOL CHEM, V265, P15860; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LEE RH, 1984, BIOCHEMISTRY-US, V23, P1972, DOI 10.1021/bi00304a014; LEE RH, 1992, J BIOL CHEM, V267, P25104; LEE RH, 1981, BIOCHEMISTRY-US, V20, P7532, DOI 10.1021/bi00529a031; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; MCDOWELL JH, 1977, BIOCHEMISTRY-US, V16, P4054, DOI 10.1021/bi00637a018; MCNAUGHTON PA, 1990, PHYSIOL REV, V70, P847, DOI 10.1152/physrev.1990.70.3.847; ORR HT, 1976, P NATL ACAD SCI USA, V73, P4442, DOI 10.1073/pnas.73.12.4442; PARK DG, 1993, J BIOL CHEM, V268, P4573; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; SHINOZAWA T, 1980, P NATL ACAD SCI-BIOL, V77, P1408, DOI 10.1073/pnas.77.3.1408; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; WILLARDSON BM, 1993, J BIOL CHEM, V268, P6371; YAMAZAKI A, 1987, J BIOL CHEM, V262, P9316	35	116	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24050	24057						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929057				2022-12-25	WOS:A1994PQ34600034
J	WHATLEY, VJ; MIHIC, SJ; ALLAN, AM; MCQUILKIN, SJ; HARRIS, RA				WHATLEY, VJ; MIHIC, SJ; ALLAN, AM; MCQUILKIN, SJ; HARRIS, RA			GAMMA-AMINOBUTYRIC ACID(A) RECEPTOR FUNCTION IS INHIBITED BY MICROTUBULE DEPOLYMERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; BENZODIAZEPINE RECEPTORS; ACETYLCHOLINE-RECEPTOR; XENOPUS OOCYTES; PHOSPHORYLATION; BRAIN; INVOLVEMENT; BINDING; TUBULIN; CELLS	Microtubules are present at postsynaptic densities in brain and are proposed to be involved in anchoring neurotransmitter receptor clusters at postsynaptic membranes. However, the influence of microtubules on gamma-aminobutyric acid(A) (GABA(A)) receptors has not been studied. Microtubule-affecting agents were tested for their actions on GABA(A) receptor function, by measuring muscimol-stimulated chloride uptake into cerebral cortical microsacs and proteoliposomes and GABA-mediated currents in Xenopus laevis oocytes expressing GABA(A) receptors. Colchicine, nocodazole, vinblastine, and taxol inhibited muscimol-stimulated chloride uptake. beta- and gamma-lumicolchicine did not inhibit GABA(A)ergic function. Colchicine decreased the potency of muscimol, a GABA agonist, to stimulate chloride uptake without affecting the specific binding of [H-3]flunitrazepam or t-[S-35]butylbicyclophosphorothionate to the GABA(A) receptor, or the allosteric modulation of binding of these ligands by muscimol. The function of purified GABA(A) receptors reconstituted in proteoliposomes, a preparation not containing microtubule components, was not affected by colchicine. In contrast to the results seen in human monocytes by other investigators, we found that colchicine decreased, rather than increased, protein kinase A activity in cortical microsacs. Thus, protein kinase A modulation of the GABA(A) receptor is not a likely mechanism for the actions of colchicine. We propose that microtubule-depolymerizing agents inhibit GABA(A)ergic function by disrupting the interaction of GABA(A) receptors with microtubules.	UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,DENVER,CO 80262; VET ADM MED CTR,DENVER,CO 80262; UNIV NEW MEXICO,DEPT PHARMACOL,ALBUQUERQUE,NM 87131	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of New Mexico			Allan, Andrea M/L-8919-2015	Allan, Andrea/0000-0002-6745-4352	NIAAA NIH HHS [AA06399] Funding Source: Medline; NIGMS NIH HHS [GM14855] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM014855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006399, R37AA006399] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BAAS PW, 1991, J NEUROSCI RES, V30, P134, DOI 10.1002/jnr.490300115; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BORISY GG, 1974, FED PROC, V33, P167; BURNS RG, 1984, EUR J BIOCHEM, V141, P609, DOI 10.1111/j.1432-1033.1984.tb08236.x; CORNET M, 1993, J MEMBRANE BIOL, V133, P161; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; DUNN SMJ, 1989, BIOCHEMISTRY-US, V28, P2545, DOI 10.1021/bi00432a030; FROEHNER SC, 1993, NATURE, V366, P719, DOI 10.1038/366719a0; FROEHNER SC, 1990, NEURON, V5, P403, DOI 10.1016/0896-6273(90)90079-U; GORDONWEEKS PR, 1982, NEUROSCIENCE, V7, P739, DOI 10.1016/0306-4522(82)90079-3; HADINGHAM KL, 1993, MOL PHARMACOL, V43, P970; HARRIS RA, 1989, BRAIN RES, V490, P26; IQBAL K, 1986, LANCET, V2, P421; JALILIANTEHRANI MH, 1986, J NEUROCHEM, V46, P1542; JONSON BD, 1993, NEURON, V10, P797; KIRSCH J, 1991, J BIOL CHEM, V266, P22242; KIRSCH J, 1993, NATURE, V366, P745, DOI 10.1038/366745a0; LEIDENHEIMER NJ, 1992, MOL PHARMACOL, V41, P1116; LEIDENHEIMER NJ, 1991, TRENDS PHARMACOL SCI, V12, P84, DOI 10.1016/0165-6147(91)90509-Q; LEIDENHEIMER NJ, 1991, J NEUROCHEM, V57, P722, DOI 10.1111/j.1471-4159.1991.tb03806.x; LIN LH, 1992, J PHARMACOL EXP THER, V263, P569; LO MMS, 1982, P NATL ACAD SCI-BIOL, V79, P680, DOI 10.1073/pnas.79.2.680; MAIMONE MM, 1993, NEURON, V11, P53, DOI 10.1016/0896-6273(93)90270-2; MANIE S, 1993, J BIOL CHEM, V268, P13675; MATSUMOTO G, 1984, J MEMBRANE BIOL, V77, P77; MCPHERSON GA, 1983, COMPUT PROG BIOMED, V17, P107, DOI 10.1016/0010-468X(83)90031-4; MENDELKOW EM, 1992, FEBS LETT, V314, P315; MOSS SJ, 1992, SCIENCE, V257, P661, DOI 10.1126/science.1323140; RAJAN VP, 1985, ENDOCRINOLOGY, V117, P2408, DOI 10.1210/endo-117-6-2408; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; STAUBER GB, 1987, EUR J BIOCHEM, V167, P125, DOI 10.1111/j.1432-1033.1987.tb13313.x; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; VELAZQUEZ JL, 1989, J NEUROSCI, V9, P2163; WALKER JH, 1984, EMBO J, V3, P2287, DOI 10.1002/j.1460-2075.1984.tb02127.x; WANDOSELL F, 1986, J BIOL CHEM, V261, P332; WHITE WF, 1981, BRAIN RES, V215, P162, DOI 10.1016/0006-8993(81)90499-6; WHITING P, 1990, P NATL ACAD SCI USA, V87, P9966, DOI 10.1073/pnas.87.24.9966; WILSON L, 1967, BIOCHEMISTRY-US, V6, P3126, DOI 10.1021/bi00862a021; WILSON L, 1974, FED PROC, V33, P158	40	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19546	19552						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	7913471				2022-12-25	WOS:A1994NY33200054
J	YAMAGUCHI, A; OYAUCHI, R; SOMEYA, Y; AKASAKA, T; SAWAI, T				YAMAGUCHI, A; OYAUCHI, R; SOMEYA, Y; AKASAKA, T; SAWAI, T			2ND-SITE MUTATION OF ALA-220 TO GLU OR ASP SUPPRESSES THE MUTATION OF ASP-285 TO ASN IN THE TRANSPOSON TN10-ENCODED METAL-TETRACYCLINE/H(+) ANTIPORTER OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRACYCLINE RESISTANCE PROTEIN; NUCLEOTIDE-SEQUENCE; BACILLUS-SUBTILIS; MEMBRANE-PROTEIN; LACTOSE PERMEASE; H+ ANTIPORTER; TN10; GENE; CARRIER; DETERMINANTS	A carboxyl group of Asp-285 is essential for tetracycline/H+ antiport mediated by the transposon Tn10-encoded metal-tetracycline/H+ antiporter (TetA) of Escherichia coli (Yamaguchi, A., Akasaka, T., Ono, N., Someya, Y., Nakatani, M., and Sawai, T. (1992) J. Biol. Chem. 267, 7490-7498). Spontaneous tetracycline resistance revertants were isolated from E. coli cells carrying the Asn-285 mutant tetA gene. All of the revertants were due to the second-site mutation at codon 220 of GCG (Ala) to GAG (Glu). The K(m) value of the tetracycline transport mediated by the revertant TetA protein was about 4-fold higher than that of the wild-type, indicating that the revertant is a low affinity mutant. A Glu-220 and Asn-285 double mutant constructed by site-directed mutagenesis showed the same properties as the revertants, confirming that the mutation of Ala-220 is solely responsible for the suppression. The Asp-220 mutation of the Asn-285 mutant resulted in a lower level of restoration of the tetracycline resistance and the transport activity than in the case of the Glu-220 mutation. A single mutation replacing Ala-220 with Glu or Asp caused about a 2-4-fold decrease in the tetracycline resistance, but no crucial change in the transport activity. It is not likely that Glu-220 is required for a charge-neutralizing salt bridge because an unpaired negative charge in a Glu-220 or Asp-220 single mutant did not cause a serious change in the activity. An alternative explanation is reasonable; Asp-285 directly contributes to the binding of a cationic substrate, metal-tetracycline chelation complex, or proton, and an acidic residue at position 220 can take over the role of Asp-285.			YAMAGUCHI, A (corresponding author), CHIBA UNIV,FAC PHARMACEUT SCI,DIV MICROBIAL CHEM,CHIBA 263,JAPAN.							ALLARD JD, 1992, J BIOL CHEM, V267, P17809; BIBI E, 1991, P NATL ACAD SCI USA, V88, P7271, DOI 10.1073/pnas.88.16.7271; CHOPRA I, 1992, J ANTIMICROB CHEMOTH, V29, P245, DOI 10.1093/jac/29.3.245; CURIALE MS, 1984, J BACTERIOL, V157, P211, DOI 10.1128/JB.157.1.211-217.1984; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P3139, DOI 10.1021/bi00063a028; ECKERT B, 1989, J BIOL CHEM, V264, P11663; FOSTER DL, 1983, J BIOL CHEM, V258, P31; HENDERSON PJF, 1990, J BIOENERG BIOMEMBR, V22, P525, DOI 10.1007/BF00762961; HILLEN W, 1983, NUCLEIC ACIDS RES, V11, P525, DOI 10.1093/nar/11.2.525; KABACK HR, 1992, INT REV CYTOL, V137A, P97; KABACK HR, 1987, BIOCHEMISTRY-US, V26, P2071, DOI 10.1021/bi00382a001; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; LEE JI, 1992, J BIOL CHEM, V267, P20758; LEVY SB, 1992, ANTIMICROB AGENTS CH, V36, P695, DOI 10.1128/AAC.36.4.695; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; MCMURRY LM, 1992, J BACTERIOL, V174, P6294, DOI 10.1128/JB.174.19.6294-6297.1992; NEYFAKH AA, 1992, ANTIMICROB AGENTS CH, V36, P484, DOI 10.1128/AAC.36.2.484; NEYFAKH AA, 1991, P NATL ACAD SCI USA, V88, P4781, DOI 10.1073/pnas.88.11.4781; NGUYEN TT, 1983, GENE, V25, P83, DOI 10.1016/0378-1119(83)90170-1; RONGEY SH, 1993, P NATL ACAD SCI USA, V90, P1325, DOI 10.1073/pnas.90.4.1325; RUBIN RA, 1990, GENE, V87, P7, DOI 10.1016/0378-1119(90)90489-E; SAHINTOTH M, 1992, P NATL ACAD SCI USA, V89, P10547, DOI 10.1073/pnas.89.21.10547; STOKER NG, 1982, GENE, V18, P335, DOI 10.1016/0378-1119(82)90172-X; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WATERS SH, 1983, NUCLEIC ACIDS RES, V11, P6089, DOI 10.1093/nar/11.17.6089; YAMAGUCHI A, 1992, BIOCHEMISTRY-US, V31, P8344, DOI 10.1021/bi00150a031; YAMAGUCHI A, 1993, J BIOL CHEM, V268, P6496; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P4809; YAMAGUCHI A, 1991, J BIOL CHEM, V266, P6045; YAMAGUCHI A, 1990, FEBS LETT, V265, P17, DOI 10.1016/0014-5793(90)80872-G; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P15525; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P7490; YAMAGUCHI A, 1993, IN PRESS BIOCHEMISTR, V32; YAMAMOTO T, 1981, J BACTERIOL, V145, P808, DOI 10.1128/JB.145.2.808-813.1981; YOSHIDA H, 1990, J BACTERIOL, V172, P6942, DOI 10.1128/jb.172.12.6942-6949.1990	36	21	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26990	26995						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	7903301				2022-12-25	WOS:A1993MM26200026
J	MYERS, LC; JACKOW, F; VERDINE, GL				MYERS, LC; JACKOW, F; VERDINE, GL			METAL DEPENDENCE OF TRANSCRIPTIONAL SWITCHING IN ESCHERICHIA-COLI ADA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; REGULATORY PROTEIN; ALKYLATING-AGENTS; ADAPTIVE RESPONSE; METHYLTRANSFERASE; REPAIR; GENE; PHOSPHOTRIESTERS; EXPRESSION; RESISTANCE	The Escherichia coli Ada protein repairs methylphos photriesters in DNA by direct, irreversible methyl transfer to one of its own cysteine residues. The methyl transfer process is autocatalyzed by coordination of the acceptor residue, Cys(69), to, a tightly bound zinc ion. Kinetic data reveal a 4-fold reduction in the methylphosphotriester repair activity for the Cd(II) form of Ada versus the native Zn(II)-bound form, thus confirming a direct role for the metal in autocatalysis. Quantitative electrophoretic mobility shift assays reveal that the specific DNA affinity of the protein is increased 10(3)-fold by transfer of a methyl group to Cys(69); the Cd(II) and the Zn(II) forms of the protein behave similarly in this respect, This methylation-sensitive stimulation of binding underlies the ability of Ada to activate inducibly the transcription of a methylation-dependent regulon, We conclude that the chemical properties of the bound metal influence the transition state for autocatalytic methyl transfer, but not the structure that ultimately results from this process.	HARVARD UNIV,PROGRAM HIGHER DEGREES BIOPHYS,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University; Harvard University								AKIMARU H, 1990, J MOL BIOL, V216, P261, DOI 10.1016/S0022-2836(05)80318-3; BALEJA JD, 1992, NATURE, V356, P450, DOI 10.1038/356450a0; BAUER R, 1976, BIOCHEMISTRY-US, V15, P334, DOI 10.1021/bi00647a015; COATES JH, 1974, NATURE, V249, P773, DOI 10.1038/249773a0; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; COTTON FA, 1988, ADV INORG CHEM RAD, P597; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; DUBEY AK, 1992, NUCLEIC ACIDS RES, V20, P3167, DOI 10.1093/nar/20.12.3167; EZAZNIKPAY K, 1994, PROTEIN SCI, V3, P132; HAKURA A, 1991, J BACTERIOL, V173, P3663, DOI 10.1128/JB.173.12.3663-3672.1991; HAMBLIN MR, 1985, FEBS LETT, V189, P315, DOI 10.1016/0014-5793(85)81047-4; KUIJPERS WHA, 1990, NUCLEIC ACIDS RES, V18, P5197, DOI 10.1093/nar/18.17.5197; LANIR A, 1975, BIOCHEMISTRY-US, V14, P242, DOI 10.1021/bi00673a008; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; MCCARTHY JG, 1983, P NATL ACAD SCI-BIOL, V80, P7380, DOI 10.1073/pnas.80.24.7380; MCCARTHY TV, 1985, NUCLEIC ACIDS RES, V13, P2683, DOI 10.1093/nar/13.8.2683; MEISTERERNST M, 1988, NUCLEIC ACIDS RES, V16, P4419, DOI 10.1093/nar/16.10.4419; Myers L C, 1994, Chem Biol, V1, P91, DOI 10.1016/1074-5521(94)90046-9; MYERS LC, 1993, SCIENCE, V261, P1164, DOI 10.1126/science.8395079; MYERS LC, 1993, BIOCHEMISTRY-US, V32, P14089, DOI 10.1021/bi00214a003; MYERS LC, 1992, BIOCHEMISTRY-US, V31, P4541, DOI 10.1021/bi00134a002; NAKABEPPU Y, 1985, J BIOL CHEM, V260, P7281; OHKUBO T, 1984, J AM CHEM SOC, V116, P6035; PAN T, 1990, BIOCHEMISTRY-US, V29, P3023, DOI 10.1021/bi00464a019; PAN T, 1990, BIOCHEMISTRY-US, V29, P9218, DOI 10.1021/bi00491a016; SAKASHITA H, 1993, FEBS LETT, V323, P252, DOI 10.1016/0014-5793(93)81351-Y; SAKUMI K, 1989, J MOL BIOL, V205, P373, DOI 10.1016/0022-2836(89)90348-3; SEDGWICK B, 1988, J BIOL CHEM, V263, P4430; TAKEDA Y, 1989, P NATL ACAD SCI USA, V86, P439, DOI 10.1073/pnas.86.2.439; TEO I, 1984, EMBO J, V3, P2151, DOI 10.1002/j.1460-2075.1984.tb02105.x; TEO I, 1986, CELL, V45, P315, DOI 10.1016/0092-8674(86)90396-X; WESTHEIMER FH, 1987, SCIENCE, V235, P1173, DOI 10.1126/science.2434996	32	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6664	6670		10.1074/jbc.270.12.6664	http://dx.doi.org/10.1074/jbc.270.12.6664			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896807	Green Submitted, hybrid			2022-12-25	WOS:A1995QQ85500038
J	RYBA, NJP; TIRINDELLI, R				RYBA, NJP; TIRINDELLI, R			A NOVEL GTP-BINDING PROTEIN GAMMA-SUBUNIT, G-GAMMA-8, IS EXPRESSED DURING NEUROGENESIS IN THE OLFACTORY AND VOMERONASAL NEUROEPITHELIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENERGIC-RECEPTOR KINASE; HETEROTRIMERIC G-PROTEINS; CENTRAL-NERVOUS-SYSTEM; BETA-GAMMA; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; ADENYLYL CYCLASE; TYROSINE-PHOSPHATASE; ODORANT RECEPTORS; GENE-EXPRESSION	A novel heterotrimeric G-protein gamma-subunit has been cloned, and its function has been confirmed by expression and purification. This gamma-subunit is only detected in the olfactory epithelium, the vomeronasal epithelium and, to a lesser extent, the olfactory bulb. It is absent from all other tissues studied including the nasal respiratory epithelium, During development, expression of G gamma 8 in the olfactory epithelium parallels neurogenesis, peaking shortly after birth and declining in the adult. In situ hybridization studies localize expression of this novel gamma-subunit to the sensory neurons; hybridization is strongest in the region of the epithelium that contains immature neurons, Unlike proteins that are expressed only in mature olfactory neurons (e.g. olfactory marker protein or Golf alpha), expression of G gamma 8 in the olfactory epithelium is relatively unaffected by olfactory bulbectomy. In the vomeronasal epithelium expression of G gamma 8 is also highest in the developing neurons. Taken together, these findings are consistent with a very specific role for G gamma 8 in the development and turnover of olfactory and vomeronasal neurons.	UNIV PARMA,I-43100 PARMA,ITALY	University of Parma	RYBA, NJP (corresponding author), NIDR,IMMUNOL LAB,BLDG 10,RM 1A09,BETHESDA,MD 20892, USA.			Ryba, Nicholas/0000-0002-2060-8393				ASANO T, 1993, J BIOL CHEM, V268, P20512; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BARBER PC, 1978, BRAIN RES, V147, P297, DOI 10.1016/0006-8993(78)90841-7; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BOYER JL, 1994, J BIOL CHEM, V269, P2814; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; COSTANZO RM, 1983, J COMP NEUROL, V215, P370, DOI 10.1002/cne.902150403; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FISHER KJ, 1992, MOL CELL BIOL, V12, P1585, DOI 10.1128/MCB.12.4.1585; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIADEI PP, 1973, TISSUE CELL, V5, P113, DOI 10.1016/S0040-8166(73)80010-2; HAGMAN J, 1993, GENE DEV, V7, P760, DOI 10.1101/gad.7.5.760; HALPERN M, 1987, ANNU REV NEUROSCI, V10, P325, DOI 10.1146/annurev.ne.10.030187.001545; HOWARD PK, 1992, CELL, V71, P637, DOI 10.1016/0092-8674(92)90597-6; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; JONES DT, 1987, J BIOL CHEM, V262, P14241; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KINSELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934, DOI 10.1073/pnas.88.20.8934; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KUDRYCKI K, 1993, MOL CELL BIOL, V13, P3002, DOI 10.1128/MCB.13.5.3002; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; MEISAMI E, 1989, DEV BRAIN RES, V46, P9, DOI 10.1016/0165-3806(89)90139-9; MENCO BPM, 1988, J CELL SCI, V89, P495; Meredith M., 1983, P199; Moulton D. G, 1970, P227; MULLER S, 1993, P NATL ACAD SCI USA, V90, P10439, DOI 10.1073/pnas.90.22.10439; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NGAI J, 1993, CELL, V72, P657, DOI 10.1016/0092-8674(93)90396-8; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; RAY K, 1992, J BIOL CHEM, V267, P6086; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; ROGERS KE, 1987, P NATL ACAD SCI USA, V84, P1704, DOI 10.1073/pnas.84.6.1704; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; UEDA N, 1994, J BIOL CHEM, V269, P4388; VANDERHAEGHEN P, 1993, J CELL BIOL, V123, P1441, DOI 10.1083/jcb.123.6.1441; VUKICEVIC S, 1994, J HISTOCHEM CYTOCHEM, V42, P869, DOI 10.1177/42.7.8014470; WALTON KM, 1993, NEURON, V11, P387, DOI 10.1016/0896-6273(93)90193-U; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WILDMAN DE, 1993, P NATL ACAD SCI USA, V90, P794, DOI 10.1073/pnas.90.3.794; WILSON KCP, 1980, BRAIN RES, V185, P103, DOI 10.1016/0006-8993(80)90675-7; XIA ZG, 1992, NEUROSCI LETT, V144, P169, DOI 10.1016/0304-3940(92)90742-P; ZIGMAN JM, 1993, ENDOCRINOLOGY, V133, P2508, DOI 10.1210/en.133.6.2508	60	69	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6757	6767		10.1074/jbc.270.12.6757	http://dx.doi.org/10.1074/jbc.270.12.6757			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896821	hybrid			2022-12-25	WOS:A1995QQ85500052
J	DOMPENCIEL, RE; GARNEPUDI, VR; SCHOENBERG, DR				DOMPENCIEL, RE; GARNEPUDI, VR; SCHOENBERG, DR			PURIFICATION AND CHARACTERIZATION OF AN ESTROGEN-REGULATED XENOPUS LIVER POLYSOMAL NUCLEASE INVOLVED IN THE SELECTIVE DESTABILIZATION OF ALBUMIN MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; 3' UNTRANSLATED REGION; BINDING PROTEIN; ENDONUCLEOLYTIC CLEAVAGE; GENE-TRANSCRIPTION; IN-VITRO; SEQUENCE; LAEVIS; DEGRADATION; INSTABILITY	A previous report from this laboratory described an estrogen-regulated endoribonuclease activity on Xenopus liver polysomes which had properties one might expect for a messenger ribonuclease involved in the regulated destabilization of albumin mRNA (Pastori, R. L., Moskaitis, J. E., and Schoenberg, D. R. (1991) Biochemistry 30, 10490-10498). This report describes the purification and properties of this ribonuclease. The purified nuclease fraction contained a doublet of 62 and 64 kDa and a small amount of a 40-kDa peptide, In situ analysis on both denaturing and nondenaturing gels using an albumin transcript as substrate showed all three proteins possess nuclease activity. Peptide mapping and Western blot with a polyclonal antiserum showed the 62- and 64-kDa peptides to be isoforms, and the 40-kDa peptide to be a degradation product of the larger species. Two-dimensional gel electrophoresis further separated the 62- and 64-kDa species into three pairs of proteins, with isoelectric points of 9.6, 9.8, and 9.8. The purified ribonuclease rapidly degraded a full-length albumin transcript, yet had no effect on either a full-length albumin antisense transcript or full-length ferritin transcript, A number of properties of the purified nuclease were characterized, including the effects of salt, divalent cations, EDTA, sulfhydryl reagents, and temperature. Treatment of the polysomal nuclease with micrococcal nuclease had no effect, indicating that this enzyme does not require an RNA cofactor for activity. Finally, primer extension mapped the major cleavage site to an overlapping repeated sequence APyrUGA, with cleavage between and adjacent to the two pyrimidine residues generating fragments with 5'-hydroxyls.	UNIFORMED SERV UNIV HLTH SCI, SCH MED, DEPT PHARMACOL, BETHESDA, MD 20814 USA	Uniformed Services University of the Health Sciences - USA			Schoenberg, Daniel/J-3423-2019	Schoenberg, Daniel/0000-0003-4570-1946	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038277] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38277] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; BANDYOPADHYAY R, 1990, MOL CELL BIOL, V10, P2060, DOI 10.1128/MCB.10.5.2060; BEINTEMA JJ, 1988, PROG BIOPHYS MOL BIO, V51, P165, DOI 10.1016/0079-6107(88)90001-6; Belasco J.G., 2012, CONTROL MESSENGER RN; BINDER R, 1989, J BIOL CHEM, V264, P16910; BINDER R, 1994, EMBO J, V13, P1969, DOI 10.1002/j.1460-2075.1994.tb06466.x; BISBEE CA, 1977, SCIENCE, V195, P785, DOI 10.1126/science.65013; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BROWN BD, 1993, GENE DEV, V7, P1620, DOI 10.1101/gad.7.8.1620; BROWN BD, 1990, GENE DEV, V4, P1925, DOI 10.1101/gad.4.11.1925; CALVERT R, 1978, FEBS LETT, V86, P247, DOI 10.1016/0014-5793(78)80572-9; CHEN CYA, 1992, MOL CELL BIOL, V12, P5748, DOI 10.1128/MCB.12.12.5748; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COUTTS M, 1993, BIOCHIM BIOPHYS ACTA, V1173, P57, DOI 10.1016/0167-4781(93)90242-6; GREENBERG ME, 1993, CONTROL MESSENGER RN; HAEFLIGER DN, 1989, J MOL EVOL, V29, P344, DOI 10.1007/BF02103621; HARFORD JB, 1993, CONTROL MESSENGER RN; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; HUA J, 1993, NUCLEIC ACIDS RES, V21, P155, DOI 10.1093/nar/21.1.155; JAFFREY SR, 1993, NUCLEIC ACIDS RES, V21, P4627, DOI 10.1093/nar/21.19.4627; KARWAN R, 1993, FEBS LETT, V319, P1, DOI 10.1016/0014-5793(93)80025-P; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWELL JE, 1992, GENE DEV, V6, P2088, DOI 10.1101/gad.6.11.2088; MARTIN MB, 1986, J BIOL CHEM, V261, P2355; MCLAREN RS, 1993, J BIOL CHEM, V268, P14637; MOSKAITIS JE, 1991, BIOCHEM BIOPH RES CO, V174, P825, DOI 10.1016/0006-291X(91)91492-U; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; MUHLRAD D, 1994, NATURE, V370, P578, DOI 10.1038/370578a0; MULLER WEG, 1992, J MOL BIOL, V226, P721, DOI 10.1016/0022-2836(92)90628-W; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; NIELSEN FC, 1992, J BIOL CHEM, V267, P19404; PASTORI RL, 1993, ARCH BIOCHEM BIOPHYS, V305, P313, DOI 10.1006/abbi.1993.1428; PASTORI RL, 1991, BIOCHEMISTRY-US, V30, P10490, DOI 10.1021/bi00107a018; PASTORI RL, 1991, MOL ENDOCRINOL, V5, P461, DOI 10.1210/mend-5-4-461; PASTORI RL, 1990, BIOCHEMISTRY-US, V29, P2599, DOI 10.1021/bi00462a024; REDINBAUGH MG, 1985, ANAL BIOCHEM, V147, P144, DOI 10.1016/0003-2697(85)90020-X; RIEGEL AT, 1987, MOL ENDOCRINOL, V1, P160, DOI 10.1210/mend-1-2-160; ROSS J, 1986, J MOL BIOL, V188, P579, DOI 10.1016/S0022-2836(86)80008-0; ROSS J, 1987, J BIOL CHEM, V262, P9374; ROSS J, 1993, CONTROL MESSENGER RN; SCHOENBERG DR, 1981, NUCLEIC ACIDS RES, V9, P6669, DOI 10.1093/nar/9.24.6669; SHAPIRO DJ, 1989, RECENT PROG HORM RES, V45, P29; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	48	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					6108	6118		10.1074/jbc.270.11.6108	http://dx.doi.org/10.1074/jbc.270.11.6108			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890744				2022-12-25	WOS:A1995QM94500060
J	FUJIWARA, Y; OHATA, H; KUROKI, T; KOYAMA, K; TSUCHIYA, E; MONDEN, M; NAKAMURA, Y				FUJIWARA, Y; OHATA, H; KUROKI, T; KOYAMA, K; TSUCHIYA, E; MONDEN, M; NAKAMURA, Y			ISOLATION OF A CANDIDATE TUMOR-SUPPRESSOR GENE ON CHROMOSOME 8P21.3-P22 THAT IS HOMOLOGOUS TO AN EXTRACELLULAR DOMAIN OF THE PDGF RECEPTOR-BETA GENE	ONCOGENE			English	Article						TUMOR SUPPRESSOR GENE; PDGF RECEPTOR BETA; COLORECTAL CANCER; HEPATOCELLULAR CARCINOMA	GROWTH-FACTOR PDGF; CELL-LINES; IDENTIFICATION; DELETION; MUTATIONS; CANCER; FAMILY; LOCUS; CARCINOMAS; EXPRESSION	We have isolated a candidate tumor suppressor gene from a 600-kb region on chromosome 8p21.3-p22 that is commonly deleted in sporadic hepatocellular carcinomas (HCC), colorectal cancers (CRC), and non-small cell lung cancers (NSCLC). As this gene encodes a protein of 375 amino acids that bears significant sequence similarity to the extracellular (ligand-binding domain of platelet-derived growth factor receptor beta, we have designated it PRLTS (PDGF-receptor beta-like tumor suppressor). Structural rearrangement involving this gene was found in a sporadic NSCLC. In addition, somatic missense and frame-shift mutations were found in two HCCs and one CRC. These findings indicate that inactivation of the PRLTS gene may play a significant role in development of some carcinomas.	CANC INST,DEPT BIOCHEM,TOKYO 170,JAPAN; CANC INST,DEPT PATHOL,TOKYO 170,JAPAN; OSAKA UNIV,SCH MED,DEPT SURG 2,SUITA,OSAKA 565,JAPAN	Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; Osaka University								AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ANTONIADES HN, 1992, P NATL ACAD SCI USA, V89, P3942, DOI 10.1073/pnas.89.9.3942; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BERGQVIST MHJ, 1992, PHYTOCHEM ANALYSIS, V3, P215, DOI 10.1002/pca.2800030503; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; EMI M, 1992, CANCER RES, V52, P5368; EMI M, 1993, GENE CHROMOSOME CANC, V7, P152, DOI 10.1002/gcc.2870070307; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUJIWARA Y, 1994, GENE CHROMOSOME CANC, V10, P7, DOI 10.1002/gcc.2870100103; FUJIWARA Y, 1993, CANCER RES, V53, P1172; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; HERMANSSON M, 1988, P NATL ACAD SCI USA, V85, P7748, DOI 10.1073/pnas.85.20.7748; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KAMP A, 1994, SCIENCE, V264, P436; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KNOWLES MA, 1993, ONCOGENE, V8, P1357; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PENTAO L, 1992, NAT GENET, V2, P292, DOI 10.1038/ng1292-292; RASKIND WH, 1991, AM J HUM GENET, V49, P1355; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; ROZENGURT E, 1985, INT J CANCER, V36, P247, DOI 10.1002/ijc.2910360218; SARIBAN E, 1988, J CLIN INVEST, V82, P1157, DOI 10.1172/JCI113712; SHIBUYA M, 1988, CANCER RES, V48, P1930; SMITS A, 1992, AM J PATHOL, V140, P639; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; YAMAKAWA K, 1991, GENOMICS, V9, P536, DOI 10.1016/0888-7543(91)90421-A; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	34	112	123	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					891	895						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898930				2022-12-25	WOS:A1995QL03800010
J	ILG, T; OVERATH, P; FERGUSON, MAJ; RUTHERFORD, T; CAMPBELL, DG; MCCONVILLE, MJ				ILG, T; OVERATH, P; FERGUSON, MAJ; RUTHERFORD, T; CAMPBELL, DG; MCCONVILLE, MJ			O-GLYCOSYLATION AND N-GLYCOSYLATION OF THE LEISHMANIA-MEXICANA SECRETED ACID-PHOSPHATASE - CHARACTERIZATION OF A NEW CLASS OF PHOSPHOSERINE-LINKED GLYCANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DONOVANI PROMASTIGOTES; MONOCLONAL-ANTIBODIES; INTRALYSOSOMAL ACCUMULATION; VIRULENCE FACTORS; LIPOPHOSPHOGLYCAN; MACROPHAGES; EPITOPES; PHOSPHATIDYLINOSITOLS; IDENTIFICATION; PHOSPHOGLYCAN	The protozoan parasite Leishmania mexicana secretes a heavily glycosylated 100-kDa acid phosphatase (sAP) which is associated with one or more polydisperse proteophosphoglycans. Most of the glycans in this complex were released using mild acid hydrolysis conditions that preferentially cleave phosphodiester linkages. The released saccharides were shown to consist of monomeric mannose and a series of neutral and phosphorylated glycans by Dionex high performance liquid chromatography, methylation analysis, exoglycosidase digestions, and one-dimensional H-1 NMR spectroscopy. The neutral species comprised a linear series of oligosaccharides with the structures [Man alpha 1-2](1-5)Man. The phosphorylated oligosaccharides were characterized as PO4-6Gal beta 1-4Man and PO4-6[Glc beta 1-3]Gal beta 4Man. The attachment of these glycans to the polypeptide backbone via the linkage, Man alpha 1-PO4-Ser, is suggested by: 1) the finding that more than 60% of the serine residues in the polypeptide are phosphorylated and 2) the resistance of the phosphoserine residues to alkaline phosphatase digestion unless the sAP was first treated with either mild acid (to release all glycans) or jack bean alpha-mannosidase (to release neutral mannose glycans). Analysis of the partially resolved components of the complex indicated that the most of the O-linked glycans on the 100-kDa phosphoglycoprotein comprised mannose and the mannoseoligosaccharides. In contrast the major O-linked glycans on the proteophosphoglycan were short phosphoglycan chains, containing on average two repeat units per chain. In addition to the O-linked glycans, both components in the sAP complex contained N-linked glycans. The N-glycanase F-released glycans were characterized by Bio-Gel P4 chromatography and exoglycosidase digestions to be the biantennary oligomannose type with the structures Glc(1)Man(6)GlcNAc(2) and Man(6)GlcNAc(2). The O-linked glycans of the sAP complex are similar to those found in the phosphoglycan chains of the abundant surface lipophosphoglycan, but differ in having much shorter phosphoglycan chains and a more diverse series of mannose cap oligosaccharides. These data suggest that there are marked differences in the ability of different glycosyltransferases to utilize peptide-linked versus glycolipid-linked accepters.	UNIV MELBOURNE,DEPT BIOCHEM,PARKVILLE,VIC 3052,AUSTRALIA; MAX PLANCK INST BIOL,MEMBRANBIOCHEM ABT,D-72076 TUBINGEN,GERMANY; UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND	University of Melbourne; Max Planck Society; University of Dundee			Ferguson, Michael A. J./F-7829-2010; Campbell, David G/K-1874-2015	Ferguson, Michael A. J./0000-0003-1321-8714; Campbell, David G/0000-0003-2278-2149	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALEXANDER J, 1992, ADV PARASIT, V31, P175, DOI 10.1016/S0065-308X(08)60022-6; ANTOINE JC, 1990, INFECT IMMUN, V58, P779, DOI 10.1128/IAI.58.3.779-787.1990; ANTOINE JC, 1987, EXP PARASITOL, V64, P485, DOI 10.1016/0014-4894(87)90063-4; BAHR V, 1993, MOL BIOCHEM PARASIT, V58, P107, DOI 10.1016/0166-6851(93)90095-F; BATES PA, 1989, EXP PARASITOL, V68, P335, DOI 10.1016/0014-4894(89)90115-X; BATES PA, 1987, MOL BIOCHEM PARASIT, V26, P289, DOI 10.1016/0166-6851(87)90081-8; BATES PA, 1987, EXP PARASITOL, V64, P157, DOI 10.1016/0014-4894(87)90139-1; BATES PA, 1988, EXP PARASITOL, V67, P199, DOI 10.1016/0014-4894(88)90067-7; BATES PA, 1990, MOL BIOCHEM PARASIT, V39, P247, DOI 10.1016/0166-6851(90)90063-R; CHAN J, 1989, P NATL ACAD SCI USA, V86, P2453, DOI 10.1073/pnas.86.7.2453; FINN DJ, 1987, BIOCHEM BIOPH RES CO, V148, P834, DOI 10.1016/0006-291X(87)90951-X; GOTTLIEB M, 1982, MOL CELL BIOL, V2, P76, DOI 10.1128/MCB.2.1.76; GREIS KD, 1992, J BIOL CHEM, V267, P5876; GUSTAFSON GL, 1984, METHOD ENZYMOL, V107, P172; GUSTAFSON GL, 1980, J BIOL CHEM, V255, P7208; HANDMAN E, 1984, EMBO J, V3, P2301, DOI 10.1002/j.1460-2075.1984.tb02130.x; HELANDER A, 1992, CARBOHYD RES, V230, P299; ILG T, 1993, EUR J BIOCHEM, V217, P603, DOI 10.1111/j.1432-1033.1993.tb18283.x; ILG T, 1991, J CELL SCI, V99, P175; ILG T, 1991, P NATL ACAD SCI USA, V88, P8774, DOI 10.1073/pnas.88.19.8774; ILG T, 1992, J BIOL CHEM, V267, P6834; ILG T, 1994, IN PRESS PARASITOLOG; JAFFE CL, 1990, MOL BIOCHEM PARASIT, V41, P233, DOI 10.1016/0166-6851(90)90186-P; JANSSON PE, 1989, CARBOHYD RES, V188, P169, DOI 10.1016/0008-6215(89)84069-8; KIELIAN MC, 1982, J CELL BIOL, V93, P875, DOI 10.1083/jcb.93.3.875; KIELIAN MC, 1982, J CELL BIOL, V93, P866, DOI 10.1083/jcb.93.3.866; KING DL, 1987, MOL BIOCHEM PARASIT, V24, P47, DOI 10.1016/0166-6851(87)90114-9; LELOIR LF, 1957, METHOD ENZYMOL, V3, P840, DOI 10.1016/S0076-6879(57)03459-X; LEYVACOBIAN F, 1988, J IMMUNOL, V141, P1445; LOVELACE JK, 1987, J PROTOZOOL, V34, P78, DOI 10.1111/j.1550-7408.1987.tb03136.x; LOVELACE JK, 1987, MOL BIOCHEM PARASIT, V22, P19, DOI 10.1016/0166-6851(87)90065-X; LOVELACE JK, 1986, AM J TROP MED HYG, V35, P1121, DOI 10.4269/ajtmh.1986.35.1121; LOVELACE JK, 1986, MOL BIOCHEM PARASIT, V20, P243, DOI 10.1016/0166-6851(86)90105-2; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MCCONVILLE MJ, 1991, CELL BIOL INT REP, V15, P779, DOI 10.1016/0309-1651(91)90033-F; MCCONVILLE MJ, 1993, PARASITOL TODAY, V9, P316, DOI 10.1016/0169-4758(93)90225-5; MEDINAACOSTA E, 1993, INFECT AGENT DIS, V2, P25; NIKOLAEV AV, 1989, BIOORG KHIM+, V15, P1649; OLAFSON RW, 1990, J BIOL CHEM, V265, P12240; PARODI AJ, 1993, GLYCOBIOLOGY, V3, P193, DOI 10.1093/glycob/3.3.193; STIERHOF YD, 1994, J CELL BIOL, V125, P321, DOI 10.1083/jcb.125.2.321; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433	43	73	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24073	24081						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929059				2022-12-25	WOS:A1994PQ34600037
J	KANG, C; SUN, N; HONZATKO, RB; FROMM, HJ				KANG, C; SUN, N; HONZATKO, RB; FROMM, HJ			REPLACEMENT OF ASP(333) WITH ASN BY SITE-DIRECTED MUTAGENESIS CHANGES THE SUBSTRATE-SPECIFICITY OF ESCHERICHIA-COLI ADENYLOSUCCINATE SYNTHETASE FROM GUANOSINE 5'-TRIPHOSPHATE TO XANTHOSINE 5'-TRIPHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSENSUS SEQUENCE; MOLECULAR-CLONING; DEHYDROGENASE; PURIFICATION; REDESIGN; PROTEIN; MUSCLE; PURA	The aspartate residue of the (N/T)KXD concensus sequence for GTP-binding proteins is present in the eight available sequences of adenylosuccinate synthetase. Reported here is a comprehensive analysis of the substrate specificity of mutant enzymes, where the conserved Asp(333) of the synthetase from Escherichia coli is changed to asparagine, glutamate, and glutamine by site-directed mutagenesis. The mutants D333N, D333E, and D333Q generally show deceased k(cat) values and increased K-m values for GTP. The decreased values of k(cat) exhibited by the mutants indicate that the interactions between Asp(333) and the guanine are relayed by some mechanism to the catalytic residues around the gamma-phosphate of GTP, and that the energy provided by the interaction between Asp(333) and the guanine moiety of GTP is utilized for rearrangement of the catalytic residues. The three mutants each have higher affinity for xanthosine 5'-triphosphate (XTP) and ITP than does the wild-type enzyme. In fact, the D333N mutant uses XTP more effectively than the wild-type enzyme employs GTP as a substrate. The side-chain of Asp(333) forms hydrogen bonds with the N-1 and the exocyclic amino group of the guanine base of GTP. In the D333N mutant, this interaction is probably replaced by hydrogen bonds between the amide side chain of Asn(333) and N-1 and the 2-oxo group of XTP. The D333Q mutant can use UTP as a substrate more effectively than the wild-type enzyme. The longer side chain of glutamine at residue 333 favors pyrimidine nucleotides over the purine nucleotides, GTP, XTP, and ITP. These results demonstrate that Asp(333) in the (N/T)KXD consensus sequence of adenylosuccinate synthetase from E. coli is a determinant for GTP-specificity.	IOWA STATE UNIV SCI & TECHNOL,DEPT BIOCHEM & BIOPHYS,AMES,IA 50010	Iowa State University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 10546] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARNARA AS, 1974, EUR J BIOCHEM, V41, P421; BASS MB, 1987, ARCH BIOCHEM BIOPHYS, V256, P335, DOI 10.1016/0003-9861(87)90454-1; BONE R, 1989, NATURE, V339, P191, DOI 10.1038/339191a0; CASHEL M, 1975, ANNU REV MICROBIOL, V29, P301, DOI 10.1146/annurev.mi.29.100175.001505; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; GUICHERIT OM, 1994, J BIOL CHEM, V269, P4488; GUICHERIT OM, 1991, J BIOL CHEM, V266, P22582; HARDY LW, 1992, P NATL ACAD SCI USA, V89, P9725, DOI 10.1073/pnas.89.20.9725; HWANG YW, 1987, J BIOL CHEM, V262, P13081; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; KANG CH, 1994, ARCH BIOCHEM BIOPHYS, V310, P475, DOI 10.1006/abbi.1994.1195; KUSANO T, 1992, J BIOL CHEM, V267, P11242; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBERMAN I, 1956, J BIOL CHEM, V223, P327; LIU F, 1992, J BIOL CHEM, V267, P2388; MANTSALA P, 1992, J BACTERIOL, V174, P1883; POLAND BW, 1993, J BIOL CHEM, V268, P25334; POWELL SM, 1992, FEBS LETT, V303, P4, DOI 10.1016/0014-5793(92)80465-S; RUDOLPH FB, 1969, J BIOL CHEM, V244, P3832; Sambrook J, 1989, MOL CLONING LABORATO; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; SPEISER DM, 1992, MOL CELL BIOL, V12, P5301, DOI 10.1128/MCB.12.12.5301; STAYTON MM, 1983, CURR TOP CELL REGUL, V22, P103; TORNHEIM K, 1972, J BIOL CHEM, V247, P162; WEIJLAND A, 1994, TRENDS BIOCHEM SCI, V19, P188, DOI 10.1016/0968-0004(94)90018-3; WENG G, 1994, PROTEIN SCI, V3, P22; WIESMULLER L, 1991, J BIOL CHEM, V266, P2480; WILKS HM, 1988, SCIENCE, V242, P1541, DOI 10.1126/science.3201242; WOLFE SA, 1988, J BIOL CHEM, V263, P19147	30	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24046	24049						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929056				2022-12-25	WOS:A1994PQ34600033
J	APODACA, G; ENRICH, C; MOSTOV, KE				APODACA, G; ENRICH, C; MOSTOV, KE			THE CALMODULIN ANTAGONIST, W-13, ALTERS TRANSCYTOSIS, RECYCLING, AND THE MORPHOLOGY OF THE ENDOCYTIC PATHWAY IN MADIN-DARBY CANINE KIDNEY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; DEPENDENT PROTEIN-KINASE; NAPHTHALENESULFONAMIDE DERIVATIVES; CALCIUM-CALMODULIN; PLATELET SECRETION; TRANSFERRIN; TRIFLUOPERAZINE; PHOSPHORYLATION; INHIBITORS; EXOCYTOSIS	The effect of the calmodulin antagonist N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide (W-13) on the endosomal system of Madin-Darby canine kidney cells was assessed. W-13 inhibited receptor-mediated IgA. transcytosis, recycling of transferrin, and caused all material endocytosed from both surfaces of the cell to be delivered to exceptionally large, novel endosomal structures, which appear to be derived from early endosomes. Treatment with other calmodulin antagonists similarly inhibited transcytosis and caused large endosomes to form. These observations raise the possibility that calmodulin may be involved in regulating membrane trafficking through the endosomes of polarized epithelial cells.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA; UNIV BARCELONA, FAC MED, DEPT BIOL CELULAR & ANAT PATOL, BARCELONA 7, SPAIN	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Barcelona	APODACA, G (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT ANAT, S-1372, SAN FRANCISCO, CA 94143 USA.		Apodaca, Gerard/HCJ-0048-2022	mostov, keith/0000-0002-8123-6247; Enrich, Carlos/0000-0003-0382-2993	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025144] Funding Source: NIH RePORTER; NIAID NIH HHS [NIAID RO1 AI25144] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BREITFELD PP, 1989, J CELL BIOL, V109, P475, DOI 10.1083/jcb.109.2.475; BREITFELD PP, 1989, METHOD CELL BIOL, V32, P329; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CARDONE M, 1993, J CELL BIOCH C S, V17; CARDONE MH, 1994, J CELL BIOL, V124, P717, DOI 10.1083/jcb.124.5.717; CHAFOULEAS JG, 1982, CELL, V28, P41, DOI 10.1016/0092-8674(82)90373-7; CITI S, 1992, J CELL BIOL, V117, P169, DOI 10.1083/jcb.117.1.169; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; DAVIS TN, 1992, CELL, V71, P557, DOI 10.1016/0092-8674(92)90590-9; DIPAOLA M, 1984, J CELL PHYSIOL, V118, P193, DOI 10.1002/jcp.1041180212; GRASSO JA, 1990, BIOCHEM J, V266, P261, DOI 10.1042/bj2660261; HENQUIN JC, 1981, BIOCHEM J, V196, P771, DOI 10.1042/bj1960771; HIDAKA H, 1981, MOL PHARMACOL, V20, P571; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HORWITZ SB, 1981, J CELL BIOL, V91, P798, DOI 10.1083/jcb.91.3.798; HUNT RC, 1986, J BIOL CHEM, V261, P3681; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KRETSINGER RH, 1992, CELL CALCIUM, V13, P363, DOI 10.1016/0143-4160(92)90050-3; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MOSTOV KE, 1994, ANNU REV IMMUNOL, V12, P63, DOI 10.1146/annurev.immunol.12.1.63; NABI IR, 1991, J CELL BIOL, V115, P1573, DOI 10.1083/jcb.115.6.1573; NISHIKAWA M, 1980, NATURE, V287, P863, DOI 10.1038/287863a0; OHYA Y, 1994, SCIENCE, V263, P963, DOI 10.1126/science.8310294; PARTON RG, 1989, J CELL BIOL, V109, P3259, DOI 10.1083/jcb.109.6.3259; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; REDDY GPV, 1992, BIOCHEMISTRY-US, V31, P10426, DOI 10.1021/bi00158a002; SCHETTINI G, 1983, NEUROENDOCRINOLOGY, V37, P229, DOI 10.1159/000123548; SCHETTINI G, 1983, ENDOCRINOLOGY, V112, P64, DOI 10.1210/endo-112-1-64; STEINHARDT RA, 1982, NATURE, V295, P154, DOI 10.1038/295154a0; SULLIVAN KMC, 1993, CELL, V73, P1411, DOI 10.1016/0092-8674(93)90366-X; TANAKA T, 1988, BIOCHEM PHARMACOL, V37, P2537; TANAKA T, 1982, MOL PHARMACOL, V22, P403; TANAKA T, 1985, CALMODULIN ANTAGONIS, P524; TOOZE J, 1991, J CELL BIOL, V115, P635, DOI 10.1083/jcb.115.3.635; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107	40	80	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19005	19013						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	7913467				2022-12-25	WOS:A1994NX32700047
J	DEAN, NM; MCKAY, R; CONDON, TP; BENNETT, CF				DEAN, NM; MCKAY, R; CONDON, TP; BENNETT, CF			INHIBITION OF PROTEIN-KINASE C-ALPHA EXPRESSION IN HUMAN A549 CELLS BY ANTISENSE OLIGONUCLEOTIDES INHIBITS INDUCTION OF INTERCELLULAR-ADHESION MOLECULE-1 (ICAM-1) MESSENGER-RNA BY PHORBOL ESTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; HUMAN-BREAST-CANCER; GENE-EXPRESSION; DOWN-REGULATION; RNASE-H; POTENT; HYDROLYSIS; AGENTS; MYC; DNA	We have identified 20-mer phosphorothioate oligodeoxynucleotides which potently (IC50 values of 100-200 nM) and specifically inhibit protein kinase C (PKC)-(alpha mRNA and protein expression in human lung carcinoma (A549) cells. These oligonucleotides target multiple, diverse sites on PKC-alpha mRNA including the AUG translation codon and 3'-untranslated sequences. 2'-O-Methyl phosphorothioate analogs of these oligonucleotides were without effect on PKC-alpha( )mRNA levels, suggesting that the reduction in targeted PKC-alpha mRNA is through RNase H-mediated cleavage. One oligonucleotide, however, was effective at inhibiting PKC-alpha protein levels as a 2'-O-methyl phosphorothioate at concentrations 2-3-fold greater than its phosphorothioate/deoxy homolog. These results suggest that the ability to serve as an RNase H substrate, although not required for all oligonucleotides, certainly increases their potency. These oligonucleotides have been used to examine the role played by PKC-alpha in mediating the phorbol ester-induced changes in mRNA levels of the cell adhesion molecule ICAM-1. In A549 cells, ICAM-1 mRNA is increased 10-20-fold by treatment of cells with the phorbol ester phorbol 12-myristate 13-acetate. When PKC-alpha protein levels are depleted by oligonucleotide treatment of A549 cells, the increase in ICAM-1 expression in response to phorbol 12-myristate 13-acetate is greatly reduced, demonstrating that PKC-alpha plays a major role in this process.			DEAN, NM (corresponding author), ISIS PHARMACEUT,DEPT MOLEC & CELLULAR BIOL,2292 FARADAY AVE,CARLSBAD,CA 92008, USA.							AGRAWAL S, 1990, P NATL ACAD SCI USA, V87, P1401, DOI 10.1073/pnas.87.4.1401; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BAXTER GT, 1992, BIOCHEMISTRY-US, V31, P10950, DOI 10.1021/bi00160a002; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BORNER C, 1989, J BIOL CHEM, V264, P13902; BORNER C, 1988, P NATL ACAD SCI USA, V85, P2110, DOI 10.1073/pnas.85.7.2110; CHANG EH, 1991, BIOCHEMISTRY-US, V30, P8283, DOI 10.1021/bi00098a001; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; CROOKE ST, 1993, ANTISENSE RES APPLIC; DEGOLS G, 1991, NUCLEIC ACIDS RES, V19, P945, DOI 10.1093/nar/19.4.945; DOLNICK BJ, 1991, CANCER INVEST, V9, P185, DOI 10.3109/07357909109044229; ECKSTEIN F, 1989, TRENDS BIOCHEM SCI, V14, P97, DOI 10.1016/0968-0004(89)90130-8; FARESE RV, 1991, ANTISENSE RES DEV, V1, P35, DOI 10.1089/ard.1991.1.35; FINKENZELLER G, 1990, NUCLEIC ACIDS RES, V18, P2183, DOI 10.1093/nar/18.8.2183; GODSON C, 1990, J BIOL CHEM, V265, P8369; HANNUN YA, 1988, J BIOL CHEM, V263, P5124; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HUWILER A, 1991, BIOCHEM J, V279, P441, DOI 10.1042/bj2790441; INOUE H, 1987, FEBS LETT, V215, P327, DOI 10.1016/0014-5793(87)80171-0; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAIER JAM, 1993, EXP CELL RES, V205, P52, DOI 10.1006/excr.1993.1057; MARKUSSEKURA CJ, 1988, ANAL BIOCHEM, V172, P289; MEYER T, 1989, INT J CANCER, V43, P851, DOI 10.1002/ijc.2910430519; MONIA BP, 1992, J BIOL CHEM, V267, P19954; MYERS CL, 1992, AM J PHYSIOL, V262, pC365, DOI 10.1152/ajpcell.1992.262.2.C365; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; ROTHLEIN R, 1988, J IMMUNOL, V141, P1665; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SHAKIN SH, 1986, J BIOL CHEM, V261, P6018; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; STRAUSS M, 1992, ONCOGENE, V7, P769; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TORTORA G, 1991, P NATL ACAD SCI USA, V88, P2011, DOI 10.1073/pnas.88.5.2011; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WATSON PH, 1991, CANCER RES, V51, P3996; WERTHEIMER SJ, 1992, J BIOL CHEM, V267, P12030; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775	44	294	314	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16416	16424						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	7911467				2022-12-25	WOS:A1994NQ72900070
J	MORELOCK, MM; ROTHLEIN, R; BRIGHT, SM; ROBINSON, MK; GRAHAM, ET; SABO, JP; OWENS, R; KING, DJ; NORRIS, SH; SCHER, DS; WRIGHT, JL; ADAIR, JR				MORELOCK, MM; ROTHLEIN, R; BRIGHT, SM; ROBINSON, MK; GRAHAM, ET; SABO, JP; OWENS, R; KING, DJ; NORRIS, SH; SCHER, DS; WRIGHT, JL; ADAIR, JR			ISOTYPE CHOICE FOR CHIMERIC ANTIBODIES AFFECTS BINDING-PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Construction of a series of chimeric antibodies (murine variable region and human constant region) derived from the murine antibody BIRR1, which recognizes intercellular adhesion molecule 1 (ICAM-1), has revealed differences in the relative binding abilities of the chimeric antibody to antigen. The chimeric antibodies show a ranking of their ability to compete with BIRR1 for antigen on the surface of cells with the order BIRR1 = cIgG(1) (100%) > cIgG(4) (30%) > cIgG(2) (10%) as demonstrated by solid-phase competitive enzyme-linked immunosorbent assay. Papain digestion yielded Fab fragments that were purified to homogeneity. Competitive enzyme-linked immunosorbent assay showed that the chimeric and murine Fab binding constants were equivalent. A solution-phase binding assay (analyzed by size exclusion high performance liquid chromatography) between the intact mAbs and recombinant soluble ICAM-1 further established that the binding constants involving the Fab arms of the two antibodies were equivalent. In summary, the murine and chimeric anti-ICAM-1 antibodies bind cellular ICAM-1 with equivalent affinities but with differing avidities.	BOEHRINGER INGELHEIM PHARMACEUT INC, CTR RES & DEV, DEPT IMMUNOL, RIDGEFIELD, CT 06877 USA; BOEHRINGER INGELHEIM PHARMACEUT INC, CTR RES & DEV, DEPT MANAGEMENT INFORMAT SYST, RIDGEFIELD, CT 06877 USA; BOEHRINGER INGELHEIM PHARMACEUT INC, CTR RES & DEV, DEPT DRUG METAB & PHARMACOKINET, RIDGEFIELD, CT 06877 USA; BOEHRINGER INGELHEIM PHARMACEUT INC, CTR RES & DEV, DEPT PHARMACEUT, RIDGEFIELD, CT 06877 USA; CELLTECH LTD, CELLTECH RES, SLOUGH SL1 4EN, BERKS, ENGLAND	Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Celltech Group Ltd	MORELOCK, MM (corresponding author), BOEHRINGER INGELHEIM PHARMACEUT INC, CTR RES & DEV, DEPT BIOCHEM, 900 RIDGEBURY RD, POB 368, RIDGEFIELD, CT 06877 USA.			Owens, Ray/0000-0002-3705-2993				ADAIR JR, 1992, IMMUNOL REV, V130, P5, DOI 10.1111/j.1600-065X.1992.tb01519.x; ANGAL S, 1993, MOL IMMUNOL, V30, P105, DOI 10.1016/0161-5890(93)90432-B; BEBBINGTON C R, 1991, Methods (Orlando), V2, P136, DOI 10.1016/S1046-2023(05)80214-2; BENJAMIN RJ, 1986, J EXP MED, V163, P1539, DOI 10.1084/jem.163.6.1539; Blottiere H M, 1991, Hum Antibodies Hybridomas, V2, P16; BORREBAECK CA, 1992, ANTIBODY ENG, P69; BRUGGEMANN M, 1987, J EXP MED, V166, P1351, DOI 10.1084/jem.166.5.1351; BURTON DR, 1992, ADV IMMUNOL, V51, P1, DOI 10.1016/S0065-2776(08)60486-1; CHATENOUD L, 1986, J IMMUNOL, V137, P830; CHATENOUD L, 1986, IMMUNOL TODAY, V7, P367, DOI 10.1016/0167-5699(86)90028-9; COLCHER D, 1989, CANCER RES, V49, P1738; COSIMI AB, 1990, J IMMUNOL, V144, P4604; DANGL JL, 1988, EMBO J, V7, P1989, DOI 10.1002/j.1460-2075.1988.tb03037.x; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DILLMAN RO, 1990, ANTIBODY IMMUNOCONJ, V3, P1; DUSTIN ML, 1986, J IMMUNOL, V137, P245; GODING JW, 1980, J IMMUNOL METHODS, V39, P285, DOI 10.1016/0022-1759(80)90230-6; HARDMAN N, 1989, INT J CANCER, V44, P424, DOI 10.1002/ijc.2910440308; HORGAN C, 1993, J IMMUNOL, V150, P5400; HUTZELL P, 1991, CANCER RES, V51, P181; JACKSON AP, 1983, BIOCHEM J, V215, P505, DOI 10.1042/bj2150505; JIN FS, 1991, J IMMUNOL, V146, P1806; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; JONKER M, 1987, EUR J IMMUNOL, V17, P1547, DOI 10.1002/eji.1830171104; KHAZAELI MB, 1988, JNCI-J NATL CANCER I, V80, P937, DOI 10.1093/jnci/80.12.937; KING DJ, 1992, BIOCHEM J, V281, P317, DOI 10.1042/bj2810317; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOBUGLIO AF, 1989, P NATL ACAD SCI USA, V86, P4220, DOI 10.1073/pnas.86.11.4220; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MARLIN SD, 1990, NATURE, V344, P70, DOI 10.1038/344070a0; MASON DW, 1980, BIOCHEM J, V187, P1; MASON DW, 1986, HDB EXPT IMMUNOLOGY, V1; MATHIESON PW, 1990, NEW ENGL J MED, V323, P250, DOI 10.1056/NEJM199007263230407; MORRISON SL, 1984, P NATL ACAD SCI-BIOL, V81, P6851, DOI 10.1073/pnas.81.21.6851; Nezlin R, 1990, Adv Immunol, V48, P1, DOI 10.1016/S0065-2776(08)60750-6; NORRIS SH, 1991, J PHARMACEUT BIOMED, V9, P211, DOI 10.1016/0731-7085(91)80149-4; NYGREN H, 1989, IMMUNOLOGY, V66, P321; OI VT, 1984, NATURE, V307, P136, DOI 10.1038/307136a0; PINCUS MR, 1981, P NATL ACAD SCI USA, V78, P5924, DOI 10.1073/pnas.78.10.5924; REYNOLDS JC, 1989, NUCL MED BIOL, V16, P121, DOI 10.1016/0883-2897(89)90182-7; RIECHMANN L, 1988, NATURE, V332, P323, DOI 10.1038/332323a0; ROMANS DG, 1977, P NATL ACAD SCI USA, V74, P2531, DOI 10.1073/pnas.74.6.2531; ROTHLEIN R, 1993, INT ARCH ALLERGY IMM, V100, P121, DOI 10.1159/000236398; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDER WP, 1988, P NATL ACAD SCI USA, V85, P2509, DOI 10.1073/pnas.85.8.2509; SCHUMAKER VN, 1991, MOL IMMUNOL, V28, P1347, DOI 10.1016/0161-5890(91)90037-K; SEARS HF, 1984, J BIOL RESP MODIF, V3, P138; SHAW DR, 1988, J NATL CANCER I, V80, P1553, DOI 10.1093/jnci/80.19.1553; SHEARMAN CW, 1991, J IMMUNOL, V146, P928; SMITH CW, 1988, J CLIN INVEST, V82, P1746, DOI 10.1172/JCI113788; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STEPHENS PE, 1989, NUCLEIC ACIDS RES, V17, P7110, DOI 10.1093/nar/17.17.7110; STEPLEWSKI Z, 1988, P NATL ACAD SCI USA, V85, P4852, DOI 10.1073/pnas.85.13.4852; TAN LK, 1990, P NATL ACAD SCI USA, V87, P162, DOI 10.1073/pnas.87.1.162; VALENTINE RC, 1967, J MOL BIOL, V27, P615, DOI 10.1016/0022-2836(67)90063-0; WAWRYK SO, 1989, IMMUNOL REV, V108, P135, DOI 10.1111/j.1600-065X.1989.tb00016.x; WHITTLE N, 1987, PROTEIN ENG, V1, P499, DOI 10.1093/protein/1.6.499	59	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					13048	13055						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	7909805				2022-12-25	WOS:A1994NH71600102
J	YUEN, PST; DOOLITTLE, LK; GARBERS, DL				YUEN, PST; DOOLITTLE, LK; GARBERS, DL			DOMINANT-NEGATIVE MUTANTS OF NITRIC OXIDE-SENSITIVE GUANYLYL CYCLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NATRIURETIC-PEPTIDE RECEPTOR; CATALYTIC ACTIVITY; ADENYLYL CYCLASE; BOVINE LUNG; RAT LUNG; EXPRESSION; CLONING; ENZYME	Since a nitric oxide-sensitive form of guanylyl cyclase exists as a heterodimer, mutations disrupting catalysis but not heterodimer formation could serve as dominant negative mutations. Two mutations within the catalytic region of the a subunit (alpha1D513A, alpha1D529A) caused complete losses of basal and sodium nitroprusside-stimulated guanylyl cyclase activity; however, the mutant alpha subunits continued to form heterodimers with wild-type beta-subunit. Rat insulinoma cells, which contain the alpha1beta1 form of guanylyl cyclase, were stably transfected with alpha1D513A or alpha1D529A. The response to sodium nitroprusside, which exceeded 200-fold in the presence of wild-type alpha1, was markedly reduced by the expression of either mutant subunit. In contrast, the mutant subunits failed to inhibit heat-stable enterotoxin-induced cGMP elevations; the bacterial peptide elevated insulinoma cell cGMP approximately 100-fold. The two point mutations, therefore, result in dominant negative proteins that can effectively and specifically block the NO/cGMP signaling pathway. These are also the first studies to show that, although both the alpha and beta subunits contain regions homologous to putative cyclase catalytic regions, a point mutation in just one of the subunits can completely inhibit cyclase activity.	UNIV TEXAS, SW MED CTR, HOWARD HUGHES INST, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			ST Yuen, Peter/B-1954-2008	ST Yuen, Peter/0000-0001-9557-3909				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BEBENEK K, 1989, NUCLEIC ACIDS RES, V17, P5408, DOI 10.1093/nar/17.13.5408; CHINKERS M, 1992, J BIOL CHEM, V267, P18589; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CLARK SA, 1990, ENDOCRINOLOGY, V127, P2779, DOI 10.1210/endo-127-6-2779; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DOMINO SE, 1991, METHOD ENZYMOL, V195, P345; GARBERS DL, 1979, J BIOL CHEM, V254, P240; GARBERS DL, 1992, CELL, V71, P1; GERZER R, 1981, FEBS LETT, V132, P71, DOI 10.1016/0014-5793(81)80429-2; HARTENECK C, 1990, FEBS LETT, V272, P221, DOI 10.1016/0014-5793(90)80489-6; HUMBERT P, 1990, EUR J BIOCHEM, V190, P273, DOI 10.1111/j.1432-1033.1990.tb15572.x; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; KAMISAKI Y, 1986, J BIOL CHEM, V261, P7236; KATSUSHIKA S, 1993, J BIOL CHEM, V268, P2273; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LOWE DG, 1992, BIOCHEMISTRY-US, V31, P10421, DOI 10.1021/bi00158a001; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; MONCADA S, 1991, PHARMACOL REV, V43, P109; NAKANE M, 1990, J BIOL CHEM, V265, P16841; NAKANE M, 1988, BIOCHEM BIOPH RES CO, V156, P1000; RAPOPORT RM, 1983, J CYCLIC NUCL PROT, V9, P281; RETTORI V, 1992, P NATL ACAD SCI USA, V89, P11543, DOI 10.1073/pnas.89.23.11543; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; TANG WJ, 1991, J BIOL CHEM, V266, P8595; THORPE DS, 1991, BIOCHEM BIOPH RES CO, V180, P538, DOI 10.1016/S0006-291X(05)81098-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VEDIA LM, 1992, J BIOL CHEM, V267, P24929; WALSETH TF, 1991, METHOD ENZYMOL, V195, P29; YUEN PST, 1992, ANNU REV NEUROSCI, V15, P193	32	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					791	793						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7904602				2022-12-25	WOS:A1994MR22000002
J	ERIJMAN, L; PALADINI, AA; LORIMER, GH; WEBER, G				ERIJMAN, L; PALADINI, AA; LORIMER, GH; WEBER, G			PLURALITY OF PROTEIN CONFORMATIONS OF RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE OXYGENASE MONOMERS PROBED BY HIGH-PRESSURE ELECTROPHORESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-BISPHOSPHATE CARBOXYLASE; GEL-ELECTROPHORESIS; HYDROSTATIC-PRESSURE; STATE	We used hydrostatic pressure in the range of 1 to 2 kbar, coupled with polyacrylamide gel electrophoresis, to investigate the properties of monomers of dimeric ribulose bisphosphate carboxylase/oxygenase. At temperatures below -5-degrees-C or pressures above 1.5 kbar, only a diffuse band with low electrophoretic mobility was observed, which is assigned to a denatured monomer. In gels run at 1.0 kbar and temperatures above 0-degrees-C, both the wild type and a mutant in which a positively charged Lys at the dimer interface is replaced by a negatively charged glutamic acid displayed several discrete bands with retardation coefficients larger than that of the dimer. Cross-linking due to oxidation of cysteines was not the reason for the multiplicity of bands, which in addition were independent on the length of the electrophoretic run in the range of 1-3 h. Binding of 1,1'-bis(4-anilino) naphthalene-5,5'-disulfonic acid to the pressure dissociated monomers stabilized the unfolded conformations. We propose that the dissociated monomers adopt various expanded conformations, which, under the experimental conditions, are stabilized to the extent necessary to be considered as distinct chemical species. Gel filtration high performance liquid chromatography analysis of bands eluted from nonstained gels run at 1 kbar (15-degrees-C) and 1.5 kbar (-5-degrees-C), respectively, was performed. In both cases the dimeric structure was fully recovered, along with the spectroscopic properties and catalytic activity characteristic of the native dimer, indicating that the unresolved unfolded conformers that appear at -5-degrees-C, as well as the set of discrete conformers obtained at 15-degrees-C, are able to reconstitute a single active conformation on reassociation.	UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801; DUPONT CO INC,EXPTL STN,CENT RES & DEV,DIV MOLEC BIOL,WILMINGTON,DE 19880; CONSEJO NACL INVEST CIENT & TECN,INGEBI,RA-1428 BUENOS AIRES,ARGENTINA	University of Illinois System; University of Illinois Urbana-Champaign; DuPont; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)			Erijman, Leonardo/AAI-1359-2020	Erijman, Leonardo/0000-0001-7525-2112	NIGMS NIH HHS [GM-11223] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ERIJMAN L, 1993, BIOCHEMISTRY-US, V32, P5187, DOI 10.1021/bi00070a030; ERIJMAN L, 1991, BIOCHEMISTRY-US, V30, P1595, DOI 10.1021/bi00220a022; EWBANK JJ, 1991, NATURE, V350, P518, DOI 10.1038/350518a0; FERGUSON KA, 1964, METABOLISM, V13, P985, DOI 10.1016/S0026-0495(64)80018-4; GOLDENBERG DP, 1984, ANAL BIOCHEM, V138, P1, DOI 10.1016/0003-2697(84)90761-9; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRIKO YV, 1988, P NATL ACAD SCI USA, V85, P3343, DOI 10.1073/pnas.85.10.3343; HEREMANS K, 1982, ANNU REV BIOPHYS BIO, V11, P1, DOI 10.1146/annurev.bb.11.060182.000245; Jaenicke R, 1986, Methods Enzymol, V131, P218; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LILLEY RM, 1974, BIOCHIM BIOPHYS ACTA, V358, P226, DOI 10.1016/0005-2744(74)90274-5; MULLER K, 1981, BIOPHYS CHEM, V14, P101, DOI 10.1016/0301-4622(81)85011-9; MURAL RJ, 1990, J BIOL CHEM, V265, P6501; NEUMAN RC, 1973, J PHYS CHEM-US, V77, P2687, DOI 10.1021/j100640a025; PALADINI AA, 1981, REV SCI INSTRUM, V52, P419, DOI 10.1063/1.1136596; PALADINI AA, 1987, ANAL BIOCHEM, V161, P358, DOI 10.1016/0003-2697(87)90463-5; PIERCE J, 1986, APPL ENVIRON MICROB, V49, P1094; PRIVALOV P, 1990, CRC CRIT REV BIOCH M, V25, P287; RODBARD D, 1970, P NATL ACAD SCI USA, V65, P970, DOI 10.1073/pnas.65.4.970; RODBARD D, 1971, ANAL BIOCHEM, V40, P95, DOI 10.1016/0003-2697(71)90086-8; SILVA JL, 1993, ANNU REV PHYS CHEM, V44, P89, DOI 10.1146/annurev.pc.44.100193.000513; VANDERVIES SM, 1992, BIOCHEMISTRY-US, V31, P3635, DOI 10.1021/bi00129a012; WEBER G, 1986, BIOCHEMISTRY-US, V25, P3626, DOI 10.1021/bi00360a022; WEBER G, 1983, Q REV BIOPHYS, V16, P89, DOI 10.1017/S0033583500004935; WEBER G, 1991, NEW TRENDS BIOL CHEM, P225	25	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25914	25919						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7902356				2022-12-25	WOS:A1993MK10000090
J	SOGAARD, M; KADZIOLA, A; HASER, R; SVENSSON, B				SOGAARD, M; KADZIOLA, A; HASER, R; SVENSSON, B			SITE-DIRECTED MUTAGENESIS OF HISTIDINE-93, ASPARTIC ACID-180, GLUTAMIC ACID-205, HISTIDINE-290, AND ASPARTIC ACID-291 AT THE ACTIVE-SITE AND TRYPTOPHAN-279 AT THE RAW STARCH BINDING-SITE IN BARLEY ALPHA-AMYLASE 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPERGILLUS-NIGER; TAKA-AMYLASE; BACILLUS-STEAROTHERMOPHILUS; RESIDUES; SEQUENCE; MALT; ALPHA-AMYLASE-1; GLUCOAMYLASE-G2; IDENTIFICATION; RESOLUTION	The pseudotetrasaccharide acarbose has high affinity for the active site (K(i,app) = 1 muM) and low affinity for a secondary site (K(d) = 2.3 mM) in barley alpha-amylase 1, distinguished by inhibition kinetics and spectral perturbation. Mutants of putative catalytic residues, D180N, E205Q, and D291N, are inactive and display low affinity for acarbose-Sepharose. H93N and H290N mutants, at invariant residues, have k(cat)/K(m) for p-nitrophenylmaltoheptaoside of 0.3 and 1.2% of wild-type. A corresponding 370- and 85-fold increased K(i,app) for acarbose and a lack of shifts in pH activity profiles indicate that these histidines participate in transition state stabilization but not directly in catalysis. This finding agrees with H bonding to OH groups of the valienamine ring of acarbose in the three-dimensional structure. Loss of inhibition above pH 6 supports that acarbose is most potent in protonated form. The low affinity site contains Trp278 and Trp279, known to bind cyclomaltoheptaose. While the W279A mutant has 10-fold decreased affinity for starch granules, production of Trp278 mutants failed. The invariant Trp278 is perhaps critical for stability or folding in cereal alpha-amylases.	CARLSBERG LAB,DEPT CHEM,GAMLE CARLSBERG VEJ 10,DK-2500 VALBY,DENMARK; FAC MED MARSEILLE,CRISTALLOG & CRISTALLISAT MACROMOLEC BIOL LAB,CNRS,F-13326 MARSEILLE 15,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite				Svensson, Birte/0000-0002-2993-8196				AJANDOUZ EH, 1992, BIOCHIM BIOPHYS ACTA, V1159, P193, DOI 10.1016/0167-4838(92)90025-9; [Anonymous], 1960, ENZYMES; BAULCOMBE DC, 1987, MOL GEN GENET, V209, P33, DOI 10.1007/BF00329833; BOEL E, 1990, BIOCHEMISTRY-US, V29, P6244, DOI 10.1021/bi00478a019; BRAUN PJ, 1985, ARCH BIOCHEM BIOPHYS, V242, P231, DOI 10.1016/0003-9861(85)90497-7; BUISSON G, 1987, EMBO J, V6, P3909, DOI 10.1002/j.1460-2075.1987.tb02731.x; CHAN YC, 1984, BIOCHEMISTRY-US, V23, P5795, DOI 10.1021/bi00319a019; CHIBA S, 1990, 15TH INT CARB S YOK; CLARKE AJ, 1984, CARLSBERG RES COMMUN, V49, P559, DOI 10.1007/BF02908684; CLARKE AJ, 1984, CARLSBERG RES COMMUN, V49, P111, DOI 10.1007/BF02913970; FOX JD, 1991, ANAL BIOCHEM, V195, P93, DOI 10.1016/0003-2697(91)90300-I; GIBSON RM, 1987, CARLSBERG RES COMMUN, V52, P373, DOI 10.1007/BF02907525; GIBSON RM, 1986, CARLSBERG RES COMMUN, V51, P295, DOI 10.1007/BF02907163; HANOZET G, 1981, J BIOL CHEM, V256, P3703; HUANG N, 1990, NUCLEIC ACIDS RES, V18, P7007, DOI 10.1093/nar/18.23.7007; ISHIKAWA K, 1992, BIOCHEM BIOPH RES CO, V183, P286, DOI 10.1016/0006-291X(92)91641-3; ISODA Y, 1992, J BIOCHEM-TOKYO, V111, P204, DOI 10.1093/oxfordjournals.jbchem.a123738; KLEIN C, 1992, BIOCHEMISTRY-US, V31, P8740, DOI 10.1021/bi00152a009; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURIKI T, 1991, J BACTERIOL, V173, P6147, DOI 10.1128/jb.173.19.6147-6152.1991; LOWE DM, 1985, BIOCHEMISTRY-US, V24, P5106, DOI 10.1021/bi00340a022; MACGREGOR AW, 1979, CEREAL CHEM, V56, P430; MACGREGOR AW, 1992, CARBOHYD RES, V227, P301, DOI 10.1016/0008-6215(92)85080-J; MacGregor E. A., 1985, In 'New approaches to research on cereal carbohydrates' [see FSTA (1986) 18 9M38]., P149; MACGREGOR EA, 1985, CARBOHYD RES, V142, P223, DOI 10.1016/0008-6215(85)85025-4; MACGREGOR EA, 1988, J PROTEIN CHEM, V7, P399, DOI 10.1007/BF01024888; MATSUURA Y, 1984, J BIOCHEM-TOKYO, V95, P697, DOI 10.1093/oxfordjournals.jbchem.a134659; Messing J, 1979, RECOMBINANT DNA TECH, V2, P43; MISAKI A, 1982, CARBOHYD RES, V109, P207, DOI 10.1016/0008-6215(82)84039-1; MOOSER G, 1991, J BIOL CHEM, V266, P8916; NAGASHIMA T, 1992, BIOSCI BIOTECH BIOCH, V56, P207, DOI 10.1271/bbb.56.207; NAKAJIMA R, 1986, APPL MICROBIOL BIOT, V23, P355; NAKAMURA A, 1992, FEBS LETT, V296, P37, DOI 10.1016/0014-5793(92)80398-Z; RAUSCHER E, 1982, FRESEN Z ANAL CHEM, V311, P454, DOI 10.1007/BF00481820; ROGERS JC, 1983, J BIOL CHEM, V258, P8169; Sambrook J, 1989, MOL CLONING LABORATO; SOGAARD M, 1990, GENE, V94, P173, DOI 10.1016/0378-1119(90)90384-4; SOGAARD M, 1991, P NATL ACAD SCI USA, V88, P8140, DOI 10.1073/pnas.88.18.8140; STRYNADKA NCJ, 1991, J MOL BIOL, V220, P401, DOI 10.1016/0022-2836(91)90021-W; SVENSSON B, 1988, FEBS LETT, V230, P72, DOI 10.1016/0014-5793(88)80644-6; SVENSSON B, 1993, J BIOTECHNOL, V29, P1, DOI 10.1016/0168-1656(93)90038-O; TAKASE K, 1992, BIOCHIM BIOPHYS ACTA, V1120, P281, DOI 10.1016/0167-4838(92)90249-D; TAKEDA Y, 1983, BIOCHIM BIOPHYS ACTA, V749, P302, DOI 10.1016/0167-4838(83)90240-6; TAO BY, 1989, BIOCHIM BIOPHYS ACTA, V995, P214, DOI 10.1016/0167-4838(89)90038-1; TRUSCHEIT E, 1981, ANGEW CHEM, V93, P738; VERNON CA, 1967, PROC R SOC SER B-BIO, V167, P389, DOI 10.1098/rspb.1967.0036; VIHINEN M, 1990, J BIOCHEM-TOKYO, V107, P267, DOI 10.1093/oxfordjournals.jbchem.a123037; Vihinen M, 1991, MOL ENG, V1, P267; WESELAKE RJ, 1983, CEREAL CHEM, V60, P98; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	51	138	176	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22480	22484						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7901200				2022-12-25	WOS:A1993MD34800046
J	SHIMIZU, A; HONJO, T				SHIMIZU, A; HONJO, T			SYNTHESIS AND REGULATION OF TRANS-MESSENGER RNA ENCODING THE IMMUNOGLOBULIN-EPSILON HEAVY-CHAIN	FASEB JOURNAL			English	Article						POLYMERASE CHAIN REACTION; TRANSGENIC MU-CHAIN; TRANSCRIPTION	SWITCH CIRCULAR DNA; ISOTYPE EXPRESSION; MEMBRANE FORM; B-CELLS; REARRANGEMENT; RECOMBINATION; MOUSE; INTERLEUKIN-4; GENES; MU	We have detected an immunoglobulin heavy-chain trans-mRNA of the epsilon class in which the variable region of the human transgenic mu chain is correctly spliced to the first exon of the endogenous mouse epsilon constant region. Together with our previous observations, all the endogenous isotypes that are targets of class switching have proved to be expressed as trans-mRNA. This indicates that immunoglobulin trans-mRNA synthesis is a general mechanism to express a second heavy-chain isotype with the variable region of the transgenic mu chain. Synthesis of epsilon trans-mRNA is regulated in a way similar to the trans-mRNAs of the gamma subclasses or class switching to epsilon, i.e., interleukin-4 can induce the germline transcript of the epsilon constant region, but costimulation with lipopolysaccharide is necessary for epsilon trans-mRNA expression. The amount of epsilon trans-mRNA induced is similar to that of gamma1 and higher than expected as judged from the rate of class switching to epsilon. All these data are consistent with our previous hypothesis that trans-mRNA is synthesized by a trans-splicing mechanism and that this mechanism is involved in the simultaneous multiple-isotype expression of immunoglobulin in a single B lymphocyte.	KYOTO UNIV,FAC MED,DEPT MED CHEM,SAKYO KU,KYOTO 60601,JAPAN	Kyoto University	SHIMIZU, A (corresponding author), KYOTO UNIV,CTR MOLEC BIOL & GENET,SAKYO KU,KYOTO 60601,JAPAN.		Honjo, Tasuku/N-4470-2016					CHEN YW, 1986, J EXP MED, V164, P562, DOI 10.1084/jem.164.2.562; ESSER C, 1990, ANNU REV IMMUNOL, V8, P717, DOI 10.1146/annurev.iy.08.040190.003441; FRIEDLANDER RM, 1990, NUCLEIC ACIDS RES, V18, P4278, DOI 10.1093/nar/18.14.4278; GERSTEIN RM, 1990, CELL, V63, P537, DOI 10.1016/0092-8674(90)90450-S; Guise J. W., 1989, Immunoglobulin genes., P275; HAN H, 1991, INT IMMUNOL, V3, P1197, DOI 10.1093/intimm/3.12.1197; HONJO T, 1983, ANNU REV IMMUNOL, V1, P499, DOI 10.1146/annurev.iy.01.040183.002435; IWASATO T, 1990, CELL, V62, P143, DOI 10.1016/0092-8674(90)90248-D; KINASHI T, 1987, GENE DEV, V1, P465, DOI 10.1101/gad.1.5.465; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; MAKI R, 1981, CELL, V24, P353, DOI 10.1016/0092-8674(81)90325-1; MATSUOKA M, 1990, CELL, V62, P135, DOI 10.1016/0092-8674(90)90247-C; MOORE KW, 1981, P NATL ACAD SCI-BIOL, V78, P1800, DOI 10.1073/pnas.78.3.1800; NOLANWILLARD M, 1992, P NATL ACAD SCI USA, V89, P1234, DOI 10.1073/pnas.89.4.1234; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; PERLMUTTER AP, 1984, P NATL ACAD SCI-BIOL, V81, P7189, DOI 10.1073/pnas.81.22.7189; PERNIS B, 1976, COLD SPRING HARB SYM, V41, P175; ROTHMAN P, 1990, MOL CELL BIOL, V10, P1672, DOI 10.1128/MCB.10.4.1672; SHIMIZU A, 1991, J EXP MED, V173, P1385, DOI 10.1084/jem.173.6.1385; SHIMIZU A, 1989, P NATL ACAD SCI USA, V86, P8020, DOI 10.1073/pnas.86.20.8020; SHIMIZU A, 1989, COLD SPRING HARB SYM, V54, P175, DOI 10.1101/SQB.1989.054.01.022; SHIMIZU A, 1984, CELL, V36, P801, DOI 10.1016/0092-8674(84)90029-1; SHINKAI Y, 1988, IMMUNOGENETICS, V27, P288, DOI 10.1007/BF00376124; Sideras P, 1989, Int Immunol, V1, P631, DOI 10.1093/intimm/1.6.631; SIEBENKOTTEN G, 1992, EUR J IMMUNOL, V22, P1827, DOI 10.1002/eji.1830220723; SNAPPER CM, 1988, J EXP MED, V167, P183, DOI 10.1084/jem.167.1.183; VANHOVE B, 1991, MOL IMMUNOL, V29, P1; VONSCHWEDLER U, 1990, NATURE, V345, P452, DOI 10.1038/345452a0; YAOITA Y, 1982, NATURE, V297, P697, DOI 10.1038/297697a0; YOSHIDA K, 1990, P NATL ACAD SCI USA, V87, P7829, DOI 10.1073/pnas.87.20.7829	30	34	36	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1993	7	1					149	154		10.1096/fasebj.7.1.7916698	http://dx.doi.org/10.1096/fasebj.7.1.7916698			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	7916698				2022-12-25	WOS:A1993KH88000022
J	CORRETTEBENNETT, SE; LOVETT, ST				CORRETTEBENNETT, SE; LOVETT, ST			ENHANCEMENT OF RECA STRAND-TRANSFER ACTIVITY BY THE RECJ EXONUCLEASE OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOLOGOUS RECOMBINATION; BRANCH MIGRATION; PROTEIN; DNA; EXCHANGE; PURIFICATION; MECHANISM; POLARITY; BINDING; GENE	We have examined coupled reactions with the RecA protein of Escherichia coli, which can mediate DNA strand exchange in vitro between homologous DNA molecules, and the RecJ exonuclease, a 5' to 3' single-stranded DNA exonuclease. In RecA-mediated strand-transfer reactions between circular single-stranded and duplex linear DNA, we have found that RecJ stimulates the rate of heteroduplex product formation. Because RecJ must be present concurrent with strand transfer and RecJ does not detectably stimulate the synapsis stage of the reaction, we believe that RecJ stimulates specifically the branch migration phase of the RecA strand-transfer reaction. RecJ also dramatically enhances the efficiency with which RecA is able to traverse regions of non-homology in the substrates. We propose a model where RecJ degrades the displaced strand produced by strand exchange which competes for pairing with the transferred strand, thus driving forward the unidirectional branch migration mediated by RecA protein. This suggests a new role for exonucleases in genetic recombination, facilitating the strand-transfer reaction itself.	BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254; BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254	Brandeis University; Brandeis University			Lovett, Susan/AAC-1810-2021	Lovett, Susan/0000-0003-2792-1857	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043889] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43889] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEDALE WA, 1993, J BIOL CHEM, V268, P15004; BIANCHI ME, 1983, CELL, V35, P511, DOI 10.1016/0092-8674(83)90185-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHASE JW, 1974, J BIOL CHEM, V249, P4553; CLARK AJ, 1991, BIOCHIMIE, V73, P523, DOI 10.1016/0300-9084(91)90124-J; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; KAHN R, 1981, P NATL ACAD SCI-BIOL, V78, P4786, DOI 10.1073/pnas.78.8.4786; KODADEK T, 1990, J BIOL CHEM, V265, P20966; KONFORTI BB, 1992, J MOL BIOL, V227, P38, DOI 10.1016/0022-2836(92)90680-I; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; LAVERY PE, 1992, J BIOL CHEM, V267, P9315; LEHMAN IR, 1964, J BIOL CHEM, V239, P2628; LOVETT ST, 1991, J BACTERIOL, V173, P353, DOI 10.1128/jb.173.1.353-364.1991; LOVETT ST, 1988, GENETICS, V120, P37; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; LOVETT ST, 1984, J BACTERIOL, V157, P190, DOI 10.1128/JB.157.1.190-196.1984; MUNIYAPPA K, 1984, P NATL ACAD SCI-BIOL, V81, P2757, DOI 10.1073/pnas.81.9.2757; PANYUTIN IG, 1993, J MOL BIOL, V230, P413, DOI 10.1006/jmbi.1993.1159; PRASHER DC, 1983, J BIOL CHEM, V258, P6340; RADDING CM, 1989, BIOCHIM BIOPHYS ACTA, V1008, P131, DOI 10.1016/0167-4781(80)90001-9; Sambrook J, 1989, MOL CLONING LABORATO; SHIBATA T, 1983, METHOD ENZYMOL, V100, P197; UHLIN BE, 1981, J BACTERIOL, V148, P386, DOI 10.1128/JB.148.1.386-390.1981; WEST SC, 1982, MOL GEN GENET, V187, P209, DOI 10.1007/BF00331119; WEST SC, 1981, P NATL ACAD SCI-BIOL, V78, P6149, DOI 10.1073/pnas.78.10.6149; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131	27	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6881	6885		10.1074/jbc.270.12.6881	http://dx.doi.org/10.1074/jbc.270.12.6881			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896836	hybrid			2022-12-25	WOS:A1995QQ85500067
J	JONES, KT; CARROLL, J; WHITTINGHAM, DG				JONES, KT; CARROLL, J; WHITTINGHAM, DG			IONOMYCIN, THAPSIGARGIN, RYANODINE, AND SPERM INDUCED CA2+ RELEASE INCREASE DURING MEIOTIC MATURATION OF MOUSE OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC FREE CALCIUM; ADRENAL CHROMAFFIN CELLS; FERTILIZED HAMSTER EGGS; PAROTID ACINAR-CELLS; INOSITOL TRISPHOSPHATE; SARCOPLASMIC-RETICULUM; SENSITIVE STORES; RAT HEPATOCYTES; CHANNEL; OSCILLATIONS	Fertilization of mature mouse oocytes triggered highly repetitive Ca2+ oscillations lasting 2-3 h, However, immature oocytes generated only two or three oscillations, which ceased within 1 h. Development of repetitive Ca2+ transients to sperm occurred late in oocyte maturation and was dependent on cytoplasmic modifications that were independent of cell cycle progression from metaphase I to metaphase II, Immature oocytes released significantly less Ca2+ from stores than mature oocytes in response to ionomycin and thapsigargin Ryanodine had no effect on intracellular Ca2+ in maturing oocytes but stimulated an increase in Ca2+ in mature oocytes, The ability of ryanodine to increase Ca2+ levels was, however, strain-dependent. Preincubation of oocytes with thapsigargin or ryanodine significantly attenuated the normal fertilization Ca2+ response, causing a decrease in the number and the rate of rise of the transients, The inhibition of sperm-induced Ca2+ transients by ryanodine was independent of its ability to cause an immediate Ca2+ in crease. Low concentrations of ryanodine had no effect on resting Ca2+ levels but inhibited Ca2+ oscillations at fertilization. Similarly Ca2+ oscillations were blocked in oocytes from a strain of mouse that showed no immediate Ca2+ increase with ryanodine, These results suggest that modifications in Ca2+ stores and ryanodine-sensitive Ca2+ release mechanisms during oocyte maturation play an important role in Ca2+ oscillations at fertilization.			JONES, KT (corresponding author), ST GEORGE HOSP,SCH MED,MRC,EXPTL EMBRYOL & TERATOL UNIT,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND.		Jones, Keith/AAA-3479-2021; Jones, Keith/C-9821-2013	Jones, Keith/0000-0002-0294-0851; Jones, Keith/0000-0002-0294-0851; Carroll, John/0000-0001-9644-5861				ANDERSON K, 1989, J BIOL CHEM, V264, P1329; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CARROLL J, 1992, J BIOL CHEM, V267, P11196; CARROLL J, 1994, DEVELOPMENT, V120, P3507; CHEEK TR, 1993, J BIOL CHEM, V268, P27076; CHEEK TR, 1991, BIOCHEM J, V275, P697, DOI 10.1042/bj2750697; CUTHBERTSON KSR, 1981, NATURE, V294, P754, DOI 10.1038/294754a0; CUTHBERTSON KSR, 1985, NATURE, V316, P541, DOI 10.1038/316541a0; DUCIBELLA T, 1990, BIOL REPROD, V43, P870, DOI 10.1095/biolreprod43.5.870; DUCIBELLA T, 1994, DEV BIOL, V165, P95, DOI 10.1006/dbio.1994.1237; DUCIBELLA T, 1993, BIOL REPROD, V48, P1251, DOI 10.1095/biolreprod48.6.1251; EDWARDS RG, 1965, NATURE, V208, P349, DOI 10.1038/208349a0; EPPIG JJ, 1994, DEV BIOL, V164, P1, DOI 10.1006/dbio.1994.1175; FOSKETT JK, 1992, AM J PHYSIOL, V262, pC656, DOI 10.1152/ajpcell.1992.262.3.C656; FOSKETT JK, 1991, J BIOL CHEM, V266, P14535; FUJIWARA T, 1993, DEV BIOL, V156, P69, DOI 10.1006/dbio.1993.1059; FULTON BP, 1978, NATURE, V273, P149, DOI 10.1038/273149a0; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; GILCHRIST JSC, 1992, J BIOL CHEM, V267, P20850; GLENISTER PH, 1967, GAMETE RES, V16, P205; HERRMANNFRANK A, 1993, FEBS LETT, V332, P237, DOI 10.1016/0014-5793(93)80640-G; HOHENEGGER M, 1993, BIOCHEM J, V296, P303, DOI 10.1042/bj2960303; IGUSA Y, 1986, J PHYSIOL-LONDON, V377, P193, DOI 10.1113/jphysiol.1986.sp016181; IGUSA Y, 1983, J PHYSIOL-LONDON, V340, P611, DOI 10.1113/jphysiol.1983.sp014783; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; KLINE D, 1992, DEV BIOL, V149, P80, DOI 10.1016/0012-1606(92)90265-I; KLINE D, 1988, DEV BIOL, V126, P346, DOI 10.1016/0012-1606(88)90145-5; KLINE D, 1992, J BIOL CHEM, V267, P17624; KLINE JT, 1994, BIOL REPROD, V50, P193, DOI 10.1095/biolreprod50.1.193; KOJIMA I, 1992, AM J PHYSIOL, V262, pE307, DOI 10.1152/ajpendo.1992.262.3.E307; KUBIAK JZ, 1989, DEV BIOL, V136, P537, DOI 10.1016/0012-1606(89)90279-0; LYNN S, 1993, FEBS LETT, V330, P227, DOI 10.1016/0014-5793(93)80279-4; MCPHERSON SM, 1992, J CELL BIOL, V116, P1111, DOI 10.1083/jcb.116.5.1111; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; MISSIAEN L, 1992, J PHYSIOL-LONDON, V455, P623, DOI 10.1113/jphysiol.1992.sp019319; MIYAZAKI S, 1992, FEBS LETT, V309, P180, DOI 10.1016/0014-5793(92)81090-9; MIYAZAKI S, 1988, J CELL BIOL, V106, P345, DOI 10.1083/jcb.106.2.345; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; MIYAZAKI S, 1993, DEV BIOL, V158, P62, DOI 10.1006/dbio.1993.1168; PENNER R, 1989, FEBS LETT, V259, P217, DOI 10.1016/0014-5793(89)81532-7; QUINN P, 1982, J REPROD FERTIL, V66, P161; ROUSSEAU E, 1987, AM J PHYSIOL, V253, pC364, DOI 10.1152/ajpcell.1987.253.3.C364; SWANN K, 1992, BIOCHEM J, V287, P79, DOI 10.1042/bj2870079; SWANN K, 1994, CELL CALCIUM, V15, P331, DOI 10.1016/0143-4160(94)90072-8; TAYLOR CT, 1993, HUM REPROD, V8, P2174, DOI 10.1093/oxfordjournals.humrep.a137999; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOMBES RM, 1992, J CELL BIOL, V117, P799, DOI 10.1083/jcb.117.4.799; USUI N, 1976, J ULTRA MOL STRUCT R, V57, P276, DOI 10.1016/S0022-5320(76)80117-7; Wassarman P.M., 1988, P69; Whittingham D G, 1971, J Reprod Fertil Suppl, V14, P7; WOODS NM, 1987, CELL CALCIUM, V8, P79, DOI 10.1016/0143-4160(87)90038-8	51	164	169	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6671	6677		10.1074/jbc.270.12.6671	http://dx.doi.org/10.1074/jbc.270.12.6671			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896808	hybrid			2022-12-25	WOS:A1995QQ85500039
J	MANI, RS; KAY, CM				MANI, RS; KAY, CM			EFFECT OF CALTROPIN ON CALDESMON-ACTIN INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT REGULATION; MUSCLE THIN-FILAMENTS; SMOOTH-MUSCLE; ATPASE ACTIVITY; MYOSIN SUBFRAGMENTS; HEAVY-MEROMYOSIN; BINDING PROTEIN; ACTOMYOSIN; TROPOMYOSIN; PURIFICATION	The binding of chicken gizzard caldesmon to actin was studied both in the presence and the absence of caltropin using Airfuge centrifugation experiments, disulfide cross-linking studies, and the fluorescent probe acrylodan (6-acryloyl-2-(dimethylamino)napththalene). In co-sedimentation studies most of the caldesmon pelleted along with actin. However, when caldesmon in the presence of caltropin was mixed with actin, caldesmon did not pellet along with actin following high speed centrifugation, suggesting that caltropin has significantly weakened its binding to actin. The caltropin effect was noticed even when tropomyosin was included in the reaction mixture. Acrylodan-labeled caldesmon, when excited at 375 nm, had an emission maximum at 515 +/- 2 nm. The addition of actin produced a nearly 70% increase in fluorescent intensity, accompanied by a blue shift in the emission maximum (i.e. lambda(em (max)) = 505 +/- 2 nm), suggesting that the probe now occupies a more nonpolar environment. Titration of labeled caldesmon with actin indicated a strong affinity (K-alpha = similar to 6 x 10(7) M(-1)). When actin was titrated with labeled caldesmon in the presence of caltropin in a 0.2 mM Ca2+ medium, its affinity for caldesmon was lowered (K-alpha = similar to 2 x 10(7) M(-1)). Caltropin, which is very effective in reversing caldesmon's inhibition of the actin-activated myosin ATPase (Mani, R. S., McCubbin, W. D., and Kay, C. M. (1992) Biochemistry 31, 11896-11901), is shown in the present study to have a pronounced effect on its binding to actin, suggesting a major role for caltropin in regulating caldesmon in smooth muscle.	UNIV ALBERTA,DEPT BIOCHEM,MRC,PROT STRUCT & FUNCT GRP,EDMONTON,AB T6G 2H7,CANADA	University of Alberta								CHALOVICH JM, 1987, J BIOL CHEM, V262, P5711; CHALOVICH JM, 1993, PHARMACOL THERAPEUT, V55, P95; CROSBIE RH, 1994, BIOCHEMISTRY-US, V33, P3210, DOI 10.1021/bi00177a010; DABROWSKA R, 1985, BIOCHIM BIOPHYS ACTA, V842, P70, DOI 10.1016/0304-4165(85)90295-8; FURST DO, 1986, EMBO J, V5, P251, DOI 10.1002/j.1460-2075.1986.tb04206.x; GRACEFFA P, 1991, J BIOL CHEM, V266, P20305; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; HEMRIC ME, 1990, J BIOL CHEM, V265, P19672; HILL TL, 1981, BIOPHYS J, V35, P99, DOI 10.1016/S0006-3495(81)84777-7; HORIUCHI KY, 1988, BIOCHEMISTRY-US, V27, P8388, DOI 10.1021/bi00422a014; HORIUCHI KY, 1986, BIOCHEM BIOPH RES CO, V136, P962, DOI 10.1016/0006-291X(86)90426-2; KATSUYAMA H, 1992, J BIOL CHEM, V267, P14555; LASH JA, 1986, J BIOL CHEM, V261, P6155; LEHMAN W, 1987, BIOCHIM BIOPHYS ACTA, V914, P35, DOI 10.1016/0167-4838(87)90158-0; LEHMAN W, 1989, J MUSCLE RES CELL M, V10, P101, DOI 10.1007/BF01739966; Lehrer S S, 1978, Methods Enzymol, V49, P222; MANI RS, 1993, BIOCHEMISTRY-US, V32, P11217, DOI 10.1021/bi00092a035; MANI RS, 1992, BIOCHEMISTRY-US, V31, P11896, DOI 10.1021/bi00162a031; MANI RS, 1990, BIOCHEMISTRY-US, V29, P1398, DOI 10.1021/bi00458a009; MARSTON S, 1992, J MUSCLE RES CELL M, V13, P206, DOI 10.1007/BF01874158; MARSTON SB, 1985, J MUSCLE RES CELL M, V6, P669, DOI 10.1007/BF00712237; MARSTON SB, 1993, J BIOL CHEM, V268, P12317; MOODY CJ, 1985, FEBS LETT, V191, P107, DOI 10.1016/0014-5793(85)81003-6; NISHIDA W, 1990, FEBS LETT, V268, P165, DOI 10.1016/0014-5793(90)80999-Y; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PFITZER G, 1994, MECHANISM MYOFILAMEN, P195; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SOBIESZEK A, 1975, EUR J BIOCHEM, V55, P49, DOI 10.1111/j.1432-1033.1975.tb02137.x; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; SOBUE K, 1985, BIOCHEM BIOPH RES CO, V132, P645, DOI 10.1016/0006-291X(85)91181-7; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; VELAZ L, 1989, J BIOL CHEM, V264, P9602; Walsh M P, 1989, Adv Exp Med Biol, V255, P337; ZHUANG S, 1994, BIOPHYS J, V66, P196	36	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6658	6663		10.1074/jbc.270.12.6658	http://dx.doi.org/10.1074/jbc.270.12.6658			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896806	hybrid			2022-12-25	WOS:A1995QQ85500037
J	LIPKA, G; SCHULTHESS, G; THURNHOFER, H; WACKER, H; WEHRLI, E; ZEMAN, K; WEBER, FE; HAUSER, H				LIPKA, G; SCHULTHESS, G; THURNHOFER, H; WACKER, H; WEHRLI, E; ZEMAN, K; WEBER, FE; HAUSER, H			CHARACTERIZATION OF LIPID EXCHANGE PROTEINS ISOLATED FROM SMALL-INTESTINAL BRUSH-BORDER MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL CARRIER PROTEIN-2; AMINO-ACID-SEQUENCE; RAT-LIVER; SUBCELLULAR-DISTRIBUTION; VESICLES; EXPRESSION; CHOLESTEROL; TISSUES; CLONING; PHOSPHATIDYLCHOLINE	Subjecting rabbit small intestinal brush border membrane vesicles (BBMV) to freeze-thaw cycles releases water-soluble lipid exchange (transfer) proteins into the supernatant. They differ widely in apparent molecular weight and catalyze cholesterol, phosphatidylcholine, and phosphatidylinositol exchange between two populations of small unilamellar lipid vesicles. In order to determine their interrelations, the smallest water-soluble lipid exchange protein was purified to homogeneity by gel filtration on Sephadex G-75 and cation exchange chromatography on Mono S. It is a basic protein of apparent molecular mass of 13 +/- 0.5 kDa. The purified protein was used to raise polyclonal antibodies, Polyclonal antibodies were also produced against a lipid exchange protein of apparent molecular mass of 100-120 kDa. By comparing lipid exchange, lipid binding, and immunological properties of the water soluble lipid exchange proteins it can be shown that the 13-kDa (peak 3) protein is related to the 100-120 kDa (peak 1) protein; the properties of these two proteins are different from those of the peak 2 lipid exchange protein of apparent molecular mass of 22 kDa. Based on the immunological cross-reactivity observed between the 13 and 100-120 kDa and the lipid binding properties of these two proteins, a working hypothesis is proposed: both proteins are probably part of an intergral membrane protein of the brush border membrane that facilitates cholesterol and phosphatidylcholine absorption in this membrane. Evidence derived from immunogold labeling of BBMV supports the notion that this protein is located on the external (luminal) side of the brush border membrane. The analogous behavior of rabbit and human small intestinal brush border membrane in terms of lipid absorption and the release of water-soluble lipid exchange proteins is discussed.	ETH ZENTRUM,BIOCHEM LAB,CH-8092 ZURICH,SWITZERLAND; UNIV ZURICH HOSP,MED POLIKLIN,DEPT INNERE MED,CH-8091 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; University Zurich Hospital			Weber, Franz E./I-7831-2019	Weber, Franz E./0000-0003-1670-2296				[Anonymous], 1976, THEORY APPL SPIN LAB; BAUM CL, 1993, J LIPID RES, V34, P729; BEHNKE O, 1986, EUR J CELL BIOL, V41, P326; BRUNNER J, 1979, J BIOL CHEM, V254, P1821; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; GAINS N, 1981, BIOCHIM BIOPHYS ACTA, V646, P211, DOI 10.1016/0005-2736(81)90327-8; GAINS N, 1984, BIOCHIM BIOPHYS ACTA, V772, P161, DOI 10.1016/0005-2736(84)90039-7; GEE AP, 1979, J IMMUNOL METHODS, V30, P119, DOI 10.1016/0022-1759(79)90086-3; HAASE W, 1978, BIOCHEM J, V172, P57, DOI 10.1042/bj1720057; HAUSER H, 1982, BIOCHEMISTRY-US, V21, P5621, DOI 10.1021/bi00265a036; HAUSER H, 1980, BIOCHIM BIOPHYS ACTA, V602, P567, DOI 10.1016/0005-2736(80)90335-1; HYATT AD, 1989, COLLOIDAL GOLD PRINC, V2, P19; KHARROUBI A, 1988, J LIPID RES, V29, P287; KLIP A, 1979, FEBS LETT, V99, P91, DOI 10.1016/0014-5793(79)80256-2; LIPKA G, 1991, BIOCHEMISTRY-US, V30, P11828, DOI 10.1021/bi00115a013; LIPKA G, 1992, STRUCTURAL DYNAMIC P, P7; MCKAY HAC, 1983, NATURE, V142, P997; MCLEAN LR, 1981, BIOCHEMISTRY-US, V20, P2893, DOI 10.1021/bi00513a028; MONCECCHI D, 1991, J BIOL CHEM, V266, P9885; MORI T, 1991, P NATL ACAD SCI USA, V88, P4338, DOI 10.1073/pnas.88.10.4338; MUTSCH B, 1986, BIOCHEMISTRY-US, V25, P2134; OSSENDORP BC, 1991, EUR J BIOCHEM, V201, P233, DOI 10.1111/j.1432-1033.1991.tb16279.x; OUCHTERLONY O, 1958, PROG ALLERGY, V5, P1, DOI 10.1159/000273347; REINHART MP, 1993, BIOCHEM J, V295, P787, DOI 10.1042/bj2950787; RIGHETTI PG, 1990, GEL ELECTROPHORESIS, P149; SCHULTHESS G, 1994, BIOCHEMISTRY-US, V33, P4500, DOI 10.1021/bi00181a009; SEEDORF U, 1991, J BIOL CHEM, V266, P630; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; THURNHOFER H, 1990, BIOCHIM BIOPHYS ACTA, V1024, P249, DOI 10.1016/0005-2736(90)90351-N; THURNHOFER H, 1991, BIOCHIM BIOPHYS ACTA, V1064, P275, DOI 10.1016/0005-2736(91)90312-V; THURNHOFER H, 1990, BIOCHEMISTRY-US, V29, P2142, DOI 10.1021/bi00460a026; THURNHOFER H, 1991, EUR J BIOCHEM, V201, P273, DOI 10.1111/j.1432-1033.1991.tb16284.x; VANHEUSDEN GPH, 1990, BIOCHIM BIOPHYS ACTA, V1046, P315, DOI 10.1016/0005-2760(90)90247-U; VANHEUSDEN GPH, 1992, METHOD ENZYMOL, V209, P535; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; WESTERMAN J, 1985, BIOCHEM BIOPH RES CO, V127, P333, DOI 10.1016/S0006-291X(85)80163-7; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73; YAMAMOTO R, 1991, P NATL ACAD SCI USA, V88, P463, DOI 10.1073/pnas.88.2.463	38	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					5917	5925		10.1074/jbc.270.11.5917	http://dx.doi.org/10.1074/jbc.270.11.5917			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890723	hybrid			2022-12-25	WOS:A1995QM94500035
J	DOBRZANSKI, P; RYSECK, RP; BRAVO, R				DOBRZANSKI, P; RYSECK, RP; BRAVO, R			SPECIFIC-INHIBITION OF RELB/P52 TRANSCRIPTIONAL ACTIVITY BY THE C-TERMINAL DOMAIN OF P100	ONCOGENE			English	Note						RELB-P52 COMPLEX; P100 C-TERMINUS; TRANSCRIPTIONAL INHIBITION	NF-KAPPA-B; REL-ASSOCIATED PP40; DNA-BINDING; ACTIVATION; PROTEIN; ALPHA; PHOSPHORYLATION; PRECURSOR; ENCODES; FAMILY	The Rel/NF-kappa B family transcriptional factors plays an important role in the regulation of immune and acute phase responses. The activity of Rel/NF-kappa B complexes is regulated by their interactions with members of the I kappa B family of inhibitors. We have previously shown that the RelB/p52 heterodimer is not effectively inhibited by any of the known I kappa B molecules: I kappa B alpha, I kappa B gamma and Bcl3. Here we report that the C-terminal domain of p100 (the putative I kappa B delta) functions as a strong inhibitor of RelB/p52 transcriptional activity. In vivo interaction with I kappa B delta leads to the cytoplasmic retention and decreased DNA binding activity of RelB/p52 complexes. Thus, I kappa B delta is the only I kappa B molecule able to efficiently modulate the activity of RelB/p52 heterodimer, In Daudi cells, a 46 kD protein, probably representing the C-terminal product of the proteolytic processing of p100, remains associated,vith Rel/NF-kappa B complexes and might have a transient regulatory function. Our results indicate a specific role for the putative I kappa B delta and suggest a possible mechanism of how the truncation of the ankyrin domain of p100, found in a number of lymphoid neoplasias, might contribute to tumorigenesis.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543	Bristol-Myers Squibb								BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOURS V, 1992, MOL CELL BIOL, V12, P343; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; FINCO TS, 1993, J BIOL CHEM, V268, P17676; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GRILLI M, 1993, INT REV CYTOL, V143, P1; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0	44	65	66	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					1003	1007						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898917				2022-12-25	WOS:A1995QL03800022
J	JIMENEZ, B; ARENDS, M; ESTEVE, P; PERONA, R; SANCHEZ, R; CAJAL, SR; WYLLIE, A; LACAL, JC				JIMENEZ, B; ARENDS, M; ESTEVE, P; PERONA, R; SANCHEZ, R; CAJAL, SR; WYLLIE, A; LACAL, JC			INDUCTION OF APOPTOSIS IN NIH3T3 CELLS AFTER SERUM DEPRIVATION BY OVEREXPRESSION OF RHO-P21, A GTPASE PROTEIN OF THE RAS SUPERFAMILY	ONCOGENE			English	Article						RHO; APOPTOSIS; TRANSFORMATION	SWISS 3T3 CELLS; BINDING PROTEIN; RHO P21; ADP-RIBOSYLATION; GENE-PRODUCT; EXPRESSION; EXCHANGE; GROWTH; ENDONUCLEASE; ACTIVATION	Oncogenes appear to influence apoptosis in two ways. Some activate cells from a growth-arrested state to one in which both apoptosis and entry to S-phase become possible, the choice between them being determined by a second signal, such as cytokine or growth factor. Cells in this state are often sensitive to apoptosis induced by a wide variety of agents, including several drugs used in cancer chemotherapy. Other oncogenes prevent activation of the apoptosis effector pathway, even in the presence of a death stimulus, the affected cells therefore being resistant to chemotherapeutic agents. In rodent fibroblasts, c-myc or the adenovirus oncogene E1A effect the first type of change, whereas bcl-2, v-abl, E1B or activated uas effect the second. Here we study in rodent fibroblast the effect of expression of rho genes, members of the ras superfamily which we have previously shown to be tumorigenic when highly expressed in this cell type. We show that expression of wild-type who from Aplysia californica stimulates apoptosis in cultured cell lines and that the apoptotic index in tumors generated by these cell lines is similar to those induced by E1A-transformed cells. In contrast, mutated rho, activated by Val(14) substitution in the GTP binding site, it less potent as a stimulator of apoptosis, generating a phenotype more similar to that obtained with activated vas. Thus, rho genes may play a critical role in the regulation of apoptosis.	CSIC, INST INVEST BIOMED, MADRID, SPAIN; UNIV EDINBURGH, DEPT PATHOL, CRC LABS, EDINBURGH, MIDLOTHIAN, SCOTLAND; CLIN PUERTA HIERRO, SERV ANAT PATOL, MADRID, SPAIN; UNIV AUTONOMA MADRID, DEPT BIOQUIM, MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Edinburgh; Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda; Autonomous University of Madrid			Espinosas, Maribel/H-8083-2012; Sanchez-Prieto, Ricardo/AAY-4271-2021; Ramon y Cajal, Santiago/H-4955-2016; Lacal, Juan Carlos/AAL-2235-2020; Cuenca, Benilde Jimenez/K-9959-2014; Sanchez-Prieto, Ricardo/B-6877-2008; Prieto, Ricardo/AAZ-7221-2021; Lacal, Juan Carlos/N-9064-2015	Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Ramon y Cajal, Santiago/0000-0002-3867-1390; Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Lacal, Juan Carlos/0000-0002-1908-2777; Jimenez Cuenca, Benilde/0000-0002-1806-6636				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AEPFELBACHER M, 1994, P NATL ACAD SCI USA, V91, P4263, DOI 10.1073/pnas.91.10.4263; ARENDS MJ, 1990, AM J PATHOL, V136, P593; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; ARENDS MJ, 1994, AM J PATHOL, V144, P1045; ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; ARENDS MJ, 1994, MOL BIOL HISTOPATHOL, P151; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; AVRAHAM H, 1990, BIOCHEM BIOPH RES CO, V168, P114, DOI 10.1016/0006-291X(90)91682-I; BALLESTERO RP, 1991, NATO ADV SCI I A-LIF, V220, P237; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHEN WN, 1994, J BIOL CHEM, V269, P820; CHU G, 1994, J BIOL CHEM, V269, P787; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HIRATA K, 1992, J BIOL CHEM, V267, P8719; HOFFMAN B, 1994, ONCOGENE, V9, P1807; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LACAL JC, 1994, ONCOL REP, V1, P677; LANG P, 1992, J BIOL CHEM, V267, P11677; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARCHETTI E, 1994, INT J ONCOL, V5, P611; MIURA Y, 1993, J BIOL CHEM, V268, P510; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; MORII N, 1992, J BIOL CHEM, V267, P20921; PERONA R, 1993, ONCOGENE, V8, P1285; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SUBRAMANIAN T, 1993, GENE, V124, P173, DOI 10.1016/0378-1119(93)90391-F; SUGAI M, 1992, J BIOL CHEM, V267, P21297; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1994, ONCOGENE, V9, P273; TILLY JL, 1993, J CELL PHYSIOL, V154, P519, DOI 10.1002/jcp.1041540310; VICENT S, 1992, MOL CELL BIOL, V12, P3138; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WYLLIE AH, 1987, BRIT J CANCER, V56, P251, DOI 10.1038/bjc.1987.186; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; ZHANG, 1994, J BIOL CHEM, V269, P2369; ZHANG J, 1993, J BIOL CHEM, V268, P22251	53	83	84	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	1995	10	5					811	816						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898922				2022-12-25	WOS:A1995QL03800001
J	CHOI, AMK; TUCKER, RW; CARLSON, SG; WIEGAND, G; HOLBROOK, NJ				CHOI, AMK; TUCKER, RW; CARLSON, SG; WIEGAND, G; HOLBROOK, NJ			CALCIUM MEDIATES EXPRESSION OF STRESS-RESPONSE GENES IN PROSTAGLANDIN A(2)-INDUCED GROWTH ARREST	FASEB JOURNAL			English	Article						GADD153; GENE EXPRESSION; HEME OXYGENASE; HSP70; C-FOS; EGR-1	SHOCK TRANSCRIPTION FACTOR; CELL-CYCLE PROGRESSION; FOS PROTO-ONCOGENE; MESSENGER-RNA; C-FOS; CYCLOPENTENONE PROSTAGLANDINS; ELEVATED EXPRESSION; SKIN FIBROBLASTS; HEME OXYGENASE; DNA DAMAGE	We have explored the mechanisms involved in the induction of five stress-response genes (heme oxygenase [HO], c-fos, Egr-1; gadd153, and HSP70) in human diploid fibroblasts growth-arrested by treatment with the antiproliferative prostaglandin A(2) (PGA(2)). The kinetics of c-fos and Egr-1 induction were found to be rapid with maximum expression occurring within 60 min of treatment, whereas maximum expression of HO, gadd153, and HSP70 occurred between 4 and 8 h of treatment. Nuclear run-on assays and measurements of mRNA clearance in the presence of actinomycin D demonstrated that increases in both the rates of gene transcription and/or mRNA stability contribute to the genetic response to PGA(2). Although the mechanisms responsible for increasing the mRNA levels differ for the individual genes, additional experiments provided evidence that alterations in intracellular calcium ([Ca2+](i)) levels were important in initiating the genetic response to PGA(2). PGA(2) treatment resulted in a rapid increase in [Ca2+](i) with the dose-response relationship for Ca2+ mobilization consistent with that seen for the induction of all five genes. [Ca2+](i) chelators that attenuate Ca2+ mobilization by PGA(2) also blocked the mRNA induction by PGA(2) treatment. Density-inhibited confluent cells were less responsive than proliferating subconfluent cells with respect to Ca2+ mobilization after PGA(2) treatment. This was correlated with a lower level of gene induction. These studies support the hypothesis that increased Ca2+ mobilization is an early and central event in the signal transduction pathway (or pathways) mediating the activation of genes in response to PGA(2) treatment.	NIA,GERONTOL RES CTR,GENE EXPRESS & AGING SECT,BALTIMORE,MD 21224; JOHNS HOPKINS MED INST,DIV PULM & CRIT CARE,BALTIMORE,MD; JOHNS HOPKINS MED INST,JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD 21205	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine					NIA NIH HHS [K11AG00516] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K11AG000516] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMICI C, 1992, P NATL ACAD SCI USA, V89, P6227, DOI 10.1073/pnas.89.14.6227; ANDREWS GK, 1987, MOL CELL BIOL, V7, P3452, DOI 10.1128/MCB.7.10.3452; BARTLETT JD, 1992, J BIOL CHEM, V267, P20465; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BREGMAN MD, 1986, CANCER RES, V46, P2740; BUSCHER M, 1988, ONCOGENE, V3, P301; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; CHOI AMK, 1992, EXP CELL RES, V199, P85, DOI 10.1016/0014-4827(92)90464-J; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; FARGNOLI J, 1990, P NATL ACAD SCI USA, V87, P846, DOI 10.1073/pnas.87.2.846; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HALLIWELL B, 1991, FEBS LETT, V281, P9, DOI 10.1016/0014-5793(91)80347-6; HOLBROOK NJ, 1992, MOL CELL BIOL, V12, P1528, DOI 10.1128/MCB.12.4.1528; HONN KV, 1985, BIOCHEM BIOPH RES CO, V129, P24; ISHIOKA C, 1988, CANCER RES, V48, P2813; KEYSE SM, 1990, MOL CELL BIOL, V10, P4967, DOI 10.1128/MCB.10.9.4967; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; KRUSZEWSKI FH, 1991, AM J PHYSIOL, V261, pC767, DOI 10.1152/ajpcell.1991.261.5.C767; LINQUIST S, 1988, ANNU REV GENET, V22, P631; MAKI A, 1992, FASEB J, V6, P919, DOI 10.1096/fasebj.6.3.1740241; MARUI N, 1990, FEBS LETT, V270, P15, DOI 10.1016/0014-5793(90)81224-C; MORGAN JI, 1988, CELL CALCIUM, V9, P303, DOI 10.1016/0143-4160(88)90011-5; NARUMIYA S, 1987, J PHARMACOL EXP THER, V242, P306; NARUMIYA S, 1986, J PHARMACOL EXP THER, V239, P500; OHNO K, 1988, J PHARMACOL EXP THER, V245, P294; OHNO K, 1986, BIOCHEM BIOPH RES CO, V139, P808, DOI 10.1016/S0006-291X(86)80062-6; OHNO K, 1988, J BIOL CHEM, V263, P19764; OUELLETTE AJ, 1990, J CLIN INVEST, V85, P766, DOI 10.1172/JCI114502; PRESTON GM, 1990, MOL CELL BIOL, V10, P442, DOI 10.1128/MCB.10.2.442; PRICE BD, 1991, MOL CELL BIOL, V11, P3365, DOI 10.1128/MCB.11.6.3365; RANGNEKAR VV, 1992, J BIOL CHEM, V267, P6240; SANTORO MG, 1986, CANCER RES, V46, P6073; SANTORO MG, 1989, P NATL ACAD SCI USA, V86, P8407, DOI 10.1073/pnas.86.21.8407; TSIEN RY, 1985, CELL CALCIUM, V6, P145, DOI 10.1016/0143-4160(85)90041-7; WARE RE, 1992, INT IMMUNOL, V5, P179; WERLEN G, 1993, J BIOL CHEM, V268, P16596; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777	41	48	48	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1994	8	13					1048	1054		10.1096/fasebj.8.13.7926370	http://dx.doi.org/10.1096/fasebj.8.13.7926370			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PN069	7926370				2022-12-25	WOS:A1994PN06900009
J	HATAKEYAMA, H; MIYAMORI, I; FUJITA, T; TAKEDA, Y; TAKEDA, R; YAMAMOTO, H				HATAKEYAMA, H; MIYAMORI, I; FUJITA, T; TAKEDA, Y; TAKEDA, R; YAMAMOTO, H			VASCULAR ALDOSTERONE - BIOSYNTHESIS AND A LINK TO ANGIOTENSIN-II-INDUCED HYPERTROPHY OF VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; STEROID 11-BETA-HYDROXYLASE; MINERALOCORTICOID RECEPTOR; PROTEIN-SYNTHESIS; GENE-EXPRESSION; MESSENGER-RNA; DNA; BINDING; CLONING; TISSUES	Mineralocorticoids have been suggested to act on blood vessels, leading to increased vasoreactivity and peripheral resistance. However, the site of their production has so far been believed to be only the adrenal cortex. Here, we show direct evidence that vascular cells per se are aldosteronogenic, possessing their own system that responds to the steroid. Using polymerase chain reaction after reverse transcription, the CYP11B2 mRNA encoding the key enzyme for the biosynthesis of aldosterone was detected in both endothelial cells and smooth muscle cells cultivated from human pulmonary artery. The aldosterone receptor (type 1 mineralocorticoid receptor) gene was also found to be expressed in smooth muscle cells and, to a lesser extent, in endothelial cells. CYP11B2 gene expression in smooth muscle cells was stimulated by angiotensin II, the effector peptide of the renin-angiotensin system. Furthermore, the angiotensin II-induced increase in [H-3]leucine incorporation in smooth muscle cells was significantly enhanced by aldosterone but inhibited by ZK 91587, a type 1 mineralocorticoid receptor antagonist. This may indicate that vascular aldosterone participates in the angiotensin II-induced hypertrophy of vascular smooth muscle cells. The present study therefore provides the starting point for a novel understanding of the molecular basis of vascular remodeling and hypertension.	KKR HOKURIKU HOSP,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,SCH MED,DEPT INTERNAL MED 2,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,SCH MED,DEPT BIOCHEM,KANAZAWA,ISHIKAWA 920,JAPAN	Kanazawa University; Kanazawa University								ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BRILLA CG, 1992, J HYPERTENS, V10, pS75; BUNKENBURG B, 1992, HYPERTENSION, V20, P746, DOI 10.1161/01.HYP.20.6.746; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CURNOW KM, 1991, MOL ENDOCRINOL, V5, P1513, DOI 10.1210/mend-5-10-1513; DZAU VJ, 1988, CIRCULATION, V77, P1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUNDER JW, 1989, ENDOCRINOLOGY, V125, P2224, DOI 10.1210/endo-125-4-2224; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GRILL HJ, 1985, J STEROID BIOCH S9, V23; IP JH, 1990, J AM COLL CARDIOL, V15, P1667, DOI 10.1016/0735-1097(90)92845-S; KAWAMOTO T, 1990, FEBS LETT, V269, P345, DOI 10.1016/0014-5793(90)81190-Y; KAWAMOTO T, 1992, P NATL ACAD SCI USA, V89, P1458, DOI 10.1073/pnas.89.4.1458; KORNEL L, 1982, CLIN EXP HYPERTENS A, V4, P1561, DOI 10.3109/10641968209061625; LOMBES M, 1992, CIRC RES, V71, P503, DOI 10.1161/01.RES.71.3.503; MCKENNA TJ, 1978, J STEROID BIOCHEM, V9, P967, DOI 10.1016/0022-4731(78)90059-6; MORNET E, 1989, J BIOL CHEM, V264, P20961; NAFTILAN AJ, 1991, J CLIN INVEST, V87, P1300, DOI 10.1172/JCI115133; OGISHIMA T, 1991, J BIOL CHEM, V266, P10731; OHMORI H, 1992, J CELL BIOL, V116, P933, DOI 10.1083/jcb.116.4.933; PAUL M, 1993, J CLIN INVEST, V91, P2058, DOI 10.1172/JCI116428; RAKUGI H, 1993, CIRCULATION, V87, P283, DOI 10.1161/01.CIR.87.1.283; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT BA, 1987, J HYPERTENS, V5, P739, DOI 10.1097/00004872-198712000-00018; TAKEDA Y, 1993, STEROIDS, V58, P282, DOI 10.1016/0039-128X(93)90074-W; ULLIAN ME, 1992, HYPERTENSION, V20, P67, DOI 10.1161/01.HYP.20.1.67; ULLIAN ME, 1993, AM J PHYSIOL, V264, pC1525, DOI 10.1152/ajpcell.1993.264.6.C1525; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717	29	285	292	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24316	24320						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929089				2022-12-25	WOS:A1994PQ34600072
J	RICHIERI, GV; OGATA, RT; KLEINFELD, AM				RICHIERI, GV; OGATA, RT; KLEINFELD, AM			EQUILIBRIUM-CONSTANTS FOR THE BINDING OF FATTY-ACIDS WITH FATTY-ACID-BINDING PROTEINS FROM ADIPOCYTE, INTESTINE, HEART, AND LIVER MEASURED WITH THE FLUORESCENT-PROBE ADIFAB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RAT-HEART; 3-DIMENSIONAL STRUCTURE; COMPLEMENTARY-DNA; CRYSTAL-STRUCTURE; BOUND PALMITATE; BOVINE LIVER; PURIFICATION; CLONING; REFINEMENT	Affinities of long chain fatty acids (FA) for fatty acid-binding proteins (FABPs) have been measured by monitoring the concentrations of the unbound or free fatty acids (FFA) in equilibrium with the FABPs using the fluorescent probe ADIFAB. This probe allows the measurement of the concentration of FFA in equilibrium with FABPs, without physical separation of any of the reactants. Equilibrium characteristics were measured at 37 degrees C for palmitate, stearate, oleate, linoleate, linolenate, and arachidonate binding to six FABPs from intestine, heart, adipose, and liver from different species. Equilibrium constants for each FA were found to be extremely sensitive to the tissue origin of the FABP but largely independent of species differences. The measured values of the dissociation constants (K-d) ranged from about 2 to 1000 nM, depending upon the tissue origin of the FABP and the FA. Binding constants for some FABPs varied considerably with different FA, as much as 80-fold in the case of the intestinal FABP. In contrast, K-d values for adipocyte FABPs exhibited less than 4-fold variation with FA type and are generally larger (lower affinities) than for the other FABPs. For all FABPs, K-d values for fatty acids with the same chain length were considerably lower for saturated as compared to polyunsaturated FA. This characteristic likely reflects the lower aqueous solubilities of the saturated fatty acids. In contrast to the other FABPs, rat liver FABP was found to have two FA-binding sites/ monomer. Each of these two sites had similar high affinities for the saturated FA,while for the unsaturated FA the two sites exhibited affinities that differ by more than 7-fold. This study disagrees with earlier investigations in finding that equilibrium binding of FA to FABPs is a sensitive function of FA type and FABP tissue origin and that FA-FABP dissociation constants are submicromolar. These results provide a framework with which to understand better the biological function of FABPs and the FA-FABP interaction.	MED BIOL INST,LA JOLLA,CA 92037						NIGMS NIH HHS [GM46931] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046931] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPERS DH, 1984, P NATL ACAD SCI-BIOL, V81, P313, DOI 10.1073/pnas.81.2.313; ANEL A, 1993, BIOCHEMISTRY-US, V32, P530, DOI 10.1021/bi00053a018; BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BASS NM, 1988, INT REV CYTOL, V111, P143, DOI 10.1016/S0074-7696(08)61733-7; BASS NM, 1985, J BIOL CHEM, V260, P1432; BAXA CA, 1989, BIOCHEMISTRY-US, V28, P8683, DOI 10.1021/bi00448a003; BILLICH S, 1988, EUR J BIOCHEM, V175, P549, DOI 10.1111/j.1432-1033.1988.tb14227.x; BRECHER P, 1984, J BIOL CHEM, V259, P3395; BUELT MK, 1992, BIOCHEMISTRY-US, V31, P3493, DOI 10.1021/bi00128a025; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P852; CHINANDER LL, 1989, J BIOL CHEM, V264, P19564; CISTOLA DP, 1989, J BIOL CHEM, V264, P2700; CISTOLA DP, 1988, BIOCHEMISTRY-US, V27, P711, DOI 10.1021/bi00402a033; CLAFFEY KP, 1987, BIOCHEMISTRY-US, V26, P7900, DOI 10.1021/bi00398a054; DUTTAROY AK, 1993, BIOCHIM BIOPHYS ACTA, V1169, P73, DOI 10.1016/0005-2760(93)90084-M; EADS J, 1993, J BIOL CHEM, V268, P26375; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FOURNIER NC, 1983, BIOCHEMISTRY-US, V22, P1863, DOI 10.1021/bi00277a019; GLATZ JFC, 1983, ANAL BIOCHEM, V132, P89, DOI 10.1016/0003-2697(83)90429-3; HAUNERLAND N, 1984, H-S Z PHYSIOL CHEM, V365, P365, DOI 10.1515/bchm2.1984.365.1.365; JAKOBY MG, 1993, BIOCHEMISTRY-US, V32, P872, DOI 10.1021/bi00054a019; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; KEUPER HJK, 1985, CHEM PHYS LIPIDS, V38, P159, DOI 10.1016/0009-3084(85)90064-7; LALONDE JM, 1994, BIOCHEMISTRY-US, V33, P4885, DOI 10.1021/bi00182a017; LOWE JB, 1985, J BIOL CHEM, V260, P3413; LOWE JB, 1987, J BIOL CHEM, V262, P5931; MATARESE V, 1988, J BIOL CHEM, V263, P14544; NEMECZ G, 1991, ARCH BIOCHEM BIOPHYS, V286, P300, DOI 10.1016/0003-9861(91)90044-J; OCKNER RK, 1972, SCIENCE, V177, P56, DOI 10.1126/science.177.4043.56; OFFNER GD, 1986, J BIOL CHEM, V261, P5584; PAULUSSEN RJA, 1988, ARCH BIOCHEM BIOPHYS, V264, P533, DOI 10.1016/0003-9861(88)90319-0; RICHIERI GV, 1992, J BIOL CHEM, V267, P23495; RICHIERI GV, 1993, BIOCHEMISTRY-US, V32, P7574, DOI 10.1021/bi00080a032; ROPSON IJ, 1990, BIOCHEMISTRY-US, V29, P9591, DOI 10.1021/bi00493a013; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SACCHETTINI JC, 1986, J BIOL CHEM, V261, P8218; SACCHETTINI JC, 1992, J BIOL CHEM, V267, P23534; SACCHETTINI JC, 1993, J BIOL CHEM, V268, P18399; SCAPIN G, 1992, J BIOL CHEM, V267, P4253; SCHULENBERGSCHELL H, 1988, EUR J BIOCHEM, V170, P565, DOI 10.1111/j.1432-1033.1988.tb13735.x; SHA RS, 1993, J BIOL CHEM, V268, P7885; SMALL DM, 1986, PHYSICAL CHEM LIPIDS, P288; STORCH J, 1989, J BIOL CHEM, V264, P8706; Tanford C, 1973, HYDROPHOBIC EFFECT, P6; VANZOELEN EJJ, 1993, BIOCHEMISTRY-US, V32, P6275, DOI 10.1021/bi00075a022; VEERKAMP JH, 1992, BIOCHEM SOC T, V20, P801, DOI 10.1042/bst0200801; VEERKAMP JH, 1991, BIOCHIM BIOPHYS ACTA, V1081, P1, DOI 10.1016/0005-2760(91)90244-C; VORK MM, 1990, MOL CELL BIOCHEM, V98, P111, DOI 10.1007/BF00231374; WILKINSON TCI, 1987, BIOCHEM J, V247, P485, DOI 10.1042/bj2470485; WOOTAN MG, 1990, BIOCHEMISTRY-US, V29, P9305, DOI 10.1021/bi00492a001; XU ZH, 1993, J BIOL CHEM, V268, P7874; XU ZH, 1992, BIOCHEMISTRY-US, V31, P3484, DOI 10.1021/bi00128a024; YOUNG ACM, 1994, IN PRESS STRUCTURE; ZANOTTI G, 1992, J BIOL CHEM, V267, P18541	54	232	246	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23918	23930						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929039				2022-12-25	WOS:A1994PQ34600014
J	SHISHEVA, A; BUXTON, J; CZECH, MP				SHISHEVA, A; BUXTON, J; CZECH, MP			DIFFERENTIAL INTRACELLULAR LOCALIZATIONS OF GDP DISSOCIATION INHIBITOR ISOFORMS - INSULIN-DEPENDENT REDISTRIBUTION OF GDP DISSOCIATION INHIBITOR-2 IN 3T3-L1 ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RESPONSIVE GLUCOSE TRANSPORTER; GTP-BINDING PROTEIN; RAT ADIPOSE-CELLS; MOLECULAR-CLONING; PLASMA-MEMBRANE; SMG P25A; GLUT4; STIMULATION; TRANSLOCATION; KINETICS	Insulin action on fat cell/skeletal muscle glucose transporter (GLUT4) redistribution to cell surface membranes appears to involve small GTP-binding proteins. It has been recently recognized that at least two GDP dissociation inhibitor (GDI) isoforms, GDI-1 and GDI-2, can bind and release GDP-bound Rab proteins from membranes (Shisheva, A., Sudhof, T. C., and Czech, M. P. (1994) Mol. Cell. Biol. 14, 3459-3468). The present studies show that a strikingly higher level of GDI-2 fractionates with total membranes of COS-1 cells, Chinese hamster ovary cells, and 3T3-L1 adipocytes compared to GDI-1, which is virtually totally cytosolic. In 3T3-L1 adipocytes, most of the membrane-bound GDI-2 was present in a low density, intracellular membrane fraction. Immunodepletion of GLUT4-enriched vesicles from this membrane fraction also depleted significant amounts of GDI-2 proteins. Localization of both GDI-2 and GLUT4 in the same perinuclear regions of these cells was established by immunofluorescence microscopy, whereas GDI-1 displayed a diffuse, cytoplasmic distribution. Insulin acutely decreased both GLUT4 and GDI-2 protein levels in the low density microsomes by about 50%. Concomitantly, GLUT4 but not GDI-2 protein content of plasma membranes increased, suggesting release of GDI-2 into the cytoplasm in response to insulin. Taken together, these data suggest functional differences for the GDI-1 and GDI-2 protein isoforms, as well as a potential role of GDI-2 in the action of insulin on membrane movements.	UNIV MASSACHUSETTS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	SHISHEVA, A (corresponding author), UNIV MASSACHUSETTS, MED CTR, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030898, R01DK030898] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30898] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDINI G, 1991, J BIOL CHEM, V266, P4037; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BELL GI, 1993, J BIOL CHEM, V268, P19161; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CLANCY BM, 1991, J BIOL CHEM, V266, P10122; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; CORMONT M, 1993, J BIOL CHEM, V268, P19491; CZECH MP, 1992, TRENDS BIOCHEM SCI, V17, P197, DOI 10.1016/0968-0004(92)90266-C; CZECH MP, 1993, J BIOL CHEM, V268, P9187; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; HARLOW E, 1988, ANTIBODIES LABORATOR, P311; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; NISHIMURA H, 1993, J BIOL CHEM, V268, P8514; NONAKA H, 1991, BIOCHEM BIOPH RES CO, V174, P556, DOI 10.1016/0006-291X(91)91453-J; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; PESSINO A, 1991, J BIOL CHEM, V266, P20213; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SHISHEVA A, 1993, ENDOCRINOLOGY, V133, P1562, DOI 10.1210/en.133.4.1562; SHISHEVA A, 1994, MOL CELL BIOL, V14, P3459, DOI 10.1128/MCB.14.5.3459; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VONMOLLARD F, 1994, TRENDS BIOCHEM SCI, V19, P164; YANG J, 1993, J BIOL CHEM, V268, P4600; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	36	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23865	23868						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929030				2022-12-25	WOS:A1994PQ34600004
J	SHUCK, ME; BOCK, JH; BENJAMIN, CW; TSAI, TD; LEE, KS; SLIGHTOM, JL; BIENKOWSKI, MJ				SHUCK, ME; BOCK, JH; BENJAMIN, CW; TSAI, TD; LEE, KS; SLIGHTOM, JL; BIENKOWSKI, MJ			CLONING SAD CHARACTERIZATION OF MULTIPLE FORMS OF THE HUMAN KIDNEY ROM-K POTASSIUM CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE FIBERS; FUNCTIONAL EXPRESSION; INWARD RECTIFICATION; SEQUENCE-ANALYSIS; MEMBRANE; INACTIVATION; DIVERSITY; PROTEIN; MOUSE; GENE	The rat kidney ROM-K1 potassium channel cDNA was used to clone the homolog from human kidney using a combination of cDNA cloning, reverse transcriptase-polymerase chain reaction (RT-PCR), and primer extension cloning methods. In addition to the human species homolog of ROM-K1, four additional transcripts that are formed by alternative splicing of a single human gene were also characterized (hROM-K2 to hROM-K5). All five transcripts share a common 3' exon that encodes the majority of the channel protein and in three of the isoforms translation is initiated at a start codon contained within this exon (hROM-K2, hROM-K4, and hROM-K5). The two other transcripts contain additional exons that potentially extend the open reading frame by either 19 amino acid residues (hROM-K1) or by 17 amino acid residues (hROM-K3). Comparison of the translation products from the three representative transcripts (hROM-K1, hROM-K2, and hROM-K3) confirmed that hROM-K1 gave the largest product (41.6 kDa) and was translated more efficiently than either hROM-K2 or hROM-K3. Also, despite the presence of several additional canonical acceptor sites for Asn-linked glycosylation relative to rat ROM-K1, all three channel polypeptides were glycosylated to a similar extent in the in vitro translation reactions when canine pancreatic microsomes were included. A survey of the tissue distribution of expression of the various forms in selected human tissues showed that the core-exon linked to all four possible 5' exons are detected almost exclusively in kidney. The core-exon was also detected in human kidney and lower amounts were detected in skeletal muscle > pancreas > spleen > brain = heart > liver RNAs by RT-PCR. Alternatively, Northern blot analysis of poly(A)(+) RNAs from these same tissues revealed a 2.8-kilobase transcript only in kidney. Heterologous expression of either the hROM-K1, hROM-K2, or hROM-K3 channel transcripts in Xenopus oocytes led to the expression of K+-selective, Ba2+-sensitive inwardly rectifying channels as measured by whole cell currents. At this level of analysis, the channel properties of the individual forms could not be distinguished.	UPJOHN LABS, DEPT CELL BIOL, KALAMAZOO, MI 49007 USA; UPJOHN LABS, DEPT BIOL MOLEC, KALAMAZOO, MI 49007 USA; UPJOHN LABS, DEPT CARDIOVASC DIS RES, KALAMAZOO, MI 49007 USA									BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; CATTERALL WA, 1993, TRENDS NEUROSCI, V16, P500, DOI 10.1016/0166-2236(93)90193-P; CHANDY KG, 1990, BIOPHYS J, V57, pA110; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GHANSHANI S, 1992, GENOMICS, V12, P190, DOI 10.1016/0888-7543(92)90365-Y; HAGIWARA S, 1974, J MEMBRANE BIOL, V18, P61, DOI 10.1007/BF01870103; HALL AE, 1963, J PHYSIOL-LONDON, V166, P225, DOI 10.1113/jphysiol.1963.sp007102; HILLE B, 1978, J GEN PHYSIOL, V72, P409, DOI 10.1085/jgp.72.4.409; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; JAN LY, 1992, ANNU REV PHYSIOL, V54, P535, DOI 10.1146/annurev.physiol.54.1.535; KACZMAREK LK, 1991, NEW BIOL, V3, P315; KANDEL ER, 1966, J PHYSIOL-LONDON, V183, P287, DOI 10.1113/jphysiol.1966.sp007867; KOZAK M, 1994, J MOL BIOL, V235, P95, DOI 10.1016/S0022-2836(05)80019-1; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KURACHI Y, 1985, J PHYSIOL-LONDON, V366, P365, DOI 10.1113/jphysiol.1985.sp015803; LEECH CA, 1981, J PHYSIOL-LONDON, V319, P295, DOI 10.1113/jphysiol.1981.sp013909; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LUNEAU C, 1991, FEBS LETT, V288, P163, DOI 10.1016/0014-5793(91)81026-5; LUNEAU CJ, 1991, P NATL ACAD SCI USA, V88, P3932, DOI 10.1073/pnas.88.9.3932; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MURAI T, 1989, BIOCHEM BIOPH RES CO, V161, P176, DOI 10.1016/0006-291X(89)91577-5; PERNEY T M, 1991, Current Opinion in Cell Biology, V3, P663, DOI 10.1016/0955-0674(91)90039-2; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; Pongs O., 1993, SEMIN NEUROSCI, V5, P93; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; SAKAMANN B, 1984, J PHYSL, V347, P641; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; SLIGHTOM JL, 1991, PHYLOGENETIC ANALYSIS OF DNA SEQUENCES, P18; STANDEN NB, 1978, J PHYSIOL-LONDON, V280, P169, DOI 10.1113/jphysiol.1978.sp012379; WYMORE RS, 1994, GENOMICS, V20, P191, DOI 10.1006/geno.1994.1153; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520; ZHOU H, 1994, AM J PHYSIOL, V266, pC809, DOI 10.1152/ajpcell.1994.266.3.C809	39	103	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24261	24270						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929082				2022-12-25	WOS:A1994PQ34600064
J	SUGIMOTO, K; HAGISHITA, Y; HIMENO, M				SUGIMOTO, K; HAGISHITA, Y; HIMENO, M			FUNCTIONAL DOMAIN-STRUCTURE OF HUMAN CENTROMERE PROTEIN-B - IMPLICATION OF THE INTERNAL AND C-TERMINAL SELF-ASSOCIATION DOMAINS IN CENTROMERIC HETEROCHROMATIN CONDENSATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENP-B; DNA-BINDING; ANTICENTROMERE ANTIBODIES; SATELLITE DNA; CELL; IMMUNOPRECIPITATION; KINETOCHORE; SEQUENCE; RECEPTOR; ANTIGEN	Centromere protein B (CENP-B) is a common centromere DNA binding protein among mammalian centromeres, CENP-B possesses the specific DNA binding activity to the 17-base pair sequence dispersed in centromeric repetitive DNA sequences. In the previous study, we have shown that its DNA-binding domain exists within the N-terminal 134 amino acid residues. Here, to clarify the whole domain structure, another functional unit required for CENP-B self association was examined. Recombinant CENP-B was expressed in Escherichia coli. First, a chemical cross linking reagent, disuccinimidyl suberate, was used to fix the physical association without losing the DNA-binding activity. The complexes with the same molecular weight as homodimer and trimer were identified after a separation by SDS-polyacrylamide gel electrophoresis. With a series of CENP-B deletion constructs, the area responsible for this oligomer formation was located at the internal region. Second, an electrophoretic mobility shift assay was also used to survey the minimum regions required for the CENP-B self-association. Three separate elements were identified by assaying the capacity to form the additional slow-migrating complex, two in the internal region and one in the C terminus. These results suggest that CENP-B molecules interact with each other at the multiple sites to fold the centromeric DNA repeats into a heterochromatin structure.			SUGIMOTO, K (corresponding author), UNIV OSAKA PREFECTURE, DEPT APPL BIOCHEM, APPL MOLEC BIOL LAB, SAKAI, OSAKA 593, JAPAN.							CHEN JD, 1992, MOL CELL BIOL, V12, P598, DOI 10.1128/MCB.12.2.598; COOKE CA, 1990, J CELL BIOL, V110, P1475, DOI 10.1083/jcb.110.5.1475; CORNELL R, 1989, J BIOL CHEM, V264, P9077; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; EARNSHAW WC, 1987, J CELL BIOL, V104, P817, DOI 10.1083/jcb.104.4.817; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; MASUMOTO H, 1989, EXP CELL RES, V181, P181, DOI 10.1016/0014-4827(89)90192-4; MASUMOTO H, 1989, J CELL BIOL, V109, P1963, DOI 10.1083/jcb.109.5.1963; MURO Y, 1992, J CELL BIOL, V116, P585, DOI 10.1083/jcb.116.3.585; MURO Y, 1990, J RHEUMATOL, V17, P1042; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PILCH PF, 1980, J BIOL CHEM, V255, P1722; PLUTA AF, 1990, TRENDS BIOCHEM SCI, V15, P181, DOI 10.1016/0968-0004(90)90158-8; RIS H, 1981, CHROMOSOMA, V82, P153, DOI 10.1007/BF00286101; Sambrook J, 1989, MOL CLONING LABORATO; SUGIMOTO K, 1992, BIOSCI BIOTECH BIOCH, V56, P1174, DOI 10.1271/bbb.56.1174; SUGIMOTO K, 1992, CELL STRUCT FUNCT, V17, P129, DOI 10.1247/csf.17.129; SUGIMOTO K, 1992, J BIOCHEM, V111, P478, DOI 10.1093/oxfordjournals.jbchem.a123783; SUGIMOTO K, 1992, ANAL BIOCHEM, V207, P114, DOI 10.1016/0003-2697(92)90511-5; SULLIVAN KF, 1991, CHROMOSOMA, V100, P360, DOI 10.1007/BF00337514; Tan E.M., 1989, ADV IMMUNOL, V44, P151, DOI [10.1016/S0065-2776(08)60641-0, DOI 10.1016/S0065-2776(08)60641-0]; WRIGHT BS, 1987, P NATL ACAD SCI USA, V84, P26, DOI 10.1073/pnas.84.1.26; YODA K, 1992, J CELL BIOL, V119, P1413, DOI 10.1083/jcb.119.6.1413	23	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24271	24276						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929083				2022-12-25	WOS:A1994PQ34600065
J	CAMP, LA; VERKRUYSE, LA; AFENDIS, SJ; SLAUGHTER, CA; HOFMANN, SL				CAMP, LA; VERKRUYSE, LA; AFENDIS, SJ; SLAUGHTER, CA; HOFMANN, SL			MOLECULAR-CLONING AND EXPRESSION OF PALMITOYL-PROTEIN THIOESTERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHETASE; SEQUENCE; IDENTIFICATION; RECEPTOR; ENZYME; DOMAIN; CELLS; CDNA; GENE; RAS	We have previously reported the purification of a palmitoyl-protein thioesterase (PPT) from bovine brain that removes palmitate from Ha-Ras (Camp, L. A., and Hofmann, S. L. (1993) J. Biol. Chem. 268, 22566-22574). In the current paper, we have isolated bovine and rat cDNA clones encoding PPT. The deduced amino acid sequence of PPT predicts a protein of 306 amino acids that contains amino acid motifs characteristic of thioesterases: ''Gly-X-Ser-X-Gly'' positioned near the NH, terminus and ''Gly-Asp-His'' positioned near the COOH terminus of the protein. The identity of the PPT cDNA was further confirmed by expression in simian COS cells and insect Sf9 cells. Comparison of the DNA and protein sequence data suggests that a hydrophobic NH2-terminal sequence of 27 amino acid residues is removed from the primary translation product. Furthermore, the recombinant protein and the native protein purified from bovine brain contain complex asparagine-linked oligosaccharides and a large proportion of the expressed PPT is secreted from COS and Sf9 cells. Thus, while the palmitoyl-protein thioesterase will deacylate intracellular palmitoylated proteins such as Ha-Ras and the alpha subunits of heterotrimeric G proteins, the physiologic substrates are likely to be externally oriented or secreted proteins.	UNIV TEXAS,SW MED CTR,SIMMONS CANC CTR,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL CANCER INSTITUTE [R01CA061823] Funding Source: NIH RePORTER; NCI NIH HHS [CA61823-01] Funding Source: Medline; NIGMS NIH HHS [GM08014] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CHO HS, 1993, J BIOL CHEM, V268, P9238; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DEREWENDA ZS, 1993, TRENDS BIOCHEM SCI, V18, P20, DOI 10.1016/0968-0004(93)90082-X; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOEG JM, 1986, J BIOL CHEM, V261, P3911; HOFMANN SL, 1987, P NATL ACAD SCI USA, V84, P6312, DOI 10.1073/pnas.84.17.6312; HUANG G, 1988, BIOCHEMISTRY-US, V27, P1395, DOI 10.1021/bi00405a001; HWANG CS, 1993, J BIOL CHEM, V268, P14278; Knudsen J, 1981, Methods Enzymol, V71 Pt C, P200, DOI 10.1016/0076-6879(81)71028-0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; NAGGERT J, 1988, J BIOL CHEM, V263, P1146; PATHAK RK, 1992, J MUSCLE RES CELL M, V13, P366, DOI 10.1007/BF01766464; PEARCE EJ, 1991, EMBO J, V10, P2741, DOI 10.1002/j.1460-2075.1991.tb07822.x; POULOSE AJ, 1985, J BIOL CHEM, V260, P5953; RANDALL WR, 1994, J BIOL CHEM, V269, P12367; RANDHAWA ZI, 1987, EUR J BIOCHEM, V162, P577, DOI 10.1111/j.1432-1033.1987.tb10678.x; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STULTS JT, 1991, AM J PHYSIOL, V261, pL118, DOI 10.1152/ajplung.1991.261.2.L118; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WITKOWSKI A, 1994, J BIOL CHEM, V269, P379; YANG CY, 1988, BIOCHEMISTRY-US, V27, P7773, DOI 10.1021/bi00420a028	30	203	205	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23212	23219						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	7916016				2022-12-25	WOS:A1994PQ16400049
J	STOLE, E; SMITH, TK; MANNING, JM; MEISTER, A				STOLE, E; SMITH, TK; MANNING, JM; MEISTER, A			INTERACTION OF GAMMA-GLUTAMYL-TRANSPEPTIDASE WITH ACIVICIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFERASE TRANSPEPTIDASE; ACID AT-125; AMINO-ACIDS; GLUTATHIONE; INHIBITION	Inactivation of gamma-glutamyl transpeptidase by acivicin (L(alpha S,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazole acetic acid) is rapid, thought to be irreversible, and associated with binding of close to 1 mol of inhibitor/mol of enzyme. Previous studies with [3-C-14]acivicin indicated binding (prevented by substrate) to a specific hydroxyl group (threonine 523) of the rat kidney enzyme. In the present work, we found that such inactivation can be reversed by treating the inhibited enzyme with hydroxylamine. Reactivation (more than 85% complete) is associated with release from the inactivated enzyme of compounds that exhibit the properties of threo-beta-hydroxy-L-gamma-glutamyl hydroxamate and 3-hydroxypyrrolidone-2-carboxylate. We found that the enzyme acts very slowly on acivicin, at a rate that is about 10(-9) that of its normal catalytic rate with glutathione, to form threo-beta-hydroxy-L-glutamate and hydroxylamine. The findings indicate that inhibition by acivicin involves its transformation on the enzyme to an inhibitory species which is attached, apparently by ester linkage, to a specific hydroxyl group of the enzyme. The very slow rate of release of this intermediate appears to account for the observed inhibition.	ROCKEFELLER UNIV,NEW YORK,NY 10021	Rockefeller University	STOLE, E (corresponding author), CORNELL UNIV,COLL MED,DEPT BIOCHEM,NEW YORK,NY 10021, USA.				NIDDK NIH HHS [2 R37 DK12034] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK012034] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN L, 1980, RES COMMUN CHEM PATH, V27, P175; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; GARDELL SJ, 1979, J BIOL CHEM, V254, P4942; GREENSTEIN JP, 1961, CHEM AMINO ACIDS, P1934; GREENSTEIN JP, 1961, CHEM AMINO ACIDS, P2419; GREENSTEIN JP, 1961, CHEM AMINO ACIDS, P927; GRIFFITH OW, 1979, J BIOL CHEM, V254, P1205; GRIFFITH OW, 1980, P NATL ACAD SCI-BIOL, V77, P3384, DOI 10.1073/pnas.77.6.3384; HAMILTON PB, 1945, J BIOL CHEM, V158, P375; IKEDA Y, 1994, FASEB J, V8, P571; LAPERCHE Y, 1989, P NATL ACAD SCI USA, V86, P3159; LEANZA WJ, 1953, J BIOL CHEM, V201, P377; LEVINTOW L, 1955, J AM CHEM SOC, V77, P5304, DOI 10.1021/ja01625a031; MANNING JM, 1969, BIOCHEMISTRY-US, V8, P2681, DOI 10.1021/bi00834a066; MCCARTY CG, 1970, CHEM CARBON NITROGEN, P403; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Meister A, 1976, ENZYMES BIOL MEMBR, Vv3, P315; Meister A, 1989, GLUTATHIONE CHEM BIO, P367; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; ORLOWSKI M, 1965, J BIOL CHEM, V240, P338; ORLOWSKI M, 1963, BIOCHIM BIOPHYS ACTA, V73, P679; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; STOLE E, 1990, P NATL ACAD SCI USA, V87, P1706, DOI 10.1073/pnas.87.5.1706; Tate S.S., 1980, ENZYMATIC BASIS DETO, VII, P95; TATE SS, 1974, J BIOL CHEM, V249, P7593; TATE SS, 1974, P NATL ACAD SCI USA, V71, P3329, DOI 10.1073/pnas.71.9.3329; TATE SS, 1985, METHOD ENZYMOL, V113, P400; TSO JY, 1980, J BIOL CHEM, V255, P6734; Wilson H, 1937, J BIOL CHEM, V119, P309	30	58	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21435	21439						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	7914892				2022-12-25	WOS:A1994PK97300010
J	KANAI, Y; STELZNER, M; NUSSBERGER, S; KHAWAJA, S; HEBERT, SC; SMITH, CP; HEDIGER, MA				KANAI, Y; STELZNER, M; NUSSBERGER, S; KHAWAJA, S; HEBERT, SC; SMITH, CP; HEDIGER, MA			THE NEURONAL AND EPITHELIAL HUMAN HIGH-AFFINITY GLUTAMATE TRANSPORTER - INSIGHTS INTO STRUCTURE AND MECHANISM OF TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTER; LONG-TERM POTENTIATION; PROTEIN-KINASE-C; DICARBOXYLIC AMINOACIDURIA; RAT-BRAIN; GLUCOSE COTRANSPORTER; EXPRESSION CLONING; MEMBRANE-VESICLES; GABA TRANSPORTER; INBORN ERROR	High affinity transport of glutamate across plasma membranes of brain neurons and epithelia is mediated by a Na+- and K+-coupled electrogenic transporter. Here we report the primary structure and functional characterization of the human high affinity glutamate transporter (HEAAC1). A unique characteristic of HEAAC1-mediated transport is that the affinity for glutamate and the maximal transport rate are strongly dependent on membrane potential. Our data provide new insights into individual steps of high affinity glutamate transport and show that the transport mechanism is distinct from that of the gamma-aminobutyric acid transporter GAT-1 and the Na+/glucose transporter SGLT1. Under voltage clamp condition, HEAAC1 mediated large substrate-evoked inward currents (up to 1 mu A). The substrate specificity, stereospecificity, the K-m value (30 +/- 3 mu M at -60 mV) of the L-glutamate-evoked current, and Northern analysis all agree with previously reported characteristics of high affinity glutamate transport in brain. In contrast to SGLT1 and GAT-1, voltage jump studies of HEAAC1 yielded only minor relaxation currents. Classic inhibitors of brain glutamate uptake such as DL-threo-beta-hydroxyaspartate, L-trans-pyrrolidine 2,4,-dicarboxylic acid (PDC), and dihydrokainate were found to be either transport substrates or to have no significant effect on glutamate transport. We also found that the maximal transport rate for PDC was markedly reduced compared to that for L-glutamate. We propose that PDC most likely reduces the turnover rate of the transporter. A search of the sequence data bases revealed weak homology of HEAAC1 to the H+- coupled vesicular monoamine transporter, suggesting an evolutionary link between plasma membrane and vesicular transporters.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV RENAL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School				Hediger, Matthias/0000-0003-1946-027X; Nussberger, Stephan/0000-0003-3619-4452	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043171] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-43171] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONSON PS, 1978, J MEMBRANE BIOL, V42, P81, DOI 10.1007/BF01870395; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; BALLATORI N, 1986, J BIOL CHEM, V261, P6216; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; BRIDGES RJ, 1991, J MED CHEM, V34, P717, DOI 10.1021/jm00106a037; CASADO M, 1993, J BIOL CHEM, V268, P27313; DANBOLT NC, 1992, NEUROSCIENCE, V51, P259; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; FUKUHARA Y, 1985, AM J PHYSIOL, V248, pF869, DOI 10.1152/ajprenal.1985.248.6.F869; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HARIG JM, 1987, BIOCHIM BIOPHYS ACTA, V903, P358, DOI 10.1016/0005-2736(87)90226-4; HEDIGER MA, 1989, P NATL ACAD SCI USA, V86, P5748, DOI 10.1073/pnas.86.15.5748; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HEDIGER MA, 1991, BIOCHIM BIOPHYS ACTA, V1064, P360, DOI 10.1016/0005-2736(91)90323-Z; HEINZ E, 1988, BIOCHIM BIOPHYS ACTA, V937, P300, DOI 10.1016/0005-2736(88)90252-0; ISAACSON JS, 1993, J NEUROPHYSIOL, V70, P2187, DOI 10.1152/jn.1993.70.5.2187; KANAI Y, 1993, FASEB J, V7, P1450, DOI 10.1096/fasebj.7.15.7903261; KANAI Y, 1993, TRENDS NEUROSCI, V16, P365, DOI 10.1016/0166-2236(93)90094-3; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KANNER BI, 1993, FEBS LETT, V325, P95, DOI 10.1016/0014-5793(93)81421-U; LEE WS, 1994, IN PRESS J BIOL CHEM, V269; LERNER J, 1987, COMP BIOCHEM PHYS B, V87, P443, DOI 10.1016/0305-0491(87)90035-6; LINDEN DJ, 1989, BRAIN RES REV, V14, P279, DOI 10.1016/0165-0173(89)90004-0; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; MELANCON SB, 1977, J PEDIATR-US, V91, P422, DOI 10.1016/S0022-3476(77)81312-7; MENNERICK S, 1994, NATURE, V368, P59, DOI 10.1038/368059a0; NELSON PJ, 1983, BIOCHEMISTRY-US, V22, P5459, DOI 10.1021/bi00292a030; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; REITHMEIER R, 1993, MOL BIOL FUNCTIONS C, V46, P161; ROTHSTEIN JD, 1993, P NATL ACAD SCI USA, V90, P6591, DOI 10.1073/pnas.90.14.6591; ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204; SARANTIS M, 1993, NEURON, V11, P541, DOI 10.1016/0896-6273(93)90158-N; SCHWARTZ EA, 1990, J PHYSIOL-LONDON, V426, P43, DOI 10.1113/jphysiol.1990.sp018126; SHAFQAT S, 1993, J BIOL CHEM, V268, P15351; SMITH CP, 1994, GENOMICS, V20, P335, DOI 10.1006/geno.1994.1183; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; SWARNA M, 1989, HUM GENET, V82, P299, DOI 10.1007/BF00291178; TEIJEMA HL, 1974, METABOLISM, V23, P115, DOI 10.1016/0026-0495(74)90108-5; WELLS RG, 1992, AM J PHYSIOL, V263, pF459, DOI 10.1152/ajprenal.1992.263.3.F459	44	116	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20599	20606						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	7914198				2022-12-25	WOS:A1994PB31700061
J	BROUILLET, A; DARBOUY, M; OKAMOTO, T; CHOBERT, MN; LAHUNA, O; GARLATTI, M; GOODSPEED, D; LAPERCHE, Y				BROUILLET, A; DARBOUY, M; OKAMOTO, T; CHOBERT, MN; LAHUNA, O; GARLATTI, M; GOODSPEED, D; LAPERCHE, Y			FUNCTIONAL-CHARACTERIZATION OF THE RAT BETA-GLUTAMYL TRANSPEPTIDASE PROMOTER THAT IS EXPRESSED AND REGULATED IN THE LIVER AND HEPATOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE COPY GENE; TRANSFERASE TRANSPEPTIDASE; BINDING PROTEIN; GLUTATHIONE METABOLISM; HETEROLOGOUS SUBUNITS; MESSENGER-RNAS; 5' ENDS; TRANSCRIPTION; DNA; SEQUENCE	gamma-Gylutamyl transpeptidase (GGT) is an enzyme encoded by multiple mRNAs (mRNA(I) to mRNA(IV)) that, in the rat, are transcribed from a single copy gene in a tissue specific manner. In the liver, GGT expression is up-regulated in transformed cells, and this induction is the most widely used marker of liver cell transformation. We characterized the GGT mRNA species expressed in the liver (mRNA(III)), and we report that this mRNA differs from the other GGT mRNA species by a 275-base alternate 5'-end sequence. Its transcription occurs on a specific promoter (promoter III) that maps on the GGT gene upstream of the two promoters coding for the GGT mRNA(I) and mRNA(II). In hepatoma cells, mRNA(III) expression is related to the differentiation state of the cells. We have shown that, in Reuber H-35-derived cell lines, the GGT mRNA(III) is transcribed in cells that express a differentiated phenotype (Fao), but not in the dedifferentiated C2 and H5 variants. Moreover, we observed a reexpression of the GGT mRNA(III) species in the C2 Rev7 variant, which has reverted from C2 toward a differentiated hepatocyte phenotype. In the proximal promoter III region, we identified a sequence that strongly enhances transcriptional activity in Fao and C2 Rev7 cells, but not in the dedifferentiated C2 variant. This motif interacts with nuclear proteins belonging to the NF-1 and NF-Y families that govern GGT promoter III expression in differentiated hepatoma cells.	HOP HENRI MONDOR,INSERM,U99,F-94010 CRETEIL,FRANCE	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)			Brouillet, Arthur/S-4499-2018; lahuna, olivier/O-7840-2017	lahuna, olivier/0000-0002-6286-3923				CEREGHINI S, 1990, EMBO J, V9, P2257, DOI 10.1002/j.1460-2075.1990.tb07396.x; CHOBERT MN, 1990, J BIOL CHEM, V265, P2352; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DARBOUY M, 1991, AM J PHYSIOL, V261, pC1130, DOI 10.1152/ajpcell.1991.261.6.C1130; DESCHATRETTE J, 1980, CELL, V19, P1043, DOI 10.1016/0092-8674(80)90095-1; ELMORE LW, 1991, CANCER RES, V51, P5752; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FINIDORI J, 1984, J BIOL CHEM, V259, P4687; GARLATTI M, 1993, J BIOL CHEM, V268, P6567; GERMAIN L, 1988, CANCER RES, V48, P4909; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRIFFITHS SA, 1989, CANCER LETT, V46, P69, DOI 10.1016/0304-3835(89)90217-6; HANIGAN M, 1983, CARCINOGENESIS, V6, P165; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; JAKOBOVITS EB, 1988, MOL CELL BIOL, V8, P5549, DOI 10.1128/MCB.8.12.5549; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KURAUCHI O, 1991, BIOCHEMISTRY-US, V30, P1618, DOI 10.1021/bi00220a025; LAHUNA O, 1992, BIOCHEMISTRY-US, V31, P9190, DOI 10.1021/bi00153a011; LAPERCHE Y, 1986, P NATL ACAD SCI USA, V83, P937, DOI 10.1073/pnas.83.4.937; LI XY, 1992, J BIOL CHEM, V267, P8984; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MAIRE P, 1987, J MOL BIOL, V197, P425, DOI 10.1016/0022-2836(87)90556-0; MEANS GD, 1991, MOL ENDOCRINOL, V5, P2005, DOI 10.1210/mend-5-12-2005; MEISTER A, 1984, HEPATOLOGY, V4, P739, DOI 10.1002/hep.1840040431; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; MITCHEL PJ, 1991, CELL, V50, P847; MULLER WH, 1985, BIOL CHEM H-S, V366, P375, DOI 10.1515/bchm3.1985.366.1.375; NASH B, 1982, J BIOL CHEM, V257, P585; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1866, DOI 10.1210/mend-4-12-1866; PALLARDO FV, 1991, BIOCHEM J, V274, P891, DOI 10.1042/bj2740891; PAWLAK A, 1988, J BIOL CHEM, V263, P9913; RAJAGOPALAN S, 1990, J BIOL CHEM, V265, P11721; RAJAGOPALAN S, 1993, P NATL ACAD SCI USA, V90, P6179, DOI 10.1073/pnas.90.13.6179; REUBER MD, 1961, J NATL CANCER I, V26, P891; SELL S, 1990, CANCER RES, V50, P3811; SIEGRIST S, 1990, BIOCHEM J, V267, P621, DOI 10.1042/bj2670621; TATE SS, 1981, MOL CELL BIOCHEM, V39, P357, DOI 10.1007/BF00232585; TEMPLETON NS, 1991, CANCER RES, V51, P6190; THOMPSON EB, 1966, P NATL ACAD SCI USA, V56, P296, DOI 10.1073/pnas.56.1.296; TSUJI A, 1990, CLIN CHIM ACTA, V104, P361; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x	42	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14878	14884						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	7910821				2022-12-25	WOS:A1994NP73800008
J	SHIMIZU, T; MURAKAMI, Y; HATANO, M				SHIMIZU, T; MURAKAMI, Y; HATANO, M			GLU(318) AND THR(319) MUTATIONS OF CYTOCHROME-P450 1A2 REMARKABLY ENHANCE HOMOLYTIC O-O CLEAVAGE OF ALKYL HYDROPEROXIDES - AN OPTICAL-ABSORPTION SPECTRAL STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; PUTATIVE DISTAL SITE; SUBSTRATE HYDROXYLATION; PROTEIN ADDUCTS; LIGAND TRANS; COMPOUND-I; HEME; OXYGEN; ENZYME; DEGRADATION	Interactions of putative distal mutants of cytochrome P450 1A2 (P450 1A2) with hydroperoxides were studied with optical absorption spectroscopy. The Soret absorption at 393 nm of the wild-type P450 1A2 decreased by adding H2O2, tert-butyl hydroperoxide (TBHP), and cumyl hydroperoxide (CHP), whereas the absorption decrease was accompanied by the appearance of a new band around 423 nm for Glu(318) and Thr(319) mutants with similar treatments. Spectral simulation based on Gaussian analyses and visible bands indicate that H2O2- and TBHP-induced intermediates' spectra of the wild type are close to that of Compound I of horseradish peroxidase, whereas TBHP- and CHP induced intermediates' spectra of the mutants are close to that of Compound II of horseradish peroxidase. Based on kinetic parameters of the spectral changes, it is suggested that: 1) TBHP and CHP mainly form porphyrin(+.)Fe(IV)=O due to heterolytic O-O scission in the wild type, while forming porphyrinFe(IV)=O for the mutants owing to homolytic O-O scission; and 2) heterolytic O-O scission of H2O2 is not changed by the mutations. Heterolytic/homolytic cleavage ratios for the P450 1A2 reactions with CHP obtained from product analysis were consistent with those obtained from spectral changes.			SHIMIZU, T (corresponding author), TOHOKU UNIV,INST CHEM REACT SCI,SENDAI 98077,JAPAN.							ADACHI S, 1993, BIOCHEMISTRY-US, V32, P241, DOI 10.1021/bi00052a031; BLAKE RC, 1981, J BIOL CHEM, V256, P2127; BRAIN WR, 1990, BIOCHEMISTRY-US, V29, P11280; CORREIA MA, 1987, ARCH BIOCHEM BIOPHYS, V258, P436, DOI 10.1016/0003-9861(87)90365-1; DAVIES HW, 1986, ARCH BIOCHEM BIOPHYS, V244, P387, DOI 10.1016/0003-9861(86)90128-1; DAWSON JH, 1982, J BIOL CHEM, V257, P3606; EGAWA T, 1992, FEBS LETT, V305, P206, DOI 10.1016/0014-5793(92)80668-7; FUNAE Y, 1987, BIOCHIM BIOPHYS ACTA, V926, P349, DOI 10.1016/0304-4165(87)90221-2; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; GUENGERICH FP, 1978, BIOCHEMISTRY-US, V17, P3633, DOI 10.1021/bi00610a033; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; HIGUCHI T, 1993, J AM CHEM SOC, V115, P7551, DOI 10.1021/ja00069a084; HIROYA K, 1994, IN PRESS ARCH BIOCH; HRYCAY EG, 1975, BIOCHEM BIOPH RES CO, V66, P209, DOI 10.1016/S0006-291X(75)80315-9; ISHIGOOKA M, 1992, BIOCHEMISTRY-US, V31, P1528, DOI 10.1021/bi00120a033; ISHIMURA Y, 1971, BIOCHEM BIOPH RES CO, V42, P140, DOI 10.1016/0006-291X(71)90373-1; Klebanoff S.J., 1991, PEROXIDASES CHEM BIO, P1; KRAINEV AG, 1991, BIOCHEMISTRY-US, V30, P11206, DOI 10.1021/bi00111a003; KRAINEV AG, 1993, BIOCHEMISTRY-US, V32, P1951, DOI 10.1021/bi00059a011; LAU SMC, 1993, BIOCHEMISTRY-US, V32, P1945, DOI 10.1021/bi00059a010; MANSUY D, 1982, TETRAHEDRON LETT, V23, P2781, DOI 10.1016/S0040-4039(00)87457-2; MANSUY D, 1989, EUR J BIOCHEM, V184, P267, DOI 10.1111/j.1432-1033.1989.tb15017.x; Marnett L.J., 1986, CYTOCHROME P 450 STR, P29; MATSUNAGA E, 1990, J BIOL CHEM, V265, P17197; MAYUZUMI H, 1993, BIOCHEMISTRY-US, V32, P5622, DOI 10.1021/bi00072a018; MCCARTHY MB, 1983, J BIOL CHEM, V258, P9153; MURAKAMI Y, 1993, 2ND INT S CYT P450 M, P21; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NORDBLOM GD, 1976, ARCH BIOCHEM BIOPHYS, V175, P524, DOI 10.1016/0003-9861(76)90541-5; OPRIAN DD, 1979, J BIOL CHEM, V254, P8895; Ortiz de Montellano P.R., 2015, CYTOCHROME P450 STRU, P912; PERRIN DD, 1988, LABORATORY CHEM, P129; POMPON D, 1988, EUR J BIOCHEM, V177, P285, DOI 10.1111/j.1432-1033.1988.tb14375.x; PORTER TD, 1991, J BIOL CHEM, V266, P13469; SCHAEFER WH, 1985, BIOCHEMISTRY-US, V24, P3254, DOI 10.1021/bi00334a027; SHIMIZU T, 1991, BIOCHEMISTRY-US, V30, P4659, DOI 10.1021/bi00233a004; SHIMIZU T, 1991, BIOCHEMISTRY-US, V30, P1490, DOI 10.1021/bi00220a007; SLIGAR SG, 1986, CYTOCHROME P450 STRU, P429; SONG WC, 1993, J BIOL CHEM, V268, P6293; TAJIMA K, 1989, INORG CHEM, V28, P709, DOI 10.1021/ic00303a020; TAJIMA K, 1993, BIOCHEM BIOPH RES CO, V191, P157, DOI 10.1006/bbrc.1993.1197; TAMURA M, 1978, HEMOPROTEIN CHEM, P53; VAZ ADN, 1990, P NATL ACAD SCI USA, V87, P5499, DOI 10.1073/pnas.87.14.5499; WAGNER GC, 1983, FEBS LETT, V156, P244, DOI 10.1016/0014-5793(83)80505-5; WHITE RE, 1982, J BIOL CHEM, V257, P3073; YAMAGUCHI K, 1993, J AM CHEM SOC, V115, P4058, DOI 10.1021/ja00063a026; YAO KQ, 1993, J BIOL CHEM, V268, P59	47	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13296	13304						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	7909807				2022-12-25	WOS:A1994NK18400039
J	MOORE, M; WANG, XH; LU, YF; WORMKE, M; CRAIG, A; GERLACH, JH; BURGHARDT, R; BARHOUMI, R; SAFE, S				MOORE, M; WANG, XH; LU, YF; WORMKE, M; CRAIG, A; GERLACH, JH; BURGHARDT, R; BARHOUMI, R; SAFE, S			BENZO[A]PYRENE-RESISTANT MCF-7 HUMAN BREAST-CANCER CELLS - A UNIQUE ARYL HYDROCARBON-NONRESPONSIVE CLONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR CONTENT; PROTEIN-DNA INTERACTIONS; MOUSE HEPATOMA LINE; AH-RECEPTOR; GENE-EXPRESSION; MULTIDRUG RESISTANCE; RESPONSIVE ELEMENT; P-GLYCOPROTEIN; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN TCDD; DEPENDENT INDUCTION	Wild-type MCF-7 human breast cancer cells were cultured for 3 months in 1 mu M benzo[a]pyrene (BaP), and resistant clones were screened for inducibility of CYP1A1 gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). One of the BaP-resistant (BaPR) clones exhibited unique genotypic expression which distinguished it from both wild type and drug-resistant (Adr(R)) variant MCF-7 cells. Glutathione levels, glutathione S-transferase activities, estrogen receptor levels, estrogen responsiveness, and expression of the multidrug-resistant MDR1 and MRP mRNA levels were similar in the wild-type and BaPR cells, whereas these parameters were reported to be altered in Adr(R) cells. In contrast, TCDD induced CYP1A1 gene expression and inhibited selected estrogen-induced responses in wild-type but not BaPR MCF-7 cells. Treatment of wild-type and BaPR cells with [H-3]TCDD resulted in formation of the radio-labeled aryl hydrocarbon (Ah) 6 S nuclear receptor complex in both cell lines, The loss of Ah responsiveness in the BaPR variant cells correlated with the failure of the nuclear or transformed cytosolic Ah receptor complex to bind genomic dioxin-responsive elements as determined in gel retardation assays.	QUEENS UNIV, DEPT BIOCHEM, KINGSTON K7L 3N6, ON, CANADA; QUEENS UNIV, CANC RES LAB, KINGSTON K7L 3N6, ON, CANADA; TEXAS A&M UNIV, DEPT VET ANAT & PUBL HLTH, COLLEGE STN, TX 77843 USA	Queens University - Canada; Queens University - Canada; Texas A&M University System; Texas A&M University College Station	MOORE, M (corresponding author), TEXAS A&M UNIV, DEPT VET PHYSIOL & PHARMACOL, COLLEGE STN, TX 77843 USA.		Burghardt, Robert C./AAF-4847-2021	Burghardt, Robert C./0000-0003-1021-8444	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004176, R01ES003843] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES04176, ES03843] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AKMAN SA, 1990, CANCER RES, V50, P1397; BATIST G, 1986, J BIOL CHEM, V261, P5544; BIEGEL L, 1990, J STEROID BIOCHEM, V37, P725, DOI 10.1016/0960-0760(90)90357-Q; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRONZERT DA, 1985, ENDOCRINOLOGY, V117, P1409, DOI 10.1210/endo-117-4-1409; BRUNNER N, 1989, CANCER CELL-MON REV, V1, P81; BRUNNER N, 1993, CANCER RES, V53, P283; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; BUTLER WB, 1992, CANCER RES, V52, P6164; BUTLER WB, 1986, CANCER RES, V46, P6339; CHEN YN, 1990, J BIOL CHEM, V265, P10073; CHO HS, 1991, MOL ENDOCRINOL, V5, P1323, DOI 10.1210/mend-5-9-1323; CLARKE R, 1989, P NATL ACAD SCI USA, V86, P3649, DOI 10.1073/pnas.86.10.3649; CLARKE R, 1990, ANN ONCOL, V1, P401, DOI 10.1093/oxfordjournals.annonc.a057790; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; COWAN KH, 1986, P NATL ACAD SCI USA, V83, P9328, DOI 10.1073/pnas.83.24.9328; CRESTEIL T, 1987, ARCH BIOCHEM BIOPHYS, V253, P233, DOI 10.1016/0003-9861(87)90656-4; CUTHILL S, 1991, MOL CELL BIOL, V11, P401, DOI 10.1128/MCB.11.1.401; DALTON WS, 1986, CANCER RES, V46, P5125; DARBON JM, 1990, BIOCHEM PHARMACOL, V40, P1785, DOI 10.1016/0006-2952(90)90357-Q; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DENISON MS, 1990, MOL CELL ENDOCRINOL, V69, P51, DOI 10.1016/0303-7207(90)90088-P; ELFERINK CJ, 1990, J BIOL CHEM, V265, P20708; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; FINE RL, 1988, P NATL ACAD SCI USA, V85, P582, DOI 10.1073/pnas.85.2.582; FOLDES RL, 1989, BIOCHEM PHARMACOL, V38, P1017, DOI 10.1016/0006-2952(89)90295-5; GERLACH JH, 1986, CANCER SURV, V5, P25; GIERTHY JF, 1987, CANCER RES, V47, P6198; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRADIN K, 1993, J BIOL CHEM, V268, P4061; HANKINSON O, 1981, SOMAT CELL GENET, V7, P373, DOI 10.1007/BF01542983; HANKINSON O, 1979, P NATL ACAD SCI USA, V76, P373, DOI 10.1073/pnas.76.1.373; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; HARPER N, 1992, TOXICOLOGIST, V12, P474; HARRIS M, 1990, CANCER RES, V50, P3579; HARRIS M, 1989, CANCER RES, V49, P4531; HINES RN, 1988, CARCINOGENESIS, V9, P1599, DOI 10.1093/carcin/9.9.1599; ISRAEL DI, 1984, J BIOL CHEM, V259, P5400; IVY SP, 1988, J BIOL CHEM, V263, P19119; JAISWAL AK, 1985, SCIENCE, V228, P80, DOI 10.1126/science.3838385; JIANG SY, 1992, MOL CELL ENDOCRINOL, V90, P77, DOI 10.1016/0303-7207(92)90104-E; JORDAN VC, 1988, BREAST CANCER RES TR, V11, P197, DOI 10.1007/BF01807278; JORDAN VC, 1987, DRUG RESISTANCE, P403; KATZENELLENBOGEN BS, 1987, CANCER RES, V47, P4355; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KRISHNAN V, 1992, ANAL BIOCHEM, V204, P137, DOI 10.1016/0003-2697(92)90152-W; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LEONESSA F, 1992, ACTA ONCOL, V31, P115, DOI 10.3109/02841869209088890; LERNER LJ, 1990, CANCER RES, V50, P4177; LIPPMAN ME, 1989, RECENT PROG HORM RES, V45, P383; LUSSKA A, 1992, J BIOL CHEM, V267, P15146; MANIATIS T, 1982, MOL CLONING LABORATO, P187; MILLER AG, 1981, J BIOL CHEM, V256, P2433; MIMNAUGH EG, 1989, CANCER RES, V49, P8; MORGAN TL, 1986, IN VITRO CELL DEV B, V22, P317, DOI 10.1007/BF02623404; MOSCOW JA, 1988, P NATL ACAD SCI USA, V85, P6518, DOI 10.1073/pnas.85.17.6518; NEMOTO N, 1991, CARCINOGENESIS, V12, P2115, DOI 10.1093/carcin/12.11.2115; NIELSEN D, 1992, BIOCHIM BIOPHYS ACTA, V1139, P169, DOI 10.1016/0925-4439(92)90131-6; PASANEN M, 1988, CHEM-BIOL INTERACT, V66, P223, DOI 10.1016/0009-2797(88)90073-7; POHL RJ, 1980, ANAL BIOCHEM, V107, P150, DOI 10.1016/0003-2697(80)90505-9; POOT M, 1991, CYTOMETRY, V12, P184, DOI 10.1002/cyto.990120214; READ LD, 1989, MOL ENDOCRINOL, V3, P295, DOI 10.1210/mend-3-2-295; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; RICE GC, 1986, CANCER RES, V46, P6105; SAFE S, 1991, PHARMACOL TOXICOL, V69, P400, DOI 10.1111/j.1600-0773.1991.tb01321.x; SANTEN RJ, 1990, ENDOCR REV, V11, P221, DOI 10.1210/edrv-11-2-221; Schinkel A H, 1991, Semin Cancer Biol, V2, P213; THOMPSON EW, 1993, CLIN EXP METASTAS, V11, P15, DOI 10.1007/BF00880062; THOMSEN JS, 1991, EUR J BIOCHEM, V197, P577, DOI 10.1111/j.1432-1033.1991.tb15946.x; VICKERS PJ, 1988, MOL ENDOCRINOL, V2, P886, DOI 10.1210/mend-2-10-886; VICKERS PJ, 1989, MOL ENDOCRINOL, V3, P157, DOI 10.1210/mend-3-1-157; WANG XH, 1992, BIOCHEM PHARMACOL, V43, P1635; WATSON AJ, 1992, MOL CELL BIOL, V12, P2115, DOI 10.1128/MCB.12.5.2115; YEH GC, 1992, CANCER RES, V52, P6692; ZACHAREWSKI T, 1991, BIOCHEM PHARMACOL, V41, P1931, DOI 10.1016/0006-2952(91)90133-P; ZAMAN GJR, 1993, CANCER RES, V53, P1747	78	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11751	11759						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7909315				2022-12-25	WOS:A1994NG37700015
J	PAPADOPOULOU, B; ROY, G; DEY, S; ROSEN, BP; OUELLETTE, M				PAPADOPOULOU, B; ROY, G; DEY, S; ROSEN, BP; OUELLETTE, M			CONTRIBUTION OF THE LEISHMANIA P-GLYCOPROTEIN-RELATED GENE LTPGPA TO OXYANION RESISTANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-TRANSLOCATING ATPASE; NUCLEOTIDE-BINDING SITE; AMPLIFIED H-CIRCLE; CANCER CELL-LINE; MULTIDRUG-RESISTANCE; DRUG-RESISTANCE; SACCHAROMYCES-CEREVISIAE; PLASMODIUM-FALCIPARUM; CARCINOMA-CELLS; MDR1 GENE	Oxyanions in the form of pentavalent antimony compounds are currently the drug of choice for treating leishmaniasis. Leishmania mutants resistant to high concentrations of the oxyanion arsenite were obtained in a stepwise selection procedure. Amplification of the H locus P-glycoprotein related gene ltpgpA, as part of extrachromosomal circles, is a frequent event in arsenite-resistant cells, but was observed only in cells resistant to high concentrations of the metalloid salts. Revertants grown in the absence of the drug lost their ltpgpA-containing amplicon and part of their resistance. The results of previous transfection experiments in Leishmania had suggested that ltpgpA is only involved in low level resistance to arsenite and antimonite. The results of this study using transfection of ltpgpA alleles isolated from arsenite resistant mutants or of whole circular amplicons containing ltpgpA demonstrate clearly that this P-glycoprotein-related gene is involved in low level resistance to oxyanions, including the pentavalent antimony-containing drug Pentostam. By site-directed mutagenesis, the LtpgpA protein was shown to require an intact nucleotide-binding site to confer arsenite resistance. Under the experimental conditions used, decreased accumulation of the (AsO2-)-As-73 drug was not observed in the ltpgpA transfectants. One possibility is that LtpgpA-mediated arsenite resistance could result from sequestration of the toxic anion in an intracellular compartment. The results indicate that despite the fact that ltpgpA amplification is a frequent event in oxyanion-resistant mutants, it contributes only slightly to the overall resistance.	CHU LAVAL,CTR RECH,SERV INFECTIOL,QUEBEC CITY G1V 4G2,PQ,CANADA; UNIV LAVAL,FAC MED,DEPT MICROBIOL,QUEBEC CITY G1V 4G2,PQ,CANADA; WAYNE STATE UNIV,SCH MED,DEPT BIOCHEM,DETROIT,MI 48201	Laval University; Laval University; Wayne State University			Ouellette, Marc/K-8694-2017	Ouellette, Marc/0000-0002-6743-9646; Rosen, Barry P./0000-0002-5230-4271	NATIONAL CANCER INSTITUTE [R01CA054141] Funding Source: NIH RePORTER; NCI NIH HHS [CA54141] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHFORD RW, 1992, PARASITOL TODAY, V8, P104, DOI 10.1016/0169-4758(92)90249-2; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BATES SE, 1992, BIOCHEMISTRY-US, V31, P6366, DOI 10.1021/bi00143a002; BERMAN JD, 1988, REV INFECT DIS, V10, P560; BERNARDS A, 1981, CELL, V27, P497, DOI 10.1016/0092-8674(81)90391-3; BEVERLEY SM, 1991, ANNU REV MICROBIOL, V45, P417, DOI 10.1146/annurev.mi.45.100191.002221; CALLAHAN HL, 1991, J BIOL CHEM, V266, P18427; CALLAHAN HL, 1992, J BIOL CHEM, V267, P24165; CHAMBERS TC, 1990, J BIOL CHEM, V265, P7679; CHIN KV, 1990, J BIOL CHEM, V265, P221; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; COLE SPC, 1991, CANCER RES, V51, P3345; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; CONKLIN DS, 1992, MOL CELL BIOL, V12, P3678, DOI 10.1128/MCB.12.9.3678; COWMAN AF, 1991, J CELL BIOL, V113, P1033, DOI 10.1083/jcb.113.5.1033; DETKE S, 1989, EXP CELL RES, V180, P161, DOI 10.1016/0014-4827(89)90220-6; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; DOU DX, 1992, J BIOL CHEM, V267, P25768; ELLENBERGER TE, 1989, J BIOL CHEM, V264, P15094; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FOOTE SJ, 1990, NATURE, V345, P255, DOI 10.1038/345255a0; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROGL M, 1992, AM J TROP MED HYG, V47, P117, DOI 10.4269/ajtmh.1992.47.117; GROGL M, 1991, AM J TROP MED HYG, V45, P98, DOI 10.4269/ajtmh.1991.45.98; GRONDIN K, 1993, NUCLEIC ACIDS RES, V21, P1895, DOI 10.1093/nar/21.8.1895; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; JACKSON JE, 1990, AM J TROP MED HYG, V43, P464, DOI 10.4269/ajtmh.1990.43.464; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KARKARIA CE, 1990, J BIOL CHEM, V265, P7832; KAUR P, 1992, J BIOL CHEM, V267, P19272; LABAN A, 1990, NATURE, V343, P572, DOI 10.1038/343572a0; MA LD, 1991, J BIOL CHEM, V266, P5593; OKOROKOV LA, 1977, EUR J BIOCHEM, V75, P373, DOI 10.1111/j.1432-1033.1977.tb11538.x; ORTIZ DF, 1992, EMBO J, V11, P3491, DOI 10.1002/j.1460-2075.1992.tb05431.x; OUELLETTE M, 1991, EMBO J, V10, P1009, DOI 10.1002/j.1460-2075.1991.tb08035.x; OUELLETTE M, 1991, RES MICROBIOL, V142, P737, DOI 10.1016/0923-2508(91)90089-S; OUELLETTE M, 1990, EMBO J, V9, P1027, DOI 10.1002/j.1460-2075.1990.tb08206.x; OUELLETTE M, 1993, PARASITOL TODAY, V9, P150, DOI 10.1016/0169-4758(93)90135-3; OWOLABI JB, 1990, J BACTERIOL, V172, P2367, DOI 10.1128/jb.172.5.2367-2371.1990; PAPADOPOULOU B, 1992, EMBO J, V11, P3601, DOI 10.1002/j.1460-2075.1992.tb05444.x; PAPADOPOULOU B, 1993, NUCLEIC ACIDS RES, V21, P4305, DOI 10.1093/nar/21.18.4305; PAPADOPOULOU B, 1994, IN PRESS MOL BIOCH P; REAY PF, 1977, ANAL BIOCHEM, V78, P557, DOI 10.1016/0003-2697(77)90117-8; ROSEN BP, 1992, ANN NY ACAD SCI, V671, P257, DOI 10.1111/j.1749-6632.1992.tb43801.x; ROSEN BP, 1984, BIOCHEM BIOPH RES CO, V124, P760, DOI 10.1016/0006-291X(84)91023-4; Sambrook J, 1989, MOL CLONING LABORATO; THOMASHOW LS, 1983, CELL, V32, P35, DOI 10.1016/0092-8674(83)90494-4; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WHITE C, 1986, FEMS MICROBIOL ECOL, V38, P277, DOI 10.1111/j.1574-6968.1986.tb01738.x; WHITE C, 1987, J GEN MICROBIOL, V133, P727; WHITE TC, 1988, J BIOL CHEM, V263, P16977; ZAMAN GJR, 1993, CANCER RES, V53, P1747	55	102	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11980	11986						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7909316				2022-12-25	WOS:A1994NG37700049
J	STRIKER, R; JACOBDUBUISSON, F; FRIEDEN, C; HULTGREN, SJ				STRIKER, R; JACOBDUBUISSON, F; FRIEDEN, C; HULTGREN, SJ			STABLE FIBER-FORMING AND NONFIBER-FORMING CHAPERONE-SUBUNIT COMPLEXES IN PILUS BIOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; PAPD; PROTEIN; BACTERIA; SURFACES; BINDING	The P pilus is a composite fiber consisting of a thin adhesive tip fibrillum joined to the pilus rod that mediates specific adherence of uropathogenic Escherichia coli to human uroepithelial cells via the PapG tip adhesin. P pilus assembly depends upon the periplasmic chaperone PapD. The interaction of PapD with different pilus subunits was investigated to gain further insight into pilus assembly PapA, the major subunit of the pilus rod, formed two periplasmic complexes (DA(2) and DA) with PapD. PapK, an adaptor protein that joins the tip fibrillum to the pilus rod, formed only one complex with PapD (DK). Only ''fiber forming'' or homopolymeric subunits, PapA in the rod and PapE in the tip fibrillum, were able to form subunit-subunit interactions in the periplasm. Subunits that are present in single or low copy in the pilus (PapK and PapG) did not form periplasmic intersubunit interactions. A pulse-chase analysis revealed that a chaperone-PapA complex is a true periplasmic intermediate in pilus assembly.	ST LOUIS UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63130	Saint Louis University; Washington University (WUSTL)			; Jacob-Dubuisson, Francoise/F-1610-2018	Striker, Rob/0000-0002-0454-895X; Jacob-Dubuisson, Francoise/0000-0002-5102-1704	NIAID NIH HHS [1RO1AI29549] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029549] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKKER D, 1991, MOL MICROBIOL, V5, P875, DOI 10.1111/j.1365-2958.1991.tb00761.x; BEACHEY EH, 1981, J INFECT DIS, V143, P325, DOI 10.1093/infdis/143.3.325; BOCK K, 1985, J BIOL CHEM, V260, P8545; BOULAY F, 1988, J CELL BIOL, V106, P629, DOI 10.1083/jcb.106.3.629; DODSON KW, 1993, P NATL ACAD SCI USA, V90, P3670, DOI 10.1073/pnas.90.8.3670; ESHDAT Y, 1981, J BACTERIOL, V148, P308, DOI 10.1128/JB.148.1.308-314.1981; GONG MF, 1992, J MOL BIOL, V228, P735, DOI 10.1016/0022-2836(92)90860-M; GRANT GA, 1992, SYNTHETIC PEPTIDES U, P185; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; HOLMGREN A, 1992, EMBO J, V11, P1617, DOI 10.1002/j.1460-2075.1992.tb05207.x; HULTGREN SJ, 1991, ANNU REV MICROBIOL, V45, P383, DOI 10.1146/annurev.micro.45.1.383; HULTGREN SJ, 1993, CELL, V73, P887, DOI 10.1016/0092-8674(93)90269-V; HULTGREN SJ, 1989, P NATL ACAD SCI USA, V86, P4357, DOI 10.1073/pnas.86.12.4357; Jacob-Dubuisson Francoise, 1993, Trends in Microbiology, V1, P50, DOI 10.1016/0966-842X(93)90032-M; JACOBDUBUISSON F, 1993, EMBO J, V12, P837, DOI 10.1002/j.1460-2075.1993.tb05724.x; JONES CH, 1993, P NATL ACAD SCI USA, V90, P8397, DOI 10.1073/pnas.90.18.8397; KUEHN MJ, 1992, NATURE, V356, P252, DOI 10.1038/356252a0; KUEHN MJ, 1991, P NATL ACAD SCI USA, V88, P10586, DOI 10.1073/pnas.88.23.10586; LINDBERG F, 1989, J BACTERIOL, V171, P6052, DOI 10.1128/jb.171.11.6052-6058.1989; LUND B, 1985, J BACTERIOL, V162, P1293, DOI 10.1128/JB.162.3.1293-1301.1985; SIMONS BL, 1990, FEMS MICROBIOL LETT, V67, P107, DOI 10.1111/j.1574-6968.1990.tb13845.x; SLONIM LN, 1992, EMBO J, V11, P4747, DOI 10.1002/j.1460-2075.1992.tb05580.x	22	36	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12233	12239						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7909317				2022-12-25	WOS:A1994NG37700085
J	ALSHAWI, MK; URBATSCH, IL; SENIOR, AE				ALSHAWI, MK; URBATSCH, IL; SENIOR, AE			COVALENT INHIBITORS OF P-GLYCOPROTEIN ATPASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-SITES; PLASMA-MEMBRANE VESICLES; HAMSTER OVARY CELLS; AMINO-ACID-SEQUENCE; MULTIDRUG-RESISTANCE; MONOCLONAL-ANTIBODIES; PYRIDOXAL 5'-DIPHOSPHO-5'-ADENOSINE; BETA-SUBUNIT; TRANSPORT; FLUORESCEIN	Verapamil stimulated ATP hydrolysis by Chinese hamster P-glycoprotein in plasma membranes was shown to occur at a site(s) which is conformationally flexible and of relatively low affinity and specificity. Such properties distinguish P glycoprotein from other transport ATPases. 8-Azido-ATP and a-azido-ATP were excellent substrates, confirming that both analogs are suitable photoaffinity labels for investigating the catalytic site(s). Inactivation of ATPase activity occurred coincident with covalent incorporation of approximately two 8-azido-ATP/P-glycoprotein, with the incorporated analog distributed equally between N- and C-terminal halves of the molecule. N-Ethylmaleimide potently inactivated in an ATP protected, dithiothreitol-irreversible manner, with maximal inactivation occurring coincident with incorporation of approximately two N-ethylmaleimide/P-glycoprotein. The critical catalytic site sulfhydryls were shown to be located equally in N- and C-terminal halves of the molecule. Sulfhydryl-substituted purines also gave substantial inhibition of P-glycoprotein ATPase activity, which was dithiothreitol reversible. The data provide guidelines for beginning investigation of catalytic site architecture by protein chemistry approaches.			ALSHAWI, MK (corresponding author), UNIV ROCHESTER,MED CTR,DEPT BIOCHEM,ROCHESTER,NY 14642, USA.							ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BRADLEY G, 1988, BIOCHIM BIOPHYS ACTA, V948, P87, DOI 10.1016/0304-419X(88)90006-6; CHAMBERS TC, 1993, J BIOL CHEM, V268, P4592; COLMAN RF, 1990, ENZYMES, V19, P283; CORNISHBOWDEN A, 1979, FUNDAMENTALS ENZYME, P94; CORNWELL MM, 1987, FASEB J, V1, P51, DOI 10.1096/fasebj.1.1.2886389; CROSS RL, 1987, P NATL ACAD SCI USA, V84, P5715, DOI 10.1073/pnas.84.16.5715; CZARNECKI JJ, 1984, BIOCHIM BIOPHYS ACTA, V800, P41, DOI 10.1016/0304-4165(84)90092-8; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P161, DOI 10.1016/0005-2736(92)90079-2; ELION GB, 1989, SCIENCE, V244, P41, DOI 10.1126/science.2649979; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FARLEY RA, 1984, J BIOL CHEM, V259, P9532; FARLEY RA, 1985, J BIOL CHEM, V260, P3899; FENG Y, 1992, J BIOL CHEM, V267, P5817; GEORGES E, 1993, J BIOL CHEM, V268, P1792; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GEORGES E, 1991, J CELL PHYSIOL, V148, P479, DOI 10.1002/jcp.1041480321; GOTTESMAN MM, 1993, CANCER RES, V53, P747; GROS P, 1992, BIOCHEMISTRY-US, V31, P1992, DOI 10.1021/bi00122a014; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOLLEMANS M, 1983, J BIOL CHEM, V258, P9307; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; LELONG IH, 1992, FEBS LETT, V304, P256, DOI 10.1016/0014-5793(92)80632-Q; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; RAO R, 1988, J BIOL CHEM, V263, P5640; RIORDAN JR, 1985, PHARMACOL THERAPEUT, V28, P51, DOI 10.1016/0163-7258(85)90082-8; RONINSON IB, 1990, PEDIATR PULM, V5, P138; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SCHURR E, 1989, CANCER RES, V49, P2729; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; SUGINO Y, 1964, J BIOL CHEM, V239, P2360; TAMURA JK, 1986, J BIOL CHEM, V261, P4126; TSOU C, 1962, SCI SINICA, V11, P1535; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YOSHIMURA A, 1989, J BIOL CHEM, V264, P16282; ZHANG JT, 1991, J BIOL CHEM, V266, P18224; ZOLLER MJ, 1979, J BIOL CHEM, V254, P8363	45	158	160	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8986	8992						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7907596				2022-12-25	WOS:A1994NB41100056
J	VANDESTOLPE, A; CALDENHOVEN, E; STADE, BG; KOENDERMAN, L; RAAIJMAKER, JAM; JOHNSON, JP; VANDERSAAG, PT				VANDESTOLPE, A; CALDENHOVEN, E; STADE, BG; KOENDERMAN, L; RAAIJMAKER, JAM; JOHNSON, JP; VANDERSAAG, PT			12-O-TETRADECANOYLPHORBOL-13-ACETATE- AND TUMOR-NECROSIS-FACTOR ALPHA-MEDIATED INDUCTION OF INTERCELLULAR-ADHESION MOLECULE-1 IS INHIBITED BY DEXAMETHASONE - FUNCTIONAL-ANALYSIS OF THE HUMAN INTERCELLULAR-ADHESION MOLECULE-1 PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROTEIN-KINASE-C; DNA-BINDING; GLUCOCORTICOID RECEPTOR; TRANSCRIPTION FACTOR; PHORBOL ESTERS; REPORTER GENE; CELL-LINES; JUN; ACTIVATION	Transcription regulation of the human intercellular adhesion molecule-1 gene by the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), tumor necrosis factor alpha (TNF alpha), and the glucocorticoid dexamethasone was studied using transient transfections in 293 cells with intercellular adhesion molecule-1 promoter-luciferase constructs (together with a glucocorticoid receptor expression vector). TPA and TNF alpha induced promoter activity, which was repressed by dexamethasone. Four TPA-responsive DNA regions were identified, each containing a potential TPA-responsive enhancer sequence: 1) -677/-340 an AP3-like sequence; 2) -290/278 a TPA-response element (TRE); 3) -227/-175 an NF kappa B-like sequence; 4) -105/-38 an AP2-like sequence. TNF alpha enhanced transcription only through region 3. The TRE in region 2 appeared to be functionally coupled to a distal TATA box at -313 and differed from the consensus TRE with respect to binding characteristics for members of the AP1 family. The newly identified NF kappa B enhancer (TGGAAATTCC) is bound by a TNF alpha-induced nuclear protein and appears to be the key element in rapid transcription induction by TNF alpha (and TPA), while transactivation of this element is repressed by the ligand-bound glucocorticoid receptor, We propose a negative cross-talk between the NF kappa B transcription factor and the glucocorticoid receptor.	NETHERLANDS INST DEV BIOL,HUBRECHT LAB,3584 CT UTRECHT,NETHERLANDS; UNIV HOSP UTRECHT,DEPT PULM DIS,UTRECHT,NETHERLANDS; UNIV MUNICH,INST IMMUNOL,W-8000 MUNICH,GERMANY	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; Utrecht University Medical Center; University of Munich				Koenderman, Leo/0000-0002-5636-6453				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BALLANTYNE CM, 1992, GENOMICS, V14, P1076, DOI 10.1016/S0888-7543(05)80132-6; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BOER PH, 1990, BIOCHEM GENET, V28, P299, DOI 10.1007/BF02401419; BOMSZTYK K, 1991, CELL REGUL, V2, P329, DOI 10.1091/mbc.2.4.329; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BUSSO N, 1987, EXP CELL RES, V173, P425, DOI 10.1016/0014-4827(87)90282-5; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; DEGITZ K, 1991, J BIOL CHEM, V266, P14024; FRIED M, 1981, NUCLEIC ACIDS RES, V13, P1431; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KRESS C, 1990, DEVELOPMENT, V109, P775; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MOFFAT GJ, 1992, BIOCHEMISTRY-US, V31, P12376, DOI 10.1021/bi00164a012; MYERS CL, 1992, AM J PHYSIOL, V263, pC767, DOI 10.1152/ajpcell.1992.263.4.C767; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PUCH BF, 1990, CELL, V61, P1187; ROTHLEIN R, 1988, J IMMUNOL, V141, P1665; ROTHLEIN R, 1986, J IMMUNOL, V137, P1279; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STADE BG, 1990, IMMUNOBIOLOGY, V182, P79, DOI 10.1016/S0171-2985(11)80585-1; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; VANDESTOLPE A, 1993, AM J RESP CELL MOL, V8, P340, DOI 10.1165/ajrcmb/8.3.340; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WAWRYK SO, 1991, INT IMMUNOL, V3, P83, DOI 10.1093/intimm/3.1.83; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WILLMANN T, 1986, NATURE, V324, P688, DOI 10.1038/324688a0; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZABEL U, 1991, J BIOL CHEM, V266, P252	47	247	253	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6185	6192						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7907090				2022-12-25	WOS:A1994MY84000105
J	WILCOX, GR; FOGH, RH; NORTON, RS				WILCOX, GR; FOGH, RH; NORTON, RS			REFINED STRUCTURE IN SOLUTION OF THE SEA-ANEMONE NEUROTOXIN SHI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; POLYPEPTIDE CARDIAC STIMULANT; DISTANCE GEOMETRY CALCULATIONS; RESTRAINED MOLECULAR-DYNAMICS; OVERHAUSER EFFECT SPECTRA; STICHODACTYLA-HELIANTHUS; PROTEIN CONFORMATIONS; ANTHOPLEURIN-A; SECONDARY STRUCTURE; DNA OCTAMER	A high resolution structure in solution has been determined for the polypeptide neurotoxin I, from the sea anemone Stichodactyla helianthus, using NMR data, distance geometry calculations, and refinement by back-calculation of two-dimensional nuclear Overhauser enhancement (NOE) spectra. A set of 913 distance constraints derived from NOEs was used, together with a large set of lower distance bounds based on the absence of NOEs in the spectrum. Eight published structures for neurotoxin I were refined independently to give structures which agree better with the experimental data, as reflected in reduced R factors calculated over well resolved cross-peaks of the two-dimensional NOE spectra and a lower total volume of peaks in back-calculated spectra that are absent from experimental spectra. The refined structures are also more precisely defined, with mean pairwise root mean square differences over backbone heavy atoms of 0.62 angstrom for well defined residues and 1.14 angstrom for all residues, compared with previous values of 1.09 and 2.41 angstrom, respectively. The consensus constraint set from the 8 refined structures was also used to generate 12 new structures, with corresponding root mean square differences of 0.76 and 1.26 angstrom. In all 20 structures the loop linking the first and second strands of the beta-sheet is considerably better defined than before. A type I beta-turn encompassing the functionally important residues Asp6, Asp7, and Glu8 is evident in the refined structures.	NMR LAB,BIOMOLEC RES INST,381 ROYAL PARADE,PARKVILLE 3052,AUSTRALIA; UNIV NEW S WALES,SCH BIOCHEM & MOLEC GENET,KENSINGTON,NSW 2033,AUSTRALIA	University of New South Wales Sydney								BALEJA JD, 1990, J MAGN RESON, V87, P375, DOI 10.1016/0022-2364(90)90015-2; BANKS KM, 1989, BIOCHEMISTRY-US, V28, P6996, DOI 10.1021/bi00443a033; BOELENS R, 1989, J MAGN RESON, V82, P290, DOI 10.1016/0022-2364(89)90032-2; BONVIN A M J J, 1991, Journal of Biomolecular NMR, V1, P305, DOI 10.1007/BF01875523; BRAUN W, 1985, J MOL BIOL, V186, P611, DOI 10.1016/0022-2836(85)90134-2; DEVLIEG J, 1986, ISRAEL J CHEM, V27, P181; ERNST RR, 1987, PRINCIPLES NUCL MAGN, P516; FOGH RH, 1989, BIOCHEMISTRY-US, V28, P1826, DOI 10.1021/bi00430a060; FOGH RH, 1990, J BIOL CHEM, V265, P13016; GOULD AR, 1990, EUR J BIOCHEM, V189, P145, DOI 10.1111/j.1432-1033.1990.tb15471.x; GOULD AR, 1992, EUR J BIOCHEM, V206, P641, DOI 10.1111/j.1432-1033.1992.tb16969.x; GUESNET JL, 1990, BIOCHEMISTRY-US, V29, P4982, DOI 10.1021/bi00472a031; HAVEL TF, 1985, J MOL BIOL, V182, P281, DOI 10.1016/0022-2836(85)90346-8; HYBERTS SG, 1992, PROTEIN SCI, V1, P736, DOI 10.1002/pro.5560010606; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KEEPERS JW, 1984, J MAGN RESON, V57, P404, DOI 10.1016/0022-2364(84)90257-9; Kem W.R., 1988, P375; KEM WR, 1989, BIOCHEMISTRY-US, V28, P3483, DOI 10.1021/bi00434a050; KIM SG, 1992, J MAGN RESON, V100, P382, DOI 10.1016/0022-2364(92)90271-8; KONING TMG, 1991, BIOCHEMISTRY-US, V30, P3787, DOI 10.1021/bi00229a028; LEFEVRE JF, 1987, BIOCHEMISTRY-US, V26, P5076, DOI 10.1021/bi00390a029; MANOLERAS N, 1992, J BIOMOL NMR, V2, P485, DOI 10.1007/BF02192811; MARION D, 1987, BIOPHYS CHEM, V28, P235, DOI 10.1016/0301-4622(87)80094-7; NEUHAUS D, 1989, NUCLEAR OVERHAUSER E, P358; NIKONOWICZ EP, 1990, BIOCHEMISTRY-US, V29, P4193, DOI 10.1021/bi00469a024; NILGES M, 1991, J MOL BIOL, V219, P499, DOI 10.1016/0022-2836(91)90189-D; Norton R S, 1990, Aust J Biotechnol, V4, P114; NORTON RS, 1991, TOXICON, V29, P1051, DOI 10.1016/0041-0101(91)90205-6; OLEJNICZAK ET, 1986, J MAGN RESON, V67, P28, DOI 10.1016/0022-2364(86)90406-3; PALLAGHY PK, 1993, IN PRESS J MOL BIOL; PENNINGTON M W, 1990, Peptide Research, V3, P228; SMITH JA, 1980, CRC CR REV BIOCH MOL, V8, P315, DOI 10.3109/10409238009105470; SUMMERS MF, 1990, BIOCHEMISTRY-US, V29, P329, DOI 10.1021/bi00454a005; THOMAS PD, 1991, P NATL ACAD SCI USA, V88, P1237, DOI 10.1073/pnas.88.4.1237; TORDA AE, 1988, FEBS LETT, V239, P266, DOI 10.1016/0014-5793(88)80931-1; TORDA AE, 1990, J MOL BIOL, V214, P223, DOI 10.1016/0022-2836(90)90157-H; VANGUNSTEREN WF, 1987, GROMOS MANUAL; WEBER PL, 1988, J MOL BIOL, V204, P483, DOI 10.1016/0022-2836(88)90589-X; WIDMER H, 1989, PROTEINS, V6, P357, DOI 10.1002/prot.340060403; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YIP P, 1989, J MAGN RESON, V83, P643, DOI 10.1016/0022-2364(89)90360-0	43	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24707	24719						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	7901218				2022-12-25	WOS:A1993MG67300032
J	BUSE, P; WOO, PL; ALEXANDER, DB; CHA, HH; REZA, A; SIROTA, ND; FIRESTONE, GL				BUSE, P; WOO, PL; ALEXANDER, DB; CHA, HH; REZA, A; SIROTA, ND; FIRESTONE, GL			TRANSFORMING GROWTH-FACTOR-ALPHA ABROGATES GLUCOCORTICOID-STIMULATED TIGHT JUNCTION FORMATION AND GROWTH SUPPRESSION IN RAT MAMMARY EPITHELIAL TUMOR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BREAST-CANCER; PROTEIN-KINASE-C; TGF-ALPHA; GENE-EXPRESSION; DOWN-REGULATION; INVITRO; COMMUNICATION; ESTROGEN; DIFFERENTIATION; OVEREXPRESSION	The glucocorticoid and transforming growth factor-alpha (TGF-alpha) regulation of growth and cell-cell contact was investigated in the Con8 mammary epithelial tumor cell line derived from a 7,12-dimethylbenz(alpha)anthracene-induced rat mammary adenocarcinoma. In Con8 cell monolayers cultured on permeable filter supports, the synthetic glucocorticoid, dexamethasone, coordinately suppressed [H-3]thymidine incorporation, stimulated monolayer transepithelial electrical resistance (TER), and decreased the paracellular leakage of [H-3]inulin or [C-14]mannitol across the monolayer. These processes dose dependently correlated with glucocorticoid receptor occupancy and function. Constitutive production of TGF-alpha in transfected cells or exogenous treatment with TGF-alpha prevented the glucocorticoid growth suppression response and disrupted tight junction formation without affecting glucocorticoid responsiveness. Treatment with hydroxyurea or araC demonstrated that de novo DNA synthesis is not a requirement for the growth factor disruption of tight junctions. Immunofluorescence analysis revealed that the ZO-1 tight junction protein is localized exclusively at the cell periphery in dexamethasone treated cells and that TGF-alpha caused ZO-1 to relocalize from the cell periphery back to a cytoplasmic compartment. Taken together, our results demonstrate that glucocorticoids can coordinately regulate growth inhibition and cell-cell contact of mammary tumor cells and that TGF-alpha, can override both effects of glucocorticoids. These results have uncovered a novel functional ''cross-talk'' between glucocorticoids and TGF-alpha which potentially regulates the proliferation and differentiation of mammary epithelial cells.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, CANC RES LAB, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley					NIDDK NIH HHS [DK-42799] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK042799, R01DK042799] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER DB, 1993, CANCER RES, V53, P1808; ARTEAGA CL, 1988, MOL ENDOCRINOL, V2, P1064, DOI 10.1210/mend-2-11-1064; BALDA MS, 1991, J MEMBRANE BIOL, V122, P193, DOI 10.1007/BF01871420; BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUNER T, 1990, INVAS METAST, V10, P31; BRAUNER T, 1990, INVAS METAST, V10, P18; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; CIARDIELLO F, 1991, ANN ONCOL, V2, P169; CITI S, 1993, J CELL BIOL, V121, P485, DOI 10.1083/jcb.121.3.485; CITI S, 1992, J CELL BIOL, V117, P169, DOI 10.1083/jcb.117.1.169; CLARKE R, 1989, MOL ENDOCRINOL, V3, P372, DOI 10.1210/mend-3-2-372; Dembinski T. C., 1987, The mammary gland. Development, regulation, and function., P355; DENEKAMP J, 1993, BRIT J RADIOL, V66, P181, DOI 10.1259/0007-1285-66-783-181; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; ELLIS B, 1992, AM J PHYSIOL, V263, pF293, DOI 10.1152/ajprenal.1992.263.2.F293; FULLER PJ, 1991, FASEB J, V5, P3092, DOI 10.1096/fasebj.5.15.1743440; GOYA L, 1993, CANCER RES, V53, P1816; GOYA L, 1993, MOL ENDOCRINOL, V7, P1121, DOI 10.1210/me.7.9.1121; GRONEMEYER H, 1992, FASEB J, V6, P2524, DOI 10.1096/fasebj.6.8.1592204; GUMBINER BM, 1993, J CELL BIOL, V123, P1631, DOI 10.1083/jcb.123.6.1631; Haslam S. Z., 1987, The mammary gland. Development, regulation, and function., P499; IMAGAWA W, 1990, ENDOCR REV, V11, P494, DOI 10.1210/edrv-11-4-494; JANECKI A, 1991, MOL CELL ENDOCRINOL, V82, P61, DOI 10.1016/0303-7207(91)90009-H; Jones JCR, 1991, CURR OPIN CELL BIOL, V3, P127, DOI 10.1016/0955-0674(91)90175-X; KLIJN JGM, 1992, ENDOCR REV, V13, P3, DOI 10.1210/er.13.1.3; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LEE SW, 1992, J CELL BIOL, V118, P1213, DOI 10.1083/jcb.118.5.1213; LIPPMAN ME, 1989, RECENT PROG HORM RES, V45, P383; LIU SC, 1987, MOL ENDOCRINOL, V1, P683, DOI 10.1210/mend-1-10-683; MADARA JL, 1993, AM J PHYSIOL, V264, pC1096, DOI 10.1152/ajpcell.1993.264.5.C1096; MANDEL LJ, 1993, NATURE, V361, P552, DOI 10.1038/361552a0; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MCDONAGH D, 1991, MODERN PATHOL, V4, P436; MEHTA PP, 1991, J MEMBRANE BIOL, V124, P207, DOI 10.1007/BF01994355; MURRAY PA, 1993, BRIT J CANCER, V67, P1408, DOI 10.1038/bjc.1993.261; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NIGAM SK, 1992, P NATL ACAD SCI USA, V89, P6162, DOI 10.1073/pnas.89.13.6162; NOGUCHI S, 1993, CANCER, V72, P131, DOI 10.1002/1097-0142(19930701)72:1<131::AID-CNCR2820720125>3.0.CO;2-Z; OKA T, 1974, J BIOL CHEM, V249, P3586; PAWSON T, 1993, PHILOS T R SOC B, V340, P279, DOI 10.1098/rstb.1993.0069; Pitelka D. R., 1978, Anderson, R. R. : Lactation. A comprehensive treatise. Vol. IV., P41; REN J, 1990, CANCER RES, V50, P358; RIUS C, 1992, J CELL SCI, V101, P395; SALOMON DS, 1992, CURRENT PERSPECTIV B, V1, P211; SCHNEEBERGER EE, 1992, AM J PHYSIOL, V262, pL647, DOI 10.1152/ajplung.1992.262.6.L647; SCHOENENBERGER CA, 1991, J CELL BIOL, V112, P873, DOI 10.1083/jcb.112.5.873; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; Segaloff A, 1966, Recent Prog Horm Res, V22, P351; SINGER KL, 1994, J BIOL CHEM, V269, P16108; SNEDEKER SM, 1991, P NATL ACAD SCI USA, V88, P276, DOI 10.1073/pnas.88.1.276; TOMITA K, 1979, CANCER RES, V39, P4407; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049; VONDERHAAR BK, 1988, CANCER TREAT RES, V40, P252; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WEBSTER MK, 1990, J BIOL CHEM, V265, P4831; WEBSTER MK, 1991, CANCER RES, V51, P6031; WELSCH CW, 1985, CANCER RES, V45, P3415; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; ZETTL KS, 1992, P NATL ACAD SCI USA, V89, P9069, DOI 10.1073/pnas.89.19.9069	64	54	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6505	6514		10.1074/jbc.270.12.6505	http://dx.doi.org/10.1074/jbc.270.12.6505			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896785	hybrid			2022-12-25	WOS:A1995QQ85500015
J	MORRISON, DF; TING, TD; VALLURY, V; HO, YK; CROUCH, RK; CORSON, DW; MANGINI, NJ; PEPPERBERG, DR				MORRISON, DF; TING, TD; VALLURY, V; HO, YK; CROUCH, RK; CORSON, DW; MANGINI, NJ; PEPPERBERG, DR			REDUCED LIGHT-DEPENDENT PHOSPHORYLATION OF AN ANALOG VISUAL PIGMENT CONTAINING 9-DEMETHYLRETINAL AS ITS CHROMOPHORE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; RHODOPSIN KINASE; 48-KDA PROTEIN; PHOSPHODIESTERASE ACTIVATION; PHOTOEXCITED RHODOPSIN; 9-DESMETHYL RHODOPSIN; AMPLIFICATION; SITES; EXCITATION; KINETICS	9-Demethyl rhodopsin (9dR), an analog of vertebrate rhodopsin, consists of opsin and a covalently attached chromophore of 11-cis 9-demthylretinal. Electrophysiological evidence that photoactivated 9dR (9dR*) undergoes abnormally slow deactivation in salamander rods (Corson, D. W., Cornwall, M. C., and Pepperberg, D. R. (1994) Visual Neurosci, 11, 91-98) raises the possibility that opsin phosphorylation, a reaction involved in visual pigment deactivation, operates abnormally on 9dR*. This possibility was tested by measuring the light-dependent phosphorylation of 9dR in preparations obtained from bovine rod outer segments. Outer segment membranes containing 9dR or regenerated rhodopsin were flash-illuminated in the presence of [gamma-P-32]ATP and rhodopsin kinase, further incubated in darkness, and then analyzed for opsin-bound [P-32]P-i. [P-32]P-i incorporation by 9dR* increased with both incubation period and bleaching extent but, under all conditions tested, was less than that measured in rhodopsin controls. Results obtained with 30-s incubation periods indicated that the maximal initial rate of incorporation by 9dR* is about 25% of that by photoactivated rhodopsin, The results imply that the low incorporation of P-i by 9dR* results from a reduced rate of phosphorylation by rhodopsin kinase and are consistent with the prolonged lifetime of 9dR* determined electrophysiologically.	UNIV ILLINOIS,DEPT OPHTHALMOL & VISUAL SCI,LIONS ILLINOIS EYE RES INST,CHICAGO,IL 60612; UNIV ILLINOIS,COLL MED,DEPT BIOCHEM,CHICAGO,IL 60612; MED UNIV S CAROLINA,DEPT OPHTHALMOL,CHARLESTON,SC 29425; MED UNIV S CAROLINA,DEPT PATHOL & LAB MED,CHARLESTON,SC 29425	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Medical University of South Carolina; Medical University of South Carolina					NATIONAL EYE INSTITUTE [R01EY005494, P30EY001792] Funding Source: NIH RePORTER; NEI NIH HHS [EY-05494, EY-06038, EY-01792] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARSHAVSKY VY, 1994, J BIOL CHEM, V269, P19882; BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; BINDER BM, 1990, J BIOL CHEM, V265, P15333; BLATZ PE, 1969, J AM CHEM SOC, V91, P5930, DOI 10.1021/ja01049a069; BUCZYLKO J, 1991, P NATL ACAD SCI USA, V88, P2568, DOI 10.1073/pnas.88.6.2568; CORSON DW, 1994, VISUAL NEUROSCI, V11, P91, DOI 10.1017/S0952523800011135; CORSON DW, 1994, P NATL ACAD SCI USA, V91, P6958, DOI 10.1073/pnas.91.15.6958; DOWLING JE, 1971, J GEN PHYSIOL, V58, P163, DOI 10.1085/jgp.58.2.163; GANTER UM, 1989, BIOCHEMISTRY-US, V28, P5954, DOI 10.1021/bi00440a036; GUREVICH VV, 1994, J BIOL CHEM, V269, P8721; HONG K, 1973, BIOCHEMISTRY-US, V12, P4517, DOI 10.1021/bi00746a033; KAHLERT M, 1990, NATURE, V345, P537, DOI 10.1038/345537a0; KROPF A, 1973, EXP EYE RES, V17, P591, DOI 10.1016/0014-4835(73)90088-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBMAN PA, 1987, ANNU REV PHYSIOL, V49, P765, DOI 10.1146/annurev.ph.49.030187.004001; MILLER JL, 1986, BIOCHEMISTRY-US, V25, P4983, DOI 10.1021/bi00366a002; MORRISON DF, 1991, J BIOL CHEM, V266, P20118; MORRISON DF, 1993, INVEST OPHTH VIS SCI, V34, P1324; MORRISON DF, 1993, BIOPHYS J, V64, pA211; PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027; PALCZEWSKI K, 1988, J BIOL CHEM, V263, P14067; PALCZEWSKI K, 1988, BIOCHEMISTRY-US, V27, P2306, DOI 10.1021/bi00407a010; PAPAC DI, 1993, BIOCHEMISTRY-US, V32, P5930, DOI 10.1021/bi00074a002; PAULSEN R, 1984, NATURE, V302, P417; PEPPERBERG DR, 1992, VISUAL NEUROSCI, V8, P9, DOI 10.1017/S0952523800006441; PEPPERBERG DR, 1988, P NATL ACAD SCI USA, V85, P5531, DOI 10.1073/pnas.85.15.5531; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; PULVERMULLER A, 1993, BIOCHEMISTRY-US, V32, P14082, DOI 10.1021/bi00214a002; ROBINSON PR, 1994, P NATL ACAD SCI USA, V91, P5411, DOI 10.1073/pnas.91.12.5411; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; SECKLER B, 1989, BIOCHEM J, V264, P489, DOI 10.1042/bj2640489; STRYER L, 1991, J BIOL CHEM, V266, P10711; WALD G, 1954, J GEN PHYSIOL, V37, P189; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; YAMAZAKI A, 1982, P NATL ACAD SCI-BIOL, V79, P3702, DOI 10.1073/pnas.79.12.3702	36	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6718	6721		10.1074/jbc.270.12.6718	http://dx.doi.org/10.1074/jbc.270.12.6718			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896815	hybrid			2022-12-25	WOS:A1995QQ85500046
J	YAKOVLEV, AG; KRUEGER, KE; FADEN, AI				YAKOVLEV, AG; KRUEGER, KE; FADEN, AI			STRUCTURE AND EXPRESSION OF A RAT KAPPA-OPIOID RECEPTOR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MOLECULAR-CLONING; DELTA; BRAIN; MU; PEPTIDES; BINDING; MOUSE	A gene encoding the rat kappa opioid receptor (KOR) was cloned and characterized. Results of rat genomic library screening and genomic Southern blot analysis show the gene represented at one copy/haploid genome. Three introns are present within the gene; however, polymerase chain reaction using different sets of primers specifying neighboring exons indicates that alternative splicing does not occur. Using reverse transcription polymerase chain reaction and primer extension techniques, we are able to demonstrate that two species of transcripts are differentially produced from the KOR gene in a tissue specific manner. The first transcript that we designate as KOR1 is equivalent to the cDNA sequence reported by other groups and is believed to correspond to KOR subtype 1. KOR1 beans with exon 1 just downstream of two TATA boxes, whereas the second transcript, which we refer to as KORx, begins in intron I and thereby retains this intronic sequence in the mature mRNA. Within this intronic sequence there are two potential translation initiation codons that are in-frame with the proposed initiation codon of KOR. The potential open reading frame that starts further upstream in KORx may lead to the translation of a variant KOR protein having a novel peptide sequence at its amino terminus.	GEORGETOWN UNIV,MED CTR,DEPT NEUROL,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,DEPT PHARMACOL,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,DEPT CELL BIOL,WASHINGTON,DC 20007	Georgetown University; Georgetown University; Georgetown University					PHS HHS [R49/CCR 306634] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BLOOM FE, 1983, ANNU REV PHARMACOL, V23, P151, DOI 10.1146/annurev.pa.23.040183.001055; CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; CHEN Y, 1993, BIOCHEM J, V295, P625, DOI 10.1042/bj2950625; CHENG J, 1992, EUR J PHARM-MOLEC PH, V226, P15, DOI 10.1016/0922-4106(92)90077-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EIDNE KA, 1989, NATURE, V342, P865, DOI 10.1038/342865a0; FADEN AI, 1993, HDB EXPT PHARM, P325; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LI SX, 1993, BIOCHEM J, V295, P629, DOI 10.1042/bj2950629; MACK KJ, 1984, LIFE SCI, V34, P281, DOI 10.1016/0024-3205(84)90600-3; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; MENG F, 1993, P NATL ACAD SCI USA, V90, P9954, DOI 10.1073/pnas.90.21.9954; MIN BH, 1994, P NATL ACAD SCI USA, V91, P9081, DOI 10.1073/pnas.91.19.9081; MINAMI M, 1993, FEBS LETT, V329, P291, DOI 10.1016/0014-5793(93)80240-U; NISHI M, 1993, FEBS LETT, V330, P770; REISINE T, 1993, TRENDS NEUROSCI, V16, P506, DOI 10.1016/0166-2236(93)90194-Q; Sambrook J, 1989, MOL CLONING LABORATO; SIMON EJ, 1991, MED RES REV, V11, P357, DOI 10.1002/med.2610110402; SPAIN JW, 1985, J NEUROSCI, V5, P584; YASUDA K, 1993, P NATL ACAD SCI USA, V90, P6736, DOI 10.1073/pnas.90.14.6736; ZAITSEV IZ, 1983, B EXP BIOL MED, V10, P84; ZUKIN RS, 1988, P NATL ACAD SCI USA, V85, P4061, DOI 10.1073/pnas.85.11.4061	22	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6421	6424		10.1074/jbc.270.12.6421	http://dx.doi.org/10.1074/jbc.270.12.6421			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896774	hybrid			2022-12-25	WOS:A1995QQ85500001
J	CHEADLE, C; IVASHCHENKO, Y; SOUTH, V; SEARFOSS, GH; FRENCH, S; HOWK, R; RICCA, GA; JAYE, M				CHEADLE, C; IVASHCHENKO, Y; SOUTH, V; SEARFOSS, GH; FRENCH, S; HOWK, R; RICCA, GA; JAYE, M			IDENTIFICATION OF A SRC SH3 DOMAIN BINDING MOTIF BY SCREENING A RANDOM PHAGE DISPLAY LIBRARY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE COMBINATORIAL LIBRARIES; EPITOPE LIBRARY; PHOSPHATIDYLINOSITOL 3-KINASE; CRYSTAL-STRUCTURE; PHOSPHOLIPASE-C; PROTEIN; LIGANDS; SELECTION; FAMILY; SITE	A phage display library was constructed in the filamentous bacteriophage fuse5. The library was made by inserting a degenerate oligonucleotide which encodes 15 variable amino acids into the NH,(2)-terminal region of the phage gene III protein. This library containing over 10(7) different phage, was screened with a glutathione S-transferase (GST) fusion protein containing the Src homology 3 (Src SH3) domain and a protein kinase A phosphorylation site (GST/PKA/Src SH3). A family of proline-rich sequences was isolated following four cycles of enrichment and amplification. Phage containing these sequences were shown to specifically bind to the GST/PHA/Src SH3 protein but not to GST/PKA only. A comparison of the inferred amino acid sequence of the different phage clones revealed a consensus sequence, RPLPXXP, which conforms to a Src SH3 domain binding motif identified independently during an affinity screen of a lambda-lox mouse embryo cDNA library using a P-32-labeled Src SH3 protein fragment as the probe (Y. Ivashchenko, manuscript in preparation). Peptides based upon the 7-amino acid SH3 binding domain core motif displayed strong binding to both the Src and to the Fyn SH3 do mains, but failed to bind to the SH3 domain of p21Ras-GTPase-activating protein (Ras GAP) and other proteins. We anticipate that further screening of the phage display library will be a useful tool for the rapid identification of additional SH3 domain binding sequences and will also help to establish the essential core motifs that define the specificity of interactions among the diverse proteins containing SH3 domains and those containing SH3 binding motifs.	RHONE POULENC RORER CENT RES,DEPT BIOL MOLEC,COLLEGEVILLE,PA 19426									BASS S, 1990, PROTEINS, V8, P309, DOI 10.1002/prot.340080405; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN JK, 1993, J AM CHEM SOC, V115, P12591, DOI 10.1021/ja00079a051; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEDMAN JR, 1993, J BIOL CHEM, V268, P23025; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; FELICI F, 1991, J MOL BIOL, V222, P301, DOI 10.1016/0022-2836(91)90213-P; FIELDS C G, 1991, Peptide Research, V4, P95; FLYNN DC, 1993, MOL CELL BIOL, V13, P7862; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; HOUGHTEN RA, 1992, BIOTECHNIQUES, V13, P412; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOHDA D, 1993, CELL, V72, P953, DOI 10.1016/0092-8674(93)90583-C; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LENSTRA JA, 1992, J IMMUNOL METHODS, V152, P149, DOI 10.1016/0022-1759(92)90136-H; LUZZAGO A, 1993, GENE, V128, P51, DOI 10.1016/0378-1119(93)90152-S; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OLDENBURG KR, 1992, P NATL ACAD SCI USA, V89, P5393, DOI 10.1073/pnas.89.12.5393; ONEIL KT, 1992, PROTEINS, V14, P509, DOI 10.1002/prot.340140411; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RON D, 1992, BIOTECHNIQUES, V13, P866; SCOTT JK, 1992, P NATL ACAD SCI USA, V89, P5398, DOI 10.1073/pnas.89.12.5398; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SMITH GP, 1993, GENE, V128, P37, DOI 10.1016/0378-1119(93)90150-2; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	41	118	129	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24034	24039						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929055				2022-12-25	WOS:A1994PQ34600031
J	NAGAN, N; KAGAN, HM				NAGAN, N; KAGAN, HM			MODULATION OF LYSYL OXIDASE ACTIVITY TOWARD PEPTIDYL LYSINE BY VICINAL DICARBOXYLIC AMINO-ACID-RESIDUES - IMPLICATIONS FOR COLLAGEN CROSS-LINKING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; III COLLAGEN; I PROCOLLAGEN; CDNA CLONE; CHAIN; PROPEPTIDE; REGION; GENE; IDENTIFICATION; BIOSYNTHESIS	The substrate specificity of lysyl oxidase has been explored with synthetic oligopeptides. k(cat)/K-m increased with increasing peptide length in Ac-(Gly)(n)-Lys-(Gly)(n)- CONH2 (n = 1-5). Using 11-mers as the standard peptide length, Glu immediately N-terminal to Lys increased k(cat)/K-m 8.8-fold over that for the -Lys-Glu- sequence and 4.9-fold over the glutamate-free control. Kinetic constants were significantly less perturbed when Glu was 2 or more residues distant from Lys. Replacement of Glu in -Glu-Lys- with Gln significantly increased K-m and lowered k(cat)/K-m. Asp rather than Glu N-terminal to Lys decreased K-m similar to that of the -Glu-Lys- 11-mer, although the k(cat) decreased considerably, indicating that lysyl oxidase responds to the side chain length of vicinal Asp or Glu at this position. -Asp-Glu-Lys- within an 11-mer was not oxidized, although this sequence is oxidized within the N-terminal telopeptide of the alpha 1(I) chain in type I collagen fibrils. Thus, lysyl oxidase exhibits distinct preferences for sequences vicinal to lysine. These results are discussed with respect to a model requiring collagen fibril formation prior to oxidation of lysine in collagen by lysyl oxidase.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	Boston University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013262, P01HL046902] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR018880] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 13262, HL 46902] Funding Source: Medline; NIAMS NIH HHS [R37 AR 18880] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Atherton E., 1990, SOLID PHASE PEPTIDE; BERGOT BJ, 1985, USER B PEPTIDE SYNTH, V3; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P5213, DOI 10.1021/bi00291a023; BODANSZKY M, 1989, PEPTIDE CHEM PRACTIC; BOEDTKER H, 1985, ANN NY ACAD SCI, V460, P85, DOI 10.1111/j.1749-6632.1985.tb51159.x; BORNSTEIN P, 1969, BIOCHEMISTRY-US, V8, P63, DOI 10.1021/bi00829a010; CHANDA VB, 1989, GENE, V78, P255; CLICK EM, 1970, BIOCHEMISTRY-US, V9, P4699; DEAK F, 1985, BIOCHEM J, V229, P189, DOI 10.1042/bj2290189; EYRE DR, 1984, ANNU REV BIOCHEM, V53, P717, DOI 10.1146/annurev.bi.53.070184.003441; FIETZEK PP, 1979, H-S Z PHYSIOL CHEM, V360, P809, DOI 10.1515/bchm2.1979.360.2.809; FIETZEK PP, 1974, BIOCHIM BIOPHYS ACTA, V365, P305, DOI 10.1016/0005-2795(74)90001-4; FRANKEL FR, 1988, DNA-J MOLEC CELL BIO, V7, P347, DOI 10.1089/dna.1.1988.7.347; FUKAE M, 1980, J BIOL CHEM, V255, P6511; FULLER F, 1981, BIOCHEMISTRY-US, V20, P996, DOI 10.1021/bi00507a054; HELSETH DL, 1979, BIOPOLYMERS, V18, P3005, DOI 10.1002/bip.1979.360181208; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; JANECZKO RA, 1989, NUCLEIC ACIDS RES, V17, P6742, DOI 10.1093/nar/17.16.6742; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; JANES SM, 1992, BIOCHEMISTRY-US, V31, P12147, DOI 10.1021/bi00163a025; KAGAN HM, 1984, J BIOL CHEM, V259, P1203; KAGAN HM, 1980, J BIOL CHEM, V255, P3656; KAGAN HM, 1981, J BIOL CHEM, V256, P5417; KAGAN HM, 1982, METHOD ENZYMOL, V82, P637; KAGAN HM, 1983, BIOCHEM BIOPH RES CO, V115, P186, DOI 10.1016/0006-291X(83)90987-7; KAGAN HM, 1986, BIOL EXTRACELLULAR M, V1, P321; KANG AH, 1970, BIOCHEMISTRY-US, V9, P796, DOI 10.1021/bi00806a012; KANG AH, 1967, BIOCHEMISTRY-US, V6, P788, DOI 10.1021/bi00855a019; KOHNO K, 1984, J BIOL CHEM, V259, P3668; KUIVANIEMI H, 1988, BIOCHEM J, V252, P633, DOI 10.1042/bj2520633; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; METSARANTA M, 1991, J BIOL CHEM, V266, P16862; PINNELL SR, 1968, P NATL ACAD SCI USA, V61, P708, DOI 10.1073/pnas.61.2.708; RAUTERBERG J, 1972, EUR J BIOCHEM, V27, P231, DOI 10.1111/j.1432-1033.1972.tb01831.x; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; Siegel R C, 1979, Int Rev Connect Tissue Res, V8, P73; SIEGEL RC, 1974, P NATL ACAD SCI USA, V71, P4826, DOI 10.1073/pnas.71.12.4826; SOLE NA, 1992, J ORG CHEM, V57, P5339; STOLTZ TR, 1972, FEBS LETT, V26, P61; SU MW, 1989, GENOMICS, V4, P438, DOI 10.1016/0888-7543(89)90353-4; TANG SS, 1983, J BIOL CHEM, V258, P4331; THOMPSON RC, 1970, P NATL ACAD SCI USA, V67, P1734, DOI 10.1073/pnas.67.4.1734; TRACKMAN PC, 1981, ANAL BIOCHEM, V113, P336, DOI 10.1016/0003-2697(81)90086-5; TRACKMAN PC, 1979, J BIOL CHEM, V254, P7831; WILLIAMS MA, 1985, ANAL BIOCHEM, V149, P430, DOI 10.1016/0003-2697(85)90594-9; WILLIAMSON PR, 1986, BIOCHEM J, V235, P597, DOI 10.1042/bj2350597; WOOD L, 1987, GENE, V61, P225, DOI 10.1016/0378-1119(87)90117-X; WU JJ, 1992, J BIOL CHEM, V267, P23007; YAMADA Y, 1983, NUCLEIC ACIDS RES, V11, P2733, DOI 10.1093/nar/11.9.2733	50	33	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22366	22371						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	7915281				2022-12-25	WOS:A1994PE09800066
J	GADDA, G; NEGRI, A; PILONE, MS				GADDA, G; NEGRI, A; PILONE, MS			REACTION OF PHENYLGLYOXAL WITH ARGININE GROUPS IN D-AMINO-ACID OXIDASE FROM RHODOTORULA-GRACILIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE ARGININE; D-ASPARTATE OXIDASE; CHEMICAL MODIFICATION; BEEF KIDNEY; PIG-KIDNEY; INACTIVATION; RESOLUTION; SEQUENCE; FLAVOCYTOCHROME-B2; 8-MERCAPTOFLAVINS	D-Amino-acid oxidase from Rhodotorula gracilis was irreversibly inactivated by phenylglyoxal in a biphasic process. The fast phase was completed in less than 1 min. Its extent was linearly dependent on phenylglyoxal concentration and was not influenced by the presence of FAD or benzoate, a pseudo substrate. The second phase of inactivation was due to a simple second-order reaction. The presence of FAD exerted only partial protection; the second-order rate constants of inactivation were 8.3 M(-1) min(-1) for holoprotein and 18.0 M(-1) min(-1) for apoprotein. The addition of benzoate completely protected against this second phase of inactivation. Efforts to isolate the enzyme modified at a single arginine residue at the end of the fast phase were unsuccessful, but analysis of the enzyme isolated at the end of the slow phase identified an arginine residue, protected by benzoate, that is highly conserved in all D-amino-acid oxidases and corresponds to Arg(283) in the pig kidney enzyme. Modification of this residue is directly involved in the inactivation process during the slow phase. This arginine may represent the basic residue ion pairing with the carboxylate group of the substrate or the residue interacting with the flavin N-1-C-2 = O locus.	UNIV MILAN,DEPT GEN PHYSIOL & BIOCHEM,I-20133 MILAN,ITALY; UNIV MILAN,INST VET PHYSIOL & BIOCHEM,I-20133 MILAN,ITALY; UNIV MILAN,CTR INTERUNIV STUDIO MACROMOLEC INFORMAZ,I-20133 MILAN,ITALY	University of Milan; University of Milan; University of Milan			Gadda, Giovanni/M-2354-2016; Negri, Armando/H-7914-2017	Gadda, Giovanni/0000-0002-7508-4195; Negri, Armando/0000-0002-8401-7437				BORDERS CL, 1975, BIOCHEMISTRY-US, V14, P4699, DOI 10.1021/bi00692a021; CASALIN P, 1991, EUR J BIOCHEM, V197, P513, DOI 10.1111/j.1432-1033.1991.tb15939.x; Curti B., 1991, CHEM BIOCH FLAVOENZY, V3, P69; FAOTTO L, 1994, IN PRESS FLAVINS FLA; FERTI C, 1981, EUR J BIOCHEM, V199, P553; FITZPATRICK PF, 1983, J BIOL CHEM, V258, P9700; Ghisla S., 1991, CHEM BIOCH FLAVOENZY, P243; GHRIR R, 1984, BIOCHEMISTRY-US, V23, P5202, DOI 10.1021/bi00317a018; HECHT HJ, 1993, J MOL BIOL, V229, P153, DOI 10.1006/jmbi.1993.1015; ISOGAI T, 1990, J BIOCHEM-TOKYO, V108, P1063, DOI 10.1093/oxfordjournals.jbchem.a123306; KOHLBRENNER WE, 1978, J BIOL CHEM, V253, P7609; KOMATSU K, 1988, CHEM ABSTR 49619S, V108; LEVY HM, 1963, J BIOL CHEM, V238, P3654; LIM LW, 1986, J BIOL CHEM, V261, P5140; LINDQVIST Y, 1989, J BIOL CHEM, V264, P3624; MASSEY V, 1965, BIOCHEMISTRY-US, V4, P1161, DOI 10.1021/bi00882a027; MASSEY V, 1979, J BIOL CHEM, V254, P9640; MEDINA M, 1992, ARCH BIOCHEM BIOPHYS, V299, P281, DOI 10.1016/0003-9861(92)90276-3; MIYAKE Y, 1991, FLAVINS AND FLAVOPROTEINS 1990, P135; MOMOI K, 1988, FEBS LETT, V238, P180, DOI 10.1016/0014-5793(88)80252-7; MUKHERJEE JJ, 1992, ARCH BIOCHEM BIOPHYS, V299, P147, DOI 10.1016/0003-9861(92)90256-V; NEGRI A, 1992, J BIOL CHEM, V267, P11865; NISHINO T, 1980, J BIOL CHEM, V255, P3610; PETERS RG, 1981, BIOCHEMISTRY-US, V20, P2564, DOI 10.1021/bi00512a031; PILONE MS, 1992, BIOTECHNOL APPL BIOC, V16, P252; POLLEGIONI L, 1992, BIOCHEM J, V286, P389, DOI 10.1042/bj2860389; POLLEGIONI L, 1993, J BIOL CHEM, V268, P13850; POLLEGIONI L, 1992, PROTEIN EXPRES PURIF, V3, P165, DOI 10.1016/S1046-5928(05)80034-8; QUAY S, 1977, BIOCHEMISTRY-US, V16, P3348, DOI 10.1021/bi00634a010; RAMAKRISHNA S, 1981, BIOCHEM J, V195, P735, DOI 10.1042/bj1950735; RONCHI S, 1982, J BIOL CHEM, V257, P8824; SIMONETTA MP, 1987, BIOCHIM BIOPHYS ACTA, V914, P136, DOI 10.1016/0167-4838(87)90056-2; SIMONETTA MP, 1989, EUR J BIOCHEM, V180, P199; TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171; TEDESCHI G, 1992, EUR J BIOCHEM, V205, P127, DOI 10.1111/j.1432-1033.1992.tb16759.x; VANBERKEL WJH, 1984, EUR J BIOCHEM, V145, P245; VANDENBERGHESNOREK S, 1985, J BIOL CHEM, V260, P3373; VANONI MA, 1987, EUR J BIOCHEM, V167, P261, DOI 10.1111/j.1432-1033.1987.tb13332.x; XIA ZX, 1990, J MOL BIOL, V212, P837, DOI 10.1016/0022-2836(90)90240-M	39	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17809	17814						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	7913089				2022-12-25	WOS:A1994NV42200011
J	LOOK, DC; PELLETIER, MR; HOLTZMAN, MJ				LOOK, DC; PELLETIER, MR; HOLTZMAN, MJ			SELECTIVE INTERACTION OF A SUBSET OF INTERFERON-GAMMA RESPONSE ELEMENT-BINDING PROTEINS WITH THE INTERCELLULAR-ADHESION MOLECULE-1 (ICAM-1) GENE PROMOTER CONTROLS THE PATTERN OF EXPRESSION ON EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; TRANSCRIPTIONAL INDUCTION; DEVELOPMENTAL REGULATION; ENHANCER ELEMENT; SYNTHETASE GENE; NUCLEAR FACTORS; REGION; IDENTIFICATION; RECEPTOR; MEDIATE	Intercellular adhesion molecule-1 (ICAM-1) modulates epithelial and endothelial leukocyte adherence, but epithelial cell ICAM-1 levels (unlike endothelial cell levels) are selectively sensitive to interferon-gamma (IFN-gamma). Nuclear run off assays indicated that IFN gamma regulation of epithelial ICAM-1 levels occurs at a transcriptional level, so the basis for selective cytokine control of ICAM-1 expression was investigated using the ICAM-1 gene promoter region. A plasmid construct containing 5.0 kilobases of ICAM-1 gene 5'-flanking region fused to a reporter gene was selectively responsive to IFN-gamma in (human tracheal) epithelial cells but not in (human umbilical vein) endothelial cells, indicating that this region is sufficient to mediate proper cell specific expression. An IFN-gamma response element (IRE) was localized to a DNA segment (nucleotides -130 to -94) in the ICAM-1 gene by comparisons of nested 5'-deletional constructs and by demonstrating that this segment confers IFN-gamma responsiveness on heterologous promoters. This same IRE formed a single major binding complex (IRE-BC) in gel retardation assays with nuclear proteins from IFN-gamma-stimulated but not unstimulated epithelial cells, and mutation of the IRE consensus motif (TTTCCGGGAAA at -116 to -106) resulted in loss of IRE-protein binding and abolished IFN-gamma responsiveness, indicating that this sequence is required for ICAM-1 IRE function. Comparison of the ICAM-1 IRE to DNA elements that confer IFN responsiveness in other human genes indicated similarity only to response regions in the Fc gamma RI and IRF-1 genes. The findings provide evidence for a distinct IRE subset that combines a DNA element common to all IFN-responsive genes (GAAA) with a distinct flanking sequence (the inverted repeat GAAA) in order to fine-tune IFN responses and activate a subset of immune response genes (ICAM-1, Fc gamma RI, and IRF-1).	WASHINGTON UNIV, SCH MED, DEPT INTERNAL MED, ST LOUIS, MO 63110 USA	Washington University (WUSTL)					NHLBI NIH HHS [HL-02920, HL-07317, HL-40078] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007317, R01HL040078, K08HL002920] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALLANTYNE CM, 1992, GENOMICS, V14, P1076, DOI 10.1016/S0888-7543(05)80132-6; BARR CL, 1991, J BIOL CHEM, V266, P3475; BOWLUS CL, 1991, J BIOL CHEM, V266, P1122; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN B, 1988, EMBO J, V7, P1411, DOI 10.1002/j.1460-2075.1988.tb02958.x; DAI W, 1990, J BIOL CHEM, V265, P19871; DEGITZ K, 1991, J BIOL CHEM, V266, P14024; DESAINTES C, 1992, J VIROL, V66, P325, DOI 10.1128/JVI.66.1.325-333.1992; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUSTIN ML, 1988, J EXP MED, V167, P1323, DOI 10.1084/jem.167.4.1323; DUSTIN ML, 1986, J IMMUNOL, V137, P245; GOODBOURN S, 1985, CELL, V41, P509, DOI 10.1016/S0092-8674(85)80024-6; HAKEM R, 1991, INT J CANCER, P2; HANSON RD, 1990, J BIOL CHEM, V265, P1524; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; HOLTZMAN MJ, 1992, J BIOL CHEM, V267, P21438; IADEMARCO MF, 1993, P NATL ACAD SCI USA, V90, P3943, DOI 10.1073/pnas.90.9.3943; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KHAN KD, 1990, MOL CELL BIOL, V10, P5150, DOI 10.1128/MCB.10.10.5150; LEITMAN DC, 1991, J BIOL CHEM, V266, P9343; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; LOOK DC, 1992, AM J PHYSIOL, V263, pL79, DOI 10.1152/ajplung.1992.263.1.L79; LUSTER AD, 1987, MOL CELL BIOL, V7, P3723, DOI 10.1128/MCB.7.10.3723; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; NAKAJIMA S, 1993, J CELL BIOCHEM, P351; PEARSE RN, 1991, P NATL ACAD SCI USA, V88, P11305, DOI 10.1073/pnas.88.24.11305; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; ROSENSTEIN Y, 1991, NATURE, V354, P233, DOI 10.1038/354233a0; ROTHLEIN R, 1988, J IMMUNOL, V141, P1665; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; RYALS J, 1985, CELL, V41, P497, DOI 10.1016/S0092-8674(85)80023-4; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHORNICK LP, 1993, J BIOL CHEM, V268, P371; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STADE BG, 1990, IMMUNOBIOLOGY, V182, P79, DOI 10.1016/S0171-2985(11)80585-1; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STREHLOW I, 1993, J BIOL CHEM, V268, P16590; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WAWRYK SO, 1991, INT IMMUNOL, V3, P83, DOI 10.1093/intimm/3.1.83; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WEINTRAUB SJ, 1992, MOL CELL BIOL, V12, P512, DOI 10.1128/MCB.12.2.512; WERTHEIMER SJ, 1992, J BIOL CHEM, V267, P12030; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964; ZINN K, 1986, CELL, V45, P611, DOI 10.1016/0092-8674(86)90293-X	57	124	125	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8952	8958						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7907595				2022-12-25	WOS:A1994NB41100051
J	REZAIE, AR; MATHER, T; SUSSMAN, F; ESMON, CT				REZAIE, AR; MATHER, T; SUSSMAN, F; ESMON, CT			MUTATION OF GLU-80 -] LYS RESULTS IN A PROTEIN-C MUTANT THAT NO LONGER REQUIRES CA2+ FOR RAPID ACTIVATION BY THE THROMBIN-THROMBOMODULIN COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GAMMA-CARBOXYGLUTAMIC ACID; CALCIUM-BINDING SITE; CRYSTAL-STRUCTURE; FACTOR-X; DOMAIN; COAGULATION; RESOLUTION; CHAIN	Binding Ca2+ to a high affinity site in protein C and Gla-domainless protein C (protein C lacking residues 1-44) results in a conformational change that is required for activation by the thrombin-thrombomodulin complex, the natural activator of protein C. Protein C modeling studies suggested the single high affinity Ca2+ binding-site might be present in a loop in the protease domain and involve Glu-70 and -80 (chymotrypsin numbering system). This loop, which is a known Ca2+-binding site in trypsin, is also conserved in other coagulation proteases, including factors VII, IX and X. In thrombin, which does not bind Ca2+, Glu-70 is replaced by Lys, creating an internal salt bridge with Glu-80. We constructed and expressed a Gla-domainless protein C mutant in which Glu-80 is replaced with Lys. The activation of the resultant mutant is accelerated by thrombomodulin in a Ca2+-independent fashion. Unlike wild type Gla-domainless protein C, Ca2+ no longer inhibits activation of the mutant by free thrombin, and Ca2+ stimulation of chromogenic activity is also absent. The characteristic Ca2+-dependent quenching of Gla-domainless protein C intrinsic fluorescence is also absent in the mutant. We conclude that the high affinity Ca2+-binding site in protein C critical for zymogen activation involves Glu-80. The Glu-80 to Lys mutation probably results in a salt bridge with Glu-70 that stabilizes protein C zymogen in a conformation similar, if not identical, to the Ca2+-stabilized conformation favorable for rapid activation by the thrombin-thrombomodulin complex.	OKLAHOMA MED RES FDN,HOWARD HUGHES MED INST,825 NE 13,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT CHEM & BIOCHEM,OKLAHOMA CITY,OK 73190; UNIV OKLAHOMA,HLTH SCI CTR,DEPT PATHOL,OKLAHOMA CITY,OK 73190; UNIV OKLAHOMA,HLTH SCI CTR,DEPT RES & EDUC COMP,OKLAHOMA CITY,OK 73190; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73190	Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center				Sussman, Fredy/0000-0003-0189-6307				BADMANABHAN K, 1993, J MOL BIOL, V232, P947; BAJAJ SP, 1992, P NATL ACAD SCI USA, V89, P152, DOI 10.1073/pnas.89.1.152; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; CHASE T, 1970, METHOD ENZYMOL, V19, P20; DITTMAN WA, 1990, BLOOD, V75, P329; ESMON NL, 1982, J BIOL CHEM, V257, P859; ESMON NL, 1983, J BIOL CHEM, V258, P5548; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GALVIN JB, 1987, J BIOL CHEM, V262, P2199; GREER J, 1990, PROTEIN-STRUCT FUNCT, V7, P312; GRINNELL BW, 1991, PROTEIN C RELATED AN, V11, P29; JOHNSON AE, 1983, J BIOL CHEM, V258, P5554; KIMURA S, 1989, J BIOCHEM-TOKYO, V105, P478, DOI 10.1093/oxfordjournals.jbchem.a122690; MANN KG, 1990, BLOOD, V76, P1; MILETICH JP, 1990, J BIOL CHEM, V265, P11397; MOMANY FA, 1992, J COMPUT CHEM, V13, P888, DOI 10.1002/jcc.540130714; MORITA T, 1985, BIOCHEM BIOPH RES CO, V130, P841, DOI 10.1016/0006-291X(85)90493-0; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; OWEN WG, 1974, J BIOL CHEM, V249, P594; PERSSON E, 1991, J BIOL CHEM, V266, P2444; REZAIE AR, 1992, J BIOL CHEM, V267, P11701; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; SUGO T, 1985, J BIOL CHEM, V130, P841; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; WILDGOOSE P, 1993, BIOCHEMISTRY-US, V32, P114, DOI 10.1021/bi00052a016	28	68	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3151	3154						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7906267				2022-12-25	WOS:A1994MV63100008
J	MERY, PF; PAVOINE, C; BELHASSEN, L; PECKER, F; FISCHMEISTER, R				MERY, PF; PAVOINE, C; BELHASSEN, L; PECKER, F; FISCHMEISTER, R			NITRIC-OXIDE REGULATES CARDIAC CA2+ CURRENT - INVOLVEMENT OF CGMP-INHIBITED AND CGMP-STIMULATED PHOSPHODIESTERASES THROUGH GUANYLYL CYCLASE ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; PIG VENTRICULAR MYOCYTES; DEPENDENT PROTEIN-KINASE; SMOOTH-MUSCLE CELLS; CALCIUM CURRENT; AMP PHOSPHODIESTERASES; SELECTIVE INHIBITORS; FROG VENTRICLE; CA-2+ CURRENT; SINGLE CELLS	The effects of the nitric oxide (NO) donor 3-morpholino-sydnonimine (SIN-1) on the L-type Ca2+ current (I(Ca)) were examined in frog ventricular myocytes under basal and phosphorylated conditions. SIN-1 was found to exert insignificant effects on basal I(Ca) but to induce a biphasic action on stimulated I(Ca). Indeed, in the nanomolar range of concentrations (0.1-10 nM), SIN-1 induced a pronounced (almost-equal-to 40%) stimulation of I(Ca) elevated by a non-maximal concentration of forskolin (0.3 muM). However, the stimulatory effects of SIN-1 on I(Ca) were not additive with those of maximal concentrations (10 muM) of forskolin or intracellular cAMP. In contrast, at higher concentrations (100 nM to 1 mM), SIN-1 strongly reduced I(Ca) (by up to 85%) which had been previously stimulated by cAMP, forskolin, or isoprenaline. All the effects of SIN-1 appeared to be mediated by the liberation of NO since they were suppressed by methylene blue and LY83583 and were not mimicked by SIN-1C, a metabolite of SIN-1. The stimulatory or inhibitory effects of SIN-1 were absent, respectively, in the presence of milrinone (10 muM) or when the hydrolysis-resistant cAMP analog 8-bromo-cAMP was used instead of cAMP to stimulate I(Ca). In addition to its effects on I(Ca), SIN-1 induced a dose-dependent stimulation of guanylyl cyclase activity in the cytosolic and membrane fractions of frog ventricle. The membrane form of guanylyl cyclase displayed a higher sensitivity to SIN-1 than the cytosolic form, which correlated with SIN-1 sensitivity of I(Ca). Our data suggest that the activatory and inhibitory effects of NO donors on I(Ca). result from an inhibition of the cGMP-inhibited cAMP-phosphodiesterase and an activation of the cGMP-stimulated cAMP-phosphodiesterase, respectively, both linked to the activation of guanylyl cyclase, possibly a membrane form of the enzyme.	UNIV PARIS SUD, FAC PHARM,INSERM,CARDIOL CELLULAIRE & MOLEC LAB, CJF 92-11, F-92296 CHATENAY MALABRY, FRANCE; HOP HENRI MONDOR, INSERM, F-94010 CRETEIL, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)			Pavoine, Catherine/N-4405-2018; Fischmeister, Rodolphe/L-6061-2018; MERY, Pierre-François/C-5903-2019	Pavoine, Catherine/0000-0002-0598-5545; Fischmeister, Rodolphe/0000-0003-2086-9865; Mery, Pierre-Francois/0000-0001-6214-5422				ALLOATTI G, 1991, J MOL CELL CARDIOL, V23, P851, DOI 10.1016/0022-2828(91)90218-B; ARGIBAY JA, 1988, J PHYSIOL-LONDON, V401, P201, DOI 10.1113/jphysiol.1988.sp017158; BALLIGAND JL, 1993, J CLIN INVEST, V91, P2314, DOI 10.1172/JCI116461; BALLIGAND JL, 1993, P NATL ACAD SCI USA, V90, P347, DOI 10.1073/pnas.90.1.347; BARBIER AJM, 1992, EUR J PHARMACOL, V219, P331, DOI 10.1016/0014-2999(92)90315-U; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BRECHLER V, 1992, J BIOL CHEM, V267, P15496; BRUNE B, 1989, J BIOL CHEM, V264, P8455; BRUTSAERT DL, 1993, NEWS PHYSIOL SCI, V8, P82; BUXTON ILO, 1993, CIRC RES, V72, P387, DOI 10.1161/01.RES.72.2.387; DEBELDER AJ, 1993, LANCET, V341, P84, DOI 10.1016/0140-6736(93)92559-C; FACH WA, 1984, Z KARDIOL, V73, P613; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; FISCHMEISTER R, 1987, J PHYSIOL-LONDON, V387, P453, DOI 10.1113/jphysiol.1987.sp016584; FISCHMEISTER R, 1991, LIFE SCI, V48, P2365, DOI 10.1016/0024-3205(91)90369-M; FISCHMEISTER R, 1990, MOL PHARMACOL, V38, P426; FISCHMEISTER R, 1986, J PHYSIOL-LONDON, V376, P183, DOI 10.1113/jphysiol.1986.sp016148; GARBERS DL, 1992, CELL, V71, P1; GARCIA JL, 1992, BRIT J PHARMACOL, V106, P563, DOI 10.1111/j.1476-5381.1992.tb14375.x; GISBERT MP, 1988, CIRC RES, V62, P660, DOI 10.1161/01.RES.62.4.660; Goldberg N D, 1975, Adv Cyclic Nucleotide Res, V5, P307; HARTZELL HC, 1992, TRENDS PHARMACOL SCI, V13, P380, DOI 10.1016/0165-6147(92)90117-O; HARTZELL HC, 1986, NATURE, V323, P273, DOI 10.1038/323273a0; HARTZELL HC, 1988, PROG BIOPHYS MOL BIO, V52, P165, DOI 10.1016/0079-6107(88)90014-4; HARTZELL HC, 1987, MOL PHARMACOL, V32, P639; HONGO K, 1993, J PHYSIOL-LONDON, V461, P185, DOI 10.1113/jphysiol.1993.sp019508; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; KIM KC, 1990, BIOCHEMISTRY-US, V29, P9281, DOI 10.1021/bi00491a025; KLABUNDE RE, 1992, EUR J PHARMACOL, V223, P1, DOI 10.1016/0014-2999(92)90810-Q; KLIMASCHEWSKI L, 1992, CIRC RES, V71, P1533, DOI 10.1161/01.RES.71.6.1533; KONTOS HA, 1993, STROKE, V24, P427, DOI 10.1161/01.STR.24.3.427; LACOMBE ML, 1983, BIOCHEM BIOPH RES CO, V116, P47, DOI 10.1016/0006-291X(83)90378-9; LAMONTAGNE D, 1991, J CARDIOVASC PHARM, V17, pS89, DOI 10.1097/00005344-199117003-00016; LEGRAND B, 1992, PFLUG ARCH EUR J PHY, V421, P486, DOI 10.1007/BF00370260; LEVI RC, 1989, PFLUG ARCH EUR J PHY, V413, P685, DOI 10.1007/BF00581823; LEVI RC, 1988, J PHARMACOL EXP THER, V246, P377; LINCOLN TM, 1981, BIOCHIM BIOPHYS ACTA, V676, P230, DOI 10.1016/0304-4165(81)90192-6; LINDEMANN JP, 1989, PHYSL PATHOPHYSIOLOG, P423; LOHMANN SM, 1991, BASIC RES CARDIOL, V86, P503, DOI 10.1007/BF02190700; MANZONI O, 1992, NEURON, V8, P653, DOI 10.1016/0896-6273(92)90087-T; MARCZIN N, 1992, J PHARMACOL EXP THER, V263, P170; MCCALL D, 1990, J MOL CELL CARDIOL, V22, P201, DOI 10.1016/0022-2828(90)91116-O; MERY PF, 1991, P NATL ACAD SCI USA, V88, P1197, DOI 10.1073/pnas.88.4.1197; MERY PF, 1990, NATURE, V345, P158, DOI 10.1038/345158a0; MERY PF, 1993, J PHYSIOL-LONDON, V459, pP420; NICHOLSON CD, 1991, TRENDS PHARMACOL SCI, V12, P19, DOI 10.1016/0165-6147(91)90484-A; ONO K, 1991, J PHYSIOL-LONDON, V443, P387, DOI 10.1113/jphysiol.1991.sp018839; OUADID H, 1992, MOL PHARMACOL, V41, P346; PAVEPREUX M, 1988, J BIOL CHEM, V263, P17459; PELZER D, 1990, REV PHYSIOL BIOCH P, V114, P107; RAMACIOTTI C, 1992, P NATL ACAD SCI USA, V89, P4033, DOI 10.1073/pnas.89.9.4033; REDEN J, 1990, BLOOD VESSELS, V27, P282; RUGG EL, 1989, BIOCHEM BIOPH RES CO, V162, P1339, DOI 10.1016/0006-291X(89)90820-6; SALTER M, 1991, FEBS LETT, V291, P145, DOI 10.1016/0014-5793(91)81123-P; SCHMIDT HHHW, 1992, J HISTOCHEM CYTOCHEM, V40, P1439, DOI 10.1177/40.10.1382087; SCHULZ R, 1991, BRIT J PHARMACOL, V104, P21, DOI 10.1111/j.1476-5381.1991.tb12378.x; SCHULZ R, 1992, BRIT J PHARMACOL, V105, P575, DOI 10.1111/j.1476-5381.1992.tb09021.x; SIMMONS MA, 1988, MOL PHARMACOL, V33, P664; SMITH JA, 1992, TRENDS PHARMACOL SCI, V13, P113, DOI 10.1016/0165-6147(92)90040-D; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; SORBERA LA, 1990, SCIENCE, V247, P969, DOI 10.1126/science.2154853; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; THELEN KI, 1992, N-S ARCH PHARMACOL, V345, P93; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; WANG R, 1991, FEBS LETT, V282, P331, DOI 10.1016/0014-5793(91)80507-Y; WEBER KT, 1992, HEART CARDIOVASCULAR, P1465; WHITE DG, 1993, BRIT J PHARMACOL, V108, P763, DOI 10.1111/j.1476-5381.1993.tb12875.x; YAMAZAKI J, 1991, J PHARMACOL EXP THER, V259, P52	69	422	429	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26286	26295						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	7902837				2022-12-25	WOS:A1993MK42500044
J	IWASAKI, S; HOMMA, T; MATSUDA, Y; KON, V				IWASAKI, S; HOMMA, T; MATSUDA, Y; KON, V			ENDOTHELIN RECEPTOR SUBTYPE-B MEDIATES AUTOINDUCTION OF ENDOTHELIN-1 IN RAT MESANGIAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; TRANSFORMING GROWTH FACTOR-BETA-1; MESSENGER-RNA EXPRESSION; GENE-EXPRESSION; NITRIC-OXIDE; PREPROENDOTHELIN-1 GENE; SECRETION; CLONING; SEQUENCE; KIDNEY	Autoinduction of endothelin-1 (ET-1) has been suggested to be involved in the profound and long-lasting effects of ET-1. We examined mechanisms that underlie autoinduction of ET-1 in cultured rat glomerular mesangial cells. Incubation of mesangial cells with ET-1 resulted in an immediate and dose-dependent stimulation of preproET-1 mRNA expression as assessed by polymerase chain reaction coupled with reverse transcription. Within 1 h of exposure to ET-1 (10(-7) M), preproET-1 mRNA expression was increased to a maximal level of 465 +/- 43% of the control value (p < 0.01), which was accompanied by significant stimulation of production of the immunoreactive ET-1 peptide. Nuclear run-off analysis revealed increases in the transcriptional rate of preproET-1 mRNA to 239 and 175% above the control values at 1 and 3 h of ET-1 stimulation, respectively. ET-1 also increased the stability of preproET-1 mRNA, resulting in an mRNA half-life of 60 min from 20 min seen in non-stimulated cells. Addition of an ET(B)-specific antagonist, RES701-1, at > 10(-9) M abolished ET-1 stimulation of preproET-1 mRNA (p < 0.001), whereas an ET(A)-specific antagonist, BQ123, was without effects (up to 10(-5) M). The ET(B) agonist, sarafotoxin S6c (10(-7) M), significantly stimulated preproET-1 mRNA expression to 201 +/- 14% above controls (p < 0.01), an effect that was lessened significantly by RES701-1 (p < 0.05). RES701-1 abolished the ET-1-induced production of the ET-1 peptide (p < 0.001). Taken together, we demonstrates that in mesangial cells, autoinduction of ET-1 occurs through the ET(B) receptor subtype via increases in both preproET-1 transcription and mRNA stability.	VANDERBILT UNIV,MED CTR N C4204,SCH MED,DEPT PEDIAT,DIV PEDIAT NEPHROL,NASHVILLE,TN 37232; KYOWA HAKKO KOGYO CO LTD,TOKYO 194,JAPAN	Vanderbilt University; Kyowa Kirin Ltd					NIDDK NIH HHS [DK42159, DK44757] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK044757, R01DK042159] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTS GF, 1994, J BIOL CHEM, V269, P10112; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARAMORI I, 1992, J BIOL CHEM, V267, P12468; AWAZU M, 1991, J AM SOC NEPHROL, V1, P1253; BASCOM CC, 1989, MOL CELL BIOL, V9, P5508, DOI 10.1128/MCB.9.12.5508; BATTISTINI B, 1993, PEPTIDES, V14, P385, DOI 10.1016/0196-9781(93)90057-N; BOULANGER C, 1990, J CLIN INVEST, V85, P587, DOI 10.1172/JCI114477; BUNCHMAN TE, 1991, J CLIN INVEST, V88, P310, DOI 10.1172/JCI115293; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; FIRTH JD, 1992, J CLIN INVEST, V90, P1023, DOI 10.1172/JCI115915; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GOLIGORSKY MS, 1994, J CELL PHYSIOL, V158, P485, DOI 10.1002/jcp.1041580313; GOTO K, 1989, P NATL ACAD SCI USA, V86, P3915, DOI 10.1073/pnas.86.10.3915; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAHN AWA, 1990, CELL REGUL, V1, P649, DOI 10.1091/mbc.1.9.649; HEXUM TD, 1990, BIOCHEM BIOPH RES CO, V167, P294, DOI 10.1016/0006-291X(90)91764-J; HIRATA Y, 1993, J CLIN INVEST, V91, P1367, DOI 10.1172/JCI116338; HORIE M, 1991, J CARDIOVASC PHARM, V17, pS222, DOI 10.1097/00005344-199100177-00064; HU RM, 1992, J BIOL CHEM, V267, P17384; HUGGINS JP, 1993, PHARMACOL THERAPEUT, V59, P55, DOI 10.1016/0163-7258(93)90041-B; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; IMAI T, 1992, HYPERTENSION, V19, P753, DOI 10.1161/01.HYP.19.6.753; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; INOUE A, 1989, J BIOL CHEM, V264, P14954; ISHIMURA E, 1991, Journal of the American Society of Nephrology, V2, P546; ITO H, 1993, J CLIN INVEST, V92, P398, DOI 10.1172/JCI116579; ITO H, 1991, CIRC RES, V69, P209, DOI 10.1161/01.RES.69.1.209; IWASAKI S, 1994, KIDNEY INT, V45, P592, DOI 10.1038/ki.1994.77; Iwasaki Shigeki, 1992, Journal of the American Society of Nephrology, V3, P760; KARNE S, 1993, J BIOL CHEM, V268, P19126; KOHAN DE, 1993, AM J KIDNEY DIS, V22, P493, DOI 10.1016/S0272-6386(12)80920-6; KOHNO M, 1994, AM J PHYSIOL, V266, pF894, DOI 10.1152/ajprenal.1994.266.6.F894; KON V, 1991, KIDNEY INT, V40, P1, DOI 10.1038/ki.1991.172; KOUREMBANAS S, 1991, J CLIN INVEST, V88, P1054, DOI 10.1172/JCI115367; KRAPF R, 1991, J CLIN INVEST, V88, P783, DOI 10.1172/JCI115377; LEE ME, 1990, J BIOL CHEM, V265, P10446; LEE ME, 1991, J BIOL CHEM, V266, P19034; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; MALEK AM, 1993, P NATL ACAD SCI USA, V90, P5999, DOI 10.1073/pnas.90.13.5999; MARSDEN PA, 1992, AM J PHYSIOL, V262, pC854, DOI 10.1152/ajpcell.1992.262.4.C854; MARTIN ER, 1990, J BIOL CHEM, V4265, P14044; MORISHITA Y, 1994, J ANTIBIOT, V47, P269, DOI 10.7164/antibiotics.47.269; OWADA A, 1994, J CLIN INVEST, V93, P556, DOI 10.1172/JCI117007; PAULSSON Y, 1987, NATURE, V328, P715, DOI 10.1038/328715a0; SAIJONMAA O, 1992, BIOCHEM BIOPH RES CO, V188, P286, DOI 10.1016/0006-291X(92)92382-8; SAKAMOTO H, 1992, KIDNEY INT, V41, P350, DOI 10.1038/ki.1992.48; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SAKURAI T, 1991, BIOCHEM BIOPH RES CO, V175, P44, DOI 10.1016/S0006-291X(05)81197-0; SHICHIRI M, 1991, J CLIN INVEST, V87, P1867, DOI 10.1172/JCI115210; SIMONSON MS, 1989, J CLIN INVEST, V83, P708, DOI 10.1172/JCI113935; SOKOLOVSKY M, 1992, J BIOL CHEM, V267, P20551; TAKEDA M, 1994, AM J PATHOL, V144, P473; TAKEDA M, 1992, KIDNEY INT, V42, P1713; TANAKA T, 1994, MOL PHARMACOL, V45, P724; VANOBBERGHENSCH.E, 1988, J BIOL CHEM, V263, P7741; WAGNER OF, 1992, J BIOL CHEM, V267, P16066; WARMER S, 1987, J EXP MED, V165, P1316; WILLIAMS DL, 1991, BIOCHEM BIOPH RES CO, V175, P556, DOI 10.1016/0006-291X(91)91601-8; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOKOKAWA K, 1991, HYPERTENSION, V18, P304, DOI 10.1161/01.HYP.18.3.304; Yoshimura Ashio, 1992, Journal of the American Society of Nephrology, V3, P624; ZOJA C, 1991, LAB INVEST, V64, P16	64	80	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6997	7003		10.1074/jbc.270.12.6997	http://dx.doi.org/10.1074/jbc.270.12.6997			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896851	hybrid			2022-12-25	WOS:A1995QQ85500082
J	NAO, SQ; HINCAPIE, M; MCCUSKER, JH; HABER, JE				NAO, SQ; HINCAPIE, M; MCCUSKER, JH; HABER, JE			MOP2 (SLA2) AFFECTS THE ABUNDANCE OF THE PLASMA-MEMBRANE H+-ATPASE OF SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; (NA+ + K+)ATPASE; INTRACELLULAR-TRANSPORT; YEAST-CELLS; FUNCTIONAL EXPRESSION; SECRETORY VESICLES; ALPHA-SUBUNIT; GENE; NA,K-ATPASE; IDENTIFICATION	The abundance of yeast plasma membrane H+-ATPase on the cell surface is tightly regulated. Modifier of pma1 (mop) mutants were isolated as enhancers of the mutant phenotypes of pma1 mutants, mop2 mutations reduce the abundance and activity of Pma1 protein on the plasma membrane without affecting the abundance of other prominent plasma membrane proteins. The MOP2 gene encodes a 108-kDa protein that has previously been identified both as a gene affecting the yeast cytoskeleton (SLA2) (Holtzman, D.A., Yang, S., and Drubin, D. G. (1993) J. Cell Biol. 122, 635-644) and as a gene affecting endocytosis (END4) (Raths, S., Roher, J., Crausaz, F., and Riezman, H. (1993) J. Cell Biol. 120, 55-65). In some strains, MOP2 (SLA2) is essential for cell viability; in others, a deletion mutant is temperature sensitive for growth. mop2 mutations do not reduce the transcription of PMA1 nor do they lead to the accumulation of Pma1 protein in any intracellular compartment. An epitope-tagged MOP2 protein behaves as a plasma membrane-associated protein whose abundance is proportional to its level of gene expression. Over-expression of MOP2 relieved the toxicity caused by the over-expression of PMA1 from a high copy plasmid; conversely, the growth of mop2 strains was inhibited by the presence of a single extra copy of PMA1. We conclude that MOP2 (SLA2) encodes a plasma membrane-associated protein that is required for the accumulation and/or maintenance of plasma membrane H+-ATPase on the cell surface.	BRANDEIS UNIV, ROSENSTIEL BASIC MED SCI RES CTR, WALTHAM, MA 02254 USA; BRANDEIS UNIV, DEPT BIOL, WALTHAM, MA 02254 USA	Brandeis University; Brandeis University				Haber, James/0000-0002-1878-0610; McCusker, John/0000-0002-8803-9131	NIGMS NIH HHS [GM39739, GM07596] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039739] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN SH, 1992, J BIOL CHEM, V267, P7386; ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; ACKERMAN SH, 1990, J BIOL CHEM, V265, P9952; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI DOI 10.1016/S0022-2836(05)80360-2; BENITO B, 1991, BIOCHIM BIOPHYS ACTA, V1063, P265, DOI 10.1016/0005-2736(91)90381-H; BOWMAN BJ, 1981, J BIOL CHEM, V256, P2343; BOWMAN BJ, 1986, J MEMBRANE BIOL, V94, P83, DOI 10.1007/BF01871190; BOWMAN S, 1991, J BIOL CHEM, V266, P7517; BRADA D, 1988, J BACTERIOL, V170, P2775, DOI 10.1128/jb.170.6.2775-2783.1988; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CARONI P, 1981, J BIOL CHEM, V256, P9371; CHANG A, 1991, J CELL BIOL, V115, P289, DOI 10.1083/jcb.115.2.289; CHANG A, 1993, P NATL ACAD SCI USA, V90, P5808, DOI 10.1073/pnas.90.12.5808; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; ERASO P, 1987, FEBS LETT, V224, P193, DOI 10.1016/0014-5793(87)80446-5; GEERING K, 1990, J MEMBRANE BIOL, V115, P109, DOI 10.1007/BF01869450; GEERING K, 1987, J CELL BIOL, V105, P2613, DOI 10.1083/jcb.105.6.2613; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; GOFFEAU A, 1988, METHOD ENZYMOL, V157, P528; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; HARRIS LS, 1994, P NATL ACAD SCI USA, V91, P10531; HIRATA R, 1993, J BIOL CHEM, V268, P961; HOLCOMB CL, 1988, J CELL BIOL, V106, P641, DOI 10.1083/jcb.106.3.641; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAUNIN P, 1992, J BIOL CHEM, V267, P577; KUCHLER K, 1993, J CELL BIOL, V120, P1203, DOI 10.1083/jcb.120.5.1203; LEMAS MV, 1992, J BIOL CHEM, V267, P20987; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LJUNGDAHL PO, 1992, CELL, V71, P463, DOI 10.1016/0092-8674(92)90515-E; MacLennan D H, 1987, Soc Gen Physiol Ser, V41, P287; MARRS JA, 1993, J CELL BIOL, V123, P149, DOI 10.1083/jcb.123.1.149; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; MCCUSKER JH, 1988, GENETICS, V119, P317; MCCUSKER JH, 1986, THESIS BRANDEIS U; MORTIMER RK, 1992, YEAST, V8, P817, DOI 10.1002/yea.320081002; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; PALMGREN MG, 1991, J BIOL CHEM, V266, P20470; PANARETOU B, 1992, EUR J BIOCHEM, V206, P635, DOI 10.1111/j.1432-1033.1992.tb16968.x; PERLIN DS, 1989, J BIOL CHEM, V264, P21857; PORTILLO F, 1989, FEBS LETT, V247, P381, DOI 10.1016/0014-5793(89)81375-4; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; REED DJG, 1990, NATURE, V347, P685; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SERRANO R, 1980, EUR J BIOCHEM, V105, P419, DOI 10.1111/j.1432-1033.1980.tb04516.x; SERRANO R, 1983, FEBS LETT, V156, P11, DOI 10.1016/0014-5793(83)80237-3; SERRANO R, 1991, BIOCHIM BIOPHYS ACTA, V1062, P157, DOI 10.1016/0005-2736(91)90387-N; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; Serrano R, 1991, MOL CELLULAR BIOL YE, P523; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SLAYMAN CL, 1986, J BIOENERG BIOMEMBR, V19, P1; SUPPLY P, 1993, J BIOL CHEM, V268, P19744; TAKEYASU K, 1989, SEIKAGAKU, V61, P394; TAKEYASU K, 1988, J BIOL CHEM, V263, P4347; VAI M, 1986, FEBS LETT, V206, P135, DOI 10.1016/0014-5793(86)81355-2; VILLALBA JM, 1992, J BIOL CHEM, V267, P12341; VOLLAND C, 1994, J BIOL CHEM, V269, P9833; WUYTACK F, 1992, J BIOENERG BIOMEMBR, V24, P285	65	46	47	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6815	6823		10.1074/jbc.270.12.6815	http://dx.doi.org/10.1074/jbc.270.12.6815			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896828	hybrid			2022-12-25	WOS:A1995QQ85500059
J	XIE, T; BELINSKY, M; XU, YH; JAISWAL, AK				XIE, T; BELINSKY, M; XU, YH; JAISWAL, AK			ARE-MEDIATED AND TRE-MEDIATED REGULATION OF GENE-EXPRESSION - RESPONSE TO XENOBIOTICS AND ANTIOXIDANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YA-SUBUNIT GENE; CONTROLLING INDUCIBLE EXPRESSION; NAD(P)H-QUINONE REDUCTASE GENE; GLUTATHIONE S-TRANSFERASES; PLANAR AROMATIC-COMPOUNDS; DNA-PROTEIN INTERACTION; TRANSCRIPTIONAL REGULATION; OXIDATIVE STRESS; PHENOLIC ANTIOXIDANTS; BIOLOGICAL FUNCTION	Antioxidant response elements (AREs) containing 12-O- tetradecanoylphorbol-13-acetate response element (TRE) (perfect AP1) and TRE-like (imperfect AP1) elements mediate high basal transcription of the NAD-(P)H:quinone oxidoreductase(1) (NQO(1)) and glutathione S-transferase Ya genes in tumor cells and its induction in response to xenobiotics and antioxidants. Mutations in the human NQO(1) gene ARE (hARE) revealed the requirement for two TRE or TRE-like elements arranged in inverse orientation at the interval of three base pairs and a GC box for optimal expression and beta-naphthoflavone induction of the NQO(1) gene. A single TRE element from the human collagenase gene failed to respond to beta-naphthoflavone. These results demonstrate that ARE (2 x TRE or TRE-like elements)-containing detoxifying enzyme genes and not genes that contain 1 x TRE are responsive to xenobiotics and antioxidants. Bandshift assays showed shifting of a complex of more or less similar mobility with hARE and TRE that could be competed by each other. Mutations in the 3'-TRE of the NQO(1) gene hARE eliminated binding of nuclear proteins to the hARE and resulted in the loss of basal and induced expression, indicating that 3'-TRE is the most important element within the hARE. 5'-TRE-like element within the NQO(1) gene hARE is required for xenobiotic response but may not bind to the nuclear proteins by itself. The GC box located immmediately following the 3'-TRE is required for optimal expression and induction of the NQO(1) gene. The comparison of AREs from several different genes indicated the requirement for specific arrangement and spacing of two TRE and TRE-like elements within the AREs.	FOX CHASE CANC CTR,DEPT PHARMACOL,PHILADELPHIA,PA 19111	Fox Chase Cancer Center					NCI NIH HHS [CA-09035] Funding Source: Medline; NIGMS NIH HHS [GM 47466] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047466, R29GM047466] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELINSKY M, 1993, CANCER METAST REV, V12, P103, DOI 10.1007/BF00689804; DAVIES LG, 1980, BASIC METHODS MOL BI, P298; DEMPLE B, 1991, ANNU REV GENET, V25, P315, DOI 10.1146/annurev.ge.25.120191.001531; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAVREAU LV, 1993, J BIOL CHEM, V268, P19875; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HARRIS CC, 1991, CANCER RES, V51, P5025; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; LI Y, 1992, J BIOL CHEM, V267, P15097; LI Y, 1993, J BIOL CHEM, V268, P21454; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NGUYEN T, 1992, J BIOL CHEM, V267, P13535; OKUDA A, 1989, J BIOL CHEM, V264, P16919; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; PRESTERA T, 1993, P NATL ACAD SCI USA, V90, P2965, DOI 10.1073/pnas.90.7.2965; RILEY RJ, 1992, BIOCHEM PHARMACOL, V43, P1657, DOI 10.1016/0006-2952(92)90694-E; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; TALALAY P, 1987, CANCER BIOL THERAPEU, P197; TSUCHIDA S, 1992, CRIT REV BIOCHEM MOL, V27, P337, DOI 10.3109/10409239209082566; WATTENBERG LW, 1985, CANCER RES, V45, P1	35	129	137	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6894	6900		10.1074/jbc.270.12.6894	http://dx.doi.org/10.1074/jbc.270.12.6894			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896838	hybrid			2022-12-25	WOS:A1995QQ85500069
J	FOX, GM; HOLST, PL; CHUTE, HT; LINDBERG, RA; JANSSEN, AM; BASU, R; WELCHER, AA				FOX, GM; HOLST, PL; CHUTE, HT; LINDBERG, RA; JANSSEN, AM; BASU, R; WELCHER, AA			CDNA CLONING AND TISSUE DISTRIBUTION OF 5 HUMAN EPH-LIKE RECEPTOR PROTEIN-TYROSINE KINASES	ONCOGENE			English	Article						PROTEIN TYROSINE KINASES	MOLECULAR-CLONING; FAMILY; IDENTIFICATION; GENE; MEMBERS; EMBRYO; EXPRESSION; CHICKEN; BRAIN; HEK	We have isolated cDNA clones from a human fetal brain library that encode five members of the EPH sub-family of receptor protein tyrosine kinases (PTKs), Comparison of the DNA sequences of these receptors to the Genbank database reveals that two of our clones correspond to the previously identified HEK and ERK receptors, two are apparently human homologues of the mouse receptors Sek and Bsk and one is novel, With these additions, the number of known human EPH sub-family members is nine and the total in all vertebrate species is 13 making it the largest known sub-family of PTKs. Analysis of the expression pattern of EPH sub-family mRNAs reveals that some are expressed in a wide variety of adult tissues while others are quite restricted, Consistent with the amplification of these sequences from a fetal brain cDNA library, all five members which we have isolated are expressed in the brain. We have named these receptors HEK4, HEK5, HEK7, HEK8 and HEK11, following the nomenclature of Wicks et al. (1992) and the numbering convention set forth by Sajjadi et al. (1991), Analysis of these new EPH sub-family members will increase our understanding of the biology of this receptor family and their isolation will provide reagents for the identification of ligands for this large family of orphan receptors.			FOX, GM (corresponding author), AMGEN INC, AMGEN CTR, DEPT IMMUNOL, THOUSAND OAKS, CA 91320 USA.							ANDRES AC, 1994, ONCOGENE, V9, P1461; BARBACID M, 1993, ONCOGENE, V8, P2033; BARTLEY M, 1994, NATURE, V368, P558; BENNETT BD, 1994, J BIOL CHEM, V269, P14211; BOHME B, 1993, ONCOGENE, V8, P2857; BOYD AW, 1992, J BIOL CHEM, V267, P3262; CHAN J, 1991, ONCOGENE, V6, P1057; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GANJU P, 1994, ONCOGENE, V9, P1613; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; IWASE T, 1993, BIOCHEM BIOPH RES CO, V194, P698, DOI 10.1006/bbrc.1993.1878; KIYOKAWA E, 1994, CANCER RES, V54, P3645; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LINDBERG RA, 1991, METHOD ENZYMOL, V200, P557; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; Maniatis T., 1982, MOL CLONING LAB MANU; MARCELLE C, 1992, ONCOGENE, V7, P2479; MARU Y, 1990, ONCOGENE RES, V5, P199; NIETO MA, 1992, DEVELOPMENT, V116, P1137; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; RUIZ JC, 1994, MECH DEVELOP, V46, P87; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHOU R, 1994, J NEUROSCI RES, V37, P129, DOI 10.1002/jnr.490370117	34	73	124	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	1995	10	5					897	905						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898931				2022-12-25	WOS:A1995QL03800011
J	DELACADENA, RA; STADNICKI, A; UKNIS, AB; SARTOR, RB; KETTNER, CA; ADAM, A; COLMAN, RW				DELACADENA, RA; STADNICKI, A; UKNIS, AB; SARTOR, RB; KETTNER, CA; ADAM, A; COLMAN, RW			INHIBITION OF PLASMA KALLIKREIN PREVENTS PEPTIDOGLYCAN-INDUCED ARTHRITIS IN THE LEWIS RAT	FASEB JOURNAL			English	Article						KININOGEN; CONTACT SYSTEM; FACTOR XI; PROTEASE INHIBITORS; INFLAMMATORY JOINT DISEASE	STREPTOCOCCAL CELL-WALL; NORMAL-FLORA BACTERIA; HAGEMAN-FACTOR; FACTOR-XII; POLYSACCHARIDE POLYMERS; ARTHROPATHIC PROPERTIES; NEUTROPHIL ELASTASE; CONTACT ACTIVATION; MOLECULAR-WEIGHT; KININ SYSTEM	We investigate whether the previously shown contact system activation plays a pathogenetic role in a rat model of acute inflammation induced by peptido-glycan-polysaccharide (PG-APS) using a new specific plasma kallikrein inhibitor, Bz-Pro-Phe-boroArg-OH (P8720). Group I(control) received neither PG-APS nor inhibitor. Group II (disease-treated) received PG-APS intraperitoneally (IF) and P8720 orally. Group III(disease-untreated) received PG-APS IP. Anemia was evident at 49 h in group III but was not present (P < 0.01) in groups I and II. Spleen weight was significantly decreased in group II compared to group III. Acute arthritis progressively developed in group III from 27 to 49 h, but P8720 decreased the joint swelling in group II by 61% (P < 0.0005). We observed a significant fall in prekallikrein and factor XI (P < 0.01) in groups II and III but not in group I. The decrease in the functional levels of high molecular weight kininogen (P < 0.05) observed in group III were prevented by P8720 in group II. The changes in T-kininogen and alpha(1)-inhibitor 3 acute-phase proteins were partially prevented by P8720. We conclude that the inflammatory reactions leading to arthritis and anemia, as well as the acute-phase reaction, are due in part to contact activation, and that specific kallikrein inhibitors may have therapeutic potential.	TEMPLE UNIV,SCH MED,DEPT LAB MED & PATHOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT PHYSIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT MED,PHILADELPHIA,PA 19140; UNIV N CAROLINA,DEPT DIGEST DIS & NUTR,CHAPEL HILL,NC 27599; DUPONT MERCK PHARMACEUT CO,EXPTL STN,WILMINGTON,DE 19880; UNIV MONTREAL,DEPT PHARM,MONTREAL,PQ H3C 3J7,CANADA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of North Carolina; University of North Carolina Chapel Hill; DuPont; Universite de Montreal	DELACADENA, RA (corresponding author), TEMPLE UNIV,SCH MED,SOL SHERRY THROMBOSIS RES CTR,3400 N BROAD ST,PHILADELPHIA,PA 19140, USA.				NHLBI NIH HHS [HL02681-04] Funding Source: Medline; NIDDK NIH HHS [DK45735, DK40249] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK045735, R01DK040249] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAM A, 1989, BIOCHEM PHARMACOL, V38, P1569, DOI 10.1016/0006-2952(89)90303-1; BEDI GS, 1983, BIOCHEM PHARMACOL, V32, P2061, DOI 10.1016/0006-2952(83)90427-6; CARVALHO AC, 1988, J LAB CLIN MED, V112, P270; CHETTY C, 1983, J EXP MED, V157, P1089, DOI 10.1084/jem.157.4.1089; COLMAN RW, 1978, J CLIN INVEST, V61, P287, DOI 10.1172/JCI108938; COLMAN RW, 1975, J CLIN INVEST, V56, P1650, DOI 10.1172/JCI108247; COLMAN RW, 1988, AM J PATHOL, V130, P418; DALLDORF FG, 1988, AM J PATHOL, V132, P258; DELACADENA RA, 1987, J LAB CLIN MED, V109, P601; DELACADENA RA, 1993, BLOOD, V81, P3313; DELACADENA RA, 1991, AM J PHYSIOL, V260, pG213, DOI 10.1152/ajpgi.1991.260.2.G213; DELACADENA RA, 1993, HEMOSTASIS THROMBOSI, P219; FOX A, 1982, INFECT IMMUN, V35, P1003, DOI 10.1128/IAI.35.3.1003-1010.1982; GERATZ JD, 1991, AM J PATHOL, V139, P921; GERATZ JD, 1990, AM J PATHOL, V136, P909; GINSBERG MH, 1980, J LAB CLIN MED, V95, P497; HEYMER B, 1977, MICROBIOLOGY 1977, P344; JANSEN PM, 1993, BLOOD, V82, pA66; JANUSZ MJ, 1987, INFLAMMATION, V11, P73, DOI 10.1007/BF00917773; KAPLAN AP, 1972, J EXP MED, V135, P81, DOI 10.1084/jem.135.1.81; KETTNER C, 1980, ARCH BIOCHEM BIOPHYS, V202, P420, DOI 10.1016/0003-9861(80)90446-4; KETTNER C, 1990, J BIOL CHEM, V265, P18289; KETTNER CA, 1984, J BIOL CHEM, V259, P5106; KNABB RM, 1992, THROMB HAEMOSTASIS, V67, P56; LAMBRIS JD, 1982, INFECT IMMUN, V35, P377, DOI 10.1128/IAI.35.1.377-380.1982; LIPSKY PE, 1989, SPRINGER SEMIN IMMUN, V11, P123; MASON JW, 1970, ANN INTERN MED, V73, P545, DOI 10.7326/0003-4819-73-4-545; MATTESON DS, 1981, J AM CHEM SOC, V103, P5241, DOI 10.1021/ja00407a051; PAGE JD, 1991, J BIOL CHEM, V266, P8143; PIXLEY RA, 1995, CRIT CARE MED, V23, P41, DOI 10.1097/00003246-199501000-00010; PIXLEY RA, 1993, J CLIN INVEST, V91, P61, DOI 10.1172/JCI116201; PROCTOR RR, 1961, AM J CLIN PATHOL, V36, P212; RAO AK, 1988, NEW ENGL J MED, V318, P1021, DOI 10.1056/NEJM198804213181603; REVAK SD, 1978, J EXP MED, V147, P719, DOI 10.1084/jem.147.3.719; SARTOR RB, 1989, INFECT IMMUN, V57, P1177, DOI 10.1128/IAI.57.4.1177-1185.1989; SARTOR RB, 1994, INFLAMM BOWEL DIS, P210; SARTOR RB, 1994, GASTROENTEROLOGY, V100, pA613; SCHAPIRA M, 1982, J CLIN INVEST, V69, P1199, DOI 10.1172/JCI110557; SCHWAB JH, 1993, INFECT IMMUN, V61, P4535, DOI 10.1128/IAI.61.11.4535-4539.1993; SCHWAB JH, 1991, INFECT IMMUN, V59, P4436, DOI 10.1128/IAI.59.12.4436-4442.1991; SCOTT CF, 1988, J LAB CLIN MED, V111, P708; SILVA MRE, 1949, AM J PHYSIOL, V156, P261, DOI 10.1152/ajplegacy.1949.156.2.261; STIMPSON SA, 1986, INFECT IMMUN, V51, P240, DOI 10.1128/IAI.51.1.240-249.1986; STIMPSON SA, 1989, PHARM METHODS CONTRO, P381; TALLARIDA RJ, 1987, MANUAL PHARM CALCULA; TOOSSI Z, 1992, P NATL ACAD SCI USA, V89, P11969, DOI 10.1073/pnas.89.24.11969; VELOSO D, 1987, BLOOD, V70, P1053; WACHTFOGEL YT, 1983, J CLIN INVEST, V72, P1672, DOI 10.1172/JCI111126; Williams J W, 1979, Methods Enzymol, V63, P437	49	33	43	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1995	9	5					446	452		10.1096/fasebj.9.5.7896018	http://dx.doi.org/10.1096/fasebj.9.5.7896018			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QP451	7896018				2022-12-25	WOS:A1995QP45100021
J	MONONEN, I; HEISTERKAMP, N; DUNDER, U; ROMPPANEN, EL; NORONKOSKI, T; KURONEN, I; GROFFEN, J				MONONEN, I; HEISTERKAMP, N; DUNDER, U; ROMPPANEN, EL; NORONKOSKI, T; KURONEN, I; GROFFEN, J			RECOMBINANT GLYCOSYLASPARAGINASE AND IN-VITRO CORRECTION OF ASPARTYLGLYCOSAMINURIA	FASEB JOURNAL			English	Article						LYSOSOMAL STORAGE DISEASE; GLYCOPROTEINOSIS; LYSOSOMAL ENZYMES; MEMBRANE RECEPTORS; ENZYME THERAPY	PHOSPHOMANNOSYL RECEPTOR; HUMAN FIBROBLASTS; LYSOSOMAL ENZYME; MAMMALIAN-CELLS; PINOCYTOSIS; DISEASE; CDNA; ASPARTYLGLUCOSAMINIDASE; GLYCOASPARAGINASE; IDURONIDASE	Aspartylglycosaminuria (AGU) is the most common disorder of glycoprotein degradation. AGU patients are deficient in glycosylasparaginase (GA), which results in accumulation of aspartylglucosamine in body fluids and tissues. Human glycosylasparaginase was stably overexpressed in NIH-3T3 mouse fibroblasts, in which the unusual posttranslational processing and maturation of the enzyme occurred in a high degree. The recombinant enzyme was isolated as two isoforms, which were both phosphorylated, and actively transported into AGU fibroblasts and lymphoblasts through mannose-6-phosphate receptor-mediated endocytosis. The rate of uptake into fibroblasts was half-maximal when the concentration of GA in the medium was 5 x 10(-8) M. Immunofluorescence microscopy suggested compartmentalization of the recombinant enzyme in the lysosomes. Supplementation of culture medium with either isoform cleared AGU lymphoblasts of stored aspartylglucosamine when glycosylasparaginase activity in the cells reached 3-4% of that in normal lymphoblasts. A relatively small amount of recombinant GA in the culture medium was sufficient to reverse pathology in the target cells, indicating high corrective quality of the enzyme preparations. The combined evidence indicates that enzyme replacement therapy with the present recombinant glycosylasparaginase might reverse pathology at least in somatic cells of AGU patients.	CHILDRENS HOSP LOS ANGELES,DEPT PATHOL,LOS ANGELES,CA 90027	Children's Hospital Los Angeles	MONONEN, I (corresponding author), KUOPIO UNIV HOSP,DEPT CLIN CHEM,POB 1777,SF-70211 KUOPIO,FINLAND.		Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273				AULA P, 1982, GENETIC ERRORS GLYCO, P123; BACH G, 1972, P NATL ACAD SCI USA, V69, P2048, DOI 10.1073/pnas.69.8.2048; BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; BROT FE, 1974, BIOCHEM BIOPH RES CO, V57, P1, DOI 10.1016/S0006-291X(74)80349-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; ELIAHU R, 1981, AM J HUM GENET, V33, P576; FISCHER HD, 1983, J CELL BIOCHEM, V22, P69, DOI 10.1002/jcb.240220202; FISHER KJ, 1990, FEBS LETT, V269, P440, DOI 10.1016/0014-5793(90)81211-6; FISHER KJ, 1993, FEBS LETT, V323, P271, DOI 10.1016/0014-5793(93)81355-4; IKONEN E, 1993, EMBO J, V12, P295, DOI 10.1002/j.1460-2075.1993.tb05656.x; IKONEN E, 1991, EMBO J, V10, P51, DOI 10.1002/j.1460-2075.1991.tb07920.x; KAARTINEN V, 1992, J BIOL CHEM, V267, P6855; KAARTINEN V, 1991, J BIOL CHEM, V266, P5860; KAARTINEN V, 1989, J CHROMATOGR-BIOMED, V490, P293, DOI 10.1016/S0378-4347(00)82787-5; KAPLAN A, 1977, P NATL ACAD SCI USA, V74, P2026, DOI 10.1073/pnas.74.5.2026; KOKKO H, 1992, ANAL BIOCHEM, V201, P311, DOI 10.1016/0003-2697(92)90344-7; MONONEN I, 1991, P NATL ACAD SCI USA, V88, P2941, DOI 10.1073/pnas.88.7.2941; MONONEN I, 1993, FASEB J, V7, P1247, DOI 10.1096/fasebj.7.13.8405810; MONONEN I, 1994, LANCET, V343, P1297, DOI 10.1016/S0140-6736(94)92187-3; MONONEN IT, 1993, ANAL BIOCHEM, V208, P372, DOI 10.1006/abio.1993.1063; NOLAN CM, 1989, METABOLIC BASIS INHE, P1589; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; SANDO GN, 1977, CELL, V12, P619, DOI 10.1016/0092-8674(77)90262-8; TALKAD V, 1983, J BIOL CHEM, V258, P7345; TOLLERSRUD OK, 1992, BIOCHEM J, V282, P891, DOI 10.1042/bj2820891; VOLKMAN DJ, 1984, J IMMUNOL, V133, P3006	26	16	19	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1995	9	5					428	433		10.1096/fasebj.9.5.7896015	http://dx.doi.org/10.1096/fasebj.9.5.7896015			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QP451	7896015				2022-12-25	WOS:A1995QP45100018
J	OCONNOR, PJ; MERRILL, GF				OCONNOR, PJ; MERRILL, GF			VENTRICULAR ARRHYTHMIAS CAUSED BY REPEAT EXPOSURE TO HYPOXIA ARE DEPENDENT ON DURATION OF REOXYGENATION	FASEB JOURNAL			English	Article						PRECONDITIONING; ADRENERGIC; PROPRANOLOL	ADENOSINE-DEAMINASE; CORONARY VASODILATION; MYOCARDIAL HYPOXIA	The three objectives of this study were: 1) to determine whether an initial exposure to systemic hypoxia could affect the ventricular ectopy caused by a second period of hypoxia, 2) to see whether the duration of the intervening period of reoxygenation was important, and 3) to determine whether propranolol could produce results similar to those caused by an inadequate period of reoxygenation. Anesthetized instrumented beagles of either sex weighing 10.2 +/- 0.4 kg (n = 25) were exposed to dual periods of hypoxia (4 min each, PO2 similar to 15 +/- 3 mmHg). Dogs were divided into four groups according to the duration of reoxygenation and propranolol treatment: group 1 (n = 7), 20 min of reoxygenation; group 2 (n = 7), 40 min of reoxygenation; group 3 (n = 6), 60 min of reoxygenation; group 4 (n = 5), 50 min of reoxygenation plus propranolol. Dogs in groups 1 and 4 experienced a significant reduction in percent ectopy during their second exposure to hypoxia [group 1; 47 +/- 9% vs. 11 +/- 6%, group 4; 50 +/- 1% vs, 1 +/- 2%, (P < 0.05)], There were no significant differences in percent ectopy between the two periods of hypoxia in either group 2 or group 3 dogs (e.g., group 2; 50 +/- 1% vs. 51 +/- 11%). The results show that a first exposure to hypoxia can precondition the myocardium against arrhythmogenic effects of a second period of hypoxia.	RUTGERS STATE UNIV, DEPT BIOL SCI, NEW BRUNSWICK, NJ 08903 USA; RUTGERS STATE UNIV, GRAD PROGRAM PHYSIOL & NEUROBIOL, NEW BRUNSWICK, NJ 08903 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick			O'Connor, Patrick/HII-2987-2022					BENSOREK ESW, 1993, ARCH INTERN MED, V153, P2701, DOI 10.1001/archinte.153.23.2701; DALY MDB, 1963, J PHYSIOL-LONDON, V165, P179; DALY MDB, 1964, J PHYSL, V73, P201; HERRMANN SC, 1992, CIRC RES, V70, P1203, DOI 10.1161/01.RES.70.6.1203; LASLEY RD, 1993, CARDIOVASC RES, V27, P565, DOI 10.1093/cvr/27.4.565; LAWSON CS, 1993, CARDIOVASC RES, V27, P681, DOI 10.1093/cvr/27.4.681; LEONE RJ, 1993, J APPL PHYSIOL, V74, P1543, DOI 10.1152/jappl.1993.74.4.1543; LEONE RJ, 1993, FASEB J, V7, pA97; LUCCHESI BR, 1961, J PHARMACOL EXP THER, V132, P372; MALOOTIAN A, 1992, CAN J PHYSIOL PHARM, V70, P94, DOI 10.1139/y92-013; MERRILL GF, 1988, CARDIOVASC RES, V22, P345, DOI 10.1093/cvr/22.5.345; MERRILL GF, 1986, AM J PHYSIOL, V250, pH579, DOI 10.1152/ajpheart.1986.250.4.H579; O'Connor P. J., 1993, BIOMED LETT, V48, P163; PELLEG A, 1993, CORONARY ARTERY DIS, V4, P109, DOI 10.1097/00019501-199301000-00010; SCHAAL SF, 1969, CARDIOVASC RES, V3, P241, DOI 10.1093/cvr/3.3.241; SHIZUKUDA Y, 1992, CARDIOVASC RES, V26, P534, DOI 10.1093/cvr/26.5.534; SHIZUKUDA Y, 1993, CARDIOVASC RES, V27, P559, DOI 10.1093/cvr/27.4.559; SOKAL RR, 1969, BIOMETRY, P127; SZEKERES L, 1993, CARDIOVASC RES, V27, P593, DOI 10.1093/cvr/27.4.593; TODOROV L, 1994, FASEB J, V8, pA375; TSUCHIDA A, 1993, CARDIOVASC RES, V27, P652, DOI 10.1093/cvr/27.4.652; VEGH A, 1993, CARDIOVASC RES, V27, P638, DOI 10.1093/cvr/27.4.638; VEGH A, 1992, BRIT J PHARMACOL, V107, P648, DOI 10.1111/j.1476-5381.1992.tb14501.x; WALKER MJA, 1988, CARDIOVASC RES, V22, P447, DOI 10.1093/cvr/22.7.447; WEI HM, 1989, AM J PHYSIOL, V257, pH1043, DOI 10.1152/ajpheart.1989.257.4.H1043; WEI HM, 1988, AM J PHYSIOL, V254, pH1004, DOI 10.1152/ajpheart.1988.254.5.H1004; WESTFALL DP, 1994, FASEB J, V8, pA375	27	8	8	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1995	9	5					387	391		10.1096/fasebj.9.5.7896008	http://dx.doi.org/10.1096/fasebj.9.5.7896008			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QP451	7896008				2022-12-25	WOS:A1995QP45100011
J	SOTHERN, RB; SMAALAND, R; MOORE, JG				SOTHERN, RB; SMAALAND, R; MOORE, JG			CIRCANNUAL RHYTHM IN DNA-SYNTHESIS (S-PHASE) IN HEALTHY-HUMAN BONE-MARROW AND RECTAL MUCOSA	FASEB JOURNAL			English	Article						GASTROINTESTINAL; BIOLOGICAL RHYTHMS; CIRCANNUAL VARIATIONS; CIRCADIAN CYCLES	METASTATIC TUMOR-GROWTH; SEASONAL-VARIATION; CIRCADIAN STAGE; ANTIBODY-FORMATION; BREAST-CANCER; PROLIFERATION; PERIODICITY; MELANOMA; DISEASE; MOUSE	Cytotoxic anti-cancer drugs are meant to interact with tumor cells to impair the replicative and/or transcriptional functions of DNA in order to reduce proliferative rate and cause cell death. These drugs also affect rapidly proliferating healthy tissues such as the bone marrow and the gastrointestinal tract, thereby resulting in toxicity-related dose reductions and/or delays in treatment. We previously demonstrated a circadian rhythm in DNA synthesis (S-phase) of total bone marrow (BM) nucleated cells in 16 healthy, diurnally active men sampled every 4 h for 24 h (19 series). Highest values determined by flow cytometry were found near midday. We also reported a circadian rhythm in DNA synthesis of the rectal mucosa (RM) in 16 healthy men sampled every 2-3 h for 24 h under fed and fasting conditions (24 series). Highest proliferative activity as reflected by in vitro [H-3]Tdr uptake, was found near the time of awakening, Circannual (about yearly) rhythmicity in cell division rates may also influence treatment effects. Our BM and RM DNA data, which were collected over several years, were reanalyzed for seasonality by ANOVA and for circannual rhythm by the least-squares fit of a 1 year cosine. Characteristics of circadian amplitudes and acrophases were also compared between seasons. In addition to a significant circadian rhythm, a significant circannual rhythm in cell proliferation in healthy BM (P = 0.008) and RM (P < 0.001) could be established on the basis of these serially independent data. The range between the lowest and highest points of the fitted 1 year cosine (circannual double amplitude) was comparable to the circadian range for BM (25%); it was at least doubled for RM (70%). Highest values occurred in the late summer for BM and mid-fall for RM. Based on limited data in some seasons, the circadian patterns were more prominent in the fall and winter, with larger amplitudes and later acrophases, when compared with summer for BM and spring and summer for RM. Thus, in addition to time of day, time of year may influence chemo- and immunotherapeutic strategies and should be considered in the design of preclinical and clinical treatment regimens and other procedures.	ST PAUL RAMSEY MED CTR, RHYTHMOMETRY LAB, MINNEAPOLIS, MN 55455 USA; UNIV BERGEN, HAUKELAND HOSP, DEPT ONCOL, BERGEN, NORWAY; UNIV UTAH, SCH MED, DEPT INTERNAL MED, DIV GASTROENTEROL, SALT LAKE CITY, UT 84148 USA	Saint Paul Ramsey Medical Center; University of Bergen; Haukeland University Hospital; Utah System of Higher Education; University of Utah	SOTHERN, RB (corresponding author), UNIV MINNESOTA, CHRONOBIOL LABS, RHYTHMOMETRY LAB, BOX 609 UMHC, MINNEAPOLIS, MN 55455 USA.		Smaaland, Rune/AAH-2149-2021					AKSLEN LA, 1989, CHRONOBIOLOGIA, V16, P257; AKSLEN LA, 1991, INVAS METAST, V11, P58; BINGHAM C, 1982, CHRONOBIOLOGIA, V9, P397; BJARNASON GA, 1994, CIRCADIAN CANC THERA, P241; BLANK MA, 1992, WORKSHOP COMPUTER ME, P245; BUCHI KN, 1991, GASTROENTEROLOGY, V101, P410, DOI 10.1016/0016-5085(91)90019-H; COHEN P, 1983, CANCER RES, V43, P892; DOUPE J, 1957, CAN J BIOCHEM PHYS, V35, P203; GODFREY HP, 1975, INT ARCH ALLER A IMM, V49, P411, DOI 10.1159/000231422; HALBERG F, 1983, International Journal of Chronobiology, V8, P225; HALBERG FE, 1990, PROG CLIN BIOL RES, V341, P567; HARTVEIT F, 1992, CLIN EXP METASTAS, V10, P329, DOI 10.1007/BF00058172; HAUS E, 1992, CHRONOBIOL INT, V9, P393; HAUS E, 1987, Chronobiologia, V14, P184; Haus E, 1988, ANN REV CHRONOPHARMA, V4, P333; HERMIDA RC, 1993, CHRONOBIOL INT, V10, P54, DOI 10.3109/07420529309064482; HOSTMARK JG, 1984, SCAND J UROL NEPHROL, V18, P107, DOI 10.3109/00365598409182176; HRUSHESKY WJM, 1982, ANN NY ACAD SCI, V397, P293, DOI 10.1111/j.1749-6632.1982.tb43441.x; HRUSHESKY WJM, 1985, CHRONOBIOLOGY 1981 1, P493; HRUSHESKY WJM, 1993, CANCER PRINCIPLES PR, P2666; KLEMFUSS H, 1993, J INTERDISCIPL CYCLE, V24, P1, DOI 10.1080/09291019309360191; KOMADA H, 1989, J INTERDISCIPL CYCLE, V20, P107; LAERUM CD, 1988, CHRONOBIOL INT, V5, P19, DOI 10.3109/07420528809078549; LEVI F, 1988, EXP HEMATOL, V16, P696; LEVI F, 1989, BIOL RHYTHMS CLIN PR, P99; MACMURRAY JP, 1983, LIFE SCI, V32, P2363, DOI 10.1016/0024-3205(83)90767-1; MASON BH, 1985, BREAST CANCER RES TR, V5, P171, DOI 10.1007/BF01805991; MAUER AM, 1965, BLOOD-J HEMATOL, V26, P1; MOJON A, 1992, CHRONOBIOL INT, V9, P403, DOI 10.3109/07420529209064552; Mormont C, 1989, CHRONOPHARMACOLOGY C, P395; NEWELL GR, 1985, JNCI-J NATL CANCER I, V74, P53; NICOLAU G Y, 1984, Chronobiology International, V1, P301, DOI 10.3109/07420528409063911; POLLMANN L, 1982, J INTERDISCIPL CYCLE, V13, P249; RATAJCZAK HV, 1993, CHRONOBIOL INT, V10, P383, DOI 10.3109/07420529309064492; RATAJCZAK HV, 1991, CHRONOBIOL INT, V8, P44, DOI 10.3109/07420529109063918; REINBERG A, 1978, ENV ENDOCRINOLOGY, P113; ROBERTSON WG, 1977, CLIN CHIM ACTA, V80, P347, DOI 10.1016/0009-8981(77)90043-2; SCHEVING LE, 1989, CHRONOPHARMACOLOGY C, P317; SHIFRINE M, 1982, J INTERDISCIPL CYCLE, V13, P157, DOI 10.1080/09291018209359774; SMAALAND R, 1993, CANCER RES, V53, P3129; SMAALAND R, 1992, BLOOD, V79, P2281; SMAALAND R, 1991, BLOOD, V77, P2603; SMAALAND R, 1994, CIRCADIAN CANCER THE, P119; Sothern R., 1972, PHYSIOL TEACH, V1, P1; SOTHERN RB, 1993, CHRONOBIOL INT, V10, P364, DOI 10.3109/07420529309064491; SOTHERN RB, 1994, CHRONOBIOLOGIA, V21, P7; SOTHERN RB, 1994, FASEB J, V8, pA927; SWERDLOW AJ, 1985, BRIT J CANCER, V52, P893, DOI 10.1038/bjc.1985.274	48	14	14	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1995	9	5					397	403		10.1096/fasebj.9.5.7896010	http://dx.doi.org/10.1096/fasebj.9.5.7896010			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QP451	7896010				2022-12-25	WOS:A1995QP45100013
J	PEDONE, PV; COSMA, MP; UNGARO, P; COLANTUONI, V; BRUNI, CB; ZARRILLI, R; RICCIO, A				PEDONE, PV; COSMA, MP; UNGARO, P; COLANTUONI, V; BRUNI, CB; ZARRILLI, R; RICCIO, A			PARENTAL IMPRINTING OF RAT INSULIN-LIKE GROWTH-FACTOR-II GENE PROMOTERS IS COORDINATELY REGULATED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 PROMOTERS; IGF2 GENE; MOUSE; EXPRESSION; METHYLATION; RELAXATION; CANCER; ALLELE	The insulin-like growth factor II (IGF-II) gene is parentally imprinted in the mouse and human species. By following the inheritance of natural polymorphisms of IGF-II mRNA, we demonstrated that the tissue-specific parental imprinting of the IGF-II gene is conserved in the rat. The expression of the paternal IGF-II allele exceeded by more than 3 orders of magnitude that of the maternal allele in livers of 3-day-old Wistar x Fisher interstrain rat crosses. In contrast, the two alleles were both expressed in the rat central nervous system, which is also the only district of the organism where this gene is active in adult rodents. We also analyzed the allelic usage of the three IGF-II promoters, which generate alternatively spliced transcripts, and showed that parental imprinting of all transcription starts sites is coordinately regulated since P1, P2, and P3 are all repressed on the maternal allele in neonatal rat liver, and all of them are activated on both alleles in the choroid plexus of the central nervous system. RNase protection assays demonstrated that the activity ratio of the three IGF-II promoters can be different in tissues that show the same imprinting mode.	CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC,I-80131 NAPLES,ITALY; UNIV NAPLES FEDERICO II,DIPARTIMENTO BIOCHIM & BIOTECNOL MED,I-80131 NAPLES,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II			Riccio, Andrea/A-4991-2015; Cosma, Maria Pia/E-8731-2015; Cerrato, Flavia/O-8315-2015; Riccio, Andrea/AAY-7571-2020; Zarrilli, Raffaele/F-5067-2012	Riccio, Andrea/0000-0001-7990-3576; Cosma, Maria Pia/0000-0003-4207-5097; Cerrato, Flavia/0000-0003-3794-3021; Riccio, Andrea/0000-0001-7990-3576; Zarrilli, Raffaele/0000-0003-4191-9032; Pedone, Paolo Vincenzo/0000-0002-0828-5843				BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; EVERSOLECIRE P, 1993, MOL CELL BIOL, V13, P4928, DOI 10.1128/MCB.13.8.4928; FERGUSONSMITH AC, 1991, NATURE, V351, P667, DOI 10.1038/351667a0; FRUNZIO R, 1986, J BIOL CHEM, V261, P7138; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; HAUGE XY, 1993, HUM MOL GENET, V2, P411, DOI 10.1093/hmg/2.4.411; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; KALSCHEUER VM, 1993, NAT GENET, V5, P74, DOI 10.1038/ng0993-74; LATHAM KE, 1994, GENE DEV, V8, P290, DOI 10.1101/gad.8.3.290; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OHLSSON R, 1994, DEVELOPMENT, V120, P361; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; PEDONE PV, 1994, HUM MOL GENET, V3, P1117, DOI 10.1093/hmg/3.7.1117; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; Rechler M. M., 1990, PEPTIDE GROWTH FACTO, P263; Rotwein P, 1991, Growth Factors, V5, P3, DOI 10.3109/08977199109000267; Sambrook J, 1989, MOL CLONING LABORATO; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; SOARES MB, 1986, J MOL BIOL, V192, P737, DOI 10.1016/0022-2836(86)90025-2; STYLIANOPOULOU F, 1988, P NATL ACAD SCI USA, V85, P141, DOI 10.1073/pnas.85.1.141; UENO T, 1987, BIOCHEM BIOPH RES CO, V148, P344, DOI 10.1016/0006-291X(87)91116-8; UENO T, 1988, BIOCHIM BIOPHYS ACTA, V950, P411, DOI 10.1016/0167-4781(88)90138-8; ZARRILLI R, 1992, EUR J BIOCHEM, V209, P445, DOI 10.1111/j.1432-1033.1992.tb17308.x; ZARRILLI R, 1994, MOL CELL ENDOCRINOL, V101, pR1, DOI 10.1016/0303-7207(94)90253-4; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61	31	44	44	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23970	23975						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929045				2022-12-25	WOS:A1994PQ34600021
J	SETOYOUNG, D; NA, SQ; MONK, BC; HABER, JE; PERLIN, DS				SETOYOUNG, D; NA, SQ; MONK, BC; HABER, JE; PERLIN, DS			MUTATIONAL ANALYSIS OF THE FIRST EXTRACELLULAR LOOP REGION OF THE H+-ATPASE FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE ATPASE; COMPETITIVE PHOTOAFFINITY INHIBITOR; SITE-DIRECTED MUTAGENESIS; RESISTANT PMA1 MUTANTS; P-TYPE ATPASE; SARCOPLASMIC-RETICULUM; NEUROSPORA-CRASSA; SALMONELLA-TYPHIMURIUM; OUABAIN SENSITIVITY; GASTRIC H,K-ATPASE	Transmembrane segments 1 and 2 of the yeast plasma membrane H+-ATPase are believed to form a helical hairpin structure that is joined by a short extracytoplasmic loop. The hairpin head region (Ala(135)-Phe(144)) was probed using site-directed mutagenesis, Scanning alanine mutagenesis produced functional H+-ATPase at all positions except Leu(138), Asp(143), and Phe(144). D140A and V142A gave strong hygromycin B resistance and low pH sensitivity suggesting a major kinetic defect in these mutant enzymes. Other amino acid substitutions, such as L138Y, were highly perturbing, while mutations S139E and D140E produced minor effects on phenotype. Small uncharged residues Gly and Ala, which were inserted between Leu(138) and Ser(139) to examine the importance of loop length on Ht-ATPase function, were well tolerated, while the insertion of a polar Ser residue was highly perturbing. Other additions were not tolerated by the enzyme. These results suggest that the turn region has limited structural flexibility. The conserved Phe(144) residue could be changed to Trp with a minor effect on phenotype. However, neither Tyr,Arg, nor small hydrophobic residues could substitute, suggesting that this region is closely packed and hydrophobic. ATP hydrolysis measurements showed that V-max was significantly reduced in nearly all. mutant enzymes, except D140E; whereas, K-m values were nearly normal. Vanadate-sensitivity and pH profiles for ATP hydrolysis were nearly normal for all mutant enzymes except insertion mutant S138+. Mutants with extreme phenotypes (S138+, Tyr(138)) showed significantly altered medium acidification profiles. These results support the notion that the hairpin head region linking transmembrane segments 1 and 2 forms a tightly packed conformationally sensitive domain that is coupled to the catalytic ATP hydrolysis domain.	PUBL HLTH RES INST CITY NEW YORK INC, NEW YORK, NY 10016 USA; BRANDEIS UNIV, ROSENSTIEL BASIC MED SCI RES CTR, DEPT BIOL, WALTHAM, MA 02254 USA; UNIV OTAGO, FAC DENT, EXPTL ORAL BIOL UNIT, DUNEDIN, NEW ZEALAND	Brandeis University; University of Otago				Monk, Brian/0000-0003-2264-3480; Haber, James/0000-0002-1878-0610	NIGMS NIH HHS [GM39737, GM38225] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038225] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARYSTARKHOVA E, 1992, J BIOL CHEM, V267, P13694; BARTS PWJ, 1980, BIOCHIM BIOPHYS ACTA, V597, P195; BIGELOW DJ, 1991, BIOCHEMISTRY-US, V30, P2113, DOI 10.1021/bi00222a016; BORSTPAUWELS GWFH, 1981, BIOCHIM BIOPHYS ACTA, V650, P88, DOI 10.1016/0304-4157(81)90002-2; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CID A, 1988, J BIOL CHEM, V263, P14134; DEBER CM, 1986, ARCH BIOCHEM BIOPHYS, V251, P68, DOI 10.1016/0003-9861(86)90052-4; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FORBUSH B, 1983, CURR TOP MEMBR TRANS, V19, P167; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; GUSTIN MC, 1986, SCIENCE, V233, P1195, DOI 10.1126/science.2426783; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; HENNESSEY JP, 1990, J BIOL CHEM, V265, P532; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INESI G, 1992, J BIOENERG BIOMEMBR, V24, P271; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13528; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; LAUGER P, 1987, PHYSIOL REV, V67, P1296, DOI 10.1152/physrev.1987.67.4.1296; LINGREL JB, 1992, J BIOENERG BIOMEMBR, V24, P263; LUTHY R, 1991, PROTEINS, V10, P229, DOI 10.1002/prot.340100307; MANDALA SM, 1989, J BIOL CHEM, V264, P16276; MATA AM, 1992, BIOCHEM J, V286, P567, DOI 10.1042/bj2860567; MATTHEWS BW, 1993, ANNU REV BIOCHEM, V62, P139, DOI 10.1146/annurev.bi.62.070193.001035; MCCLARY JA, 1989, BIOTECHNIQUES, V7, P282; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; MEWES HW, 1981, FEBS LETT, V131, P7, DOI 10.1016/0014-5793(81)80875-7; MIDGLEY M, 1986, FEMS MICROBIOL LETT, V34, P187; MODYANOV N, 1992, ACTA PHYSIOL SCAND, V146, P49; MONK BC, 1991, J BACTERIOL, V173, P6826, DOI 10.1128/jb.173.21.6826-6836.1991; MONK BC, 1991, J BIOL CHEM, V266, P18097; MONK BC, 1994, J BIOENERG BIOMEMBR, V26, P101, DOI 10.1007/BF00763222; MUNSON KB, 1991, J BIOL CHEM, V266, P18976; MUNSON KB, 1988, BIOCHEMISTRY-US, V27, P3932, DOI 10.1021/bi00411a007; NA SQ, 1993, J BIOL CHEM, V268, P11792; NAKAMOTO RK, 1989, ANN NY ACAD SCI, V574, P165; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PERLIN DS, 1989, J BIOL CHEM, V264, P21857; PERLIN DS, 1988, J BIOL CHEM, V263, P18118; PRICE EM, 1989, J BIOL CHEM, V264, P21902; PRICE EM, 1990, J BIOL CHEM, V265, P6638; RABON EC, 1990, ANNU REV PHYSIOL, V52, P321; RAO US, 1991, J BIOL CHEM, V266, P14740; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; ROSE MD, 1990, METHODS YEAST GENETI, P126; SACHS G, 1992, J BIOENERG BIOMEMBR, V24, P301; SCHULTHEIS PJ, 1993, J BIOL CHEM, V268, P22686; SCHULTHEIS PJ, 1993, BIOCHEMISTRY-US, V32, P544, DOI 10.1021/bi00053a020; SCOTT TL, 1985, J BIOL CHEM, V260, P4421; SERRANO R, 1990, BIOCHIM BIOPHYS ACTA, V1018, P195, DOI 10.1016/0005-2728(90)90247-2; SERRANO R, 1989, ANNU REV PLANT PHYS, V40, P61; SETOYOUNG D, 1992, BIOCHIM BIOPHYS ACTA, V1102, P213, DOI 10.1016/0167-4838(92)90512-C; SETOYOUNG D, 1991, J BIOL CHEM, V266, P1383; SLAYMAN CL, 1973, J MEMBRANE BIOL, V14, P305, DOI 10.1007/BF01868083; SLAYMAN CL, 1987, J BIOENERG BIOMEMBR, V19, P1; SMITH DL, 1993, J BIOL CHEM, V268, P22469; SNAVELY MD, 1991, J BIOL CHEM, V266, P815; STOCK JB, 1992, J BIOL CHEM, V267, P19753; TRAMONTANO A, 1989, PROTEINS, V6, P382, DOI 10.1002/prot.340060405; VANDEMORTEL JBJ, 1990, BIOCHIM BIOPHYS ACTA, V1026, P220, DOI 10.1016/0005-2736(90)90067-X; WACH A, 1992, J BIOENERG BIOMEMBR, V24, P309	62	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23988	23995						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929048				2022-12-25	WOS:A1994PQ34600024
J	DENU, JM; FITZPATRICK, PF				DENU, JM; FITZPATRICK, PF			PH AND KINETIC ISOTOPE EFFECTS ON THE OXIDATIVE HALF-REACTION OF D-AMINO-ACID OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELF-ASSOCIATION MODE; HOG KIDNEY; SUBSTRATE; FEATURES; PROTON	D Amino-acid oxidase catalyzes the oxidation of D-amino acids to imino acids. In the oxidative half-reaction, oxygen reacts with the reduced enzyme-imino acid complex to reoxidize the bound FAD. This is then followed by dissociation of the imino acid. The effects of pH and D2O on the kinetics of the oxidative half-reaction of D-amino-acid oxidase have been determined with glycine, D-alanine, and D-serine as substrates. Reaction of the reduced enzyme with oxygen requires that a group with a pK(alpha) value of about 10.5 be protonated and a group with a pK(alpha) value of 8.5 be deprotonated. The former value is not seen with D-alanine as substrate; the latter is only seen with glycine. No solvent isotope effects are seen on the V/K-O2, value with D-alanine, consistent with rate-limiting electron transfer. Product release involves a pH-dependent conformational change. This is rate-limiting at all pH values with D-alanine as substrate. Significant solvent isotope effects are seen on the V-max value with D-alanine. The proton inventory at high pH is linear, consistent with release of a single proton in the slow step; at pH 6 the solvent inventory is bowl-shaped, consistent with a solvent isotope effect on the conformation of the protein. With glycine the V-D value increases to the intrinsic value at pH 10.5; this establishes that CH bond cleavage becomes rate-limiting with this substrate above pH 10.	TEXAS A&M UNIV,DEPT BIOCHEM & BIOPHYS,COLLEGE STN,TX 77843; TEXAS A&M UNIV,DEPT CHEM,COLLEGE STN,TX 77843	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station								ANTONINI E, 1966, J BIOL CHEM, V241, P2358; Bright H.B., 1975, ENZYMES, V12B, P421; BRUMBY PE, 1968, BIOCHEM PREP, V12, P29; Cleland W W, 1979, Methods Enzymol, V63, P103; DENU JM, 1992, BIOCHEMISTRY-US, V31, P8207, DOI 10.1021/bi00150a013; DENU JM, 1994, IN PRESS BIOCHEMISTR, V33; EBERLEIN G, 1983, J AM CHEM SOC, V105, P6685, DOI 10.1021/ja00360a024; FITZPATRICK PF, 1982, J BIOL CHEM, V257, P9958; FITZPATRICK PF, 1982, J BIOL CHEM, V257, P2916; FITZPATRICK PF, 1982, J BIOL CHEM, V257, P1166; GHISLA S, 1974, BIOCHEMISTRY-US, V13, P589, DOI 10.1021/bi00700a029; Ghisla S., 1982, FLAVINS FLAVOPROTEIN, P133; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; MASSEY V, 1965, BIOCHEMISTRY-US, V4, P1161, DOI 10.1021/bi00882a027; MASSEY V, 1966, J BIOL CHEM, V241, P2347; Massey V, 1988, Prog Clin Biol Res, V274, P147; MASSEY V, 1980, FLAVINS FLAVOPROTEIN, P1; Palmer G, 1968, BIOL OXIDATIONS, P263; PORTER DJT, 1977, J BIOL CHEM, V252, P4464; PURDY DE, 1982, THESIS U PENNSYLVANI; QUAY S, 1977, BIOCHEMISTRY-US, V16, P3348, DOI 10.1021/bi00634a010; RICARD J, 1985, EUR J BIOCHEM, V152, P557, DOI 10.1111/j.1432-1033.1985.tb09231.x; SCHOWEN KB, 1982, METHOD ENZYMOL, V87, P551; SHIGA K, 1972, BIOCHIM BIOPHYS ACTA, V263, P294, DOI 10.1016/0005-2795(72)90082-7; TOJO H, 1985, J BIOL CHEM, V260, P2607; TOJO H, 1985, J BIOL CHEM, V260, P2615; YAGI K, 1973, J BIOCHEM-TOKYO, V73, P909, DOI 10.1093/oxfordjournals.jbchem.a130173	27	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15054	15059						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	7910822				2022-12-25	WOS:A1994NP73800034
J	MCLAGGAN, D; NAPRSTEK, J; BUURMAN, ET; EPSTEIN, W				MCLAGGAN, D; NAPRSTEK, J; BUURMAN, ET; EPSTEIN, W			INTERDEPENDENCE OF K+ AND GLUTAMATE ACCUMULATION DURING OSMOTIC ADAPTATION OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; PROLINE TRANSPORT; CATION-TRANSPORT; GENE-EXPRESSION; OSMOREGULATION; BACTERIA; TREHALOSE; PRESSURE; MEMBRANE; BETAINE	Escherichia coli responds to an increase in medium osmolarity by accumulating K+ and glutamate. At low osmolarity a large fraction of cytoplasmic K+ serves to balance charge on macromolecular anions. That fraction of K+ is here referred to as ''bound,'' as distinguished from ''free'' K+ that serves to balance charge of small anions. At higher osmolarity where cytoplasmic K+ increases markedly, the bound fraction decreases but the absolute amount of bound K+ expressed per unit of dry weight increases. The increase in bound K+ can be explained largely by the reduction of cytoplasmic putrescine at high osmolarity. At high osmolarity, glutamate is the major cytoplasmic anion, equal to at least 70% of free cytoplasmic K+. A sudden increase in the osmolarity of the medium stimulates glutamate synthesis with a lag of only about a minute; glutamate synthesis is almost totally dependent on K+ uptake. The high rate of flow of nitrogen through the glutamate pool under control conditions of growth at low osmolarity indicates that glutamate accumulation immediately after shift to high osmolarity must be due to inhibition of utilization of glutamate in the synthesis of other nitrogen-containing compounds rather than stimulation of glutamate synthesis. In agreement with this reasoning we find the kinetics of glutamate accumulation to be independent of the specific path of synthesis, whether, by glutamate dehydrogenase or by glutamate synthase. Synthesis of glutamate appears to be required to attain normal values of the electrical membrane potential after shift to high osmolarity.	UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,920 E 58TH ST,CHICAGO,IL 60637	University of Chicago				McLaggan, Debbie/0000-0003-3044-7287				ALEXANDROWICZ Z, 1962, J POLYM SCI, V56, P115, DOI 10.1002/pol.1962.1205616311; ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; BAKKER EP, 1990, FEMS MICROBIOL LETT, V75, P319, DOI 10.1111/j.1574-6968.1990.tb04105.x; BAKKER EP, 1987, J BACTERIOL, V169, P3743, DOI 10.1128/jb.169.8.3743-3749.1987; BERRIER C, 1992, EUR J BIOCHEM, V206, P559, DOI 10.1111/j.1432-1033.1992.tb16960.x; BERRIER C, 1989, FEBS LETT, V259, P27, DOI 10.1016/0014-5793(89)81486-3; BOLTON ET, 1957, YB 1956, P122; BRITTEN RJ, 1962, BACTERIOL REV, V26, P292, DOI 10.1128/MMBR.26.3.292-335.1962; BROWN AD, 1972, J GEN MICROBIOL, V72, P589, DOI 10.1099/00221287-72-3-589; CAIRNEY J, 1985, J BACTERIOL, V164, P1218, DOI 10.1128/JB.164.3.1218-1223.1985; CAIRNEY J, 1985, J BACTERIOL, V164, P1224, DOI 10.1128/JB.164.3.1224-1232.1985; CASTLE AM, 1986, J BIOL CHEM, V261, P7797; CAYLEY DS, 1990, J MOL BIOL, V222, P281; CAYLEY S, 1992, J BACTERIOL, V174, P1586, DOI 10.1128/jb.174.5.1586-1595.1992; CAYLEY S, 1989, J BACTERIOL, V171, P3597, DOI 10.1128/jb.171.7.3597-3602.1989; COHN EJ, 1943, PROTEINS AMINO ACIDS, P111; COLLINS SH, 1976, J BACTERIOL, V126, P1224, DOI 10.1128/JB.126.3.1224-1231.1976; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; CSONKA LN, 1989, MICROBIOL REV, V53, P121, DOI 10.1128/MMBR.53.1.121-147.1989; CSONKA LN, 1982, J BACTERIOL, V151, P1433, DOI 10.1128/JB.151.3.1433-1443.1982; DAVSON H, 1964, TXB GENERAL PHYSL, P376; DINNIBIER U, 1988, ARCH MICROBIOL, V150, P348, DOI 10.1007/BF00408306; DUNLAP VJ, 1985, J BACTERIOL, V163, P296, DOI 10.1128/JB.163.1.296-304.1985; EPSTEIN W, 1965, J GEN PHYSIOL, V49, P221, DOI 10.1085/jgp.49.2.221; GIAEVER HM, 1988, J BACTERIOL, V170, P2841, DOI 10.1128/jb.170.6.2841-2849.1988; GOWRISHANKAR J, 1985, J BACTERIOL, V164, P434, DOI 10.1128/JB.164.1.434-445.1985; HOUSSIN C, 1991, BIOCHIM BIOPHYS ACTA, V1056, P76, DOI 10.1016/S0005-2728(05)80075-1; KIM SY, 1990, J BACTERIOL, V172, P6127, DOI 10.1128/jb.172.10.6127-6128.1990; KRULWICH TA, 1985, J BACTERIOL, V162, P768, DOI 10.1128/JB.162.2.768-772.1985; LAIMINS LA, 1981, P NATL ACAD SCI-BIOL, V78, P464, DOI 10.1073/pnas.78.1.464; LARSEN PI, 1987, ARCH MICROBIOL, V147, P1, DOI 10.1007/BF00492896; LUND P, 1984, METHOD ENZYMAT AN, V8, P357; MALOY SR, 1981, J BACTERIOL, V145, P1110, DOI 10.1128/JB.145.2.1110-1111.1981; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; MCLAGGAN D, 1990, J BACTERIOL, V172, P3631, DOI 10.1128/jb.172.7.3631-3636.1990; MEASURES JC, 1975, NATURE, V257, P398, DOI 10.1038/257398a0; MILNER JL, 1988, J BIOL CHEM, V263, P14900; MUNRO GF, 1972, J BIOL CHEM, V247, P1272; OHWADA T, 1987, ARCH BIOCHEM BIOPHYS, V259, P157, DOI 10.1016/0003-9861(87)90481-4; PADAN E, 1976, EUR J BIOCHEM, V63, P533, DOI 10.1111/j.1432-1033.1976.tb10257.x; PAHEL G, 1978, J BACTERIOL, V133, P139, DOI 10.1128/JB.133.1.139-148.1978; REIZER LJ, 1987, ESCHERICHIA COLI SAL, V1, P302; RHOADS DB, 1978, J GEN PHYSIOL, V72, P283, DOI 10.1085/jgp.72.3.283; RICHEY B, 1987, J BIOL CHEM, V262, P7157; Rottenberg H, 1979, Methods Enzymol, V55, P547; SINGER M, 1989, MICROBIOL REV, V53, P1; SLONCZEWSKI JL, 1982, J BACTERIOL, V152, P384; STORTS DR, 1988, J BACTERIOL, V170, P1541, DOI 10.1128/jb.170.4.1541-1547.1988; TEMPEST DW, 1970, J GEN MICROBIOL, V64, P171, DOI 10.1099/00221287-64-2-171; TSAPIS A, 1977, BIOCHIM BIOPHYS ACTA, V469, P1, DOI 10.1016/0005-2736(77)90320-0; WELSH DT, 1991, J GEN MICROBIOL, V137, P745, DOI 10.1099/00221287-137-4-745	51	166	182	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1911	1917						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	7904996				2022-12-25	WOS:A1994MR98800056
J	BUCHHOLZ, D; SCOTT, P; SHASTRI, N				BUCHHOLZ, D; SCOTT, P; SHASTRI, N			PRESENTATION WITHOUT PROTEOLYTIC CLEAVAGE OF ENDOGENOUS PRECURSORS IN THE MHC CLASS-I ANTIGEN-PROCESSING PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; DROSOPHILA-MELANOGASTER CELLS; PROTEASOME-RELATED GENE; T-CELLS; VIRAL PEPTIDES; LYMPHOCYTES-T; LINKED LMP; MOLECULES; RECOGNITION; SUBUNITS	The antigen presentation pathway yields peptide-MHC class I complexes on the antigen presenting cell (APC) surface for recognition by appropriate T-cells. Expression of the peptide MHC complex on APC surface is preceded by several steps that include the generation of peptide fragments in the cytoplasm and their assembly with MHC molecules in the endoplasmic reticulum. It is now clear that MHC binding to optimally processed peptides in the endoplasmic reticulum is obligatory for their stable expression on the cell surface. However, whether a similar obligatory relationship exists between generation of processed peptides and their expression as peptide-MHC on APC surface is not known. Here, we addressed this question by analyzing the processing of ovalbumin (aa257-264, SL8) or influenza nucleoprotein (aa366-374, AM9) analogs. We examined the generation of naturally processed peptides using pre cursors that did, or did not, contain residues flanking the optimal MHC binding peptides. By characterizing the peptides generated from these precursors by T-cell stimulation assays and by high performance liquid chromatography analysis, we established that intracellular assembly of peptide-MHC complexes and their expression on the cell surface can occur with peptides that lack flanking residues. The presentation of these endogenously synthesized perfect fit peptides demonstrates that the cleavage of precursor polypeptides is an independent step in the antigen presentation pathway.	UNIV CALIF BERKELEY,DEPT MOLEC CELL BIOL,DIV IMMUNOL,BERKELEY,CA 94720	University of California System; University of California Berkeley					NIAID NIH HHS [AI-26604] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026604, R21AI026604] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIYAMA KY, 1994, SCIENCE, V265, P1231, DOI 10.1126/science.8066462; ANDERSON K, 1991, J EXP MED, V174, P489, DOI 10.1084/jem.174.2.489; ANDROLEWICZ MJ, 1994, IMMUNITY, V1, P7, DOI 10.1016/1074-7613(94)90004-3; ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; BACIK I, 1994, J IMMUNOL, V152, P381; BLUESTONE JA, 1992, J EXP MED, V176, P1757, DOI 10.1084/jem.176.6.1757; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; CATIPOVIC B, 1992, J EXP MED, V176, P1611, DOI 10.1084/jem.176.6.1611; COX AL, 1994, SCIENCE, V264, P716, DOI 10.1126/science.7513441; DICK LR, 1994, J IMMUNOL, V152, P3884; EISENLOHR LC, 1909, CELL, V71, P963; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FALK K, 1993, CELL IMMUNOL, V150, P447, DOI 10.1006/cimm.1993.1212; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; HEATH WR, 1989, NATURE, V341, P749, DOI 10.1038/341749a0; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JOYCE S, 1994, P NATL ACAD SCI USA, V91, P4145, DOI 10.1073/pnas.91.10.4145; KARTTUNEN J, 1991, P NATL ACAD SCI USA, V88, P3972, DOI 10.1073/pnas.88.9.3972; KARTTUNEN J, 1992, P NATL ACAD SCI USA, V89, P6020, DOI 10.1073/pnas.89.13.6020; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAPHAM CK, 1993, J EXP MED, V177, P1633, DOI 10.1084/jem.177.6.1633; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MALARKANNAN S, 1995, J IMMUNOL, V154, P585; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MATSUMURA M, 1992, J BIOL CHEM, V267, P23589; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MOMBURG F, 1994, NATURE, V367, P648, DOI 10.1038/367648a0; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; RAJAGOPALAN S, 1994, J EXP MED, V180, P407, DOI 10.1084/jem.180.1.407; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V1, P213; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; ROTZSCHKE O, 1991, EUR J IMMUNOL, V21, P2891, DOI 10.1002/eji.1830211136; SCHUMACHER TNM, 1994, J EXP MED, V179, P533, DOI 10.1084/jem.179.2.533; SHASTRI N, 1993, J IMMUNOL, V150, P2724; SHASTRI N, 1995, J BIOL CHEM, V270, P1088, DOI 10.1074/jbc.270.3.1088; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1984, CELL, V39, P13, DOI 10.1016/0092-8674(84)90187-9; UDAKA K, 1993, P NATL ACAD SCI USA, V90, P11272, DOI 10.1073/pnas.90.23.11272; URBAN RG, 1994, P NATL ACAD SCI USA, V91, P1534, DOI 10.1073/pnas.91.4.1534; VANBLEEK GM, 1990, NATURE, V348, P213; VANKAER L, 1994, IMMUNITY, V1, P533, DOI 10.1016/1074-7613(94)90043-4; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; YANG Y, 1992, P NATL ACAD SCI USA, V89, P4928, DOI 10.1073/pnas.89.11.4928; YEWDELL J, 1994, J IMMUNOL, V152, P1163; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5; ZWEERINK HJ, 1993, J IMMUNOL, V150, P1763	66	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6515	6522		10.1074/jbc.270.12.6515	http://dx.doi.org/10.1074/jbc.270.12.6515			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896786	hybrid			2022-12-25	WOS:A1995QQ85500016
J	FLINK, IL; MORKIN, E				FLINK, IL; MORKIN, E			ALTERNATIVELY PROCESSED ISOFORMS OF CELLULAR NUCLEIC ACID-BINDING PROTEIN INTERACT WITH A SUPPRESSOR REGION OF THE HUMAN BETA-MYOSIN HEAVY-CHAIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-ACTING ELEMENT; MESSENGER-RNA; VENTRICULAR MYOCARDIUM; FINGER PROTEIN; CARDIAC-MUSCLE; ALPHA-MYOSIN; DNA; EXPRESSION; HEART; IDENTIFICATION	Analysis of a series of human beta-myosin heavy chain (MHC) constructs with progressive deletions in the 5'-flanking region has localized a strong positive element at positions -298/-277 with a repressor region located immediately upstream at -332/-300 (FLink, I. L., Edwards, J. G., Bahl, J. J., Liew, C.-C., Sole, M., and Morkin, E. (1992) J. Biol. Chem. 267, 9917-9924). A 49-base pair restriction fragment containing the suppressor element was used to screen a cardiac expression library. The 0.65-kilobase pair cDNA identified by this procedure was similar in sequence, except for the absence of a 21-base pair region encoding seven amino acids, to cellular nucleic acid-binding protein (CNBP), a 19-kDa zinc finger DNA-binding protein isolated earlier from liver, which may be involved in negative regulation of cholesterol biosynthesis (Rajavashisth, T. B., Taylor, A. K., Andalibi, A., Svenson, K. L., and Lusis, A. J. (1989) Science 245, 640-643). An additional clone identical to the one originally found in liver, referred to as CNBP alpha, was isolated from the cardiac library by hybridization screening. Gel mobility shift analysis indicated that CNBP alpha and CNBP beta isoforms preferentially interact with single-stranded DNA corresponding to the proximal and distal regions of the suppressor. When cotransfected with a beta-MHC reporter construct, CNBP alpha repressed activity in a dosage-dependent manner, whereas repression was not observed with the shorter construct (CNBP beta). Cotransfection of a combination of CNBP alpha and CNBP beta repressed reporter activity to an extent similar to cotransfection with CNBP alpha alone, suggesting that CNBP beta is not translationally active under these conditions. The results of RNase protection assays and genomic sequencing indicated that the alpha and beta isoforms are formed by alternative use of 5' donor sites within a single exon. These results suggest that CNBP isoforms may modulate the activity of the beta-MHC gene by interaction with a repressor region.	UNIV ARIZONA,CTR HEART,TUCSON,AZ 85724; UNIV ARIZONA,DEPT INTERNAL MED,TUCSON,AZ 85724; UNIV ARIZONA,DEPT PHYSIOL,TUCSON,AZ 85724; UNIV ARIZONA,DEPT PHARMACOL,TUCSON,AZ 85724	University of Arizona; University of Arizona; University of Arizona; University of Arizona					NHLBI NIH HHS [P01 HL20984] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020984] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOUVAGNET P, 1984, CIRC RES, V55, P794, DOI 10.1161/01.RES.55.6.794; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COVEY SN, 1986, NUCLEIC ACIDS RES, V14, P623, DOI 10.1093/nar/14.2.623; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; EDWARDS JG, 1994, BIOCHEM BIOPH RES CO, V199, P1482, DOI 10.1006/bbrc.1994.1398; EDWARDS JG, 1992, BIOCHEM BIOPH RES CO, V189, P504, DOI 10.1016/0006-291X(92)91586-F; EMERSON CP, 1987, ANNU REV BIOCHEM, V56, P695, DOI 10.1146/annurev.bi.56.070187.003403; EPERON LP, 1986, NATURE, V324, P280, DOI 10.1038/324280a0; EVANS SM, 1991, J CELL BIOCHEM     S, V15, P194; EVERETT AW, 1984, BIOCHEMISTRY-US, V23, P1596, DOI 10.1021/bi00303a002; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FLINK IL, 1992, J BIOL CHEM, V267, P9917; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORZA L, 1984, CIRC RES, V54, P694, DOI 10.1161/01.RES.54.6.694; GREEN M, 1992, ANN REV CELL BIOL, V7, P559; KOTHEKAR V, 1990, FEBS LETT, V274, P217, DOI 10.1016/0014-5793(90)81367-W; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LIEW CC, 1990, NUCLEIC ACIDS RES, V18, P3647, DOI 10.1093/nar/18.12.3647; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; LUSIS AJ, 1990, GENOMICS, V8, P411, DOI 10.1016/0888-7543(90)90303-C; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; MAHDAVI V, 1986, UCLA S MOL CELL BIOL, V29, P345; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MARDON HJ, 1987, NUCLEIC ACIDS RES, V15, P7725, DOI 10.1093/nar/15.19.7725; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; MORKIN E, 1993, CIRCULATION, V87, P1451, DOI 10.1161/01.CIR.87.5.1451; OSBORNE TF, 1992, J BIOL CHEM, V267, P18973; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PERIASAMY M, 1984, J BIOL CHEM, V259, P3573; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; SATO SM, 1991, DEVELOPMENT, V112, P747; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; TAKECHI H, 1994, MOL CELL BIOL, V14, P567, DOI 10.1128/MCB.14.1.567; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; XU HP, 1992, MOL BIOL CELL, V3, P721, DOI 10.1091/mbc.3.7.721; YU YT, 1989, MOL CELL BIOL, V9, P1839, DOI 10.1128/MCB.9.5.1839	41	62	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6959	6965		10.1074/jbc.270.12.6959	http://dx.doi.org/10.1074/jbc.270.12.6959			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896846				2022-12-25	WOS:A1995QQ85500077
J	KNAB, AM; FERTALA, J; BJORNSTI, MA				KNAB, AM; FERTALA, J; BJORNSTI, MA			A CAMPTOTHECIN-RESISTANT DNA TOPOISOMERASE-I MUTANT EXHIBITS ALTERED SENSITIVITIES TO OTHER DNA TOPOISOMERASE POISONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE TYROSINE; ANTITUMOR AGENT; CYTO-TOXICITY; CELL-CYCLE; CLEAVAGE; YEAST; INDUCTION; ANALOGS; REPLICATION; DERIVATIVES	The cytotoxic plant alkaloid camptothecin promotes DNA topoisomerase I-linked nicks in DNA by stabilizing a covalently bound enzyme-DNA complex. In the yeast Saccharomyces cerevisiae, substitution of Arg and Ala for the amino acid residues immediately N-terminal to the active site tyrosine in the yeast and human DNA topoisomerase I mutants, top1 vac, results in camptothecin resistance. To examine the mechanism of drug resistance, we assessed the sensitivity of these enzymes to several classes of DNA topoisomerase poisons, Yeast cells expressing the camptothecin-resistant top1 vac mutants were resistant to all of the camptothecin derivatives cytotoxic to wild-type TOP1-expressing cells. This correlated with a significant reduction in drug-induced DNA cleavage in vitro. However, the yeast and human mutant enzymes differed in their responses to the minor groove binding ligand netropsin and to saintopin, a DNA intercalator that targets both DNA topoisomerase I and II. The yeast mutant enzyme demonstrated enhanced sensitivity to the action of saintopin but was resistant to the inhibitory effects of netropsin. In contrast, the human Top1 vac enzyme was resistant to saintopin and indistinguishable from the wild-type enzyme in its response to the netropsin, These results are discussed in terms of enzyme function and the different modes of action of these DNA topoisomerase poisons.	THOMAS JEFFERSON UNIV,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107	Jefferson University					NATIONAL CANCER INSTITUTE [R01CA058755] Funding Source: NIH RePORTER; NCI NIH HHS [CA58755] Funding Source: Medline; NIGMS NIH HHS [GM44810] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN AH, 1985, NUCLEIC ACIDS RES, V13, P1543, DOI 10.1093/nar/13.5.1543; BENEDETTI P, 1993, CANCER RES, V53, P4343; BJORNSTI MA, 1987, P NATL ACAD SCI USA, V84, P8971, DOI 10.1073/pnas.84.24.8971; BJORNSTI MA, 1989, CANCER RES, V49, P6318; BJORNSTI MA, 1994, CANCER CHEMOTHER PHA, V34, P51; Bjornsti MA, 1991, CURR OPIN STRUC BIOL, V1, P99, DOI 10.1016/0959-440X(91)90017-N; BOROS I, 1984, GENE, V30, P257, DOI 10.1016/0378-1119(84)90130-6; CHAMPOUX JJ, 1989, J BIOL CHEM, V264, P1010; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; CHEN AY, 1993, CANCER RES, V53, P1332; CHEN AY, 1993, P NATL ACAD SCI USA, V90, P8131, DOI 10.1073/pnas.90.17.8131; DARPA P, 1990, CANCER RES, V50, P6919; DELBINO G, 1990, CANCER RES, V50, P5746; ENG WK, 1988, MOL PHARMACOL, V34, P755; FUJII N, 1993, J BIOL CHEM, V268, P13160; GIOVANELLA BC, 1989, SCIENCE, V246, P1046, DOI 10.1126/science.2555920; GUPTA M, 1992, J BIOL CHEM, V269, P573; HERTZBERG RP, 1990, J BIOL CHEM, V265, P19287; HOLM C, 1989, CANCER RES, V49, P6365; HORWITZ MS, 1971, BIOCHEM BIOPH RES CO, V45, P723; HOUGHTON PJ, 1993, CANCER RES, V53, P2823; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; HSIANG YH, 1989, CANCER RES, V49, P4385; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAXEL C, 1991, J BIOL CHEM, V266, P20418; KINGSBURY WD, 1991, J MED CHEM, V34, P98, DOI 10.1021/jm00105a017; KNAB AM, 1993, J BIOL CHEM, V268, P22322; LETEURTRE F, 1994, J BIOL CHEM, V269, P28702; LEVIN NA, 1993, GENETICS, V133, P799; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; PODDEVIN B, 1993, MOL PHARMACOL, V44, P767; POTMESIL M, 1994, CANCER RES, V54, P1431; POTMESIL M, 1991, DNA TOPOISOMERASES C, P299; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P9793, DOI 10.1073/pnas.86.24.9793; SNOUNOU G, 1983, J MOL BIOL, V167, P211, DOI 10.1016/S0022-2836(83)80043-6; WALL ME, 1991, DNA TOPOISOMERASES C, P93; Wang J. C., 1990, DNA TOPOLOGY ITS BIO, P321; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WANI MC, 1987, J MED CHEM, V30, P1774, DOI 10.1021/jm00393a016; YAMASHITA Y, 1991, BIOCHEMISTRY-US, V30, P5838, DOI 10.1021/bi00238a005; YAMASHITA Y, 1992, BIOCHEMISTRY-US, V31, P12069, DOI 10.1021/bi00163a015	45	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					6141	6148		10.1074/jbc.270.11.6141	http://dx.doi.org/10.1074/jbc.270.11.6141			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890748	hybrid			2022-12-25	WOS:A1995QM94500064
J	MATLACK, KES; WALTER, P				MATLACK, KES; WALTER, P			THE 70 CARBOXYL-TERMINAL AMINO-ACIDS OF NASCENT SECRETORY PROTEINS ARE PROTECTED FROM PROTEOLYSIS BY THE RIBOSOME AND THE PROTEIN TRANSLOCATION APPARATUS OF THE ENDOPLASMIC-RETICULUM MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOGNITION PARTICLE RECEPTOR; IMMUNOGLOBULIN LIGHT-CHAINS; MICROSOMAL MEMBRANE; PHOTOCROSS-LINKING; SIGNAL SEQUENCE; ER; INSERTION; COMPLEX; SEC61P; IDENTIFICATION	We have used proteolysis to examine the environment through which nascent secretory proteins are translocated across the membrane of the endoplasmic reticulum. After solubilization of rough microsomes with detergent, fragments comprised of the approximately 70 carboxyl-terminal amino acids of translocating nascent chains initiated and targeted in vivo were protected from digestion by added proteases. About 40 amino acids of nascent chains were protected from proteolysis by the ribosome; thus, membrane-derived components protect an additional 30 amino acids, Under conditions in which those 30 additional amino acids are protected, only a small set of integral membrane proteins remained associated with the ribosome. These proteins include the Sec61 complex previously identified as the core component of the membrane-bound protein translocation apparatus, These results support the concept of a translocation pore that makes intimate contact with the ribosome and thereby protects nascent chains from proteolytic digestion for an additional, constant length.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco								BERGMAN LW, 1979, J BIOL CHEM, V254, P8869; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GLABE CG, 1980, J BIOL CHEM, V255, P9236; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HARTMANN E, 1993, EUR J BIOCHEM, V214, P375, DOI 10.1111/j.1432-1033.1993.tb17933.x; HELENIUS A, 1975, BIOCHIM BIOPHYS ACTA, V415, P29, DOI 10.1016/0304-4157(75)90016-7; HIGH S, 1993, J CELL BIOL, V121, P743, DOI 10.1083/jcb.121.4.743; HIGH S, 1991, J CELL BIOL, V113, P25, DOI 10.1083/jcb.113.1.25; HIGH S, 1993, J BIOL CHEM, V268, P26745; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KUHN LA, 1985, BIOCHIM BIOPHYS ACTA, V828, P351, DOI 10.1016/0167-4838(85)90316-4; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; MAURER HR, 1972, Z KLIN CHEM KLIN BIO, V10, P220; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHEELE G, 1980, J CELL BIOL, V87, P611, DOI 10.1083/jcb.87.3.611; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; TAJIMA S, 1986, J CELL BIOL, V103, P1167, DOI 10.1083/jcb.103.4.1167; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WIEDMANN M, 1989, FEBS LETT, V257, P263, DOI 10.1016/0014-5793(89)81549-2; YOSHIDA H, 1987, BIOCHEM J, V245, P811, DOI 10.1042/bj2450811	36	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					6170	6180		10.1074/jbc.270.11.6170	http://dx.doi.org/10.1074/jbc.270.11.6170			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890751	hybrid			2022-12-25	WOS:A1995QM94500068
J	PEREZSALA, D; COLLADOESCOBAR, D; MOLLINEDO, F				PEREZSALA, D; COLLADOESCOBAR, D; MOLLINEDO, F			INTRACELLULAR ALKALINIZATION SUPPRESSES LOVASTATIN-INDUCED APOPTOSIS IN HL-60 CELLS THROUGH THE INACTIVATION OF A PH-DEPENDENT ENDONUCLEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; PROTEIN-KINASE-C; TUMOR-NECROSIS-FACTOR; NA+/H+ ANTIPORT; ISOPRENOID METABOLISM; SIGNAL-TRANSDUCTION; DNA FRAGMENTATION; U937 CELLS; ACTIVATION; DEATH	Protein isoprenylation is a post-translational modification essential for the biological activity of G-proteins. Inhibition of protein isoprenylation by lovastatin (LOV) induces apoptosis in HL-60 cells, a process of active cell death characterized by the internucleosomal degradation of genomic DNA. In this article we show that LOV-induced apoptosis is associated with intracellular acidification and that activation of the Na+/H+ antiporter induces a raise in pH(i) which is sufficient to prevent or arrest DNA digestion. First, LOV induced a decrease in pH(i) which was dose-dependent and correlated with the extent of DNA degradation, Flow cytometry analysis revealed that this acidification was due to the appearance of a subpopulation of cells whose pH(i) was 0.9 pH units below control values, Cell sorting experiments demonstrated that DNA degradation had occurred only in those cells which had suffered intracellular acidification, LOV-induced apoptosis could be suppressed by me valonate supplementation, inhibition of protein synthesis, and protein kinase C activation by phorbol myristate acetate, In all three cases, intracellular acidification was abolished. Inhibition of the Na+/H+ antiporter by 5-N-ethyl-N-isopropyl amiloride induced DNA degradation in HL-60 cells per se and suppressed the protective effect of phorbol myristate acetate, LOV-induced intracellular acidification was not due to a complete inhibition of the Na+/H+ antiporter, In fact, LOV-treated cells were able to respond to phorbol myristate acetate stimulation of the Na+/H+ antiporter with a marked increase in pH,. This effect was accompanied by a rapid arrest of DNA digestion, These observations illustrate the strong pH dependence of LOV-induced DNA degradation, thus providing a connection between the activation of the Na+/H+ antiporter and the suppression of apoptosis.	CSIC,INST LOPEZ NEYRA,GRANADA,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN)	PEREZSALA, D (corresponding author), CSIC,CTR INVEST BIOL,C VELAZQUEZ 144,E-28006 MADRID,SPAIN.		Perez-Sala, Dolores/L-5969-2014	Perez-Sala, Dolores/0000-0003-0600-665X				AIHARA H, 1991, P NATL ACAD SCI USA, V88, P11062, DOI 10.1073/pnas.88.24.11062; ALVAREZ J, 1989, EUR J BIOCHEM, V183, P709, DOI 10.1111/j.1432-1033.1989.tb21102.x; ARELLANO R, 1993, FEBS LETT, V332, P247, DOI 10.1016/0014-5793(93)80642-8; BARBER DL, 1992, J BIOL CHEM, V267, P20607; BARRY MA, 1993, CANCER RES, V53, P2349; BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; BARRY MA, 1992, BIOCHEM BIOPH RES CO, V186, P782, DOI 10.1016/0006-291X(92)90814-2; BOKOCH GM, 1992, J CLIN INVEST, V89, P402, DOI 10.1172/JCI115599; CACERESCORTES J, 1994, J BIOL CHEM, V269, P12084; CASEY PJ, 1992, J LIPID RES, V33, P1731; COHEN JJ, 1984, J IMMUNOL, V132, P38; COLLINS MKL, 1993, TRENDS BIOCHEM SCI, V18, P307, DOI 10.1016/0968-0004(93)90042-L; CUTTS JL, 1989, J CELL PHYSIOL, V139, P550, DOI 10.1002/jcp.1041390314; DEANIN GG, 1991, J IMMUNOL, V146, P3528; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; FENTON RG, 1992, J CELL BIOL, V117, P347, DOI 10.1083/jcb.117.2.347; FLIEGEL L, 1993, BIOCHEM J, V296, P273, DOI 10.1042/bj2960273; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GONG JP, 1993, J CELL PHYSIOL, V157, P263; GREENBLATT MS, 1992, BLOOD, V80, P1339; JAKOBISIAK M, 1991, P NATL ACAD SCI USA, V88, P3628, DOI 10.1073/pnas.88.9.3628; KITA T, 1980, J CLIN INVEST, V66, P1094, DOI 10.1172/JCI109938; LADOUX A, 1988, EUR J BIOCHEM, V175, P455, DOI 10.1111/j.1432-1033.1988.tb14216.x; LALLEMAIN G, 1984, J BIOL CHEM, V259, P5809; LASTER SM, 1988, J IMMUNOL, V141, P2629; Lee S, 1993, CURR OPIN CELL BIOL, V5, P286, DOI 10.1016/0955-0674(93)90118-A; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; LI GD, 1993, BIOCHEM J, V289, P379, DOI 10.1042/bj2890379; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MOLENAAR WH, 1983, NATURE, V304, P645; MUSGROVE E, 1986, CYTOMETRY, V7, P347, DOI 10.1002/cyto.990070409; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; NG LL, 1991, AM J PHYSIOL, V261, pC780, DOI 10.1152/ajpcell.1991.261.5.C780; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; PEREZSALA D, 1994, BIOCHEM BIOPH RES CO, V199, P1209, DOI 10.1006/bbrc.1994.1359; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAJOTTE D, 1992, J BIOL CHEM, V267, P9980; RESTREPO D, 1988, J GEN PHYSIOL, V92, P489, DOI 10.1085/jgp.92.4.489; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SIFFERT W, 1990, J BIOL CHEM, V265, P15441; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; VAIRO G, 1992, J BIOL CHEM, V267, P19043; VALLANCE SJ, 1990, BIOCHEM J, V265, P359, DOI 10.1042/bj2650359; VAUX DL, 1993, MOL CELL BIOL, V13, P7000, DOI 10.1128/MCB.13.11.7000; VIGNE P, 1983, BIOCHEM BIOPH RES CO, V116, P86, DOI 10.1016/0006-291X(83)90384-4; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G	50	292	302	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					6235	6242		10.1074/jbc.270.11.6235	http://dx.doi.org/10.1074/jbc.270.11.6235			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890761	Green Submitted, hybrid			2022-12-25	WOS:A1995QM94500078
J	SPITZNER, JR; CHUNG, IK; MULLER, MT				SPITZNER, JR; CHUNG, IK; MULLER, MT			DETERMINATION OF 5' AND 3' DNA TRIPLEX INTERFERENCE BOUNDARIES REVEALS THE CORE DNA-BINDING SEQUENCE FOR TOPOISOMERASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED DNA; DOUBLE-HELICAL DNA; EUKARYOTIC TOPOISOMERASE; ANTITUMOR DRUGS; CLEAVAGE SITES; GENOMIC DNA; SINGLE-SITE; INHIBITION; YEAST; TRANSCRIPTION	Previous studies have shown that formation of intermolecular DNA triplexes at sequences that overlap protein binding sites inhibits DNA binding by these proteins. We show that DNA cleavage by eukaryotic topoisomerase II is blocked by tripler formation at sites overlapping and adjacent to the triple binding site. To map precisely the boundaries of tripler interference, we constructed a vector containing enzyme binding sites of different lengths and flanked both 5' and 3' by DNA triplexes. We call this method Tripler Interference Mapping by Binding Element Replacement (TIMBER). Triplex regions within 3 bases 5' or 7 bases 3' of cleavage sites blocked DNA cleavage; tripler formation outside of this region had no effect upon cleavage activity. We conclude that topoisomerase II binding requires unhindered access to the major groove of a duplex DNA binding site in this 10-base region. In addition, the inclusion of topoisomerase II inhibitors yielded the same results for the tripler interference assays despite alterations in DNA cleavage site selection. The statistical analyses of over 500 topoisomerase II cleavage sites (in the presence or absence of inhibitors) suggest a model consistent with the region spanning -3 to +7 (relative to the cleavage site) containing most of the base-specific contacts for topoisomerase II. This tripler interference assay may prove valuable in the characterization of DNA binding sites for other proteins as well, particularly in conjunction with deletion analysis.	OHIO STATE UNIV, DEPT MOLEC GENET, COLUMBUS, OH 43210 USA	Ohio State University					NIAID NIH HHS [AI128362] Funding Source: Medline; NIGMS NIH HHS [GM-14335] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI128362] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014335] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOOTHMAN DA, 1989, CANCER RES, V49, P605; CAPRANICO G, 1990, NUCLEIC ACIDS RES, V18, P6611, DOI 10.1093/nar/18.22.6611; CAPRANICO G, 1990, BIOCHEMISTRY-US, V29, P562, DOI 10.1021/bi00454a033; CAPRANICO G, 1994, J MOL BIOL, V235, P1218, DOI 10.1006/jmbi.1994.1075; CHEN GL, 1984, J BIOL CHEM, V259, P3560; CHUNG IK, 1993, MOLECULAR BIOLOGY OF DNA TOPOISOMERASES AND ITS APPLICATION CHEMOTHERAPY, P105; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DARPA P, 1989, BIOCHIM BIOPHYS ACTA, V989, P163, DOI 10.1016/0304-419X(89)90041-3; DIDONATO JA, 1991, J MOL BIOL, V219, P451, DOI 10.1016/0022-2836(91)90186-A; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DUVALVALENTIN G, 1992, P NATL ACAD SCI USA, V89, P504, DOI 10.1073/pnas.89.2.504; FOSSE P, 1991, NUCLEIC ACIDS RES, V19, P2861, DOI 10.1093/nar/19.11.2861; FRANCOIS JC, 1989, J BIOL CHEM, V264, P5891; Gootz Thomas D., 1993, P139; HANVEY JC, 1990, NUCLEIC ACIDS RES, V18, P157, DOI 10.1093/nar/18.1.157; HARTMAN DA, 1992, J BIOL CHEM, V267, P5488; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HUANG CC, 1992, BIOCHEMISTRY-US, V31, P993, DOI 10.1021/bi00119a007; KIESSLING LL, 1992, BIOCHEMISTRY-US, V31, P2829, DOI 10.1021/bi00125a026; LEDOAN T, 1987, NUCLEIC ACIDS RES, V15, P8643, DOI 10.1093/nar/15.21.8643; LEE MP, 1989, J BIOL CHEM, V264, P21779; LUND K, 1990, J BIOL CHEM, V265, P13856; LYAMICHEV VI, 1988, NUCLEIC ACIDS RES, V16, P2165, DOI 10.1093/nar/16.5.2165; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; MULLER MT, 1988, BIOCHEMISTRY-US, V27, P8369, DOI 10.1021/bi00422a012; NELSON EM, 1984, P NATL ACAD SCI-BIOL, V81, P1361, DOI 10.1073/pnas.81.5.1361; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; POMMIER Y, 1991, NUCLEIC ACIDS RES, V19, P5973, DOI 10.1093/nar/19.21.5973; POMMIER Y, 1991, J MOL BIOL, V222, P909, DOI 10.1016/0022-2836(91)90585-T; POVSIC TJ, 1990, J AM CHEM SOC, V112, P9428, DOI 10.1021/ja00181a075; PRASEUTH D, 1988, P NATL ACAD SCI USA, V85, P1349, DOI 10.1073/pnas.85.5.1349; RAJAGOPAL P, 1989, BIOCHEMISTRY-US, V28, P7859, DOI 10.1021/bi00445a048; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; ROY C, 1993, NUCLEIC ACIDS RES, V21, P2845, DOI 10.1093/nar/21.12.2845; Sambrook J, 1989, MOL CLONING LABORATO; SANDER M, 1985, NUCLEIC ACIDS RES, V13, P1057, DOI 10.1093/nar/13.4.1057; SPITZLEY T, 1989, RATIO, V2, P63, DOI 10.1111/j.1467-9329.1989.tb00127.x; SPITZNER JR, 1988, NUCLEIC ACIDS RES, V16, P5533, DOI 10.1093/nar/16.12.5533; SPITZNER JR, 1990, NUCLEIC ACIDS RES, V18, P1, DOI 10.1093/nar/18.1.1; STORMO GD, 1990, METHOD ENZYMOL, V183, P211; STORMO GD, 1988, ANNU REV BIOPHYS BIO, V17, P241; STROBEL SA, 1991, NATURE, V350, P172, DOI 10.1038/350172a0; STROBEL SA, 1988, J AM CHEM SOC, V110, P7927, DOI 10.1021/ja00231a082; STROBEL SA, 1990, SCIENCE, V249, P73, DOI 10.1126/science.2195655; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; ZECHIEDRICH EL, 1989, BIOCHEMISTRY-US, V28, P6229, DOI 10.1021/bi00441a014	49	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					5932	5943		10.1074/jbc.270.11.5932	http://dx.doi.org/10.1074/jbc.270.11.5932			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890724	hybrid			2022-12-25	WOS:A1995QM94500037
J	BHANDARI, B; WENZEL, UO; MARRA, F; ABBOUD, HE				BHANDARI, B; WENZEL, UO; MARRA, F; ABBOUD, HE			A NUCLEAR-PROTEIN IN MESANGIAL CELLS THAT BINDS TO THE PROMOTER REGION OF THE PLATELET-DERIVED GROWTH FACTOR-A CHAIN GENE - INDUCTION BY PHORBOL ESTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROVASCULAR ENDOTHELIAL-CELLS; NF-KAPPA-B; MAJOR HISTOCOMPATIBILITY COMPLEX; GLUTAMINE-SYNTHETASE GENE; VIRUS TYPE-1 ENHANCER; SMOOTH-MUSCLE CELLS; TRANSCRIPTION FACTOR; MESSENGER-RNAS; EXPRESSION; SEQUENCE	Mesangial cells predominantly express platelet-derived growth factor (PDGF)-A chain mRNA and release PDGF. Mesangial cell PDGF-A chain mRNA abundance is regulated by several agents including phorbol esters. We have recently demonstrated that induction of PDGF-A chain mRNA abundance in response to phorbol 12-myristate 13-acetate is primarily due to gene transcription. We have now analyzed the 5'-flanking region of the PDGF-A chain promoter to identify DNA binding protein(s) which have the potential to regulate PDGF-A chain gene transcription in human mesangial cells. DNase I footprint analysis of the 5'-flanking region of the PDGF-A chain promoter identifies a DNase I protected region at the location -82 to -102 corresponding to the sequence 5'-GGCCCGGAATCCGGGGGAGGC-3'. Therefore, nuclear extracts from human mesangial cells contain a protein, PDGF-A-BP-1, that binds to a DNA sequence (-82 to -102) in the promoter region of the PDGF-A chain gene. Gel mobility shift analysis using labeled oligomer corresponding to the binding site for PDGF-A-BP-1 indicates that PDGF-A-BP-1 is induced by phorbol ester in mesangial cells as well as fat-storing cells (>20 fold). Egr-1. protein does not bind to labeled PDGF-A-BP-1 oligomer and does not compete with the binding of PDGF-A-BP-1. In addition, SP-1 binding sequence does not compete with the binding sequence of the mesangial cell protein. PDGF-A-BP-1 appears to represent a novel protein which is induced by phorbol ester and thus has the potential for an important role in the transcriptional regulation of the PDGF-A chain gene in mesangial cells and other vascular pericytes.	AUDIE L MURPHY MEM VET ADM MED CTR,SAN ANTONIO,TX 78284	US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	BHANDARI, B (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT MED,DIV NEPHROL,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.		Marra, Fabio/K-7263-2016	Marra, Fabio/0000-0001-8629-0878	NIDDK NIH HHS [DK 43988] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043988] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDWIN AS, 1990, MOL CELL BIOL, V10, P1406, DOI 10.1128/MCB.10.4.1406; BHANDARI B, 1993, MOL CELL ENDOCRINOL, V91, P185, DOI 10.1016/0303-7207(93)90271-K; BHANDARI B, 1988, P NATL ACAD SCI USA, V85, P5789, DOI 10.1073/pnas.85.16.5789; BHANDARI B, 1991, J BIOL CHEM, V266, P7784; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; DANIEL TO, 1986, J BIOL CHEM, V261, P9579; DAYNES RA, 1991, J EXP MED, V174, P1323, DOI 10.1084/jem.174.6.1323; DESCHEEMAEKER KA, 1992, J BIOL CHEM, V267, P15086; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; GALLINARI P, 1989, MOL CELL BIOL, V9, P1566, DOI 10.1128/MCB.9.4.1566; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; HAHN AWA, 1993, J VASC RES, V30, P192, DOI 10.1159/000158994; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HENSELING U, 1990, MOL CELL BIOL, V10, P4100, DOI 10.1128/MCB.10.8.4100; HUTCHINS JB, 1992, DEV BRAIN RES, V67, P121, DOI 10.1016/0165-3806(92)90213-G; KAVANAUGH WM, 1988, J BIOL CHEM, V263, P8470; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KNAUSS TC, 1990, J BIOL CHEM, V265, P14457; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LENARDO M, 1989, EMBO J, V8, P3351, DOI 10.1002/j.1460-2075.1989.tb08497.x; MAEKAWA T, 1989, J BIOL CHEM, V264, P14591; MARRA F, 1993, J CLIN INVEST, V92, P1674, DOI 10.1172/JCI116753; MERCOLA M, 1990, DEV BIOL, V138, P114, DOI 10.1016/0012-1606(90)90181-H; ORRURTREGER A, 1992, DEVELOPMENT, V115, P289; RON D, 1991, MOL CELL BIOL, V11, P2887, DOI 10.1128/MCB.11.5.2887; RUSTGI AK, 1990, P NATL ACAD SCI USA, V87, P8707, DOI 10.1073/pnas.87.22.8707; Sambrook J, 1989, MOL CLONING LABORATO; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P959, DOI 10.1128/MCB.9.3.959; SHULTZ PJ, 1988, AM J PHYSIOL, V255, pF674, DOI 10.1152/ajprenal.1988.255.4.F674; SILVER BJ, 1989, P NATL ACAD SCI USA, V85, P1056; STARKSEN NF, 1987, J BIOL CHEM, V262, P14381; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SUVA LJ, 1991, MOL CELL BIOL, V11, P2503, DOI 10.1128/MCB.11.5.2503; TAKIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P1686, DOI 10.1073/pnas.88.5.1686; WANG ZY, 1992, J BIOL CHEM, V267, P13669; WANG ZY, 1992, J BIOL CHEM, V267, P17022; WU FK, 1988, EMBO J, V7, P2117, DOI 10.1002/j.1460-2075.1988.tb03051.x; YEB HJ, 1991, CELL, V64, P209; ZWIJSEN RML, 1992, BIOCHEM BIOPH RES CO, V186, P1410, DOI 10.1016/S0006-291X(05)81563-3	44	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5541	5548		10.1074/jbc.270.10.5541	http://dx.doi.org/10.1074/jbc.270.10.5541			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890673	hybrid			2022-12-25	WOS:A1995QL58000089
J	CHOI, KY; LU, F; ZALKIN, H				CHOI, KY; LU, F; ZALKIN, H			MUTAGENESIS OF AMINO-ACID-RESIDUES REQUIRED FOR BINDING OF COREPRESSORS TO THE PURINE REPRESSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; FUNCTIONAL SIMILARITY; REGULON REPRESSOR; GENE-EXPRESSION; LAC REPRESSOR; D-GALACTOSE; L-ARABINOSE; D-RIBOSE; PROTEIN; SEQUENCE	The corepressor binding domain of the Escherichia coli purine repressor (PurR) is homologous with several periplasmic sugar-binding proteins. Four amino acids in PurR were investigated for a role in binding of corepressors. Three of the residues, Asp(146), Arg(196), and Asp(275) conserved in periplasmic binding proteins for ribose, glucose/galactose, and arabinose and function to bind sugars. A fourth amino acid, Trp(147), required for corepressor binding to PurR, corresponds to residues in glucose/galactose, ribose, and arabinose that also have a role in sugar binding. The four mutations that were constructed perturbed the binding of both hypoxanthine and guanine thus providing evidence for a single corepressor site/PurR subunit, The decreased corepressor binding affinity resulted in reduced affinity of mutant repressors for operator DNA in vitro and decreased capacity for repression in vivo. The corepressor-binding site in PurR appears to be similar to the conserved ligand-binding sites in the three periplasmic sugar-binding proteins and in the LacI family of repressors.	PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024658, R01GM024658] Funding Source: NIH RePORTER; NIDDK NIH HHS [P60DK20542] Funding Source: Medline; NIGMS NIH HHS [GM24658] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIN H, 1993, J BACTERIOL, V175, P3598, DOI 10.1128/jb.175.11.3598-3606.1993; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; CHOI KY, 1992, J BACTERIOL, V174, P6207, DOI 10.1128/JB.174.19.6207-6214.1992; CHOI KY, 1990, J BACTERIOL, V172, P3201, DOI 10.1128/jb.172.6.3201-3207.1990; CHOI KY, 1994, J BACTERIOL, V176, P1767, DOI 10.1128/jb.176.6.1767-1772.1994; GROARKE JM, 1983, J BIOL CHEM, V258, P2952; HE B, 1990, J BACTERIOL, V172, P4555, DOI 10.1128/jb.172.8.4555-4562.1990; HE B, 1992, J BACTERIOL, V174, P7121, DOI 10.1128/jb.174.22.7121-7127.1992; HOULBERG U, 1983, J BACTERIOL, V153, P837, DOI 10.1128/JB.153.2.837-845.1983; KILSTRUP M, 1989, J BACTERIOL, V171, P2124, DOI 10.1128/jb.171.4.2124-2127.1989; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; LIU YC, 1993, J BIOL CHEM, V268, P23239; LIU YC, 1994, J BIOL CHEM, V269, P1692; MAHONEY WC, 1981, J BIOL CHEM, V256, P4350; MANIATIS T, 1982, MOL CLONING LABORATO, P464; MAUZY CA, 1992, PROTEIN SCI, V1, P843, DOI 10.1002/pro.5560010702; MENG LM, 1990, MOL MICROBIOL, V4, P2187, DOI 10.1111/j.1365-2958.1990.tb00580.x; MENG LM, 1990, EUR J BIOCHEM, V187, P373, DOI 10.1111/j.1432-1033.1990.tb15314.x; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; MOWBRAY SL, 1992, J MOL BIOL, V227, P418, DOI 10.1016/0022-2836(92)90898-T; ROLFES RJ, 1988, J BIOL CHEM, V263, P19649; ROLFES RJ, 1990, J BACTERIOL, V172, P5758, DOI 10.1128/jb.172.10.5758-5766.1990; ROLFES RJ, 1990, J BACTERIOL, V172, P5637, DOI 10.1128/jb.172.10.5637-5642.1990; SAMS CF, 1984, NATURE, V310, P429, DOI 10.1038/310429a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUMACHER MA, 1993, J BIOL CHEM, V268, P12282; SCRIPTURE JB, 1987, J MOL BIOL, V197, P37, DOI 10.1016/0022-2836(87)90607-3; SPOTTS RO, 1991, J BIOL CHEM, V266, P22998; STEIERT JG, 1990, J BACTERIOL, V172, P3799, DOI 10.1128/jb.172.7.3799-3803.1990; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VYAS NK, 1991, J BIOL CHEM, V266, P5226; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; WILSON HR, 1990, J BACTERIOL, V172, P3208, DOI 10.1128/jb.172.6.3208-3213.1990	36	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24066	24072						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929058				2022-12-25	WOS:A1994PQ34600036
J	CHU, KT; LITTMAN, DR				CHU, KT; LITTMAN, DR			REQUIREMENT FOR KINASE-ACTIVITY OF CD4-ASSOCIATED P56(LCK) IN ANTIBODY-TRIGGERED T-CELL SIGNAL-TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; RECEPTOR ZETA-CHAIN; ANTIGEN RECEPTOR; ALPHA-3 DOMAIN; PHOSPHOLIPASE C-GAMMA-1; THYMOCYTE DEVELOPMENT; NEGATIVE SELECTION; BINDING-SITE; CD4; ACTIVATION	The lymphoid-specific Src family protein tyrosine kinase p56(lck) (Lck) is non-covalently associated with the cytoplasmic tail of CD4 and has an essential role in T cell activation. Engagement of ligand by the T cell antigen receptor (TCR) is followed by rapid tyrosine phosphorylation of several cellular proteins, including phospholipase C gamma 1 (PLC) and the TCR-associated CD3 zeta polypeptides. Tyrosine phosphorylation of PLC gamma 1 results in activation of PLC and subsequent phosphatidylinositol turnover, We have studied the effects of the CD4-associated Lck molecule on TCR-mediated activation of the protein tyrosine kinase (PTK) pathway in a murine T cell hybridoma. Antibodies against CD3 elicited the expected PTK activation, which was enhanced upon co-cross-linking of CD4. In contrast, anti-TCR-alpha beta antibodies had no effect on the PTK pathway unless CD4 was co-cross-linked. Antibody cross-linking of CD4 alone failed to induce the same pattern of tyrosine phosphorylation. Similar results were obtained when a chimeric protein consisting of the extracellular and transmembrane domains of CD4 linked to the intracellular Lck molecule was used in place of CD4. The tyrosine kinase activity of Lck was essential for the activity of the chimeric protein. Cross-linking of the CD4/Lck chimera to a CD8/zeta chimeric molecule also facilitated induction of the PTK pathway with anti-CD8 antibodies. Moreover, the interaction of the two chimeric proteins, either in vitro or in vivo, resulted in tyrosine phosphorylation of CD8/zeta. The effects of CD4/Lck on tyrosine phosphorylation and activation of PLC correlated well with the effects on PTK activation. Our results suggest that the Lck molecule positively regulates the TCR-coupled PTK pathway by phosphorylating tyrosines on the TCR-associated CD3 zeta polypeptides.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco	CHU, KT (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143, USA.							ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ALDRICH CJ, 1991, NATURE, V352, P718, DOI 10.1038/352718a0; ANDERSON SJ, 1992, EMBO J, V11, P4877, DOI 10.1002/j.1460-2075.1992.tb05594.x; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BOLEN JB, 1989, TRENDS BIOCHEM SCI, V14, P404, DOI 10.1016/0968-0004(89)90288-0; CAMBIER JC, 1992, CURR OPIN IMMUNOL, V4, P257, DOI 10.1016/0952-7915(92)90074-O; CAMMAROTA G, 1992, NATURE, V356, P799, DOI 10.1038/356799a0; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHAN AC, 1992, CURR OPIN IMMUNOL, V4, P246, DOI 10.1016/0952-7915(92)90072-M; DIEZOREJAS R, 1994, EMBO J, V13, P90, DOI 10.1002/j.1460-2075.1994.tb06238.x; GASSMANN M, 1992, EUR J IMMUNOL, V22, P283, DOI 10.1002/eji.1830220142; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; INGOLD AL, 1991, NATURE, V352, P721, DOI 10.1038/352721a0; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1991, CURR OPIN IMMUNOL, V3, P287, DOI 10.1016/0952-7915(91)90026-W; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KILLEEN N, 1992, J EXP MED, V176, P89, DOI 10.1084/jem.176.1.89; KILLEEN N, 1993, NATURE, V364, P729, DOI 10.1038/364729a0; KILLEEN N, 1993, PHILOS T ROY SOC B, V342, P25, DOI 10.1098/rstb.1993.0131; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; Ledbetter J A, 1990, Semin Immunol, V2, P99; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LEVIN SD, 1993, J EXP MED, V178, P245, DOI 10.1084/jem.178.1.245; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LUO KX, 1990, MOL CELL BIOL, V10, P5304; MICELI MC, 1993, ADV IMMUNOL, V53, P59, DOI 10.1016/S0065-2776(08)60498-8; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NEWELL MK, 1990, NATURE, V347, P286, DOI 10.1038/347286a0; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PENNINGER J, 1993, SCIENCE, V260, P358, DOI 10.1126/science.8469988; POTTER TA, 1987, J EXP MED, V166, P956, DOI 10.1084/jem.166.4.956; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; SAIZAWA K, 1987, NATURE, V328, P260, DOI 10.1038/328260a0; SALTER RD, 1989, NATURE, V338, P345, DOI 10.1038/338345a0; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SANCHO J, 1992, J BIOL CHEM, V267, P7871; SEFTON BM, 1991, ANNU REV CELL BIOL, V7, P257, DOI 10.1146/annurev.cellbio.7.1.257; Siegel J N, 1991, Semin Immunol, V3, P325; SOULA M, 1992, INT IMMUNOL, V4, P295, DOI 10.1093/intimm/4.2.295; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VONBOEHMER H, 1992, IMMUNOL TODAY, V13, P454, DOI 10.1016/0167-5699(92)90075-I; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0	52	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24095	24101						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929062				2022-12-25	WOS:A1994PQ34600040
J	LEEBLUNDBERG, LMF; SONG, XH; MATHIS, SA				LEEBLUNDBERG, LMF; SONG, XH; MATHIS, SA			FOCAL ADHESION-ASSOCIATED PROTEINS P125(FAK) AND PAXILLIN ARE SUBSTRATES FOR BRADYKININ-STIMULATED TYROSINE PHOSPHORYLATION IN SWISS 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C; ANGIOTENSIN-II; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; FREE CA-2+; BOMBESIN; VASOPRESSIN; FIBROBLASTS; CALCIUM; IDENTIFICATION	In this study we examined the involvement of the focal adhesion-associated proteins p125(FAK) and paxillin as substrates for bradykinin (BK)-stimulated tyrosine phosphorylation in Swiss 3T3 cells and the potential role of protein kinase C and Ca2+ in these events. BK (1 mu M) stimulated tyrosine phosphorylation of p125(FAK) and paxillin. In addition, BK also increased the phosphotyrosine content of the src transformation-associated protein p130. The responses were rapid and transient and peaked at similar to 1 min after BK addition. Furthermore, the responses were dose-dependent with half-maximal effects occurring at 1-10 nM BK. The phosphotyrosine content of p125(FAK), paxillin, and p130 was also increased following stimulation with phorbol 12-myristate 13-acetate (PMA) (0.1 mu M). In contrast, PMA had no effect on the phosphotyrosine content of p125, a Ras-GAP-associated tyrosine phosphoprotein that we recently identified. Long term pretreatment (18 h) of cells with 0.3 mu M PMA partially attenuated BK-stimulated phosphorylation of p125(FAK) but was without effect on phosphorylation of paxillin and Ras-GAP-associated p125. Furthermore, only a small inhibition of BK- and PMA-stimulated phosphorylation of p125(FAK) was observed following pretreatment with 25 mu M BAPTA/AM. In all, these results show that multiple mechanisms are involved in BK-stimulated tyrosine phosphorylation of p1Z5(FAK), paxillin, Ras-GAP-associated p125, and are transformation-associated p130.			LEEBLUNDBERG, LMF (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041659, R29GM041659] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41659] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BORNER C, 1992, J BIOL CHEM, V267, P12892; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; FORCE T, 1991, J BIOL CHEM, V266, P6650; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GOMEZCAMBRONERO J, 1991, J BIOL CHEM, V266, P6240; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HESLOP JP, 1986, CELL, V47, P703, DOI 10.1016/0092-8674(86)90513-1; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; ISSANDOU M, 1990, J BIOL CHEM, V265, P11890; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LEE KM, 1993, J BIOL CHEM, V268, P9945; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LEEBLUNDBERG LMF, 1993, J BIOL CHEM, V268, P8151; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; LOPEZRIVAS A, 1987, P NATL ACAD SCI USA, V84, P5768, DOI 10.1073/pnas.84.16.5768; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MALGAROLI A, 1987, J CELL BIOL, V105, P2145, DOI 10.1083/jcb.105.5.2145; MCALLISTER BS, 1993, ARCH BIOCHEM BIOPHYS, V304, P294, DOI 10.1006/abbi.1993.1352; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MILLAR JBA, 1990, J BIOL CHEM, V265, P19973; MONCK JR, 1988, J BIOL CHEM, V263, P4569; MUNOZ CM, 1992, ARCH BIOCHEM BIOPHYS, V301, P336; OLIVIER AR, 1992, J CELL PHYSIOL, V152, P240, DOI 10.1002/jcp.1041520204; OLSEN R, 1988, J BIOL CHEM, V263, P18030; PANDIELLA A, 1989, J BIOL CHEM, V264, P3122; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; TAKAYAMA H, 1991, BIOCHEM BIOPH RES CO, V174, P922, DOI 10.1016/0006-291X(91)91506-8; TSUDA T, 1991, FEBS LETT, V285, P44, DOI 10.1016/0014-5793(91)80721-E; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911; WILKINSON SE, 1994, TRENDS PHARMACOL SCI, V15, P53, DOI 10.1016/0165-6147(94)90110-4; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	52	89	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24328	24334						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929090				2022-12-25	WOS:A1994PQ34600074
J	PERLMAN, KL; PRAHL, JM; SMITH, C; KUTNER, A; DELUCA, HF				PERLMAN, KL; PRAHL, JM; SMITH, C; KUTNER, A; DELUCA, HF			26,27-DIHOMO-1-ALPHA-HYDROXY-VITAMIN-D-2 AND 26,27-DIHOMO-24-EPI-1-ALPHA,25-DIHYDROXYVITAMIN-D-2 ANALOGS THAT DIFFER MARKEDLY IN BIOLOGICAL-ACTIVITY IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-D; METABOLISM; RATS; 1,25-DIHYDROXYCHOLECALCIFEROL; RECEPTOR; CALCIUM	26,27-Dihomo-1 alpha-hydroxyvitamin D-2, 26,27-dihomo-24-epi-1 alpha-hydroxyvitamin D-2, and 26,27-dihomo-24-epi-1 alpha,25-dihydroxyvitamin D-2 have been synthesized. In contrast to 1 alpha-hydroxyvitamin D-2 and 24-epi-1 alpha-hydroxyvitamin D-2, 26,27-dihomo-1 alpha-hydroxyvitamin D-2 (1) and the 24-epi analog (2) have no activity in intestinal calcium transport, bone calcium mobilization, or skeleton mineralization. On the other hand, 26,27-dihomo-24-epi-1 alpha,25-dihydroxyvitamin D-2 is equal to 1,25-dihydroxyvitamin D-3 in biological activity. Vitamin D 25-hydroxylase readily converts 1 alpha-hydroxyvitamin D-2 to 1,25-dihydroxyvitamin D-2. In contrast, the same preparations fail to hydroxylate 26,27-dihomo-1 alpha-hydroxyvitamin D-2 and 26,27-dihomo-24-epi-1 alpha-hydroxyvitamin D-2 on carbon 25. Thus, homologation of carbons 26 and 27 of the vitamin D compound likely sterically hinders vitamin D 25-hydroxylase.	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison			KUTNER, ANDRZEJ/P-8823-2015; Kutner, Andrzej/AAB-6213-2020	Kutner, Andrzej/0000-0002-9518-4142	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK014881] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-14881] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DELUCA HF, 1988, AM J PHYSIOL, V254, pE402, DOI 10.1152/ajpendo.1988.254.4.E402; HOLICK MF, 1975, SCIENCE, V190, P576, DOI 10.1126/science.1188356; KUTNER A, 1988, J ORG CHEM, V53, P3450, DOI 10.1021/jo00250a009; KUTNER A, 1987, TETRAHEDRON LETT, V28, P6129, DOI 10.1016/S0040-4039(00)61826-9; LAM HYP, 1974, SCIENCE, V186, P1038; MADHOK TC, 1979, BIOCHEM J, V184, P491, DOI 10.1042/bj1840491; NAPOLI JL, 1979, ARCH BIOCHEM BIOPHYS, V197, P193, DOI 10.1016/0003-9861(79)90236-4; PERLMAN K, 1990, BIOCHEMISTRY-US, V29, P190, DOI 10.1021/bi00453a026; PERLMAN KL, 1992, TETRAHEDRON LETT, V33, P2937, DOI 10.1016/S0040-4039(00)79565-7; PERLMAN KL, 1989, J CHEM SOC CHEM COMM, P1113, DOI 10.1039/c39890001113; PINAZZI CP, 1975, B SOC CHIM FR II-CH, P201; REEVE LE, 1978, ARCH BIOCHEM BIOPHYS, V186, P164, DOI 10.1016/0003-9861(78)90475-7; SICINSKI RR, 1985, BIOORG CHEM, V13, P158, DOI 10.1016/0045-2068(85)90018-5; Snedecor G.W., 1980, STAT METHODS, V7; SOLLADIE G, 1981, SYNTHESIS-STUTTGART, P185; SORENSEN H, 1990, BIOCHEM PHARMACOL, V39, P391, DOI 10.1016/0006-2952(90)90039-N; SUDA T, 1970, J NUTR, V100, P1049, DOI 10.1093/jn/100.9.1049; TANAKA Y, 1973, ENDOCRINOLOGY, V92, P417, DOI 10.1210/endo-92-2-417; UHLANDSMITH A, 1993, J NUTR, V123, P1777, DOI 10.1093/jn/123.11.1777; UHLANDSMITH A, 1992, J NUTR, V122, P2316, DOI 10.1093/jn/122.12.2316; 1955, US PHARMACOPOEIA, P889	21	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24014	24019						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929052				2022-12-25	WOS:A1994PQ34600028
J	SARAS, J; CLAESSONWELSH, L; HELDIN, CH; GONEZ, LJ				SARAS, J; CLAESSONWELSH, L; HELDIN, CH; GONEZ, LJ			CLONING AND CHARACTERIZATION OF PTPL1, A PROTEIN-TYROSINE-PHOSPHATASE WITH SIMILARITIES TO CYTOSKELETAL-ASSOCIATED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; TUMOR SUPPRESSOR GENE; GROWTH-FACTOR; FOCAL ADHESIONS; SEQUENCE HOMOLOGY; HUMAN-PLATELETS; MESSENGER-RNAS; CDNA CLONING; SH3 DOMAINS; CELL-LINES	A novel cytoplasmic protein tyrosine phosphatase (PTP), PTPL1, was identified and cloned using a polymerase chain reaction-based approach. Overlapping cDNA clones encompass an open reading frame of 7398 base pairs, predicting a protein of 2466 amino acid residues with a molecular mass of 275 kDa. PTPL1 has a wide tissue distribution, a 9.5-kilobase transcript being expressed in most tissues. Peptide antisera against PTPL1 specifically precipitate a protein with an apparent mass of 250 kDa. PTPL1 has a PTP domain located in the COOP terminus, and the protein was shown to dephosphorylate P-32-labeled myelin basic protein. In the non-enzymatic part of PTPL1, three different structural motifs can be identified. Two of these are often found in proteins at the interface between the plasma membrane and the cytoskeleton, i.e. a 300-amino acid domain with similarity to the band 4.1 superfamily, and a region consisting of five GLGF repeats, an 80-amino acid repeat found in a variety of cytoskeleton associated proteins. In addition to these structures PTPL1 has a region that fulfills the criteria for a leucine zipper motif. PTPL1 is the hitherto largest PTP identified and the only one known which contains a leucine zipper motif.	LUDWIG INST CANC RES,CTR BIOMED,S-75124 UPPSALA,SWEDEN	Ludwig Institute for Cancer Research								ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUCKLAND R, 1989, NATURE, V338, P547, DOI 10.1038/338547a0; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CONBOY J, 1986, P NATL ACAD SCI USA, V83, P8512; COOL DE, 1992, P NATL ACAD SCI USA, V89, P5422, DOI 10.1073/pnas.89.12.5422; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; DENHERTOG J, 1992, BIOCHEM BIOPH RES CO, V184, P1241, DOI 10.1016/S0006-291X(05)80015-4; FAZIOLI F, 1993, ONCOGENE, V8, P1335; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; FU YH, 1989, MOL CELL BIOL, V9, P1120, DOI 10.1128/MCB.9.3.1120; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; HONDA H, 1993, LEUKEMIA, V7, P742; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRIEG J, 1992, J BIOL CHEM, V267, P19258; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; MAHER PA, 1985, P NATL ACAD SCI USA, V82, P6576, DOI 10.1073/pnas.82.19.6576; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCCORMACK K, 1989, NATURE, V340, P103, DOI 10.1038/340103a0; MIYAZONO K, 1987, J BIOL CHEM, V262, P4098; NISTER M, 1988, CANCER RES, V48, P3910; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PERKINS KK, 1990, GENE DEV, V4, P822, DOI 10.1101/gad.4.5.822; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; POT DA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P35, DOI 10.1016/0167-4889(92)90082-M; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SHARMA S, 1989, ONCOGENE RES, V5, P91; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1991, COLD SH Q B, V56, P265; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WHITE MK, 1989, NATURE, V340, P103, DOI 10.1038/340103b0; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350	72	97	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24082	24089						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929060				2022-12-25	WOS:A1994PQ34600038
J	YAMAGUCHI, T; KOMODA, Y; NAKAJIMA, H				YAMAGUCHI, T; KOMODA, Y; NAKAJIMA, H			BILIVERDIN-IX-ALPHA REDUCTASE AND BILIVERDIN-IX-BETA REDUCTASE FROM HUMAN LIVER - PURIFICATION AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; HEME OXYGENASE; MOLECULAR-FORMS; MULTIPLE FORMS; PATTERN; KIDNEY; EXPRESSION; BROMOBENZENE; VARIANTS	This report describes for the first time the identification of four forms of biliverdin reductase including two biliverdin-Mg reductases and two biliverdin-IX alpha reductases, designated isozymes I and II and isozymes III and IV, respectively, in human liver cytosolic fractions. The four forms of biliverdin reductase were purified to homogeneity. There was a 7,800-15,000-fold increase in specific activity when compared with the crude preparation, and the recovery was 8-26%. The purified enzymes were monomers with a molecular weight of about 21,000 (isozymes I and II) and 34,000 (isozymes III and IV). The enzymes were strictly specific for biliverdin, and no other oxidoreductase activities were detected in the purified preparations. The purified enzymes used NADPH and NADH as electron donors for the reduction of biliverdin. The apparent K-m values of isozymes I, II, III, and IV for NADPH were 35.9, 13.1, 10.9, and 34.1 mu M, respectively, whereas those for NADH were 5.6, 8.2, 7.9, and 23.4 mM, respectively. It was assumed that NADPH rather than NADH was the physiological electron donor in the intracellular reduction of biliverdin. The apparent K-m value of isozymes I and II for biliverdin-IX beta in the NADPH system was 0.3 mu M whereas those of isozymes III and IV for biliverdin-IX alpha were 1.0 and 0.8 mu M, respectively. Isozymes I and II used biliverdin-IX beta, -IX gamma, and -IX delta as substrates but not biliverdin-IX alpha and isozymes III and IV preferred biliverdin-IX alpha as the most effective substrate among the four biliverdin isomers. The NADPH-dependent enzyme activities were inhibited by substrate concentrations in excess of 3-4 mu M. The NADPH-dependent enzyme activities, especially isozymes III and IV, were sensitive to SH reagents including iodoacetamide, p-chloromercuribenzoic acid, and N-ethylmaleimide. The optimum pH of the reaction with NADPH for isozymes I and II was 8.2 whereas that for isozymes III and IV was 7.4. The proportion of the total activity of isozymes I and II to that of isozymes III and IV was considerably higher in the fetal than in the adult liver.	TOKYO MED & DENT UNIV, INST MED & DENT ENGN, DIV MED CHEM, TOKYO 113, JAPAN	Tokyo Medical & Dental University (TMDU)	YAMAGUCHI, T (corresponding author), TOKYO MED & DENT UNIV, MED RES INST, DEPT BIOCHEM GENET, TOKYO 113, JAPAN.							BELL JE, 1988, ARCH BIOCHEM BIOPHYS, V263, P1, DOI 10.1016/0003-9861(88)90607-8; BLANCKAERT N, 1976, BIOCHEM J, V155, P405, DOI 10.1042/bj1550405; BRINDLE NJM, 1986, BIOCHEM J, V236, P303, DOI 10.1042/bj2360303; CASCONE O, 1989, EUR J BIOCHEM, V179, P123, DOI 10.1111/j.1432-1033.1989.tb14529.x; COLLERAN E, 1977, CHEM PHYSL BILE PIGM, P69; FAKHRAI H, 1992, J BIOL CHEM, V267, P4023; FRYDMAN RB, 1983, BIOCHIM BIOPHYS ACTA, V759, P257, DOI 10.1016/0304-4165(83)90321-5; FRYDMAN RB, 1987, BIOCHIM BIOPHYS ACTA, V916, P500, DOI 10.1016/0167-4838(87)90197-X; FRYDMAN RB, 1982, BIOCHEM BIOPH RES CO, V105, P752, DOI 10.1016/0006-291X(82)91498-X; HUANG TJ, 1989, ARCH BIOCHEM BIOPHYS, V270, P513, DOI 10.1016/0003-9861(89)90533-X; HUANG TJ, 1990, MOL PHARMACOL, V37, P25; HUANG TJ, 1989, J BIOL CHEM, V264, P7844; KUTTY RK, 1983, BIOCHEM PHARMACOL, V32, P2095, DOI 10.1016/0006-2952(83)90432-X; KUTTY RK, 1981, J BIOL CHEM, V256, P3956; LEMBERG R, 1949, HEMATIN COMPOUNDS BI, P114; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAINES MD, 1990, MOL PHARMACOL, V38, P481; MAINES MD, 1993, ARCH BIOCHEM BIOPHYS, V300, P320, DOI 10.1006/abbi.1993.1044; MAINES MD, 1977, J BIOL CHEM, V252, P5900; MAINES MD, 1986, J BIOL CHEM, V261, P411; NAKAJIMA H, 1963, J BIOL CHEM, V238, P3784; NOGUCHI M, 1979, J BIOCHEM, V86, P833, DOI 10.1093/oxfordjournals.jbchem.a132615; O'CARRA P, 1971, Biochemical Journal, V125, p110P; SINGLETON JW, 1965, J BIOL CHEM, V240, P4780; Sols A., 1970, CURRENT TOPICS CELLU, V2, P227; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; TENHUNEN R, 1970, BIOCHEMISTRY-US, V9, P298, DOI 10.1021/bi00804a016; WATT J, 1976, BIOCHEM SOC T, V4, P866, DOI 10.1042/bst0040866; WEBER K, 1969, J BIOL CHEM, V244, P4406; YAMAGUCHI T, 1979, P JPN ACAD B-PHYS, V55, P84, DOI 10.2183/pjab.55.84; YOSHIDA T, 1978, J BIOL CHEM, V253, P4224; YOSHINAGA T, 1982, J BIOL CHEM, V257, P7778	32	73	76	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24343	24348						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929092				2022-12-25	WOS:A1994PQ34600076
J	FARRES, J; WANG, XP; TAKAHASHI, K; CUNNINGHAM, SJ; WANG, TT; WEINER, H				FARRES, J; WANG, XP; TAKAHASHI, K; CUNNINGHAM, SJ; WANG, TT; WEINER, H			EFFECTS OF CHANGING GLUTAMATE-487 TO LYSINE IN RAT AND HUMAN LIVER MITOCHONDRIAL ALDEHYDE DEHYDROGENASE - A MODEL TO STUDY HUMAN (ORIENTAL TYPE) CLASS-2 ALDEHYDE DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLMALONATE-SEMIALDEHYDE DEHYDROGENASE; HORSE LIVER; ESCHERICHIA-COLI; MOLECULAR-CLONING; CYTOPLASMIC ISOENZYME; ALCOHOL-DEHYDROGENASE; CATALYTIC ACTIVITY; MESSENGER-RNA; CDNA; GENE	Many Oriental people possess a liver mitochondrial aldehyde dehydrogenase where glutamate at position 487 has been replaced by a lysine, and they have very low levels of mitochondrial aldehyde dehydrogenase activity. To investigate the cause of the lack of activity of this aldehyde dehydrogenase, we mutated residue 487 of rat and human liver mitochondrial aldehyde dehydrogenase to a lysine and expressed the mutant and native enzyme forms in Escherichia coli. Both rat and human recombinant aldehyde dehydrogenases showed the same molecular and kinetic properties as the enzyme isolated from liver mitochondria. The E487K mutants were found to be active but possessed altered kinetic properties when compared to the glutamate enzyme. The K-m for NAD(+) at pH 7.4 increased more than 150-fold, whereas k(cat) decreased 2-10-fold with respect to the recombinant native enzymes. Detailed steady-state kinetic analysis showed that the binding of NAD(+) to the mutant enzyme was impaired, and it could be calculated that this resulted in a decreased nucleophilicity of the active site cysteine residue. The rate-limiting step for the rat E487K mutant was also different from that of the recombinant rat liver aldehyde dehydrogenase in that no pre-steady state burst of NADH formation was found with the mutant enzyme. Both the rat native enzyme and the E487K mutant oxidized chloroacetaldehyde twice as fast as acetaldehyde, indicating that the rate limiting step was not hydride transfer or coenzyme dissociation but depended upon nucleophilic attack. Each enzyme form showed a 2-fold activation upon the addition of Mg2+ ions. Substituting a glutamine for the glutamate did not grossly affect the properties of the enzyme. Glutamate 487 may interact directly with the positive nicotinamide ring of NAD(+) for the K-i of NADH was the same in the lysine enzyme as it was in the glutamate form. Because of the altered NAD(+) binding properties and k(cat) of the E487K variant, it is assumed that people possessing this form will not have a functional mitochondrial aldehyde dehydrogenase.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907; UNIV AUTONOMA BARCELONA,DEPT BIOQUIM & BIOL MOLEC,UNITAT CIENCIES,BARCELONA,SPAIN; OKAYAMA UNIV,SCH DENT,DEPT BIOCHEM,OKAYAMA 700,JAPAN; NCI,NUTR & MOLEC REGULAT LAB,FREDERICK,MD 21702	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Autonomous University of Barcelona; Okayama University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Farrés, Jaume/F-8648-2016	Farrés, Jaume/0000-0001-9069-3987	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA005812, R37AA005812] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA00028, AA05812] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ABRIOLA DP, 1990, BIOCHEM J, V266, P179, DOI 10.1042/bj2660179; AMBROZIAK W, 1989, BIOCHEMISTRY-US, V28, P5367, DOI 10.1021/bi00439a008; BLACKWELL LF, 1987, BIOCHEM J, V242, P803, DOI 10.1042/bj2420803; BOYD LA, 1991, GENE, V103, P45, DOI 10.1016/0378-1119(91)90389-S; BRAUN T, 1987, FEBS LETT, V215, P233, DOI 10.1016/0014-5793(87)80152-7; BURNELL JC, 1987, BIOCHEM BIOPH RES CO, V146, P1227, DOI 10.1016/0006-291X(87)90779-0; CHRISTENSEN EL, 1979, BIOCH PHARMACOLOGY E, V1, P191; COOK RJ, 1991, J BIOL CHEM, V266, P4965; CRABB DW, 1989, J CLIN INVEST, V83, P314, DOI 10.1172/JCI113875; DUNN TJ, 1989, J BIOL CHEM, V264, P13057; EKLUND H, 1987, BIOL MACROMOL, V3, P74; FARRES J, 1989, EUR J BIOCHEM, V180, P67, DOI 10.1111/j.1432-1033.1989.tb14616.x; FELDMAN RI, 1972, J BIOL CHEM, V247, P267; FERENCZBIRO K, 1984, BIOCHEM BIOPH RES CO, V118, P97, DOI 10.1016/0006-291X(84)91072-6; GHENBOT G, 1992, PROTEIN EXPRES PURIF, V3, P470, DOI 10.1016/1046-5928(92)90064-4; GOEDDE HW, 1979, HUM GENET, V51, P331; GOODWIN GW, 1989, J BIOL CHEM, V264, P14965; GREENFIELD NJ, 1977, BIOCHIM BIOPHYS ACTA, V483, P35, DOI 10.1016/0005-2744(77)90005-5; GUAN K, 1990, ARCH BIOCHEM BIOPHYS, V277, P351, DOI 10.1016/0003-9861(90)90590-U; GUAN KL, 1988, ALCOHOL CLIN EXP RES, V12, P713, DOI 10.1111/j.1530-0277.1988.tb00270.x; HEIM R, 1991, GENE, V99, P15, DOI 10.1016/0378-1119(91)90028-A; HEMPEL J, 1984, FEBS LETT, V173, P367, DOI 10.1016/0014-5793(84)80807-8; HEMPEL J, 1985, EUR J BIOCHEM, V153, P13, DOI 10.1111/j.1432-1033.1985.tb09260.x; HEMPEL J, 1991, PROTEINS, V11, P176, DOI 10.1002/prot.340110303; HEMPEL J, 1984, EUR J BIOCHEM, V141, P21, DOI 10.1111/j.1432-1033.1984.tb08150.x; HEMPEL J, 1987, ENZYMOLOGY MOL BIOL, P1; HEMPEL JD, 1982, ALCOHOL CLIN EXP RES, V6, P417, DOI 10.1111/j.1530-0277.1982.tb05001.x; HIDALGO E, 1991, J BACTERIOL, V173, P6118, DOI 10.1128/jb.173.19.6118-6123.1991; HSU LC, 1991, J BIOL CHEM, V266, P12257; Hsu LC, 1988, GENOMICS, V2, P57, DOI 10.1016/0888-7543(88)90109-7; HURLEY TD, 1992, J MOL BIOL, V227, P1255, DOI 10.1016/0022-2836(92)90536-S; IKAWA M, 1983, J BIOL CHEM, V258, P6282; JENG JJ, 1991, ARCH BIOCHEM BIOPHYS, V289, P214, DOI 10.1016/0003-9861(91)90464-T; JOHANSSON J, 1988, EUR J BIOCHEM, V172, P527, DOI 10.1111/j.1432-1033.1988.tb13920.x; JONES DE, 1988, P NATL ACAD SCI USA, V85, P1782, DOI 10.1073/pnas.85.6.1782; JORNVALL H, 1984, P NATL ACAD SCI-BIOL, V81, P3024, DOI 10.1073/pnas.81.10.3024; KEDISHVILI NY, 1992, J BIOL CHEM, V267, P19724; KOK M, 1989, J BIOL CHEM, V264, P5442; LINDAHL R, 1984, J BIOL CHEM, V259, P1991; LINDAHL R, 1984, J BIOL CHEM, V259, P1986; LINDROS KO, 1982, ARCH BIOCHEM BIOPHYS, V218, P429, DOI 10.1016/0003-9861(82)90364-2; MIYAUCHI K, 1991, J BIOL CHEM, V266, P19536; MIZOI Y, 1979, PHARMACOL BIOCHEM BE, V10, P303, DOI 10.1016/0091-3057(79)90105-9; NORDLUND I, 1990, BIOCHIM BIOPHYS ACTA, V1049, P227, DOI 10.1016/0167-4781(90)90046-5; OHLSSON I, 1974, J MOL BIOL, V89, P339, DOI 10.1016/0022-2836(74)90523-3; PARSOT C, 1991, J BACTERIOL, V173, P2842, DOI 10.1128/JB.173.9.2842-2851.1991; PICKETT M, 1987, GENE, V51, P217, DOI 10.1016/0378-1119(87)90310-6; PIETRUSZKO R, 1981, ALCOHOL CLIN EXP RES, V5, P78; PLOWMAN KM, 1972, ENZYME KINETICS, P40; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINGH S, 1989, HUM GENET, V83, P119, DOI 10.1007/BF00286702; SKARZYNSKI T, 1987, J MOL BIOL, V193, P171, DOI 10.1016/0022-2836(87)90635-8; SRIDHARA S, 1969, J BIOL CHEM, V244, P5233; TAKAHASHI K, 1981, BIOCHEMISTRY-US, V20, P2720, DOI 10.1021/bi00513a003; TAKAHASHI K, 1980, ARCH BIOCHEM BIOPHYS, V205, P571, DOI 10.1016/0003-9861(80)90140-X; TAKAHASHI K, 1980, J BIOL CHEM, V255, P8206; VALLARI RC, 1981, ARCH BIOCHEM BIOPHYS, V212, P9, DOI 10.1016/0003-9861(81)90338-6; VALLARI RC, 1984, J BIOL CHEM, V259, P4922; VONBAHRLINDSTROM H, 1985, BIOCHEMISTRY-US, V24, P5847, DOI 10.1021/bi00342a023; VONBAHRLINDSTROM H, 1984, EUR J BIOCHEM, V141, P37; WEINER H, 1976, J BIOL CHEM, V251, P3853; WEINER H, 1982, ENZYMOLOGY CARBONYL, P1; WERETILNYK EA, 1989, ARCH BIOCHEM BIOPHYS, V271, P56, DOI 10.1016/0003-9861(89)90255-5; WERETILNYK EA, 1990, P NATL ACAD SCI USA, V87, P2745, DOI 10.1073/pnas.87.7.2745; YOSHIDA A, 1984, P NATL ACAD SCI-BIOL, V81, P258, DOI 10.1073/pnas.81.1.258; ZHENG CF, 1993, ALCOHOL CLIN EXP RES, V17, P828, DOI 10.1111/j.1530-0277.1993.tb00849.x	66	120	123	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13854	13860						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	7910607				2022-12-25	WOS:A1994NL60600023
J	SCHMIDT, M; BUCHNER, J; TODD, MJ; LORIMER, GH; VIITANEN, PV				SCHMIDT, M; BUCHNER, J; TODD, MJ; LORIMER, GH; VIITANEN, PV			ON THE ROLE OF GROES IN THE CHAPERONIN-ASSISTED FOLDING REACTION - 3 CASE-STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; ESCHERICHIA-COLI; MOLECULAR CHAPERONE; RIBULOSEBISPHOSPHATE CARBOXYLASE; ATP HYDROLYSIS; BETA-LACTAMASE; GENE-PRODUCTS; PROTEIN; IDENTIFICATION; INVITRO	The mechanism by which correctly folded proteins are recovered from stable complexes with groEL is not well understood. Certain target proteins require ATP and groES, while others seemingly dispense with the co-chaperonin. Here, we examine the chaperonin-assisted folding of ribulose-1,5-bisphosphate carboxylase, malate dehydrogenase, and citrate synthase, three proteins that are believed to require both chaperonin components for successful reactivation. Surprisingly, in all cases, the need for groES depended on the folding environment. Under ''non-permissive'' conditions, where unassisted spontaneous folding could not occur, reactivation to the native state required the complete chaperonin system (e.g. groEL, groES, and MgATP). However, under ''permissive'' conditions where spontaneous folding could occur groES was no longer mandatory. Instead, upon the addition of ATP alone, all three target proteins could be released from groEL, in a form that was capable of reaching the native state. In the permissive setting, groES merely accelerated the rate of the ATP dependent release process. The results suggest that the incompletely folded protein species that are released from groEL, in the absence of groES, are not necessarily committed to the native state. Similar to the unassisted folding reaction, they still partition between productive and unproductive folding pathways in an environment-dependent manner. It follows that the mechanistic contribution of the co-chaperonin, groES, and its physiological significance in cellular protein folding, could be entirely missed in a permissive in vitro environment.	DUPONT CO INC, DEPT CENT RES & DEV, DIV MOLEC BIOL, EXPTL STN, WILMINGTON, DE 19880 USA; UNIV REGENSBURG, INST BIOPHYS & PHYS BIOCHEM, W-8400 REGENSBURG, GERMANY	DuPont; University of Regensburg			Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BANEYX F, 1992, J BIOL CHEM, V267, P11637; BERTSCH U, 1992, P NATL ACAD SCI USA, V89, P8696, DOI 10.1073/pnas.89.18.8696; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; GRAY TE, 1993, J MOL BIOL, V232, P1197, DOI 10.1006/jmbi.1993.1471; GRIMM R, 1993, J BIOL CHEM, V268, P5220; GUTTERIDGE S, 1989, BIOCHEM J, V260, P711, DOI 10.1042/bj2600711; HANSEN JE, 1993, J BIOL CHEM, V268, P21632; HARTMAN DJ, 1992, P NATL ACAD SCI USA, V89, P3394, DOI 10.1073/pnas.89.8.3394; HARTMAN DJ, 1993, P NATL ACAD SCI USA, V90, P2276, DOI 10.1073/pnas.90.6.2276; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HUBBS AE, 1993, J BIOL CHEM, V268, P13519; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KERN G, 1992, FEBS LETT, V305, P203, DOI 10.1016/0014-5793(92)80667-6; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; LORIMER GH, 1993, PHILOS T R SOC B, V339, P297, DOI 10.1098/rstb.1993.0028; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MILLER AD, 1993, BIOCHEM J, V291, P139, DOI 10.1042/bj2910139; MIZOBATA T, 1992, J BIOL CHEM, V267, P17773; PAJOT P, 1976, EUR J BIOCHEM, V63, P263, DOI 10.1111/j.1432-1033.1976.tb10228.x; PICKETTS DJ, 1989, J BIOL CHEM, V264, P12001; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; ROSPERT S, 1993, P NATL ACAD SCI USA, V90, P10967, DOI 10.1073/pnas.90.23.10967; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; TILLY K, 1982, J BACTERIOL, V149, P1082, DOI 10.1128/JB.149.3.1082-1088.1982; TILLY K, 1981, P NATL ACAD SCI-BIOL, V78, P1629, DOI 10.1073/pnas.78.3.1629; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VANDERVIES SM, 1992, BIOCHEMISTRY-US, V31, P3635, DOI 10.1021/bi00129a012; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WANG Z, 1992, PROTEIN SCI, V1, P522; WEAVER AJ, 1993, BIOPHYS J, V64, pA350; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; ZAHN R, 1992, BIOCHEMISTRY-US, V31, P3249, DOI 10.1021/bi00127a029; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	59	156	156	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10304	10311						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7908292				2022-12-25	WOS:A1994NF01700022
J	SAUK, JJ; SMITH, T; NORRIS, K; FERREIRA, L				SAUK, JJ; SMITH, T; NORRIS, K; FERREIRA, L			HSP47 AND THE TRANSLATION-TRANSLOCATION MACHINERY COOPERATE IN THE PRODUCTION OF ALPHA-1(I) CHAINS OF TYPE-I PROCOLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY PROTEIN TRANSLOCATION; ENDOPLASMIC-RETICULUM MEMBRANE; SIGNAL RECOGNITION PARTICLE; COLLAGEN-BINDING PROTEIN; HEAT-SHOCK PROTEIN; POLYPEPTIDE TRANSLOCATION; MICROSOMAL-MEMBRANES; NASCENT POLYPEPTIDES; POLYACRYLAMIDE GELS; CROSS-LINKING	Hsp47, an endoplasmic reticulum resident protein, has gelatin-binding and procollagen binding properties and has been hypothesized to function as a molecular chaperone in regulating procollagen folding and/or assembly. In this report, we further investigate the interaction of Hsp47 with polysome associated alpha 1(I) procollagen chains following antisense treatment of 3T6 cells. For these studies, we employed phosphorothioate oligo-deoxynucleotides directed to the first five codons of Hsp47 that straddle the predicted translation initiation site of mouse Hsp47. Cells depleted of Hsp47 in this manner were observed to produce diminished amounts of fully elongated nascent alpha 1(I) procollagen while accumulating shorter procollagen peptides associated with peptidyl-tRNA. Pulse-labeling of cells with [S-35]methionine followed by treatment with puromycin and immunoprecipitation with anti-Hsp47 and anti-procollagen antibodies revealed that Hsp47 is associated with alpha 1(I) procollagen at a very early point during translocation of the nascent procollagen chains. Although Hsp47 appears to possess properties similar to grp78/BiP, Hsp47 binding early during translocation favors a more specialized specific function relative to chain selection or completion of stable folding in type I procollagen.			SAUK, JJ (corresponding author), UNIV MARYLAND, SCH DENT, DEPT PATHOL, BALTIMORE, MD 21201 USA.			Sauk, John/0000-0002-9208-5739	NIAMS NIH HHS [AR41572] Funding Source: Medline; NIDCR NIH HHS [DE08648] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008648] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADELMAN MR, 1973, J CELL BIOL, V56, P206, DOI 10.1083/jcb.56.1.206; BECKMANN RP, 1992, J CELL BIOL, V117, P1137, DOI 10.1083/jcb.117.6.1137; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BERGMAN LW, 1977, BIOCHEMISTRY-US, V16, P4490, DOI 10.1021/bi00639a025; BONIFACINO JS, 1988, J BIOL CHEM, V263, P8965; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CAZENAVE C, 1989, NUCLEIC ACIDS RES, V17, P4255, DOI 10.1093/nar/17.11.4255; CLARKE EP, 1992, BIOCHIM BIOPHYS ACTA, V1129, P246, DOI 10.1016/0167-4781(92)90498-O; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; FOELLMER HG, 1983, EUR J BIOCHEM, V134, P183, DOI 10.1111/j.1432-1033.1983.tb07549.x; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; HOFFMAN KE, 1988, J BIOL CHEM, V263, P4381; KANG PJ, 1990, NATURE, V333, P330; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KIRK TZ, 1987, J BIOL CHEM, V262, P5540; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; KURKINEN M, 1984, J BIOL CHEM, V259, P5915; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINGAPPA VR, 1991, CELL, V65, P527, DOI 10.1016/0092-8674(91)90081-9; LOMANT AJ, 1976, J MOL BIOL, V104, P243, DOI 10.1016/0022-2836(76)90011-5; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MIYAISHI O, 1992, J HISTOCHEM CYTOCHEM, V40, P1021, DOI 10.1177/40.7.1607635; NAGATA K, 1986, J BIOL CHEM, V261, P7531; NAKAI A, 1990, J BIOL CHEM, V265, P992; NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903; NANDAN D, 1990, ARCH BIOCHEM BIOPHYS, V278, P291, DOI 10.1016/0003-9861(90)90263-X; OOI CE, 1992, CELL, V71, P87, DOI 10.1016/0092-8674(92)90268-H; PERARA E, 1986, SCIENCE, V232, P348, DOI 10.1126/science.3961485; REED JC, 1990, CANCER RES, V50, P6565; ROTH RA, 1987, BIOCHEMISTRY-US, V26, P4179, DOI 10.1021/bi00388a001; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SAUK JJ, 1990, BIOCHEM BIOPH RES CO, V172, P135, DOI 10.1016/S0006-291X(05)80183-4; SHROFF B, 1993, CONNECT TISSUE RES, V29, P273, DOI 10.3109/03008209309016833; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; TAKECHI H, 1992, EUR J BIOCHEM, V206, P323, DOI 10.1111/j.1432-1033.1992.tb16930.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VEDELER A, 1991, MOL CELL BIOCHEM, V100, P183; VEIS A, 1985, P NATL ACAD SCI USA, V82, P3693, DOI 10.1073/pnas.82.11.3693; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1992, NATURE, V357, P22, DOI 10.1038/357022a0	49	119	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3941	3946						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7905876				2022-12-25	WOS:A1994MW98900009
J	BOCHKAREVA, ES; HOROVITZ, A; GIRSHOVICH, AS				BOCHKAREVA, ES; HOROVITZ, A; GIRSHOVICH, AS			DIRECT DEMONSTRATION THAT ATP IS IN CONTACT WITH CYS-137 IN CHAPERONIN GROEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BACTERIOPHAGE-T7 DNA-POLYMERASE; ESCHERICHIA-COLI; PROTEIN; COOPERATIVITY; PURIFICATION; MUTAGENESIS	The nonhydrolyzable ATP analogue ATPgammaS (adenosine 5'-3-O-(thio)triphosphate) is affinity cross-linked to GroEL by formation of a disulfide bridge in a peroxide-promoted reaction. By replacing with serine each of 3 cysteine residues in GroEL, it is shown that ATpgammaS specifically cross-links to Cys-137. It is thus demonstrated that the ATP bound to GroEL is in direct contact with Cys-137.			BOCHKAREVA, ES (corresponding author), WEIZMANN INST SCI,DEPT STRUCT BIOL,IL-76100 REHOVOT,ISRAEL.							BANEYX F, 1992, J BIOL CHEM, V267, P11637; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BROCKLEHURST K, 1982, METHOD ENZYMOL, V87, P427; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GIRSHOVICH AS, 1981, J MOL BIOL, V151, P229, DOI 10.1016/0022-2836(81)90513-1; GONEK T, 1992, INT J BIOCHEM, V24, P1533; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HOROVITZ A, 1993, J BIOL CHEM, V268, P9957; HOROVITZ A, 1993, J MOL BIOL, V231, P58, DOI 10.1006/jmbi.1993.1256; Kenny J W, 1979, Methods Enzymol, V59, P534; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; MENDOZA JA, 1992, J PROTEIN CHEM, V11, P589, DOI 10.1007/BF01024958; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TABOR S, 1989, J BIOL CHEM, V264, P6447	26	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					44	46						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	7903969				2022-12-25	WOS:A1994MR21900012
J	KOHNO, T; MORISHITA, K; TAKANO, H; SHAPIRO, DN; YOKOTA, J				KOHNO, T; MORISHITA, K; TAKANO, H; SHAPIRO, DN; YOKOTA, J			HOMOZYGOUS DELETION AT CHROMOSOME 2Q33 IN HUMAN SMALL-CELL LUNG-CARCINOMA IDENTIFIED BY ARBITRARILY PRIMED PCR GENOMIC FINGERPRINTING	ONCOGENE			English	Article							TUMOR SUPPRESSOR GENES; HUMAN DNA; CANCER; HETEROZYGOSITY; LINES; ADENOCARCINOMA; LOCALIZATION; EXPRESSION; SEQUENCES	We have searched for novel genetic alterations in human cancer cell lines by using the arbitrarily primed polymerase chain reaction (AP-PCR), which is a PCR-based genomic fingerprinting. A homozygous deletion was detected in a small-cell lung carcinoma (SCLC) cell line, NCI-H82. Since homozygous deletion is a critical genetic alteration for the inactivation of tumor suppressor gene, we defined the locus of homozygous deletion. Fluorescence in situ hybridization analysis revealed that the deletion was localized at chromosome 2q33. Allelic loss on chromosome 2q was detected in 29.4% (5/17) of SCLC and 37.5% (12/32) one non-SCLC by restriction fragment length polymorphism analysis. Considerably high incidence of allelic loss on chromosome 2q was also detected in colorectal carcinoma and neuroblastoma. These results suggest the presence of a novel tumor suppressor gene at 2q33, which is involved in the development of several human cancers. The size of the homozygous deletion in the NCI-H82 cell line was more than 20 kilobase pairs. Seven loci mapped to 2q32-qter were all retained in this cell line, suggesting the presence of submicroscopic interstitial deletion in this cell line. Homozygous deletion detected in this study should be an invaluable tool for positional cloning of the target tumor suppressor gene at 2q33.	NATL CANC CTR, RES INST, CHUO KU, TOKYO 104, JAPAN; ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, MEMPHIS, TN 38101 USA	National Cancer Center - Japan; St Jude Children's Research Hospital				takano, hirokuni/0000-0002-6465-7883	NCI NIH HHS [CA-21765, CA-23099] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023099, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BROWN AG, 1993, NAT GENET, V3, P67, DOI 10.1038/ng0193-67; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CARNEY DN, 1985, CANCER RES, V45, P2913; DARIAVACH P, 1988, EUR J IMMUNOL, V18, P1901, DOI 10.1002/eji.1830181206; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; EHRENBORG E, 1991, BIOCHEM BIOPH RES CO, V176, P1250, DOI 10.1016/0006-291X(91)90420-C; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; KOHLER A, 1993, GENOMICS, V15, P233, DOI 10.1006/geno.1993.1045; KOHNO T, 1993, ONCOGENE, V8, P1825; KUBOTA Y, 1987, FEBS LETT, V212, P159, DOI 10.1016/0014-5793(87)81577-6; LEE KP, 1990, J IMMUNOL, V145, P344; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; Maniatis T., 1982, MOL CLONING; MATSUMOTO T, 1991, JPN J CANCER RES, V82, P820, DOI 10.1111/j.1349-7006.1991.tb02708.x; MATSUMURA Y, 1992, CANCER RES, V52, P2174; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MORI N, 1989, CANCER RES, V49, P5130; MORISS SW, 1991, BLOOD, V78, P2013; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MURTY VVVS, 1992, P NATL ACAD SCI USA, V89, P11006, DOI 10.1073/pnas.89.22.11006; OOKAWA K, 1993, INT J CANCER, V53, P382, DOI 10.1002/ijc.2910530307; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PEINADO MA, 1992, P NATL ACAD SCI USA, V89, P10065, DOI 10.1073/pnas.89.21.10065; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SUGIMURA T, 1992, SCIENCE, V258, P603, DOI 10.1126/science.1411570; TAKAYAMA H, 1992, ONCOGENE, V7, P1185; THEIN SL, 1987, BRIT J CANCER, V55, P353, DOI 10.1038/bjc.1987.71; TSUCHIYA E, 1992, CANCER RES, V52, P2478; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WELSH J, 1991, NUCLEIC ACIDS RES, V19, P5275, DOI 10.1093/nar/19.19.5275; WELSH J, 1990, NUCLEIC ACIDS RES, V18, P7213, DOI 10.1093/nar/18.24.7213; WHANGPENG J, 1982, CANCER GENET CYTOGEN, V6, P119, DOI 10.1016/0165-4608(82)90077-2; WIELAND I, 1992, P NATL ACAD SCI USA, V89, P9705, DOI 10.1073/pnas.89.20.9705; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; YAMADA T, 1985, JPN J CANCER RES, V76, P967; YAMAKAWA K, 1993, ONCOGENE, V8, P327; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; 1991, CYTOGENET CELL GENET, V58, P1	44	74	75	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					103	108						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	7905618				2022-12-25	WOS:A1994MW24700013
J	MORII, N; KUMAGAI, N; NUREKAMAL, MSA; NARUMIYA, S; MARUTA, H				MORII, N; KUMAGAI, N; NUREKAMAL, MSA; NARUMIYA, S; MARUTA, H			RHO GAP OF 28 KDA (GAP2), BUT NOT OF 190 KDA (P190), REQUIRES ASP(65) AND ASP(67) OF RHO GTPASE FOR ITS ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOTULINUM ADP-RIBOSYLTRANSFERASE; GENE-PRODUCT; SUPPRESSOR ACTIVITY; BINDING PROTEIN; RAS P21; PURIFICATION; SEQUENCE; CLONING; DOMAIN; SUBSTRATE	Two distinct GTPase-activating proteins (GAPs), i.e. rho GAPs of 28 kDa (GAP2) and of 190 kDa (p190), stimulate the intrinsic GTPase activity of the rho protein. The rho GAP activity of p190 resides in its C-terminal domain (p190C). Neither GAP2 nor p190C activates the ras GTPase. We replaced Asp65 and Asp67 residues of rho GTPase with the corresponding ras residues and examined whether the domain containing them is involved in its activation by rho GAPs. Mutation of either Asp65 to Glu or Asp67 to Ser did not change the K(d) value for GTPgammaS of the rho protein. The Ser67 mutation reduced the intrinsic GTPase activity of the rho protein, while no change was observed with the Glu65 mutation. Both mutations abolished activation of rho GTPase by GAP2. The GAP2-dependent activation of rho GTPase was inhibited by the addition of GTPgammaS-bound wild type rho but not by either GTPgammaS-bound Glu65- or Ser67-rho, indicating that both Asp65 and Asp67 are essential for interaction of rho protein with GAP2. On the contrary, p190C activated both Glu65- and Ser67-rho GTPases to the extent and in a dose dependence to those seen in the wild GTPase. These results suggest that GAP2 and p190 interact with different residues or domains of the rho GTPase for their activation.	ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,PARKVILLE,VIC 3050,AUSTRALIA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital	MORII, N (corresponding author), KYOTO UNIV,FAC MED,DEPT PHARMACOL,SAKYO KU,KYOTO 606,JAPAN.							ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; GARRETT MD, 1991, BIOCHEM J, V276, P833, DOI 10.1042/bj2760833; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HOLDEN JL, 1991, J BIOL CHEM, V266, P16992; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MORII N, 1991, J BIOL CHEM, V266, P7646; MORII N, 1992, J BIOL CHEM, V267, P20921; MORII N, 1988, J BIOL CHEM, V263, P12420; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NICE E, 1991, J BIOL CHEM, V267, P1546; NUREKAMAL MSA, 1992, J BIOL CHEM, V267, P1415; NUREKAMAL MSA, 1992, MOL BIOL CELL, V3, P1437, DOI 10.1091/mbc.3.12.1437; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	35	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27160	27163						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	7903304				2022-12-25	WOS:A1993MM26200049
J	RIGGS, DL; PETERSON, CL; WICKHAM, JQ; MILLER, LM; CROWELL, JA; SERGERE, JC				RIGGS, DL; PETERSON, CL; WICKHAM, JQ; MILLER, LM; CROWELL, JA; SERGERE, JC			CHARACTERIZATION OF THE COMPONENTS OF RECONSTITUTED SACCHAROMYCES-CEREVISIAE RNA-POLYMERASE-I TRANSCRIPTION COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; WHOLE-CELL EXTRACT; FACTOR TIF-IA; EUKARYOTIC TRANSCRIPTION; DEPENDENT TRANSCRIPTION; HORMONAL-REGULATION; INITIATION; YEAST; RDNA; GENE	We have reconstituted specific RNA polymerase I transcription from three partially purified chromatographic fractions (termed A, B, and C). Here, we present the chromatographic scheme and the initial biochemical characterization of these fractions, The A fraction contained the RNA polymerase I transcription factor(s), which was necessary and sufficient to form stable preinitiation complexes at the promoter. Of the three fractions, only fraction A contained a significant amount of the TATA binding factor, The B fraction contributed RNA polymerase I, and it contained an essential RNA polymerase I transcription factor that was specifically inactivated in response to a significant decrease in growth rate, The function of the C fraction remains unclear, This reconstituted transcription system provides a starting point for the biochemical dissection of the yeast RNA polymerase I transcription complex, thus allowing in vitro experiments designed to elucidate the molecular mechanisms controlling rRNA synthesis.			RIGGS, DL (corresponding author), UNIV OKLAHOMA,DEPT BOT & MICROBIOL,NORMAN,OK 73019, USA.			Wickham, John/0000-0001-9057-9973	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047881] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47881] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; BAZETTJONES DP, 1994, SCIENCE, V264, P1134, DOI 10.1126/science.8178172; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN BR, 1989, P NATL ACAD SCI USA, V86, P2530, DOI 10.1073/pnas.86.8.2530; BRUN RP, 1994, MOL CELL BIOL, V14, P5010, DOI 10.1128/MCB.14.7.5010; BUTTGEREIT D, 1985, NUCLEIC ACIDS RES, V13, P8165, DOI 10.1093/nar/13.22.8165; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; CULOTTA VC, 1985, MOL CELL BIOL, V5, P1582, DOI 10.1128/MCB.5.7.1582; EBERHARD D, 1993, NUCLEIC ACIDS RES, V21, P4180, DOI 10.1093/nar/21.18.4180; HU CH, 1994, MOL CELL BIOL, V14, P2871, DOI 10.1128/MCB.14.5.2871; KERMEKCHIEV M, 1993, NUCLEIC ACIDS RES, V21, P447, DOI 10.1093/nar/21.3.447; KUHN A, 1992, P NATL ACAD SCI USA, V89, P7340, DOI 10.1073/pnas.89.16.7340; LARSON DE, 1993, P NATL ACAD SCI USA, V90, P7933, DOI 10.1073/pnas.90.17.7933; LUE NF, 1990, J BIOL CHEM, V265, P18091; MAHAJAN PB, 1990, J BIOL CHEM, V265, P16244; MAHAJAN PB, 1990, J BIOL CHEM, V265, P16225; OMAHONY DJ, 1992, J BIOL CHEM, V267, P35; PIKAARD CS, 1989, GENE DEV, V3, P1779, DOI 10.1101/gad.3.11.1779; POON D, 1993, J BIOL CHEM, V268, P15325; PUTNAM CD, 1994, MOL CELL BIOL, V14, P6476, DOI 10.1128/MCB.14.10.6476; REEDER RH, 1992, TRANSCRIPTIONAL REGU, V1, P315; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; RIGGS DL, 1990, J BIOL CHEM, V265, P7596; SCHNAPP A, 1990, NUCLEIC ACIDS RES, V18, P1385, DOI 10.1093/nar/18.6.1385; SCHNAPP A, 1990, EMBO J, V9, P2857, DOI 10.1002/j.1460-2075.1990.tb07475.x; SCHULTZ LD, 1976, P NATL ACAD SCI USA, V73, P1029, DOI 10.1073/pnas.73.4.1029; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SCHULTZ MC, 1991, P NATL ACAD SCI USA, V88, P1004, DOI 10.1073/pnas.88.3.1004; Smith S. David, 1993, Gene Expression, V3, P229; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; SOLLNERWEBB B, 1986, ANNU REV BIOCHEM, V55, P801, DOI 10.1146/annurev.bi.55.070186.004101; STEINBERG TH, 1990, J BIOL CHEM, V265, P499; TOWER J, 1987, CELL, V50, P873, DOI 10.1016/0092-8674(87)90514-9; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; WOONTNER M, 1990, J BIOL CHEM, V265, P8979	38	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					6205	6210		10.1074/jbc.270.11.6205	http://dx.doi.org/10.1074/jbc.270.11.6205			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890756	hybrid			2022-12-25	WOS:A1995QM94500073
J	KLEINNULEND, J; VANDERPLAS, A; SEMEINS, CM; AJUBI, NE; FRANGOS, JA; NIJWEIDE, PJ; BURGER, EH				KLEINNULEND, J; VANDERPLAS, A; SEMEINS, CM; AJUBI, NE; FRANGOS, JA; NIJWEIDE, PJ; BURGER, EH			SENSITIVITY OF OSTEOCYTES TO BIOMECHANICAL STRESS IN-VITRO	FASEB JOURNAL			English	Article						HYDROSTATIC COMPRESSION; FLUID FLOW; FLUID SHEAR STRESS; PROSTAGLANDINS	BONE LOADING INVIVO; FUNCTIONAL STRAINS; SHEAR-STRESS; PROSTAGLANDIN-E2; CELLS; FLOW	It has been known for more than a century that bone tissue adapts to functional stress by changes in structure and mass, However, the mechanism by which stress is translated into cellular activities of bone formation and resorption is unknown, We studied the response of isolated osteocytes derived from embryonic chicken calvariae to intermittent hydrostatic compression as well as pulsating fluid flow, and compared their response to osteoblasts and periosteal fibroblasts. Osteocytes, but not osteoblasts or periosteal fibroblasts, reacted to 1 h pulsating fluid flow with a sustained release of prostaglandin E(2). Intermittent hydrostatic compression stimulated prostaglandin production to a lesser extent: after 6 and 24 h in osteocytes and after 6 h in osteoblasts. These data provide evidence that osteocytes are the most mechanosensitive cells in bone involved in the transduction of mechanical stress into a biological response. The results support the hypothesis that stress on bone causes fluid flow in the lacunar-canalicular system, which stimulates the osteocytes to produce factors that regulate bone metabolism.	LEIDEN UNIV,DEPT CELL BIOL,LEIDEN,NETHERLANDS; PENN STATE UNIV,DEPT CHEM ENGN,UNIVERSITY PK,PA 16802	Leiden University; Leiden University - Excl LUMC; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	KLEINNULEND, J (corresponding author), FREE UNIV AMSTERDAM,ACTA,DEPT ORAL CELL BIOL,VAN BOECHORSTSTRAAT 7,1081 BT AMSTERDAM,NETHERLANDS.							BASSETT CAL, 1991, ELECTROMAGNETICS IN MEDICINE AND BIOLOGY, P1; BASSETT CAL, 1962, SCIENCE, V137, P1063, DOI 10.1126/science.137.3535.1063; BERTRAM JEA, 1991, BIOL REV, V66, P245, DOI 10.1111/j.1469-185X.1991.tb01142.x; BURGER EH, 1993, BONE, V0007, P00037; Cowin, 1991, ADV BIOENGIN, V20, P313; DOTY SB, 1981, CALCIFIED TISSUE INT, V33, P509, DOI 10.1007/BF02409482; FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488; FRANGOS JA, 1988, BIOTECHNOL BIOENG, V32, P1053, DOI 10.1002/bit.260320812; KAMIYA A, 1984, B MATH BIOL, V46, P127, DOI 10.1016/S0092-8240(84)80038-5; KLEINNULEND J, 1986, ARTHRITIS RHEUM-US, V29, P1002, DOI 10.1002/art.1780290809; KRUYT HR, 1960, INTRO PHYSICAL CHEM; KUFAHL RH, 1990, J BIOMECH, V23, P171, DOI 10.1016/0021-9290(90)90350-C; MURRAY DW, 1990, CALCIFIED TISSUE INT, V47, P35, DOI 10.1007/BF02555863; NIJWEIDE PJ, 1986, PHYSIOL REV, V66, P855, DOI 10.1152/physrev.1986.66.4.855; NIJWEIDE PJ, 1981, CALCIFIED TISSUE INT, V33, P529, DOI 10.1007/BF02409485; Pauwels F, 1980, BIOMECHANICS LOCOMOT; PEAD MJ, 1988, CALCIFIED TISSUE INT, V43, P92, DOI 10.1007/BF02555153; PIEKARSKI K, 1977, NATURE, V269, P80, DOI 10.1038/269080a0; REICH KM, 1990, J CELL PHYSIOL, V143, P100, DOI 10.1002/jcp.1041430113; REICH KM, 1991, AM J PHYSIOL, V261, pC428, DOI 10.1152/ajpcell.1991.261.3.C428; RUBIN CT, 1982, J EXP BIOL, V101, P187; RUBIN CT, 1990, J BIOMECH, V23, P43, DOI 10.1016/0021-9290(90)90040-A; RUBIN CT, 1984, J BONE JOINT SURG AM, V66A, P397, DOI 10.2106/00004623-198466030-00012; SALZSTEIN RA, 1987, J BIOMECH, V20, P271, DOI 10.1016/0021-9290(87)90294-6; SKERRY TM, 1989, J BONE MINER RES, V4, P783, DOI 10.1002/jbmr.5650040519; SOMJEN D, 1980, BIOCHIM BIOPHYS ACTA, V627, P91, DOI 10.1016/0304-4165(80)90126-9; THOMPSON DD, 1988, J BONE MINER RES, V3, P409; TURNER CH, 1994, FASEB J, V8, P875, DOI 10.1096/fasebj.8.11.8070637; VANDERPLAS A, 1992, J BONE MINER RES, V7, P389; VANDERPLAS A, 1994, J BONE MINER RES, V9, P1697; WEINBAUM S, 1994, J BIOMECH, V27, P339, DOI 10.1016/0021-9290(94)90010-8; Wolff J, 1892, GESETZ TRANSFORMATIO	32	577	596	2	36	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1995	9	5					441	445		10.1096/fasebj.9.5.7896017	http://dx.doi.org/10.1096/fasebj.9.5.7896017			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QP451	7896017				2022-12-25	WOS:A1995QP45100020
J	WARREN, JB; LOI, RK				WARREN, JB; LOI, RK			CAPTOPRIL INCREASES SKIN MICROVASCULAR BLOOD-FLOW SECONDARY TO BRADYKININ, NITRIC-OXIDE, AND PROSTAGLANDINS	FASEB JOURNAL			English	Article						ANGIOTENSIN CONVERTING ENZYME; CYCLOOXYGENASE; HEART FAILURE; VASODILATION; ENDOTHELIUM	ANGIOTENSIN-CONVERTING ENZYME; ENDOTHELIUM-DERIVED BRADYKININ; MOLECULAR-WEIGHT KININOGEN; VASCULAR-RESPONSES; HEART-FAILURE; RABBIT SKIN; INHIBITION; CELLS; MICROCIRCULATION; POTENT	Angiotensin converting enzyme inhibitors (ACEIs) are a cornerstone of treatment of hypertension and heart failure yet their mechanism of action is still debated. This study was designed to test whether the ACEI captopril increases skin microvascular blood flow by a bradykinin-dependent mechanism. Local changes in microvascular blood flow were measured in the skin of rabbits and of human volunteers using a laser Doppler flow probe. Captopril injected intradermally increased skin blood flow over the dose range of 10(-12)-10(-8) mol site in rabbits and humans. In both species the response was abolished by coinjecting either a nitric oxide synthase (NOS) inhibitor or a cyclooxygenase inhibitor. Intradermal bradykinin also increased rabbit skin microvascular blood flow; at 10(-11) mol site it increased mean +/- SE basal blood flow by 88 +/- 12%. The responses to bradykinin or captopril were abolished by coinjecting a bradykinin antagonist, a specific bradykinin B-2 receptor antagonist, or inhibitors of NOS or cyclooxygenase. Injecting a specific angiotensin II receptor antagonist at a dose that antagonized the constrictor effects of exogenous angiotensin II did not cause a significant increase in rabbit skin blood flow. This suggests that endogenous angiotensin II does not influence microvascular blood flow in this model. The results indicate that captopril increases skin microvascular blood flow in rabbits and humans secondary to an increase in endogenous tissue bradykinin; this stimulates B-2 receptors with subsequent release of prostaglandins and nitric oxide, ACEIs may increase microvascular perfusion by a bradykinin-dependent mechanism.			WARREN, JB (corresponding author), NATL HEART & LUNG INST, DEPT APPL PHARMACOL, DOVEHOUSE ST, LONDON SW3 6LY, ENGLAND.							BENJAMIN N, 1989, J PHYSIOL-LONDON, V412, P543, DOI 10.1113/jphysiol.1989.sp017630; BRAUNWALD E, 1991, NEW ENGL J MED, V325, P351, DOI 10.1056/NEJM199108013250508; BUSSE R, 1991, N-S ARCH PHARMACOL, V344, P126; CHATTERJEE K, 1987, Cardiovascular Drugs and Therapy, V1, P1, DOI 10.1007/BF02125827; CHERRY PD, 1982, P NATL ACAD SCI-BIOL, V79, P2106, DOI 10.1073/pnas.79.6.2106; EDWARDS RM, 1983, AM J PHYSIOL, V244, pF526, DOI 10.1152/ajprenal.1983.244.5.F526; FERREIRA SH, 1965, BRIT J PHARM CHEMOTH, V24, P163, DOI 10.1111/j.1476-5381.1965.tb02091.x; FULLER RW, 1987, BRIT J CLIN PHARMACO, V23, P88, DOI 10.1111/j.1365-2125.1987.tb03014.x; GERRITSEN ME, 1983, J CLIN INVEST, V72, P1658, DOI 10.1172/JCI111125; HILDITCH A, 1994, BRIT J PHARMACOL, V111, P137, DOI 10.1111/j.1476-5381.1994.tb14035.x; KALEY G, 1989, AM J PHYSIOL, V256, pH720, DOI 10.1152/ajpheart.1989.256.3.H720; KIOWSKI W, 1992, CIRCULATION, V85, P1; KOLLER A, 1989, AM J PHYSIOL, V257, pH1966, DOI 10.1152/ajpheart.1989.257.6.H1966; LAMMEK B, 1990, PEPTIDES, V11, P1041, DOI 10.1016/0196-9781(90)90031-Y; LAMONTAGNE D, 1992, J CARDIOVASC PHARM, V20, P652, DOI 10.1097/00005344-199210000-00020; LINZ W, 1990, J CARDIOVASC PHARM, V15, pS99, DOI 10.1097/00005344-199015061-00018; MACFADYEN RJ, 1991, BRIT J CLIN PHARMACO, V31, P1; MANINTVELD AJ, 1979, BRIT MED J, V2, P1110, DOI 10.1136/bmj.2.6198.1110; Messina E J, 1980, Adv Prostaglandin Thromboxane Res, V7, P719; MOORE TJ, 1981, HYPERTENSION, V3, P168, DOI 10.1161/01.HYP.3.2.168; MOOSER V, 1990, J CARDIOVASC PHARM, V15, P276, DOI 10.1097/00005344-199002000-00015; MORAVEC CS, 1990, CIRCULATION, V82, P1973, DOI 10.1161/01.CIR.82.6.1973; NISHIMURA H, 1989, AM HEART J, V117, P100, DOI 10.1016/0002-8703(89)90662-5; NUSSBERGER J, 1985, HYPERTENSION, V7, pI1, DOI 10.1161/01.HYP.7.3_Pt_2.I1; PONS F, 1993, EUR J PHARMACOL, V239, P23, DOI 10.1016/0014-2999(93)90971-J; PORSTI I, 1994, BRIT J PHARMACOL, V111, P652; RIVERS RJ, 1990, AM J PHYSIOL, V258, pH606, DOI 10.1152/ajpheart.1990.258.2.H606; ROBERTSON MJ, 1992, BRIT J PHARMACOL, V107, P1173, DOI 10.1111/j.1476-5381.1992.tb13425.x; SCHINI VB, 1990, J PHARMACOL EXP THER, V252, P581; SCHMAIER AH, 1988, J BIOL CHEM, V263, P16327; SELLKE FW, 1990, CIRCULATION, V81, P1586, DOI 10.1161/01.CIR.81.5.1586; SWARTZ SL, 1980, J CLIN INVEST, V65, P1257, DOI 10.1172/JCI109788; SWARTZ SL, 1982, AM J CARDIOL, V49, P1405, DOI 10.1016/0002-9149(82)90351-4; TONEY GM, 1993, NEUROPHARMACOLOGY, V32, P581, DOI 10.1016/0028-3908(93)90054-7; VANIWAARDEN F, 1988, BLOOD, V71, P1268; WARREN JB, 1993, FASEB J, V7, P1394, DOI 10.1096/fasebj.7.14.7693536; WARREN JB, 1992, BRIT J PHARMACOL, V106, P331, DOI 10.1111/j.1476-5381.1992.tb14336.x; WARREN JB, 1994, FASEB J, V8, P247, DOI 10.1096/fasebj.8.2.7509761; WARREN JB, 1994, AM J PHYSIOL, V266, pH1846, DOI 10.1152/ajpheart.1994.266.5.H1846; WIEMER G, 1992, AGENT ACTION SUPPL, V38, P196; WIEMER G, 1991, HYPERTENSION, V18, P558, DOI 10.1161/01.HYP.18.4.558; WIEMER G, 1994, CARDIOVASC RES, V28, P166, DOI 10.1093/cvr/28.2.166; WILSON AJ, 1993, BRIT J PHARMACOL, V110, P633, DOI 10.1111/j.1476-5381.1993.tb13858.x; WOLIN MS, 1990, J PHARMACOL EXP THER, V254, P872	44	42	44	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1995	9	5					411	418		10.1096/fasebj.9.5.7896012	http://dx.doi.org/10.1096/fasebj.9.5.7896012			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QP451	7896012				2022-12-25	WOS:A1995QP45100015
J	MICHNOFF, CH; PARIKH, VS; LELSZ, DL; TUCKER, PW				MICHNOFF, CH; PARIKH, VS; LELSZ, DL; TUCKER, PW			MUTATIONS WITHIN THE NH2-TERMINAL TRANSMEMBRANE DOMAIN OF MEMBRANE IMMUNOGLOBULIN (IG)-M ALTERS IG-ALPHA AND IG-BETA ASSOCIATION AND SIGNAL-TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; PROTEIN TYROSINE KINASES; MOLECULAR-COMPONENTS; LYMPHOCYTES-B; SRC FAMILY; COMPLEX; ACTIVATION; EXPRESSION; ANTIBODIES; SURFACE	Potentiation of initial signal transduction events through the cross-linking of the B cell antigen receptor complex appears to be dependent upon the association of membrane immunoglobulin (mIg) with Ig alpha and Ig beta. We made two groups of mutations within the COOH terminus of mIgM substituting: 1) the spacer, transmembrane, and cytoplasmic domains and 2) the NH2-terminal 2-8 amino acids within the transmembrane domain (NL-WTTAST). We then evaluated the ability of the mutated receptors to associate with Ig alpha and Ig beta and to initiate signal transduction events (Ca2+ mobilization and phosphorylation by tyrosine protein kinases) after crosslinking mIgM receptors. Mutant mIgM receptors containing substitutions of gamma 2b (spacer, transmembrane, and cytoplasmic domains), AA for TT, and AAAAA for TTAST bound Ig alpha and Ig beta and initiated signal transduction events after mIgM receptor cross-linking. However, substitutions of I-A alpha (spacer, transmembrane, and cytoplasmic domains) or TTVVCALGL for NLWTTAST blocked association of Ig alpha and Ig beta and initiation of signal transduction events. Results indicate that residues within the first 8 amino acids of the transmembrane domain other than TTAST are necessary for receptor function and association with Ig alpha and Ig beta.	UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIAID NIH HHS [AI18016] Funding Source: Medline; NIGMS NIH HHS [GM 31689] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018016, R01AI018016] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM031689] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUM JH, 1993, J BIOL CHEM, V268, P27236; BURKHARDT AL, 1994, MOL CELL BIOL, V14, P1095, DOI 10.1128/MCB.14.2.1095; CAMBIER JC, 1992, CURR OPIN IMMUNOL, V4, P257, DOI 10.1016/0952-7915(92)90074-O; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; DAS C, 1992, P NATL ACAD SCI USA, V89, P9749, DOI 10.1073/pnas.89.20.9749; DESIDERIO SV, 1992, CURR OPIN IMMUNOL, V4, P252, DOI 10.1016/0952-7915(92)90073-N; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GRONOWICZ ES, 1980, J IMMUNOL, V125, P976; GRUPP SA, 1993, J BIOL CHEM, V268, P25776; Harlow E., 1988, ANTIBODIES LABORATOR, P511; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOMBACH J, 1988, EMBO J, V7, P3451, DOI 10.1002/j.1460-2075.1988.tb03219.x; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HOMBACH J, 1990, EUR J IMMUNOL, V20, P2795, DOI 10.1002/eji.1830201239; HUGHES SD, 1991, J BIOL CHEM, V266, P4521; ISHIHARA K, 1992, P NATL ACAD SCI USA, V89, P633, DOI 10.1073/pnas.89.2.633; ISHIHARA K, 1993, J IMMUNOL, V150, P2253; KASHIWAMURA SI, 1990, J IMMUNOL, V145, P337; KIM KJ, 1979, J IMMUNOL, V122, P549; KIM KM, 1993, EUR J IMMUNOL, V23, P911, DOI 10.1002/eji.1830230422; LACHMANN PJ, 1986, CIBA F SYMP, V119, P25; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIM PL, 1986, MOL IMMUNOL, V23, P909; LIN JJ, 1992, J IMMUNOL, V149, P1548; NEUBERGER MS, 1993, IMMUNOL REV, V132, P147, DOI 10.1111/j.1600-065X.1993.tb00841.x; NOMURA J, 1991, INT IMMUNOL, V3, P117, DOI 10.1093/intimm/3.2.117; OETTGEN HC, 1986, NATURE, V320, P272, DOI 10.1038/320272a0; PARIKH VS, 1991, J EXP MED, V174, P1103, DOI 10.1084/jem.174.5.1103; PARIKH VS, 1992, J EXP MED, V176, P1025, DOI 10.1084/jem.176.4.1025; PATEL KJ, 1993, CELL, V74, P939, DOI 10.1016/0092-8674(93)90473-4; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; RETH M, 1991, IMMUNOL TODAY, V12, P196, DOI 10.1016/0167-5699(91)90053-V; SANCHEZ M, 1993, J EXP MED, V178, P1049, DOI 10.1084/jem.178.3.1049; STEVENS TL, 1994, J IMMUNOL, V152, P4397; TRAVIS A, 1991, MOL CELL BIOL, V11, P5756, DOI 10.1128/MCB.11.11.5756; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; WEBB CF, 1989, P NATL ACAD SCI USA, V86, P1977, DOI 10.1073/pnas.86.6.1977; WIENANDS J, 1990, EMBO J, V9, P449, DOI 10.1002/j.1460-2075.1990.tb08130.x; WILLIAMS GT, 1990, J EXP MED, V171, P947, DOI 10.1084/jem.171.3.947	41	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24237	24244						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929080				2022-12-25	WOS:A1994PQ34600061
J	REIFELMILLER, AE; CALNEK, DS; GRINNELL, BW				REIFELMILLER, AE; CALNEK, DS; GRINNELL, BW			TYROSINE PHOSPHORYLATION REGULATES THE DNA-BINDING ACTIVITY OF A NUCLEAR FACTOR 1-LIKE REPRESSOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSCRIPTION FACTOR; SIGNAL TRANSDUCTION; ENHANCER ACTIVITY; GENE-EXPRESSION; ADENOVIRUS; PHOSPHATASE; CELLS; ACTIVATION; INHIBITOR; VANADATE	We have previously identified an ubiquitous repressor binding site that binds a nuclear factor 1 (NF-1)-like transcription factor designated BEF-1. The DNA binding activity of BEF-1, a 98-kDa protein, is increased by the oncoproteins of adenovirus, the early region la proteins (E1a), which results in the induction of further repression. Using the prototype repressor sequence, first identified in the enhancer of the human polyoma virus BKV-P2, we have shown that phosphorylation of BEF-1 is required for its DNA binding activity. We demonstrate here that the inhibition of DNA binding by BEF-1 dephosphorylated with potato acid phosphatase or calf intestinal alkaline phosphatase was reversed by sodium orthovanadate, a specific inhibitor of phosphotyrosyl-protein phosphatases, In addition, BEF-1 binding activity, but not the binding of related factor NF-1, could be inhibited by dephosphorylation with a specific phosphotyrosine phosphatase. We found that both polyclonal and monoclonal phosphotyrosine-specific antibodies blocked binding of the repressor protein to the BEF-1 site. Moreover, BEF-1 activity could be adsorbed on an anti-phosphotyrosine antibody column and specially eluted with phosphotyrosine. In transfection studies in HeLa cells, which contain high levels of BEF-1, we show that E1a-induced repression mediated by BEF-1 was relieved with the tyrosine kinase inhibitors genistein and tyrphostin. Together, these results demonstrate that a phosphotyrosine on the BEF-1 repressor protein regulates DNA binding activity and thus regulates repression of the BKV-P2 enhancer. This report represents the first demonstration that the phosphorylated state of a tyrosine can control gene expression by altering the DNA binding activity of a transcription factor.	ELI LILLY & CO,LILLY CORP CTR,LILLY RES LABS,DEPT CARDIOVASC RES 0522,INDIANAPOLIS,IN 46285; ELI LILLY & CO,LILLY RES LAB,DEPT DIABET,INDIANAPOLIS,IN 46285	Eli Lilly; Eli Lilly								AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BERG DT, 1989, MOL CELL BIOL, V9, P5248, DOI 10.1128/MCB.9.11.5248; BERG DT, 1988, NUCLEIC ACIDS RES, V16, P9057, DOI 10.1093/nar/16.18.9057; BOHMANN D, 1990, CANCER CELL-MON REV, V2, P337; DAVID M, 1993, MOL CELL BIOL, V13, P7515, DOI 10.1128/MCB.13.12.7515; DAVID M, 1992, SCIENCE, V257, P813, DOI 10.1126/science.1496402; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GRINNELL BW, 1988, MOL CELL BIOL, V8, P3448, DOI 10.1128/MCB.8.8.3448; GRINNELL BW, 1986, MOL CELL BIOL, V6, P3596, DOI 10.1128/MCB.6.11.3596; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; LEVITZKI A, 1992, FASEB J, V6, P3275, DOI 10.1096/fasebj.6.14.1426765; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; MONTESANO R, 1988, J CELL PHYSIOL, V134, P460, DOI 10.1002/jcp.1041340318; NELSON RL, 1984, MOL CELL BIOL, V4, P1003, DOI 10.1128/MCB.4.6.1003; RAYCHAUDHURI P, 1989, GENE DEV, V3, P620, DOI 10.1101/gad.3.5.620; REIFELMILLER AE, 1991, J BIOL CHEM, V266, P13873; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; SWARUP G, 1982, J BIOL CHEM, V257, P7298; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; ZHONG XH, 1990, MOL CELL BIOL, V10, P770, DOI 10.1128/MCB.10.2.770	26	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23861	23864						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929029				2022-12-25	WOS:A1994PQ34600003
J	ZAIDI, SHE; MALTER, JS				ZAIDI, SHE; MALTER, JS			AMYLOID PRECURSOR PROTEIN MESSENGER-RNA STABILITY IS CONTROLLED BY A 29-BASE ELEMENT IN THE 3'-UNTRANSLATED REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; 3' UNTRANSLATED REGION; URIDINE BINDING-FACTOR; T-CELL ACTIVATION; ALZHEIMERS-DISEASE; PHORBOL ESTER; GM-CSF; EXPRESSION; DEGRADATION; SEQUENCE	In the accompanying paper (Zaidi, S. H. E., Denman, R., and Malter, J. S. (1994) J. Biol. Chem. 269, 24000-24006) we demonstrate that in tumor and normal cells, multiple cytosolic proteins interact with a 29-base sequence in the 3'-untranslated region of amyloid precursor protein (APP) mRNA. These data suggested that APP gene expression may be modulated by regulated APP mRNA decay. We have investigated this prediction by measuring the decay rates of APP mRNA in resting and mitogen-treated peripheral blood mononuclear cells and H4 and K562 tumor cell lines. In resting peripheral blood mononuclear cells, APP mRNA decayed with a half-life of 4 h. Under these conditions, the activity of APP mRNA-binding proteins was not detectable. After activation, binding protein activities were induced, and APP mRNA decay was blocked with a half-life of >12 h. In log phase neuronal or lymphoid tumor cell lines, binding activity was constitutively present and APP mRNA displayed a half-life of >12 h. Protein synthesis inhibition by cycloheximide had no effect on APP mRNA decay in normal or tumor cells. Transfected wild type or mutant APP mRNAs that lacked the 29-base region were stable (t(1/2) > 10 h) in K562 tumor cells. Therefore, we conclude that the 29-base region functions in cis to destabilize APP mRNA in resting, normal cells. Upon activation APP mRNA-binding proteins are induced, interact with the 29-base region, and likely participate in stabilization of the mRNA.	UNIV WISCONSIN,DEPT PATHOL & LAB MED,NEUROSCI PROGRAM,MADISON,WI 53792; UNIV WISCONSIN,INST AGING,MADISON,WI 53792	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NIA NIH HHS [R01-AG 10675] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG010675] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P986, DOI 10.1016/0006-291X(92)92301-D; ATWATER JA, 1990, ANNU REV GENET, V24, P519; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CARMANKRZAN M, 1991, J NEUROCHEM, V56, P636, DOI 10.1111/j.1471-4159.1991.tb08197.x; CHANG L, 1993, P NATL ACAD SCI USA, V90, P4455; CHEN FY, 1993, EMBO J, V12, P3977, DOI 10.1002/j.1460-2075.1993.tb06075.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUVAL C, 1990, MOL CELL BIOL, V10, P4123, DOI 10.1128/MCB.10.8.4123; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; JACOBSEN JS, 1991, NEUROBIOL AGING, V12, P585, DOI 10.1016/0197-4580(91)90090-7; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MONNING U, 1990, FEBS LETT, V277, P261, DOI 10.1016/0014-5793(90)80861-C; MONNING U, 1992, J BIOL CHEM, V267, P23950; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; ROSS HJ, 1991, BLOOD, V77, P1787; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SHARMA N, 1991, GLIA, V4, P572, DOI 10.1002/glia.440040604; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SILJANDER P, 1993, FEBS LETT, V315, P81, DOI 10.1016/0014-5793(93)81138-P; STEPHENS JM, 1992, J BIOL CHEM, V267, P8336; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WALZ G, 1991, CELL IMMUNOL, V134, P511, DOI 10.1016/0008-8749(91)90322-3; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; YOU Y, 1992, MOL CELL BIOL, V12, P2931, DOI 10.1128/MCB.12.7.2931; ZAIDI SHE, 1994, J BIOL CHEM, V269, P24000	35	87	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24007	24013						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929051				2022-12-25	WOS:A1994PQ34600027
J	GOHDA, K; OKA, K; TOMITA, K; HAKOSHIMA, T				GOHDA, K; OKA, K; TOMITA, K; HAKOSHIMA, T			CRYSTAL-STRUCTURE OF RNASE T1 COMPLEXED WITH THE PRODUCT 3'-GMP - STRUCTURAL EVIDENCE FOR DIRECT INTERACTION OF HISTIDINE-40 AND GLUTAMIC-ACID-58 WITH THE 2'-HYDROXYL GROUP OF THE RIBOSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEAST-SQUARES REFINEMENT; 3-DIMENSIONAL STRUCTURE; SUBSITE INTERACTIONS; X-RAY; FURANOSE RING; GPN TRANSESTERIFICATION; SUBSTRATE-BINDING; 1.9-A RESOLUTION; RIBONUCLEASE-T1; PHOSPHATE	The crystal structure of RNase T1 complexed with 3'-GMP has been determined. The glycosyl conformation of 3'-GMP is in the syn conformation, and the ribose adopts the O4'-endo pucker. This observed pucker is different from that in any complex structures of RNase T1. In the present complex, this energetically unfavorable conformation is stabilized by the water molecule with the bridged hydrogen bonds between the O2' and the O3' atoms of the ribose. The guanine base is recognized in the same manner as observed in the complex of 2'-GMP. The 2'-hydroxyl group of the ribose shows a tight hydrogen bond to both His-40 and Glu-58 with the suitable geometry for the proton transfer. These hydrogen bonds suggest that the two residues can participate directly in the proton transfer. His-92 is hydrogen banded to two oxygen atoms of the phosphate group. Based on the geometry in the active site, the O1P atom may correspond to the O5' atom of the leaving nucleotide in the phosphoryl transfer or a water molecule as a nucleophile in the hydrolysis reaction. In the present complex, the conformations of the 3'-GMP molecule and the side chains of the catalytic residues would be represented as the conformation before the phosphoryl transfer reaction and/or after the hydrolysis reaction.	OSAKA UNIV,FAC PHARMACEUT SCI,SUITA,OSAKA 565,JAPAN	Osaka University				Gohda, Keigo/0000-0002-9345-2377				ALTONA C, 1972, J AM CHEM SOC, V94, P8205, DOI 10.1021/ja00778a043; ARNI R, 1988, J BIOL CHEM, V263, P15358; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CAMBILLOU C, 1989, SILICON GRAPHICS GEO, P1; COULTER CL, 1973, J AM CHEM SOC, V95, P570, DOI 10.1021/ja00783a042; ECKSTEIN F, 1972, BIOCHEMISTRY-US, V11, P3507, DOI 10.1021/bi00769a002; Egami F, 1980, Mol Biol Biochem Biophys, V32, P250; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; HAKOSHIMA T, 1992, J MOL BIOL, V223, P1013, DOI 10.1016/0022-2836(92)90259-M; HEINEMANN U, 1982, NATURE, V299, P27, DOI 10.1038/299027a0; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; HILL C, 1983, TRENDS BIOCHEM SCI, V8, P364, DOI 10.1016/0968-0004(83)90363-8; INAGAKI F, 1985, BIOCHEMISTRY-US, V24, P1013, DOI 10.1021/bi00325a031; IRIE M, 1967, J BIOCHEM-TOKYO, V61, P550, DOI 10.1093/oxfordjournals.jbchem.a128585; ITOH T, 1991, J BIOCHEM-TOKYO, V110, P677, DOI 10.1093/oxfordjournals.jbchem.a123639; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KOELLNER G, 1992, J MOL BIOL, V224, P701, DOI 10.1016/0022-2836(92)90554-W; KOEPKE J, 1989, J MOL BIOL, V206, P475, DOI 10.1016/0022-2836(89)90495-6; KOSTREWA D, 1989, BIOCHEMISTRY-US, V28, P7592, DOI 10.1021/bi00445a014; LENZ A, 1991, J BIOL CHEM, V266, P7661; LEVITT M, 1978, J AM CHEM SOC, V100, P2607, DOI 10.1021/ja00477a004; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MALIN R, 1991, J BIOL CHEM, V266, P4848; MARTINEZOYANEDEL J, 1991, J MOL BIOL, V222, P335, DOI 10.1016/0022-2836(91)90215-R; MEIERING EM, 1993, BIOCHEMISTRY-US, V32, P10975, DOI 10.1021/bi00092a006; MORIOKA H, 1989, THESIS OSAKA U JAPAN; MOSSAKOWSKA DE, 1989, BIOCHEMISTRY-US, V28, P3843, DOI 10.1021/bi00435a033; NISHIKAWA S, 1987, BIOCHEMISTRY-US, V26, P8620, DOI 10.1021/bi00400a019; NISHIKAWA S, 1986, BIOCHEM BIOPH RES CO, V138, P789, DOI 10.1016/S0006-291X(86)80566-6; NORTH ACT, 1968, ACTA CRYSTALL A-CRYS, VA 24, P351, DOI 10.1107/S0567739468000707; OLSON WK, 1982, J AM CHEM SOC, V104, P270, DOI 10.1021/ja00365a049; OLSON WK, 1982, J AM CHEM SOC, V104, P278, DOI 10.1021/ja00365a050; OSTERMAN HL, 1978, BIOCHEMISTRY-US, V17, P4124, DOI 10.1021/bi00613a003; OSTERMAN HL, 1979, BIOCHEMISTRY-US, V18, P1984, DOI 10.1021/bi00577a021; PAVLOVSKII AG, 1987, DOKL AKAD NAUK SSSR+, V292, P1253; SATO K, 1957, J BIOCHEM-TOKYO, V44, P753, DOI 10.1093/oxfordjournals.jbchem.a126717; SEVCIK J, 1991, ACTA CRYSTALLOGR B, V47, P240, DOI 10.1107/S0108768190009569; SHIMADA I, 1990, BIOCHEMISTRY-US, V29, P757, DOI 10.1021/bi00455a024; STEYAERT J, 1991, BIOCHEMISTRY-US, V30, P8661, DOI 10.1021/bi00099a024; STEYAERT J, 1990, BIOCHEMISTRY-US, V29, P9064, DOI 10.1021/bi00490a025; STEYAERT J, 1991, BIOCHEMISTRY-US, V30, P8666, DOI 10.1021/bi00099a025; STEYAERT J, 1993, J MOL BIOL, V229, P770, DOI 10.1006/jmbi.1993.1078; STORER JW, 1991, J AM CHEM SOC, V113, P5216, DOI 10.1021/ja00014a012; SUGIO S, 1985, FEBS LETT, V183, P115, DOI 10.1016/0014-5793(85)80966-2; SUGIO S, 1988, J BIOCHEM-TOKYO, V103, P354, DOI 10.1093/oxfordjournals.jbchem.a122274; TAIRA K, 1991, NUCLEIC ACIDS RES, V19, P2747, DOI 10.1093/nar/19.10.2747; TAKAHASHI K, 1972, J BIOCHEM-TOKYO, V67, P833; Takahashi K., 1982, ENZYMES, V15, p435 468; WALZ FG, 1976, BIOCHEMISTRY-US, V15, P2837, DOI 10.1021/bi00658a021	52	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17531	17536						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	7912696				2022-12-25	WOS:A1994NU12800032
J	JAMES, R; ERLER, T; KAZENWADEL, J				JAMES, R; ERLER, T; KAZENWADEL, J			STRUCTURE OF THE MURINE HOMEOBOX GENE CDX-2 - EXPRESSION IN EMBRYONIC AND ADULT INTESTINAL EPITHELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA HOMEODOMAIN PROTEINS; MOUSE SMALL-INTESTINE; DNA-BINDING; MESSENGER-RNA; DISTAL COLON; CELL-TYPES; RAT COLON; DIFFERENTIATION; SEQUENCE; DOMAIN	To gain insight into the mechanisms which govern cellular identity in the intestinal epithelium we have begun a detailed study of the murine cdx-2 homeobox gene, We isolated and sequenced both cDNA and genomic clones in order to define the open reading frame and mature transcript. A detailed analysis of cdx-2 transcript levels late in embryogenesis showed that they increased 6-7-fold at a time when the gut undergoes a major develop mental transition. In the adult, cdx-2 was expressed in colon in a region-specific manner with transcripts some 5-fold more abundant in the cecum as compared with the rectum. In situ hybridization and immunohistochemical experiments showed cdx-2 transcripts and protein were present in all epithelial cells in the proximal colon irrespective of their degree of differentiation. In distal colon, however, transcripts were most abundant in undifferentiated cells at the bottom of crypts, whereas the highest protein levels were present in mature cells in the upper half of crypts. We conclude that cdx-2 is expressed specifically in gut epithelium where it is not restricted to a particular cell lineage. Rather, the rostrocaudal expression gradient suggests that it may play a role in specifying positional identity.	UNIV MELBOURNE,DEPT MED,PARKVILLE,VIC 3050,AUSTRALIA	University of Melbourne	JAMES, R (corresponding author), UNIV MELBOURNE,ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,DEPT MED,MELBOURNE TUMOR BIOL BRANCH,MELBOURNE,VIC 3050,AUSTRALIA.		Kazenwadel, Jan/E-6620-2012	Kazenwadel, Jan/0000-0001-6216-3444				AMASINO RM, 1986, ANAL BIOCHEM, V152, P304, DOI 10.1016/0003-2697(86)90413-6; ANANTHAN J, 1993, MOL CELL BIOL, V13, P1599, DOI 10.1128/MCB.13.3.1599; BERGMAN EN, 1990, PHYSIOL REV, V70, P567, DOI 10.1152/physrev.1990.70.2.567; BLAU HM, 1992, ANNU REV BIOCHEM, V61, P1213, DOI 10.1146/annurev.bi.61.070192.010025; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHANG WWL, 1975, AM J ANAT, V144, P39, DOI 10.1002/aja.1001440104; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHENG H, 1982, ANAT REC, V203, P251, DOI 10.1002/ar.1092030207; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLONY PC, 1985, GASTROENTEROLOGY, V89, P294, DOI 10.1016/0016-5085(85)90329-4; COLONY PC, 1983, DEV BIOL, V97, P349, DOI 10.1016/0012-1606(83)90092-1; COLONY PC, 1989, CELLULAR MOL BIOL CO, P2; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; CROWSON MS, 1992, J BIOL CHEM, V267, P13740; DAUCA M, 1990, International Journal of Developmental Biology, V34, P205; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; FITZPATRICK VD, 1992, NATURE, V356, P610, DOI 10.1038/356610a0; GAVIS ER, 1991, DEVELOPMENT, V112, P1077; GRIFFITHS DFR, 1988, NATURE, V333, P461, DOI 10.1038/333461a0; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HAN HY, 1993, P NATL ACAD SCI USA, V90, P3806, DOI 10.1073/pnas.90.9.3806; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HU YL, 1993, J BIOL CHEM, V268, P27214; JAMES R, 1991, J BIOL CHEM, V266, P3246; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KROZOWSKI Z, 1992, MOL CELL ENDOCRINOL, V85, P21, DOI 10.1016/0303-7207(92)90121-L; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; MORITA T, 1988, GENE, V68, P109; ODENWALD WF, 1989, GENE DEV, V3, P158, DOI 10.1101/gad.3.2.158; PAN LX, 1993, HISTOCHEM J, V25, P57, DOI 10.1007/BF00161045; PEREZTOMAS R, 1993, GASTROENTEROLOGY, V104, P789, DOI 10.1016/0016-5085(93)91014-9; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; PONDER BAJ, 1985, NATURE, V313, P689, DOI 10.1038/313689a0; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; ROTH KA, 1992, AM J PHYSIOL, V263, pG174, DOI 10.1152/ajpgi.1992.263.2.G174; RUBIN DC, 1989, P NATL ACAD SCI USA, V86, P1278, DOI 10.1073/pnas.86.4.1278; RUBIN DC, 1992, J BIOL CHEM, V267, P15122; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT GH, 1988, DEVELOPMENT, V103, P785; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; STURZL M, 1990, ANAL BIOCHEM, V185, P164, DOI 10.1016/0003-2697(90)90274-D; TESSAROLLO L, 1992, DEVELOPMENT, V115, P11; TRONCHE F, 1992, BIOESSAYS, V14, P579, DOI 10.1002/bies.950140902; VISVADER JE, 1992, EMBO J, V11, P4557, DOI 10.1002/j.1460-2075.1992.tb05557.x; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WHITEHEAD RH, 1992, IMMUNOL CELL BIOL, V70, P227, DOI 10.1038/icb.1992.30; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WRIGHT EM, 1990, DEVELOPMENT CAMB, V110, P477	51	263	275	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15229	15237						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	7910823				2022-12-25	WOS:A1994NP73800057
J	VERNET, T; ZIOMEK, E; RECKTENWALD, A; SCHRAG, JD; DEMONTIGNY, C; TESSIER, DC; THOMAS, DY; CYGLER, M				VERNET, T; ZIOMEK, E; RECKTENWALD, A; SCHRAG, JD; DEMONTIGNY, C; TESSIER, DC; THOMAS, DY; CYGLER, M			CLONING AND EXPRESSION OF GEOTRICHUM-CANDIDUM LIPASE-II GENE IN YEAST - PROBING OF THE ENZYME ACTIVE-SITE BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC CHOLESTEROL ESTERASE; SACCHAROMYCES-CEREVISIAE; ALPHA-FACTOR; TRIAD FORMS; ACETYLCHOLINESTERASE; PROTEINS; DNA; EFFICIENT; VECTORS; IDENTIFICATION	The three-dimensional structure of lipase II of Geotrichum candidum strain ATCC34614 (GCL II) has provided insights with respect to the nature of the catalytic machinery of lipases. To support these structural observations, we have carried out an analysis of GCL II by mutagenesis. The gene encoding lipase II of Geotrichum candidum strain ATCC34614 (GCL II) was amplified using the polymerase chain reaction, cloned, and sequenced. The intronless lipase gene was expressed and secreted from Saccharomyces cerevisiae at approximately 5 mg/liter of culture. Recombinant GCL II was purified by immunoaffinity chromatography and characterized using a combination of substrates and independent analytical methods. The recombinant enzyme and the enzyme isolated from its natural source have comparable specific activities against triolein of about 1000 mumol of oleic acid released/min/mg of protein. The putative catalytic triad Ser217-His463-Glu354 was probed by site-directed mutagenesis. The substitution of Ser217 by either Cys or Thr and of His463 by Ala led to a complete elimination of the activity against both triolein and tributyrin. Substitution of Glu354 by either Ser, Ala or Gln renders the enzyme inactive and also perturbs the enzyme stability. However, the enzyme with the conservative replacement Glu354Asp is stable and displays only a small decrease of triolein activity but a 10-fold decrease in activity against tributyrin. There was no appreciable difference in esterase activity between the native, recombinant wild type, and Glu354 Asp mutant. These results confirm that the triad formed by Ser217-Glu354-His463 is essential for catalytic activity. They also show that the active site of GCL II is more tolerant to a conservative change of the carboxylic side chain within the triad than are other hydrolases with similar catalytic triads.	NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, 6100 AVE ROYALMOUNT, MONTREAL H4P 2R2, PQ, CANADA	National Research Council Canada			Vernet, Thierry/G-1118-2012; Thomas, David/M-7661-2017	Thomas, David/0000-0002-8854-762X				[Anonymous], 1972, ENZYMES; ARENDS J, 1979, J IMMUNOL METHODS, V25, P171, DOI 10.1016/0022-1759(79)90052-8; AVRAMEAS S, 1971, IMMUNOCHEMISTRY, V8, P1175, DOI 10.1016/0019-2791(71)90395-8; BAILLARGEON MW, 1991, LIPIDS, V26, P831, DOI 10.1007/BF02536165; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; BRAKE AJ, 1989, YEAST GENETIC ENG, P269; BROMME D, 1993, J BIOL CHEM, V268, P4832; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; CARTER P, 1988, NATURE, V332, P561; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHAPUS C, 1976, BIOCHEMISTRY-US, V15, P4988, DOI 10.1021/bi00668a007; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; COREY DR, 1992, J AM CHEM SOC, V114, P1784, DOI 10.1021/ja00031a037; CYGLER M, 1993, PROTEIN SCI, V2, P366; CYGLER M, 1992, BIOTECHNOL GENET REV, V10, P141; DIPERSIO LP, 1990, J BIOL CHEM, V265, P16801; DIPERSIO LP, 1993, J BIOL CHEM, V268, P300; DIPERSIO LP, 1991, J BIOL CHEM, V266, P4033; ERGAN F, 1989, LIPIDS, V24, P76, DOI 10.1007/BF02535268; ERNST JF, 1988, DNA-J MOLEC CELL BIO, V7, P355, DOI 10.1089/dna.1.1988.7.355; ERNST JF, 1986, DNA CELL BIOL, V5, P8; FOURNIER D, 1992, J BIOL CHEM, V267, P14270; GIBNEY G, 1990, P NATL ACAD SCI USA, V87, P7546, DOI 10.1073/pnas.87.19.7546; GROCHULSKI P, 1993, J BIOL CHEM, V268, P12843; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JENSEN RG, 1965, J AM OIL CHEM SOC, V42, P1029, DOI 10.1007/BF02636897; JONES EW, 1991, METHOD ENZYMOL, V194, P428; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; JULIUS D, 1983, CELL, V32, P837; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Livingston D M, 1974, Methods Enzymol, V34, P723; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEYER E, 1992, PROTEIN SCI, V1, P1543, DOI 10.1002/pro.5560011203; NEVILLE LF, 1990, J BIOL CHEM, V265, P20735; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; ROMANOS MA, 1992, YEAST, V8, P423, DOI 10.1002/yea.320080602; SAMAD MYA, 1989, J MICROBIOL METH, V9, P51, DOI 10.1016/0167-7012(89)90030-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRAG JD, 1993, J MOL BIOL, V230, P575, DOI 10.1006/jmbi.1993.1171; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SHAFFERMAN A, 1992, J BIOL CHEM, V267, P17640; Sherman F., 1982, METHODS YEAST GENETI; SHIMADA Y, 1989, J BIOCHEM-TOKYO, V106, P383, DOI 10.1093/oxfordjournals.jbchem.a122862; SHIMADA Y, 1990, J BIOCHEM-TOKYO, V107, P703, DOI 10.1093/oxfordjournals.jbchem.a123112; SIDEBOTTOM CM, 1991, EUR J BIOCHEM, V202, P485, DOI 10.1111/j.1432-1033.1991.tb16398.x; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; SZEWCZUK A, 1985, AFFINITY CHROMATOGR, P117; TSAI PK, 1984, J BIOL CHEM, V259, P3805; VERNET T, 1991, J BIOL CHEM, V266, P21451; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; VERNET T, 1993, PROTEIN ENG, V6, P213, DOI 10.1093/protein/6.2.213; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; YAMAGUCHI S, 1992, BIOSCI BIOTECH BIOCH, V56, P315, DOI 10.1271/bbb.56.315; ZIOMEK E, 1984, CAN J MICROBIOL, V30, P1197, DOI 10.1139/m84-190; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	60	35	37	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26212	26219						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	7902836				2022-12-25	WOS:A1993MK42500033
J	LEGRANDPOELS, S; BOURS, V; PIRET, B; PFLAUM, M; EPE, B; RENTIER, B; PIETTE, J				LEGRANDPOELS, S; BOURS, V; PIRET, B; PFLAUM, M; EPE, B; RENTIER, B; PIETTE, J			TRANSCRIPTION FACTOR NF-KAPPA-B IS ACTIVATED BY PHOTOSENSITIZATION GENERATING OXIDATIVE DNA DAMAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR-NECROSIS-FACTOR; T-CELL CLONE; PROTEIN-KINASE; NUCLEIC-ACIDS; INTACT-CELLS; SUBSTRATE-SPECIFICITY; IONIZING-RADIATION; MAMMALIAN-CELLS; SINGLET-OXYGEN	Reactive oxygen intermediates like hydrogen peroxide (H2O2) have been shown to serve as messengers in the induction of NF-kappa B and, then, in the activation and replication of human immunodeficiency virus (HIV)-1 in human cells. Because H2O2 can be converted into the highly reactive OH. at various locations inside the cells, we started to investigate the generation of Reactive oxygen intermediates by photosensitization. This technique is based on the use of a photosensitizer which is a molecule absorbing visible light and which can be located at various sites inside the cell depending on its physicochemical properties. In this work, we used proflavine (PF), a cationic molecule having a high affinity for DNA, capable of intercalating between DNA base pairs. Upon visible light irradiation, intercalated PF molecules oxidize guanine residues and generate DNA single-strand breaks. In lymphocytes or monocytes latently infected with HIV-1 (ACH-2 or U1, respectively), this photosensitizing treatment induced a cytotoxicity, an induction of NF-kappa B, and a reactivation of HIV-1 in cells surviving the treatment. NF-kappa B induction by PF-mediated photosensitization was not affected by the presence of N-acetyl-L-cysteine while strong inhibition was recorded when the induction was triggered by H2O2 or by phorbol 12-myristate 13-acetate. Another transcription factor like AP-1 is less activated by this photosensitizing treatment. In comparison with other inducing treatments, such as phorbol 12-myristate 13-acetate or tumor necrosis factor alpha, the activation of NF-kappa B is slow, being optimal 120 min after treatment. These kinetic data were obtained by following, on the same samples, both the appearance of NF-kappa B in the nucleus and the disappearance of I kappa B-alpha in cytoplasmic extracts. These data allow us to postulate that signaling events, initiated by DNA oxidative damages, are transmitted into the cytoplasm where the inactive NF-kappa B factor is resident and allow the translocation of p50/p65 subunits of NF-kappa B to the nucleus leading to HIV-1 gene expression.	UNIV LIEGE, INST PATHOL B23, MED CHEM LAB, B-4000 LIEGE, BELGIUM; UNIV WURZBURG, INST TOXICOL, D-97078 WURZBURG, GERMANY	University of Liege; University of Wurzburg	LEGRANDPOELS, S (corresponding author), UNIV LIEGE, INST PATHOL B23, VIROL LAB, B-4000 LIEGE, BELGIUM.							ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARENZANASEISDEDOS F, 1993, J VIROL, V67, P6596, DOI 10.1128/JVI.67.11.6596-6604.1993; ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BERMAN HM, 1981, ANNU REV BIOPHYS BIO, V10, P87, DOI 10.1146/annurev.bb.10.060181.000511; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CADET J, 1983, ISRAEL J CHEM, V23, P420; Cadet J., 1990, BIOORGANIC PHOTOCHEM, V1, P1; CLOUSE KA, 1989, J IMMUNOL, V142, P431; Davies K.J.A., 1991, OXIDATIVE DAMAGE REP; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINARELLO CA, 1992, CHEM IMMUNOL, V51, P1; EPE B, 1994, METHOD ENZYMOL, V234, P122; EPE B, 1993, MUTAT RES, V299, P135, DOI 10.1016/0165-1218(93)90091-Q; FLOYD RA, 1989, ARCH BIOCHEM BIOPHYS, V273, P106, DOI 10.1016/0003-9861(89)90167-7; FOLKS TM, 1988, J IMMUNOL, V140, P1117; FOOTE CS, 1988, PHOTOSENSITIZATION M, P125; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; GENEST D, 1981, BIOPHYS CHEM, V13, P89, DOI 10.1016/0301-4622(81)80028-2; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HASELTINE W, 1988, CONTROL HUMAN RETROV; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HAZAN U, 1990, P NATL ACAD SCI USA, V87, P7861, DOI 10.1073/pnas.87.20.7861; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HOFF SF, 1983, J HISTOCHEM CYTOCHEM, V31, P613, DOI 10.1177/31.5.6841967; HOFFMAN AD, 1985, VIROLOGY, V147, P326, DOI 10.1016/0042-6822(85)90135-7; HOLBROOK NJ, 1993, FREE RADICAL BIO MED, V15, P543, DOI 10.1016/0891-5849(93)90454-3; HORVAT RT, 1989, J IMMUNOL, V143, P2745; ISRAEL N, 1989, J IMMUNOL, V143, P3956; KANOFSKY JR, 1993, FREE RADICAL BIO MED, V15, P527, DOI 10.1016/0891-5849(93)90397-D; KASAI H, 1992, J AM CHEM SOC, V114, P9692, DOI 10.1021/ja00050a078; KESSEL D, 1993, SPECTRUM-J STATE GOV, V6, P1; KOHN KW, 1976, BIOCHEMISTRY-US, V15, P4629, DOI 10.1021/bi00666a013; LEE PCC, 1987, PHOTOCHEM PHOTOBIOL, V45, P79, DOI 10.1111/j.1751-1097.1987.tb08407.x; LEGRANDPOELS S, 1990, AIDS RES HUM RETROV, V6, P1389, DOI 10.1089/aid.1990.6.1389; LEMAY P, 1983, BIOCHEM BIOPH RES CO, V111, P1074, DOI 10.1016/0006-291X(83)91409-2; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LERMAN LS, 1961, J MOL BIOL, V3, P18, DOI 10.1016/S0022-2836(61)80004-1; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LUETHY JD, 1992, CANCER RES, V52, P5; MCMURRAY CT, 1986, P NATL ACAD SCI USA, V83, P8472, DOI 10.1073/pnas.83.22.8472; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NEIDLE S, 1988, NUCLEIC ACIDS RES, V16, P8999, DOI 10.1093/nar/16.18.8999; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PIETTE J, 1991, J PHOTOCH PHOTOBIO B, V11, P241, DOI 10.1016/1011-1344(91)80030-L; PIETTE J, 1982, PHOTOCHEM PHOTOBIOL, V35, P705, DOI 10.1111/j.1751-1097.1982.tb02633.x; PIETTE J, 1986, PHOTOCHEM PHOTOBIOL, V44, P793, DOI 10.1111/j.1751-1097.1986.tb05539.x; POLI G, 1990, P NATL ACAD SCI USA, V87, P782, DOI 10.1073/pnas.87.2.782; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RUCK A, 1992, J PHOTOCH PHOTOBIO B, V12, P403, DOI 10.1016/1011-1344(92)85044-U; SACHSENMAIER C, 1994, BIOCHEM PHARMACOL, V47, P129, DOI 10.1016/0006-2952(94)90446-4; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; STAAL FJT, 1993, AIDS RES HUM RETROV, V9, P299, DOI 10.1089/aid.1993.9.299; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUZUKI YJ, 1992, BIOCHEM BIOPH RES CO, V189, P1709, DOI 10.1016/0006-291X(92)90275-P; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TONGSTARKSEN S, 1989, P NATL ACAD SCI USA, V87, P7861; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VALERIE K, 1990, New Biologist, V2, P712; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; VIRELIZIER JL, 1990, CURR OPIN IMMUNOL, V2, P409, DOI 10.1016/0952-7915(89)90151-9; WARING MJ, 1981, ANNU REV BIOCHEM, V50, P159, DOI 10.1146/annurev.bi.50.070181.001111; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; YAROSH DB, 1993, J INVEST DERMATOL, V100, P790, DOI 10.1111/1523-1747.ep12476573; ZHOU Z, 1993, CELL, V75, P1119, DOI 10.1016/0092-8674(93)90321-G	81	68	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6925	6934		10.1074/jbc.270.12.6925	http://dx.doi.org/10.1074/jbc.270.12.6925			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896842	hybrid, Green Submitted			2022-12-25	WOS:A1995QQ85500073
J	LIN, JL; ADDISON, R				LIN, JL; ADDISON, R			A NOVEL INTEGRATION SIGNAL THAT IS COMPOSED OF 2 TRANSMEMBRANE SEGMENTS IS REQUIRED TO INTEGRATE THE NEUROSPORA PLASMA-MEMBRANE H+-ATPASE INTO MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; RECOGNITION PARTICLE; SEQUENCE; PROTEIN; CRASSA; INSERTION; CONFORMATION; ENVIRONMENTS; INVERTASE; BEHAVIOR	The Neurospora plasma membrane H+-ATPase belongs to a family of cation-motive porters called P-type ATPases. Putative transmembrane segments of these enzymes contain one or more charged residues. Conditions were determined by which a transmembrane segment with charged residues is integrated into its cognate membrane. We constructed fusion proteins flanked by the hydrophilic domains of the amino and carboxyl termini of the H+-ATPase that contained either one or two transmembrane segments. Neurospora in vitro translation system supplemented with homologous microsomes was programmed with RNA transcripts of these constructs. When transmembrane segment number one (M1) or number two (M2) of the H+-ATPase was engineered into the construct, the resultant protein did not integrate into microsomes. When M1 and M2 were placed in tandem, the resultant protein integrated into microsomes as judged by the criteria of resistance to extraction at pH 11.5 and protection from protease digestion. The integration event depended on ATP and GTP and on microsomal protein(s). We posited that membrane topology of the amino terminal third of the H+-ATPase, and perhaps of other P-type ATPases is achieved by inserting transmembrane segments into membrane in pairs.			LIN, JL (corresponding author), UNIV TENNESSEE,CTR HLTH SCI,DEPT BIOCHEM,MEMPHIS,TN 38163, USA.							ADDISON R, 1990, BIOCHIM BIOPHYS ACTA, V1030, P127, DOI 10.1016/0005-2736(90)90247-L; ADDISON R, 1987, J BIOL CHEM, V262, P17031; ADDISON R, 1986, J BIOL CHEM, V261, P4896; ADDISON R, 1981, J BIOL CHEM, V256, P3165; ADDISON R, 1993, BIOCHIM BIOPHYS ACTA, V1152, P119, DOI 10.1016/0005-2736(93)90238-U; ADDISON R, 1991, BIOCHIM BIOPHYS ACTA, V1065, P130, DOI 10.1016/0005-2736(91)90222-T; ANDERSON DJ, 1983, P NATL ACAD SCI-BIOL, V80, P7249, DOI 10.1073/pnas.80.23.7249; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BURR FA, 1983, METHOD ENZYMOL, V96, P239; CALAMIA J, 1992, J MOL BIOL, V224, P539, DOI 10.1016/0022-2836(92)90542-R; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; EMR SD, 1980, NATURE, V285, P82, DOI 10.1038/285082a0; EMR SD, 1993, P NATL ACAD SCI USA, V80, P4599; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; HOMAREDA H, 1989, MOL CELL BIOL, V9, P5742, DOI 10.1128/MCB.9.12.5742; LI SC, 1993, J BIOL CHEM, V268, P22975; LIN J, 1994, J BIOL CHEM, V269, P3887; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; MITCHELL P, 1967, ADV ENZYMOL RAMB, V29, P33; NOUWEN N, 1994, J BIOL CHEM, V269, P16029; RAO US, 1991, J BIOL CHEM, V266, P14740; RIZO J, 1993, BIOCHEMISTRY-US, V32, P4881, DOI 10.1021/bi00069a025; ROTHMAN RE, 1988, J BIOL CHEM, V263, P10470; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; Scharf SJ, 1990, PCR PROTOCOLS GUIDE, P84; SIEGEL V, 1988, EMBO J, V7, P1769, DOI 10.1002/j.1460-2075.1988.tb03007.x; SKACH WR, 1993, J BIOL CHEM, V268, P23552; TAUSSIG R, 1983, NUCLEIC ACIDS RES, V11, P1943, DOI 10.1093/nar/11.6.1943; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8	32	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6935	6941		10.1074/jbc.270.12.6935	http://dx.doi.org/10.1074/jbc.270.12.6935			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896843	hybrid			2022-12-25	WOS:A1995QQ85500074
J	SMITH, MM; SHI, LH; NAVRE, M				SMITH, MM; SHI, LH; NAVRE, M			RAPID IDENTIFICATION OF HIGHLY-ACTIVE AND SELECTIVE SUBSTRATES FOR STROMELYSIN AND MATRILYSIN USING BACTERIOPHAGE PEPTIDE DISPLAY LIBRARIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN FIBROBLAST STROMELYSIN; MONOVALENT PHAGE DISPLAY; MATRIX METALLOPROTEINASES; SEQUENCE SPECIFICITIES; SYNTHETIC PEPTIDES; ENZYME SPECIFICITY; CLEAVAGE SITES; LIGANDS; COLLAGENASE	The discovery of useful peptide substrates for proteases that recognize many amino acids in their active sites is often a slow process due to the lack of initial substrate data and the expense of analyzing large numbers of peptide substrate. To overcome these obstacles, we have made use of bacteriophage peptide display libraries. We prepared a random hexamer library in the fd-derived vector fAFF-1 and included a ''tether'' sequence that could be recognized by monoclonal antibodies. We chose the matrix metalloproteinases stromelysin and matrilysin as the targets for our studies, as they are known to require at least 6 amino acids in a peptide substrate for cleavage. The phage library was treated in solution with protease and cleaved phage separated from uncleaved phage using a mixture of tether-binding monoclonal antibodies and Protein A-bearing cells followed by precipitation. Clones were screened by the use of a rapid screening assay that identified phage encoding peptide sequences susceptible to cleavage by the enzymes. The nucleotide sequence of the random hexamer region of 43 such clones was determined for stromelysin and 23 for matrilysin. Synthetic peptides were prepared whose sequences were based on some of the positive clones, as well as consensus sequences built from the positive clones. Many of the peptides have k(cat)/K-M values as good or better than those of previously reported substrates, and in fact, we were able to produce stromelysin and matrilysin substrates that are both the most active and smallest reported to date. In addition, the phage data predicted selectivity in the P-2 and P'(1) positions of the two enzymes that were supported by the kinetic analysis of the peptides. This work demonstrates that the phage selection techniques enable the rapid identification of highly active and selective protease substrates without making any a priori assumptions about the specificity or the ''physiological substrate'' of the protease under study.	AFFYMAX RES INST, DEPT BIOCHEM, SANTA CLARA, CA 95051 USA				Smith, Matthew M./AAL-1697-2020					BARRETT RW, 1992, ANAL BIOCHEM, V204, P357, DOI 10.1016/0003-2697(92)90252-3; BASS S, 1990, PROTEINS, V8, P309, DOI 10.1002/prot.340080405; BAUM EZ, 1990, P NATL ACAD SCI USA, V87, P10023, DOI 10.1073/pnas.87.24.10023; BERMAN J, 1992, J BIOL CHEM, V267, P1434; BIRKETT AJ, 1991, ANAL BIOCHEM, V196, P137, DOI 10.1016/0003-2697(91)90129-H; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DASMAHAPATRA B, 1992, P NATL ACAD SCI USA, V89, P4159, DOI 10.1073/pnas.89.9.4159; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; Fersht A, 1985, ENZYME STRUCTURE MEC, P105; FIELDS GB, 1990, BIOCHEMISTRY-US, V29, P6670, DOI 10.1021/bi00480a017; GRAMSCH C, 1983, J NEUROCHEM, V40, P1220, DOI 10.1111/j.1471-4159.1983.tb13560.x; GRIFFITHS JT, 1992, BIOCHEMISTRY-US, V31, P5193, DOI 10.1021/bi00137a015; HELLEN CUT, 1989, BIOCHEMISTRY-US, V28, P9881, DOI 10.1021/bi00452a001; HOESS RH, 1993, CURR OPIN STRUC BIOL, V3, P572, DOI 10.1016/0959-440X(93)90085-Y; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; KRAUSSLICH HG, 1989, P NATL ACAD SCI USA, V86, P807, DOI 10.1073/pnas.86.3.807; LOWMAN HB, 1991, BIOCHEMISTRY-US, V30, P10832, DOI 10.1021/bi00109a004; MARCY AI, 1991, BIOCHEMISTRY-US, V30, P6476, DOI 10.1021/bi00240a018; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; Model P., 1988, BACTERIOPHAGES, P375; NETZELARNETT S, 1991, J BIOL CHEM, V266, P6747; NETZELARNETT S, 1991, ANAL BIOCHEM, V195, P86, DOI 10.1016/0003-2697(91)90299-9; NETZELARNETT S, 1993, BIOCHEMISTRY-US, V32, P6427, DOI 10.1021/bi00076a016; NIEDZWIECKI L, 1992, BIOCHEMISTRY-US, V31, P12618, DOI 10.1021/bi00165a011; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; PETITHORY JR, 1991, P NATL ACAD SCI USA, V88, P11510, DOI 10.1073/pnas.88.24.11510; POORMAN RA, 1991, J BIOL CHEM, V266, P14554; SCHELLENBERGER V, 1993, BIOCHEMISTRY-US, V32, P4349, DOI 10.1021/bi00067a026; SCHELLENBERGER V, 1993, BIOCHEMISTRY-US, V32, P4344, DOI 10.1021/bi00067a025; SCOTT JK, 1992, TRENDS BIOCHEM SCI, V17, P241, DOI 10.1016/0968-0004(92)90401-T; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SELTZER JL, 1990, J BIOL CHEM, V265, P20409; SMITH TA, 1991, P NATL ACAD SCI USA, V88, P5159, DOI 10.1073/pnas.88.12.5159; STACK MS, 1989, J BIOL CHEM, V264, P4277; TEAHAN J, 1989, BIOCHEMISTRY-US, V28, P8497, DOI 10.1021/bi00447a034; TOMASSELLI AG, 1991, J BIOL CHEM, V266, P14548; TOZSER J, 1992, BIOCHEMISTRY-US, V31, P4793, DOI 10.1021/bi00135a008	37	133	160	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6440	6449		10.1074/jbc.270.12.6440	http://dx.doi.org/10.1074/jbc.270.12.6440			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896777	hybrid			2022-12-25	WOS:A1995QQ85500006
J	JENSEN, PH; SCHULER, E; WOODROW, G; RICHARDSON, M; GOSS, N; HOJRUP, P; PETERSEN, TE; RASMUSSEN, LK				JENSEN, PH; SCHULER, E; WOODROW, G; RICHARDSON, M; GOSS, N; HOJRUP, P; PETERSEN, TE; RASMUSSEN, LK			A UNIQUE INTERHELICAL INSERTION IN PLASMINOGEN-ACTIVATOR INHIBITOR-2 CONTAINS 3 GLUTAMINES, GLN(83), GLN(84), GLN(86), ESSENTIAL FOR TRANSGLUTAMINASE-MEDIATED CROSS-LINKING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRIN-STABILIZING FACTOR; HUMAN-PLACENTA; SEQUENCE; SITE; OVALBUMIN; VITRONECTIN; EXPRESSION; COMPLEXES; SUBSTRATE; ACCEPTOR	Plasminogen activator inhibitor type 2 (PAI-2) prevents fibrinolysis by blocking plasminogen activators. It is expressed principally by trophoblast cells and macrophages. PAI-2 in trophoblast membranes has been found cross-linked to large complexes apparently catalyzed by trophoblast transglutaminase (Jensen, P. H., Lorand, L., Ebbesen, P., and Gliemann, J. (1993) Eur. J. Biochem. 214, 141-146). Recombinant human PAI-2 was labeled with [C-14]putrescine catalyzedby guinea pig liver transglutaminase. The [C-14]putrescine-labeled PAI-2 was digested with cyanogen bromide and trypsin, and the peptides were purified by reverse-phase high performance chromatography. Amino acid sequencing and plasma desorption mass spectrometry of the labeled peptides revealed [C-14]putrescine incorporation at Gln(83), Gln(84), and Gln(86). These residues are present in a PAI-2-specific region of 33 amino acids that is inserted between helices C and D and which probably represents a unique solvent-exposed domain. A PAI-2 mutant lacking this insertion was determined not to be a substrate for transglutaminase by [C-14]putrescine incorporation and could not form transglutaminase catalyzed polymers. Thus, the unique PAI-2 insertion represents a functional domain that, by virtue of its transglutaminase acceptor sites, allows participation in binding reactions without affecting the inhibitory function of PAI-2.	AARHUS UNIV,DEPT MOLEC BIOL,PROT CHEM LAB,DK-8000 AARHUS,DENMARK; AARHUS UNIV,DEPT MED BIOCHEM,DK-8000 AARHUS,DENMARK; ODENSE UNIV,DEPT MOLEC BIOL,ODENSE,DENMARK; BEHRINGWERKE AG,MARBURG,GERMANY; BIOTECH AUSTRALIA,ROSEVILLE,NSW,AUSTRALIA	Aarhus University; Aarhus University; University of Southern Denmark			Højrup, Peter/ABG-8477-2020	Jensen, Poul Henning/0000-0002-4439-9020				AESCHLIMANN D, 1992, J BIOL CHEM, V267, P11316; ANTALIS TM, 1988, P NATL ACAD SCI USA, V85, P985, DOI 10.1073/pnas.85.4.985; ASTEDT B, 1986, THROMB HAEMOSTASIS, V56, P63; BELIN D, 1989, EMBO J, V8, P3287, DOI 10.1002/j.1460-2075.1989.tb08489.x; BERBERS GAM, 1984, P NATL ACAD SCI-BIOL, V81, P7017, DOI 10.1073/pnas.81.22.7017; CHRISTENSEN S, 1992, FEBS LETT, V312, P100, DOI 10.1016/0014-5793(92)81419-M; FEINBERG RF, 1989, LAB INVEST, V61, P20; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; JENSEN PH, 1993, EUR J BIOCHEM, V214, P141, DOI 10.1111/j.1432-1033.1993.tb17906.x; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; JENSEN PH, 1989, BIOCHIM BIOPHYS ACTA, V986, P135, DOI 10.1016/0005-2736(89)90282-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; MCDONAGH RP, 1981, FEBS LETT, V127, P174, DOI 10.1016/0014-5793(81)80198-6; MORTENSEN SB, 1981, FEBS LETT, V129, P314, DOI 10.1016/0014-5793(81)80191-3; NIELSEN PF, 1988, BIOMED ENVIRON MASS, V17, P137, DOI 10.1002/bms.1200170212; PURVES L, 1987, BIOCHEMISTRY-US, V26, P4640, DOI 10.1021/bi00389a008; RADTKE KP, 1990, BIOL CHEM H-S, V371, P1119, DOI 10.1515/bchm3.1990.371.2.1119; REMOLDODONNELL E, 1993, FEBS LETT, V315, P105, DOI 10.1016/0014-5793(93)81143-N; SAKATA Y, 1980, J CLIN INVEST, V65, P290, DOI 10.1172/JCI109671; SKORSTENGAARD K, 1990, FEBS LETT, V262, P269, DOI 10.1016/0014-5793(90)80208-Z; SPRANG SR, 1992, TRENDS BIOCHEM SCI, V17, P49, DOI 10.1016/0968-0004(92)90495-U; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; TAMAKI T, 1982, J BIOL CHEM, V257, P4767; WOHLWEND A, 1987, J EXP MED, V165, P320, DOI 10.1084/jem.165.2.320; WUN TC, 1987, J BIOL CHEM, V262, P3646; YE RD, 1987, J BIOL CHEM, V262, P3718; YE RD, 1989, J BIOL CHEM, V264, P5495	32	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15394	15398						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	7910824				2022-12-25	WOS:A1994NP73800080
J	BARKER, EL; WESTPHAL, RS; SCHMIDT, D; SANDERSBUSH, E				BARKER, EL; WESTPHAL, RS; SCHMIDT, D; SANDERSBUSH, E			CONSTITUTIVELY ACTIVE 5-HYDROXYTRYPTAMINE(2C) RECEPTORS REVEAL NOVEL INVERSE AGONIST ACTIVITY OF RECEPTOR LIGANDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SEROTONIN 1C RECEPTOR; CHOROID-PLEXUS; INTRINSIC ACTIVITY; ANTAGONISTS; BINDING; 5-HT1C; ACTIVATION; TRANSFORMATION; CELLS	5-HT2C receptor antagonists, such as mianserin and mesulergine, exhibit negative intrinsic activity, defined as a decrease in agonist-independent, receptor mediated, phosphoinositide hydrolysis in cells transfected with the 5-HT2C receptor cDNA These drugs are classified as inverse agonists. Guanine nucleotides reciprocally modulate the binding of an agonist and inverse agonist, suggesting that an inverse agonist binds preferentially to the G protein uncoupled form of the 5-HT2C receptor. Another 5 HT2C receptor antagonist, 2-bromolysergic acid diethylamide, functions as a neutral antagonist with no intrinsic activity, but is able to block both agonist and inverse agonist. Chronic treatment of choroid plexus cells with an inverse agonist, but not with the neutral antagonist, causes 5-HT2C receptor down-regulation, suggesting that the biological effects of 5-HT2C receptor antagonists are not solely due to antagonism of endogenous agonist. These results provide evidence that constitutively active 5-HT2C receptors are biologically significant. The functionally distinct properties of inverse agonists and neutral antagonists may elucidate the mechanisms controlling basal receptor activity states and lead to novel approaches in the development of therapeutic agents.	VANDERBILT UNIV, SCH MED, DEPT PHARMACOL, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, SCH MED, DEPT PSYCHIAT, NASHVILLE, TN 37232 USA	Vanderbilt University; Vanderbilt University					NIMH NIH HHS [MH 34007] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH034007, R37MH034007] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BARKER EL, 1991, BRAIN RES, V552, P330, DOI 10.1016/0006-8993(91)90099-H; BARKER EL, 1993, MOL PHARMACOL, V44, P725; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAESTRUP C, 1982, SCIENCE, V216, P1241, DOI 10.1126/science.6281892; CANTON H, 1990, EUR J PHARMACOL, V191, P93, DOI 10.1016/0014-2999(90)94100-C; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CONN PJ, 1987, PSYCHOPHARMACOLOGY, V92, P267, DOI 10.1007/BF00210830; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; COSTA T, 1992, MOL PHARMACOL, V41, P549; ESTERLE TM, 1992, J NEUROSCI, V12, P4775; HOYER D, 1989, N-S ARCH PHARMACOL, V339, P252; HUMPHREY PPA, 1993, TRENDS PHARMACOL SCI, V14, P233, DOI 10.1016/0165-6147(93)90016-D; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KENNETT GA, 1989, EUR J PHARMACOL, V164, P445, DOI 10.1016/0014-2999(89)90252-5; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; MOREAU JL, 1993, PSYCHOPHARMACOLOGY, V110, P140, DOI 10.1007/BF02246963; ONARAN HO, 1993, MOL PHARMACOL, V43, P245; PRANZATELLI MR, 1993, EUR J PHARM-MOLEC PH, V244, P1, DOI 10.1016/0922-4106(93)90052-B; REN Q, 1993, J BIOL CHEM, V268, P16483; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SANDERSBUSH E, 1991, PSYCHOPHARMACOLOGY, V105, P340, DOI 10.1007/BF02244428; SANDERSBUSH E, 1988, J PHARMACOL EXP THER, V247, P169; SCHMIDT D, 1990, BIOMED CHROMATOGR, V4, P215, DOI 10.1002/bmc.1130040509; SCHUTZ W, 1992, TRENDS PHARMACOL SCI, V13, P376, DOI 10.1016/0165-6147(92)90116-N	27	254	265	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11687	11690						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7909313				2022-12-25	WOS:A1994NG37700004
J	SARKAR, FH; SMITH, MR; HOOVER, T; PRINCLER, G; CRISSMAN, JD; VISSCHER, DW; LONGO, DL; KUNG, HF; RAZIUDDIN				SARKAR, FH; SMITH, MR; HOOVER, T; PRINCLER, G; CRISSMAN, JD; VISSCHER, DW; LONGO, DL; KUNG, HF; RAZIUDDIN			C-ERBB-2 PROMOTER-SPECIFIC DNA-BINDING PROTEIN ISOLATED FROM HUMAN BREAST-CANCER TISSUES DISPLAYS MITOGENIC ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-RECEPTOR; LONG TERMINAL REPEAT; HUMAN MAMMARY-TUMORS; NEU PROTOONCOGENE; EGF RECEPTOR; CELL-LINE; ONCOGENE; TRANSFORMATION; REGION; GENE	Amplification and overexpression of the c-erbB-2 gene appears to play a role in the pathogenesis of human breast and other cancers. Frequent amplification (20-30%) of the c-erbB-2 gene was observed in human adenocarcinomas of kidney, pancreas, lung, ovarian, and breast cancer. The gene product is a 185-kDa glycoprotein that has intrinsic tyrosine kinase activity and is believed to be a receptor. Several candidate ligands have been described. In the present study we have identified and purified a novel DNA-binding protein from malignant human breast tissues. The protein binds to a core element (-22 to +9, +1 being the transcription start site) of the c-erbB-2 promoter region in a sequence-specific manner. The affinity-purified protein has the ability to induce DNA synthesis in quiescent NIH/3T3 cells, suggesting that the factor has mitogenic activity. The purified protein induces c-erbB-2 expression on the surface of microinjected NIH/3T3 cells. This DNA-binding protein is a sequence-specific cellular factor that is associated with high level expression of the c-erbB-2 gene and appears to play a role in cell transformation. Understanding the control and expression of this DNA-binding protein may shed light on the mechanism(s) of c-erbB-2 gene regulation and its potential role in the pathogenesis of human adenocarcinomas.	NCI,FREDERICK CANC RES & DEV CTR,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21702; WAYNE STATE UNIV,SCH MED,DEPT PATHOL,DETROIT,MI 48201; NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Wayne State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Longo, Dan L./F-6022-2011					BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; CALVERT I, 1991, GENE, V101, P171, DOI 10.1016/0378-1119(91)90408-4; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; HENRY JL, 1993, CANCER RES, V53, P1403; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUDSON LG, 1990, J BIOL CHEM, V265, P4389; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; ISHII S, 1987, P NATL ACAD SCI USA, V84, P4374, DOI 10.1073/pnas.84.13.4374; KERN JA, 1990, CANCER RES, V50, P5184; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LAZARISKARATZAS A, 1992, GENE DEV, V6, P1631, DOI 10.1101/gad.6.9.1631; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MAGUIRE HC, 1989, J INVEST DERMATOL, V92, P786, DOI 10.1111/1523-1747.ep12696796; MIKOVITS JAR, 1991, P NATL ACAD SCI USA, V88, P9426; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; RUSSELL KS, 1992, CANCER RES, V52, P6624; SALMON DJ, 1987, SCIENCE, V235, P177; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SMITH M R, 1990, New Biologist, V2, P648; SMITH MR, 1990, MOL CELL BIOL, V10, P3828, DOI 10.1128/MCB.10.7.3828; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VARLEY JM, 1987, ONCOGENE, V1, P423; WEST M, 1992, J BIOL CHEM, V267, P24948; WILLIAMS TM, 1991, PATHOBIOLOGY, V59, P46, DOI 10.1159/000163614; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179; YOKOTA J, 1986, LANCET, V1, P765	39	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12285	12289						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7909319				2022-12-25	WOS:A1994NG37700092
J	JACKLE, S; BEISIEGEL, U; RINNINGER, F; BUCK, F; GRIGOLEIT, A; BLOCK, A; GROGER, I; GRETEN, H; WINDLER, E				JACKLE, S; BEISIEGEL, U; RINNINGER, F; BUCK, F; GRIGOLEIT, A; BLOCK, A; GROGER, I; GRETEN, H; WINDLER, E			ANNEXIN-VI, A MARKER PROTEIN OF HEPATOCYTIC ENDOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED PHOSPHOLIPID-BINDING; RECEPTOR-MEDIATED ENDOCYTOSIS; LIPOPROTEIN RECEPTORS; CELLULAR-DISTRIBUTION; RAT HEPATOCYTES; PLASMA-MEMBRANE; COATED PITS; CALCIUM; LIVER; P68	Three highly purified endosomal fractions from rat liver were used to purify and characterize a major protein of endosomal membranes. Intravenously injected ligands, which are taken up via receptor-mediated endocytosis, accumulate first in the fraction of intermediate density, the compartment of uncoupling of receptors and ligands. The high density membranous fraction is highly enriched in a receptor recycling compartment. The endosomal fraction of lowest density is composed of multivesicular bodies, which appear to be the immediate prelysosomal compartment. The most prominent membrane protein of these endosomes is one of 68 kDa, as revealed by silver and Coomassie Brilliant Blue staining of SDS-gel electrophoretograms. This protein dominates profiles obtained from purified membranes of the compartment of uncoupling of receptors and ligands, multivesicular bodies, and receptor recycling compartment, but is greatly reduced in those obtained from plasma membranes and lysosomes. The 68-kDa protein was purified from endosomes and digested with trypsin, and cleavage products were analyzed by protein sequencing. The tryptic fragments of the endosomal 68-kDa protein share 96% identity with corresponding sequences of mouse annexin VI and 91% identity with sequences of human annexin VI. Using immunoblots, high concentrations of annexin VI with an apparent molecular mass of 68 kDa were detected in endosomal membranes by specific antiserum to annexin VI. Significant amounts of annexin VI were also detected in Golgi membranes. Yet, the concentration was substantially lower than that of the three endosomal fractions. The association of annexin VI with endosomal membranes is calcium-dependent, as revealed by the complete solubilization from endosomal membranes by EGTA. Incubation of intact endosomes with Pronase leads to a complete degradation of annexin VI without any detectable disintegration of proteins localized on the luminal surface of endosomal membranes. Evidently, annexin VI is localized on the cytoplasmatic leaflet of the membrane of endosomes and may be of significance for their intracellular trafficking.	UNIV KRANKENHAUS EPPENDORF,INST ZELLBIOCHEM & KLIN NEUROBIOL,D-20246 HAMBURG,GERMANY	University of Hamburg; University Medical Center Hamburg-Eppendorf	BEISIEGEL, U (corresponding author), UNIV KRANKENHAUS EPPENDORF,MED KERNKLIN & POLIKLIN,MARTINISTR 52,D-20246 HAMBURG,GERMANY.							ALI SM, 1989, NATURE, V340, P313, DOI 10.1038/340313a0; BAENZIGER JU, 1986, J BIOL CHEM, V261, P7445; BANDOROWICZ J, 1992, BIOCHIM BIOPHYS ACTA, V1105, P201, DOI 10.1016/0005-2736(92)90195-R; BAREL M, 1991, J IMMUNOL, V147, P1286; BEISIEGEL U, 1982, J BIOL CHEM, V257, P3150; BELCHER JD, 1987, P NATL ACAD SCI USA, V84, P6785, DOI 10.1073/pnas.84.19.6785; BIANCHI R, 1992, FEBS LETT, V296, P158, DOI 10.1016/0014-5793(92)80369-R; BURGOYNE RD, 1988, NATURE, V331, P20, DOI 10.1038/331020a0; CASCIOLAROSEN LA, 1992, J BIOL CHEM, V267, P11856; CHAO Y, 1979, J BIOL CHEM, V254, P1360; CLARK DM, 1991, HISTOCHEMISTRY, V96, P405, DOI 10.1007/BF00315998; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; CROMPTON MR, 1988, EMBO J, V7, P21, DOI 10.1002/j.1460-2075.1988.tb02779.x; CRUMPTON MJ, 1990, NATURE, V345, P212, DOI 10.1038/345212a0; DIAZMUNOZ M, 1990, J BIOL CHEM, V265, P15894; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; EDWARDS HC, 1987, J CELL BIOL, V105, P303, DOI 10.1083/jcb.105.1.303; EDWARDS HC, 1991, EUR J BIOCHEM, V198, P121, DOI 10.1111/j.1432-1033.1991.tb15994.x; ENRICH C, 1990, BIOCHEM J, V271, P171, DOI 10.1042/bj2710171; GASSAMADIAGNE A, 1990, J BIOL CHEM, V265, P4309; GEISOW M, 1984, EMBO J, V3, P2969, DOI 10.1002/j.1460-2075.1984.tb02242.x; GEISOW MJ, 1987, BIOCHEM SOC T, V15, P800, DOI 10.1042/bst0150800; GERKE V, 1990, BIOCHEM SOC T, V18, P1106, DOI 10.1042/bst0181106; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GLENNEY JR, 1987, J CELL BIOL, V104, P503, DOI 10.1083/jcb.104.3.503; GOLDBERG M, 1991, CELL TISSUE RES, V263, P81, DOI 10.1007/BF00318402; GOLDSTEIN JL, 1979, NATURE, V279, P679, DOI 10.1038/279679a0; HAMILTON RL, 1991, J LIPID RES, V32, P529; HAVEL RJ, 1988, HEPATOLOGY, V8, P1689, DOI 10.1002/hep.1840080637; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HAZARIKA P, 1991, J CELL BIOCHEM, V46, P78, DOI 10.1002/jcb.240460112; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; HULLIN F, 1989, J BIOL CHEM, V264, P3506; JACKLE S, 1991, J LIPID RES, V32, P485; JACKLE S, 1991, J BIOL CHEM, V266, P1396; JACKLE S, 1993, HEPATOLOGY, V17, P455, DOI 10.1016/0270-9139(93)90058-U; JACKLE S, 1989, P NATL ACAD SCI USA, V86, P1880; JOHNSTON PA, 1990, J BIOL CHEM, V265, P11382; JOSTVU E, 1986, HISTOCHEMISTRY, V85, P457, DOI 10.1007/BF00508427; KHAN MN, 1986, J BIOL CHEM, V261, P8462; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; KOVANEN PT, 1981, P NATL ACAD SCI-BIOL, V78, P1396, DOI 10.1073/pnas.78.3.1396; KRETSINGER RH, 1986, NATURE, V320, P573, DOI 10.1038/320573a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN HC, 1992, CELL, V70, P283, DOI 10.1016/0092-8674(92)90102-I; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MEERS P, 1991, BIOCHEMISTRY-US, V30, P2903, DOI 10.1021/bi00225a025; MOSS SE, 1988, EUR J BIOCHEM, V177, P21, DOI 10.1111/j.1432-1033.1988.tb14340.x; NAKATA T, 1990, J CELL BIOL, V110, P13, DOI 10.1083/jcb.110.1.13; NEWMAN R, 1989, J MOL BIOL, V206, P213, DOI 10.1016/0022-2836(89)90534-2; OWENS RJ, 1984, EMBO J, V3, P945, DOI 10.1002/j.1460-2075.1984.tb01912.x; OWENS RJ, 1984, BIOCHEM J, V219, P309, DOI 10.1042/bj2190309; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; SCHROER TA, 1988, J CELL BIOL, V107, P1785, DOI 10.1083/jcb.107.5.1785; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; SEKIMOTO S, 1991, J NEUROCHEM, V56, P1774, DOI 10.1111/j.1471-4159.1991.tb02080.x; SILVA FG, 1986, DIFFERENTIATION, V33, P175, DOI 10.1111/j.1432-0436.1986.tb00423.x; SMALLWOOD M, 1990, BIOCHEM J, V270, P157, DOI 10.1042/bj2700157; SMITH VL, 1986, J BIOL CHEM, V261, P5815; STOEHR SJ, 1990, J IMMUNOL, V144, P3936; SUBRAMANIAM VN, 1992, J BIOL CHEM, V267, P12016; SUDHOF TC, 1988, P NATL ACAD SCI USA, V85, P664, DOI 10.1073/pnas.85.3.664; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATTIAUX R, 1978, J CELL BIOL, V78, P349, DOI 10.1083/jcb.78.2.349; WEISIGER R, 1981, SCIENCE, V211, P1048, DOI 10.1126/science.6258226; YOSHIZAKI H, 1991, CHEM PHARM BULL, V39, P2617	66	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1026	1032						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7904597				2022-12-25	WOS:A1994MR22000041
J	YEN, PM; IKEDA, M; BRUBAKER, JH; FORGIONE, M; SUGAWARA, A; CHIN, WW				YEN, PM; IKEDA, M; BRUBAKER, JH; FORGIONE, M; SUGAWARA, A; CHIN, WW			ROLES OF V-ERBA HOMODIMERS AND HETERODIMERS IN MEDIATING DOMINANT-NEGATIVE ACTIVITY BY V-ERBA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; LIGAND-BINDING DOMAIN; RETINOID-X-RECEPTOR; RESPONSE ELEMENTS; GENERALIZED RESISTANCE; DNA-BINDING; NUCLEAR RECEPTORS; AUXILIARY PROTEIN; ONCOGENE PROTEIN; ACID RECEPTORS	v-erbA, a viral oncogenic homolog of thyroid hormone receptor (TR), blocks the effect of T3 in TR-mediated transcription. The mechanism(s) for this dominant negative effect by v-erbA on TRs is unknown but may involve competition between v-erbA and TR-containing complexes for binding to thyroid hormone response elements (TREs) and/or protein-protein interactions between v-erbA and TR. To investigate these potential mechanisms, we used the electrophoretic mobility shift assay to compare in vitro translated v-erbA and TRalpha binding to two TREs-chick lysozyme TRE (F2) and direct repeat TRE (DR4). v-erbA bound as a homodimer to these TREs, whereas TRalpha bound as a homodimer and monomer. T3 decreased TRalpha homodimer binding to the TREs as we reported previously; however, surprisingly, high concentrations of T3 (10(-6) M) also decreased v-erbA homodimer binding to the TREs. Additionally, v-erbA formed heterodimers with nuclear proteins such as retinoid X receptor and T3 receptor auxiliary protein as well as with TRalpha. These dimers remained bound to DNA in the presence of T3. Finally, v-erbA could not mediate ligand-dependent transcriptional activation even at 10(-6) M T3 but could block ligand-dependent TR-mediated transactivation in co-transfection experiments. v-erbA also exhibited differential dominant negative activity on F2 and DR4 suggesting that half-site sequence and/or orientation may influence v-erbA-dominant negative activity. In sum, there are multiple v-erbA complexes that bind to TREs in the presence of T3, which all may contribute to v-erbA's dominant negative effect on TR-mediated transcription by competing with TR-containing complexes for binding to TREs.	BRIGHAM & WOMENS HOSP,HOWARD HUGHES MED INST,DEPT MED,DIV GENET,GW THORN RES BLDG,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School			Yen, Paul M/V-9857-2019	Yen, Paul/0000-0002-3790-8114; Sugawara, Akira/0000-0003-4511-8101				ANDERSSON ML, 1992, NUCLEIC ACIDS RES, V20, P4803, DOI 10.1093/nar/20.18.4803; BANIAHMAD A, 1992, P NATL ACAD SCI USA, V89, P10633, DOI 10.1073/pnas.89.22.10633; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; BRENT G A, 1989, New Biologist, V1, P329; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; CHATTERJEE VKK, 1991, J CLIN INVEST, V87, P1977; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DARLING DS, 1993, J BIOL CHEM, V268, P10221; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; FORMAN BM, 1991, GENE, V105, P9, DOI 10.1016/0378-1119(91)90507-8; FORREST D, 1990, ONCOGENE, V5, P309; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; HERMANN T, 1993, ONCOGENE, V8, P55; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LAZAR MA, 1990, J CLIN INVEST, V86, P1777, DOI 10.1172/JCI114906; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MEIER CA, 1992, MOL ENDOCRINOL, V6, P248, DOI 10.1210/me.6.2.248; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAGAYA T, 1992, J BIOL CHEM, V267, P13014; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PRIVALSKY ML, 1988, MOL CELL BIOL, V8, P4510, DOI 10.1128/MCB.8.10.4510; PRIVALSKY ML, 1990, CELL, V63, P1277, DOI 10.1016/0092-8674(90)90423-C; RIBIERO RCJ, 1992, MOL ENDOCRINOL, V6, P142; SAKURAI A, 1990, MOL ENDOCRINOL, V4, P1988, DOI 10.1210/mend-4-12-1988; SAKURAI A, 1989, P NATL ACAD SCI USA, V86, P8977, DOI 10.1073/pnas.86.22.8977; Sambrook J, 1989, MOL CLONING LABORATO; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SELMI S, 1991, J BIOL CHEM, V266, P11589; SPANJAARD RA, 1991, P NATL ACAD SCI USA, V88, P8587, DOI 10.1073/pnas.88.19.8587; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; USALA SJ, 1990, J CLIN INVEST, V85, P93, DOI 10.1172/JCI114438; YEN PM, 1992, J BIOL CHEM, V267, P3565; YEN PM, 1992, ENDOCRINOLOGY, V130, P1539, DOI 10.1210/en.130.3.1539; YEN PM, 1992, J CLIN INVEST, V90, P1825, DOI 10.1172/JCI116058; YEN PM, 1992, J BIOL CHEM, V267, P23248; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1991, NEW BIOL, V3, P169; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	50	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					903	909						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7904604				2022-12-25	WOS:A1994MR22000023
J	ZIERE, GJ; BIJSTERBOSCH, MK; VANBERKEL, TJC				ZIERE, GJ; BIJSTERBOSCH, MK; VANBERKEL, TJC			REMOVAL OF 14 N-TERMINAL AMINO-ACIDS OF LACTOFERRIN ENHANCES ITS AFFINITY FOR PARENCHYMAL LIVER-CELLS AND POTENTIATES THE INHIBITION OF BETA-VERY LOW-DENSITY-LIPOPROTEIN BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; CHYLOMICRON REMNANTS; ARGININE RESIDUES; KUPFFER CELLS; SEQUENCE; PROTEIN; INVIVO; RECOGNITION; DEGRADATION; SITE	Lactoferrin inhibits the hepatic uptake of lipoprotein remnants, and we showed earlier that arginine residues of lactoferrin are involved. In this study, lactoferrin was treated with aminopeptidase M (APM), which resulted in removal of 14 N-terminal amino acids, including 4 clustered arginine residues at positions 2-5 (APM-lactoferrin). After intravenous injection into rats, I-125-labeled APM-lactoferrin was cleared within 10 min by the liver parenchymal cells (74.7% of the dose). In contrast to native lactoferrin, APM-lactoferrin was rapidly internalized after liver association (>80% of the liver-associated radioactivity was internalized within 10 min). Binding of APM-lactoferrin to isolated parenchymal liver cells was saturable with a K(d) of 186 nm (750,000 sites/cell). This is in striking contrast to the binding of native lactoferrin (K(d) 10 muM; 20 x 10(6) sites/cell). Preinjection of rats with 20 mg of APM-lactoferrin/kg of body weight reduced the liver association of beta-very low density lipoprotein (beta-VLDL) by 50%, whereas lactoferrin had no effect at this dose. With isolated parenchymal liver cells, APM-lactoferrin was a more effective competitor for beta-VLDL binding than native lactoferrin (50% inhibition at 0.5 mg/ml versus 8.0 mg/ml). Selective modification of the arginines of APM-lactoferrin with 1,2-cyclohexanedione reduced the liver association by approximately 60% and abolished the capacity of APM-lactoferrin to inhibit the binding of I-125-labeled beta-VLDL in vitro. In conclusion, our data indicate that the four-arginine cluster of lactoferrin at positions 2-5 is involved in its massive, low affinity association of lactoferrin with the liver, possibly to proteoglycans, but is not essential for the inhibition of lipoprotein remnant uptake. The Arg-Lys sequence at positions 25-31, which resembles the binding site of apolipoprotein E, may mediate the high affinity binding of lactoferrin and block the binding of beta-VLDL to the remnant receptor with high efficiency.	LEIDEN UNIV,SYLVIUS LAB,LEIDEN AMSTERDAM CTR DRUG RES,DIV BIOPHARMACEUT,2300 RA LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC			Van Berkel, Theo/ABD-7677-2021					BENNETT RM, 1979, CLIN SCI, V57, P453, DOI 10.1042/cs0570453; BENSADOUM A, 1991, ANN REV NUTR, V1, P217; BIJSTERBOSCH MK, 1989, MOL PHARMACOL, V36, P484; BLOUIN A, 1977, J CELL BIOL, V72, P441, DOI 10.1083/jcb.72.2.441; BLUARDDECONINCK JM, 1978, BIOCHEM J, V171, P321, DOI 10.1042/bj1710321; CASTELEIJN E, 1986, FEBS LETT, V201, P1193; CASTER WO, 1955, AM J PHYSIOL, V183, P317, DOI 10.1152/ajplegacy.1955.183.2.317; DEWATER R, 1990, EUR J BIOCHEM, V192, P419, DOI 10.1111/j.1432-1033.1990.tb19243.x; EHRLICH HJ, 1991, BIOCHEMISTRY-US, V30, P1021, DOI 10.1021/bi00218a020; FURUKAWA T, 1990, J BIOCHEM-TOKYO, V108, P297, DOI 10.1093/oxfordjournals.jbchem.a123197; GORIUS JB, 1980, AM J PATHOL, V99, P413; GUTTERIDGE JMC, 1981, BIOCHEM J, V199, P259, DOI 10.1042/bj1990259; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HARKES L, 1984, BIOCHEM J, V224, P21, DOI 10.1042/bj2240021; HUETTINGER M, 1992, J BIOL CHEM, V267, P18551; HUETTINGER M, 1988, CLIN BIOCHEM, V21, P87, DOI 10.1016/S0009-9120(88)80093-6; IMBER MJ, 1983, BIOCHEM J, V212, P249, DOI 10.1042/bj2120249; KARLE H, 1979, SCAND J HAEMATOL, V23, P303; LEE BR, 1991, J LIPID RES, V32, P165; LEGER D, 1977, ANN BIOL ANIM BIOCH, V17, P737, DOI 10.1051/rnd:19770609; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MASSON PL, 1969, J EXP MED, V130, P643, DOI 10.1084/jem.130.3.643; MASSON PL, 1986, PROTIDES BIOL FLUIDS, V14, P115; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; METZBOUTIGUE MH, 1984, EUR J BIOCHEM, V145, P659, DOI 10.1111/j.1432-1033.1984.tb08607.x; MOGUILEVSKY N, 1984, LAB INVEST, V50, P335; MULDER M, 1992, BIOCHEM BIOPH RES CO, V185, P582, DOI 10.1016/0006-291X(92)91664-C; NAGELKERKE JF, 1983, J BIOL CHEM, V258, P2221; NAKANISHI M, 1989, J BIOCHEM, V106, P818, DOI 10.1093/oxfordjournals.jbchem.a122937; PATTHY L, 1975, J BIOL CHEM, V250, P557; PITTMAN RC, 1983, BIOCHEM J, V212, P791, DOI 10.1042/bj2120791; PRIEELS JP, 1978, P NATL ACAD SCI USA, V75, P2215, DOI 10.1073/pnas.75.5.2215; QUERINJE.P, 1971, EUR J BIOCHEM, V20, P420, DOI 10.1111/j.1432-1033.1971.tb01408.x; RECOECZI E, 1985, AM J PHYSIOL, V248, pG8; RETEGUI LA, 1984, LAB INVEST, V50, P323; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SPIK G, 1966, CR ACAD SCI D NAT, V263, P893; SPITZNAGEL JK, 1972, J CLIN INVEST, V51, pA93; VANBERKEL TJC, 1987, BIOCHEM J, V243, P715, DOI 10.1042/bj2430715; VANDIJK MCM, 1992, EUR J BIOCHEM, V205, P775, DOI 10.1111/j.1432-1033.1992.tb16842.x; VANDIJK MCM, 1991, BIOCHEM J, V279, P863, DOI 10.1042/bj2790863; VANTOL A, 1978, ATHEROSCLEROSIS, V29, P449, DOI 10.1016/0021-9150(78)90173-9; ZIERE GJ, 1992, J BIOL CHEM, V267, P11229	44	46	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27069	27075						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	7903302				2022-12-25	WOS:A1993MM26200037
J	GREENE, NM; WILLIAMS, DS; NEWTON, AC				GREENE, NM; WILLIAMS, DS; NEWTON, AC			KINETICS AND LOCALIZATION OF THE PHOSPHORYLATION OF RHODOPSIN BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; LIGHT-MEDIATED BREAKDOWN; PHOSPHOLIPASE-C; PHOTORECEPTOR CELLS; BOVINE RHODOPSIN; RECEPTOR; SITES; DESENSITIZATION; SPECIFICITY; RETINA	Protein kinase C isolated from retina catalyzes the stoichiometric phosphorylation of bovine rhodopsin, Enzymological studies using receptor in rod outer segment membranes stripped of peripheral proteins reveal that the phosphorylation is independent of receptor conformation or liganded state; the half-time for phosphorylation of unbleached (dark-adapted) rhodopsin, bleached (light-activated) rhodopsin, and opsin (chromophore removed) is the same. The phosphorylation by protein kinase C is Ca2+ and lipid regulated; the K-m for Ca2+ decreases with increasing concentrations of membrane, consistent with known properties of Ca2+-regulated protein kinase Cs. The K-m for ATP is 27 mu M, with an optimal concentration for MgCl2 of approximately 1 mM. The phosphorylation of rhodopsin by protein kinase C is inhibited by the protein kinase C-selective inhibitor sangivamycin. Proteolysis by Asp-N reveals that all the protein kinase C phosphorylation sites are on the carboxyl terminus of the receptor. Cleavage with trypsin indicates that Ser(338), the primary phosphorylation site of rhodopsin kinase, is not phosphorylated significantly; rather, the primary phosphorylation site of protein kinase C is on the membrane proximal half of the carboxyl terminus. The protein kinase C catalyzed phosphorylation of rhodopsin is analogous to the ligand-independent phosphorylation of other G protein-coupled receptors that is catalyzed by second messenger-regulated kinases.	INDIANA UNIV, DEPT CHEM, BLOOMINGTON, IN 47405 USA; INDIANA UNIV, SCH OPTOMETRY, BLOOMINGTON, IN 47405 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington					NATIONAL EYE INSTITUTE [R01EY008820] Funding Source: NIH RePORTER; NEI NIH HHS [EY08820] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AZARIAN SM, 1993, J CELL SCI, V105, P787; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; CHAKRAVARTHY BR, 1991, ANAL BIOCHEM, V196, P144, DOI 10.1016/0003-2697(91)90130-L; DAEMEN FJM, 1973, BIOCHIM BIOPHYS ACTA, V300, P255, DOI 10.1016/0304-4157(73)90006-3; DAS ND, 1987, CELL STRUCT FUNCT, V12, P471, DOI 10.1247/csf.12.471; DAWSON TM, 1993, SCIENCE, V259, P825, DOI 10.1126/science.8381559; FERREIRA PA, 1993, P NATL ACAD SCI USA, V90, P6042, DOI 10.1073/pnas.90.13.6042; GEHM BD, 1990, BIOCHEMISTRY-US, V29, P5447, DOI 10.1021/bi00475a006; GHALAYINI A, 1984, BIOCHEM BIOPH RES CO, V124, P503, DOI 10.1016/0006-291X(84)91582-1; GHALAYINI AJ, 1991, J NEUROCHEM, V57, P1405, DOI 10.1111/j.1471-4159.1991.tb08307.x; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAYASHI F, 1985, BIOCHEM BIOPH RES CO, V128, P954, DOI 10.1016/0006-291X(85)90139-1; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; HONG K, 1972, P NATL ACAD SCI USA, V69, P2617, DOI 10.1073/pnas.69.9.2617; INGLESE J, 1993, J BIOL CHEM, V268, P23735; JEAN T, 1986, J BIOL CHEM, V261, P6414; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; KELLEHER DJ, 1986, J BIOL CHEM, V261, P4749; KHOVRATOVICH VI, 1991, BIOL MEMBR, V4, P1392; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; LEE RH, 1992, J BIOL CHEM, V267, P25104; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOOMIS CR, 1988, J BIOL CHEM, V263, P1682; McDowell J. H., 1993, PHOTORECEPTOR CELLS, V15, P123; MCDOWELL JH, 1993, BIOCHEMISTRY-US, V32, P4968, DOI 10.1021/bi00069a036; MILLAR FA, 1988, BIOCHIM BIOPHYS ACTA, V970, P205, DOI 10.1016/0167-4889(88)90180-2; MILLER JL, 1984, VISION RES, V24, P1509, DOI 10.1016/0042-6989(84)90313-4; MOSIOR M, 1993, BIOCHEMISTRY-US, V32, P65, DOI 10.1021/bi00052a010; MOSIOR M, 1994, J BIOL CHEM, V269, P13798; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; NEWTON AC, 1991, J BIOL CHEM, V266, P17725; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; NEWTON AC, 1993, J BIOL CHEM, V268, P18181; NEWTON AC, 1993, TRENDS BIOCHEM SCI, V18, P275, DOI 10.1016/0968-0004(93)90032-I; NEWTON AC, 1987, J BIOL CHEM, V262, P10185; NEWTON AC, 1993, METH NEUROSCI, V15, P261; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; ORR JW, 1992, J BIOL CHEM, V267, P15263; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; PALCZEWSKI K, 1988, J BIOL CHEM, V263, P14067; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1988, BIOCHEMISTRY-US, V27, P2306, DOI 10.1021/bi00407a010; PAPAC DI, 1993, BIOCHEMISTRY-US, V32, P5930, DOI 10.1021/bi00074a002; PHILLIPS WJ, 1994, BIOCHEM J, V299, P351, DOI 10.1042/bj2990351; RICHARDSON RM, 1992, J BIOL CHEM, V267, P10127; SCHLEICHER S, 1993, P NATL ACAD SCI USA, V90, P1420, DOI 10.1073/pnas.90.4.1420; STEMMER PM, 1994, BIOCHEMISTRY-US, V33, P6859, DOI 10.1021/bi00188a015; THORPE GHG, 1985, CLIN CHEM, V31, P1335; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; WILLIAMS DS, 1993, INVEST OPHTH VIS SCI, V34, P1361	55	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6710	6717		10.1074/jbc.270.12.6710	http://dx.doi.org/10.1074/jbc.270.12.6710			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896814	hybrid			2022-12-25	WOS:A1995QQ85500045
J	LIN, JL; ADDISON, R				LIN, JL; ADDISON, R			THE MEMBRANE TOPOLOGY OF THE CARBOXYL-TERMINAL 3RD OF THE NEUROSPORA PLASMA-MEMBRANE H(+)ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM MEMBRANE; H+-ATPASE; PROTEIN; SEQUENCE; SURFACE; CRASSA; AMINO; CA-2+-ATPASE; GENE	To localize transmembrane segments in the carboxyl-terminal third of the Neurospora plasma membrane H+-ATPase, we constructed fusion proteins on the cDNA level. These contained DNA fragments encoding hydrophilic residues of the amino and carboxyl termini of the H+-ATPase with a DNA fragment encoding the putative transmembrane segment. To report translocation into microsomes, a DNA fragment encoding three consensus N-linked glycosylation sites was engineered carboxyl-terminal to the putative transmembrane segment. Fusion proteins were synthesized in a Neurospora in vitro translation system supplemented with homologous microsomes. By the criteria of glycosylation of fusion proteins by microsomes, sedimentation of products with microsomes after alkaline extraction, and analysis of protected fragments generated from proteinase K digestion of integrated products, we localized six transmembrane segments in the carboxyl-terminal third of the H+-ATPase. These results support a 10-segment model of the Neurospora H+-ATPase.			LIN, JL (corresponding author), UNIV TENNESSEE,CTR HLTH SCI,DEPT BIOCHEM,MEMPHIS,TN 38163, USA.							ADDISON R, 1987, J BIOL CHEM, V262, P17031; ADDISON R, 1986, J BIOL CHEM, V261, P4896; AUDIGIER Y, 1987, P NATL ACAD SCI USA, V84, P5783, DOI 10.1073/pnas.84.16.5783; BAMBERG K, 1994, J BIOL CHEM, V269, P16909; CLARKE DM, 1990, J BIOL CHEM, V265, P17405; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; EBELE BE, 1987, MOL CELL BIOL, V7, P3591; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; EMR SD, 1983, P NATL ACAD SCI-BIOL, V80, P4599, DOI 10.1073/pnas.80.15.4599; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; LIN J, 1994, J BIOL CHEM, V269, P3887; LIN JL, 1995, J BIOL CHEM, V270, P6935, DOI 10.1074/jbc.270.12.6935; MANDALA SM, 1989, J BIOL CHEM, V264, P16276; MOHRAZ M, 1994, J BIOL CHEM, V269, P2929; RAO US, 1991, J BIOL CHEM, V266, P14740; REITHMEIER RAF, 1981, J BIOL CHEM, V256, P5957; Scharf SJ, 1990, PCR PROTOCOLS GUIDE, P84; SENGSTAG C, 1990, MOL CELL BIOL, V10, P672, DOI 10.1128/MCB.10.2.672; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SMITH DL, 1993, J BIOL CHEM, V268, P22469; TAUSSIG R, 1983, NUCLEIC ACIDS RES, V11, P1943, DOI 10.1093/nar/11.6.1943; TAYLOR KA, 1994, J BIOL CHEM, V269, P10107; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0	24	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6942	6948		10.1074/jbc.270.12.6942	http://dx.doi.org/10.1074/jbc.270.12.6942			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896844	hybrid			2022-12-25	WOS:A1995QQ85500075
J	ZHANG, LX; MILLS, KJ; DAWSON, MI; COLLINS, SJ; JETTEN, AM				ZHANG, LX; MILLS, KJ; DAWSON, MI; COLLINS, SJ; JETTEN, AM			EVIDENCE FOR THE INVOLVEMENT OF RETINOIC ACID RECEPTOR RAR-ALPHA-DEPENDENT SIGNALING PATHWAY IN THE INDUCTION OF TISSUE TRANSGLUTAMINASE AND APOPTOSIS BY RETINOIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUROBLASTOMA-CELLS; LUNG-CARCINOMA CELLS; GENE-EXPRESSION; NUCLEAR RECEPTORS; EPIDERMAL-CELLS; HL-60 CELLS; DEATH; RXR; DIFFERENTIATION; IDENTIFICATION	In this study, we show that all-trans-retinoic acid (RA) is a potent inducer of tissue transglutaminase (TGase II) and apoptosis in the rat tracheobronchial epithelial cell line SPOC-1. We demonstrate that these cells express the retinoid receptors RAR alpha, RAR gamma, and RXR beta. To identify which of these receptors are involved in regulating these processes, we analyzed the effects of several receptor-selective agonists, an antagonist, and a dominant-negative RAR alpha. We show that the RAR-selective retinoid SRI-6751-84 strongly increased TGase II expression at both the protein and mRNA levels, whereas the RXR-selective retinoid SR11217 had little effect. The RAR alpha-selective retinoid Ro40-6055 was also able to induce TGase II, whereas the RAR gamma-selective retinoid CD437 was inactive. The induction of TGase II by the RAR-selective retinoid was completely inhibited by the RAR alpha-antagonist Ro41-5253. Overexpression of a truncated RAR alpha gene with dominant-negative activity also inhibited the induction of TGase II expression. The increase in TGase II is associated with an induction of apoptosis as revealed by DNA fragmentation and the generation of apoptotic cells. We demonstrate that apoptosis is affected by retinoids in a manner similar to TGase II. Our results suggest that the induction of TGase II expression and apoptosis in SPOC-1 cells are mediated through an RAR alpha-dependent signaling pathway.	NIEHS,PULM PATHOBIOL LAB,CELL BIOL SECT,RES TRIANGLE PK,NC 27709; SRI INT,BIOORGAN CHEM LAB,MENLO PK,CA 94025; FRED HUTCHINSON CANC RES CTR,PROGRAM MOLEC MED,SEATTLE,WA 98104	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); SRI International; Fred Hutchinson Cancer Center			Jetten, Anton/C-3736-2019	Jetten, Anton/0000-0003-0954-4445	NATIONAL CANCER INSTITUTE [R01CA055397] Funding Source: NIH RePORTER; NCI NIH HHS [CA-55397] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725; APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; BIRCKBICHLER PJ, 1985, HYBRIDOMA, V4, P179, DOI 10.1089/hyb.1985.4.179; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CHIOCCA EA, 1988, J BIOL CHEM, V263, P11584; DAMM K, 1990, P NATL ACAD SCI USA, V90, P2989; DAVIES PJA, 1985, J BIOL CHEM, V260, P5166; DAVIES PJA, 1992, RETINOIDS NORMAL DEV, P249; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; DENNING MF, 1991, BIOCHEM BIOPH RES CO, V175, P344, DOI 10.1016/S0006-291X(05)81241-0; DOHERTY MM, 1995, IN PRESS AM J RESPIR; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; EITAN S, 1993, SCIENCE, V261, P106, DOI 10.1126/science.8100369; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FLOYD EE, 1989, MOL CELL BIOL, V9, P4846, DOI 10.1128/MCB.9.11.4846; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; GEORGE MD, 1990, J BIOL CHEM, V265, P11098; GORMAN CM, 1982, MOL CELL BIOL, V2, P1041; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; Jetten A M, 1992, J Natl Cancer Inst Monogr, P93; Jetton A. M., 1994, Retinoids: from basic science to clinical applications., P243; JIANG H, 1992, TERATOLOGY, V46, P333, DOI 10.1002/tera.1420460404; KOJIMA S, 1993, J CELL BIOL, V121, P439, DOI 10.1083/jcb.121.2.439; LEHMANN JM, 1991, CANCER RES, V51, P4804; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MARTIN B, 1992, SKIN PHARMACOL, V5, P57; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; NERVI C, 1991, EXP CELL RES, V195, P163, DOI 10.1016/0014-4827(91)90512-S; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; PIACENTINI M, 1992, INT J CANCER, V52, P271, DOI 10.1002/ijc.2910520220; PIACENTINI M, 1993, FEBS LETT, V320, P150, DOI 10.1016/0014-5793(93)80081-5; PRESTON GA, 1994, CANCER RES, V54, P4214; ROSAMUND LK, 1993, EUR J CELL BIOL, V60, P210; RUBIN AL, 1986, CANCER RES, V46, P21356; SCHRADER M, 1993, J BIOL CHEM, V268, P17830; SCOTT KFF, 1982, P NATL ACAD SCI-BIOL, V79, P4093, DOI 10.1073/pnas.79.13.4093; SPORN MB, 1994, RETINOIDS BIOL MED; TARCSA E, 1992, J BIOL CHEM, V267, P25648; TATE BF, 1994, MOL CELL BIOL, V14, P2323, DOI 10.1128/MCB.14.4.2323; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; TOMEI LD, 1994, APOPTOSIS, V2, P147; TSAI S, 1992, GENE DEV, V6, P2258, DOI 10.1101/gad.6.12a.2258; VOLLBERG TM, 1992, AM J RESP CELL MOL, V7, P10, DOI 10.1165/ajrcmb/7.1.10; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; YUSPA SH, 1982, J BIOL CHEM, V257, P9906; ZHANG LX, 1992, CANCER RES, V52, P5707; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0	54	130	135	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					6022	6029		10.1074/jbc.270.11.6022	http://dx.doi.org/10.1074/jbc.270.11.6022			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890733	hybrid			2022-12-25	WOS:A1995QM94500049
J	UCHIDA, T; WADA, C; WANG, CX; ISHIDA, H; EGAWA, S; YOKOYAMA, E; OHTANI, H; KOSHIBA, K				UCHIDA, T; WADA, C; WANG, CX; ISHIDA, H; EGAWA, S; YOKOYAMA, E; OHTANI, H; KOSHIBA, K			MICROSATELLITE INSTABILITY IN PROSTATE-CANCER	ONCOGENE			English	Note						MICROSATELLITE INSTABILITY; PROSTATE CANCER	GENETIC INSTABILITY; ALLELIC LOSS; MUTATIONS; GROWTH; COLON	Assessment of the genetic instability of a microsatellite has indicated a new mechanism in human carcinogenesis. Examination was made to determine whether microsatellite instability is associated with the onset of prostate cancer. Twenty-nine DNA samples from 24 primary prostate cancer, two metastatic lymph-node and three benign prostatic hypertrophy patients were used. Differences in unrelated microsatellites for tumor and normal DNA were detected in nine of 24 (37.5%) cases. Seven of 11 (63.6%) with poorly differentiated adenocarcinomas and seven of 15 (46.7%) stage D metastatic patients showed somatic instability in a number of microsatellites. Statistically significant differences in well to moderately differentiated tumors and poorly differentiated cancer (P=0.015, Chi-square test), were detected but not for stages A-C and D (P=0.2311). Genetic alterations would thus appear to be rare in low grade and/or early prostate cancers but more common in high grade and/or advanced prostate cancers.	KITASATO UNIV,SCH MED,DEPT CLIN PATHOL,KANAGAWA 228,JAPAN	Kitasato University	UCHIDA, T (corresponding author), KITASATO UNIV,SCH MED,DEPT UROL,KANAGAWA 228,JAPAN.							AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ANWAR K, 1992, CANCER RES, V52, P5991; ATKIN NB, 1985, HUM GENET, V70, P359, DOI 10.1007/BF00295378; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOVA GS, 1993, CANCER RES, V53, P3869; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; DAVIES P, 1991, J ENDOCRINOL, V131, P5, DOI 10.1677/joe.0.1310005; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GONZALEZZULUETA M, 1993, CANCER RES, V53, P5620; HAN HJ, 1993, CANCER RES, V53, P5087; HONCHEL R, 1994, CANCER RES, V54, P1159; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; RISINGER JI, 1993, CANCER RES, V53, P5100; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; STORMONT TJ, 1993, UROLOGY, V41, P3, DOI 10.1016/0090-4295(93)90233-Z; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; THOMPSON TC, 1990, CANCER CELL-MON REV, V2, P345; THOMPSON TC, 1990, CELL, V56, P917; UCHIDA T, 1994, CANCER RES, V54, P3682; UCHIDA T, 1993, BRIT J CANCER, V68, P751, DOI 10.1038/bjc.1993.423; WEBER JL, 1989, AM J HUM GENET, V144, P388; 1991, HTLH WELFARE STATIST, P417; 1992, GENERAL RULE CLIN PA	26	62	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					1019	1022						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898920				2022-12-25	WOS:A1995QL03800025
J	ARNIS, S; FAHMY, K; HOFMANN, KP; SAKMAR, TP				ARNIS, S; FAHMY, K; HOFMANN, KP; SAKMAR, TP			A CONSERVED CARBOXYLIC-ACID GROUP MEDIATES LIGHT-DEPENDENT PROTON UPTAKE AND SIGNALING BY RHODOPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METARHODOPSIN-II; BOVINE RHODOPSIN; CONFORMATIONAL-CHANGES; TRANSDUCIN; MUTANTS; GENE	A carboxylic acid residue is conserved at the cytoplasmic border of the third transmembrane segment among nearly all G protein-coupled receptors. In the visual receptor rhodopsin, replacement of the conserved Glu(134) by a neutral glutamine results in enhanced transducin activation. Here we show that a key event in forming the active state of rhodopsin is proton uptake by Glu(134) in the metarhodopsin II (MII) photoproduct. Site-directed mutants E134D and E134Q were studied by flash photolysis, where formation rates of their photoproducts and rates of pH change could be monitored simultaneously. Both mutants showed normal MII formation rates. However, E134D displayed a slowed rate of proton uptake and E134Q displayed a loss of light-induced uptake of two protons from the aqueous phase. Thus, Glu(134) mediates light-dependent proton uptake by MII. We propose that receptor activation requires a light-induced conformational change that allows protonation of Glu(134) and subsequent protonation of a second group. The strong conservation of Glu(134) in G protein-coupled receptors implies a general requirement for a proton acceptor group at this position to allow light- or ligand-dependent receptor activation.	ROCKEFELLER UNIV, HOWARD HUGHES MED INST, MOLEC BIOL & BIOCHEM LAB, NEW YORK, NY 10021 USA; UNIV FREIBURG, INST BIOPHYS & STRAHLENBIOL, W-7800 FREIBURG, GERMANY	Howard Hughes Medical Institute; Rockefeller University; University of Freiburg			Sakmar, Thomas P/D-1833-2015; Fahmy, Karim/B-2708-2017	Sakmar, Thomas P/0000-0002-2836-8953; Fahmy, Karim/0000-0002-8752-5824				ARNIS S, 1993, P NATL ACAD SCI USA, V90, P7849, DOI 10.1073/pnas.90.16.7849; BENNETT N, 1980, EUR J BIOCHEM, V111, P99; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EMEIS D, 1982, FEBS LETT, V143, P29, DOI 10.1016/0014-5793(82)80266-4; FAHMY K, 1993, P NATL ACAD SCI USA, V90, P10206, DOI 10.1073/pnas.90.21.10206; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; FARAHBAKHSH ZT, 1993, SCIENCE, V262, P1416, DOI 10.1126/science.8248781; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; HOFMANN KP, 1986, PHOTOBIOCH PHOTOBIOP, V13, P309; KIBELBEIS J, 1991, BIOCHEMISTRY-US, V36, P6761; KOENIG B, 1989, Proceedings of the National Academy of Sciences of the United States of America, V86, P6878; MATTHEWS RG, 1963, J GEN PHYSIOL, V47, P215, DOI 10.1085/jgp.47.2.215; NATHANS J, 1987, ANNU REV NEUROSCI, V10, P163; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; PARKES JH, 1984, BIOCHEMISTRY-US, V23, P5054, DOI 10.1021/bi00316a035; RADDING CR, 1965, GEN PHYSL, V30, P909; RESEK JF, 1993, BIOCHEMISTRY-US, V32, P12025, DOI 10.1021/bi00096a012; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; WEITZ CJ, 1993, BIOCHEMISTRY-US, V32, P14176, DOI 10.1021/bi00214a016	23	186	188	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23879	23881						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929034				2022-12-25	WOS:A1994PQ34600008
J	NUNOKI, K; ISHII, K; OKADA, H; YAMAGISHI, T; MURAKOSHI, H; TAIRA, N				NUNOKI, K; ISHII, K; OKADA, H; YAMAGISHI, T; MURAKOSHI, H; TAIRA, N			HYBRID POTASSIUM CHANNELS BY TANDEM LINKAGE OF INACTIVATING AND NONINACTIVATING SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSIENT OUTWARD CURRENT; CARDIAC PURKINJE-FIBERS; SHAKER K+ CHANNEL; STOICHIOMETRY; CELLS; MODULATION; NEURONS; BINDING; REGION; HEART	We constructed tandem cDNA by linking the 5' end of a delayed rectifier-type (Kv1.2) clone to the 3' end of a transient-type (Kv1.4) K+ channel clone. Fusion genes were also constructed, consisting of Kv1.4 and mutants of Kv1.2, which have a single amino acid substitution in the S4-S5 loop. From electrophysiolog;ical characterization, it is likely that two pairs of tandem heterodimer constructs can form hybrid channels. In addition, it has been revealed that the wild-type hybrid channel shows a time constant of inactivation very similar to that observed in the homotetrameric Kv1.4 channel. Difference of inactivation kinetics between wild-type and mutant hybrid K+ channels suggests that not only the S4-S5 loop of Kv1.4 but also that of Kv1.2 can serve as the acceptor sites for the inactivation gates, and that all of four sets of loops should be functional for rapid inactivation. From these results, in the hybrid channels the structure and composition of the acceptor sites could be important factors for determining the rate of inactivation.			NUNOKI, K (corresponding author), TOHOKU UNIV,SCH MED,DEPT PHARMACOL,2-1 SEIRYO MACHI,SENDAI,MIYAGI 980,JAPAN.							CHRISTIE MJ, 1990, NEURON, V2, P405; CORABOEUF E, 1982, PFLUG ARCH EUR J PHY, V392, P352, DOI 10.1007/BF00581631; ESCANDE D, 1987, AM J PHYSIOL, V252, pH142, DOI 10.1152/ajpheart.1987.252.1.H142; GILES WR, 1985, J PHYSIOL-LONDON, V368, P243, DOI 10.1113/jphysiol.1985.sp015856; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; Hille B., 1992, IONIC CHANNELS EXCIT; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; ISHII K, 1992, BIOCHEM BIOPH RES CO, V184, P1484, DOI 10.1016/S0006-291X(05)80050-6; JAN LY, 1989, CELL, V56, P13, DOI 10.1016/0092-8674(89)90979-3; JOSEPHSON IR, 1984, CIRC RES, V54, P157, DOI 10.1161/01.RES.54.2.157; KACZMAREK LK, 1984, J NEUROPHYSIOL, V52, P340, DOI 10.1152/jn.1984.52.2.340; KENYON JL, 1987, J GEN PHYSIOL, V89, P921, DOI 10.1085/jgp.89.6.921; KIRSCH GE, 1993, NEURON, V11, P503, DOI 10.1016/0896-6273(93)90154-J; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MACKINNON R, 1993, SCIENCE, V262, P757, DOI 10.1126/science.7694359; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MCCORMACK K, 1992, BIOPHYS J, V63, P1406, DOI 10.1016/S0006-3495(92)81703-4; NAKAYAMA T, 1985, CIRC RES, V57, P65, DOI 10.1161/01.RES.57.1.65; OKADA H, 1992, BIOCHEM BIOPH RES CO, V189, P430, DOI 10.1016/0006-291X(92)91576-C; PEROZO E, 1992, BIOPHYS J, V62, P160, DOI 10.1016/S0006-3495(92)81802-7; PO S, 1993, CIRC RES, V72, P1326, DOI 10.1161/01.RES.72.6.1326; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SEGAL M, 1984, J NEUROSCI, V4, P604; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; SHIBATA EF, 1989, AM J PHYSIOL, V257, pH1773, DOI 10.1152/ajpheart.1989.257.6.H1773; TSENG GN, 1989, CIRC RES, V64, P633, DOI 10.1161/01.RES.64.4.633; YAO JA, 1992, CIRCULATION, V86, P77; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	32	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24138	24142						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929069				2022-12-25	WOS:A1994PQ34600047
J	PORTER, DJT				PORTER, DJT			DEHALOGENATING AND NADPH-MODIFYING ACTIVITIES OF DIHYDROPYRIMIDINE DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; PIG-LIVER; ANTITUMOR-ACTIVITY; 5-FLUOROURACIL; PURIFICATION; MECHANISM; INACTIVATION; 5-ETHYNYLURACIL; OXIDATION; ACID	Dihydropyrimidine dehydrogenase (DPDase) catalyzed the debromination of 8-bromo-5,6-dihydrouracil (BrUH2) to uracil at pH 7.7 and 37 degrees C. The debrominating activity of DPDase was increased 5-fold by treatment with H2O2, whereas the dehydrogenating activity was inhibited by this treatment. The time course for increasing the debrominating activity by H2O2 was similar to that for decreasing the dehydrogenating activity. Thus, the relative amounts of debrominating and dehydrogenating activities of DPDase were reciprocally related. H2O2 treatment of DPDase decreased the number of thiol groups reactive with 5,5'-dithiobis(2-nitrobenzoate) from eight/subunit to less than one. The k(cat) for debromination of BrUH2 by H2O2-treated DPDase (OxDPDase) was 1.9 s(-1), which was comparable with k(cat) for reduction of thymine (2.1 s(-1)) by DPDase. Even though the debromination of BrUH2 to uracil does not involve a net reduction of BrUH2, NADPH was required for this activity. The reaction of OxDPDase with 5-iodo-5,6 dihydrouracil (IUH2) was more complicated than that with BrUH2. Aerobically, OxDPDase catalyzed the deiodination of IUH2 to uracil and the iodination of NADPH to 5-iodo-6-hydroxy-1,4,6-trihydronicotinamide adenine dinucleotide phosphate. The turnover number for the iodination reaction was enhanced by NaI and had a value of 3.5 s(-1) in the presence of 4 mM IUH2 and 50 mM NaI. Anaerobically, OxDPDase catalyzed the above reactions, the deiodination of IUH2 to 5,6-dihydrouracil, and the hydration of NADPH to 6-hydroxy-1,2,3,4-tetrahydronicotinamide adenine dinucleotide phosphate. The turnover number for the anaerobic hydration of NADPH was similar to that for the aerobic iodination of NADPH.			PORTER, DJT (corresponding author), WELLCOME RES LABS, DIV EXPTL THERAPY, RES TRIANGLE PK, NC 27709 USA.							ACHESON SA, 1988, BIOCHEMISTRY-US, V27, P7371, DOI 10.1021/bi00419a030; BACCANARI DP, 1993, P NATL ACAD SCI USA, V90, P11064, DOI 10.1073/pnas.90.23.11064; CHAYKIN S, 1956, J BIOL CHEM, V220, P811; DELLACOR.E, 1972, BIOCHEM J, V126, P739, DOI 10.1042/bj1260739; DESGRANGES C, 1986, CANCER RES, V46, P1094; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GELDERMANN AH, 1985, BIOCHEMISTRY-US, V4, P1511; HARRIS BE, 1991, CANCER, V68, P499, DOI 10.1002/1097-0142(19910801)68:3<499::AID-CNCR2820680309>3.0.CO;2-F; HILVERS AG, 1966, BIOCHIM BIOPHYS ACTA, V128, P74, DOI 10.1016/0926-6593(66)90143-3; HUENNEKENS FM, 1955, J BIOL CHEM, V213, P951; IIGO M, 1988, BIOCHEM PHARMACOL, V37, P1609; LESKOVAC V, 1987, MONATSH CHEM, V118, P1119, DOI 10.1007/BF00811285; LU ZH, 1992, J BIOL CHEM, V267, P17102; MARGOLIS SA, 1978, J LIQ CHROMATOGR, V1, P669, DOI 10.1080/01483917808060026; MIKSIC JR, 1978, BIOCHEMISTRY-US, V17, P2234, DOI 10.1021/bi00604a034; MIKSIC JR, 1977, J CHROMATOGR, V142, P641, DOI 10.1016/S0021-9673(01)92074-6; NAGUIB FNM, 1989, BIOCHEM PHARMACOL, V38, P1471, DOI 10.1016/0006-2952(89)90187-1; OPPENHEIMER NJ, 1974, BIOCHEMISTRY-US, V13, P4675, DOI 10.1021/bi00720a001; OPPENHEIMER NJ, 1974, BIOCHEMISTRY-US, V13, P4685, DOI 10.1021/bi00720a002; PODSCHUN B, 1993, J BIOL CHEM, V268, P3407; PODSCHUN B, 1989, EUR J BIOCHEM, V185, P219, DOI 10.1111/j.1432-1033.1989.tb15105.x; PODSCHUN B, 1990, J BIOL CHEM, V265, P12966; PODSCHUN B, 1992, BIOCHEM BIOPH RES CO, V182, P609, DOI 10.1016/0006-291X(92)91776-M; PORTER DJT, 1991, J BIOL CHEM, V266, P19988; PORTER DJT, 1992, J BIOL CHEM, V267, P5236; RAFTER GW, 1954, J BIOL CHEM, V208, P799; REGUEIRO B, 1970, PHYSIOL CHEM PHYS M, V2, P445; ROMAN R, 1972, BIOCHEMISTRY-US, V11, P2076, DOI 10.1021/bi00761a013; RORK GS, 1975, J AM CHEM SOC, V97, P5566, DOI 10.1021/ja00852a041; SANDER EG, 1976, BIOORG CHEM, V5, P231, DOI 10.1016/0045-2068(76)90032-8; SHEN H, 1993, ARCH BIOCHEM BIOPHYS, V300, P137, DOI 10.1006/abbi.1993.1019; SHIOTANI T, 1981, J BIOL CHEM, V256, P219; STOCK A, 1961, LIEBIGS ANN CHEM, V647, P188; TATSUMI K, 1987, JPN J CANCER RES, V78, P748; VELICK SF, 1955, METHOD ENZYMOL, V1, P401, DOI 10.1016/0076-6879(55)01065-3; WAUD WR, 1976, ARCH BIOCHEM BIOPHYS, V172, P365, DOI 10.1016/0003-9861(76)90088-6	36	6	6	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24177	24182						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929074				2022-12-25	WOS:A1994PQ34600053
J	HA, J; DANIEL, S; BROYLES, SS; KIM, KH				HA, J; DANIEL, S; BROYLES, SS; KIM, KH			CRITICAL PHOSPHORYLATION SITES FOR ACETYL-COA CARBOXYLASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; BACTERIOPHAGE-T7 RNA-POLYMERASE; ACTIVATED PROTEIN-KINASE; FATTY-ACID SYNTHESIS; MESSENGER-RNA; 5' END; ISOLATED ADIPOCYTES; CODING SEQUENCE; MALONYL-COA; EXPRESSION	Acetyl CoA carboxylase (ACC) is rapidly regulated by reversible phosphorylation; phosphorylation inactivates ACC, whereas dephosphorylation activates the enzyme. Among protein kinases only cAMP-dependent protein kinase and 5'-AMP-dependent protein kinase can inactivate ACC; cAMP-dependent protein kinase phosphorylates Ser-77 and -1200; 5'-AMP-dependent protein kinase phosphorylates Ser-79, -1200, and -1215. In this report, the construction and expression of ACC cDNA containing the entire coding region (7.2 kilobase pairs) is described. In order to identify the critical phosphorylation site(s) for each protein kinase, we introduced site-specific mutations at Ser-77, -79, -1200, and -1215 of ACC cDNA and a series of mutated ACCs containing various combinations of these four mutated sites was expressed. By examination of the various mutant ACCs, we provided evidence that the effect of cAMP-dependent protein kinase is entirely mediated by the phosphorylation of Ser-1200 and that Ser-79 is important for 5'-AMP-dependent protein kinase action in vitro.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NCI NIH HHS [CA 46882] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046882] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AIVARAM P, 1990, J BIOL CHEM, V265, P5774; BEATY NB, 1983, J BIOL CHEM, V258, P3043; CARSON CA, 1979, ARCH BIOCHEM BIOPHYS, V164, P490; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; DAVIES SP, 1990, EUR J BIOCHEM, V187, P183, DOI 10.1111/j.1432-1033.1990.tb15293.x; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GOODRIDGE AG, 1972, J BIOL CHEM, V247, P6946; GURDON JB, 1977, METHOD CELL BIOL, V16, P215; GUY PS, 1981, FEBS LETT, V132, P67, DOI 10.1016/0014-5793(81)80428-0; HA J, 1994, EUR J BIOCHEM, V219, P297, DOI 10.1111/j.1432-1033.1994.tb19941.x; HARDIE DG, 1989, TRENDS BIOCHEM SCI, V14, P19; HAYSTEAD TAJ, 1988, EUR J BIOCHEM, V175, P339, DOI 10.1111/j.1432-1033.1988.tb14202.x; HAYSTEAD TAJ, 1988, EUR J BIOCHEM, V175, P347, DOI 10.1111/j.1432-1033.1988.tb14203.x; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; KIM KH, 1983, CURR TOP CELL REGUL, V22, P143; KIM KH, 1989, FASEB J, V3, P2250, DOI 10.1096/fasebj.3.11.2570725; KONG IS, 1990, J BIOL CHEM, V265, P13695; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE KH, 1979, J BIOL CHEM, V254, P1450; LOPEZCASILLAS F, 1988, P NATL ACAD SCI USA, V85, P5784, DOI 10.1073/pnas.85.16.5784; LOPEZCASILLAS F, 1989, J BIOL CHEM, V264, P7176; LOPEZCASILLAS F, 1989, GENE, V83, P311, DOI 10.1016/0378-1119(89)90117-0; LUO XC, 1990, NUCLEIC ACIDS RES, V18, P3249, DOI 10.1093/nar/18.11.3249; LUO XC, 1989, P NATL ACAD SCI USA, V86, P4042, DOI 10.1073/pnas.86.11.4042; MCGARRY JD, 1978, J BIOL CHEM, V253, P4128; MUNDAY MR, 1988, EUR J BIOCHEM, V175, P331, DOI 10.1111/j.1432-1033.1988.tb14201.x; Numa S, 1984, FATTY ACID METABOLIS, P1; PAPE ME, 1988, MOL ENDOCRINOL, V2, P395, DOI 10.1210/mend-2-5-395; SIM ATR, 1988, FEBS LETT, V233, P294, DOI 10.1016/0014-5793(88)80445-9; SONG CS, 1981, J BIOL CHEM, V256, P7786; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SWANSON RF, 1967, P NATL ACAD SCI USA, V58, P1243, DOI 10.1073/pnas.58.3.1243; THAMPY KG, 1988, J BIOL CHEM, V263, P6447; THAMPY KG, 1986, ADV PROTEIN PHOSPHAT, V3, P257; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WITTERS LA, 1983, J BIOL CHEM, V258, P5463	38	264	276	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22162	22168						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	7915280				2022-12-25	WOS:A1994PE09800038
J	MIAO, SC; MCCARTER, JD; GRACE, ME; GRABOWSKI, GA; AEBERSOLD, R; WITHERS, SG				MIAO, SC; MCCARTER, JD; GRACE, ME; GRABOWSKI, GA; AEBERSOLD, R; WITHERS, SG			IDENTIFICATION OF GLU(340) AS THE ACTIVE-SITE NUCLEOPHILE IN HUMAN GLUCOCEREBROSIDASE BY USE OF ELECTROSPRAY TANDEM MASS-SPECTROMETRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACID BETA-GLUCOSIDASE; GAUCHER DISEASE; ENZYME INTERMEDIATE; MOLECULAR-BIOLOGY; GLYCOSIDASE; MECHANISM; SEQUENCE; BINDING	disease is an inherited lysosomal storage disorder caused by a deficiency of human acid beta-glucosidase (glucocerebrosidase). This enzyme is inactivated by the specific, mechanism-based enzyme inactivator 2-deoxy-2-fluoro-beta-D-glucopyranosyl fluoride, which functions by forming a stable 2-deoxy-2-fluoro-alpha-D-glucopyranosyl-enzyme intermediate. The key nucleophilic amino acid residue involved in formation of this intermediate was conclusively identified by tandem mass spectrometry as Glu340, and not Asp443 as thought previously. This was confirmed by site-directed mutagenesis. Identification, and mass determination, of the labeled peptide in a proteolytic hydrolysate involved detection of a collision-induced fragmentation reaction specific to the sugar-peptide linkage. Confirmation of the identity of the labeled peptide was obtained both by tandem mass spectrometric sequencing and by chemical degradation of the purified peptide. This method allowed the rapid, sensitive, and non-isotopic determination of an essential amino acid residue in a clinically important enzyme.	UNIV BRITISH COLUMBIA,DEPT CHEM,VANCOUVER V6T 1Z1,BC,CANADA; CHILDRENS HOSP MED CTR,DEPT PEDIAT,DIV HUMAN GENET,CINCINNATI,OH 45229; MT SINAI MED CTR,DEPT HUMAN GENET,NEW YORK,NY 10029; UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER V6T 1Z1,BC,CANADA	University of British Columbia; Cincinnati Children's Hospital Medical Center; Icahn School of Medicine at Mount Sinai; University of British Columbia								BALLARDIE F, 1973, J CHEM SOC PERK T 1, P2418, DOI 10.1039/p19730002418; BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; BARTON NW, 1990, P NATL ACAD SCI USA, V87, P1913, DOI 10.1073/pnas.87.5.1913; BERGFUSSMAN A, 1993, J BIOL CHEM, V268, P14861; BRADY RO, 1966, J CLIN INVEST, V45, P1112, DOI 10.1172/JCI105417; BUSCH KL, 1983, TANDEM MASS SPECTROM, P31; DINUR T, 1986, P NATL ACAD SCI USA, V83, P1660, DOI 10.1073/pnas.83.6.1660; ERICKSON AH, 1985, J BIOL CHEM, V260, P4319; FALLET S, 1992, PEDIATR RES, V31, P496, DOI 10.1203/00006450-199205000-00018; FIGUEROA ML, 1992, NEW ENGL J MED, V327, P1632, DOI 10.1056/NEJM199212033272304; GEBLER JC, 1992, J BIOL CHEM, V267, P11126; GRABOWSKI GA, 1990, CRIT REV BIOCHEM MOL, V25, P385, DOI 10.3109/10409239009090616; GRABOWSKI GA, 1988, LIPID STORAGE DISORD, P793; Grabowski Gregory A., 1993, V21, P377; GRACE ME, 1990, J BIOL CHEM, V265, P6827; GRACE ME, 1994, J BIOL CHEM, V269, P2283; HALL L, 1971, CAN J CHEM, V47, P118; HESS D, 1993, PROTEIN SCI, V2, P1342, DOI 10.1002/pro.5560020817; LEGLER G, 1990, ADV CARBOHYD CHEM BI, V48, P319, DOI 10.1016/S0065-2318(08)60034-7; ONEILL RR, 1989, P NATL ACAD SCI USA, V86, P5049, DOI 10.1073/pnas.86.13.5049; OSIECKINEWMAN K, 1988, ENZYME, V40, P173, DOI 10.1159/000469161; OSIECKINEWMAN KM, 1986, ENZYME, V35, P147, DOI 10.1159/000469336; PASTORES GM, 1993, BLOOD, V82, P408; SCHIMMEL P, 1990, BIOCHEMISTRY-US, V29, P9495, DOI 10.1021/bi00493a001; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SORGE J, 1985, P NATL ACAD SCI USA, V82, P7289, DOI 10.1073/pnas.82.21.7289; STREET IP, 1992, BIOCHEMISTRY-US, V31, P9970, DOI 10.1021/bi00156a016; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; TAKASAKI S, 1984, J BIOL CHEM, V259, P112; TYBULEWICZ VLJ, 1992, NATURE, V357, P407, DOI 10.1038/357407a0; WANG QP, 1993, J BIOL CHEM, V268, P14096; WITHERS SG, 1992, BIOCHEMISTRY-US, V31, P9979, DOI 10.1021/bi00156a017; WITHERS SG, 1988, J AM CHEM SOC, V110, P8551, DOI 10.1021/ja00233a045; WITHERS SG, 1988, J BIOL CHEM, V263, P7929; WITHERS SG, 1990, J AM CHEM SOC, V112, P5887, DOI 10.1021/ja00171a043	35	82	84	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					10975	10978						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7908905				2022-12-25	WOS:A1994NF96600003
J	MOYLE, M; FOSTER, DL; MCGRATH, DE; BROWN, SM; LAROCHE, Y; DEMEUTTER, J; STANSSENS, P; BOGOWITZ, CA; FRIED, VA; ELY, JA; SOULE, HR; VLASUK, GP				MOYLE, M; FOSTER, DL; MCGRATH, DE; BROWN, SM; LAROCHE, Y; DEMEUTTER, J; STANSSENS, P; BOGOWITZ, CA; FRIED, VA; ELY, JA; SOULE, HR; VLASUK, GP			A HOOKWORM GLYCOPROTEIN THAT INHIBITS NEUTROPHIL FUNCTION IS A LIGAND OF THE INTEGRIN CD11B CD18	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; MONOCLONAL-ANTIBODY; LEUKOCYTE DIFFERENTIATION; HEMORRHAGIC-SHOCK; ENDOTHELIAL-CELLS; MAC-1; ADHESION; RECEPTOR; LFA-1; ADHERENCE	The chronic survival of many endoparasites is dependent on the ability of these organisms to escape the host immune response. Identification of the molecular mechanisms by which these organisms evade this response may yield novel approaches in the development of anti-inflammatory agents. We describe here the discovery and characterization of a novel 41-kilodalton glycoprotein from the canine hookworm (Ancylostoma caninum) that potently inhibits CD11/CD18-dependent neutrophil function in vitro. Neutrophil inhibitory factor (NIF) blocks the adhesion of activated human neutrophils to vascular endothelial cells as well as the release of H2O2 from activated neutrophils, over a similar concentration range (IC50 10-20 nM). Studies aimed at determining the nature of the NIF binding site on neutrophils revealed selective, high affinity binding of this protein to the integrin CD11b/CD18. A cDNA encoding NIF was isolated from a canine hookworm cDNA library. NIF comprises a mature polypeptide of 257 amino acids, preceded by a 17-amino acid leader. The mature protein has 10 cysteines and has seven potential N-linked glycosylation sites. NIF has no significant sequence homologies to any previously reported protein. As such, NIF represents a prototype of a novel class of leukocyte function inhibitors.	CORVAS INT NV, GHENT, BELGIUM; NEW YORK MED COLL, DEPT CELL BIOL & ANAT, VALHALLA, NY 10595 USA	New York Medical College	MOYLE, M (corresponding author), CORVAS INT INC, 3030 SCI PK RD, SAN DIEGO, CA 92121 USA.							ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ARNAOUT MA, 1983, J CLIN INVEST, V72, P171, DOI 10.1172/JCI110955; BREARD J, 1980, J IMMUNOL, V124, P1943; CREGG JM, 1993, BIO-TECHNOL, V11, P905, DOI 10.1038/nbt0893-905; CREGG JM, 1985, MOL CELL BIOL, V5, P3376, DOI 10.1128/MCB.5.12.3376; CYBULSKY MI, 1988, LAB INVEST, V58, P365; DAVIES M, 1978, CLIN SCI MOL MED, V54, P233, DOI 10.1042/cs0540233; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; HARLAN JM, 1987, ACTA MED SCAND, P123; HARLAN JM, 1992, ADHESION ITS ROLE IN, P117; HERNANDEZ LA, 1987, AM J PHYSIOL, V253, pH699, DOI 10.1152/ajpheart.1987.253.3.H699; HITZEMAN RA, 1990, METHOD ENZYMOL, V185, P421; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANIER LL, 1985, EUR J IMMUNOL, V15, P713, DOI 10.1002/eji.1830150714; LO SK, 1989, J IMMUNOL, V143, P3325; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MAIZELS RM, 1993, NATURE, V365, P797, DOI 10.1038/365797a0; MIEDEMA F, 1984, EUR J IMMUNOL, V14, P518, DOI 10.1002/eji.1830140607; MILLER LJ, 1986, J IMMUNOL, V137, P2891; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; PICK E, 1980, J IMMUNOL METHODS, V38, P161, DOI 10.1016/0022-1759(80)90340-3; PRIETO J, 1988, IMMUNOLOGY, V63, P631; ROMSON JL, 1983, CIRCULATION, V67, P1016, DOI 10.1161/01.CIR.67.5.1016; RUSSELL DG, 1988, J EXP MED, V168, P279, DOI 10.1084/jem.168.1.279; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPPELL SB, 1990, J IMMUNOL, V144, P2702; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SMITH SM, 1987, GASTROENTEROLOGY, V93, P466, DOI 10.1016/0016-5085(87)90907-3; TONNESEN MG, 1989, J CLIN INVEST, V83, P637, DOI 10.1172/JCI113928; VEDDER NB, 1988, J CLIN INVEST, V81, P939, DOI 10.1172/JCI113407; VONASMUTH EJU, 1991, J IMMUNOL, V147, P3869; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALLIS WJ, 1986, BLOOD, V67, P1007; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699	40	208	214	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					10008	10015						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	7908286				2022-12-25	WOS:A1994NE05300092
J	SHAROM, FJ; YU, XH; DOIGE, CA				SHAROM, FJ; YU, XH; DOIGE, CA			FUNCTIONAL RECONSTITUTION OF DRUG TRANSPORT AND ATPASE ACTIVITY IN PROTEOLIPOSOMES CONTAINING PARTIALLY PURIFIED P-GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL PERIPLASMIC PERMEASES; HAMSTER OVARY CELLS; MULTIDRUG-RESISTANCE; MEMBRANE-VESICLES; BINDING; PROTEIN; VINBLASTINE; HYDROLYSIS	P-glycoprotein, the multidrug transporter, is proposed to act as an ATP-driven drug efflux pump. We previously reported the partial purification of P-glycoprotein from multidrug-resistant cells (Doige, C. A., Yu, X., and Sharom, F. J. (1992) Biochim. Biophys. Acta 1109, 149-160). We now report the reconstitution of this preparation into phospholipid bilayers using rapid detergent removal by gel filtration chromatography. The resulting proteoliposomes displayed ATP-dependent [H-3]colchicine uptake over a time period of 0-4 min. No drug uptake was observed for liposomes of lipid alone, or liposomes reconstituted with a similar extract from drug-sensitive cells. Drug uptake was osmotically sensitive, and abolished by detergent permeabilization, indicating that it represented true transport into the vesicle lumen. Steady-state levels of drug uptake increased with drug concentration, approaching saturation at approximately 150 muM colchicine, with half-maximal accumulation at 50 muM. Drug was accumulated actively against a 5.6-fold concentration gradient. Multidrug resistance spectrum drugs and chemosensitizers inhibited colchicine uptake by P-glycoprotein proteoliposomes, whereas cytosine arabinoside and methotrexate had no effect. Reconstituted liposomes showed high levels of ATPase activity, which was stimulated over 2-fold by verapamil and trifluoperazine. These results suggest that P-glycoprotein functions as an active drug transporter with constitutive ATPase activity.			SHAROM, FJ (corresponding author), UNIV GUELPH,GUELPH WATERLOO CTR GRAD WORK CHEM,DEPT CHEM & BIOCHEM,GUELPH N1G 2W1,ONTARIO,CANADA.		Sharom, Frances/A-1613-2010	Sharom, Frances/0000-0002-9521-5367				AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; AMES GFL, 1990, J BACTERIOL, V172, P4133, DOI 10.1128/jb.172.8.4133-4137.1990; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN CC, 1984, J BIOL CHEM, V259, P150; CHICKEN CA, 1983, BIOCHIM BIOPHYS ACTA, V729, P200, DOI 10.1016/0005-2736(83)90486-8; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; Doige C A, 1991, Protein Expr Purif, V2, P256, DOI 10.1016/1046-5928(91)90081-S; DOIGE CA, 1993, BIOCHIM BIOPHYS ACTA, V1146, P65, DOI 10.1016/0005-2736(93)90339-2; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P161, DOI 10.1016/0005-2736(92)90079-2; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HORIO M, 1991, BIOCHIM BIOPHYS ACTA, V1061, P106, DOI 10.1016/0005-2736(91)90274-C; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; KANE SE, 1990, J BIOENERG BIOMEMBR, V22, P593, DOI 10.1007/BF00762963; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; LOE DW, 1993, BRIT J CANCER, V68, P342, DOI 10.1038/bjc.1993.338; PASTAN I, 1991, ANNU REV MED, V42, P277, DOI 10.1146/annurev.me.42.020191.001425; SAEKI T, 1992, BIOCHIM BIOPHYS ACTA, V1107, P105, DOI 10.1016/0005-2736(92)90334-I; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SHIMABUKU AM, 1992, J BIOL CHEM, V267, P4308; VANZOELEN EJJ, 1978, EUR J BIOCHEM, V86, P539	23	253	258	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24197	24202						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	7901214				2022-12-25	WOS:A1993MF29400072
J	MESEGUER, I; TORREBLANCA, M; KONISHI, T				MESEGUER, I; TORREBLANCA, M; KONISHI, T			SPECIFIC-INHIBITION OF THE HALOBACTERIAL NA+/H+ ANTIPORTER BY HALOCIN H6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENVELOPE VESICLES; MEMBRANE-VESICLES; DELTA-PSI; HALOBIUM; PH; EXCHANGE; CELLS; TRANSPORT; H-4; NOV	Halocins H6 and H4 are bacteriocin-like substances capable of killing sensitive halobacterial cells by affecting the bioenergetic steady state across the membrane, The effect of either halocin on living cells is similar, but the primary target of each is different. Halocin H6 inhibited light induced Na+ out-flow in membrane vesicles of Halobacterium halobium. H4 did not, but instead slowed the H+ return-flow in the dark after illumination. Halocin H6 adsorbs firmly to both whole cells and membrane vesicles, The conclusion is that the primary target of halocin H6 is the Na+/H+ antiporter. This is important not only insofar as it outlines the mechanism by which a halocin works, but also for the fact that it is the first specific physiological inhibitor of the halobacterial Na+/H+ antiporter to be described.	NIIGATA COLL PHARM, DEPT RADIOCHEM BIOPHYS, NIIGATA 95021, JAPAN		MESEGUER, I (corresponding author), UNIV ALICANTE, FAC MED, DEPT GENET & MICROBIOL, CAMPUS SAN JUAN, APARTADO 374, E-03080 ALACANT, SPAIN.							BAKKER EP, 1976, BIOCHIM BIOPHYS ACTA, V440, P557, DOI 10.1016/0005-2728(76)90042-6; BOOTH IR, 1985, MICROBIOL REV, V49, P359, DOI 10.1128/MMBR.49.4.359-378.1985; CHRISTIAN JHB, 1962, BIOCHIM BIOPHYS ACTA, V65, P506, DOI 10.1016/0006-3002(62)90453-5; DUNDAS ID, 1963, CAN J MICROBIOL, V9, P619, DOI 10.1139/m63-079; GINZBURG M, 1970, Journal of General Physiology, V55, P187, DOI 10.1085/jgp.55.2.187; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HELGERSON SL, 1983, BIOCHEMISTRY-US, V22, P5746, DOI 10.1021/bi00294a011; KAGAN BL, 1983, NATURE, V302, P709, DOI 10.1038/302709a0; KONISHI T, 1988, FEBS LETT, V226, P270, DOI 10.1016/0014-5793(88)81437-6; KONISHI T, 1992, BIOCHIM BIOPHYS ACTA, V1140, P1, DOI 10.1016/0005-2728(92)90012-Q; KRULWICH TA, 1983, BIOCHIM BIOPHYS ACTA, V726, P245, DOI 10.1016/0304-4173(83)90011-3; LANYI JK, 1978, MICROBIOL REV, V42, P682, DOI 10.1128/MMBR.42.4.682-706.1978; LANYI JK, 1976, BIOCHEMISTRY-US, V15, P4608, DOI 10.1021/bi00666a010; MACDONALD RE, 1977, BIOCHEMISTRY-US, V16, P3227, DOI 10.1021/bi00633a029; MESEGUER I, 1986, FEMS MICROBIOL LETT, V36, P177; MESEGUER I, 1985, FEMS MICROBIOL LETT, V28, P177; MESEGUER I, 1986, J GEN MICROBIOL, V132, P3061; MESEGUER I, 1991, NATO ADV SCI I A-LIF, V201, P157; MURAKAMI N, 1987, BIOCHEM INT, V15, P215; MURAKAMI N, 1990, ARCH BIOCHEM BIOPHYS, V281, P13, DOI 10.1016/0003-9861(90)90406-O; MURAKAMI N, 1988, J BIOCHEM-TOKYO, V103, P231, DOI 10.1093/oxfordjournals.jbchem.a122253; MURAKAMI N, 1985, J BIOCHEM-TOKYO, V98, P897, DOI 10.1093/oxfordjournals.jbchem.a135369; MURAKAMI N, 1989, ARCH BIOCHEM BIOPHYS, V271, P515, DOI 10.1016/0003-9861(89)90303-2; PADAN E, 1981, BIOCHIM BIOPHYS ACTA, V650, P151, DOI 10.1016/0304-4157(81)90004-6; RODRIGUEZVALERA F, 1982, CAN J MICROBIOL, V28, P151, DOI 10.1139/m82-019; RODRIGUEZVALERA F, 1983, SYST APPL MICROBIOL, V4, P369, DOI 10.1016/S0723-2020(83)80021-6; SAHL HG, 1985, J BACTERIOL, V162, P833, DOI 10.1128/JB.162.2.833-836.1985; TORREBLANCA M, 1990, BIOCHEM CELL BIOL, V68, P396, DOI 10.1139/o90-056; TORREBLANCA M, 1989, J GEN MICROBIOL, V135, P2655; TORREBLANCA M, 1986, SYST APPL MICROBIOL, V8, P89, DOI 10.1016/S0723-2020(86)80155-2; WEISS MJ, 1978, P NATL ACAD SCI USA, V75, P2483, DOI 10.1073/pnas.75.5.2483; YANG CC, 1984, J BACTERIOL, V158, P757, DOI 10.1128/JB.158.2.757-759.1984	32	35	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6450	6455		10.1074/jbc.270.12.6450	http://dx.doi.org/10.1074/jbc.270.12.6450			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896778	hybrid			2022-12-25	WOS:A1995QQ85500007
J	XU, JM; MCKEEHAN, K; MATSUZAKI, K; MCKEEHAN, WL				XU, JM; MCKEEHAN, K; MATSUZAKI, K; MCKEEHAN, WL			INHIBIN ANTAGONIZES INHIBITION OF LIVER-CELL GROWTH BY ACTIVIN BY A DOMINANT-NEGATIVE MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASE; TGF-BETA; II RECEPTOR; EXPRESSION CLONING; SPECIFICITY; HEPATOCYTES; AUTOCRINE; BINDING; GENE; RAT	The beta:beta activin homodimer and alpha:beta inhibin heterodimer are mutual antagonists which share a common beta subunit. Recently, it has been shown that, similar to transforming growth factor-beta 1, activin is an inhibitor of hepatocyte DNA synthesis, The activin receptor appears to be an obligatory complex of genetically distinct type I and II transmembrane serine/threonine kinases. Activin type I receptors, SKR1 and SKR2, were first cloned from well differentiated human hepatoma cells (HepG2). This prompted us to investigate the binding of activin and inhibin to receptors from HepG2 cells and the effect of the two ligands on DNA synthesis. Here we show that beta:beta activin binds to the activin type II receptor kinase (ActRII) which induces activin binding to the type I receptor kinase SKR2 to form ActRII .beta:beta . SKR2 complexes in which an activin beta chain occupies each receptor subunit, Inhibin also binds to ActRII through its beta subunit, competes with the binding of activin to ActRII, but fails to form the ActRII . SKR2 complex. No specific binding site for inhibin could be demonstrated in HepG2 cells. Inhibin, which had no activity of its own, antagonized the inhibitory effect of activin on DNA synthesis, The results suggest that inhibin may be a natural antagonist of assembly of the heterodimeric activin receptor complex through a dominant-negative mechanism.	TEXAS A&M UNIV,ALBERT B ALKEK INST BIOSCI & TECHNOL,DEPT BIOCHEM & BIOPHYS,HOUSTON,TX 77030	Texas A&M University System					NATIONAL CANCER INSTITUTE [R01CA059971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038639, R01DK035310] Funding Source: NIH RePORTER; NCI NIH HHS [CA59971] Funding Source: Medline; NIDDK NIH HHS [DK38639, DK35310] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; HE WW, 1993, DEV DYNAM, V196, P133, DOI 10.1002/aja.1001960207; KAN M, 1989, P NATL ACAD SCI USA, V86, P7432, DOI 10.1073/pnas.86.19.7432; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATSUZAKI K, 1993, J BIOL CHEM, V268, P12719; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MCCARTHY SA, 1994, J BIOL CHEM, V269, P3909; MERCOLA M, 1990, GENE DEV, V4, P2333, DOI 10.1101/gad.4.12b.2333; ROBERTS VJ, 1994, ENDOCRINOLOGY, V134, P914, DOI 10.1210/en.134.2.914; SCHWALL RH, 1993, HEPATOLOGY, V18, P347, DOI 10.1016/0270-9139(93)90018-I; SHI E, 1993, MOL CELL BIOL, V13, P3907, DOI 10.1128/MCB.13.7.3907; SPORN MB, 1990, PEPTIDE GROWTH FACTO, V2, P211; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1993, ONCOGENE, V8, P2879; TSUCHIDA K, 1993, P NATL ACAD SCI USA, V90, P11242, DOI 10.1073/pnas.90.23.11242; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; XU JM, 1992, J BIOL CHEM, V267, P17792; XU JM, 1994, P NATL ACAD SCI USA, V91, P7957, DOI 10.1073/pnas.91.17.7957; YASUDA H, 1993, J CLIN INVEST, V92, P1491, DOI 10.1172/JCI116727	26	115	121	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					6308	6313		10.1074/jbc.270.11.6308	http://dx.doi.org/10.1074/jbc.270.11.6308			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890768	hybrid			2022-12-25	WOS:A1995QM94500089
J	NIEWOLIK, D; VOJTESEK, B; KOVARIK, J				NIEWOLIK, D; VOJTESEK, B; KOVARIK, J			P53 DERIVED FROM HUMAN TUMOR-CELL LINES AND CONTAINING DISTINCT POINT MUTATIONS CAN BE ACTIVATED TO BIND ITS CONSENSUS TARGET SEQUENCE	ONCOGENE			English	Article						P53; PROTEIN-DNA INTERACTIONS; PROTEIN CONFORMATION	WILD-TYPE P53; DNA-BINDING; MUTANT P53; TRANSCRIPTIONAL ACTIVATION; IMMUNOCHEMICAL ANALYSIS; MONOCLONAL-ANTIBODIES; SIMIAN VIRUS-40; GENE-EXPRESSION; PROTEIN; CANCER	Mutation of the p53 gene is one of the most common genetic lesions observed in human cancer. The p53 protein functions as a transcription factor, however it is still unresolved to what extend this property is related to its tumour suppressor activity. Since there is evidence that protein modifications as well as protein-protein interactions may regulate p53 function, we have studied p53 protein-DNA complex formation in nuclear extracts prepared from human tumour cell lines. In 13 different cell lines PAb421-induced DNA binding activity was compared to the level and conformation of the endogenous p53 protein. Surprisingly, sequence-specific p53 DNA binding activity was detected not only in cell lines that express wild-type p53, but also in seven cell lines which contain only mutant protein. Oligonucleotide competition analyses with various p53 target sequences and methylation interference experiments establish that wild-type and mutant p53 differ significantly in their sequence-specific interactions. Our analysis also provides evidence that the PAb1620 conformation is neither sufficient nor essential for DNA binding of endogenous p53 and that the cellular environment in addition to the specific point mutation may influence p53 DNA binding activity.	MASARYK MEM CANC INST,DEPT CELLULAR & MOLEC ONCOL,CR-65653 BRNO,CZECH REPUBLIC	Masaryk Memorial Cancer Institute								ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BARTEK J, 1990, ONCOGENE, V5, P893; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN JY, 1993, ONCOGENE, V8, P2159; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHUMAKOV AM, 1993, ONCOGENE, V8, P3005; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRITSCHE M, 1993, ONCOGENE, V8, P307; FROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1994, ONCOGENE, V9, P299; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HALL PA, 1993, ONCOGENE, V8, P203; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Maxam A M, 1980, Methods Enzymol, V65, P499; MEEK DW, 1992, BIOCHEM J, V287, P1; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILNER J, 1987, ONCOGENE, V1, P453; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NITSCH D, 1993, MOL CELL BIOL, V13, P4494, DOI 10.1128/MCB.13.8.4494; OFVERSTEDT LG, 1984, BIOCHIM BIOPHYS ACTA, V782, P120, DOI 10.1016/0167-4781(84)90014-9; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OROURKE RW, 1990, ONCOGENE, V5, P1829; PARK DJ, 1994, ONCOGENE, V9, P1899; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P73, DOI 10.1093/nar/17.1.73; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROMANO JW, 1989, ONCOGENE, V4, P1483; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHIIO Y, 1993, ONCOGENE, V8, P2059; SOUSSI T, 1990, ONCOGENE, V5, P945; STRATTON MR, 1990, ONCOGENE, V5, P1297; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; VOJTESEK B, 1993, J CELL SCI, V105, P607; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529; ZHANG W, 1993, ONCOGENE, V8, P2555	91	68	70	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					881	890						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898929				2022-12-25	WOS:A1995QL03800009
J	ZAIDI, SHE; DENMAN, R; MALTER, JS				ZAIDI, SHE; DENMAN, R; MALTER, JS			MULTIPLE PROTEINS INTERACT AT A UNIQUE CIS-ELEMENT IN THE 3'-UNTRANSLATED REGION OF AMYLOID PRECURSOR PROTEIN MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; URIDINE BINDING-FACTOR; MESSENGER-RNA DEGRADATION; ALZHEIMERS-DISEASE; 1ST STEP; EXPRESSION; CELLS; SEQUENCE; BRAIN; GENE	Growing evidence suggests that Alzheimer's disease results from dysregulated production and deposition of beta-amyloid in the central nervous system. beta-Amyloid is derived from proteolytic processing of one of multiple amyloid precursor protein (APP) isoforms. The production of APP in many somatic tissues and tumor cell lines provides a more accessible model to study the regulation of APP gene expression. Recent data suggest that APP mRNAs accumulate in activated lymphocytes and neuronal tumor lines. We are interested in defining the contribution of alterations in stability to changes in steady-state APP mRNA levels in these model systems. Herein we demonstrate by mobility shift assay that the 3'-untranslated region of APP RNAs which contain a contiguous 29-base region interacts in vitro with multiple mRNA-binding proteins found in cytosolic lysates prepared from normal and transformed human cells. UV cross-linking of radiolabeled APP RNAs to cytosolic protein extracts followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis identified six distinct RNA-protein complexes of 42, 47, 65, 73, 84, and 104 kDa Competition assays with APP, AU-rich, or irrelevant RNAs demonstrated that binding was specific and in some cases preferential for AU- or U-rich sequences by which we tentatively place the binding site of the proteins along the 29-base region. APP mRNA-binding proteins were constitutively active in all tumor lines examined as web as at diminished levels in whole human brain cytosolic lysates. The core element is AU-rich and highly conserved between human and some murine APP mRNAs. In the accompanying paper (Zaidi, S. H. E. and Malter, J. S. (1994) J. Biol. Chem. 269, 24007-24013) we show that this 29-base element in the 3'-untranslated region regulates the stability of APP mRNA. Cumulatively these data suggest that steady-state APP mRNA levels are modulated by cytosolic protein-RNA interactions.	UNIV WISCONSIN, DEPT PATHOL & LAB MED, NEUROSCI PROGRAM, MADISON, WI 53792 USA; UNIV WISCONSIN, INST AGING, MADISON, WI 53792 USA; NEW YORK STATE INST BASIC RES DEV DISABIL, STATEN ISL, NY 10314 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Institute for Basic Research in Developmental Disabilities					NATIONAL INSTITUTE ON AGING [R01AG010675] Funding Source: NIH RePORTER; NIA NIH HHS [AGO-4221, R01-AG 10675] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; ISHIURA S, 1991, J NEUROCHEM, V56, P363, DOI 10.1111/j.1471-4159.1991.tb08160.x; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MONNING U, 1990, FEBS LETT, V277, P261, DOI 10.1016/0014-5793(90)80861-C; MONNING U, 1992, J BIOL CHEM, V267, P23950; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; PANTOPOULOS K, 1992, EUR J BIOCHEM, V207, P1045, DOI 10.1111/j.1432-1033.1992.tb17141.x; RAMAKRISHNA N, 1991, BIOCHEM BIOPH RES CO, V174, P983, DOI 10.1016/0006-291X(91)91515-E; SASSO MP, 1991, NUCLEIC ACIDS RES, V19, P6469, DOI 10.1093/nar/19.23.6469; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; STEPHENS JM, 1992, J BIOL CHEM, V267, P8336; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; YOU Y, 1992, MOL CELL BIOL, V12, P2931, DOI 10.1128/MCB.12.7.2931; ZAIDI SHE, 1994, J BIOL CHEM, V269, P24007	26	54	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24000	24006						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929050				2022-12-25	WOS:A1994PQ34600026
J	HOOF, T; DEMMER, A; HADAM, MR; RIORDAN, JR; TUMMLER, B				HOOF, T; DEMMER, A; HADAM, MR; RIORDAN, JR; TUMMLER, B			CYSTIC FIBROSIS-TYPE MUTATIONAL ANALYSIS IN THE ATP-BINDING CASSETTE TRANSPORTER SIGNATURE OF HUMAN P-GLYCOPROTEIN MDR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; HAMSTER OVARY CELLS; RESISTANT HUMAN-CELLS; MULTIDRUG-RESISTANCE; BACTERIAL TRANSPORT; ESCHERICHIA-COLI; CHLORIDE CHANNEL; CFTR GENE; DELTA-F508 MUTATION; EXPRESSION VECTOR	Members of the ATP-binding cassette transporter superfamily such as the P-glycoproteins (MDR) and the cystic fibrosis transmembrane conductance regulator (CFTR) share conserved sequence motifs in their nucleotide binding fold that are the major targets for CFTR mutations in patients with cystic fibrosis. Cystic fibrosis-type mutations were introduced at analogous positions into the human MDR1 gene. Heterologous expression of wild-type or mutated MDR1 revealed similar mRNA transcript levels in Chinese hamster ovary K1 recipients, but the subsequent processing was defective for all mutations that give rise to severe cystic fibrosis in the case of CFTR. Functional multidrug transporter MDR1, however, was obtained when amino acid substitutions were introduced into a less conserved position of the ATP-binding cassette transporter signature (codon 536 in MDR1). The profile of cross-resistance and chemosensitization was modulated in these codon 536 variants, which suggests that this region is involved in the drug transport function of P-glycoprotein.	HANNOVER MED SCH, PADIAT PNEUMOL ABT, D-30623 HANNOVER, GERMANY; HOSP SICK CHILDREN, RES INST, TORONTO M5G 1X8, ON, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO M5G 1X8, ON, CANADA; UNIV TORONTO, DEPT CLIN BIOCHEM, TORONTO M5G 1X8, ON, CANADA	Hannover Medical School; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	HOOF, T (corresponding author), HANNOVER MED SCH, ZENTRUM BIOCHEM, BIOPHYS CHEM ABT, OE 4350, KONSTANTY GUTSCHOW STR 8, D-30623 HANNOVER, GERMANY.							AMES GF, 1986, CELL, V47, P323, DOI 10.1016/0092-8674(86)90585-4; AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; AMES GFL, 1992, ADV ENZYMOL RELAT AR, V6, P2660; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BEAR CE, 1991, J BIOL CHEM, V266, P19142; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BUSCHE R, 1989, MOL PHARMACOL, V35, P414; BUSCHE R, 1989, EUR J BIOCHEM, V183, P189, DOI 10.1111/j.1432-1033.1989.tb14912.x; CABRAL F, 1980, CELL, V20, P29, DOI 10.1016/0092-8674(80)90231-7; CANOGAUCI DF, 1991, MOL CELLULAR BIOL MU, P337; CHEN CJ, 1990, J BIOL CHEM, V265, P506; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CORNWELL MM, 1991, MOL CELLULAR BIOL MU, P229; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; DORK T, 1991, HUM GENET, V87, P441; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FENG DF, 1985, J MOL EVOL, V21, P112, DOI 10.1007/BF02100085; Fonknechten N., 1992, Human Molecular Genetics, V1, P281, DOI 10.1093/hmg/1.4.281; GEIGER R, 1989, BIOCHEMISTRY-US, V28, P2667, DOI 10.1021/bi00432a046; GIBBS TW, 1992, MOL GEN GENET, V234, P121, DOI 10.1007/BF00272353; GILL DR, 1986, MOL GEN GENET, V205, P134, DOI 10.1007/BF02428043; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HAMADA H, 1991, MOL CELLULAR BIOL MU, P373; HAMOSH A, 1992, AM J HUM GENET, V51, P245; HAMOSH A, 1991, J CLIN INVEST, V88, P1880, DOI 10.1172/JCI115510; HIGGINS CF, 1982, NATURE, V298, P723, DOI 10.1038/298723a0; HIGGINS CF, 1990, J BIOENERG BIOMEMBR, V22, P571, DOI 10.1007/BF00762962; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOOF T, 1991, ANAL BIOCHEM, V196, P161, DOI 10.1016/0003-2697(91)90133-E; HOOF T, 1993, EUR J PHARM-MOLEC PH, V246, P53, DOI 10.1016/0922-4106(93)90009-X; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; KAJIJI S, 1993, BIOCHEMISTRY-US, V32, P4185, DOI 10.1021/bi00067a005; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KOMIJO K, 1992, BIOCHIM BIOPHYS ACTA, V1129, P323; KRAMER W, 1981, NUCLEIC ACIDS RES, V8, P8441; LI CH, 1993, NAT GENET, V3, P311, DOI 10.1038/ng0493-311; LING V, 1983, CANCER TREAT REP, V67, P869; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RIORDAN JR, 1985, PHARMACOL THERAPEUT, V28, P51, DOI 10.1016/0163-7258(85)90082-8; RIORDAN JR, 1985, NATURE, V316, P817, DOI 10.1038/316817a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; RONINSON IBE, 1991, MOL CELLULAR BIOL MU; SANGIUOLO F, 1991, GENOMICS, V9, P788, DOI 10.1016/0888-7543(91)90380-W; SCHNEIDER E, 1991, MOL MICROBIOL, V5, P1375, DOI 10.1111/j.1365-2958.1991.tb00784.x; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; SUGIMOTO Y, 1991, MOL CELLULAR BIOL MU, P57; TEEM JL, 1993, CELL, V73, P335, DOI 10.1016/0092-8674(93)90233-G; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; Tsui Lap-Chee, 1992, Human Mutation, V1, P197, DOI 10.1002/humu.1380010304; TSURUO T, 1991, MOL CELLULAR BIOL MU, P349; TWENTYMAN PR, 1992, BIOCHEM PHARMACOL, V43, P109, DOI 10.1016/0006-2952(92)90668-9; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	80	67	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20575	20583						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	7914197				2022-12-25	WOS:A1994PB31700058
J	RANDI, AM; HOGG, N				RANDI, AM; HOGG, N			I-DOMAIN OF BETA(2) INTEGRIN LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1 CONTAINS A BINDING-SITE FOR LIGAND INTERCELLULAR-ADHESION MOLECULE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ALPHA-SUBUNIT; VONWILLEBRAND-FACTOR; LEUKOCYTE ADHESION; P150,95 MOLECULE; GLYCOPROTEIN; RECEPTOR; LFA-1; SUPERFAMILY; MECHANISMS; DISTINCT	Lymphocyte function-associated antigen-1 (LFA-1) is a beta(2) integrin that participates in a broad range of leukocyte functions through binding to its ligand intercellular adhesion molecule-1 (ICAM-1). The location of the ICAM-1 binding site on LFA-1 is not known. A similar to 200-amino acid ''inserted'' or ''I'' domain, which is part of the beta(2) integrin alpha subunit, is homologous to the ''A'' domains found in the adhesive protein von Willebrand factor and in a number of other proteins. In von Willebrand factor the A domains are involved in ligand binding, but their function in the other proteins is still unclear. In this report, we show that the LFA-1 I domain contains a binding site for ICAM-1, which can be expressed as an isolated functional unit. The I domain contains the epitopes for 18 out of 20 anti-LFA-1 monoclonal antibodies, many of which interfere with the interaction between LFA-1 and ICAM-1. The I domain binds directly to purified recombinant ICAM-1 and also inhibits LFA-1-dependent T cell adhesion to ICAM-1. This report establishes the I domain as an ICAM-1 binding region in LFA-1 and the first ligand binding site to be identified in a beta(2) integrin.	IMPERIAL CANC RES FUND,LEUKOCYTE ADHES LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK								ADAMS GA, 1985, MOL CELL BIOL, V5, P1442, DOI 10.1128/MCB.5.6.1442; BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; CABANAS C, 1993, P NATL ACAD SCI USA, V90, P5838, DOI 10.1073/pnas.90.12.5838; CAMPANERO MR, 1993, J CELL BIOL, V123, P1007, DOI 10.1083/jcb.123.4.1007; COLOMBATTI A, 1991, BLOOD, V77, P2305; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; CORBI AL, 1988, J BIOL CHEM, V263, P12403; CORBI AL, 1990, J BIOL CHEM, V265, P2782; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DRANSFIELD I, 1992, J CELL BIOL, V116, P1527, DOI 10.1083/jcb.116.6.1527; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DRANSFIELD I, 1989, EMBO J, V8, P3759, DOI 10.1002/j.1460-2075.1989.tb08552.x; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FEDERICI AB, 1989, BRIT J HAEMATOL, V73, P93, DOI 10.1111/j.1365-2141.1989.tb00226.x; FLEMING JC, 1993, J IMMUNOL, V150, P480; GOLDMAN R, 1992, EUR J IMMUNOL, V22, P1109, DOI 10.1002/eji.1830220502; HART MK, 1987, CELL IMMUNOL, V109, P306, DOI 10.1016/0008-8749(87)90314-5; HEIDENREICH R, 1990, BIOCHEMISTRY-US, V29, P1232, DOI 10.1021/bi00457a020; HOGG N, 1993, CURR OPIN IMMUNOL, V5, P383, DOI 10.1016/0952-7915(93)90057-Y; JOHNSTON SC, 1990, J IMMUNOL, V145, P1181; KNOTT HM, 1992, BIOCHEMISTRY-US, V31, P11152, DOI 10.1021/bi00160a028; LANDIS RC, 1993, J CELL BIOL, V120, P1519, DOI 10.1083/jcb.120.6.1519; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; Luk John, 1993, Tissue Antigens, V42, P272; MARLIN SD, 1990, NATURE, V344, P70, DOI 10.1038/344070a0; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; PARDI R, 1992, IMMUNOL TODAY, V13, P224, DOI 10.1016/0167-5699(92)90159-5; SADLER JE, 1991, J BIOL CHEM, V266, P22777; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SCHMIDT RE, 1989, LEUKOCYTE TYPING, V4, P517; SIMMONS DL, 1993, CELLULAR INTERACTION, P93; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; VONKOOYK Y, 1989, NATURE, V342, P811; YON J, 1989, NUCLEIC ACIDS RES, V17, P4895, DOI 10.1093/nar/17.12.4895	37	143	159	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12395	12398						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	7909800				2022-12-25	WOS:A1994NH71600004
J	SEPULVEDA, AR; CARTER, BZ; HABIB, GM; LEBOVITZ, RM; LIEBERMAN, MW				SEPULVEDA, AR; CARTER, BZ; HABIB, GM; LEBOVITZ, RM; LIEBERMAN, MW			THE MOUSE GAMMA-GLUTAMYL-TRANSPEPTIDASE GENE IS TRANSCRIBED FROM AT LEAST 5 SEPARATE PROMOTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; LIVER EPITHELIAL-CELLS; ALDOLASE-A GENE; RAT-LIVER; TRANSFERASE TRANSPEPTIDASE; RESPONSIVE ELEMENT; KIDNEY; SEQUENCE; ENHANCER; BINDING	The mouse gamma-glutamyl transpeptidase (gamma GT) gene encodes six distinct mRNAs that differ in their 5'-untranslated regions but appear to code for the same protein. To elucidate the mechanisms that generate these different mRNAs we determined the transcription start sites of gamma GT kidney mRNAs and investigated the ability of the 5'-flanking regions of mRNAs I, II, IV, V, and VI to direct transcription of chloramphenicol acetyltransferase (CAT) reporter gene constructs in a mouse kidney cell line. Types I, II, and VI mRNAs show heterogenous start sites, whereas types TV and V have more precise initiation sites. Only the type V 5'-flanking region contains a TATA-like element. The highest CAT activities were observed with 416 base pairs of type II and 240 base pairs of type IV flanking regions. We have also shown that types II and IV represent the predominant gamma GT mRNAs in kidney; therefore, these CAT activities correlate well with the relative amount of each gamma GT mRNA. This study shows that the mouse gamma GT gene is transcribed from at least five and possibly six different promoters. In addition, the gamma GT promoters show cell specificity because no significant CAT activity was detected when these constructs were introduced into NIH-3T3 fibroblasts.	BAYLOR COLL MED, DEPT PATHOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine					NCI NIH HHS [CA-39392] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA039392, R01CA039392] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEER DG, 1987, ARCH TOXICOL, P68; CHOBERT MN, 1990, J BIOL CHEM, V265, P2352; CONCORDET JP, 1991, NUCLEIC ACIDS RES, V19, P4173, DOI 10.1093/nar/19.15.4173; CONCORDET JP, 1993, MOL CELL BIOL, V13, P9, DOI 10.1128/MCB.13.1.9; FRIDOVICHKEIL JL, 1991, BIOTECHNIQUES, V11, P572; GARCIA M, 1986, EMBO J, V5, P127, DOI 10.1002/j.1460-2075.1986.tb04186.x; GARRITY PA, 1990, MOL CELL BIOL, V10, P5646, DOI 10.1128/MCB.10.11.5646; GHOSH D, 1990, NUCLEIC ACIDS RES, V18, P1749, DOI 10.1093/nar/18.7.1749; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRECO A, 1989, MOL CELL BIOL, V9, P2350, DOI 10.1128/MCB.9.6.2350; GRIFFITHS SA, 1989, CANCER LETT, V46, P69, DOI 10.1016/0304-3835(89)90217-6; HABIB GM, 1992, MOL CARCINOGEN, V5, P75; HANIGAN MH, 1985, CARCINOGENESIS, V6, P165, DOI 10.1093/carcin/6.2.165; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Innis M. A., 1990, PCR PROTOCOLS GUIDE, P21; JACQUEMIN E, 1990, J PEDIATR GASTR NUTR, V11, P89, DOI 10.1097/00005176-199007000-00018; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KURAUCHI O, 1991, BIOCHEMISTRY-US, V30, P1618, DOI 10.1021/bi00220a025; LAHUNA O, 1992, BIOCHEMISTRY-US, V31, P9190, DOI 10.1021/bi00153a011; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LI Y, 1989, ONCOGENE, V4, P795; LI YC, 1988, P NATL ACAD SCI USA, V85, P344, DOI 10.1073/pnas.85.2.344; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; MAIRE P, 1987, J MOL BIOL, V197, P425, DOI 10.1016/0022-2836(87)90556-0; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; PENOTTI FE, 1990, J MOL BIOL, V213, P37, DOI 10.1016/S0022-2836(05)80120-2; PERLINO E, 1987, EMBO J, V6, P2767, DOI 10.1002/j.1460-2075.1987.tb02571.x; PRESTERA T, 1993, P NATL ACAD SCI USA, V90, P2965, DOI 10.1073/pnas.90.7.2965; RAJAGOPALAN S, 1990, J BIOL CHEM, V265, P11721; RAJAGOPALAN S, 1993, P NATL ACAD SCI USA, V90, P6179, DOI 10.1073/pnas.90.13.6179; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SCHAFFNER DL, 1993, AM J PATHOL, V142, P1051; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHAPIRO LH, 1991, J BIOL CHEM, V266, P11999; SIEGRIST S, 1990, BIOCHEM J, V267, P621, DOI 10.1042/bj2670621; SINHA S, 1986, CANCER RES, V46, P1440; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; TATE SS, 1985, METHOD ENZYMOL, V113, P400; VANDIJK MA, 1991, MOL CELL ENDOCRINOL, V81, P81, DOI 10.1016/0303-7207(91)90207-9; VINA J, 1990, GLUTATHIONE METABOLI, P79; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383; WUTHRICH RP, 1990, KIDNEY INT, V37, P783, DOI 10.1038/ki.1990.46	47	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10699	10705						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7908294				2022-12-25	WOS:A1994NF01700076
J	JOSHI, AA; MCDONALD, MJ				JOSHI, AA; MCDONALD, MJ			ROLE OF ALPHA-CARBOXYL-TERMINAL AND BETA-CARBOXYL-TERMINAL RESIDUES IN THE KINETICS OF HUMAN OXYHEMOGLOBIN DIMER ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-HEMOGLOBIN; CHAIN; STATE	Human oxyhemoglobin assembly was evaluated in the Soret region by rapidly mixing normal and carboxypeptidase-digested chains (1-10 x 10(-6) M, heme basis) in 0.1 M Tris-HCl, 0.1 M NaCl, 1 mM EDTA, pH 7.4, at 21.5 degrees C. Rate constants of 1.14 (+/- 0.09) and 2.11 (+/- 0.06) x 10(5) M(-1) s(-1) were measured for the association of Des(Arg-141)alpha with beta(A) and alpha(A) with beta(A) chains, respectively. The slower combination rate of Des(Arg-141)alpha with beta(A) chains is in agreement with that predicted solely on the basis of electrostatic considerations, as are the measured rate constants of 0.75 (+/- 0.12) and 1.86 (+/- 0.08) x 10(5) M(-1) s(-1) obtained for the combination of Des(Arg-141)alpha with variant beta(S) (Glu-6 --> Val) and beta(N Baltimore) (Lys-95 --> Glu) chains, respectively. However, the combination rates of alpha(A) and Des(Arg-141)alpha with beta(A) chains measured in the pH range from 7.0 to 9.0 demonstrated that the altered overall surface charge was not the only determinant of the assembly rates observed for Des(Arg-141)alpha chains. Furthermore, a rate constant of 11.3 (+/- 0.05) x 10(5) M(-1) s(-1) (which is 5.4-fold faster than the rate of alpha(A) beta(A) dimer assembly) was observed for Des(His-146,Tyr-145)beta chains. These kinetic studies suggest a critical role for the carboxyl-terminal domain in the assembly of human hemoglobin in vitro and perhaps in vivo.	UNIV MASSACHUSETTS,COLL ARTS & SCI,DEPT CHEM,BIOCHEM PROGRAM,LOWELL,MA 01854	University of Massachusetts System; University of Massachusetts Lowell					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038456] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 38456] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERS GK, 1985, ANNU REV BIOCHEM, V54, P597, DOI 10.1146/annurev.bi.54.070185.003121; ANTONINI E, 1966, J MOL BIOL, V17, P29, DOI 10.1016/S0022-2836(66)80092-X; ARNONE A, 1982, HEMOGLOBIN OXYGEN BI, P127; BAUDIN V, 1993, PROTEIN SCI, V2, P1320, DOI 10.1002/pro.5560020815; BONAVENT.J, 1972, P NATL ACAD SCI USA, V69, P2174, DOI 10.1073/pnas.69.8.2174; BUCCI E, 1965, J BIOL CHEM, V240, pPC551; BUNN HF, 1983, NATURE, V306, P498, DOI 10.1038/306498a0; BUNN HF, 1987, BLOOD, V69, P1; CHIANCONE E, 1974, J BIOL CHEM, V249, P5689; Creighton T.E., 1992, PROTEIN FOLDING, P405; FRIEDMAN FK, 1979, ANNU REV BIOCHEM, V48, P217, DOI 10.1146/annurev.bi.48.070179.001245; HEWITT JA, 1973, J MOL BIOL, V74, P489, DOI 10.1016/0022-2836(73)90041-7; JANIN J, 1990, J BIOL CHEM, V265, P16027; KAWAMURA Y, 1983, J BIOCHEM-TOKYO, V93, P1159, DOI 10.1093/oxfordjournals.jbchem.a134241; Kilmartin J V, 1981, Methods Enzymol, V76, P167; KILMARTIN JV, 1970, NATURE, V228, P766, DOI 10.1038/228766a0; KURTZ A, 1978, BIOCHEM BIOPH RES CO, V84, P852, DOI 10.1016/0006-291X(78)91662-5; KWIATKOWSKI LD, 1982, J BIOL CHEM, V257, P8891; MCDONALD MJ, 1981, J BIOL CHEM, V256, P6487; MCDONALD MJ, 1987, J BIOL CHEM, V262, P5951; MCGOVERN P, 1976, J BIOL CHEM, V251, P7871; MRABET NT, 1986, J BIOL CHEM, V261, P5222; PERUTZ MF, 1971, COLD SPRING HARB SYM, V36, P295; PERUTZ MF, 1987, MOL BASIS BLOOD DISE, P127; POYART C, 1980, J BIOL CHEM, V255, P9465; ROLLEMA HS, 1980, J BIOL CHEM, V255, P2756; SUGITA Y, 1975, J BIOL CHEM, V250, P1251; TURCI SM, 1985, J CHROMATOGR, V343, P168, DOI 10.1016/S0378-4347(00)84581-8; VALDES R, 1977, J BIOL CHEM, V252, P74; WINSLOW RM, 1976, J CLIN INVEST, V57, P772, DOI 10.1172/JCI108336	30	19	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8549	8553						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7907594				2022-12-25	WOS:A1994NB40900108
J	CHEN, M; CHEN, LR; FROMM, HJ				CHEN, M; CHEN, LR; FROMM, HJ			REPLACEMENT OF GLUTAMIC-ACID-29 WITH GLUTAMINE LEADS TO A LOSS OF COOPERATIVITY FOR AMP WITH PORCINE FRUCTOSE-1,6-BISPHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT LIVER FRUCTOSE-1,6-BISPHOSPHATASE; FRUCTOSE 2,6-BISPHOSPHATE; 2.8-A RESOLUTION; INHIBITION; PHOSPHOFRUCTOKINASE; BISPHOSPHATASE; STIMULATOR; MECHANISM; GLUCAGON; GLUCOSE	Mutations in the AMP binding site of porcine fructose-1,6-bisphosphatase were carried out by site-specific mutagenesis based on the crystal structure of the enzyme (Re, Ef., Zhang, Y., and Lipscomb, m. L. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 5243-5247). The mutant and wild-type enzymes were characterized by SDS-polyacrylamide gel electrophoresis, circular dichroism spectrometry, and initial rate kinetics. One of the mutant forms of fructose-1,6-bisphosphatase, Glu-29 --> Gln, is ligated to the phosphoryl moiety of AMP, a potent inhibitor of the reaction, whereas the other mutant, Thr-31 --> Val, is associated with the purine base of AMP. No discernible alteration in structure as measured by circular dichroism spectrometry was noted for the mutants relative to the wild-type enzyme. As expected, major changes in kinetic parameters between the mutants and the wild-type enzyme were associated with inhibition by AMP. AMP, a competitive inhibitor with respect to Mg2+ in the fructose-1,6-bisphosphatase reaction, exhibits cooperativity in the case of the wild-type and the mutant Thr-31 --> Val enzymes with a Hill coefficient of 2.0. On the other hand, cooperativity is completely lost in the case of Glu-29 --> Gln fructose-1,6-bisphosphatase.			CHEN, M (corresponding author), IOWA STATE UNIV SCI & TECHNOL, DEPT BIOCHEM & BIOPHYS, AMES, IA 50011 USA.		Chen, Meng/C-7109-2014	Chen, Meng/0000-0003-0351-5897	NINDS NIH HHS [NS10546] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENKOVIC SJ, 1982, ADV ENZYMOL RAMB, V53, P45; BURTON VA, 1993, BIOCHEM BIOPH RES CO, V192, P511, DOI 10.1006/bbrc.1993.1445; CHEN LR, 1993, ARCH BIOCHEM BIOPHYS, V307, P350, DOI 10.1006/abbi.1993.1599; ELMAGHRABI MR, 1992, J BIOL CHEM, V267, P6526; Gomori G, 1943, J BIOL CHEM, V148, P139; HERS HG, 1982, BIOCHEM J, V206, P1; KE H, 1990, J MOL BIOL, V212, P513, DOI 10.1016/0022-2836(90)90329-K; KE HM, 1990, P NATL ACAD SCI USA, V87, P5243, DOI 10.1073/pnas.87.14.5243; KE HM, 1989, P NATL ACAD SCI USA, V86, P1475, DOI 10.1073/pnas.86.5.1475; LEATHERBARROW RJ, 1987, ENZFITTER, P13; LIU F, 1988, J BIOL CHEM, V263, P9122; LIU F, 1990, J BIOL CHEM, V265, P7401; MARCUS F, 1982, P NATL ACAD SCI-BIOL, V79, P7161, DOI 10.1073/pnas.79.23.7161; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NIMMO HG, 1975, EUR J BIOCHEM, V58, P575, DOI 10.1111/j.1432-1033.1975.tb02408.x; NIMMO HG, 1975, EUR J BIOCHEM, V58, P567, DOI 10.1111/j.1432-1033.1975.tb02407.x; OPIE LH, 1967, BIOCHEM J, V104, P353, DOI 10.1042/bj1040353; PILKIS SJ, 1981, J BIOL CHEM, V256, P3619; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEFFLER JE, 1986, BIOCHEMISTRY-US, V25, P6659, DOI 10.1021/bi00369a050; STONE SR, 1980, BIOCHEMISTRY-US, V19, P620, DOI 10.1021/bi00545a003; TAKETA K, 1965, J BIOL CHEM, V240, P651; TEJWANI GA, 1983, ADV ENZYMOL RAMB, V54, P121; Ulm E H, 1975, Methods Enzymol, V42, P369; VANSCHAFTINGEN E, 1980, BIOCHEM BIOPH RES CO, V96, P1524; VANSCHAFTINGEN E, 1981, P NATL ACAD SCI-BIOL, V78, P2861; VANSCHAFTINGEN E, 1980, BIOCHEM J, V192, P887, DOI 10.1042/bj1920887; VANSCHAFTINGEN E, 1980, BIOCHEM J, V192, P897, DOI 10.1042/bj1920897	28	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5554	5558						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7907084				2022-12-25	WOS:A1994MY84000016
J	TOYOFUKU, T; KURZYDLOWSKI, K; TADA, M; MACLENNAN, DH				TOYOFUKU, T; KURZYDLOWSKI, K; TADA, M; MACLENNAN, DH			AMINO-ACIDS GLU(2) TO ILE(18) IN THE CYTOPLASMIC DOMAIN OF PHOSPHOLAMBAN ARE ESSENTIAL FOR FUNCTIONAL ASSOCIATION WITH THE CA2+-ATPASE OF SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3'-5'-MONOPHOSPHATE-DEPENDENT PROTEIN KINASE; SITE-SPECIFIC MUTAGENESIS; CALCIUM-TRANSPORT; CA-2+ TRANSPORT; PUMP ATPASE; PHOSPHORYLATION; MECHANISM; SEQUENCE; RECONSTITUTION; CA-2+-ATPASE	Phospholamban inhibits the Ca2+-ATPase of cardiac sarcoplasmic reticulum by lowering its affinity for Ca2+. In earlier studies (Toyofuku, T., Kazimierz, K., Tada, M., and MacLennan, D. H. (1993) J. Biol. Chem. 268, 2809-2815), parts of the phosphorylation and nucleotide binding/hinge domains of the Ca2+-ATPase were shown to be essential for phospholamban interaction. In order to identify the sites in phospholamban which interact with the Ca2+-ATPase, a series of mutants containing amino acid replacements in the cytoplasmic and transmembrane regions of phospholamban were co-expressed with the cardiac/slow-twitch muscle Ca2+-ATPase isozyme, SERCA2a, in HEK-293 cells. Mutation of residues in the cytoplasmic 1A domain of phospholamban, including positively charged residues, Lys3, Arg9, Arg13, and Arg14, negatively charged residue, Glu2, hydrophobic residues, Val4, Leu7, Ala11, Ile12, Ala15, and Ile18, and phosphorylation site residues, Ser16 and Thr17, resulted in loss of the inhibitory effect of phospholamban on Ca2+ transport by the Ca2+-ATPase. By contrast, mutation of Met1, Gln5, Tyr6, Thr8, Ser10, Glu19, or Met20 or of residues in the cytoplasmic 1B domain (Pro21 to Asn30) and of Cys41 in the transmembrane domain (Leu31 to Leu52) did not diminish the inhibitory effects of phospholamban on Ca2+ transport. These results suggest that a region essential for functional association of phospholamban with the Ca2+-ATPase lies in the cytoplasmic 1A domain of phospholamban.	UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,112 COLL ST,TORONTO M5G 1L6,ONTARIO,CANADA; OSAKA UNIV,SCH MED,DEPT MED 1,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT PATHOPHYSIOL,OSAKA 565,JAPAN	University of Toronto; Osaka University; Osaka University								CHIESI M, 1989, FEBS LETT, V244, P241, DOI 10.1016/0014-5793(89)81201-3; CHOTHIA C, 1975, NATURE, V256, P705, DOI 10.1038/256705a0; COLYER J, 1991, J BIOL CHEM, V266, P17486; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FUJII J, 1989, J BIOL CHEM, V264, P12950; FUJII J, 1987, J CLIN INVEST, V79, P301, DOI 10.1172/JCI112799; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; INUI M, 1986, J BIOL CHEM, V261, P1794; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; KIM HW, 1990, J BIOL CHEM, V265, P1702; KINGSTON RE, 1992, CURRENT PROTOCOLS MO; KIRCHBERGER MA, 1974, J BIOL CHEM, V249, P6166; KIRCHBERGER MA, 1986, BIOCHEMISTRY-US, V25, P5484, DOI 10.1021/bi00367a021; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LYTTON J, 1992, J BIOL CHEM, V267, P14483; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MAHONY L, 1986, J BIOL CHEM, V261, P5257; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MORRIS GL, 1991, J BIOL CHEM, V266, P11270; SASAKI T, 1992, J BIOL CHEM, V267, P1674; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; SUZUKI T, 1986, J BIOL CHEM, V261, P7081; TADA M, 1989, BIOESSAYS, V10, P157, DOI 10.1002/bies.950100505; TADA M, 1974, J BIOL CHEM, V249, P6174; TADA M, 1982, ANNU REV PHYSIOL, V44, P401, DOI 10.1146/annurev.ph.44.030182.002153; TERZI E, 1992, FEBS LETT, V309, P413, DOI 10.1016/0014-5793(92)80819-3; TOYOFUKU T, 1993, J BIOL CHEM, V268, P2809; TOYOFUKU T, 1992, J BIOL CHEM, V267, P14490; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; XU ZC, 1989, J BIOL CHEM, V264, P16644; YOUNG EF, 1989, MEMBRANE BIOCHEM, V8, P95, DOI 10.3109/09687688909082263	32	156	159	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					3088	3094						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	7905483				2022-12-25	WOS:A1994MV43200104
J	ZIMNIAK, P; SINGHAL, SS; SRIVASTAVA, SK; AWASTHI, S; SHARMA, R; HAYDEN, JB; AWASTHI, YC				ZIMNIAK, P; SINGHAL, SS; SRIVASTAVA, SK; AWASTHI, S; SHARMA, R; HAYDEN, JB; AWASTHI, YC			ESTIMATION OF GENOMIC COMPLEXITY, HETEROLOGOUS EXPRESSION, AND ENZYMATIC CHARACTERIZATION OF MOUSE GLUTATHIONE-S-TRANSFERASE MGSTA4-4 (GST-5.7)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; CATALYTIC ACTIVITY; RAT-LIVER; HUMAN LUNG; PURIFICATION; PROTEINS; CLONING; ISOZYMES; ACID; STEP	We have previously isolated a cDNA clone for a unique mouse lung glutathione S-transferase, mGSTA4-4 (GST 5.7) (Zimniak, P., Eckles, M. A., Saxena, M., and Awasthi, Y. C. (1992) FEBS Lett. 313,173-176). By genomic Southern blotting and polymerase chain reaction single strand conformation polymorphism analysis we have now demonstrated the presence of at least two mGSTA4-related genes in the mouse. The heterogeneity of mGSTA4-4 was further examined by comparing the structural and kinetic properties of mGSTA4-4 isolated from mouse lung with those of recomhinant recmGSTA4-4 expressed in Escherichia coli. Except for the isoelectric point, the physical properties of the two proteins were indistinguishable. Western blots using antibodies against rec-mGSTA4-4 have shown selective expression of the enzyme in mouse tissues. Even though the substrate specificity profiles of the tissue-isolated and recombinant enzymes, which point to a role of mGSTA4-4 in the detoxification of lipid peroxidation products, were generally similar, significant differences were observed with selected substrates. The existence of functionally distinct forms of mGSTA4-4 and the presence of more than one gene strongly suggest that the previously observed differences in properties of mGSTA4-4 isolated from various mouse tissues (Awasthi, S., Singhal, S. S., Srivastava, S. K., and Awasthi, Y. C. (1993) Arch. Biochem. Biophys. 301, 143-150) may be due to tissue-specific expression of mGSTA4-related genes.	UNIV TEXAS, MED BRANCH, DEPT HUMAN BIOL CHEM & GENET, 2138 MED RES BLDG, GALVESTON, TX 77550 USA; UNIV TEXAS, MED BRANCH, DEPT INTERNAL MED, GALVESTON, TX 77550 USA; UNIV ARKANSAS MED SCI HOSP, DEPT MED, LITTLE ROCK, AR 72205 USA; UNIV ARKANSAS MED SCI HOSP, DEPT BIOCHEM & MOLEC BIOL, LITTLE ROCK, AR 72205 USA; VET ADM JOHN MCCLELLAN MEM HOSP, LITTLE ROCK, AR USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences			Awasthi, Sanjay/R-4904-2019	Awasthi, Sanjay/0000-0002-5214-5717	NATIONAL CANCER INSTITUTE [R01CA027967] Funding Source: NIH RePORTER; NCI NIH HHS [CA-27967] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMAD H, 1988, ARCH BIOCHEM BIOPHYS, V266, P416, DOI 10.1016/0003-9861(88)90273-1; AHMAD H, 1989, ENZYME, V42, P129, DOI 10.1159/000469022; ALIN P, 1989, BIOCHEM J, V261, P531, DOI 10.1042/bj2610531; ALIN P, 1985, FEBS LETT, V179, P267, DOI 10.1016/0014-5793(85)80532-9; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AWASTHI S, 1993, BIOCHIM BIOPHYS ACTA, V1164, P173, DOI 10.1016/0167-4838(93)90245-M; AWASTHI S, 1993, ARCH BIOCHEM BIOPHYS, V301, P143, DOI 10.1006/abbi.1993.1126; AWASTHI YC, 1975, J BIOL CHEM, V250, P5144; AWASTHI YC, 1985, COMP BIOCHEM PHYS B, V82, P17, DOI 10.1016/0305-0491(85)90121-X; BALDINO F, 1989, METHOD ENZYMOL, V168, P761; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUETLER TM, 1992, J ENVIRON SCI HEAL C, V10, P181; CAMPBELL E, 1990, J BIOL CHEM, V265, P9188; CHANG LH, 1993, EUR J BIOCHEM, V211, P805, DOI 10.1111/j.1432-1033.1993.tb17612.x; CHANG LH, 1992, BIOCHEM J, V281, P545, DOI 10.1042/bj2810545; Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUAN YJ, 1988, J BIOL CHEM, V263, P19003; GOON D, 1993, TOXICOL APPL PHARM, V119, P175, DOI 10.1006/taap.1993.1058; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HE M, 1990, NUCLEIC ACIDS RES, V18, P1660, DOI 10.1093/nar/18.6.1660; Jakoby W B, 1978, Adv Enzymol Relat Areas Mol Biol, V46, P383; JENSSON H, 1986, FEBS LETT, V203, P207, DOI 10.1016/0014-5793(86)80743-8; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; JOHNSON JA, 1992, BIOCHEM J, V282, P279, DOI 10.1042/bj2820279; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1992, BIOCHEM J, V282, P305, DOI 10.1042/bj2820305; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEDH RD, 1991, BIOCHEM J, V278, P793, DOI 10.1042/bj2780793; MEDH RD, 1990, CLIN CHEM ENZYM COMM, V3, P267; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; Sambrook J, 1989, MOL CLONING LABORATO; SARKAR G, 1992, NUCLEIC ACIDS RES, V20, P871, DOI 10.1093/nar/20.4.871; SCHOWALTER DB, 1989, ANAL BIOCHEM, V177, P90, DOI 10.1016/0003-2697(89)90019-5; SHARMA R, 1991, J BIOCHEM TOXICOL, V6, P147, DOI 10.1002/jbt.2570060209; SHARMA R, 1993, COMP BIOCHEM PHYS C, V105, P31, DOI 10.1016/0742-8413(93)90053-N; SIMONS PC, 1977, ANAL BIOCHEM, V82, P334, DOI 10.1016/0003-2697(77)90169-5; SINGHAL SS, 1992, ARCH BIOCHEM BIOPHYS, V299, P232, DOI 10.1016/0003-9861(92)90269-3; SINGHAL SS, 1991, ARCH BIOCHEM BIOPHYS, V285, P64, DOI 10.1016/0003-9861(91)90329-H; SINGHAL SS, 1990, ARCH BIOCHEM BIOPHYS, V279, P45, DOI 10.1016/0003-9861(90)90461-7; SINGHAL SS, 1992, BIOCHIM BIOPHYS ACTA, V1116, P137, DOI 10.1016/0304-4165(92)90110-G; SINGHAL SS, 1991, BIOCHIM BIOPHYS ACTA, V1079, P285, DOI 10.1016/0167-4838(91)90071-7; SRIVASTAVA SK, 1993, BIOCHEM ARCH, V9, P73; STENBERG G, 1992, BIOCHEM J, V284, P313, DOI 10.1042/bj2840313; SUZUKI Y, 1990, ONCOGENE, V5, P1037; TELAKOWSKIHOPKINS CA, 1986, P NATL ACAD SCI USA, V83, P9393, DOI 10.1073/pnas.83.24.9393; TOUNG YPS, 1993, J BIOL CHEM, V268, P9737; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUCHIDA S, 1992, CRIT REV BIOCHEM MOL, V27, P337, DOI 10.3109/10409239209082566; WAXMAN DJ, 1988, BIOCHEM PHARMACOL, V37, P71, DOI 10.1016/0006-2952(88)90756-3; ZIMNIAK P, 1992, FEBS LETT, V313, P173, DOI 10.1016/0014-5793(92)81438-R; ZIMNIAK P, 1993, HDB EXPT PHARM, V105, P123	56	113	114	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					992	1000						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7904605				2022-12-25	WOS:A1994MR22000036
J	SADDIK, M; GAMBLE, J; WITTERS, LA; LOPASCHUK, GD				SADDIK, M; GAMBLE, J; WITTERS, LA; LOPASCHUK, GD			ACETYL-COA CARBOXYLASE REGULATION OF FATTY-ACID OXIDATION IN THE HEART	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; RAT-HEART; CARNITINE PALMITOYLTRANSFERASE; MALONYL-COA; PHOSPHORYLATION STATE; LIVER-MITOCHONDRIA; PROTEIN-KINASE; MESSENGER-RNA; KI VALUES; INHIBITION	The role of acetyl-coenzyme A carboxylase (ACC) in regulating fatty acid oxidation was investigated in isolated fatty acid perfused working rat hearts. Overall fatty acid oxidation rates were determined by addition of 1.2 mM [H-3]palmitate to the perfusate of hearts in which the endogenous triglyceride pool was prelabeled with [C-14]palmitate. Rates of both exogenous and endogenous fatty acid oxidation were measured by simultaneous measurement of (H2O)-H-3 and (CO2)-C-14 production, respectively. A second series of hearts were perfused under similar conditions except that [U-C-14]glucose was present in the perfusate for measurement of glucose oxidation rates. Addition of dichloroacetate (DCA, 1 mM) to the perfusate resulted in a dramatic stimulation of glucose oxidation (a 411% increase), with a parallel decrease in fatty acid oxidation (from 305 +/- 51 to 206 +/- 40 nmol/g dry weight.min.unit work). DCA treatment increased the contribution of glucose oxidation to ATP production from 7.1 to 30.6%, while decreasing the contribution of overall fatty acid oxidation from 92.9 to 69.4%. Tissue levels of malonyl-CoA in hearts treated with DCA were higher compared to controls (14.0 +/- 0.6 and 10.0 +/- 0.7 nmol/g dry weight, respectively) and were negatively correlated (r = -0.85) with overall fatty acid oxidation rates. Acetyl-CoA levels were also significantly higher in DCA-treated hearts, and a positive correlation (r = 0.88) was seen between myocardial acetyl-CoA and malonyl-CoA levels. This suggests that DCA treatment increased the supply of acetyl-CoA for ACC. Western blots revealed the presence of both the 280-kDa (ACC-280) and the 265-kDa (ACC-265) isoforms of ACC in cardiac tissue, with a predominance of ACC-280. The activity of ACC extracted from hearts was similar in both groups when assayed under optimal conditions of acetyl-CoA and citrate. However, using affinity purified ACC, it was demonstrated that heart ACC (predominantly ACC-280) had a higher K(m) for acetyl-CoA than ACC isolated from white adipose tissue (predominantly ACC-265). We conclude that ACC is an important regulator of fatty acid oxidation in the heart and that acetyl-CoA supply is a key determinant of heart ACC-280 activity. As acetyl-CoA levels increase, ACC-280 is activated resulting in an increase in malonyl-CoA inhibition of fatty acid oxidation.	UNIV ALBERTA, DEPT PEDIAT, CARDIOVASC DIS RES GRP, 423 HERITAGE MED RES BLDG, EDMONTON T6G 2S2, AB, CANADA; UNIV ALBERTA, DEPT PHARMACOL, LIPID & LIPOPROT RES GRP, EDMONTON T6G 2S2, AB, CANADA; DARTMOUTH COLL, HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT MED, DIV ENDOCRINE METAB, HANOVER, NH 03756 USA; DARTMOUTH COLL, HITCHCOCK MED CTR, DARTMOUTH MED SCH, DEPT BIOCHEM, HANOVER, NH 03756 USA	University of Alberta; University of Alberta; Dartmouth College; Dartmouth College					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035712] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 35712] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIANCHI A, 1990, J BIOL CHEM, V265, P1502; BOWYER DE, 1977, J CHROMATOGR, V143, P473, DOI 10.1016/S0378-4347(00)81794-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREMER J, 1981, BIOCHIM BIOPHYS ACTA, V665, P628, DOI 10.1016/0005-2760(81)90282-4; BRODERICK TL, 1992, J BIOL CHEM, V267, P3758; COOK GA, 1984, J BIOL CHEM, V259, P2030; COOK GA, 1987, J BIOL CHEM, V262, P2050; COOK GA, 1992, MOL CELL BIOCHEM, V116, P39, DOI 10.1007/BF01270567; DAVIES SP, 1992, EUR J BIOCHEM, V203, P615, DOI 10.1111/j.1432-1033.1992.tb16591.x; HOLLAND R, 1984, EUR J BIOCHEM, V140, P325, DOI 10.1111/j.1432-1033.1984.tb08105.x; HULSMANN WC, 1966, BIOCHIM BIOPHYS ACTA, V178, P137; IDELLWENGER JA, 1982, ANAL BIOCHEM, V125, P269, DOI 10.1016/0003-2697(82)90006-9; IDELLWENGER JA, 1978, J BIOL CHEM, V253, P4310; IVERSON AJ, 1990, BIOCHEM J, V269, P365, DOI 10.1042/bj2690365; JAMIL H, 1987, J BIOL CHEM, V262, P638; JAMIL H, 1987, J BIOL CHEM, V262, P630; KING MT, 1988, METHOD ENZYMOL, V166, P70; KONG IS, 1990, J BIOL CHEM, V265, P13695; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE MD, 1979, CRC CR REV BIOCH MOL, V7, P121, DOI 10.3109/10409237909105429; LOPASCHUK GD, 1992, MOL CELL BIOCHEM, V116, P111, DOI 10.1007/BF01270577; LOPEZCASILLAS F, 1989, J BIOL CHEM, V264, P7176; LYSIAK W, 1986, J BIOL CHEM, V261, P3698; LYSIAK W, 1988, J BIOL CHEM, V263, P1151; MABROUK GM, 1990, J BIOL CHEM, V265, P6330; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; PAPE ME, 1988, ARCH BIOCHEM BIOPHYS, V267, P104, DOI 10.1016/0003-9861(88)90013-6; PAULSON DJ, 1984, FEBS LETT, V176, P381, DOI 10.1016/0014-5793(84)81201-6; PEARSON DJ, 1967, BIOCHEM J, V105, P953, DOI 10.1042/bj1050953; SADDIK M, 1991, J BIOL CHEM, V266, P8162; SCHOLTE HR, 1986, FEBS LETT, V198, P47, DOI 10.1016/0014-5793(86)81182-6; SINGH B, 1984, ANAL BIOCHEM, V138, P107, DOI 10.1016/0003-2697(84)90776-0; SWENSON TL, 1985, J BIOL CHEM, V260, P3791; THAMPY KG, 1985, J BIOL CHEM, V260, P6318; THAMPY KG, 1988, J BIOL CHEM, V263, P6454; THAMPY KG, 1989, J BIOL CHEM, V264, P17631; TIPPER JP, 1982, BIOCHIM BIOPHYS ACTA, V715, P162, DOI 10.1016/0304-4165(82)90354-3; TRUMBLE GE, 1991, LIFE SCI, V49, P39, DOI 10.1016/0024-3205(91)90577-X; WAKIL SJ, 1958, BIOCHIM BIOPHYS ACTA, V29, P225, DOI 10.1016/0006-3002(58)90177-X; Williamson J R, 1979, Methods Enzymol, V55, P200; WITTERS LA, 1988, P NATL ACAD SCI USA, V85, P5473, DOI 10.1073/pnas.85.15.5473; WITTERS LA, 1986, ADV PROTEIN PHOSPHAT, V3, P201	43	315	322	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25836	25845						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7902355				2022-12-25	WOS:A1993MK10000081
J	BEAUMELLE, B; ALAMI, M; HOPKINS, CR				BEAUMELLE, B; ALAMI, M; HOPKINS, CR			ATP-DEPENDENT TRANSLOCATION OF RICIN ACROSS THE MEMBRANE OF PURIFIED ENDOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; A-CHAIN IMMUNOTOXINS; CYTO-TOXIC ACTIVITY; DIPHTHERIA-TOXIN; BREFELDIN-A; PROTEIN TRANSLOCATION; INTERNALIZED RICIN; B-CHAIN; CELLS; LYMPHOCYTES	Ricin translocation was demonstrated (using both fluorescence- and radiolabel-based assays) across the membrane of endosomes purified from mouse lymphocytes. Selectivity of the process was shown by the absence of translocation 'activity of transferrin and horseradish peroxidase used as membrane-bound and fluid-phase endosome labels, respectively. Endocytosed I-125-ricin translocation was found to be strictly ATP- (K(m) almost-equal-to 4 mM) and temperature-dependent, with up to 30% endosomal I-125-ricin appearing in the external medium after 2 h at 37-degrees-C. No treatments neutralizing the acidic endosome pH (ammonium chloride, nigericin, chloroquine) significantly impaired ricin translocation, and the pH gradient across the endosome membrane is not required for this process. Chase experiments showed that the ability of I-125-ricin to translocate increases with its depth in the endocytic system (i.e. plasma membrane << early endosomes < late endosomes). Both A and B ricin chains displayed translocation ability as demonstrated by the results of our assay on ricin, ricin B, transferrin-ricin A, and transferrin-ricin B conjugates. Biological activity of both ricin chains is preserved after translocation as shown by the inhibitory effect of the A chain on cell-free protein synthesis and the binding of the B chain to lactose-agarose.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOCHEM, LONDON SW7 2AY, ENGLAND; UNIV LONDON UNIV COLL, MRC, MOLEC CELL BIOL LAB, LONDON WC1E 6BT, ENGLAND	Imperial College London; University of London; University College London	BEAUMELLE, B (corresponding author), UNIV MONTPELLIER 2, DEPT BIOL SANTE, CNRS, URA 530, CASE 107, F-34095 MONTPELLIER 5, FRANCE.			Beaumelle, Bruno/0000-0002-4912-9134				BEAUMELLE B, 1992, J BIOL CHEM, V267, P11525; BEAUMELLE BD, 1990, J CELL BIOL, V111, P1811, DOI 10.1083/jcb.111.5.1811; BEAUMELLE BD, 1989, BIOCHEM J, V264, P137, DOI 10.1042/bj2640137; CALAFAT J, 1988, CANCER RES, V48, P3822; CARLSSON J, 1978, BIOCHEM J, V173, P723, DOI 10.1042/bj1730723; CARRIERE D, 1989, EXP CELL RES, V182, P114, DOI 10.1016/0014-4827(89)90284-X; CREWS JR, 1992, INT J CANCER, V51, P772, DOI 10.1002/ijc.2910510518; DIAZ R, 1988, J BIOL CHEM, V263, P6093; EMMANUEL F, 1988, ANAL BIOCHEM, V173, P134, DOI 10.1016/0003-2697(88)90170-4; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FRENOY JP, 1992, BIOCHEM J, V284, P249, DOI 10.1042/bj2840249; HOWELL KE, 1989, TRENDS BIOCHEM SCI, V14, P44, DOI 10.1016/0968-0004(89)90040-6; HUDSON TH, 1988, J BIOL CHEM, V263, P4773; HUDSON TH, 1991, J BIOL CHEM, V266, P18586; HUDSON TH, 1987, J BIOL CHEM, V262, P16484; HUNZIKER W, 1992, FEBS LETT, V307, P93, DOI 10.1016/0014-5793(92)80908-Y; HURTLEY SM, 1990, TRENDS BIOCHEM SCI, V15, P211, DOI 10.1016/0968-0004(90)90026-8; ISHIDA B, 1983, J BIOL CHEM, V258, P5933; KNOWLES PP, 1987, ANAL BIOCHEM, V160, P440, DOI 10.1016/0003-2697(87)90073-X; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; Meyer D I, 1991, Trends Cell Biol, V1, P154, DOI 10.1016/0962-8924(91)90016-3; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; OLSNES S, 1973, BIOCHEMISTRY-US, V12, P3121, DOI 10.1021/bi00740a028; OLSNES S, 1988, TRENDS BIOCHEM SCI, V13, P348, DOI 10.1016/0968-0004(88)90105-3; Olsnes S, 1988, Cancer Treat Res, V37, P39; OLSNES S, 1989, IMMUNOL TODAY, V10, P291; PELHAM H R B, 1992, Trends in Cell Biology, V2, P183, DOI 10.1016/0962-8924(92)90230-K; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PREIJERS FWMB, 1988, BRIT J HAEMATOL, V70, P289, DOI 10.1111/j.1365-2141.1988.tb02484.x; PRESS OW, 1988, J IMMUNOL, V141, P4410; RASO V, 1984, J BIOL CHEM, V259, P1143; RINK TJ, 1982, J CELL BIOL, V95, P189, DOI 10.1083/jcb.95.1.189; SANDVIG K, 1991, J CELL BIOL, V115, P971, DOI 10.1083/jcb.115.4.971; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; TIMAR J, 1991, BRIT J CANCER, V64, P655, DOI 10.1038/bjc.1991.377; VANDEURS B, 1988, J CELL BIOL, V106, P253, DOI 10.1083/jcb.106.2.253; VANDEURS B, 1989, INT REV CYTOL, V117, P131; VANDEURS B, 1985, EXP CELL RES, V159, P287, DOI 10.1016/S0014-4827(85)80003-3; VANDEURS B, 1986, J CELL BIOL, V102, P37, DOI 10.1083/jcb.102.1.37; Vitetta E S, 1991, Semin Cell Biol, V2, P47; WALES R, 1992, EXP CELL RES, V203, P1, DOI 10.1016/0014-4827(92)90032-4; WARGALLA UC, 1989, P NATL ACAD SCI USA, V86, P5146, DOI 10.1073/pnas.86.13.5146; YOSHIDA T, 1991, EXP CELL RES, V192, P389, DOI 10.1016/0014-4827(91)90056-Z; YOULE RJ, 1982, J BIOL CHEM, V257, P1598; YOULE RJ, 1987, J BIOL CHEM, V262, P4676	48	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23661	23669						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7901210				2022-12-25	WOS:A1993MF51500106
J	CROSS, AR; CURNUTTE, JT				CROSS, AR; CURNUTTE, JT			THE CYTOSOLIC ACTIVATING FACTORS P47(PHAX) AND P67(PHAX) HAVE DISTINCT ROLES IN THE REGULATION OF ELECTRON FLOW IN NADPH OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; SUPEROXIDE-GENERATING OXIDASE; CYTOCHROME-B; HUMAN-NEUTROPHILS; PLASMA-MEMBRANE; GALACTOSE-OXIDASE; BINDING-SITE; REDUCTION; PROTEIN	We have previously shown that the human neutrophil superoxide-generating NADPH oxidase possesses a novel dye reductase activity (Cross, A. R., Yarchover, J. L., and Curnutte, J. T. (1994) J. Biol. Chem. 269, 21448-21454). This activity exhibited an absolute requirement for the cytosolic activating factor p67(phox) but not far p47(phox), suggesting that p67(phox) and p47(phox) have individual roles in controlling electron flow from NADPH to oxygen. Here, we provide direct evidence that p67(phox) alone can facilitate electron flow from NADPH to the flavin center of NADPH oxidase in the absence of p47(phox), resulting in the reduction of enzyme FAD, whereas the presence of p47(phox) is required in order for electron transfer to proceed beyond the flavin center to the heme in cytochrome b(-245) and thence to oxygen.			CROSS, AR (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, CAL-1, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024838] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00833] Funding Source: Medline; NIAID NIH HHS [AI24838] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BABIOR BM, 1992, ADV ENZYMOL RAMB, V65, P49; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CROSS AR, 1981, BIOCHEM J, V194, P599, DOI 10.1042/bj1940599; CROSS AR, 1985, BIOCHEM J, V226, P881, DOI 10.1042/bj2260881; CROSS AR, 1984, BIOCHEM J, V223, P337, DOI 10.1042/bj2230337; CROSS AR, 1982, BIOCHEM J, V204, P479, DOI 10.1042/bj2040479; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; CROSS AR, 1994, J BIOL CHEM, V269, P21448; CROSS AR, 1982, BIOCHEM J, V208, P758; CURNUTTE JT, 1993, CLIN IMMUNOL IMMUNOP, V67, pS2, DOI 10.1006/clin.1993.1078; CURNUTTE JT, 1989, P NATL ACAD SCI USA, V86, P825, DOI 10.1073/pnas.86.3.825; CURNUTTE JT, 1987, J BIOL CHEM, V262, P6450; DOUSSIERE J, 1993, BIOCHEMISTRY-US, V32, P8880, DOI 10.1021/bi00085a020; ELLIS JA, 1989, BIOCHEM J, V262, P575, DOI 10.1042/bj2620575; ENGLANDER SW, 1987, ANAL BIOCHEM, V161, P300, DOI 10.1016/0003-2697(87)90454-4; EZEKOWITZ RAB, 1991, NEW ENGL J MED, V324, P509, DOI 10.1056/NEJM199102213240801; FORREST CB, 1988, HEMATOL ONCOL CLIN N, V2, P253, DOI 10.1016/S0889-8588(18)30619-1; HOOGLAND H, 1987, BIOCHIM BIOPHYS ACTA, V916, P76, DOI 10.1016/0167-4838(87)90212-3; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; KAKINUMA K, 1986, J BIOL CHEM, V2651, P9426; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LAPORTE F, 1991, EUR J BIOCHEM, V196, P59, DOI 10.1111/j.1432-1033.1991.tb15785.x; MARGOLIS DM, 1990, J INFECT DIS, V162, P723, DOI 10.1093/infdis/162.3.723; MIKI T, 1992, J BIOL CHEM, V267, P18695; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; MUIRWOOD P, 1974, FEBS LETT, V44, P22, DOI 10.1016/0014-5793(74)80297-8; NAKANISHI A, 1992, J BIOL CHEM, V267, P19072; ODAJIMA T, 1970, BIOCHIM BIOPHYS ACTA, V206, P71, DOI 10.1016/0005-2744(70)90083-5; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; QUINN MT, 1992, BLOOD, V79, P2438; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; ROTROSEN D, 1993, J BIOL CHEM, V268, P14256; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SUMIMOTO H, 1992, BIOCHEM BIOPH RES CO, V186, P1368, DOI 10.1016/S0006-291X(05)81557-8; WEENING RS, 1985, J PEDIATR-US, V107, P102, DOI 10.1016/S0022-3476(85)80626-0; WHITTAKER MM, 1988, J BIOL CHEM, V263, P6074; YOSHIDA LS, 1992, BIOCHIM BIOPHYS ACTA, V1135, P245	40	94	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6543	6548		10.1074/jbc.270.12.6543	http://dx.doi.org/10.1074/jbc.270.12.6543			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896790	hybrid			2022-12-25	WOS:A1995QQ85500020
J	ORMO, M; REGNSTROM, K; WANG, ZG; QUE, L; SAHLIN, M; SJOBERG, BM				ORMO, M; REGNSTROM, K; WANG, ZG; QUE, L; SAHLIN, M; SJOBERG, BM			RESIDUES IMPORTANT FOR RADICAL STABILITY IN RIBONUCLEOTIDE REDUCTASE FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PHENOTYPIC SELECTION; SUBUNIT INTERACTION; PHOTOSYSTEM-II; IRON CENTER; PROTEIN R2; ACTIVATION; MECHANISM; SYSTEM; DNA	The R2 protein of ribonucleotide reductase contains at the side chain of tyrosine 122 a stable free radical, which is essential for enzyme catalysis. The tyrosyl radical is buried in the protein matrix close to a dinuclear iron center and a cluster of three hydrophobic residues (Phe 208, Phe-212, and Ile-234) conserved throughout the R2 family. A key step in the generation of the tyrosyl radical is the activation of molecular oxygen at the iron center. It has been suggested that the hydrophobic cluster provides an inert binding pocket for molecular oxygen bound to the iron center and that it may play a role in directing the oxidative power of a highly reactive intermediate toward tyrosine 122. We have tested these hypotheses by constructing the following mutant R2 proteins: F208Y, F212Y, F212W, and I234N. The resulting mutant proteins all have the ability to form a tyrosine radical, which indicates that binding of molecular oxygen can occur. In the case of F208Y, the yield of tyrosyl radical is substantially lower than in the wild-type case. A competing reaction resulting in hydroxylation of Tyr-208 implies that the phenylalanine at position 208 may influence the choice of target for electron abstraction. The most prominent result is that all mutant proteins show impaired radical half-life; in three of the four mutants, the half-lives are several orders of magnitude shorter than that of the wild type radical. This suggests that the major role of the hydrophobic pocket is to stabilize the tyrosyl radical. This hypothesis is corroborated by comparative studies of the environment of other naturally occurring tyrosyl radicals.	UNIV STOCKHOLM, DEPT MOLEC BIOL, S-10691 STOCKHOLM, SWEDEN; UNIV MINNESOTA, DEPT CHEM, MINNEAPOLIS, MN 55455 USA	Stockholm University; University of Minnesota System; University of Minnesota Twin Cities				Sjoberg, Britt-Marie/0000-0001-5953-3360				ABERG A, 1993, NATURE, V361, P276, DOI 10.1038/361276a0; ABERG A, 1993, BIOCHEMISTRY-US, V32, P9845; ATKIN CL, 1973, J BIOL CHEM, V248, P7464; ATTA M, 1992, J BIOL CHEM, V267, P20682; Bernitz U, 1993, NYA KONKURRENSLAGEN; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; CLIMENT I, 1991, BIOCHEMISTRY-US, V30, P5164, DOI 10.1021/bi00235a008; CLIMENT I, 1992, BIOCHEMISTRY-US, V31, P4801, DOI 10.1021/bi00135a009; DEBUS RJ, 1988, P NATL ACAD SCI USA, V85, P427, DOI 10.1073/pnas.85.2.427; ELGREN TE, 1991, J BIOL CHEM, V266, P19265; FONTECAVE M, 1992, ADV ENZYMOL RAMB, V65, P147; GREENE PJ, 1974, METHODS MOLECULAR BI, V7, P87; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; LARSSON A, 1988, J BIOL CHEM, V263, P17780; LING JS, 1994, J BIOL CHEM, V269, P5595; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; ORMO M, 1992, J BIOL CHEM, V267, P8711; PETERSSON L, 1980, J BIOL CHEM, V255, P6706; REGNSTROM K, 1994, J BIOL CHEM, V269, P6355; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; SAHLIN M, 1990, BIOCHEM BIOPH RES CO, V167, P813, DOI 10.1016/0006-291X(90)92098-K; SAHLIN M, 1987, BIOCHEMISTRY-US, V26, P5541, DOI 10.1021/bi00391a049; SAHLIN M, 1989, BIOCHEMISTRY-US, V28, P2618, DOI 10.1021/bi00432a039; SAHLIN M, 1982, J BIOL CHEM, V257, P366; SJOBERG BM, 1983, J BIOL CHEM, V258, P8060; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; SJOBERG BM, 1994, STRUCTURE, V2, P793, DOI 10.1016/S0969-2126(94)00080-8; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; STUBBE JA, 1980, J BIOL CHEM, V255, P8027; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SVENSSON B, 1991, Z NATURFORSCH C, V46, P765; SVENSSON B, 1990, EMBO J, V9, P2051, DOI 10.1002/j.1460-2075.1990.tb07372.x; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Thelander L, 1978, Methods Enzymol, V51, P227; TWEEDY NB, 1990, BIOCHEMISTRY-US, V29, P1539, DOI 10.1021/bi00458a027; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; ZHANG JH, 1992, P NATL ACAD SCI USA, V89, P7065, DOI 10.1073/pnas.89.15.7065	43	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6570	6576		10.1074/jbc.270.12.6570	http://dx.doi.org/10.1074/jbc.270.12.6570			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896794	hybrid			2022-12-25	WOS:A1995QQ85500024
J	WITHERS, BE; DUNBAR, JC				WITHERS, BE; DUNBAR, JC			SEQUENCE-SPECIFIC DNA RECOGNITION BY THE SMAI ENDONUCLEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECORV RESTRICTION ENDONUCLEASE; RI ENDONUCLEASE; BASE ANALOG; CLEAVAGE; BINDING; CATALYSIS; REPRESSOR; DIFFUSION; SITE	SmaI endonuclease recognizes and cleaves the sequence CCC down arrow GGG. The enzyme requires magnesium for catalysis; however, equilibrium binding assays revealed that the enzyme binds specifically to DNA in the absence of magnesium. A specific association constant of 0.9 x 10(8) M(-1) was determined for SmaI binding to a 22-base duplex oligonucleotide. Furthermore, the K-A was a function of the length of the DNA substrate and the enzyme exhibited an affinity of 1.2 x 10(9) M(-1) for a 195-base pair fragment and which represented a 10(4)-fold increase in affinity over binding to nonspecific sequences. A K-m of 17.5 nM was estimated from kinetic assays based on cleavage of the 22 base oligonucleotide and is not significantly different from the K-D estimated from the thermodynamic analyses. Footprinting (dimethyl sulfate and missing nucleoside) analyses revealed that SmaI interacts with each of the base pairs within the recognition sequence. Ethylation interference assays suggested that the protein contacts three adjacent phosphates on each strand of the recognition sequence. Significantly, a predicted protein contact with the phosphate 3' of the scissile bond may have implications in the mechanism of catalysis by SmaI.	WAYNE STATE UNIV,SCH MED,CTR MOLEC MED & GENET,DETROIT,MI 48201	Wayne State University								AIKEN CR, 1991, J BIOL CHEM, V266, P19063; AIKEN CR, 1991, J BIOL CHEM, V266, P1070; ANDERSON JE, 1993, CURR OPIN STRUC BIOL, V3, P24, DOI 10.1016/0959-440X(93)90197-S; ATHANASIADIS A, 1994, NAT STRUCT BIOL, V1, P469, DOI 10.1038/nsb0794-469; BRENNAN CA, 1986, J BIOL CHEM, V261, P7270; BROOKS JE, 1991, NUCLEIC ACIDS RES, V19, P841, DOI 10.1093/nar/19.4.841; BRUNELLE A, 1987, P NATL ACAD SCI USA, V84, P6673, DOI 10.1073/pnas.84.19.6673; BURLEY SK, 1994, CURR OPIN STRUC BIOL, V4, P3, DOI 10.1016/S0959-440X(94)90053-1; CHENG XD, 1994, EMBO J, V13, P3927, DOI 10.1002/j.1460-2075.1994.tb06708.x; Fersht A., 1985, ENZYME STRUCTURE MEC; GHOSH SS, 1990, NUCLEIC ACIDS RES, V18, P5063, DOI 10.1093/nar/18.17.5063; GRIEP MA, 1989, J BIOL CHEM, V264, P11294; HA JH, 1992, J MOL BIOL, V228, P252, DOI 10.1016/0022-2836(92)90504-D; HARRAN TE, 1987, J BIOMOL STRUCT DYN, V5, P199; HEIDMANN S, 1989, NUCLEIC ACIDS RES, V23, P9783; HEITMAN J, 1992, BIOESSAYS, V14, P445, DOI 10.1002/bies.950140704; JACK WE, 1982, P NATL ACAD SCI-BIOL, V79, P4010, DOI 10.1073/pnas.79.13.4010; JELTSCH A, 1992, FEBS LETT, V304, P4, DOI 10.1016/0014-5793(92)80576-3; JELTSCH A, 1993, P NATL ACAD SCI USA, V90, P8499, DOI 10.1073/pnas.90.18.8499; JENJACOBSON L, 1986, CELL, V45, P619, DOI 10.1016/0092-8674(86)90294-1; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; MCLAUGHLIN LW, 1987, BIOCHEMISTRY-US, V26, P7238, DOI 10.1021/bi00397a007; MODRICH P, 1976, J BIOL CHEM, V251, P5866; NEWMAN M, 1994, NATURE, V368, P660, DOI 10.1038/368660a0; NEWMAN PC, 1990, BIOCHEMISTRY-US, V29, P9902, DOI 10.1021/bi00494a021; RAUMANN BE, 1994, CURR OPIN STRUC BIOL, V4, P36, DOI 10.1016/S0959-440X(94)90057-4; Rosenberg JM, 1991, CURR OPIN STRUC BIOL, V1, P104, DOI 10.1016/0959-440X(91)90018-O; SAKONJU S, 1982, CELL, V31, P395, DOI 10.1016/0092-8674(82)90133-7; Segel I.H., 1975, ENZYME KINETICS; SELENT U, 1992, BIOCHEMISTRY-US, V31, P4801; SIEBENLIST U, 1980, P NATL ACAD SCI USA, V77, P121; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; TAYLOR JD, 1991, BIOCHEMISTRY-US, V30, P8743, DOI 10.1021/bi00100a005; TERRY BJ, 1985, J BIOL CHEM, V260, P3130; TERRY BJ, 1983, J BIOL CHEM, V258, P9820; THIELKING V, 1991, BIOCHEMISTRY-US, V30, P6416, DOI 10.1021/bi00240a011; THIELKING V, 1992, BIOCHEMISTRY-US, V15, P3727; VERMOTE CLM, 1992, BIOCHEMISTRY-US, V31, P6082, DOI 10.1021/bi00141a018; VONHIPPEL P, 1993, SCIENCE, V263, P769; WATERS TR, 1994, BIOCHEMISTRY-US, V33, P1812, DOI 10.1021/bi00173a026; WILSON GG, 1991, ANNU REV GENET, V25, P585, DOI 10.1146/annurev.ge.25.120191.003101; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6948, DOI 10.1021/bi00527a029; WITHERS BE, 1993, NUCLEIC ACIDS RES, V21, P2571, DOI 10.1093/nar/21.11.2571; ZEBALA JA, 1992, J BIOL CHEM, V267, P8106	45	15	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6496	6504		10.1074/jbc.270.12.6496	http://dx.doi.org/10.1074/jbc.270.12.6496			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896784	hybrid			2022-12-25	WOS:A1995QQ85500014
J	SHORE, P; BISSET, L; LAKEY, J; WALTHO, JP; VIRDEN, R; SHARROCKS, AD				SHORE, P; BISSET, L; LAKEY, J; WALTHO, JP; VIRDEN, R; SHARROCKS, AD			CHARACTERIZATION OF THE ELK-1 ETS DNA-BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; CIRCULAR-DICHROISM; TRANSCRIPTIONAL ACTIVATION; NMR-SPECTRA; BEND DNA; C-FOS; COMPLEXES; SEQUENCE; FAMILY; MOTIF	The ETS domain family of transcription factors is comprised of several important proteins that are involved in controlling key cellular events such as proliferation, differentiation, and development, One such protein, Elk-1, regulates the activity of the c-fos promoter in response to extracellular stimuli. Elk-1 is representative of a subgroup of ETS domain proteins that utilize a bipartite recognition mechanism that is mediated by both protein-DNA and protein-protein interactions, In this study, we have overexpressed, purified, and characterized the ETS DNA-binding domain of Elk-1 (Elk-93), Elk-93 was expressed in Escherichia coli as a fusion protein with glutathione S-transferase and purified to homogeneity from both the soluble and insoluble fractions using a two-column protocol. A combination of CD, NMR, and fluorescence spectroscopy demonstrates that Elk-93 represents an independently folded domain of mixed alpha/beta structure in which the three conserved tryptophans appear to contribute to the hydrophobic core of the protein, Moreover, DNA binding studies demonstrate that Elk-93 binds DNA with both high affinity (K-d approximate to 0.85 x 10(-10) M) and specificity, Circular permutation analysis indicates that DNA binding by Elk-93 does not induce significant bending of the DNA. Our results are discussed with respect to predictive models for the structure of the ETS DNA-binding domain.	UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT BIOCHEM & GENET,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; UNIV SHEFFIELD,KREBS INST,DEPT MOLEC BIOL & BIOTECHNOL,SHEFFIELD S10 2UH,S YORKSHIRE,ENGLAND	Newcastle University - UK; University of Sheffield				Waltho, Jonathan/0000-0002-7402-5492; Lakey, Jeremy/0000-0003-4646-9085; Shore, Paul/0000-0002-1832-5976	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERG JM, 1993, CURR OPIN STRUC BIOL, V3, P11, DOI 10.1016/0959-440X(93)90195-Q; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CHOU PY, 1978, ADV ENZYMOLOGY RELAT, V0047, P00145; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DEGNAN BM, 1993, NUCLEIC ACIDS RES, V21, P3479, DOI 10.1093/nar/21.15.3479; DEGROOT RP, 1994, ONCOGENE, V9, P463; EFTINK MR, 1994, BIOPHYS J, V66, P482, DOI 10.1016/S0006-3495(94)80799-4; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FISHER DE, 1992, P NATL ACAD SCI USA, V89, P11779, DOI 10.1073/pnas.89.24.11779; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GILLE H, 1992, NATURE, V358, P415; GUSTAFSON TA, 1989, P NATL ACAD SCI USA, V86, P2162, DOI 10.1073/pnas.86.7.2162; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HIPSKIND RA, 1991, NATURE, V354, P351; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KUMAR S, 1992, BIOCHEMISTRY-US, V31, P8648, DOI 10.1021/bi00151a035; LAGET MP, 1993, NUCLEIC ACIDS RES, V21, P5987, DOI 10.1093/nar/21.25.5987; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; MANAVALAN P, 1983, NATURE, V305, P831, DOI 10.1038/305831a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARION D, 1989, J MAGN RESON, V84, P425, DOI 10.1016/0022-2364(89)90391-0; MAVROTHALASSITI.G, 1994, ONCOGENE, V9, P425; MURDOCH FE, 1991, BIOCHEMISTRY-US, V30, P10838, DOI 10.1021/bi00109a005; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RANCE M, 1983, J MAGN RESON, V52, P221, DOI 10.1016/0022-2364(83)90190-7; RANCE M, 1987, J MAGN RESON, V74, P557, DOI 10.1016/0022-2364(87)90277-0; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RECORD MT, 1991, METHOD ENZYMOL, V208, P291; SAIKUMAR P, 1994, ONCOGENE, V9, P1279; SAMBROOK J, 1990, MOL CLONING LABORATO; SHARROCKS AD, 1993, NUCLEIC ACIDS RES, V21, P215, DOI 10.1093/nar/21.2.215; SHARROCKS AD, 1993, MOL CELL BIOL, V13, P123, DOI 10.1128/MCB.13.1.123; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; SMITH DB, 1985, GENE AMST, V67, P31; SZILAGYI L, 1994, IN PRESS PROG NMR SP, V27; TEI H, 1992, P NATL ACAD SCI USA, V89, P6856, DOI 10.1073/pnas.89.15.6856; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; VERRIJZER CP, 1991, EMBO J, V10, P3007, DOI 10.1002/j.1460-2075.1991.tb07851.x; WALTHO JP, 1993, J MAGN RESON SER A, V103, P338, DOI 10.1006/jmra.1993.1176; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	63	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					5805	5811		10.1074/jbc.270.11.5805	http://dx.doi.org/10.1074/jbc.270.11.5805			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890710				2022-12-25	WOS:A1995QM94500020
J	ROMANO, A; WONG, WT; SANTORO, M; WIRTH, PJ; THORGEIRSSON, SS; DIFIORE, PP				ROMANO, A; WONG, WT; SANTORO, M; WIRTH, PJ; THORGEIRSSON, SS; DIFIORE, PP			THE HIGH TRANSFORMING POTENCY OF ERBB-2 AND RET IS ASSOCIATED WITH PHOSPHORYLATION OF PAXILLIN AND A 23 KDA PROTEIN	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; GUANINE-NUCLEOTIDE EXCHANGE; DNA-BINDING PROTEINS; NIH 3T3 CELLS; SIGNAL-TRANSDUCTION; TYROSINE KINASE; EGF RECEPTOR; INTERFERON-GAMMA; ADAPTER PROTEIN; RAS	Two-dimensional gel maps of proteins phosphorylated by the epidermal growth factor receptor (EGFR) and erbB-2 kinases were obtained, to investigate the molecular basis of the different biological properties of these two molecules. Several proteins were phosphorylated by EGFR or erbB-2 with different stoichiometry. Differences were either quantitative or qualitative. In NIH3T3 cells, erbB-2 is 100-fold more transforming than EGFR. In the same cell line several proteins were preferentially phosphorylated by erbB-2, as compared to EGFR. To identify which of these substrates might be directly involved in mitogenic signaling, we obtained two-dimensional maps of proteins phosphorylated on tyrosine by EGFR/ret and an EGFR/erbB-2(TK) chimeric receptors. Both these chimerae behaved indistinguishably from erbB-2 in a number of bioassays and potently transformed NIH3T3 cells. Paxillin and a 23 kDa substrate were invariably phosphorylated to higher stoichiometry whenever potent mitogenic and transforming signals were activated. We propose that paxillin and the 23 kDa substrate are important elements in the erbB-2 and ret-activated mitogenic and transforming signaling.	NCI,EXPTL CARCINOGENESIS LAB,BETHESDA,MD 20892; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,I-80125 NAPLES,ITALY; FAC MED & CHIRURG NAPLES,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC L CAL,NAPLES,ITALY; FAC MED & CHIRURG BARI,IST MICROBIOL,BARI,ITALY	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Universita degli Studi di Bari Aldo Moro			Di Fiore, Pier Paolo/K-2130-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIFIORE PP, 1992, EMBO J, V11, P3927, DOI 10.1002/j.1460-2075.1992.tb05486.x; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HART MJ, 1990, J BIOL CHEM, V265, P5990; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; HOCHSTRASSER DF, 1988, ANAL BIOCHEM, V173, P424, DOI 10.1016/0003-2697(88)90209-6; HYNES NE, 1990, MOL CELL BIOL, V10, P4027, DOI 10.1128/MCB.10.8.4027; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LONARDO F, 1990, New Biologist, V2, P992; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; MONTMINY M, 1993, SCIENCE, V261, P1694, DOI 10.1126/science.8397444; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROUSSEL MF, 1989, P NATL ACAD SCI USA, V86, P7924, DOI 10.1073/pnas.86.20.7924; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SORKIN A, 1993, ONCOGENE, V8, P3021; TAVERNA D, 1991, CELL GROWTH DIFFER, V2, P145; TURNER CE, 1993, J CELL SCI, V105, P637; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WIRTH PJ, 1991, ELECTROPHORESIS, V12, P931, DOI 10.1002/elps.1150121112	50	21	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2923	2933						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	7916147				2022-12-25	WOS:A1994PG82200018
J	HAYASHI, Y; DEPAOLI, AM; BURANT, CF; REFETOFF, S				HAYASHI, Y; DEPAOLI, AM; BURANT, CF; REFETOFF, S			EXPRESSION OF A THYROID HORMONE-RESPONSIVE RECOMBINANT GENE INTRODUCED INTO ADULT MICE LIVERS BY REPLICATION-DEFECTIVE ADENOVIRUS CAN BE REGULATED BY ENDOGENOUS THYROID-HORMONE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MEDIATED TRANSFER; TRANSCRIPTIONAL REGULATION; CYSTIC-FIBROSIS; MUSCLE; DELIVERY; TYPE-5; DNA	We constructed a recombinant adenovirus carrying the firefly luciferase gene driven by the thymidine kinase promoter and controlled by the palindromic thyroid hormone/retinoic acid-responsive element. The same adenovirus vector without the hormone-responsive element was used as control. Regulation of the luciferase gene expression was tested in pituitary-derived GH cells and hepatoma-derived HepG2 cells infected with the recombinant adenoviruses. Administration of triiodothyronine to GH cells and all-trans-retinoic acid to HepG2 cells resulted in 8.0 +/- 0.3-fold and 4.6 +/- 0.5-fold induction of luciferase activity, respectively. No significant increase was observed with the control adenovirus. Hormonal regulation was also examined in adult mice. Mice depleted of thyroid hormone were injected intravenously with the recombinant adenoviruses and given 4 times the replacement dose of triiodothyronine or vehicle only for 4 days. Hormone administration resulted in 4.2-fold increase of luciferase activity in liver homogenates, No significant effect was observed in animals injected with the control adenovirus. This recombinant adenovirus provides a new experimental system in the study of thyroid hormone and retinoic acid action and offers the potential to regulate by physiological means the expression of genes transferred for the purpose of therapy.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PEDIAT,CHICAGO,IL 60637; UNIV CHICAGO,JOSEPH P KENNEDY JR MENTAL RETARDAT RES CTR,CHICAGO,IL 60637	University of Chicago; University of Chicago; University of Chicago			Refetoff, Samuel/ABB-1263-2021; Burant, Charles/GPC-5690-2022; Hayashi, Yoshitaka/I-6168-2014	Refetoff, Samuel/0000-0003-0164-8231; Burant, Charles/0000-0001-9189-5003; Hayashi, Yoshitaka/0000-0002-7557-4303	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK015070, R01DK015070] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK15070] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BERKNER KL, 1988, BIOTECHNIQUES, V6, P616; DAMM K, 1993, P NATL ACAD SCI USA, V90, P2989, DOI 10.1073/pnas.90.7.2989; DELUZE A, 1993, P NATL ACAD SCI USA, V90, P7322, DOI 10.1073/pnas.90.15.7322; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; Gluzman Y., 1982, EUKARYOTIC VIRAL VEC, P187; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRAUPNER G, 1989, NATURE, V340, P635; HALLENBECK PL, 1993, J BIOL CHEM, V268, P3825; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MCPHAUL MJ, 1993, J BIOL CHEM, V268, P26063; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; RAGOT T, 1993, NATURE, V361, P647, DOI 10.1038/361647a0; RENTOUMIS A, 1990, MOL ENDOCRINOL, V4, P1522, DOI 10.1210/mend-4-10-1522; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; SHIH W, 1991, MOL ENDOCRINOL, V5, P300; SMITH TAG, 1993, NAT GENET, V5, P397, DOI 10.1038/ng1293-397; YANG YP, 1993, P NATL ACAD SCI USA, V90, P4601, DOI 10.1073/pnas.90.10.4601; ZABNER J, 1993, CELL, V75, P207, DOI 10.1016/0092-8674(93)80063-K	24	34	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23872	23875						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929032				2022-12-25	WOS:A1994PQ34600006
J	ZWEIER, JL; BRODERICK, R; KUPPUSAMY, P; THOMPSONGORMAN, S; LUTTY, GA				ZWEIER, JL; BRODERICK, R; KUPPUSAMY, P; THOMPSONGORMAN, S; LUTTY, GA			DETERMINATION OF THE MECHANISM OF FREE-RADICAL GENERATION IN HUMAN AORTIC ENDOTHELIAL-CELLS EXPOSED TO ANOXIA AND REOXYGENATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT SUPEROXIDE-DISMUTASE; MYOCARDIAL ISCHEMIA-REPERFUSION; XANTHINE-OXIDASE; NITRIC-OXIDE; HYDROGEN-PEROXIDE; RELAXING FACTOR; INJURY; IRON; IDENTIFICATION; INVITRO	Endothelial cell-derived oxygen free radicals are important mediators of postischemic injury; however, the mechanisms that trigger this radical generation are not known, and it is not known if this process can occur in human cells and tissues. The enzyme xanthine oxidase can be an important source of radical generation; however, it has been reported that this enzyme may not be present in human endothelium. To determine the presence and mechanisms of radical generation in human vascular endothelial cells subjected to anoxia and reoxygenation, electron paramagnetic resonance measurements were performed on cultured human aortic endothelial cells using the spin trap 5,5-dimethyl-1-pyrroline N-oxide (DMPO). These measurements were correlated with cellular injury, xanthine oxidase activity, and alterations in cellular nucleotides. Upon reoxygenation after 60 min of anoxia, large DMPO-OH (a(N) = a(H) = 14.9 G) and smaller DMPO-R (a(N) = 15.8 G, a(H) = 22.8 G) signals were seen. Superoxide dismutase totally quenched this radical generation. The ferric iron chelator deferoxamine prevented cell death and totally quenched the DMPO-R signal with a 40% decrease in the DMPO-OH signal. Xanthine oxidase was shown to be present in these cells and to be the primary source of free radicals. While the concentration of this enzyme did not change after anoxia, the concentration of its substrate, hypoxanthine, markedly increased, resulting in increased free radical generation upon reoxygenation. Thus, reoxygenated human vascular endothelial cells generate superoxide free radicals, which further react with iron to form the reactive hydroxyl radical, which in turn causes cell death. Xanthine oxidase was the primary source of radical generation with this process triggered by the breakdown of ATP to the substrate hypoxanthine during anoxia.	JOHNS HOPKINS UNIV, SCH MED, WILMER OPHTHALMOL INST, BALTIMORE, MD 21224 USA; UNIV MARYLAND, SCH MED, DEPT PHARMACOL, BALTIMORE, MD 21201 USA	Johns Hopkins University; Johns Hopkins Medicine; University System of Maryland; University of Maryland Baltimore	ZWEIER, JL (corresponding author), JOHNS HOPKINS UNIV, SCH MED,JOHNS HOPKINS ASTHMA & ALLERGY CTR, DEPT MED,EPR LABS, RM LA-14, BALTIMORE, MD 21224 USA.				NHLBI NIH HHS [HL-17655, HL-38324, HL-07227] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038324, P50HL017655, R01HL038324] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMBROSIO G, 1987, CIRCULATION, V76, P906, DOI 10.1161/01.CIR.76.4.906; ARROYO CM, 1987, FEBS LETT, V221, P101, DOI 10.1016/0014-5793(87)80360-5; BALLA G, 1991, ARTERIOSCLER THROMB, V11, P1700, DOI 10.1161/01.ATV.11.6.1700; BALLA G, 1990, J LAB CLIN MED, V116, P546; BALLA G, 1991, LAB INVEST, V64, P648; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BLASIG IE, 1986, STUD BIOPHYS, V116, P35; CERUTTI PA, 1988, OXYRADICALS MOL BIOL, P1; EDDY LJ, 1987, AM J PHYSIOL, V253, pH709, DOI 10.1152/ajpheart.1987.253.3.H709; FINKELSTEIN E, 1982, MOL PHARMACOL, V21, P262; FREDERIKS WM, 1993, INT J EXP PATHOL, V74, P21; GRILL HP, 1992, J AM COLL CARDIOL, V20, P1604, DOI 10.1016/0735-1097(92)90457-X; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; HOSHI H, 1986, IN VITRO CELL DEV B, V22, P51; HULLRYDE EA, 1986, J CHROMATOGR, V377, P165, DOI 10.1016/S0378-4347(00)80771-9; IGNARRO LJ, 1987, CIRC RES, V61, P866, DOI 10.1161/01.RES.61.6.866; JARASCH ED, 1986, ACTA PHYSIOL SCAND, V126, P39; JOSEPHSON RA, 1991, J BIOL CHEM, V266, P2354; KUPPUSAMY P, 1989, J BIOL CHEM, V264, P9880; KUPPUSAMY P, 1993, APPL RADIAT ISOTOPES, V44, P367, DOI 10.1016/0969-8043(93)90249-A; LEFER DJ, 1993, CIRCULATION, V88, P1779, DOI 10.1161/01.CIR.88.4.1779; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; MORIWAKI Y, 1993, BIOCHIM BIOPHYS ACTA, V1164, P327, DOI 10.1016/0167-4838(93)90266-T; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; SHANDELYA SML, 1993, CIRCULATION, V87, P536, DOI 10.1161/01.CIR.87.2.536; TAYLOR AE, 1986, PHYSL OXYGEN RADICAL, P1; THOMPSONGORMAN SL, 1990, J BIOL CHEM, V265, P6656; VARANI J, 1992, LAB INVEST, V66, P708; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404; ZWEIER JL, 1988, J BIOL CHEM, V263, P1353; ZWEIER JL, 1987, J CLIN INVEST, V80, P1728, DOI 10.1172/JCI113264; ZWEIER JL, 1988, P NATL ACAD SCI USA, V85, P4046, DOI 10.1073/pnas.85.11.4046; ZWEIER JL, 1989, J BIOL CHEM, V264, P18890	34	194	199	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24156	24162						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929072				2022-12-25	WOS:A1994PQ34600050
J	RODRIGUEZ, JC; GILGOMEZ, G; HEGARDT, FG; HARON, D				RODRIGUEZ, JC; GILGOMEZ, G; HEGARDT, FG; HARON, D			PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR MEDIATES INDUCTION OF THE MITOCHONDRIAL 3-HYDROXY-3 METHYLGLUTARYL-COA SYNTHASE GENE BY FATTY-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; CARNITINE PALMITOYLTRANSFERASE-I; RAT HYDRATASE-DEHYDROGENASE; 3-HYDROXY-3-METHYLGLUTARYL-COA SYNTHASE; RESPONSIVE ELEMENT; CLOFIBRIC ACID; OXIDASE GENE; KETOGENESIS; PROTEIN; EXPRESSION	Fatty acids induce an increase in the transcription of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) synthase gene, which encodes an enzyme that has been proposed as a control site of ketogenesis. We studied whether the peroxisome proliferator-activated receptor (PPAR) is involved in the mechanism of this transcriptional induction. We found that cotransfection of a rat mitochondrial HMG-CoA synthase promoter-chloramphenicol acetyltransferase reporter plasmid and a PPAR expression plasmid in the presence of the peroxisome proliferator clofibrate led to a more than 30-fold increase in chloramphenicol acetyltransferase activity, relative to the activity in the absence of both PPAR and inducer. Linoleic acid, a polyunsaturated fatty acid, increased this activity as potently as does clofibrate and more effectively than does monounsaturated oleic acid. We have identified, by deletional analysis, an element located 104 base pairs upstream of the mitochondrial HMG-CoA synthase gene, which confers PPAR responsiveness to homologous and heterologous promoters. This is the first example of a peroxisome proliferator-responsive element (PPRE) in a gene encoding a mitochondrial protein. This element contains an imperfect direct repeat that is similar to those described in the PPREs of other genes. Furthermore, gel retardation and cotransfection assays revealed that, as for other genes, PPAR heterodimerizes with retinoid X receptor and that both receptors cooperate for binding to the mitochondrial HMG-CoA synthase PPRE and subsequent activation of the gene. In conclusion, our data demonstrate that regulation of mitochondrial HMG-CoA synthase gene expression by fatty acids is mediated by PPAR, supporting the hypothesis that PPAR has an important role at the transcriptional level in the regulation of lipid metabolism.	UNIV BARCELONA,SCH PHARM,FAC FARM,BIOCHEM UNIT,E-08028 BARCELONA,SPAIN	University of Barcelona			Haro, Diego/I-4623-2015; Gil-Gomez, G/H-6307-2014	Haro, Diego/0000-0001-9147-0486; Gil-Gomez, G/0000-0002-9790-7308				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; AYTE J, 1990, P NATL ACAD SCI USA, V87, P3874, DOI 10.1073/pnas.87.10.3874; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; CASALS N, 1992, BIOCHEM J, V283, P261, DOI 10.1042/bj2830261; DASHTI N, 1979, BIOCHEM MED METAB B, V22, P365, DOI 10.1016/0006-2944(79)90024-3; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; GILGOMEZ G, 1993, EUR J BIOCHEM, V213, P773, DOI 10.1111/j.1432-1033.1993.tb17819.x; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GRANTHAM BD, 1988, BIOCHEM J, V249, P409, DOI 10.1042/bj2490409; GRANTHAM BD, 1986, BIOCHEM J, V239, P485, DOI 10.1042/bj2390485; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GUZMAN M, 1993, BIOCHIM BIOPHYS ACTA, V1167, P227, DOI 10.1016/0005-2760(93)90224-W; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; ISSEMANN I, 1992, BIOCHEM SOC T, V20, P824, DOI 10.1042/bst0200824; ISSEMANN I, 1993, BIOCHIMIE, V75, P251, DOI 10.1016/0300-9084(93)90084-6; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LOWE DM, 1985, BIOCHEM J, V232, P37, DOI 10.1042/bj2320037; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARCUS SL, 1993, P NATL ACAD SCI USA, V90, P5723, DOI 10.1073/pnas.90.12.5723; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; MIYATA KS, 1993, J BIOL CHEM, V268, P19169; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; QUANT PA, 1990, EUR J BIOCHEM, V187, P169, DOI 10.1111/j.1432-1033.1990.tb15291.x; QUANT PA, 1991, EUR J BIOCHEM, V195, P449, DOI 10.1111/j.1432-1033.1991.tb15724.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOFIELD PS, 1987, BIOCHEM J, V241, P475, DOI 10.1042/bj2410475; SERRA D, 1993, ARCH BIOCHEM BIOPHYS, V307, P40, DOI 10.1006/abbi.1993.1557; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WILLIAMS.DH, 1968, BIOCHEM J, V108, P353, DOI 10.1042/bj1080353; ZHANG BW, 1993, J BIOL CHEM, V268, P12939; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541	37	342	345	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18767	18772						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	7913466				2022-12-25	WOS:A1994NX32700015
J	BOEHLEIN, SK; RICHARDS, NGJ; SCHUSTER, SM				BOEHLEIN, SK; RICHARDS, NGJ; SCHUSTER, SM			GLUTAMINE-DEPENDENT NITROGEN TRANSFER IN ESCHERICHIA-COLI ASPARAGINE SYNTHETASE-B - SEARCHING FOR THE CATALYTIC TRIAD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SITE-DIRECTED MUTAGENESIS; AMIDE TRANSFER-FUNCTION; PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE; NUCLEOTIDE-SEQUENCE; CARBAMYL-PHOSPHATE; MECHANISM; CYSTEINE; GENES; PURF	The mechanism of nitrogen transfer in glutamine dependent amidotransferases remains to be unambiguously established. We now report the overexpression, purification, and kinetic characterization of both the glutamine- and ammonia-dependent activities of Escherichia coli asparagine synthetase B (AS-B) and a series of mutants. In common with other members of the purF family of amidotransferases, the recombinant enzyme possesses an NH, terminal cysteine residue. Replacement of Cys-1 by either alanine or serine results in a loss of glutaminase and glutamine dependent activity, without any significant effect upon ammonia-dependent asparagine synthesis. As previously observed for human AS (Sheng, S., Moraga-Amador, D., Van Heeke, G., Allison, R. D., Richards, N. G. J., and Schuster, S. M. (1993) J. Biol. Chem. 268, 16771-16780), glutamine is an inhibitor of the ammonia-dependent reaction catalyzed by both the Cys-1 --> Ala (C1A) and Cys-1 --> Ser (C1S) mutants of AS-B. In the case of C1A, the inhibition pattern suggests that an abortive complex is formed. This is consistent with a recent proposal implicating the formation of an imide intermediate in the nitrogen transfer reaction (Richards, N. G. J., and Schuster, S. M. (1992) FEBS Lett. 313, 98-102). In contrast, glutamine appears to be only a competitive inhibitor of the ammonia-dependent activity of C1S. Cys-1 does not appear to be required for glutamine binding. Replacement of Asp-33 by either asparagine or glutamic acid has little effect on the kinetic properties of the mutant enzymes when compared to wild-type AS-B. Cys-1 and Asp-33 are cognate to residues Cys-1 and Asp-29 in glutamine phosphoribosylpyrophosphate amidotransferase which have been proposed to be members of a catalytic triad responsible for mediating nitrogen transfer in this enzyme (Mei, B., and Zalkin, H. (1989) J. Biol. Chem. 264, 16613-16619). In the case of AS-B, although Cys-1 is essential for glutamine-dependent activity, Asp-33 does not appear to participate in mediating nitrogen transfer. In an effort to locate other residues which might form part of a ''catalytic triad'' in the glutamine amidotransferase domain of AS-B, we have expressed and characterized mutant proteins in which His-29 and His-80, which are conserved within the glutamine amidotransferase domain of purF amidotransferases, are replaced by alanine (H29A and H80A). For both mutant enzymes, although the kinetic parameters for the ammonia-dependent activity of H29A and H80A are unchanged with respect to wild type AS-B, the apparent glutamine K-m is increased by a factor of 4.5 in glutamine-dependent asparagine synthesis.	UNIV FLORIDA, COLL MED, DEPT BIOCHEM & MOLEC BIOL, GAINESVILLE, FL 32610 USA; UNIV FLORIDA, INTERDISCIPLINARY CTR BIOTECHNOL RES, GAINESVILLE, FL 32610 USA; UNIV FLORIDA, DEPT CHEM, GAINESVILLE, FL 32611 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida					NCI NIH HHS [CA-28725] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028725] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMURO N, 1985, J BIOL CHEM, V260, P4844; ANDRULIS IL, 1987, MOL CELL BIOL, V7, P2435, DOI 10.1128/MCB.7.7.2435; BADET B, 1987, BIOCHEMISTRY-US, V26, P1940, DOI 10.1021/bi00381a023; BAKER EN, 1976, J MOL BIOL, V101, P185, DOI 10.1016/0022-2836(76)90371-5; BARTLETT PA, 1983, BIOCHEMISTRY-US, V22, P4618, DOI 10.1021/bi00289a002; BERAN RK, 1981, INT J BIOCHEM, V13, P165, DOI 10.1016/0020-711X(81)90152-X; BROOME JD, 1968, J EXP MED, V127, P1055, DOI 10.1084/jem.127.6.1055; BURCHALL JJ, 1964, J BIOL CHEM, V239, P1794; CEDAR H, 1969, J BIOL CHEM, V244, P4112; CEDAR H, 1969, J BIOL CHEM, V244, P4122; CHAPARIAN MG, 1991, J BIOL CHEM, V266, P3387; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRENTH J, 1971, ENZYMES, V3, P609; FELTON J, 1980, J BACTERIOL, V142, P221, DOI 10.1128/JB.142.1.221-228.1980; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HOROWITZ B, 1972, J BIOL CHEM, V247, P6708; HUANG YZ, 1975, ENZYME, V19, P314, DOI 10.1159/000459006; HUMBERT R, 1980, J BACTERIOL, V142, P212, DOI 10.1128/JB.142.1.212-220.1980; LEVITZKI A, 1971, BIOCHEMISTRY-US, V10, P3371, DOI 10.1021/bi00794a009; LUEHR CA, 1985, ARCH BIOCHEM BIOPHYS, V237, P335, DOI 10.1016/0003-9861(85)90285-1; LUSTY CJ, 1993, BIOCHEMISTRY-US, V32, P1278, DOI 10.1021/bi00056a012; MACPHEE KG, 1983, J BACTERIOL, V156, P475, DOI 10.1128/JB.156.1.475-478.1983; MANTSALA P, 1984, J BIOL CHEM, V259, P4230; MARKIN RS, 1981, BIOCHEMISTRY-US, V20, P7226, DOI 10.1021/bi00528a027; MEHLHAFF PM, 1985, BIOCHEMISTRY-US, V24, P1104, DOI 10.1021/bi00326a006; MEI B, 1989, J BIOL CHEM, V264, P16613; MILMAN HA, 1979, BIOCHEM J, V181, P51, DOI 10.1042/bj1810051; MILMAN HA, 1980, J BIOL CHEM, V255, P1862; OBRIEN WE, 1976, ANAL BIOCHEM, V76, P423, DOI 10.1016/0003-2697(76)90337-7; PFEIFFER NE, 1987, J BIOL CHEM, V262, P11565; RAMOS F, 1980, EUR J BIOCHEM, V108, P373, DOI 10.1111/j.1432-1033.1980.tb04732.x; RAVEL JM, 1962, J BIOL CHEM, V237, P2845; REITZER LJ, 1982, J BACTERIOL, V151, P1299, DOI 10.1128/JB.151.3.1299-1313.1982; RICHARDS NGJ, 1992, FEBS LETT, V313, P98, DOI 10.1016/0014-5793(92)81421-H; RUBINO SD, 1986, J BIOL CHEM, V261, P1320; SATAR G, 1990, BIOTECHNIQUES, V8, P404; SCOFIELD MA, 1990, J BIOL CHEM, V265, P12895; SHAW E, 1990, ADV ENZYMOL RAMB, V63, P271; SHENG S, 1993, J BIOL CHEM, V268, P16771; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SURIN BP, 1988, MOL MICROBIOL, V2, P173, DOI 10.1111/j.1365-2958.1988.tb00019.x; TEMPEST DW, 1970, BIOCHEM J, V117, P405, DOI 10.1042/bj1170405; TSO JY, 1982, J BIOL CHEM, V257, P3525; TSO JY, 1982, J BIOL CHEM, V257, P3532; VANHEEKE G, 1989, J BIOL CHEM, V264, P19475; WINTERBU.PJ, 1971, BIOCHEM J, V121, P701, DOI 10.1042/bj1210701; Zalkin H, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P203; ZALKIN H, 1977, J BIOL CHEM, V252, P5431	49	60	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7450	7457						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7907328				2022-12-25	WOS:A1994NA03200067
J	RICHARME, G; KOHIYAMA, M				RICHARME, G; KOHIYAMA, M			AMINO-ACID SPECIFICITY OF THE ESCHERICHIA-COLI CHAPERONE GROEL (HEAT-SHOCK PROTEIN-60)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-BINDING; SURFACE; DNAK; CATALYSTS	The chaperones GroEL/hsp60 are present in all prokaryotes and in mitochondria and chloroplasts of eukaryotic cells. They are involved in protein folding, protein targeting to membranes, protein renaturation, and control of protein-protein interactions. They interact with many polypeptides in an ATP-dependent manner and possess a peptide-dependent ATPase activity. The nature of the structural elements of substrate proteins recognized by GroEL/hsp60 is still unknown. In this study, we show that the GroEL chaperone of Escherichia coli interacts with single amino acids. The hydrophobic amino acids Ile, Phe, Val, Leu, and Trp present the strongest interaction with GroEL. While most of these hydrophobic amino acids are beta-sheet formers, GroEL interacts also with the alpha-helix formers Glu, Ale, Gln, and His. The multiple interactions of GroEL with the side chains of hydrophobic and polar amino acids, including the strongest alpha-helix and beta-sheet formers would allow this chaperone to act as an amphiphilic organizer of protein folding.			RICHARME, G (corresponding author), UNIV PARIS 07,INST JACQUES MONOD,2 PL JUSSIEU,F-75005 PARIS,FRANCE.							CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; DUGGLEBY RG, 1981, ANAL BIOCHEM, V110, P9, DOI 10.1016/0003-2697(81)90104-4; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HERINGA J, 1991, J MOL BIOL, V220, P151, DOI 10.1016/0022-2836(91)90388-M; KUSUKAWA N, 1988, GENE DEV, V2, P874, DOI 10.1101/gad.2.7.874; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; MORIMOTO R I, 1990, P1; PTITSYN OB, 1992, CONFORMATIONS FORCES, P155; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; SCHULZ GE, 1988, ANNU REV BIOPHYS BIO, V17, P1; VONHEIJNE G, 1981, EUR J BIOCHEM, V116, P419; WILLIAMS RW, 1987, BIOCHIM BIOPHYS ACTA, V916, P200, DOI 10.1016/0167-4838(87)90109-9	25	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7095	7098						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7907325				2022-12-25	WOS:A1994NA03200011
J	LEHNER, R; KUKSIS, A				LEHNER, R; KUKSIS, A			PURIFICATION OF AN ACYL-COA HYDROLASE FROM RAT INTESTINAL MICROSOMES - A CANDIDATE ACYL-ENZYME INTERMEDIATE IN GLYCEROLIPID ACYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOACYLGLYCEROL LIPASE; MEMBRANE-PROTEINS; LIVER MICROSOMES; LIPID PROFILES; COENZYME; ACID; SIMPLIFICATION; CHROMATOGRAPHY; BRAIN	We have purified to apparent homogeneity an acyl-CoA hydrolase activity from rat intestinal villus cell microsomes by heparin and anion exchange and affinity chromatography. The purified 54-kDa acyl-CoA hydrolase along with several microsomal proteins form a covalent acyl-protein bond upon incubation with an activated fatty acid (acyl-CoA). The acyl moiety of the acylated acyl-CoA hydrolase is stable to denaturation and extraction with organic solvents, but is displaced by neutral hydroxylamine or mercaptoethanol, indicating a labile high energy (thio)ester linkage. The enzyme activity is inhibited by thiol-directed reagents and activated by the presence of dithiothreitol suggesting the presence of a cysteine residue(s) at or near the active site. Common serine-esterase inhibitors (NaF, phenylmethylsulfonyl fluoride) and activators (Mg2+, Ca2+) had no effect on the hydrolase activity. The enzyme hydrolyzed (transferred to water) 14-20 carbon acyl-CoA with similar efficiencies and did not utilize glycerophospholipids or mono- and diacylglycerols as potential acyl donors/acceptors. Phospholipids and mono- and diradylglycerols at concentrations below 100 muM or polyclonal antibodies raised against the purified hydrolase did not inhibit the enzyme activity. However, the acyl-CoA hydrolase activity could be immunoprecipitated from solubilized microsomes or purified enzyme preparations with corresponding decrease of the hydrolase activity in the supernatant of the immunoprecipitate. Immunoblotting studies show cross-reactivity with a protein of an identical molecular mass in other rat or human tissues. It is concluded that the microsomal acyl-CoA hydrolase deserves consideration as a candidate acyl-enzyme intermediate in glycerolipid synthesis when associated with appropriate acyltransferases.	UNIV TORONTO,CH BEST INST,BANTING & BEST DEPT MED RES,112 COLL ST,TORONTO M5G 1L6,ONTARIO,CANADA	University of Toronto				Lehner, Richard/0000-0002-6008-1805				ANDERSON AD, 1971, J NEUROCHEM, V18, P1179, DOI 10.1111/j.1471-4159.1971.tb00216.x; BERGE RK, 1979, BIOCHIM BIOPHYS ACTA, V574, P321, DOI 10.1016/0005-2760(79)90013-4; BILLHEIMER JT, 1990, J BIOL CHEM, V265, P8632; DEJONG BJP, 1978, BIOCHIM BIOPHYS ACTA, V530, P56, DOI 10.1016/0005-2760(78)90126-1; FOLCH J, 1957, J BIOL CHEM, V226, P449; GREENSPAN MD, 1969, J BIOL CHEM, V244, P6477; GROSS RW, 1984, BIOCHIM BIOPHYS ACTA, V802, P197, DOI 10.1016/0304-4165(84)90161-2; GROSS RW, 1983, BIOCHEMISTRY-US, V22, P5641, DOI 10.1021/bi00293a028; HOFFMAN AGD, 1979, CAN J PHYSIOL PHARM, V57, P832, DOI 10.1139/y79-127; KNAUER TE, 1979, BIOCHEM J, V179, P515, DOI 10.1042/bj1790515; KUKSIS A, 1975, J CHROMATOGR SCI, V13, P423, DOI 10.1093/chromsci/13.9.423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHNER R, 1993, LIPIDS, V28, P29, DOI 10.1007/BF02536356; LEHNER R, 1992, BIOCHIM BIOPHYS ACTA, V1125, P171, DOI 10.1016/0005-2760(92)90042-T; LIN AY, 1985, NEUROCHEM RES, V9, P1571; MAGEE AI, 1982, BIOCHIM BIOPHYS ACTA, V694, P279, DOI 10.1016/0304-4157(82)90008-9; MANGANARO F, 1985, CAN J BIOCHEM CELL B, V63, P107, DOI 10.1139/o85-016; MENTLEIN R, 1984, ARCH BIOCHEM BIOPHYS, V228, P230, DOI 10.1016/0003-9861(84)90064-X; MENTLEIN R, 1988, BIOCHIM BIOPHYS ACTA, V964, P319, DOI 10.1016/0304-4165(88)90032-3; MYHER JJ, 1979, CAN J BIOCHEM CELL B, V57, P117, DOI 10.1139/o79-015; MYHER JJ, 1984, J BIOCHEM BIOPH METH, V10, P13, DOI 10.1016/0165-022X(84)90046-0; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PIND S, 1987, BIOCHIM BIOPHYS ACTA, V901, P78, DOI 10.1016/0005-2736(87)90258-6; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; RIENDEAU D, 1986, J BIOL CHEM, V261, P976; RUDNICK DA, 1990, J BIOL CHEM, V265, P13370; SANJANWALA M, 1987, ARCH BIOCHEM BIOPHYS, V258, P299, DOI 10.1016/0003-9861(87)90348-1; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SKINNER MK, 1983, BIOCHEM J, V209, P281, DOI 10.1042/bj2090281; WALL L, 1986, J BIOL CHEM, V261, P5981	30	25	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24726	24733						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	7901219				2022-12-25	WOS:A1993MG67300034
J	CAMP, LA; HOFMANN, SL				CAMP, LA; HOFMANN, SL			PURIFICATION AND PROPERTIES OF A PALMITOYL-PROTEIN THIOESTERASE THAT CLEAVES PALMITATE FROM H-RAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHETASE; GTP-BINDING PROTEINS; GUANINE-NUCLEOTIDE; COA HYDROLASE; BETA-GAMMA; MONOACYLGLYCEROL LIPASE; PLASMA-MEMBRANE; HUMAN-PLATELETS; MAMMARY-GLAND; SUBUNITS	H-Ras, the protein product of the cellular homologue of the Harvey ras oncogene, undergoes a complex series of post-translational modifications that include C-terminal isoprenylation, proteolysis, methylation, and palmitoylation. Palmitoylation has been shown to enhance the transformation efficiency of H-Pas about 10-fold in vivo. A recent study (Magee, A. I., Gutierrez, L., McKay, I. A., Marshall, C. J., and Hall, A. (1987) EMBO J. 6, 3353-3357) has provided strong evidence that the palmitate undergoes a dynamic acylation-deacylation cycle, but details concerning the enzymology of this process and its regulation are lacking. To begin to dissect this event, we have developed an assay for the enzymatic removal of palmitate from [H-3]palmitate-labeled H-Ras. This substrate was produced in a baculovirus expression system and was used to purify to homogeneity a novel 37-kDa enzyme from bovine brain cytosol that removes the radiolabeled palmitate. The purified enzyme is sensitive to diethyl pyrocarbonate and insensitive to phenylmethyl-sulfonyl fluoride and N-ethylmaleimide. Interestingly, the thioesterase recognizes H-Ras as a substrate only when H-Ras is in its native conformation (bound to Mg2+ and guanine nucleotide). The palmitoylated alpha subunits of the heterotrimeric G proteins are also substrates for the enzyme.	UNIV TEXAS, SW MED CTR, SIMMONS CANC CTR, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; UNIV TEXAS, DEPT INTERNAL MED, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas					NIGMS NIH HHS [GM08014] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALL JC, 1981, BIOCHEMISTRY-US, V20, P899, DOI 10.1021/bi00507a038; BERGE RK, 1979, EUR J BIOCHEM, V96, P393, DOI 10.1111/j.1432-1033.1979.tb13051.x; BERGER M, 1986, J BIOL CHEM, V261, P4912; BHULLAR RP, 1987, BIOCHEM J, V245, P617, DOI 10.1042/bj2450617; BIELINSKI DF, 1989, J BIOL CHEM, V264, P18363; BIZZOZERO OA, 1992, J BIOL CHEM, V267, P7886; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURDON RH, 1986, TECHNIQUES LIPIDOL 2, V3, P107; BURDON RH, 1986, TECHNIQUES LIPIDOL 2, V3, P290; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; DERENOBALES M, 1980, ARCH BIOCHEM BIOPHYS, V205, P464, DOI 10.1016/0003-9861(80)90129-0; Deschenes RJ, 1990, CURR OPIN CELL BIOL, V2, P1108, DOI 10.1016/0955-0674(90)90164-A; DOLE VP, 1956, J CLIN INVEST, V35, P150, DOI 10.1172/JCI103259; ERLANSON CH, 1970, SCAND J GASTROENTERO, V5, P333; Evans T, 1991, CURR OPIN CELL BIOL, V3, P185, DOI 10.1016/0955-0674(91)90137-N; FEUERSTEIN J, 1987, J BIOL CHEM, V262, P8455; GORBUNOFF MJ, 1990, METHOD ENZYMOL, V182, P329; GRABER SG, 1992, J BIOL CHEM, V267, P1271; GRAND RJA, 1989, FEBS LETT, V253, P281, DOI 10.1016/0014-5793(89)80976-7; GROEBE DR, 1990, NUCLEIC ACIDS RES, V18, P403; HALL A, 1986, J BIOL CHEM, V261, P963; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HOFMANN SL, 1982, ARCH BIOCHEM BIOPHYS, V215, P237, DOI 10.1016/0003-9861(82)90300-9; HOSHINO M, 1987, J BIOCHEM-TOKYO, V102, P503, DOI 10.1093/oxfordjournals.jbchem.a122082; HUANG EM, 1989, BIOCHIM BIOPHYS ACTA, V1011, P134, DOI 10.1016/0167-4889(89)90200-0; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JING S, 1987, EMBO J, V6, P327, DOI 10.1002/j.1460-2075.1987.tb04758.x; Kato K, 1992, Semin Cancer Biol, V3, P179; KITTS PA, 1990, NUCLEIC ACIDS RES, V18, P5667, DOI 10.1093/nar/18.19.5667; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1987, P NATL ACAD SCI USA, V84, P2261, DOI 10.1073/pnas.84.8.2261; LIBERTINI LJ, 1978, J BIOL CHEM, V253, P1393; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; MENTLEIN R, 1984, ARCH BIOCHEM BIOPHYS, V228, P230, DOI 10.1016/0003-9861(84)90064-X; MENTLEIN R, 1988, BIOCHIM BIOPHYS ACTA, V964, P319, DOI 10.1016/0304-4165(88)90032-3; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; NAGGERT J, 1988, J BIOL CHEM, V263, P1146; NORTHUP JK, 1980, P NATL ACAD SCI-BIOL, V77, P6516, DOI 10.1073/pnas.77.11.6516; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PAGE MJ, 1989, J BIOL CHEM, V264, P19147; PAZIRANDEH M, 1989, J BIOL CHEM, V264, P18195; Penefsky H S, 1979, Methods Enzymol, V56, P527; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; Shaltiel S, 1974, Methods Enzymol, V34, P126; STAUFENBIEL M, 1988, J BIOL CHEM, V263, P13615; STAUFENBIEL M, 1987, MOL CELL BIOL, V7, P2981, DOI 10.1128/MCB.7.8.2981; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; SUMMERS MD, 1987, B TEXAS AGR EXPT STA, V1555, P10; TAI MH, 1993, P NATL ACAD SCI USA, V90, P1852, DOI 10.1073/pnas.90.5.1852; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; WITKOWSKI A, 1991, J BIOL CHEM, V266, P18514; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	59	294	295	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22566	22574						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7901201				2022-12-25	WOS:A1993MD34800059
J	BHARADWAJ, D; HARRIS, RJ; KISIEL, W; SMITH, KJ				BHARADWAJ, D; HARRIS, RJ; KISIEL, W; SMITH, KJ			ENZYMATIC REMOVAL OF SIALIC-ACID FROM HUMAN FACTOR-IX AND FACTOR-X HAS NO EFFECT ON THEIR COAGULANT ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOTTING FACTOR-IX; STRUCTURAL-ANALYSIS; TISSUE FACTOR; ACTIVATION; IDENTIFICATION; PURIFICATION; SERINE-61; RESIDUES; CHAINS; FUCOSE	Factor IX and factor X have sialic acid in O-linked and N-linked oligosaccharides on their activation peptides, and a terminal sialic acid is found on a recently described O-linked tetrasaccharide at Ser-61 in the light chain of human factor Ma. In studies presented here, the potential role of sialic acid residues in mediating activity of human coagulation factors IX and X was tested after enzymatic removal of sialic acid residues. In contrast to previous reports, treatment of factor IX or factor Ma with recombinant sialidase did not decrease the rate of factor IX activation or proteolytic properties of human factor IXa. The activation rates of factor IX and desialated factor IX were indistinguishable when treated with factor XIa, with factor VIIa/tissue factor complex, and with the factor X activating enzyme from Russell's viper venom. Desialated human factor Ma showed full activity in the non-activated partial thromboplastin time assay and retained full ''tenase'' activity in a coupled amidolytic assay. Similar experiments with human factor X showed no detectable loss of clotting activity in the prothrombin time assay after desialation. Additionally, desialated human factor X was cleaved by the factor X activating enzyme from Russell's viper venom and intrinsic tenase at the same rate as untreated factor X when analyzed by SDS-polyacrylamide gel electrophoresis. These studies have shown that factor IX and factor X clotting activity are not dependent on sialic acid content. Further studies are needed to determine whether desialated factor IX binds to endothelial cells, and whether factors IX and X are more rapidly cleared from circulation or have altered susceptibility to proteolysis after enzymatic removal of sialic acid.	UNIV NEW MEXICO,SCH MED,DEPT PATHOL,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,SCH MED,DEPT BIOCHEM,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,SCH MED,DEPT MED,ALBUQUERQUE,NM 87131; GENENTECH INC,DEPT ANALYT CHEM,S SAN FRANCISCO,CA 94080	University of New Mexico; University of New Mexico; University of New Mexico; Roche Holding; Genentech				Bharadwaj, Dwaipayan/0000-0001-5268-8482				AGARWALA KL, 1994, BIOCHEMISTRY-US, V33, P5167, DOI 10.1021/bi00183a021; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BROZE GJ, 1985, J BIOL CHEM, V260, P917; CHAVIN SI, 1984, J BIOL CHEM, V259, P3387; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; DO SI, 1990, J BIOL CHEM, V265, P114; GIANNELLI F, 1993, NUCLEIC ACIDS RES, V21, P3075, DOI 10.1093/nar/21.13.3075; HAJJAR KA, 1994, J CLIN INVEST, V93, P703, DOI 10.1172/JCI117023; HAMAMOTO T, 1993, J BIOL CHEM, V268, P8704; HARRIS RJ, 1993, GLYCOBIOLOGY, V3, P219, DOI 10.1093/glycob/3.3.219; HARRIS RJ, 1993, BIOCHEMISTRY-US, V32, P6539, DOI 10.1021/bi00077a007; INOUE K, 1993, EUR J BIOCHEM, V218, P153, DOI 10.1111/j.1432-1033.1993.tb18361.x; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4901, DOI 10.1021/bi00667a023; KURACHI K, 1982, P NATL ACAD SCI-BIOL, V79, P6461, DOI 10.1073/pnas.79.21.6461; KURAYA N, 1993, J BIOCHEM-TOKYO, V114, P763, DOI 10.1093/oxfordjournals.jbchem.a124252; LIN SW, 1990, J BIOL CHEM, V265, P144; LINK RP, 1983, BIOCHEMISTRY-US, V22, P4033, DOI 10.1021/bi00286a007; LUNDBLAD RL, 1975, BIOCHEM BIOPH RES CO, V66, P482, DOI 10.1016/0006-291X(75)90536-7; MORELL AG, 1968, J BIOL CHEM, V243, P155; NISHIMURA H, 1992, J BIOL CHEM, V267, P17520; SINHA U, 1993, J BIOL CHEM, V268, P3048; SMITH KJ, 1988, BLOOD, V72, P1269; THOMPSON AR, 1986, BLOOD, V67, P565	23	16	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6537	6542		10.1074/jbc.270.12.6537	http://dx.doi.org/10.1074/jbc.270.12.6537			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896789	hybrid			2022-12-25	WOS:A1995QQ85500019
J	WILCKE, M; HULTENBY, K; ALEXSON, SEH				WILCKE, M; HULTENBY, K; ALEXSON, SEH			NOVEL PEROXISOMAL POPULATIONS IN SUBCELLULAR-FRACTIONS FROM RAT-LIVER - IMPLICATIONS FOR PEROXISOME STRUCTURE AND BIOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROBODY TARGETING SIGNAL; ACYL-COA OXIDASE; ZELLWEGER SYNDROME; 3-DIMENSIONAL RECONSTRUCTION; ENDOPLASMIC-RETICULUM; HEPATIC PEROXISOMES; MEMBRANE-PROTEINS; MAMMALIAN-CELLS; CYTO-CHEMISTRY; FREE POLYSOMES	According to current concepts, new peroxisomes are formed by division of pre-existing peroxisomes or by budding from a peroxisomal reticulum. Recent cytochemical and biochemical data indicate that protein content in peroxisomes are heterogenous and that import of newly synthesized proteins may be restricted to certain protein import-competent peroxisomal subcompartments (Yamamoto, K., and Fahimi, H. D. (1987) J. Cell Biol. 105, 713-722; Heinemann, P., and Just, W. W. (1992) FEBS Lett. 300, 179-182; Luers, G., Hashimoto, T., Fahimi, H. D., and Volkl, A. (1993) J. Cell Biol. 121, 1271-1280). We have observed that substantial amounts of peroxisomal proteins are found together with ''microsomes'' (100,000 x g pellet) after subcellular fractionation of rat liver homogenates. In this study we have investigated the origin of these peroxisomal proteins by modified gradient centrifugation procedures in Nycodenz and by analysis of enzyme activity distributions, Western blotting, and immunoelectron microscopy. It is concluded that much of this material is confined to novel populations of ''peroxisomes.'' Immunocytochemistry on gradient fractions showed that some vesicles were enriched in acyl-CoA oxidase and peroxisomal multifunctional enzyme (''catalase-negative'') whereas others were enriched in catalase and thiolase (''acyl-CoA oxidase-negative''). Double immunolabeling experiments verified the strong heterogeneity in the protein contents of these vesicles and also identified peroxisomes varying in size from about 0.5 mu m (''normal peroxisomes'') to extremely small vesicles of less than 100 nm in diameter. The possibility that these vesicles may be related to different subcompartments of a larger peroxisomal structure involved in protein import and biogenesis will be discussed.	HUDDINGE UNIV HOSP,KAROLINSKA INST,DEPT CLIN CHEM,S-14186 HUDDINGE,SWEDEN; UNIV STOCKHOLM,ARRHENIUS LAB F3,WENNER GREN INST,DEPT METAB RES,STOCKHOLM,SWEDEN; HUDDINGE HOSP,CLIN RES CTR,S-14186 HUDDINGE,SWEDEN	Karolinska Institutet; Stockholm University								AIKAWA J, 1991, P NATL ACAD SCI USA, V88, P10084, DOI 10.1073/pnas.88.22.10084; AITCHISON JD, 1991, J BIOL CHEM, V266, P23197; ALEXSON SEH, 1985, J CELL BIOL, V101, P294, DOI 10.1083/jcb.101.1.294; BALFE A, 1990, PEDIATR RES, V27, P304, DOI 10.1203/00006450-199003000-00023; BAUDHUIN P, 1964, BIOCHEM J, V92, P179, DOI 10.1042/bj0920179; BAUMGART E, 1989, J CELL BIOL, V108, P2221, DOI 10.1083/jcb.108.6.2221; BAUMGART E, 1987, LAB INVEST, V56, P554; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; Bergmeyer HU, 1974, METHODS ENZYMATIC AN; BLATTNER J, 1992, J CELL BIOL, V119, P1129, DOI 10.1083/jcb.119.5.1129; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DONALDSO.RP, 1972, ARCH BIOCHEM BIOPHYS, V152, P199, DOI 10.1016/0003-9861(72)90208-1; ESSNER E, 1967, LAB INVEST, V17, P71; FAHIMI HD, 1993, BIOCHIMIE, V75, P201, DOI 10.1016/0300-9084(93)90078-7; FLATMARK T, 1981, EUR J CELL BIOL, V24, P62; FUJIKI Y, 1984, P NATL ACAD SCI-BIOL, V81, P7127, DOI 10.1073/pnas.81.22.7127; GOGLIA F, 1989, EXP BIOL, V48, P127; GOLDFISCHER S, 1973, SCIENCE, V182, P62, DOI 10.1126/science.182.4107.62; GOLDMAN BM, 1978, P NATL ACAD SCI USA, V75, P5066, DOI 10.1073/pnas.75.10.5066; GORGAS K, 1984, ANAT EMBRYOL, V169, P261, DOI 10.1007/BF00315631; GORGAS K, 1985, ANAT EMBRYOL, V172, P21, DOI 10.1007/BF00318940; GORGAS K, 1982, ANN NY ACAD SCI, V386, P519, DOI 10.1111/j.1749-6632.1982.tb21468.x; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; GULATI S, 1992, ARCH BIOCHEM BIOPHYS, V295, P90, DOI 10.1016/0003-9861(92)90492-F; HASHIMOTO T, 1982, ANN NY ACAD SCI, V386, P5, DOI 10.1111/j.1749-6632.1982.tb21403.x; HEINEMANN P, 1992, FEBS LETT, V300, P179, DOI 10.1016/0014-5793(92)80191-I; JUST WW, 1982, EUR J CELL BIOL, V26, P249; KELLER GA, 1987, P NATL ACAD SCI USA, V84, P3264, DOI 10.1073/pnas.84.10.3264; KELLER GA, 1991, J CELL BIOL, V114, P893, DOI 10.1083/jcb.114.5.893; KLUCIS E, 1991, BIOCHIM BIOPHYS ACTA, V1074, P294, DOI 10.1016/0304-4165(91)90167-F; Lazarow P. B., 1980, 31ST MOSB C BIOL CHE, P187, DOI [DOI 10.1007/978-3-642-81557-7_14, 10.1007/978-3-642-81557-7_14]; Lazarow P. B., 1989, METABOLIC BASIS INHE, P1479; LAZAROW PB, 1973, J CELL BIOL, V59, P507, DOI 10.1083/jcb.59.2.507; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; LUERS G, 1990, EUR J CELL BIOL, V52, P175; LUERS G, 1993, J CELL BIOL, V121, P1271, DOI 10.1083/jcb.121.6.1271; MEIJER J, 1993, EUR J CELL BIOL, V60, P291; MIURA S, 1994, J BIOCHEM-TOKYO, V115, P1064, DOI 10.1093/oxfordjournals.jbchem.a124458; MIURA S, 1994, EUR J BIOCHEM, V223, P141, DOI 10.1111/j.1432-1033.1994.tb18975.x; MIURA S, 1992, J BIOL CHEM, V267, P14405; Novikoff A.B., 1964, J MICROSC-PARIS, V3, P187; NOVIKOFF PM, 1973, J HISTOCHEM CYTOCHEM, V21, P540, DOI 10.1177/21.6.540; OHNO S, 1990, HISTOCHEM J, V22, P143, DOI 10.1007/BF01003534; OSUMI T, 1978, BIOCHEM BIOPH RES CO, V83, P479, DOI 10.1016/0006-291X(78)91015-X; PALOSAARI PM, 1990, J BIOL CHEM, V265, P10750; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; POOLE B, 1969, J CELL BIOL, V41, P536, DOI 10.1083/jcb.41.2.536; RACHUBINSKI RA, 1984, J CELL BIOL, V99, P2241, DOI 10.1083/jcb.99.6.2241; SANTOS MJ, 1988, J BIOL CHEM, V263, P10502; SANTOS MJ, 1988, SCIENCE, V239, P1536, DOI 10.1126/science.3281254; SHIO H, 1981, J HISTOCHEM CYTOCHEM, V29, P1263, DOI 10.1177/29.11.6274950; STAUBLI W, 1977, J CELL BIOL, V74, P665, DOI 10.1083/jcb.74.3.665; SUZUKI Y, 1992, CELL STRUCT FUNCT, V17, P1, DOI 10.1247/csf.17.1; SWINKELS BW, 1992, FEBS LETT, V305, P133, DOI 10.1016/0014-5793(92)80880-P; THOMPSON SL, 1990, J BIOL CHEM, V265, P5731; TOKUYASU KT, 1973, J CELL BIOL, V57, P551, DOI 10.1083/jcb.57.2.551; TSUKAMOTO T, 1994, J BIOL CHEM, V269, P6001; VEENHUIS M, 1989, ARCH MICROBIOL, V151, P105, DOI 10.1007/BF00414422; WALTON PA, 1992, MOL CELL BIOL, V12, P531, DOI 10.1128/MCB.12.2.531; WATERHAM HR, 1993, EMBO J, V12, P4785, DOI 10.1002/j.1460-2075.1993.tb06167.x; WATERHAM HR, 1992, J BACTERIOL, V174, P4057, DOI 10.1128/jb.174.12.4057-4063.1992; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0; YAMAMOTO K, 1987, J CELL BIOL, V105, P713, DOI 10.1083/jcb.105.2.713; YAMAMOTO K, 1987, EUR J CELL BIOL, V43, P293; ZHANG JW, 1993, MOL BIOL CELL, V4, P1351, DOI 10.1091/mbc.4.12.1351	68	57	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6949	6958		10.1074/jbc.270.12.6949	http://dx.doi.org/10.1074/jbc.270.12.6949			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896845	hybrid			2022-12-25	WOS:A1995QQ85500076
J	BEERLI, RR; WELS, W; HYNES, NE				BEERLI, RR; WELS, W; HYNES, NE			INTRACELLULAR EXPRESSION OF SINGLE-CHAIN ANTIBODIES REVERTS ERBB-2 TRANSFORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; GROWTH-FACTOR RECEPTOR; HER-2 NEU ONCOGENE; TUMOR-CELL GROWTH; HUMAN-BREAST; MONOCLONAL-ANTIBODIES; EXTRACELLULAR DOMAIN; PROTEIN EXPRESSION; GENE; CANCER	We report a novel approach for specific in vivo inactivation of the ErbB-2 receptor tyrosine kinase and suppression of ErbB-2-induced transformation. Genes encoding single chain antibodies that specifically bind to the extracellular domain of human ErbB-2 were constructed and expressed intracellularly in NIH/3T3 fibroblasts transformed by activated ErbB-2. The single chain antibodies are derived from monoclonal antibodies FRP5 and FWP51 (Harwerth, I. M., Wels, W., Marte, B. M., and Hynes, N. E. (1992) J. Biol. Chem. 267, 15160-15167) and are composed of heavy and light chain variable domains connected by a flexible peptide linker. The antibodies were provided with: 1) an N-terminal hydrophobic leader sequence to target their synthesis to the lumen of the endoplasmic reticulum, and 2) a C-terminal retention signal to prevent secretion. When expressed in ErbB-2-transformed cells, the single chain antibodies bound to the receptor and prevented its transit through the endoplasmic reticulum. This resulted in the functional inactivation of the receptor and reversion of the transformed phenotype. This is the first demonstration of a targeted and stable inactivation of a cellular onco-protein via intracellular antibody expression. The use of such a strategy represents a simple and powerful approach to study the in vivo function of receptors and other cellular proteins.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research				Wels, Winfried/0000-0001-9858-3643				AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERGER MS, 1988, CANCER RES, V48, P1238; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; CARLSON JR, 1988, MOL CELL BIOL, V8, P2638, DOI 10.1128/MCB.8.6.2638; CEPKO C, 1992, CURR PROTOCOLS MOL B, V1; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; HARWERTH IM, 1992, J BIOL CHEM, V267, P15160; HARWERTH IM, 1993, BRIT J CANCER, V68, P1140, DOI 10.1038/bjc.1993.494; HUANG SS, 1990, J BIOL CHEM, V265, P3340; HUANG SS, 1988, J BIOL CHEM, V263, P12608; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; HYNES NE, 1989, J CELL BIOCHEM, V39, P167, DOI 10.1002/jcb.240390208; KABAT EA, 1991, US DHHS NIH913242 PU, P23; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; MARASCO WA, 1993, P NATL ACAD SCI USA, V90, P7889, DOI 10.1073/pnas.90.16.7889; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; ORLANDI R, 1989, P NATL ACAD SCI USA, V86, P3833, DOI 10.1073/pnas.86.10.3833; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; RICHNER J, 1990, ANN ONCOL, V1, P263, DOI 10.1093/oxfordjournals.annonc.a057745; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SHAWVER LK, 1994, CANCER RES, V54, P1367; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120; TANG Y, 1991, P NATL ACAD SCI USA, V88, P8784, DOI 10.1073/pnas.88.19.8784; TAVLADORAKI P, 1993, NATURE, V366, P469, DOI 10.1038/366469a0; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; WELS W, 1992, BIO-TECHNOL, V10, P1128, DOI 10.1038/nbt1092-1128; WELS W, 1992, CANCER RES, V52, P6310; WELS W, 1992, J STEROID BIOCHEM, V43, P1, DOI 10.1016/0960-0760(92)90180-Q; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	43	144	154	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23931	23936						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929040				2022-12-25	WOS:A1994PQ34600015
J	HENRICKSEN, LA; WOLD, MS				HENRICKSEN, LA; WOLD, MS			REPLICATION PROTEIN-A MUTANTS LACKING PHOSPHORYLATION SITES FOR P34(CDC2) KINASE SUPPORT DNA-REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; CELL-CYCLE; BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; A PHOSPHORYLATION; POLYMERASE-ALPHA; MULTIPLE STAGES; RP-A; INVITRO; CDC2	Replication Protein A (RPA) is a multisubunit, single-stranded DNA-binding protein essential for DNA metabolism in eukaryotic cells. The 32-kDa subunit of RPA is phosphorylated in a cell cycle-dependent manner becoming phosphorylated during S phase. It has been postulated that this phosphorylation may regulate the activities of RPA and that the family of p34(cdc2) kinases directly catalyzes the phosphorylation of RPA in the cell, We have mutated the two consensus p34(cdc2) sites in the 32-kDa subunit of RPA individually and in combination and purified the mutant protein complexes. Mutant RPA with both consensus p34(cdc2) sites converted to alanine was not phosphorylated by purified p34(cdc2) kinase. Nevertheless, we found that the properties of these RPA mutants were identical to those of the wild-type protein. The mutated RPA proteins had normal single-stranded DNA binding activity and were completely functional for DNA replication. In addition, the mutants became hyperphosphorylated when incubated under DNA replication conditions. These results demonstrate that phosphorylation by p34(cdc2) kinase is not essential for RPA function in DNA replication in vitro. Possible roles of RPA phosphorylation on DNA metabolism are discussed.	UNIV IOWA, COLL MED, DEPT BIOCHEM, IOWA CITY, IA 52242 USA	University of Iowa			Wold, Marc/F-5806-2010	Wold, Marc/0000-0002-4580-1624	NIGMS NIH HHS [GM44721] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044721] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; BROWN GW, 1994, MOL BIOCHEM PARASIT, V63, P135, DOI 10.1016/0166-6851(94)90016-7; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FANG F, 1993, J CELL SCI, V106, P983; FOTEDAR R, 1992, EMBO J, V11, P2177, DOI 10.1002/j.1460-2075.1992.tb05277.x; GEORGAKI A, 1993, NUCLEIC ACIDS RES, V21, P3659, DOI 10.1093/nar/21.16.3659; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SH, 1991, J BIOL CHEM, V266, P22707; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; MELENDY T, 1993, J BIOL CHEM, V268, P3389; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PAN ZQ, 1993, J BIOL CHEM, V268, P20443; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SEO YS, 1991, J BIOL CHEM, V266, P13161; THOMMES P, 1992, J BIOL CHEM, V267, P6063; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P3839, DOI 10.1128/MCB.9.9.3839; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1989, J BIOL CHEM, V264, P2801; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523	33	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24203	24208						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929076				2022-12-25	WOS:A1994PQ34600057
J	MACLACHLAN, I; NIMPF, J; SCHNEIDER, WJ				MACLACHLAN, I; NIMPF, J; SCHNEIDER, WJ			AVIAN RIBOFLAVIN BINDING-PROTEIN BINDS TO LIPOPROTEIN RECEPTORS IN ASSOCIATION WITH VITELLOGENIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; EGG-WHITE RIBOFLAVIN; CHICKEN OOCYTE RECEPTOR; YOLK-RIBOFLAVIN; CALCIUM-PHOSPHATE; SEQUENCE; CHAINS; SITE	Riboflavin binding protein (ribBP) is an essential component of chicken eggs; it supplies the oocyte (i.e. yolk) and egg white with sufficient amounts of the vitamin riboflavin to sustain embryonic development until hatching. There are three forms of ribBP in the laying hen; synthesized by the liver under the control of estrogen, it enters the serum (sribBP) and is delivered to yolk where it becomes carboxyl-terminally truncated (yribBP). The egg white form (wribBP), synthesized by the oviduct, is a product of the same gene as sribBP but has a different glycosylation pattern. Our efforts to delineate the mechanism for uptake of yolk precursors into rapidly growing chicken oocytes have previously identified a multifunctional oocyte-specific 95-kDa lipoprotein receptor that belongs to the low density lipoprotein receptor gem family (Barber, D. L., Sanders, E. J., Aebersold, R., and Schneider, W. J. (1991) J. Biol. Chem. 266, 18761-18770). We now report that in serum, ribBP associates with another yolk precursor, the lipid-, phosphate, and ion-carrier vitellogenin (VTG), a known ligand of the 95-kDa receptor. In the presence of VTG, I-125-labeled sribBP binds to the 95-kDa receptor and, under certain conditions, also to the avian oocyte low density lipoprotein receptor-related protein (Stifani, S., Barber, D. L., Aebersold, R., Steyrer, E., Shen, X., Nimpf, J., and Schneider, W. J. (1991) J. Biol. Chem. 266, 19079-19087). The interaction between ribBP and the 95-kDa receptor and/or VTG requires Ca2+ and PO43-. Interestingly, sribBP, yribBP, and wribBP are all capable of VTG-associated receptor binding. This demonstrates that (i) the carboxyl-terminal 11 or 13 amino acids, which are removed from sribBP upon oocytic uptake, are not involved in receptor binding and (ii) receptor binding and/or association of ribBP with VTG is not dependent on the carbohydrate structure present on sribBP. The results indicate that the oocytic uptake of sribBP is mediated, through association with VTG, by the 95-kDa receptor and possibly other oocytic members of the low density lipoprotein receptor gene family, adding an interesting and novel variation to ligand recognition by these receptors.	UNIV & BIOCTR VIENNA,DEPT MOLEC GENET,A-1030 VIENNA,AUSTRIA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2H7,AB,CANADA	University of Vienna; University of Alberta				Nimpf, Johannes/0000-0002-9273-3492				ABRAMS VAM, 1988, COMP BIOCHEM PHYS B, V90, P243, DOI 10.1016/0305-0491(88)90068-5; ABRAMS VAM, 1989, COMP BIOCHEM PHYS B, V93, P291, DOI 10.1016/0305-0491(89)90084-9; AOKI T, 1993, ARCH BIOCHEM BIOPHYS, V305, P242, DOI 10.1006/abbi.1993.1417; AOKI T, 1987, BIOCHIM BIOPHYS ACTA, V911, P238, DOI 10.1016/0167-4838(87)90013-6; BAILEY GS, 1990, RADIOISOTOPES BIOL P, P191; BARBER DL, 1991, J BIOL CHEM, V266, P18761; BEISIEGEL U, 1981, J BIOL CHEM, V256, P4071; BENOREPARSONS M, 1988, NUTR RES, V8, P789, DOI 10.1016/S0271-5317(88)80159-3; BENOREPARSONS M, 1986, TRANSPORT RIBOFLAVIN; FREUND J, 1956, Bibl Tuberc, P130; GEORGE R, 1987, J BIOL CHEM, V262, P16838; HAMAZUME Y, 1984, J BIOCHEM-TOKYO, V95, P1633, DOI 10.1093/oxfordjournals.jbchem.a134776; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIKHOSHERSTOV LM, 1991, BIOORG KHIM+, V17, P246; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLACHLAN I, 1993, J BIOL CHEM, V268, P23222; MALHOTRA P, 1991, BIOCHEM INT, V23, P127; MILLER MS, 1982, J BIOL CHEM, V257, P6818; MILLER MS, 1986, METHOD ENZYMOL, V122, P227; MILLER MS, 1982, BIOCHIM BIOPHYS ACTA, V715, P126, DOI 10.1016/0304-4165(82)90058-7; MURTHY US, 1976, BIOCHIM BIOPHYS ACTA, V434, P69, DOI 10.1016/0005-2795(76)90036-2; NIMPF J, 1994, J BIOL CHEM, V269, P212; NORIOKA N, 1985, J BIOCHEM-TOKYO, V97, P19, DOI 10.1093/oxfordjournals.jbchem.a135044; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; RETZEK H, 1992, DNA CELL BIOL, V11, P661, DOI 10.1089/dna.1992.11.661; Schneider Wolfgang J., 1993, Current Opinion in Lipidology, V4, P205, DOI 10.1097/00041433-199306000-00005; STEYRER E, 1990, J BIOL CHEM, V265, P19575; STIFANI S, 1990, J BIOL CHEM, V265, P882; STIFANI S, 1990, BIOCHIM BIOPHYS ACTA, V1045, P271, DOI 10.1016/0005-2760(90)90130-P; STIFANI S, 1988, BIOCHEM J, V250, P467, DOI 10.1042/bj2500467; STIFANI S, 1991, J BIOL CHEM, V266, P19079; STIFANI S, 1990, P NATL ACAD SCI USA, V87, P1955, DOI 10.1073/pnas.87.5.1955; TARUTANI M, 1993, J BIOCHEM-TOKYO, V113, P677, DOI 10.1093/oxfordjournals.jbchem.a124102; WALKER M, 1991, COMP BIOCHEM PHYS B, V100, P77, DOI 10.1016/0305-0491(91)90088-U; WHITE HB, 1986, BIOCHEM J, V238, P671, DOI 10.1042/bj2380671; WHITE HB, 1988, ANNU REV NUTR, V8, P279, DOI 10.1146/annurev.nu.08.070188.001431; WINTER WP, 1967, COMP BIOCHEM PHYSIOL, V22, P897, DOI 10.1016/0010-406X(67)90780-3; WINTER WP, 1967, COMP BIOCHEM PHYSIOL, V22, P889, DOI 10.1016/0010-406X(67)90779-7; ZHENG DB, 1988, J BIOL CHEM, V263, P11126	39	62	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24127	24132						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929067				2022-12-25	WOS:A1994PQ34600045
J	NELSON, H; MANDIYAN, S; NELSON, N				NELSON, H; MANDIYAN, S; NELSON, N			THE SACCHAROMYCES-CEREVISIAE VMA7 GENE ENCODES A 14-KDA SUBUNIT OF THE VACUOLAR H+-ATPASE CATALYTIC SECTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE PROTON PUMP; TRANSLOCATING ATPASE; MUTATIONAL ANALYSIS; NEUROSPORA-CRASSA; BOVINE KIDNEY; V-ATPASES; MEMBRANE; EVOLUTION; PURIFICATION; TRIPHOSPHATASE	Yeast vacuoles contain an H+-ATPase that acidifies the vacuolar lumen and generates an electrochemical gradient of protons across their membranes. Five polypeptides, denoted as subunits A to E in the order of decreasing molecular masses from 69 to 27 kDa, were identified in the catalytic sector of the enzyme. However, other polypeptides may be necessary for the activity of the enzyme. When a 14-kDa polypeptide was suggested to be a subunit of a specialized V-ATPase in Manduca sexta, and a homologous short sequence was detected downstream of the UGA1 gene in yeast, we cloned this counterpart gene from yeast. The gene VMA7 encodes a protein Vma7p of about 14 kDa. The predicted protein is highly homologous to the above mentioned M. sexta protein. The Delta vma7::URA3 null mutant exhibits growth characteristics typical of other VMA disruptant mutants in genes encoding subunits of the catalytic sector. The Delta vma7::URA3 null mutants are not able to grow on a medium buffered at pH 7.5, they fail to accumulate quinacrine into their vacuoles and the other subunits of the catalytic sector are not assembled onto the vacuolar membrane in its absence. Epitope-tagged Vma7p was constructed and the proton uptake activity of isolated vacuoles from this yeast strain was markedly inhibited by a monoclonal antibody against the epitope-tag. A cold inactivation experiment demonstrated that Vma7p is a genuine subunit of the catalytic sector of V-ATPase and it is denoted as subunit F.	ROCHE INST MOLEC BIOL, ROCHE RES CTR, NUTLEY, NJ 07110 USA	Roche Holding								ADACHI I, 1990, J BIOL CHEM, V265, P967; ARAI H, 1988, J BIOL CHEM, V263, P8796; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BELTRAN C, 1992, J BIOL CHEM, V267, P774; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BOWMAN BJ, 1992, J BIOENERG BIOMEMBR, V24, P361, DOI 10.1007/BF00762529; FANGER BO, 1987, ANAL BIOCHEM, V162, P11, DOI 10.1016/0003-2697(87)90004-2; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FOURY F, 1990, J BIOL CHEM, V265, P18554; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GLUCK S, 1992, J EXP BIOL, V172, P29; GLUCK S, 1987, J BIOL CHEM, V262, P15780; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; GRAF R, 1994, J BIOL CHEM, V269, P3767; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HIRSCH S, 1988, P NATL ACAD SCI USA, V85, P3004, DOI 10.1073/pnas.85.9.3004; HO MN, 1993, J BIOL CHEM, V268, P221; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1992, J BIOL CHEM, V267, P447; KLIONSKY DJ, 1992, J BIOL CHEM, V267, P3416; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MORIYAMA Y, 1989, J BIOL CHEM, V264, P18445; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; MORIYAMA Y, 1989, BIOCHIM BIOPHYS ACTA, V980, P241, DOI 10.1016/0005-2736(89)90405-7; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON H, 1990, J BIOL CHEM, V265, P20390; NELSON N, 1989, J BIOENERG BIOMEMBR, V21, P553, DOI 10.1007/BF00808113; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; NELSON N, 1992, Current Opinion in Cell Biology, V4, P654, DOI 10.1016/0955-0674(92)90086-R; NELSON N, 1988, METHOD ENZYMOL, V157, P619; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; OHYA Y, 1991, J BIOL CHEM, V266, P13971; PEREZCASTINEIRA JR, 1990, BIOCHEM J, V271, P127, DOI 10.1042/bj2710127; Sambrook J, 1989, MOL CLONING LABORATO; Sherman F., 1983, METHODS YEAST GENETI; SHIN CK, 1988, MOL CELL BIOL, V8, P3094; STEVENS TH, 1992, J EXP BIOL, V172, P47; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; SZE H, 1992, J BIOENERG BIOMEMBR, V24, P371, DOI 10.1007/BF00762530; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; WARD JM, 1992, PLANT PHYSIOL, V99, P925, DOI 10.1104/pp.99.3.925	48	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24150	24155						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929071				2022-12-25	WOS:A1994PQ34600049
J	SPARKS, AB; QUILLIAM, LA; THORN, JM; DER, CJ; KAY, BK				SPARKS, AB; QUILLIAM, LA; THORN, JM; DER, CJ; KAY, BK			IDENTIFICATION AND CHARACTERIZATION OF SRC SH3 LIGANDS FROM PHAGE-DISPLAYED RANDOM PEPTIDE LIBRARIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							C-SRC; SIGNALING PROTEINS; DOMAINS; BINDING; SH3-DOMAIN; ACTIVATOR; TYROSINE; AFFINITY; OOCYTES; KINASE	We have used the Src homology 3 (SH3) domain to screen two phage displayed random peptide libraries, each containing 2 x 10(8) unique members, and have identified a series of high affinity peptide ligands. The peptides possess similar proline-rich regions, which yield a consensus Src SH3-binding motif of RPLPPLP. We have confirmed this motif by screening a phage-displayed peptide library biased for SH3 ligands and identifying the same consensus sequence. Binding studies using synthetic peptides suggest that the RPLPPLP motif is important for SH3 binding and confers specificity for the Src SH3 domain, and that residues which flank the motif may also contribute to binding. Peptides that contain the RPLPPLP motif compete Src, but not Abl or phospholipase C gamma, SH3 interactions with SH3-binding proteins from cell lysates (IC50 = 1-5 mu M). Furthermore, RPLPPLP-related peptides are able to accelerate progesterone-induced maturation of Xenopus laevis oocytes. A similar acceleration has been observed in oocytes treated with activated, but not normal, Xenopus Src, suggesting the possibility that the peptides are able to antagonize the negative regulation of Src activity by Src SH3 in vivo.	UNIV N CAROLINA, CURRICULUM GENET & MOLEC BIOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Quilliam, Lawrence/B-6447-2015; Quilliam, Lawrence/Q-4987-2019	Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA052072, R01CA042978, R01CA055008] Funding Source: NIH RePORTER; NCI NIH HHS [CA42978, CA52072, CA55008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; DEDMAN JR, 1993, J BIOL CHEM, V268, P23025; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KAY BK, 1991, METHOD CELL BIOL, V36, P663; KAY BK, 1993, GENE, V128, P59, DOI 10.1016/0378-1119(93)90153-T; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; OKADA M, 1993, J BIOL CHEM, V268, P18070; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Potts W M, 1988, Oncogene Res, V3, P343; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUDOL M, 1993, MOL BASIS HUMAN CANC, P203; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; UNGER TF, 1992, MOL CELL BIOL, V12, P5485, DOI 10.1128/MCB.12.12.5485; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	33	149	166	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23853	23856						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929027				2022-12-25	WOS:A1994PQ34600001
J	TANAKA, T; NISHIDA, J; MITANI, K; OGAWA, S; YAZAKI, Y; HIRAI, H				TANAKA, T; NISHIDA, J; MITANI, K; OGAWA, S; YAZAKI, Y; HIRAI, H			EVI-1 RAISES AP-1 ACTIVITY AND STIMULATES C-FOS PROMOTER TRANSACTIVATION WITH DEPENDENCE ON THE 2ND ZINC-FINGER DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; MYELOID-TRANSFORMING GENE; PROTO-ONCOGENE FOS; DNA-BINDING ACTIVITY; RETROVIRAL INSERTIONS; AUTO-REGULATION; GROWTH-FACTOR; EXPRESSION; DIFFERENTIATION; JUN	Evi-1 is a gene, encoding a zinc finger protein, associated with a common viral integration site in murine leukemias. It is suggested that Evi-1 plays important roles in embryogenesis and transformation of myeloid cells. To elucidate mechanisms by which Evi-1 induces such biological effects, we analyzed the relationship between Evi-1 and AP-1 which could regulate cellular proliferation and differentiation. When Evi-1 was expressed, transactivation through a 12-O-tetradecanoylphorbol 13-acetate-responsive element was observed in NIH3T3 and P19 cells. Evi-1-transfected P19 cells showed some differentiated phenotypes and increased expression of endogenous c-Jun and c-Fos. These results indicate that Evi-1 raises AP-1 activity. Evi-1 caused stimulation of the c-fos promoter transactivation, which seems to be a main mechanism of AP-1 activation, through at least two portions of the promoter. Evi-1 has the first zinc finger domain at the N terminus and the second zinc finger domain near the C-terminus. We constructed deletion mutants of Evi-1 and investigated the functions of these domains. It was shown that the second zinc finger domain is essential for the activation of AP-1 and transactivation of the c-fos promoter,	JICHI MED SCH,DEPT MOLEC BIOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN	Jichi Medical University; University of Tokyo			Tanaka, Tomoyuki U/A-4775-2008					ADAMKIEWICZ J, 1990, ONCOGENE, V5, P525; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; CACERES J, 1990, ONCOGENE, V5, P59; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; DARLAND T, 1991, ONCOGENE, V6, P1367; DEGROOT RP, 1990, NUCLEIC ACIDS RES, V18, P3195, DOI 10.1093/nar/18.11.3195; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; DESCHAMPS J, 1985, SCIENCE, V230, P1174, DOI 10.1126/science.3865371; DETOGNI P, 1988, MOL CELL BIOL, V8, P2251, DOI 10.1128/MCB.8.5.2251; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; DONY C, 1987, NATURE, V328, P711, DOI 10.1038/328711a0; EDWARDS SA, 1988, DEV BIOL, V129, P91, DOI 10.1016/0012-1606(88)90164-9; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; FICHELSON S, 1992, LEUKEMIA, V6, P93; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MATSUZAWA Y, 1991, ONCOGENE, V6, P1561; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORISHITA K, 1990, ONCOGENE, V5, P963; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; MUMMERY CL, 1987, DEV BIOL, V121, P10, DOI 10.1016/0012-1606(87)90133-3; OVAL J, 1992, LEUKEMIA, V6, P446; PERKINS AS, 1991, MOL CELL BIOL, V11, P2665, DOI 10.1128/MCB.11.5.2665; PERKINS AS, 1991, DEVELOPMENT, V111, P479; Robertson E. J., 1987, TERATOCARCINOMAS EMB; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SAGA S, 1987, J CELL BIOL, V105, P517, DOI 10.1083/jcb.105.1.517; SAKAI R, 1989, P NATL ACAD SCI USA, V86, P9946, DOI 10.1073/pnas.86.24.9946; Sambrook J, 1989, MOL CLONING LABORATO; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SATAKE M, 1988, ONCOGENE, V3, P69; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TROUCHE D, 1993, NATURE, V363, P79, DOI 10.1038/363079a0; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; VISVADER J, 1988, P NATL ACAD SCI USA, V85, P9474, DOI 10.1073/pnas.85.24.9474; YAMAGUCHIIWAI Y, 1990, P NATL ACAD SCI USA, V87, P8670, DOI 10.1073/pnas.87.21.8670	59	95	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24020	24026						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929053				2022-12-25	WOS:A1994PQ34600029
J	HARRISON, KA; DRUEY, KM; DEGUCHI, Y; TUSCANO, JM; KEHRL, JH				HARRISON, KA; DRUEY, KM; DEGUCHI, Y; TUSCANO, JM; KEHRL, JH			A NOVEL HUMAN HOMEOBOX GENE DISTANTLY RELATED TO PROBOSCIPEDIA IS EXPRESSED IN LYMPHOID AND PANCREATIC TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; DROSOPHILA HOMEOTIC GENES; CELL-SURFACE-ANTIGEN; HUMAN-BONE-MARROW; ANTENNAPEDIA HOMEODOMAIN; TRANSCRIPTION FACTOR; DNA-SEQUENCES; HUMAN PROTEIN; BINDING; DOMAIN	A novel human homeobox gene, HB9, was isolated from a cDNA library prepared from in vitro stimulated human tonsil B lymphocytes and from a human genomic library. The HB9 gene is composed of 3 exons spread over 6 kilobases of DNA. An open reading frame of 1206 nucleotides is in frame with a diverged homeodomain. The predicted HB9 protein has a molecular mass of 41 kilodaltons and is enriched for alanine, glycine, and leucine. The HB9 homeodomain is most similar to that of the Drosophila melanogaster homeobox gene proboscipedia. Northern blot analysis of poly(A) RNA purified from the human B cell line RPMI 8226 and from activated T cells revealed a major mRNA transcript of 2.2 kilobases. Similar analysis of poly(A) RNA from a variety of adult tissues demonstrated HB9 transcripts in pancreas, small intestine, and colon. Reverse transcriptase-polymerase chain reaction was used to examine HB9 RNA transcripts in hematopoietic cell lines. HB9 RNA transcripts were most prevalent in several human B cell lines and K562 cells. In addition, transcripts were detected in RNA prepared from tonsil B cells and in situ hybridization studies localized them in the germinal center region of adult tonsil. These findings suggest the involvement of HB9 in regulating gene transcription in lymphoid and pancreatic tissues.	NIAID, IMMUNOREGULAT LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Kehrl, John/AAE-6292-2019	Kehrl, John/0000-0002-6526-159X				ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; AKAM M, 1987, DEVELOPMENT, V101, P1; BAIER LJ, 1991, BLOOD, V78, P1047; BARAD M, 1988, EMBO J, V7, P2151, DOI 10.1002/j.1460-2075.1988.tb03054.x; BEACHY PA, 1988, CELL, V55, P1069, DOI 10.1016/0092-8674(88)90251-6; BILLETER M, 1990, J MOL BIOL, V214, P183, DOI 10.1016/0022-2836(90)90155-F; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BONCINELLI E, 1989, GENOME, V31, P745, DOI 10.1139/g89-133; BURGLIN TR, 1991, NATURE, V351, P703, DOI 10.1038/351703a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CIVIN CI, 1984, J IMMUNOL, V133, P157; CIVIN CI, 1987, EXP HEMATOL, V15, P10; CRIBBS DL, 1992, EMBO J, V11, P1437, DOI 10.1002/j.1460-2075.1992.tb05188.x; DEGUCHI Y, 1991, NUCLEIC ACIDS RES, V19, P3742, DOI 10.1093/nar/19.13.3742; DEGUCHI Y, 1991, NEW BIOL, V3, P353; DEGUCHI Y, 1993, LEUKEMIA, V7, P446; DEGUCHI Y, 1991, BLOOD, V78, P323; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DESPLAN C, 1985, NATURE, V318, P630, DOI 10.1038/318630a0; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; FOX CH, 1989, J INFECT DIS, V159, P467, DOI 10.1093/infdis/159.3.467; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GRAZIOSI C, 1993, CURR PROTOCOLS IMMUN, V5; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HERMANSON GG, 1989, P NATL ACAD SCI USA, V86, P7341, DOI 10.1073/pnas.86.19.7341; HOEY T, 1988, MOL CELL BIOL, V8, P4598, DOI 10.1128/MCB.8.11.4598; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JAYNES JB, 1991, EMBO J, V10, P1427, DOI 10.1002/j.1460-2075.1991.tb07663.x; KEHRL JH, 1994, CRIT REV ONCOL HEMAT, V16, P145, DOI 10.1016/1040-8428(94)90046-9; KIN Y, 1989, P NATL ACAD SCI USA, V86, P7716; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KO HS, 1988, CELL, V55, P135, DOI 10.1016/0092-8674(88)90016-5; LAUGHON A, 1984, NATURE, V310, P25, DOI 10.1038/310025a0; LAWRENCE HJ, 1992, BLOOD, V80, P2445; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; LEVINE M, 1984, CELL, V38, P667, DOI 10.1016/0092-8674(84)90261-7; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LIU YJ, 1992, IMMUNOL TODAY, V13, P17, DOI 10.1016/0167-5699(92)90199-H; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; Maniatis T., 1982, MOL CLONING LAB MANU, P191; MAVILIO F, 1986, NATURE, V324, P664, DOI 10.1038/324664a0; MCGINNIS W, 1984, CELL, V37, P403, DOI 10.1016/0092-8674(84)90370-2; MLODZIK M, 1988, EMBO J, V7, P2569, DOI 10.1002/j.1460-2075.1988.tb03106.x; MOORE KL, 1988, DEV HUMAN, P89; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; MURAGUCHI A, 1983, J EXP MED, V157, P530, DOI 10.1084/jem.157.2.530; NAJFELD V, 1992, GENE CHROMOSOME CANC, V5, P343, DOI 10.1002/gcc.2870050410; NASMYTH KA, 1980, COLD SPRING HARB SYM, V45, P961; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; OTTING G, 1988, EMBO J, V7, P4305, DOI 10.1002/j.1460-2075.1988.tb03329.x; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUGHART K, 1989, P NATL ACAD SCI USA, V86, P7067, DOI 10.1073/pnas.86.18.7067; SCOTT MP, 1993, NUCLEIC ACIDS RES, V21, P1687, DOI 10.1093/nar/21.8.1687; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SIMEONE A, 1987, P NATL ACAD SCI USA, V84, P4914, DOI 10.1073/pnas.84.14.4914; SMALL KM, 1993, GENE DEV, V7, P2318, DOI 10.1101/gad.7.12a.2318; TEDDER TF, 1988, P NATL ACAD SCI USA, V85, P208, DOI 10.1073/pnas.85.1.208; TOMLINSON A, 1988, CELL, V55, P771, DOI 10.1016/0092-8674(88)90133-X; WEDEEN CJ, 1990, NUCLEIC ACIDS RES, V18, P1908, DOI 10.1093/nar/18.7.1908; WRIGHT CVE, 1989, DEVELOPMENT, V105, P787	66	76	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19968	19975						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	7914194				2022-12-25	WOS:A1994PA12600049
J	HAGIWARA, H; SAKAGUCHI, H; ITAKURA, M; YOSHIMOTO, T; FURUYA, M; TANAKA, S; HIROSE, S				HAGIWARA, H; SAKAGUCHI, H; ITAKURA, M; YOSHIMOTO, T; FURUYA, M; TANAKA, S; HIROSE, S			AUTOCRINE REGULATION OF RAT CHONDROCYTE PROLIFERATION BY NATRIURETIC PEPTIDE-C AND ITS RECEPTOR, NATRIURETIC PEPTIDE RECEPTOR-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; GROWTH-FACTOR-BETA; GUANYLATE-CYCLASE; PORCINE BRAIN; ENDOTHELIAL-CELLS; ATRIAL; HORMONE; CNP; FAMILY; VASODILATORS	Natriuretic peptide receptor-B (NPR-B) was identified in rat chondrocytes, and its physiological functions were investigated. Rat tissues, including the xiphoid cartilage, brain, lung, liver, adrenal gland, and kidney, were screened for NPR-B activity, which we assayed by receptor guanylate cyclase activity specifically stimulated by C-type natriuretic peptide (CNP), a known selective activator of NPR-B. Cartilage showed distinctly higher NPR-B activity. Furthermore, exposure of cultured rat chondrocytes to CNP (10(-6) M) resulted in a large increase in intracellular cGMP production (376 +/- 38 pmol/well), with threshold responses occurring between 10(-10) and 10(-9) M CNP. Atrial natriuretic peptide and brain natriuretic peptide also stimulated cGMP production in rat chondrocytes but with a potency that was at least 10 times less than that of CNP. Polymerase chain reaction analysis also demonstrated NPR-B gene expression in adult rat xiphisternum and cultured chondrocytes. These findings indicate that NPR-B is present in rat chondrocytes. In rat chondrocytes exposed to CNP, [H-3]thymidine incorporation was inhibited in a dose-dependent manner (half-maximal response, 10(-11) M). However, much higher concentrations of atrial natriuretic peptide were required to induce the inhibition of thymidine incorporation. Interestingly, CNP-like immunoreactivity was detected in the conditioned medium from chondrocyte cultures. In addition, TGF-beta 1, a multifunctional cytokine, induced a marked increase in CNP se cretion and CNP mRNA levels in chondrocytes. These results indicate that autocrine CNP inhibits mitogenesis in chondrocytes via NPR-B under the control of TGF-beta 1.	SUNTORY INST BIOMED RES,SHIMAMOTO,OSAKA 618,JAPAN	Suntory Holdings Ltd	HAGIWARA, H (corresponding author), TOKYO INST TECHNOL,DEPT BIOL SCI,MIDORI KU,4259 NAGATSUTA CHO,YOKOHAMA 227,JAPAN.							APPEL RG, 1992, AM J PHYSIOL, V262, pF911, DOI 10.1152/ajprenal.1992.262.6.F911; APPEL RG, 1990, AM J PHYSIOL, V259, pE312, DOI 10.1152/ajpendo.1990.259.3.E312; CAHILL PA, 1993, J CELL PHYSIOL, V154, P28, DOI 10.1002/jcp.1041540105; CANAANKUHL S, 1992, ENDOCRINOLOGY, V130, P550, DOI 10.1210/en.130.1.550; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISMAN TD, 1993, J BIOL CHEM, V268, P3698; DEBOLD AJ, 1981, LIFE SCI, V28, P89, DOI 10.1016/0024-3205(81)90370-2; DUDA T, 1993, BIOCHEMISTRY-US, V32, P1391, DOI 10.1021/bi00057a001; EGUCHI S, 1992, EUR J PHARM-MOLEC PH, V225, P79, DOI 10.1016/0922-4106(92)90043-U; FULLER F, 1988, J BIOL CHEM, V263, P9395; FURUYA M, 1991, BIOCHEM BIOPH RES CO, V177, P927, DOI 10.1016/0006-291X(91)90627-J; FURUYA M, 1990, BIOCHEM BIOPH RES CO, V170, P201, DOI 10.1016/0006-291X(90)91260-Y; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GARG UC, 1989, AM J PHYSIOL, V257, pF60, DOI 10.1152/ajprenal.1989.257.1.F60; HIRAKI Y, 1988, BIOCHIM BIOPHYS ACTA, V969, P91, DOI 10.1016/0167-4889(88)90092-4; HOLDER AT, 1980, J ENDOCRINOL, V85, P35, DOI 10.1677/joe.0.0850035; HOSKINS WE, 1977, J DENT RES, V56, P509, DOI 10.1177/00220345770560051101; ISAKSSON OGP, 1982, SCIENCE, V216, P1237, DOI 10.1126/science.7079756; ISHIZAKA Y, 1992, BIOCHEM BIOPH RES CO, V189, P697, DOI 10.1016/0006-291X(92)92257-X; ITOH H, 1990, J CLIN INVEST, V86, P1690, DOI 10.1172/JCI114893; KARIYA K, 1989, ATHEROSCLEROSIS, V80, P143, DOI 10.1016/0021-9150(89)90022-1; KATAFUCHI T, 1992, J BIOL CHEM, V267, P7624; KOJIMA M, 1990, FEBS LETT, V276, P209, DOI 10.1016/0014-5793(90)80544-S; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; KOMATSU Y, 1991, ENDOCRINOLOGY, V129, P1104, DOI 10.1210/endo-129-2-1104; KONRAD EM, 1992, REGUL PEPTIDES, V39, P177, DOI 10.1016/0167-0115(92)90539-7; LEVIN ER, 1991, AM J PHYSIOL, V261, pR453, DOI 10.1152/ajpregu.1991.261.2.R453; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; MINAMINO N, 1990, BIOCHEM BIOPH RES CO, V170, P973, DOI 10.1016/0006-291X(90)92187-5; MIZUNO T, 1990, BIOCHEM BIOPH RES CO, V173, P886, DOI 10.1016/S0006-291X(05)80869-1; OHYAMA Y, 1992, BIOCHEM BIOPH RES CO, V183, P743, DOI 10.1016/0006-291X(92)90546-W; PINES M, 1988, ENDOCRINOLOGY, V123, P360, DOI 10.1210/endo-123-1-360; RATHINAVELU A, 1991, BIOCHEM J, V276, P493, DOI 10.1042/bj2760493; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLECHTER NL, 1986, AM J PHYSIOL, V250, pE231, DOI 10.1152/ajpendo.1986.250.3.E231; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0; SUGA S, 1992, J CLIN INVEST, V90, P1145, DOI 10.1172/JCI115933; SUGA SI, 1992, ENDOCRINOLOGY, V130, P229, DOI 10.1210/en.130.1.229; THORELL JI, 1971, BIOCHIM BIOPHYS ACTA, V251, P363, DOI 10.1016/0005-2795(71)90123-1; TSCHAN T, 1993, J BIOL CHEM, V268, P5156; VIGNE P, 1992, BIOCHEM BIOPH RES CO, V183, P640, DOI 10.1016/0006-291X(92)90530-X; WILCOX JN, 1991, MOL CELL BIOL, V11, P3454, DOI 10.1128/MCB.11.7.3454	47	105	121	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10729	10733						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7908295				2022-12-25	WOS:A1994NF01700080
J	LOO, TW; CLARKE, DM				LOO, TW; CLARKE, DM			RECONSTITUTION OF DRUG-STIMULATED ATPASE ACTIVITY FOLLOWING COEXPRESSION OF EACH HALF OF HUMAN P-GLYCOPROTEIN AS SEPARATE POLYPEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCHANGING HOMOLOGOUS DOMAINS; RESISTANT HUMAN-CELLS; MULTIDRUG-RESISTANCE; SARCOPLASMIC-RETICULUM; INSECT CELLS; MOUSE MDR1; FUNCTIONAL-ANALYSIS; BINDING SITES; KB CELLS; PROTEINS	P-glycoprotein consists of two homologous halves, each composed of six potential transmembrane sequences and an ATP-binding domain. The cDNA coding for human P-glycoprotein was divided in half and subcloned into separate plasmids in order to express each half as a separate polypeptide and to characterize its contribution to function. Expression of cDNAs coding for either the NH2- or COOH-terminal half-molecules in HEK 293 cells yielded products of 88 and 64 kDa, respectively. The NH2-terminal half-molecule was glycosylated, since its size decreased from 88 to 79 kDa when expressed in the presence of tunicamycin. No change was observed in the size of the COOH-terminal half-molecule when it was expressed in the presence of tunicamycin, indicating that it was not glycosylated. The cDNAs coding for each half of P-glycoprotein were transfected into NIH-3T3 cells to test for biological activity. No drug-resistant colonies were obtained when cells were transfected with cDNA coding for each half-molecule or when cells were co-transfected with both cDNAs, although stable expression of each half-molecule was detected. The inability to confer drug resistance was likely due to a defect in targeting of the half-molecules to the cell surface. Each half-molecule was then expressed in Sf9 insect cells using a baculovirus vector to allow measurement of partial function. The half-molecules exhibited ATPase activity, but their activities were not stimulated by drug substrates. Drug-stimulatable ATPase activity was present, however, when the half-molecules were expressed together. These results suggest that coupling of ATPase activity to drug binding requires interaction between both halves of P-glycoprotein.	UNIV TORONTO,DEPT MED,MED RES COUNCIL,MEMBRANE BIOL GRP,TORONTO M5S 1A8,ON,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A8,ON,CANADA	University of Toronto; University of Toronto			Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188				ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; BETZ R, 1987, J BIOL CHEM, V262, P546; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; BUSCHMAN E, 1991, MOL CELL BIOL, V11, P595, DOI 10.1128/MCB.11.2.595; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CORNWELL MM, 1987, FASEB J, V1, P51, DOI 10.1096/fasebj.1.1.2886389; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; DHIR R, 1992, BIOCHEMISTRY-US, V31, P6103, DOI 10.1021/bi00141a021; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P161, DOI 10.1016/0005-2736(92)90079-2; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; Gartner J, 1993, Semin Cell Biol, V4, P45, DOI 10.1006/scel.1993.1006; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; GREENBERGER LM, 1991, J BIOL CHEM, V266, P20744; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HIGGINS CF, 1993, SEMIN CELL BIOL, V4, P1; KANE SE, 1990, J BIOENERG BIOMEMBR, V22, P593, DOI 10.1007/BF00762963; Koronakis V, 1993, Semin Cell Biol, V4, P7, DOI 10.1006/scel.1993.1002; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOO TW, 1993, J BIOL CHEM, V268, P3143; LOO TW, 1993, J BIOL CHEM, V268, P19965; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; RICHERT ND, 1988, BIOCHEMISTRY-US, V27, P7607, DOI 10.1021/bi00420a006; RONINSON IBE, 1991, MOL CELLULAR BIOL MU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SCHURR E, 1989, CANCER RES, V49, P2729; SHIMABUKU AM, 1992, J BIOL CHEM, V267, P4308; SKACH WR, 1993, J BIOL CHEM, V268, P6903; SMITH GE, 1985, P NATL ACAD SCI USA, V82, P8404, DOI 10.1073/pnas.82.24.8404; Summers MD, 1987, TEXAS AGR EXPT STATI; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Townsend A, 1993, Semin Cell Biol, V4, P53, DOI 10.1006/scel.1993.1007; YOSHIMURA A, 1989, J BIOL CHEM, V264, P16282; ZHANG JT, 1991, J BIOL CHEM, V266, P18224; ZUBRZYCKAGAARN E, 1984, J BIOENERG BIOMEMBR, V16, P441, DOI 10.1007/BF00743238	47	176	178	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7750	7755						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7907331				2022-12-25	WOS:A1994NA03200110
J	BECKER, S; PALM, D; SCHINZEL, R				BECKER, S; PALM, D; SCHINZEL, R			DISSECTING DIFFERENTIAL BINDING IN THE FORWARD AND REVERSE REACTION OF ESCHERICHIA-COLI MALTODEXTRIN PHOSPHORYLASE USING 2-DEOXYGLUCOSYL SUBSTRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-PHOSPHORYLASE; PYRIDOXAL 5'-PHOSPHATE; ALPHA; PHOSPHATE; COMPLEX; SITE; SPECIFICITY; DERIVATIVES; ACTIVATION; CATALYSIS	Substrate analogs are used in combination with site-directed mutagenesis to probe specific interactions between substrate and enzyme in the forward and reverse direction of the Escherichia coli maltodextrin phosphorylase reaction. In the phosphorolysis (degradation) mode, removal of the 2-OH group of the terminal glucose of the polysaccharide results in a 30-fold reduction of K(m) awhile similar changes were of no influence when the same polysaccharide was used for priming the synthesis. Mutation of active site residues Glu637 or Tyr538 does not change apparent affinity of substrates during degradation. In the synthesis mode, 2-deoxyglucose-1-P as substrate causes a 2-fold reduction of the wild-type k(cat)/K(m) while for the Y538F mutant a approximately 7-fold reduction is observed. In contrast, the mutation of Glu637 to Asp causes a 10-fold increase in k(cat)/K(m). Therefore, different binding sites for the terminal glucose residue of the oligosaccharide and glucose-1-P exist. Glu637 and Tyr-538 are part of the glucose-1-P binding site and do not interact with the terminal glucose residue. A 2-fold increase in rate was observed in both directions using the 2-deoxy derivatives. This confirms the role of intrinsic electronic effects in stabilizing the transition state. Uncompetitive substrate inhibition at high concentrations of maltoheptaose in the phosphorolysis direction is explained by inhibitory binding of the sugar in the synthesis mode.	THEODOR BOVERI INST BIOWISSENSCH, BIOZENTRUM PHYSIOL CHEM I, HUBLAND, D-97074 WURZBURG, GERMANY									BARFORD D, 1989, NATURE, V218, P233; Bergmeyer H.U., 1983, METHOD ENZYMAT AN, V2, P204; BISSWANGER H, 1979, THEORIE ENZYMKINETIK, P101; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAO J, 1969, BIOCHEMISTRY-US, V8, P1459, DOI 10.1021/bi00832a022; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FRENCH D, 1953, J AM CHEM SOC, V75, P4490, DOI 10.1021/ja01114a028; GOLD MH, 1974, ARCH BIOCHEM BIOPHYS, V161, P515, DOI 10.1016/0003-9861(74)90334-8; GOLDSMITH EJ, 1989, SCIENCE, V245, P528, DOI 10.1126/science.2756432; JOHNSON LN, 1992, FASEB J, V6, P2274, DOI 10.1096/fasebj.6.6.1544539; JOHNSON LN, 1990, J MOL BIOL, V211, P645, DOI 10.1016/0022-2836(90)90271-M; KASVINSKY PJ, 1978, J BIOL CHEM, V253, P1290; KLEIN HW, 1982, BIOCHEMISTRY-US, V21, P6675, DOI 10.1021/bi00269a010; LEATHERBARROW RJ, 1992, GRAFIT VERSION 30; LEONIDAS DD, 1992, PROTEIN SCI, V1, P1112, DOI 10.1002/pro.5560010905; MADSEN NB, 1986, COENZYMES COFACTORS, V1, P355; MARTIN JL, 1990, BIOCHEMISTRY-US, V29, P10745, DOI 10.1021/bi00500a005; NEWGARD CB, 1989, CRIT REV BIOCHEM MOL, V24, P69, DOI 10.3109/10409238909082552; PALM D, 1990, BIOCHEMISTRY-US, V29, P1099, DOI 10.1021/bi00457a001; PALM D, 1991, INT UNION B, V199, P377; PHILIP G, 1982, BIOCHEMISTRY-US, V21, P3043, DOI 10.1021/bi00256a002; SAHEKI S, 1985, ANAL BIOCHEM, V148, P277, DOI 10.1016/0003-2697(85)90229-5; SCHINZEL R, 1990, BIOCHEMISTRY-US, V29, P9956, DOI 10.1021/bi00494a028; SEGEL I, 1975, ENZYME KINETICS, P316; SIERKS MR, 1992, PROTEIN ENG, V5, P185, DOI 10.1093/protein/5.2.185; SPRANG SR, 1991, SCIENCE, V254, P1367, DOI 10.1126/science.1962195; SPRANG SR, 1992, PROTEIN SCI, V1, P1100, DOI 10.1002/pro.5560010904; STREET IP, 1989, BIOCHEMISTRY-US, V28, P1581, DOI 10.1021/bi00430a024; STREET IP, 1986, BIOCHEMISTRY-US, V25, P6021, DOI 10.1021/bi00368a028; SUGANUMA T, 1991, CARBOHYD RES, V217, P213, DOI 10.1016/0008-6215(91)84131-W; WITHERS SG, 1986, CARBOHYD RES, V154, P127, DOI 10.1016/S0008-6215(00)90028-4	31	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2485	2490						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	7905479				2022-12-25	WOS:A1994MV43200024
J	POUPOT, R; MARTINEZROMERO, E; GAUTIER, N; PROME, JC				POUPOT, R; MARTINEZROMERO, E; GAUTIER, N; PROME, JC			WILD-TYPE RHIZOBIUM-ETLI, A BEAN SYMBIONT, PRODUCES ACETYL-FUCOSYLATED, N-METHYLATED, AND CARBAMOYLATED NODULATION FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPO-OLIGOSACCHARIDE SIGNALS; PHASEOLUS-VULGARIS L; NOD GENE INDUCERS; HOST-SPECIFICITY; BRADYRHIZOBIUM-JAPONICUM; ROOT NODULE; MELILOTI; STRAINS; TROPICI; MOIETY	Phaseolus vulgaris (common bean) can be nodulated by different Rhizobium species. A new species has been recently proposed: Rhizobium etli. Following transcriptional activation of the bacterial nodulation genes using naringenin or bean seed exudate, we have isolated, purified, and characterized R. etli extracellular nodulation factors. They are chitopentameric compounds that are N-methyl-N-vaccenoylated at their non-reducing end. At position 6 of the reducing N-acetyl-D-glucosamine, they are 4-O-acetyl-L-fucosylated. Minor compounds bear a carbamate group on the terminal non-reducing saccharidic residue.	CNRS, PHARMACOL & TOXICOL FONDAMENTALES LAB, F-31077 TOULOUSE, FRANCE; UNIV NACL AUTONOMA MEXICO, CTR INVEST FIJAC NITROGENO, CUERNAVACA 62191, MORELOS, MEXICO	Centre National de la Recherche Scientifique (CNRS); Universidad Nacional Autonoma de Mexico				martinez-romero, esperanza/0000-0002-2295-2606				ALTONA C, 1980, ORG MAGN RESONANCE, V13, P417, DOI 10.1002/mrc.1270130606; BECFERTE MP, 1994, BIOCHEMISTRY-US, V33, P11782, DOI 10.1021/bi00205a014; CARLSON RW, 1993, J BIOL CHEM, V268, P18372; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DENARIE J, 1993, CELL, V74, P951, DOI 10.1016/0092-8674(93)90717-5; EHRHARDT DW, 1992, SCIENCE, V256, P998, DOI 10.1126/science.10744524; FISHER RF, 1992, NATURE, V357, P655, DOI 10.1038/357655a0; GERWIG GJ, 1979, CARBOHYD RES, V77, P1, DOI 10.1016/S0008-6215(00)83788-X; GOTTFERT M, 1993, FEMS MICROBIOL LETT, V104, P39, DOI 10.1016/0378-1097(93)90503-T; HUNGRIA M, 1991, PLANT PHYSIOL, V97, P751, DOI 10.1104/pp.97.2.751; HUNGRIA M, 1991, PLANT PHYSIOL, V97, P759, DOI 10.1104/pp.97.2.759; ISONO K, 1968, TETRAHEDRON LETT, P1133, DOI 10.1016/S0040-4039(01)98906-3; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; LEROUGE P, 1994, GLYCOBIOLOGY, V4, P127, DOI 10.1093/glycob/4.2.127; LONG SR, 1989, CELL, V56, P203, DOI 10.1016/0092-8674(89)90893-3; MARTINEZ E, 1993, CURR PLANT SCI BIOT, V17, P171; MARTINEZROMERO E, 1991, INT J SYST BACTERIOL, V41, P417, DOI 10.1099/00207713-41-3-417; MERGAERT P, 1993, P NATL ACAD SCI USA, V90, P1551, DOI 10.1073/pnas.90.4.1551; NAP JP, 1990, SCIENCE, V250, P948, DOI 10.1126/science.250.4983.948; PETERS NK, 1986, SCIENCE, V233, P977, DOI 10.1126/science.3738520; POUPOT R, 1993, BIOCHEMISTRY-US, V32, P10430, DOI 10.1021/bi00090a019; PRICE NPJ, 1992, MOL MICROBIOL, V6, P3575, DOI 10.1111/j.1365-2958.1992.tb01793.x; PROME JC, 1987, RAPID COMMUN MASS SP, V1, P50; RELIC B, 1993, MOL PLANT MICROBE IN, V6, P764, DOI 10.1094/MPMI-6-764; ROCHE P, 1991, CELL, V67, P1131, DOI 10.1016/0092-8674(91)90290-F; SANJUAN J, 1992, P NATL ACAD SCI USA, V89, P8789, DOI 10.1073/pnas.89.18.8789; SEGOVIA L, 1993, INT J SYST BACTERIOL, V43, P374, DOI 10.1099/00207713-43-2-374; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; STOKKERMANS TJW, 1994, PLANTA, V193, P413, DOI 10.1007/BF00201821; TRUCHET G, 1991, NATURE, V351, P670, DOI 10.1038/351670a0; YU RK, 1986, CHEM PHYS LIPIDS, V42, P27, DOI 10.1016/0009-3084(86)90041-1	31	55	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					6050	6055		10.1074/jbc.270.11.6050	http://dx.doi.org/10.1074/jbc.270.11.6050			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890737	hybrid			2022-12-25	WOS:A1995QM94500053
J	PROSTKO, CR; DHOLAKIA, JN; BROSTROM, MA; BROSTROM, CO				PROSTKO, CR; DHOLAKIA, JN; BROSTROM, MA; BROSTROM, CO			ACTIVATION OF THE DOUBLE-STRANDED RNA-REGULATED PROTEIN-KINASE BY DEPLETION OF ENDOPLASMIC RETICULAR CALCIUM STORES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT EIF-2-ALPHA KINASE; MONOCLONAL-ANTIBODIES; CHAIN INITIATION; 3T3-F442A CELLS; MECHANISM; PHOSPHORYLATION; EXPRESSION; INHIBITION	Perturbants of the endoplasmic reticulum (ER), including Ca2+-mobilizing agents, provoke a rapid suppression of translational initiation in conjunction with an increased phosphorylation of the alpha-subunit of eukaryotic initiation factor (eIF)-2. Depletion of ER Ca2+ stores was found to signal the activation of a specific eIF-2 alpha kinase, Analysis of extracts derived from cultured cells that had been pretreated with Ca2+ ionophore A23187 or thapsigargin revealed a 2-3-fold increase in eIF-2 alpha kinase activity without detectable changes in eIF-2 alpha phosphatase activity. A peptide of 65-68 kDa, which was phosphorylated concurrently with eIF-2 alpha in extracts of pretreated cells, was identified as the interferon-inducible, double-stranded RNA (dsRNA)-regulated protein kinase (PKR). Depletion of ER Ca2+ stores did not alter the PKR contents of extracts. When incubated with reovirus dsRNA, extracts derived from cells with depleted ER Ca2+ stores displayed greater degrees of phosphorylation of PKR and of eIF-2 alpha than did control extracts, The enhanced dsRNA dependent phosphorylation of PKR was observed regardless of prior induction of the kinase with interferon. Lower concentrations of dsRNA were required for maximal phosphorylation of PKR in extracts of treated as compared to control preparations. These findings suggest that PKR mediates the translational suppression occurring in response to perturbation of ER Ca2+ homeostasis.	UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT PHARMACOL, PISCATAWAY, NJ 08854 USA; UNIV LOUISVILLE, SCH MED, DEPT BIOCHEM, LOUISVILLE, KY 40292 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Louisville					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035393] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 35393] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARBER GN, 1994, P NATL ACAD SCI USA, V91, P4278, DOI 10.1073/pnas.91.10.4278; BROSTROM CO, 1989, J BIOL CHEM, V264, P1644; BROSTROM CO, 1983, J BIOL CHEM, V258, P4390; BROSTROM MA, 1995, J BIOL CHEM, V270, P4127, DOI 10.1074/jbc.270.8.4127; DHOLAKIA JN, 1989, J BIOL CHEM, V264, P546; DUBOIS MF, 1989, J BIOL CHEM, V264, P12165; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; ITO T, 1994, P NATL ACAD SCI USA, V91, P7455, DOI 10.1073/pnas.91.16.7455; JUDWARE R, 1991, MOL CELL BIOL, V11, P3259, DOI 10.1128/MCB.11.6.3259; KIMBALL SR, 1991, J BIOL CHEM, V266, P1969; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGLAND JO, 1992, J BIOL CHEM, V267, P10729; LAURENT AG, 1985, P NATL ACAD SCI USA, V82, P4341, DOI 10.1073/pnas.82.13.4341; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LI JH, 1991, EUR J BIOCHEM, V195, P41, DOI 10.1111/j.1432-1033.1991.tb15673.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MUNDSCHAU LJ, 1992, J BIOL CHEM, V267, P23092; PAL JK, 1991, BIOCHEMISTRY-US, V30, P2555, DOI 10.1021/bi00223a037; PATEL RC, 1994, J BIOL CHEM, V269, P18593; PETRYSHYN R, 1988, P NATL ACAD SCI USA, V85, P1427, DOI 10.1073/pnas.85.5.1427; PROSTKO CR, 1992, J BIOL CHEM, V267, P16751; PROSTKO CR, 1993, MOL CELL BIOCHEM, V128, P255, DOI 10.1007/BF01076776; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; SAMUEL CE, 1992, PHARMACOL THERAPEUT, V54, P307, DOI 10.1016/0163-7258(92)90005-K; THOMIS DC, 1992, VIROLOGY, V188, P33, DOI 10.1016/0042-6822(92)90732-5; THOMIS DC, 1993, J VIROL, V67, P7695, DOI 10.1128/JVI.67.12.7695-7700.1993	31	120	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					6211	6215		10.1074/jbc.270.11.6211	http://dx.doi.org/10.1074/jbc.270.11.6211			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890757	hybrid			2022-12-25	WOS:A1995QM94500074
J	TAHARA, H; SATO, E; NODA, A; IDE, T				TAHARA, H; SATO, E; NODA, A; IDE, T			INCREASE IN EXPRESSION LEVEL OF P21(SDI1/CIP1/WAF1) WITH INCREASING DIVISION AGE IN BOTH NORMAL AND SV40-TRANSFORMED HUMAN FIBROBLASTS	ONCOGENE			English	Article						P21/SDI1/CIP1/WAF1; CELLULAR SENESCENCE; P53; T-ANTIGEN; HUMAN FIBROBLAST	CYCLIN-DEPENDENT KINASES; DNA-SYNTHESIS; T-ANTIGEN; CELLS; INHIBITOR; MUTANT; P21	p21(sdil/cip1/waf1) gene, whose product inhibits Cyclin/Cdk kinase and blocks cell proliferation, is known to be upregulated by p53 and to be expressed at high levels in senescent human fibroblasts. The present paper reports that p21 expression level was much lower in SV40ts T-antigen transformed cells than in normal cells and that after inactivation of ts T-antigen it recovered to that of normal cells. However, cell division age-dependent increase in expression level of p21 occurred not only in normal human fibroblasts but also in SV40ts T-antigen transformed fibroblasts with active T-antigen. These results suggest that cell age-dependent increase in p21 occurs independently upon the function of T-antigen binding proteins including p53, while the basal expression level of p21 is up-regulated by p53 as previously reported.	HIROSHIMA UNIV,SCH MED,DEPT CELLULAR & MOLEC BIOL,HIROSHIMA 734,JAPAN; MEIJI CELL TECHNOL CTR,RES DIV CELLULAR REGULAT,ODAWARA 250,JAPAN	Hiroshima University; Meiji Holdings Co., Ltd.				Noda, Asao/0000-0002-9029-9813				AFSHARI CA, 1993, EXP CELL RES, V209, P231, DOI 10.1006/excr.1993.1306; BURMER GC, 1983, EXP CELL RES, V145, P79, DOI 10.1016/S0014-4827(83)80010-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; IDE T, 1984, EXP CELL RES, V150, P321, DOI 10.1016/0014-4827(84)90575-5; KUCHINO T, 1975, J VIROL, V15, P1302, DOI 10.1128/JVI.15.6.1302-1307.1975; LUMPKIN CK, 1986, SCIENCE, V232, P393, DOI 10.1126/science.2421407; MATSUO M, 1982, J GERONTOL, V37, P33, DOI 10.1093/geronj/37.1.33; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NORWOOD TH, 1974, P NATL ACAD SCI USA, V71, P2231, DOI 10.1073/pnas.71.6.2231; TAHARA H, 1994, BIOCHEM BIOPH RES CO, V199, P1108, DOI 10.1006/bbrc.1994.1345; TSUYAMA N, 1991, CELL STRUCT FUNCT, V16, P55, DOI 10.1247/csf.16.55; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAMAGUCHI N, 1975, J VIROL, V15, P1297, DOI 10.1128/JVI.15.6.1297-1301.1975; YANISHEVSKY RM, 1980, EXP CELL RES, V126, P469, DOI 10.1016/0014-4827(80)90290-6	19	117	117	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					835	840						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898925				2022-12-25	WOS:A1995QL03800004
J	ASKEW, GR; LINGREL, JB				ASKEW, GR; LINGREL, JB			IDENTIFICATION OF ALL AMINO-ACID SUBSTITUTION IN HUMAN ALPHA-1 NA,K-ATPASE WHICH CONFERS DIFFERENTIALLY REDUCED AFFINITY FOR 2 RELATED CARDIAC-GLYCOSIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; OUABAIN-RESISTANT ENZYME; SUBUNIT; SENSITIVITY; MUTATION; SEQUENCE; RESIDUES; BINDING; CELLS	The ouabain-resistant cell line H1C1 displays a 30-fold differential of reduced sensitivity to the structurally related cardiac glycosides digoxin and digitoxin (Baker, R. M. (1976) in Biogenesis and Turnover of Membrane Macromolecules (Cook, J. S., ed) pp. 93-103, Raven Press, New York). Since these ligand congeners differ only by the presence of a hydroxyl group at C-12 of digoxin we predicted that the H1C1 phenotype must reflect a mutation which alters the binding site of the cardiac glycoside receptor (Na,K-ATPase). Complementary DNA encoding the al Na,g-ATPase was prepared from H1C1 cell total RNA by reverse transcription-coupled polymerase chain reaction and these cDNAs were cloned. Sequence analysis of the reverse transcriptase-polymerase chain reaction clones revealed several independent isolates containing a G>A transition at nucleotide 332 of the propeptide coding sequence, generating the amino acid substitution C108Y. The ability of this substitution to confer differential sensitivity for digoxin and digitoxin was tested and confirmed by expressing a human al C108Y-Na,K-ATPase in wild type HeLa cells and assaying for inhibition of cell growth and inhibition of Na,K-ATPase activity. Phenylalanine or alanine substitutions of this cysteine also confer this pattern of ligand discrimination. Ouabain-resistant Na,K-ATPase substitutions, at positions other than Cys-108 failed to exhibit differential sensitivity indicating that this ligand discrimination is unique to Cys-108 substitutions rather than a general property of cardiac glycoside resistant mutants. It is proposed that differential resistance of the C108Y receptor for these ligands is a consequence of altering two features of the ligand-receptor interaction; one, a disruption of a common hydrogen bond resulting in general loss of affinity for cardiac glycosides and the other, formation of a new H-bond between the C-12 hydroxyl of digoxin and the receptor, specifically augmenting the stability of this ligand-receptor complex.	UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati					NHLBI NIH HHS [HL 41496] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akera T., 1978, PHARMACOL REV, V29, P187; BAKER RM, 1976, BIOGENESIS TURNOVER, P93; BURNS EL, 1993, J BIOL CHEM, V268, P25632; CANESSA CM, 1993, J BIOL CHEM, V268, P17722; CANESSA CM, 1992, EMBO J, V11, P1681, DOI 10.1002/j.1460-2075.1992.tb05218.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FENG JN, 1994, BIOCHEMISTRY-US, V33, P4218, DOI 10.1021/bi00180a015; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FORBUSH B, 1983, CURR TOP MEMBR TRANS, V19, P167; GREGORET LM, 1991, PROTEINS, V9, P99, DOI 10.1002/prot.340090204; GRUPP G, 1987, MOL CELL BIOCHEM, V76, P97; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; KAWAKAMI K, 1986, J BIOCHEM-TOKYO, V100, P389, DOI 10.1093/oxfordjournals.jbchem.a121726; MCPARLAND RA, 1991, SODIUM PUMP RECENT D, P297; MERCER RW, 1993, J CELL BIOL, V121, P579, DOI 10.1083/jcb.121.3.579; NAIDOO BK, 1974, J PHARM SCI, V63, P1391, DOI 10.1002/jps.2600630912; OBRIEN WJ, 1993, J BIOL CHEM, V268, P7707; PERRY KM, 1993, BIOCHEMISTRY-US, V32, P7116, DOI 10.1021/bi00079a007; PRICE EM, 1989, J BIOL CHEM, V264, P21902; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; SCHULTHEIS PJ, 1993, J BIOL CHEM, V268, P22686; SCHULTHEIS PJ, 1993, BIOCHEMISTRY-US, V32, P544, DOI 10.1021/bi00053a020; SCHWARTZ A, 1969, J PHARMACOL EXP THER, V168, P31; Thomas R., 1990, ADV DRUG RES, P311; ZHOU C, 1990, BIOTECHNIQUES, V8, P172	27	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24120	24126						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929066				2022-12-25	WOS:A1994PQ34600044
J	CASSARDDOULCIER, AM; LAROSE, M; MATAMALA, JC; CHAMPIGNY, O; BOUILLAUD, F; RICQUIER, D				CASSARDDOULCIER, AM; LAROSE, M; MATAMALA, JC; CHAMPIGNY, O; BOUILLAUD, F; RICQUIER, D			IN-VITRO INTERACTIONS BETWEEN NUCLEAR PROTEINS AND UNCOUPLING PROTEIN GENE PROMOTER REVEAL SEVERAL PUTATIVE TRANSACTIVATING FACTORS INCLUDING ETS1, RETINOID-X RECEPTOR, THYROID-HORMONE RECEPTOR, AND A CACCC BOX-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; TRANSCRIPTION FACTORS; RESPONSE ELEMENTS; TRANSGENIC MICE; EXPRESSION; TISSUE; ACID; REGION; UCP	Previous studies of rat ucp (uncoupling protein) gene organization carried out in this laboratory identified regulatory sequences located in the 5'-flanking region. In this work, DNase I footprint analysis of the enhancer revealed two domains at base pairs (bp) -2444 to -2423 and bp -2352 to -2319. The former domain can bind in vitro, in a cooperative manner, factors related to nuclear factor 1 and Ets1; the latter domain contains a type 3 directly repeated sequence that was shown to be able to bind the retinoid X and triiodothyronine receptors. Moreover, a positive effect of retinoic acid on ucp mRNA levels in immortalized brown adipocytes was observed. DNase I footprint analysis identified two hypersensitive regions, A and B, at bp -509 to -472 and bp -403 to -350, respectively; region A contains a repeated CACCC box, and region B can bind protein related to Ets1. The A box differentially binds liver and brown adipose tissue nuclear proteins and could be involved in uncoupling protein induction. Further analysis showed three footprinted boxes, C-E, at bp -182 to -159, -147 to -120, and -111 to -85, able to bind in vitro proteins related to nuclear factor 1, cAMP response element-binding protein, and Sp1, respectively.	CNRS,CEREMOD,F-92190 MEUDON,FRANCE; UNIV ILLES BALEARS,DEPT BIOL FONAMENTAL & CIENCES SALUT,E-07071 PALMA DE MALLORCA,SPAIN	Centre National de la Recherche Scientifique (CNRS); Universitat de les Illes Balears			Bouillaud, Frédéric R/L-3238-2017; CASSARD, Anne-Marie/B-6095-2019	Bouillaud, Frédéric R/0000-0002-7518-9237; CASSARD, Anne-Marie/0000-0002-1813-5128				BERNIER D, 1993, MOL CELL BIOL, V13, P1619, DOI 10.1128/MCB.13.3.1619; BIANCO AC, 1988, J BIOL CHEM, V263, P18168; BOUILLAUD F, 1988, BIOCHEM BIOPH RES CO, V157, P783, DOI 10.1016/S0006-291X(88)80318-8; BOYER BB, 1991, MOL CELL BIOL, V11, P4147, DOI 10.1128/MCB.11.8.4147; CANNON B, 1985, ESSAYS BIOCHEM, V20, P111; CASSARD AM, 1990, J CELL BIOCHEM, V43, P255, DOI 10.1002/jcb.240430306; CASSARDDOULCIER AM, 1993, MOL ENDOCRINOL, V7, P497, DOI 10.1210/me.7.4.497; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; IRELAND RC, 1986, J BIOL CHEM, V261, P1779; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLAUS S, 1994, J CELL SCI, V107, P313; KLAUS S, 1991, INT J BIOCHEM, V23, P791, DOI 10.1016/0020-711X(91)90062-R; KLAUS S, 1991, J CELL BIOL, V115, P1783, DOI 10.1083/jcb.115.6.1783; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KOZAK LP, 1988, J BIOL CHEM, V263, P12274; KOZAK UC, 1994, MOL CELL BIOL, V14, P59, DOI 10.1128/MCB.14.1.59; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MADER S, 1993, J BIOL CHEM, V268, P591; MARTINEZ E, 1991, EMBO J, V10, P263, DOI 10.1002/j.1460-2075.1991.tb07946.x; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; ROSS SR, 1992, P NATL ACAD SCI USA, V89, P7561, DOI 10.1073/pnas.89.16.7561; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; TSUKIYAMA T, 1992, NUCLEIC ACIDS RES, V20, P1477, DOI 10.1093/nar/20.7.1477; TSUKIYAMA T, 1992, MOL CELL BIOL, V12, P1286, DOI 10.1128/MCB.12.3.1286; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WANG YK, 1993, MOL CELL BIOL, V13, P5691, DOI 10.1128/MCB.13.9.5691; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; YUBERO P, 1994, BIOCHEM BIOPH RES CO, V198, P653, DOI 10.1006/bbrc.1994.1095	31	85	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24335	24342						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929091				2022-12-25	WOS:A1994PQ34600075
J	REYNAUD, D; DEMIN, P; PACEASCIAK, CR				REYNAUD, D; DEMIN, P; PACEASCIAK, CR			HEPOXILIN A(3) FORMATION IN THE RAT PINEAL-GLAND SELECTIVELY UTILIZES (12S)-HYDROPEROXYEICOSATETRAENOIC ACID (HPETE), BUT NOT (12R)-HPETE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; ARACHIDONIC-ACID; HUMAN-PLATELETS; 8,11,12-TRIHYDROXYEICOSATRIENOIC ACID; CATALYZED TRANSFORMATION; PANCREATIC-ISLETS; HUMAN NEUTROPHILS; NERVOUS-SYSTEM; PRODUCTS; APLYSIA	Hepoxilins A(3) and B-3 have previously been shown to be formed from 12-hydroperoxyeicosatetraenoic acid (12-HPETE) through a heat-insensitive ferriheme catalysis as indicated by experiments with hemin or hemoglobin, typical of nonenzymatic rearrangement (Pace-Asciak, C. B (1984) Biochim. Biophys. Acta 793, 485-488; Pace-Asciak, C. R. (1984) J. Biol. Chem. 259, 8332-8337). In this paper, we demonstrate through use of a mixture of (12S)- and (12R)-HPETE that an enzyme system exists in the rat pineal gland that selectively utilizes (12S)-HPETE for the transformation into hepoxilin A(3), while the hemin catalyzed transformation is not selective, with both (12S)- and (12R)-HPETE being utilized. A new procedure was established to rapidly extract (in the absence of acid) and directly derivatize from the incubation mixture the products of incubation using 9-anthryldiazomethane reagent to form the 9-anthryldiazomethane derivatives of the hydroxyeicosatetraenoic acids (HETEs), hepoxilins and trioxilins, which could be detected by high performance liquid chromatography using a flow-through fluorescence detector. The following observations were made: 1) the pineal experiments showed a high preference for the formation of hepoxilin A(3) with minor amounts of hepoxilin B-3, while experiments with heme catalysis showed formation of both hepoxilins B-3 and A(3); 2) chiral phase analysis of the HETEs recovered from the incubation mixture showed the predominance of (12R)-HETE from the pineal experiments, indicating that (12S)-HPETE was selectively used up, whereas both (12S)- and (12R)-HPETE were utilized in the hemin experiments; 3) chiral phase analysis of hepoxilin A(3) indicated the presence in the pineal experiments of only hepoxilin with the 11S,12S-configuration formed from (12S)-HPETE, while the hemin experiments contained both the native 11S,12S-configuration as well as the unnative or ''bis-epi''-11R,12R-configuration in the epoxide group of hepoxilin A(3); 4) reverse phase analysis of the epoxide hydrolase product of hepoxilin A(3), i.e. trioxilin A(3), showed that the pineal experiments contained only the products of enzymatic hydrolysis derived from the native hepoxilin A(3), whose formation was inhibited by the epoxide hydrolase inhibitor, trichloropropene oxide. The pineal system is heat-sensitive, with formation of hepoxilins being abolished by tissue boiling, while the hemin system is insensitive to boiling. These experiments demonstrate that hepoxilin A(3) formation in the pineal gland utilizes (12S)-HPETE exclusively, being transformed by a ''hepoxilin synthase'' primarily into hepoxilin A(3).	HOSP SICK CHILDREN, RES INST, DIV NEUROSCI, TORONTO M5G 1X8, ON, CANADA; UNIV TORONTO, FAC MED, DEPT PHARMACOL, TORONTO M5S 1A8, ON, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								BELARDETTI F, 1989, NEURON, V3, P497, DOI 10.1016/0896-6273(89)90208-0; BRYANT RW, 1979, PROSTAGLANDINS, V17, P9, DOI 10.1016/0090-6980(79)90071-6; BRYANT RW, 1980, BIOCHEM BIOPH RES CO, V92, P268, DOI 10.1016/0006-291X(80)91548-X; CARLEN PL, 1994, NEUROSCIENCE, V58, P493, DOI 10.1016/0306-4522(94)90075-2; CARLEN PL, 1989, BRAIN RES, V497, P171, DOI 10.1016/0006-8993(89)90984-0; DEMIN PM, 1991, BIOORG KHIM+, V17, P1133; DEMIN PM, 1994, 207TH AM CHEM SOC M; DHO S, 1990, BIOCHEM J, V266, P63, DOI 10.1042/bj2660063; HADA T, 1994, BBA-LIPID LIPID MET, V1211, P221, DOI 10.1016/0005-2760(94)90272-0; JONES RL, 1978, PROSTAGLANDINS, V16, P583, DOI 10.1016/0090-6980(78)90188-0; LANEUVILLE O, 1991, EICOSANOIDS, V4, P95; LANEUVILLE O, 1990, J BIOL CHEM, V265, P21415; LANEUVILLE O, 1993, BIOCHEM J, V295, P393, DOI 10.1042/bj2950393; LANEUVILLE O, 1992, BRIT J PHARMACOL, V107, P808, DOI 10.1111/j.1476-5381.1992.tb14528.x; LANEUVILLE O, 1992, BRIT J PHARMACOL, V105, P297, DOI 10.1111/j.1476-5381.1992.tb14249.x; LANEUVILLE O, 1991, PROSTAGLANDINS LEUKO; MARGALIT A, 1993, P NATL ACAD SCI USA, V90, P2589, DOI 10.1073/pnas.90.7.2589; MARGALIT A, 1993, J MEMBRANE BIOL, V136, P1; NIGAM S, 1993, DEV ONCOL, V71, P249; NIGAM S, 1990, BIOCHEM BIOPH RES CO, V171, P944, DOI 10.1016/0006-291X(90)90775-I; PACEASCIAK CR, 1989, J BIOL CHEM, V264, P9310; PACEASCIAK CR, 1982, BIOCHIM BIOPHYS ACTA, V712, P142, DOI 10.1016/0005-2760(82)90095-9; PACEASCIAK CR, 1983, PROSTAGLANDINS, V25, P79, DOI 10.1016/0090-6980(83)90137-5; PACEASCIAK CR, 1986, BIOCHIM BIOPHYS ACTA, V875, P406, DOI 10.1016/0005-2760(86)90193-1; PACEASCIAK CR, 1990, BIOCHEM BIOPH RES CO, V173, P949, DOI 10.1016/S0006-291X(05)80877-0; PACEASCIAK CR, 1984, J BIOL CHEM, V259, P8332; PACEASCIAK CR, 1989, BIOCHEM BIOPH RES CO, V163, P1230, DOI 10.1016/0006-291X(89)91109-1; PACEASCIAK CR, 1990, P NATL ACAD SCI USA, V87, P3037, DOI 10.1073/pnas.87.8.3037; PACEASCIAK CR, 1993, GEN PHARMACOL-VASC S, V24, P805, DOI 10.1016/0306-3623(93)90153-O; PACEASCIAK CR, 1984, BIOCHIM BIOPHYS ACTA, V793, P485, DOI 10.1016/0005-2760(84)90267-4; PACEASCIAK CR, 1983, J BIOL CHEM, V258, P6835; PACEASCIAK CR, 1984, PROSTA LEUKOTR MED, V16, P173, DOI 10.1016/0262-1746(84)90069-6; PACEASCIAK CR, 1985, BIOCHEM BIOPH RES CO, V128, P942, DOI 10.1016/0006-291X(85)90137-8; PACEASCIAK CR, 1990, ADV PROSTAGLANDIN TH, V21, P731; PACEASCIAK CR, 1990, BIOL OXIDATION SYSTE, V2, P725; PIOMELLI D, 1987, J NEUROSCI, V7, P3675; PIOMELLI D, 1989, P NATL ACAD SCI USA, V86, P1721, DOI 10.1073/pnas.86.5.1721; REYNAUD D, 1994, J NEUROCHEM, V62, P126; VASILJEVA LL, 1993, TETRAHEDRON, V49, P4099, DOI 10.1016/S0040-4020(01)89921-X; YAMAKI K, 1986, CHEM PHARM BULL, V34, P3526	40	43	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23976	23980						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929046				2022-12-25	WOS:A1994PQ34600022
J	HANSON, RL; WASYLYK, JM; NANDURI, VB; CAZZULINO, DL; PATEL, RN; SZARKA, LJ				HANSON, RL; WASYLYK, JM; NANDURI, VB; CAZZULINO, DL; PATEL, RN; SZARKA, LJ			SITE-SPECIFIC ENZYMATIC-HYDROLYSIS OF TAXANES AT C-10 AND C-13	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE TAXOL ANALOGS; TAXUS-BREVIFOLIA; BACCATIN-III; SIDE-CHAINS; EFFICIENT; AGENT	The production of large amounts of paclitaxel for use as an anticancer treatment has been a challenging problem because of the low concentration of the compound in yew trees and its occurrence as part of a mixture of other taxanes. Two novel enzymes were isolated to facilitate the production of 10-deacetylbaccatin III, a precursor used for semisynthesis of paclitaxel and analogs. A strain of Nocardioides albus (SC13911) was isolated from soil and found to produce an extracellular enzyme that specifically removed the C-13 side chain from paclitaxel, cephalomannine, 7-beta-xylosyltaxol, 7-beta-xylosyl-10-deacetyltaxol, and 10-deacetyltaxol, The enzyme was purified to near homogeneity to give a polypeptide with 47,000 M(r) on a sodium dodecyl sulfate gel. A strain of Nocardioides luteus (SC13912) isolated from soil was found to produce an intracellular 10-deacetylase that removed the 10 acetate from baccatin III and paclitaxel. The 10-deacetylase was purified to give a polypeptide with 40,000 M(r) on a sodium dodecyl sulfate gel. Treatment of extracts prepared from a variety of yew cultivars with the C-13-deacylase and C-10-deacetylase converted a complex mixture of taxanes primarily to 10-deacetylbaccatin III and increased the amount of this key precursor by 4-24 times.			HANSON, RL (corresponding author), BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT MICROBIAL TECHNOL,1 SQUIBB DR,NEW BRUNSWICK,NJ 08903, USA.							CHEN SH, 1993, TETRAHEDRON, V49, P2805, DOI 10.1016/S0040-4020(01)80381-1; COMMERCON A, 1992, TETRAHEDRON LETT, V33, P5185, DOI 10.1016/S0040-4039(00)79128-3; DENIS JN, 1988, J AM CHEM SOC, V110, P5917, DOI 10.1021/ja00225a063; GEORG GI, 1992, J MED CHEM, V35, P4230, DOI 10.1021/jm00100a031; GEORG GI, 1992, BIOORG MED CHEM LETT, V2, P295, DOI 10.1016/S0960-894X(01)80203-1; HOLMES FA, 1991, J NATL CANCER I, V83, P1797, DOI 10.1093/jnci/83.24.1797-a; HOLTON RA, 1990, CHEM ABST 16458Q, V114; HOLTON RA, 1991, CHEM ABST 159485B, V115; KINGSTONDGI, 1991, PHARMACOL THERAPEUT, V52, P1; MAGRI NF, 1986, J ORG CHEM, V51, P3239, DOI 10.1021/jo00366a043; OJIMA I, 1992, TETRAHEDRON, V48, P6985, DOI 10.1016/S0040-4020(01)91210-4; RAO KV, 1993, PHARMACEUT RES, V10, P521, DOI 10.1023/A:1018937700459; ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SENILH V, 1984, CR ACAD SCI II, V299, P1039; SWINDELL CS, 1991, J MED CHEM, V34, P1176, DOI 10.1021/jm00107a042; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045	17	38	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22145	22149						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	7915279				2022-12-25	WOS:A1994PE09800035
J	ZHU, Y; TASSI, L; LANE, W; MENDELSOHN, ME				ZHU, Y; TASSI, L; LANE, W; MENDELSOHN, ME			SPECIFIC BINDING OF THE TRANSGLUTAMINASE, PLATELET FACTOR-XIII, TO HSP27	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; RECEPTOR-MEDIATED ENDOCYTOSIS; CATALYZED CROSS-LINKING; TUMOR-NECROSIS-FACTOR; ALPHA-B-CRYSTALLIN; TRANSAMIDATING ENZYMES; STRUCTURAL PROTEINS; ESTROGEN-RECEPTOR; SEQUENCE-ANALYSIS; ACTIN-FILAMENTS	HSP27, the unique mammalian low molecular weight heat shock protein, is prominently phosphorylated upon activation of a wide variety of cells and has a role in thermotolerance, growth events, and regulation of actin cytoskeletal dynamics. In thrombin-stimulated platelets, HSP27 is rapidly and prominently phosphorylated in a manner highly correlated with platelet secretion. However, the function of HSP27 and the identity of proteins that interact with HSP27 remain unknown. To identify specific HSP27-protein interactions, a recombinant fusion protein affinity reagent was constructed and used to identify proteins associating with HSP27 from human platelet lysates and erythroleukemia cells. An 84-kDa protein was found to associate specifically with HSP27 and was isolated from platelet lysates, resolved on preparative gels, transferred to nitrocellulose, subjected to enzymatic digestion, and microsequenced. A 20-amino acid sequence derived from p84 proved identical to amino acids 484-503 of the transglutaminase, platelet Factor XIII. Immunoblotting studies were used to confirm the binding of FXIII from fresh platelet lysates to the HSP27 fusion protein. FXIII also was shown to coprecipitate with HSP27 in immunoprecipitation studies and to colocalize with HSP27 in immunofluorescence studies of intact glass-activated platelets. The data thus demonstrate specific binding of platelet FXIII to HSP27 and suggest that HSP27 may participate in the cellular localization and/or enzymatic regulation of platelet FXIII.	TUFTS UNIV, NEW ENGLAND MED CTR, SCH MED, MOLEC CARDIOL RES CTR, BOSTON, MA 02111 USA; HARVARD UNIV, SCH MED, HARVARD MICROCHEM FACIL, BOSTON, MA 02111 USA	Tufts Medical Center; Tufts University; Harvard University; Harvard Medical School					NHLBI NIH HHS [HL02154] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002154] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; ASIJEE GM, 1988, BIOCHIM BIOPHYS ACTA, V954, P303, DOI 10.1016/0167-4838(88)90085-4; BITAR KN, 1991, BIOCHEM BIOPH RES CO, V181, P1192, DOI 10.1016/0006-291X(91)92065-R; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUNGAY PJ, 1986, BIOCHEM J, V235, P269, DOI 10.1042/bj2350269; CAIRNS J, 1994, J BIOL CHEM, V269, P9176; CHAMBARD JC, 1983, BIOCHEM BIOPH RES CO, V111, P1034, DOI 10.1016/0006-291X(83)91404-3; COFFER AI, 1985, CANCER RES, V45, P3694; COHEN I, 1981, BIOCHIM BIOPHYS ACTA, V676, P137, DOI 10.1016/0304-4165(81)90181-1; COHEN I, 1980, BIOCHIM BIOPHYS ACTA, V628, P365, DOI 10.1016/0304-4165(80)90386-4; COHEN I, 1979, ARCH BIOCHEM BIOPHYS, V192, P100, DOI 10.1016/0003-9861(79)90075-4; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; Goldschmidt-Clermont P. J., 1992, Current Biology, V2, P669, DOI 10.1016/0960-9822(92)90135-W; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GRINNELL F, 1984, J CELL BIOCHEM, V26, P107, DOI 10.1002/jcb.240260206; GROENEN PJTA, 1992, EUR J BIOCHEM, V205, P671, DOI 10.1111/j.1432-1033.1992.tb16827.x; GUESDON F, 1993, J BIOL CHEM, V268, P4236; HARTWIG JH, 1991, J CELL BIOL, V112, P407, DOI 10.1083/jcb.112.3.407; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; HASLAM RJ, 1980, PLATELETS CELLULAR R, P213; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAHN DR, 1981, BIOCHIM BIOPHYS ACTA, V668, P490, DOI 10.1016/0005-2795(81)90184-7; KLEMENZ R, 1993, J CELL BIOL, V120, P639, DOI 10.1083/jcb.120.3.639; KROLL MH, 1989, BLOOD, V74, P1181; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LEICHT BG, 1986, P NATL ACAD SCI USA, V83, P90, DOI 10.1073/pnas.83.1.90; LEVIN EG, 1991, J BIOL CHEM, V266, P174; LEVITZKI A, 1980, P NATL ACAD SCI-BIOL, V77, P2706, DOI 10.1073/pnas.77.5.2706; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LOPACIUK S, 1976, THROMB RES, V8, P453, DOI 10.1016/0049-3848(76)90223-1; LORAND L, 1979, ANAL BIOCHEM, V93, P453, DOI 10.1016/S0003-2697(79)80178-5; LORAND L, 1972, ANAL BIOCHEM, V50, P623, DOI 10.1016/0003-2697(72)90074-7; MENDELSOHN ME, 1990, J BIOL CHEM, V265, P19028; MENDELSOHN ME, 1991, P NATL ACAD SCI USA, V88, P11212, DOI 10.1073/pnas.88.24.11212; MERCK KB, 1993, J BIOL CHEM, V268, P1046; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; MITCHELL CA, 1990, P NATL ACAD SCI USA, V87, P9396, DOI 10.1073/pnas.87.23.9396; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MUSZBEK L, 1993, THROMB HAEMOSTASIS, V69, P282; PETKO L, 1986, CELL, V45, P885, DOI 10.1016/0092-8674(86)90563-5; PONCZ M, 1987, BLOOD, V69, P219; PRATT WB, 1993, J BIOL CHEM, V268, P21455; REED GL, 1992, THROMB HAEMOSTASIS, V68, P315; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; SAKLATVALA J, 1991, BIOCHEM J, V277, P635, DOI 10.1042/bj2770635; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; WALLACE WC, 1980, J BIOL CHEM, V255, P1932; WELCH WJ, 1985, J BIOL CHEM, V260, P3058; WHITE JG, 1987, ANN NY ACAD SCI, V509, P156, DOI 10.1111/j.1749-6632.1987.tb30993.x; ZHU Y, 1992, CIRCULATION, V86, P2941	63	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22379	22384						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	7915282				2022-12-25	WOS:A1994PE09800068
J	POTTER, LR; GARBERS, DL				POTTER, LR; GARBERS, DL			PROTEIN-KINASE C-DEPENDENT DESENSITIZATION OF THE ATRIAL-NATRIURETIC-PEPTIDE RECEPTOR IS MEDIATED BY DEPHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP ACCUMULATION; SMOOTH-MUSCLE CELLS; GUANYLATE-CYCLASE; PHORBOL ESTER; CGMP ACCUMULATION; RAT; INHIBITION; ACTIVATION; CHIMAERIN; BINDING	Stimulation of guanylyl cyclase A (GC-A) by atrial natriuretic peptide (ANP) is antagonized by activators of protein kinase C (PKC). Thus, it has been suggested that PHC phosphorylates and desensitizes GC-A. Here, we have developed stable GC-A transfectants of NIH3T3 cells, which display marked reductions in hormone-dependent cGMP elevations and guanylyl cyclase activity after incubation with ANP or phorbol 12-myristate 13-acetate (PMA). ANP binding and immunoblot analysis indicated that the decreases were not due to receptor internalization or degradation. GC-A isolated from (PO4)-P-32-labeled cells contained phosphoserine and phosphothreonine. ANP and/or PMA addition caused substantial decreases in the P-32 content of the receptor that coincided with reductions in hormone-dependent guanylyl cyclase activity. The specific PKC inhibitor, GF-109203X, completely blocked the PMA-dependent dephosphorylation and desensitization of GC-A but failed to inhibit either ANP-dependent process. Tryptic phosphopeptide maps of GC-A isolated from ANP- or PMA-treated cells were unique, suggesting that the sites that dephosphorylated in response to each agent were different. In contrast to previous reports, we conclude that PMA and ANP desensitization of GC-A are distinct events mediated by dephosphorylation of specific residues through PHC-dependent and -independent pathways, respectively.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	POTTER, LR (corresponding author), VANDERBILT UNIV, DEPT MOLEC PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD010254] Funding Source: NIH RePORTER; NICHD NIH HHS [HD10254] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BOTTARI SP, 1992, BIOCHEM BIOPH RES CO, V183, P206, DOI 10.1016/0006-291X(92)91629-5; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; CAMPO MS, 1985, DNA CLONING, V2, P213; CHINKERS M, 1991, J BIOL CHEM, V266, P4088; CHINKERS M, 1992, J BIOL CHEM, V267, P18589; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; CHRISMAN TD, 1993, J BIOL CHEM, V268, P3698; DOMINO SE, 1991, METHOD ENZYMOL, V195, P345; DUDA T, 1990, MOL CELL BIOCHEM, V93, P179; GARBERS DL, 1992, CELL, V71, P1; HANEDA M, 1991, KIDNEY INT, V40, P188, DOI 10.1038/ki.1991.199; HARDMAN JG, 1971, ANN NY ACAD SCI, V185, P27; JAISWAL RK, 1992, BIOCHEM BIOPH RES CO, V182, P395, DOI 10.1016/S0006-291X(05)80158-5; JAISWAL RK, 1988, FEBS LETT, V227, P47, DOI 10.1016/0014-5793(88)81411-X; KOLLER KJ, 1993, J BIOL CHEM, V268, P5997; KUROSE H, 1987, FEBS LETT, V219, P375, DOI 10.1016/0014-5793(87)80256-9; LOWE DG, 1992, BIOCHEMISTRY-US, V31, P10421, DOI 10.1021/bi00158a001; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; NAMBI P, 1986, P NATL ACAD SCI USA, V83, P8492, DOI 10.1073/pnas.83.22.8492; NAMBI P, 1987, BIOCHEM J, V244, P481, DOI 10.1042/bj2440481; POTTER LR, 1992, J BIOL CHEM, V267, P14531; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SMITH JB, 1987, AM J PHYSIOL, V253, pC147, DOI 10.1152/ajpcell.1987.253.1.C147; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0; YASUNARI K, 1992, HYPERTENSION, V19, P314, DOI 10.1161/01.HYP.19.4.314	31	114	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14636	14642						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7910166				2022-12-25	WOS:A1994NM06500053
J	DURIEUTRAUTMANN, O; CHAVEROT, N; CAZAUBON, S; STROSBERG, AD; COURAUD, PO				DURIEUTRAUTMANN, O; CHAVEROT, N; CAZAUBON, S; STROSBERG, AD; COURAUD, PO			INTERCELLULAR-ADHESION MOLECULE-1 ACTIVATION INDUCES TYROSINE PHOSPHORYLATION OF THE CYTOSKELETON-ASSOCIATED PROTEIN CORTACTIN IN BRAIN MICROVESSEL ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-ACTIVITY; SIGNAL TRANSDUCTION; ICAM-1; GROWTH; IDENTIFICATION; MODULATION; PP60C-SRC; SUBSTRATE; RECEPTORS; SYSTEM	Inflammatory diseases of the central nervous system, such as multiple sclerosis or experimental autoimmune encephalomyelitis, are characterized by adhesion of lymphocytes on cerebral microvascular endothelium, followed by transendothelial migration into the brain parenchyma. T lymphocyte adhesion to vascular endothelial cells is mediated by several types of adhesion molecules, including the integrin leukocyte function associated molecule 1 and its endothelial counter receptor intercellular adhesion molecule 1 (ICAM-1), of the immunoglobulin superfamily. In order to understand the molecular mechanisms that support lymphocyte extravasation, we intended to investigate a putative role of ICAM-1 in signal transduction in brain microvessel endothelial cells. Here we describe, using a well differentiated rat brain endothelial cell line (RBE4 cells), that ICAM-1 activation by a specific monoclonal antibody, or by syngeneic encephalitogenic T cells, induces tyrosine phosphorylation of several proteins together with stimulation of the tyrosine kinase p60(src) activity. One of the major tyrosine-phosphorylated proteins, of 85 kDa, has been identified by immunoprecipitation and immunoblotting, as the recently described actin-binding protein, p60(src) substrate, cortactin. These findings demonstrate that ICAM-1 activation transduces signals in brain endothelial cells, which may lead to cytoskeleton changes and transendothelial migration of lymphocytes into the brain.	UNIV PARIS 07,INST COCHIN GENET MOLEC,CNRS,UPR 0415,IMMUNOPHARMACOL MOLEC LAB,F-75014 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite								BENNUN A, 1981, EUR J IMMUNOL, V11, P195, DOI 10.1002/eji.1830110307; BERAUD E, 1993, J NEUROIMMUNOL, V47, P41, DOI 10.1016/0165-5728(93)90283-5; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPEN O, 1992, J CELL BIOL, V118, P1223, DOI 10.1083/jcb.118.5.1223; CAZAUBON S, 1993, BIOCHEM J, V293, P381, DOI 10.1042/bj2930381; CUSHLEY W, 1993, BIOCHEM J, V292, P313, DOI 10.1042/bj2920313; Doherty P, 1992, Curr Opin Neurobiol, V2, P595, DOI 10.1016/0959-4388(92)90024-F; DURIEUTRAUTMANN O, 1993, J CELL PHYSIOL, V155, P104, DOI 10.1002/jcp.1041550114; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KELLIE S, 1991, J CELL SCI, V99, P207; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LIAO F, 1992, P NATL ACAD SCI USA, V89, P3659, DOI 10.1073/pnas.89.8.3659; MAA MC, 1992, ONCOGENE, V7, P2429; McEver Rodger P., 1992, Current Opinion in Cell Biology, V4, P840, DOI 10.1016/0955-0674(92)90109-P; OPPENHEIMERMARKS N, 1991, J IMMUNOL, V147, P2913; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; RANKIN BM, 1993, J IMMUNOL, V150, P605; ROUX F, 1994, IN PRESS J CELL PHYS; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SHIMIZU Y, 1991, J CELL BIOL, V113, P1203, DOI 10.1083/jcb.113.5.1203; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VOGETSEDER W, 1991, IMMUNOBIOLOGY, V182, P143, DOI 10.1016/S0171-2985(11)80198-1; VOLBERG T, 1991, CELL REGUL, V2, P105, DOI 10.1091/mbc.2.2.105; WEKERLE H, 1986, TRENDS NEUROSCI, V9, P271, DOI 10.1016/0166-2236(86)90077-9; WONG S, 1992, ONCOGENE, V7, P2407; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631	37	212	213	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12536	12540						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	7909803				2022-12-25	WOS:A1994NH71600028
J	LOW, SH; TANG, BL; WONG, SH; HONG, WJ				LOW, SH; TANG, BL; WONG, SH; HONG, WJ			GOLGI RETARDATION IN MADIN-DARBY CANINE KIDNEY AND CHINESE-HAMSTER OVARY CELLS OF A TRANSMEMBRANE CHIMERA OF 2 SURFACE-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL PEPTIDASE-IV; ASPARAGINE-LINKED OLIGOSACCHARIDES; BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; ROUGH ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEIN; AMINOPEPTIDASE-N; RETENTION; TRANSPORT; APPARATUS; DOMAIN	Dipeptidyl peptidase IV (DDD) is a type II plasma membrane protein. Replacement of its transmembrane domain with that of another surface protein, aminopeptidase N, resulted in accumulation in the Golgi apparatus of Madin-Darby canine kidney cells and a delayed Golgi to surface transport in Chinese hamster ovary (CHO) cells. The compartment of retardation was identified as post medial-Golgi, most likely to be the trans-Golgi/trans Golgi network (TGN). Compared to native DDD, the rate of endoplasmic reticulum to Golgi transport for the chimera was largely unchanged in both cell types. On the other hand, Golgi to surface transport was delayed by more than 2 h in CHO cells and essentially undetectable up to 22 h of chase in Madin-Darby canine kidney cells. The decrease in the rate of Golgi to surface transport in CHO cells resulted in a significant accumulation of the fusion protein in the trans-Golgi/TGN. This phenomena is very unlikely to be due to any drastic conformational changes, as neither the enzyme activity nor the dimerization of the constructed molecule was affected. The findings of this study indicate that the transmembrane domain, in the context of its flanking sequences, is important for efficient Golgi to cell surface transport.	NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,MEMBRANE BIOL LAB,10 KENT RIDGE CRESCENT,SINGAPORE 0511,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore			Tang, Bor Luen/E-4548-2012; HONG, Wanjin/E-9927-2010	Tang, Bor Luen/0000-0002-1925-636X; 				AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DUNPHY WG, 1985, CELL, V40, P463, DOI 10.1016/0092-8674(85)90161-8; DUNPHY WG, 1983, J CELL BIOL, V97, P270, DOI 10.1083/jcb.97.1.270; FARQUHAR MG, 1981, J CELL BIOL, V91, pS77, DOI 10.1083/jcb.91.3.77s; GABEL CA, 1985, J CELL BIOL, V101, P460, DOI 10.1083/jcb.101.2.460; GARTEN W, 1992, J VIROL, V66, P1495, DOI 10.1128/JVI.66.3.1495-1505.1992; GUAN JL, 1984, CELL, V37, P779, DOI 10.1016/0092-8674(84)90413-6; HAURI HP, 1985, P NATL ACAD SCI USA, V82, P4423, DOI 10.1073/pnas.82.13.4423; HONG WJ, 1989, EXP CELL RES, V182, P256, DOI 10.1016/0014-4827(89)90296-6; HONG WJ, 1990, J CELL BIOL, V111, P323, DOI 10.1083/jcb.111.2.323; HONG WJ, 1989, BIOCHEMISTRY-US, V28, P8474, DOI 10.1021/bi00447a030; HONG WJ, 1993, BIOESSAYS, V15, P231, DOI 10.1002/bies.950150403; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JASCUR T, 1991, BIOCHEMISTRY-US, V30, P1908, DOI 10.1021/bi00221a025; KENNY AJ, 1982, PHYSIOL REV, V62, P91, DOI 10.1152/physrev.1982.62.1.91; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEE EU, 1989, J BIOL CHEM, V264, P13848; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; LOW SH, 1991, J BIOL CHEM, V266, P19710; LOW SH, 1991, J BIOL CHEM, V266, P13391; Machamer C E, 1991, Trends Cell Biol, V1, P141, DOI 10.1016/0962-8924(91)90001-P; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MIZUNO M, 1993, P NATL ACAD SCI USA, V90, P5732, DOI 10.1073/pnas.90.12.5732; MORAN P, 1992, J CELL BIOL, V119, P763, DOI 10.1083/jcb.119.4.763; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; OLSEN J, 1988, FEBS LETT, V238, P307, DOI 10.1016/0014-5793(88)80502-7; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; ROTH J, 1982, J CELL BIOL, V92, P223; ROTHMAN JE, 1987, CELL, V50, P521, DOI 10.1016/0092-8674(87)90024-9; RUSSO RN, 1992, J BIOL CHEM, V267, P9241; Sambrook J, 1989, MOL CLONING LABORATO; SIVASUBRAMANIAN N, 1987, P NATL ACAD SCI USA, V84, P1, DOI 10.1073/pnas.84.1.1; STIEGER B, 1988, J CELL BIOL, V106, P1853, DOI 10.1083/jcb.106.6.1853; TANG BL, 1992, J BIOL CHEM, V267, P7072; TERASAKI M, 1984, CELL, V38, P101, DOI 10.1016/0092-8674(84)90530-0; WARREN G, 1993, NATURE, V362, P297, DOI 10.1038/362297a0; WESSELS HP, 1990, J CELL BIOL, V111, P2923, DOI 10.1083/jcb.111.6.2923; WONG SH, 1992, J CELL BIOL, V117, P245, DOI 10.1083/jcb.117.2.245	52	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1985	1994						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	7904997				2022-12-25	WOS:A1994MR98800068
J	HANDFORD, P; DOWNING, AK; RAO, ZH; HEWETT, DR; SYKES, BC; KIELTY, CM				HANDFORD, P; DOWNING, AK; RAO, ZH; HEWETT, DR; SYKES, BC; KIELTY, CM			THE CALCIUM-BINDING PROPERTIES AND MOLECULAR-ORGANIZATION OF EPIDERMAL GROWTH FACTOR-LIKE DOMAINS IN HUMAN FIBRILLIN-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-LIKE MODULE; HUMAN FACTOR-IX; MARFAN-SYNDROME; FACTOR-X; EGF; GENE; MICROFIBRILS; COMPONENT; MUTATION; RESIDUES	Human fibrillin-1 is a 350-kDa glycoprotein found in 10-nm connective tissue microfibrils. Mutations in the gene encoding this protein cause the Marfan syndrome, a disease characterized by cardiovascular, ocular, and skeletal abnormalities. Fibrillin-1 has a modular structure that includes 47 epidermal growth factor-like (EGF-like) domains, 43 of which contain a consensus sequence associated with calcium binding. A mutation causing an Asn-2144 --> Ser amino acid change in one of the potential calcium binding residues has been described in a patient with the Marfan syndrome. We have chemically synthesized a wild-type EGF-like domain (residues 2126-2165 of human fibrillin-1) and a mutant EGF-like domain containing the Asn-2144 --> Ser amino acid change and measured calcium binding to each using H-1-NMR spectroscopy. The wild-type domain binds calcium with a similar affinity to isolated EGF-like domains from coagulation factors IX and X; however, the mutant domain exhibits >5-fold reduction in affinity. Rotary shadowing of fibrillin-containing microfibrils, isolated from dermal fibroblast cultures obtained from the Marfan patient, shows that the mutation does not prevent assembly of fibrillin into microfibrils but does alter the appearance of the interbead region. We have modeled a region of fibrillin-1 (residues 2126-2331) encompassing five calcium binding FGF-like domains, using data derived from the recently determined crystal structure of a calcium binding EGF-like domain from human factor IX. Our model suggests that these fibrillin-1 EGF-like domains adopt a helical arrangement stabilized by calcium and that defective calcium binding to a single EGF-like domain results in distortion of the helix. We propose a mechanism for the interaction of contiguous arrays of calcium binding EGF-like domains within the microfibril.	UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND; LAB MOLEC BIOPHYS,OXFORD OX1 3QU,ENGLAND; JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND; UNIV MANCHESTER,SCH BIOL SCI,MANCHESTER,LANCS,ENGLAND	University of Oxford; University of Oxford; University of Oxford; University of Manchester	HANDFORD, P (corresponding author), UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,S PARKS RD,OXFORD OX1 3RE,ENGLAND.		Rao, Zihe/HCH-6944-2022					BARON M, 1992, PROTEIN SCI, V1, P81; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; DIETZ HC, 1993, GENOMICS, V17, P468, DOI 10.1006/geno.1993.1349; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; GLANVILLE RW, 1994, 3RD INT S MARF S BER; HANDFORD PA, 1991, NATURE, V353, P395, DOI 10.1038/353395a0; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HEWETT DR, 1993, HUM MOL GENET, V2, P475, DOI 10.1093/hmg/2.4.475; JAENICKE R, 1989, PROTEIN STRUCTURE PR, P208; KAINULAINEN K, 1994, NAT GENET, V6, P64, DOI 10.1038/ng0194-64; KIELTY CM, 1993, MATRIX, V13, P103, DOI 10.1016/S0934-8832(11)80069-7; KIELTY CM, 1993, FEBS LETT, V336, P323, DOI 10.1016/0014-5793(93)80829-J; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; MASLEN CL, 1993, 9TH ANN C NAT MARF F; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; PERSSON E, 1989, J BIOL CHEM, V264, P16897; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; RING CS, 1993, FASEB J, V7, P783, DOI 10.1096/fasebj.7.9.8330685; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SELANDER M, 1990, BIOCHEMISTRY-US, V29, P8111, DOI 10.1021/bi00487a018; VALCARCE C, 1993, J BIOL CHEM, V268, P26673	24	93	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6751	6756		10.1074/jbc.270.12.6751	http://dx.doi.org/10.1074/jbc.270.12.6751			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896820	hybrid			2022-12-25	WOS:A1995QQ85500051
J	JENSEN, DE; RICH, CB; TERPSTRA, AJ; FARMER, SR; FOSTER, JA				JENSEN, DE; RICH, CB; TERPSTRA, AJ; FARMER, SR; FOSTER, JA			TRANSCRIPTIONAL REGULATION OF THE ELASTIN GENE BY INSULIN-LIKE GROWTH-FACTOR-I INVOLVES DISRUPTION OF SP1 BINDING - EVIDENCE FOR THE ROLE OF RB IN MEDIATING SP1 BINDING IN AORTIC SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5'-FLANKING REGION; MESSENGER-RNA; PROMOTER; TROPOELASTIN; EXPRESSION; PROTEINS; ELEMENT; ELASTOGENESIS; ACTIVATION; SEQUENCE	We have recently identified a novel element (EFE 5/6) in the human elastin gene promoter that modulates the ability of insulin-like growth factor I (IGF-I) to up-regulate elastin gene transcription in aortic smooth muscle cells. In the present study, we have pursued the identification of those nuclear proteins binding to the EFE 5/6 element and affected by IGF-I treatment. Chelation inactivation and metal reactivation experiments together with supershift gel analyses demonstrated that Spl was one of the proteins affected by IGF-I. Southwestern and Western analyses showed that Sp1 was present in IGF-I nuclear extracts and capable of binding DNA after fractionation. Addition of retinoblastoma gene product (Rb) antibody mimicked the effect of IGF-I in gel shift analysis, suggesting that Sp1 binding may be regulated by an inhibitor normally associated with Rb. The fact that the phosphorylation state of Rb was affected by IGF-I was shown by Western blot analysis. The control smooth muscle. cells transcribed the elastin gene at a high level without addition of IGF-I, so it is likely that disruption of Sp1 binding is the first step in allowing the binding of a more potent activating factor.	BOSTON UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02118 USA	Boston University				Farmer, Stephen/0000-0003-2483-2795	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013262, T32HL007429] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL13262, HL07429] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEMANY J, 1992, BIOCHEM BIOPH RES CO, V183, P659, DOI 10.1016/0006-291X(92)90533-Q; ALEMANY J, 1990, P NATL ACAD SCI USA, V87, P3353, DOI 10.1073/pnas.87.9.3353; BASHIR MM, 1989, J BIOL CHEM, V264, P8887; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BURNETT W, 1980, BIOCHEMISTRY-US, V19, P1106, DOI 10.1021/bi00547a010; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; DAVIDSON JM, 1986, BIOL EXTRACELLULAR M, V1, P177; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAZIO MJ, 1990, J INVEST DERMATOL, V94, P191, DOI 10.1111/1523-1747.ep12874495; FOSTER J, 1987, COLLAGEN REL RES, V7, P161; FOSTER JA, 1989, MATRIX, V9, P328, DOI 10.1016/S0934-8832(89)80009-5; FOSTER JA, 1990, J GERONTOL, V45, pB113, DOI 10.1093/geronj/45.4.B113; GLOSS B, 1990, J VIROL, V64, P5577, DOI 10.1128/JVI.64.11.5577-5584.1990; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAHARI VM, 1992, J BIOL CHEM, V267, P26134; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KUTOH E, 1993, BIOCHEM BIOPH RES CO, V194, P1475, DOI 10.1006/bbrc.1993.1991; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFEVRE M, 1983, BIOCHIM BIOPHYS ACTA, V743, P338, DOI 10.1016/0167-4838(83)90391-6; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; RICH CB, 1993, BIOCHEM BIOPH RES CO, V196, P1316, DOI 10.1006/bbrc.1993.2396; RICH CB, 1992, AM J PHYSIOL, V263, pL276, DOI 10.1152/ajplung.1992.263.2.L276; RITZENTHALER JD, 1991, BIOCHEM J, V280, P157, DOI 10.1042/bj2800157; SAMBROOK J, 1989, MOL CLONING LABORATO, pL42; SHIBAHARA S, 1981, BIOCHEMISTRY-US, V20, P6577, DOI 10.1021/bi00526a009; SYKES K, 1990, MOL CELL BIOL, V10, P95, DOI 10.1128/MCB.10.1.95; TERPSTRA AJ, 1994, THESIS BOSTON U, P55; TOSELLI P, 1992, MATRIX, V12, P321, DOI 10.1016/S0934-8832(11)80084-3; TOWBIN H, 1982, J BIOL CHEM, V257, P2709; WOLFE BL, 1993, J BIOL CHEM, V268, P12418; YEH H, 1989, BIOCHEMISTRY-US, V28, P2365, DOI 10.1021/bi00432a003; YU CY, 1991, J BIOL CHEM, V266, P8907	35	78	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6555	6563		10.1074/jbc.270.12.6555	http://dx.doi.org/10.1074/jbc.270.12.6555			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896792	hybrid			2022-12-25	WOS:A1995QQ85500022
J	LESAUTEUR, L; WEI, L; GIBBS, BF; SARAGOVI, HU				LESAUTEUR, L; WEI, L; GIBBS, BF; SARAGOVI, HU			SMALL PEPTIDE MIMICS OF NERVE GROWTH-FACTOR BIND TRKA RECEPTORS AND AFFECT BIOLOGICAL RESPONSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY NGF RECEPTOR; PHEOCHROMOCYTOMA CELLS; NEUROTROPHIN RECEPTORS; MOLECULAR-CLONING; GENE-TRANSFER; PROTOONCOGENE; ANTIBODIES; BDNF; DIFFERENTIATION; ASSOCIATION	Small monomeric cyclic analogs that mimic the beta-turn regions of nerve growth factor (NGF) were designed and synthesized. Potent competitive antagonists were de rived from the NGF beta-turn C-D, which inhibited [I-125] NGF binding to TrkA receptors and specifically inhibited optimal NGF-mediated neurite outgrowth in PC12 cells. The cyclic beta-turn A'-A'' analog also inhibited NGF binding to TrkA receptors but with lower potency. These data indicate that beta-turns C-D and A'-A'' are critical for TrkA binding and may confer neurotrophin receptor specificity. Furthermore, structural requirements for binding are absolute, because unconstrained analogs derived from the same regions had no effect. Compounds that mimic NGF will be useful in deciphering the interactions of NGF and its receptors and in rational drug design.	MCGILL UNIV,DEPT THERAPEUT & PHARMACOL,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,CTR CANC,MONTREAL,PQ H3G 1Y6,CANADA; BIOTECHNOL RES INST,MONTREAL,PQ H4P 2R2,CANADA	McGill University; McGill University; National Research Council Canada								BERG MM, 1992, J BIOL CHEM, V267, P13; BERND P, 1984, J BIOL CHEM, V259, P5509; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHEN SX, 1992, P NATL ACAD SCI USA, V89, P5872, DOI 10.1073/pnas.89.13.5872; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; DELAPAZ P, 1986, EMBO J, V5, P415, DOI 10.1002/j.1460-2075.1986.tb04227.x; EBENDAL T, 1989, J NEUROSCI RES, V22, P223, DOI 10.1002/jnr.490220302; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; IBANEZ CF, 1991, EMBO J, V10, P2105, DOI 10.1002/j.1460-2075.1991.tb07743.x; IBANEZ CF, 1993, EMBO J, V12, P2281, DOI 10.1002/j.1460-2075.1993.tb05882.x; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAHLE P, 1992, J BIOL CHEM, V267, P22707; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LOEB DM, 1993, J NEUROSCI, V13, P2919; LONGO FM, 1990, CELL REGUL, V1, P189, DOI 10.1091/mbc.1.2.189; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; MCDONALD NQ, 1991, NATURE, V345, P411; MEIER R, 1986, EMBO J, V5, P1489, DOI 10.1002/j.1460-2075.1986.tb04387.x; MURPHY RA, 1993, J NEUROSCI, V13, P2853; NANDURI J, 1994, J NEUROSCI RES, V37, P433, DOI 10.1002/jnr.490370402; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; SARAGOVI HU, 1991, SCIENCE, V253, P792, DOI 10.1126/science.1876837; SARAGOVI HU, 1992, BIO-TECHNOL, V10, P773, DOI 10.1038/nbt0792-773; SARAGOVI HU, 1992, IMMUNOMETHODS, V1, P3; Server A C, 1977, Adv Protein Chem, V31, P339, DOI 10.1016/S0065-3233(08)60221-1; SIBANDA BL, 1985, NATURE, V316, P170, DOI 10.1038/316170a0; SIBANDA BL, 1989, J MOL BIOL, V206, P759, DOI 10.1016/0022-2836(89)90583-4; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; VOLONTE C, 1993, J BIOL CHEM, V268, P21410	43	106	128	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6564	6569		10.1074/jbc.270.12.6564	http://dx.doi.org/10.1074/jbc.270.12.6564			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896793	hybrid			2022-12-25	WOS:A1995QQ85500023
J	NAGAI, K; TAKATA, M; YAMAMURA, H; KUROSAKISO, T				NAGAI, K; TAKATA, M; YAMAMURA, H; KUROSAKISO, T			TYROSINE PHOSPHORYLATION OF SHC IS MEDIATED THROUGH LYN AND SYK IN B-CELL RECEPTOR SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; EPIDERMAL GROWTH-FACTOR; ANTIGEN RECEPTOR; LYMPHOCYTES-B; IG-ALPHA; ZETA-CHAIN; PROTEIN; RAS; ACTIVATION; KINASES	She protein is tyrosine phosphorylated upon B cell receptor (BCR) activation and after its phosphorylation interacts with the adaptor protein Grb2. In turn, Grb2 interacts with the guanine nucleotide exchange factor for Ras, mSOS. Several protein-tyrosine kinases (PTKs) participate in BCR signaling. However, it is not clear which PTK is involved in the phosphorylation of Shc, resulting in coupling to the Ras pathway. Tyrosine phosphorylation of Shc and its association with Grb2 were profoundly reduced in both Lyn- and Syk-deficient B cells upon BCR stimulation. Furthermore, kinase activity of these PTKs was required for phosphorylation of Shc. Shc interacted with Syk in B cells. This interaction and the requirement of Syk kinase activity for phosphorylation of Shc were also demonstrated by cotransfection in COS cells. Because Lyn is required for activation of Syk upon receptor stimulation, our results suggest that the Lyn-activated Syk phosphorylates Shc during BCR signaling.	AMER CYANAMID CO,LEDERLE LABS,DEPT CARDIOVASC MOLEC BIOL,PEARL RIVER,NY 10965; FUKUI MED SCH,DEPT BIOCHEM,MATUOKA,FUKUI 91011,JAPAN; YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510	University of Fukui; Yale University				Takata, Minoru/0000-0002-4926-3675				BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURG DL, 1994, J BIOL CHEM, V269, P28136; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; EAGAN SE, 1993, NATURE, V363, P45; FLASWINKEL H, 1994, EMBO J, V13, P83, DOI 10.1002/j.1460-2075.1994.tb06237.x; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GULBINS E, 1994, J IMMUNOL, V152, P2123; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HARWOOD AE, 1993, J IMMUNOL, V151, P4513; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; KIM KM, 1993, EUR J IMMUNOL, V23, P911, DOI 10.1002/eji.1830230422; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KUROSAKI T, 1991, P NATL ACAD SCI USA, V88, P3837, DOI 10.1073/pnas.88.9.3837; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LAW DA, 1993, CURR BIOL, V3, P645, DOI 10.1016/0960-9822(93)90062-S; LAZARUS AH, 1993, J EXP MED, V178, P1765, DOI 10.1084/jem.178.5.1765; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MUROYA K, 1992, ONCOGENE, V7, P277; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLEIMAN CM, 1994, P NATL ACAD SCI USA, V91, P4268, DOI 10.1073/pnas.91.10.4268; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SANCHEZ M, 1993, J EXP MED, V178, P1049, DOI 10.1084/jem.178.3.1049; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SAXTON TM, 1994, J IMMUNOL, V153, P623; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMIT L, 1994, J BIOL CHEM, V269, P20209; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TAKEUCHI F, 1993, BIOCHEM BIOPH RES CO, V194, P91, DOI 10.1006/bbrc.1993.1789; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TORDAI A, 1994, J BIOL CHEM, V269, P7538; YAMADA T, 1993, EUR J BIOCHEM, V213, P455, DOI 10.1111/j.1432-1033.1993.tb17781.x; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903	58	87	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6824	6829		10.1074/jbc.270.12.6824	http://dx.doi.org/10.1074/jbc.270.12.6824			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896829	hybrid			2022-12-25	WOS:A1995QQ85500060
J	AITKEN, A; HOWELL, S; JONES, D; MADRAZO, J; PATEL, Y				AITKEN, A; HOWELL, S; JONES, D; MADRAZO, J; PATEL, Y			14-3-3-ALPHA AND 14-3-3-DELTA ARE THE PHOSPHORYLATED FORMS OF RAF-ACTIVATING 14-3-3-BETA AND 14-3-3-ZETA - IN-VIVO STOICHIOMETRIC PHOSPHORYLATION IN BRAIN AT A SER-PRO-GLU-LYS MOTIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							C INHIBITOR PROTEINS; SHEEP BRAIN; KINASE-II; TYROSINE; PURIFICATION; SEQUENCE; ISOFORMS; FAMILY	The 14-3-3 protein family has received considerable attention recently in the literature, because of the finding that beta and zeta isoforms interact with and activate Raf. We had previously shown that these 14-3-3 isoforms also exist as phosphorylated forms in mammalian and avian brain. The presence of this modification enhances the activity of 14-3-3 as an inhibitor of protein kinase C nearly 2-fold. In this report we show by a combination of electrospray mass spectrometry and protein microsequencing that alpha and delta are in vivo post-translationally modified forms of beta and zeta, respectively, and the site of phosphorylation, serine 185, is in a consensus sequence motif for proline-directed kinases.	CIGB,HAVANA,CUBA		AITKEN, A (corresponding author), NATL INST MED RES,PROT STRUCT LAB,MILL HILL,LONDON NW7 1AA,ENGLAND.			Soneji, Yasmina/0000-0001-9189-6348	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AITKEN A, 1990, NATURE, V344, P594; AITKEN A, 1994, J PROTEIN CHEM, V13, P463; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; AITKEN A, 1990, IDENTIFICATION PROTE, P1; AITKEN A, 1989, PROTEIN SEQUENCING P, P43; AITKEN A, 1994, IN PRESS MOL CELL BI; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FERL RJ, 1994, GENETICA, V92, P129, DOI 10.1007/BF00163762; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; GEISOW MJ, 1989, PROTEIN SEQUENCING P, P85; HARDIE DG, 1993, PROTEIN PHOSPHORYLAT, P61; HIRSCH S, 1992, FEBS LETT, V296, P222, DOI 10.1016/0014-5793(92)80384-S; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; ICHIMURA T, 1987, FEBS LETT, V219, P79, DOI 10.1016/0014-5793(87)81194-8; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; ISOBE T, 1992, FEBS LETT, V308, P121, DOI 10.1016/0014-5793(92)81257-M; KAY I, 1993, RAPID COMMUN MASS SP, V7, P744, DOI 10.1002/rcm.1290070812; MARTENS GJM, 1992, BIOCHEM BIOPH RES CO, V184, P1456, DOI 10.1016/S0006-291X(05)80046-4; MARTIN H, 1993, FEBS LETT, V331, P296, DOI 10.1016/0014-5793(93)80356-Y; MOORE B W, 1968, PHYSIOLOGICAL AND BIOCHEMICAL ASPECTS OF NERVOUS INTEGRATION, P343; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PARKER PJ, 1982, EUR J BIOCHEM, V124, P47, DOI 10.1111/j.1432-1033.1982.tb05904.x; PATEL Y, 1995, BIOCHIM BIOPHYS ACTA, V1222, P405; PEARSON RB, 1993, PROTEIN PHOSPHORYLAT, P265; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; ROBINSON K, 1994, BIOCHEM J, V299, P853, DOI 10.1042/bj2990853; ROSEBOOM PH, 1994, DNA CELL BIOL, V13, P629, DOI 10.1089/dna.1994.13.629; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; SWANSON KD, 1992, GENE, V113, P183, DOI 10.1016/0378-1119(92)90394-5; TOKER A, 1992, EUR J BIOCHEM, V206, P453, DOI 10.1111/j.1432-1033.1992.tb16946.x; TOKER A, 1990, EUR J BIOCHEM, V191, P421, DOI 10.1111/j.1432-1033.1990.tb19138.x; VANHEUSDEN GPH, 1992, FEBS LETT, V302, P145, DOI 10.1016/0014-5793(92)80426-H; WANG WF, 1994, GENE, V147, P215, DOI 10.1016/0378-1119(94)90068-X	37	164	172	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					5706	5709		10.1074/jbc.270.11.5706	http://dx.doi.org/10.1074/jbc.270.11.5706			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890696	hybrid			2022-12-25	WOS:A1995QM94500006
J	HENDERSON, LM; BANTING, G; CHAPPELL, JB				HENDERSON, LM; BANTING, G; CHAPPELL, JB			THE ARACHIDONATE-ACTIVABLE, NADPH OXIDASE-ASSOCIATED H+ CHANNEL - EVIDENCE THAT GP91-PHOX FUNCTIONS AS AN ESSENTIAL PART OF THE CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; NEUTROPHIL CYTOCHROME-B; HYDROGEN-ION CURRENTS; SUPEROXIDE GENERATION; PLASMA-MEMBRANE; POLYMORPHONUCLEAR LEUKOCYTES; RESPIRATORY BURST; INTRACELLULAR PH; CYTOPLASMIC PH; LYMPHOCYTES-B	The human neutrophil NADPH oxidase-associated H+ channel acts as a charge compensator for the electrogenic generation of superoxide (O-2(.-)). The expression of the channel activity was found to increase in parallel with that of the stimulatable generation of O-2(.-) in differentiated HL60 cells, HL60 cells induced to differentiate in the presence of succinyl acetone (a inhibitor of heme synthesis) were unable to generate O-2(.-), failed to express p22-phox but retained H+ channel activity. EBV transformed B lymphocyte cell lines from normal and CGD patients lacking expression of either p47-phox or p67-phox all expressed unaltered channel activity; however, the activity was completely absent in the lymphocyte cell line lacking gp91-phox. CHO cells and undifferentiated HL60 cells transfected with gp91-phox cDNA expressed H+ channel activity correlating with the expression of gp91-phox. We therefore conclude that the large subunit of the NADPH oxidase cytochrome b (gp91-phox) is the arachidonate activable H+ channel of human neutrophils.			HENDERSON, LM (corresponding author), UNIV BRISTOL,SCH MED SCI,DEPT BIOCHEM,UNIV WALK,BRISTOL BS8 1TD,AVON,ENGLAND.			Banting, George/0000-0001-8249-1621				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BASHFORD CL, 1985, BIOCHIM BIOPHYS ACTA, V817, P174, DOI 10.1016/0005-2736(85)90080-X; BELETSKY IP, 1990, J IMMUNOL METHODS, V134, P201, DOI 10.1016/0022-1759(90)90381-5; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; DAVIS RC, 1987, DEV BIOL, V119, P164, DOI 10.1016/0012-1606(87)90218-1; DECOURSEY TE, 1993, BIOPHYS J, V65, P1590, DOI 10.1016/S0006-3495(93)81198-6; DEMAUREX N, 1993, J PHYSL, V466, P323; DINAUER MC, 1987, NATURE, V327, P717, DOI 10.1038/327717a0; EBERT PS, 1979, BIOCHEM BIOPH RES CO, V88, P1382, DOI 10.1016/0006-291X(79)91133-1; GRINSTEIN S, 1986, J BIOL CHEM, V261, P512; GRINSTEIN S, 1985, AM J PHYSIOL, V248, pC379, DOI 10.1152/ajpcell.1985.248.3.C379; HANCOCK JT, 1990, IMMUNOLOGY, V71, P213; HANCOCK JT, 1991, EUR J CLIN INVEST, V21, P208; HENDERSON LM, 1987, BIOCHEM J, V246, P325, DOI 10.1042/bj2460325; HENDERSON LM, 1992, BIOCHEM J, V283, P171, DOI 10.1042/bj2830171; HENDERSON LM, 1988, BIOCHEM J, V255, P285; HENDERSON LM, 1988, BIOCHEM J, V251, P563, DOI 10.1042/bj2510563; HENDERSON LM, 1994, BLOOD, V84, P474; HURST JK, 1991, J BIOL CHEM, V266, P1627; KAPUS A, 1993, J GEN PHYSIOL, V102, P729, DOI 10.1085/jgp.102.4.729; KORCHAK HM, 1983, P NATL ACAD SCI-BIOL, V80, P4968, DOI 10.1073/pnas.80.16.4968; KUROKI M, 1982, BIOCHIM BIOPHYS ACTA, V693, P326, DOI 10.1016/0005-2736(82)90439-4; LEVY R, 1990, J IMMUNOL, V145, P2595; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MALY FE, 1989, J IMMUNOL, V142, P1260; MARIDONNEAUPARI.I, 1991, J CLIN INVEST, V87, P901; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; NANDA A, 1993, P NATL ACAD SCI USA, V90, P760, DOI 10.1073/pnas.90.2.760; NANDA A, 1994, J CLIN INVEST, V93, P1770, DOI 10.1172/JCI117162; NANDA A, 1994, J BIOL CHEM, V269, P27280; NEWBURGER PE, 1984, J BIOL CHEM, V259, P3771; NUGENT JHA, 1989, BIOCHEM J, V264, P921, DOI 10.1042/bj2640921; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; QUINN MT, 1992, J BIOL CHEM, V267, P7303; REAVES B, 1994, FEBS LETT, V351, P448, DOI 10.1016/0014-5793(94)00813-2; ROBERTS PJ, 1982, J CELL BIOL, V95, P720, DOI 10.1083/jcb.95.3.720; ROOS D, 1994, IMMUNOL REV, V138, P121, DOI 10.1111/j.1600-065X.1994.tb00850.x; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; Sambrook J, 1989, MOL CLONING LABORATO; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SELIGMANN BE, 1980, J MEMBRANE BIOL, V52, P257, DOI 10.1007/BF01869194; SHOTTON D, 1989, TRENDS BIOCHEM SCI, V14, P435, DOI 10.1016/0968-0004(89)90096-0; SHOTTON DM, 1989, J CELL SCI, V94, P175; TEAHAN C, 1987, NATURE, V327, P720, DOI 10.1038/327720a0; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; THOMAS RC, 1982, NATURE, V299, P826, DOI 10.1038/299826a0; UENO I, 1991, FEBS LETT, V281, P130, DOI 10.1016/0014-5793(91)80375-D; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557	53	98	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					5909	5916		10.1074/jbc.270.11.5909	http://dx.doi.org/10.1074/jbc.270.11.5909			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890722	hybrid			2022-12-25	WOS:A1995QM94500034
J	LEVITAN, ES; GEALY, R; TRIMMER, JS; TAKIMOTO, K				LEVITAN, ES; GEALY, R; TRIMMER, JS; TAKIMOTO, K			MEMBRANE DEPOLARIZATION INHIBITS KV1.5 VOLTAGE-GATED K+ CHANNEL GENE-TRANSCRIPTION AND PROTEIN EXPRESSION IN PITUITARY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN-RELEASING-HORMONE; POTASSIUM CHANNEL; RAT-BRAIN; CALCIUM CHANNELS; DIFFERENTIAL EXPRESSION; NERVOUS-SYSTEM; MESSENGER-RNA; GH3 CELLS; CLONING; HEART	Voltage-gated K+ channels play an essential role in the production of action potential activity by excitable cells, Recent studies have suggested that expression of K+ channel genes may be regulated by stimuli that affect electrical activity. Elevating the concentration of extracellular KCl causes membrane depolarization and, thus, is widely used for studying electrical activity-dependent changes in neurons, muscle, and endocrine cells. Here we show that elevated KCl decreases Kv1.5 K+ channel mRNA expression in clonal pituitary cells without affecting Ev1.4 and Rv2.1 mRNA levels, K+ channel blockers, which cause depolarization, also produce down-regulation of Kv1.5 mRNA, while NaCl addition had no effect. Thus, the effect of KCl is mediated by K+-induced membrane depolarization. Unlike many known effects of K down-regulation of Kv1.5 mRNA does not require Ca2+ or Na+ influx, or Na+-H+ exchange. Furthermore, the decrease in Kv1.5 mRNA expression is due to inhibition of channel gene transcription and persists after inhibition of protein synthesis, excluding a role for induction of intermediary regulatory proteins. Finally, immunoblots with antibody specific for the Kv1.5 polypeptide show that depolarization for 8 h reduces the expression of Kv1.5 channel protein. The decrease in K+ channel protein expression caused by depolarization-induced Ca2+-independent inhibition of Kv1.5 gene transcription may produce a longterm enhancement of pituitary cell excitability and secretory activity.	SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	LEVITAN, ES (corresponding author), UNIV PITTSBURGH,DEPT PHARMACOL E1355BST,PITTSBURGH,PA 15261, USA.				NINDS NIH HHS [NS 29876, NS 29804] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R55NS029876, R29NS029804] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBERT PR, 1984, J BIOL CHEM, V259, P5827; ATTARDI B, 1993, RECEPTOR CHANNEL, V1, P287; BECKH S, 1990, EMBO J, V9, P777, DOI 10.1002/j.1460-2075.1990.tb08173.x; BLACK IB, 1987, SCIENCE, V236, P1263, DOI 10.1126/science.2884727; BONINI JA, 1991, BIOTECHNIQUES, V11, P708; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DREWE JA, 1992, J NEUROSCI, V12, P538; FOLANDER K, 1990, P NATL ACAD SCI USA, V87, P2975, DOI 10.1073/pnas.87.8.2975; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; FUJIMOTO J, 1992, ENDOCRINOLOGY, V130, P1879, DOI 10.1210/en.130.4.1879; GERSHENGORN MC, 1985, ENDOCRINOLOGY, V116, P591, DOI 10.1210/endo-116-2-591; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; HONORE E, 1994, P NATL ACAD SCI USA, V91, P1937, DOI 10.1073/pnas.91.5.1937; KRAMER RH, 1991, NEURON, V6, P557, DOI 10.1016/0896-6273(91)90058-8; LAUFER R, 1989, MOL NEUROBIOL, V3, P1, DOI 10.1007/BF02935587; LEVITAN ES, 1991, MOL ENDOCRINOL, V5, P1903, DOI 10.1210/mend-5-12-1903; LEVITAN ES, 1991, SOC NEUR ABSTR, V17, P1098; LOPEZBARNEO J, 1992, RECEPTOR CHANNEL, V1, P61; MARIOT P, 1993, ENDOCRINOLOGY, V132, P846, DOI 10.1210/en.132.2.846; MATSUBARA H, 1993, J CLIN INVEST, V92, P1659, DOI 10.1172/JCI116751; MATTESON DR, 1986, J GEN PHYSIOL, V87, P161, DOI 10.1085/jgp.87.1.161; MEYERHOF W, 1992, J NEUROENDOCRINOL, V4, P245, DOI 10.1111/j.1365-2826.1992.tb00166.x; MORGAN JI, 1988, CELL CALCIUM, V9, P303, DOI 10.1016/0143-4160(88)90011-5; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MORI Y, 1993, J BIOL CHEM, V268, P26482; PARDO LA, 1992, P NATL ACAD SCI USA, V89, P2466, DOI 10.1073/pnas.89.6.2466; PASSAFARO M, 1992, J NEUROSCI, V12, P3372; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; RAMPE D, 1993, MOL PHARMACOL, V44, P1240; RAMPE D, 1993, MOL PHARMACOL, V44, P642; RIHERA AG, 1990, NEURON, V5, P691; ROBERDS SL, 1991, P NATL ACAD SCI USA, V88, P1798, DOI 10.1073/pnas.88.5.1798; ROBERDS SL, 1991, FEBS LETT, V284, P152, DOI 10.1016/0014-5793(91)80673-Q; SIMASKO SM, 1988, AM J PHYSIOL, V254, pE328, DOI 10.1152/ajpendo.1988.254.3.E328; SNYDERS DJ, 1992, MOL PHARMACOL, V41, P322; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; TAKIMOTO K, 1994, CIRC RES, V75, P1006, DOI 10.1161/01.RES.75.6.1006; TAKIMOTO K, 1993, NEURON, V11, P359, DOI 10.1016/0896-6273(93)90191-S; TAKIMOTO K, 1995, J NEUROSCI, V15, P449; TAKIMOTO K, IN PRESS BIOCH BIOPH; TORNQUIST K, 1991, ENDOCRINOLOGY, V128, P242; TSAUR ML, 1992, NEURON, V8, P1055, DOI 10.1016/0896-6273(92)90127-Y; WAECHTER CJ, 1983, J BIOL CHEM, V258, P5117	43	63	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					6036	6041		10.1074/jbc.270.11.6036	http://dx.doi.org/10.1074/jbc.270.11.6036			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890735	hybrid			2022-12-25	WOS:A1995QM94500051
J	ONO, SJ; SONG, Z				ONO, SJ; SONG, Z			MAPPING OF THE INTERACTION SITE OF THE DEFECTIVE TRANSCRIPTION FACTOR IN THE CLASS-II MAJOR HISTOCOMPATIBILITY COMPLEX MUTANT-CELL LINE CLONE-13 TO THE DIVERGENT X2-BOX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-BOX-BINDING; BARE LYMPHOCYTE SYNDROME; HLA-DRA GENE; B-CELL; INTERFERON-GAMMA; C-FOS; EXPRESSION; PROMOTERS; PROTEIN; CLONING	We have previously described a mutant B lymphoblastoid cell line, Clone-13, that expresses HLA-DQ in the absence of HLA-DR and -DP, Several criteria indicated that the defect in this cell line influences the activity of an isotype-specific transcription factor. Indeed, transient transfection of HLA-DRA and DQB reporter constructs indicated that the affected factor operates via cis-elements located between -141 base pairs and the transcription initiation site. A series of hybrid DRA/DQB reporter constructs was generated to further map the relevant cis-elements in this system, Insertion of oligonucleotides spanning the DQB X-box (but not the DQB-W region or the DQB Y-box) upstream of -141 in a DRA reporter plasmid rescued expression to nearly wild-type levels, Substitution promoters were then generated where the entire X-box, or only the X1- or X2-boxes of HLA-DRA were replaced with the analogous regions of HLA-DQB. The DQB X2-box was able to restore expression to the silent DRA reporter construct. Moreover, replacement of the DQB X2-box with the DRA X2-box markedly diminished the activity of the DQB promoter in the mutant cell, None of the hybrid reporter constructs were defective when transfected into the wild-type, HLA-DR/-DQ positive that the divergent X2-box of the class II major histocompatibility complex promoters plays an important role in influencing differential expression of the human class II isotypes.	JOHNS HOPKINS UNIV,SCH MED,LUCILLE P MARKEY GRAD PROGRAM CELLULAR MOLEC MED,BALTIMORE,MD 21224; JOHNS HOPKINS UNIV,SCH PUBL HLTH,DEPT MOLEC MICROBIOL & IMMUNOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	ONO, SJ (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MED,5501 HOPKINS BAYVIEW CIR,RM 2A38,BALTIMORE,MD 21224, USA.							BENICHOU B, 1991, P NATL ACAD SCI USA, V88, P4285, DOI 10.1073/pnas.88.10.4285; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BOOTHBY M, 1989, J IMMUNOL, V142, P1005; DAS HK, 1983, P NATL ACAD SCI-BIOL, V80, P3543, DOI 10.1073/pnas.80.12.3543; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FINN PW, 1990, J EXP MED, V171, P2159, DOI 10.1084/jem.171.6.2159; FINN PW, 1990, EMBO J, V9, P1543, DOI 10.1002/j.1460-2075.1990.tb08273.x; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GLADSTONE P, 1978, NATURE, V271, P459, DOI 10.1038/271459a0; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; HENLE W, 1967, SCIENCE, V157, P1064, DOI 10.1126/science.157.3792.1064; HESTON L, 1982, NATURE, V295, P160, DOI 10.1038/295160a0; Hinuma Y, 1967, J Virol, V1, P1045; KAPPES D, 1988, ANNU REV BIOCHEM, V57, P991, DOI 10.1146/annurev.bi.57.070188.005015; KARA CJ, 1991, SCIENCE, V252, P709, DOI 10.1126/science.1902592; KOBR M, 1990, MOL CELL BIOL, V10, P965, DOI 10.1128/MCB.10.3.965; LUCEY DR, 1989, P NATL ACAD SCI USA, V86, P1348, DOI 10.1073/pnas.86.4.1348; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; ONO SJ, 1991, P NATL ACAD SCI USA, V88, P4304, DOI 10.1073/pnas.88.10.4304; ONO SJ, 1991, P NATL ACAD SCI USA, V88, P4309, DOI 10.1073/pnas.88.10.4309; ONO SJ, 1991, J EXP MED, V173, P629, DOI 10.1084/jem.173.3.629; PUJOLBORRELL R, 1987, NATURE, V326, P304, DOI 10.1038/326304a0; REITH W, 1988, CELL, V53, P897, DOI 10.1016/S0092-8674(88)90389-3; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; REITH W, 1989, P NATL ACAD SCI USA, V86, P4200, DOI 10.1073/pnas.86.11.4200; SONG ZM, 1994, J EXP MED, V180, P1763, DOI 10.1084/jem.180.5.1763; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; SYMINGTON FW, 1985, J IMMUNOL, V135, P1026; TING JP, 1993, IMMUNOL RES, V12, P65, DOI 10.1007/BF02918369; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VILEN BJ, 1992, J BIOL CHEM, V267, P23728; VOLIVA CF, 1993, P NATL ACAD SCI USA, V90, P3408, DOI 10.1073/pnas.90.8.3408; WRIGHT KL, 1992, P NATL ACAD SCI USA, V89, P7601, DOI 10.1073/pnas.89.16.7601; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x	36	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					6396	6402		10.1074/jbc.270.11.6396	http://dx.doi.org/10.1074/jbc.270.11.6396			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890777	hybrid			2022-12-25	WOS:A1995QM94500100
J	LEE, KD; HOLLENBECK, PJ				LEE, KD; HOLLENBECK, PJ			PHOSPHORYLATION OF KINESIN IN-VIVO CORRELATES WITH ORGANELLE ASSOCIATION AND NEURITE OUTGROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; LIGHT-CHAINS; PROTEIN-PHOSPHORYLATION; CYTOPLASMIC DYNEIN; AXONAL-TRANSPORT; PC12 CELLS; BINDING; MELANOPHORES; CYTOSKELETON; MOTILITY	The motor protein kinesin is implicated in organelle movement toward the plus ends of microtubules, but little is known about its interaction with organelle membranes or about the physiological role of the phosphorylation of kinesin and its associated protein kinectin seen in neurons in vivo (Hollenbeck, P. J. (1993) J. Neurochem, 60, 2265-2275). Here we have demonstrated that the kinesin heavy chain (KHC), light chain, and kinectin isolated from chick brain or sympathetic neurons exist in several isoelectric forms. Metabolic labeling followed by phosphatase treatment showed that these are phosphoisoforms, and that phosphorylation is reversible in vitro. To assess the capability of phosphorylation to regulate kinesin's state and/or activity, we performed P-32 and S-35 pulse-chase experiments with neuronal cultures and determined that kinesin-associated phosphate turns over 3-4 times faster than the proteins themselves. When the phosphoisoform distributions for different kinesin pools were analyzed, it was found that membrane associated KHC contained predominantly the most highly phosphorylated isoform, while soluble kinesin consisted of less phosphorylated KHC isoforms. Nerve growth factor-induced neurite outgrowth in PC12 cells was found to increase significantly kinesin's P-32 specific activity while doubling the relative abundance of the most highly phosphorylated IMC isoform. These results demonstrate that the phosphorylation state of kinesin is closely coupled to its organelle binding and to the magnitude of organelle transport in the cell. We propose that the phosphorylation state of kinesin and associated proteins may regulate motility via association with organelle membranes and, specifically, that KHC phosphorylation induces membrane association.	HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NINDS NIH HHS [NS27073] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS027073, R01NS027073] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMARATUNGA A, 1993, J BIOL CHEM, V268, P17427; BRADY ST, 1991, NEURON, V7, P521, DOI 10.1016/0896-6273(91)90365-7; CITI S, 1987, BIOESSAYS, V7, P155, DOI 10.1002/bies.950070404; CUTLER DF, 1990, J CELL BIOL, V110, P721, DOI 10.1083/jcb.110.3.721; CYR JL, 1991, P NATL ACAD SCI USA, V88, P10114, DOI 10.1073/pnas.88.22.10114; FERREIRA A, 1992, J CELL BIOL, V117, P595, DOI 10.1083/jcb.117.3.595; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HACKNEY DD, 1992, J BIOL CHEM, V267, P8696; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; Hirokawa Nobutaka, 1993, Current Opinion in Neurobiology, V3, P724, DOI 10.1016/0959-4388(93)90144-N; HOLLENBECK PJ, 1986, J CELL BIOL, V103, P1539, DOI 10.1083/jcb.103.4.1539; HOLLENBECK PJ, 1993, J CELL BIOL, V121, P305, DOI 10.1083/jcb.121.2.305; HOLLENBECK PJ, 1993, J NEUROCHEM, V60, P2265, DOI 10.1111/j.1471-4159.1993.tb03513.x; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; INGOLD AL, 1988, J CELL BIOL, V107, P2657, DOI 10.1083/jcb.107.6.2657; JACOBS JR, 1986, J CELL BIOL, V103, P895, DOI 10.1083/jcb.103.3.895; JOHNSON CS, 1990, CELL MOTIL CYTOSKEL, V16, P204, DOI 10.1002/cm.970160307; KOTZ KJ, 1994, J CELL BIOL, V124, P463, DOI 10.1083/jcb.124.4.463; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN SXH, 1993, J CELL SCI, V105, P579; LYNCH TJ, 1986, J BIOL CHEM, V261, P4212; LYNCH TJ, 1986, J BIOL CHEM, V261, P4204; MATTHIES HJG, 1993, J BIOL CHEM, V268, P11176; MCILVAIN JM, 1994, J BIOL CHEM, V269, P19176; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PALAZZO RE, 1989, CELL MOTIL CYTOSKEL, V13, P21, DOI 10.1002/cm.970130104; RODIONOV VI, 1991, P NATL ACAD SCI USA, V88, P4956, DOI 10.1073/pnas.88.11.4956; ROZDZIAL MM, 1986, CELL, V47, P1061, DOI 10.1016/0092-8674(86)90821-4; ROZDZIAL MM, 1986, J CELL BIOL, V103, P2755, DOI 10.1083/jcb.103.6.2755; SAMMAK PJ, 1992, J CELL BIOL, V117, P57, DOI 10.1083/jcb.117.1.57; Satir Peter, 1993, Trends in Cell Biology, V3, P409, DOI 10.1016/0962-8924(93)90092-F; SATOYOSHITAKE R, 1992, J BIOL CHEM, V267, P23930; SAWIN KE, 1993, BIOESSAYS, V15, P399, DOI 10.1002/bies.950150606; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SCHROER TA, 1991, ANNU REV PHYSIOL, V53, P629, DOI 10.1146/annurev.ph.53.030191.003213; SKOUFIAS DA, 1994, J BIOL CHEM, V269, P1477; Skoufias DA, 1993, CURR OPIN CELL BIOL, V5, P95, DOI 10.1016/S0955-0674(05)80014-6; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TASH JS, 1989, CELL MOTIL CYTOSKEL, V14, P332, DOI 10.1002/cm.970140303; THALER CD, 1990, J CELL BIOL, V111, P1939, DOI 10.1083/jcb.111.5.1939; TOYOSHIMA I, 1992, J CELL BIOL, V118, P1121, DOI 10.1083/jcb.118.5.1121; WALCZAK CE, 1994, CELL MOTIL CYTOSKEL, V27, P101, DOI 10.1002/cm.970270202; YU H, 1992, J BIOL CHEM, V267, P20457; ZHAO LP, 1993, MOL BIOL CELL, V4, P162	45	106	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5600	5605		10.1074/jbc.270.10.5600	http://dx.doi.org/10.1074/jbc.270.10.5600			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890679	hybrid			2022-12-25	WOS:A1995QL58000097
J	HAN, EKH; SGAMBATO, A; JIANG, W; ZHANG, YJ; SANTELLA, RM; DOKI, Y; CACACE, AM; SCHIEREN, I; WEINSTEIN, IB				HAN, EKH; SGAMBATO, A; JIANG, W; ZHANG, YJ; SANTELLA, RM; DOKI, Y; CACACE, AM; SCHIEREN, I; WEINSTEIN, IB			STABLE OVEREXPRESSION OF CYCLIN D1 IN A HUMAN MAMMARY EPITHELIAL-CELL LINE PROLONGS THE S-PHASE AND INHIBITS GROWTH	ONCOGENE			English	Article						CYCLINS; CELL CYCLE; BREAST CANCER	PROTEIN-KINASE-C; HEPATOCELLULAR-CARCINOMA; RETINOBLASTOMA PROTEIN; RAT FIBROBLASTS; DEPENDENT KINASES; CHROMOSOME 11Q13; MAMMALIAN-CELLS; SQUAMOUS-CELL; BREAST-CANCER; EXPRESSION	Amplification and/or increased expression of cyclin D1 occurs in an appreciable fraction of primary human breast carcinomas and several other types of human cancer. In addition, overexpression of cyclin D1 in rodent fibroblasts enhances growth and malignant transformation. The present study demonstrates that the extent of amplification and expression of cyclin D1 varies widely amongst a series of cell lines established from normal human mammary epithelium or human breast carcinomas, The HBL-100;mammary epithelial cell line did not display amplification or increased expression of cyclin D1. We used retrovirus-mediated transduction to obtain derivatives of this cell line that stably expressed relatively high levels of an exogenous cyclin D1 cDNA. These derivatives displayed an increased doubling time, decreased saturation density, decreased cloning efficiency, decreased anchorage-independent growth, an increased fraction of cells in the S-phase, and decreased tumorigenicity. Thus, increased expression of cyclin D1 in this cell line markedly inhibits rather than enhances growth, which may be due to the prolongation of S-phase.	COLUMBIA UNIV,COLL PHYS & SURG,COLUMBIA PRESBYTERIAN CANC CTR,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,CANC RES INST,NEW YORK,NY 10032	Columbia University; Columbia University			; Sgambato, Alessandro/K-7266-2016	Jiang, Wei/0000-0002-2309-9571; Sgambato, Alessandro/0000-0002-9487-4563				BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BERENSON JR, 1990, ONCOGENE, V5, P1343; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CACACE AM, 1993, ONCOGENE, V8, P2095; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; DEFROMENTEL CC, 1985, EXP CELL RES, V160, P83, DOI 10.1016/0014-4827(85)90238-1; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1994, CANCER RES, V54, P1169; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANTL V, 1993, CANCER SURV, V18, P77; FAVOLORO J, 1980, METHOD ENZYMOL, V65, P718; GAFFNEY EV, 1982, CELL TISSUE RES, V227, P563, DOI 10.1007/BF00204786; GILLETT C, 1994, CANCER RES, V54, P1812; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HAN EKH, 1993, J CELL BIOL, V122, P461, DOI 10.1083/jcb.122.2.461; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; HUNTER T, 1993, CURR OPIN GENET DEV, V3, P1, DOI 10.1016/S0959-437X(05)80333-8; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; JIANG W, 1992, CANCER RES, V52, P2980; KAMB A, 1994, SCIENCE, V264, P440; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LOVEC H, 1994, ONCOGENE, V9, P323; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETERS G, 1994, NATURE, V371, P204, DOI 10.1038/371204a0; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, GENE DEV, V8, P9; PROCTOR AJ, 1991, ONCOGENE, V6, P789; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SAINTRUF C, 1988, EXP CELL RES, V176, P60, DOI 10.1016/0014-4827(88)90120-6; SCHAUER IE, 1994, P NATL ACAD SCI USA, V91, P7827, DOI 10.1073/pnas.91.16.7827; SCHUURING E, 1992, ONCOGENE, V7, P355; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SOUTTOU B, 1994, CELL GROWTH DIFFER, V5, P615; TAM SW, 1994, ONCOGENE, V9, P2663; TSAI LH, 1993, ONCOGENE, V8, P1593; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WANG J, 1992, ONCOGENE, V7, P1653; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WIMMEL A, 1994, ONCOGENE, V9, P995; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350	76	99	103	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					953	961						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898937				2022-12-25	WOS:A1995QL03800017
J	KANEKO, Y; NONOGUCHI, K; FUKUYAMA, H; TAKANO, S; HIGASHITSUJI, H; NISHIYAMA, H; TAKENAWA, J; NAKAYAMA, H; FUJITA, J				KANEKO, Y; NONOGUCHI, K; FUKUYAMA, H; TAKANO, S; HIGASHITSUJI, H; NISHIYAMA, H; TAKENAWA, J; NAKAYAMA, H; FUJITA, J			PRESENCE OF ALTERNATIVE 5'-UNTRANSLATED SEQUENCES AND IDENTIFICATION OF CELLS EXPRESSING CTK TRANSCRIPTS IN THE BRAIN AND TESTIS	ONCOGENE			English	Article						CTK; PROTEIN TYROSINE KINASE; BRAIN; TESTIS; ALTERNATIVE SPLICING; MALE GERM CELLS	PROTEIN-TYROSINE KINASES; RAT-BRAIN; C-SRC; MOUSE; FAMILY; GENE; CSK; LOCALIZATION; ACTIVATION; PP60C-SRC	From a mouse brain cDNA library, two species of the Csk-type tyrosine kinase (ctk) gene containing different 5' untranslated sequences were cloned, Using the common as well as specific nucleotide sequences of the two clones as probes, we examined the expression of ctk in various mouse tissues by Northern blot analysis, The results indicated that both species of ctk were expressed in the brain, testis and bone marrow, By in sits histochemistry of the brain, ctk transcript was detected in neurons throughout the entire brain, especially those of the cortex, the hippocampus and the cerebellum. This distribution pattern is similar to that of the Src family kinases including Yes, Src, Fyn and Lyn. In the testis, the major transcript (0.7 kb) was shorter than that expressed in the brain and the bone marrow (2.0 kb), A subsequent Northern blot analysis of fractionated germ cell populations and in situ histochemistry revealed that the short and long transcripts were expressed in germ cells and somatic cells, respectively, and that the expression level was quantitatively regulated during germ cell development. These results suggest that Ctk is involved in the regulation of neural function and differentiation of male germ cells through interactions with member(s) of the Src family kinases.	KYOTO UNIV, FAC MED, DEPT CLIN MOLEC BIOL, SAKYO KU, KYOTO 606, JAPAN; KYOTO UNIV, FAC MED, DEPT NEUROSCI, SAKYO KU, KYOTO 606, JAPAN; NIIGATA UNIV, FAC SCI, DEPT BIOL, NIIGATA 95021, JAPAN	Kyoto University; Kyoto University; Niigata University								BARE DJ, 1993, ONCOGENE, V8, P1429; BENNETT BD, 1994, J BIOL CHEM, V269, P1068; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; Bishop JM, 1985, RNA TUMOR VIRUSES, P249; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CAUGHMAN SW, 1988, J BIOL CHEM, V263, P19048; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; DUGGAL RN, 1987, ANN NY ACAD SCI, V513, P112, DOI 10.1111/j.1749-6632.1987.tb25002.x; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; KANEKO Y, 1993, BIOCHEM BIOPH RES CO, V197, P625, DOI 10.1006/bbrc.1993.2525; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MCVICAR DW, 1994, ONCOGENE, V9, P2037; MISKIMINS K, 1990, IRON TRANSPORT STORA, P119; MIYASAKA H, 1992, BIOCHEM BIOPH RES CO, V185, P818, DOI 10.1016/0006-291X(92)91700-Z; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; ROSS CA, 1988, P NATL ACAD SCI USA, V85, P9831, DOI 10.1073/pnas.85.24.9831; ROSSI P, 1992, DEV BIOL, V152, P203, DOI 10.1016/0012-1606(92)90172-D; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SAKANO S, 1994, ONCOGENE, V9, P1155; SANCHEZ MP, 1994, P NATL ACAD SCI USA, V91, P1819, DOI 10.1073/pnas.91.5.1819; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; ZHAO YH, 1991, ONCOGENE, V6, P1725	35	15	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	1995	10	5					945	952						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898936				2022-12-25	WOS:A1995QL03800016
J	YEH, JY; BEILSTEIN, MA; ANDREWS, JS; WHANGER, PD				YEH, JY; BEILSTEIN, MA; ANDREWS, JS; WHANGER, PD			TISSUE DISTRIBUTION AND INFLUENCE OF SELENIUM STATUS ON LEVELS OF SELENOPROTEIN-W	FASEB JOURNAL			English	Article						WESTERN BLOTS; POLYCLONAL ANTIBODIES; RATS; RABBITS; SHEEP; CATTLE	PLASMA GLUTATHIONE-PEROXIDASE; IODOTHYRONINE 5'-DEIODINASE; PARENTERAL-NUTRITION; RAT MUSCLE; CDNA; SELENOENZYME; PROTEINS; ENZYME; PURIFICATION; EXPRESSION	Rabbits were immunized with two synthetic peptides based on hydrophilic regions of selenoprotein W from rat muscle, The resulting polyclonal antibodies were used in Western blots to determine the compartmentation and tissue distribution of selenoprotein W, and to determine the influence of selenium on the levels of this selenoprotein in rat muscle. Selenoprotein W exists mainly in cytosol, but very small amounts were associated with membranes, Western blots revealed selenoprotein W in muscle, spleen, testis, and brain of rats. Rats were fed diets of either no addition of selenium (0 ppm Se) or additions of 0.1 and 4.0 mg selenium/g (0.1 ppm Se and 4.0 ppm Se) diet for 6 wk. Selenoprotein W was undetectable in skeletal muscle of rats fed the basal diet, detectable in those fed 0.1 ppm selenium in the diet, and much higher in muscle from rats fed 4 ppm selenium diet. In a species comparison, Western blots indicated the presence of selenoprotein W in muscle of rabbits, sheep, and cattle.	OREGON STATE UNIV, DEPT AGR CHEM, CORVALLIS, OR 97331 USA; OREGON STATE UNIV, CTR GENE RES & BIOTECHNOL, CORVALLIS, OR 97331 USA	Oregon State University; Oregon State University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038306] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 38306] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARTHUR JR, 1990, BIOCHEM J, V272, P537, DOI 10.1042/bj2720537; BEHNE D, 1990, BIOCHEM BIOPH RES CO, V173, P1143, DOI 10.1016/S0006-291X(05)80905-2; BEHNE D, 1988, BIOCHIM BIOPHYS ACTA, V966, P12, DOI 10.1016/0304-4165(88)90123-7; BEILSTEIN MA, 1984, J NUTR, V114, P929, DOI 10.1093/jn/114.5.929; BEILSTEIN MA, 1993, FASEB J, V7, pA289; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODT P, 1983, ANNU REV MICROBIOL, V37, P447, DOI 10.1146/annurev.mi.37.100183.002311; BROWN MR, 1986, AM J CLIN NUTR, V43, P549, DOI 10.1093/ajcn/43.4.549; CHEN XS, 1980, BIOL TRACE ELEM RES, V2, P91, DOI 10.1007/BF02798589; CHU FF, 1993, J BIOL CHEM, V268, P2571; DEAGEN JT, 1993, ANAL BIOCHEM, V208, P176, DOI 10.1006/abio.1993.1025; FARESE RV, 1992, BIOCHEM J, V288, P319, DOI 10.1042/bj2880319; FIELDS C G, 1991, Peptide Research, V4, P95; FLOHE L, 1973, FEBS LETT, V32, P132, DOI 10.1016/0014-5793(73)80755-0; GUNZLER WA, 1984, H-S Z PHYSIOL CHEM, V365, P195, DOI 10.1515/bchm2.1984.365.1.195; HAWKES WC, 1985, J INORG BIOCHEM, V23, P77, DOI 10.1016/0162-0134(85)83011-7; HILL KE, 1991, J BIOL CHEM, V266, P10050; HO YS, 1988, NUCLEIC ACIDS RES, V16, P5207, DOI 10.1093/nar/16.11.5207; KARIMPOUR I, 1992, DNA CELL BIOL, V11, P693, DOI 10.1089/dna.1992.11.693; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OH SH, 1974, BIOCHEMISTRY-US, V13, P1825, DOI 10.1021/bi00706a008; POND FR, 1983, J REPROD FERTIL, V69, P411, DOI 10.1530/jrf.0.0690411; READ R, 1990, J BIOL CHEM, V265, P17899; ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588; SCHUBERT JR, 1961, FED PROC, V20, P689; SCHUCKELT R, 1991, FREE RADICAL RES COM, V14, P343, DOI 10.3109/10715769109093424; SCHWARZ K, 1957, J AM CHEM SOC, V79, P3292, DOI 10.1021/ja01569a087; TAKAHASHI K, 1990, J BIOCHEM-TOKYO, V108, P145, DOI 10.1093/oxfordjournals.jbchem.a123172; TAKAHASHI K, 1987, ARCH BIOCHEM BIOPHYS, V256, P677, DOI 10.1016/0003-9861(87)90624-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; USA American Institute of Nutrition, 1977, Journal of Nutrition, V107, P1340; VANRIJ AM, 1981, JPEN-PARENTER ENTER, V5, P120, DOI 10.1177/0148607181005002120; VENDELAND SC, 1993, J BIOL CHEM, V268, P17103; WHANGER PD, 1987, SELENIUM BIOL MED, P197; WHANGER PD, 1993, SOME BIOCH PROPERTIE, P119; YANG JG, 1989, J NUTR, V119, P1010, DOI 10.1093/jn/119.7.1010; YOSHIMURA S, 1991, J BIOCHEM-TOKYO, V109, P918, DOI 10.1093/oxfordjournals.jbchem.a123480	40	80	90	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1995	9	5					392	396		10.1096/fasebj.9.5.7896009	http://dx.doi.org/10.1096/fasebj.9.5.7896009			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QP451	7896009				2022-12-25	WOS:A1995QP45100012
J	URBANCIKOVA, M; HITCHCOCKDEGREGORI, SE				URBANCIKOVA, M; HITCHCOCKDEGREGORI, SE			REQUIREMENT OF AMINO-TERMINAL MODIFICATION FOR STRIATED-MUSCLE ALPHA-TROPOMYOSIN FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COILED-COIL; POLYMERIZABLE TROPOMYOSIN; LYSINE REACTIVITIES; ESCHERICHIA-COLI; SMOOTH-MUSCLE; TROPONIN; ACTIN; BINDING; RESOLUTION; FILAMENT	Striated muscle cy-tropomyosin expressed in Escherichia coli is unacetylated, polymerizes poorly, and binds weakly to F-actin (Hitchcock-DeGregori, S. E., and Heald, R. W. (1987) J. Biol. Chem. 262, 9730-9735). To define the structural requirements of NH2-terminal modification for striated tropomyosin function, an acetylated recombinant tropomyosin and an unacetylated short fusion recombinant tropomyosin were compared. An acetylated recombinant chicken striated muscle alpha-tropomyosin was expressed in insect Sf9 cells using the baculovirus expression vector system. The purified tropomyosin (similar to 15 mg/liter of insect cell suspension) polymerized, comigrated with chicken striated alpha-tropomyosin purified from muscle on two-dimensional polyacrylamide gels, was blocked at the NH2 terminus, and had the same actin affinity as muscle tropomyosin. These results conclusively show the importance of NH2-terminal acetylation for striated tropomyosin function. To learn if a short fusion peptide would substitute for amino-terminal acetylation, tropomyosin with AlaSer-Arg on the NH2 terminus was constructed and expressed in E. coli as an unacetylated protein. This f3-tropomyosin bound to actin with a 10-fold higher affinity than striated muscle alpha-TM and, unlike muscle tropomyosin, exhibited a shear dependent viscosity. The altered function of f3-tropomyosin shows that the naturally occurring acetylated NH2 terminus is required for full, normal function. It is proposed that a major requirement for cooperative binding of striated muscle tropomyosin to actin is modification of the alpha-amino group of methionine to be an amide, as when acetylated or in a peptide bond in a fusion protein, to make the extreme NH2 terminus more hydrophobic. The results are discussed in terms of known coiled coil structure.	RUTGERS STATE UNIV, ROBERT WOOD JOHNSON MED SCH, DEPT NEUROSCI & CELL BIOL, PISCATAWAY, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center					NHLBI NIH HHS [HL 35726] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BUTTERS CA, 1993, J BIOL CHEM, V268, P15565; CHO YJ, 1990, J BIOL CHEM, V265, P538; CHO YJ, 1991, P NATL ACAD SCI USA, V88, P10153, DOI 10.1073/pnas.88.22.10153; DABROWSKA R, 1983, J MUSCLE RES CELL M, V4, P143, DOI 10.1007/BF00712027; GOA J, 1953, SCAND J CLIN LAB INV, V5, P218, DOI 10.3109/00365515309094189; GOODING C, 1987, NUCLEIC ACIDS RES, V15, P8105, DOI 10.1093/nar/15.19.8105; GRACEFFA P, 1992, BIOCHIM BIOPHYS ACTA, V1120, P205, DOI 10.1016/0167-4838(92)90271-E; GREENFIELD NJ, 1994, PROTEIN SCI, V3, P402; HEALD RW, 1988, J BIOL CHEM, V263, P5254; HEELEY DH, 1989, J BIOL CHEM, V264, P2424; HEELEY DH, 1994, EUR J BIOCHEM, V221, P129, DOI 10.1111/j.1432-1033.1994.tb18721.x; HITCHCOCKDEGREGORI SE, 1982, J BIOL CHEM, V257, P2573; HITCHCOCKDEGREGORI SE, 1987, J BIOL CHEM, V262, P9730; HITCHCOCKDEGREGORI SE, 1985, BIOCHEMISTRY-US, V24, P3305, DOI 10.1021/bi00334a035; ISHII Y, 1992, PROTEIN SCI, V1, P1319, DOI 10.1002/pro.5560011011; JOHNSON P, 1977, BIOCHEMISTRY-US, V16, P2264, DOI 10.1021/bi00629a035; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; MAK AS, 1981, BIOCHEM BIOPH RES CO, V101, P208, DOI 10.1016/S0006-291X(81)80032-0; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MONTEIRO PB, 1994, J BIOL CHEM, V269, P10461; NOVY RE, 1993, BIOCHIM BIOPHYS ACTA, V1162, P255, DOI 10.1016/0167-4838(93)90289-4; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PHILLIPS GN, 1986, J MOL BIOL, V192, P111, DOI 10.1016/0022-2836(86)90468-7; PITTENGER MF, 1992, J CELL BIOL, V118, P841, DOI 10.1083/jcb.118.4.841; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; Sambrook J, 1989, MOL CLONING LABORATO; STONE D B, 1989, Biophysical Journal, V55, p277A; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; SUMMERS MD, 1987, MANUAL METHODS BACUL, V1555; TEMPST P, 1989, ANAL BIOCHEM, V183, P290, DOI 10.1016/0003-2697(89)90482-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UENO H, 1976, J BIOCHEM, V80, P283, DOI 10.1093/oxfordjournals.jbchem.a131275; Urbancikova M., 1993, Molecular Biology of the Cell, V4, p259A; URBANCIKOVA M, 1993, BIOPHYS J, V64, pA137; WEBB N R, 1990, Technique (Philadelphia), V2, P173; WHITBY FG, 1992, J MOL BIOL, V227, P441, DOI 10.1016/0022-2836(92)90899-U; WILLADSEN KA, 1992, J BIOL CHEM, V267, P23746; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	42	111	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24310	24315						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929088				2022-12-25	WOS:A1994PQ34600071
J	BUESA, C; MARTINEZGONZALEZ, J; CASALS, N; HARO, D; PIULACHS, MD; BELLES, X; HEGARDT, FG				BUESA, C; MARTINEZGONZALEZ, J; CASALS, N; HARO, D; PIULACHS, MD; BELLES, X; HEGARDT, FG			BLATTELLA-GERMANICA HAS 2 HMG-COA SYNTHASE GENES - BOTH ARE REGULATED IN THE OVARY DURING THE GONADOTROPIC CYCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A SYNTHASE; 3-HYDROXY-3-METHYLGLUTARYL COENZYME; CORPORA ALLATA; JUVENILE-HORMONE; ISOPRENOID SYNTHESIS; NUCLEOTIDE-SEQUENCE; MESSENGER-RNA; CDNA; REDUCTASE; CELLS	The isoprenoid pathway leads to various essential non-sterol products in insects. These end products have a crucial role in growth, differentiation, sexual maturation, and reproduction. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) synthase (EC 4.1.3.5.) has generally been considered one of the committed steps of the pathway. We had previously reported the cloning of a cytosolic HMG-CoA synthase cDNA in Blattella germanica; we have now isolated and characterized a new cDNA clone for HMG-CoA synthase in this insect. Analysis of this 1716 base pair cDNA reveals a deduced protein of 455 residues with a molecular mass of 51,424 Da. The two HMG-CoA synthases have 69% identical amino acid residues, and both lack an N-terminal leader peptide to target the protein into mitochondria. This HMG-CoA synthase cDNA can revert the Chinese hamster ovary-K1-derived cell line, Mev-1, which is a defective mutant for HMG-CoA synthase. Both HMG-CoA synthase genes are expressed differently throughout development. Analysis of adult tissues shows higher expression in ovary and fat body. The expression of HMG-CoA synthase (EC 4.1.3.5.) and reductase (EC 1.1.1.34) genes during the gonadotrophic cycle in B. germanica shows that the three genes of the isoprenoid pathway are developmentally regulated in the ovary.	UNIV BARCELONA,SCH PHARM,BIOCHEM UNIT,E-08028 BARCELONA,SPAIN; CSIC,CID,DEPT AGROBIOL,E-08034 BARCELONA,SPAIN	University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion y Desarrollo Pascual Vila (CID-CSIC)			Casals, Nuria/L-3378-2014; Piulachs, Maria-Dolors/C-3992-2011; Belles, Xavier/G-2354-2015; Haro, Diego/I-4623-2015	Casals, Nuria/0000-0002-6719-4300; Piulachs, Maria-Dolors/0000-0002-4500-2718; Belles, Xavier/0000-0002-1566-303X; Haro, Diego/0000-0001-9147-0486; Martinez-Gonzalez, Jose/0000-0002-3894-7166				AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; AYTE J, 1990, P NATL ACAD SCI USA, V87, P3874, DOI 10.1073/pnas.87.10.3874; AYTE J, 1990, NUCLEIC ACIDS RES, V18, P3642, DOI 10.1093/nar/18.12.3642; BACHVAROVA RF, 1992, CELL, V69, P895, DOI 10.1016/0092-8674(92)90606-D; BEENAKKERS AMT, 1985, PROG LIPID RES, V24, P19; BELLES X, 1987, INSECT BIOCHEM, V17, P1007, DOI 10.1016/0020-1790(87)90111-9; BELLES X, 1993, TISSUE CELL, V25, P195, DOI 10.1016/0040-8166(93)90019-H; CHAUBET N, 1991, PLANT MOL BIOL, V17, P935, DOI 10.1007/BF00037077; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Clinkenbeard K D, 1975, Methods Enzymol, V35, P160, DOI 10.1016/0076-6879(75)35151-3; COUILLAUD F, 1991, MOL CELL ENDOCRINOL, V77, P159, DOI 10.1016/0303-7207(91)90070-9; COUILLAUD F, 1991, ARCH INSECT BIOCHEM, V18, P273, DOI 10.1002/arch.940180409; COUILLAUD F, 1991, INSECT BIOCHEM, V21, P131, DOI 10.1016/0020-1790(91)90042-D; DELPINO JC, 1989, INSECT BIOCHEM, V19, P657, DOI 10.1016/0020-1790(89)90101-7; Feyereisen R., 1985, P391; GAUGER A, 1987, DEVELOPMENT, V100, P237; GERTLER FB, 1988, MOL CELL BIOL, V8, P2713, DOI 10.1128/MCB.8.7.2713; GIBBONS GF, 1984, J BIOL CHEM, V259, P4399; GIL G, 1986, J BIOL CHEM, V261, P3710; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HASEL KW, 1990, NUCLEIC ACIDS RES, V18, P4019, DOI 10.1093/nar/18.13.4019; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KATTARCOOLEY PA, 1990, ARCH BIOCHEM BIOPHYS, V283, P523, DOI 10.1016/0003-9861(90)90677-Q; Kaulenas M, 1992, INSECT ACCESSORY REP, P33; Koeppe J.K., 1985, P165; KOEPPE JK, 1984, JUVENILE HORMONE BIO, P215; LAPOINTE MC, 1985, J INSECT PHYSIOL, V31, P187, DOI 10.1016/0022-1910(85)90119-2; LUSTIGMAN S, 1985, EXP PARASITOL, V59, P59, DOI 10.1016/0014-4894(85)90057-8; MALTESE WA, 1988, J BIOL CHEM, V263, P10104; MARTINEZGONZALEZ J, 1993, EUR J BIOCHEM, V213, P233, DOI 10.1111/j.1432-1033.1993.tb17753.x; MARTINEZGONZALEZ J, 1993, EUR J BIOCHEM, V217, P691, DOI 10.1111/j.1432-1033.1993.tb18295.x; MISRA I, 1993, J BIOL CHEM, V268, P12129; MONGER DJ, 1985, METHOD ENZYMOL, V110, P51; PASCUAL N, 1992, J INSECT PHYSIOL, V38, P339, DOI 10.1016/0022-1910(92)90058-L; PIULACHS MD, 1992, COMP BIOCHEM PHYS A, V102, P477, DOI 10.1016/0300-9629(92)90197-X; Regier J.C., 1985, P113; ROYO T, 1991, BIOCHEM J, V280, P61, DOI 10.1042/bj2800061; RUSS AP, 1992, BIOCHIM BIOPHYS ACTA, V1132, P329, DOI 10.1016/0167-4781(92)90172-V; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIPERSTEIN MD, 1984, J LIPID RES, V25, P1462; TANAKA A, 1976, Kontyu, V44, P512; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WOODWARD HD, 1988, J BIOL CHEM, V263, P2513	48	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11707	11713						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7909314				2022-12-25	WOS:A1994NG37700009
J	VALERA, A; PELEGRIN, M; ASINS, G; FILLAT, C; SABATER, J; PUJOL, A; HEGARDT, FG; BOSCH, F				VALERA, A; PELEGRIN, M; ASINS, G; FILLAT, C; SABATER, J; PUJOL, A; HEGARDT, FG; BOSCH, F			OVEREXPRESSION OF MITOCHONDRIAL 3-HYDROXY-3-METHYLGLUTARYL-COA SYNTHASE IN TRANSGENIC MICE CAUSES HEPATIC HYPERKETOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; GROWTH-HORMONE GENE; DIETARY-REGULATION; MESSENGER-RNA; RAT; LIVER; TRANSCRIPTION; EXPRESSION; KETOGENESIS; METABOLISM	Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase (HMG-CoA synthase) is a key enzyme in the ketone body pathway. To determine its role in the regulation of liver ketogenesis, transgenic mice expressing a P-enol-pyruvate carboxykinase/HMG-CoA synthase chimeric gene have been obtained. An increase in the concentration of mitochondrial HMG-CoA synthase mRNA was detected in these mice, which was associated with a 3-fold increase in HMG-CoA synthase activity in liver mitochondrial extracts. Transgenic mice were normoglycemic and had normal levels of plasma triglycerides and lower free fatty acids. However, the plasma concentration of ketone bodies was about three times higher in transgenic mice than in control animals. Hepatocytes in primary culture from transgenic mice expressed the chimeric gene in a regulated manner and showed a 3-fold increase in beta-hydroxybutyrate and acetoacetate concentrations in the medium. This animal model thus shows that the overexpression of mitochondrial HMG-CoA synthase causes ketone body overproduction, suggesting that this enzyme may be a regulatory step in liver ketogenesis.	AUTONOMOUS UNIV BARCELONA,SCH VET MED,DEPT BIOCHEM & MOLEC BIOL,E-08193 BARCELONA,SPAIN; UNIV BARCELONA,SCH PHARM,BIOCHEM UNIT,E-08028 BARCELONA,SPAIN	Autonomous University of Barcelona; University of Barcelona			Fillat, Cristina/ABH-1674-2020	Fillat, Cristina/0000-0002-0801-3338; BOSCH, FATIMA/0000-0002-7705-5515; Pelegrin, Mireia/0000-0002-0117-2010; Pujol, Anna/0000-0002-3484-598X				AVOGARO A, 1992, DIABETES, V41, P968, DOI 10.2337/diabetes.41.8.968; AYTE J, 1990, P NATL ACAD SCI USA, V87, P3874, DOI 10.1073/pnas.87.10.3874; BERGMEYER HU, 1974, METHODS ENZYMATIC AN, V4; BERGMEYER HU, 1974, METHODS ENZYMATIC AN, V3; BOHME J, 1989, SCIENCE, V244, P1179, DOI 10.1126/science.2499048; CASALS N, 1992, BIOCHEM J, V283, P261, DOI 10.1042/bj2830261; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLINKENBEARD KD, 1975, J BIOL CHEM, V250, P3108; DECAUX JF, 1988, FEBS LETT, V232, P156, DOI 10.1016/0014-5793(88)80407-1; GARCIARUIZ JP, 1978, P NATL ACAD SCI USA, V75, P4189; GIRARD JR, 1973, J CLIN INVEST, V52, P3190, DOI 10.1172/JCI107519; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; HOGAN B, 1986, MANIPULATING MOUSE E, P81; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; KIOUSSIS D, 1978, J BIOL CHEM, V253, P4327; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LECAM A, 1976, EXP CELL RES, V98, P382, DOI 10.1016/0014-4827(76)90448-1; LIU JS, 1991, J BIOL CHEM, V266, P19095; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; QUANT PA, 1990, EUR J BIOCHEM, V187, P169, DOI 10.1111/j.1432-1033.1990.tb15291.x; QUANT PA, 1991, EUR J BIOCHEM, V195, P449, DOI 10.1111/j.1432-1033.1991.tb15724.x; QUANT PA, 1989, BIOCHEM J, V262, P159, DOI 10.1042/bj2620159; REED WD, 1975, J BIOL CHEM, V250, P3117; SERRA D, 1993, ARCH BIOCHEM BIOPHYS, V301, P445, DOI 10.1006/abbi.1993.1169; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; THUMELIN S, 1993, BIOCHEM J, V292, P493, DOI 10.1042/bj2920493; TILGHMAN S M, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1304, DOI 10.1073/pnas.71.4.1304; YOOWARREN H, 1983, P NATL ACAD SCI-BIOL, V80, P3656, DOI 10.1073/pnas.80.12.3656; ZAMMIT VA, 1984, PROG LIPID RES, V23, P39, DOI 10.1016/0163-7827(84)90005-5	32	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6267	6270						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7907092				2022-12-25	WOS:A1994MZ50300003
J	BALZARINI, J; KARLSSON, A; WANG, LY; BOHMAN, C; HORSKA, K; VOTRUBA, I; FRIDLAND, A; VANAERSCHOT, A; HERDEWIJN, P; DECLERCQ, E				BALZARINI, J; KARLSSON, A; WANG, LY; BOHMAN, C; HORSKA, K; VOTRUBA, I; FRIDLAND, A; VANAERSCHOT, A; HERDEWIJN, P; DECLERCQ, E			EICAR (5-ETHYNYL-1-BETA-D-RIBOFURANOSYLIMIDAZOLE-4-CARBOXAMIDE) - A NOVEL POTENT INHIBITOR OF INOSINATE DEHYDROGENASE-ACTIVITY AND GUANYLATE BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-BETA-D-RIBOFURANOSYLTHIAZOLE-4-CARBOXAMIDE NSC 286193; IMP DEHYDROGENASE; MECHANISM; TIAZOFURIN; RIBAVIRIN; CHEMOTHERAPY; METABOLITES; NUCLEOSIDE; EXPRESSION; VIRAZOLE	EICAR (5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide) is a cytostatic agent that inhibits murine leukemia L1210 and human lymphocyte CEM cells at a 50% inhibitory concentration of 0.80-1.4 muM, respectively. EICAR causes a rapid and marked inhibition of inosinate (IMP) dehydrogenase (EC 1.1.1.205) activity in intact L1210 and CEM cells reflected by a concentration-dependent accumulation of IMP and depletion of GTP and dGTP levels. EICAR 5'-monophosphate is a potent inhibitor of purified L1210 cell IMP dehydrogenase (K(i)/K(m) 0.06). Inhibition of IMP dehydrogenase by EICAR 5'-monophosphate is competitive with respect to IMP. L1210 cells that were selected for resistance to the cytostatic action of EICAR proved to be adenosine kinase-deficient. Also, studies with other mutant L1210 and CEM cell lines revealed that adenosine kinase, as well as an alternative pathway, may be responsible for the conversion of EICAR to its 5'-monophosphate. Purified 2'-deoxycytidine kinase, 2'-deoxyguanosine kinase, cytosolic 5'-nucleotidase, and nicotinamide dinucleotide (NAD) pyrophosphorylase do not seem to be markedly involved in the metabolism of EICAR.	KAROLINSKA INST, S-10401 STOCKHOLM 60, SWEDEN; ACAD SCI CZECH REPUBL, INST ORGAN CHEM & BIOCHEM, CS-16610 PRAGUE 6, CZECHOSLOVAKIA; ST JUDE CHILDRENS RES HOSP, MEMPHIS, TN 38105 USA	Karolinska Institutet; Czech Academy of Sciences; Institute of Organic Chemistry & Biochemistry of the Czech Academy of Sciences; St Jude Children's Research Hospital	BALZARINI, J (corresponding author), CATHOLIC UNIV LEUVEN, REGA INST MED RES, B-3000 LOUVAIN, BELGIUM.		Karlsson, Anna/E-7945-2018	Herdewijn, Piet/0000-0003-3589-8503; Van Aerschot, Arthur/0000-0003-3528-8588; De Clercq, Erik/0000-0002-2985-8890; Karlsson, Anna/0000-0001-6843-6685				BALZARINI J, 1991, J BIOL CHEM, V266, P21509; BALZARINI J, 1992, BIOCHEM J, V287, P785, DOI 10.1042/bj2870785; BOHMAN C, 1988, BIOCHEMISTRY-US, V27, P4258, DOI 10.1021/bi00412a009; BROWNE MJ, 1979, ANTIMICROB AGENTS CH, V15, P747, DOI 10.1128/AAC.15.6.747; COONEY DA, 1982, BIOCHEM PHARMACOL, V31, P2133, DOI 10.1016/0006-2952(82)90436-1; DECLERCQ E, 1991, ANTIMICROB AGENTS CH, V35, P679, DOI 10.1128/AAC.35.4.679; EARLE MF, 1983, CANCER RES, V43, P133; GARRETT C, 1979, ANAL BIOCHEM, V99, P268, DOI 10.1016/S0003-2697(79)80005-6; IKEGAMI T, 1987, LIFE SCI, V40, P2277, DOI 10.1016/0024-3205(87)90064-6; JAYARAM HN, 1982, BIOCHEM PHARMACOL, V31, P3839, DOI 10.1016/0006-2952(82)90300-8; JAYARAM HN, 1982, BIOCHEM PHARMACOL, V31, P2557, DOI 10.1016/0006-2952(82)90071-5; JAYARAM HN, 1982, BIOCHEM PHARMACOL, V31, P2371, DOI 10.1016/0006-2952(82)90532-9; KHYM JX, 1975, CLIN CHEM, V21, P1245; KUTTAN R, 1982, BIOCHEM BIOPH RES CO, V107, P862, DOI 10.1016/0006-291X(82)90602-7; LUI MS, 1984, J BIOL CHEM, V259, P5078; MATSUDA A, 1988, CHEM PHARM BULL, V36, P2730; NAGAI M, 1991, CANCER RES, V51, P3886; SCHOLTISSEK C, 1976, ARCH VIROL, V50, P349, DOI 10.1007/BF01317961; STREETER DG, 1973, P NATL ACAD SCI USA, V70, P1174, DOI 10.1073/pnas.70.4.1174; VERHOEF V, 1981, CANCER RES, V41, P4478; WEBER G, 1991, CANCER COMMUN-US, V3, P61, DOI 10.3727/095535491820873579; WEBER G, 1990, BIOCHEM SOC T, V18, P74, DOI 10.1042/bst0180074; WEBER G, 1983, CANCER RES, V43, P3466; YAMADA Y, 1988, BIOCHEMISTRY-US, V27, P2193, DOI 10.1021/bi00406a057; YOSHIKAWA M, 1969, B CHEM SOC JPN, V42, P3505, DOI 10.1246/bcsj.42.3505; YVES DH, 1978, METHOD ENZYMOL, V51, P337	26	75	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24591	24598						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	7901217				2022-12-25	WOS:A1993MG67300016
J	BUERMEYER, AB; STRASHEIM, LA; MCMAHON, SL; FARNHAM, PJ				BUERMEYER, AB; STRASHEIM, LA; MCMAHON, SL; FARNHAM, PJ			IDENTIFICATION OF CIS-ACTING ELEMENTS THAT CAN OBVIATE A REQUIREMENT FOR THE C-TERMINAL DOMAIN OF RNA-POLYMERASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE-REDUCTASE PROMOTER; ACCURATE TRANSCRIPTION INITIATION; TATA-BINDING PROTEIN; MAJOR LATE PROMOTER; LARGEST SUBUNIT; CELL-CYCLE; NONPHOSPHORYLATED FORM; FUNCTIONAL INTERACTION; PREINITIATION COMPLEX; SEQUENCES DOWNSTREAM	We have used an in vitro RNA polymerase II (RNAP II) inhibition-restimulation assay to investigate the inability of a form of RNAP II (RNAP IIB) that lacks the conserved, C-terminal heptapeptide repeat domain (CTD) to transcribe the dihydrofolate reductase (dhfr) promoter. Our previous studies demonstrated promoter-specific responses to RNAP IIB in the inhibition-restimulation assay and suggested the existence of cis-acting elements that alleviate the requirement for the CTD. We have now identified elements from two different classes of promoters that can convert dhfr to a CTD-independent promoter. First, addition of a consensus TATA box to the dhfr promoter resulted in a promoter capable of CTD-independent transcription and increased the promoter's affinity for the general transcription factor TFIID. These results suggest that high affinity for TFIID correlates with an ability to be transcribed by RNAP IIB, supporting a proposed interaction between the CTD and TFIID. Second, transfer of a combination of two elements (located at -25 and +1) from the rep-3b promoter, which does not contain a consensus TATA box but can nonetheless be transcribed by RNAP IIB, into the dhfr promoter also allowed CTD-independent transcription. These elements do not constitute a high affinity binding site for TFIID, indicating that an additional mechanism exists to allow CTD-independent transcription. Thus, elements from two classes of CTD-independent promoters that can obviate a requirement for the CTD appear to function via distinct mechanisms. Our finding that a change in a basal element can affect a requirement for the CTD is consistent with a role for the CTD during the formation of the transcriptional preinitiation complex.	UNIV WISCONSIN,SCH MED,MCARDLE LAB CANC RES,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison			Buermeyer, Andrew/AAW-4099-2020	Buermeyer, Andrew/0000-0003-4502-4666; Farnham, Peggy/0000-0003-4469-7914	NCI NIH HHS [CA59524, CA45240] Funding Source: Medline; NIGMS NIH HHS [GM07215] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045240, R01CA059524, R29CA045240] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BUERMEYER AB, 1992, MOL CELL BIOL, V12, P2250, DOI 10.1128/MCB.12.5.2250; BURATOWSKI S, 1990, MOL CELL BIOL, V10, P5562, DOI 10.1128/MCB.10.10.5562; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CONAWAY RC, 1992, J BIOL CHEM, V267, P8464; DAHMUS ME, 1994, PROG NUCLEIC ACID RE, V48, P143, DOI 10.1016/S0079-6603(08)60855-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EMANUEL PA, 1993, P NATL ACAD SCI USA, V90, P8449, DOI 10.1073/pnas.90.18.8449; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FARNHAM PJ, 1991, GENE EXPRESSION, V1, P137; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HUANG XF, 1994, BIOCHEM BIOPH RES CO, V198, P712, DOI 10.1006/bbrc.1994.1103; KANG ME, 1993, J BIOL CHEM, V268, P25033; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KIM WY, 1989, J BIOL CHEM, V264, P3169; KOKUBO T, 1993, P NATL ACAD SCI USA, V90, P5896, DOI 10.1073/pnas.90.13.5896; KOLLMAR R, 1993, P SOC EXP BIOL MED, V203, P127; KOLLMAR R, 1994, J BIOL CHEM, V269, P2252; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; MALIK S, 1993, MOL CELL BIOL, V13, P6253, DOI 10.1128/MCB.13.10.6253; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MEANS AL, 1991, THESIS U WISCONSIN M; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; PURNELL BA, 1993, MOL CELL BIOL, V13, P2593, DOI 10.1128/MCB.13.4.2593; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; Sambrook J, 1989, MOL CLONING LABORATO; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SCHILLING LJ, 1989, MOL CELL BIOL, V9, P4568, DOI 10.1128/MCB.9.10.4568; SLANSKY JE, 1993, MOL CELL BIOL, V13, P7201; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SOPTA M, 1985, J BIOL CHEM, V260, P353; SUZUKI M, 1990, NATURE, V344, P562, DOI 10.1038/344562a0; THOMPSON NE, 1992, BIOCHEMISTRY-US, V31, P7003, DOI 10.1021/bi00145a019; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; ZEHRING WA, 1990, J BIOL CHEM, V265, P8351; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	51	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6798	6807		10.1074/jbc.270.12.6798	http://dx.doi.org/10.1074/jbc.270.12.6798			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896826	hybrid			2022-12-25	WOS:A1995QQ85500057
J	SECKL, MJ; MORII, N; NARUMIYA, S; ROZENGURT, E				SECKL, MJ; MORII, N; NARUMIYA, S; ROZENGURT, E			GUANOSINE 5'-3-O-(THIO)TRIPHOSPHATE STIMULATES TYROSINE PHOSPHORYLATION OF P125(FAK) AND PAXILLIN IN PERMEABILIZED SWISS 3T3 CELLS - ROLE OF P21(RHO)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FOCAL ADHESION KINASE; GTP-BINDING PROTEIN; RAPIDLY STIMULATE; ADP-RIBOSYLTRANSFERASE; BOMBESIN STIMULATION; ANGIOTENSIN-II; PHORBOL ESTERS; RNA-POLYMERASE; GENE-PRODUCT	Addition of guanosine 5'-3-O-(thio) triphosphate (GTP gamma S) to streptolysin O-permeabilized Swiss 3T3 cells induced tyrosine phosphorylation of M(r) 110,000-130,000 and 70,000-80,000 bands. Specifically, GTP gamma S stimulated tyrosine phosphorylation of both focal adhesion kinase (p125(FAK)) and paxillin. GTP gamma S induced tyrosine phosphorylation was dose-dependent (EC(50) of 2.5 mu M) and reached maximum levels after 1.5 min for the M(r) 110,000-130,000 band and 2 min for the M(r) 70,000-80,000 paxillin band. Guanosine 5'-O-(2-thiodiphosphate) inhibited GTP gamma S-induced tyrosine phosphorylation with an IC50 of 100 mu M. Protein kinase C did not mediate GTP gamma S-induced tyrosine phosphorylation. Varying the Ca2+ concentration from 0 to 6 mu M did not increase tyrosine phosphorylation above basal levels and did not affect the ability of GTP gamma S to induce tyrosine phosphorylation. GTP gamma S was able to stimulate tyrosine phosphorylation in the presence of nanomolar concentrations of Mg2+. Furthermore, 30 mu M AlF4- only weakly induced tyrosine phosphorylation in permeabilized cells. Pretreatment with the Clostridium botulinum C3 exoenzyme which inactivates p21(rho), markedly reduced the ability of GTP gamma S to stimulate tyrosine phosphorylation of M(r) 110,000-130,000 and 70,000-80,000 bands including p125(FAK) and paxillin in permeabilized Swiss 3T3 cells. Furthermore, a peptide of p21(rho) (p21(rho17-44)) inhibited GTP gamma S-induced tyrosine phosphorylation in a dose-dependent manner (IC50 1 mu M). This peptide also inhibited tyrosine phosphorylation of p125(FAK) and paxillin. In contrast, 20 mu M p21(ras17-44) peptide failed to inhibit GTP gamma S-induced tyrosine phosphorylation. Using permeabilized cells, our findings demonstrate that GTP gamma S stimulates tyrosine phosphorylation of p125(FAK) and paxillin and that a functional p21(rho) is implicated in this process.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; KYOTO UNIV,FAC MED,DEPT PHARMACOL 2,SAKYO KU,KYOTO 606,JAPAN	Cancer Research UK; Kyoto University								AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BUCKINGHAM L, 1983, BIOCHIM BIOPHYS ACTA, V729, P115, DOI 10.1016/0005-2736(83)90462-5; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; COLLINS MKL, 1984, J CELL PHYSIOL, V118, P133, DOI 10.1002/jcp.1041180205; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FORCE T, 1991, J BIOL CHEM, V266, P6650; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KUMAGAI N, 1993, FEBS LETT, V329, P273, DOI 10.1016/0014-5793(93)80236-N; KUMAGAI N, 1993, J BIOL CHEM, V238, P24535; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MISTOU MY, 1992, EUR J BIOCHEM, V204, P179, DOI 10.1111/j.1432-1033.1992.tb16621.x; MIURA Y, 1993, J BIOL CHEM, V268, P510; MURPHY AC, 1992, J BIOL CHEM, V267, P25296; NEMOTO Y, 1991, J BIOL CHEM, V266, P19312; PELLETIER AJ, 1992, MOL BIOL CELL, V3, P989, DOI 10.1091/mbc.3.9.989; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RANKIN S, 1994, J BIOL CHEM, V269, P704; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SECKL M, 1993, J BIOL CHEM, V268, P9548; SECKL MJ, 1995, IN PRESS J CELL PHYS; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SELF AJ, 1993, ONCOGENE, V8, P655; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TURNER CE, 1993, J CELL SCI, V105, P637; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; VUORI K, 1993, J BIOL CHEM, V268, P21459; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; XUEMIN X, 1994, J BIOL CHEM, V269, P23569; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	57	71	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6984	6990		10.1074/jbc.270.12.6984	http://dx.doi.org/10.1074/jbc.270.12.6984			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896849	hybrid			2022-12-25	WOS:A1995QQ85500080
J	SHEN, JR; VERMAAS, W; INOUE, Y				SHEN, JR; VERMAAS, W; INOUE, Y			THE ROLE OF CYTOCHROME C-550 AS STUDIED THROUGH REVERSE GENETICS AND MUTANT CHARACTERIZATION IN SYNECHOCYSTIS SP PCC-6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANOBACTERIAL PHOTOSYSTEM-II; MANGANESE-STABILIZING POLYPEPTIDE; PHOTOSYNTHETIC REACTION CENTER; SP PCC-6803; CHLAMYDOMONAS-REINHARDTII; PEROXIDASE-ACTIVITY; OXYGEN EVOLUTION; 12-KDA PROTEIN; DELETION; COMPLEX	The gene coding for cytochrome c-550 in Synechocystis sp. PCC 6803 was cloned based on the N-terminal sequence of the mature polypeptide. Using the most probable translation start codon, the gene is expected to code for 160 amino acid residues. This includes a cleavable N-terminal leader sequence of 25 residues. This leader sequence has an Arg-Asn-Arg sequence immediately before the cleavage site; this is characteristic for transit peptides in prokaryotes. Comparison of this sequence with the leader sequence of the photosystem II-associated extrinsic 33-kDa protein from the same cyanobacterium showed an identity of 13 out of 25 residues. These results suggest that after synthesis of the apoprotein, cytochrome c-550 is transported into the thylakoid lumen. Using the cloned gene, insertion and deletion mutants of Synechocystis sp. PCC 6803 were constructed. In the absence of cytochrome c-550, both mutants were capable of photoautotrophic growth but at a significantly reduced rate. Atrazine binding and Western blot analysis showed that these mutants on a per-chlorophyll basis contained 53-67% of the amount of photosystem II as compared with wild type. The photosystem II- specific oxygen-evolving activity at saturating light intensity was reduced to about 40% of that in the wild type strain. Taken together, these results indicate that the cytochrome c-550 is transported into the thylakoid lumen and contributes to optimal functional stability of photosystem II in cyanobacteria. This supports our biochemical evidence that cytochrome c-550 is associated with the lumenal side of photosystem II as one of the extrinsic proteins enhancing oxygen evolution (Shen, J.-R., Ikeuchi, M., and Inoue, Y. (1992) FEBS Lett. 301, 145-149; Shen, J.-R., and Inoue, Y. (1993) Biochemistry 32, 1825-1832). Based on these results, the gene for cytochrome c-550 was named psbV. The possible evolutionary relationship among extrinsic proteins of the photosystem II donor side is discussed.	ARIZONA STATE UNIV, DEPT BOT, TEMPE, AZ 85287 USA; ARIZONA STATE UNIV, CTR STUDY EARLY EVENTS PHOTOSYNTH, TEMPE, AZ 85287 USA	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe	SHEN, JR (corresponding author), INST PHYS & CHEM RES, SOLAR ENERGY RES GRP, WAKO, SAITAMA 35101, JAPAN.		Shen, Jian-Ren/B-2558-2011					BURNAP RL, 1991, BIOCHEMISTRY-US, V30, P440, DOI 10.1021/bi00216a020; BURNAP RL, 1992, BIOCHEMISTRY-US, V31, P7404, DOI 10.1021/bi00147a027; COHN CL, 1989, ARCH BIOCHEM BIOPHYS, V270, P227, DOI 10.1016/0003-9861(89)90024-6; ELHAI J, 1988, GENE, V68, P119, DOI 10.1016/0378-1119(88)90605-1; GIERASCH LM, 1994, NATO ASI SERIES H, V82, P191; GOLBECK JH, 1991, CURR TOP BIOENERG, V16, P83; GUIKEMA JA, 1981, BIOCHIM BIOPHYS ACTA, V637, P189, DOI 10.1016/0005-2728(81)90157-2; HAN KC, 1994, FEBS LETT, V355, P121, DOI 10.1016/0014-5793(94)01182-6; HURT EC, 1984, FEBS LETT, V168, P149, DOI 10.1016/0014-5793(84)80225-2; IKEUCHI M, 1988, PLANT CELL PHYSIOL, V29, P1233; IKEUCHI M, 1989, FEBS LETT, V251, P155, DOI 10.1016/0014-5793(89)81446-2; KANG C, 1994, FEBS LETT, V344, P5, DOI 10.1016/0014-5793(94)00341-6; Krogmann D.W., 1990, CURRENT RES PHOTOSYN, VII, P687; KROGMANN DW, 1991, BIOCHIM BIOPHYS ACTA, V1058, P35, DOI 10.1016/S0005-2728(05)80264-6; MATHEWS FS, 1985, PROG BIOPHYS MOL BIO, V45, P1, DOI 10.1016/0079-6107(85)90004-5; MAYES SR, 1991, BIOCHIM BIOPHYS ACTA, V1060, P1, DOI 10.1016/S0005-2728(05)80112-4; MAYFIELD SP, 1987, EMBO J, V6, P313, DOI 10.1002/j.1460-2075.1987.tb04756.x; MAYFIELD SP, 1987, P NATL ACAD SCI USA, V84, P749, DOI 10.1073/pnas.84.3.749; MIYAO M, 1987, TOPICS PHOTOSYNTHESI, V9, P289; NISHIYAMA Y, 1994, PLANT PHYSIOL, V105, P1313, DOI 10.1104/pp.105.4.1313; NITSCHKE W, 1991, TRENDS BIOCHEM SCI, V16, P241, DOI 10.1016/0968-0004(91)90095-D; OKKELS JS, 1992, J BIOL CHEM, V267, P21139; OMATA T, 1984, BIOCHIM BIOPHYS ACTA, V766, P395, DOI 10.1016/0005-2728(84)90255-X; PHILBRICK JB, 1988, MOL GEN GENET, V212, P418, DOI 10.1007/BF00330845; PHILBRICK JB, 1991, J BIOL CHEM, V266, P13370; SANDMANN G, 1986, ARCH MICROBIOL, V145, P76, DOI 10.1007/BF00413030; SANDMANN G, 1983, ARCH MICROBIOL, V134, P23, DOI 10.1007/BF00429401; SHEN JR, 1993, J BIOL CHEM, V268, P20408; SHEN JR, 1992, FEBS LETT, V301, P145, DOI 10.1016/0014-5793(92)81235-E; SHEN JR, 1993, BIOCHEMISTRY-US, V32, P1825, DOI 10.1021/bi00058a017; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; TOMMOS C, 1993, BIOCHEMISTRY-US, V32, P5436, DOI 10.1021/bi00071a020; VASS I, 1992, BIOCHIM BIOPHYS ACTA, V1102, P195, DOI 10.1016/0005-2728(92)90100-G; VERMAAS W, 1990, Z NATURFORSCH C, V45, P359; Whitmarsh J., 1986, ENCY PLANT PHYSL, V19, P508; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; YU JJ, 1990, PLANT CELL, V2, P315	37	78	79	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6901	6907		10.1074/jbc.270.12.6901	http://dx.doi.org/10.1074/jbc.270.12.6901			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896839	hybrid			2022-12-25	WOS:A1995QQ85500070
J	LEE, GY; HE, DY; YU, L; YU, CA				LEE, GY; HE, DY; YU, L; YU, CA			IDENTIFICATION OF THE UBIQUINONE-BINDING DOMAIN IN QPS1 OF SUCCINATE-UBIQUINONE REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-REDUCTASE; DEHYDROGENASE; COMPLEX; PROTEIN; HEART; RECONSTITUTION; OXIDOREDUCTASE	An azidoubiquinone derivative, 3-azido-2-methyl-5-methoxy[H-3]-6-decyl-1,4-benzoquinone ([H-3]azido-Q), was used to study the ubiquinone-protein interaction and to identify ubiquinone-binding proteins in bovine heart mitochondrial succinate-ubiquinone reductase, When the reductase was incubated with [H-3]azido-Q and illuminated with long wavelength UV light, the decrease in the enzymatic activity correlated with the amount of azido-Q incorporated into the protein. When the illuminated, [H-3]azido-Q-treated reductase was extracted with organic solvent and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis, radioactivity was found primarily in the QPs1 subunit. The [H-3]azido-Q-labeled QPs1 was purified from labeled reductase by a procedure involving ammonium sulfate fractionation, dialysis, organic solvent extraction, lyophilization, preparative sodium dodecyl sulfate polyacrylamide gel electrophoresis, and cold acetone precipitation, The purified, [H-3]azido-Q-labeled QPs1 protein was subjected to reductive carboxymethylation prior to digestion by trypsin, One azido-Q-linked peptide, with a retention time of 66.9 min, was obtained by high performance liquid chromatographic separation, The partial amino-terminal sequence of this peptide is GLTISQL-, indicating that this tryptic peptide comprises amino acid residues 113-140 of the revised amino acid sequence of QPs1. The Q-binding domain, using the proposed structure of QPs1, is probably located in the stretch connecting transmembrane helices 2 and 3 that extrude from the surface of the M side of the inner membrane.			LEE, GY (corresponding author), OKLAHOMA STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, STILLWATER, OK 74078 USA.				NIGMS NIH HHS [GM30721] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030721, R01GM030721] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; ACKRELL BAC, 1980, J BIOL CHEM, V255, P2761; BIRCHMACHIN MA, 1992, J BIOL CHEM, V267, P11553; CAMMACK R, 1986, IRON SULFUR PROTEIN, P40; DAVIS KA, 1971, BIOCHEMISTRY-US, V10, P2509; DOYLE MP, 1989, J BIOL CHEM, V264, P1387; HATEFI Y, 1980, J BIOL CHEM, V255, P5530; HE DY, 1994, J BIOL CHEM, V269, P2292; HEDERSTEDT L, 1992, MOL MECHANISMS BIOEN, P163; JENNER ER, 1973, Patent No. 3737516; KEILIN D, 1958, NATURE, V181, P1520, DOI 10.1038/1811520a0; King T.E., 1967, METHOD ENZYMOL, V10, P322, DOI DOI 10.1016/0076-6879(67)10061-X; LEGENDRE N, 1993, PRACTICAL GUIDE PROT, P71; MIKI T, 1992, ARCH BIOCHEM BIOPHYS, V293, P61, DOI 10.1016/0003-9861(92)90365-4; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; WEBER K, 1969, J BIOL CHEM, V244, P4406; XU Y, 1987, BIOCHEM BIOPH RES CO, V144, P315, DOI 10.1016/S0006-291X(87)80512-0; YAO Y, 1986, IRON SULFUR PROTEIN, P240; YU CA, 1980, BIOCHEMISTRY-US, V19, P3579, DOI 10.1021/bi00556a025; YU L, 1985, J BIOL CHEM, V260, P963; YU L, 1982, J BIOL CHEM, V257, P2016; YU L, 1987, J BIOL CHEM, V262, P1137; YU L, 1987, BIOCHEMISTRY-US, V26, P3658, DOI 10.1021/bi00386a060; YU L, 1992, J BIOL CHEM, V267, P24508	24	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					6193	6198		10.1074/jbc.270.11.6193	http://dx.doi.org/10.1074/jbc.270.11.6193			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890754	hybrid			2022-12-25	WOS:A1995QM94500071
J	LINDEMAN, GJ; HARRIS, AW; BATH, ML; EISENMAN, RN; ADAMS, JM				LINDEMAN, GJ; HARRIS, AW; BATH, ML; EISENMAN, RN; ADAMS, JM			OVEREXPRESSED MAX IS NOT ONCOGENIC AND ATTENUATES MYC-INDUCED LYMPHOPROLIFERATION AND LYMPHOMAGENESIS IN TRANSGENIC MICE	ONCOGENE			English	Note						MAX; MYC; TRANSGENIC MICE; LYMPHOMA; LYMPHOID DEVELOPMENT	C-MYC; DNA-BINDING; PROTEIN; GENE; COTRANSFORMATION; TRANSCRIPTION; DIMERIZATION; ACTIVATION; EXPRESSION; LEUKEMIA	The cellular growth promoting function of the Myc oncoprotein requires its heterodimerization with the Max protein, but Max can also form complexes that inhibit Myc action. To determine whether man overexpression in vivo is oncogenic and whether it can modulate the action of Myc, we generated transgenic mice in which the max gene was directed to express in lymphoid cells by a linked immunoglobulin heavy chain enhancer (E mu). Expression of the transgene at substantially higher levels than the endogenous max gene did not perturb lymphoid homeostasis in adult animals nor predispose to lymphomagenesis. The numbers of B-lymphoid cells in very young animals were reduced. Moreover, analysis of bi-transgenic E mu-myc/E mu-max mice revealed that man overexpression attenuated the premalignant B-lymphoproliferative state induced by an Ep-myr: transgene and reduced the rate of lymphoma onset. These results suggest that elevation of Max expression in vivo inhibits the function of Myc.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,MELBOURNE,VIC 3050,AUSTRALIA; FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,SEATTLE,WA 98104	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Fred Hutchinson Cancer Center			Adams, Jerry M/E-1199-2013	Adams, Jerry/0000-0002-4360-8628; Lindeman, Geoffrey/0000-0001-9386-2416	NCI NIH HHS [CA57138, CA20525, CA43540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA020525, R01CA020525, R01CA057138, R37CA057138, R01CA043540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1991, BIOCHIM BIOPHYS ACTA, V1072, P9, DOI 10.1016/0304-419X(91)90004-5; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BERBERICH S, 1992, ONCOGENE, V7, P775; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; EVANS RJ, 1992, J APPROX THEORY, V69, P1, DOI 10.1016/0021-9045(92)90045-P; FISHER F, 1993, EMBO J, V12, P5075, DOI 10.1002/j.1460-2075.1993.tb06201.x; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LEE E T, 1972, Computer Programs in Biomedicine, V2, P315, DOI 10.1016/0010-468X(72)90019-0; LINDEMAN GJ, 1994, IMMUNITY, V1, P517, DOI 10.1016/1074-7613(94)90094-9; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; NUSSENZWEIG MC, 1988, NATURE, V336, P446, DOI 10.1038/336446a0; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	30	35	35	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					1013	1017						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898919				2022-12-25	WOS:A1995QL03800024
J	WHITE, DW; ROY, A; GILMORE, TD				WHITE, DW; ROY, A; GILMORE, TD			THE V-REL ONCOPROTEIN BLOCKS APOPTOSIS AND PROTEOLYSIS OF I-KAPPA-B-ALPHA IN TRANSFORMED CHICKEN SPLEEN-CELLS	ONCOGENE			English	Article						V-REL; I-KAPPA-B; APOPTOSIS; TEMPERATURE-SENSITIVE MUTANTS	DEATH GENE CED-3; C-REL; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; ONCOGENIC TRANSFORMATION; RECOGNITION SEQUENCE; PROTEIN; FIBROBLASTS; EXPRESSION; ENCODES	The v-Rel oncoprotein of the avian Rev-T retrovirus malignantly transforms chicken spleen cells in vivo and in vitro. We previously described two temperature-sensitive (ts) mutants of v-Rel (v-G37E and v-R273H) that show a ts ability to transform chicken spleen cells and to bind to DNA in vitro. We now show that spleen cell lines transformed by ts v-Rel proteins at the permissive temperature undergo apoptosis when cells are shifted to the nonpermissive temperature. The levels of most proteins (including v-Rel, p53, c-Myc, Rb and Bcl-2) do not change in these cells even at advanced stages of apoptosis, However, the chicken I kappa B-alpha protein (also called p40), which is in a complex with v-Rel in transformed cells, is degraded when ts v-Rel-transformed cells are shifted to the nonpermissive temperature. In v-R273H-transformed cells, p40 is degraded without the appearance of proteolytic intermediates. In contrast, in v-G37E-transformed cells, p40 is cleaved to an intermediate species that is missing approximately 3-4 kDa from its amino terminus, This truncated form of p40 is found in a detergent-insoluble fraction and can also be detected in wild-type v-Rel-transformed cells that are induced to undergo apoptosis by treatment with cycloheximide, Both ts v-Rel proteins are ts for interaction with p40 in vitro. The results reported here indicate that v-Rel blocks a normal pathway of programmed cell death and that I kappa B-alpha can undergo multiple degradative pathways, which can be induced by alterations in the structure of the Rel protein to which it is bound.	BOSTON UNIV,DEPT BIOL,BOSTON,MA 02215; W VIRGINIA UNIV,DEPT MICROBIOL & IMMUNOL,MORGANTOWN,WV 26506	Boston University; West Virginia University					NCI NIH HHS [CAY1450, CA47763] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047763, R29CA047763] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CAPOBIANCO AJ, 1991, ONCOGENE, V6, P2203; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DIEHL JA, 1993, MOL CELL BIOL, V13, P1769, DOI 10.1128/MCB.13.3.1769; DIEHL JA, 1993, J VIROL, V67, P7161, DOI 10.1128/JVI.67.12.7161-7171.1993; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GELINAS C, 1988, ONCOGENE, V3, P349; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90200-A; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GILMORE TD, 1992, CANCER SURV, V15, P69; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; HALDAR S, 1989, NATURE, V342, P195, DOI 10.1038/342195a0; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HRDLICKOVA R, 1995, IN PRESS J VIROL, V69; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; KUMAR S, 1993, P NATL ACAD SCI USA, V90, P8962, DOI 10.1073/pnas.90.19.8962; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; MORIN PJ, 1993, NUCLEIC ACIDS RES, V21, P2157, DOI 10.1093/nar/21.9.2157; MORRISON LE, 1991, ONCOGENE, V6, P1657; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; MOSIALOS G, 1993, ONCOGENE, V8, P721; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5858; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RICHARDSON PM, 1991, J VIROL, V65, P1322; Sambrook J, 1989, MOL CLONING LABORATO; SARKAR S, 1993, ONCOGENE, V8, P2245; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SIF S, 1993, J VIROL, V67, P7612, DOI 10.1128/JVI.67.12.7612-7617.1993; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WHITE DW, 1993, J VIROL, V67, P6876, DOI 10.1128/JVI.67.11.6876-6881.1993; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	68	56	56	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					857	868						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898928				2022-12-25	WOS:A1995QL03800007
J	MOSCKOVITZ, R; UDENFRIEND, S; FELIX, A; HEIMER, E; TATE, SS				MOSCKOVITZ, R; UDENFRIEND, S; FELIX, A; HEIMER, E; TATE, SS			MEMBRANE TOPOLOGY OF THE RAT-KIDNEY NEUTRAL AND BASIC-AMINO-ACID TRANSPORTER	FASEB JOURNAL			English	Article						BRUSH BORDER MEMBRANES; ANTIPEPTIDE ANTIBODIES; IMMUNOFLUORESCENCE; LIMITED PROTEOLYSIS	EXPRESSION CLONING; PROTEINS; CDNA; CYSTINE; LOCALIZATION; BIOSYNTHESIS; ANTIBODIES; PEPTIDASES; SYSTEM	A recently cloned rat kidney protein (NBAT) mediates the sodium-independent transport of neutral as well as basic amino acids and cystine when expressed in Xenopus laevis oocytes. The human equivalent of this transporter may be the one that is defective in cystinuria. Immunocytochemical studies have indicated that NBAT is primarily localized in the brush border membranes of rat kidney and intestinal epithelial cells, a localization consistent with its proposed role in amino acid transport. Two contrasting topological models have been proposed for NBAT: a four membrane-spanning domain (MSD) Nin-Cin model and a single MSD Nin-Cout model. We have investigated the topology of this membrane protein using two different approaches. One method was an immunofluorescent labeling technique in which intact or membrane-permeabilized cells expressing NBAT were probed with antibodies directed against putative extracellular and intracellular domains of the protein. In the second method, fragments generated by limited surface proteolysis of intact brush border membrane vesicles were subjected to immunoblot analysis using several site-specific antibodies. Both approaches yielded results consistent with a four MSD Nin-Cin topological model for NBAT.	CORNELL UNIV,COLL MED,DEPT BIOCHEM,NEW YORK,NY 10021; ROCHE INST MOLEC BIOL,ROCHE RES CTR,NUTLEY,NJ 07110; HOFFMANN LA ROCHE INC,DEPT PEPTIDE RES,NUTLEY,NJ 07110	Cornell University; Roche Holding; Roche Holding								BERTRAN J, 1993, J BIOL CHEM, V268, P14842; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; JENNINGS ML, 1989, ANNU REV BIOCHEM, V58, P999; KODUKULA K, 1993, J CELL BIOL, V120, P657, DOI 10.1083/jcb.120.3.657; LEE WS, 1993, J CLIN INVEST, V91, P1959, DOI 10.1172/JCI116415; MALATHI P, 1979, BIOCHIM BIOPHYS ACTA, V554, P259, DOI 10.1016/0005-2736(79)90023-3; MOSCKOVITZ R, 1993, P NATL ACAD SCI USA, V90, P4022, DOI 10.1073/pnas.90.9.4022; PICKEL VM, 1993, P NATL ACAD SCI USA, V90, P7779, DOI 10.1073/pnas.90.16.7779; SEMENZA G, 1986, ANNU REV CELL BIOL, V2, P255, DOI 10.1146/annurev.cellbio.2.1.255; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; TATE SS, 1985, METHOD ENZYMOL, V113, P471; TSANG VCW, 1983, METHOD ENZYMOL, V92, P377; UHL GR, 1992, TRENDS PHARMACOL SCI, V13, P421, DOI 10.1016/0165-6147(92)90133-Q; VANWINKLE LJ, 1988, J BIOL CHEM, V263, P3150; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596	17	45	45	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1994	8	13					1069	1074		10.1096/fasebj.8.13.7926373	http://dx.doi.org/10.1096/fasebj.8.13.7926373			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PN069	7926373				2022-12-25	WOS:A1994PN06900012
J	DONG, AC; HUANG, P; ZHAO, XJ; SAMPATH, V; CAUGHEY, WS				DONG, AC; HUANG, P; ZHAO, XJ; SAMPATH, V; CAUGHEY, WS			CHARACTERIZATION OF SITES OCCUPIED BY THE ANESTHETIC NITROUS-OXIDE WITHIN PROTEINS BY INFRARED-SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; CARBON-MONOXIDE BINDING; BOVINE HEART MYOGLOBIN; MOLECULAR MECHANISMS; GENERAL-ANESTHETICS; SERUM-ALBUMIN; SECONDARY STRUCTURE; SULFHYDRYL GROUPS; LIGAND-BINDING; HEMOGLOBIN	We report here a comprehensive infrared spectroscopic study of the interactions between the anesthetic nitrous oxide (N2O) and six proteins: lysozyme, cytochrome c, myoglobin, hemoglobin, serum albumin, and cytochrome c oxidase. Sites occupied by N2O molecules within these proteins were characterized. Three types of hydrophobic sites were found within the proteins. One with nu(3) near 2225 cm(-1) is likely to be near peptide bond carbonyls; one with nu(3) near 2219 cm(-1) may be near a benzene-like structure such as the side chains of phenylalanine and tyrosine; and the other with nu(3) near 2215 cm(-1) is likely to be in a nonpolar alkane-like environment provided by the side chains of Leu, Ile, and Val residues. The amount of N2O molecules bound to myoglobin increases as the pH decreases from 9.2 to 5.2. N2O-protein interactions produced no detectable changes in the ligand-binding pockets of myoglobin, hemoglobin, and cytochrome c oxidase. N2O-induced secondary structure changes were detected only in the fully reduced cytochrome c oxidase, not in the fully oxidized oxidase and the other five proteins. N2O-indueed conformational changes in the alpha beta-interface of hemoglobin and the h2 and h3 alpha-helices of human serum albumin were detected by monitoring the S-H stretch vibrations of cysteine residues. These findings provide direct evidence that anesthetic N2O interacts with proteins and occupies sites in the interior of the proteins.	COLORADO STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,FT COLLINS,CO 80523	Colorado State University								ALBEN JO, 1974, NATURE, V252, P736, DOI 10.1038/252736a0; BALASUBR.D, 1966, P NATL ACAD SCI USA, V55, P762, DOI 10.1073/pnas.55.4.762; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; BARE GH, 1975, BIOCHEMISTRY-US, V14, P1578, DOI 10.1021/bi00679a005; BOWLER BE, 1993, BIOCHEMISTRY-US, V32, P183, DOI 10.1021/bi00052a024; BROWN FF, 1976, PROC R SOC SER B-BIO, V193, P387, DOI 10.1098/rspb.1976.0053; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CAUGHEY JM, 1977, BIOCHEM BIOPH RES CO, V78, P897, DOI 10.1016/0006-291X(77)90507-1; Caughey W. S., 1980, METHODS DETERMINING, P95; CAUGHEY WS, 1993, J BIOENERG BIOMEMBR, V25, P81, DOI 10.1007/BF00762850; CAUGHEY WS, 1981, P NATL ACAD SCI-BIOL, V78, P2903, DOI 10.1073/pnas.78.5.2903; CAUGHEY WS, 1985, HDB METHODS OXYGEN R, P95; CHIRGADZE YN, 1975, BIOPOLYMERS, V14, P679, DOI 10.1002/bip.1975.360140402; CURRY S, 1990, BIOCHEMISTRY-US, V29, P4641, DOI 10.1021/bi00471a020; DODSON BA, 1984, MOL CELL BIOCHEM, V64, P97; DONG A, 1992, BIOCHEMISTRY-US, V31, P182, DOI 10.1021/bi00116a027; DONG A, 1992, BIOCHEMISTRY-US, V31, P9364, DOI 10.1021/bi00154a006; DONG A, 1990, BIOCHEMISTRY-US, V29, P3303, DOI 10.1021/bi00465a022; DONG A, 1989, J CELL BIOL, V107, pA641; DONG AC, 1994, METHOD ENZYMOL, V232, P139; DUBOIS BW, 1992, BIOCHEMISTRY-US, V31, P7069, DOI 10.1021/bi00146a007; EINARSDOTTIR O, 1988, J BIOL CHEM, V263, P9199; FIRESTONE LL, 1986, SEMIN ANESTH PERIO M, V5, P286; FRANKS NP, 1981, NATURE, V292, P248, DOI 10.1038/292248a0; FRANKS NP, 1982, NATURE, V300, P487, DOI 10.1038/300487a0; FRANKS NP, 1985, NATURE, V316, P349, DOI 10.1038/316349a0; FRANKS NP, 1984, NATURE, V310, P599, DOI 10.1038/310599a0; GORGA JC, 1985, ARCH BIOCHEM BIOPHYS, V240, P734, DOI 10.1016/0003-9861(85)90082-7; HALSEY MJ, 1984, BRIT J ANAESTH, V56, pS9; HAZZARD JH, 1985, ARCH BIOCHEM BIOPHYS, V240, P747, DOI 10.1016/0003-9861(85)90083-9; HAZZARD JH, 1982, BIOPHYS J, V37, pA154; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; HEIDNER EJ, 1976, J MOL BIOL, V104, P707, DOI 10.1016/0022-2836(76)90130-3; KAGANN RH, 1982, J MOL SPECTROSC, V95, P297, DOI 10.1016/0022-2852(82)90130-8; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; LAASBERG LH, 1971, J BIOL CHEM, V246, P4886; MASHIMO T, 1986, MOL PHARMACOL, V29, P149; Meyer HZur, 1899, ARCH EXP PATHOL PHAR, V42, P109, DOI [10.1007/BF01834479, DOI 10.1007/BF01834479]; MILLER KW, 1985, INT REV NEUROBIOL, V27, P1, DOI 10.1016/S0074-7742(08)60555-3; MOH PP, 1987, BIOCHEMISTRY-US, V26, P6243, DOI 10.1021/bi00393a044; MORIKIS D, 1989, BIOCHEMISTRY-US, V28, P4791, DOI 10.1021/bi00437a041; Overton E., 1901, STUDIEN NARKOSE; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PLYLER EK, 1964, J RES NBS A PHYS CH, VA 68, P79, DOI 10.6028/jres.068A.006; POTTER WT, 1990, BIOCHEMISTRY-US, V29, P6283, DOI 10.1021/bi00478a025; RAMSDEN J, 1989, BIOCHEMISTRY-US, V28, P3125, DOI 10.1021/bi00434a001; RICHARDS CD, 1978, NATURE, V276, P775, DOI 10.1038/276775a0; RICHARDS CD, 1980, TOPICAL REV ANAESTHE, V1, P1; SACHSENHEIMER W, 1977, FEBS LETT, V79, P310, DOI 10.1016/0014-5793(77)80809-0; SCHOENBO.BP, 1967, NATURE, V214, P1120, DOI 10.1038/2141120a0; SCHOENBORN BP, 1969, J MOL BIOL, V45, P297, DOI 10.1016/0022-2836(69)90106-5; SCHOENBORN BP, 1965, NATURE, V207, P28, DOI 10.1038/207028a0; SCHOENBORN BP, 1976, P NATL ACAD SCI USA, V73, P4195, DOI 10.1073/pnas.73.11.4195; SEEMAN P, 1972, PHARMACOL REV, V24, P583; SHAANAN B, 1983, J MOL BIOL, V171, P31, DOI 10.1016/S0022-2836(83)80313-1; SHIMADA H, 1982, J BIOL CHEM, V257, P1893; SHULMAN RG, 1970, J MOL BIOL, V48, P517, DOI 10.1016/0022-2836(70)90063-X; SOWA S, 1987, BIOCHEM BIOPH RES CO, V144, P643, DOI 10.1016/S0006-291X(87)80014-1; SUSI H, 1986, METHOD ENZYMOL, V130, P290; TILTON RF, 1984, BIOCHEMISTRY-US, V23, P2849, DOI 10.1021/bi00308a002; TORII H, 1992, J CHEM PHYS, V96, P3379, DOI 10.1063/1.461939; UEDA I, 1984, ANESTH ANALG, V63, P929; Vincent-Geisse J., 1970, Canadian Journal of Chemistry, V48, P3918, DOI 10.1139/v70-657; VINCENTGEISSE J, 1971, BERICH BUNSEN GESELL, V75, P348; YOSHIKAWA S, 1982, J BIOL CHEM, V257, P412; ZHU L, 1992, J MOL BIOL, V224, P207, DOI 10.1016/0022-2836(92)90584-7	66	26	26	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23911	23917						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929038				2022-12-25	WOS:A1994PQ34600013
J	STARBORG, M; BRUNDELL, E; GELL, K; HOOG, C				STARBORG, M; BRUNDELL, E; GELL, K; HOOG, C			A NOVEL MURINE GENE ENCODING A 216-KDA PROTEIN IS RELATED TO A MITOTIC CHECKPOINT REGULATOR PREVIOUSLY IDENTIFIED IN ASPERGILLUS-NIDULANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CONTROL; DNA-REPLICATION SITES; CHROMOSOME CONDENSATION; BINDING PROTEIN; RCC1 PROTEIN; SACCHAROMYCES-CEREVISIAE; CHROMATIN-CONDENSATION; CONFOCAL MICROSCOPY; LARGE NUMBER; S-PHASE	We describe the isolation and characterization of a novel mouse gene, tsg24, which displays striking sequence similarities to the Aspergillus nidulans bimE gene. The bimE gene has been shown to be a mitotic checkpoint regulator, negatively regulating entry into mitosis in A. nidulans. The tsg24 gene was found to contain a long open reading frame of 1944 amino acids, encoding a polypeptide with a calculated molecular mass of 216,087 Da. We have developed an antibody directed against the product of the tsg24 gene and identified a protein with a molecular mass of approximately 200 kDa. This protein was found to be uniformly expressed throughout interphase of the cell cycle, whereas the level of this protein was lower in protein extracts prepared from mitotic cells.	KAROLINSKA INST,MED NOBEL INST,DEPT MOLEC & CELL BIOL,GENET MOLEC LAB,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet								BAIROCH A, 1993, NUCLEIC ACIDS RES, V21, P3097, DOI 10.1093/nar/21.13.3097; BAUER GA, 1990, NUCLEIC ACIDS RES, V18, P261, DOI 10.1093/nar/18.2.261; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BJORKLUND S, 1992, EMBO J, V11, P4953, DOI 10.1002/j.1460-2075.1992.tb05602.x; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; CLARK KL, 1991, CELL REGUL, V2, P781, DOI 10.1091/mbc.2.10.781; DASSO M, 1993, TRENDS BIOCHEM SCI, V18, P96, DOI 10.1016/0968-0004(93)90161-F; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Doree M, 1990, CURR OPIN CELL BIOL, V2, P269, DOI 10.1016/0955-0674(90)90018-A; ENGLE DB, 1990, J BIOL CHEM, V265, P16132; ENOCH T, 1991, CELL, V65, P921, DOI 10.1016/0092-8674(91)90542-7; FORRESTER W, 1992, GENE DEV, V6, P1914, DOI 10.1101/gad.6.10.1914; FOX MH, 1991, J CELL SCI, V99, P247; FRASCH M, 1991, EMBO J, V10, P1225, DOI 10.1002/j.1460-2075.1991.tb08064.x; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HOOG C, 1991, NUCLEIC ACIDS RES, V19, P6123, DOI 10.1093/nar/19.22.6123; HUMBERT C, 1992, J CELL SCI, V103, P97; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; MATSUMOTO T, 1993, MOL BIOL CELL, V4, P337, DOI 10.1091/mbc.4.3.337; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; MORRIS NR, 1976, EXP CELL RES, V98, P204, DOI 10.1016/0014-4827(76)90480-8; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; MURRAY AW, 1993, CURR BIOL, V3, P291, DOI 10.1016/0960-9822(93)90182-N; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; NISHIMOTO T, 1992, Current Opinion in Cell Biology, V4, P174, DOI 10.1016/0955-0674(92)90029-C; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; NISHITANI H, 1990, J BIOCHEM-TOKYO, V107, P228, DOI 10.1093/oxfordjournals.jbchem.a123031; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1976, MOL GEN GENET, V146, P1667; OHTSUBO M, 1987, GENE DEV, V1, P585, DOI 10.1101/gad.1.6.585; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; REN MD, 1993, J CELL BIOL, V120, P313, DOI 10.1083/jcb.120.2.313; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SAZER S, 1994, EMBO J, V13, P606, DOI 10.1002/j.1460-2075.1994.tb06298.x; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; SEINO H, 1992, J CELL SCI, V102, P393; STARBORG M, 1992, MOL REPROD DEV, V33, P243, DOI 10.1002/mrd.1080330303; TOBEY RA, 1967, J CELL PHYSIOL, V70, P63, DOI 10.1002/jcp.1040700109; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; WASEEM NH, 1992, EMBO J, V11, P5111, DOI 10.1002/j.1460-2075.1992.tb05618.x; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120	47	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24133	24137						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929068				2022-12-25	WOS:A1994PQ34600046
J	SCOTT, GK; DANIEL, JC; XIONG, XH; MAKI, RA; KABAT, D; BENZ, CC				SCOTT, GK; DANIEL, JC; XIONG, XH; MAKI, RA; KABAT, D; BENZ, CC			BINDING OF AN ETS-RELATED PROTEIN WITHIN THE DNASE-I HYPERSENSITIVE SITE OF THE HER2/NEU PROMOTER IN HUMAN BREAST-CANCER CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; NEU PROTOONCOGENE; NUCLEAR FACTOR; MESSENGER-RNA; GENE; EXPRESSION; ONCOGENE; C-ERBB-2; OVEREXPRESSION; REPRESSION	Promoter elements accounting for HER2 (c-erbB-2/ neu) overexpression were searched for in several human breast cancer cell lines (MDA-453, BT-474, ZR-75-1, MCF-7) known to express constitutively a 30-fold range in HER2 transcripts per gene copy. HER2 overexpress ing cells showed a single prominent DNase I hypersensitive site near a conserved and hitherto unrecognized ets response element (GAGGAA), located 38 bases down-stream from the CAAT box and directly 5' of the TATA box in the human HERB promoter. Transient transfection of HER2 promoter constructs (0.125, 0.5, and 2.0 kilobase pairs (kb)) demonstrated that the most proximal promoter region (0.125 kb) was capable of conferring up to 30-fold enhanced activity in HER2-overexpressing cell lines relative to low HER2-expressing control lines. Site directed mutagenesis of the ets response element (GAGGAA --> GAGAGA) caused a greater than or equal to 60% reduction in promoter activity affecting at least 0.5 kb of upstream HERB regulatory sequence. Gel-shift assays with nuclear extracts and oligonucleotide sequences spanning the 0.125-kb promoter region detected an ETS-immunoreactive complex, present most abundantly in cells overexpressing HERB, whose high-affinity binding depended on the GAGGAA response element. Methylation interference confirmed the ETS-specific pattern of protein binding by this complex to guanine bases in the ets response element. UV cross-linking and immunoprecipitation implicate a similar to 60-kDa ETS protein, and candidate ETS genes expressed in these breast cancer cells include GABP alpha, elk-1, elf-1, and PEA3.	UNIV CALIF SAN FRANCISCO, CANC RES INST, SAN FRANCISCO, CA 94143 USA; LA JOLLA CANC RES FDN, LA JOLLA, CA 92037 USA; OREGON HLTH SCI UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, PORTLAND, OR 97201 USA	University of California System; University of California San Francisco; Sanford Burnham Prebys Medical Discovery Institute; Oregon Health & Science University					NCI NIH HHS [CA-58207, CA-44768, CA-36773] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058207, R01CA036773, P01CA044768] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENZ CC, 1989, JNCI-J NATL CANCER I, V81, P1704, DOI 10.1093/jnci/81.22.1704; BERGER MS, 1988, CANCER RES, V48, P1238; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BRUDER JT, 1989, MOL CELL BIOL, V9, P5143, DOI 10.1128/MCB.9.11.5143; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FERNANDEZPOL JA, 1989, J BIOL CHEM, V264, P4151; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; HUDSON LG, 1990, J BIOL CHEM, V265, P4389; HYNES NE, 1989, J CELL BIOCHEM, V39, P167, DOI 10.1002/jcb.240390208; ISHII S, 1987, P NATL ACAD SCI USA, V84, P4374, DOI 10.1073/pnas.84.13.4374; KAMEDA T, 1990, CANCER RES, V50, P8002; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KEITH DH, 1986, MOL CELL BIOL, V6, P4122, DOI 10.1128/MCB.6.11.4122; KEMPER B, 1987, MOL CELL BIOL, V7, P2059, DOI 10.1128/MCB.7.6.2059; KERN JA, 1990, CANCER RES, V50, P5184; KING CR, 1989, CANCER RES, V49, P4185; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIN CS, 1993, J BIOL CHEM, V268, P2793; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MAGUIRE HC, 1989, SEMIN ONCOL, V16, P148; MANIATIS T, 1989, MOL CLONING LABORATO, P16; Maxam A M, 1980, Methods Enzymol, V65, P499; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PASLEAU F, 1993, ONCOGENE, V8, P849; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; RAY D, 1990, ONCOGENE, V5, P663; RUSSELL KS, 1992, CANCER RES, V52, P6624; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SINGLETON TP, 1992, PATHOL ANNU, V27, P165; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; TAL M, 1987, MOL CELL BIOL, V7, P2597, DOI 10.1128/MCB.7.7.2597; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; Tripathy D., 1993, ONCOGENES TUMOR SUPP, P15; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; WHITE MRA, 1992, ONCOGENE, V7, P677; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YU DH, 1992, J BIOL CHEM, V267, P10203; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499	51	93	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19848	19858						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	7914192				2022-12-25	WOS:A1994PA12600032
J	CASSARMALEK, I; MARCHAL, S; ALTABEF, M; WRUTNIAK, C; SAMARUT, J; CABELLO, G				CASSARMALEK, I; MARCHAL, S; ALTABEF, M; WRUTNIAK, C; SAMARUT, J; CABELLO, G			V-ERBA STIMULATES QUAIL MYOBLAST DIFFERENTIATION IN A T3 INDEPENDENT, CELL-SPECIFIC MANNER	ONCOGENE			English	Article							THYROID-HORMONE RECEPTOR; AVIAN ERYTHROBLASTOSIS VIRUS; RETINOIC ACID RECEPTOR; DNA-BINDING DOMAIN; C-ERBA; GENE-EXPRESSION; ERYTHROID-DIFFERENTIATION; SKI ONCOGENE; TRANSCRIPTIONAL ACTIVATION; TERMINAL DIFFERENTIATION	The v-erbA oncoprotein represents a mutated version of a thyroid hormone receptor, responsible for the induction of a differentiation arrest in chicken erythroid cells. We have studied the influence of v-erbA on proliferation and differentiation of avian myoblasts. Secondary quail myoblast cultures were infected either with an avian retrovirus carrying the v-erbA oncogene in association with the neomycin resistance gene, or with a control deleted v-erbA/neo(R) retrovirus. We report here that v-erbA expression led to an increase in myoblast proliferation and to a surprising stimulation of quail myoblast terminal differentiation. In addition, these effects occurred in the presence or absence of T3, and v-erbA did not suppress T3 influence on myoblasts. Transient transfection assays demonstrated that, in contrast to its action in HeLa cells, v-erbA was unable to repress the transcriptional activation of a TRE-CAT reporter gene by liganded c-erbA alpha receptors in quail myoblasts. We also observed that the AP-1/c-erbA/v-erbA interactions are not functional in quail myoblasts. These data suggest that, in these cells, v-erbA action does not interfere with T3 induced mechanisms. They also demonstrate a cell specificity for the v-erbA pathway. Lastly, expression of c-erbA/v-erbA chimeric proteins and of the S61G v-erbA mutant indicates that the DNA binding domain of v-erbA, and more specifically serine 61, is directly involved in the enhancement of myoblast differentiation by the oncoprotein.	INRA, DIFFERENCIAT CELLULAIRE & CROISSANCE LAB, UNITE ENDOCRINOL CELLULAIRE, F-34060 MONTPELLIER 01, FRANCE; ECOLE NORMALE SUPER LYON, INRA, BIOL CELLULAIRE & MOLEC LAB, CNRS, UMR40, F-69364 LYON 07, FRANCE	INRAE; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); INRAE			Samarut, Jacques/AAD-2587-2019; , Cassar-Malek/AAW-6386-2020	, Cassar-Malek/0000-0001-7407-1408				ANTIN PB, 1991, DEV BIOL, V143, P111, DOI 10.1016/0012-1606(91)90058-B; BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BONDE BG, 1991, J VIROL, V65, P2037, DOI 10.1128/JVI.65.4.2037-2046.1991; CARNAC G, 1992, MOL ENDOCRINOL, V6, P1185, DOI 10.1210/me.6.8.1185; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DESBOIS C, 1991, ONCOGENE, V6, P2129; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DEVERNEUIL H, 1990, NUCLEIC ACIDS RES, V18, P4489; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FALCONE G, 1991, MOL CELL BIOL, V11, P3331, DOI 10.1128/MCB.11.6.3331; FALCONE G, 1990, CIBA F SYMP, V150, P250; FORMAN BM, 1988, MOL ENDOCRINOL, V2, P902, DOI 10.1210/mend-2-10-902; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; GANDRILLON O, 1994, ONCOGENE, V9, P749; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GAZZOLO L, 1980, CELL, V22, P683, DOI 10.1016/0092-8674(80)90544-9; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GROSSI M, 1991, ONCOGENE, V6, P1767; GROSSI M, 1989, PATHOLOGY GENE EXPRE, P313; HERMANN T, 1993, ONCOGENE, V8, P55; KHAZAIE K, 1991, ONCOGENE, V6, P21; KING DB, 1987, J EXP ZOOL, P291; LARSEN J, 1992, ONCOGENE, V7, P1903; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCHAL S, 1993, BIOL CELL, V78, P191, DOI 10.1016/0248-4900(93)90129-3; Markwell M A, 1981, Methods Enzymol, V72, P296; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; MUSCAT GEO, 1994, NUCLEIC ACIDS RES, V22, P583, DOI 10.1093/nar/22.4.583; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; PAIN B, 1990, New Biologist, V2, P284; PRIVALSKY ML, 1988, MOL CELL BIOL, V8, P4510, DOI 10.1128/MCB.8.10.4510; PRIVALSKY ML, 1990, CELL, V63, P1277, DOI 10.1016/0092-8674(90)90423-C; SAATCIOGLU F, 1993, MOL CELL BIOL, V13, P3675, DOI 10.1128/MCB.13.6.3675; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHROEDER C, 1992, ONCOGENE, V7, P203; SCHROEDER C, 1990, ONCOGENE, V5, P1445; SCHROEDER C, 1992, ONCOGENE, V7, P217; SCOW RO, 1951, ENDOCRINOLOGY, V49, P641, DOI 10.1210/endo-49-5-641; SHAINBERG A, 1984, J ENDOCRINOL, V101, P141, DOI 10.1677/joe.0.1010141; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; SHARIF M, 1992, ONCOGENE, V7, P953; SMITMCBRIDE Z, 1993, ONCOGENE, V8, P1465; SNEDECOR GW, 1961, STATISTICAL METHODS; STOCKDALE FE, 1977, REGULATION CELL PROL, P165; SU HY, 1991, ONCOGENE, V6, P1759; SUTRAVE P, 1991, ONCOGENE, V6, P353; VENNSTROM B, 1980, J VIROL, V36, P575; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YAMAMOTO T, 1983, CELL, V34, P225, DOI 10.1016/0092-8674(83)90153-8; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016	60	21	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1994	9	8					2197	2206						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	7913543				2022-12-25	WOS:A1994NX62900011
J	KAGAWA, N; OGO, A; TAKAHASHI, Y; IWAMATSU, A; WATERMAN, MR				KAGAWA, N; OGO, A; TAKAHASHI, Y; IWAMATSU, A; WATERMAN, MR			A CAMP-REGULATORY SEQUENCE (CRS1) OF CYP17 IS A CELLULAR TARGET FOR THE HOMEODOMAIN PROTEIN PBX1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN PROTOONCOGENE PBX1; PRE-B; TRANSCRIPTION FACTOR; DEVELOPMENTAL EXPRESSION; TRANSLOCATION PROTEIN; FREE-EXTRACTS; GENE; P-45017-ALPHA; DROSOPHILA; RESPONSIVENESS	Cytochrome P450c17 encoded by CYP17, whose expression is regulated by peptide hormones via cAMP, is required for cortisol and sex hormone biosynthesis thereby playing a key role in biological processes including sexual differentiation. Utilizing the cAMP-regulatory sequence CRS1 of the bovine CYP17 gene as an affinity ligand, four CRS1-binding proteins have been purified from nuclear extracts of mouse adrenocortical Y1 cells and shown to enhance the in vitro transcription of a reporter gene promoted by CRS1. Microsequencing of these four proteins established two of them to be the homeodomain proteins Pbx1a and Pbx1b, originally discovered by their involvement in the t(1;19) chromosomal translocation in pre-B-cell acute lymphoblastic leukemias. Overexpression of Pbx1 in Y1 cells enhances cAMP-dependent transcription of the CRS1-dependent reporter gene. These results identify the CRS1 of bovine CYP17 as a cellular target for Pbx1 and suggest that one role of this homeodomain protein is in the regulation of steroidogenesis and subsequently sexual development.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; KIRIN BREWERY CO LTD,CENT LABS KEY TECHNOL,KANAZAWA KU,YOKOHAMA,KANAGAWA 221,JAPAN	Vanderbilt University; Kirin Brewery Company Limited					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK28350] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BLU H, 1987, ELECTROPHORESIS, V8, P93; BURGLIN TR, 1992, NAT GENET, V1, P319, DOI 10.1038/ng0892-319; FLEGEL WA, 1993, MECH DEVELOP, V41, P155, DOI 10.1016/0925-4773(93)90045-Y; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; JOHN ME, 1986, P NATL ACAD SCI USA, V83, P4715, DOI 10.1073/pnas.83.13.4715; KAGAWA N, 1992, J BIOL CHEM, V267, P25213; KAGAWA N, 1991, J BIOL CHEM, V266, P11199; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KEMP BE, 1977, J BIOL CHEM, V252, P4888; LUND J, 1990, J BIOL CHEM, V265, P3304; LUND J, 1988, J BIOL CHEM, V263, P16195; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MCGINNIS W, 1984, CELL, V37, P403, DOI 10.1016/0092-8674(84)90370-2; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; YANASE T, 1991, ENDOCR REV, V12, P91, DOI 10.1210/edrv-12-1-91; ZANGER UM, 1991, J BIOL CHEM, V266, P11417; ZUBER MX, 1986, J BIOL CHEM, V261, P2475	27	54	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18716	18719						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	7913464				2022-12-25	WOS:A1994NX32700004
J	KATZ, J; WALS, P; LEE, WNP				KATZ, J; WALS, P; LEE, WNP			ISOTOPOMER STUDIES OF GLUCONEOGENESIS AND THE KREBS CYCLE WITH C-13-LABELED LACTATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFUSED-RAT-LIVER; C-14-LABELED LACTATE; GLYCOGEN-SYNTHESIS; PYRUVATE-KINASE; STARVED RATS; METABOLISM; <U-C-13>GLUCOSE; PATHWAYS; INSULIN; INVIVO	Fasted rats were intragastrically infused with either [2,3-C-13]lactate or [1,2,3-C-13]lactate. The infusate also contained C-14-labeled lactate and [3-H-3]glucose. Glucose, alanine, glutamate, and glutamine were isolated from liver and blood. There was near complete equilibration of lactate and alanine, and the relative specific activities and relative enrichments were the same in blood and liver. Glucose was cleaved enzymatically to lactate. The compounds were examined by gas chromatography-mass spectroscopy. From the mass isotopomer spectra of the lactate, glutamate, and glutamine and their cleavage fragments the positional isotopomer composition of these compounds was obtained. The enrichment and isotopomer pattern in the lactate from cleaved glucose represents that in phosphoenolpyruvate (PEP). When [1,2,3-C-13]lactate was infused the mass isotopomer spectrum of glutamates consisted only of compounds containing either one, two, or three C-13 carbons per molecule (m1, m2, and m3). There was little C-13 in C-4 and C-5 of glutamate. The rate of pyruvate decarboxylation is low, and 3-4% of the acetyl-CoA flux in the Krebs cycle is contributed by lactate carbon. The major isotopomers in lactate, alanine, and PEP were m3 and m2 with C-13 in C-2 and C-3. The predominant isotopomer in PEP from [2,3-C-13]lactate was m2 with C-13 in C-2 and C-3. There was much more of m1 isotopomer with C-13 in C-3 and C-2 than the m1 isotopomer with C-13 in C-1. There was very little m3, the isotopomer with C-13 in all three carbons. Most of the C-13 in C-3 and C-4 of glucose and C-1 of glutamate was introduced via (CO2)-C-13 fixation. From the isotopomer distribution and the rate of glucose turnover we deduced, applying the analysis described in the ''Appendix,'' the absolute rates of gluconeogenic pathways, recycling of PEP and the Cori cycle, and flux in the Krebs cycle. The flux from oxaloacetate (OAA) --> PEP was seven times that of OAA --> citrate, and about half of PEP was recycled to pyruvate via pyruvate kinase. The mass isotopomer patterns in glutamate and glutamine were similar but differed from those of lactate and glucose. It appears that the glutamates are derived from alpha-ketoglutarate from a different Krebs cycle pool than PEP. The flux from OAA to PEP in this pool was two to three times that of OAA to citrate. Our results indicate that the oxidation via the Krebs cycle is not sufficient for the energy needs of the cell and that fatty acids rather than the Krebs cycle provide most of the energy needs of gluconeogenic cells. A major regulatory role of pyruvate kinase is suggested.	UNIV CALIF LOS ANGELES, HARBOR MED CTR, TORRANCE, CA 90502 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	KATZ, J (corresponding author), CEDARS SINAI MED CTR, LOS ANGELES, CA 90048 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036449] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 4271] Funding Source: Medline; NIDDK NIH HHS [R01 DK36449] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLAIR JB, 1976, J BIOL CHEM, V251, P3756; COHEN SM, 1987, BIOCHEMISTRY-US, V26, P573, DOI 10.1021/bi00376a032; CONSOLI A, 1993, DIABETES, V42, P732, DOI 10.2337/diabetes.42.5.732; DIDONATO L, 1993, J BIOL CHEM, V268, P4170; DIDONATO L, 1992, FASEB J*, V1520, P3381; DRAKE RL, 1983, J BIOL CHEM, V258, P6008; FELL DA, 1992, BIOCHEM J, V286, P313, DOI 10.1042/bj2860313; FREEDMAN AD, 1958, J BIOL CHEM, V233, P292; FRIEDMANN B, 1971, ARCH BIOCHEM BIOPHYS, V143, P566; GAWEHN K, 1984, METHOD ENZYMAT AN, V6, P588; GEBHARDT R, 1992, PHARMACOL THERAPEUT, V53, P275, DOI 10.1016/0163-7258(92)90055-5; GROEN AK, 1983, J BIOL CHEM, V258, P4346; GRUNNET N, 1978, BIOCHEM J, V172, P595, DOI 10.1042/bj1720595; HAUSSINGER D, 1990, BIOCHEM J, V267, P281; KATZ J, 1985, AM J PHYSIOL, V248, pR391, DOI 10.1152/ajpregu.1985.248.4.R391; KATZ J, 1989, J BIOL CHEM, V264, P12994; KATZ J, 1976, H-S Z PHYSIOL CHEM, V357, P1387, DOI 10.1515/bchm2.1976.357.2.1387; KATZ J, 1991, P NATL ACAD SCI USA, V88, P2103, DOI 10.1073/pnas.88.6.2103; KATZ J, 1979, TECHNIQUES METABOLIC, P1; KOEPPE RE, 1955, J BIOL CHEM, V216, P813; KRAUSFRIEDMAN N, 1981, PHYSIOL REV, V64, P170; Lee W. N. P., 1989, J BIOL CHEM, V264, P13002; LEE WNP, 1991, BIOL MASS SPECTROM, V20, P451, DOI 10.1002/bms.1200200804; LEIMER KR, 1977, J CHROMATOGR, V141, P121, DOI 10.1016/S0021-9673(00)99131-3; MAGNUSSON I, 1991, J BIOL CHEM, V266, P6975; MALLOY CR, 1988, J BIOL CHEM, V263, P6964; NIEWOEHNER CB, 1988, DIABETES, V37, P1559, DOI 10.2337/diabetes.37.11.1559; OKAJIMA F, 1981, BIOCHEM J, V194, P525, DOI 10.1042/bj1940525; ROGNSTAD R, 1968, ANAL BIOCHEM, V25, P448, DOI 10.1016/0003-2697(68)90121-8; ROGNSTAD R, 1988, Medical Science Research, V16, P293; RONGSTAD R, 1977, J BIOL CHEM, V252, P1831; RONGSTAD R, 1976, INT J BIOCHEM, V7, P403; SCHUMANN WC, 1991, J BIOL CHEM, V266, P6985; STRISOWER EH, 1952, J BIOL CHEM, V198, P115; TOMERA JF, 1982, BIOCHEM J, V208, P231, DOI 10.1042/bj2080231; TSERNG KY, 1984, ANAL CHEM, V56, P517, DOI 10.1021/ac00267a049; WALS PA, 1993, IN PRESS METABOLISM	37	113	114	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25509	25521						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7902352				2022-12-25	WOS:A1993MK10000037
J	ANDRESSON, T; SPARKOWSKI, J; GOLDSTEIN, DJ; SCHLEGEL, R				ANDRESSON, T; SPARKOWSKI, J; GOLDSTEIN, DJ; SCHLEGEL, R			VACUOLAR H+-ATPASE MUTANTS TRANSFORM CELLS AND DEFINE A BINDING-SITE FOR THE PAPILLOMAVIRUS E5 ONCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; PORE-FORMING PROTEIN; PROTON PUMP; RECONSTITUTION; KERATINOCYTES; ACTIVATION; COMPONENT; COMPLEX; YEAST; GENE	The 16K subunit of the vacuolar H+-ATPase binds specifically to the bovine (BPV) and human (HPV) papillomavirus E5 oncoproteins, and it has been suggested that this interaction may contribute to cell transformation (Goldstein, D. J., and Schlegel, R. (1990) EMBO J. 9, 137-146; Goldstein, D. J., Finbow, M. E., Andresson, T., McLean, P., Smith, K., Bubb, V. J., and Schlegel, R. (1991) Nature 352, 347-349; Conrad, M., Bubb, V. J., and Schlegel, R. (1993) J. Virol. 67, 6170-6178; Goldstein, D. J., Toyama, R., Schlegel, R., and Dhar, R. (1992) Virology 190, 889-893). We generated mutations within the 16K protein to define binding domains for BPV-1 E5 as well as to characterize the role of 16K in cell transformation. 16K consists predominantly of 4 transmembrane (TM) domains. We showed that mutations within the TM4 domain severely inhibited E5 binding. More specifically, conversion of glutamic acid 143 to arginine within TM4 severely reduced 16K/E5 binding, suggesting that charged interactions facilitated efficient binding. This hypothesis was confirmed by demonstrating that binding to the defective 16K arginine mutant could be restored by complementary charge mutations in E5; conversion of E5 glutamine 17 to glutamic acid or aspartic acid enhanced interactions with the 16K arginine mutant. Surprisingly, mutants in TM4 not only bound poorly to wild-type E5 but were converted into an oncoprotein and induced anchorage-independent growth of NIH 3T3 cells. These data define glutamic acid 143 in the 16K TM4 domain and glutamine 17 within E5 as important contributors to E5/16K binding and suggest a role for the 16K protein in the regulation of cell proliferation.	GEORGETOWN UNIV,SCH MED,DEPT PATHOL,WASHINGTON,DC 20007; GEORGETOWN UNIV,SCH MED,DEPT OBSTET & GYNECOL,WASHINGTON,DC 20007	Georgetown University; Georgetown University								ARAI H, 1988, J BIOL CHEM, V258, P8796; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; COHEN BD, 1993, J VIROL, V6, P5303; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; FORGAC M, 1992, J BIOENERG BIOMEMBR, V24, P341, DOI 10.1007/BF00762527; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GILLIES RJ, 1990, P NATL ACAD SCI USA, V87, P7414, DOI 10.1073/pnas.87.19.7414; GOLDSTEIN DJ, 1990, EMBO J, V9, P137, DOI 10.1002/j.1460-2075.1990.tb08089.x; GOLDSTEIN DJ, 1992, VIROLOGY, V190, P889, DOI 10.1016/0042-6822(92)90932-F; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; GOLDSTEIN DJ, 1992, J VIROL, V66, P404; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARIKUMAR P, 1983, J BIOL CHEM, V258, P403; HOLZENBURG A, 1993, EUR J BIOCHEM, V213, P21, DOI 10.1111/j.1432-1033.1993.tb17730.x; KLINNSKY DJ, 1992, J EXP BIOL, V172, P83; LIM PS, 1990, J INFECT DIS, V162, P1623; MANDEL M, 1988, P NATL ACAD SCI USA, V88, P5521; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MELLMAN I, 1992, J EXP BIOL, V172, P39; MILLER AD, 1985, J VIROL, V55, P521, DOI 10.1128/JVI.55.3.521-526.1985; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORIYAMA Y, 1986, BIOCHIM BIOPHYS ACTA, V854, P102, DOI 10.1016/0005-2736(86)90069-6; MYERS M, 1993, J CELL PHYSIOL, V156, P35, DOI 10.1002/jcp.1041560106; NELSON N, 1989, J BIOENERG BIOMEMBR, V21, P553, DOI 10.1007/BF00808113; NELSON N, 1992, J EXP BIOL, V172, P19; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; PEI XF, 1993, VIROLOGY, V196, P855, DOI 10.1006/viro.1993.1546; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PETTI L, 1992, P NATL ACAD SCI USA, V89, P8736; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; SCHLEGEL R, 1987, CANCER CELL, V5, P87; SPARKOWSKI J, 1994, J VIROL, V68, P6120, DOI 10.1128/JVI.68.9.6120-6123.1994; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; SUN SZ, 1987, J BIOL CHEM, V262, P14790; WATERS CM, 1992, J CELL PHYSIOL, V152, P253, DOI 10.1002/jcp.1041520206; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YANG YC, 1985, NATURE, V318, P575, DOI 10.1038/318575a0; ZHANG F, 1983, BIOCHEM BIOPH RES CO, V114, P620, DOI 10.1016/0006-291X(83)90825-2; ZHANG JM, 1992, J BIOL CHEM, V267, P9773	40	63	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6830	6837		10.1074/jbc.270.12.6830	http://dx.doi.org/10.1074/jbc.270.12.6830			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896830	hybrid			2022-12-25	WOS:A1995QQ85500061
J	KRAMER, B; WIEGMANN, K; KRONKE, M				KRAMER, B; WIEGMANN, K; KRONKE, M			REGULATION OF THE HUMAN TNF PROMOTER BY THE TRANSCRIPTION FACTOR ETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA GENE; DNA-BINDING; FACTOR CACHECTIN; CELL-LINES; T-CELL; EXPRESSION; ELEMENT; SEQUENCES; FAMILY	Tumor necrosis factor (TNF) affects the growth, differentiation, and function of a multitude of cell types and is viewed as a potent mediator of inflammation and cellular immune responses. In order to delineate functional domains that control TNF gene transcription, we have analyzed a 5' flanking region of the human TNF promoter spanning base pairs -115 to -98. This region contains a PEA3/Ets-1 binding motif 5' GAGGA 3' in direct juxtaposition to an AP-1/ATF-like palindromic sequence motif 5' TGAGCTCA 3'. Specific binding of Ets and Jun to their respective elements is demonstrated by competition analysis as well as by supershift assays. As shown by promoter deletion analysis, these two binding sites were essential for both basal promoter activity and responsiveness to the phorbol ester phorbol 12-myristate 13-acetate. Cotransfection of c-ets or c-jun expression plasmids along with TNF promoter-CAT reporter constructs revealed the participation of both transcription factors in the regulation of TNF gene transcription. Correspondingly, site specific mutation of either Ets or Jun sites led to a complete loss of responsiveness to the respective transcription factor. These data suggest an essential role of Ets for the activation of TNF gene transcription.	TECH UNIV MUNICH,INST MED MIKROBIOL & HYG,D-81675 MUNICH,GERMANY	Technical University of Munich								ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHANTRY D, 1989, J IMMUNOL, V142, P4295; COLLART MA, 1986, J EXP MED, V164, P2113, DOI 10.1084/jem.164.6.2113; CUTURI MC, 1987, J EXP MED, V165, P1581, DOI 10.1084/jem.165.6.1581; ECONOMOU JS, 1989, J EXP MED, V170, P321, DOI 10.1084/jem.170.1.321; ESSNER R, 1989, J IMMUNOL, V142, P3857; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HELD W, 1990, P NATL ACAD SCI USA, V87, P2239, DOI 10.1073/pnas.87.6.2239; HENSEL G, 1989, LYMPHOKINE RES, V8, P347; HENSEL G, 1987, LYMPHOKINE RES, V6, P119; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KARIN M, 1989, TRENDS GENET, V5, P65, DOI 10.1016/0168-9525(89)90027-9; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; KRONKE M, 1988, CANCER RES, V48, P5417; KRUPPA G, 1992, J IMMUNOL, V148, P3152; LEITMAN DC, 1991, J BIOL CHEM, V266, P9343; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; LIMB GA, 1989, IMMUNOLOGY, V68, P514; Maxam A M, 1980, Methods Enzymol, V65, P499; NEDWIN GE, 1985, NUCLEIC ACIDS RES, V13, P6361, DOI 10.1093/nar/13.17.6361; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; OHNO I, 1990, IMMUNOLOGY, V70, P88; OLD LJ, 1985, SCIENCE, V230, P680; PIERCE JW, 1988, P NATL ACAD SCI USA, V85, P1482, DOI 10.1073/pnas.85.5.1482; PIGUET PF, 1987, J EXP MED, V166, P1280, DOI 10.1084/jem.166.5.1280; RAO VN, 1992, ONCOGENE, V7, P65; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; ROESLER WJ, 1988, TRENDS GENET, V5, P65; ROSENBERG ZF, 1990, IMMUNOL TODAY, V11, P176, DOI 10.1016/0167-5699(90)90070-P; SMITH DB, 1988, GENE AMST, P29541; SMITH DB, 1988, GENE AMST, P25708; Spriggs D R, 1992, Immunol Ser, V56, P3; TANNENBAUM CS, 1989, J IMMUNOL, V142, P1274; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; TRACEY KJ, 1989, CURR OPIN IMMUNOL, V1, P454, DOI 10.1016/0952-7915(88)90026-X; TRACEY KJ, 1988, J EXP MED, V167, P1211, DOI 10.1084/jem.167.3.1211; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	51	119	126	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6577	6583						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896795				2022-12-25	WOS:A1995QQ85500025
J	PARKER, EM; SWIGART, P; NUNNALLY, MH; PERKINS, JP; ROSS, EM				PARKER, EM; SWIGART, P; NUNNALLY, MH; PERKINS, JP; ROSS, EM			CARBOXYL-TERMINAL DOMAINS IN THE AVIAN BETA(1)-ADRENERGIC RECEPTOR THAT REGULATE AGONIST-PROMOTED ENDOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; PROTEIN-COUPLED RECEPTORS; INDUCED DOWN-REGULATION; ASTROCYTOMA-CELLS; DESENSITIZATION; MEMBRANE; INTERNALIZATION; CATECHOLAMINE; BINDING; TRANSFERRIN	Most G protein-coupled receptors, including the mammalian beta(2)-adrenergic receptor, are endocytosed to an intracellular, vesicular compartment upon continued exposure to agonist. The long form of the avian beta(1)-adrenergic receptor, which contains a carboxyl-terminal 59-amino acid extension, does not undergo agonist-promoted endocytosis. We constructed and expressed turkey beta(1)-adrenergic receptor cDNAs with regularly spaced carboxyl-terminal truncations and studied their agonist-promoted endocytosis. Removal of 34-86 amino acids from the carboxyl terminus of the turkey receptor allowed its efficient endocytosis, with optimal endocytosis observed upon re moval of 59 residues. Removal of only 18 residues allowed some endocytosis. A receptor that lacks the entire carboxyl-terminal region (124 residues) was not endocytosed. We also constructed a chimeric hamster beta(2)-adrenergic recep tor with the added 59-residue carboxyl-terminal domain of the turkey receptor. The chimera was not significantly endocytosed. These data indicate that residues 450-465 in the carboxyl-terminal region of the beta(1)-adrenergic receptor can act independently to block agonist-promoted endocytosis and that other carboxyl-terminal structures nearer to the seventh membrane span are required for endocytosis.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIGMS NIH HHS [GM36254, GM 30355] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030355, R01GM030355, R01GM036254] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; CLARK RB, 1989, MOL PHARMACOL, V36, P343; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; DOSS RC, 1981, J BIOL CHEM, V256, P2281; FREDERICH RC, 1983, J CYCLIC NUCL PROT, V9, P103; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; HANSKI E, 1978, LIFE SCI, V22, P53, DOI 10.1016/0024-3205(78)90411-3; HARDEN TK, 1980, SCIENCE, V210, P441, DOI 10.1126/science.6254143; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HERTEL C, 1984, N-S ARCH PHARMACOL, V328, P51, DOI 10.1007/BF00496106; HERTEL C, 1983, J CYCLIC NUCL PROT, V9, P119; HERTEL C, 1990, J BIOL CHEM, V265, P17988; HERTEL C, 1983, BIOCHEM J, V216, P669, DOI 10.1042/bj2160669; INSEL PA, 1982, J BIOL CHEM, V257, P9717; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LIAO JF, 1993, MOL PHARMACOL, V44, P364; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; MINNEMAN KP, 1980, MOL PHARMACOL, V17, P1; MUNTZ KH, 1994, CIRC RES, V74, P369, DOI 10.1161/01.RES.74.3.369; NANTEL F, 1993, MOL PHARMACOL, V43, P548; NEVE KA, 1985, J PHARMACOL EXP THER, V235, P657; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; PARKER EM, 1991, J BIOL CHEM, V266, P9987; PERKINS JP, 1990, BETA ADRENERGIC RECE, P73; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; RUDOLPH SA, 1977, P NATL ACAD SCI USA, V74, P3404, DOI 10.1073/pnas.74.8.3404; Sambrook J., 1989, MOL CLONING; SHAPIRO RA, 1989, BIOCHEMISTRY-US, V28, P8946, DOI 10.1021/bi00448a039; SIMANTOV R, 1978, FEBS LETT, V90, P69, DOI 10.1016/0014-5793(78)80300-7; SIMPSON IA, 1980, FEBS LETT, V115, P113, DOI 10.1016/0014-5793(80)80738-1; SUZUKI T, 1992, MOL PHARMACOL, V412, P542; VALIQUETTE M, 1990, P NATL ACAD SCI USA, V87, P5089, DOI 10.1073/pnas.87.13.5089; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WALDO GL, 1984, MOL PHARMACOL, V26, P424; WANG J, 1982, J BIOL CHEM, V270, P6488; YARDEN Y, 1986, P NATL ACAD SCI USA, V83, P6795, DOI 10.1073/pnas.83.18.6795; YU SS, 1993, J BIOL CHEM, V268, P337; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	40	33	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6482	6487		10.1074/jbc.270.12.6482	http://dx.doi.org/10.1074/jbc.270.12.6482			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896782	hybrid			2022-12-25	WOS:A1995QQ85500012
J	FUKUNAGA, K; MULLER, D; MIYAMOTO, E				FUKUNAGA, K; MULLER, D; MIYAMOTO, E			INCREASED PHOSPHORYLATION OF CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE-II AND ITS ENDOGENOUS SUBSTRATES IN THE INDUCTION OF LONG-TERM POTENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; MESSENGER-RNA; CA-2+-INDEPENDENT ACTIVITY; SYNAPTIC TRANSMISSION; HIPPOCAMPAL-NEURONS; DENTATE GYRUS; NITRIC-OXIDE; SYNAPSIN-I; CALMODULIN; CALCIUM	Induction of long term potentiation in the CA1 region of hippocampal slices is associated with increased activity of Ca2+/calmodulin-dependent protein kinase II (CaM kinase II) (Fukunaga, K., Stoppini, L., Miyamoto, E., and Muller, D. (1993) J. Biol. Chem. 268, 7863-7867), Here we report that application of high but not low frequency stimulation to two groups of afferents in the CA1 region of P-32-labeled slices resulted in the phosphorylation of two major substrates of this enzyme, synapsin I and microtubule-associated protein 2, as well as in the autophosphorylation of CaM kinase II, Furthermore, immunoblotting analysis revealed that long term potentiation induction was associated with an increase in the amount of CaM kinase II in the same region. All these changes were prevented when high frequency stimulation was applied in the presence of the N-methyl-D-aspartate receptor antagonist, D-2-amino-B-phosphonopentanoate. These results indicate that activation of CaM kinase II is involved in the induction of synaptic potentiation in both the postsynaptic and presynaptic regions,	CTR MED UNIV GENEVA,DEPT PHYSIOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva	FUKUNAGA, K (corresponding author), KUMAMOTO UNIV,SCH MED,DEPT PHARMACOL,KUMAMOTO 860,JAPAN.							BENSON DL, 1992, NEUROSCIENCE, V46, P851, DOI 10.1016/0306-4522(92)90189-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGIN KE, 1990, J NEUROSCI, V10, P1788; CHARRIAUTMARLANGUE, 1991, P NATL ACAD SCI USA, V88, P10232; CHICUREL ME, 1993, J NEUROSCI, V13, P4054; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7518, DOI 10.1073/pnas.84.21.7518; ERONDU NE, 1985, J NEUROSCI, V5, P3270; FIGUROV A, 1993, EUR J NEUROSCI, V5, P1035, DOI 10.1111/j.1460-9568.1993.tb00956.x; FREY U, 1989, NEUROSCI LETT, V97, P135, DOI 10.1016/0304-3940(89)90152-3; FUKUNAGA K, 1988, J NEUROCHEM, V51, P1070, DOI 10.1111/j.1471-4159.1988.tb03070.x; FUKUNAGA K, 1992, J BIOL CHEM, V267, P22527; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; FUKUNAGA K, 1990, Molecular and Cellular Neuroscience, V1, P133; GEINISMAN Y, 1992, HIPPOCAMPUS, V2, P445, DOI 10.1002/hipo.450020412; GIANOTTI C, 1992, NEURON, V8, P843, DOI 10.1016/0896-6273(92)90198-M; HUTTNER WB, 1979, P NATL ACAD SCI USA, V76, P5402, DOI 10.1073/pnas.76.10.5402; KITANO T, 1987, J NEUROSCI, V7, P1520; KLANN E, 1992, J NEUROCHEM, V58, P1576, DOI 10.1111/j.1471-4159.1992.tb11382.x; KLANN E, 1991, J BIOL CHEM, V266, P24253; KLEIMAN R, 1990, NEURON, V5, P821, DOI 10.1016/0896-6273(90)90341-C; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN JW, 1990, P NATL ACAD SCI USA, V87, P8257, DOI 10.1073/pnas.87.21.8257; LOVINGER DM, 1987, BRAIN RES, V436, P177, DOI 10.1016/0006-8993(87)91573-3; MACKLER SA, 1992, NEURON, V9, P539, DOI 10.1016/0896-6273(92)90191-F; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; OTANI S, 1989, NEUROSCIENCE, V28, P519, DOI 10.1016/0306-4522(89)90001-8; OUIMET CC, 1984, P NATL ACAD SCI-BIOL, V81, P5604, DOI 10.1073/pnas.81.17.5604; REYMANN KG, 1988, BRAIN RES, V461, P388, DOI 10.1016/0006-8993(88)90274-0; SACKTOR TC, 1993, P NATL ACAD SCI USA, V90, P8342, DOI 10.1073/pnas.90.18.8342; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SCHWORER CM, 1988, J BIOL CHEM, V263, P13486; SILVA AJ, 1993, SCIENCE, V257, P201; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; YANO S, 1994, J BIOL CHEM, V269, P5428	40	192	199	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	1995	270	11					6119	6124		10.1074/jbc.270.11.6119	http://dx.doi.org/10.1074/jbc.270.11.6119			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QM945	7890745	hybrid			2022-12-25	WOS:A1995QM94500061
J	WEIR, L; CHEN, DF; PASTORE, C; ISNER, JM; WALSH, K				WEIR, L; CHEN, DF; PASTORE, C; ISNER, JM; WALSH, K			EXPRESSION OF GAX, A GROWTH ARREST HOMEOBOX GENE, IS RAPIDLY DOWN-REGULATED IN THE RAT CAROTID-ARTERY DURING THE PROLIFERATIVE RESPONSE TO BALLOON INJURY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; POLYMERASE CHAIN-REACTION; MESSENGER-RNA; PROTEIN; SYSTEM; ATHEROSCLEROSIS; TRANSCRIPTION; PATHOGENESIS; QUANTITATION; MARKERS	gax is a recently described homeobox gene whose expression in the adult is largely confined to cardiovascular tissues. gax has been shown to be rapidly down-regulated in cultured vascular smooth muscle cells (VSMC) upon stimulation by serum or platelet-derived growth factor. The temporal profile of gax expression in vitro matches that of two families of growth arrest genes: the gas genes and the gadd genes. All of these genes are expressed at their highest levels in quiescent cells and are down-regulated following mitogen activation. Here we report that gax is also down-regulated in vivo in the vascular wall in response to endothelial denudation by balloon angioplasty. The reduction in steady state levels of gax mRNA is transient and occurs with a similar time course to that seen in vitro. The down-regulation of gax in response to balloon injury mirrors the up-regulation seen in a number of early response genes such as c-myc and c-fos. This report is the first to document the in vivo expression of a growth arrest gene which regulates proliferation of vascular smooth muscle cells. In addition, in contrast with previous reports which have demonstrated up-regulation of several genes following balloon injury and/or angioplasty, the present report demonstrates the down-regulation of a regulatory gene within hours of balloon injury. The characteristics of gax suggest it may be required to maintain the gene expression of proteins in VSMC that are associated with the nonproliferative or contractile phenotype in smooth muscle cells.	TUFTS UNIV,ST ELIZABETHS MED CTR,SCH MED,DEPT MED CARDIOL,BOSTON,MA 02135; TUFTS UNIV,ST ELIZABETHS MED CTR,SCH MED,DEPT BIOMED RES,BOSTON,MA 02135	St. Elizabeth's Medical Center; Tufts University; St. Elizabeth's Medical Center; Tufts University					NHLBI NIH HHS [HL 02428, HL 40518] Funding Source: Medline; NIAMS NIH HHS [AR 40580] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002428, R01HL040518] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR040580] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AIKAWA M, 1993, CIRC RES, V73, P1000, DOI 10.1161/01.RES.73.6.1000; AUSTIN GE, 1985, J AM COLL CARDIOL, V6, P369, DOI 10.1016/S0735-1097(85)80174-1; BRANCOLINI C, 1992, J CELL BIOL, V117, P1251, DOI 10.1083/jcb.117.6.1251; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CICCARELLI C, 1990, MOL CELL BIOL, V10, P1525, DOI 10.1128/MCB.10.4.1525; CLOWES AW, 1983, LAB INVEST, V49, P327; COCCIA EM, 1992, MOL CELL BIOL, V12, P3514, DOI 10.1128/MCB.12.8.3514; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DILLEY RJ, 1988, ARCH SURG-CHICAGO, V123, P691; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FU YH, 1993, SCIENCE, V260, P235, DOI 10.1126/science.8469976; GABBIANI G, 1984, J CLIN INVEST, V73, P148, DOI 10.1172/JCI111185; GALLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725; GORSKI DH, 1993, MOL CELL BIOL, V13, P3722, DOI 10.1128/MCB.13.6.3722; GORSKI DH, 1993, TRENDS CARDIOVAS MED, V3, P184, DOI 10.1016/1050-1738(93)90004-P; KAWAMOTO S, 1987, J BIOL CHEM, V262, P7282; KIM DK, 1994, J CLIN INVEST, V93, P355, DOI 10.1172/JCI116967; KOCHER O, 1984, LAB INVEST, V50, P645; KOCHER O, 1985, CIRC RES, V56, P829, DOI 10.1161/01.RES.56.6.829; KUROO M, 1989, J BIOL CHEM, V264, P18292; LECLERC G, 1992, CIRCULATION, V85, P543, DOI 10.1161/01.CIR.85.2.543; MAJESKY MW, 1992, CIRC RES, V71, P759, DOI 10.1161/01.RES.71.4.759; MANIFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924; MIANO JM, 1990, AM J PATHOL, V137, P761; MIANO JM, 1993, ARTERIOSCLER THROMB, V13, P211, DOI 10.1161/01.ATV.13.2.211; MUNRO JM, 1988, LAB INVEST, V58, P249; MURPHY LD, 1990, BIOCHEMISTRY-US, V29, P10351, DOI 10.1021/bi00497a009; NIKKARI ST, 1994, AM J PATHOL, V144, P1348; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PASTORE C, 1993, CIRCULATION, V88, P1658; PAUL M, 1993, J CLIN INVEST, V91, P2058, DOI 10.1172/JCI116428; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SALOMON RS, 1991, P NATL ACAD SCI USA, V89, P2814; Sambrook J, 1989, MOL CLONING LABORATO; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SPREYER P, 1991, EMBO J, V10, P3661, DOI 10.1002/j.1460-2075.1991.tb04933.x; TAUBMAN M, 1991, CIRC RES, V70, P314; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P7195, DOI 10.1073/pnas.88.16.7195; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	44	89	101	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5457	5461		10.1074/jbc.270.10.5457	http://dx.doi.org/10.1074/jbc.270.10.5457			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890661	hybrid			2022-12-25	WOS:A1995QL58000077
J	JOHNSON, TS; KNIGHT, CRL; ELALAOUI, S; MIAN, S; REES, RC; GENTILE, V; DAVIES, PJA; GRIFFIN, M				JOHNSON, TS; KNIGHT, CRL; ELALAOUI, S; MIAN, S; REES, RC; GENTILE, V; DAVIES, PJA; GRIFFIN, M			TRANSFECTION OF TISSUE TRANSGLUTAMINASE INTO A HIGHLY MALIGNANT HAMSTER FIBROSARCOMA LEADS TO A REDUCED INCIDENCE OF PRIMARY TUMOR-GROWTH	ONCOGENE			English	Article							PROGRAMMED CELL-DEATH; RAT-LIVER; HUMAN LEUKEMIA; APOPTOSIS; EXPRESSION; METASTASIS; ACTIVATION; RECEPTOR; ADHESION; IDENTIFICATION	Reduced expression of the tissue transglutaminase in both murine and human tumours has been consistently associated with tumour growth and progression. To investigate the functional effects of transglutaminase expression are have transfected a constitutive human tissue transglutaminase expression construct into a highly malignant hamster fibrosarcoma cell line Met B. - Met B clones expressing the exogenous tissue transglutaminase exhibited a reduced incidence of primary tumour formation and an increased adherence to tissue culture plastic and fibronectin coated surfaces when compared to transfected and non transfected control cells. Transglutaminase transfected clones exhibited no significant differences in their growth rates measured in vitro, cell morphology or levels of spontaneous apoptosis measured by the determination of detergent insoluble apoptotic envelopes. The data demonstrates a suppressive effect of tissue transglutaminase on tumour growth and confirms its importance in the phenotypic changes associated with the cancer process.	NOTTINGHAM POLYTECH,DEPT LIFE SCI,NOTTINGHAM NG11 8NS,ENGLAND; UNIV TEXAS,HLTH SCI CTR,SCH MED,DEPT PHARMACOL,HOUSTON,TX; UNIV SHEFFIELD,SCH MED,INST CANC STUDIES,SHEFFIELD S10 2RX,ENGLAND	Nottingham Trent University; University of Texas System; University of Texas Health Science Center Houston; University of Sheffield			Gentile, Vittorio/N-1685-2019; Gentile, Vittorio/A-3045-2008	Gentile, Vittorio/0000-0001-7792-8294; Gentile, Vittorio/0000-0001-7792-8294; MIAN, SYED SHARIQ/0000-0001-7563-5121; Griffin, Martin/0000-0003-3824-306X				ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; AESCHLIMANN D, 1991, J BIOL CHEM, V266, P15308; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BARNES RN, 1985, CARCINOGENESIS, V6, P459, DOI 10.1093/carcin/6.3.459; BIRKBICHLER PJ, 1977, CANCER RES, V37, P1340; BOWNESS JM, 1987, J BIOL CHEM, V262, P1022; BYRD JC, 1987, J BIOL CHEM, V262, P11699; CAI D, 1991, BIOCHEM BIOPH RES CO, V175, P1119, DOI 10.1016/0006-291X(91)91681-2; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; DE LUCA LM, 1990, METHOD ENZYMOL, V190, P81; DELCROS JG, 1986, FEBS LETT, V196, P325, DOI 10.1016/0014-5793(86)80272-1; EGHBALI B, 1990, P NATL ACAD SCI USA, V87, P1328, DOI 10.1073/pnas.87.4.1328; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FESUS L, 1989, FEBS LETT, V245, P150, DOI 10.1016/0014-5793(89)80210-8; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FESUS L, 1981, MOL IMMUNOL, V18, P633, DOI 10.1016/0161-5890(81)90034-1; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FUKUDA K, 1993, HEPATOLOGY, V17, P118, DOI 10.1002/hep.1840170121; GENTILE V, 1992, J CELL BIOL, V119, P463, DOI 10.1083/jcb.119.2.463; GENTILE V, 1991, J BIOL CHEM, V266, P478; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GRIFFIN M, 1989, BIOCHEM SOC T, V17, P714, DOI 10.1042/bst0170714; GRIFFIN M, 1982, ANAL BIOCHEM, V124, P406, DOI 10.1016/0003-2697(82)90057-4; HAND D, 1987, BIOCHIM BIOPHYS ACTA, V930, P432, DOI 10.1016/0167-4889(87)90016-4; HAND D, 1988, BIOCHIM BIOPHYS ACTA, V970, P137, DOI 10.1016/0167-4889(88)90172-3; HAND D, 1989, BIOCHIM BIOPHYS ACTA, V970, P137; HAND D, 1986, BIOSCIENCE REP, V5, P1079; JIANG SY, 1992, JNCI-J NATL CANCER I, V84, P580, DOI 10.1093/jnci/84.8.580; KERR JFR, 1973, VIRCHOWS ARCH B, V13, P87; KNIGHT CRL, 1993, IMMUNOLOGY, V79, P535; KNIGHT CRL, 1991, BIOCHIM BIOPHYS ACTA, V1096, P312, DOI 10.1016/0925-4439(91)90067-J; KNIGHT CRL, 1990, BIOCHIM BIOPHYS ACTA, V1053, P13, DOI 10.1016/0167-4889(90)90019-A; KNIGHT RL, 1993, EUR J CELL BIOL, V60, P210; KORNER G, 1989, BIOCHEM J, V262, P633, DOI 10.1042/bj2620633; LENNON SV, 1992, CLIN EXP IMMUNOL, V87, P465; LESTER BR, 1992, CANCER METAST REV, V11, P31, DOI 10.1007/BF00047601; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; LORAND L, 1972, ANN ACAD SCI, V206, P6; PIACENTINI M, 1991, CELL TISSUE RES, V263, P227, DOI 10.1007/BF00318764; RICE RH, 1978, J CELL BIOL, V76, P705, DOI 10.1083/jcb.76.3.705; ROCH AM, 1991, INT J CANCER, V48, P215, DOI 10.1002/ijc.2910480211; SCHMIDT R, 1985, FEBS LETT, V186, P201, DOI 10.1016/0014-5793(85)80708-0; TEALE DM, 1987, INVAS METAST, V7, P129; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZIRVI KA, 1991, CANCER LETT, V60, P85, DOI 10.1016/0304-3835(91)90052-J	46	58	60	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2935	2942						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	7916148				2022-12-25	WOS:A1994PG82200019
J	SUPEK, F; SUPEKOVA, L; MANDIYAN, S; PAN, YCE; NELSON, H; NELSON, N				SUPEK, F; SUPEKOVA, L; MANDIYAN, S; PAN, YCE; NELSON, H; NELSON, N			A NOVEL ACCESSORY SUBUNIT FOR VACUOLAR H+-ATPASE FROM CHROMAFFIN GRANULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE PROTON PUMP; SACCHAROMYCES-CEREVISIAE; TRANSLOCATING ATPASE; MUTATIONAL ANALYSIS; GENE ENCODES; YEAST; SEQUENCE; POLYPEPTIDE; MEMBRANES; EVOLUTION	Three subunits, Ac115, Ac39, and the proteolipid, were positively identified in the membrane sectors of V-ATPases from different sources. We searched for organelle-specific protein in purified preparations of V-ATPase from bovine chromaffin granules. A diffused protein band at a position of about 45 kDa was identified in SDS-polyacrylamide gels of the above preparation. Following digestion with endopeptidase Glu-C (V-8), a polypeptide of about 10 kDa was isolated and subjected to amino acid sequencing. Hence, the cDNA encoding the protein Ac45 was cloned from a bovine adrenal me dulla library. The cDNA sequence contains an open read ing frame encoding a protein of 468 amino acids with a calculated molecular mass of 51,786 daltons. A potential signal sequence comprised of the first 35 amino acids and a potential transmembrane domain at the C terminus of the protein were identified. There exist seven potential glycosylation sites between the aforementioned protein motifs. Experiments with a specific antibody against Ac45 demonstrated that it is copurifying with the V-ATPase from chromaffin granules. Immuno logical cross-reactivity was observed with purified V-ATPase from bovine kidney microsomes but not from plasma membranes of epithelial cells. Cell-free expression of the protein from synthetic mRNA produced a single protein band at about 50 kDa on SDS gels. Upon inclusion of dog pancreas microsomes in the reaction mixture, a slow migrating band sensitive to peptide:N-glycosidase F was observed.	ROCHE INST MOLEC BIOL, ROCHE RES CTR, NUTLEY, NJ 07110 USA	Roche Holding								ARAI H, 1988, J BIOL CHEM, V263, P8796; BELTRAN C, 1992, J BIOL CHEM, V267, P774; BELTRAN C, 1992, ACTA PHYSIOL SCAND, V146, P41; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; FOURY F, 1990, J BIOL CHEM, V265, P18554; FREEZE HH, 1993, CURR PROT MOL BIOL, V2, P1; HEMKEN P, 1992, J BIOL CHEM, V267, P9948; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HIRSCH S, 1988, P NATL ACAD SCI USA, V85, P3004, DOI 10.1073/pnas.85.9.3004; KANE PM, 1992, J BIOL CHEM, V267, P447; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P1064; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORIYAMA Y, 1989, J BIOL CHEM, V264, P18445; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; MORIYAMA Y, 1987, J BIOL CHEM, V262, P9175; MORIYAMA Y, 1989, BIOCHIM BIOPHYS ACTA, V980, P241, DOI 10.1016/0005-2736(89)90405-7; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON H, 1990, J BIOL CHEM, V265, P20390; NELSON N, 1983, METHOD ENZYMOL, V97, P510; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; PERIN MS, 1991, J BIOL CHEM, V266, P3877; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; PUOPOLO K, 1991, J BIOL CHEM, V266, P24564; Sambrook J, 1989, MOL CLONING LABORATO; STEVENS TH, 1992, J EXP BIOL, V172, P47; SZE H, 1992, J EXP BIOL, V172, P123; WANG SY, 1988, J BIOL CHEM, V263, P17638	38	104	108	3	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24102	24106						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929063				2022-12-25	WOS:A1994PQ34600041
J	PETIT, MA; BEDALE, W; OSIPIUK, J; LU, C; RAJAGOPALAN, M; MCINERNEY, P; GOODMAN, MF; ECHOLS, H				PETIT, MA; BEDALE, W; OSIPIUK, J; LU, C; RAJAGOPALAN, M; MCINERNEY, P; GOODMAN, MF; ECHOLS, H			SEQUENTIAL FOLDING OF UMUC BY THE HSP70 AND HSP60 CHAPERONE COMPLEXES OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMBDA-DNA-REPLICATION; HEAT-SHOCK PROTEINS; UV MUTAGENESIS; RECA PROTEIN; REPRESSOR CLEAVAGE; RNA-POLYMERASE; GROE MUTANTS; PURIFICATION; MUTATIONS; GRPE	Replication-blocking lesions generate a signal in Escherichia coli that leads to the induction of the multigene SOS response. Among the SOS-induced genes are umuD and umuC, whose products are necessary for the increased mutation rate in induced bacteria. The mutations are likely to result from replication across the DNA lesion, and such a bypass event has been reconstituted in vitro (Rajagopalan, M., Lu, C., Woodgate, R., O'Donnel, M., Goodman, M. F., Echols, H. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 10777-10781). In this work, we show that the chaperone proteins promote the proper folding of UmuC protein in vitro. We treated purified and inactive UmuC with Hsp70 and Hsp60. After Hsp70 treatment, the DNA binding activity of UmuC was recovered, but the ability to promote replication across DNA lesions was not. However, lesion bypass activity was recovered upon further treatment with Hsp60. The biological significance of such a folding pathway for UmuC protein is strengthened by in vivo evidence for a role of DnaK in UV-induced mutagenesis.	UNIV CALIF BERKELEY, DIV BIOCHEM & MOLEC BIOL, BERKELEY, CA 94720 USA; UNIV SO CALIF, DEPT BIOL SCI, LOS ANGELES, CA 90089 USA	University of California System; University of California Berkeley; University of Southern California				Petit, Marie-Agnes/0000-0003-2242-2768; Bedale, Wendy/0000-0002-0122-4255	NCI NIH HHS [CA 41655] Funding Source: Medline; NIGMS NIH HHS [GM-42554, GM-21422] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042554, R37GM021422, R01GM021422] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUCKHARDT SE, 1988, P NATL ACAD SCI USA, V85, P1811; BUKAU B, 1990, EMBO J, V9, P4027, DOI 10.1002/j.1460-2075.1990.tb07624.x; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; DONNELLY CE, 1989, J BACTERIOL, V171, P6117, DOI 10.1128/jb.171.11.6117-6125.1989; DONNELLY CE, 1992, J BACTERIOL, V174, P3133, DOI 10.1128/jb.174.10.3133-3139.1992; DUTREIX M, 1989, J BACTERIOL, V171, P2415, DOI 10.1128/jb.171.5.2415-2423.1989; ECHOLS H, 1990, MUTAT RES, V236, P301, DOI 10.1016/0921-8777(90)90013-U; ECHOLS H, 1982, BIOCHIMIE, V64, P571, DOI 10.1016/S0300-9084(82)80089-8; ENNIS DG, 1989, J BACTERIOL, V171, P2533, DOI 10.1128/jb.171.5.2533-2541.1989; FRANCKE B, 1971, VIROLOGY, V44, P168, DOI 10.1016/0042-6822(71)90163-2; FRANK EG, 1993, P NATL ACAD SCI USA, V90, P8169, DOI 10.1073/pnas.90.17.8169; GEORGOPOULOS CP, 1977, MOL GEN GENET, V151, P35, DOI 10.1007/BF00446910; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOFFMANN HJ, 1992, P NATL ACAD SCI USA, V89, P12108, DOI 10.1073/pnas.89.24.12108; KUBO T, 1993, J BIOL CHEM, V268, P19346; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LAVERY PE, 1992, J BIOL CHEM, V267, P20648; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; MADIRAJU MVVS, 1988, P NATL ACAD SCI USA, V85, P6592, DOI 10.1073/pnas.85.18.6592; MADIRAJU MVVS, 1992, BIOCHEMISTRY-US, V31, P10529, DOI 10.1021/bi00158a016; MAKI H, 1988, J BIOL CHEM, V263, P6570; MILLER JH, 1992, SHORT COURSE BACTERI, P293; NOHMI T, 1988, P NATL ACAD SCI USA, V85, P1816, DOI 10.1073/pnas.85.6.1816; Radman M., 1975, MOL MECHANISMS REPAI, P355; RAJAGOPALAN M, 1992, P NATL ACAD SCI USA, V89, P10777, DOI 10.1073/pnas.89.22.10777; RANDALL SK, 1987, J BIOL CHEM, V262, P6864; SCHENDEL PF, 1978, J BACTERIOL, V135, P466, DOI 10.1128/JB.135.2.466-475.1978; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SHINAGAWA H, 1988, P NATL ACAD SCI USA, V85, P1816; SOMMER S, 1993, MOL MICROBIOL, V10, P963, DOI 10.1111/j.1365-2958.1993.tb00968.x; SWEASY JB, 1990, J BACTERIOL, V172, P3030, DOI 10.1128/jb.172.6.3030-3036.1990; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WILD J, 1992, P NATL ACAD SCI USA, V89, P7139, DOI 10.1073/pnas.89.15.7139; WITKIN EM, 1976, BACTERIOL REV, V40, P869, DOI 10.1128/MMBR.40.4.869-907.1976; WOODGATE R, 1989, P NATL ACAD SCI USA, V86, P7301, DOI 10.1073/pnas.86.19.7301; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425; ZYLICZ M, 1984, J BIOL CHEM, V259, P8820; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591	40	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23824	23829						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	7916347				2022-12-25	WOS:A1994PQ34500066
J	JACOBDUBUISSON, F; STRIKER, R; HULTGREN, SJ				JACOBDUBUISSON, F; STRIKER, R; HULTGREN, SJ			CHAPERONE-ASSISTED SELF-ASSEMBLY OF PILI INDEPENDENT OF CELLULAR-ENERGY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; BACTERIAL OUTER MEMBRANES; SALMONELLA-TYPHIMURIUM; PROTEIN TRANSLOCATION; PROTONMOTIVE FORCE; RECEPTOR-BINDING; VIBRIO-CHOLERAE; SECRETION; TRANSPORT; SUBUNITS	Assembly of P pili on the surface of pyelonephritic Escherichia coli proceeds from periplasmic chaperone-subunit complexes. The outer membrane protein PapC, which has been termed a molecular usher, is thought to be the site of assembly, where the chaperone dissociates from the subunits as they are incorporated into the pilus across the outer membrane. The kinetics of assembly and the energy requirements of the ''secretion'' events at the outer membrane were investigated using a pulse-chase analysis in which preformed labeled periplasmic chaperone-subunit complexes were assembled into pili in synchrony by the induction of PapC. Provided that a sufficient amount of PapC was present and functional in the outer membrane, the incorporation of the major PapA subunit into pili was shown to be completed in less than 5 min. Our results also indicated that the targeting of PapC to the outer membrane may be a rate-limiting factor for pilus assembly. Following the arrival of PapC, the formation of pili seemed to proceed spontaneously and was not sensitive to a pH shift or an inhibitor of the electrochemical gradient across the cytoplasmic membrane. We suggest that the secretion of pili across the outer membrane may be independent of cellular energy and thermodynamically driven.	WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Jacob-Dubuisson, Françoise/F-1610-2018	Jacob-Dubuisson, Françoise/0000-0002-5102-1704; Striker, Rob/0000-0002-0454-895X	NIAID NIH HHS [R01AI29549] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029549] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMES GF, 1974, J BACTERIOL, V117, P406, DOI 10.1128/JB.117.2.406-416.1974; BAKKER EP, 1984, EMBO J, V3, P895, DOI 10.1002/j.1460-2075.1984.tb01902.x; BRAUN V, 1993, MOL MICROBIOL, V8, P261, DOI 10.1111/j.1365-2958.1993.tb01570.x; COVACCI A, 1993, MOL MICROBIOL, V8, P429, DOI 10.1111/j.1365-2958.1993.tb01587.x; DODD DC, 1984, J BACTERIOL, V160, P227, DOI 10.1128/JB.160.1.227-232.1984; DODD DC, 1984, J BACTERIOL, V159, P1077, DOI 10.1128/JB.159.3.1077-1079.1984; DODSON KW, 1993, P NATL ACAD SCI USA, V90, P3670, DOI 10.1073/pnas.90.8.3670; DRIESSEN AJM, 1992, EMBO J, V11, P847, DOI 10.1002/j.1460-2075.1992.tb05122.x; GONG MF, 1992, J MOL BIOL, V228, P735, DOI 10.1016/0022-2836(92)90860-M; GOODELL EW, 1987, J BACTERIOL, V169, P3861, DOI 10.1128/jb.169.8.3861-3865.1987; HANNAVY K, 1990, J MOL BIOL, V216, P897, DOI 10.1016/S0022-2836(99)80009-6; HIRST TR, 1987, P NATL ACAD SCI USA, V84, P7418, DOI 10.1073/pnas.84.21.7418; HIRST TR, 1987, J BACTERIOL, V169, P1037, DOI 10.1128/jb.169.3.1037-1045.1987; HOLMGREN A, 1992, EMBO J, V11, P1617, DOI 10.1002/j.1460-2075.1992.tb05207.x; HULTGREN SJ, 1993, CELL, V73, P887, DOI 10.1016/0092-8674(93)90269-V; HULTGREN SJ, 1989, P NATL ACAD SCI USA, V86, P4357, DOI 10.1073/pnas.86.12.4357; JACOBDUBUISSON F, 1993, EMBO J, V12, P837, DOI 10.1002/j.1460-2075.1993.tb05724.x; JIANG B, 1992, MOL MICROBIOL, V6, P1351, DOI 10.1111/j.1365-2958.1992.tb00856.x; JONES CH, 1993, P NATL ACAD SCI USA, V90, P8397, DOI 10.1073/pnas.90.18.8397; KORONAKIS V, 1991, EMBO J, V10, P3263, DOI 10.1002/j.1460-2075.1991.tb04890.x; KUEHN MJ, 1992, NATURE, V356, P252, DOI 10.1038/356252a0; KUEHN MJ, 1991, P NATL ACAD SCI USA, V88, P10586, DOI 10.1073/pnas.88.23.10586; KUPERSZTOCH YM, 1990, J BACTERIOL, V172, P2427, DOI 10.1128/jb.172.5.2427-2432.1990; LEVENGOOD SK, 1991, P NATL ACAD SCI USA, V88, P5939, DOI 10.1073/pnas.88.14.5939; LINDBERG F, 1987, NATURE, V328, P84, DOI 10.1038/328084a0; LINDBERG F, 1989, J BACTERIOL, V171, P6052, DOI 10.1128/jb.171.11.6052-6058.1989; LORY S, 1992, J BACTERIOL, V174, P3423; MARSH JL, 1984, GENE, V32, P481, DOI 10.1016/0378-1119(84)90022-2; Miller J.H., 1992, SHORT COURSE BACTERI, P150; NIKAIDO H, 1992, MOL MICROBIOL, V6, P435, DOI 10.1111/j.1365-2958.1992.tb01487.x; NIKAIDO H, 1992, SCIENCE, V258, P936, DOI 10.1126/science.1279804; NORGREN M, 1987, MOL MICROBIOL, V1, P169, DOI 10.1111/j.1365-2958.1987.tb00509.x; PAGES JM, 1988, EUR J BIOCHEM, V176, P655, DOI 10.1111/j.1432-1033.1988.tb14327.x; PARKER CT, 1992, J BACTERIOL, V174, P2525, DOI 10.1128/jb.174.8.2525-2538.1992; PUGSLEY AP, 1992, P NATL ACAD SCI USA, V89, P12058, DOI 10.1073/pnas.89.24.12058; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SEN K, 1988, J BIOL CHEM, V263, P1182; SHIOZUKA K, 1990, J BIOL CHEM, V265, P18843; SLONIM LN, 1992, EMBO J, V11, P4747, DOI 10.1002/j.1460-2075.1992.tb05580.x; STRIKER R, 1994, J BIOL CHEM, V269, P12233; TURNER LR, 1993, J BACTERIOL, V175, P4962, DOI 10.1128/JB.175.16.4962-4969.1993; WANDERSMAN C, 1993, MOL MICROBIOL, V7, P141, DOI 10.1111/j.1365-2958.1993.tb01105.x; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WONG KR, 1989, SCIENCE, V246, P654, DOI 10.1126/science.2814486	45	102	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12447	12455						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	7909802				2022-12-25	WOS:A1994NH71600015
J	KUROSE, H; LEFKOWITZ, RJ				KUROSE, H; LEFKOWITZ, RJ			DIFFERENTIAL DESENSITIZATION AND PHOSPHORYLATION OF 3 CLONED AND TRANSFECTED ALPHA-2-ADRENERGIC RECEPTOR SUBTYPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; AGONIST-PROMOTED DESENSITIZATION; BETA-2-ADRENERGIC RECEPTOR; DEPENDENT PHOSPHORYLATION; G-PROTEINS; KINASE; EXPRESSION; CLONING; FAMILY; MECHANISMS	Genes encoding 3 distinct subtypes of human alpha2-adrenergic receptor are known and are found, respectively, on chromosome 10, 4, and 2 (alpha2-C10 alpha2-C4, and alpha2-C2 adrenergic receptors). All 3 receptors inhibit adenylyl cyclase via G(i) proteins. To study and compare their regulatory properties we assessed the ability of each to undergo agonist-promoted desensitization and phosphorylation. When Chinese hamster ovary cells stably expressing each of the three receptor genes were incubated with epinephrine for 20 min, a marked decrease in sensitivity to subsequent agonist-mediated inhibition of adenylyl cyclase was observed for the alpha2-C10 and alpha2-C2 receptors but not for the alpha2-C4 receptors. When similar incubations were performed with P-32i-labeled cells and the receptors were immunoprecipitated with specific antibodies, alpha2-C10 and alpha2-C2 receptors were found to undergo an approximately 3-fold increase in receptor phosphorylation after epinephrine exposure. When transfected into COS cells epinephrine also stimulated phosphorylation of alpha2-C10 and alpha2-C2 receptors while having only a slight effect on alpha2-C4 receptors. Cotransfection of the cells with the cDNA encoding the beta-adrenergic receptor kinase further increased receptor phosphorylation for alpha2-C10 and alpha2-C2 receptors while having little or no effect on alpha2-C4 receptors. Moreover purified and reconstituted recombinant alpha2-C10 receptors could be phosphorylated in an agonist-dependent fashion whereas alpha2-C4 receptors could not. These observations suggest receptor subtype-specific differences in susceptibility to regulatory phosphorylation and desensitization.	DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, BOX 3821, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University			Lefkowitz, Robert/AAW-2649-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARRIZA JL, 1992, J NEUROSCI, V12, P4045; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYLUND DB, 1992, FASEB J, V6, P832, DOI 10.1096/fasebj.6.3.1346768; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EASON MG, 1992, J BIOL CHEM, V267, P15795; EASON MG, 1992, J BIOL CHEM, V267, P25473; EASON MG, 1993, BIOCHEM BIOPH RES CO, V193, P318, DOI 10.1006/bbrc.1993.1626; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; JONES SB, 1990, J PHARMACOL EXP THER, V254, P294; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KUROSE H, 1991, BIOCHEMISTRY-US, V30, P3335, DOI 10.1021/bi00227a024; KUROSE H, 1993, MOL PHARMACOL, V43, P444; KWATRA MM, 1987, J BIOL CHEM, V262, P16314; LEEBLUNDBERG LMF, 1985, P NATL ACAD SCI USA, V82, P5651, DOI 10.1073/pnas.82.17.5651; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; LOMASNEY JW, 1990, P NATL ACAD SCI USA, V87, P5094, DOI 10.1073/pnas.87.13.5094; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; PITCHER J, 1992, BIOCHEMISTRY-US, V31, P3193, DOI 10.1021/bi00127a021; PLASSAT JL, 1993, MOL PHARMACOL, V44, P229; REGAN JW, 1988, P NATL ACAD SCI USA, V85, P6301, DOI 10.1073/pnas.85.17.6301; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SIBLEY DR, 1992, TRENDS PHARMACOL SCI, V13, P61, DOI 10.1016/0165-6147(92)90025-2	33	96	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					10093	10099						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	7908287				2022-12-25	WOS:A1994NE05300104
J	FRANCO, PJ; BROOKER, RJ				FRANCO, PJ; BROOKER, RJ			FUNCTIONAL ROLES OF GLU-269 AND GLU-325 WITHIN THE LACTOSE PERMEASE OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAC PERMEASE; MEMBRANE-VESICLES; CARRIER PROTEIN; DIRECTED MUTAGENESIS; ENHANCED RECOGNITION; PLASMID DNA; TRANSPORT; MUTANTS; MECHANISM; MALTOSE	Acidic residues which are found on transmembrane segments within the lactose permease may play an important role in H+ and/or sugar recognition. To examine the functional roles of Glu-269 and Glu-325, we have constructed a variety of amino acid substitutions (e.g. aspartate, glycine, alanine, serine, or glutamine) via site-directed mutagenesis. At position 269, all mutations appear to have a detrimental effect on sugar affinity, downhill transport, and counterflow. The Asp-269 mutant was able to accumulate lactose against a concentration gradient, whereas all of the nonionizable substitutions at position 269 were completely defective. Nevertheless, in spite of their inability to actively accumulate sugars, Gly-269, Ala-269, and Gln-269 mutants were observed to transport H+ upon the addition of galactosides. Mutations at position 325 had a markedly different phenotype. For example, the Asp-325, Gly-325, and Gln-325 mutants exhibited an apparent K-m for lactose transport (e.g. 0.21, 0.47, and 0.50 mM, respectively), which was actually lower than that of the wild-type strain (1.44 mM). In counterflow assays, all position 325 mutants also appear to catalyze lactose exchange. Similar to the results obtained at position 269, the Asp-325 mutant exhibited moderate levels of accumulation, whereas none of the nonionizable mutations at position 325 were able to accumulate galactosides against a concentration gradient. However, unlike the position 269 mutants, no H+ transport was observed in the Gly-325, Ala-325, Ser-325, or Gln-325 strains upon the addition of lactose, S-beta-D-galactopyranosyl-(1,1)-beta-thiogalactopy- ranoside, 1-O-methyl-beta-D-galactopyranoside, or melibiose. Furthermore, in these mutants, the efflux of lactose during counterflow assays became insensitive to Delta pH. Overall, these results are consistent with the notion that an acidic residue at position 325 is required for H+ transport via the lactose permease. Alternative hypotheses are also discussed.	UNIV MINNESOTA,DEPT GENET & CELL BIOL,ST PAUL,MN 55108; UNIV MINNESOTA,INST ADV STUDIES BIOL PROC TECHNOL,ST PAUL,MN 55108	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NIAID NIH HHS [AI24204] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024204] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOYER PD, 1988, TRENDS BIOCHEM SCI, V13, P5, DOI 10.1016/0968-0004(88)90005-9; BROOKER RJ, 1990, RES MICROBIOL, V141, P309, DOI 10.1016/0923-2508(90)90004-A; BROOKER RJ, 1985, P NATL ACAD SCI USA, V82, P3959, DOI 10.1073/pnas.82.12.3959; BROOKER RJ, 1990, J BIOL CHEM, V265, P4155; BROOKER RJ, 1991, J BIOL CHEM, V266, P4131; BUCHEL DE, 1980, NATURE, V283, P541, DOI 10.1038/283541a0; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CARRASCO N, 1989, BIOCHEMISTRY-US, V28, P2533, DOI 10.1021/bi00432a028; CARRASCO N, 1986, BIOCHEMISTRY-US, V25, P4486, DOI 10.1021/bi00364a004; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; COLLINS JC, 1989, J BIOL CHEM, V264, P14698; CRANE RK, 1977, REV PHYSIOL BIOCH P, V78, P99, DOI 10.1007/BFb0027722; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P3139, DOI 10.1021/bi00063a028; FLAGG JL, 1977, J MEMBRANE BIOL, V31, P223; FOSTER DL, 1983, J BIOL CHEM, V258, P31; FRANCO PJ, 1989, J BIOL CHEM, V264, P15988; FRANCO PJ, 1991, J BIOL CHEM, V266, P6693; HINKLE PC, 1990, BIOCHEMISTRY-US, V29, P10989, DOI 10.1021/bi00501a017; HOPPE J, 1980, FEBS LETT, V109, P107, DOI 10.1016/0014-5793(80)81321-4; KABACK HR, 1974, SCIENCE, V186, P882, DOI 10.1126/science.186.4167.882; KACZOROWSKI GJ, 1979, BIOCHEMISTRY-US, V18, P3691, DOI 10.1021/bi00584a009; KACZOROWSKI GJ, 1979, BIOCHEMISTRY-US, V18, P3697, DOI 10.1021/bi00584a010; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; KING SC, 1989, BIOCHIM BIOPHYS ACTA, V982, P253, DOI 10.1016/0005-2736(89)90062-X; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE JI, 1993, J BIOL CHEM, V268, P20007; LOLKEMA JS, 1988, BIOCHEMISTRY-US, V27, P8307, DOI 10.1021/bi00422a003; Mandel M, 1970, J MOL BIOL, V53, P154; Miller J. H., 1972, EXPT MOL GENETICS, P433; Mitchell P., 1963, BIOCHEM SOC SYMP, V22, P142; NEWMAN MJ, 1981, J BIOL CHEM, V256, P1804; NEWMAN MJ, 1980, J BIOL CHEM, V255, P583; OTTO H, 1990, P NATL ACAD SCI USA, V87, P1018, DOI 10.1073/pnas.87.3.1018; RICKENBERG HV, 1956, ANN I PASTEUR PARIS, V91, P829; ROEPE PD, 1990, RES MICROBIOL, V141, P290, DOI 10.1016/0923-2508(90)90003-9; SAHINTOTH M, 1992, P NATL ACAD SCI USA, V89, P10547, DOI 10.1073/pnas.89.21.10547; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEBALD W, 1978, ENERGY CONSERVATION, P228; TEATHER RM, 1978, MOL GEN GENET, V159, P239, DOI 10.1007/BF00268260; TEATHER RM, 1980, EUR J BIOCHEM, V108, P223, DOI 10.1111/j.1432-1033.1980.tb04715.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	45	81	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7379	7386						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7907327				2022-12-25	WOS:A1994NA03200055
J	ARIGA, T; TAO, RV; LEE, BC; YAMAWAKI, M; YOSHINO, H; SCARSDALE, NJ; KASAMA, T; KUSHI, Y; YU, RK				ARIGA, T; TAO, RV; LEE, BC; YAMAWAKI, M; YOSHINO, H; SCARSDALE, NJ; KASAMA, T; KUSHI, Y; YU, RK			GLYCOLIPID COMPOSITION OF HUMAN CATARACTOUS LENSES - CHARACTERIZATION OF LEWIS(X) GLYCOLIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITOMETRIC DETERMINATION; PHEOCHROMOCYTOMA CELLS; NEUTRAL GLYCOLIPIDS; MASS-SPECTROMETRY; EMBRYONIC ANTIGEN; SENILE CATARACT; TYPE-2 CHAIN; LUNG-CANCER; GANGLIOSIDES; BRAIN	We have studied the glycolipid composition of human cataractous lenses. Neutral and acidic lipid fractions were isolated by column chromatographies on DEAE-Sephadex and Iatrobeads. The neutral glycolipid fraction and acidic glycolipid fraction contained 0.6-0.9 mug of lipid-bound glucose (Glc) per mg of protein and 0.8-1.3 mug of lipid-bound sialic acid (NeuAc) per mg of protein, respectively. The neutral glycolipid fraction was found to contain LacCer (39.0% of total neutral glycolipids), Gb3 (16.2%), Gb4 (1.1%), nLc4 (5.0%), X (29.0%), and Y (9.2%). The acidic lipid fraction was found to contain mainly GM3 (33.1% of the total ganglioside fraction), GM1 (8.3%), LM1 (7.3%), GD1a (16.0%), and G (30.1%). The structures of neutral glycolipids X and Y and ganglioside G were elucidated by high performance thin-layer chromatography overlay method of glycolipids, gas-liquid chromatography, proton NMR spectrometry, and liquid secondary ion mass spectrometry as follows: 1) X, Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4Glcbeta1-1'Cer, III3FucnLc4 (Le(x)); 2) Y, Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4Glcbeta1-'Cer, V3FucIII3FucnLc6; and 3) G, NeuAcalpha1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Gal-beta1-4Glcbeta1-1'Cer, IV3NeuAcIII3FucnLc4 (sialosyl-Le(x)). A minor neutral glycolipid Z was isolated and tentatively characterized as GlcNAcbeta1-3?Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4Glcbeta1-1'Cer (GlcNAc-Le(x)), suggesting that may be the precursor of glycolipid Y. The major long-chain base of these human cataract glycolipids was C18:0 sphingosine (sphinganine). The major fatty acids were C16:0, C24:1 and C24:0, and monounsaturated fatty acids accounted for 40-55% of the total fatty acids.	UNIV ILLINOIS, MED CTR, DEPT OPHTHALMOL, CHICAGO, IL 60612 USA; TOKYO MED & DENT UNIV, DEPT BIOCHEM, BUNKYO KU, TOKYO 113, JAPAN	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Tokyo Medical & Dental University (TMDU)	ARIGA, T (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT BIOCHEM & MOLEC BIOPHYS, 1101 E MARSHALL ST, RICHMOND, VA 23298 USA.				NEI NIH HHS [EY-01821] Funding Source: Medline; NINDS NIH HHS [NS-11853] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY001821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011853] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDO S, 1978, ANAL BIOCHEM, V89, P437, DOI 10.1016/0003-2697(78)90373-1; ANDO S, 1979, J BIOL CHEM, V254, P2224; [Anonymous], 1976, LIPIDS, V12, P455; ARIGA T, 1988, BIOCHEMISTRY-US, V27, P52, DOI 10.1021/bi00401a010; ARIGA T, 1991, BIOCHEMISTRY-US, V30, P7953, DOI 10.1021/bi00246a012; ARIGA T, 1982, J BIOL CHEM, V257, P2230; ARIGA T, 1980, J LIPID RES, V21, P879; ARIGA T, 1987, J BIOL CHEM, V262, P14146; BLOEMENDAL H, 1977, SCIENCE, V197, P127, DOI 10.1126/science.877544; CARTER HE, 1967, J LIPID RES, V8, P391; FELDMAN GERALD L., 1965, INVEST OPHTHAL MOL, V4, P162; FELDMAN GL, 1965, J AM OIL CHEM SOC, V42, P742, DOI 10.1007/BF02540054; FENDERSON BA, 1986, DEV BIOL, V114, P12, DOI 10.1016/0012-1606(86)90379-9; FUKSHI Y, 1984, J BIOL CHEM, V259, P4681; FUKUDA MN, 1986, J BIOL CHEM, V261, P2376; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; HAKOMORI S, 1984, ANNU REV IMMUNOL, V2, P103, DOI 10.1146/annurev.iy.02.040184.000535; HAKOMORI S, 1984, J BIOL CHEM, V259, P4672; HAKOMORI SI, 1983, J NATL CANCER I, V63, P843; HAKOMORI SI, 1981, BIOCHEM BIOPH RES CO, V10, P1578; HIRABAYASHI Y, 1986, BIOCHIM BIOPHYS ACTA, V876, P178; KASAI N, 1982, LIPIDS, V17, P107, DOI 10.1007/BF02535184; KASAMA T, 1991, BIOCHEMISTRY-US, V30, P5621, DOI 10.1021/bi00236a041; KYOGASHIMA M, 1989, ARCH BIOCHEM BIOPHYS, V275, P309, DOI 10.1016/0003-9861(89)90378-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATYAS GR, 1987, P NATL ACAD SCI USA, V84, P6065, DOI 10.1073/pnas.84.17.6065; OGISO M, 1990, EXP EYE RES, V50, P51, DOI 10.1016/0014-4835(90)90010-R; OGISO M, 1990, INVEST OPHTH VIS SCI, V31, P2171; OGISO M, 1992, J BIOL CHEM, V267, P6467; RAUVALA H, 1976, J BIOL CHEM, V251, P7517; REN SL, 1992, J BIOL CHEM, V267, P12632; ROSENFELD L, 1981, EXP EYE RES, V33, P641, DOI 10.1016/S0014-4835(81)80104-2; SAITO M, 1985, ANAL BIOCHEM, V148, P54, DOI 10.1016/0003-2697(85)90627-X; SARKAR CP, 1982, BIOCHIM BIOPHYS ACTA, V711, P503, DOI 10.1016/0005-2760(82)90065-0; SEKINE M, 1984, J BIOCHEM-TOKYO, V96, P237, DOI 10.1093/oxfordjournals.jbchem.a134818; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; SWINDELL RT, 1988, OPHTHALMIC RES, V20, P232, DOI 10.1159/000266650; TAO R V P, 1983, Current Eye Research, V2, P427; TAO RVP, 1975, BIOCHIM BIOPHYS ACTA, V409, P329, DOI 10.1016/0005-2760(75)90029-6; TAO RVP, 1983, BIOCHIM BIOPHYS ACTA, V753, P89, DOI 10.1016/0005-2760(83)90102-9; VANCE DE, 1967, J LIPID RES, V8, P391; VAUGHN D, 1989, GENERAL OPHTHALMOLOG, P144; WINDELER AS, 1970, BIOCHIM BIOPHYS ACTA, V202, P361, DOI 10.1016/0005-2760(70)90199-2; YANG HJ, 1971, J BIOL CHEM, V246, P1192; YU RK, 1970, J LIPID RES, V11, P506; YU RK, 1986, CHEM PHYS LIPIDS, V42, P42; ZELENKA PS, 1984, CURR EYE RES, V3, P1337, DOI 10.3109/02713688409007421; ZENITA K, 1988, INT J CANCER, V41, P344, DOI 10.1002/ijc.2910410304	48	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2667	2675						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	7905480				2022-12-25	WOS:A1994MV43200049
J	BIARDI, L; SREEDHAR, A; ZOKAEI, A; VARTAK, NB; BOZEAT, RL; SHACKELFORD, JE; KELLER, GA; KRISANS, SK				BIARDI, L; SREEDHAR, A; ZOKAEI, A; VARTAK, NB; BOZEAT, RL; SHACKELFORD, JE; KELLER, GA; KRISANS, SK			MEVALONATE KINASE IS PREDOMINANTLY LOCALIZED IN PEROXISOMES AND IS DEFECTIVE IN PATIENTS WITH PEROXISOME DEFICIENCY DISORDERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER PEROXISOMES; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE; IMMUNOELECTRON MICROSCOPY; CHOLESTEROL-SYNTHESIS; ZELLWEGER SYNDROME; MOLECULAR-CLONING; ACETOACETYL-COA; REFSUMS DISEASE; ACETYL-COA; METABOLISM	We reported recently that mevalonate kinase (EC 2.7.1.36; ATP:mevalonate 5-phosphotransferase) that was isolated from rat liver and believed to be a cytosolic protein was localized in rat liver peroxisomes. In addition, we found that the mevalonate kinase monoclonal antibody used in the study also reacted with several other proteins present in the mitochondrial and cytosolic fractions. These findings raised the prospect of the presence of several isoenzymes of mevalonate kinase localized in different compartments of the cell. In the current study we produced four new polyclonal antibodies against different epitopes of mevalonate kinase to investigate the subcellular localization of the protein by several different approaches: (i) by analytical subcellular fractionation and immunoblotting of mevalonate kinase in the isolated subcellular fractions with the monospecific antibodies; (ii) by immunocryoelectron microscopy techniques; and (iii) by expressing the CDNA encoding mevalonate kinase in maMmalian cells. The data obtained demonstrate that there is only one mevalonate kinase protein that is predominately localized in peroxisomes. We also illustrate that the protein is targeted to and imported into peroxisomes. In addition, we show that in cells and tissues obtained from patients with peroxisomal deficiency diseases mevalonate kinase protein and its activity are severely reduced.	SAN DIEGO STATE UNIV,DEPT BIOL,SAN DIEGO,CA 92182; GENENTECH INC,DEPT PRECLIN PHARMACOL,S SAN FRANCISCO,CA 94080	California State University System; San Diego State University; Roche Holding; Genentech					NIDDK NIH HHS [DK 32852, DK 44350] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032852, R01DK044350] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARTH PG, 1987, J INHERIT METAB DIS, V10, P253, DOI 10.1007/BF01800071; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; ERIKSSON AM, 1992, FEBS LETT, V308, P211, DOI 10.1016/0014-5793(92)81276-R; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GORDON JA, 1990, J CLIN INVEST, V85, P1173, DOI 10.1172/JCI114550; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HODGE VJ, 1991, BIOCHEM BIOPH RES CO, V181, P537, DOI 10.1016/0006-291X(91)91222-X; HOVIK R, 1991, J LIPID RES, V32, P993; KELLER GA, 1986, J CELL BIOL, V103, P875, DOI 10.1083/jcb.103.3.875; KELLER GA, 1984, P NATL ACAD SCI-BIOL, V81, P5744, DOI 10.1073/pnas.81.18.5744; KELLER GA, 1989, J CELL BIOL, V108, P1353, DOI 10.1083/jcb.108.4.1353; KELLER GA, 1985, P NATL ACAD SCI USA, V82, P770, DOI 10.1073/pnas.82.3.770; KRISANS SK, 1992, AM J RESP CELL MOL, V7, P358, DOI 10.1165/ajrcmb/7.4.358; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lazarow P. B., 1989, METABOLIC BASIS INHE, P1479; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; NOLTMANN EA, 1966, METHOD ENZYMOL, V9, P557; PARKER RA, 1989, J BIOL CHEM, V264, P4877; POLLTHE BT, 1987, EUR J PEDIATR, V146, P477, DOI 10.1007/BF00441598; POULOS A, 1984, NEUROLOGY, V34, P1606, DOI 10.1212/WNL.34.12.1606; Sambrook J, 1989, MOL CLONING LABORATO; SAWAMURA M, 1992, J BIOL CHEM, V267, P6051; SCHAFER BL, 1992, J BIOL CHEM, V267, P13229; SCHMIDT E, 1974, METHOD ENZYMAT AN, V2, P650; SCOTTO JM, 1982, J INHERIT METAB DIS, V5, P83, DOI 10.1007/BF01799998; SMALL GM, 1988, ANAL BIOCHEM, V169, P405, DOI 10.1016/0003-2697(88)90304-1; STAMELLO SKD, 1992, J BIOL CHEM, V267, P5560; STAMELLOS KD, 1993, J BIOL CHEM, V268, P12825; SUZUKI Y, 1990, CELL STRUCT FUNCT, V15, P301, DOI 10.1247/csf.15.301; TANAKA RD, 1990, P NATL ACAD SCI USA, V87, P2872, DOI 10.1073/pnas.87.8.2872; TANAKA RD, 1990, J BIOL CHEM, V265, P9123; THOMPSON SL, 1990, J BIOL CHEM, V265, P5731; TOKUYASU KT, 1973, J CELL BIOL, V57, P551, DOI 10.1083/jcb.57.2.551	36	75	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1197	1205						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7904598				2022-12-25	WOS:A1994MR22000068
J	GROENEN, PJTA; GROOTJANS, JJ; LUBSEN, NH; BLOEMENDAL, H; DEJONG, WW				GROENEN, PJTA; GROOTJANS, JJ; LUBSEN, NH; BLOEMENDAL, H; DEJONG, WW			LYS-17 IS THE AMINE-DONOR SUBSTRATE SITE FOR TRANSGLUTAMINASE IN BETA-A3-CRYSTALLIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MONOMERIC GAMMA-CRYSTALLIN; PROGRAMMED CELL-DEATH; BETA-CRYSTALLIN; TISSUE TRANSGLUTAMINASE; LENS TRANSGLUTAMINASE; ACCEPTOR SITES; PROTEINS; LYSINE; IDENTIFICATION; APOPTOSIS	The bovine lens protein betaA3-crystallin has recently been shown to be an amine-donor (Lys) substrate for tissue-type transglutaminase, using a newly developed amine-acceptor hexapeptide as a probe (Groenen, P. J. T. A., Seccia, M., Smulders, R. H. P. H., Gravela, E., Cheeseman, K. H., Bloemendal, H., and de Jong, W. W. (1993) Biochem. J. 295, 399-404). In the present study, the reactive amine-donor site has been identified by site-directed mutagenesis of the putative substrate lysine. The mutation Lys-17 --> Arg abolishes the substrate capacity. This residue, located in the N-terminal extension of the polypeptide, thus acts as the sole amine-donor substrate in betaA3-crystallin. Our finding reinforces the notion that, in the crystallins, all amine-donor as well as amine-acceptor substrate sites reside in the N- or C-terminal arms. Transglutaminase-mediated cross-linking of betaA3-crystallin also gives rise to a betaA3 dimer, presumably due to the fact that Lys-17 can be cross-linked to the previously established Gln-7 or Gln-8 amine-acceptor site.	CATHOLIC UNIV NIJMEGEN,DEPT BIOCHEM,POB 9101,6500 HB NIJMEGEN,NETHERLANDS; CATHOLIC UNIV NIJMEGEN,DEPT MOLEC BIOL,6500 HB NIJMEGEN,NETHERLANDS	Radboud University Nijmegen; Radboud University Nijmegen			Lubsen, Nicolette H./B-8426-2011; Groenen, Patricia/L-4336-2015	Groenen, Patricia/0000-0003-4314-228X				AARTS HJM, 1989, J MOL EVOL, V28, P313, DOI 10.1007/BF02103427; BAX B, 1990, NATURE, V347, P776, DOI 10.1038/347776a0; BERBERS GAM, 1984, P NATL ACAD SCI-BIOL, V81, P7017, DOI 10.1073/pnas.81.22.7017; BERBERS GAM, 1984, EUR J BIOCHEM, V139, P467, DOI 10.1111/j.1432-1033.1984.tb08029.x; BIRCKBICHLER PJ, 1977, CANCER RES, V37, P1340; BUNGAY PJ, 1986, BIOCHEM J, V235, P269, DOI 10.1042/bj2350269; CARVER JA, 1992, FEBS LETT, V311, P143, DOI 10.1016/0014-5793(92)81386-Z; CARVER JA, 1993, EUR J BIOCHEM, V213, P313, DOI 10.1111/j.1432-1033.1993.tb17764.x; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; GORIN MB, 1984, CURR EYE RES, V3, P939, DOI 10.3109/02713688409167211; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GROENEN PJTA, 1993, BIOCHEM J, V295, P399, DOI 10.1042/bj2950399; GROENEN PJTA, 1992, EUR J BIOCHEM, V205, P671, DOI 10.1111/j.1432-1033.1992.tb16827.x; KNIGHT CRL, 1991, BIOCHIM BIOPHYS ACTA, V1096, P312, DOI 10.1016/0925-4439(91)90067-J; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPATTO R, 1991, J MOL BIOL, V222, P1067, DOI 10.1016/0022-2836(91)90594-V; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; LORAND L, 1992, P NATL ACAD SCI USA, V89, P11161, DOI 10.1073/pnas.89.23.11161; LORAND L, 1981, P NATL ACAD SCI-BIOL, V78, P1356, DOI 10.1073/pnas.78.3.1356; MCFALNGAI M, 1986, CURR EYE RES, V5, P387, DOI 10.3109/02713688609025178; MERCK KB, 1992, BIOCHIM BIOPHYS ACTA, V1130, P267, DOI 10.1016/0167-4781(92)90439-7; MERCK KB, 1993, J BIOL CHEM, V268, P1046; MULDERS JWM, 1987, EXP CELL RES, V171, P296, DOI 10.1016/0014-4827(87)90163-7; PORTA R, 1991, BIOCHEMISTRY-US, V30, P3114, DOI 10.1021/bi00226a019; PUCCI P, 1988, BIOCHEM BIOPH RES CO, V154, P735, DOI 10.1016/0006-291X(88)90201-X; QUAXJEUKEN Y, 1984, J MOL BIOL, V180, P457, DOI 10.1016/0022-2836(84)90022-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; WISTOW G, 1981, FEBS LETT, V133, P9, DOI 10.1016/0014-5793(81)80460-7	32	31	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					831	833						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7904603				2022-12-25	WOS:A1994MR22000013
J	DANIELLO, A; DONOFRIO, G; PISCHETOLA, M; DANIELLO, G; VETERE, A; PETRUCELLI, L; FISHER, GH				DANIELLO, A; DONOFRIO, G; PISCHETOLA, M; DANIELLO, G; VETERE, A; PETRUCELLI, L; FISHER, GH			BIOLOGICAL ROLE OF D-AMINO-ACID OXIDASE AND D-ASPARTATE OXIDASE - EFFECTS OF D-AMINO ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN BASIC-PROTEIN; PERFORMANCE LIQUID-CHROMATOGRAPHY; D-ALANINE; HUMAN-BRAIN; VULGARIS LAM; PIG-KIDNEY; D-SERINE; RACEMIZATION; PURIFICATION; RAT	D-Amino acids administered to animals are absorbed by the intestine and transported through the blood-stream to solid tissues where they are oxidized in vivo by D-amino acid oxidase and D-aspartate oxidase to produce the same compounds they do in vitro; i.e. NH3, H2O2, and the keto acid corresponding to the amino acid ingested. In the liver and kidneys of the animals, an inverse relationship exists between the occurrence of D-amino acids and these oxidative enzymes. For example, younger animals have lower amounts of these oxidases and consequently higher concentrations of free D-amino acids compared to adult animals. If the ingested D-amino acids are not metabolized by these enzymes, they will accumulate in the tissues and may provoke serious damage, e.g. suppression of the synthesis of other essential enzymes and inhibition of the growth rate of the animals. A specific enzyme induction for these D-amino acid oxidases exists in young rats following ingestion of free D-amino acids by the mother. Specifically, when a mother rat ingests D-Ala or D-Asp during pregnancy and suckling, an increase in D-amino acid oxidase or D-aspartate oxidase is observed in the liver and kidneys of the baby rats. These results suggest that the in vivo biological role of these oxidases in animals is to act as detoxifying agents to metabolize D-amino acids which may have accumulated during aging.	BARRY UNIV, DEPT CHEM, MIAMI, FL 33161 USA		DANIELLO, A (corresponding author), STAZ ZOOL ANTON DOHRN, DEPT BIOCHEM & MOLEC BIOL, VILLA COMUNALE, I-80121 NAPLES, ITALY.			Vetere, Amedeo/0000-0001-5608-0773				ARMANI E, 1988, J CHROMATOGR, V441, P287, DOI 10.1016/S0021-9673(01)83872-3; BLASCHKO H, 1952, BIOCHEM J, V52, P306, DOI 10.1042/bj0520306; BURNS CL, 1984, BIOCHEM BIOPH RES CO, V125, P1039, DOI 10.1016/0006-291X(84)91388-3; CONNO R, 1988, BIOCHIM BIOPHYS ACTA, V297, P382; CONNO R, 1988, BIOCHEM J, V261, P285; CORRIGAN JJ, 1969, SCIENCE, V164, P142, DOI 10.1126/science.164.3876.142; CURTI B, 1973, BIOCHIM BIOPHYS ACTA, V327, P266, DOI 10.1016/0005-2744(73)90409-9; DANIELLO A, 1993, LIFE SCI, V52, P733, DOI 10.1016/0024-3205(93)90235-U; DANIELLO A, 1975, COMP BIOCHEM PHYSIOL, V50, P209, DOI 10.1016/0305-0491(75)90324-7; DANIELLO A, 1984, J BIOL CHEM, V259, P4237; DANIELLO A, 1978, J NEUROCHEM, V31, P1107, DOI 10.1111/j.1471-4159.1978.tb00155.x; DANIELLO A, 1980, COMP BIOCHEM PHYS B, V66, P319, DOI 10.1016/0305-0491(80)90071-1; DANIELLO A, 1977, J NEUROCHEM, V29, P1053, DOI 10.1111/j.1471-4159.1977.tb06508.x; DANIELLO A, 1990, COMP BIOCHEM PHYS B, V97, P291, DOI 10.1016/0305-0491(90)90283-Y; DANIELLO A, 1990, BIOCHIM BIOPHYS ACTA, V1037, P200, DOI 10.1016/0167-4838(90)90168-F; DANIELLO A, 1992, COMP BIOCHEM PHYS B, V102, P795, DOI 10.1016/0305-0491(92)90082-3; DANIELLO A, 1992, BRAIN RES, V592, P44, DOI 10.1016/0006-8993(92)91656-Y; DANIELLO A, 1987, ITAL J BIOCHEM, V36, pA322; DANIELLO A, 1972, COMP BIOCHEM PHYSIOL, V41, P625, DOI 10.1016/0305-0491(72)90124-1; DAVIES LP, 1975, J NEUROCHEM, V25, P299; DEMARCHI WJ, 1969, J NEUROCHEM, V16, P355; DEMARCO C, 1967, ENZYMOLOGIA, V33, P325; DEMARCO C, 1969, ENZYMOLOGIA, V36, P111; DEMORAES GHK, 1987, POULTRY SCI, V66, P98, DOI 10.3382/ps.0660098; DIXON M, 1967, BIOCHIM BIOPHYS ACTA, V146, P54, DOI 10.1016/0005-2744(67)90073-3; DIXON M, 1965, BIOCHIM BIOPHYS ACTA, V96, P357, DOI 10.1016/0005-2787(65)90556-3; DUNLOP DS, 1986, BIOCHEM BIOPH RES CO, V141, P27, DOI 10.1016/S0006-291X(86)80329-1; FELBECK H, 1985, J EXP ZOOL, V234, P145, DOI 10.1002/jez.1402340116; FELBECK H, 1987, BIOL BULL, V173, P252, DOI 10.2307/1541877; FICKEISEN DH, 1977, J FISH BIOL, V10, P457, DOI 10.1111/j.1095-8649.1977.tb04078.x; FISHER GH, 1992, BRAIN RES BULL, V28, P127, DOI 10.1016/0361-9230(92)90239-T; FISHER GH, 1992, NEUROSCI LETT, V143, P215, DOI 10.1016/0304-3940(92)90268-C; FISHER GH, 1986, BIOCHEM BIOPH RES CO, V135, P683, DOI 10.1016/0006-291X(86)90047-1; FISHER GH, 1991, BRAIN RES BULL, V26, P983, DOI 10.1016/0361-9230(91)90266-M; Fishman WH, 1942, J BIOL CHEM, V145, P345; FRANK H, 1978, J CHROMATOGR, V167, P187, DOI 10.1016/S0021-9673(00)91157-9; FRIEDMAN M, 1981, J FOOD SCI, V46, P127, DOI 10.1111/j.1365-2621.1981.tb14545.x; FUKUI K, 1987, BIOCHEMISTRY-US, V26, P3612, DOI 10.1021/bi00386a054; GOLDSTEIN DB, 1966, J NEUROCHEM, V13, P1011, DOI 10.1111/j.1471-4159.1966.tb10299.x; GROENEN PJTA, 1990, FEBS LETT, V269, P109, DOI 10.1016/0014-5793(90)81131-7; HAMILTON GA, 1979, P NATL ACAD SCI USA, V76, P2625, DOI 10.1073/pnas.76.6.2625; HASHIMOTO A, 1992, FEBS LETT, V296, P33, DOI 10.1016/0014-5793(92)80397-Y; HELFMAN PM, 1976, NATURE, V262, P279, DOI 10.1038/262279b0; HELLERMA.L, 1965, J BIOL CHEM, V240, P290; KLEINKAUF H, 1987, ANNU REV MICROBIOL, V41, P259, DOI 10.1146/annurev.mi.41.100187.001355; KONNO R, 1982, COMP BIOCHEM PHYS B, V71, P735, DOI 10.1016/0305-0491(82)90490-4; KREBS HANS ADOLF, 1935, BIOCHEM JOUR, V29, P1620; LIARDON R, 1981, J CHROMATOGR, V203, P385, DOI 10.1016/S0021-9673(00)80309-X; MAN EH, 1987, J NEUROCHEM, V48, P510, DOI 10.1111/j.1471-4159.1987.tb04122.x; MAN EH, 1987, ANNU REV NUTR, V7, P209, DOI 10.1146/annurev.nu.07.070187.001233; MAN EH, 1983, SCIENCE, V220, P1407, DOI 10.1126/science.6857259; MASSEY V, 1966, J BIOL CHEM, V241, P2347; MASTERS PM, 1977, NATURE, V268, P71, DOI 10.1038/268071a0; NAGATA Y, 1989, EXPERIENTIA, V45, P330, DOI 10.1007/BF01957466; NAGATA Y, 1987, CLIN SCI, V73, P105, DOI 10.1042/cs0730105; NAGATA Y, 1985, ANAL BIOCHEM, V150, P238, DOI 10.1016/0003-2697(85)90465-8; NAGATA Y, 1992, BIOCHIM BIOPHYS ACTA, V1115, P208, DOI 10.1016/0304-4165(92)90055-Y; NAGATA Y, 1988, COMP BIOCHEM PHYS B, V91, P503, DOI 10.1016/0305-0491(88)90012-0; NEGRI A, 1987, J BIOL CHEM, V262, P10026; NEIDLE A, 1990, LIFE SCI, V46, P1517, DOI 10.1016/0024-3205(90)90424-P; NEIMS AH, 1970, ANNU REV BIOCHEM, V39, P867, DOI 10.1146/annurev.bi.39.070170.004251; NEIMS AH, 1966, J NEUROCHEM, V13, P163, DOI 10.1111/j.1471-4159.1966.tb07508.x; NEIMS AH, 1962, J BIOL CHEM, V237, pP976; PALLA G, 1989, J CHROMATOGR, V475, P45, DOI 10.1016/S0021-9673(00)91414-6; PAYAN IL, 1992, NEUROCHEM RES, V17, P187, DOI 10.1007/BF00966798; PISTORIUS EK, 1977, BIOCHIM BIOPHYS ACTA, V481, P395, DOI 10.1016/0005-2744(77)90273-X; PRESTON RL, 1987, COMP BIOCHEM PHYS B, V87, P55, DOI 10.1016/0305-0491(87)90470-6; PRESTON RL, 1987, COMP BIOCHEM PHYS B, V87, P63, DOI 10.1016/0305-0491(87)90471-8; RONCHI S, 1982, J BIOL CHEM, V257, P8824; SHAPIRA R, 1988, J NEUROCHEM, V50, P649, DOI 10.1111/j.1471-4159.1988.tb02960.x; SHAPIRA R, 1987, BIOCHEM BIOPH RES CO, V146, P1342, DOI 10.1016/0006-291X(87)90797-2; SHAPIRA R, 1988, J NEUROCHEM, V50, P69, DOI 10.1111/j.1471-4159.1988.tb13231.x; SIMONETTA MP, 1982, FEMS MICROBIOL LETT, V15, P27, DOI 10.1016/0378-1097(82)90006-4; STILL JL, 1950, J BIOL CHEM, V182, P585; TADA M, 1990, GENE, V90, P293, DOI 10.1016/0378-1119(90)90193-U; WEIMAR WR, 1977, J NEUROCHEM, V29, P649, DOI 10.1111/j.1471-4159.1977.tb07782.x; YAGI K, 1962, BIOCHIM BIOPHYS ACTA, V56, P413, DOI 10.1016/0006-3002(62)90592-9; YAGI K, 1967, J BIOCHEM-TOKYO, V61, P580, DOI 10.1093/oxfordjournals.jbchem.a128588; 1974, J CLIN LAB INV, V33, P287	79	232	243	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26941	26949						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	7903300				2022-12-25	WOS:A1993MM26200019
J	HU, YL; KAZENWADEL, J; JAMES, R				HU, YL; KAZENWADEL, J; JAMES, R			ISOLATION AND CHARACTERIZATION OF THE MURINE HOMEOBOX GENE CDX-1 REGULATION OF EXPRESSION IN INTESTINAL EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE SMALL-INTESTINE; TRANSGENIC MICE; BINDING-PROTEIN; CPG ISLANDS; TRANSCRIPTION INVITRO; DENOVO METHYLATION; CORE PROMOTER; TATA BOX; DIFFERENTIATION; DNA	The murine homeobox gene Cdx-1 is postulated to play an important role in the process of cellular commitment in the intestinal epithelium based upon its graded, tissue-specific expression pattern in the adult animal. We have isolated and sequenced both cDNA and genomic clones in order to understand how this expression pattern is regulated and to determine the amino acid sequence of the encoded protein. Our studies show that the Cdx-1 gene contains 3 exons and 2 introns and encodes a 268-amino acid protein which is translated from a 1.7-1.8-kilobase mRNA. Transcription of the Cdx-1 gene initiates some 30 base pairs downstream from a typical TATA box which, together with the 5' end of the gene, is located within a CpG island. Transient transfection experiments have shown three regions which regulate Cdx-1 gene expression. These include a typical silencer element at -589 to -380, an element at -887 to -1040 which blocks the effect of the silencer and a positive element at -47 to +66; the only one which shows epithelial cell specificity. Using gel shift and footprinting assays we have detected proteins in nuclear extracts prepared from colonic epithelial cells which bind to the silencer element. These initial results suggest that Cdx-1 gene expression is regulated by multiple positive and negative transcription factors.	UNIV MELBOURNE,ROYAL MELBOURNE HOSP,DEPT MED,MELBOURNE,VIC 3050,AUSTRALIA; ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,MELBOURNE TUMOR BIOL BRANCH,PARKVILLE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; University of Melbourne; Ludwig Institute for Cancer Research; Royal Melbourne Hospital			Kazenwadel, Jan/E-6620-2012; Hu, Yinling/G-5682-2015	Kazenwadel, Jan/0000-0001-6216-3444; Hu, Yinling/0000-0002-4795-8537				ALLEN JD, 1991, GENE DEV, V5, P509, DOI 10.1101/gad.5.4.509; AMASINO RM, 1986, ANAL BIOCHEM, V152, P304, DOI 10.1016/0003-2697(86)90413-6; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BIEBERICH CJ, 1990, P NATL ACAD SCI USA, V87, P8462, DOI 10.1073/pnas.87.21.8462; BIGGIN MD, 1989, CELL, V58, P433, DOI 10.1016/0092-8674(89)90424-8; BIRD AP, 1989, NUCLEIC ACIDS RES, V17, P9485, DOI 10.1093/nar/17.22.9485; BLAU HM, 1992, ANNU REV BIOCHEM, V61, P1213, DOI 10.1146/annurev.bi.61.070192.010025; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHENG H, 1982, ANAT REC, V203, P251, DOI 10.1002/ar.1092030207; COLONY PC, 1989, CELLULAR MOL BIOL CO, P2; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; DESMARAIS D, 1992, EMBO J, V11, P2971, DOI 10.1002/j.1460-2075.1992.tb05367.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P8242, DOI 10.1073/pnas.82.23.8242; FALB D, 1992, MOL CELL BIOL, V12, P4093, DOI 10.1128/MCB.12.9.4093; FINELY D, 1989, NATURE, V338, P394; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FRUMKIN A, 1991, DEVELOPMENT, V112, P207; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HAFFEN K, 1989, HUMAN GASTROINTESTIN, P19; HAGENBUCHLE O, 1992, NUCLEIC ACIDS RES, V14, P3555; HAN JH, 1986, P NATL ACAD SCI USA, V83, P110, DOI 10.1073/pnas.83.1.110; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JAMES R, 1991, J BIOL CHEM, V266, P3246; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; KEDINGER M, 1987, CELL DIFFER DEV, V20, P171, DOI 10.1016/0045-6039(87)90431-3; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRESS C, 1990, DEVELOPMENT, V109, P775; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MASKENS AP, 1981, CELL TISSUE KINET, V14, P467, DOI 10.1111/j.1365-2184.1981.tb00553.x; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCORMICK A, 1991, GENE DEV, V5, P1490, DOI 10.1101/gad.5.8.1490; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MONTGOMERY RK, 1981, DEV BIOL, V87, P76, DOI 10.1016/0012-1606(81)90062-2; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; PARVIN JD, 1991, J BIOL CHEM, V266, P22878; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; PUSCHEL AW, 1991, DEVELOPMENT, V112, P279; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; ROTH KA, 1990, J CELL BIOL, V110, P1791, DOI 10.1083/jcb.110.5.1791; RUBIN DC, 1992, J BIOL CHEM, V267, P15122; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SIMON J, 1990, EMBO J, V9, P3945, DOI 10.1002/j.1460-2075.1990.tb07615.x; STALLMACH A, 1989, GUT, V30, P959, DOI 10.1136/gut.30.7.959; STOVER DM, 1992, MOL CELL BIOL, V12, P2230, DOI 10.1128/MCB.12.5.2230; SWEETSER DA, 1988, GENE DEV, V2, P1318, DOI 10.1101/gad.2.10.1318; TAMURA T, 1990, EMBO J, V9, P3101, DOI 10.1002/j.1460-2075.1990.tb07507.x; THOMPSON EM, 1990, DEVELOPMENT, V110, P477; THOMPSON J, 1987, ANAL BIOCHEM, V163, P281, DOI 10.1016/0003-2697(87)90225-9; TUGGLE CK, 1990, GENE DEV, V4, P180, DOI 10.1101/gad.4.2.180; WHITEHEAD RH, 1992, IMMUNOL CELL BIOL, V70, P227, DOI 10.1038/icb.1992.30; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WINTON DJ, 1990, P ROY SOC B-BIOL SCI, V241, P13, DOI 10.1098/rspb.1990.0059	64	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27214	27225						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	7903305				2022-12-25	WOS:A1993MM26200058
J	SEN, I; KASTURI, S; JABBAR, MA; SEN, GC				SEN, I; KASTURI, S; JABBAR, MA; SEN, GC			MUTATIONS IN 2 SPECIFIC RESIDUES OF TESTICULAR ANGIOTENSIN-CONVERTING ENZYME CHANGE ITS CATALYTIC PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL CARBOXYPEPTIDASE; HOMOLOGOUS DOMAINS; MESSENGER-RNAS; EXPRESSION; ISOENZYMES; ACTIVATION; SUBSTRATE; RABBIT; GENE	Chemical modifications of 2 specific residues present in angiotensin-converting enzyme (ACE) result in its inactivation, thereby suggesting that these 2 residues may be important for its enzyme activity. We directly tested this hypothesis by substituting Tyr-236 with Phe and Lys-154 with Glu in rabbit testicular ACE (ACE(T)) using site-directed mutagenesis of the corresponding cDNA. Wild type ACE(T), the two single mutants, and the double mutant were expressed in HeLa cells using the vaccinia virus-T7 polymerase expression system. The rate of synthesis, post-translational modifications, and cleavage secretion pattern of all four proteins were indistinguishable. The enzymatic properties of the two single mutants and the wild type enzyme were also very similar. In contrast, the double mutant had about a 20-fold lower specific activity although its K(m) was only 6-fold higher than that of the wild type protein. The double mutant also had a 100-fold higher K(i) for lisinopril, a competitive inhibitor of ACE(T), and was 17-fold less sensitive to stimulation by NaCl, an activator of ACE(T). These results directly demonstrate that Tyr-236 and Lys-154 are indeed critical for the catalytic activity, lisinopril inhibition, and NaCl activation of ACE(T).	CLEVELAND CLIN FDN,DEPT MOLEC BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation	SEN, I (corresponding author), CLEVELAND CLIN FDN,DEPT CARDIOVASC BIOL,FFB,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048258] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-48258] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALHENCGELAS F, 1983, J LAB CLIN MED, V101, P83; BERG T, 1986, J HISTOCHEM CYTOCHEM, V34, P753, DOI 10.1177/34.6.3009604; BERNSTEIN KE, 1989, J BIOL CHEM, V264, P11945; BUNNING P, 1990, BIOCHEMISTRY-US, V29, P10488; BUNNING P, 1983, BIOCHEMISTRY-US, V22, P110, DOI 10.1021/bi00270a016; CHEN YNP, 1990, BIOCHEMISTRY-US, V29, P10493, DOI 10.1021/bi00498a011; CHEN YNP, 1992, BIOCHEM BIOPH RES CO, V184, P306, DOI 10.1016/0006-291X(92)91193-T; DAS M, 1975, J BIOL CHEM, V250, P6762; DIXON M, 1972, BIOCHEM J, V129, P197, DOI 10.1042/bj1290197; EHLERS MRW, 1988, BIOCHEMISTRY-US, V27, P5538, DOI 10.1021/bi00415a023; ELDORRY HA, 1982, P NATL ACAD SCI-BIOL, V79, P4295, DOI 10.1073/pnas.79.14.4295; ELDORRY HA, 1982, J BIOL CHEM, V257, P4128; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; HUBERT C, 1991, J BIOL CHEM, V266, P15377; KINOSHITA A, 1991, J BIOL CHEM, V266, P19192; KUMAR RS, 1991, J BIOL CHEM, V266, P3854; KUMAR RS, 1989, J BIOL CHEM, V264, P16754; LANZILLO JJ, 1976, BIOCHIM BIOPHYS ACTA, V439, P125, DOI 10.1016/0005-2795(76)90168-9; NG KKF, 1967, NATURE, V216, P762, DOI 10.1038/216762a0; Patchett A A, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P1; Safer R. L., 1981, BIOCH REGULATION BLO, P123; SEN I, 1991, J BIOL CHEM, V266, P21985; SHAPIRO R, 1983, BIOCHEMISTRY-US, V22, P3850, DOI 10.1021/bi00285a021; SKEGGS LT, 1954, J EXP MED, V99, P275, DOI 10.1084/jem.99.3.275; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; WEI L, 1992, J BIOL CHEM, V267, P13398; WEI L, 1991, J BIOL CHEM, V266, P9002; YANG HYT, 1970, BIOCHIM BIOPHYS ACTA, V214, P374, DOI 10.1016/0005-2795(70)90017-6	30	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25748	25754						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7902354				2022-12-25	WOS:A1993MK10000069
J	WEITZMANN, CJ; CUNNINGHAM, PR; NURSE, K; OFENGAND, J				WEITZMANN, CJ; CUNNINGHAM, PR; NURSE, K; OFENGAND, J			CHEMICAL EVIDENCE FOR DOMAIN ASSEMBLY OF THE ESCHERICHIA-COLI 30S RIBOSOME	FASEB JOURNAL			English	Article						INVITRO TRANSCRIPT; RIBOSOMAL PROTEINS; 5' DOMAIN; 16S RNA; RIBOSOME ASSEMBLY	DECODING SITE C1400; 16S-RIBOSOMAL RNA; SUBUNIT; TRANSCRIPTION; REGION; MODEL	A fragment of 16S RNA corresponding to most of the 5'-domain (residues 1-526) was prepared by in vitro run-off transcription. When this fragment was incubated with a mixture of 30S proteins under conditions known to result in the in vitro assembly of a complete, functional 30S ribosome from a full-length transcript, a discrete 16S particle was formed. This particle contained near stoichiometric amounts of ribosomal proteins S4, S16, S17, and S20. These four proteins are the same, and only, ones that have been shown to interact with the 5' domain of 16S RNA in the intact 30S ribosome in the footprinting studies of Noller and co-workers. We conclude that the 5' fragment 1-526 is capable of folding independently of the rest of the molecule so as to generate the protein binding sites for the same four proteins with which the corresponding segment of full-length 16S RNA normally interacts. These sites not only include those for S4, S17, and S20 that are known to bind directly to the RNA, but also the site for S16, which requires the prior binding of S4 and S20.	ROCHE INST MOLEC BIOL,ROCHE RES CTR,NUTLEY,NJ 07110	Roche Holding								BRIMACOMBE R, 1988, J MOL BIOL, V199, P115, DOI 10.1016/0022-2836(88)90383-X; BRIMACOMBE R, 1991, BIOCHIMIE, V73, P927, DOI 10.1016/0300-9084(91)90134-M; BRIMACOMBE R, 1985, BIOCHEM J, V229, P1; CORMACK RS, 1991, J BIOL CHEM, V266, P18525; CUNNINGHAM PR, 1992, BIOCHEMISTRY-US, V31, P7629, DOI 10.1021/bi00148a026; CUNNINGHAM PR, 1990, RIBOSOME, P243; CUNNINGHAM PR, 1990, BIOCHIM BIOPHYS ACTA, V1050, P18, DOI 10.1016/0167-4781(90)90135-O; DENMAN R, 1989, BIOCHEMISTRY-US, V28, P1002, DOI 10.1021/bi00429a013; DENMAN R, 1989, BIOCHEMISTRY-US, V28, P1012, DOI 10.1021/bi00429a014; DRAPER DE, 1990, RIBOSOME, P160; GUTELL RR, 1985, PROG NUCLEIC ACID RE, V32, P155, DOI 10.1016/S0079-6603(08)60348-7; HELD WA, 1974, J BIOL CHEM, V249, P3103; HUBBARD JM, 1991, J MOL BIOL, V221, P889, DOI 10.1016/0022-2836(91)80182-T; KRZYZOSIAK WJ, 1988, ANAL BIOCHEM, V175, P373, DOI 10.1016/0003-2697(88)90560-X; MACKIE GA, 1978, J MOL BIOL, V121, P17, DOI 10.1016/0022-2836(78)90260-7; MANDIYAN V, 1991, P NATL ACAD SCI USA, V88, P8174, DOI 10.1073/pnas.88.18.8174; NOLLER HF, 1984, ANNU REV BIOCHEM, V53, P119, DOI 10.1146/annurev.bi.53.070184.001003; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; NOLLER HF, 1981, SCIENCE, V212, P403, DOI 10.1126/science.6163215; NOWOTNY V, 1988, BIOCHEMISTRY-US, V27, P7051, DOI 10.1021/bi00418a057; RAUE HA, 1988, PROG BIOPHYS MOL BIO, V51, P77, DOI 10.1016/0079-6107(88)90011-9; SCHENBORN ET, 1985, NUCLEIC ACIDS RES, V13, P6223, DOI 10.1093/nar/13.17.6223; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; STERN S, 1986, J MOL BIOL, V192, P101, DOI 10.1016/0022-2836(86)90467-5; STERN S, 1988, J MOL BIOL, V204, P447, DOI 10.1016/0022-2836(88)90588-8; STERN S, 1988, J MOL BIOL, V200, P291, DOI 10.1016/0022-2836(88)90241-0; VARTIKAR JV, 1989, J MOL BIOL, V209, P221, DOI 10.1016/0022-2836(89)90274-X; Zimmermann R. A., 1980, RIBOSOMES STRUCTURE, P135	28	69	70	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1993	7	1					177	180		10.1096/fasebj.7.1.7916699	http://dx.doi.org/10.1096/fasebj.7.1.7916699			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	7916699				2022-12-25	WOS:A1993KH88000027
